PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	KRUMHOLZ, HM; PASTERNAK, RC; WEINSTEIN, MC; FRIESINGER, GC; RIDKER, PM; TOSTESON, ANA; GOLDMAN, L				KRUMHOLZ, HM; PASTERNAK, RC; WEINSTEIN, MC; FRIESINGER, GC; RIDKER, PM; TOSTESON, ANA; GOLDMAN, L			COST-EFFECTIVENESS OF THROMBOLYTIC THERAPY WITH STREPTOKINASE IN ELDERLY PATIENTS WITH SUSPECTED ACUTE MYOCARDIAL-INFARCTION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							WORCESTER HEART-ATTACK; MORTALITY; PROGNOSIS; RATES	Background. There is a lack of consensus among cardiologists about the potential benefit of thrombolytic therapy for suspected acute myocardial infarction in older patients. To investigate this issue, we constructed a decision-analytic model for patients 75 years of age or older who present with ST-segment elevation within six hours of the onset of symptoms suggesting acute myocardial infarction. Methods. The variables incorporated in this model were the probability that the patient has an acute myocardial infarction, the probability of in-hospital death among patients with acute myocardial infarction who do not receive thrombolytic therapy, the probability of a fatal or incapacitating complication resulting from thrombolytic therapy, and the expected relative reduction in the risk of death associated with thrombolytic therapy in patients with acute myocardial infarction. Our analyses were based primarily on the use of streptokinase as the thrombolytic agent. Results. Given our base-line assumptions, the probability of dying in the hospital was 21.4 percent if thrombolytic therapy was given and 24.4 percent if it was not given. In one-way sensitivity analyses, thrombolytic therapy decreased the risk of dying if the probability that the patient had an acute myocardial infarction was assumed to be greater than 9 percent, if the probability of dying in the hospital after an acute myocardial infarction without thrombolytic therapy was assumed to be greater than 3 percent, if the rate of fatal or incapacitating complications due to thrombolytic therapy was assumed to be 4 percent or less, or if the relative reduction in the risk of death associated with thrombolytic therapy was assumed to be greater than 1 percent. On the basis of our base-line assumptions, our estimate of the cost effectiveness of streptokinase therapy (the cost per year of life saved) for an 80-year-old patient with suspected acute myocardial infarction was $21,200. For a wide range of assumptions about risks, benefits, and costs, the cost per year of life saved remained less than $55,000. Conclusions. Within the limitations imposed by the assumptions used in our analysis, thrombolytic therapy with streptokinase was found to be a beneficial and cost-effective treatment for suspected acute myocardial infarction in elderly patients in a wide variety of clinical circumstances.	HARVARD UNIV, BETH ISRAEL HOSP,SCH MED,DEPT MED,DIV CARDIOVASC, BOSTON, MA 02215 USA; HARVARD UNIV, BETH ISRAEL HOSP,SCH MED,DEPT MED, DIV CLIN EPIDEMIOL, BOSTON, MA 02215 USA; HARVARD UNIV, BRIGHAM & WOMENS HOSP, SCH MED, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT HLTH POLICY & MANAGEMENT, BOSTON, MA 02115 USA; VANDERBILT UNIV, MED CTR, DIV CARDIOVASC, NASHVILLE, TN 37240 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Vanderbilt University			, Harlan/AAI-2875-2020		AHRQ HHS [1P01HS06341, 1R01HS06452, 1R01HS06258] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		[Anonymous], 1987, Lancet, V2, P871; [Anonymous], 1988, LANCET, V2, P349; [Anonymous], 1986, LANCET, V1, P397; [Anonymous], 1989, NEW ENGL J MED, V320, P618; CHAMBERLAIN DA, 1988, LANCET, V1, P545; CHAMBERLAIN DA, 1990, LANCET, V335, P427; CRAGG DR, 1991, ANN INTERN MED, V115, P173, DOI 10.7326/0003-4819-115-3-173; GOLDBERG RJ, 1989, AM HEART J, V117, P543, DOI 10.1016/0002-8703(89)90727-8; GOLDBERG RJ, 1988, AM HEART J, V115, P761, DOI 10.1016/0002-8703(88)90876-9; GOLDMAN L, 1988, NEW ENGL J MED, V318, P797, DOI 10.1056/NEJM198803313181301; GRINES CL, 1990, J AM COLL CARDIOL, V16, P223, DOI 10.1016/0735-1097(90)90482-5; GUNNAR RM, 1990, J AM COLL CARDIOL, V16, P249, DOI 10.1016/0735-1097(90)90575-A; GURWITZ JH, 1991, JAMA-J AM MED ASSOC, V265, P1720, DOI 10.1001/jama.265.13.1720; Hodgson T A, 1984, Health Care Financ Rev, V5, P1; LITTENBERG B, 1990, ANN INTERN MED, V112, P192, DOI 10.7326/0003-4819-112-3-192; MULLER DWM, 1990, ANN INTERN MED, V113, P949, DOI 10.7326/0003-4819-113-12-949; OCONNOR CM, 1990, J AM COLL CARDIOL, V16, P533, DOI 10.1016/0735-1097(90)90338-P; PASTERNAK RC, 1992, HEART DISEASE TXB CA, P1232; PFEFFER MA, 1991, JAMA-J AM MED ASSOC, V266, P528, DOI 10.1001/jama.266.4.528; ROIG E, 1987, CIRCULATION, V76, P280, DOI 10.1161/01.CIR.76.2.280; SHERRY S, 1991, J AM COLL CARDIOL, V17, P1237, DOI 10.1016/0735-1097(91)90859-8; WEAVER WD, 1991, J AM COLL CARDIOL, V18, P657, DOI 10.1016/0735-1097(91)90784-7; WEINSTEIN MC, 1987, AM J PUBLIC HEALTH, V77, P1417, DOI 10.2105/AJPH.77.11.1417; WILCOX RG, 1988, LANCET, V2, P525; 1988, AGING AM TRENDS PROJ; 1991, CIRCULATION S2, V84, P230	26	160	160	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 2	1992	327	1					7	13		10.1056/NEJM199207023270102	http://dx.doi.org/10.1056/NEJM199207023270102			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JA761	1598117				2023-01-03	WOS:A1992JA76100002
J	STIEGMANN, GV; GOFF, JS; MICHALETZONODY, PA; KORULA, J; LIEBERMAN, D; SAEED, ZA; REVEILLE, RM; SUN, JH; LOWENSTEIN, SR				STIEGMANN, GV; GOFF, JS; MICHALETZONODY, PA; KORULA, J; LIEBERMAN, D; SAEED, ZA; REVEILLE, RM; SUN, JH; LOWENSTEIN, SR			ENDOSCOPIC SCLEROTHERAPY AS COMPARED WITH ENDOSCOPIC LIGATION FOR BLEEDING ESOPHAGEAL-VARICES	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RANDOMIZED CONTROLLED TRIAL; CONTROLLED CLINICAL-TRIAL; DISTAL SPLENORENAL SHUNT; LONG-TERM MANAGEMENT; INJECTION SCLEROTHERAPY; COMPLICATIONS; SURVIVAL	Background. Endoscopic sclerotherapy is an accepted treatment for bleeding esophageal varices, but it is associated with substantial local and systemic complications. Endoscopic ligation, a new form of endoscopic treatment for bleeding varices, may be safer. We compared the effectiveness and safety of the two techniques. Methods. In this randomized trial we compared endoscopic sclerotherapy and endoscopic ligation in 129 patients with cirrhosis who had proved bleeding from esophageal varices. Sixty-five patients were treated with sclerotherapy, and 64 with ligation. Initial treatment for acute bleeding was followed by elective retreatment to eradicate varices. The patients were followed for a mean of 10 months, during which we determined the incidence of complications and recurrences of bleeding, the number of treatments needed to eradicate varices, and survival. Results. Active bleeding at the first treatment was controlled by sclerotherapy in 10 of 13 patients (77 percent) and by ligation in 12 of 14 patients (86 percent). Slightly more sclerotherapy-treated patients had recurrent hemorrhage during the study (48 percent vs. 36 percent for the ligation-treated patients, P = 0.072). The eradication of varices required a lower mean (+/- SD) number of treatments with ligation (4 +/- 2 vs. 5 +/- 2, P = 0.056) than with sclerotherapy. The mortality rate was significantly higher in the sclerotherapy group (45 percent vs. 28 percent, P = 0.041), as was the rate of complications (22 percent vs. 2 percent, P < 0.001). The complications of sclerotherapy were predominantly esophageal strictures, pneumonias, and other infections. Conclusions. Patients with cirrhosis who have bleeding esophageal varices have fewer treatment-related complications and better survival rates when they are treated by esophageal ligation than when they are treated by sclerotherapy.	UNIV COLORADO,DEPT MED,DENVER,CO 80202; UNIV COLORADO,EMERGENCY MED RES CTR,DENVER,CO 80202; DENVER VET AFFAIRS HOSP,DENVER,CO; BAYLOR COLL MED,DEPT MED,HOUSTON,TX 77030; HOUSTON VET AFFAIRS HOSP,HOUSTON,TX; UNIV SO CALIF,SCH MED,LIVER UNIT,DOWNEY,CA 90242; OREGON HLTH SCI UNIV,DEPT MED,PORTLAND,OR 97201; PORTLAND VET AFFAIRS HOSP,PORTLAND,OR	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Denver; US Department of Veterans Affairs; Veterans Health Administration (VHA); Veterans Affairs Medical Center - Denver; Baylor College of Medicine; US Department of Veterans Affairs; Veterans Health Administration (VHA); Michael E DeBakey VA Medical Center; University of Southern California; Oregon Health & Science University	STIEGMANN, GV (corresponding author), UNIV COLORADO,HLTH SCI CTR,DEPT SURG,C-313,4200 E 9TH AVE,DENVER,CO 80262, USA.							EL-NEWIHI H, 1991, Gastroenterology, V100, pA59; HALPERIN M, 1968, J CHRON DIS, V21, P13, DOI 10.1016/0021-9681(68)90082-9; INFANTERIVARD C, 1989, GASTROENTEROLOGY, V96, P1087, DOI 10.1016/0016-5085(89)91627-2; KORULA J, 1985, HEPATOLOGY, V5, P584, DOI 10.1002/hep.1840050410; LARSON AW, 1986, JAMA-J AM MED ASSOC, V255, P497, DOI 10.1001/jama.255.4.497; LORGAT F, 1990, SURG ENDOSC-ULTRAS, V4, P18, DOI 10.1007/BF00591406; LOW DE, 1986, ARCH INTERN MED, V146, P569, DOI 10.1001/archinte.146.3.569; Paquet K J, 1988, Surg Endosc, V2, P18, DOI 10.1007/BF00591393; PUGH RNH, 1973, BRIT J SURG, V60, P646, DOI 10.1002/bjs.1800600817; RIKKERS LF, 1987, ANN SURG, V206, P261, DOI 10.1097/00000658-198709000-00004; SANDY H, 1983, GASTROINTEST ENDOSC, V31, P243; SARLES HE, 1985, AM J GASTROENTEROL, V80, P595; SCHUMAN BM, 1987, AM J GASTROENTEROL, V82, P823; SPINA GP, 1990, ANN SURG, V211, P178, DOI 10.1097/00000658-199002000-00010; STIEGMANN G, 1990, GASTROINTEST ENDOSC, V36, P188; STIEGMANN GV, 1990, AM J SURG, V159, P21; TERBLANCHE J, 1983, LANCET, V2, P1328; VANSTIEGMANN G, 1986, GASTROINTEST ENDOSC, V32, P230, DOI 10.1016/S0016-5107(86)71815-4; WARREN WD, 1986, ANN SURG, V203, P454, DOI 10.1097/00000658-198605000-00002; WESTABY D, 1985, HEPATOLOGY, V5, P827, DOI 10.1002/hep.1840050520; WESTABY D, 1989, HEPATOLOGY, V9, P274, DOI 10.1002/hep.1840090219; WESTABY D, 1992, GASTROINTEST ENDOSC, V2, P121; 1991, NEW ENGL J MED, V324, P1779; 1984, NEW ENGL J MED, V311, P1594	24	519	525	0	7	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 4	1992	326	23					1527	1532		10.1056/NEJM199206043262304	http://dx.doi.org/10.1056/NEJM199206043262304			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HW972	1579136				2023-01-03	WOS:A1992HW97200004
J	JARMAN, B; HIRSCH, S; WHITE, P; DRISCOLL, R				JARMAN, B; HIRSCH, S; WHITE, P; DRISCOLL, R			PREDICTING PSYCHIATRIC ADMISSION RATES	BRITISH MEDICAL JOURNAL			English	Article							UNDERPRIVILEGED AREAS; INPATIENT CARE; SCHIZOPHRENIA	Objective - To determine the numbers of actual and expected psychiatric admissions for the residents of the district health authorities of England and to develop a model to indicate which social, health status, and service provision factors best explain the variation of the actual from the expected psychiatric admissions; to use this model to predict psychiatric admissions for district health authorities as an aid to resource allocation. Design - The actual psychiatric admissions for district health authority residents were extracted from data of the 1986 Mental Health Enquiry. Expected admissions were calculated using the age, sex, and marital status structure of each district health authority and the national psychiatric admission rates related to age, sex, and marital status. Standardised psychiatric admission ratios were calculated as the ratios of the numbers of actual to expected psychiatric admissions. A wide range of social, health status, and service provision data were used as the explanatory variables in regression analyses to determine which combination of factors best explained the variation between districts of standardised psychiatric admission ratios. Setting - The 168652 psychiatric admissions recorded for the 1986 Mental Health Enquiry, after exclusion of mental handicap and psychogeriatric admissions. Results - The actual number of psychiatric admissions varied from 79% above to 54% below the expected number of admissions from age, sex, and marital status for the districts of England. The most powerful variables to explain this variation were the rate of notification of drug misusers, standardised mortality ratios, and levels of illegitimacy in each district. A complex. model was developed which could be used to predict district psychiatric admissions as an aid to resource allocation. A simpler model was also developed (which was less powerful than the more complex model) based on the under-privileged area score. One advantage of this model was that it could be used at the level of electoral wards as well as district health authorities.	CHARING CROSS & WESTMINSTER MED SCH,DEPT PSYCHIAT,LONDON W6 8RP,ENGLAND; ST MARYS HOSP,SCH MED,DEPT GEN PRACTICE,LONDON NW8 8EG,ENGLAND	Imperial College London; Imperial College London			White, Patrick/AAN-7799-2020	White, Patrick/0000-0002-2047-8787				BUGLASS D, 1980, REGISTER SOCIAL MED; BURKE AW, 1976, BRIT J PSYCHIAT, V128, P534, DOI 10.1192/bjp.128.6.534; CHORNICROFT G, 1991, BRIT J PSYCHIAT, V158, P475; COOPER JE, 1987, BRIT J PSYCHIAT, V151, P619, DOI 10.1192/bjp.151.5.619; Durkheim E., 1952, SUICIDE; Faris Robert E.L, 1939, MENTAL DISORDERS URB; Goldberg D., 1983, INT J REHABIL RES, V6, P127, DOI [10.1097/00004356-198303000-00021, DOI 10.1097/00004356-198303000-00021]; GOODMAN AB, 1983, AM J PSYCHIAT, V140, P166; JARMAN B, 1984, BRIT MED J, V289, P1587, DOI 10.1136/bmj.289.6458.1587; JARMAN B, 1983, BRIT MED J, V286, P1705, DOI 10.1136/bmj.286.6379.1705; JARMAN B, 1985, MED ANN, P224; MILLER GH, 1986, CAN J PSYCHIAT, V31, P424, DOI 10.1177/070674378603100508; ODEGAARD O, 1932, ACTA PSYCHIATRICA S, V4; PLATT S, 1985, PSYCHOL MED, V15, P113, DOI 10.1017/S0033291700020973; RICHMAN A, 1984, PSYCHOL MED, V14, P175, DOI 10.1017/S0033291700003184; SAINSBURY P, 1955, SUICIDE; SHEPHERD M, 1957, MAUDSLEY MONOGRAPH, V3; Townsend P., 1986, INEQUALITIES HLTH NO; 1983, INFORMATION NOTE DEP, V2; 1990, HLTH PERSONAL SOCIAL; 1976, SHARING RESOURCES HL; 1986, INPATIENT STATISTICS; 1988, PSYCHIATRIC BEDS RES; 1988, REV RESOURCE ALLOCAT	24	88	88	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 2	1992	304	6835					1146	1151		10.1136/bmj.304.6835.1146	http://dx.doi.org/10.1136/bmj.304.6835.1146			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HT232	1392792	Green Published, Bronze			2023-01-03	WOS:A1992HT23200020
J	OBRIEN, T; KELLY, M; SAUNDERS, C				OBRIEN, T; KELLY, M; SAUNDERS, C			MOTOR-NEURON DISEASE - A HOSPICE PERSPECTIVE	BRITISH MEDICAL JOURNAL			English	Article								Objective - To describe and evaluate the management of patients with motor neurone disease from the perspective of a hospice. Design - Retrospective analysis of hospice medical and nursing notes. Setting - Established 62 bed teaching and research hospice. Subjects - 124 patients with motor neurone disease cared for by the hospice between january 1980 and November 1990. Main outcome measures - Patient profile; functional status; symptom control and use of opioids; insight; mode and management of death. Results - 124 patients (67 women, 57 men) had a mean age 63.9 years. The median length of admission was 61.5 days (range 1 to 2147). 84 patients (68%) were aware of their diagnosis and its implications when first seen by a hospice doctor. Functionally, the patients were very dependent. Symptoms such as pain, dyspnoea, and insomnia were major problems that responded well to opioids. Many patients were noted to deteriorate "suddenly," and in 58% of cases death occurred within 24 hours of this deterioration. When dying, 106 patients (94%) were peaceful and settled. 101 patients (89%) received opioids during this dying period. No patient choked to death. Conclusions - Although motor neurone disease is an uncommon disorder, many of its symptoms occur commonly in medical practice and must be actively treated. Opioids are both safe and effective for such treatment. The term choking is both inaccurate and inappropriate in describing the cause of death in motor neurone disease and its use should be abandoned.	ST CHRISTOPHERS HOSPICE,LONDON SE26 6DZ,ENGLAND									COCHRANE GM, 1987, MANAGEMENT MOTOR NEU; GAWEL MJ, 1989, CLIN REHABILITATION, V3, P309; Hillel A D, 1987, Adv Exp Med Biol, V209, P201; HOWARD RS, 1989, BRAIN, V112, P1155, DOI 10.1093/brain/112.5.1155; KONDO K, 1984, RES PROGR MOTOR NEUR, P20; Mulder D W, 1987, Adv Exp Med Biol, V209, P325; MULDER DW, 1976, MAYO CLIN PROC, V51, P537; NEWRICK PG, 1984, BRIT MED J, V289, P539, DOI 10.1136/bmj.289.6444.539; NEWRICK PG, 1985, J NEUROL NEUROSUR PS, V48, P838, DOI 10.1136/jnnp.48.8.838; Norris F H, 1989, Rinsho Shinkeigaku, V29, P1485; NORRIS FH, 1985, BRIT MED J, V291, P259, DOI 10.1136/bmj.291.6490.259; OLIVER D, 1989, MOTOR NEURONE DISEAS; Rose F C, 1987, Adv Exp Med Biol, V209, P167; ROSIN A J, 1976, Age and Ageing, V5, P37, DOI 10.1093/ageing/5.1.37; ROWLAND LP, 1980, DIAGNOSIS TREATMENT, P7; Saunders C., 1981, HOSPICE LIVING IDEA, P126; Schiffer D, 1987, Adv Exp Med Biol, V209, P255; SMITH RA, 1980, DIAGNOSIS TREATMENT, P241; 1989, CHURCHILLS MED DICT; 1986, CANCER PAIN RELIEF	20	101	102	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 22	1992	304	6825					471	473		10.1136/bmj.304.6825.471	http://dx.doi.org/10.1136/bmj.304.6825.471			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HF555	1547416	Green Published, Bronze			2023-01-03	WOS:A1992HF55500019
J	SUTTER, RW; COCHI, SL				SUTTER, RW; COCHI, SL			PERTUSSIS HOSPITALIZATIONS AND MORTALITY IN THE UNITED-STATES, 1985-1988 - EVALUATION OF THE COMPLETENESS OF NATIONAL REPORTING	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							WHOOPING-COUGH; SURVEILLANCE; TRANSMISSION; EPIDEMIC	Objective. - To determine the magnitude of hospitalizations for pertussis and pertussis mortality and to estimate the total burden of clinically significant pertussis in the United States. Design. - Capture-recapture methods for estimating population size from independent surveillance systems were used to analyze morbidity and mortality data from case report forms received at the Centers for Disease Control (CDC) from the states, and compared these data with pertussis hospitalizations compiled from a database of US hospitals participating in the Commission on Professional and Hospital Activities-Professional Activities Survey (CPHA-PAS) and death certificate reports compiled by the National Center for Health Statistics (NCHS). Population Studied. - All pertussis hospitalizations and pertussis-related deaths in the United States, 1985 through 1988. Results. - We estimated that 13 557 pertussis hospitalizations (95% confidence interval [CI], 12953 to 14162) and 98 pertussis deaths had occurred during the 4-year study period (an average of more than 3300 hospitalizations and 25 deaths per year). The completeness of reporting hospitalizations to the CDC was 32% and to the CPHA-PAS, 23%, while the completeness of reporting pertussis deaths to the CDC was 33% and to NCHS, 23%. Patients who were hospitalized with per-tussis and reported to CDC were at a higher risk for developing pneumonia (31.0% vs 20.0%, relative risk [RR], 1.6; 95% CI, 1.4 to 1.7), seizures (3.7% vs 2.1 %; RR, 1.9; 95% CI, 1.4 to 2.5) and encephalitis (1.2% vs 0.2%; RR, 5.3; 95% CI, 2.4 to 11.6) compared with patients recorded in the CPHA-PAS system. Conclusions. - Our study suggests that there is substantial underreporting of pertussis, that severe complications of pertussis (including hospitalizations) are reported preferentially to the CDC, and that the national health impact of pertussis based on these indicators is considerably higher than previously published reports have suggested.			SUTTER, RW (corresponding author), CTR DIS CONTROL,NATL CTR PREVENT SERV,DIV IMMUNIZAT,INFORMAT SERV,MAILSTOP E07,ATLANTA,GA 30333, USA.							BIELLIK RJ, 1988, J INFECT DIS, V157, P1134, DOI 10.1093/infdis/157.6.1134; BIELLIK RJ, 1989, 29TH INT C ANT AG CH, P145; BOWIE C, 1990, LANCET, V335, P397, DOI 10.1016/0140-6736(90)90220-Y; BROOME CV, 1981, J INFECT DIS, V144, P187, DOI 10.1093/infdis/144.2.187; Chapman DG., 1951, U CALIFORNIA PUBLICA, V1, P131, DOI DOI 10.1371/journal.pone.0112174; CHERRY JD, 1990, JAMA-J AM MED ASSOC, V263, P1679; COCHI SL, 1989, AM J EPIDEMIOL, V129, P349, DOI 10.1093/oxfordjournals.aje.a115138; Cormack R. M., 1969, Oceanogr. mar. Biol., V6, P455; EDDINS DL, 1985, 20TH IMM C P DALL, P51; GRIFFITH AH, 1989, VACCINE, V7, P199, DOI 10.1016/0264-410X(89)90229-6; HALPERIN SA, 1989, J PEDIATR-US, V115, P686, DOI 10.1016/S0022-3476(89)80643-2; HICKS T, 1987, PERTUSSIS HAWAII COM; JENKINSON D, 1983, BRIT MED J, V287, P185, DOI 10.1136/bmj.287.6386.185; LONG SS, 1990, J INFECT DIS, V161, P480, DOI 10.1093/infdis/161.3.480; MILLER CL, 1976, BRIT MED J, P117; MORTIMER EA, 1990, J INFECT DIS, V161, P473, DOI 10.1093/infdis/161.3.473; NKOWANE BM, 1986, AM J DIS CHILD, V140, P433, DOI 10.1001/archpedi.1986.02140190043021; ONORATO IM, 1987, PEDIATR INFECT DIS J, V6, P145, DOI 10.1097/00006454-198702000-00002; POLLOCK TM, 1984, ARCH DIS CHILD, V59, P162, DOI 10.1136/adc.59.2.162; SACKS JJ, 1985, AM J PUBLIC HEALTH, V75, P1420, DOI 10.2105/AJPH.75.12.1420; SNEDEOR GW, 1989, STATISTICAL METHODS; SUTTER RW, 1990, AM J EPIDEMIOL, V131, P132, DOI 10.1093/oxfordjournals.aje.a115466; WASSILAK S, 1983, 18TH P IMM C ATL GA, P37; 1987, PEDIATRIC LENGTH STA; 1988, PEDIATRIC LENGTH STA; 1985, MMWR, V34, P399; 1991, REPORT COMMITTEE INF, P358; 1991, MMWR, V40, P1; 1989, STATE IMMUNIZATION R; 1987, VITAL STATISTICS US, V2; 1989, PEDIATRIC LENGTH STA; 1977, INT CLASSIFICATION D; 1985, MMWR, V34, P390; 1983, MMWR, V32, P297; 1987, VERSION 6; 1990, MMWR, V38, P51; 1988, CATALOGUE PUBLIC USE; 1953, REPORTED INCIDENCE S; 1986, PEDIATRIC LENGTH STA	40	139	141	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 15	1992	267	3					386	391		10.1001/jama.267.3.386	http://dx.doi.org/10.1001/jama.267.3.386			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GY437	1309387				2023-01-03	WOS:A1992GY43700036
J	BREO, DL				BREO, DL			MD-AIDED SUICIDE VOTED DOWN - BOTH SIDES SAY DEBATE TO CONTINUE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																		HUMPHRY, FINAL EXIT; JEANS WAY	2	3	3	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 27	1991	266	20					2895	&		10.1001/jama.266.20.2895	http://dx.doi.org/10.1001/jama.266.20.2895			0	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GQ722	1942460				2023-01-03	WOS:A1991GQ72200041
J	DELGUSTE, P; AUBERTTULKENS, G; RODENSTEIN, DO				DELGUSTE, P; AUBERTTULKENS, G; RODENSTEIN, DO			UPPER AIRWAY-OBSTRUCTION DURING NASAL INTERMITTENT POSITIVE-PRESSURE HYPERVENTILATION IN SLEEP	LANCET			English	Note							VENTILATION; NIGHT	Episodes of apnoea for up to 1 min were observed in association with hypocapnia caused by passive nasal intermittent positive-pressure mechanical hyperventilation in 3 of 4 patients during sleep. Apnoea seemed to be caused by complete upper airways obstruction; we suggest that this finding was caused by active glottic closure. Avoidance of excessive hypocapnia during positive-pressure ventilation might help to avoid central-nervous-system mediated apnoeic episodes.	CATHOLIC UNIV LOUVAIN,CLIN ST LUC,SPEECH PATHOL & AUDIOL UNIT,B-1200 BRUSSELS,BELGIUM; CATHOLIC UNIV LOUVAIN,CLIN ST LUC,REHABIL UNIT,B-1200 BRUSSELS,BELGIUM; CATHOLIC UNIV LOUVAIN,CLIN ST LUC,ELECTROPHYSIOL UNIT,B-1200 BRUSSELS,BELGIUM	Universite Catholique Louvain; Universite Catholique Louvain; Universite Catholique Louvain								HECKMATT JZ, 1990, LANCET, V335, P579, DOI 10.1016/0140-6736(90)90357-B; HENKE KG, 1988, AM REV RESPIR DIS, V138, P8, DOI 10.1164/ajrccm/138.1.8; MEDURI GU, 1989, CHEST, V95, P865, DOI 10.1378/chest.95.4.865; ONAL E, 1986, J APPL PHYSIOL, V61, P1438, DOI 10.1152/jappl.1986.61.4.1438; REMMERS JE, 1990, J APPL PHYSIOL, V68, P1286, DOI 10.1152/jappl.1990.68.3.1286; RODENSTEIN DO, 1989, EUR RESPIR J, V2, P473; WEIL JV, 1987, AM REV RESPIR DIS, V136, P755, DOI 10.1164/ajrccm/136.3.755	7	35	36	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 23	1991	338	8778					1295	1297		10.1016/0140-6736(91)92593-Q	http://dx.doi.org/10.1016/0140-6736(91)92593-Q			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GR023	1682687				2023-01-03	WOS:A1991GR02300005
J	LAMM, DL; BLUMENSTEIN, BA; CRAWFORD, ED; MONTIE, JE; SCARDINO, P; GROSSMAN, HB; STANISIC, TH; SMITH, JA; SULLIVAN, J; SAROSDY, MF; CRISSMAN, JD; COLTMAN, CA				LAMM, DL; BLUMENSTEIN, BA; CRAWFORD, ED; MONTIE, JE; SCARDINO, P; GROSSMAN, HB; STANISIC, TH; SMITH, JA; SULLIVAN, J; SAROSDY, MF; CRISSMAN, JD; COLTMAN, CA			A RANDOMIZED TRIAL OF INTRAVESICAL DOXORUBICIN AND IMMUNOTHERAPY WITH BACILLE CALMETTE-GUERIN FOR TRANSITIONAL-CELL CARCINOMA OF THE BLADDER	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CANCER; THERAPY; PROPHYLAXIS; THIOTEPA; TUMORS	Background. In carcinoma of the bladder, both intravesical chemotherapy and immunotherapy can induce tumor regression and reduce the rate of recurrence, but the relative merits of these two therapies are unclear. We conducted a multi-institutional study to address this question. Methods. Patients with rapidly recurrent (stage Ta or T1) or in situ transitional-cell carcinoma of the bladder were randomly assigned to receive either doxorubicin administered intravesically or bacille Calmette-Guerin (BCG) administered both intravesically and percutaneously. The 262 eligible patients were followed for a median of 65 months. Complete responses to treatment of carcinoma in situ were confirmed by biopsy and cytologic analysis of the urine. Results. For patients with Ta and T1 tumors without carcinoma in situ, the estimated probability of being disease free at five years was 17 percent after doxorubicin, as compared with 37 percent after immunotherapy with BCG (P = 0.015). The median times to treatment failure (termination of treatment due to persistence, recurrence, or progression of disease) were 10.4 and 22.5 months, respectively. For patients with carcinoma in situ the complete-response probability estimates (i.e., the estimated probability of documented disappearance of disease) were 34 percent for doxorubicin (23 of 67 patients) and 70 percent for BCG (45 of 64 patients) (P < 0.001); the median times to treatment failure were 5.1 and 39 months, respectively. The probability of being disease-free at five years' survival among the patients with carcinoma in situ was 18 percent after treatment with doxorubicin and 45 percent after BCG therapy. Patients treated with BCG had a higher incidence of toxic systemic effects and a larger number of local irritative symptoms than patients treated with doxorubicin, but few of these adverse reactions were severe. Conclusions. As compared with intravesical doxorubicin, immunotherapy with BCG provides improved protection against the recurrence of superficial bladder cancer.	LOUISIANA STATE UNIV,MED CTR,NEW ORLEANS,LA 70112; SW ONCOL GRP,CTR STAT,SEATTLE,WA; UNIV MICHIGAN,ANN ARBOR,MI 48109; VANDERBILT UNIV,MED CTR,NASHVILLE,TN 37240; BAYLOR COLL MED,HOUSTON,TX 77030; UNIV TEXAS,HLTH SCI CTR,SAN ANTONIO,TX 78284; HENRY FORD HOSP,DETROIT,MI 48202; W VIRGINIA UNIV,MED CTR,MORGANTOWN,WV 26506; UNIV COLORADO,DENVER,CO 80202; UNIV ARIZONA,CTR CANC,TUCSON,AZ 85721; WAYNE STATE UNIV,DETROIT,MI 48202	Louisiana State University System; Southwest Oncology Group; University of Michigan System; University of Michigan; Vanderbilt University; Baylor College of Medicine; University of Texas System; University of Texas Health San Antonio; Henry Ford Health System; Henry Ford Hospital; West Virginia University; University of Colorado System; University of Colorado Denver; University of Arizona; Wayne State University	LAMM, DL (corresponding author), SW ONCOL GRP,8216-38,OPERAT OFF,5430 FREDERICKSBURG RD,SUITE 618,SAN ANTONIO,TX 78229, USA.				NCI NIH HHS [CA-42777, CA-37429, CA-04915] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U10CA037429, U10CA004915, U10CA042777] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADOLPHS HD, 1983, J UROLOGY, V129, P29, DOI 10.1016/S0022-5347(17)51902-3; ANDERSON S, 1980, STATISTICAL METHODS; BROSMAN SA, 1982, J UROLOGY, V128, P27, DOI 10.1016/S0022-5347(17)52736-6; CATALONA WJ, 1987, J UROLOGY, V137, P220, DOI 10.1016/S0022-5347(17)43959-0; DERESIEWICZ RL, 1990, J UROLOGY, V144, P1331, DOI 10.1016/S0022-5347(17)39732-X; EDSMYR F, 1978, UROL RES, V6, P263, DOI 10.1007/BF00262632; GARNICK MB, 1984, J UROLOGY, V131, P43, DOI 10.1016/S0022-5347(17)50189-5; HERR HW, 1988, J CLIN ONCOL, V6, P1450, DOI 10.1200/JCO.1988.6.9.1450; HERR HW, 1987, J UROLOGY, V138, P1363, DOI 10.1016/S0022-5347(17)43644-5; JAKSE G, 1981, J UROLOGY, V125, P185, DOI 10.1016/S0022-5347(17)54959-9; KALISH LA, 1987, J CLIN ONCOL, V5, P2004, DOI 10.1200/JCO.1987.5.12.2004; Koss LG, 1975, TUMORS URINARY BLADD; KOWALKOWSKI TS, 1988, CURRENT TREND UROLOG, P89; LAMM DL, 1982, J UROLOGY, V128, P931, DOI 10.1016/S0022-5347(17)53283-8; LAMM DL, 1988, UROLOGY ONCOLOGY DIL, P107; LUTZEYER W, 1982, J UROLOGY, V127, P250, DOI 10.1016/S0022-5347(17)53725-8; MARTINEZPINEIRO JA, 1990, J UROLOGY, V143, P502, DOI 10.1016/S0022-5347(17)40002-4; MORALES A, 1976, J UROLOGY, V116, P180, DOI 10.1016/S0022-5347(17)58737-6; PINSKY CM, 1982, IMMUNOTHERAPY HUMAN, P309; PROUT GR, 1983, J UROLOGY, V130, P677, DOI 10.1016/S0022-5347(17)51400-7; RAWLS WH, 1990, J UROLOGY, V144, P1328, DOI 10.1016/S0022-5347(17)39731-8; REITSMA DJ, 1989, BCG SUPERFICIAL BLAD, V310, P171; SCHELLHAMMER PF, 1986, J UROLOGY, V135, P261, DOI 10.1016/S0022-5347(17)45603-5	23	485	497	3	15	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 24	1991	325	17					1205	1209		10.1056/NEJM199110243251703	http://dx.doi.org/10.1056/NEJM199110243251703			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GL282	1922207				2023-01-03	WOS:A1991GL28200003
J	BARRETTCONNOR, E				BARRETTCONNOR, E			POSTMENOPAUSAL ESTROGEN AND PREVENTION BIAS	ANNALS OF INTERNAL MEDICINE			English	Note						ESTROGEN REPLACEMENT THERAPY; PREVENTIVE HEALTH SERVICES; HEALTH BEHAVIOR; LIPOPROTEINS, HDL CHOLESTEROL; BIAS (EPIDEMIOLOGY)	REPLACEMENT THERAPY; BREAST-CANCER; WOMEN; RISK	A mailed health survey questionnaire was returned by 1008 of 1057 (95%) previously studied older women from Rancho Bernardo, a socioeconomiclaly upper-middle-class California community where replacement estrogen use was known to be common. Women currently using estrogen had significantly healthier behaviors and more preventive services by physicians (recent cholesterol check, rectal examination, papanicolaou smear, and mammogram) than nonusers. These differences may explain some of the benefits and risks currently attributed to hormone replacement therapy.			BARRETTCONNOR, E (corresponding author), UNIV CALIF SAN DIEGO,DEPT COMMUNITY & FAMILY MED,9500 GILMAN DR,LA JOLLA,CA 92093, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL040207] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R37AG007181, R01AG007181] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 40207] Funding Source: Medline; NIA NIH HHS [AGO 7181] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BARRETTCONNOR E, 1991, JAMA-J AM MED ASSOC, V265, P1861, DOI 10.1001/jama.265.14.1861; BARRETTCONNOR E, 1989, JAMA-J AM MED ASSOC, V261, P2095, DOI 10.1001/jama.261.14.2095; BARRETTCONNOR E, 1990, MENOPAUSE, P199; BERGKVIST L, 1989, NEW ENGL J MED, V321, P293, DOI 10.1056/NEJM198908033210505; BERGKVIST L, 1989, AM J EPIDEMIOL, V130, P221, DOI 10.1093/oxfordjournals.aje.a115328; CAULEY JA, 1990, AM J OBSTET GYNECOL, V163, P1438, DOI 10.1016/0002-9378(90)90602-4; ERNSTER VL, 1988, PREV MED, V17, P201, DOI 10.1016/0091-7435(88)90064-3; HORWITZ RI, 1990, LANCET, V336, P542, DOI 10.1016/0140-6736(90)92095-Y; TIKKANEN MJ, 1978, LANCET, V2, P490; 1980, NEW ENGL J MED, V303, P1038	10	347	351	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572	0003-4819			ANN INTERN MED	Ann. Intern. Med.	SEP 15	1991	115	6					455	456		10.7326/0003-4819-115-6-455	http://dx.doi.org/10.7326/0003-4819-115-6-455			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GE810	1872493				2023-01-03	WOS:A1991GE81000007
J	ARRIAGADA, R; RUTQVIST, LE				ARRIAGADA, R; RUTQVIST, LE			ADJUVANT CHEMOTHERAPY IN EARLY BREAST-CANCER AND INCIDENCE OF NEW PRIMARY MALIGNANCIES	LANCET			English	Article							RADIOTHERAPY; LEUKEMIA; TAMOXIFEN; CARCINOMA; RADIATION; THERAPY; TRIAL	Adjuvant chemotherapy is increasingly being given to patients with early breast cancer. Long-term follow-up studies suggest a higher frequency of secondary tumours, especially leukaemias, among women receiving such cytotoxic drugs. We studied the frequency of new primary malignancies in 1113 patients with early breast cancer who had been included in a randomised trial to compare chemotherapy as an adjunct to primary surgery with adjuvant locoregional radiotherapy. The estimated rate of new primary malignancies at ten years was significantly lower (p < 0.0003) in the chemotherapy group (1%) than in the radiotherapy group (6%). The corresponding rate among 1986 patients treated with surgery alone was 5%. Our findings suggest that adjuvant chemotherapy in early breast cancer may protect against the development of new primary tumours in the first ten years of follow-up.	KAROLINSKA HOSP,RADIUMHEMMET,CTR ONCOL,S-10401 STOCKHOLM 60,SWEDEN	Karolinska Institutet; Karolinska University Hospital	ARRIAGADA, R (corresponding author), INST GUSTAVE ROUSSY,RUE CAMILLE DESMOULINS,F-94805 VILLEJUIF,FRANCE.							ALPER JC, 1985, J AM ACAD DERMATOL, V13, P567, DOI 10.1016/S0190-9622(85)70198-3; BOIVIN JF, 1986, AM J EPIDEMIOL, V123, P993, DOI 10.1093/oxfordjournals.aje.a114351; BRAMBILLA E, 1991, J CLIN ONCOL, V9, P50, DOI 10.1200/JCO.1991.9.1.50; Early Breast Cancer Trialists' Collaborative Group, 1990, TREATMENT EARLY BREA, V1; FISHER B, 1985, J CLIN ONCOL, V3, P1640, DOI 10.1200/JCO.1985.3.12.1640; FORNANDER T, 1989, LANCET, V1, P117; GELLER RB, 1989, CANCER, V64, P629, DOI 10.1002/1097-0142(19890801)64:3<629::AID-CNCR2820640311>3.0.CO;2-L; GELMAN R, 1990, J CLIN ONCOL, V8, P548, DOI 10.1200/JCO.1990.8.3.548; HAYBITTLE JL, 1989, BRIT MED J, V298, P1611, DOI 10.1136/bmj.298.6688.1611; HERRING M, AM J CLIN ONCOL-CANC, V9, P269; HONG WK, 1990, NEW ENGL J MED, V323, P795, DOI 10.1056/NEJM199009203231205; HORN PL, 1988, YALE J BIOL MED, V1, P223; KALDOR J, 1990, ACTA ONCOL, V29, P647, DOI 10.3109/02841869009090070; KRAMAR A, 1987, STAT MED, V6, P785, DOI 10.1002/sim.4780060709; LAVEY RS, 1990, CANCER, V66, P874, DOI 10.1002/1097-0142(19900901)66:5<874::AID-CNCR2820660511>3.0.CO;2-6; MATTSON B, 1984, THESIS U STOCKHOLM S, P7; MEYSKENS FL, 1990, NEW ENGL J MED, V323, P825, DOI 10.1056/NEJM199009203231210; ROSNER F, 1978, AM J HEMATOL, V4, P151, DOI 10.1002/ajh.2830040207; RUTQVIST LE, 1987, BREAST CANCER RES TR, V10, P255, DOI 10.1007/BF01805762; RUTQVIST LE, 1989, INT J RADIAT ONCOL, V16, P629, DOI 10.1016/0360-3016(89)90478-1; TUBIANA M, 1988, INNOVATIONS RAD ONCO, P265; VALAGUSSA P, 1987, J CLIN ONCOL, V5, P1138, DOI 10.1200/JCO.1987.5.8.1138	22	32	32	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 31	1991	338	8766					535	538		10.1016/0140-6736(91)91100-9	http://dx.doi.org/10.1016/0140-6736(91)91100-9			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GD002	1678800				2023-01-03	WOS:A1991GD00200004
J	SHEWRING, DJ; WALLACE, D; HEALY, CMJ				SHEWRING, DJ; WALLACE, D; HEALY, CMJ			LESSON OF THE WEEK - SKIN AVULSION DURING MANIPULATION OF FRACTURES	BRITISH MEDICAL JOURNAL			English	Article							COLLES		ADDENBROOKES HOSP,DEPT PLAST & RECONSTRUCT SURG,CAMBRIDGE CB2 2QQ,ENGLAND	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge	SHEWRING, DJ (corresponding author), ADDENBROOKES HOSP,DEPT ORTHOPAED & TRAUMA,CAMBRIDGE CB2 2QQ,ENGLAND.							Benjamin A, 1982, WATSON JONES FRACTUR, P650; CASSEBAUM WH, 1950, JAMA-J AM MED ASSOC, V143, P963, DOI 10.1001/jama.1950.02910460021006; FATAH MF, 1984, BRIT J PLAST SURG, V37, P184, DOI 10.1016/0007-1226(84)90008-0; MCQUEEN M, 1988, J BONE JOINT SURG BR, V70, P649, DOI 10.1302/0301-620X.70B4.3403617; MCQUEEN MM, 1986, J BONE JOINT SURG BR, V68, P232, DOI 10.1302/0301-620X.68B2.3958009; RYAN TJ, 1987, OXFORD TXB MED, P20; SOUTHWOOD W F, 1955, Plast Reconstr Surg (1946), V15, P423; [No title captured]	8	3	3	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 31	1991	303	6801					513	514		10.1136/bmj.303.6801.513	http://dx.doi.org/10.1136/bmj.303.6801.513			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GD804	1912865	Green Published, Bronze			2023-01-03	WOS:A1991GD80400022
J	PEDERSENBJERGAARD, J; DAUGAARD, G; HANSEN, SW; PHILIP, P; LARSEN, SO; RORTH, M				PEDERSENBJERGAARD, J; DAUGAARD, G; HANSEN, SW; PHILIP, P; LARSEN, SO; RORTH, M			INCREASED RISK OF MYELODYSPLASIA AND LEUKEMIA AFTER ETOPOSIDE, CISPLATIN, AND BLEOMYCIN FOR GERM-CELL TUMORS	LANCET			English	Article							ACUTE NONLYMPHOCYTIC LEUKEMIA; THERAPY-RELATED LEUKEMIA; ACUTE MYELOID-LEUKEMIA; DISSEMINATED TESTICULAR CANCER; NON-HODGKINS LYMPHOMA; ALKYLATING-AGENTS; COMBINATION CHEMOTHERAPY; OVARIAN-CARCINOMA; CYTO-TOXICITY; SOLID TUMORS	Among the cytostatic drugs only the alkylating agents have been firmly established as being leukaemogenic. This report describes 4 cases of acute myeloid leukaemia and 1 of myelodysplasia occurring in a cohort of 212 patients with germ-cell tumours treated with etoposide, cisplatin, and bleomycin. The mean cumulative risk of leukaemic complications was 4.7% (SE 2.3) 5.7 years after start of etoposide-containing chemotherapy, and, compared with the risk in the general population, the relative risk of overt leukaemia was 336 (95% Cl 92-861). No leukaemias were detected in a previous cohort of 127 patients with germ-cell tumours treated with cisplatin, bleomycin, and vinblastine. The increased risk of leukaemia was most probably due to etoposide alone or in combination with cisplatin or bleomycin, since other published work has also not revealed an excess of leukaemias among patients with germ-cell tumours treated with only cisplatin, bleomycin, and vinblastine. The risk of leukaemia was dose related since all 5 patients with leukaemic complications were among the 82 who had received a cumulative dose of more than 2000 mg/m2 etoposide, whereas no leukaemias were observed among 130 patients who had received up to 2000 mg/m2 (p = 0.004). 3 of the leukaemic patients had balanced chromosome translocations affecting bands 11q23 and 21q22. These translocations, and perhaps also other balanced aberrations, seem to be characteristic of myelodysplasia and acute leukaemia occurring after therapy with cytostatic agents acting on DNA-topoisomerase II.	STATE SERUM INST,DEPT BIOSTAT,COPENHAGEN,DENMARK; RIGSHOSP,DEPT ONCOL ONK,DK-2100 COPENHAGEN,DENMARK; RIGSHOSP,FINSEN LAB,DK-2100 COPENHAGEN,DENMARK	Statens Serum Institut; Rigshospitalet; University of Copenhagen; Rigshospitalet; University of Copenhagen	PEDERSENBJERGAARD, J (corresponding author), RIGSHOSP,DEPT HAEMATOL L4132,9 BLEGDAMSVEJ,DK-2100 COPENHAGEN,DENMARK.		Daugaard, Gedske/AAD-4009-2019	Daugaard, Gedske/0000-0002-9618-9180				ANDERSSON M, 1990, CANCER, V65, P2460, DOI 10.1002/1097-0142(19900601)65:11<2460::AID-CNCR2820651110>3.0.CO;2-S; BAE YS, 1988, P NATL ACAD SCI USA, V85, P2076, DOI 10.1073/pnas.85.7.2076; BASSETT WB, 1986, J CLIN ONCOL, V4, P614; BLAYNEY DW, 1987, NEW ENGL J MED, V316, P710, DOI 10.1056/NEJM198703193161203; CHAGANTI RSK, 1989, GENE CHROMOSOME CANC, V1, P83, DOI 10.1002/gcc.2870010113; CHAK LY, 1984, J CLIN ONCOL, V2, P385, DOI 10.1200/JCO.1984.2.5.385; CHAMBERS SK, 1989, CANCER, V64, P2459, DOI 10.1002/1097-0142(19891215)64:12<2459::AID-CNCR2820641210>3.0.CO;2-T; CUZICK J, 1987, BRIT J CANCER, V55, P523, DOI 10.1038/bjc.1987.107; EDER JP, 1987, J CLIN INVEST, V79, P1524, DOI 10.1172/JCI112983; EINHORN LH, 1977, ANN INTERN MED, V87, P293, DOI 10.7326/0003-4819-87-3-293; GREENE MH, 1982, NEW ENGL J MED, V307, P1416, DOI 10.1056/NEJM198212023072302; GREENE MH, 1983, CANCER RES, V43, P1891; INGRAM L, 1987, BRIT J CANCER, V55, P463, DOI 10.1038/bjc.1987.91; KANTARJIAN HM, 1986, CANCER, V58, P924, DOI 10.1002/1097-0142(19860815)58:4<924::AID-CNCR2820580420>3.0.CO;2-Y; KANTARJIAN HM, 1986, J CLIN ONCOL, V4, P1748, DOI 10.1200/JCO.1986.4.12.1748; KAUFMANN SH, 1991, CANCER RES, V51, P1129; LEBEAU MM, 1986, J CLIN ONCOL, V4, P325, DOI 10.1200/JCO.1986.4.3.325; LIU LF, 1989, ANNU REV BIOCHEM, V58, P351, DOI 10.1146/annurev.bi.58.070189.002031; NICHOLS CR, 1990, NEW ENGL J MED, V322, P1425, DOI 10.1056/NEJM199005173222004; OZOLS RF, 1988, J CLIN ONCOL, V6, P1031, DOI 10.1200/JCO.1988.6.6.1031; PECKHAM MJ, 1983, BRIT J CANCER, V47, P613, DOI 10.1038/bjc.1983.99; PEDERSENBJERGAARD J, 1991, BLOOD, V78, P1147; PEDERSENBJERGAARD J, 1985, BLOOD, V66, P1393; PEDERSENBJERGAARD J, 1987, LANCET, V2, P83, DOI 10.1016/S0140-6736(87)92744-9; PEDERSENBJERGAARD J, 1985, ANN INTERN MED, V103, P195, DOI 10.7326/0003-4819-103-2-195; PEDERSENBJERGAARD J, 1980, CANCER-AM CANCER SOC, V45, P19, DOI 10.1002/1097-0142(19800101)45:1<19::AID-CNCR2820450106>3.0.CO;2-L; PEDERSENBJERGAARD J, 1990, BLOOD, V76, P1083; POMMIER Y, 1988, CANCER RES, V48, P512; PUI CH, 1989, NEW ENGL J MED, V321, P136, DOI 10.1056/NEJM198907203210302; PUI CH, 1990, LANCET, V336, P417, DOI 10.1016/0140-6736(90)91956-B; RATAIN MJ, 1987, BLOOD, V70, P1412; RUBIN CM, 1990, BLOOD, V76, P2594; TAN KB, 1987, P NATL ACAD SCI USA, V84, P7668, DOI 10.1073/pnas.84.21.7668; TUCKER MA, 1988, NEW ENGL J MED, V318, P76, DOI 10.1056/NEJM198801143180203; VANIMHOFF GW, 1986, CANCER, V57, P984, DOI 10.1002/1097-0142(19860301)57:5<984::AID-CNCR2820570518>3.0.CO;2-H; WILLIAMS SD, 1987, NEW ENGL J MED, V316, P1435, DOI 10.1056/NEJM198706043162302	36	316	318	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 10	1991	338	8763					359	363		10.1016/0140-6736(91)90490-G	http://dx.doi.org/10.1016/0140-6736(91)90490-G			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GA607	1713639				2023-01-03	WOS:A1991GA60700015
J	TACHAKRA, SS; PAWSEY, S; BECKETT, M; POTTS, D; IDOWU, A				TACHAKRA, SS; PAWSEY, S; BECKETT, M; POTTS, D; IDOWU, A			OUTCOME OF PATIENTS WITH CHEST PAIN DISCHARGED FROM AN ACCIDENT AND EMERGENCY DEPARTMENT	BRITISH MEDICAL JOURNAL			English	Article									W MIDDLESEX HOSP,DEPT ACCID & EMERGENCY,ISLEWORTH TW7 6AF,ENGLAND	Imperial College London	TACHAKRA, SS (corresponding author), CENT MIDDLESEX HOSP,DEPT ACCID & EMERGENCY,LONDON NW10 7NS,ENGLAND.							COLQUHOUN MC, 1989, BMJ-BRIT MED J, V299, P433, DOI 10.1136/bmj.299.6696.433; Slosberg B, 1977, JACEP, V6, P445; TACHAKRA SS, 1987, BRIT J ACCIDENT EMER, V2, P8; WILCOX RG, 1981, BRIT MED J, V282, P431, DOI 10.1136/bmj.282.6262.431; 1985, LANCET, V2, P578	5	8	8	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 2	1991	302	6775					504	505		10.1136/bmj.302.6775.504	http://dx.doi.org/10.1136/bmj.302.6775.504			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FB055	2012846	Bronze, Green Published			2023-01-03	WOS:A1991FB05500019
J	ZARCHY, TM; ERSHOFF, D				ZARCHY, TM; ERSHOFF, D			WHICH CLINICAL-VARIABLES PREDICT AN ABNORMAL DOUBLE-CONTRAST BARIUM ENEMA RESULT	ANNALS OF INTERNAL MEDICINE			English	Article							CANCER	Objective: To determine the relations among patient history, symptoms, objective indicators, and abnormal double-contrast barium enema results in outpatients. Patients and Setting: Seven hundred and ninety-four patients receiving care in a large multispecialty medical group. Design: Physicians completed a form before ordering a double-contrast barium enema, listing information about patient history, symptoms, and objective findings, including the results of a complete blood count, stool hemoccult, and sigmoidoscopy. Measurements and Main Results: Outcome measures were colon cancer and any abnormal finding. The results of 18.6% of the barium enemas were abnormal. The most frequent positive findings were of polyps (8.8%) and colon cancer (2.9%). Over 50% of the barium enemas were ordered solely on the basis of symptoms, yet there was no statistical correlation between symptoms and colon cancer or any positive finding. Using logistic regression, four variables were shown to be significant predictors of colon cancer (P < 0.05): abnormal sigmoidoscopy, iron deficiency anemia, positive stool hemoccult results, and relevant history. The respective odds ratios of these variables were 3.76 (95% CI, 2.89 to 4.90); 2.86 (CI, 2.13 to 3.74); 1.87 (CI, 1.46 to 2.39); and 1.91 (CI, 1.44 to 2.52), respectively. In a patient without any of these indicators, the predicted probability of having colon cancer was only 0.7%. In a patient with at least two objective indicators, the probability of having colon cancer was greater than 15%. Conclusions: Symptoms without objective indicators or pertinent risk factors do not correlate with an abnormal double-contrast barium enema result. Objective indicators are useful predictors of an abnormal barium enema result, particularly when looking for colon cancer.	HAWTHORNE COMMUNITY MED GRP, LOS ANGELES, CA USA; SO CALIF PERMANENTE MED GRP, PASADENA, CA USA	Kaiser Permanente; Southern California Permanente Medical Group (SCPMG); Permanente Medical Groups								BARRY MJ, 1987, GASTROENTEROLOGY, V93, P301, DOI 10.1016/0016-5085(87)91019-5; DEVROEDE G, 1989, GASTROINTESTINAL DIS, P331; DROSSMAN DA, 1988, HOSP PRACT, V23, P119; DROSSMAN DA, 1989, ANN INTERN MED, V111, P627, DOI 10.7326/0003-4819-111-8-627; EDDY DM, 1990, ANN INTERN MED, V113, P373, DOI 10.7326/0003-4819-113-5-373; FLEISCHER DE, 1989, JAMA-J AM MED ASSOC, V261, P580, DOI 10.1001/jama.261.4.580; GERSON DE, 1979, RADIOLOGY, V130, P297, DOI 10.1148/130.2.297; GROSSMAN S, 1988, GASTROENTEROLOGY, V94, P395, DOI 10.1016/0016-5085(88)90427-1; HARVEY RF, 1987, LANCET, V1, P963; LODD DD, 1985, CARCINOMA LARGE BOWE, P133; MACEWAN DW, 1978, RADIOLOGY, V126, P39, DOI 10.1148/126.1.39; OTT DJ, 1985, SOUTHERN MED J, V78, P1033, DOI 10.1097/00007611-198509000-00002; TEDESCO FJ, 1978, ANN INTERN MED, V89, P907, DOI 10.7326/0003-4819-89-6-907; ZARCHY TM, 1984, GASTROENTEROLOGY, V86, P1307; 1987, MEDICARE BARIUM ENEM	15	13	13	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 15	1991	114	2					137	141		10.7326/0003-4819-114-2-137	http://dx.doi.org/10.7326/0003-4819-114-2-137			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ER534	1984389				2023-01-03	WOS:A1991ER53400007
J	ROUSE, F				ROUSE, F			THE CRUZAN CASE	LANCET			English	Editorial Material																			0	4	4	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 12	1991	337	8733					105	106		10.1016/0140-6736(91)90757-G	http://dx.doi.org/10.1016/0140-6736(91)90757-G			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ER477	1670690				2023-01-03	WOS:A1991ER47700019
J	MALONE, PS; RANSLEY, PG; KIELY, EM				MALONE, PS; RANSLEY, PG; KIELY, EM			PRELIMINARY-REPORT - THE ANTEGRADE CONTINENCE ENEMA	LANCET			English	Article									HOSP SICK CHILDREN,DEPT UROL,LONDON WC1N 3JH,ENGLAND; HOSP SICK CHILDREN,DEPT PAEDIAT SURG,LONDON WC1N 3JH,ENGLAND	University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust	MALONE, PS (corresponding author), SOUTHAMPTON GEN HOSP,WESSEX REG CTR PAEDIAT SURG,TREMONA RD,SOUTHAMPTON SO9 4XY,HANTS,ENGLAND.							DUDLEY HAF, 1980, BRIT J SURG, V67, P80, DOI 10.1002/bjs.1800670203; HEWITT J, 1973, LANCET, V2, P337; MITROFANOFF P, 1980, CHIR PEDIATR, V21, P297; MUIR EG, 1968, J ROYAL SOC MED, V61, P401; RADCLIFFE AG, 1983, SURG GYNECOL OBSTET, V156, P721; SHANDLING B, 1987, J PEDIATR SURG, V22, P271, DOI 10.1016/S0022-3468(87)80345-7	6	564	582	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 17	1990	336	8725					1217	1218		10.1016/0140-6736(90)92834-5	http://dx.doi.org/10.1016/0140-6736(90)92834-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EJ064	1978072				2023-01-03	WOS:A1990EJ06400005
J	DAVIES, SW; RANJADAYALAN, K; WICKENS, DG; DORMANDY, TL; TIMMIS, AD				DAVIES, SW; RANJADAYALAN, K; WICKENS, DG; DORMANDY, TL; TIMMIS, AD			LIPID-PEROXIDATION ASSOCIATED WITH SUCCESSFUL THROMBOLYSIS	LANCET			English	Article									NEWHAM DIST GEN HOSP, LONDON, ENGLAND; WHITTINGTON HOSP, LONDON N19 5NF, ENGLAND	University of London; University College London	DAVIES, SW (corresponding author), LONDON CHEST HOSP, DEPT CARDIAC, BONNER RD, LONDON E2, ENGLAND.							[Anonymous], 1988, LANCET, V2, P349; [Anonymous], 1986, Lancet, V1, P397; BORER JS, 1980, AM J CARDIOL, V46, P1, DOI 10.1016/0002-9149(80)90598-6; BOROW KM, 1980, AM J MED, V68, P655, DOI 10.1016/0002-9343(80)90251-X; BRAUNWALD E, 1982, CIRCULATION, V66, P1146, DOI 10.1161/01.CIR.66.6.1146; BURRELL CJ, 1989, BRIT HEART J, V61, P4; CAWOOD P, 1984, OXYGEN RADICALS CHEM, P355; CHESEBRO JH, 1987, CIRCULATION, V76, P142, DOI 10.1161/01.CIR.76.1.142; DAVIES SW, 1989, FREE RADICALS DISEAS, P97; DELNIDO PJ, 1987, CIRCULATION, V76, P174; FERREIRA R, 1988, AM HEART J, V115, P307, DOI 10.1016/0002-8703(88)90475-9; FORMAN MB, 1988, CIRCULATION, V78, P202, DOI 10.1161/01.CIR.78.1.202; FUSTER V, 1981, AM J CARDIOL, V47, P525, DOI 10.1016/0002-9149(81)90534-8; GARLICK PB, 1987, CIRC RES, V61, P757, DOI 10.1161/01.RES.61.5.757; GUARNIERI C, 1978, J MOL CELL CARDIOL, V10, P893, DOI 10.1016/0022-2828(78)90336-X; GUARNIERI C, 1980, J MOL CELL CARDIOL, V12, P797, DOI 10.1016/0022-2828(80)90081-4; HEARSE DJ, 1988, J MOL CELL CARDIOL, V20, P213, DOI 10.1016/S0022-2828(88)80054-3; HESS ML, 1981, J MOL CELL CARDIOL, V13, P767, DOI 10.1016/0022-2828(81)90258-3; IVERSEN SA, 1985, ANN CLIN BIOCHEM, V22, P137, DOI 10.1177/000456328502200204; KUSAM Y, 1988, CIRCULATION S2, V78, P2; MATHUR VS, 1975, AM J CARDIOL, V36, P252, DOI 10.1016/0002-9149(75)90534-2; MEERSON F Z, 1981, Byulleten' Eksperimental'noi Biologii i Meditsiny, V92, P281; OLSON HG, 1986, AM HEART J, V111, P1021, DOI 10.1016/0002-8703(86)90001-3; REIMER KA, 1979, LAB INVEST, V40, P633; RITCHIE JL, 1984, CIRCULATION, V70, P867, DOI 10.1161/01.CIR.70.5.867; SCHEIBER TL, 1986, AM J CARDIOL, V58, P47; SCHRODER R, 1986, NEW ENGL J MED, V314, P1465; VANDEWERF F, 1989, LANCET, V1, P1367; WESTLIN W, 1988, CIRCULATION, V77, P30; WHITE HD, 1987, NEW ENGL J MED, V317, P850, DOI 10.1056/NEJM198710013171402; YAGI K, 1982, LIPID PEROXIDES BIOL, P223	31	112	116	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 31	1990	335	8692					741	743						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CW994	1969508				2023-01-03	WOS:A1990CW99400001
J	[Anonymous]				[Anonymous]			EXCHANGE-TRANSFUSION IN FALCIPARUM-MALARIA	LANCET			English	Editorial Material																		BAMBAUER R, 1984, PLASMA THER TRANSFUS, V5, P343; FILES JC, 1984, ANN INTERN MED, V100, P396, DOI 10.7326/0003-4819-100-3-396; MILLER KD, 1989, NEW ENGL J MED, V321, P65, DOI 10.1056/NEJM198907133210201; SADDLER M, 1990, NEW ENGL J MED, V322, P58, DOI 10.1056/NEJM199001043220113; SHWE T, 1988, T ROY SOC TROP MED H, V82, P665, DOI 10.1016/0035-9203(88)90187-3; STURCHLER D, 1989, PARASITOL TODAY, V5, P39, DOI 10.1016/0169-4758(89)90188-9; WARRELL DA, 1982, NEW ENGL J MED, V306, P313, DOI 10.1056/NEJM198202113060601; White N. J., 1986, Clinics in Tropical Medicine and Communicable Diseases, V1, P55; WHITE NJ, 1988, EUR J CLIN PHARMACOL, V34, P1, DOI 10.1007/BF01061409; 1986, T R SOC TROP MED H S, V80, P1; 1979, CHINESE MED J, V92, P811	11	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 10	1990	335	8685					324	325						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CM846	1967774				2023-01-03	WOS:A1990CM84600009
J	BODOR, N; PROKAI, L; WU, WM; FARAG, H; JONALAGADDA, S; KAWAMURA, M; SIMPKINS, J				BODOR, N; PROKAI, L; WU, WM; FARAG, H; JONALAGADDA, S; KAWAMURA, M; SIMPKINS, J			A STRATEGY FOR DELIVERING PEPTIDES INTO THE CENTRAL-NERVOUS-SYSTEM BY SEQUENTIAL METABOLISM	SCIENCE			English	Article							BLOOD-BRAIN-BARRIER; RAT-BRAIN; ENKEPHALIN; AMINOPEPTIDASE	Most peptides do not enter the central nervous system because of their hydrophilic character and the presence of peptidolytic enzymes in the lipoidal blood-brain barrier. To achieve brain delivery of a peptide conjugate, an opioid peptide (enkephalin) was placed in a molecular environment that disguises its peptide nature and provides biolabile, lipophilic functions to penetrate the blood-brain barrier by passive transport. The strategy also incorporates a 1,4-dihydrotrigonellinate targetor that undergoes an enzymatically mediated oxidation to a hydrophilic, membrane-impermeable trigonellinate salt. The polar targetor-peptide conjugate that is trapped behind the lipoidal blood-brain barrier is deposited in the central nervous system. Analgesia was observed with "packaged" enkephalin but not with the unmodified peptide or lipophilic peptide precursors.			BODOR, N (corresponding author), UNIV FLORIDA,J HILLIS MILLER HLTH CTR,COLL PHARM,CTR DRUG DISCOVERY,GAINESVILLE,FL 32610, USA.			Prokai, Laszlo/0000-0002-4559-3458	NIA NIH HHS [1 PO AG10485] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [P01AG010485] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BEGLEY DJ, 1990, J NEUROCHEM, V55, P1222, DOI 10.1111/j.1471-4159.1990.tb03128.x; BODOR N, 1983, SCIENCE, V221, P65, DOI 10.1126/science.6857264; Bodor N., 1983, PHARMACOL THERAPEUT, V19, P337; BRIGHTMAN MW, 1977, EXP EYE RES, V25, P1, DOI 10.1016/S0014-4835(77)80008-0; GIBSON AM, 1989, NEUROPEPTIDES, V13, P259, DOI 10.1016/0143-4179(89)90079-6; GORENSTEIN C, 1980, PROC R SOC SER B-BIO, V210, P123, DOI 10.1098/rspb.1980.0123; HAMBROOK JM, 1976, NATURE, V262, P782, DOI 10.1038/262782a0; HERSH LB, 1987, PEPTIDES, V8, P523, DOI 10.1016/0196-9781(87)90019-2; HOEK JB, 1988, BIOCHEM J, V254, P1; ITO F, 1984, MOL CELL ENDOCRINOL, V36, P165, DOI 10.1016/0303-7207(84)90032-7; McKelvy J.F., 1983, P117; NEUWELT EA, 1984, FED PROC, V43, P214; OLDENDORF WH, 1971, AM J PHYSIOL, V221, P1629, DOI 10.1152/ajplegacy.1971.221.6.1629; PARDRIDGE WM, 1981, ENDOCRINOLOGY, V109, P1138, DOI 10.1210/endo-109-4-1138; PARDRIDGE WM, 1986, ENDOCR REV, V7, P314, DOI 10.1210/edrv-7-3-314; PARDRIDGE WM, 1991, PEPTIDE DRUG DELIVER, P244; POPLACK DG, 1981, NEUROBIOLOGY CEREBRO, P561; TSUZUKI N, 1991, BIOCHEM PHARMACOL, V41, pR5, DOI 10.1016/0006-2952(91)90616-D	18	128	139	1	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 18	1992	257	5077					1698	1700		10.1126/science.1529356	http://dx.doi.org/10.1126/science.1529356			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JN501	1529356				2023-01-03	WOS:A1992JN50100035
J	TOMITA, T; WATANABE, M; YASUDA, T				TOMITA, T; WATANABE, M; YASUDA, T			INFLUENCE OF MEMBRANE FLUIDITY ON THE ASSEMBLY OF STAPHYLOCOCCUS-AUREUS ALPHA-TOXIN, A CHANNEL-FORMING PROTEIN, IN LIPOSOME MEMBRANE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							Y1 TUMOR-CELLS; PLASMA-MEMBRANE; PORE FORMATION; EARLY EVENTS; CHOLESTEROL; DAMAGE; MECHANISM; BILAYERS; BINDING	By use of multilamellar phosphatidylcholine (PC) liposomes of different acyl composition and cholesterol content as model membranes, we studied whether or not membrane fluidity affects the assembly process of Staphylococcus aureus alpha-toxin. Under conditions using fluid and solid membranes, we assayed accessibility (or hemolytic activity) of liposome-bound alpha-toxin to rabbit erythrocytes added, hexamerization of membrane-bound toxin using sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) under nondenaturating conditions, and susceptibility of liposome-bound toxin to trypsin digestion. Our data indicated 1) that alpha-toxin bound to PC membrane as a hemolytically active monomer (or reversibly bound state); 2) that when the membrane was fluidized either by phase transition of PC or by inclusion of cholesterol over 20 mol %, the hemolytically active monomer of the toxin was irreversibly converted to nonhemolytic monomer (and/or unstable oligomer) in a first-order kinetics with a t1/2 of about 1 min, and thereafter hexamerization of the toxin gradually proceeded in the following 60-90 min; 3) that alpha-toxin might have different topology and/or conformation in PC membrane, depending on the presence or absence of cholesterol in the PC membrane; and 4) that coexistence of unsaturated acyl chain-carrying PC and cholesterol was a prerequisite for efficient hexamerization of alpha-toxin in membrane. Thus, increase in membrane fluidity promoted the assembly process of S. aureus alpha-toxin.	OKAYAMA UNIV, SCH MED, OKAYAMA 700, JAPAN	Okayama University	TOMITA, T (corresponding author), UNIV TOKYO, INST MED SCI, 4-6-1 SHIROKANEDAI, MINATO KU, TOKYO 108, JAPAN.							BASHFORD CL, 1986, J BIOL CHEM, V261, P9300; BELMONTE G, 1987, EUR BIOPHYS J BIOPHY, V14, P349; BERNHEIMER AW, 1965, ANN NY ACAD SCI, V128, P112, DOI 10.1111/j.1749-6632.1965.tb11633.x; BHAKDI S, 1984, INFECT IMMUN, V46, P318, DOI 10.1128/IAI.46.2.318-323.1984; BHAKDI S, 1987, REV PHYSIOL BIOCH P, V107, P147, DOI 10.1007/BFb0027646; BHAKDI S, 1988, J EXP MED, V168, P527, DOI 10.1084/jem.168.2.527; BLOMQVIST L, 1986, INFECT IMMUN, V53, P636, DOI 10.1128/IAI.53.3.636-640.1986; Chapman D., 1973, FORM FUNCTION PHOSPH, P117; DAVIS PJ, 1981, BIOCHEMISTRY-US, V20, P3633, DOI 10.1021/bi00515a051; DODGE JT, 1963, ARCH BIOCHEM BIOPHYS, V100, P119, DOI 10.1016/0003-9861(63)90042-0; FAIRBANKS G, 1971, BIOCHEMISTRY-US, V10, P2606, DOI 10.1021/bi00789a030; FORTI S, 1989, EUR J BIOCHEM, V181, P767, DOI 10.1111/j.1432-1033.1989.tb14790.x; FREER JH, 1982, PHARMACOL THERAPEUT, V19, P55, DOI 10.1016/0163-7258(82)90042-0; FREER JH, 1968, J BACTERIOL, V95, P1153, DOI 10.1128/JB.95.3.1153-1168.1968; FUSSLE R, 1981, J CELL BIOL, V91, P83, DOI 10.1083/jcb.91.1.83; GERLACH E, 1963, BIOCHEM Z, V337, P477; HARSHMAN S, 1989, J BIOL CHEM, V264, P14978; IKIGAI H, 1987, J BIOL CHEM, V262, P2156; IKIGAI H, 1987, J BIOL CHEM, V262, P2150; IKIGAI H, 1985, BIOCHEM BIOPH RES CO, V130, P175, DOI 10.1016/0006-291X(85)90398-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCGEE MP, 1983, INFECT IMMUN, V39, P439, DOI 10.1128/IAI.39.1.439-444.1983; MOELLBY, 1983, STAPHYLOCOCCI STAPHY, V2, P619; REICHWEIN J, 1987, INFECT IMMUN, V55, P2940, DOI 10.1128/IAI.55.12.2940-2944.1987; THELESTAM M, 1988, TOXICON, V26, P51, DOI 10.1016/0041-0101(88)90137-7; TOBKES N, 1985, BIOCHEMISTRY-US, V24, P1915, DOI 10.1021/bi00329a017; VANDIJCK PWM, 1976, BIOCHIM BIOPHYS ACTA, V455, P576, DOI 10.1016/0005-2736(76)90326-6; VERMA SP, 1976, BIOCHIM BIOPHYS ACTA, V436, P307, DOI 10.1016/0005-2736(76)90196-6; WATANABE M, 1987, BIOCHIM BIOPHYS ACTA, V898, P257, DOI 10.1016/0005-2736(87)90065-4	30	68	70	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	1992	267	19					13391	13397						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JB746	1618841				2023-01-03	WOS:A1992JB74600048
J	PAGLIARO, L; DAMICO, G; SORENSEN, TIA; LEBREC, D; BURROUGHS, AK; MORABITO, A; TINE, F; POLITI, F; TRAINA, M				PAGLIARO, L; DAMICO, G; SORENSEN, TIA; LEBREC, D; BURROUGHS, AK; MORABITO, A; TINE, F; POLITI, F; TRAINA, M			PREVENTION OF 1ST BLEEDING IN CIRRHOSIS - A METAANALYSIS OF RANDOMIZED TRIALS OF NONSURGICAL TREATMENT	ANNALS OF INTERNAL MEDICINE			English	Review							PROPHYLACTIC SCLEROTHERAPY; ESOPHAGEAL-VARICES; HEMORRHAGE; PROPRANOLOL; NADOLOL; LIVER	Objective: To assess the effectiveness of beta-blockers and endoscopic sclerotherapy in the prevention of first bleeding and reduction of mortality in patients with cirrhosis and esophagogastric varices. Data Sources: Pertinent studies were selected using MEDLINE (1980 to 1990), reference lists from published articles or reviews, and congress abstract lists. Study Selection: Randomized trials comparing beta-blockers or sclerotherapy with a nonactive treatment. Nine randomized clinical trials of beta-blockers and 19 trials of sclerotherapy were reviewed. Seven trials of beta-blockers and 15 of sclerotherapy were published as full papers. Data Extraction: Crude rates of bleeding and death in treated and control groups were extracted from each trial by three independent observers according to the intention-to-treat principle. The quality of published papers was systematically assessed and scored. Data Synthesis: The Mantel-Haenszel-Peto method was used for statistical evaluation of heterogeneity and for pooling of the results. No substantial heterogeneity was found, and the incidence of bleeding in trials of beta-blockers was significantly reduced (pooled odds ratio, 0.54; 95% Cl, 0.39 to 0.74), particularly in patients with large or medium-sized varices or in those with varices and a hepatic vein pressure gradient above 12 mm Hg; however, only a trend toward reduced mortality was obtained. Solerotherapy trials were highly heterogeneous in the direction of the treatment effects on both bleeding (pooled odds ratio, 0.6; Cl, 0.49 to 0.74) and mortality (pooled odds ratio, 0.76; Cl, 0.61 to 0.94). The quality of the trials and the rate of bleeding in the untreated groups were the major sources of heterogeneity. The favorable results of sclerotherapy were obtained in trials with high bleeding rates among controls; several of these trials had a low quality score. Conclusions: Beta-blockers may be recommended for prevention of first bleeding in cirrhotic patients with varices who have a high risk for bleeding. The effectiveness of sclerotherapy remains undetermined. Further trials in high-risk patients may prove useful if improved criteria to predict bleeding risk become available.	OSPED V CERVELLO, DIV MED GEN, MED CLIN R, VIA TRABUCCO 180, I-90146 PALERMO, ITALY; INST BIOMETRIA, MILAN, ITALY; UNIV COPENHAGEN, HVIDOVRE HOSP, DK-2650 HVIDOVRE, DENMARK; HOP BEAUJON, INSERM, U24, F-92118 CLICHY, FRANCE; ROYAL FREE HOSP, SCH MED, LONDON, ENGLAND	University of Copenhagen; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Beaujon - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School			traina, mario/A-1309-2012; Burroughs, Andrew K/C-5645-2009	Burroughs, Andrew K/0000-0001-6527-457X; politi, flavia/0000-0002-6162-8972; Traina, Mario/0000-0001-5041-0858				ANDREANI T, 1990, HEPATOLOGY, V12, P1413, DOI 10.1002/hep.1840120624; BENDSTEN F, 1991, HEPATOLOGY, V14, P1016; BOSCH J, 1984, HEPATOLOGY, V4, P1200, DOI 10.1002/hep.1840040617; BURROUGHS AK, 1992, THERAPY IN LIVER DISEASES, P114; COLLINS R, 1987, STAT MED, V6, P245, DOI 10.1002/sim.4780060308; COLLINS R, 1985, BMJ-BRIT MED J, V290, P17, DOI 10.1136/bmj.290.6461.17; COLMAN J, 1990, HEPATOLOGY, V12, P851; CONN HO, 1991, HEPATOLOGY, V13, P902, DOI 10.1002/hep.1840130517; DAMICO G, 1990, GASTROENTEROLOGY, V99, P1558, DOI 10.1016/0016-5085(90)90458-D; DEFRANCHIS R, 1991, GASTROENTEROLOGY, V101, P1087; FLEIG WE, 1987, METHODOLOGY REV CLIN, P291; FLEIG WE, 1988, HEPATOLOGY S, V7, pS128; GREGORY PB, 1991, NEW ENGL J MED, V324, P1779; HAYES PC, 1985, GUT, V26, P1103; IDEO G, 1988, HEPATOLOGY, V8, P6, DOI 10.1002/hep.1840080103; JAESCHKE R, 1990, AM J MED, V88, P279, DOI 10.1016/0002-9343(90)90154-6; Kobe E, 1987, Dtsch Z Verdau Stoffwechselkr, V47, P151; KOCH H, 1986, ENDOSCOPY, V18, P40, DOI 10.1055/s-2007-1018322; KORULA J, 1991, GASTROENTEROLOGY, V101, P800, DOI 10.1016/0016-5085(91)90542-S; LABBE KA, 1987, ANN INTERN MED, V107, P224, DOI 10.7326/0003-4819-107-2-224; LAUPACIS A, 1988, NEW ENGL J MED, V318, P1728, DOI 10.1056/NEJM198806303182605; LEBREC D, 1982, HEPATOLOGY, V2, P523; LEBREC D, 1988, J HEPATOL, V7, P118, DOI 10.1016/S0168-8278(88)80515-4; NICOLUCCI A, 1989, JAMA-J AM MED ASSOC, V262, P2101, DOI 10.1001/jama.262.15.2101; PAGLIARO L, 1989, GASTROENTEROL INT, V2, P71; PAQUET KJ, 1982, ENDOSCOPY, V14, P4, DOI 10.1055/s-2007-1021560; PASCAL JP, 1987, NEW ENGL J MED, V317, P856, DOI 10.1056/NEJM198710013171403; PASTA L, 1989, J HEPATOL, V9, P75; PIAI G, 1988, HEPATOLOGY, V8, P1495, DOI 10.1002/hep.1840080605; PIAI G, 1991, Gastroenterology, V100, pA784; PLANAS R, 1989, Journal of Hepatology, V9, pS73, DOI 10.1016/0168-8278(89)90322-X; POTZI R, 1989, GUT, V30, P873, DOI 10.1136/gut.30.6.873; POYNARD T, 1991, NEW ENGL J MED, V324, P1532, DOI 10.1056/NEJM199105303242202; RUSSO A, 1989, WORLD J SURG, V13, P149, DOI 10.1007/BF01658391; SAGGIORO A, 1986, DIGEST DIS SCI, V31, pS504; SANTANGELO WC, 1988, NEW ENGL J MED, V318, P814, DOI 10.1056/NEJM198803313181304; SAUERBRUCH T, 1988, NEW ENGL J MED, V319, P8, DOI 10.1056/NEJM198807073190102; STRAUSS E, 1988, HEPATOLOGY, V8, P1395; TERBLANCHE J, 1986, LANCET, V1, P961; TRIGER DR, 1991, HEPATOLOGY, V13, P117, DOI 10.1002/hep.1840130117; VOROBIOFF J, 1987, HEPATOLOGY, V7, P648, DOI 10.1002/hep.1840070406; WITZEL L, 1985, LANCET, V1, P773; 1990, NEW ENGL J MED, V322, P863	43	285	292	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 1	1992	117	1					59	70		10.7326/0003-4819-117-1-59	http://dx.doi.org/10.7326/0003-4819-117-1-59			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JA435	1350716				2023-01-03	WOS:A1992JA43500011
J	HJORTDAHL, P; LAERUM, E				HJORTDAHL, P; LAERUM, E			CONTINUITY OF CARE IN GENERAL-PRACTICE - EFFECT ON PATIENT SATISFACTION	BRITISH MEDICAL JOURNAL			English	Article							MEDICAL-CARE; META-ANALYSIS; DIMENSIONS	Objective-To evaluate the influence of continuity of care on patient satisfaction with consultations. Design-Directed and episodic specific evaluation of patient satisfaction with recent consultation. Setting and subjects-A representative sample of 3918 Norwegian primary care patients were asked to evaluate their consultations by filling in a questionnaire. The response rate was 78%. Main outcome measures-The patient's overall satisfaction with the consultation was rated on a six point scale. Continuity of care was recorded as the duration and intensity of the present patient-doctor relationship and as patients' perception of the present doctor being their personal doctor or not. Results-The multivariate analysis indicated that an overall personal patient-doctor relationship increased the odds of the patient being satisfied with the consultation sevenfold (95% confidence interval 4.9 to 9.9) as compared with consultations where no such relationships existed. The duration of the patient-doctor relationship had a weak but significant association with patient satisfaction, while the intensity of contacts showed no such association. Conclusion-Personal, continuous care is linked with patient satisfaction. If patient satisfaction is accepted as an integral part of quality health care, reinforcing personal care may be one way of increasing this quality.			HJORTDAHL, P (corresponding author), UNIV OSLO,DEPT GEN PRACTICE,N-0264 OSLO,NORWAY.							BANAHAN BF, 1981, J FAM PRACTICE, V12, P767; FITZPATRICK R, 1991, BMJ-BRIT MED J, V302, P1129, DOI 10.1136/bmj.302.6785.1129; FITZPATRICK R, 1991, BRIT MED J, V302, P887, DOI 10.1136/bmj.302.6781.887; FITZPATRICK RM, 1983, SOC SCI MED, V17, P501, DOI 10.1016/0277-9536(83)90057-6; FREEMAN G, 1984, FAM PRACT, V1, P245, DOI 10.1093/fampra/1.4.245; HALL JA, 1988, SOC SCI MED, V27, P637, DOI 10.1016/0277-9536(88)90012-3; HALL JA, 1988, SOC SCI MED, V27, P935, DOI 10.1016/0277-9536(88)90284-5; HARRIS RT, 1978, J APPL BEHAV SCI, V14, P382, DOI 10.1177/002188637801400313; Hirschman A. O., 1970, EXIT VOICE LOYALTY; HJORTDAHL P, 1991, BRIT MED J, V303, P1181, DOI 10.1136/bmj.303.6811.1181; HJORTDAHL P, 1989, FAM PRACT, V6, P292, DOI 10.1093/fampra/6.4.292; Hosmer D., 2000, APPL LOGISTIC REGRES, V2; KEELEY D, 1991, BMJ-BRIT MED J, V302, P1514, DOI 10.1136/bmj.302.6791.1514; Lamberts H., 1987, ICPC INT CLASSIFICAT; MARQUIS MS, 1983, MED CARE, V21, P821, DOI 10.1097/00005650-198308000-00006; McWhinney IR, 1989, TXB FAMILY MED; MURPHY M, 1989, BRIT MED J, V298, P1331, DOI 10.1136/bmj.298.6684.1331; Pascoe G C, 1983, Eval Program Plann, V6, P185, DOI 10.1016/0149-7189(83)90002-2; PENDLETON D, 1984, CONSULTATON APPROACH; ROTER DL, 1987, MED CARE, V25, P437, DOI 10.1097/00005650-198705000-00007; RUTLE O, 1983, 11983 STAT I FOLK RE; WARE JE, 1975, MED CARE, V13, P669, DOI 10.1097/00005650-197508000-00006	22	263	268	0	14	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 16	1992	304	6837					1287	1290		10.1136/bmj.304.6837.1287	http://dx.doi.org/10.1136/bmj.304.6837.1287			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HV086	1606434	Green Published, Bronze			2023-01-03	WOS:A1992HV08600026
J	POUCHOT, J; LOMBRAIL, P; SITBON, P; CALLANQUIN, M; VINCENEUX, P				POUCHOT, J; LOMBRAIL, P; SITBON, P; CALLANQUIN, M; VINCENEUX, P			SEDATIVE AND HYPNOTIC WITHDRAWAL STATES IN INPATIENTS	LANCET			English	Letter									UNIV PARIS 07,HOP BICHAT,DEPT PUBL HLTH,F-75221 PARIS 05,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; UDICE-French Research Universities; Universite Paris Cite	POUCHOT, J (corresponding author), UNIV PARIS 07,HOP LOUIS MOURIER,DEPT INTERNAL MED & PHARM,F-92700 COLOMBES,FRANCE.			LOMBRAIL, Pierre/0000-0002-5436-2475				MOSS, 1991, LANCET, V338, P575	1	1	1	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 19	1991	338	8773					1022	1022		10.1016/0140-6736(91)91886-Y	http://dx.doi.org/10.1016/0140-6736(91)91886-Y			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GK974	1681329				2023-01-03	WOS:A1991GK97400048
J	STEIN, C; COMISEL, K; HAIMERL, E; YASSOURIDIS, A; LEHRBERGER, K; HERZ, A; PETER, K				STEIN, C; COMISEL, K; HAIMERL, E; YASSOURIDIS, A; LEHRBERGER, K; HERZ, A; PETER, K			ANALGESIC EFFECT OF INTRAARTICULAR MORPHINE AFTER ARTHROSCOPIC KNEE SURGERY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MCGILL PAIN QUESTIONNAIRE; OPIOID RECEPTORS; INFLAMMATION; ANTINOCICEPTION; NOCICEPTION	Background. Opioids can produce potent antinociceptive effects by interacting with local opioid receptors in inflamed peripheral tissue. In this study we examined the analgesic effects of the intraarticular, as compared with intravenous, administration of morphine after arthroscopic knee surgery. Methods. In a double-blind, randomized trial, we studied 52 patients who had received one of four injections at the end of surgery. The patients in group 1 (n = 18) received 1 mg of morphine intraarticularly and saline intravenously; those in group 2 (n = 15), saline intraarticularly and 1 mg of morphine intravenously; those in group 3 (n = 10), 0.5 m of morphine intraarticularly and saline intravenously; and those in group 4 (n = 9), 1 mg of morphine and 0.1 mg of naloxone intraarticularly and saline intravenously. The volume of the intraarticular injections was 40 ml, and that of the intravenous injections was 1 ml. After 1, 2, 3, 4, 6, and 24 hours, postoperative pain was assessed with a visual-analogue scale, a numerical-rating scale, and the McGill pain questionnaire. The need for supplemental analgesic agents, the patients' vital signs, and the occurrence of side effects were monitored. Results. All pain scores were lower in group 1 than in group 2 at all times. The differences were significant (P < 0.05) at three, four, and six hours (mean [+/- SD] visual-analogue score at six hours, 9 +/- 13 mm vs. 37 +/- 31 mm). The mean (+/- SD) consumption of supplemental analgesic medication per 24 hours was significantly lower in group 1 (36 +/- 51 mg of diclofenac and 1.2 +/- 3.4 mg of meperidine) than in group 2 (75 +/- 42 mg of diclofenac and 14 +/- 18 mg of meperidine, P < 0.05). The visual-analogue scores in group 3 were slightly but not significantly higher than those in group 1 at all times except 6 and 24 hours after injection. The visual-analogue scores were significantly higher in group 4 than in group 1 one to four hours after injection (P < 0.05), indicating that the analgesic effect of intraarticular morphine was reversible by naloxone. Conclusions. Low doses of intraarticular morphine can significantly reduce pain after knee surgery through an action specific to local opioid receptors that reaches its maximal effect three to six hours after injection.	UNIV MUNICH,KLINIKUM GROSSHADERN,DEPT ORTHOPED,W-8000 MUNICH 70,GERMANY; MAX PLANCK INST PSYCHIAT,DEPT NEUROPHARMACOL,W-8033 MARTINSRIED,GERMANY; MAX PLANCK INST PSYCHIAT,DEPT BIOSTAT,W-8033 MARTINSRIED,GERMANY	University of Munich; Max Planck Society; Max Planck Society	STEIN, C (corresponding author), UNIV MUNICH,KLINIKUM GROSSHADERN,DEPT ANESTHESIOL,W-8000 MUNICH 70,GERMANY.			Stein, Christoph/0000-0001-5240-6836				BARTHO L, 1990, N-S ARCH PHARMACOL, V342, P666, DOI 10.1007/BF00175710; CHAPMAN CR, 1985, PAIN, V22, P1, DOI 10.1016/0304-3959(85)90145-9; de Castro J, 1979, Acta Anaesthesiol Belg, V30, P5; FERREIRA SH, 1979, PROSTAGLANDINS, V18, P191, DOI 10.1016/0090-6980(79)90104-7; JAFFE JH, 1985, GOODMAN GILMANS PHAR, P491; JORIS JL, 1987, ANESTH ANALG, V66, P1277; Kirk Roger, 1982, EXPT DESIGN PROCEDUR, V2nd; MELZACK R, 1975, PAIN, V1, P277, DOI 10.1016/0304-3959(75)90044-5; SCOTT J, 1976, PAIN, V2, P175, DOI 10.1016/0304-3959(76)90113-5; STEIN C, 1990, P NATL ACAD SCI USA, V87, P5935, DOI 10.1073/pnas.87.15.5935; STEIN C, 1990, J NEUROSCI, V10, P1292; STEIN C, 1988, NEUROSCI LETT, V84, P225, DOI 10.1016/0304-3940(88)90412-0; STEIN C, 1989, J PHARMACOL EXP THER, V248, P1269; STEIN C, 1988, EUR J PHARMACOL, V155, P255, DOI 10.1016/0014-2999(88)90511-0; STEIN C, 1988, PAIN, V32, P251, DOI 10.1016/0304-3959(88)90074-7	15	427	449	0	9	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 17	1991	325	16					1123	1126		10.1056/NEJM199110173251602	http://dx.doi.org/10.1056/NEJM199110173251602			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GK538	1653901				2023-01-03	WOS:A1991GK53800002
J	CHAMBERLAIN, G				CHAMBERLAIN, G			ABC OF ANTENATAL CARE - MULTIPLE PREGNANCY	BRITISH MEDICAL JOURNAL			English	Article											CHAMBERLAIN, G (corresponding author), ST GEORGE HOSP,SCH MED,DEPT OBSTET & GYNAECOL,LONDON,ENGLAND.								0	5	5	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 13	1991	303	6794					111	115		10.1136/bmj.303.6794.111	http://dx.doi.org/10.1136/bmj.303.6794.111			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FW586	1859986	Bronze, Green Published			2023-01-03	WOS:A1991FW58600030
J	SHARMA, HM; TRIGUNA, BD; MARTAND, AV; CHOPRA, D				SHARMA, HM; TRIGUNA, BD; MARTAND, AV; CHOPRA, D			MAHARISHI AYUR-VEDA - MODERN INSIGHTS INTO ANCIENT-MEDICINE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							TRANSCENDENTAL MEDITATION; ANTINEOPLASTIC PROPERTIES; CARE		ALL INDIA AYUR VEDA CONGRESS,NEW DELHI,INDIA; AMER ASSOC AYURVED MED,LANCASTER,MA		SHARMA, HM (corresponding author), OHIO STATE UNIV,COLL MED,DEPT PATHOL,ROOM M3685L,320 W 10TH AVE,COLUMBUS,OH 43210, USA.							ALEXANDER CN, 1989, J PERS SOC PSYCHOL, V57, P950, DOI 10.1037/0022-3514.57.6.950; CHOPRA D, 1990, PERFECT HLTH; Chopra Deepak, 1989, QUANTUM HEALING EXPL; Chopra R., 1982, INDIGENOUS DRUGS IND; DILEEPAN KN, 1990, BIOCHEM ARCH, V6, P267; GHISAGRANTNE KL, 1963, SUSHRUTA SAMHITA; Janssen G., 1989, NED TIJDSCHR GENEES, V5, P586; NIWA Y, 1991, INDIAN J CLIN PRACT, V1, P23; ORMEJOHNSON D, 1987, PSYCHOSOM MED, V49, P493, DOI 10.1097/00006842-198709000-00006; ORMEJOHNSON DW, 1988, J CONFLICT RESOLUT, V32, P776, DOI 10.1177/0022002788032004009; PATEL V, 1990, FASEB Journal, V4, pA637; PRASAD KN, 1990, 8TH BIENN M INT SOC; SCHNEIDER RH, 1990, J SOC BEHAV PERS, V5, P1; SHARMA HM, 1990, EUR J PHARMACOL, V183, P193, DOI 10.1016/0014-2999(90)93027-N; SHARMA HM, 1990, PHARMACOL BIOCHEM BE, V35, P767, DOI 10.1016/0091-3057(90)90356-M; SHARMA HM, 1989, CLIN TER CARDIOVAS, V8, P227; SHARMA RK, 1977, CHARAKA SAMHITA; THYAGARAJAN SP, 1988, LANCET, V2, P764; VASISHTA SD, 1983, ESSENCE PULSE DIAGNO; WALLACE RK, 1970, SCIENCE, V167, P1751, DOI 10.1126/science.167.3926.1751; Zaman H, 1974, TRADITIONAL MED, P231	21	29	29	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 22	1991	265	20					2633	&						0	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FL989	1817464				2023-01-03	WOS:A1991FL98900001
J	MEYERS, A; SIEGEL, B; VINCI, R				MEYERS, A; SIEGEL, B; VINCI, R			ECONOMIC BARRIERS TO THE USE OF ORAL REHYDRATION THERAPY - A CASE-REPORT	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							DIARRHEAL	Diarrheal dehydration is a highly prevalent condition among young children and is readily prevented and treated with oral rehydration therapy. We report a death due to hypernatremic dehydration caused by rotavirus diarrhea of a 9-month-old infant whose mother attempted to purchase oral glucose-electrolyte solution in a pharmacy but was unable to afford it. While efforts such as the National ORT Project should help to promote the proper at-home treatment of this condition, we conclude that oral rehydration therapy will not be used optimally by the parents of children living in poverty until the economic barriers to its use are removed.	BOSTON UNIV,SCH MED,BOSTON,MA 02118	Boston University	MEYERS, A (corresponding author), BOSTON CITY HOSP,DEPT PEDIAT,818 HARRISON AVE,BOSTON,MA 02118, USA.		Meyers, MD, MBA, Arlen/ABE-8184-2021	Siegel, Benjamin/0000-0003-3572-2575; Vinci, Robert/0000-0002-2616-1879				AVERY ME, 1990, NEW ENGL J MED, V323, P891, DOI 10.1056/NEJM199009273231307; Bloom B, 1990, Adv Data, P1; FINBERG L, 1990, CONT PEDIATR, V7, P45; HO MS, 1988, J INFECT DIS, V158, P1112, DOI 10.1093/infdis/158.5.1112; HO MS, 1988, JAMA-J AM MED ASSOC, V260, P3281, DOI 10.1001/jama.260.22.3281; LAUDICINA SS, 1988, MEDICAID POOR CHILDR, P53; LITOVITZ TL, 1990, AM J EMERG MED, V8, P394, DOI 10.1016/0735-6757(90)90234-Q; SNYDER JD, 1991, PEDIATRICS, V87, P28; WALDMAN R, 1990, LINKS HLTH DEV REP, V7, P9; WIECHA JL, 1989, AM J PUBLIC HEALTH, V79, P591, DOI 10.2105/AJPH.79.5.591; 1990, 5 MILLION CHILDREN S; 1990, STATE WORLDS CHILDRE, P22; 1990, AJDC, V144, P627	13	16	16	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 3	1991	265	13					1724	1725		10.1001/jama.265.13.1724	http://dx.doi.org/10.1001/jama.265.13.1724			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FD659	2002575				2023-01-03	WOS:A1991FD65900030
J	SACHS, GA; MILES, SH; LEVIN, RA				SACHS, GA; MILES, SH; LEVIN, RA			LIMITING RESUSCITATION - EMERGING POLICY IN THE EMERGENCY MEDICAL SYSTEM	ANNALS OF INTERNAL MEDICINE			English	Article							PROSPECTIVE PAYMENT SYSTEM	Patients, families, and physicians frequently decide that a hospitalized patient will forgo cardiopulmonary resuscitation and document this decision with a do-not-resuscitate (DNR) order. In community settings (home, nursing home, hospice), these orders may conflict with paramedics' standing orders to provide cardiopulmonary resuscitation whenever it is medically indicated. We did a nationwide telephone survey of state offices for coordination of emergency medical services (EMS) to see how the states deal with this potential conflict. We identified eight states that have specific policies enabling EMS personnel to accept DNR orders for patients being transported by ambulance. State officials identified administrative complexities and legal concerns as the primary barriers to enacting prehospitalization DNR policies. We also identified 21 local EMS systems that have developed policies for accepting orders to withhold life-sustaining treatment. Four types of policy models, characterized according to procedure for validating DNR orders and telephone accessing the EMS system, show that regulatory reform can address policy barriers in the absence of enabling legislation.	UNIV CHICAGO, PRITZKER SCH MED, CHICAGO, IL 60637 USA; UNIV MINNESOTA, HENNEPIN CTY MED CTR, MINNEAPOLIS, MN 55415 USA	University of Chicago; Hennepin County Medical Center; University of Minnesota System; University of Minnesota Twin Cities								CRIMMINS TJ, 1988, MINN MED, V71, P708; CRIMMINS TJ, 1990, PREHOSP DISASTER MED, V5, P47; FITZGERALD JF, 1988, NEW ENGL J MED, V319, P1392, DOI 10.1056/NEJM198811243192106; LEWIS MA, 1985, GERONTOLOGIST, V25, P382, DOI 10.1093/geront/25.4.382; MARSHALL L, 1985, J EMERG MED SERV, P24; MILES SH, 1985, JAMA-J AM MED ASSOC, V254, P525, DOI 10.1001/jama.254.4.525; MILES SH, 1987, J AM GERIATR SOC, V35, P74, DOI 10.1111/j.1532-5415.1987.tb01323.x; MILES SH, 1989, PROTOCOLS ELECTIVE U; President's Commission for the Study of Ethical Problems in Medicine and Biomedical and Behavioral Research, 1983, DECIDING FOREGO LIFE; SAGER MA, 1989, NEW ENGL J MED, V320, P433, DOI 10.1056/NEJM198902163200705; WAGNER A, 1984, NEW ENGL J MED, V310, P1129, DOI 10.1056/NEJM198404263101732; 1986, JAMA-J AM MED ASSOC, V255, P2979; 1988, ANN EMERG MED, V17, P1106; 1988, LONG TERM CARE STAND, P27; 1987, ACEP NEWS, V6, P11; 1987, GUIDELINES TERMINATI; 1985, PHYSICIAN HOPELESSLY; 1988, ACCREDITATION MANUAL, P90	18	29	29	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 15	1991	114	2					151	154		10.7326/0003-4819-114-2-151	http://dx.doi.org/10.7326/0003-4819-114-2-151			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ER534	1984394				2023-01-03	WOS:A1991ER53400012
J	MAZUMDER, RN; NATH, SK; ASHRAF, H; PATRA, FC; ALAM, AN				MAZUMDER, RN; NATH, SK; ASHRAF, H; PATRA, FC; ALAM, AN			ORAL REHYDRATION SOLUTION CONTAINING TRISODIUM CITRATE FOR TREATING SEVERE DIARRHEA - CONTROLLED CLINICAL-TRIAL	BRITISH MEDICAL JOURNAL			English	Article							SODIUM-CITRATE; BICARBONATE; THERAPY				MAZUMDER, RN (corresponding author), INT CTR DIARRHOEL DIS RES,CLIN RES CTR,POB 128,DHAKA 1000,BANGLADESH.							HOFFMAN SL, 1985, J INFECT DIS, V152, P1159, DOI 10.1093/infdis/152.6.1159; ISLAM MR, 1984, GUT, V25, P900, DOI 10.1136/gut.25.8.900; NEWSOME PM, 1983, SCAND J GASTROENTERO, V18, P119; PATRA FC, 1989, BMJ-BRIT MED J, V298, P1353, DOI 10.1136/bmj.298.6684.1353; SIEWERT M, 1983, PHARMAZEUTISCHE ZEIT, V128, P1169	5	3	3	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 12	1991	302	6768					88	89		10.1136/bmj.302.6768.88	http://dx.doi.org/10.1136/bmj.302.6768.88			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ER951	1847315	Green Published, Bronze			2023-01-03	WOS:A1991ER95100019
J	THOMPSON, C; STINSON, D; SMITH, A				THOMPSON, C; STINSON, D; SMITH, A			SEASONAL AFFECTIVE-DISORDER AND SEASON-DEPENDENT ABNORMALITIES OF MELATONIN SUPPRESSION BY LIGHT	LANCET			English	Article									ST GEORGE HOSP, LONDON, ENGLAND; CHARING CROSS HOSP, LONDON W6 8RP, ENGLAND; UNIV SOUTHAMPTON, ROYAL S HANTS HOSP, DEPT PSYCHIAT, SOUTHAMPTON SO9 5NH, HANTS, ENGLAND	St Georges University London; Imperial College London; University of Southampton; University Hospital Southampton NHS Foundation Trust; Royal South Hants Hospital								ARENDT J, 1989, SEASONAL AFFECTIVE D, P133; BOJKOWSKI CJ, 1987, HORM METAB RES, V19, P437, DOI 10.1055/s-2007-1011846; CARLSSON A, 1980, ACTA PSYCHIAT SCAND, V61, P75, DOI 10.1111/acps.1980.61.s280.75; CUMMINGS MA, 1989, PSYCHIAT RES, V27, P351, DOI 10.1016/0165-1781(89)90149-2; ECONOMOU SG, 1979, ACTA PSYCHIAT SCAND, V60, P155, DOI 10.1111/j.1600-0447.1979.tb03583.x; EMRICH HM, 1984, PSYCHIAT RES, V13, P355, DOI 10.1016/0165-1781(84)90084-2; FRASER S, 1983, CLIN CHEM, V29, P396; JACOBSEN FM, 1987, ARCH GEN PSYCHIAT, V44, P1086; KROPF D, 1986, NEUROPSYCHOBIOLOGY, V15, P34, DOI 10.1159/000118239; LEWY AJ, 1985, AM J PSYCHIAT, V142, P725; LEWY AJ, 1980, SCIENCE, V210, P1267, DOI 10.1126/science.7434030; LEWY AJ, 1981, LANCET, V1, P383; LEWY AJ, 1983, PSYCHOPHARMACOL BULL, V19, P523; MCINTYRE IM, 1990, LANCET, V335, P488, DOI 10.1016/0140-6736(90)90732-K; MCINTYRE IM, 1989, LIFE SCI, V45, P327, DOI 10.1016/0024-3205(89)90142-2; MCINTYRE IM, 1989, PSYCHONEUROENDOCRINO, V14, P187, DOI 10.1016/0306-4530(89)90016-4; Minors D, 1981, CIRCADIAN RHYTHMS HU, DOI 10.1016/C2013-0-06453-5; MURPHY DGM, 1989, SEASONAL AFFECTIVE D, P233; OROURKE D, 1989, J CLIN PSYCHIAT, V50, P343; OROURKE DA, 1987, PSYCHOPHARMACOL BULL, V23, P358; REME C, IN PRESS ARCH GEN PS; ROSENTHAL NE, 1984, ARCH GEN PSYCHIAT, V41, P72; TERMAN M, 1985, ANN NY ACAD SCI, V453, P147, DOI 10.1111/j.1749-6632.1985.tb11807.x; TERMAN M, 1989, NEUROPSYCHOPHARMACOL, V2, P1, DOI 10.1016/0893-133X(89)90002-X; THOMPSON C, 1985, BRIT J PSYCHIAT, V147, P389, DOI 10.1192/bjp.147.4.389; THOMPSON C, 1988, J AFFECT DISORDERS, V14, P1, DOI 10.1016/0165-0327(88)90065-1; THOMPSON C, 1990, J AFFECT DISORDERS, V18, P129; ULLRICH A, 1985, ACTA PSYCHIAT SCAND, V72, P113, DOI 10.1111/j.1600-0447.1985.tb02581.x; YEREVANIAN BI, 1986, PSYCHIAT RES, V18, P355, DOI 10.1016/0165-1781(86)90020-X; 1987, DIAGNOSTIC STATISTIC	30	91	92	0	9	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 22	1990	336	8717					703	706		10.1016/0140-6736(90)92202-S	http://dx.doi.org/10.1016/0140-6736(90)92202-S			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DZ624	1975891				2023-01-03	WOS:A1990DZ62400002
J	[Anonymous]				[Anonymous]			PHRENIC-NERVE PACING IN QUADRIPLEGIA	LANCET			English	Editorial Material																		BIERING-SORENSEN F, 1990, Ugeskrift for Laeger, V152, P1143; BUSCH K, 1989, 3RD P VIENN INT WORK, P145; CARTER RE, 1989, MANAGEMENT HIGH QUAD, P149; COLEMAN M, 1980, ARCH DIS CHILD, V55, P901, DOI 10.1136/adc.55.11.901; GIRSCH W, 1989, 3RD P VIENN INT WORK, P141; GLENN WWL, 1984, NEW ENGL J MED, V310, P1150, DOI 10.1056/NEJM198405033101804; GLENN WWL, 1972, NEW ENGL J MED, V286, P513, DOI 10.1056/NEJM197203092861004; GLENN WWL, 1986, PACE, V9, P780, DOI 10.1111/j.1540-8159.1986.tb06627.x; GLENN WWL, 1985, NEUROSURGERY, V17, P974, DOI 10.1227/00006123-198512000-00021; HOLLE J, 1974, WIEN KLIN WOCHENSCHR, V86, P23; IBAWI MN, 1981, ANN THORAC SURG, V31, P61; JONES DA, 1980, BIOCH EXERCISE, V14, P377; MILLER JI, 1990, J THORAC CARDIOV SUR, V99, P35; PARKES JD, 1985, SLEEP ITS DISORDERS, P384	14	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 14	1990	336	8707					88	90						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DN793	1975327				2023-01-03	WOS:A1990DN79300007
J	JOHNSON, IS; ROGERS, C; BISWAS, B; AHMEDZAI, S				JOHNSON, IS; ROGERS, C; BISWAS, B; AHMEDZAI, S			WHAT DO HOSPICES DO - A SURVEY OF HOSPICES IN THE UNITED-KINGDOM AND REPUBLIC-OF-IRELAND	BRITISH MEDICAL JOURNAL			English	Article											JOHNSON, IS (corresponding author), LEICESTERSHIRE HOSPICE,LEICESTER LE3 9QE,ENGLAND.		biswas, biswajit/N-8291-2019	biswas, biswajit/0000-0002-3448-3827; Ahmedzai, Sam/0000-0002-2028-8510				ALDERSON MR, 1973, BRIT MED J, V1, P170, DOI 10.1136/bmj.1.5846.170; [Anonymous], 1980, REPORT WORKING GROUP; Hill F, 1984, Health Trends, V16, P9; LUNT B, 1980, TERMINAL CANCER CARE; PORTER KRO, 1973, BRIT MED J, V1, P40, DOI 10.1136/bmj.1.5844.40; SMITH T, 1985, BRIT MED J, V291, P1670, DOI 10.1136/bmj.291.6510.1670; WARD AWM, 1985, HOME CARE SERVICES T; WILKES E, 1965, LANCET, V1, P799; 1988, 1988 DIRECTORY HOSPI	9	20	20	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 24	1990	300	6727					791	793		10.1136/bmj.300.6727.791	http://dx.doi.org/10.1136/bmj.300.6727.791			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CW227	1691031	Bronze, Green Published			2023-01-03	WOS:A1990CW22700025
J	[Anonymous]				[Anonymous]			NONCORONARY THROMBOLYSIS	LANCET			English	Editorial Material														Belch, Jill JF/0000-0001-8280-6689				ABBOTT WM, 1984, SURG GYNECOL OBSTET, V159, P533; AMERY A, 1970, BRIT MED J, V4, P639, DOI 10.1136/bmj.4.5736.639; DELZOPPO GJ, 1988, ANN EMERG MED, V17, P1196, DOI 10.1016/S0196-0644(88)80068-4; DELZOPPO GJ, 1988, STROKE, V19, P307, DOI 10.1161/01.STR.19.3.307; DOTTER CT, 1974, RADIOLOGY, V111, P31, DOI 10.1148/111.1.31; EARNSHAW JJ, 1988, BRIT J SURG, V75, P1196, DOI 10.1002/bjs.1800751217; EARNSHAW JJ, 1987, BRIT J SURG, V74, P504, DOI 10.1002/bjs.1800740629; FIESSINGER JN, 1976, COEUR MED INTERNE, V15, P453; FLETCHER AP, 1976, STROKE, V7, P135, DOI 10.1161/01.STR.7.2.135; GALLUS AS, 1986, CLIN HAEMATOL, V15, P509; GRAOR RA, 1984, RADIOLOGY, V152, P35, DOI 10.1148/radiology.152.1.6729135; GRAOR RA, 1986, CIRCULATION, V74, P15; GRAOR RA, 1989, THROMBOLYSIS CARDIOV, P381; HACKE W, 1988, STROKE, V19, P1216, DOI 10.1161/01.STR.19.10.1216; HANAWAY J, 1976, STROKE, V7, P143, DOI 10.1161/01.STR.7.2.143; HESS H, 1987, RADIOLOGY, V163, P753, DOI 10.1148/radiology.163.3.3575727; KONDSTAAL PJ, 1988, BRIT MED J, V297, P1571; LANG EK, 1985, RADIOLOGY, V154, P75, DOI 10.1148/radiology.154.1.3964956; MCNICOL GP, 1963, BMJ-BRIT MED J, P1508; MOHR JP, 1978, NEUROLOGY, V28, P754, DOI 10.1212/WNL.28.8.754; MORI E, 1988, STROKE, V19, P802, DOI 10.1161/01.STR.19.7.802; RICOTTA JJ, 1987, J VASC SURG, V6, P45, DOI 10.1067/mva.1987.avs0060045; VERSTRAETE M, 1989, DRUGS, V38, P801, DOI 10.2165/00003495-198938050-00006; WILCOX RG, 1988, LANCET, V2, P525; 1987, LANCET, V1, P871; 1988, STROKE, V19, P134	26	4	4	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 24	1990	335	8691					691	693						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CV305	1969062				2023-01-03	WOS:A1990CV30500005
J	WHITEHEAD, MI; FRASER, D; SCHENKEL, L; CROOK, D; STEVENSON, JC				WHITEHEAD, MI; FRASER, D; SCHENKEL, L; CROOK, D; STEVENSON, JC			TRANSDERMAL ADMINISTRATION OF ESTROGEN PROGESTAGEN HORMONE REPLACEMENT THERAPY	LANCET			English	Article									WYNN INST METAB RES LONDON, LONDON, ENGLAND; CIBA GEIGY AG, CH-4002 BASEL, SWITZERLAND	Imperial College London; Novartis	WHITEHEAD, MI (corresponding author), KINGS COLL, SCH MED, ACAD DEPT OBSTET & GYNAECOL, MENOPAUSE CLIN, DENMARK HILL, LONDON SE5 8RX, ENGLAND.			Crook, David/0000-0002-9587-3730				BUSH TL, 1987, CIRCULATION, V75, P1102, DOI 10.1161/01.CIR.75.6.1102; CHETKOWSKI RJ, 1986, NEW ENGL J MED, V314, P1615, DOI 10.1056/NEJM198606193142505; FRASER D, 1989, BRIT J OBSTET GYNAEC, V96, P776, DOI 10.1111/j.1471-0528.1989.tb03315.x; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; GIDEZ LI, 1982, J LIPID RES, V23, P1206; JENSEN J, 1986, BRIT J OBSTET GYNAEC, V93, P613, DOI 10.1111/j.1471-0528.1986.tb08035.x; MOUNT JN, 1988, J CLIN PATHOL, V41, P471, DOI 10.1136/jcp.41.4.471; OTTOSSON UB, 1985, AM J OBSTET GYNECOL, V151, P746, DOI 10.1016/0002-9378(85)90509-5; PAGANINIHILL A, 1989, BRIT J CANCER, V59, P445, DOI 10.1038/bjc.1989.91; PERSSON I, 1989, BRIT MED J, V298, P147, DOI 10.1136/bmj.298.6667.147; PETERSON HB, 1986, MENOPAUSE PHYSL PHAR, P275; ROSS RK, 1986, MENOPAUSE PHYSL PHAR, P209; WARNICK GR, 1978, J LIPID RES, V19, P65; WHITEHEAD MI, 1987, OBSTET GYN CLIN N AM, V14, P299; WHITEHEAD MI, 1981, NEW ENGL J MED, V305, P1599, DOI 10.1056/NEJM198112313052701	15	76	77	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 10	1990	335	8685					310	312		10.1016/0140-6736(90)90605-5	http://dx.doi.org/10.1016/0140-6736(90)90605-5			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CM846	1967769				2023-01-03	WOS:A1990CM84600003
J	EDWARDS, MJ; TOLLE, SW				EDWARDS, MJ; TOLLE, SW			DISCONNECTING A VENTILATOR AT THE REQUEST OF A PATIENT WHO KNOWS HE WILL THEN DIE - THE DOCTORS ANGUISH	ANNALS OF INTERNAL MEDICINE			English	Editorial Material						ETHICS, MEDICAL; VENTILATORS; RIGHT TO DIE; DECISION MAKING; LIFE SUPPORT CARE		An awake ventilator-dependent patient asked to have the ventilator disconnected, knowing he would die. We share the conflicting feelings that arose from our respecting his wishes and our own emotional difficulties in sedating him, stopping the ventilator, and watching him die.	OREGON HLTH SCI UNIV, CTR ETH HLTH CARE, L101, 3181 SW SAM JACKSON PK RD, PORTLAND, OR 97201 USA	Oregon Health & Science University									0	62	63	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 1	1992	117	3					254	256		10.7326/0003-4819-117-3-254	http://dx.doi.org/10.7326/0003-4819-117-3-254			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JF304	1616221				2023-01-03	WOS:A1992JF30400014
J	BRAHAMS, D				BRAHAMS, D			LIFE-SUSTAINING TREATMENT FOR BRAIN-DAMAGED CHILD	LANCET			English	Editorial Material																			0	3	3	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 13	1992	339	8807					1472	1473		10.1016/0140-6736(92)92052-H	http://dx.doi.org/10.1016/0140-6736(92)92052-H			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HY317	1351139				2023-01-03	WOS:A1992HY31700017
J	CLINTON, JJ				CLINTON, JJ			ACUTE PAIN MANAGEMENT CAN BE IMPROVED	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											CLINTON, JJ (corresponding author), AGCY HLTH CARE POLICY & RES,OFF FORUM,SUITE 401,2101 E JEFFERSON ST,ROCKVILLE,MD 20852, USA.							1987, PAIN, V30, P69; 1989, ANESTHESIOL CLIN N A, V7, P1	2	6	6	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 20	1992	267	19					2580	2580		10.1001/jama.267.19.2580	http://dx.doi.org/10.1001/jama.267.19.2580			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HT823	1573734				2023-01-03	WOS:A1992HT82300004
J	GUENGERICH, FP				GUENGERICH, FP			CHARACTERIZATION OF HUMAN CYTOCHROME-P450 ENZYMES	FASEB JOURNAL			English	Article						CYTOCHROME-P450; DRUGS; CARCINOGENS; STEROIDS; HUMAN STUDIES	HUMAN-LIVER CYTOCHROME-P-450; OXIDATIVE DRUG-METABOLISM; HUMAN-FETAL LIVERS; GENETIC-POLYMORPHISM; PARTIAL-PURIFICATION; SPECIFICITY; EXPRESSION; RABBIT; RAT; MICROSOMES	Many biochemical approaches have been applied to the human cytochrome P450 enzymes, and more than 20 different gene products have been characterized with regard to their properties and catalytic specificities. The complement of the various cytochrome P450 enzymes in a given individual varies markedly, and dramatic differences may be seen in drug metabolism, pharmacological response, and susceptibility to toxic effects. An understanding of the nature of the individual cytochrome P450 enzymes and their regulation should be useful in determining the most suitable animal models, ascertaining risk from chemicals, and in avoiding undesirable drug interactions.	VANDERBILT UNIV,MED CTR,SCH MED,CTR MOLEC TOXICOL,NASHVILLE,TN 37232	Vanderbilt University	GUENGERICH, FP (corresponding author), VANDERBILT UNIV,MED CTR,SCH MED,DEPT BIOCHEM,NASHVILLE,TN 37232, USA.				NCI NIH HHS [CA 44353] Funding Source: Medline; NIEHS NIH HHS [ES 00267] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA044353] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000267] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BEAUNE P, 1979, BIOCHEM BIOPH RES CO, V88, P826, DOI 10.1016/0006-291X(79)91482-7; BOLT HM, 1977, ACTA ENDOCRINOL-COP, V85, P189; BRIAN WR, 1989, BIOCHEMISTRY-US, V28, P4993, DOI 10.1021/bi00438a014; COLE PA, 1990, J MED CHEM, V33, P2933, DOI 10.1021/jm00173a001; CONNEY AH, 1982, CANCER RES, V42, P4875; Distlerath L. M., 1987, MAMMALIAN CYTOCHROME, V1, P133; DISTLERATH LM, 1985, J BIOL CHEM, V260, P9057; GONZALEZ FJ, 1989, PHARMACOL REV, V40, P243; GUENGERICH FP, 1986, J BIOL CHEM, V261, P5051; GUENGERICH FP, 1990, LIFE SCI, V47, P1981; GUENGERICH FP, 1989, ANNU REV PHARMACOL, V29, P241; GUENGERICH FP, 1990, CARCINOGENESIS, V11, P2275, DOI 10.1093/carcin/11.12.2275; GUENGERICH FP, 1991, CHEM RES TOXICOL, V4, P391, DOI 10.1021/tx00022a001; GUENGERICH FP, 1991, CHEM RES TOXICOL, V4, P168, DOI 10.1021/tx00020a008; GUENGERICH FP, 1992, IN PRESS ENV HLTH PR; HIGASHI Y, 1991, J BIOCHEM-TOKYO, V109, P638, DOI 10.1093/oxfordjournals.jbchem.a123433; HUANG MT, 1981, J BIOL CHEM, V256, P897; JOHNSON EF, 1988, J BIOL CHEM, V263, P17672; KASCHNITZ RM, 1975, BIOCHEM PHARMACOL, V24, P259; KITADA M, 1987, BIOCHEM PHARMACOL, V36, P453, DOI 10.1016/0006-2952(87)90350-9; KITADA M, 1979, BIOCHEM PHARMACOL, V28, P793; KLEHR H, 1987, BIOL CHEM H-S, V368, P895, DOI 10.1515/bchm3.1987.368.2.895; KRAUT J, 1988, SCIENCE, V242, P533, DOI 10.1126/science.3051385; KUNTZMAN R, 1966, J PHARMACOL EXP THER, V152, P151; LEVIN W, 1987, ARCH BIOCHEM BIOPHYS, V258, P630, DOI 10.1016/0003-9861(87)90386-9; LINDBERG RLP, 1989, NATURE, V339, P632, DOI 10.1038/339632a0; MOREL F, 1990, EUR J BIOCHEM, V191, P437, DOI 10.1111/j.1432-1033.1990.tb19140.x; NEBERT DW, 1991, DNA CELL BIOL, V10, P1, DOI 10.1089/dna.1991.10.1; REITZ RH, 1989, TOXICOL APPL PHARM, V97, P230, DOI 10.1016/0041-008X(89)90328-1; REMMER H, 1957, N-S ARCH PHARMACOL, V237, P296; SCHWAB GE, 1988, MOL PHARMACOL, V33, P493; SHAYIQ RM, 1989, BIOCHEMISTRY-US, V28, P7546, DOI 10.1021/bi00445a008; SHIMADA T, 1989, P NATL ACAD SCI USA, V86, P462, DOI 10.1073/pnas.86.2.462; SLOAN TP, 1978, BRIT MED J, V2, P655, DOI 10.1136/bmj.2.6138.655; SRIVASTAVA PK, 1991, MOL PHARMACOL, V40, P69; WANG P, 1980, ARCH BIOCHEM BIOPHYS, V199, P206, DOI 10.1016/0003-9861(80)90274-X; WATKINS PB, 1985, P NATL ACAD SCI USA, V82, P6310, DOI 10.1073/pnas.82.18.6310; WATKINS PB, 1990, CLIN PHARMACOL THER, V48, P120, DOI 10.1038/clpt.1990.126; WRIGHTON SA, 1990, MOL PHARMACOL, V38, P207; YUN CH, 1991, MOL PHARMACOL, V40, P679	40	229	234	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JAN 6	1992	6	2					745	748		10.1096/fasebj.6.2.1537465	http://dx.doi.org/10.1096/fasebj.6.2.1537465			4	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	GZ440	1537465				2023-01-03	WOS:A1992GZ44000016
J	TAYLOR, JE; HENDERSON, IS; STEWART, WK; BELCH, JJF				TAYLOR, JE; HENDERSON, IS; STEWART, WK; BELCH, JJF			ERYTHROPOIETIN AND SPONTANEOUS PLATELET-AGGREGATION IN HEMODIALYSIS-PATIENTS	LANCET			English	Note							RECOMBINANT-HUMAN-ERYTHROPOIETIN; RENAL-FAILURE; BLOOD	Erythropoietin significantly, reversibly, and reproducibly increased in-vitro whole-blood spontaneous platelet aggregation in 15 patients on haemodialysis. During erythropoietin treatment, spontaneous platelet aggregation was significantly higher in these subjects than in non-uraemic controls; concomitant treatment with 300 mg aspirin daily reversed platelet hyperaggregability. Erythropoietin may promote thrombosis by an effect on platelet function.	UNIV DUNDEE, NINEWELLS HOSP & MED SCH, DEPT MED, DUNDEE DD1 9SY, SCOTLAND	University of Dundee	TAYLOR, JE (corresponding author), UNIV DUNDEE, NINEWELLS HOSP & MED SCH, RENAL UNIT, DUNDEE DD1 9SY, SCOTLAND.		Belch, Jill/AAE-9189-2019	Belch, Jill/0000-0001-8280-6689				DIMINNO G, 1985, AM J MED, V79, P552, DOI 10.1016/0002-9343(85)90051-8; HEIDENREICH S, 1991, KIDNEY INT, V39, P259, DOI 10.1038/ki.1991.31; HOCKEN AG, 1982, NEPHRON, V32, P28, DOI 10.1159/000182727; KINDLER J, 1989, NEPHROL DIAL TRANSPL, V4, P345, DOI 10.1093/oxfordjournals.ndt.a091888; RAINE AEG, 1988, LANCET, V1, P97; SANIABADI AR, 1987, ATHEROSCLEROSIS, V66, P175, DOI 10.1016/0021-9150(87)90061-X; SANIABADI AR, 1989, ATHEROSCLEROSIS, V76, P149, DOI 10.1016/0021-9150(89)90098-1; TRIP MD, 1990, NEW ENGL J MED, V322, P1549, DOI 10.1056/NEJM199005313222201; VANGEET C, 1990, THROMB HAEMOSTASIS, V64, P7; WINEARLS CG, 1986, LANCET, V2, P1175, DOI 10.1016/S0140-6736(86)92192-6	10	60	63	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 30	1991	338	8779					1361	1362		10.1016/0140-6736(91)92239-X	http://dx.doi.org/10.1016/0140-6736(91)92239-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GR773	1682739				2023-01-03	WOS:A1991GR77300006
J	GMUR, J; BURGER, J; SCHANZ, U; FEHR, J; SCHAFFNER, A				GMUR, J; BURGER, J; SCHANZ, U; FEHR, J; SCHAFFNER, A			SAFETY OF STRINGENT PROPHYLACTIC PLATELET TRANSFUSION POLICY FOR PATIENTS WITH ACUTE-LEUKEMIA	LANCET			English	Article							THROMBOCYTOPENIA	Early studies suggested that the risk of haemorrhagic complications become unacceptable when platelet counts drop below 20 x 10(9)/l. Because there are insufficient data to define 20 x 10(9)/l as the threshold for prophylactic platelet transfusions, the practicability of a more restrictive transfusion policy has been assessed prospectively in 102 consecutive patients being treated for acute leukaemia. Besides platelet count, the transfusion protocol took into consideration factors such as presence of bleeding, fever, coagulation disorders, and intention to do therapeutic procedures. 31 major bleeding episodes occurred on 1.9% of the study days when platelet counts were 10 x 10(9)/l or less and on 0-07% of study days when counts were 10-20 x 10(9)/l. The findings indicate that the threshold for prophylactic transfusions can safely be set at 5 x 10(9)/l in patients without fever or bleeding manifestations and at 10 x 10(9)/l in patients with such signs. For patients with coagulation disorders or anatomical lesions, or for those on heparin, the threshold should be at least 20 x 10(9)/l. Such a restrictive platelet transfusion policy, which is applicable not only to thrombocytopenia associated with acute leukaemia but also to other forms of hypoproliferative thrombocytopenia, reduces exposure of such patients to blood donors and results in substantial health-care savings.			GMUR, J (corresponding author), UNIV HOSP ZURICH, DEPT INTERNAL MED, RAMISTR 100, CH-8091 ZURICH, SWITZERLAND.							ADERKA D, 1986, AM J MED SCI, V291, P147, DOI 10.1097/00000441-198603000-00001; BERNSTEIN MJ, 1987, JAMA-J AM MED ASSOC, V257, P1777; BISHOP JF, 1988, BLOOD, V71, P383; DUTCHER JP, 1981, BLOOD, V57, P395; GAYDOS LA, 1962, NEW ENGL J MED, V266, P905, DOI 10.1056/NEJM196205032661802; GMUR J, 1990, PROG CLIN BIOL RES, P45; GMUR J, 1983, BLOOD, V62, P473; MURPHY S, 1982, AM J HEMATOL, V12, P347, DOI 10.1002/ajh.2830120406; SCOTT E, 1985, TRANSFUSION, V25, P469; SILVER SS, 1987, CAN MED ASSOC J, V137, P128; SLICHTER SJ, 1978, CLIN HAEMATOL, V7, P523; SOLOMON J, 1978, LANCET, V1, P267	12	252	255	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 16	1991	338	8777					1223	1226		10.1016/0140-6736(91)92098-M	http://dx.doi.org/10.1016/0140-6736(91)92098-M			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GQ166	1682642				2023-01-03	WOS:A1991GQ16600001
J	MACKENZIE, A; BARNES, G				MACKENZIE, A; BARNES, G			RANDOMIZED CONTROLLED TRIAL COMPARING ORAL AND INTRAVENOUS REHYDRATION THERAPY IN CHILDREN WITH DIARRHEA	BRITISH MEDICAL JOURNAL			English	Article							UNITED-STATES	Objective - To determine the effectiveness of oral rehydration in children with moderate dehydration caused by gastroenteritis, and to compare the complications of oral and intravenous treatment. Design - Randomised controlled trial. Setting - Emergency department and infectious diseases ward in a large urban teaching hospital. Patients - 111 children aged 3-36 months who had been previously healthy, had had diarrhoea for seven days or less, had clinical signs of dehydration, and were not in shock. Six children were withdrawn because the diagnosis was incorrect (four in oral group, two in intravenous group) and one (oral group) was withdrawn at her parents' request. Interventions - Oral rehydration fluid was given by mouth or nasogastric tube, or both to 52 children. The remaining 52 received intravenous rehydration fluids but were allowed to drink. Main outcome measures - Success or failure of rehydration. Number of times child vomited or passed stool after starting treatment. Time taken to rehydrate. Results - Oral treatment failed in two children (failure rate 3.8%, upper 95% confidence limit 11.6%) and intravenous treatment in none. Vomiting was more common in the oral group (p < 0.01): 26 of 50 children (52%) in the oral group and 11 of 50 (22%) in the intravenous group vomited during rehydration. There was no significant difference between the two treatment groups in the number of stools passed during rehydration (p = 0.09). None of the children had serious complications of treatment. Conclusion - Rehydration by mouth or nasogastric tube is a safe and effective treatment for moderately dehydrated children with gastroenteritis.	ROYAL CHILDRENS HOSP,DEPT GASTROENTEROL,PARKVILLE,VIC 3052,AUSTRALIA	Royal Children's Hospital Melbourne								ARMITAGE P, 1987, STATISTICAL METHODS, P119; AVERY ME, 1990, NEW ENGL J MED, V323, P891, DOI 10.1056/NEJM199009273231307; BEHRMAN RE, 1987, NELSON TXB PEDIATRIC, P197; CANDY CE, 1987, J ADV NURS, V12, P95, DOI 10.1111/j.1365-2648.1987.tb01307.x; COLTON T, 1974, STAT MED, P162; ECCKELS R, 1989, SPECIALISED BIBLIO S, V13; LISTERNICK R, 1986, AM J DIS CHILD, V140, P211, DOI 10.1001/archpedi.1986.02140170037024; MACKENZIE A, 1989, LANCET, V2, P605; PIZARRO D, 1991, NEW ENGL J MED, V324, P517, DOI 10.1056/NEJM199102213240802; ROBINSON MJ, 1986, PRACTICAL PAEDIATRIC, P482; SANTOSHAM M, 1982, NEW ENGL J MED, V306, P1070, DOI 10.1056/NEJM198205063061802; Santosham M, 1987, Pediatr Rev, V8, P273, DOI 10.1542/pir.8-9-273; TAMER AM, 1985, J PEDIATR-US, V107, P14, DOI 10.1016/S0022-3476(85)80606-5; VESIKARI T, 1987, ACTA PAEDIATR SCAND, V76, P300, DOI 10.1111/j.1651-2227.1987.tb10464.x; WALKERSMITH JA, 1988, DRUGS S4, V36, P99; 1983, RESIDENTS HDB	16	42	46	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 17	1991	303	6799					393	396		10.1136/bmj.303.6799.393	http://dx.doi.org/10.1136/bmj.303.6799.393			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GB599	1789830	Bronze, Green Published			2023-01-03	WOS:A1991GB59900016
J	GELBER, RD; GOLDHIRSCH, A; CAVALLI, F				GELBER, RD; GOLDHIRSCH, A; CAVALLI, F			QUALITY-OF-LIFE-ADJUSTED EVALUATION OF ADJUVANT THERAPIES FOR OPERABLE BREAST-CANCER	ANNALS OF INTERNAL MEDICINE			English	Article							ENDPOINT; WOMEN	Objective: To evaluate a single cycle of adjuvant chemotherapy compared with longer duration chemotherapy for premenopausal women or chemoendocrine therapy for postmenopausal women with operable breast cancer using a quality-of-life-oriented end point, Q-TWiST (quality-adjusted analysis of TWiST: Time Without Symptoms and Toxicity). Design: Multicenter randomized clinical trial-International Breast Cancer Study Group (IBCSG: formerly Ludwig Group) Trial V. Setting: IBCSG participating centers in Sweden, Switzerland, Australia, Yugoslavia, Spain, New Zealand, Italy, Germany, and South Africa. Patients: Data were available for 1229 eligible patients with node-positive breast cancer who were randomized to receive one of three adjuvant treatments after at least a total mastectomy and axillary clearance. Interventions: Patients received either a single cycle of perioperative chemotherapy consisting of cyclophosphamide, methotrexate, fluorouracil, and leucovorin; or six cycles (6 months) of a conventionally timed chemotherapy consisting of cyclophosphamide, methotrexate, fluorouracil, and prednisone for premenopausal women or this combination plus tamoxifen for postmenopausal women; or both perioperative and conventionally timed chemotherapy for a 7-month course of adjuvant therapy. Results: At 5 years of median follow-up, patients who received the longer duration therapies had an improved 5-year disease-free survival percentage (53% compared with 36%; P < 0.001) and 5-year overall survival percentage (73% compared with 63%; P = 0.001) compared with those who received the single perioperative cycle alone. By 3.5 years, the greater burden of toxic effects associated with the longer duration treatments was balanced by their superior control of disease. Within 5 years of follow-up, even after subtracting time with adjuvant treatment toxicity, patients gained an average of 2.2 months of Q-TWiST if treated with the longer duration therapies compared with the single cycle (P = 0.03). The gain for premenopausal patients was 2.8 months (P = 0.05), whereas the gain for postmenopausal women was 1.5 months (P > 0.2). Conclusions: Six or seven months of adjuvant chemotherapy or chemoendocrine therapy improve both the quantity and quality of life for patients with node-positive breast cancer compared with a single short course of perioperative combination chemotherapy.	INT BREAST CANC STUDY GRP, OPERAT OFF, BERN, SWITZERLAND	International Breast Cancer Study Group	GELBER, RD (corresponding author), HARVARD UNIV, SCH MED, DANA FARBER CANC INST, DIV BIOSTAT & EPIDEMIOL, 44 BINNEY ST, BOSTON, MA 02115 USA.							[Anonymous], 1988, NEW ENGL J MED, V319, P1681; BONADONNA G, 1985, BREAST CANCER RES TR, V5, P95, DOI 10.1007/BF01805984; FISHER B, 1990, J CLIN ONCOL, V8, P1005, DOI 10.1200/JCO.1990.8.6.1005; FISHER B, 1986, J CLIN ONCOL, V4, P929, DOI 10.1200/JCO.1986.4.6.929; GELBER RD, 1986, J CLIN ONCOL, V4, P1772, DOI 10.1200/JCO.1986.4.12.1772; GELBER RD, 1989, BIOMETRICS, V45, P781, DOI 10.2307/2531683; GLASZIOU PP, 1990, STAT MED, V9, P1259, DOI 10.1002/sim.4780091106; GOLDHIRSCH A, 1988, J CLIN ONCOL, V6, P89, DOI 10.1200/JCO.1988.6.1.89; GOLDHIRSCH A, 1989, NEW ENGL J MED, V320, P491; GOLDHIRSCH A, 1989, J CLIN ONCOL, V7, P36, DOI 10.1200/JCO.1989.7.1.36; GOLDHIRSCH A, 1988, NEW ENGL J MED, V319, P677; PRITCHARD KI, 1989, ANN INTERN MED, V111, P1, DOI 10.7326/0003-4819-111-1-1; RIVKIN S, 1990, AM SOC CLIN ONCOLOGY, V9, P24; STEWART HJ, 1987, LANCET, V2, P171; TORRANCE GW, 1987, J CHRON DIS, V40, P593, DOI 10.1016/0021-9681(87)90019-1; Weinstein MC, 1980, CLIN DECISION ANAL; 1990, APR C STAT ADJ THER	17	141	141	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 15	1991	114	8					621	628		10.7326/0003-4819-114-8-621	http://dx.doi.org/10.7326/0003-4819-114-8-621			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FG031	2003707				2023-01-03	WOS:A1991FG03100002
J	DUFFY, EJ; PARKER, ET; MUTUCUMARANA, VP; JOHNSON, AE; LOLLAR, P				DUFFY, EJ; PARKER, ET; MUTUCUMARANA, VP; JOHNSON, AE; LOLLAR, P			BINDING OF FACTOR-VIIIA AND FACTOR-VIII TO FACTOR-IXA ON PHOSPHOLIPID-VESICLES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PORCINE FACTOR-VIII; FACTOR-X ACTIVATION; ACTIVE-SITE; PROTHROMBINASE COMPLEX; VONWILLEBRAND-FACTOR; MONOCLONAL-ANTIBODIES; SUBUNIT STRUCTURE; PROTEIN-C; THROMBIN; THROMBOMODULIN	The activation of factor X by factor IXa (fIXa) in the presence of phosphatidylcholine-phosphatidylserine (PCPS) vesicles is markedly accelerated by thrombin-activated factor VIII (fVIIIa). The interaction between highly purified fVIIIa and fIXa in this complex was studied fluorometrically at 25-degrees-C by using a derivative of D-phenylalanyl-prolyl-arginyl-fIXa which was modified at the active site with fluorescein-5-maleimide (Fl-M-FPR-fIXa). Titration of Fl-M-FPR-fIXa with fVIIIa at fixed PCPS resulted in a large, saturable increase in anisotropy (DELTA-r = 0.09). The titration data were fit to a model assuming a reversible equilibrium between fVIIIa and fIXa, resulting in an apparent dissociation constant of 2 nM and a stoichiometry of 1 mol of fVIIIa/mol of Fl-M-FPR-fIXa. The initial velocity of factor X activation was measured under identical conditions except that active fIXa and factor X were included, which yielded binding parameters similar to those determined fluorometrically. Thus, the fluorescence method accurately reflects complex formation between fVIIIa and fIXa on the phospholipid surface, and the fVIIIa-fIXa interaction is not influenced by the presence of the substrate, factor X. Addition of fVIII to Fl-M-FPR-fIXa and PCPS produced a small, saturable increase in anisotropy (DELTA-r = 0.03), followed by a larger increase (DELTA-r = 0.07) upon addition of thrombin to activate fVIII. Thus, fVIII binds fIXa, but proteolytic modification of fVIII must occur before the complete fVIIIa-dependent structural change in the active site of fIXa, as reflected in the anisotropy change, occurs.	EMORY UNIV,DEPT MED,DIV HEMATOL ONCOL,DRAWER AJ,1003 WOODRUFF MEM BLDG,ATLANTA,GA 30322; UNIV OKLAHOMA,DEPT CHEM & BIOCHEM,NORMAN,OK 73019	Emory University; University of Oklahoma System; University of Oklahoma - Norman			Johnson, Arthur E/G-3457-2012		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL040921, R01HL032934] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL40921, R01 HL 32934] Funding Source: Medline; PHS HHS [R01 46215] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ANDERSSON LO, 1981, BIOCHEM J, V200, P161, DOI 10.1042/bj2000161; ANDERSSON LO, 1986, P NATL ACAD SCI USA, V83, P2979, DOI 10.1073/pnas.83.9.2979; BARENHOLZ Y, 1977, BIOCHEMISTRY-US, V16, P2806, DOI 10.1021/bi00631a035; Bevington P.R., 1969, DATA REDUCTION ERROR; BOCK PE, 1988, BIOCHEMISTRY-US, V27, P6633, DOI 10.1021/bi00417a063; CHASE T, 1970, METHOD ENZYMOL, V19, P20; CHURCH WR, 1984, P NATL ACAD SCI-BIOL, V81, P6934, DOI 10.1073/pnas.81.22.6934; COOPER HA, 1975, J CLIN INVEST, V56, P751, DOI 10.1172/JCI108146; DAVIE EW, 1987, HEMOSTASIS THROMBOSI, P242; DUFFY EJ, 1992, J BIOL CHEM, V267, P7821; EATON D, 1986, BIOCHEMISTRY-US, V25, P505, DOI 10.1021/bi00350a035; FASS DN, 1982, BLOOD, V59, P594; FAY PJ, 1991, J BIOL CHEM, V266, P8957; FAY PJ, 1986, BIOCHIM BIOPHYS ACTA, V871, P268, DOI 10.1016/0167-4838(86)90208-6; FAY PJ, 1987, BIOCHIM BIOPHYS ACTA, V952, P181; FULCHER CA, 1983, BLOOD, V61, P807; GILBERT GE, 1990, J BIOL CHEM, V265, P815; GREEN GDJ, 1979, ANAL BIOCHEM, V93, P223, DOI 10.1016/S0003-2697(79)80070-6; HEMKER HC, 1967, NATURE, V215, P1201, DOI 10.1038/2151201a0; HILLEUBANKS DC, 1989, P NATL ACAD SCI USA, V86, P6508, DOI 10.1073/pnas.86.17.6508; HULTIN MB, 1981, BLOOD, V57, P476; HULTIN MB, 1982, J CLIN INVEST, V69, P950, DOI 10.1172/JCI110534; HUSTEN EJ, 1987, J BIOL CHEM, V262, P12953; KOEDAM JA, 1990, EUR J BIOCHEM, V189, P229, DOI 10.1111/j.1432-1033.1990.tb15481.x; KRISHNASWAMY S, 1990, J BIOL CHEM, V265, P3807; LAJMANOVICH A, 1981, BIOCHIM BIOPHYS ACTA, V678, P12; LAKOWICZ JR, 1983, PRINCIPLES FLUORESCE, P112; LOLLAR P, 1990, J BIOL CHEM, V265, P1688; LOLLAR P, 1985, BIOCHEMISTRY-US, V24, P8056, DOI 10.1021/bi00348a033; LOLLAR P, 1988, J BIOL CHEM, V263, P10451; LOLLAR P, 1984, ARCH BIOCHEM BIOPHYS, V233, P438, DOI 10.1016/0003-9861(84)90465-X; LOLLAR P, 1984, BLOOD, V63, P1303; LOLLAR P, 1989, BIOCHEMISTRY-US, V28, P666, DOI 10.1021/bi00428a038; LOLLAR P, 1988, BLOOD, V71, P137; LOLLAR P, 1991, J BIOL CHEM, V266, P12481; LU RL, 1989, J BIOL CHEM, V264, P12956; MANN KG, 1988, ANNU REV BIOCHEM, V57, P915, DOI 10.1146/annurev.bi.57.070188.004411; MCGEE MP, 1991, J BIOL CHEM, V266, P8079; MUTUCUMARANA VP, 1992, J BIOL CHEM, V267, P17012; NESHEIM ME, 1981, J BIOL CHEM, V256, P6537; NEUENSCHWANDER P, 1988, BLOOD, V72, P1761; RAPAPORT SI, 1963, BLOOD, V21, P221, DOI 10.1182/blood.V21.2.221.221; ROSING J, 1980, J BIOL CHEM, V255, P274; ROSING J, 1985, BLOOD, V65, P619; ROTBLAT F, 1985, BIOCHEMISTRY-US, V24, P4294, DOI 10.1021/bi00337a007; STERN DM, 1985, J BIOL CHEM, V260, P6717; TOOLE JJ, 1984, NATURE, V312, P342, DOI 10.1038/312342a0; VANDIEIJEN G, 1981, J BIOL CHEM, V256, P3433; VANDIEIJEN G, 1985, THROMB HAEMOSTASIS, V53, P396; VEHAR GA, 1984, NATURE, V312, P337, DOI 10.1038/312337a0; VEHAR GA, 1980, BIOCHEMISTRY-US, V19, P401, DOI 10.1021/bi00544a001; YE J, 1991, J BIOL CHEM, V266, P23016; 1976, J BIOL CHEM, V251, P6879	53	88	88	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1992	267	24					17006	17011						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JL053	1512239				2023-01-03	WOS:A1992JL05300045
J	ANGELETTI, LR; AGRIMI, U; CURIA, C; FRENCH, D; MARIANICOSTANTINI, R				ANGELETTI, LR; AGRIMI, U; CURIA, C; FRENCH, D; MARIANICOSTANTINI, R			HEALING RITUALS AND SACRED SERPENTS	LANCET			English	Article							EPIDERMAL GROWTH-FACTOR	Votive tablets found during the excavation of shrines of the Graeco-Roman god of medicine (Asklepios or Aesculapius) associate the healing of superficial lesions with contact with the oral cavity of non-poisonous serpents. We suggest that this may have been the empirical exploitation of the healing properties of salivary growth factors. By immunohistochemistry and immunoblotting we demonstrate the expression of the epidermal growth factor and its receptor in the oral, upper digestive, and salivary epithelia of Elaphe quatuorlineata, a species probably used in healing rituals.	UNIV CASSINO,DEPT PHILOL & HIST,MED HIST SECT,CASSINO,ITALY; IST SUPER SANITA,VET LAB,I-00161 ROME,ITALY; UNIV ROME LA SAPIENZA,DEPT EXPTL MED,I-00185 ROME,ITALY; GABRIELE DANNUNZIO UNIV,INST HUMAN PATHOL,CHIETI,ITALY	University of Cassino; Istituto Superiore di Sanita (ISS); Sapienza University Rome; G d'Annunzio University of Chieti-Pescara			Mariani-Costantini, Renato/B-6637-2012; Agrimi, Umberto/C-9956-2015	Mariani-Costantini, Renato/0000-0002-4440-1848; Agrimi, Umberto/0000-0001-7828-0186				ALDROVANDI U, 1640, SERPENTUM DRACONUM H, P67; ANGLETTI LR, 1989, MED SECOLI, V1, P273; ANGLETTI LR, 1991, TRENDS EXP MED, V1, P4; BISHOP JM, 1985, RNA TUMOR VIRUSES S, V2, P249; BROWN GL, 1986, J EXP MED, V163, P1319; Bruno S, 1990, SERPENTI ITALIA EURO; BURGESS AW, 1989, BRIT MED BULL, V45, P401, DOI 10.1093/oxfordjournals.bmb.a072331; CARPENTER G, 1979, ANNU REV BIOCHEM, V48, P193, DOI 10.1146/annurev.bi.48.070179.001205; COHEN S, 1962, J BIOL CHEM, V237, P1555; EDELSTEIN L, 1945, ASCLEPIUS, P233; FACCIOLATI J, 1827, TYPIS SEMINARII, P195; FRATI C, 1973, CHRON DERMATOL, V4, P57; Jones W H. S., 1918, PAUSANIAS DESCRIPTIO; LAURENCE DJR, 1990, TUMOR BIOL, V11, P229, DOI 10.1159/000217659; Lyons AS, 1978, MED ILLUSTRATED HIST; METAZA L, 1823, MONOGRAFIA SERPENTI; Morse D., 1976, MED HIST, V20, P461; MURARO R, 1991, INT S BIOTECHNOLOGY; RHEINWALD JG, 1977, NATURE, V265, P421, DOI 10.1038/265421a0; 1981, HIPPOCRATES DECORUM, V2, P289; 1940, HIST NATURALIS, V11; 1940, HIST NATURALIS, V8	22	50	52	0	6	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 25	1992	340	8813					223	225		10.1016/0140-6736(92)90480-Q	http://dx.doi.org/10.1016/0140-6736(92)90480-Q			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JE758	1353146				2023-01-03	WOS:A1992JE75800014
J	CHARO, RA				CHARO, RA			MANDATORY CONTRACEPTION	LANCET			English	Editorial Material														Charo, Robin Alta/0000-0003-3710-1043				POTTS N, 1991, LANCET, V338, P303; Shapiro Thomas, 1985, POPULATION CONTROL P; 1992, JAMA-J AM MED ASSOC, V267, P1812	3	1	1	2	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 2	1992	339	8801					1104	1105						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HR446	1349114				2023-01-03	WOS:A1992HR44600016
J	KOES, BW; BOUTER, LM; VANMAMEREN, H; ESSERS, AHM; VERSTEGEN, GMJR; HOFHUIZEN, DM; HOUBEN, JP; KNIPSCHILD, PG				KOES, BW; BOUTER, LM; VANMAMEREN, H; ESSERS, AHM; VERSTEGEN, GMJR; HOFHUIZEN, DM; HOUBEN, JP; KNIPSCHILD, PG			RANDOMIZED CLINICAL-TRIAL OF MANIPULATIVE THERAPY AND PHYSIOTHERAPY FOR PERSISTENT BACK AND NECK COMPLAINTS - RESULTS OF ONE YEAR FOLLOW-UP	BRITISH MEDICAL JOURNAL			English	Article							PAIN	Objective - To compare the effectiveness of manipulative therapy, physiotherapy, treatment by the general practitioner, and placebo therapy in patients with persistent non-specific back and neck complaints. Design - Randomised clinical trial. Setting - Primary health care in the Netherlands. Patients - 256 patients with non-specific back and neck complaints of at least six weeks' duration who had not received physiotherapy or manipulative therapy in the past two years. Interventions - At the discretion of the manipulative therapists, physiotherapists, and general practitioners. Physiotherapy consisted of exercises, massage, and physical therapy (heat, electrotherapy, ultrasound, shortwave diathermy). Manipulative therapy consisted of manipulation and mobilisation of the spine. Treatment by general practitioners consisted of drugs (for example, analgesics), advice about posture, home exercises, and (bed)rest. Placebo treatment consisted of detuned shortwave diathermy (10 minutes) and detuned ultrasound (10 minutes). Main outcome measures - Changes in severity of the main complaint and limitation of physical functioning measured on 10 point scales by a blinded research assistant and global perceived effect measured on a 6 point scale by the patients. Results - Many patients in the general practitioner and placebo groups received other treatment during follow up. Improvement in the main complaint was larger with manipulative therapy (4.5) than with physiotherapy (3.8) after 12 months' follow up (difference 0.9; 95% confidence interval 0.1 to 1.7). Manipulative therapy also gave larger improvements in physical functioning (difference 0.6; -0.1 to 1.3). The global perceived effect after six and 12 months' follow up was similar for both treatments. Conclusions - Manipulative therapy and physiotherapy are better than general practitioner and placebo treatment. Furthermore, manipulative therapy is slightly better than physiotherapy after 12 months.	UNIV LIMBURG,DEPT ANAT & EMBRYOL,6200 MD MAASTRICHT,NETHERLANDS; UNIV LIMBURG HOSP,DEPT PHYSIOTHERAPY,MAASTRICHT,NETHERLANDS; INST HIGHER EDUC,DEPT PHYSIOTHERAPY,HEERLEN,NETHERLANDS; PHYSIOTHERAPY & MANUAL THERAPY PRACTICE,MAASTRICHT,NETHERLANDS	Hasselt University; Maastricht University; Maastricht University Medical Centre (MUMC)	KOES, BW (corresponding author), UNIV LIMBURG,DEPT EPIDEMIOL & BIOSTAT,POB 616,6200 MD MAASTRICHT,NETHERLANDS.		Koes, Bart w/K-4614-2016	Koes, Bart w/0000-0002-0450-9969; Bouter, Lex/0000-0002-2659-5482				BERGQUISTULLMAN M, 1977, ACTA ORTHOP SCAND S, V170, P11; COXHEAD CE, 1981, LANCET, V1, P1065; DEYO RA, 1983, JAMA-J AM MED ASSOC, V250, P1057; Dixon W. J., 1990, BMDP STATISTICAL SOF; DORAN DML, 1975, BRIT MED J, V2, P161, DOI 10.1136/bmj.2.5964.161; FRYMOYER JW, 1988, NEW ENGL J MED, V318, P291, DOI 10.1056/NEJM198802043180506; KOES BW, 1991, BRIT MED J, V303, P1298, DOI 10.1136/bmj.303.6813.1298; KOES BW, 1991, BRIT MED J, V302, P1572, DOI 10.1136/bmj.302.6792.1572; KOES BW, IN PRESS SPINE; KOES BW, IN PRESS J MANIPULAT; MEADE TW, 1990, BRIT MED J, V300, P1431, DOI 10.1136/bmj.300.6737.1431; NACHEMSON A, 1979, SCAND J REHABIL MED, V11, P143; Siehl D, 1971, J Am Osteopath Assoc, V70, P433; SIMSWILLIAMS H, 1978, BMJ-BRIT MED J, V2, P1338, DOI 10.1136/bmj.2.6148.1338; SIMSWILLIAMS H, 1979, BMJ-BRIT MED J, V2, P1318, DOI 10.1136/bmj.2.6201.1318; SPITZER WO, 1987, SPINE S1, V1, P59; WADDELL G, 1987, SPINE, V12, P632, DOI 10.1097/00007632-198709000-00002	17	177	179	0	13	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 7	1992	304	6827					601	605		10.1136/bmj.304.6827.601	http://dx.doi.org/10.1136/bmj.304.6827.601			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HH733	1532760	Green Published, Bronze			2023-01-03	WOS:A1992HH73300021
J	PELL, ACH; MILLER, HC; ROBERTSON, CE; FOX, KAA				PELL, ACH; MILLER, HC; ROBERTSON, CE; FOX, KAA			EFFECT OF FAST TRACK ADMISSION FOR ACUTE MYOCARDIAL-INFARCTION ON DELAY TO THROMBOLYSIS	BMJ-BRITISH MEDICAL JOURNAL			English	Article							TISSUE PLASMINOGEN-ACTIVATOR; LEFT-VENTRICULAR FUNCTION; GENERAL-PRACTITIONER; CARE UNIT; STREPTOKINASE; THERAPY; REDUCTION; PATIENT; POLICY; TIME	Objective - To evaluate the impact of a fast track triage system for patients with acute myocardial infarction. Design - Comparison of delays in admission to hospital and in receiving thrombolytic treatment before and after introducing fast track system with delays recorded in 1987-8. Patients fulfilling clinical and electrocardiographic criteria for myocardial infarction were selected for rapid access to the cardiac care team, bypassing evaluation by the medical registrar. Setting - Major accident and emergency, cardiac and trauma centre. Subjects - 359 patients admitted to the cardiac care unit during 1 February to 31 July 1990 with suspected acute infarction. Main outcome measures - Accuracy of diagnosis and delay from arrival at hospital to thrombolytic treatment. Results - 248 of the 359 patients had myocardial infarction confirmed, of whom 127 received thrombolytic treatment. The fast track system correctly identified 79 out of 127 (62%) patients who subsequently required thrombolytic treatment. 95% (79/83) of patients treated with thrombolysis after fast track admission had the diagnosis confirmed by electrocardiography and enzyme analysis. The median delay from hospital admission to thrombolytic treatment fell from 93 minutes in 1987-8 to 49 minutes in fast track patients (p < 0.001). Delay in admission to the cardiac care unit was reduced by 47% for fast track patients (median 60 minutes in 1987-8 v 32 minutes in 1990, p < 0.001) and by 25% for all patients (60 minutes v 45 minutes, p < 0.001). Conclusion - This fast track system requires no additional staff or equipment, and it halves in-hospital delay to thrombolytic treatment without affecting the accuracy of diagnosis among patients requiring thrombolysis.	ROYAL INFIRM, DEPT CARDIOL, EDINBURGH EH3 9YW, MIDLOTHIAN, SCOTLAND	Royal Infirmary of Edinburgh				Fox, Keith/0000-0002-0140-2752				[Anonymous], 1988, LANCET, V2, P349; [Anonymous], 1986, Lancet, V1, P397; BOSSAERT LL, 1988, CRIT CARE MED, V16, P823, DOI 10.1097/00003246-198809000-00001; BURNS JMA, 1989, BRIT HEART J, V61, P322; CASTAIGNE AD, 1989, AM J CARDIOL, V64, pA30, DOI 10.1016/0002-9149(89)90927-2; CHAMBERLAIN DA, 1988, LANCET, V1, P545; FOX KAA, 1990, BMJ-BRIT MED J, V300, P867, DOI 10.1136/bmj.300.6728.867; KNABB RM, 1987, J NUCL MED, V28, P1563; KOREN G, 1985, NEW ENGL J MED, V313, P1384, DOI 10.1056/NEJM198511283132204; LEIZOROVICZ A, 1988, EUR HEART J, V9, P118; MACCALLUM AG, 1990, EUR HEART J, V11, P48, DOI 10.1093/eurheartj/11.suppl_F.48; MCNEILL AJ, 1991, Q J MED, V79, P487; PASSAMANI E, 1987, J AM COLL CARDIOL, V10, pB51, DOI 10.1016/S0735-1097(87)80429-1; PELL A C H, 1990, Health Bulletin (Edinburgh), V48, P225; RAWLES JM, 1988, BRIT MED J, V296, P882, DOI 10.1136/bmj.296.6626.882; RIDKER P, 1990, Journal of the American College of Cardiology, V15, p167A; ROTH A, 1990, J AM COLL CARDIOL, V15, P932, DOI 10.1016/0735-1097(90)90219-F; SHARKEY SW, 1989, JAMA-J AM MED ASSOC, V262, P3171, DOI 10.1001/jama.262.22.3171; SHEEHAN FH, 1983, AM J CARDIOL, V52, P431, DOI 10.1016/0002-9149(83)90002-4; VANDEWERF F, 1988, BMJ-BRIT MED J, V297, P1374, DOI 10.1136/bmj.297.6660.1374; WEAVER WD, 1990, J AM COLL CARDIOL, V15, P925, DOI 10.1016/0735-1097(90)90218-E; WILCOX RG, 1988, LANCET, V2, P525	22	99	97	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 11	1992	304	6819					83	87		10.1136/bmj.304.6819.83	http://dx.doi.org/10.1136/bmj.304.6819.83			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HA171	1737145	Green Published, Bronze			2023-01-03	WOS:A1992HA17100021
J	SEHGAL, A; GALBRAITH, A; CHESNEY, M; SCHOENFELD, P; CHARLES, G; LO, B				SEHGAL, A; GALBRAITH, A; CHESNEY, M; SCHOENFELD, P; CHARLES, G; LO, B			HOW STRICTLY DO DIALYSIS PATIENTS WANT THEIR ADVANCE DIRECTIVES FOLLOWED	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CHOOSING DEATH; RESUSCITATION; WITHDRAWAL; CARE	Objective. - The Cruzan case and the Patient Self-Determination Act will encourage patients to specify in advance which life-sustaining treatments they would want if they become mentally incompetent. However, strictly following such advance directives may not always be in a patient's best interests. We sought to determine whether patients diff er in how strictly they want advance directives followed. Design. - Interview study. Setting. - Seven outpatient chronic dialysis centers. Participants. - One hundred fifty mentally competent dialysis patients. Intervention. - Using a structured questionnaire, we asked the subjects whether they would want dialysis continued or stopped if they developed advanced Alzheimer's disease. We then asked how much leeway their physician and surrogate should have to override that advance directive if overriding were in their best interests, Subjects granting leeway were also asked what factors should be considered in making decisions for them. Results. - Subjects varied greatly in how much leeway they would give surrogates to override their advance directives: "no leeway" (39%), "a little leeway" (19%), "a lot of leeway" (11%), and "complete leeway" (31%). Subjects also varied in how much they wanted various factors considered in making decisions, such as pain or suffering, quality of life, possibility of a new treatment, indignity caused by continued treatment, financial impact of treatment on family members, and religious beliefs. Conclusions. - Strictly following all advance directives may not truly reflect patients' preferences. To improve advance directives, we recommend that physicians explicitly ask patients how strictly they want their advance directives followed and what factors they want considered in making decisions.	DEPT VET AFFAIRS,SAN FRANCISCO,CA; UNIV CALIF SAN FRANCISCO,DEPT EPIDEMIOL & BIOSTAT,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DIV NEPHROL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DIV NEPHROL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,PROGRAM MED ETH,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DIV GEN INTERNAL MED,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	SEHGAL, A (corresponding author), UNIV CALIF SAN FRANCISCO,ROBERT WOOD JOHNSON CLIN SCHOLARS PROGRAM,BOX 0903,SAN FRANCISCO,CA 94143, USA.							ANNAS GJ, 1991, NEW ENGL J MED, V324, P1210, DOI 10.1056/NEJM199104253241711; BEDELL SE, 1986, JAMA-J AM MED ASSOC, V256, P233, DOI 10.1001/jama.256.2.233; BOPP J, 1990, HASTINGS CENT REP, V20, P42, DOI 10.2307/3562976; BUCHANAN AE, 1991, ANN INTERN MED, V114, P895; Dresser R S, 1989, Law Med Health Care, V17, P234; EMANUEL LL, 1989, JAMA-J AM MED ASSOC, V261, P3288, DOI 10.1001/jama.261.22.3288; EMANUEL LL, 1991, NEW ENGL J MED, V324, P889, DOI 10.1056/NEJM199103283241305; EVANS DA, 1989, JAMA-J AM MED ASSOC, V262, P2551, DOI 10.1001/jama.262.18.2551; FULLER, 1941, COL L REV, V41, P799; LO B, 1986, ARCH INTERN MED, V146, P1613, DOI 10.1001/archinte.146.8.1613; LO B, 1991, JAMA-J AM MED ASSOC, V265, P1874, DOI 10.1001/jama.265.14.1874; NEU S, 1986, NEW ENGL J MED, V314, P14, DOI 10.1056/NEJM198601023140103; PORT FK, 1989, AM J NEPHROL, V9, P145, DOI 10.1159/000167954; President's Commission for the Study of Ethical Problems in Medicine and Biomedical and Behavioral Research, 1983, DECIDING FOREGO LIFE; Rhoden N, 1989, Law Med Health Care, V17, P264; ROBERTS JC, 1988, ACTA MED SCAND, V223, P181; SCHNEIDERMAN LJ, 1985, ANN INTERN MED, V102, P693, DOI 10.7326/0003-4819-102-5-693; SHMERLING RH, 1988, J GEN INTERN MED, V3, P317, DOI 10.1007/BF02595786; SILVERSTEIN MD, 1991, MAYO CLIN PROC, V66, P906, DOI 10.1016/S0025-6196(12)61577-8; STEINBROOK R, 1984, NEW ENGL J MED, V310, P1598, DOI 10.1056/NEJM198406143102411; TOMLINSON T, 1990, JAMA-J AM MED ASSOC, V264, P1276, DOI 10.1001/jama.264.10.1276; YOUNGER SJ, 1988, JAMA-J AM MED ASSOC, V260, P2094, DOI 10.1001/jama.260.14.2094; 1989, USRDS1989 NAT I HLTH	23	239	239	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 1	1992	267	1					59	63		10.1001/jama.267.1.59	http://dx.doi.org/10.1001/jama.267.1.59			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GW848	1489360				2023-01-03	WOS:A1992GW84800024
J	WILENSKY, GR				WILENSKY, GR			FINANCING CARE FOR PATIENTS WITH AIDS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	7	7	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 25	1991	266	24					3404	3404						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GV878	1744948				2023-01-03	WOS:A1991GV87800005
J	AARONS, EJ; BEECHING, NJ				AARONS, EJ; BEECHING, NJ			SURVEY OF DO NOT RESUSCITATE ORDERS IN A DISTRICT GENERAL-HOSPITAL	BRITISH MEDICAL JOURNAL			English	Article							CARDIOPULMONARY RESUSCITATION; SURVIVAL	Objective - To evaluate the local use of written "Do not resuscitate" orders to designate inpatients unsuitable for cardiopulmonary resuscitation in the event of cardiac arrest. Design - Point prevalence questionnaire survey of inpatients' medical and nursing records. Setting - 10 acute medical and six acute surgical wards of a district general hospital. Participants - Questionnaires were filled in anonymously by nurses and doctors working on the wards surveyed. Main outcome measures - Responses to questionnaire items concerning details about each patient, written orders not to resuscitate in the medical case notes and nursing records, whether prognosis had been discussed with patients' relatives, whether a "crash call" was perceived as appropriate for each patient, and whether the "crash team" would be called in the event of arrest. Results - Information was obtained on 297 (93.7%) of 317 eligible patients. Prognosis had been discussed with the relatives of 32 of 88 patients perceived by doctors as unsuitable for resuscitation. Of these 88 patients, 24 had orders not to resuscitate in their medical notes, and only eight of these had similar orders in their nursing notes. Conclusions - In the absence of guidelines on decisions about resuscitation, orders not to resuscitate are rarely included in the notes of patients for whom cardiopulmonary resuscitation is thought to be inappropriate. Elective decisions not to resuscitate are not effectively communicated to nurses. There should be more discussion of patients' suitability for resuscitation between doctors, nurses, patients, and patients' relatives. Suitability for resuscitation should be reviewed on every consultant ward round.	FAZAKERLEY DIST GEN HOSP,REG INFECT DIS UNIT,LIVERPOOL L9 7AL,ENGLAND		BEECHING, NJ (corresponding author), FAZAKERLEY DIST GEN HOSP,REG INFECT DIS UNIT,LIVERPOOL L9 7AL,ENGLAND.		Beeching, Nicholas J/L-5363-2017	Beeching, Nicholas/0000-0002-7019-8791				ASPLUND K, 1990, J INTERN MED, V228, P139; BEDELL SE, 1983, NEW ENGL J MED, V309, P569, DOI 10.1056/NEJM198309083091001; DENT THS, 1990, BRIT MED J, V300, P713, DOI 10.1136/bmj.300.6726.713; GLEESON K, 1990, ARCH INTERN MED, V150, P1057, DOI 10.1001/archinte.150.5.1057; Halligan M, 1985, Health Prog, V66, P26; HALLIGAN M, 1985, HLTH PROGR, V66, P600; KAMER RS, 1990, AM J MED, V88, P108, DOI 10.1016/0002-9343(90)90457-O; KEATINGE RM, 1989, J ROY SOC MED, V82, P402, DOI 10.1177/014107688908200711; MCCLUNG JA, 1990, NEW ENGL J MED, V323, P270, DOI 10.1056/NEJM199007263230411; PEATFIELD RC, 1977, LANCET, V1, P1223; STOLMAN CJ, 1990, ARCH INTERN MED, V150, P653, DOI 10.1001/archinte.150.3.653; URBURG M, 1987, J FAM PRACTICE, V25, P41; WANZER SH, 1989, NEW ENGL J MED, V320, P844, DOI 10.1056/NEJM198903303201306; 1984, CODE PROFESSIONAL CO	14	45	45	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 14	1991	303	6816					1504	1506		10.1136/bmj.303.6816.1504	http://dx.doi.org/10.1136/bmj.303.6816.1504			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GV476	1782488	Bronze, Green Published			2023-01-03	WOS:A1991GV47600019
J	KWON, IC; BAE, YH; KIM, SW				KWON, IC; BAE, YH; KIM, SW			ELECTRICALLY ERODIBLE POLYMER GEL FOR CONTROLLED RELEASE OF DRUGS	NATURE			English	Article							INTERMACROMOLECULAR COMPLEXES; SENSITIVE POLYMERS; PHASE-TRANSITION; DELIVERY; MEMBRANE	NEW controlled drug-delivery systems are being explored to overcome the disadvantages of conventional dosage forms 1. For example, stimulated drug-delivery has been used to overcome the tolerance problems that occur with a constant delivery rate, to mimic the physiological pattern of hormonal concentration and to supply drugs on demand 1,2. Stimuli-sensitive polymers, which are potentially useful for pulsed drug delivery, experience changes in either their structure or their chemical properties in response to changes in environmental conditions 2. Environmental stimuli include temperature 3,4, pH 5,6, light (ultraviolet 7 or visible 8), electric field 9-12 or certain chemicals 13. Volume changes of stimuli-sensitive gel networks are particularly responsive to external stimuli, but swelling is slow to occur 14,15. As well as being useful in the controlled release of drugs, such systems also provide insight into intermolecular interactions 16. Here we report on a novel polymeric system, which rapidly changes from a solid state to solution in response to small electric currents, by disintegration of the solid polymer complex into two water-soluble polymers. We show that the modulated release of insulin, and by extension other macromolecules, can be achieved with this polymeric system.			KWON, IC (corresponding author), UNIV UTAH,CTR CONTROLLED CHEM DELIVERY,421 WAKARA WAY,SALT LAKE CITY,UT 84108, USA.		KWON, ICK CHAN/AAS-4776-2020	KWON, ICK CHAN/0000-0003-1272-7074				BAE YH, 1987, MAKROMOL CHEM-RAPID, V8, P481; CHEN FL, 1988, POLYMER, V29, P2285, DOI 10.1016/0032-3861(88)90123-1; EISENBERG SR, 1984, J MEMBRANE SCI, V19, P173, DOI 10.1016/S0376-7388(00)80207-0; HIROKAWA Y, 1984, J CHEM PHYS, V81, P6379, DOI 10.1063/1.447548; HOFFMAN A S, 1986, Journal of Controlled Release, V4, P213; HOPFENBERG HB, 1976, CONTROLLED RELEASE P, pCH3; ILMAIN F, 1991, NATURE, V349, P400, DOI 10.1038/349400a0; ISHIHARA K, 1984, J POLYM SCI POL CHEM, V22, P881, DOI 10.1002/pol.1984.170220341; ISHIHARA K, 1984, J APPL POLYM SCI, V29, P211, DOI 10.1002/app.1984.070290119; Kost J., 1990, PULSED SELF REGULATE; KUHN W, 1950, NATURE, V165, P514, DOI 10.1038/165514a0; KWON IC, 1990, MAKROMOL CHEM-M SYMP, V33, P265, DOI 10.1002/masy.19900330123; LANGER R, 1990, SCIENCE, V249, P1527, DOI 10.1126/science.2218494; LICHKUS AM, 1988, MACROMOLECULES, V21, P2636, DOI 10.1021/ma00186a054; OSADA Y, 1981, J POLYM SCI POL LETT, V19, P303, DOI 10.1002/pol.1981.130190605; SIEGEL RA, 1988, MACROMOLECULES, V21, P3254, DOI 10.1021/ma00189a021; SUZUKI A, 1990, NATURE, V346, P345, DOI 10.1038/346345a0; TANAKA T, 1982, SCIENCE, V218, P467, DOI 10.1126/science.218.4571.467; TSUCHIDA E, 1982, ADV POLYM SCI, V45, P1	19	607	683	2	114	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 28	1991	354	6351					291	293		10.1038/354291a0	http://dx.doi.org/10.1038/354291a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GT204	1956379				2023-01-03	WOS:A1991GT20400042
J	WRIGHT, D; MACKENZIE, SJ; BUCHAN, I; CAIRNS, CS; PRICE, LE				WRIGHT, D; MACKENZIE, SJ; BUCHAN, I; CAIRNS, CS; PRICE, LE			CRITICAL INCIDENTS IN THE INTENSIVE THERAPY UNIT	LANCET			English	Article								Preventable mishaps in an intensive therapy unit were studied over 12 months by the critical incident technique. Staff were encouraged to complete confidential questionnaires describing incidents in which they had participated or had observed. This allowed classification of the events and examination of the views of staff on causes, detection, and prevention. 110 (80%) of 137 events were felt to have been due to human error; the remainder were due to equipment failure. Inexperience with equipment and shortage of trained staff were the factors most often felt to contribute to incidents. The critical incident technique is a useful way of improving standards of clinical care.			WRIGHT, D (corresponding author), WESTERN GEN HOSP,INTENS THERAPY UNIT,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND.							COOPER JB, 1978, ANESTHESIOLOGY, V49, P399, DOI 10.1097/00000542-197812000-00004; FLANAGAN JC, 1954, PSYCHOL BULL, V51, P327, DOI 10.1037/h0061470; VINCENT CA, 1989, BMJ-BRIT MED J, V299, P1150, DOI 10.1136/bmj.299.6708.1150; WILLINGHAM JJ, 1985, AUDITING-J PRACT TH, V5, P57; 1988, LANCET, V1, P1373	5	63	67	1	9	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 14	1991	338	8768					676	678		10.1016/0140-6736(91)91243-N	http://dx.doi.org/10.1016/0140-6736(91)91243-N			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GF105	1679483				2023-01-03	WOS:A1991GF10500014
J	STAMPFER, MJ; COLDITZ, GA; WILLETT, WC; MANSON, JE; ROSNER, B; SPEIZER, FE; HENNEKENS, CH				STAMPFER, MJ; COLDITZ, GA; WILLETT, WC; MANSON, JE; ROSNER, B; SPEIZER, FE; HENNEKENS, CH			POSTMENOPAUSAL ESTROGEN THERAPY AND CARDIOVASCULAR-DISEASE - 10-YEAR FOLLOW-UP FROM THE NURSES HEALTH STUDY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CORONARY HEART-DISEASE; RISK-FACTORS; PROSPECTIVE COHORT; WOMEN; REPRODUCIBILITY; QUESTIONNAIRE; MENOPAUSE; VALIDITY; CANCER; STROKE	Background. The effect of postmenopausal estrogen therapy on the risk of cardiovascular disease remains controversial. Our 1985 report in the Journal, based on four years of follow-up, suggested that estrogen therapy reduced the risk of coronary heart disease, but a report published simultaneously from the Framingham Study suggested that the risk was increased. In addition, studies of the effect of estrogens on stroke have yielded conflicting results. Methods. We followed 48,470 postmenopausal women, 30 to 63 years old, who were participants in the Nurses' Health Study and who did not have a history of cancer or cardiovascular disease at base line. During up to 10 years of follow-up (337,854 person-years), we documented 224 strokes, 405 cases of major coronary disease (nonfatal myocardial infarctions or deaths from coronary causes), and 1263 deaths from all causes. Results. After adjustment for age and other risk factors, the overall relative risk of major coronary disease in women currently taking estrogen was 0.56 (95 percent confidence interval, 0.40 to 0.80); the risk was significantly reduced among women with either natural or surgical menopause. We observed no effect of the duration of estrogen use independent of age. The findings were similar in analyese limited to women who had recently visited their physicians (relative risk, 0.45; 95 percent confidence interval, 0.31 to 0.66) and in a low-risk group that excluded women reporting current cigarette smoking, diabetes, hypertension, hypercholesterolemia, or a Quetelet index above the 90th percentile (relative risk, 0.53; 95 percent confidence interval, 0.31 to 0.91). The relative risk for current and former users of estrogen as compared with those who had never used it was 0.89 (95 percent confidence interval, 0.78 to 1.00) for total mortality and 0.72 (95 percent confidence interval, 0.55 to 0.95) for mortality from cardiovascular disease. The relative risk of stroke when current users were compared with those who had never used estrogen was 0.97 (95 percent confidence interval, 0.65 to 1.45), with no marked differences according to type of stroke. Conclusions. Current estrogen use is associated with a reduction in the incidence of coronary heart disease as well as in mortality from cardiovascular disease, but it is not associated with any change in the risk of stroke.	HARVARD UNIV, SCH MED, CHANNING LAB, DEPT PREVENT MED, BOSTON, MA 02115 USA; BRIGHAM & WOMENS HOSP, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT EPIDEMIOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT NUTR, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT BIOSTAT, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT ENVIRONM HLTH, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health	STAMPFER, MJ (corresponding author), HARVARD UNIV, SCH MED, CHANNING LAB, DEPT MED, 180 LONGWOOD AVE, BOSTON, MA 02115 USA.		Colditz, Graham/A-3963-2009	Colditz, Graham/0000-0002-7307-0291	NATIONAL CANCER INSTITUTE [R37CA040356, R01CA040356] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL034594] Funding Source: NIH RePORTER; NCI NIH HHS [CA 40356] Funding Source: Medline; NHLBI NIH HHS [HL 34594] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAILAR JC, 1985, NEW ENGL J MED, V313, P1080, DOI 10.1056/NEJM198510243131709; BOYSEN G, 1988, STROKE, V19, P1345, DOI 10.1161/01.STR.19.11.1345; BUSH TL, 1986, MENOPAUSE PHYSL PHAR, P187; COLDITZ GA, 1986, AM J EPIDEMIOL, V123, P48, DOI 10.1093/oxfordjournals.aje.a114223; COLDITZ GA, 1987, AM J EPIDEMIOL, V126, P319, DOI 10.1093/aje/126.2.319; COLDITZ GA, 1986, AM J EPIDEMIOL, V123, P894, DOI 10.1093/oxfordjournals.aje.a114319; COLDITZ GA, 1990, JAMA-J AM MED ASSOC, V264, P2648, DOI 10.1001/jama.264.20.2648; COLDITZ GA, 1987, NEW ENGL J MED, V316, P1105, DOI 10.1056/NEJM198704303161801; Colditz GA, 1990, CURR PROB OBST GYN F, V13, P129; COX DR, 1972, J R STAT SOC B, V34, P187; EAKER ED, 1987, CORONARY HEART DISEA, P122; GRUCHOW HW, 1988, AM HEART J, V115, P954, DOI 10.1016/0002-8703(88)90063-4; HENDERSON BE, 1991, ARCH INTERN MED, V151, P75, DOI 10.1001/archinte.151.1.75; HILLNER BE, 1986, AM J MED, V80, P1115, DOI 10.1016/0002-9343(86)90674-1; JUDD HL, 1980, AM J OBSTET GYNECOL, V136, P859, DOI 10.1016/0002-9378(80)91043-1; LOBO RA, 1990, ANN NY ACAD SCI, V592, P286; MCFARLAND KF, 1989, AM HEART J, V117, P1209, DOI 10.1016/0002-8703(89)90398-0; PAGANINIHILL A, 1988, BMJ-BRIT MED J, V297, P519, DOI 10.1136/bmj.297.6647.519; ROTHMAN KJ, 1979, NIH791649 PHS PUBL; STAMPFER MJ, 1984, AM J EPIDEMIOL, V119, P837, DOI 10.1093/oxfordjournals.aje.a113804; STAMPFER MJ, 1990, ANN NY ACAD SCI, V592, P193; STAMPFER MJ, 1991, PREV MED, V20, P47, DOI 10.1016/0091-7435(91)90006-P; STAMPFER MJ, 1985, NEW ENGL J MED, V313, P1044, DOI 10.1056/NEJM198510243131703; STAMPFER MJ, 1987, CORONARY HEART DISEA, P112; SULLIVAN JM, 1988, ANN INTERN MED, V108, P358, DOI 10.7326/0003-4819-108-3-358; Walker AE, 1981, STROKE S1, V12, P13; Weinstein M C, 1983, Obstet Gynecol Surv, V38, P445, DOI 10.1097/00006254-198308000-00001; WILLETT W, 1986, AM J EPIDEMIOL, V124, P17, DOI 10.1093/oxfordjournals.aje.a114366; WILLETT WC, 1985, AM J EPIDEMIOL, V122, P51, DOI 10.1093/oxfordjournals.aje.a114086; WILSON PWF, 1985, NEW ENGL J MED, V313, P1038, DOI 10.1056/NEJM198510243131702; [No title captured]	31	1872	1903	0	66	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 12	1991	325	11					756	762		10.1056/NEJM199109123251102	http://dx.doi.org/10.1056/NEJM199109123251102			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GE456	1870648				2023-01-03	WOS:A1991GE45600002
J	ODARCEDERLOF, I; THEODORSSON, E; ERICSSON, F; KJELLSTRAND, CM				ODARCEDERLOF, I; THEODORSSON, E; ERICSSON, F; KJELLSTRAND, CM			PLASMA-CONCENTRATIONS OF CALCITONIN GENE-RELATED PEPTIDE IN FLUID OVERLOAD	LANCET			English	Note							ATRIAL-NATRIURETIC-PEPTIDE	To investigate the hypothesis that calcitonin gene-related peptide (CGRP), a potent vasodilator, is an important physiological defence against fluid overload, plasma CGRP concentrations were measured in various degrees of fluid overload in 26 haemodialysis patients, for whom diuresis, mediated by atrial natriuretic peptide (ANP), is not a possible defence mechanism. Plasma CGRP concentrations were positively correlated with the degree of fluid excess (r = 0.815, p = 0.0001) and were significantly higher in 5 patients with severe fluid overload than in those less severely affected (143 [SE 14] vs 52 [11] pmol/l; p < 0.001). CGRP may be an effective defence against complications of fluid overload since if can increase capitance by vasodilatation.	KAROLINSKA HOSP,DEPT CLIN CHEM,S-10401 STOCKHOLM 60,SWEDEN; UNIV ALBERTA HOSP,DEPT MED,DIV NEPHROL,EDMONTON T6G 2B7,ALBERTA,CANADA	Karolinska Institutet; Karolinska University Hospital; University of Alberta	ODARCEDERLOF, I (corresponding author), KAROLINSKA HOSP,DEPT INTERNAL MED,DIV NEPHROL,BOX 60500,S-10401 STOCKHOLM 60,SWEDEN.		Theodorsson, Elvar/H-2096-2011	Theodorsson, Elvar/0000-0003-0756-7723				BERGLUND H, 1990, BRIT HEART J, V64, P9; BRAIN SD, 1985, NATURE, V313, P54, DOI 10.1038/313054a0; CURRIE MG, 1983, SCIENCE, V221, P71, DOI 10.1126/science.6857267; ERICSSON F, 1983, NEPHRON, V33, P173, DOI 10.1159/000182937; GENNARI C, 1990, CARDIOVASC RES, V3, P239; GREENBERG B, 1987, BRIT J PHARMACOL, V92, P789, DOI 10.1111/j.1476-5381.1987.tb11382.x; LANG RE, 1985, NATURE, V314, P264, DOI 10.1038/314264a0; ODARCEDERLOF I, 1989, J INTERN MED, V226, P177, DOI 10.1111/j.1365-2796.1989.tb01376.x; TALARTSCHIK J, 1988, Z KARDIOL, V77, P72; YAMAMOTO A, 1988, BIOCHEM BIOPH RES CO, V155, P1452, DOI 10.1016/S0006-291X(88)81304-4	10	31	31	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 17	1991	338	8764					411	412		10.1016/0140-6736(91)91035-S	http://dx.doi.org/10.1016/0140-6736(91)91035-S			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GB446	1678085				2023-01-03	WOS:A1991GB44600006
J	GARDULF, A; HAMMARSTROM, L; SMITH, CIE				GARDULF, A; HAMMARSTROM, L; SMITH, CIE			HOME TREATMENT OF HYPOGAMMAGLOBULINEMIA WITH SUBCUTANEOUS GAMMA-GLOBULIN BY RAPID INFUSION	LANCET			English	Article							IMMUNOGLOBULIN REPLACEMENT THERAPY; IMMUNE SERUM GLOBULIN; INTRAVENOUS IMMUNOGLOBULIN; GAMMA-GLOBULIN; ANTIBODY DEFICIENCY; ADVERSE REACTIONS; SELF-INFUSION; AGAMMAGLOBULINEMIA; IMMUNODEFICIENCY; CORTICOSTEROIDS	Intramuscular and intravenous gammaglobulin treatment for hypogammaglobulinaemia is often associated with systemic adverse reactions in some patients. Subcutaneous infusions of gammaglobulin are usually given at a slow rate. To assess the safety of home treatment with subcutaneous gammaglobulin, rapid infusions (34-40 ml/h) given by small portable pumps were used to treat twenty-five patients with hypogammaglobulinaemia. Fifteen patients had previously had adverse reactions to intramuscular or intravenous gammaglobulin treatment. After the patients had been taught how to use the pumps during 6 months of treatment in hospital, in which they initially received 100 mg of an intramuscular gammaglobulin preparation/kg per week, they went on to use the pumps at home or at work. So far, the patients have given themselves 3232 rapid subcutaneous infusions (2308 in home therapy). A median pre-infusion serum IgG concentration of 8.1 g/l resulted after 6 months of treatment. There were only 30 (0.93%) mild systemic adverse reactions; there were fewer reactions with subcutaneous gammaglobulin than with previously given intramuscular injections (n = 21, p < 0.001) or intravenous infusions (n = 9, p < 0.001) in this group of patients. Overall, the patients spent 0.2 days a year in hospital due to respiratory tract infections. The findings show that the method for subcutaneous administration is very easy to learn and is appreciated by the patients; moreover, the infusions can be given much faster than previously reported without any pronounced local reaction.	KAROLINSKA HOSP,KAROLINSKA INST,DEPT INTERNAL MED,NURSING RES UNIT,S-10401 STOCKHOLM 60,SWEDEN	Karolinska Institutet; Karolinska University Hospital	GARDULF, A (corresponding author), KAROLINSKA HOSP,KAROLINSKA INST,DEPT CLIN IMMUNOL,F71,S-10401 STOCKHOLM 60,SWEDEN.			SMITH, C. I. Edvard/0000-0003-1907-3392				AITKEN RCB, 1969, P ROY SOC MED, V62, P989, DOI 10.1177/003591576906201005; [Anonymous], 1969, Lancet, V1, P163; ASHIDA ER, 1986, J CLIN IMMUNOL, V6, P306, DOI 10.1007/BF00917331; BAYSTON K, 1985, NZ MED J, P652; BERGER M, 1980, ANN INTERN MED, V93, P55, DOI 10.7326/0003-4819-93-1-55; BJORKANDER J, 1985, INFECTION, V13, P102, DOI 10.1007/BF01642867; BLEEKER WK, 1989, CLIN EXP IMMUNOL, V77, P338; CHAPEL H, 1988, CLIN EXP IMMUNOL, V73, P160; CUNNINGHAMRUNDLES C, 1985, VOX SANG, V49, P8, DOI 10.1111/j.1423-0410.1985.tb01138.x; Effersoe H, 1985, Ugeskr Laeger, V147, P3303; GISLASON D, 1978, VOX SANG, V34, P143, DOI 10.1111/j.1423-0410.1978.tb02456.x; HAMMARSTROM L, 1986, LANCET, V1, P743; HANSON LA, 1980, DHHS FDA809005 US DE, P151; HOLMES S, 1989, INT J NURS STUD, V26, P69, DOI 10.1016/0020-7489(89)90047-3; JORUPRONSTROM C, 1989, INFECTION, V17, P301, DOI 10.1007/BF01650712; KAMME C, 1966, ACTA MED SCAND, V179, P679; KOHLER PF, 1966, NATURE, V210, P1070, DOI 10.1038/2101070a0; LEAHY MF, 1986, LANCET, V2, P48; LEDERMAN HM, 1985, MEDICINE, V64, P145, DOI 10.1097/00005792-198505000-00001; LEDERMAN HM, 1986, AM J MED, V81, P443, DOI 10.1016/0002-9343(86)90296-2; OCHS HD, 1987, J INFECT DIS, V156, P652, DOI 10.1093/infdis/156.4.652; OCHS HD, 1986, LANCET, V1, P610; POLLACK S, 1986, POSTGRAD MED J, V62, P939, DOI 10.1136/pgmj.62.732.939; ROIFMAN CM, 1987, LANCET, V1, P1075; ROORD JJ, 1982, LANCET, V1, P689; RYAN A, 1988, LANCET, V2, P793; SMITH CIE, 1985, OBSTET GYNECOL, V66, P395; SMITH GN, 1972, LANCET, V1, P1208; UGAZIO AG, 1982, LANCET, V1, P226; 1990, LANCET, V336, P470; 1983, CLIN EXP IMMUNOL, V52, P417	31	178	184	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 20	1991	338	8760					162	166						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FX424	1712881				2023-01-03	WOS:A1991FX42400014
J	CAPLAN, RA; POSNER, KL; CHENEY, FW				CAPLAN, RA; POSNER, KL; CHENEY, FW			EFFECT OF OUTCOME ON PHYSICIAN JUDGMENTS OF APPROPRIATENESS OF CARE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							QUALITY	Is a permanent injury more likely to elicit a rating of inappropriate care than a temporary injury? To explore this question, we asked 112 practicing anesthesiologists to judge the appropriateness of care in 21 cases involving adverse anesthetic outcomes. The original outcome in each case was classified as either temporary or permanent. The authors then generated a matching alternate case identical to the original in every respect except that a plausible outcome of opposite severity was substituted. The original and alternate cases were randomly divided into two sets and assigned to reviewers who were blind to the intent of the study. The reviewers were asked to rate independently the care in each case as appropriate, less than appropriate, or impossible to judge, based on their personal (implicit) judgment of reasonable and prudent practice. A significant inverse relationship between severity of outcome and judgments of appropriateness of care was observed in 15 (71%) of the 21 matched pairs of cases. Overall, the proportion of ratings for appropriate care decreased by 31 percentage points when the outcome was changed from temporary to permanent and increased by 28 percentage points when the outcome was changed from permanent to temporary. We conclude that knowledge of the severity of outcome can influence a reviewer's judgment of the appropriateness of care.	UNIV WASHINGTON,SCH MED,DEPT ANESTHESIOL,SEATTLE,WA 98195	University of Washington; University of Washington Seattle	CAPLAN, RA (corresponding author), VIRGINIA MASON MED CTR,DEPT ANESTHESIOL,POB 900,SEATTLE,WA 98111, USA.							BRENNAN TA, 1989, MED CARE, V27, P1148, DOI 10.1097/00005650-198912000-00006; BROOK RH, 1977, NEW ENGL J MED, V296, P170, DOI 10.1056/NEJM197701202960311; BROOK RH, 1973, NEW ENGL J MED, V288, P1323, DOI 10.1056/NEJM197306212882504; BRUNNER EA, 1984, INT ANESTHESIOL CLIN, V22, P17, DOI 10.1097/00004311-198408000-00004; CAPLAN R A, 1988, Anesthesiology (Hagerstown), V69, pA722, DOI 10.1097/00000542-198809010-00722; CAPLAN RA, 1990, ANESTHESIOLOGY, V72, P828, DOI 10.1097/00000542-199005000-00010; CHASSIN MR, 1987, JAMA-J AM MED ASSOC, V258, P2533, DOI 10.1001/jama.258.18.2533; CHENEY FW, 1989, JAMA-J AM MED ASSOC, V261, P1599, DOI 10.1001/jama.261.11.1599; COHEN J, 1987, STATISTICAL POWER AN, P215; DUBOIS RW, 1988, ANN INTERN MED, V109, P582, DOI 10.7326/0003-4819-109-7-582; EDGINGTON ES, 1987, RANDOMIZATION TESTS, P34; FESSEL WJ, 1972, NEW ENGL J MED, V286, P134, DOI 10.1056/NEJM197201202860305; FLEISS JL, 1971, PSYCHOL BULL, V76, P378, DOI 10.1037/h0031619; KORAN LM, 1975, NEW ENGL J MED, V293, P642, DOI 10.1056/NEJM197509252931307; KROLL DA, 1990, ANESTHESIOLOGY, V73, P202, DOI 10.1097/00000542-199008000-00002; Leape L L, 1990, QRB Qual Rev Bull, V16, P42; LOHR KN, 1990, NEW ENGL J MED, V322, P707, DOI 10.1056/NEJM199003083221031; NOBREGA FT, 1977, NEW ENGL J MED, V296, P145, DOI 10.1056/NEJM197701202960305; POSNER KL, 1990, STAT MED, V9, P1103, DOI 10.1002/sim.4780090917; SCHNEIDER AJL, 1983, SURG CLIN N AM, V63, P1113; WINSLOW CM, 1988, NEW ENGL J MED, V318, P721, DOI 10.1056/NEJM198803243181201	21	282	283	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 17	1991	265	15					1957	1960		10.1001/jama.265.15.1957	http://dx.doi.org/10.1001/jama.265.15.1957			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FF768	2008024				2023-01-03	WOS:A1991FF76800020
J	SARTORI, S; NIELSEN, I; INDELLI, M; TREVISANI, L; PAZZI, P; GRANDI, E				SARTORI, S; NIELSEN, I; INDELLI, M; TREVISANI, L; PAZZI, P; GRANDI, E			BARRETT-ESOPHAGUS AFTER CHEMOTHERAPY WITH CYCLOPHOSPHAMIDE, METHOTREXATE, AND 5-FLUOROURACIL (CMF) - AN IATROGENIC INJURY	ANNALS OF INTERNAL MEDICINE			English	Note							COLUMNAR-LINED ESOPHAGUS; AGENTS	Methotrexate and 5-fluorouracil can provoke oral mucosal erosions and ulceration that may extend throughout the esophagus. This study was conducted to determine whether prolonged chemotherapy-induced esophageal damage may cause the development of Barrett esophagus. Sixteen women who had breast cancer and had been selected to receive at least six breast cancer and had been selected to receive at least six courses of chemotherapy with cyclophosphamide, methotrexate, and 5-flourouracil were included in the study. They had esophagoscopy, and several biopsy specimens were taken from the lower esophagus (3, 6, and 9 cm above the lower esophageal sphincter) before chemotherapy was begun and 1 month after the sixth course of chemotherapy. All patients had a normal esophagus at the first examination. After finishing chemotherapy, 10 (63%) had developed Barrett esophagus. One patient had the junctional type, 2 patients had the fundic type, 4 patients had a combination of the junctional and fundic types, and 3 patients had the intestinal type. These results suggest that chemotherapy-induced esophageal injury may have been responsible for the development of Barrett esophagus in our patients.	UNIV FERRARA, SCH MED, I-44100 FERRARA, ITALY	University of Ferrara	SARTORI, S (corresponding author), ST ANNA GEN HOSP, CORSO GIOVECCA 230, I-44100 FERRARA, ITALY.		sartori, samantha/AAL-8884-2020					ADRIAN RM, 1980, CA-CANCER J CLIN, V30, P143, DOI 10.3322/canjclin.30.3.143; DAHMS BB, 1987, CANCER, V60, P2896, DOI 10.1002/1097-0142(19871215)60:12<2896::AID-CNCR2820601208>3.0.CO;2-P; LEWIS JH, 1986, AM J GASTROENTEROL, V81, P819; MCCLAVE SA, 1987, GASTROINTEST ENDOSC, V33, P413, DOI 10.1016/S0016-5107(87)71676-9; ROTHERY GA, 1986, GUT, V27, P1062, DOI 10.1136/gut.27.9.1062; SARTORI S, 1989, HEPATO-GASTROENTEROL, V36, P304; SAVARY M, 1985, ESOPHAGEAL DISORDERS, P101; SPECHLER SJ, 1986, NEW ENGL J MED, V315, P362, DOI 10.1056/NEJM198608073150605; TYTGAT GNJ, 1989, ENDOSCOPY, V21, P177, DOI 10.1055/s-2007-1012937	9	53	54	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 1	1991	114	3					210	211		10.7326/0003-4819-114-3-210	http://dx.doi.org/10.7326/0003-4819-114-3-210			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EV339	1984745				2023-01-03	WOS:A1991EV33900007
J	TOWNSEND, J; FRANK, AO; FERMONT, D; DYER, S; KARRAN, O; WALGROVE, A; PIPER, M				TOWNSEND, J; FRANK, AO; FERMONT, D; DYER, S; KARRAN, O; WALGROVE, A; PIPER, M			TERMINAL CANCER CARE AND PATIENTS PREFERENCE FOR PLACE OF DEATH - A PROSPECTIVE-STUDY	BRITISH MEDICAL JOURNAL			English	Article											TOWNSEND, J (corresponding author), NORTHWICK PK HOSP & CLIN RES CTR,MRC,EPIDEMIOL & MED CARE UNIT,HARROW HA1 3UJ,MIDDX,ENGLAND.							ALLBROOK D, 1984, MED J AUSTRALIA, V141, P143, DOI 10.5694/j.1326-5377.1984.tb113057.x; BATES T, 1981, LANCET, V1, P1201, DOI 10.1016/S0140-6736(81)92361-8; CARTWRIGHT A, 1973, LIFE DEATH; Doyle D, 1982, J R Coll Gen Pract, V32, P285; FORD GR, 1978, HLTH TRENDS, V10, P73; HOCKLEY JM, 1988, BRIT MED J, V296, P1715, DOI 10.1136/bmj.296.6638.1715; HOSKIN PJ, 1988, J ROY SOC MED, V81, P341, DOI 10.1177/014107688808100615; MORRIS JN, 1986, J CHRON DIS, V39, P47, DOI 10.1016/0021-9681(86)90106-2; PARKES CM, 1985, LANCET, V1, P155; REES WD, 1982, BRIT MED J, V285, P1766, DOI 10.1136/bmj.285.6357.1766; Saunders C, 1981, HOSPICE LIVING IDEA; SPITZER WO, 1981, J CHRON DIS, V34, P585, DOI 10.1016/0021-9681(81)90058-8; TOWNSEND J, 1988, CONTINUING TERMINAL; 1987, CARE DYING GUIDE HLT; 1981, TERMINAL CARE REPORT; 1989, MORTALITY STATISTICS	16	380	384	1	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 1	1990	301	6749					415	417		10.1136/bmj.301.6749.415	http://dx.doi.org/10.1136/bmj.301.6749.415			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DW782	1967134	Green Published, Bronze			2023-01-03	WOS:A1990DW78200018
J	COLQUHOUN, D				COLQUHOUN, D			REANALYSIS OF CLINICAL-TRIAL OF HOMEOPATHIC TREATMENT IN FIBROSITIS	LANCET			English	Letter											COLQUHOUN, D (corresponding author), UNIV LONDON UNIV COLL,DEPT PHARMACOL,LONDON WC1E 6BT,ENGLAND.		Colquhoun, David/C-1664-2008	Colquhoun, David/0000-0002-4263-017X				ARMITAGE P, 1987, STATISTICAL METHODS; ARMITAGE P, 1982, STATISTICIAN, V31, P119; COLQUHOUN D, 1971, LECTURES BIOSTATISTI, P1370; FISHER P, 1989, BRIT MED J, V299, P365, DOI 10.1136/bmj.299.6695.365; MAINLAND D, 1963, ELEMENTARY MED STATI	5	16	16	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 18	1990	336	8712					441	442		10.1016/0140-6736(90)91989-N	http://dx.doi.org/10.1016/0140-6736(90)91989-N			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DV277	1974969				2023-01-03	WOS:A1990DV27700044
J	DOOREY, AJ; MICHELSON, EL; TOPOL, EJ				DOOREY, AJ; MICHELSON, EL; TOPOL, EJ			THROMBOLYTIC THERAPY OF ACUTE MYOCARDIAL-INFARCTION - KEEPING THE UNFULFILLED PROMISES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							TISSUE PLASMINOGEN-ACTIVATOR; CARDIOPULMONARY-RESUSCITATION; EMERGENCY ROOM; INTRAVENOUS STREPTOKINASE; CORONARY THROMBOLYSIS; CHEST PAIN; PHASE-II; INTRACORONARY STREPTOKINASE; INTRACEREBRAL HEMORRHAGE; VENTRICULAR-FUNCTION	Objective.-To assess the use of thrombolytic therapy for acute myocardial infarction, evaluating whether inclusion and exclusion criteria should be altered as well as the public health implications of any such alterations. Data Sources.-Data obtained were from English-language articles on the use of thrombolytic therapy in acute myocardial infarction. Articles that reported on inclusion and exclusion criteria as well as specific complications of this therapy were specifically sought. The review included articles under the terms thrombolytic therapy and acute myocardial infarction in the National Library of Medicine's MEDLINE database. Study Selection.-Studies selected for detailed review were those reporting specifics about inclusion and exclusion criteria and efficacy. Data extraction guidelines for assessing data quality included study size, patient population, detail of patient information acquired, and consecutive patient enrollment. Data Synthesis.-Thrombolytic therapy can provide substantial decrements of morbidity and mortality of acute myocardial infarction in the subset of patients who receive this therapy, but is underused in the United States. Advanced age per se should not be an exclusion criterion. Improvements can be made in electrocardiographic diagnosis of acute myocardial infarction. Many of the clinical conditions initially excluded from thrombolytic consideration, such as hypertension or having received cardiopulmonary resuscitation, are only relative contraindications. The benefit/risk ratio in treatment of these patients is often acceptable. Several well-documented points of delay from onset of symptoms to treatment can be minimized, and accelerated therapy can result in a reduction in mortality rates. Conclusion.-Significant public health benefits will result from greater use of thrombolytic therapy in acute myocardial infarction.	THOMAS JEFFERSON UNIV, JEFFERSON MED COLL, PHILADELPHIA, PA 19107 USA; HAHNEMANN UNIV, DEPT MED, DIV CARDIOVASC DIS, PHILADELPHIA, PA 19102 USA; CLEVELAND CLIN EDUC FDN, DEPT CARDIOL, CLEVELAND, OH 44106 USA	Jefferson University; Drexel University; Cleveland Clinic Foundation	DOOREY, AJ (corresponding author), CARDIOL CONSULTANTS PA, MED CTR DELAWARE,DEPT MED,DIV CARDIOL, 4745 OGLETOWN STANTON RD, SUITE 220, NEWARK, DE 19713 USA.							ADOLPH RJ, 1990, J AM COLL CARDIOL, V16, P793, DOI 10.1016/S0735-1097(10)80323-7; ALTHOUSE R, 1990, AM J CARDIOL, V66, P1298, DOI 10.1016/0002-9149(90)91157-2; ANDERSON JL, 1991, AM J CARDIOL, V68, P166, DOI 10.1016/0002-9149(91)90738-7; [Anonymous], 1988, LANCET, V2, P349; [Anonymous], 1986, Lancet, V1, P397; BARBASH GI, 1990, AM J CARDIOL, V66, P261, DOI 10.1016/0002-9149(90)90832-L; BATTLE R, 1991, Journal of the American College of Cardiology, V17, p311A; BAYER AJ, 1986, J AM GERIATR SOC, V34, P263, DOI 10.1111/j.1532-5415.1986.tb04221.x; BEDELL SE, 1983, NEW ENGL J MED, V309, P569, DOI 10.1056/NEJM198309083091001; BEHAR S, 1991, AM J CARDIOL, V68, P1291, DOI 10.1016/0002-9149(91)90233-B; BEHAR S, 1991, CIRCULATION, V84, P63; BLOHM M, 1992, AM J CARDIOL, V69, P411, DOI 10.1016/0002-9149(92)90244-S; BOVILL EG, 1991, ANN INTERN MED, V115, P256, DOI 10.7326/0003-4819-115-4-256; BRAUNWALD E, 1989, J AM COLL CARDIOL, V14, P1570, DOI 10.1016/0735-1097(89)90400-2; BRAUNWALD E, 1990, CIRCULATION, V82, P1510, DOI 10.1161/01.CIR.82.4.1510; BUSH HS, 1991, AM HEART J, V121, P1591, DOI 10.1016/0002-8703(91)90001-X; CALIFF RM, 1990, J AM COLL CARDIOL, V15, P937, DOI 10.1016/0735-1097(90)90220-J; CALIFF RM, 1992, AM J CARDIOL, V69, pA12, DOI 10.1016/0002-9149(92)91168-4; CHAITMAN BR, 1989, J AM COLL CARDIOL, V14, P1159, DOI 10.1016/0735-1097(89)90410-5; CHAITMAN BR, 1988, J AM COLL CARDIOL, V12, P1167, DOI 10.1016/0735-1097(88)92595-8; CHAMBERLAIN DA, 1990, LANCET, V335, P427; CHAMBERLAIN DA, 1992, THROMBOLYSIS CAN WE; CHESEBRO JH, 1987, CIRCULATION, V76, P142, DOI 10.1161/01.CIR.76.1.142; CHOP WM, 1991, J FAM PRACTICE, V33, P79; COLLINS R, 1991, CIRCULATION, V84, P230; CRAGG DR, 1991, ANN INTERN MED, V115, P173, DOI 10.7326/0003-4819-115-3-173; CROSS SJ, 1991, BMJ-BRIT MED J, V303, P1242, DOI 10.1136/bmj.303.6812.1242; DEGREGORIO B, 1985, AM HEART J, V109, P908, DOI 10.1016/0002-8703(85)90660-X; DEJAEGERE PP, 1992, J AM COLL CARDIOL, V19, P289, DOI 10.1016/0735-1097(92)90480-B; DOOREY AJ, 1987, J AM COLL CARDIOL, V10, P1357, DOI 10.1016/S0735-1097(87)80141-9; EISENBERG MS, 1989, ANN EMERG MED, V18, P838, DOI 10.1016/S0196-0644(89)80207-0; FEIRING AJ, 1987, CIRCULATION, V75, P980, DOI 10.1161/01.CIR.75.5.980; FRANZOSI MG, 1992, CHEST, V101, pS116, DOI 10.1378/chest.101.4.116S; GIBLER WB, 1991, AM HEART J, V121, P1, DOI 10.1016/0002-8703(91)90948-H; GLIKSON M, 1991, AM HEART J, V121, P1542, DOI 10.1016/0002-8703(91)90164-D; GONZALEZ E R, 1991, Journal of the American College of Cardiology, V17, p247A; GORE JM, 1991, CIRCULATION, V83, P448, DOI 10.1161/01.CIR.83.2.448; GRINES CL, 1990, J AM COLL CARDIOL, V16, P223, DOI 10.1016/0735-1097(90)90482-5; GURWITZ JH, 1991, JAMA-J AM MED ASSOC, V265, P1720, DOI 10.1001/jama.265.13.1720; HERLITZ J, 1989, AM J CARDIOL, V64, P90, DOI 10.1016/0002-9149(89)90659-0; HLATKY MA, 1988, AM J CARDIOL, V61, P510, DOI 10.1016/0002-9149(88)90755-2; HO MT, 1989, ANN EMERG MED, V18, P727, DOI 10.1016/S0196-0644(89)80004-6; Ho MT, 1990, J AM COLL CARDIOL, V15, p192A; HOLMBERG S, 1990, AM J CARDIOL, V65, P401; HUEY BL, 1988, J AM COLL CARDIOL, V12, P1156, DOI 10.1016/0735-1097(88)92594-6; KARLSON BW, 1990, AM HEART J, V120, P1213, DOI 10.1016/0002-8703(90)90138-N; KASE CS, 1990, ANN INTERN MED, V112, P17, DOI 10.7326/0003-4819-112-1-17; KENNEDY JW, 1990, ANN INTERN MED, V113, P907, DOI 10.7326/0003-4819-113-12-907; KENNEDY JW, 1985, NEW ENGL J MED, V312, P1073, DOI 10.1056/NEJM198504253121701; KENNEDY JW, 1988, J AM COLL CARDIOL, V11, P446, DOI 10.1016/0735-1097(88)90114-3; KEREIAKES DJ, 1990, AM HEART J, V120, P773, DOI 10.1016/0002-8703(90)90192-Z; KOWALENKO T, 1992, AM HEART J, V123, P181, DOI 10.1016/0002-8703(92)90764-M; KRUMHOLZ H M, 1992, Journal of the American College of Cardiology, V19, p378A; KRUMHOLZ HM, 1992, NEW ENGL J MED, V327, P7, DOI 10.1056/NEJM199207023270102; KUDENCHUK PJ, 1991, J AM COLL CARDIOL, V17, P1486, DOI 10.1016/0735-1097(91)90636-N; LEE TH, 1989, ANN INTERN MED, V110, P957, DOI 10.7326/0003-4819-110-12-957; LEIZOROVICZ A, 1990, CIRCULATION, V82, P255; LEW AS, 1987, AM J CARDIOL, V59, P1, DOI 10.1016/S0002-9149(87)80059-0; MACCALLUM AG, 1990, EUR HEART J, V11, P48, DOI 10.1093/eurheartj/11.suppl_F.48; MAGGIONI A, 1991, BMJ-BRIT MED J, V302, P1428, DOI 10.1136/bmj.302.6790.1428; MAGGIONI AP, 1992, NEW ENGL J MED, V327, P1, DOI 10.1056/NEJM199207023270101; MARK DB, 1988, J AM COLL CARDIOL, V12, pA32, DOI 10.1016/0735-1097(88)92639-3; MAYNARD C, 1989, AM J CARDIOL, V63, P1296, DOI 10.1016/0002-9149(89)91038-2; MITIC WR, 1984, CAN J PUBLIC HEALTH, V75, P414; MOHR JP, 1983, HARRISONS PRINCIPLES, P2050; MOLINA JE, 1992, AM J SURG, V163, P375, DOI 10.1016/0002-9610(92)90036-Q; MONTAGUE TJ, 1991, AM J CARDIOL, V68, P843, DOI 10.1016/0002-9149(91)90397-4; MOSES HW, 1991, AM J CARDIOL, V68, P251, DOI 10.1016/0002-9149(91)90754-9; MULLER DWM, 1990, ANN INTERN MED, V113, P949, DOI 10.7326/0003-4819-113-12-949; MURRAY N, 1987, BRIT HEART J, V57, P144; NECHES RB, 1991, CLIN CARDIOL, V14, P616, DOI 10.1002/clc.4960140715; NEUHAUS KL, 1989, J AM COLL CARDIOL, V14, P1566, DOI 10.1016/0735-1097(89)90399-9; O'CONNOR C M, 1990, Journal of the American College of Cardiology, V15, p34A; OCONNOR CM, 1990, J AM COLL CARDIOL, V16, P533, DOI 10.1016/0735-1097(90)90338-P; PASTERNAK RC, 1992, HEART DISEASE TXB CA, P1200; PEPINE CJ, 1990, CLIN CARDIOL, V13, P12; PEPINE CJ, 1991, J MYOCARDIAL ISCHEMI, V3, P10; PETO R, 1991, 40TH ANN SCI SESS AM; PFEFFER MA, 1991, JAMA-J AM MED ASSOC, V266, P528, DOI 10.1001/jama.266.4.528; RICH MW, 1990, CARDIO, V7, P79; RIDKER PM, 1992, AM J CARDIOL, V70, P10, DOI 10.1016/0002-9149(92)91381-D; SCHMIDT SB, 1990, AM J CARDIOL, V65, P1411, DOI 10.1016/0002-9149(90)91345-7; SCHOLZ KH, 1992, AM J CARDIOL, V69, P724, DOI 10.1016/0002-9149(92)90494-J; SCHROEDER JS, 1978, AM J MED, V64, P742, DOI 10.1016/0002-9343(78)90512-0; SCHWEITZER P, 1990, AM HEART J, V119, P642, DOI 10.1016/S0002-8703(05)80288-1; SHARKEY SW, 1989, JAMA-J AM MED ASSOC, V262, P3171, DOI 10.1001/jama.262.22.3171; SHERRY S, 1980, ANN INTERN MED, V93, P141, DOI 10.7326/0003-4819-93-1-141; SLEIGHT P, 1991, 7TH INT WORKSH THROM; SLOAN MA, 1992, AM J CARDIOL, V69, pA21, DOI 10.1016/0002-9149(92)91169-5; SMITH M, 1987, ANN EMERG MED, V16, P592, DOI 10.1016/S0196-0644(87)80698-4; SMITH SC, 1990, J AM COLL CARDIOL, V16, P784, DOI 10.1016/S0735-1097(10)80322-5; TENAGLIA AN, 1991, AM J CARDIOL, V68, P1015, DOI 10.1016/0002-9149(91)90488-7; TIEFENBRUNN AJ, 1989, JAMA-J AM MED ASSOC, V261, P2107; TIEFENBRUNN AJ, 1992, AM J CARDIOL, V69, pA3, DOI 10.1016/0002-9149(92)91167-3; TJOE SL, 1972, CHEST, V61, P617, DOI 10.1378/chest.61.7.617; TOPOL EJ, 1987, J AM COLL CARDIOL, V10, P1173, DOI 10.1016/S0735-1097(87)80114-6; TOPOL EJ, 1990, J AM COLL CARDIOL, V15, P922, DOI 10.1016/0735-1097(90)90217-D; TOPOL EJ, 1992, NEW ENGL J MED, V327, P45, DOI 10.1056/NEJM199207023270109; VERHEUGT FWA, 1989, AM HEART J, V117, P1018, DOI 10.1016/0002-8703(89)90856-9; VERSTRAETE M, 1988, CIRCULATION, V77, P353, DOI 10.1161/01.CIR.77.2.353; VONDERLEYEN H, 1991, CIRCULATION, V84, P62; WASSERMAN AG, 1989, AM J CARDIOL, V64, pB17, DOI 10.1016/S0002-9149(89)80004-9; WEAVER WD, 1990, J AM COLL CARDIOL, V15, P925, DOI 10.1016/0735-1097(90)90218-E; WEAVER WD, 1991, J AM COLL CARDIOL, V18, P657, DOI 10.1016/0735-1097(91)90784-7; WEAVER WD, 1992, 41ST SCI SESS AM COL; WILCOX RG, 1990, LANCET, V335, P1175; WILELRSON JT, 1991, NEW ENGL J MED, V325, P1166; WITTRY MD, 1989, GERIATRICS-US, V44, P28; 1991, 1991 HEART STROKE FA	109	54	54	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 2	1992	268	21					3108	3114		10.1001/jama.268.21.3108	http://dx.doi.org/10.1001/jama.268.21.3108			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KA002	1433742				2023-01-03	WOS:A1992KA00200035
J	COCKERILL, FR; MULLER, SR; ANHALT, JP; MARSH, HM; FARNELL, MB; MUCHA, P; GILLESPIE, DJ; ILSTRUP, DM; LARSONKELLER, JJ; THOMPSON, RL				COCKERILL, FR; MULLER, SR; ANHALT, JP; MARSH, HM; FARNELL, MB; MUCHA, P; GILLESPIE, DJ; ILSTRUP, DM; LARSONKELLER, JJ; THOMPSON, RL			PREVENTION OF INFECTION IN CRITICALLY ILL PATIENTS BY SELECTIVE DECONTAMINATION OF THE DIGESTIVE-TRACT	ANNALS OF INTERNAL MEDICINE			English	Article						INFECTION CONTROL; DIGESTIVE SYSTEM; DECONTAMINATION; INTENSIVE CARE UNITS; CEFOTAXIME	INTENSIVE-CARE UNIT; COLONIZATION; NORFLOXACIN; SEPSIS	Objective: To determine whether selective decontamination of the digestive tract using oral and nonabsorbable antimicrobial agents and parenteral cefotaxime prevents infection in critically ill patients. Design: Randomized, controlled trial without blinding. Setting: Surgical trauma and medical intensive care units in a tertiary referral hospital. Patients: One hundred fifty patients admitted to surgical trauma and medical intensive care units during a 3-year interval, whose condition suggested a prolonged stay (> 3 days). Intervention: Patients were randomly allocated to an experimental group (n = 75) that received cefotaxime, 1 g intravenously every 8 hours for the first 3 days only, and oral, nonabsorbable antibiotics (gentamicin, polymyxin, and nystatin by oral paste and oral liquid) for the entire stay in the intensive care unit. Control patients (n = 75) received usual care. Measurements: The number of infections, total hospital days, and deaths, as well as the number of days in intensive care unit, were recorded. Results: Control patients experienced more infections (36 compared with 12, P = 0.04), including bacteremias (14 compared with 4, P = 0.05) and pulmonary infections (14 compared with 4, P = 0.03). Although total hospital days, days in intensive care, and the overall death rate all were lower in the treatment group, these differences were not statistically significant. Clinically important complications of selective decontamination of the digestive tract were not encountered. Conclusions: Selective decontamination of the digestive tract decreases subsequent infection rates, especially by gram-negative bacilli, in selected patients during long-term stays in the intensive care unit.			COCKERILL, FR (corresponding author), MAYO CLIN & MAYO FDN, ROCHESTER, MN 55905 USA.		/AAL-3363-2020					BOW EJ, 1988, AM J MED, V84, P847, DOI 10.1016/0002-9343(88)90062-9; BRUNBUISSON C, 1989, ANN INTERN MED, V110, P873, DOI 10.7326/0003-4819-110-11-873; CHAMPION HR, 1980, CRIT CARE MED, V8, P201, DOI 10.1097/00003246-198004000-00001; FLAHERTY J, 1990, J INFECT DIS, V162, P1393, DOI 10.1093/infdis/162.6.1393; HALEY RW, 1981, AM J MED, V70, P51, DOI 10.1016/0002-9343(81)90411-3; HARTENAUER U, 1990, INFECTION, V18, pS22, DOI 10.1007/BF01644483; KERVER AJH, 1988, CRIT CARE MED, V16, P1087, DOI 10.1097/00003246-198811000-00001; KNAUS WA, 1986, ANN INTERN MED, V104, P410, DOI 10.7326/0003-4819-104-3-410; LEDINGHAM IM, 1988, LANCET, V1, P785; MCCLELLAND P, 1990, CRIT CARE MED, V18, P935, DOI 10.1097/00003246-199009000-00006; MILLER PJ, 1989, REV INFECT DIS, V11, P284; Miranda D R, 1983, Acta Anaesthesiol Belg, V34, P223; STOUTENBEEK CP, 1984, INTENS CARE MED, V10, P185, DOI 10.1007/BF00259435; STOUTENBEEK CP, 1987, J ANTIMICROB CHEMOTH, V19, P513, DOI 10.1093/jac/19.4.513; ULRICH C, 1989, INTENS CARE MED, V15, P424, DOI 10.1007/BF00255597; WASHINGTON JA, 1985, LABORATORY PROCEDURE	16	86	90	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 1	1992	117	7					545	553		10.7326/0003-4819-117-7-545	http://dx.doi.org/10.7326/0003-4819-117-7-545			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JQ226	1524328				2023-01-03	WOS:A1992JQ22600001
J	MAGGIONI, AP; FRANZOSI, MG; SANTORO, E; WHITE, H; VANDEWERF, F; TOGNONI, G				MAGGIONI, AP; FRANZOSI, MG; SANTORO, E; WHITE, H; VANDEWERF, F; TOGNONI, G			THE RISK OF STROKE IN PATIENTS WITH ACUTE MYOCARDIAL-INFARCTION AFTER THROMBOLYTIC AND ANTITHROMBOTIC TREATMENT	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ECHOCARDIOGRAPHY	Background. Many trials in patients with acute myocardial infarction have demonstrated that thrombolytic therapy is not associated with an excessive risk of stroke, as compared with conventional treatment. However, the incidence of various forms of stroke in patients treated,with different thrombolytic and antithrombotic regimens and the associated effect of risk factors for stroke are largely unknown. Methods. Strokes occurring in patients hospitalized with acute myocardial infarction who were enrolled in either of two large trials were analyzed. The patients were randomly assigned to receive streptokinase (1.5 million units) or recombinant tissue plasminogen activator (t-PA) (100 mg) and also randomly assigned to receive subcutaneous heparin or no heparin. Ninety-one percent of the patients also received aspirin. Results. Complete data were available on 20,768 patients. A total of 236 (1.14 percent) had strokes in the hospital; 0.36 percent had hemorrhagic strokes, 0.48 percent ischemic strokes, and 0.30 percent strokes of undefined cause. Patients treated with t-PA had a small but significant excess of stroke as compared with those who received streptokinase (1.33 vs. 0.94 percent; adjusted odds ratio, 1.42; 95 percent confidence interval, 1.09 to 1.84). The administration of subcutaneous heparin in addition to a thrombolytic agent did not increase the risk of stroke (risk with heparin, 1.13 percent; without heparin, 1.14 percent). Older age, a higher Killip class, and the occurrence of anterior infarction significantly increased the risk of stroke, whereas a higher body-mass index or a history of hypertension, diabetes, or smoking did not. Conclusions. Patients with acute myocardial infarction who receive thrombolytic therapy have a small risk of stroke. Treatment with t-PA as compared with streptokinase resulted in a small but significant excess of stroke. Subcutaneous heparin, given together with t-PA or streptokinase and aspirin, did not result in an increased risk of stroke.	UNIV HOSP GASTHUISBERG, DIV CARDIOL, INT STUDY GRP, B-3000 LOUVAIN, BELGIUM	KU Leuven; University Hospital Leuven	MAGGIONI, AP (corresponding author), GRP ITALIANO STUDIO SOPRAVVIVENZA INFARTO MIOCARDI, COORDINATING CTR, VIA ERITREA 62, I-20157 MILAN, ITALY.		Simes, Robert John/P-1497-2014; Leonardi, Giuseppe/AAY-1205-2020; Maggioni, Aldo Pietro/AAL-5334-2020; santoro, eugenio/ABG-7901-2020	Maggioni, Aldo Pietro/0000-0003-2764-6779; santoro, eugenio/0000-0002-5719-9896				[Anonymous], 1990, LANCET, V336, P65; [Anonymous], 1988, LANCET, V2, P349; [Anonymous], 1986, LANCET, V1, P397; [Anonymous], 1989, NEW ENGL J MED, V320, P618; [Anonymous], 1988, BRIT MED J, V296, P320; ASINGER RW, 1981, NEW ENGL J MED, V305, P297, DOI 10.1056/NEJM198108063050601; CALIFF RM, 1988, ACUTE CORONARY CARE, P539; CHAMBERLAIN DA, 1990, LANCET, V335, P427; DEBONO DP, 1992, BRIT HEART J, V67, P122; FIEBACH NH, 1990, JAMA-J AM MED ASSOC, V263, P1092, DOI 10.1001/jama.263.8.1092; GORE JM, 1991, CIRCULATION, V83, P448, DOI 10.1161/01.CIR.83.2.448; GRINES CL, 1990, J AM COLL CARDIOL, V16, P223, DOI 10.1016/0735-1097(90)90482-5; HUNT D, 1992, LANCET, V339, P753; KOMRAD MS, 1984, NEUROLOGY, V34, P1403, DOI 10.1212/WNL.34.11.1403; MAGGIONI A, 1991, BMJ-BRIT MED J, V302, P1428, DOI 10.1136/bmj.302.6790.1428; OCONNOR CM, 1990, J AM COLL CARDIOL, V16, P533, DOI 10.1016/0735-1097(90)90338-P; ODONNELL M, 1991, BRIT MED J, V302, P1259, DOI 10.1136/bmj.302.6787.1259; ROBERTS R, 1991, CIRCULATION, V83, P422, DOI 10.1161/01.CIR.83.2.422; Schlesselman JJ, 1982, CASE CONTROL STUDIES, P171; SCHLESSELMAN JJ, 1982, CASE CONTROL STUDIES, P227; THOMPSON PL, 1978, BRIT MED J, V2, P457, DOI 10.1136/bmj.2.6135.457; VANDEWERF F, 1990, LANCET, V336, P71; WEINREICH DJ, 1984, ANN INTERN MED, V100, P789, DOI 10.7326/0003-4819-100-6-789; WILCOX RG, 1988, LANCET, V2, P525	24	213	214	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 2	1992	327	1					1	6		10.1056/NEJM199207023270101	http://dx.doi.org/10.1056/NEJM199207023270101			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JA761	1598096	Bronze			2023-01-03	WOS:A1992JA76100001
J	TOPOL, EJ; CALIFF, RM				TOPOL, EJ; CALIFF, RM			THROMBOLYTIC THERAPY FOR ELDERLY PATIENTS	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							ACUTE MYOCARDIAL-INFARCTION		DUKE UNIV, SCH MED, DURHAM, NC 27710 USA	Duke University	TOPOL, EJ (corresponding author), CLEVELAND CLIN FDN, CLEVELAND, OH 44195 USA.							[Anonymous], 1990, LANCET, V336, P65; [Anonymous], 1988, LANCET, V2, P349; [Anonymous], 1986, LANCET, V1, P397; CRAVER JM, 1990, CIRCULATION, V82, P360; DEJAEGERE PP, 1992, J AM COLL CARDIOL, V19, P289, DOI 10.1016/0735-1097(92)90480-B; FEIT F, 1990, CIRCULATION, V82, P666; GORE JM, 1991, CIRCULATION, V83, P448, DOI 10.1161/01.CIR.83.2.448; GURWITZ JH, 1991, JAMA-J AM MED ASSOC, V265, P1720, DOI 10.1001/jama.265.13.1720; HUNT D, 1992, LANCET, V339, P753; KAPANTAIS G, 1989, ADV VITAL HLTH STATI, V172; KOLATA G, 1992, NY TIMES        0216, P6; KRUMHOLZ HM, 1992, NEW ENGL J MED, V327, P7, DOI 10.1056/NEJM199207023270102; MAGGIONI AP, 1992, NEW ENGL J MED, V327, P1, DOI 10.1056/NEJM199207023270101; MULLER DWM, 1990, ANN INTERN MED, V113, P949, DOI 10.7326/0003-4819-113-12-949; SOLDO BJ, 1988, GERIATRIC MED, P12; TOPOL EJ, 1992, J AM COLL CARDIOL, V19, P1123, DOI 10.1016/0735-1097(92)90312-B; WEAVER WD, 1991, J AM COLL CARDIOL, V18, P657, DOI 10.1016/0735-1097(91)90784-7	17	54	55	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 2	1992	327	1					45	47		10.1056/NEJM199207023270109	http://dx.doi.org/10.1056/NEJM199207023270109			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JA761	1598101				2023-01-03	WOS:A1992JA76100009
J	GIETEMA, JA; SLEIJFER, DT; WILLEMSE, PHB; KOOPS, HS; VANITTERSUM, E; VERSCHUREN, WMM; KROMHOUT, D; SLUITER, WJ; MULDER, NH; DEVRIES, EGE				GIETEMA, JA; SLEIJFER, DT; WILLEMSE, PHB; KOOPS, HS; VANITTERSUM, E; VERSCHUREN, WMM; KROMHOUT, D; SLUITER, WJ; MULDER, NH; DEVRIES, EGE			LONG-TERM FOLLOW-UP OF CARDIOVASCULAR RISK-FACTORS IN PATIENTS GIVEN CHEMOTHERAPY FOR DISSEMINATED NONSEMINOMATOUS TESTICULAR CANCER	ANNALS OF INTERNAL MEDICINE			English	Article						TESTICULAR NEOPLASMS; CARDIOVASCULAR DISEASES; CISPLATIN; HYPERCHOLESTEROLEMIA	GERM-CELL TUMORS; COMBINATION CHEMOTHERAPY; DENSITY LIPOPROTEIN; RAYNAUDS-PHENOMENON; SERUM-CHOLESTEROL; RENAL-FUNCTION; CISPLATIN; VINBLASTINE; BLEOMYCIN; TOXICITY	. Objective: To assess cardiovascular risk factors over time in patients who received chemotherapy for disseminated testicular cancer and were apparently cured. . Design: Cohort study. . Setting: Referral center. . Patients: Fifty-seven consecutive patients (median age, 28 years; range, 16 to 43 years) who received cisplatin-containing chemotherapy between 1978 and 1985. . Measurements: Serum cholesterol and high-density lipoprotein (HDL) levels, body mass index (BMI), blood pressure, kidney function, and hormonal status were monitored during follow-up after chemotherapy (median follow-up, 88 months; range, 56 to 143 months). The BMI and cholesterol values obtained 4 to 6 years after chemotherapy were compared with values from a sample of healthy, age-matched Dutch men; the cholesterol level was also compared with that of 31 patients treated with orchidectomy for stage I disease. . Results: The mean cholesterol level in patients at the start of chemotherapy was 3.96 +/- 0.98 mmol/L [153 +/- 38 mg/dL], increasing 4 to 6 years later to 6.12 +/- 1.20 mmol/L [237 +/- 46 mg/dL] (P < 0.001); 49 of 57 patients had an elevated low-density lipoprotein (LDL) cholesterol level (> 3.4 mmol/L [130 mg/dL]), with a mean level of 4.47 +/- 1.05 mmol/L [173 +/- 41 mg/dL]. Compared with a sample of healthy Dutch men, the chemotherapy group had an elevated cholesterol level (P < 0.05). At 4 to 6 years, the mean HDL cholesterol level was 0.76 +/- 0.18 mmol/L [29 +/- 7 mg/dL], which was low compared with that of the healthy Dutch men (P < 0.05). The mean BMI for all patients was 2.8% higher than expected 4 to 6 years after chemotherapy (P < 0.01) but was not higher than expected 7 to 10 years after chemotherapy. . Conclusions: In addition to other known late side effects of chemotherapy in patients with testicular cancer, hypercholesterolemia and overweight might represent risk factors for cardiovascular disease in such patients, especially in those who are younger.	UNIV GRONINGEN HOSP, DEPT INTERNAL MED, DIV MED ONCOL, OOSTERSINGEL 59, 9713 EZ GRONINGEN, NETHERLANDS; NATL INST PUBL HLTH & ENVIRONM PROTECT, BILTHOVEN, NETHERLANDS	University of Groningen; Netherlands National Institute for Public Health & the Environment			Kromhout, Daan/A-8566-2014	de Vries, Elisabeth/0000-0002-8949-7425; Gietema, Jourik/0000-0003-0629-7354				ADOUE D, 1984, ANN INTERN MED, V100, P770, DOI 10.7326/0003-4819-100-5-770_2; ALBERS JJ, 1978, CLIN CHEM, V24, P853; ANDRES R, 1985, ANN INTERN MED, V103, P1030, DOI 10.7326/0003-4819-103-6-1030; BENFANTE R, 1990, JAMA-J AM MED ASSOC, V263, P393, DOI 10.1001/jama.263.3.393; BOYER M, 1990, J CLIN ONCOL, V8, P21, DOI 10.1200/JCO.1990.8.1.21; CAMORIANO JK, 1990, J CLIN ONCOL, V8, P1327, DOI 10.1200/JCO.1990.8.8.1327; DOLL DC, 1986, ANN INTERN MED, V105, P48, DOI 10.7326/0003-4819-105-1-48; EDWARDS GS, 1979, CANCER TREAT REP, V63, P551; EINHORN LH, 1990, J CLIN ONCOL, V8, P1777, DOI 10.1200/JCO.1990.8.11.1777; FOSSA SD, 1986, CANCER, V58, P2600, DOI 10.1002/1097-0142(19861215)58:12<2600::AID-CNCR2820581208>3.0.CO;2-D; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; GINSBERG H, 1982, ANN INTERN MED, V96, P311, DOI 10.7326/0003-4819-96-3-311; HANSEN SW, 1990, J CLIN ONCOL, V8, P1695, DOI 10.1200/JCO.1990.8.10.1695; HANSEN SW, 1988, J CLIN ONCOL, V6, P1728, DOI 10.1200/JCO.1988.6.11.1728; HENRIKSSON P, 1990, LANCET, V336, P1178; KROMHOUT D, 1989, 528901002 NAT I PUBL; LEITNER SP, 1986, J CLIN ONCOL, V4, P1500, DOI 10.1200/JCO.1986.4.10.1500; LEJONC JL, 1980, LANCET, V2, P692; MEIJER S, 1983, CANCER, V51, P2035, DOI 10.1002/1097-0142(19830601)51:11<2035::AID-CNCR2820511113>3.0.CO;2-8; MILLER SR, 1981, JNCI-J NATL CANCER I, V67, P297; NYDEGGER UE, 1972, CANCER RES, V32, P1756; OPPENHEIM DS, 1989, ANN INTERN MED, V111, P288, DOI 10.7326/0003-4819-111-4-288; ROOKUS MA, 1987, HUM BIOL, V59, P599; ROTH BJ, 1988, J CLIN ONCOL, V6, P1239, DOI 10.1200/JCO.1988.6.8.1239; SAMUELS BL, 1987, INT J ANDROL, V10, P363, DOI 10.1111/j.1365-2605.1987.tb00204.x; SAMUELS BL, 1987, CANCER CHEMOTH PHARM, V19, P253; SEGAL KR, 1987, J CLIN INVEST, V80, P1050, DOI 10.1172/JCI113159; STOTER G, 1989, J CLIN ONCOL, V7, P1099, DOI 10.1200/JCO.1989.7.8.1099; STUART NSA, 1990, BRIT J CANCER, V61, P479, DOI 10.1038/bjc.1990.106; SUBAR M, 1986, CANCER TREAT REP, V70, P690; VANBARNEVELD PWC, 1984, AM REV RESPIR DIS, V130, P1078; VANITALLIE TB, 1985, ANN INTERN MED, V103, P983, DOI 10.7326/0003-4819-103-6-983; VOGELZANG NJ, 1981, ANN INTERN MED, V95, P288, DOI 10.7326/0003-4819-95-3-288; VOGELZANG NJ, 1980, CANCER TREAT REP, V64, P1159; WILLEMSE PHB, 1983, INT J ANDROL, V6, P497, DOI 10.1111/j.1365-2605.1983.tb00341.x; 1988, ACH INTERN MED, V148, P36	36	82	82	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 1	1992	116	9					709	715		10.7326/0003-4819-116-9-709	http://dx.doi.org/10.7326/0003-4819-116-9-709			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HQ623	1558341				2023-01-03	WOS:A1992HQ62300002
J	DENMAN, SJ; BURTON, JR				DENMAN, SJ; BURTON, JR			FLUID INTAKE AND URINARY-TRACT INFECTION IN THE ELDERLY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											DENMAN, SJ (corresponding author), JOHNS HOPKINS UNIV,FRANCIS SCOTT KEY MED CTR,SCH MED,BALTIMORE,MD 21218, USA.							ANDRIOLE VT, 1968, J LAB CLIN MED, V71, P1; FRIEDMAN SA, 1970, J UROLOGY, V105, P428; Kaye D, 1975, Urol Clin North Am, V2, P407; LONERGAN ET, 1988, GERIATRICS, V43, P23; NUNEZ JFM, 1987, RENAL FUNCTION DISEA, P84; WHELTON A, 1978, JOHNS HOPKINS MED J, V142, P8	6	10	10	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 22	1992	267	16					2245	&		10.1001/jama.267.16.2245	http://dx.doi.org/10.1001/jama.267.16.2245			0	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HN841	1556802				2023-01-03	WOS:A1992HN84100040
J	SMITH, J; CROWE, C; JOHNSON, C; DONOVAN, M				SMITH, J; CROWE, C; JOHNSON, C; DONOVAN, M			TRANSFERS FROM PRISON FOR URGENT PSYCHIATRIC-TREATMENT - A STUDY OF SECTION-48 ADMISSIONS	BRITISH MEDICAL JOURNAL			English	Article											DONOVAN, M (corresponding author), LANGDON HOSP,BUTLER CLIN,DAWLISH EX7 0NR,DEVON,ENGLAND.							GROUNDS A, 1990, PRINCIPLES PRACTICE; Joseph P L, 1990, Health Trends, V22, P51; MCCLURE GMG, 1987, BRIT J PSYCHIAT, V150, P309, DOI 10.1192/bjp.150.3.309; Smith J, 1991, J FORENSIC PSYCHIATR, V2, P95; 1990, WORKING PARTY REPORT; 1990, 6690 HOM OFF CIRC	6	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 11	1992	304	6832					967	969		10.1136/bmj.304.6832.967	http://dx.doi.org/10.1136/bmj.304.6832.967			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HP064	1581722	Green Published, Bronze			2023-01-03	WOS:A1992HP06400027
J	WASSON, J; GAUDETTE, C; WHALEY, F; SAUVIGNE, A; BARIBEAU, P; WELCH, HG				WASSON, J; GAUDETTE, C; WHALEY, F; SAUVIGNE, A; BARIBEAU, P; WELCH, HG			TELEPHONE CARE AS A SUBSTITUTE FOR ROUTINE CLINIC FOLLOW-UP	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MULTIVARIATE PREDICTION MODEL; RAPID ESTIMATION; CONTROLLED TRIAL; CHARGES	Design. - Randomized trial.(~)Setting. - A primary care clinic.(~)Patients. - Four hundred ninety-seven men aged 54 years or older. Objective. - We examined the hypothesis that substituting clinician-initiated telephone calls (telephone care) for some clinic visits would reduce medical care utilization without adversely affecting patient health. Intervention. - Clinicians were asked to double their recommended interval for face-to-face follow-up and schedule three intervening telephone contacts; for control patients, the follow-up interval recommended by their clinician was unchanged. Main Outcome Measures. - Use of medical services and health status. Results. - During the 2-year follow-up period, 7% of patients withdrew or became unavailable. Telephone-care patients had fewer total clinic visits, scheduled and unscheduled, than usual-care patients (19%, P < .001). In addition, telephone-care patients had less medication use (14%, P = .006), fewer admissions, and shorter stays in the hospital (28% fewer total hospital days, P = .005), and 41% fewer intensive care unit days (P = .03). Estimated total expenditures for telephone care were 28% less per patient for the 2 years ($1656, P = .004). For the subgroup of patients with fair or poor overall health at the beginning of the study (n = 180), savings were somewhat greater ($1976, P = .01). In this subgroup, improvement in physical function from baseline (P = .02) and a possible reduction in mortality (P = .06) were also observed. Conclusion. - We conclude that substituting telephone care for selected clinic visits significantly reduces utilization of medical services. For more severely ill patients, the increased contact made possible by telephone care may also improve health status and reduce mortality.	DARTMOUTH COLL, DEPT COMMUNITY & FAMILY MED, HANOVER, NH 03755 USA; DARTMOUTH COLL, DEPT MED, HANOVER, NH 03755 USA	Dartmouth College; Dartmouth College	WASSON, J (corresponding author), DARTMOUTH COLL, CTR AGING, 7265 STRASENBURGH HALL, HANOVER, NH 03755 USA.							APPLEGATE WB, 1990, NEW ENGL J MED, V322, P1572, DOI 10.1056/NEJM199005313222205; BERTERA EM, 1981, AM J PUBLIC HEALTH, V71, P626, DOI 10.2105/AJPH.71.6.626; EGGERT GM, 1988, HLTH CARE FINANCIN S, V1988, P57; FINKLER SA, 1982, ANN INTERN MED, V96, P102, DOI 10.7326/0003-4819-96-1-102; FISCHER PM, 1979, J FAM PRACTICE, V8, P321; Greenlick M R, 1973, Med Care, V11, P121, DOI 10.1097/00005650-197303000-00004; HALLAM L, 1989, FAM PRACT, V6, P47, DOI 10.1093/fampra/6.1.47; HENDRIKSEN C, 1984, BMJ-BRIT MED J, V289, P1522, DOI 10.1136/bmj.289.6457.1522; JOHNSON BE, 1990, J GEN INTERN MED, V5, P234, DOI 10.1007/BF02600541; KUKULL WA, 1986, MED CARE, V24, P961, DOI 10.1097/00005650-198610000-00009; NELSON EC, 1990, MED CARE, V28, P1111, DOI 10.1097/00005650-199012000-00001; QUADE D, 1982, BIOMETRICS, V38, P597, DOI 10.2307/2530042; RUBENSTEIN L Z, 1991, Journal of the American Geriatrics Society, V39, p37S; SPENCER DC, 1988, J FAM PRACTICE, V27, P201; Ware J E Jr, 1983, Eval Program Plann, V6, P247, DOI 10.1016/0149-7189(83)90005-8; WASSON JH, 1984, JAMA-J AM MED ASSOC, V252, P2413; WASSON JH, 1987, MED CARE, V25, P1002, DOI 10.1097/00005650-198710000-00008; WEINGARTEN MA, 1982, J ROY COLL GEN PRACT, V32, P766; WEISSMAN JS, 1991, ANN INTERN MED, V114, P325, DOI 10.7326/0003-4819-114-4-325; WELCH HG, 1989, MED CARE, V27, P900, DOI 10.1097/00005650-198909000-00005; 1989, RELATIVE VALUES PHYS; 1991, FED REG         1125, V56, P59501	22	303	304	0	9	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 1	1992	267	13					1788	1793		10.1001/jama.267.13.1788	http://dx.doi.org/10.1001/jama.267.13.1788			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HK672	1545464				2023-01-03	WOS:A1992HK67200028
J	SFORZINI, S; LATINI, R; MINGARDI, G; VINCENTI, A; REDAELLI, B				SFORZINI, S; LATINI, R; MINGARDI, G; VINCENTI, A; REDAELLI, B			VENTRICULAR ARRHYTHMIAS AND 4-YEAR MORTALITY IN HEMODIALYSIS-PATIENTS	LANCET			English	Note							AMBULATORY PERITONEAL-DIALYSIS; HEMODIALYSIS; TRANSPLANTATION	127 randomly selected patients on haemodialysis showed a high prevalence of ventricular arrhythmias, the frequency of which rose significantly during and after dialysis. These patients have now been followed up for 4 years. Only age and ischaemic heart disease correlated independently with mortality. Although ventricular arrhythmias are often associated with cardiac disease in patients on chronic haemodialysis, they do not seem to predict overall mortality.	OSPED SAN GERARDO, DIV RENAL & DIALYSIS, MONZA, ITALY; OSPED RIUNITI BERGAMO, DIV RENAL & DIALYSIS, I-24100 BERGAMO, ITALY; MARIO NEGRI INST PHARMACOL RES, I-20157 MILAN, ITALY; OSPED SAN GERARDO, DIV CARDIOL, MONZA, ITALY	San Gerardo Hospital; Ospedali Riuniti di Bergamo; Istituto di Ricerche Farmacologiche Mario Negri IRCCS; San Gerardo Hospital			Latini, Roberto/AAB-1410-2020	Latini, Roberto/0000-0002-3729-4650				BRADLEY JR, 1987, LANCET, V1, P295; BRUNNER FP, 1988, NEPHROL DIAL TRANSPL, V2, P109; BRYNGER H, 1980, 7TH P C EUR DIAL TRA, P36; BURTON PR, 1987, LANCET, V1, P1115; DEGOULET P, 1982, NEPHRON, V31, P103, DOI 10.1159/000182627; GOKAL R, 1987, LANCET, V2, P1105; KJELLSTRAND CM, 1990, AM J KIDNEY DIS, V15, P483, DOI 10.1016/S0272-6386(12)70365-7; LATINI R, 1988, LANCET, V2, P305	8	60	61	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 25	1992	339	8787					212	213		10.1016/0140-6736(92)90008-Q	http://dx.doi.org/10.1016/0140-6736(92)90008-Q			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HA589	1346174				2023-01-03	WOS:A1992HA58900005
J	KEMENY, N; SEITER, K; MARTIN, D; URMACHER, C; NIEDZWIECKI, D; KURTZ, RC; COSTA, P; MURRAY, M				KEMENY, N; SEITER, K; MARTIN, D; URMACHER, C; NIEDZWIECKI, D; KURTZ, RC; COSTA, P; MURRAY, M			A NEW SYNDROME - ASCITES, HYPERBILIRUBINEMIA, AND HYPOALBUMINEMIA AFTER BIOCHEMICAL MODULATION OF FLUOROURACIL WITH N-PHOSPHONACETYL-L-ASPARTATE (PALA)	ANNALS OF INTERNAL MEDICINE			English	Article							N-(PHOSPHONACETYL)-L-ASPARTIC ACID PALA; PHASE-I TRIAL; COLORECTAL-CANCER; L-ASPARAGINASE; 5-FLUOROURACIL INCORPORATION; CARCINOMA; INFUSION; THERAPY; ENHANCEMENT; COMBINATION	Objective: To report a new syndrome of ascites, hyperbilirubinemia, and hypoalbuminemia after treatment with N-phosphonacetyl-L-aspartate (PALA) and fluorouracil for metastatic colorectal cancer. Design: Retrospective analysis. Setting: Regional cancer treatment center. Patients: Forty-four previously untreated patients with metastatic colorectal cancer in a phase I-II trial of PALA-fluorouracil. Measurements and Main Results: One or more transient hepatic abnormalities frequently occurred in 15 of the 17 responding patients. Within the first 10 weeks of treatment, 5 patients developed ascites, 12 had a decrease in the serum albumin level, 6 developed bilirubin elevations, and 7 had transaminase elevations, all in the presence of a complete or partial tumor response. Prolongations of the prothrombin time and elevations of serum glucose levels were also seen. Conclusions: An unusual syndrome of ascites, hyperbilirubinemia, and hypoalbuminemia is associated with a PALA-fluorouracil regimen. These abnormalities, which may be related to decreased hepatic protein synthesis, occurred more often in patients whose tumor was responding to chemotherapy. Clinicians must recognize that in patients undergoing chemotherapy with these agents, ascites and elevated liver function tests may be secondary to drug administration and are not necessarily due to disease progression.	CATHOLIC MED CTR BROOKLYN & QUEENS INC, DEPT SURG, JAMAICA, NY 11432 USA		KEMENY, N (corresponding author), MEM SLOAN KETTERING CANC CTR, 1275 YORK AVE, NEW YORK, NY 10021 USA.			Niedzwiecki, Donna/0000-0002-3566-0450	NCI NIH HHS [P01-CA-25842] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA025842] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANSFIELD F, 1977, CANCER-AM CANCER SOC, V39, P34, DOI 10.1002/1097-0142(197701)39:1<34::AID-CNCR2820390107>3.0.CO;2-2; ARBUCK SG, 1989, CANCER, V63, P1036, DOI 10.1002/1097-0142(19890315)63:6+<1036::AID-CNCR2820631309>3.0.CO;2-K; ARDALAN B, 1988, J CLIN ONCOL, V6, P1053, DOI 10.1200/JCO.1988.6.6.1053; BORHANMANESH F, 1989, ARCH INTERN MED, V149, P2127, DOI 10.1001/archinte.149.9.2127; BUROKER TR, 1985, J CLIN ONCOL, V3, P1624, DOI 10.1200/JCO.1985.3.12.1624; CAPIZZI RL, 1970, ANNU REV MED, V21, P433, DOI 10.1146/annurev.me.21.020170.002245; CHABNER B, 1982, PHARM PRINCIPLES CAN, P397; COLLINS KD, 1971, J BIOL CHEM, V246, P6599; Cooney D A, 1975, Adv Pharmacol Chemother, V12, P185, DOI 10.1016/S1054-3589(08)60222-7; ERLICHMAN C, 1980, RECENT RES CANCER, V74, P65; ERVIN TJ, 1980, CANCER TREAT REP, V64, P1067; GRALLA RJ, 1980, CANCER TREAT REP, V64, P1301; GRALNICK HR, 1971, CANCER, V27, P1313, DOI 10.1002/1097-0142(197106)27:6<1313::AID-CNCR2820270606>3.0.CO;2-W; HANSEN RM, 1989, ONCOLOGY, V46, P245; HOLCENBERG JS, 1977, ANNU REV PHARMACOL, V17, P97, DOI 10.1146/annurev.pa.17.040177.000525; KEMENY N, 1987, SEMIN SURG ONCOL, V3, P190, DOI 10.1002/ssu.2980030312; KOVACH JS, 1979, CANCER TREAT REP, V63, P1909; KUFE DW, 1981, J BIOL CHEM, V256, P9802; KUFE DW, 1981, BIOCHEM PHARMACOL, V30, P129, DOI 10.1016/0006-2952(81)90183-0; MADDREY WC, 1985, GASTROENTEROLOGY, P2922; MARSH JC, 1991, J CLIN ONCOL, V9, P371, DOI 10.1200/JCO.1991.9.3.371; MARTIN DS, 1983, CANCER RES, V43, P2317; MENARD DB, 1980, GASTROENTEROLOGY, V78, P142; MOYER JD, 1979, CANCER RES, V39, P3089; MUGGIA FM, 1987, CANCER TREAT REP, V71, P253; OCONNELL MJ, 1982, CANCER TREAT REP, V66, P77; ODWYER PJ, 1990, J CLIN ONCOL, V8, P1497, DOI 10.1200/JCO.1990.8.9.1497; OHNUMA T, 1970, CANCER RES, V30, P2297; PETERS GJ, 1990, EUR J CANCER, V26, P516, DOI 10.1016/0277-5379(90)90029-S; PRATT CB, 1971, CANCER, V28, P361, DOI 10.1002/1097-0142(197108)28:2<361::AID-CNCR2820280215>3.0.CO;2-3; PRESANT CA, 1983, MED PEDIATR ONCOL, V11, P162, DOI 10.1002/mpo.2950110305; RUBIN J, 1981, CANCER TREAT REP, V65, P335; SILLS RH, 1978, MED PEDIATR ONCOL, V4, P311, DOI 10.1002/mpo.2950040406; VANECHO DA, 1980, CANCER TREAT REP, V64, P339; WEISS GR, 1982, CANCER CHEMOTH PHARM, V8, P301; WINDSCHITL HE, 1990, CANCER, V66, P853, DOI 10.1002/1097-0142(19900901)66:5<853::AID-CNCR2820660507>3.0.CO;2-V	36	20	20	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 15	1991	115	12					946	951		10.7326/0003-4819-115-12-946	http://dx.doi.org/10.7326/0003-4819-115-12-946			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GU417	1824554				2023-01-03	WOS:A1991GU41700006
J	BAETEN, CGMI; KONSTEN, J; SPAANS, F; VISSER, R; HABETS, AMMC; BOURGEOIS, IM; WAGENMAKERS, AJM; SOETERS, PB				BAETEN, CGMI; KONSTEN, J; SPAANS, F; VISSER, R; HABETS, AMMC; BOURGEOIS, IM; WAGENMAKERS, AJM; SOETERS, PB			DYNAMIC GRACILOPLASTY FOR TREATMENT OF FECAL INCONTINENCE	LANCET			English	Article							FECAL INCONTINENCE; NEOANAL SPHINCTER; GRACILIS MUSCLE; SKELETAL-MUSCLE; CONSTRUCTION; TRANSFORMATION; TRANSPOSITION; NEOSPHINCTER; STIMULATION; NEORECTUM	Serious faecal incontinence due to anal sphincter damage should be treated by surgery. Graciloplasty has had limited success because the gracilis is a fast-twitch muscle and fatigues quickly. A favourable outcome in a patient who had dynamic (electrically stimulated) graciloplasty encouraged us to further assess this procedure. Gracilis muscle transposition was done in ten patients with complete anal incontinence due to anal atresia, sphincter damage, or neurogenic causes, and who had had several other unsuccessful treatments. 6 weeks after muscle transposition, intramuscular leads were implanted and connected to an implantable electric stimulator. Eight patients became continent, one patient still has a diverting colostomy, and a fistula developed in the other patient. Anal sphincter pressure improved from 35 mm Hg without stimulation to 62 mm Hg with stimulation at 8 weeks (mean increase 28 mm Hg [95% confidence interval 18, 36), p < 0.01). Retention time of a phosphate enema increased from 22 to 281 s (mean increase 259 s (82, 436], p < 0.01). Defaecography showed that the new sphincter was functioning. Defaecation was possible when the stimulator was turned "off" with a magnet. Dynamic graciloplasty can restore continence and it improves quality of life in faecally incontinent patients for whom other treatments have been unsuccessful.	UNIV LIMBURG HOSP,DEPT CLIN NEUROPHYSIOL,6202 AZ MAASTRICHT,NETHERLANDS; BAKKEN RES CTR,MAASTRICHT,NETHERLANDS; UNIV LIMBURG,DEPT HUMAN BIOL,6200 MD MAASTRICHT,NETHERLANDS	Maastricht University; Maastricht University Medical Centre (MUMC); Medtronic Bakken Research Center B.V.; Hasselt University; Maastricht University	BAETEN, CGMI (corresponding author), UNIV LIMBURG HOSP,DEPT SURG,POB 5800,6202 AZ MAASTRICHT,NETHERLANDS.		Wagenmakers, Anton/H-7625-2014	Wagenmakers, Anton/0000-0003-1916-3822				BAETEN C, 1988, DIS COLON RECTUM, V31, P134, DOI 10.1007/BF02562646; BAETEN CGMI, 1990, BRIT J SURG, V77, P473, DOI 10.1002/bjs.1800770433; CARPENTIER A, 1986, BIOMECHANICAL CARDIA, P85; CAVINA E, 1990, INT J COLORECTAL DIS, V5, P6, DOI 10.1007/BF00496141; CHACHQUES JC, 1986, BIOMECHANICAL CARDIA, P59; CHRISTIANSEN J, 1990, BRIT J SURG, V77, P1039, DOI 10.1002/bjs.1800770928; CORMAN ML, 1979, DIS COLON RECTUM, V22, P290, DOI 10.1007/BF02609307; EDSTROM L, 1986, MUSCLE NERVE, V9, P104, DOI 10.1002/mus.880090203; EISENBERG BR, 1984, CELL TISSUE RES, V238, P221; HALLAN RI, 1990, BRIT J SURG, V77, P208, DOI 10.1002/bjs.1800770226; HAVENITH MG, 1990, HISTOCHEMISTRY, V93, P497, DOI 10.1007/BF00266407; LEIGH RJ, 1982, LANCET, V1, P1349; PETTE D, 1984, MED SCI SPORT EXER, V16, P517; PICKRELL KL, 1952, ANN SURG, V135, P853, DOI 10.1097/00000658-195206000-00010; SALMONS S, 1981, MUSCLE NERVE, V4, P94, DOI 10.1002/mus.880040204; WILLIAMS NS, 1989, BRIT J SURG, V76, P1191, DOI 10.1002/bjs.1800761124; WILLIAMS NS, 1990, ANN ROY COLL SURG, V72, P108	17	178	183	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 9	1991	338	8776					1163	1165		10.1016/0140-6736(91)92030-6	http://dx.doi.org/10.1016/0140-6736(91)92030-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GP034	1682590				2023-01-03	WOS:A1991GP03400002
J	UDVARHELYI, IS; JENNISON, K; PHILLIPS, RS; EPSTEIN, AM				UDVARHELYI, IS; JENNISON, K; PHILLIPS, RS; EPSTEIN, AM			COMPARISON OF THE QUALITY OF AMBULATORY CARE FOR FEE-FOR-SERVICE AND PREPAID PATIENTS	ANNALS OF INTERNAL MEDICINE			English	Article						QUALITY OF HEALTH CARE; AMBULATORY CARE; FEES, MEDICAL; HEALTH MAINTENANCE ORGANIZATIONS; HYPERTENSION	HEALTH-MAINTENANCE ORGANIZATIONS; RANDOMIZED CONTROLLED TRIAL; FINANCIAL INCENTIVES; HOSPITAL SERVICES; COST; HYPERTENSION; PHYSICIANS; IMPACT; HMOS	Objective: To determine whether the quality of care for common ambulatory conditions is adversely affected when physicians are provided with incentives to limit the use of health services. Design: Retrospective cohort study over a 2-year period. Setting: Four group practices that cared for both fee-for-service patients and prepaid patients within a network model health maintenance organization (HMO). Patients: Equal numbers of prepaid (HMO) and fee-for-service patients were selected by randomly choosing medical records from each group practice: 246 patients with chronic uncomplicated hypertension and 250 women without chronic diseases who received preventive care. Main Outcome Measures: Adequate hypertension control was defined as a mean blood pressure of less than 150/90. Adequate preventive care was defined as the provision of blood pressure screening, colon cancer screening, breast cancer screening, and cervical cancer screening within guidelines recommended by the 1989 U.S. Preventive Services Task Force. Resource use was measured by the annual number of visits and tests. Main Results: The adjusted relative odds of HMO patients having controlled hypertension, compared with fee-for-service patients, were 1.82 (95% Cl, 1.02 to 3.27). The relative risks of HMO patients receiving preventive care within established guidelines were 1.19 (Cl, 0.93 to 1.51) for colon cancer screening, 1.78 (Cl, 1.11 to 2.84) for annual breast examinations, 1.75 (Cl, 1.08 to 2.84) for biannual mammography, and 1.35 (Cl, 1.13 to 1.60) for Papanicolaou smears every 3 years. Prepaid patients had visit rates that were 18% to 22% higher than those of fee-for-service patients. Conclusions: In the type of network model HMO we studied, the quality and quantity of ambulatory care for HMO patients was equal to or better than that for fee-for-service patients. In this setting, the incentives for physicians to limit resource use may be offset by lack of disincentives for HMO patients to seek care.	HARVARD UNIV, SCH MED,DEPT HLTH CARE POLICY,25 SHATTUCK ST, PARCEL B,1ST FLOOR, BOSTON, MA 02115 USA; HARVARD UNIV, BRIGHAM & WOMENS HOSP, BOSTON, MA 02115 USA; HARVARD UNIV, BETH ISRAEL HOSP, DIV CLIN EPIDEMIOL, BOSTON, MA 02215 USA; HARVARD UNIV, SCH PUBL HLTH, BOSTON, MA 02115 USA; HARVARD COMMUNITY HLTH PLAN, DEPT QUAL CARE MEASUREMENT, BROOKLINE, MA 02147 USA	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard T.H. Chan School of Public Health								[Anonymous], 1989, GUIDE CLIN PREVENTIV; BROOK RH, 1983, NEW ENGL J MED, V309, P1426, DOI 10.1056/NEJM198312083092305; CLANCY CM, 1989, ARCH INTERN MED, V149, P917, DOI 10.1001/archinte.149.4.917; EPSTEIN AM, 1986, NEW ENGL J MED, V314, P1089, DOI 10.1056/NEJM198604243141706; HILLMAN AL, 1987, NEW ENGL J MED, V317, P1743, DOI 10.1056/NEJM198712313172725; HORNBROOK MC, 1985, MED CARE, V23, P484, DOI 10.1097/00005650-198505000-00011; Kleinbaum D.G, 1988, APPL REGRESSION ANAL; KLEINBAUM DG, 1982, EPIDEMIOLOGIC RES; LOGERFO JP, 1975, JAMA-J AM MED ASSOC, V233, P245, DOI 10.1001/jama.233.3.245; LUFT HS, 1982, MILBANK FUND Q, V60, P268, DOI 10.2307/3349769; LUFT HS, 1978, NEW ENGL J MED, V298, P1336, DOI 10.1056/NEJM197806152982404; LUFT HS, 1978, MILBANK FUND Q, V56, P140, DOI 10.2307/3349516; LUFT HS, 1981, HLTH MAINTENANCE ORG; LUKE RD, 1980, MED CARE, V18, P219, DOI 10.1097/00005650-198002000-00008; LURIE N, 1987, AM J PUBLIC HEALTH, V77, P801, DOI 10.2105/AJPH.77.7.801; MANNING WG, 1984, NEW ENGL J MED, V310, P1505, DOI 10.1056/NEJM198406073102305; NEWHOUSE JP, 1981, NEW ENGL J MED, V305, P1501, DOI 10.1056/NEJM198112173052504; OGRADY KF, 1985, NEW ENGL J MED, V313, P484, DOI 10.1056/NEJM198508223130806; RELMAN AS, 1985, NEW ENGL J MED, V313, P749, DOI 10.1056/NEJM198509193131209; SCITOVSKY AA, 1980, MED CARE, V18, P30, DOI 10.1097/00005650-198001000-00003; SCITOVSKY AA, 1981, SOC SCI MED-MED ECON, V15, P107, DOI 10.1016/0160-7995(81)90024-1; SHAPIRO MF, 1986, ANN INTERN MED, V104, P246, DOI 10.7326/0003-4819-104-2-246; SHULMAN NB, 1986, AM J PUBLIC HEALTH, V76, P1105, DOI 10.2105/AJPH.76.9.1105; WARE JE, 1986, LANCET, V1, P1017; WOLINSKY FD, 1980, MILBANK FUND Q, V58, P537, DOI 10.2307/3349806; YELIN EH, 1985, NEW ENGL J MED, V312, P962, DOI 10.1056/NEJM198504113121506; 1990, MARION MANAGED CARE; 1980, GUIDELINES CANCER RE, V30, P194; 1987, WORKING GUIDELINES E; 1990, CA, V40, P77; 1988, ANN INTERN MED, V148, P1023	31	73	73	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 1	1991	115	5					394	400		10.7326/0003-4819-115-5-394	http://dx.doi.org/10.7326/0003-4819-115-5-394			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GC065	1863030				2023-01-03	WOS:A1991GC06500011
J	SWAN, IRC; GATEHOUSE, S				SWAN, IRC; GATEHOUSE, S			CLINICAL AND FINANCIAL AUDIT OF DIAGNOSTIC PROTOCOLS FOR LESIONS OF THE CEREBELLOPONTINE ANGLE	BRITISH MEDICAL JOURNAL			English	Article							AUDIOLOGIC EVALUATION; ACOUSTIC NEUROMA; TESTS	Objective-To assess the diagnostic efficiency and costs of protocols used for investigating patients with suspected lesions of the cerebellopontine angle. Design-Prospective evaluation of tests of auditory brain stem responses and acoustic reflex thresholds, electronystagmography, and calorics. Positive test results were confirmed or refuted by high resolution computed tomography with intravenous enhancement. Setting-Single general otolaryngology clinic in a teaching hospital. Patients-270 consecutive patients with sensorineural hearing loss requiring investigation to exclude a lesion of the cerebellopontine angle. Main outcome measures-Estimated costs of various diagnostic protocols and performance in detecting tumours of the cerebellopontine angle. Results-Protocols including tests of auditory brain stem responses and acoustic reflex thresholds as sifting tests before computed tomography were clinically acceptable and presented considerable savings over the use of computed tomography in all patients (74000 pounds or 84000 pounds v 122000 pounds). The use of electronystagmography and calorics could not be justified on clinical or financial grounds. Conclusions-Audiological tests of auditory brain stem responses and acoustic reflex thresholds followed by computed tomography constitute the most cost effective protocol for determining suspected lesions of the cerebellopontine angle. Implications-The cost effectiveness of diagnostic protocols should be evaluated throughout the health service.	GLASGOW ROYAL INFIRM,MRC,INST HEARING RES,SCOTTISH SECT,GLASGOW G4 0SF,SCOTLAND	University of Glasgow	SWAN, IRC (corresponding author), UNIV GLASGOW,ROYAL INFIRM,DEPT OTOLARYNGOL,GLASGOW G4 0SF,SCOTLAND.							BARRS DM, 1987, OTOLARYNG HEAD NECK, V96, P523, DOI 10.1177/019459988709600601; CASHMAN MZ, 1983, J OTOLARYNGOL, V12, P180; Harder H, 1988, Acta Otolaryngol Suppl, V452, P5; HART RG, 1981, NEUROSURGERY, V9, P450, DOI 10.1227/00006123-198110000-00021; JERGER S, 1983, AUDIOLOGY, V22, P144; JOHNSON EW, 1977, ARCH OTOLARYNGOL, V103, P152; Jongkees L B, 1973, Otolaryngol Clin North Am, V6, P73; JOSEY A F, 1987, Ear and Hearing, V8, p19S, DOI 10.1097/00003446-198708001-00006; MAIR IWS, 1988, SCAND AUDIOL, V17, P163, DOI 10.3109/01050398809042188; MOFFAT DA, 1989, J LARYNGOL OTOL, V103, P51, DOI 10.1017/S0022215100108023; MUSIEK FE, 1986, EAR HEARING, V7, P100, DOI 10.1097/00003446-198604000-00008; Norre M E, 1978, Acta Otorhinolaryngol Belg, V32, P421; PRIEDE VM, 1984, J LARYNGOL OTOL, V88, P641; REIMER A, 1987, SCAND AUDIOL, V16, P101, DOI 10.3109/01050398709042163; SANDERS JW, 1974, ARCH OTOLARYNGOL, V100, P283; THOMSEN J, 1988, ACTA OTOLARYNGOL S S, V452, P16; TURNER RG, 1984, EAR HEARING, V5, P187, DOI 10.1097/00003446-198407000-00002; 1988, LANCET, V2, P1294	18	12	12	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 23	1991	302	6778					701	704		10.1136/bmj.302.6778.701	http://dx.doi.org/10.1136/bmj.302.6778.701			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FE333	1902384	Green Published, Bronze			2023-01-03	WOS:A1991FE33300027
J	PARADIS, NA; MARTIN, GB; ROSENBERG, J; RIVERS, EP; GOETTING, MG; APPLETON, TJ; FEINGOLD, M; CRYER, PE; WORTSMAN, J; NOWAK, RM				PARADIS, NA; MARTIN, GB; ROSENBERG, J; RIVERS, EP; GOETTING, MG; APPLETON, TJ; FEINGOLD, M; CRYER, PE; WORTSMAN, J; NOWAK, RM			THE EFFECT OF STANDARD-DOSE AND HIGH-DOSE EPINEPHRINE ON CORONARY PERFUSION-PRESSURE DURING PROLONGED CARDIOPULMONARY-RESUSCITATION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CLOSED-CHEST RESUSCITATION; AORTIC DIASTOLIC PRESSURE; RIGHT ATRIAL PRESSURES; CARDIAC-ARREST; BLOOD-FLOW; VENTRICULAR-FIBRILLATION; PLASMA-CATECHOLAMINES; MYOCARDIAL PERFUSION; HUMAN-BEINGS; DOGS	We studied the effect of standard and high doses of epinephrine on coronary perfusion pressure during cardiopulmonary resuscitation in 32 patients whose cardiac arrest was refractory to advanced cardiac life support. Simultaneous aortic and right atrial pressures were measured and plasma epinephrine levels were sampled. Patients remaining in cardiac arrest after multiple 1-mg doses of epinephrine received a high dose of 0.2 mg/kg. The increase in the coronary perfusion pressures was 3.7 +/- 5.0 mm Hg following a standard dose, not a statistically significant change. The increase after a high dose was 11.3 +/- 10.0 mm Hg; this was both statistically different than before administration and larger than after a standard dose. High-dose epinephrine was more likely to raise the coronary perfusion pressure above the previously demonstrated critical value of 15 mm Hg. The highest arterial plasma epinephrine level after a standard dose was 152 +/- 162 ng/mL, and after a high dose, 393 +/- 289 ng/mL. Because coronary perfusion pressure is a good predictor of outcome in cardiac arrest, the increase after high-dose epinephrine may improve rates of return of spontaneous circulation.	HENRY FORD HOSP,DEPT EMERGENCY MED,2799 W GRAND BLVD,DETROIT,MI 48202; HENRY FORD HOSP,DEPT PEDIAT,DETROIT,MI 48202; HENRY FORD HOSP,DIV BIOSTAT & RES EPIDEMIOL,DETROIT,MI 48202; WASHINGTON UNIV,DEPT MED,ST LOUIS,MO 63130; SO ILLINOIS UNIV,SCH MED,DEPT MED,SPRINGFIELD,IL 62708	Henry Ford Health System; Henry Ford Hospital; Henry Ford Health System; Henry Ford Hospital; Henry Ford Health System; Henry Ford Hospital; Washington University (WUSTL); Southern Illinois University System; Southern Illinois University								ABRAMSON NS, 1985, CRIT CARE MED, V13, P930, DOI 10.1097/00003246-198511000-00020; ABRAMSON NS, 1986, JAMA-J AM MED ASSOC, V255, P2466, DOI 10.1001/jama.255.18.2466; BARTON CW, 1990, ANN EMERG MED, V19, P490; BROWN CG, 1987, CRIT CARE MED, V15, P682, DOI 10.1097/00003246-198707000-00011; BROWN CG, 1987, CIRCULATION, V75, P491, DOI 10.1161/01.CIR.75.2.491; BROWN CG, 1986, ANN EMERG MED, V15, P1138, DOI 10.1016/S0196-0644(86)80853-8; CALLAHAM ML, 1990, ANN EMERG MED, V19, P479; CRILE GW, 1902, CLEVELAND MED J, V2, P35; CRILE GW, 1904, T S SURG GYNECOL ASS, V16, P362; DITCHEY RV, 1982, CIRCULATION, V66, P297, DOI 10.1161/01.CIR.66.2.297; EITEL DR, 1988, ANN EMERG MED, V17, P808, DOI 10.1016/S0196-0644(88)80560-2; GOETTING MG, 1989, CRIT CARE MED, V17, P1258, DOI 10.1097/00003246-198912000-00004; GONZALEZ ER, 1989, ANN EMERG MED, V18, P920, DOI 10.1016/S0196-0644(89)80453-6; HAFT JI, 1974, PROG CARDIOVASC DIS, V17, P73, DOI 10.1016/0033-0620(74)90039-5; HOLMES HR, 1980, CRIT CARE MED, V8, P137, DOI 10.1097/00003246-198003000-00009; KERN KB, 1989, CRIT CARE MED, V17, P786, DOI 10.1097/00003246-198908000-00013; KOSCOVE EM, 1988, JAMA-J AM MED ASSOC, V259, P3031, DOI 10.1001/jama.259.20.3031; KOSNIK JW, 1985, ANN EMERG MED, V14, P204, DOI 10.1016/S0196-0644(85)80440-6; LEVINE RD, 1981, NEW YORK STATE J MED, V81, P1669; LITTLE RA, 1985, Q J MED, V54, P133; MARTIN GB, 1986, ANN EMERG MED, V15, P125, DOI 10.1016/S0196-0644(86)80005-1; MICHAEL JR, 1984, CIRCULATION, V69, P822, DOI 10.1161/01.CIR.69.4.822; NIEMANN JT, 1984, ANN EMERG MED, V13, P849, DOI 10.1016/S0196-0644(84)80458-8; OTTO CW, 1985, AM J EMERG MED, V3, P285, DOI 10.1016/0735-6757(85)90048-8; OTTO CW, 1981, CRIT CARE MED, V9, P321, DOI 10.1097/00003246-198104000-00008; PARADIS NA, 1990, JAMA-J AM MED ASSOC, V263, P1106, DOI 10.1001/jama.263.8.1106; PARADIS NA, 1989, CIRCULATION, V80, P361, DOI 10.1161/01.CIR.80.2.361; PARADIS NA, 1990, ANN EMERG MED, V19, P457; PEARSON JW, 1963, ANESTH ANALG, V42, P599; PEARSON JW, 1967, ANESTH ANALG, V46, P746; PIONKOWSKI RS, 1983, ANN EMERG MED, V12, P733, DOI 10.1016/S0196-0644(83)80245-5; QUINTON DN, 1987, LANCET, V1, P828; RALSTON SH, 1985, ANN EMERG MED, V14, P1044, DOI 10.1016/S0196-0644(85)80916-1; RALSTON SH, 1984, ANN EMERG MED, V13, P79, DOI 10.1016/S0196-0644(84)80566-1; REDDING JS, 1963, ANESTHESIOLOGY, V24, P203, DOI 10.1097/00000542-196303000-00008; REDDING JS, 1968, J AMER MED ASSOC, V203, P255; SAFAR P, 1988, CRIT CARE MED, V16, P923, DOI 10.1097/00003246-198810000-00003; SANDERS AB, 1984, CRIT CARE MED, V12, P871, DOI 10.1097/00003246-198410000-00007; SHAH SD, 1985, J LAB CLIN MED, V106, P624; SWENSON RD, 1988, CIRCULATION, V78, P630, DOI 10.1161/01.CIR.78.3.630; WATERS LL, 1950, SCIENCE, V111, P634, DOI 10.1126/science.111.2893.634; WORTSMAN J, 1984, AM J MED, V77, P779, DOI 10.1016/0002-9343(84)90512-6; YAKAITIS RW, 1979, CRIT CARE MED, V7, P293, DOI 10.1097/00003246-197907000-00001; 1986, JAMA-J AM MED ASSOC, V255, P2841	44	115	121	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 6	1991	265	9					1139	1144		10.1001/jama.265.9.1139	http://dx.doi.org/10.1001/jama.265.9.1139			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EZ474	1996000				2023-01-03	WOS:A1991EZ47400031
J	MOSER, M; BLAUFOX, MD; FREIS, E; GIFFORD, RW; KIRKENDALL, W; LANGFORD, H; SHAPIRO, A; SHEPS, S				MOSER, M; BLAUFOX, MD; FREIS, E; GIFFORD, RW; KIRKENDALL, W; LANGFORD, H; SHAPIRO, A; SHEPS, S			WHO REALLY DETERMINES YOUR PATIENTS PRESCRIPTIONS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							FOLLOW-UP; HYPERTENSION; DIURETICS; GLUCOSE; LIPIDS; TRIAL		YALE UNIV,SCH MED,DEPT MED,NEW HAVEN,CT 06510; YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT MED,BRONX,NY 10461; VET ADM,WASHINGTON,DC 20420; CLEVELAND CLIN EDUC FDN,CLEVELAND,OH 44106; UNIV TEXAS,HLTH SCI CTR,HOUSTON,TX 77225; UNIV MISSISSIPPI,MED CTR,SCH MED,JACKSON,MS 39216; UNIV PITTSBURGH,SCH MED,PITTSBURGH,PA 15261; MAYO CLIN & MAYO FDN,ROCHESTER,MN 55905	Yale University; Yeshiva University; Albert Einstein College of Medicine; Cleveland Clinic Foundation; University of Texas System; University of Texas Health Science Center Houston; University of Mississippi; University of Mississippi Medical Center; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Mayo Clinic			Blaufox, MDonald/AAF-6965-2020	Blaufox, MDonald/0000-0002-4148-6866				AMES RP, 1986, DRUGS, V32, P260, DOI 10.2165/00003495-198632030-00003; [Anonymous], 1981, LANCET, V2, P539; COLLINS R, 1990, LANCET, V335, P827, DOI 10.1016/0140-6736(90)90944-Z; CURB JD, 1986, PROG CARDIOVASC DIS, V29, P73; EDELSON JT, 1990, JAMA-J AM MED ASSOC, V263, P407, DOI 10.1001/jama.263.3.407; FREIS ED, 1989, ARCH INTERN MED, V149, P2649; GREENBERG G, 1984, AM J MED, V76, P45, DOI 10.1016/0002-9343(84)90956-2; MACMAHON S, 1989, HYPERTENSION S1, V13, P145; MOSER M, 1989, CARDIOVASC DRUG THER, V3, P743, DOI 10.1007/BF01857624; MOSER M, 1989, AM HEART J, V118, P1362, DOI 10.1016/0002-8703(89)90059-8; MOSER M, 1985, J HYPERTENS, V3, P437; MOSER M, 1989, AM FAM PHYSICIAN, V40, P213; MURPHY MB, 1982, LANCET, V2, P1293; PARVING HH, 1987, BRIT MED J, V294, P1443, DOI 10.1136/bmj.294.6585.1443; POLLARE T, 1989, NEW ENGL J MED, V321, P868, DOI 10.1056/NEJM198909283211305; SHAPIRO AP, 1961, NEW ENGL J MED, V265, P1028, DOI 10.1056/NEJM196111232652102; SHEKELLE RB, 1984, ATHER REV, V12, P113; 1980, LANCET, V1, P1261; 1985, AM J CARDIOL, V56, P913; 1979, JAMA-J AM MED ASSOC, V242, P2562; 1980, AM J MED, V69, P725; 1988, JAMA-J AM MED ASSOC, V259, P2113; 1990, CIRCULATION, V82, P1616; 1985, JAMA-J AM MED ASSOC, V291, P97; 1985, LANCET, V1, P1349; 1982, JAMA-J AM MED ASSOC, V248, P1996	26	30	30	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 23	1991	265	4					498	500		10.1001/jama.265.4.498	http://dx.doi.org/10.1001/jama.265.4.498			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ET377	1985236				2023-01-03	WOS:A1991ET37700031
J	GERACI, E				GERACI, E			ENROLLMENT IN TRIALS OF THROMBOLYSIS	LANCET			English	Letter											GERACI, E (corresponding author), V CEVELLO HOSP,DIV CARDIOL,I-90146 PALERMO,ITALY.							ARMSTRONG PW, 1989, J AM COLL CARDIOL, V13, P1469, DOI 10.1016/0735-1097(89)90334-3; GUERCI AD, 1987, NEW ENGL J MED, V317, P1613, DOI 10.1056/NEJM198712243172601; HINE LK, 1988, LANCET, V2, P1318; KENNEDY JW, 1988, CIRCULATION, V77, P345, DOI 10.1161/01.CIR.77.2.345; OROURKE M, 1988, CIRCULATION, V77, P1311, DOI 10.1161/01.CIR.77.6.1311; VANDEWERF F, 1988, BMJ-BRIT MED J, V297, P1374, DOI 10.1136/bmj.297.6660.1374; Wang-Gillam A., 2016, LANCET, V387, P545; WILCOX, 1990, LANCET, V335, P1175; 1988, LANCET, V1, P213; 1990, AM J CARDIOL, V65, P401	10	3	3	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 27	1990	336	8722					1069	1070		10.1016/0140-6736(90)92540-X	http://dx.doi.org/10.1016/0140-6736(90)92540-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EF076	1977042				2023-01-03	WOS:A1990EF07600038
J	HENRICH, JB				HENRICH, JB			THE POSTMENOPAUSAL ESTROGEN BREAST-CANCER CONTROVERSY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							REPLACEMENT THERAPY; EXOGENOUS ESTROGENS; WOMENS HEALTH; HORMONE USE; RISK; EPIDEMIOLOGY; ASSOCIATION; MORTALITY	Objective.-To provide an overview of the postmenopausal estrogen/breast cancer controversy emphasizing the sources of disagreement in the literature and their clinical and research implications. Data Source and Selection.-A MEDLINE search of the English-language literature and a review of bibliographies of meta-analyses describing the association between postmenopausal estrogen use and breast cancer risk. Data Extraction.-Twenty-four original articles and three meta-analyses were reviewed. In addition, five studies that attempted to minimize detection bias were reviewed to assess the potential role of this bias on risk estimates. Data Synthesis.-Among the original articles, risk estimates ranged from a protective to an adverse effect in women who ever used estrogens; no consistent quantitative effects of estrogens on breast cancer risk were found. In the meta-analyses, summary risk estimates were not significantly elevated in women who ever used estrogen. Findings from European-based studies may account for the increased risk associated with increasing duration of use reported in one meta-analysis. In studies that controlled for detection bias, risk estimates were 1 or less in the ever-used category; there was no consistent effect across other categories of use. Conclusion.-These findings do not support an overall increased risk of breast cancer in women who ever used postmenopausal estrogens or a conclusive or consistent effect across other measures of use. Cross-national differences in estrogen use and inequalities in breast cancer detection between estrogen users and nonusers may account for the increased risk estimates reported in some studies. Newer estrogen and progestin-opposed regimens need to be evaluated further.	YALE UNIV,SCH MED,DEPT MED,NEW HAVEN,CT 06510	Yale University								BARRETTCONNOR E, 1991, ANN INTERN MED, V115, P455, DOI 10.7326/0003-4819-115-6-455; BERGKVIST L, 1989, NEW ENGL J MED, V321, P293, DOI 10.1056/NEJM198908033210505; BERGKVIST L, 1989, AM J EPIDEMIOL, V130, P221, DOI 10.1093/oxfordjournals.aje.a115328; BRINTON LA, 1986, BRIT J CANCER, V54, P825, DOI 10.1038/bjc.1986.246; BROWNSON RC, 1988, ARCH INTERN MED, V148, P140, DOI 10.1001/archinte.148.1.140; BURING JE, 1987, AM J EPIDEMIOL, V125, P939, DOI 10.1093/oxfordjournals.aje.a114632; COLDITZ GA, 1990, JAMA-J AM MED ASSOC, V264, P2648, DOI 10.1001/jama.264.20.2648; DUPONT WD, 1991, ARCH INTERN MED, V151, P67, DOI 10.1001/archinte.151.1.67; DUPONT WD, 1989, CANCER-AM CANCER SOC, V63, P948, DOI 10.1002/1097-0142(19890301)63:5<948::AID-CNCR2820630527>3.0.CO;2-U; EWERTZ M, 1988, INT J CANCER, V42, P832, DOI 10.1002/ijc.2910420606; GAMBRELL RD, 1983, OBSTET GYNECOL, V62, P435; HEALY B, 1991, JAMA-J AM MED ASSOC, V266, P566, DOI 10.1001/jama.266.4.566; HENDERSON BE, 1991, ARCH INTERN MED, V151, P75, DOI 10.1001/archinte.151.1.75; HENDERSON IC, 1991, CANCER SOC NEWSLETTE, V2, P1; HIATT RA, 1984, CANCER, V54, P139, DOI 10.1002/1097-0142(19840701)54:1<139::AID-CNCR2820540128>3.0.CO;2-X; HOOVER R, 1981, J NATL CANCER I, V67, P815; HORWITZ RI, 1984, AM J MED, V76, P192, DOI 10.1016/0002-9343(84)90773-3; HULKA BS, 1982, AM J OBSTET GYNECOL, V143, P638, DOI 10.1016/0002-9378(82)90108-9; HUNT K, 1987, BRIT J OBSTET GYNAEC, V94, P620, DOI 10.1111/j.1471-0528.1987.tb03166.x; KAUFMAN DW, 1984, JAMA-J AM MED ASSOC, V252, P63, DOI 10.1001/jama.252.1.63; KAUFMAN DW, 1991, AM J EPIDEMIOL, V134, P1375, DOI 10.1093/oxfordjournals.aje.a116041; KELSEY JL, 1988, CANCER RES, V48, P5615; KELSEY JL, 1981, JNCI-J NATL CANCER I, V67, P327; LIPPMAN ME, 1986, BREAST CANCER RES TR, V7, P59, DOI 10.1007/BF01806790; MILLS PK, 1989, CANCER, V64, P591, DOI 10.1002/1097-0142(19890801)64:3<591::AID-CNCR2820640305>3.0.CO;2-U; NOMURA AMY, 1986, INT J CANCER, V37, P49, DOI 10.1002/ijc.2910370109; PALCA J, 1991, SCIENCE, V254, P792, DOI 10.1126/science.1948061; PALMER JR, 1991, AM J EPIDEMIOL, V134, P1386, DOI 10.1093/oxfordjournals.aje.a116042; ROHAN TE, 1988, MED J AUSTRALIA, V148, P217; ROSS RK, 1980, JAMA-J AM MED ASSOC, V243, P1635, DOI 10.1001/jama.243.16.1635; SHERMAN B, 1983, CANCER, V51, P1527, DOI 10.1002/1097-0142(19830415)51:8<1527::AID-CNCR2820510828>3.0.CO;2-T; STEINBERG KK, 1991, JAMA-J AM MED ASSOC, V265, P1985, DOI 10.1001/jama.265.15.1985; THOMAS DB, 1982, JNCI-J NATL CANCER I, V69, P1017; WINGO PA, 1987, JAMA-J AM MED ASSOC, V257, P209, DOI 10.1001/jama.257.2.209	34	54	54	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 14	1992	268	14					1900	1902		10.1001/jama.268.14.1900	http://dx.doi.org/10.1001/jama.268.14.1900			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JR439	1404715				2023-01-03	WOS:A1992JR43900040
J	ALBRIGHT, JF; OPPENHEIM, JJ				ALBRIGHT, JF; OPPENHEIM, JJ			CONTEMPORARY TOPICS IN IMMUNOLOGY - APPROACHES TO IMMUNOTHERAPY EMERGING FROM BASIC RESEARCH	FASEB JOURNAL			English	Article						T-CELL RECEPTOR MHC PEPTIDE INTERACTIONS; B-CELL TOLERANCE; ANERGY-INFLAMMATORY DISEASE; TRANSGENIC RATS; INTERLEUKIN-10; TRANSFORMING GROWTH FACTOR-BETA	CELL STIMULATORY FACTOR; B-CELLS	The seventh symposium in thc series "Contemporary Topics in Immunology" was held on April 21, 1991, at the FASEB meeting in Atlanta, Georgia. It was sponsored by the National Institute of Allergy and Infectious Diseases, The American Association of Immunologists, and the Clinical Immunology Society. Five topics were discussed by leading researchers in areas of immunology that currently are of exceptional interest and show promise of leading to new advances in the prevention and treatment of human diseases. The topics included: the interactions between immunogenic peptides, class I MHC molecules and T cell receptors; initiation, maintenance, and breakdown of self-tolerance in B lymphocytes; inflammatory disease in HLA-B27 transgenic rats; properties and functions of interleukin-10; and transforming growth factor-beta in reproductive immunology. The exceptional quality of the presentations in this seventh symposium exemplified perfectly the path of basic research that often leads from the laboratory to the clinic.	NCI,FREDERICK CANC RES FACIL,MOLEC IMMUNOREGULAT LAB,FREDERICK,MD 21701	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	ALBRIGHT, JF (corresponding author), NIAID,DIV ALLERGY IMMUNOL & TRANSPLANTAT,BASIC IMMUNOL BRANCH,BETHESDA,MD 20892, USA.							ADELSTEIN S, 1991, SCIENCE, V251, P1223, DOI 10.1126/science.1900950; ALTMAN DJ, 1990, J EXP MED, V172, P1391, DOI 10.1084/jem.172.5.1391; GO NF, 1990, J EXP MED, V172, P1625, DOI 10.1084/jem.172.6.1625; HAMMER RE, 1990, CELL, V63, P1099, DOI 10.1016/0092-8674(90)90512-D; LEE F, 1986, P NATL ACAD SCI USA, V83, P2061, DOI 10.1073/pnas.83.7.2061; VANBLEEK GM, 1990, NATURE, V348, P213	6	3	3	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	AUG	1992	6	11					2890	2894		10.1096/fasebj.6.11.1644254	http://dx.doi.org/10.1096/fasebj.6.11.1644254			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	JJ665	1644254				2023-01-03	WOS:A1992JJ66500002
J	ZUGER, A				ZUGER, A			MONDAY MORNING CLINIC	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 22	1992	268	4					468	468						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JD472	1619737				2023-01-03	WOS:A1992JD47200009
J	COHEN, TJ; TUCKER, KJ; LURIE, KG; REDBERG, RF; DUTTON, JP; DWYER, KA; SCHWAB, TM; CHIN, MC; GELB, AM; SCHEINMAN, MM; SCHILLER, NB; CALLAHAM, ML				COHEN, TJ; TUCKER, KJ; LURIE, KG; REDBERG, RF; DUTTON, JP; DWYER, KA; SCHWAB, TM; CHIN, MC; GELB, AM; SCHEINMAN, MM; SCHILLER, NB; CALLAHAM, ML			ACTIVE COMPRESSION-DECOMPRESSION - A NEW METHOD OF CARDIOPULMONARY-RESUSCITATION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							TIDAL CARBON-DIOXIDE; OPEN-CHEST CPR; CARDIAC-ARREST; PROGNOSTIC INDICATOR; CORONARY PERFUSION; ABDOMINAL BINDING; HUMAN-BEINGS; VENTILATION; DOGS; SURVIVAL	Objective. --To describe and compare with standard cardiopulmonary resuscitation (CPR) in humans a new form of CPR that involves both active compression and active decompression of the chest. Design. --Patients in cardiac arrest in whom standard advanced cardiac life support failed were randomized to receive 2 minutes of either standard or active compression-decompression (ACD) CPR using a custom, hand-held suction device, followed by 2 minutes of the alternate technique. The ACD device was applied midsternum and used to perform CPR according to the guidelines of the American Heart Association: 80 compressions per minute, compression depth of 3.8 to 5 cm, 50% duty cycle, and constant-volume ventilation. Mechanical Thumper CPR was also compared in five patients. End-tidal carbon dioxide (ETCO2) concentrations and hemodynamic variables were measured. Transesophageal Doppler echocardiography was used to assess contractility, the velocity time integral (an analogue of cardiac output), and diastolic myocardial filling times. Results. --Ten patients were enrolled. The mean +/- SD ETCO2 was 4.3 +/- 3.8 mm Hg with standard CPR and 9.0 +/- 3.9 mm Hg with ACD CPR (P < .0001). Systolic arterial pressure with standard CPR was 52.5 +/- 14.0 mm Hg and with ACD CPR, 88.9 +/- 24.7 mm Hg (P < .003). The velocity time integral increased from 7.3 +/- 2.6 cm with standard CPR to 17.5 +/- 5.6 cm with ACD CPR (P < .0001), and diastolic filling times increased from 0.23 +/- .09 seconds with standard CPR to 0.37 +/- .12 seconds with ACD CPR (P < .004). Mechanical Thumper CPR consistently underperformed both standard and ACD CPR. Minute ventilation obtained in four patients during ACD CPR without endotracheal ventilation was 6.6 +/- 0.9 L/min. After 1 hour of standard CPR failed, three of 10 patients randomized to ACD CPR rapidly converted to a hemodynamically stable rhythm following 2 minutes of ACD CPR. Conclusion. --ACD CPR is a simple manual technique that improved cardiopulmonary circulation in 10 patients during cardiac arrest. Although ACD CPR may have produced a return of spontaneous circulation in three patients refractory to standard measures, its impact on survival when used early in cardiac arrest remains to be determined.	SAN FRANCISCO GEN HOSP,DEPT EMERGENCY,SAN FRANCISCO,CA 94110; UNIV CALIF SAN FRANCISCO,DIV EMERGENCY MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,CARDIOVASC RES INST,SAN FRANCISCO,CA 94143	San Francisco General Hospital Medical Center; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	COHEN, TJ (corresponding author), N SHORE UNIV HOSP,CORNELL UNIV MED COLL,DIV CARDIOL,300 COMMUNITY DR,MANHASSET,NY 11030, USA.			Callaham, Michael/0000-0003-2284-256X				BEDELL SE, 1983, NEW ENGL J MED, V309, P569, DOI 10.1056/NEJM198309083091001; BERRYMAN CR, 1984, ANN EMERG MED, V13, P226, DOI 10.1016/S0196-0644(84)80467-9; BIRCHER N, 1980, CRIT CARE MED, V8, P147, DOI 10.1097/00003246-198003000-00012; BIRCHER N, 1981, CRIT CARE MED, V9, P384, DOI 10.1097/00003246-198105000-00016; BLACK IW, 1991, J AM COLL CARDIOL, V18, P398, DOI 10.1016/0735-1097(91)90592-W; CALLAHAM M, 1990, CRIT CARE MED, V18, P358, DOI 10.1097/00003246-199004000-00002; CALLAHAM M, IN PRESS CRIT CARE M; CHANDRA N, 1981, AM J CARDIOL, V48, P1053, DOI 10.1016/0002-9149(81)90320-9; CHANDRA NC, 1990, CRIT CARE MED, V18, P929, DOI 10.1097/00003246-199009000-00005; CHANDRA NC, 1991, CIRCULATION, V84, P279, DOI 10.1161/01.CIR.84.1.279; COHEN TJ, 1991, CIRCULATION, V84, P9; CRILEY JM, 1976, JAMA-J AM MED ASSOC, V236, P1246, DOI 10.1001/jama.236.11.1246; DELGUERCIO LR, 1963, NEW ENGL J MED, V269, P1398, DOI 10.1056/NEJM196312262692603; EISENBERG MS, 1980, NEW ENGL J MED, V302, P1379, DOI 10.1056/NEJM198006193022502; EISENBERG MS, 1979, JAMA-J AM MED ASSOC, V241, P1905, DOI 10.1001/jama.241.18.1905; EISENBERG MS, 1982, NEW ENGL J MED, V306, P1340, DOI 10.1056/NEJM198206033062206; FISHER DC, 1983, CIRCULATION, V67, P872, DOI 10.1161/01.CIR.67.4.872; GARNETT AR, 1987, JAMA-J AM MED ASSOC, V257, P512, DOI 10.1001/jama.257.4.512; GOETTING MG, 1991, CRIT CARE MED, V19, P1012, DOI 10.1097/00003246-199108000-00007; GUDIPATI CV, 1988, CIRCULATION, V77, P234, DOI 10.1161/01.CIR.77.1.234; HALPERIN HR, 1986, CIRCULATION, V74, P1407, DOI 10.1161/01.CIR.74.6.1407; HOWARD M, 1987, ANN EMERG MED, V16, P253, DOI 10.1016/S0196-0644(87)80169-5; KAPLAN BC, 1973, J TRAUMA, V13, P843, DOI 10.1097/00005373-197313100-00001; KOEHLER RC, 1983, CIRCULATION, V67, P266, DOI 10.1161/01.CIR.67.2.266; KOUWENHOVEN WB, 1960, JAMA-J AM MED ASSOC, V173, P1064, DOI 10.1001/jama.1960.03020280004002; KRISCHER JP, 1989, CRIT CARE MED, V17, P1263, DOI 10.1097/00003246-198912000-00005; LEWIS JF, 1984, CIRCULATION, V70, P425, DOI 10.1161/01.CIR.70.3.425; LURIE KG, 1990, JAMA-J AM MED ASSOC, V264, P1661, DOI 10.1001/jama.1990.03450130031020; MARTIN GB, 1986, ANN EMERG MED, V15, P125, DOI 10.1016/S0196-0644(86)80005-1; MCDONALD JL, 1982, ANN EMERG MED, V11, P292, DOI 10.1016/S0196-0644(82)80125-X; MEIJBOOM EJ, 1983, CIRCULATION, V68, P437, DOI 10.1161/01.CIR.68.2.437; NIEMANN JT, 1984, AM J CARDIOL, V53, P269, DOI 10.1016/0002-9149(84)90438-7; NIEMANN JT, 1985, AM J CARDIOL, V55, P199, DOI 10.1016/0002-9149(85)90328-5; ORNATO JP, 1989, ANN EMERG MED, V18, P732, DOI 10.1016/S0196-0644(89)80005-8; PEATFIELD RC, 1977, LANCET, V1, P1223; SACK J B, 1991, Journal of the American College of Cardiology, V17, p179A; SANDERS AB, 1989, JAMA-J AM MED ASSOC, V262, P1347, DOI 10.1001/jama.262.10.1347; SANDERS AB, 1985, AM J EMERG MED, V3, P147, DOI 10.1016/0735-6757(85)90039-7; SANDERS AB, 1985, ANN EMERG MED, V14, P948, DOI 10.1016/S0196-0644(85)80235-3; SPALDING JMK, 1963, CLIN PRACTICE PHYSL; TREVINO RP, 1985, CRIT CARE MED, V13, P910, DOI 10.1097/00003246-198511000-00012; WALKER JW, 1984, AM J EMERG MED, V2, P391, DOI 10.1016/0735-6757(84)90039-1; WEIL MH, 1985, CRIT CARE MED, V13, P907, DOI 10.1097/00003246-198511000-00011; 1986, JAMA-J AM MED ASSOC, V255, P2905	44	150	191	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 3	1992	267	21					2916	2923		10.1001/jama.267.21.2916	http://dx.doi.org/10.1001/jama.267.21.2916			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HW133	1583761				2023-01-03	WOS:A1992HW13300029
J	TUNSTALLPEDOE, H; BAILEY, L; CHAMBERLAIN, DA; MARSDEN, AK; WARD, ME; ZIDEMAN, DA				TUNSTALLPEDOE, H; BAILEY, L; CHAMBERLAIN, DA; MARSDEN, AK; WARD, ME; ZIDEMAN, DA			SURVEY OF 3765 CARDIOPULMONARY RESUSCITATIONS IN BRITISH HOSPITALS (THE BRESUS STUDY) - METHODS AND OVERALL RESULTS	BRITISH MEDICAL JOURNAL			English	Article							BASIC LIFE SUPPORT; CARDIAC-ARREST; INTENSIVE-CARE; EMERGENCY; SURVIVAL; ACCIDENT; GUIDELINES	Objective-To determine the circumstances, incidence, and outcome of cardiopulmonary resuscitation in British hospitals. Design-Hospitals registered all cardiopulmonary resuscitation attempts for 12 months or longer and followed survival to one year. Setting-12 metropolitan, provincial, teaching, and non-teaching hospitals across Britain. Subjects-3765 patients in whom a resuscitation attempt was performed, including 927 in whom the onset of arrest was outside the hospital. Main outcome measure-Survival after initial resuscitation, at 24 hours, at discharge from hospital, and at one year, calculated by the life table method. Results-There were 417 known survivors at one year, with 214 lost to follow up. By life table analysis for every eight attempted resuscitations there were three immediate survivors, two at 24 hours, 1.5 leaving hospital alive, and one alive at one year. Survival at one year was 12.5% including out of hospital cases and 15.0% not including these cases. Each hospital year averaged 30 survivors at one year: three who had an arrest outside hospital, seven who had one in the accident and emergency department, seven in the cardiac care unit, 10 in the general wards, and three in other, non-ward areas. Within the hospitals survival rates were best in those who had an arrest in the accident and emergency department, the cardiac care unit, or other specialised units. Outcome varied 12-fold in subgroups defined by age, type of arrest, and place of arrest. Conclusion-71% of the mortality at one year in patients undergoing attempted resuscitation occurred during the initial arrest. Hospital resuscitation is life saving and cost effective and warrants appropriate attention, training, coordination, and equipment.	UNIV SUSSEX,BRIGHTON BN1 9RH,E SUSSEX,ENGLAND; ROYAL SUSSEX CTY HOSP,BRIGHTON BN2 5BE,E SUSSEX,ENGLAND; PINDERFIELDS HOSP,ACCID & EMERGENCY MED,WAKEFIELD,ENGLAND; JOHN RADCLIFFE HOSP,OXFORD OX3 9DU,ENGLAND; HAMMERSMITH HOSP,LONDON W12 0HS,ENGLAND	University of Sussex; University of Brighton; Pinderfields Hospital; University of Oxford; Imperial College London	TUNSTALLPEDOE, H (corresponding author), UNIV DUNDEE,NINEWELLS HOSP & MED SCH,CARDIOVASC EPIDEMIOL UNIT,DUNDEE DD1 9SY,SCOTLAND.							BEDELL SE, 1983, NEW ENGL J MED, V309, P569, DOI 10.1056/NEJM198309083091001; CASEY WF, 1984, J ROY SOC MED, V77, P921, DOI 10.1177/014107688407701105; CHAMBERLAIN DA, 1989, BRIT MED J, V299, P446, DOI 10.1136/bmj.299.6696.446; COBBE SM, 1991, BRIT MED J, V302, P1517, DOI 10.1136/bmj.302.6791.1517; COPE AR, 1987, J ROY SOC MED, V80, P746, DOI 10.1177/014107688708001207; CUMMINS RO, 1991, CIRCULATION, V84, P960, DOI 10.1161/01.CIR.84.2.960; DEBARD ML, 1981, ANN EMERG MED, V10, P408, DOI 10.1016/S0196-0644(81)80307-1; DELOOZ HH, 1989, RESUSCITATION, V17, pS1, DOI 10.1016/0300-9572(89)90085-3; EVANS TR, 1990, ABC RESUSCITATION; GEORGE AL, 1989, AM J MED, V87, P28; GRAY WA, 1991, NEW ENGL J MED, V325, P1393, DOI 10.1056/NEJM199111143252001; HERSHEY CO, 1982, LANCET, V1, P31, DOI 10.1016/S0140-6736(82)92567-3; KAYE W, 1981, HEART LUNG, V10, P860; MARSDEN AK, 1989, BRIT MED J, V299, P442, DOI 10.1136/bmj.299.6696.442; MCGRATH RB, 1987, ANN EMERG MED, V16, P1365, DOI 10.1016/S0196-0644(87)80420-1; ROBERTSON CE, 1984, ARCH EMERG MED, V1, P17; ROSER LA, 1967, ARCH SURG-CHICAGO, V95, P658; SCOTT RPF, 1981, ANAESTHESIA, V36, P526, DOI 10.1111/j.1365-2044.1981.tb10290.x; SKINNER DV, 1985, BRIT MED J, V290, P1549, DOI 10.1136/bmj.290.6481.1549; SMITH GB, 1987, INTENS CARE MED, V13, P260, DOI 10.1007/BF00265115; SULJAGAPECHTEL K, 1984, RESUSCITATION, V12, P77, DOI 10.1016/0300-9572(84)90061-3; TAFFET GE, 1988, JAMA-J AM MED ASSOC, V260, P2069, DOI 10.1001/jama.260.14.2069; WARDROPE J, 1986, ARCH EMERG MED, V3, P183; WILDSMITH JA, 1972, BRIT J ANAESTH, V44, P716; WYNNE G, 1987, BRIT MED J, V294, P1198, DOI 10.1136/bmj.294.6581.1198; ZIDEMAN DA, 1985, J WORLD ASS EMERGENC, V1, P291; 1980, JAMA-J AM MED ASSOC, V244, P453; 1987, J R COLL PHYSICIANS, V21, P1	28	233	237	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 23	1992	304	6838					1347	1351		10.1136/bmj.304.6838.1347	http://dx.doi.org/10.1136/bmj.304.6838.1347			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HW417	1611332	Green Published, Bronze			2023-01-03	WOS:A1992HW41700022
J	ALEXANDER, JM; GRANT, AM; CAMPBELL, MJ				ALEXANDER, JM; GRANT, AM; CAMPBELL, MJ			RANDOMIZED CONTROLLED TRIAL OF BREAST SHELLS AND HOFFMAN EXERCISES FOR INVERTED AND NON-PROTRACTILE NIPPLES	BRITISH MEDICAL JOURNAL			English	Article								Objective - To determine the value of recommending breast shells or Hoffman's exercises, or both, to pregnant women with inverted or non-protractile nipples who intend to breast feed. Design - Randomised controlled trial with a two treatment by two level factorial design. Setting - Antenatal clinics in a district general hospital and the community. Subjects - 96 nulliparous women recruited between 25 and 35 completed weeks in a singleton pregnancy with at least one inverted or non-protractile nipple. Main outcome measures - Anatomical change of nipples, judged blindly before first breast feeding, and success of breast feeding reported by postal questionnaire six weeks postnatally. Results - Sustained improvement in nipple anatomy was more common in the untreated groups but the differences were not significant (52% (25/48) shells v 60% (29/48) no shells; difference -8% (95% confidence interval -28% to 11%) and 54% (26/48) exercises v 58% (28/48) no exercises; -4% (-24% to 16%)). 24 (50%) women not recommended shells and 14 (29%) recommended shells (21%; 40% to 2%) were breast feeding six weeks after delivery (p = 0.05), reflecting more women recommended shells both deciding to bottle feed before delivery and discontinuing breast feeding. The same number of women in exercise and no exercise groups were successfully breast feeding (0%; -20% to 20%). 13% of women approached about the trial (and planning to breast feed) did not attempt breast feeding. Conclusions - Recommending nipple preparation with breast shells may reduce the chances of successful breast feeding. While there is no clear evidence that the treatments offered are effective antenatal nipple examination should be abandoned.	NATL PERINATAL EPIDEMIOL UNIT,PERINATAL TRIALS SERV,OXFORD OX2 6HE,ENGLAND	University of Oxford	ALEXANDER, JM (corresponding author), UNIV SOUTHAMPTON,SOUTHAMPTON GEN HOSP,DEPT NURSING STUDIES,SOUTHAMPTON S09 4XY,ENGLAND.		Campbell, Michael J/I-4253-2014	Campbell, Michael J/0000-0003-3529-2739				AKRE J, 1990, B WHO S, V67, P47; AKRE J, 1990, B WHO S, V67, P55; AKRE J, 1990, B WHO S, V67, P19; ALEXANDER J, 1991, THESIS U SOUTHAMPTON; BLAIKLEY J, 1953, J OBSTET GYN BRIT EM, V60, P657; CHALMERS I, 1982, EFFECTIVENESS SATISF, P209; COCHRAN WG, 1957, EXPT DESIGNS, P148; DELEE JB, 1947, PRINCIPLES PRACTICE, P99; GARDNER MJ, 1986, BMJ-BRIT MED J, V292, P746, DOI 10.1136/bmj.292.6522.746; GUNTHER M, 1973, INFANT FEEDING, P104; HOFFMAN JB, 1953, AM J OBSTET GYNECOL, V66, P346; HYTTEN FE, 1958, LANCET, V1, P1201; HYTTEN FE, 1954, BMJ-BRIT MED J, V2, P1447, DOI 10.1136/bmj.2.4902.1447; INCH S, 1989, EFFECTIVE CARE PREGN, P335; LARSEN LLV, 1990, INT J CHILDBIRTH FEB, P33; LESPERANCE CM, 1980, BIRTH FAM J, V7, P21, DOI 10.1111/j.1523-536X.1980.tb01361.x; MARTIN J, 1988, INFANT FEEDING 1985; Pocock SJ, 1983, CLIN TRIALS PRACTICA, P138; POOLE K, 1987, NEW GENERATION, V6, P33; RENFREW MJ, 1992, WOMENS HLTH MATTERS, P81; RIORDAN J, 1983, PRACTICAL GUIDE BREA; WALLER H, 1946, ARCH DIS CHILD, V21, P1, DOI 10.1136/adc.21.105.1; [No title captured]; 1944, 91 MIN HLTH PUBL HLT	24	45	45	1	8	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 18	1992	304	6833					1030	1032		10.1136/bmj.304.6833.1030	http://dx.doi.org/10.1136/bmj.304.6833.1030			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HQ142	1586788	Green Published, Bronze			2023-01-03	WOS:A1992HQ14200024
J	HANSENFLASCHEN, JH; BRAZINSKY, S; BASILE, C; LANKEN, PN				HANSENFLASCHEN, JH; BRAZINSKY, S; BASILE, C; LANKEN, PN			USE OF SEDATING DRUGS AND NEUROMUSCULAR BLOCKING-AGENTS IN PATIENTS REQUIRING MECHANICAL VENTILATION FOR RESPIRATORY-FAILURE - A NATIONAL SURVEY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CRITICALLY ILL PATIENTS; ICU; ATRACURIUM; VECURONIUM; INFUSIONS; CARE; ITU	Objective. - To assess current use of sedating drugs and neuromuscular blocking agents in patients requiring mechanical ventilation at US hospitals that participate in the training of pulmonary fellows. Design. - Surveys were mailed in September 1990 to the head nurses of medical intensive care units at 265 US hospitals that were listed in an annual guide listing pulmonary fellowship training programs. In the survey, sedating drugs were defined as medications prescribed to treat anxiety, agitation, or sleeplessness. These included opiates, anesthetics, or neuroleptic agents when used for any of these purposes. Survey Respondents. - Surveys were received from nurses at 164 hospitals (62% response rate) representing 93 medical schools and 100 pulmonary fellowship training programs. Nearly half of the respondents worked at university hospitals. Most worked as head nurses in medical (70%) or medical-surgical (21 %) intensive care units (ICUs). Results. - Sedating drugs were given to patients undergoing mechanical ventilation at virtually all the ICUs surveyed, and 36% used these drugs routinely (> 70% of patients). Opiates and benzodiazepines were employed most commonly; haloperidol lactate was widely used as well. Intermittent intravenous injection was the preferred method of administration; 62% of the ICUs also gave these drugs by continuous intravenous infusion. Neuromuscular blocking agents were also used at nearly all the ICUs surveyed; however, most gave these drugs to fewer than 20% of patients experiencing respiratory failure. Orders for the use of sedating drugs and neuromuscular blocking agents were written exclusively by house staff at 65% of the ICUs surveyed. Conclusions. - Sedating drugs and neuromuscular blocking agents are widely used for patients requiring mechanical ventilation in ICUs at US teaching hospitals. There is considerable variation in the choice, frequency, and method of administration. Given the expense (up to $1000 a day) and the potential hazards to patients of prolonged deep sedation and paralysis, more research is warranted to determine optimal use of these drugs during mechanical ventilation.			HANSENFLASCHEN, JH (corresponding author), HOSP UNIV PENN,DEPT MED,DEPT PULM & CRIT CARE,874 MALONEY BLDG,3600 SPRUCE ST,PHILADELPHIA,PA 19104, USA.			Hansen-Flaschen, John/0000-0003-1989-7244				AITKENHEAD AR, 1989, LANCET, V2, P704, DOI 10.1016/S0140-6736(89)90770-8; BEEMER GH, 1987, ANAESTH INTENS CARE, V15, P83, DOI 10.1177/0310057X8701500111; BEVAN DR, 1988, MUSCLE RELAXANTS CLI; BION JF, 1987, INTENS CARE MED, V13, P215; CRIPPEN DW, 1990, CRIT CARE CLIN, V6, P369; DURBIN CG, 1991, CRIT CARE CLIN, V7, P489, DOI 10.1016/S0749-0704(18)30292-6; FARINA ML, 1981, INTENS CARE MED, V7, P125, DOI 10.1007/BF01738615; FIGGE H, 1987, J CRIT CARE, V2, P199, DOI 10.1016/0883-9441(87)90008-6; FISHMAN AP, 1988, PULMONARY DISEASES D; GRAMSTAD L, 1985, BRIT J ANAESTH, V57, P1052, DOI 10.1093/bja/57.11.1052; GRIFFITHS RB, 1986, ANAESTHESIA, V41, P375, DOI 10.1111/j.1365-2044.1986.tb13221.x; HANSENFLASCHEN JH, 1991, PULMONARY DISEASES D, P383; HARRIS CE, 1985, ANAESTHESIA, V45, P366; KENDALL MJ, 1972, BMJ, V2, P354; MARTYN J, 1986, ANESTHESIOLOGY, V65, P67, DOI 10.1097/00000542-198607000-00011; MENZA MA, 1988, HEART LUNG, V17, P238; MERRIMAN HM, 1981, INTENS CARE MED, V7, P217, DOI 10.1007/BF01702623; MILLERJONES CMH, 1980, ANAESTHESIA, V35, P1104, DOI 10.1111/j.1365-2044.1980.tb05052.x; NAGASHIMA H, 1988, CAN J ANAESTH, V35, P134, DOI 10.1007/BF03010652; OLDENHOF H, 1988, CLIN PHARMACOL THER, V43, P263, DOI 10.1038/clpt.1988.31; PARKER CJR, 1988, BRIT J ANAESTH, V61, P531, DOI 10.1093/bja/61.5.531; PARKER MM, 1984, CRIT CARE MED, V12, P69, DOI 10.1097/00003246-198401000-00018; PEAT SJ, 1988, ANAESTHESIA, V43, P962, DOI 10.1111/j.1365-2044.1988.tb05663.x; ROGERS RM, 1990, AM REV RESPIR DIS, V142, P495, DOI 10.1164/ajrccm/142.3.495; SEGREDO V, 1990, ANESTHESIOLOGY, V72, P566, DOI 10.1097/00000542-199003000-00030; SHOEMAKER W, 1989, TXB CRITICAL CARE; SLATER RM, 1988, ANAESTHESIA, V43, P250; Stevens DS, 1990, J INTENSIVE CARE MED, V5, P258; VESELIS RA, 1990, CRIT CARE CLIN, V6, P295; VIBYMOGENSEN J, 1982, BRIT J ANAESTH, V54, P209, DOI 10.1093/bja/54.2.209; WADON AJ, 1986, BRIT J ANAESTH, V58, pS64, DOI 10.1093/bja/58.suppl_1.64S; 1990, AM REV RESPIR DIS, V142, P955; 1989, AM HOSPITAL ASS GUID; 1991, AM BOARD INTERNA SPR	34	218	222	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 27	1991	266	20					2870	2875		10.1001/jama.266.20.2870	http://dx.doi.org/10.1001/jama.266.20.2870			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GQ722	1942456				2023-01-03	WOS:A1991GQ72200037
J	BLACK, ME; SCHEUER, MA; VICTOR, C; BENZEVAL, M; GILL, M; JUDGE, K				BLACK, ME; SCHEUER, MA; VICTOR, C; BENZEVAL, M; GILL, M; JUDGE, K			UTILIZATION BY HOMELESS PEOPLE OF ACUTE HOSPITAL SERVICES IN LONDON	BRITISH MEDICAL JOURNAL			English	Article								Objectives - To estimate the numbers and distribution of homeless people in London; to quantify the utilisation of acute inpatient services by homeless people in two health authorities; and to predict the total numbers of admissions in homeless people in district health authorities across London. Design - Data were collected from various sources on the distribution of homeless people across London boroughs. All unplanned acute inpatient admissions during November 1990 to relevant hospitals were identified. Setting - Bloomsbury and Paddington and North Kensington, two former inner London district health authorities. Subjects - Homeless people in London residing in bed and breakfast and private sector leased accommodation, residing in hostels, and of no fixed abode. Main outcome measures - Number and cost of acute unplanned admissions in homeless people in two health authorities in November 1990; predicted number of such admissions each year in district health authorities in London. Results - There were at least 60000 homeless people in London in March 1990. The majority were housed in temporary accommodation (55 412). There were at least 3295 hostel dwellers and 651 people sleeping rough. Homeless people accounted for 105 (8%) of the 1256 acute unbooked admissions in residents of Bloomsbury and Paddington and North Kensington health authorities in November 1990. Considerable variations in the pattern of acute unplanned admissions in homeless people were observed in the two districts with respect to housing status and specialty of admission. The total number of acute unplanned admissions in homeless people across London each year was estimated at 7598, ranging from 38 in Bexley to 1515 in Parkside. Conclusions - The results have fundamental implications for resource allocation across London. Allocation must take better account of the heterogeneity, uneven distribution, and extra health needs of homeless people.	KINGS FUND INST,LONDON NW1 7NF,ENGLAND; BLOOMSBURY & ISLINGTON HLTH AUTHOR,DEPT PUBL HLTH MED,LONDON WC1E 6DB,ENGLAND; PARKSIDE HLTH AUTHOR,DEPT PUBL HLTH MED,LONDON W2 1PF,ENGLAND				Benzeval, Michaela/J-3163-2015	Benzeval, Michaela/0000-0002-0372-2098; Victor, Christina/0000-0002-4213-3974				BARRY A, 1991, 84 U YORK CTR HLTH E; BRAMLEY G, 1987, HOMELESSNESS LONDON; CANTER D, 1990, FACES HOMELESSNESS L; CONNELLY J, 1990, PUBLIC HEALTH, V104, P109, DOI 10.1016/S0033-3506(05)80361-0; CONWAY J, 1988, PRESCRIPTION POOR HL; EVANS A, 1989, RESPONDING HOMELESSN; NEWMAN R, 1989, LONDON HOSTELS DIREC; PRIEST RG, 1976, J PSYCHIATRY, V128, P130; SCHEUER MA, 1991, 4 KINGS FUND I OCC P; SHANKS NJ, 1988, J EPIDEMIOL COMMUN H, V42, P183, DOI 10.1136/jech.42.2.183; STERN R, 1988, MARGINS MAINSTREAM C; THOMAS A, 1989, LIVING TEMPORARY ACC; VICTOR CR, 1989, BRIT MED J, V229, P725; 1991, 1991 CENSUS PRELIMIN; 1991, HOUSING HOMELESSNESS; 1989, WORKING PATIENTS; 1990, EL90MB22 DEP HLTH; 1989, HOMELESS FAMILIES TH; 1990, ACTIONS LOCAL AUTHOR; 1990, LOCATION HOMELESS HO; 1988, HOMELESSNESS USE TEM	21	13	13	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 19	1991	303	6808					958	961		10.1136/bmj.303.6808.958	http://dx.doi.org/10.1136/bmj.303.6808.958			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GL127	1954419	Green Published, Bronze			2023-01-03	WOS:A1991GL12700021
J	TREGASKIS, B; MAYBERRY, JF				TREGASKIS, B; MAYBERRY, JF			ELDERLY PEOPLE AT HOME WHO CANNOT COPE	LANCET			English	Editorial Material											TREGASKIS, B (corresponding author), LEICESTER GEN HOSP,LEICESTER LE5 4PW,ENGLAND.		Mayberry, John/AAP-2392-2020					FORSTER DP, 1980, BRIT MED J, V280, P739, DOI 10.1136/bmj.280.6215.739; GRAY JAM, 1990, J PUBLIC HEALTH MED, V12, P28, DOI 10.1093/oxfordjournals.pubmed.a042502; GRAY JAM, 1980, PUBLIC HEALTH, V94, P296, DOI 10.1016/S0033-3506(80)80078-3; Hoggett B., 1984, MENTAL HLTH LAW; MAYBERRY JF, 1991, THESIS U WALES; TOWLER JN, 1988, PUBLIC HEALTH, V102, P485, DOI 10.1016/S0033-3506(88)80087-8	6	1	1	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 6	1991	338	8758					47	47		10.1016/0140-6736(91)90026-L	http://dx.doi.org/10.1016/0140-6736(91)90026-L			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FV296	1676095				2023-01-03	WOS:A1991FV29600019
J	ASHBY, M; STOFFELL, B				ASHBY, M; STOFFELL, B			THERAPEUTIC RATIO AND DEFINED PHASES - PROPOSAL OF ETHICAL FRAMEWORK FOR PALLIATIVE CARE	BRITISH MEDICAL JOURNAL			English	Article							CANCER-PATIENTS		ROYAL ADELAIDE HOSP,PALLIAT MED,ADELAIDE,SA 5006,AUSTRALIA; FLINDERS UNIV,MED CTR,MED ETH UNIT,BEDFORD PK,SA 5042,AUSTRALIA	Royal Adelaide Hospital; Flinders University South Australia								AHRONHEIM JC, 1990, LANCET, P278; BLACK D, 1990, BRIT MED J, V300, P1321, DOI 10.1136/bmj.300.6735.1321; CASSIDY S, 1986, J ROY SOC MED, V79, P717; GILHOOLY MLM, 1988, PALLIATIVE MED, V2, P64; GLOVER J, 1977, CAUSING DEATH SAVING; HIGGINSON I, 1989, PALLIATIVE MED, V3, P267; HIRSCHFIELD MJ, 1989, PALLIATIVE MED, V4, P25; JONES A, 1980, CLIN RADIOL, V31, P121, DOI 10.1016/S0009-9260(80)80135-8; KEARSLEY JH, 1986, BMJ-BRIT MED J, V293, P871, DOI 10.1136/bmj.293.6551.871; LUNT B, 1987, PALLIATIVE MED, V1, P136; MITCHELL JRA, 1979, BRIT MED J, V1, P1523, DOI 10.1136/bmj.1.6177.1523; RACHELS J, 1986, END LIFE; SLEVIN ML, 1988, BRIT J CANCER, V57, P109, DOI 10.1038/bjc.1988.20; SMITH T, 1988, BRIT MED J, V297, P438, DOI 10.1136/bmj.297.6646.438; STOLL BA, 1990, J MED ETHICS, V16, P71, DOI 10.1136/jme.16.2.71; SUTHERLAND HJ, 1989, J ROY SOC MED, V82, P260, DOI 10.1177/014107688908200506; TIMOTHY AR, 1988, BRIT MED J, V297, P471, DOI 10.1136/bmj.297.6646.471; 1989, LANCET, V1, P476	18	24	24	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 1	1991	302	6788					1322	1324		10.1136/bmj.302.6788.1322	http://dx.doi.org/10.1136/bmj.302.6788.1322			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FQ444	1711907	Green Published, Bronze			2023-01-03	WOS:A1991FQ44400024
J	BLOLAND, PB; REDD, SC; KAZEMBE, P; TEMBENU, R; WIRIMA, JJ; CAMPBELL, CC				BLOLAND, PB; REDD, SC; KAZEMBE, P; TEMBENU, R; WIRIMA, JJ; CAMPBELL, CC			COTRIMOXAZOLE FOR CHILDHOOD FEBRILE ILLNESS IN MALARIA-ENDEMIC REGIONS	LANCET			English	Note								The efficacy of co-trimoxazole for the treatment of Plasmodium falciparum parasitaemia in children younger than 5 years of age was evaluated in Malawi. 46 children with P falciparum parasitaemia, 37% of whom also met clinical criteria for a diagnosis of acute lower respiratory tract infection, were treated with 20 mg/kg co-trimoxazole twice daily for five days. Parasitaemia (mean clearance time 2.7 days) and symptoms were rapidly abolished and improvement was maintained during follow-up for 14 days. Co-trimoxazole may be an effective single treatment for febrile illness in young children in areas where malaria is endemic, resources are few, and diagnosis must rely on clinical findings alone.	CTR DIS CONTROL,INT HLTH PROGRAM OFF,ATLANTA,GA 30333; MINIST HLTH,LILONGWE,MALAWI	Centers for Disease Control & Prevention - USA	BLOLAND, PB (corresponding author), CTR DIS CONTROL,CTR INFECT DIS,DIV PARASIT DIS,MALARIA BRANCH,F-12,ATLANTA,GA 30333, USA.							CAMPBELL H, 1988, LANCET, V2, P1182; GOOSEN TJ, 1976, CHEMOTHERAPY PARASIT, V6, P67; MOUNT DL, 1989, B WORLD HEALTH ORGAN, V67, P295; 1990, SUPERVISORY SKILLS M; 1981, B WORLD HEALTH ORGAN, V59, P707; 1986, WHO TECH REP SER, V735; 1984, WHO TECH REP SER, V711	7	39	39	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 2	1991	337	8740					518	520		10.1016/0140-6736(91)91299-A	http://dx.doi.org/10.1016/0140-6736(91)91299-A			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EZ874	1671892				2023-01-03	WOS:A1991EZ87400006
J	GOODWIN, JS				GOODWIN, JS			MERCY KILLING - MERCY FOR WHOM	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	13	13	1	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 16	1991	265	3					326	326		10.1001/jama.265.3.326	http://dx.doi.org/10.1001/jama.265.3.326			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ER256	1984530				2023-01-03	WOS:A1991ER25600009
J	HUGHES, JR; HIGGINS, EM; DUVIVIER, AWP				HUGHES, JR; HIGGINS, EM; DUVIVIER, AWP			ACNE ASSOCIATED WITH INHALED GLUCOCORTICOSTEROIDS	BRITISH MEDICAL JOURNAL			English	Letter							CORTICOSTEROIDS				HUGHES, JR (corresponding author), UNIV LONDON KINGS COLL HOSP,DEPT DERMATOL,LONDON SE5 9RS,ENGLAND.							CAPEWELL S, 1990, BRIT MED J, V300, P1548, DOI 10.1136/bmj.300.6739.1548; HIGGINS EM, 1991, CLIN EXP DERMATOL, V16, P244, DOI 10.1111/j.1365-2230.1991.tb00366.x; KAIDBEY KH, 1974, J INVEST DERMATOL, V62, P31, DOI 10.1111/1523-1747.ep12676716; PLEWIG G, 1973, ARCH DERMATOL FORSCH, V247, P29, DOI 10.1007/BF00595699; SNEDDON I, 1969, BRIT MED J, V4, P49, DOI 10.1136/bmj.4.5674.49-a; STEAD RJ, 1989, BRIT MED J, V298, P403, DOI 10.1136/bmj.298.6671.403	6	4	4	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 24	1992	305	6860					1000	1000		10.1136/bmj.305.6860.1000	http://dx.doi.org/10.1136/bmj.305.6860.1000			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JV776	1458105	Bronze, Green Published, Green Submitted			2023-01-03	WOS:A1992JV77600031
J	BIRKHEAD, JS				BIRKHEAD, JS			TIME DELAYS IN PROVISION OF THROMBOLYTIC TREATMENT IN 6 DISTRICT HOSPITALS	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ACUTE MYOCARDIAL-INFARCTION; SYMPTOMS; THERAPY	Objective-To measure the delays between onset of symptoms and admission to hospital and provision of thrombolysis in patients with possible acute myocardial infarction. Design-Observational study of patients admitted with suspected myocardial infarction during six months. Setting- Six district general hospitals in Britain. Subjects-1934 patients admitted with suspected myocardial infarction. Main outcome measures-Route of admission to hospital and time to admission and thrombolysis. Results-Patients who made emergency calls did so sooner after onset of symptoms than those who called their doctor (median time 40 (95% confidence interval 30 to 52) minutes v 70 (60 to 90) minutes). General practitioners took a median of 20 (20 to 25) minutes to visit patients, rising to 30 (20 to 30) minutes during 0800-1200. The median time from call to arrival in hospital was 41 (38 to 47) minutes for patients who called an ambulance from home and 90 (90 to 94) minutes for those who contacted their doctor. The median time from arrival at hospital to thrombolysis was 80 (75 to 85) minutes for patients who were treated in the cardiac care unit and 31 (25 to 35) minutes for those treated in the accident and emergency department. Conclusion-The time from onset of symptoms to thrombolysis could be reduced substantially by more effective use of emergency services and faster provision of thrombolysis in accident and emergency departments.			BIRKHEAD, JS (corresponding author), NORTHAMPTON GEN HOSP, DEPT MED, NORTHAMPTON NN1 5BD, ENGLAND.							[Anonymous], 1988, LANCET, V2, P349; [Anonymous], 1986, Lancet, V1, P397; CAMERON M, 1975, BRIT MED J, V1, P384, DOI 10.1136/bmj.1.5954.384; COLLING A, 1976, BRIT MED J, V2, P1169, DOI 10.1136/bmj.2.6045.1169; EMERSON PA, 1989, Q J MED, V70, P213; KENNEDY JW, 1989, AM J CARDIOL, V64, pA8, DOI 10.1016/0002-9149(89)90922-3; KEREIAKES DJ, 1990, AM HEART J, V120, P773, DOI 10.1016/0002-8703(90)90192-Z; KOREN G, 1985, NEW ENGL J MED, V313, P1384, DOI 10.1056/NEJM198511283132204; LEIZOROVICZ A, 1988, EUR HEART J, V9, P118; MATHEY DG, 1985, J AM COLL CARDIOL, V6, P518, DOI 10.1016/S0735-1097(85)80107-8; PANTRIDG.JF, 1967, LANCET, V2, P271; PARRY G, 1991, BRIT HEART J, V66, P39; PELL ACH, 1992, BMJ-BRIT MED J, V304, P83, DOI 10.1136/bmj.304.6819.83; RAWLES JM, 1990, EUR HEART J, V11, P643, DOI 10.1093/oxfordjournals.eurheartj.a059770; RAWLES JM, 1989, ABERDEEN POSTGRAD ME, V23, P1; ROWLEY JM, 1992, BRIT HEART J, V67, P255; SCHROEDER JS, 1978, AM J MED, V64, P742, DOI 10.1016/0002-9343(78)90512-0; SHARKEY SW, 1989, JAMA-J AM MED ASSOC, V262, P3171, DOI 10.1001/jama.262.22.3171; SMYLLIE HC, 1972, BRIT MED J, V1, P34, DOI 10.1136/bmj.1.5791.34; WILCOX RG, 1988, LANCET, V2, P525; 1987, LANCET, V1, P871	21	109	109	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 22	1992	305	6851					445	448		10.1136/bmj.305.6851.445	http://dx.doi.org/10.1136/bmj.305.6851.445			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JK680	1392956	Bronze, Green Published, Green Submitted			2023-01-03	WOS:A1992JK68000020
J	BLEICH, A; DYCIAN, A; KOSLOWSKY, M; SOLOMON, Z; WIENER, M				BLEICH, A; DYCIAN, A; KOSLOWSKY, M; SOLOMON, Z; WIENER, M			PSYCHIATRIC IMPLICATIONS OF MISSILE ATTACKS ON A CIVILIAN POPULATION - ISRAELI LESSONS FROM THE PERSIAN-GULF-WAR	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							LEBANON WAR	Objective.-To determine the proportion of hospitalized patients who had stress reactions as a result of missile attacks during the Persian Gulf War and evaluate the factors that influenced their evacuation. Design.-Review of medical records of patients hospitalized as a result of missile attacks. Setting.-During the Persian Gulf War in the winter of 1991, Israel received 18 missile attacks involving 39 surface-to-surface Scud missiles. The uncertainty in time, place, and type of warhead, conventional or chemical, was a source of chronic stress and the immediate cause for many traumatic stress reactions at or near the missile attack sites. Participants.-Data from victims who were injured after each missile attack were available through a central hookup between 12 local hospitals and the Medical Corps of the Israeli Defence Force. Main Outcome Measure.-The number of persons diagnosed in the hospital as psychological casualties after each missile attack. Results.-Approximately 43% of the 773 casualties evacuated to hospitals were diagnosed as psychological casualties, and an additional 27% had mistakenly injected themselves with atropine. Data also indicated that triage of psychological casualties to hospitals was more a function of the rescue team's training and preparation than the severity or extent of injury or damage. Conclusions.-Optimal treatment during events that cause mass casualties requires proper preparation of rescue teams as well as reorganization of the hospital' s psychiatric services. The threat of chemical warfare affected the number and nature of stress reactions.	TEL AVIV UNIV,SACKLER SCH MED,TEL AVIV,ISRAEL; TEL AVIV UNIV,SHAPEL SCH SOCIAL WORK,IL-69978 TEL AVIV,ISRAEL; BAR ILAN UNIV,DEPT PSYCHOL,RAMAT GAN,ISRAEL	Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv University; Bar Ilan University	BLEICH, A (corresponding author), ISRAEL DEF FORCES,MED CORPS,DEPT MENTAL HLTH,MIL POB 02149,JERUSALEM,ISRAEL.							BELENKY GL, 1987, PSYCHIAT ANN, V17, P528, DOI 10.3928/0048-5713-19870801-06; BURKLE F M JR, 1991, Emergency Medicine Clinics of North America, V9, P87; BUYDENSBRANCHEY L, 1990, J NERV MENT DIS, V178, P582, DOI 10.1097/00005053-199009000-00005; DUNN CL, 1952, EMERGENCY MED SERVIC, V1, P170; HISS J, 1992, BRIT MED J, V304, P92, DOI 10.1136/bmj.304.6819.92; KARSENTY E, 1991, ISRAEL J MED SCI, V27, P603; Kormos HR, 1978, STRESS DISORDERS VIE, P3; NEWHOUSE P, 1987, CONT STUDIES COMBAT, P185; NOY S, 1984, ISRAEL J MED SCI, V20, P360; OBALLANCE E, 1988, GULF WAR, P103; RACHMAN SJ, 1990, FEAR COURAGE, P25; SMITH EM, 1990, AM J PSYCHIAT, V147, P202; SOLOMON Z, 1986, AM J PSYCHIAT, V143, P613	13	67	67	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 5	1992	268	5					613	615		10.1001/jama.268.5.613	http://dx.doi.org/10.1001/jama.268.5.613			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	JF473	1629988				2023-01-03	WOS:A1992JF47300025
J	CARR, A; TINDALL, B; BREW, BJ; MARRIOTT, DJ; HARKNESS, JL; PENNY, R; COOPER, DA				CARR, A; TINDALL, B; BREW, BJ; MARRIOTT, DJ; HARKNESS, JL; PENNY, R; COOPER, DA			LOW-DOSE TRIMETHOPRIM-SULFAMETHOXAZOLE PROPHYLAXIS FOR TOXOPLASMIC ENCEPHALITIS IN PATIENTS WITH AIDS	ANNALS OF INTERNAL MEDICINE			English	Article						TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION; ACQUIRED IMMUNODEFICIENCY SYNDROME; TOXOPLASMOSIS; PNEUMONIA, PNEUMOCYSTIS-CARINII; DOSE-RESPONSE RELATIONSHIP, DRUG	NERVOUS-SYSTEM TOXOPLASMOSIS; ACQUIRED IMMUNODEFICIENCY SYNDROME; HIV-INFECTED PATIENTS; PYRIMETHAMINE; PREVALENCE; EFFICACY; THERAPY; GONDII	Objective: To determine the efficacy of low-dose trimethoprim-sulfamethoxazole (trimethoprim, 160 mg plus sulfamethoxazole, 800 mg; one tablet twice daily, 2 days per week) as primary prophylaxis against toxoplasmic encephalitis in patients with human immunodeficiency virus (HIV) infection and previous Pneumocystis carinii pneumonia. Design: A retrospective study. Setting: Tertiary referral teaching hospital. Patients: During a 3-year period after primary episodes of P. carinii pneumonia, 60 patients received trimethoprim-sulfamethoxazole, and 95 patients received pentamidine (aerosolized in 78 patients and intravenous in 17 patients) as secondary prophylaxis. Results: No patient in the trimethoprim-sulfamethoxazole group and no patient seronegative for Toxoplasma gondii developed toxoplasmic encephalitis, compared with 12 of 36 (33%; 95% CI, 19% to 51%) seropositive patients in the pentamidine group (trimethoprim-sulfamethoxazole compared with pentamidine, P = 0.008). A significant difference was seen in the time to development of toxoplasmic encephalitis between the trimethoprim-sulfamethoxazole group (no case at 1153 days) and the pentamidine group (median time, 460 days) (P = 0.004). Neither the CD4+ lymphocyte count at the start of prophylaxis nor zidovudine therapy during the period of prophylaxis influenced the rate of toxoplasmic encephalitis in any group. Conclusions: Low-dose trimethoprim-sulfamethoxazole (four tablets per week) appears to be effective prophylaxis against toxoplasmic encephalitis in HIV-infected patients with previous P. carinii pneumonia. A prospective, randomized, controlled study is needed to further evaluate these findings.	NATL CTR HIV EPIDEMIOL & CLIN RES, SYDNEY 2010, AUSTRALIA	University of New South Wales Sydney; Kirby Institute	CARR, A (corresponding author), ST VINCENTS HOSP, CTR IMMUNOL, SYDNEY, NSW 2010, AUSTRALIA.		McLean, Emma/F-4616-2012; Brew, Bruce/J-6513-2012					CARR A, 1992, AIDS, V6, P165, DOI 10.1097/00002030-199202000-00004; COHN JA, 1989, AM J MED, V86, P521, DOI 10.1016/0002-9343(89)90378-1; DEROUIN F, 1990, AIDS, V4, P1036; GRANT IH, 1990, AIDS, V4, P519, DOI 10.1097/00002030-199006000-00004; GRUNEWALD T, 1991, JUN NEUR HIV INF PAD; HERRERA G, 1991, 7TH INT C AIDS FLOR; HOLLIMAN RE, 1990, EPIDEMIOL INFECT, V105, P415, DOI 10.1017/S0950268800047993; HUGHES WT, 1987, NEW ENGL J MED, V316, P1627, DOI 10.1056/NEJM198706253162604; ISRAELSKI DM, 1989, ANTIMICROB AGENTS CH, V33, P30, DOI 10.1128/AAC.33.1.30; ISRAELSKI DM, 1990, MED MANAGEMENT AIDS, P241; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; LEPORT C, 1988, AM J MED, V84, P94, DOI 10.1016/0002-9343(88)90014-9; LIDMAN C, 1989, SCAND J INFECT DIS, V21, P381, DOI 10.3109/00365548909167441; LINDSAY DS, 1991, ANTIMICROB AGENTS CH, V35, P1914, DOI 10.1128/AAC.35.9.1914; LUFT BJ, 1990, AIDS, V4, P593, DOI 10.1097/00002030-199006000-00018; MASLO M, 1991, 7TH INT C AIDS FLOR; MENICHETTI F, 1991, 7TH INT C AIDS FLOR; NIELSEN TL, 1990, 6TH INT C AIDS SAN F; OFARRELL N, 1991, 7TH INT C AIDS FLOR; PEDROL E, 1990, AIDS, V4, P511, DOI 10.1097/00002030-199006000-00003; RAVIGLIONE MC, 1990, REV INFECT DIS, V12, P1127; RAVIGLIONE MC, 1990, LANCET, V336, P180, DOI 10.1016/0140-6736(90)91701-B; RUSKIN J, 1991, LANCET, V337, P468, DOI 10.1016/0140-6736(91)93402-U; WEISS LM, 1988, J INFECT DIS, V157, P580, DOI 10.1093/infdis/157.3.580; 1990, BRIT MED J, V301, P226; 1985, SAS STAT GUIDE PERSO; 1989, MMWR, V38, P1	27	231	235	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 15	1992	117	2					106	111		10.7326/0003-4819-117-2-106	http://dx.doi.org/10.7326/0003-4819-117-2-106			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JD123	1351371				2023-01-03	WOS:A1992JD12300002
J	HADORN, DC; MCCORMICK, K; DIOKNO, A				HADORN, DC; MCCORMICK, K; DIOKNO, A			AN ANNOTATED ALGORITHM APPROACH TO CLINICAL GUIDELINE DEVELOPMENT	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PATIENT-CARE; MEDICINE	The Urinary Incontinence in Adults Guideline Panel facilitated the ready elucidation of its guideline's management recommendations through the use of an annotated algorithm approach. The algorithms created as part of this guideline differ from previous algorithms in two ways: (1) they employ systematic annotation to link explicitly the algorithms' recommendations to the literature, and (2) they contain patient counseling and decision nodes to depict the major preference-dependent decision or branch points in the algorithm. We believe that these two innovations can help ensure the clinical validity of guidelines' algorithms while preserving appropriate clinical flexibility and respecting patient preferences.	WILLIAM BEAUMONT HOSP, ROYAL OAK, MI 48072 USA; RAND CORP, SANTA MONICA, CA 90406 USA; NIA, GERIATR RES CTR, BETHESDA, MD 20892 USA	Beaumont Health; RAND Corporation; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)					AHRQ HHS [T32 HS 00007] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		[Anonymous], 1982, CRITERIA STANDARDS Q; Field MJ, 1990, CLIN PRACTICE GUIDEL; Gottlieb L K, 1990, QRB Qual Rev Bull, V16, P80; GREENFIELD S, 1981, MED CARE, V19, P255, DOI 10.1097/00005650-198103000-00002; GREENFIELD S, 1990, PROVIDING QUALITY CA; GRIMM RH, 1975, NEW ENGL J MED, V292, P507, DOI 10.1056/NEJM197503062921005; KASSIRER JP, 1990, HOSP PRACT, P23; KOMAROFF AL, 1982, AM J PUBLIC HEALTH, V72, P10, DOI 10.2105/AJPH.72.1.10; KOMAROFF AL, 1974, NEW ENGL J MED, V290, P307, DOI 10.1056/NEJM197402072900605; MARGOLIS CZ, 1983, JAMA-J AM MED ASSOC, V249, P627, DOI 10.1001/jama.249.5.627; PALMER RH, 1984, MED CARE, V22, P632, DOI 10.1097/00005650-198407000-00005; SOX HC, 1973, NEW ENGL J MED, V288, P818, DOI 10.1056/NEJM197304192881605; 1992, AHCPR920038 AG HLTH	13	44	44	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 24	1992	267	24					3311	3314		10.1001/jama.267.24.3311	http://dx.doi.org/10.1001/jama.267.24.3311			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HY944	1597913				2023-01-03	WOS:A1992HY94400030
J	MCFARLANE, J; PARKER, B; SOEKEN, K; BULLOCK, L				MCFARLANE, J; PARKER, B; SOEKEN, K; BULLOCK, L			ASSESSING FOR ABUSE DURING PREGNANCY - SEVERITY AND FREQUENCY OF INJURIES AND ASSOCIATED ENTRY INTO PRENATAL-CARE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							PHYSICAL ABUSE; VIOLENCE; CONFLICT; WOMEN	Objective. - To assess the occurrence, frequency, and severity of physical abuse during pregnancy and associated initiation of prenatal care. Design. - Stratified, prospective cohort analysis. Setting. - Public prenatal clinics in Houston, Tex, and Baltimore, Md. Participants. - Total population-based sample of 691 black, Hispanic, and white pregnant women. All of the women were urban residents and most of the Hispanic women were Mexican American. All participants were invited into the study at the first prenatal visit and were followed up until delivery. Main Outcome Measure. - Identification of abuse status. Results. - A three-question Abuse Assessment Screen detected a 17% (1/6) prevalence of physical or sexual abuse during pregnancy, which is more than double all previous published reports. When evaluated against nationally tested research instruments, the three-question screen that was asked at the first prenatal visit was sensitive and specific to abuse status. Abuse was recurrent, with 60% of abused women reporting two or more episodes of assault. Location of abuse focused on the head. Frequency and severity of abuse and potential danger of homicide was appreciably worse for white women. Abused women were twice as likely as nonabused women to begin prenatal care during the third trimester. Conclusions. - A simple clinical assessment screen completed by the health care provider in a private setting and with the male partner absent is as effective as research instruments in identifying abused women. Straightforward, routine clinical assessment is recommended as essential in preventing potential trauma, interrupting existing abuse, and protecting health.	UNIV MARYLAND,BALTIMORE,MD 21201; UNIV OTAGO,DUNEDIN,NEW ZEALAND	University System of Maryland; University of Maryland Baltimore; University of Otago	MCFARLANE, J (corresponding author), TEXAS WOMANS UNIV,1130 MD ANDERSON BLVD,HOUSTON,TX 77030, USA.				PHS HHS [R49/CCR603514-01] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AMARO H, 1990, AM J PUBLIC HEALTH, V80, P575, DOI 10.2105/AJPH.80.5.575; BERENSON A, 1991, AM J OBSTET GYNECOL, V164, P491; CAMPBELL J, IN PRESS RES NURS HL; CAMPBELL JC, 1986, ADV NURS SCI, V8, P36, DOI 10.1097/00012272-198607000-00006; HELTON AS, 1987, AM J PUBLIC HEALTH, V77, P1337, DOI 10.2105/AJPH.77.10.1337; HILLARD PJA, 1985, OBSTET GYNECOL, V66, P185; HUDSON WW, 1981, J MARRIAGE FAM, V43, P873, DOI 10.2307/351344; JORGENSEN SR, 1977, J MARRIAGE FAM, V39, P653, DOI 10.2307/350472; LAZARRO M, 1991, J NURS ADMIN, V21, P24; MCFARLANE J, 1989, WOMEN HEALTH, V15, P69, DOI 10.1300/J013v15n03_06; MCFARLANE J, 1991, PUBLIC HEALTH NURS, V8, P245, DOI 10.1111/j.1525-1446.1991.tb00664.x; MCFARLANE J, 1991, VIOLENCE WOMEN NURSI; MCFARLANE J, 1991, DATING VIOLENCE YOUN; Parker B, 1991, MCN Am J Matern Child Nurs, V16, P161, DOI 10.1097/00005721-199105000-00013; SCHEI B, 1989, BRIT J OBSTET GYNAEC, V96, P1379, DOI 10.1111/j.1471-0528.1989.tb06298.x; Steinmetz S., 1977, CYCLE VIOLENCE ASSER; STRAUS MA, 1979, J MARRIAGE FAM, V41, P75, DOI 10.2307/351733; STRAUS MA, 1986, J MARRIAGE FAM, V48, P465, DOI 10.2307/352033; STRAUS MA, 1981, CLOSED DOORS VIOLENC; 1988, ABUSED WOMAN; 1986, SURGEON GENERALS WOR; 1989, BATTERED WOMAN	22	715	727	0	22	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 17	1992	267	23					3176	3178		10.1001/jama.267.23.3176	http://dx.doi.org/10.1001/jama.267.23.3176			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HX918	1593739				2023-01-03	WOS:A1992HX91800027
J	DICK, PH; CROMBIE, IK; DURHAM, T; MCFEE, C; PRIMROSE, M; MITCHELL, S				DICK, PH; CROMBIE, IK; DURHAM, T; MCFEE, C; PRIMROSE, M; MITCHELL, S			UNNECESSARY HOSPITALIZATION IN A PSYCHIATRIC REHABILITATION UNIT	BRITISH MEDICAL JOURNAL			English	Article									UNIV DUNDEE,NINEWELLS HOSP & MED SCH,DEPT EPIDEMIOL & PUBL HLTH,DUNDEE DD1 9SY,SCOTLAND	University of Dundee	DICK, PH (corresponding author), ROYAL LIFF HOSP,DUNDEE PSYCHIAT REHABIL SERV,DUNDEE DD2 5NF,SCOTLAND.							AFFLECK JW, 1984, BRIT J PSYCHIAT, V145, P517, DOI 10.1192/bjp.145.5.517; Dick P H, 1990, Int J Rehabil Res, V13, P119, DOI 10.1097/00004356-199006000-00003; MCCREADIE RG, 1983, BRIT J PSYCHIAT, V143, P564, DOI 10.1192/bjp.143.6.564; MCCREADIE RG, 1991, BRIT J PSYCHIAT, V158, P398, DOI 10.1192/bjp.158.3.398; 1989, CARING PEOPLE COMMUN	5	3	3	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 13	1992	304	6841					1544	1544		10.1136/bmj.304.6841.1544	http://dx.doi.org/10.1136/bmj.304.6841.1544			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HZ178	1628055	Green Published, Bronze			2023-01-03	WOS:A1992HZ17800026
J	BRAHAMS, D				BRAHAMS, D			ANESTHESIA AWARENESS - AN ORTHOPEDIC CASE	LANCET			English	Editorial Material																			0	1	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 11	1992	339	8785					116	116		10.1016/0140-6736(92)91016-2	http://dx.doi.org/10.1016/0140-6736(92)91016-2			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GZ156	1345832				2023-01-03	WOS:A1992GZ15600061
J	PRINCE, RL; SMITH, M; DICK, IM; PRICE, RI; WEBB, PG; HENDERSON, NK; HARRIS, MM				PRINCE, RL; SMITH, M; DICK, IM; PRICE, RI; WEBB, PG; HENDERSON, NK; HARRIS, MM			PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS - A COMPARATIVE-STUDY OF EXERCISE, CALCIUM SUPPLEMENTATION, AND HORMONE-REPLACEMENT THERAPY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BONE MASS; SPINAL OSTEOPOROSIS; PARATHYROID-HORMONE; WOMEN; FOREARM; FRACTURES; DENSITY; RADIUS; CALCITRIOL; ESTROGEN	Background. Osteoporosis among older women is a major public health problem. We studied the effects of three approaches to the prevention of osteoporosis in women with low bone density. Methods. One hundred twenty postmenopausal women (mean [+/- SD] age, 56 +/- 4) who were selected because they had low forearm bone density were enrolled in a double-blind, placebo-controlled, randomized study comparing the effects of an exercise regimen (exercise group, n = 41), exercise plus dietary calcium supplementation (exercise-calcium group, n = 39), and exercise plus continuous replacement of estrogen and progesterone (exercise-estrogen group, n = 40). Periodically during the two-year study period, we measured the women's bone density at three forearm sites, measured indexes of calcium metabolism, and recorded symptom scores. A comparison group of 42 women (mean age, 55.5 +/- 3.1) with normal bone density was also followed for two years. Results. Significant bone loss in the distal forearm occurred in the group with normal bone density (control group) and the exercise group (change, -2.7 percent and -2.6 percent of the base-line value per year, respectively). Bone loss at the distal forearm site was significantly lower in the exercise-calcium group (-0.5 percent of the base-line value per year), and bone density increased at this site in the exercise-estrogen group (+2.7 percent of the base-line value per year). Bone loss at the median forearm site was significantly lower in the exercise-calcium group (-1.3 percent of the base-line value per year) than in the exercise group (-2.4 percent), and bone density at this site increased significantly in the exercise-estrogen group (+0.8 percent of the base-line value per year). Breast tenderness occurred in 47 percent of the women in the exercise-estrogen group but in only 20 percent in the other two treatment groups. Vaginal bleeding occurred at some time in 52 percent of the women who had not had a hysterectomy in the exercise-estrogen group, as compared with 11 percent and 12.5 percent, respectively, in the exercise and exercise-calcium groups. Conclusions. In postmenopausal women with low bone density, bone loss can be slowed or prevented by exercise plus calcium supplementation or estrogen-progesterone replacement. Although the exercise-estrogen regimen was more effective than exercise and calcium supplementation in increasing bone mass, it also caused more side effects.	KING EDWARD MEM HOSP WOMEN,SUBIACO,WA,AUSTRALIA; UNIV WESTERN AUSTRALIA,SIR CHARLES GAIRDNER HOSP,DEPT CLIN BIOCHEM,NEDLANDS,WA 6009,AUSTRALIA; UNIV WESTERN AUSTRALIA,SIR CHARLES GAIRDNER HOSP,DEPT ENDOCRINOL & DIABET,NEDLANDS,WA 6009,AUSTRALIA	King Edward Memorial Hospital; University of Western Australia; University of Western Australia; University of Western Australia	PRINCE, RL (corresponding author), UNIV WESTERN AUSTRALIA,SIR CHARLES GAIRDNER HOSP,DEPT MED,NEDLANDS,WA 6009,AUSTRALIA.			Briffa, Kathy/0000-0002-0731-4112				BIJVOET OLM, 1969, CLIN SCI, V37, P23; CHOW R, 1987, BMJ-BRIT MED J, V295, P1441, DOI 10.1136/bmj.295.6611.1441; CUMMINGS SR, 1989, J BONE MINER RES  S1, V4, pS327; DAWSONHUGHES B, 1990, NEW ENGL J MED, V323, P878, DOI 10.1056/NEJM199009273231305; HAGENFELDT Y, 1988, J STEROID BIOCHEM, V31, P49, DOI 10.1016/0022-4731(88)90204-X; HUI SL, 1988, J CLIN INVEST, V81, P1804, DOI 10.1172/JCI113523; HUTCHINSON TA, 1979, LANCET, V2, P705; KANDERS B, 1988, J BONE MINER RES, V3, P145; KENT JC, 1979, BIOCHEM BIOPH RES CO, V89, P155, DOI 10.1016/0006-291X(79)90957-4; KROLNER B, 1980, SCAND J CLIN LAB INV, V40, P665, DOI 10.3109/00365518009091979; LINDSAY R, 1980, LANCET, V2, P1151; MAZESS RB, 1984, J NUCL MED, V25, P281; MCARDLE WD, 1986, EXERCISE PHYSL ENERG, P642; NICHOLSON GC, 1985, CLIN ENDOCRINOL, V22, P597, DOI 10.1111/j.1365-2265.1985.tb02995.x; NORDIN BEC, 1991, J CLIN ENDOCR METAB, V72, P401, DOI 10.1210/jcem-72-2-401; NORDIN BEC, 1987, MED J AUSTRALIA, V146, P300; PRICE RI, 1989, J BONE MINER RES, V4, P149; PRINCE R, 1988, METABOLISM, V37, P727, DOI 10.1016/0026-0495(88)90005-4; PRINCE RL, 1990, J CLIN ENDOCR METAB, V70, P1119, DOI 10.1210/jcem-70-4-1119; PRINCE RL, 1985, BRIT MED J, V290, P735, DOI 10.1136/bmj.290.6470.735; RIGGS BL, 1987, J CLIN INVEST, V80, P979, DOI 10.1172/JCI113191; RIIS B, 1987, NEW ENGL J MED, V316, P173, DOI 10.1056/NEJM198701223160401; ROSS PD, 1988, J BONE MINER RES, V3, P1; SCHLENKER RA, 1976, CALC TISS RES, V20, P41, DOI 10.1007/BF02546396; SHEIKH MS, 1988, J CLIN INVEST, V81, P126, DOI 10.1172/JCI113283; STJOHN A, 1988, CLIN CHIM ACTA, V178, P215, DOI 10.1016/0009-8981(88)90227-6; WEISS NS, 1980, NEW ENGL J MED, V303, P1195, DOI 10.1056/NEJM198011203032102; 1989, J BONE MINER RES S2, V4, P1	28	438	449	0	21	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 24	1991	325	17					1189	1195		10.1056/NEJM199110243251701	http://dx.doi.org/10.1056/NEJM199110243251701			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GL282	1922205				2023-01-03	WOS:A1991GL28200001
J	ANDERSSON, M; STORM, HH; MOURIDSEN, HT				ANDERSSON, M; STORM, HH; MOURIDSEN, HT			ADJUVANT CHEMOTHERAPY AND SUBSEQUENT MALIGNANT DISEASE	LANCET			English	Letter									DANISH BREAST CANC COOPERAT GRP,COPENHAGEN,DENMARK	Danish Breast Cancer Cooperative Group (DBCG)	ANDERSSON, M (corresponding author), DANISH CANC REGISTRY,INST CANC EPIDEMIOL,DK-2100 COPENHAGEN,DENMARK.			Storm, Hans/0000-0001-7223-8198				ARRIAGADA, 1991, LANCET, V338, P535	1	1	1	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 5	1991	338	8771					885	886		10.1016/0140-6736(91)91539-7	http://dx.doi.org/10.1016/0140-6736(91)91539-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GH945	1681236				2023-01-03	WOS:A1991GH94500035
J	WALSH, DC; HINGSON, RW; MERRIGAN, DM; LEVENSON, SM; CUPPLES, LA; HEEREN, T; COFFMAN, GA; BECKER, CA; BARKER, TA; HAMILTON, SK; MCGUIRE, TG; KELLY, CA				WALSH, DC; HINGSON, RW; MERRIGAN, DM; LEVENSON, SM; CUPPLES, LA; HEEREN, T; COFFMAN, GA; BECKER, CA; BARKER, TA; HAMILTON, SK; MCGUIRE, TG; KELLY, CA			A RANDOMIZED TRIAL OF TREATMENT OPTIONS FOR ALCOHOL-ABUSING WORKERS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INPATIENT; CONSUMPTION; PROGRAMS; OUTCOMES; 6-MONTH	Background. Employee-assistance programs sponsored by companies or labor unions identify workers who abuse alcohol and refer them for care, often to inpatient rehabilitation programs. Yet the effectiveness of inpatient treatment, as compared with a variety of less intensive alternatives, has repeatedly been called into question. In this study, anchored in the work site, we compared the effectiveness of mandatory in-hospital treatment with that of required attendance at the meetings of a self-help group and a choice of treatment options. Methods. We randomly assigned a series of 227 workers newly identified as abusing alcohol to one of three rehabilitation regimens: compulsory inpatient treatment, compulsory attendance at Alcoholics Anonymous (AA) meetings, and a choice of options. Inpatient backup was provided if needed. The groups were compared in terms of 12 job-performance variables and 12 measures of drinking and drug use during a two-year follow-up period. Results. All three groups improved, and no significant differences were found among the groups in job-related outcome variables. On seven measures of drinking and drug use, however, we found significant differences at several follow-up assessments. The hospital group fared best and that assigned to AA the least well; those allowed to choose a program had intermediate outcomes. Additional inpatient treatment was required significantly more often (P < 0.0001) by the AA group (63 percent) and the choice group (38 percent) than by subjects assigned to initial treatment in the hospital (23 percent). The differences among the groups were especially pronounced for workers who had used cocaine within six months before study entry. The estimated costs of inpatient treatment for the AA and choice groups averaged only 10 percent less than the costs for the hospital groups because of their higher rates of additional treatment. Conclusions. Even for employed problem drinkers who are not abusing drugs and who have no serious medical problems, an initial referral to AA alone or a choice of programs, although less costly than inpatient care, involves more risk than compulsory inpatient treatment and should be accompanied by close monitoring for signs of incipient relapse.	HARVARD UNIV,SCH PUBL HLTH,DEPT SOCIAL & BEHAV SCI,BOSTON,MA 02115; HARVARD UNIV,SCH PUBL HLTH,DEPT EPIDEMIOL & BIOSTAT,BOSTON,MA 02115; BOSTON UNIV,CTR DATA COORDINATING,SCH PUBL HLTH,BOSTON,MA 02215; BOSTON UNIV,INST HLTH POLICY,BOSTON,MA 02215; BOSTON UNIV,DEPT ECON,BOSTON,MA 02215	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Boston University; Boston University; Boston University				Heeren, Timothy/0000-0001-5643-3559; Coffman, Gerald/0000-0002-0044-6219; Levenson, Suzette/0000-0002-1979-2373	NIAAA NIH HHS [R01 AA06461] Funding Source: Medline; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA006461] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Armor D. J., 1976, ALCOHOLISM TREATMENT; CHAPMAN PLH, 1988, BRIT J ADDICT, V83, P67; EDWARDS G, 1977, J STUD ALCOHOL, V38, P1004, DOI 10.15288/jsa.1977.38.1004; EMRICK CD, 1975, J STUD ALCOHOL, V36, P88, DOI 10.15288/jsa.1975.36.88; HAYASHIDA M, 1989, NEW ENGL J MED, V320, P358, DOI 10.1056/NEJM198902093200605; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Lawless J.F., 1982, STAT MODELS METHODS, P52; LONGABAUGH R, 1983, J STUD ALCOHOL, V44, P1049, DOI 10.15288/jsa.1983.44.1049; MCLACHLAN JFC, 1982, J STUD ALCOHOL, V43, P261, DOI 10.15288/jsa.1982.43.261; MIDANIK L, 1982, BRIT J ADDICT, V77, P357; MILLER WR, 1986, AM PSYCHOL, V41, P794, DOI 10.1037/0003-066X.41.7.794; MILLER WR, 1989, HDB ALCOHOLISM TREAT, P261; MULFORD HA, 1977, J STUD ALCOHOL, V38, P2197, DOI 10.15288/jsa.1977.38.2197; OFARRELL TJ, 1987, ADV BEHAV RES THER, V9, P91, DOI 10.1016/0146-6402(87)90010-5; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; Roman P M, 1988, Recent Dev Alcohol, V6, P131; SELZER ML, 1975, J STUD ALCOHOL, V36, P117, DOI 10.15288/jsa.1975.36.117; SMITH PF, 1990, AM J PUBLIC HEALTH, V80, P309, DOI 10.2105/AJPH.80.3.309; TRICE HM, 1984, J STUD ALCOHOL, V45, P393, DOI 10.15288/jsa.1984.45.393; WALSH DC, 1985, J OCCUP ENVIRON MED, V27, P745; WALSH DC, 1991, J STUD ALCOHOL, V52, P17, DOI 10.15288/jsa.1991.52.17; WALSH DC, 1982, MILBANK FUND Q, V60, P492, DOI 10.2307/3349803; WANBERG KW, 1974, INT J MENT HEALTH, V3, P160, DOI 10.1080/00207411.1974.11448664; WEEISNER CM, 1990, I MED BROADENING BAS, P579; WILSON GT, 1987, BRIT J ADDICT, V82, P343; 1983, HLTH TECHNOLOGY CASE; 1972, ANN INTERN MED, V7, P249; 1990, BROADENING BASE TREA; 1990, NATIONAL DRUG CONTRO; 1980, DIAGNOSTIC STATISTIC, P163; 1982, DIAGNOSTIC INTERVIEW; 1989, PREVENTION TREATMENT	32	202	203	0	13	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 12	1991	325	11					775	782		10.1056/NEJM199109123251105	http://dx.doi.org/10.1056/NEJM199109123251105			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GE456	1870651				2023-01-03	WOS:A1991GE45600005
J	LINDELOF, B; SIGURGEIRSSON, B; TEGNER, E; LARKO, O; JOHANNESSON, A; BERNE, B; CHRISTENSEN, OB; ANDERSSON, T; TORNGREN, M; MOLIN, L; NYLANDERLUNDQVIST, E; EMTESTAM, L				LINDELOF, B; SIGURGEIRSSON, B; TEGNER, E; LARKO, O; JOHANNESSON, A; BERNE, B; CHRISTENSEN, OB; ANDERSSON, T; TORNGREN, M; MOLIN, L; NYLANDERLUNDQVIST, E; EMTESTAM, L			PUVA AND CANCER - A LARGE-SCALE EPIDEMIOLOGIC-STUDY	LANCET			English	Article							8-YEAR FOLLOW-UP; GENITAL TUMORS; SKIN-CANCER; PSORIASIS; PHOTOCHEMOTHERAPY; MEN	There is concern about the long-term carcinogenic effects of psoralen and ultraviolet A radiation (PUVA) therapy for treatment of skin disorders. A study of 4799 Swedish patients (2343 males, 2056 females; mean age at first treatment 45.3 years, range 6-93; mean follow-up 6.9 years males, 7.2 years females) who received PUVA between 1974 and 1985 showed a dose-dependent increase in the risk of squamous cell cancer of the skin. Male patients who had received more than 200 treatments had over 30 times the incidence of squamous cell cancer found in the general population. Significant increases (p < 0.05) were also found in the incidences of respiratory cancer in males and females, pancreatic cancer in males, and kidney and colonic cancer in females. This study confirms previous reports of a dose-dependent increase in the incidence of squamous cell cancer in patients treated with PUVA.	UNIV LUND HOSP,S-22185 LUND,SWEDEN; SAHLGRENS UNIV HOSP,S-41345 GOTHENBURG,SWEDEN; SWEDISH PSORIASIS ASSOC,STOCKHOLM,SWEDEN; UNIV HOSP UPPSALA,UPPSALA,SWEDEN; MALMO GEN HOSP,S-21401 MALMO,SWEDEN; LINKOPING UNIV HOSP,S-58185 LINKOPING,SWEDEN; DANDERYD HOSP,STOCKHOLM,SWEDEN; OREBRO MED CTR HOSP,OREBRO,SWEDEN; UMEA UNIV HOSP,S-90185 UMEA,SWEDEN; HUDDINGE HOSP,S-14186 HUDDINGE,SWEDEN	Lund University; Skane University Hospital; Sahlgrenska University Hospital; Uppsala University; Uppsala University Hospital; Linkoping University; Danderyds Hospital; Umea University	LINDELOF, B (corresponding author), KAROLINSKA HOSP,DEPT DERMATOL,S-10401 STOCKHOLM 60,SWEDEN.		Sigurgeirsson, Bárður/B-6130-2011; Sigurgeirsson, Bardur/AAP-7755-2020	Sigurgeirsson, Bardur/0000-0002-9733-9742				FORMAN AB, 1989, ARCH DERMATOL, V125, P515, DOI 10.1001/archderm.125.4.515; HENSELER T, 1987, J AM ACAD DERMATOL, V16, P108, DOI 10.1016/S0190-9622(87)70010-3; LINDELOF B, IN PRESS ACTA DERM V; MATTSSON B, 1984, THESIS KAROLINSKA I, P1; MCGARRY GW, 1990, NEW ENGL J MED, V323, P684; PERKINS W, 1990, LANCET, V336, P1248, DOI 10.1016/0140-6736(90)92860-K; SIGURGEIRSSON B, IN PRESS COMPUT METH; STERN RS, 1984, NEW ENGL J MED, V310, P1156, DOI 10.1056/NEJM198405033101805; STERN RS, 1990, NEW ENGL J MED, V322, P1093, DOI 10.1056/NEJM199004193221601; STERN RS, 1988, J INVEST DERMATOL, V91, P120, DOI 10.1111/1523-1747.ep12464137; STERN RS, 1988, J INVEST DERMATOL, V91, P197, DOI 10.1111/1523-1747.ep12464847; TANEW A, 1986, J AM ACAD DERMATOL, V15, P960, DOI 10.1016/S0190-9622(86)70257-0	12	191	192	0	7	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 13	1991	338	8759					91	93		10.1016/0140-6736(91)90083-2	http://dx.doi.org/10.1016/0140-6736(91)90083-2			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FW161	1676477				2023-01-03	WOS:A1991FW16100012
J	CHANTELAU, E; LEE, DM; HEMMANN, DM; ZIPFEL, U; ECHTERHOFF, S				CHANTELAU, E; LEE, DM; HEMMANN, DM; ZIPFEL, U; ECHTERHOFF, S			WHAT MAKES INSULIN INJECTIONS PAINFUL	BRITISH MEDICAL JOURNAL			English	Article									UNIV DUSSELDORF,MED DEPT NUTR & METAB DIS,W-4000 DUSSELDORF 1,GERMANY	Heinrich Heine University Dusseldorf								HODGE RH, 1980, JAMA-J AM MED ASSOC, V244, P266, DOI 10.1001/jama.244.3.266; KRALL LP, 1978, JOSLIN DIABETES MANU, P81; SCOTT J, 1976, PAIN, V2, P175, DOI 10.1016/0304-3959(76)90113-5; THOW J, 1990, BRIT MED J, V301, P3, DOI 10.1136/bmj.301.6742.3; WILLIAMS G, 1983, DIABETES, V32, P466, DOI 10.2337/diabetes.32.5.466	5	40	44	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 6	1991	303	6793					26	27		10.1136/bmj.303.6793.26	http://dx.doi.org/10.1136/bmj.303.6793.26			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FW128	1859951	Green Published, Bronze			2023-01-03	WOS:A1991FW12800022
J	SIMELL, T; KAPRIO, EA; MAENPAA, J; TUOMINEN, J; SIMELL, O				SIMELL, T; KAPRIO, EA; MAENPAA, J; TUOMINEN, J; SIMELL, O			RANDOMIZED PROSPECTIVE-STUDY OF SHORT-TERM AND LONG-TERM INITIAL STAY IN HOSPITAL BY CHILDREN WITH DIABETES-MELLITUS	LANCET			English	Article							SMALL-AREA VARIATIONS; INSULIN THERAPY; COMPLICATIONS	To assess how an isolated change in the pattern of care influences outcome of care and hospital use, a randomised prospective 2-year study was done in which 31 of 61 consecutive children with newly diagnosed insulin-dependent diabetes mellitus (IDDM) were admitted to hospital at disease onset for about a week and compared with the other 30 children who were admitted for about 4 weeks. Insulin treatment and education about diabetes were similar in the two groups. Duration of initial stay in hospital had no effect on metabolic control during the 2 years but time since diagnosis was significant with respect to effect on haemoglobin A1 (p = 0.001), haemoglobin A1c (p = 0.004), and insulin dose (p < 0.001). At 2 years, 45% of the children in the short-term group and 29% in the long-term group were C-peptide positive (p = NS); C-peptide positivity correlated with age. A change in the pattern of care of children with IDDM, led to a pronounced decrease in hospital use by this patient group. Irrespective of the length of initial stay in hospital, equally good metabolic control was obtained in both groups for 2 years.	AURORA CITY HOSP,HELSINKI,FINLAND; UNIV HELSINKI,CHILDRENS HOSP,SF-00100 HELSINKI 10,FINLAND; UNIV TURKU,DEPT BIOSTAT,SF-20500 TURKU 50,FINLAND; UNIV TURKU,CARDIORESP RES UNIT,SF-20500 TURKU 50,FINLAND	University of Helsinki; University of Turku; University of Turku	SIMELL, T (corresponding author), UNIV TURKU,CHILDRENS HOSP,KIINAMYLLYNKATU 4-8,SF-20520 TURKU 52,FINLAND.							CLARSON C, 1987, DIABETES CARE, V10, P33, DOI 10.2337/diacare.10.1.33; DELAMATER AM, 1990, DIABETES CARE, V13, P492, DOI 10.2337/diacare.13.5.492; Diabetes Epidemiology Research International Group, 1988, DIABETES, V37, P1113; DUNCAN JA, 1986, CONT PEDIAT, V3, P79; HAMMAN RF, 1985, DIABETES CARE, V8, P94, DOI 10.2337/diacare.8.1.S94; JENNRICH RI, 1986, BIOMETRICS, V42, P805, DOI 10.2307/2530695; KARJALAINEN J, 1989, NEW ENGL J MED, V320, P881, DOI 10.1056/NEJM198904063201401; KROLEWSKI AS, 1987, NEW ENGL J MED, V317, P1390; Laron Z, 1979, Diabetes Care, V2, P342, DOI 10.2337/diacare.2.4.342; MACLURE A, 1984, LANCET, V2, P682; MCPHERSON K, 1982, NEW ENGL J MED, V307, P1310, DOI 10.1056/NEJM198211183072104; MULLIS P, 1988, DIABETOLOGIA, V31, P351, DOI 10.1007/BF02341502; PERRIN JM, 1989, NEW ENGL J MED, V320, P1183, DOI 10.1056/NEJM198905043201805; SCHNEIDER AJ, 1983, AM J DIS CHILD, V137, P782, DOI 10.1001/archpedi.1983.02140340062017; SHAH SC, 1989, NEW ENGL J MED, V320, P550, DOI 10.1056/NEJM198903023200902; SIMELL T, 1990, NEW ENGL J MED, V322, P206; SIMELL T, 1987, CLIN JUDGEMENT DECIS, P376; SPAULDING RH, 1976, CAN MED ASSOC J, V114, P780; STENMAN UH, 1984, J CHROMATOGR, V297, P327, DOI 10.1016/S0021-9673(01)89052-X; SZAPIRO N, 1990, NEW ENGL J MED, V322, P206; TUOMILEHTO J, 1990, Diabetologia, V33, pA197; WENNBERG J, 1973, SCIENCE, V182, P1102, DOI 10.1126/science.182.4117.1102; 1989, LANCET, V1, P1235; [No title captured]	24	25	26	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 16	1991	337	8742					656	660		10.1016/0140-6736(91)92464-D	http://dx.doi.org/10.1016/0140-6736(91)92464-D			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FB730	1672001				2023-01-03	WOS:A1991FB73000014
J	PIZARRO, D; POSADA, G; SANDI, L; MORAN, JR				PIZARRO, D; POSADA, G; SANDI, L; MORAN, JR			RICE-BASED ORAL ELECTROLYTE-SOLUTIONS FOR THE MANAGEMENT OF INFANTILE DIARRHEA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							REHYDRATION SOLUTIONS; CONTROLLED TRIAL; UNITED-STATES; THERAPY; CHILDREN; EFFICACY; POWDER	Background. In infants the treatment of acute diarrhea with glucose-based solutions results in rehydration but does not reduce the severity of diarrhea. Oral rehydration with solutions based on rice powder may reduce stool output as well as restore fluid volume. Methods. We designed a prospective, randomized, double-blind study to evaluate the efficacy of two rice-based rehydration solutions and a conventional glucose-based solution. Solution A contained only rice-syrup solids, solution B contained rice-syrup solids and casein hydrolysate, and solution C, the glucose-based solution, served as control. The study subjects were 86 mildly to moderately dehydrated infant boys, 3 to 18 months old, who were admitted to a children's hospital with acute diarrhea. We measured fluid intake, fecal and urine output, and absorption and retention of fluid, sodium, and potassium at intervals for 48 hours in all 86 infants. Results. The mean (+/- SE) fecal output was significantly lower in the infants given solution A (group A infants) than in the infants given solution C (group C) (29 +/- 4 vs. 46 +/- 7 ml per kilogram of body weight, P < 0.05) during the first six hours of therapy. The infants in group A also had greater fluid absorption (221 +/- 16 vs. 167 +/- 9 ml per kilogram, P < 0.05) over the entire 48 hours of therapy and greater potassium absorption (1.6 +/- 0.2 vs. 0.6 +/- 0.1 mmol per kilogram, P < 0.05) during the first six hours than the infants in group C. Solution B offered no advantages over solution A. Conclusions. Solutions containing rice-syrup solids were effective in the rehydration of infants with acute diarrhea. They decreased stool output and promoted greater absorption and retention of fluid and electrolytes than did a glucose-based solution.	MEAD JOHNSON RES CTR, EVANSVILLE, IN USA		PIZARRO, D (corresponding author), HOSP NACL NINOS DR CARLOS SAENZ HERRERA, DEPT EMERGENCY MED, SAN JOSE, COSTA RICA.							AZAD MAK, 1990, PEDIATR RES, V27, pA100; BHAN MK, 1987, J PEDIATR GASTR NUTR, V6, P392, DOI 10.1097/00005176-198705000-00016; CARPENTER CCJ, 1988, NEW ENGL J MED, V319, P1346, DOI 10.1056/NEJM198811173192009; DEVIZIA B, 1975, J PEDIATR-US, V86, P50, DOI 10.1016/S0022-3476(75)80703-7; FIELD M, 1989, NEW ENGL J MED, V321, P879; GARCIA LS, 1983, J CLIN MICROBIOL, V18, P185, DOI 10.1128/JCM.18.1.185-190.1983; HIRSCHHORN N, 1980, AM J CLIN NUTR, V33, P637, DOI 10.1093/ajcn/33.3.637; HUNT J B, 1988, Clinical Science (London), V74, p2P; KLISH WJ, 1985, PEDIATR REV, V7, P27; LEBENTHAL E, 1980, J PEDIATR-US, V97, P389, DOI 10.1016/S0022-3476(80)80187-9; MATA LJ, 1970, J INFECT DIS, V122, P170, DOI 10.1093/infdis/122.3.170; MOHAN M, 1986, J PEDIATR GASTR NUTR, V5, P423, DOI 10.1097/00005176-198605000-00015; MOLLA AM, 1982, LANCET, V1, P1317; MORRIS GK, 1985, MANUAL CLIN MICROBIO, V302, P8; PATRA FC, 1982, ARCH DIS CHILD, V57, P910, DOI 10.1136/adc.57.12.910; PATRA FC, 1984, ACTA PAEDIATR SCAND, V73, P18, DOI 10.1111/j.1651-2227.1984.tb09891.x; PIZARRO D, 1987, PEDIATRICS, V79, P190; RAHMAN ASMM, 1985, LANCET, V2, P539; SACK DA, 1980, J PEDIATR-US, V96, P20, DOI 10.1016/S0022-3476(80)80317-9; SANTOSHAM M, 1986, J PEDIATR-US, V109, P795, DOI 10.1016/S0022-3476(86)80696-5; SANTOSHAM M, 1982, NEW ENGL J MED, V306, P1070, DOI 10.1056/NEJM198205063061802; SATHANAKRISHNAN B R, 1985, Indian Journal of Pediatrics, V52, P479, DOI 10.1007/BF02751022; TAMER AM, 1985, J PEDIATR-US, V107, P14, DOI 10.1016/S0022-3476(85)80606-5; TAMER AM, 1986, J PEDIATR-US, V108, P160, DOI 10.1016/S0022-3476(86)80801-0; VESIKARI T, 1986, ARCH DIS CHILD, V61, P372, DOI 10.1136/adc.61.4.372; WILSON R, 1990, CEREAL BASED ORAL RE, P13; YOLKEN RH, 1977, LANCET, V2, P263; 1985, SAS USERS GUDIE STAT	28	48	50	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 21	1991	324	8					517	521		10.1056/NEJM199102213240802	http://dx.doi.org/10.1056/NEJM199102213240802			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EX918	1992304				2023-01-03	WOS:A1991EX91800002
J	JELICIC, M; BONKE, B; APPELBOOM, DK				JELICIC, M; BONKE, B; APPELBOOM, DK			INDIRECT MEMORY FOR WORDS PRESENTED DURING ANESTHESIA	LANCET			English	Letter									ERASMUS UNIV,DEPT PSYCHOTHERAPY,3000 DR ROTTERDAM,NETHERLANDS; ST LUCAS HOSP,DEPT ANAESTHESIA,AMSTERDAM,NETHERLANDS	Erasmus University Rotterdam; Sint Lucas Andreas Hospital	JELICIC, M (corresponding author), ERASMUS UNIV,DEPT MED PSYCHOL,3000 DR ROTTERDAM,NETHERLANDS.							BLACHER RS, 1975, JAMA-J AM MED ASSOC, V234, P67, DOI 10.1001/jama.234.1.67; BONKE B, 1990, MEMORY AWARENESS ANA; DAVIS R, 1987, MED J AUSTRALIA, V146, P4, DOI 10.5694/j.1326-5377.1987.tb120114.x; EVANS C, 1988, LANCET, V2, P491, DOI 10.1016/S0140-6736(88)90131-6; MILLER RD, 1989, YB ANESTHESIA, P7; ROORDAHRDLICKOV.V, 1990, MEMORY AWARENESS ANA, P150; SCOTT DL, 1972, CAN ANAESTH SOC J, V19, P173, DOI 10.1007/BF03005047; WILSON ME, 1986, LANCET, V2, P1338; 1986, LANCET, V2, P1019	9	28	29	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 28	1990	336	8709					249	249		10.1016/0140-6736(90)91776-7	http://dx.doi.org/10.1016/0140-6736(90)91776-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DQ701	1973797				2023-01-03	WOS:A1990DQ70100040
J	BRAHAMS, D				BRAHAMS, D			EUTHANASIA IN THE NETHERLANDS	LANCET			English	Editorial Material																		BRAHAMS D, 1981, LANCET, V2, P1101; BRAHAMS D, 1989, LANCET, V2, P1407; Devlin P., 1985, EASING PASSING; LEENEN HJJ, 1990, BRIT MED J, V300, P69; LEVIN B, 1989, TIMES           1211; RIGHTER H, 1988, BRIT MED J, V297, P1593; Sluyters B, 1989, Med Leg J, V57 ( Pt 1), P34; 1988, EUTHANASIA REPORT RE; 1988, MED LEG J, V56, P179	9	5	5	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 10	1990	335	8689					591	592						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CT653	1689795				2023-01-03	WOS:A1990CT65300016
J	DER, G; GUPTA, S; MURRAY, RM				DER, G; GUPTA, S; MURRAY, RM			IS SCHIZOPHRENIA DISAPPEARING	LANCET			English	Article									INST PSYCHIAT, DE CRESPIGNY PK, DENMARK HILL, LONDON SE5 8AF, ENGLAND				; Mortensen, Preben Bo/D-2358-2015; murray, robin/F-8658-2012	Der, Geoff/0000-0002-8677-073X; Mortensen, Preben Bo/0000-0002-5230-9865; murray, robin/0000-0003-0829-0519				Bleuler M., 1978, SCHIZOPHRENIC DISORD; COOPER JE, 1987, BRIT J PSYCHIAT, V151, P619, DOI 10.1192/bjp.151.5.619; DICKSON WE, 1986, PSYCHOL MED, V16, P521, DOI 10.1017/S003329170001028X; EAGLES JM, 1988, BRIT J PSYCHIAT, V152, P793, DOI 10.1192/bjp.152.6.793; EAGLES JM, 1985, BRIT J PSYCHIAT, V146, P151, DOI 10.1192/bjp.146.2.151; Hafner H., 1987, SEARCH CAUSES SCHIZO, P47; HARE E, 1986, BRIT J PSYCHIAT, V149, P554, DOI 10.1192/bjp.149.5.554; HARE E, 1983, BRIT J PSYCHIAT, V142, P439, DOI 10.1192/bjp.142.5.439; HARE EH, 1974, J PSYCHOSOM RES, V18, P283, DOI 10.1016/0022-3999(74)90011-7; JOYCE PR, 1987, AUST NZ J PSYCHIAT, V21, P82, DOI 10.3109/00048678709160903; MAHENDRA B, 1981, PSYCHOL MED, V11, P669, DOI 10.1017/S0033291700041155; MUNKJORGENSEN P, 1986, ACTA PSYCHIAT SCAND, V74, P379, DOI 10.1111/j.1600-0447.1986.tb06257.x; MUNKJORGENSEN P, 1986, ACTA PSYCHIAT SCAND, V73, P645, DOI 10.1111/j.1600-0447.1986.tb02738.x; ODEGARD O, 1971, SOC PSYCHIATR, V6, P53, DOI 10.1007/BF00578029; Oedegaard O, 1952, PSYCHIAT QUART, V26, P212, DOI 10.1007/BF01568460; PARKER G, 1985, BRIT J PSYCHIAT, V146, P377, DOI 10.1192/bjp.146.4.377; SARTORIUS N, 1986, PSYCHOL MED, V16, P909, DOI 10.1017/S0033291700011910; SAUGSTAD LF, 1989, SCHIZOPHRENIA BULL, V15, P9, DOI 10.1093/schbul/15.1.9; SYMONDS RL, 1981, PSYCHOL MED, V11, P193, DOI 10.1017/S0033291700053411; TORREY EF, 1989, PSYCHOL MED, V19, P285, DOI 10.1017/S0033291700012320; 1964, STATISTICAL REPORT S, V4; 1964, STATISTICAL REPORT S, V5; 1972, PSYCHIATRIC HOSPITAL; 1964, STATISTICAL REPORT S, V12; 1964, STATISTICAL REPORT S, V11; 1952, SUPPLEMENTS MENTAL H	26	161	163	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 3	1990	335	8688					513	516		10.1016/0140-6736(90)90745-Q	http://dx.doi.org/10.1016/0140-6736(90)90745-Q			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CT015	1968536				2023-01-03	WOS:A1990CT01500012
J	ROSENLOF, K; FYHRQUIST, F; TENHUNEN, R				ROSENLOF, K; FYHRQUIST, F; TENHUNEN, R			ERYTHROPOIETIN, ALUMINUM, AND ANEMIA IN PATIENTS ON HEMODIALYSIS	LANCET			English	Article									UNIV HELSINKI, CENT HOSP, DEPT CLIN CHEM, SF-00170 HELSINKI 17, FINLAND	University of Helsinki; Helsinki University Central Hospital	ROSENLOF, K (corresponding author), UNIV HELSINKI, CENT HOSP, DEPT MED 4, UNIONINKATU 38, SF-00170 HELSINKI 17, FINLAND.							ALTMANN P, 1988, LANCET, V1, P1012; BEAUMONT C, 1984, EXP CELL RES, V154, P474, DOI 10.1016/0014-4827(84)90171-X; BROWN S, 1984, CLIN CHEM, V30, P1216; COCHRAN M, 1984, FEBS LETT, V176, P129, DOI 10.1016/0014-5793(84)80926-6; ESCHBACH JW, 1987, NEW ENGL J MED, V316, P73, DOI 10.1056/NEJM198701083160203; GRONHAGENRISKA C, 1989, ALUMINIUM AND IRON OVERLOAD IN HAEMODIALYSIS, P56; JACOBS K, 1985, NATURE, V313, P806, DOI 10.1038/313806a0; MCGONIGLE RJS, 1985, NEPHRON, V39, P1, DOI 10.1159/000183328; MLADENOVIC J, 1988, J CLIN INVEST, V81, P1661, DOI 10.1172/JCI113502; MOREB J, 1983, NEPHRON, V35, P196, DOI 10.1159/000183074; PASANEN AVO, 1980, INT J BIOCHEM, V12, P969; PASANEN AVO, 1985, SCAND J HAEMATOL, V34, P235; PASANEN AVO, 1982, ANN CLIN RES, V14, P61; ROSENLOF K, 1989, J INTERN MED, V226, P311, DOI 10.1111/j.1365-2796.1989.tb01401.x; RUTHERFORD T, 1979, P NATL ACAD SCI USA, V76, P833, DOI 10.1073/pnas.76.2.833; SANO S, 1961, J BIOL CHEM, V236, P1173; SASSA S, 1979, P NATL ACAD SCI USA, V76, P5321, DOI 10.1073/pnas.76.10.5321; TRAPP GA, 1983, LIFE SCI, V33, P311, DOI 10.1016/S0024-3205(83)80002-2; Van de Vyver F L, 1987, Contrib Nephrol, V55, P198; WINEARLS CG, 1986, LANCET, V2, P1175, DOI 10.1016/S0140-6736(86)92192-6	20	92	93	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 3	1990	335	8684					247	249						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CL815	1967718				2023-01-03	WOS:A1990CL81500002
J	CHONN, A; SEMPLE, SC; CULLIS, PR				CHONN, A; SEMPLE, SC; CULLIS, PR			ASSOCIATION OF BLOOD PROTEINS WITH LARGE UNILAMELLAR LIPOSOMES INVIVO - RELATION TO CIRCULATION LIFETIMES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COATED LIPOSOMES; PLASMA-PROTEINS; CHOLESTEROL; CLEARANCE; LIVER; SIZE; ADSORPTION; STABILITY; INVITRO; CHARGE	The proteins associated with liposomes in the circulation of mice were analyzed in order to determine whether bound proteins significantly influence the fate of liposomes in vivo. Liposomes were administered intravenously via the dorsal tail vein of CD1 mice and were isolated from blood after 2 min in the absence of coagulation inhibitors using a rapid "spin column" procedure. Various negatively charged liposomes exhibiting markedly different clearance properties were studied; notably, these included liposomes containing 10 mol % ganglioside G(M1) which has been previously shown to effectively limit liposomal uptake by the fixed macrophages of the reticuloendothelial system. The protein binding ability (P(B); g of protein/mol of lipid) of the liposomes was quantitated and related to the Circulation half-life (tau-1/2) of the liposomes. Liposomes having similar membrane surface charge imparted by different anionic phospholipids were found to exhibit markedly different protein binding potentials. Furthermore, P(B) values determined from the in vivo experiments were found to be inversely related to circulation half-lives. P(B) values in excess of 50 g of protein/mol of lipid were observed for rapidly cleared liposomes such as those containing cardiolipin or phosphatidic acid (tau-1/2 < 2 min). P(B) values for ganglioside G(M1)-containing liposomes (tau-1/2 > 2 h) were significantly less (PB < 15 g of total protein/mol of total lipid). P(B) values were also determined for liposomes recovered from in vitro incubations with isolated human serum; relative P(B) values obtained from these in vitro experiments were in agreement with relative P(B) values measured from in vivo experiments. P(B) values, therefore, could be a useful parameter for predicting the clearance behavior of liposomes in the circulation. Liposomes exhibiting increased P(B) values in vivo were shown by immunoblot analysis to bind more immune opsonins, leading to a higher probability of phagocytic uptake. Finally, based on results obtained using the in vitro system, it is suggested that the mechanism by which ganglioside G(M1) prolongs the murine circulation half-life of liposomes is by reducing the total amount of blood protein bound to the liposomes in a relatively nonspecific manner.			CHONN, A (corresponding author), UNIV BRITISH COLUMBIA, FAC MED, DEPT BIOCHEM, 2146 HLTH SCI MALL, VANCOUVER V6T 1Z3, BC, CANADA.							ABRA RM, 1981, BIOCHIM BIOPHYS ACTA, V666, P493, DOI 10.1016/0005-2760(81)90311-8; ALLEN TM, 1987, FEBS LETT, V223, P42, DOI 10.1016/0014-5793(87)80506-9; ALVING CR, 1984, BIOCHEM SOC T, V12, P342, DOI 10.1042/bst0120342; ANDRADE JD, 1987, ANN NY ACAD SCI, V516, P158, DOI 10.1111/j.1749-6632.1987.tb33038.x; BLACK CDV, 1976, BIOCHEM SOC T, V4, P253; BLUME G, 1990, BIOCHIM BIOPHYS ACTA, V1029, P91, DOI 10.1016/0005-2736(90)90440-Y; BONTE F, 1986, CHEM PHYS LIPIDS, V40, P359, DOI 10.1016/0009-3084(86)90079-4; CHONN A, 1991, BIOCHIM BIOPHYS ACTA, V1070, P215, DOI 10.1016/0005-2736(91)90167-7; CHONN A, 1991, J IMMUNOL, V146, P4234; DERKSEN JTP, 1987, BIOCHIM BIOPHYS ACTA, V931, P33, DOI 10.1016/0167-4889(87)90047-4; Fiske CH, 1925, J BIOL CHEM, V66, P375; GABIZON A, 1988, P NATL ACAD SCI USA, V85, P6949, DOI 10.1073/pnas.85.18.6949; GREEN SR, 1989, J LIPID RES, V30, P1405; GREGORIADIS G, 1980, FEBS LETT, V119, P43, DOI 10.1016/0014-5793(80)80994-X; Gregoriadis G., 1988, LIPOSOMES DRUG CARRI, P3; Halperin G, 1986, Methods Enzymol, V129, P816; HOPE MJ, 1985, BIOCHIM BIOPHYS ACTA, V812, P55, DOI 10.1016/0005-2736(85)90521-8; HORBETT TA, 1987, PROTEINS INTERFACES, P1; JULIANO RL, 1975, BIOCHEM BIOPH RES CO, V63, P651, DOI 10.1016/S0006-291X(75)80433-5; JULIANO RL, 1980, LIPOSOMES IMMUNOBIOL, P49; KESSLER RJ, 1986, ANAL BIOCHEM, V159, P138, DOI 10.1016/0003-2697(86)90318-0; KIRBY C, 1980, BIOCHEM J, V186, P591, DOI 10.1042/bj1860591; KLIBANOV AL, 1990, FEBS LETT, V268, P235, DOI 10.1016/0014-5793(90)81016-H; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; PAPAHADJOPOULOS D, 1987, ANN NY ACAD SCI, V507, P64, DOI 10.1111/j.1749-6632.1987.tb45792.x; PATEL HM, 1983, BIOCHIM BIOPHYS ACTA, V761, P142, DOI 10.1016/0304-4165(83)90223-4; RABILLOUD T, 1988, ELECTROPHORESIS, V9, P288, DOI 10.1002/elps.1150090608; ROERDINK FH, 1989, BIOCHIM BIOPHYS ACTA, V980, P234, DOI 10.1016/0005-2736(89)90404-5; SENIOR J, 1986, FEBS LETT, V196, P54, DOI 10.1016/0014-5793(86)80213-7; SENIOR JH, 1987, CRC CR REV THER DRUG, V3, P123; SOMMERMAN EF, 1966, THESIS U BRIT COLUMB; STEIN Y, 1980, FEBS LETT, V111, P104, DOI 10.1016/0014-5793(80)80771-X; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6	33	391	402	0	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	1992	267	26					18759	18765						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JN502	1527006				2023-01-03	WOS:A1992JN50200078
J	NADELMAN, RB; LUGER, SW; FRANK, E; WISNIEWSKI, M; COLLINS, JJ; WORMSER, GP				NADELMAN, RB; LUGER, SW; FRANK, E; WISNIEWSKI, M; COLLINS, JJ; WORMSER, GP			COMPARISON OF CEFUROXIME AXETIL AND DOXYCYCLINE IN THE TREATMENT OF EARLY LYME-DISEASE	ANNALS OF INTERNAL MEDICINE			English	Article						CEFUROXIME; DOXYCYCLINE; LYME DISEASE; ERYTHEMA CHRONICUM MIGRANS	BORRELIA-BURGDORFERI; INVIVO SUSCEPTIBILITY; ANTIMICROBIAL AGENTS; PENICILLIN; CEFTRIAXONE; INVITRO; MANIFESTATIONS; SPIROCHETE; THERAPY	Objective: To compare the efficacy of cefuroxime axetil and doxycycline in the treatment of patients with Lyme disease associated with erythema migrans. Design: Randomized, multicenter, investigator-blinded clinical trial with clinical evaluations during treatment (8 to 12 days) and at 1 to 5 days and 1, 3, 6, 9, and 12 months post-treatment. Setting: Three university referral centers and one private practice. Patients: A total of 123 patients with physician-documented erythema migrans. Intervention: Patients were treated orally for 20 days with either cefuroxime axetil, 500 mg twice daily (63 patients), or doxycycline, 100 mg three times daily (60 patients). Measurements: Resolution of erythema migrans and of signs and symptoms related to early Lyme disease as well as prevention of late Lyme disease. Results: A satisfactory clinical outcome (success or improvement) was achieved in 51 of 55 (93%) evaluable patients treated with cefuroxime axetil and in 45 of 51 (88%) patients treated with doxycycline (difference, 5%; 95% Cl, - 5% to 14%). The only complication at 1 month post-treatment was Lyme arthritis in one patient who received doxycycline. Of the patients with satisfactory outcomes at 1 month post-treatment who were evaluable at 1 year post-treatment, a satisfactory outcome was achieved in 43 of 48 (90%) and in 35 of 38 (92%) patients treated with cefuroxime axetil and doxycycline, respectively (difference, - 2%; Cl, - 12% to 7%). Lyme arthritis did not develop in any patient after 1 month post-treatment, whereas peripheral neuropathy was suspected in one patient treated with cefuroxime axetil. Thirty percent of patients treated with cefuroxime axetil and 32% of those treated with doxycycline had one or more drug-related adverse events. Doxycycline was associated with more photosensitivity reactions (15% compared with 0%; P = 0.001) and cefuroxime axetil with more diarrhea (21% compared with 7%; P = 0.035) and Jarisch-Herxheimer reactions (29% compared with 8%; P = 0.005). Conclusions: Cefuroxime axetil is well tolerated and appears to be equally as effective as doxycycline in the treating of early Lyme disease and in preventing the subsequent development of late Lyme disease.	OLD LYME FAMILY PRACTICE PC, OLD LYME, CT 06371 USA; JERSEY SHORE MED CTR, DEPT MED, NEPTUNE, NJ 07753 USA; GLAXO INC, RES INST, RES TRIANGLE PK, NC 27709 USA	Jersey Shore University Medical Center; GlaxoSmithKline	NADELMAN, RB (corresponding author), NEW YORK MED COLL, WESTCHESTER CTY MED CTR, DIV INFECT DIS, MACY PAVIL 209 SE, VALHALLA, NY 10595 USA.							BENACH JL, 1983, NEW ENGL J MED, V308, P740, DOI 10.1056/NEJM198303313081302; BUTLER T, 1978, J INFECT DIS, V137, P573, DOI 10.1093/infdis/137.5.573; DATTWYLER RJ, 1988, LANCET, V1, P1191; DATTWYLER RJ, 1987, ARTHRITIS RHEUM, V30, P448, DOI 10.1002/art.1780300414; DATTWYLER RJ, 1990, LANCET, V336, P1404, DOI 10.1016/0140-6736(90)93103-V; DATTWYLER RJ, 1987, J INFECT DIS, V155, P1322, DOI 10.1093/infdis/155.6.1322; DONOWITZ GR, 1990, PRINCIPLES PRACTICE, P246; EMMERSON AM, 1988, J ANTIMICROB CHEMOTH, V22, P101, DOI 10.1093/jac/22.2.101; FINN A, 1987, BIOPHARM DRUG DISPOS, V8, P519, DOI 10.1002/bdd.2510080604; FROST P, 1972, ARCH DERMATOL, V105, P681, DOI 10.1001/archderm.105.5.681; GREEN GR, 1971, J ALLERGY CLIN IMMUN, V48, P331, DOI 10.1016/0091-6749(71)90079-0; HASSLER D, 1990, INFECTION MUNICH, V18, P24; HOLLSTROM E, 1951, Acta Derm Venereol, V31, P235; JAMES NC, 1991, ANTIMICROB AGENTS CH, V35, P1860, DOI 10.1128/AAC.35.9.1860; JOHNSON RC, 1987, ANTIMICROB AGENTS CH, V31, P164, DOI 10.1128/AAC.31.2.164; JOHNSON RC, 1990, ANTIMICROB AGENTS CH, V34, P2133, DOI 10.1128/AAC.34.11.2133; KENDALL MG, 1979, ADV THEORY STATISTIC, V2; LANDIS JR, 1978, INT STAT REV, V46, P237, DOI 10.2307/1402373; LUFT BJ, 1989, REV INFECT DIS, V11, pS1518; LUFT BJ, 1988, ANN NY ACAD SCI, V539, P93; MANDELL GL, 1990, GOODMAN GILMANS PHAR, P1081; MARX MA, 1988, DRUG INTEL CLIN PHAR, V22, P651, DOI 10.1177/106002808802200901; MURSIC VP, 1987, EUR J CLIN MICROBIOL, V6, P424, DOI 10.1007/BF02013102; NEU HC, 1988, ANN NY ACAD SCI, V539, P314, DOI 10.1111/j.1749-6632.1988.tb31865.x; PFISTER HW, 1989, ARCH NEUROL-CHICAGO, V46, P1190, DOI 10.1001/archneur.1989.00520470044025; RUBIN DA, 1990, PACE, V13, P1367, DOI 10.1111/j.1540-8159.1990.tb04009.x; SAXON A, 1987, ANN INTERN MED, V107, P204, DOI 10.7326/0003-4819-107-2-204; SMITH JW, 1966, NEW ENGL J MED, V274, P998, DOI 10.1056/NEJM196605052741804; Standiford H. C., 1990, PRINCIPLES PRACTICE, P284; STEERE AC, 1980, ANN INTERN MED, V93, P1, DOI 10.7326/0003-4819-93-1-1; STEERE AC, 1980, ANN INTERN MED, V93, P8, DOI 10.7326/0003-4819-93-1-8; STEERE AC, 1989, NEW ENGL J MED, V321, P586, DOI 10.1056/NEJM198908313210906; STEERE AC, 1983, ANN INTERN MED, V99, P22, DOI 10.7326/0003-4819-99-1-22; STEERE AC, 1983, NEW ENGL J MED, V308, P733, DOI 10.1056/NEJM198303313081301; VANELTEREN P, 1960, B INT STATIST INST, V37, P351; WEBER K, 1990, INFECTION, V18, P91, DOI 10.1007/BF01641422; 1991, DOXYCYCLINE HYCLATE; 1989, MED LETT, V31, P57; 1991, MEDISPAN PRESCRIPTIO	39	155	156	1	12	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 15	1992	117	4					273	280		10.7326/0003-4819-117-4-273	http://dx.doi.org/10.7326/0003-4819-117-4-273			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JH464	1637021				2023-01-03	WOS:A1992JH46400001
J	STRACHAN, DP; ANDERSON, HR				STRACHAN, DP; ANDERSON, HR			TRENDS IN HOSPITAL ADMISSION RATES FOR ASTHMA IN CHILDREN	BRITISH MEDICAL JOURNAL			English	Article							PREVALENCE; HEALTH				STRACHAN, DP (corresponding author), ST GEORGE HOSP,SCH MED,DEPT PUBL HLTH SCI,LONDON SW17 0RE,ENGLAND.							ANDERSON HR, 1989, THORAX, V44, P614, DOI 10.1136/thx.44.8.614; ANDERSON HR, 1989, ARCH DIS CHILD, V64, P172, DOI 10.1136/adc.64.1.172; BURNEY PGJ, 1990, BRIT MED J, V300, P1306, DOI 10.1136/bmj.300.6735.1306; Burr ML, 1989, ARCH DIS CHILD, V64, P1118; HILL R, 1989, BRIT MED J, V299, P898, DOI 10.1136/bmj.299.6704.898	5	73	73	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 28	1992	304	6830					819	820		10.1136/bmj.304.6830.819	http://dx.doi.org/10.1136/bmj.304.6830.819			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HL827	1392711	Green Published, Bronze			2023-01-03	WOS:A1992HL82700023
J	WADE, DT; COLLEN, FM; ROBB, GF; WARLOW, CP				WADE, DT; COLLEN, FM; ROBB, GF; WARLOW, CP			PHYSIOTHERAPY INTERVENTION LATE AFTER STROKE AND MOBILITY	BRITISH MEDICAL JOURNAL			English	Article							CONTROLLED TRIAL; GAIT ASSESSMENT; SCALE	Objective - To determine whether the intervention of a physiotherapist improved mobility in patients seen more than one year after stroke. Design - Randomised crossover trial comparing two groups offered intervention by a physiotherapist, one immediately after entry into the trial and the other after a delay of three months. The intervention consisted of identifying problems and offering advice and help to solve the problems. Setting - Patients' homes in Oxfordshire. Subjects - Patients who had reduced mobility due to a stroke more than one year before entry; 60 were recruited from a community stroke register and 34 in other ways. Main outcome measures - Standard measures of mobility including gait speed, functional ambulation categories, the Nottingham extended activities of daily living index, and individual items from the Barthel activities of daily living index and the Frenchay activities index. Measures of manual dexterity, depression, and anxiety were used as controls. Results - 94 patients entered the trial and 49 were randomised to immediate and 45 to delayed physiotherapy; 89 were compared at the crossover point. At randomisation the two groups were comparable. At three months the group given early therapy showed an improvement in gait speed whereas the untreated group had declined (differences of -3.9 v 6.4 s to walk 10 m; p < 0.01); between three and six months the group given delayed therapy showed improvement and the previously treated group declined (differences of 6.5 v -3.9 s to walk 10 m; p < 0.01). A 9% (95% confidence interval 0% to 18%) decrease in time taken to walk 10 m was associated with treatment and a 12% (2% to 19%) increase when patients were untreated. Other measures did not change significantly. Conclusion - Intervention of an experienced physiotherapist late after stroke specifically improves mobility, albeit by a small amount, but the effects do not seem to be maintained, perhaps because there is an underlying decline in mobility in these patients. Gait speed offers a simple and sensitive measure of outcome.	WESTERN GEN HOSP,DEPT CLIN NEUROSCI,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND	University of Edinburgh	WADE, DT (corresponding author), RIVERMEAD REHABIL CTR,OXFORD OX1 4XD,ENGLAND.			Wade, Derick/0000-0002-1188-8442				ARMITAGE P, 1987, STATISTICAL METHODS; BAMFORD J, 1988, J NEUROL NEUROSUR PS, V51, P1373, DOI 10.1136/jnnp.51.11.1373; BRADSTATER ME, 1983, ARCH PHYS MED REHAB, V64, P583; BURNSIDE IG, 1982, ARCH PHYS MED REHAB, V63, P217; Chin P., 1982, ADV STROKE THERAPY, P197; Collen F M, 1991, Int Disabil Stud, V13, P50; Collen F M, 1991, Int Disabil Stud, V13, P12; Collen F M, 1990, Int Disabil Stud, V12, P6; Collin C, 1988, Int Disabil Stud, V10, P61; COLLIN C, 1990, J NEUROL NEUROSUR PS, V53, P567; Corcoran P J, 1970, Arch Phys Med Rehabil, V51, P69; HELLER A, 1987, J NEUROL NEUROSUR PS, V50, P714, DOI 10.1136/jnnp.50.6.714; HOLDEN MK, 1984, PHYS THER, V64, P35, DOI 10.1093/ptj/64.1.35; LEHMANN JF, 1975, ARCH PHYS MED REHAB, V56, P375; Lincoln N, 1979, Physiotherapy, V65, P48; May D, 1985, Int Rehabil Med, V7, P182; Nouri FMLN., 1987, CLIN REHABIL, V1, P301, DOI DOI 10.1177/026921558700100409; POCOCK SJ, 1983, CLIN TRIALS PRACTICA, P110; SMITH DS, 1981, BMJ-BRIT MED J, V282, P517, DOI 10.1136/bmj.282.6263.517; Stewart D., 1990, CLIN REHABIL, V4, P273, DOI 10.1177/026921559000400404; WADE D, 1987, SCANDINAVIAN J REHAB, V9, P25; Wade D T, 1985, Int Rehabil Med, V7, P176; Wade D.T., 1992, MEASUREMENT NEUROLOG, P78; WADE DT, 1987, J NEUROL NEUROSUR PS, V50, P177, DOI 10.1136/jnnp.50.2.177; WOLFSON L, 1990, J GERONTOL, V45, pM12, DOI 10.1093/geronj/45.1.M12; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	26	174	181	0	8	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 7	1992	304	6827					609	613		10.1136/bmj.304.6827.609	http://dx.doi.org/10.1136/bmj.304.6827.609			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HH733	1559090	Green Published, Bronze			2023-01-03	WOS:A1992HH73300023
J	BEWLEY, S; BEWLEY, TH				BEWLEY, S; BEWLEY, TH			DRUG-DEPENDENCE WITH ESTROGEN REPLACEMENT THERAPY	LANCET			English	Editorial Material							ESTRADIOL IMPLANTS; ESTROGEN DEFICIENCY; HORMONE IMPLANTS; SYMPTOMS; WOMEN	Dependence on some drugs can be hard to recognise. Hormone replacement therapy (HRT) has been widely prescribed only in the past two decades, and the indications for treatment and the risk/benefit ratio are still disputed. Oestrogens are psychoactive: they lift mood, can be given by injection, and their use has powerful psychological effects. Reports of women with supraphysiological oestradiol concentrations may represent tolerance and withdrawal. Dependence on substances occurring naturally in the body has been reported before. We propose that HRT dependence occurs.	ST GEORGE HOSP,SCH MED,DEPT ADDICT BEHAV,LONDON SW17,ENGLAND	St Georges University London	BEWLEY, S (corresponding author), UNIV COLL HOSP LONDON,DEPT OBSTET & GYNAECOL,LONDON WC1E 6HX,ENGLAND.			bewley, susan/0000-0001-8064-652X				APPLEBY L, 1991, PROGR OBSTETRICS GYN, V9, P289; BRINCAT M, 1984, LANCET, V1, P16; BROWER KJ, 1991, BRIT J ADDICT, V86, P759; CAMPBELL S, 1977, CLIN OBSTET GYNAECOL, V4, P31; GANGAR K, 1989, BRIT MED J, V299, P601, DOI 10.1136/bmj.299.6699.601-a; GANGAR K, 1991, BRIT J OBSTET GYNAEC, V98, P607, DOI 10.1111/j.1471-0528.1991.tb10383.x; GANGAR KF, 1990, BRIT MED J, V300, P436, DOI 10.1136/bmj.300.6722.436; GARNETT T, 1990, BRIT J OBSTET GYNAEC, V97, P917, DOI 10.1111/j.1471-0528.1990.tb02447.x; GINSBURG J, 1991, BRIT MED J, V302, P1601; LADER M, 1981, AUST NZ J PSYCHIAT, V15, P1, DOI 10.3109/00048678109159402; Magos AL, 1984, PROGR OBSTETRICS GYN, V4, P334; MONTGOMERY JC, 1987, LANCET, V1, P297; NOTT PN, 1976, BRIT J PSYCHIAT, V128, P379, DOI 10.1192/bjp.128.4.379; SHERWIN BB, 1985, PSYCHONEUROENDOCRINO, V10, P325, DOI 10.1016/0306-4530(85)90009-5; STUDD J, 1989, BRIT MED J, V299, P1400, DOI 10.1136/bmj.299.6712.1400-b; STUDD J, 1991, BRIT J OBSTET GYNAEC, V5, P502; WILKES HC, 1991, BRIT MED J, V302, P1317, DOI 10.1136/bmj.302.6788.1317; 1987, DIAGNOSTIC STATISTIC, P167; 1990, MENTAL BEHAVIOURAL D, P54; 1988, HLTH CONSEQUENCES SM, V4, P177	20	19	19	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 1	1992	339	8788					290	291		10.1016/0140-6736(92)91344-8	http://dx.doi.org/10.1016/0140-6736(92)91344-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HB529	1346294				2023-01-03	WOS:A1992HB52900016
J	van der Maas, PJ; VANDELDEN, JJM; PIJNENBORG, L; LOOMAN, CWN				van der Maas, PJ; VANDELDEN, JJM; PIJNENBORG, L; LOOMAN, CWN			EUTHANASIA AND OTHER MEDICAL DECISIONS CONCERNING THE END OF LIFE	LANCET			English	Article							NETHERLANDS	This article presents the first results of the Dutch nationwide study on euthanasia and other medical decisions concerning the end of life (MDEL). The study was done at the request of the Dutch government in preparation for a discussion about legislation on euthanasia. Three studies were undertaken: detailed interviews with 405 physicians, the mailing of questionnaires to the physicians of a sample of 7000 deceased persons, and the collecting of information about 2250 deaths by a prospective survey among the respondents to the interviews. The alleviation of pain and symptoms with such high dosages of opioids that the patient's life might be shortened was the most important MDEL in 17.5% of all deaths. In another 17.5% a non-treatment decision was the most important MDEL. Euthanasia by administering lethal drugs at the patient's request seems to have been done in 1.8% of all deaths. Since MDEL were taken in 38% of all deaths (and in 54% of all non-acute deaths) we conclude that these decisions are common medical practice and should get more attention in research, teaching, and public debate.	CENT BUR STATS, THE HAGUE, NETHERLANDS		van der Maas, PJ (corresponding author), ERASMUS UNIV, DEPT PUBL HLTH & SOCIAL MED, 3000 DR ROTTERDAM, NETHERLANDS.							ANGELL M, 1988, NEW ENGL J MED, V319, P1348, DOI 10.1056/NEJM198811173192010; BARTELDS AIM, 1989, DUTCH SENTINEL PRACT, P259; BROWN NK, 1979, NEW ENGL J MED, V300, P1246, DOI 10.1056/NEJM197905313002204; Fenigsen R, 1989, Hastings Cent Rep, V19, P22, DOI 10.2307/3561967; Gevers J K M, 1987, Bioethics, V1, P156, DOI 10.1111/j.1467-8519.1987.tb00024.x; KUHSE H, 1987, MED J AUSTRALIA, V147, P394, DOI 10.5694/j.1326-5377.1987.tb133560.x; LEENEN HJJ, 1987, HEALTH POLICY, V8, P197, DOI 10.1016/0168-8510(87)90062-5; NEU S, 1986, NEW ENGL J MED, V314, P14, DOI 10.1056/NEJM198601023140103; OLIEMANS AP, 1986, MED CONTACT, V41, P691; RIGTER H, 1989, HASTINGS CENT REP, V19, P31, DOI 10.2307/3561968; SCHUDEL WJ, 1987, EPIDEMIOL B GG GD 19; SMEDIRA NG, 1990, NEW ENGL J MED, V322, P309, DOI 10.1056/NEJM199002013220506; VANDERWAL G, 1991, MED CONTACT, V46, P174; VANDERWAL G, 1991, MED DECISIONS END LI; VOS M, 1985, MEDISCH CONTACT, V40, P1059; 1991, MED DECISIONS END LI; 1991, END LIFE MED PRACTIC; 1987, GG GD1986 AM PEILST; 1988, ETHANASIA	19	457	460	2	83	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	SEP 14	1991	338	8768					669	674		10.1016/0140-6736(91)91241-L	http://dx.doi.org/10.1016/0140-6736(91)91241-L			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GF105	1715962				2023-01-03	WOS:A1991GF10500012
J	CARCILLO, JA; DAVIS, AL; ZARITSKY, A				CARCILLO, JA; DAVIS, AL; ZARITSKY, A			ROLE OF EARLY FLUID RESUSCITATION IN PEDIATRIC SEPTIC SHOCK	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NOREPINEPHRINE THERAPY; MYOCARDIAL DEPRESSION; CARDIAC DYSFUNCTION; CANINE MODEL; SEPSIS; CHILDREN	Objective. - To examine the association of the volume of fluid administered at 1 and 6 hours after presentation, with survival and the occurrence of the adult respiratory distress syndrome, cardiogenic pulmonary edema, and persistent hypovolemia during the resuscitation of children with septic shock. Setting and Patients. - All pediatric patients with septic shock presenting to the emergency department over a 6-year period and having a pulmonary artery catheter inserted by 6 hours after presentation were identified. Methods. - Patients were analyzed together and in three groups based on fluid volume in the first hour: group 1, less than 20 mL/kg; group 2,20 to 40 mL/kg; and group 3, more than 40 mL/kg. Adult respiratory distress syndrome was diagnosed by the presence of alveolar infiltrates, hypoxemia, and a pulmonary capillary wedge pressure of 15 mm Hg or less. Cardiogenic pulmonary edema was diagnosed similarly, except the pulmonary capillary wedge pressure was greater than 15 mm Hg. Hypovolemia was diagnosed by the presence of oliguria, hypotension, and a pulmonary capillary wedge pressure of 8 mm Hg or less 6 hours after presentation. Results. - We identified 34 patients (median age, 13.5 months). At 1 and 6 hours, respectively, group 1 (n = 14) received 11 +/- 6 and 71 +/- 29 mL/kg (mean +/- SD) of fluid; group 2 received 32 +/- 5 and 108 +/- 54 mL/kg of fluid; and group 3 received 69 +/- 19 and 117 +/- 29 mL/kg of fluid. Survival in group 3 (eight of nine patients) was significantly better than in group 1 (six of 14 patients) or group 2 (four of 11 patients). Adult respiratory distress syndrome developed in 11 patients (32%) and cardiogenic pulmonary edema developed in five patients (15%). Having adult respiratory distress syndrome was associated with increased mortality, but adult respiratory distress syndrome was not increased in any group. Similarly, cardiogenic pulmonary edema was not associated with the fluid volume received or with decreased survival. Hypovolemia occurred in six patients in group 1 and two patients in group 2; all eight subsequently died. Conclusion. - Rapid fluid resuscitation in excess of 40 mL/kg in the first hour following emergency department presentation was associated with improved survival, decreased occurrence of persistent hypovolemia, and no increase in the risk of cardiogenic pulmonary edema or adult respiratory distress syndrome in this group of pediatric patients with septic shock.	GEORGE WASHINGTON UNIV,CHILDRENS HOSP,NATL MED CTR,DEPT ANESTHESIOL & CRIT CARE MED,WASHINGTON,DC 20010	Children's National Health System; George Washington University								BONE RC, 1989, CRIT CARE MED, V17, P389, DOI 10.1097/00003246-198905000-00002; BOUCEK MM, 1984, J PEDIATR-US, V105, P538, DOI 10.1016/S0022-3476(84)80416-3; CARROLL GC, 1982, AM J PHYSIOL, V243, pR131, DOI 10.1152/ajpregu.1982.243.1.R131; CHAMEIDES L, 1988, TXB PEDIATRIC ADV LI, P47; CHERNOW B, 1986, CIRC SHOCK, V18, P141; DESJARS P, 1987, CRIT CARE MED, V15, P134, DOI 10.1097/00003246-198702000-00011; KAUFMAN BS, 1984, CHEST, V85, P336, DOI 10.1378/chest.85.3.336; MEADOWS D, 1988, CRIT CARE MED, V16, P663, DOI 10.1097/00003246-198807000-00003; MONSALVE F, 1984, CRIT CARE MED, V12, P1021, DOI 10.1097/00003246-198412000-00003; NATANSON C, 1986, J CLIN INVEST, V78, P259, DOI 10.1172/JCI112559; NATANSON C, 1989, J CLIN INVEST, V83, P243, DOI 10.1172/JCI113866; PARKER MM, 1984, ANN INTERN MED, V100, P483, DOI 10.7326/0003-4819-100-4-483; POWELL KR, 1990, J PEDIATR-US, V117, P515, DOI 10.1016/S0022-3476(05)80682-1; RACKOW EC, 1987, CIRC SHOCK, V22, P11; REILLY JM, 1989, CHEST, V95, P1072, DOI 10.1378/chest.95.5.1072; ROTH BL, 1959, MOL CELLULAR MECHANI, P41; WEIL M, 1977, ANN CLIN RES, V9, P181; WEIL MH, 1978, AM J MED, V64, P920, DOI 10.1016/0002-9343(78)90444-8; WILES JB, 1980, CRIT CARE MED, V8, P55, DOI 10.1097/00003246-198002000-00001; WILSON RF, 1971, ANN SURG, V174, P939, DOI 10.1097/00000658-197112000-00009; [No title captured]; [No title captured]	22	250	257	0	8	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 4	1991	266	9					1242	1245		10.1001/jama.266.9.1242	http://dx.doi.org/10.1001/jama.266.9.1242			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GC858	1870250				2023-01-03	WOS:A1991GC85800033
J	VOIGT, LF; WEISS, NS; CHU, J; DALING, JR; MCKNIGHT, B; VANBELLE, G				VOIGT, LF; WEISS, NS; CHU, J; DALING, JR; MCKNIGHT, B; VANBELLE, G			PROGESTAGEN SUPPLEMENTATION OF EXOGENOUS ESTROGENS AND RISK OF ENDOMETRIAL CANCER	LANCET			English	Article							REPLACEMENT THERAPY; CLIMACTERIC WOMEN; ESTROGENS; PROGESTOGENS; BIOCHEMISTRY; PREVENTION; PATTERNS; DISEASE; RECALL	The favourable effects of exogenous progestagen on the endometrium are well known, but have not been adequately quantified with respect to endometrial cancer. The benefits of progestagen need to be weighted against its possible untoward effects on the risk of breast cancer and cardiovascular disease. A population-based case-control study of endometrial cancer was undertaken to evaluate the benefits of progestagen use. 158 incident cases were identified between 1985 and 1987 among women aged 40-64 years who were residents of King County, Washington. Detailed interviews were conducted and the responses were compared with those of 182 controls selected by random telephone digit dialling. The risk of endometrial cancer among women who had used unopposed oestrogen for more than 3 years was over five times that of women who had used no hormones (relative risk [RR] 5.7, 95% confidence interval [Cl] 2.5-12.8), whereas those who had also used a progestagen for at least six months of that time had an RR of only 1.6 (95% Cl 0.6-3.9). The RR differed according to days per month that progestagen was used: 2.4 (0.6-9.3) for progestagen use of less than 10 days per month versus 1.1 (0.4-3.6) for use of 10 or more days per month. These results provide additional evidence that the use of progestagen for 10 or more days per cycle can reduce the excess risk of endometrial cancer associated with long-term postmenopausal oestrogen use.	UNIV WASHINGTON,SCH PUBL HLTH & COMMUNITY MED,DEPT EPIDEMIOL,SEATTLE,WA 98195; UNIV WASHINGTON,SCH MED,SEATTLE,WA 98195; UNIV WASHINGTON,SCH PUBL HLTH & COMMUNITY MED,DEPT BIOSTAT,SEATTLE,WA 98195	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	VOIGT, LF (corresponding author), FRED HUTCHINSON CANC RES CTR,SEATTLE,WA 98195, USA.				NCI NIH HHS [5R35CA39779] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA039779] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BERESFORD SAA, 1989, AM J EPIDEMIOL, V130, P202, DOI 10.1093/oxfordjournals.aje.a115313; FIGUEROACASAS PR, 1988, MATURITAS, V9, P309, DOI 10.1016/0378-5122(88)90096-5; GAMBRELL RD, 1986, MATURITAS, V8, P159, DOI 10.1016/0378-5122(86)90022-8; GELFAND MM, 1989, OBSTET GYNECOL, V74, P398; GRUBER JS, 1986, ADV CANC CONTROL HLT, P325; HARLOW BL, 1983, AM J EPIDEMIOL, V117, P632, DOI 10.1093/oxfordjournals.aje.a113586; HARLOW BL, 1988, AM J EPIDEMIOL, V127, P857, DOI 10.1093/oxfordjournals.aje.a114869; HUNT K, 1987, BRIT J OBSTET GYNAEC, V94, P620, DOI 10.1111/j.1471-0528.1987.tb03166.x; KENNEDY DL, 1985, OBSTET GYNECOL, V65, P441; PAGANINIHILL A, 1982, AM J EPIDEMIOL, V116, P114; PAGANINIHILL A, 1989, BRIT J CANCER, V59, P445, DOI 10.1038/bjc.1989.91; PATERSON MEL, 1980, BRIT MED J, V280, P822, DOI 10.1136/bmj.280.6217.822; PERSSON I, 1989, BRIT MED J, V298, P147, DOI 10.1136/bmj.298.6667.147; SCHLESSELMAN JJ, 1982, CASE CONTROL STUDIES, P33; STADEL BV, 1975, AM J EPIDEMIOL, V102, P209, DOI 10.1093/oxfordjournals.aje.a112149; THOM MH, 1979, LANCET, V2, P455; VOIGT LF, 1989, ENDOMETRIAL CANCER, P1; WAKSBERG J, 1978, J AM STAT ASSOC, V73, P40, DOI 10.2307/2286513; WHITEHEAD MI, 1981, NEW ENGL J MED, V305, P1599, DOI 10.1056/NEJM198112313052701; WHITEHEAD MI, 1979, J ROY SOC MED, V72, P322	20	235	243	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 3	1991	338	8762					274	277		10.1016/0140-6736(91)90417-N	http://dx.doi.org/10.1016/0140-6736(91)90417-N			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FZ565	1677110				2023-01-03	WOS:A1991FZ56500003
J	STEIGER, MJ; QUINN, NP				STEIGER, MJ; QUINN, NP			HORMONE REPLACEMENT THERAPY INDUCED CHOREA	BRITISH MEDICAL JOURNAL			English	Article							SYSTEMIC LUPUS-ERYTHEMATOSUS				STEIGER, MJ (corresponding author), UNIV LONDON,INST NEUROL,DEPT CLIN NEUROL,LONDON WC1N 3BG,ENGLAND.							BOUCHEZ B, 1985, REV NEUROL-FRANCE, V141, P571; BRUYN GW, 1984, EUR NEUROL, V23, P278, DOI 10.1159/000115743; NAUSIEDA PA, 1979, NEUROLOGY, V29, P1605, DOI 10.1212/WNL.29.12.1605; NAUSIEDA PA, 1980, NEUROLOGY, V30, P331, DOI 10.1212/WNL.30.3.331; Willson P, 1932, ARCH INTERN MED, V49, P471, DOI 10.1001/archinte.1932.00150100128011	5	8	8	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 30	1991	302	6779					762	762		10.1136/bmj.302.6779.762	http://dx.doi.org/10.1136/bmj.302.6779.762			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FF229	1850638	Bronze, Green Published			2023-01-03	WOS:A1991FF22900025
J	HELD, PJ; LEVIN, NW; BOVBJERG, RR; PAULY, MV; DIAMOND, LH				HELD, PJ; LEVIN, NW; BOVBJERG, RR; PAULY, MV; DIAMOND, LH			MORTALITY AND DURATION OF HEMODIALYSIS-TREATMENT	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DIALYSIS	Decrease in the average duration of hemodialysis treatment time is a continuing phenomenon. We investigated the relationship of 3-year mortality to duration of dialysis in a 1984-1985 national random sample of 600 hemodialysis patients from 36 dialysis units. Mortality was negatively associated with duration of dialysis treatments, as shown by the Cox model, adjusted for other patient and dialysis unit covariates. With adjustment for other covariates, patients receiving an average dialysis treatment duration of less than 3.5 hours had relative mortality risks of 1.17 to 2.18 compared with those with treatments longer than 3.5 hours (mortality risk of 1.0). Reverse causation (the possibility that more seriously ill patients received dialysis for a shorter time) appears unlikely. We conclude that duration of the dialysis procedure is an important element in determining patient mortality as one of the factors determining the adequacy of dialysis.	BETH ISRAEL MED CTR,DEPT NEPHROL,NEW YORK,NY 10003; UNIV PENN,WHARTON SCH,PHILADELPHIA,PA 19104; GEORGETOWN UNIV,DEPT NEPHROL,WASHINGTON,DC 20057; DIST COLUMBIA GEN HOSP,WASHINGTON,DC 20003	Harvard University; Beth Israel Deaconess Medical Center; University of Pennsylvania; Georgetown University	HELD, PJ (corresponding author), URBAN INST,RENAL RES PROGRAM,2100 M ST NW,WASHINGTON,DC 20037, USA.							ALEXANDER VD, 1984, SAMPLE DESIGN NATION; DAUGIRDAS JT, 1989, INT J ARTIF ORGANS, V12, P411; GILL RD, 1988, ANN STAT, V16, P1069, DOI 10.1214/aos/1176350948; GOTCH FA, 1990, AM J KIDNEY DIS, V15, P511, DOI 10.1016/S0272-6386(12)70369-4; GOTCH FA, 1985, KIDNEY INT, V28, P526, DOI 10.1038/ki.1985.160; HARRELL F, 1980, SAS SUPPLEMENTAL LIB, P119; HELD PJ, 1987, JAMA-J AM MED ASSOC, V257, P645, DOI 10.1001/jama.257.5.645; HELD PJ, 1987, EFFECTS 1983 COMPOSI; HELD PJ, AM J KIDNEY DIS, V15, P441; KMENTA J, 1973, ELEMENTS ECONOMETRIC; KRAKAUER H, 1986, ISRAEL J MED SCI, V22, P3; LAIRD NM, 1983, KIDNEY INT, pS101; LOWRIE EG, 1990, AM J KIDNEY DIS, V15, P458, DOI 10.1016/S0272-6386(12)70364-5; SANTIAGO G, 1983, KIDNEY INT S13, V23, pS95; SARGENT JA, 1983, KIDNEY INT S13, V23, pS19; VARDI Y, 1982, ANN STAT, V10, P616, DOI 10.1214/aos/1176345802; 1990, USRDS 1990 ANN DATA; 1987, RES REPORT END STAGE; 1989, INSTRUCTION MANUAL R; 1983, FED REG         0511, V48, P21254	20	211	213	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 20	1991	265	7					871	875		10.1001/jama.265.7.871	http://dx.doi.org/10.1001/jama.265.7.871			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EX587	1899455				2023-01-03	WOS:A1991EX58700037
J	WINKLER, J; NEUMANLEVIN, M; BONER, G				WINKLER, J; NEUMANLEVIN, M; BONER, G			A SUCCESSFUL TREATMENT OF AN INTRARENAL ARTERIOVENOUS-FISTULA BY PERCUTANEOUS EMBOLIZATION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note								A 37-year-old woman patient, known to have poorly controlled arterial hypertension that was diagnosed following a cerebrovascular accident at the age of 15 years, was referred to our outpatient clinic for investigation in 1987. An intrarenal arteriovenous fistula was diagnosed by selective renal angiography. Embolization of the fistula was performed using four 15-mm/5-cm coils, which induced thrombosis and obstructed the fistula. The vascularization of the affected kidney improved immediately. During the following 4 months, the antihypertensive treatment was stopped gradually, and the patient remained normotensive. This is an unusual case of a large intrarenal arteriovenous fistula, whose etiology was not clear, that was successfully treated by percutaneous embolization.	BEILINSON MED CTR,NEPHROL UNIT,IL-49100 PETAH TIQWA,ISRAEL; BEILINSON MED CTR,DEPT RADIOL,IL-49100 PETAH TIQWA,ISRAEL; TEL AVIV UNIV,SACKLER SCH MED,TEL AVIV,ISRAEL	Rabin Medical Center; Rabin Medical Center; Tel Aviv University; Sackler Faculty of Medicine								BECKER GJ, 1984, SEMIN INTERVENT RAD, V1, P118; CHO KJ, 1984, SEM INTERVENT RADIOL, V1, P130; INGRAM CW, 1987, CHEST, V92, P1117, DOI 10.1378/chest.92.6.1117; JAHNKE RW, 1976, J UROLOGY, V115, P646; KIRKPATRICK JR, 1984, J TRAUMA, V15, P363; MALDONADO JE, 1964, AM J MED, V37, P499, DOI 10.1016/0002-9343(64)90064-6; MAZER MJ, 1984, SEMINARS INTERVENT R, V1, P95; MCALHANY JC, 1971, AM J SURG, V122, P117, DOI 10.1016/0002-9610(71)90363-1; OBRIEN DP, 1974, SURG GYNECOL OBSTET, V139, P739; RIBA LW, 1967, J UROLOGY, V98, P293, DOI 10.1016/S0022-5347(17)62873-8; TADAVARTHY SM, 1984, SEMIN INTERVENT RAD, V1, P101; THOMAS RG, 1962, BRIT J RADIOL, V35, P128, DOI 10.1259/0007-1285-35-410-128; TYNES WV, 1970, J UROLOGY, V103, P692, DOI 10.1016/S0022-5347(17)62029-9	13	7	7	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 6	1991	265	5					631	632		10.1001/jama.265.5.631	http://dx.doi.org/10.1001/jama.265.5.631			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EV718	1987414				2023-01-03	WOS:A1991EV71800022
J	NITTA, T; SATO, K; YAGITA, H; OKUMURA, K; ISHII, S				NITTA, T; SATO, K; YAGITA, H; OKUMURA, K; ISHII, S			PRELIMINARY TRIAL OF SPECIFIC TARGETING THERAPY AGAINST MALIGNANT GLIOMA	LANCET			English	Article									JUNTENDO UNIV,SCH MED,DEPT IMMUNOL,2-1-1 HONGO,BUNKYO KU,TOKYO 113,JAPAN; JUNTENDO UNIV,SCH MED,DEPT NEUROL SURG,TOKYO 113,JAPAN	Juntendo University; Juntendo University								BURGER PC, 1987, CANCER, V59, P1617, DOI 10.1002/1097-0142(19870501)59:9<1617::AID-CNCR2820590916>3.0.CO;2-X; ETTINGHAUSEN SE, 1988, JNCI-J NATL CANCER I, V80, P177, DOI 10.1093/jnci/80.3.177; GRIMM EA, 1982, J EXP MED, V155, P1823, DOI 10.1084/jem.155.6.1823; GRIMM EA, 1983, J EXP MED, V157, P884, DOI 10.1084/jem.157.3.884; ITOH K, 1988, J EXP MED, V168, P1419, DOI 10.1084/jem.168.4.1419; JACOBS SK, 1986, CANCER RES, V46, P2101; JOHNSON GD, 1978, HDB EXPT IMMUNOLOGY, V3, P1; JUNG G, 1988, IMMUNOL TODAY, V9, P257, DOI 10.1016/0167-5699(88)91304-7; LOTZE MT, 1986, CANCER, V58, P2764, DOI 10.1002/1097-0142(19861215)58:12<2764::AID-CNCR2820581235>3.0.CO;2-Z; MERCHANT RE, 1988, NEUROSURGERY, V23, P725, DOI 10.1227/00006123-198812000-00007; NITTA T, 1989, EUR J IMMUNOL, V19, P1437, DOI 10.1002/eji.1830190814; PEREZ P, 1986, J EXP MED, V163, P166, DOI 10.1084/jem.163.1.166; PEREZ P, 1986, J IMMUNOL, V137, P2069; ROSENBERG SA, 1987, NEW ENGL J MED, V316, P889, DOI 10.1056/NEJM198704093161501; ROSENBERG SA, 1985, NEW ENGL J MED, V313, P1485, DOI 10.1056/NEJM198512053132327; ROSENBERG SA, 1986, SCIENCE, V233, P1318, DOI 10.1126/science.3489291; ROSENSTEIN M, 1986, J IMMUNOL, V137, P1735; STAERZ UD, 1985, NATURE, V314, P628, DOI 10.1038/314628a0; TITUS JA, 1987, J IMMUNOL, V138, P4018; UEDA R, 1988, LUNG CANCER, V4, P96; WEST WH, 1987, NEW ENGL J MED, V316, P898, DOI 10.1056/NEJM198704093161502; 1979, HISTOLOGICAL TYPING	22	236	277	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 17	1990	335	8686					368	371		10.1016/0140-6736(90)90205-J	http://dx.doi.org/10.1016/0140-6736(90)90205-J			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CN988	1968115				2023-01-03	WOS:A1990CN98800002
J	LEHNER, PJ; DAVIES, KA; WALPORT, MJ; COPE, AP; WURZNER, R; ORREN, A; MORGAN, BP; COHEN, J				LEHNER, PJ; DAVIES, KA; WALPORT, MJ; COPE, AP; WURZNER, R; ORREN, A; MORGAN, BP; COHEN, J			MENINGOCOCCAL SEPTICEMIA IN A C6-DEFICIENT PATIENT AND EFFECTS OF PLASMA TRANSFUSION ON LIPOPOLYSACCHARIDE RELEASE	LANCET			English	Note							NEISSERIA-MENINGITIDIS INFECTIONS; 6TH COMPONENT; COMPLEMENT; DEFICIENCY; DISEASE	Patients whose blood is deficient in the terminal component of complement have an increased susceptibility to meningococcal infection. However, mortality from meningococcal infection is lower in these patients than in immunocompetent subjects, We studied a C6-deficient patient with meningococcal sepsis who received fresh frozen plasma (FFP). The patient's initial plasma endotoxin, C6, and terminal-complement-complex concentrations were low, but rose sharply after treatment with FFP. Samples of the patient's serum taken shortly after admission did not cause endotoxin release from Escherichia coli J5 in vitro, but endotoxin-releasing activity was restored in serum samples taken after infusion of FFP. It is possible that C6-deficient patients have reduced mortality from meningococcal infection because their serum cannot cause acute release of endotoxin from the invading organism and extensive tissue damage is thus avoided.	HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,DEPT INFECT DIS & BACTERIOL,DUCANE RD,LONDON W12 0NN,ENGLAND; HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,DEPT MED,LONDON W12 0NN,ENGLAND; CHARING CROSS SUNLEY MED RES CTR,LONDON,ENGLAND; MRC,MOLEC IMMUNOPATHOL UNIT,CAMBRIDGE CB2 2QH,ENGLAND; UNIV WALES COLL MED,DEPT MED BIOCHEM,CARDIFF CF4 4XN,S GLAM,WALES	Imperial College London; Imperial College London; University of Oxford; Cardiff University				Cope, Andrew/0000-0001-6735-5496; Lehner, Paul Joseph/0000-0001-9383-1054; Walport, Mark/0000-0001-7220-5273; Morgan, Paul/0000-0003-4075-7676	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BRANDTZAEG P, 1989, J INFECT DIS, V159, P195, DOI 10.1093/infdis/159.2.195; COHEN J, 1984, J INFECT DIS, V150, P916, DOI 10.1093/infdis/150.6.916; CRAVEN DE, 1982, INFECT IMMUN, V37, P132, DOI 10.1128/IAI.37.1.132-137.1982; DUNCAN RL, 1984, J IMMUNOL, V132, P1416; MORRISON DC, 1987, ANNU REV MED, V38, P417, DOI 10.1146/annurev.me.38.020187.002221; ORREN A, 1987, IMMUNOLOGY, V62, P249; POTTER PC, 1990, J INFECT DIS, V161, P932, DOI 10.1093/infdis/161.5.932; ROSS SC, 1984, MEDICINE, V63, P243, DOI 10.1097/00005792-198409000-00001; WURZNER R, 1991, CLIN EXP IMMUNOL, V83, P430	9	61	62	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 5	1992	340	8832					1379	1381		10.1016/0140-6736(92)92561-S	http://dx.doi.org/10.1016/0140-6736(92)92561-S			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KB202	1360091				2023-01-03	WOS:A1992KB20200005
J	BRAHAMS, D				BRAHAMS, D			EUTHANASIA - DOCTOR CONVICTED OF ATTEMPTED MURDER	LANCET			English	Editorial Material																			0	7	7	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 26	1992	340	8822					782	783		10.1016/0140-6736(92)92314-6	http://dx.doi.org/10.1016/0140-6736(92)92314-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JP869	1356188				2023-01-03	WOS:A1992JP86900016
J	MERTENS, WC; BRAMWELL, VHC; GWADRYSRIDHAR, F; ROMANO, W; BANERJEE, D; LALA, PK				MERTENS, WC; BRAMWELL, VHC; GWADRYSRIDHAR, F; ROMANO, W; BANERJEE, D; LALA, PK			EFFECT OF INDOMETHACIN PLUS RANITIDINE IN ADVANCED MELANOMA PATIENTS ON HIGH-DOSE INTERLEUKIN-2	LANCET			English	Note							METASTATIC MALIGNANT-MELANOMA; ACTIVATED KILLER-CELLS; CONTINUOUS INFUSION INTERLEUKIN-2; PHASE-II; THERAPY	Preclinical models of advanced melanoma have shown that chronic indomethacin therapy combined with interleukin 2 (IL-2) can eradicate experimental metastases. A phase II trial was done in patients with advanced melanoma. Indomethacin and ranitidine were begun at least one week before IL-2. Of the objective responses in 3 patients, 2 were achieved on ranitidine and indomethacin alone, before start of IL-2. Indomethacin and ranitidine may be responsible for some responses in melanoma patients previously attributed to IL-2.	UNIV MICHIGAN,DEPT RADIOL,ANN ARBOR,MI 48109; UNIV WESTERN ONTARIO,DEPT PATHOL,LONDON N6A 3K7,ONTARIO,CANADA; UNIV WESTERN ONTARIO,DEPT ANAT,LONDON N6A 3K7,ONTARIO,CANADA	University of Michigan System; University of Michigan; Western University (University of Western Ontario); Western University (University of Western Ontario)	MERTENS, WC (corresponding author), LONDON REG CANC CTR,DEPT MED ONCOL,790 COMMISS RD E,LONDON N6A 4L6,ONTARIO,CANADA.							BAR MH, 1990, J CLIN ONCOL, V8, P1138, DOI 10.1200/JCO.1990.8.7.1138; DUTCHER JP, 1991, J CLIN ONCOL, V9, P641, DOI 10.1200/JCO.1991.9.4.641; DUTCHER JP, 1989, J CLIN ONCOL, V7, P477, DOI 10.1200/JCO.1989.7.4.477; LALA PK, 1988, CANCER RES, V48, P1072; MANDANAS R, 1991, AM J CLIN ONCOL-CANC, V14, P397, DOI 10.1097/00000421-199110000-00007; PARKINSON DR, 1990, J CLIN ONCOL, V8, P1650, DOI 10.1200/JCO.1990.8.10.1650; ROSENBERG SA, 1989, CANCER TREAT REV, V16, P115, DOI 10.1016/0305-7372(89)90031-5; SMITH T, 1987, ARCH INTERN MED, V147, P1815, DOI 10.1001/archinte.147.10.1815; SMITH T, 1990, Comprehensive Therapy, V16, P8	9	24	26	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 15	1992	340	8816					397	398		10.1016/0140-6736(92)91474-M	http://dx.doi.org/10.1016/0140-6736(92)91474-M			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JJ449	1353559	Green Submitted			2023-01-03	WOS:A1992JJ44900007
J	SIMON, TL; STEHLING, L				SIMON, TL; STEHLING, L			INDICATIONS FOR AUTOLOGOUS TRANSFUSIONS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											SIMON, TL (corresponding author), UNITED BLOOD SERV,SCOTTSDALE,AZ, USA.							AuBuchon J P, 1989, Transfus Med Rev, V3, P290, DOI 10.1016/S0887-7963(89)70089-4; CREGAN P, 1991, TRANSFUSION, V31, P172, DOI 10.1046/j.1537-2995.1991.31291142950.x; 1988, JAMA-J AM MED ASSOC, V260, P2700	3	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 20	1992	267	19					2669	2669						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HT823	1573760				2023-01-03	WOS:A1992HT82300039
J	GASTINNE, H; WOLFF, M; DELATOUR, F; FAURISSON, F; CHEVRET, S				GASTINNE, H; WOLFF, M; DELATOUR, F; FAURISSON, F; CHEVRET, S			A CONTROLLED TRIAL IN INTENSIVE-CARE UNITS OF SELECTIVE DECONTAMINATION OF THE DIGESTIVE-TRACT WITH NONABSORBABLE ANTIBIOTICS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CONTINUOUS MECHANICAL VENTILATION; ORGAN-SYSTEM FAILURE; INTESTINAL DECONTAMINATION; ARTIFICIAL-VENTILATION; RESPIRATORY-TRACT; PREVENTION; INFECTION; COLONIZATION; PNEUMONIA; BACTERIA	Background. Selective decontamination of the digestive tract with topical nonabsorbable antibiotics has been reported to prevent nosocomial infections in patients receiving mechanical ventilation, and the procedure is used widely in Europe. However, it is unclear whether selective decontamination improves survival. Methods. We conducted a randomized, double-blind multicenter study in which 445 patients receiving mechanical ventilation in 15 intensive care units were given either prophylactic nonabsorbable antibiotics (n = 220) or a placebo (n = 225). Topical antibiotics (tobramycin, colistin sulfate, and amphotericin B) or placebo was administered through a nasogastric tube and applied to the oropharynx throughout the period of ventilation. The main end points were the mortality rate in the intensive care unit and the mortality rate within 60 days of randomization. Results. A total of 142 patients died in the intensive care unit: 75 (34 percent) in the treatment group and 67 (30 percent) in the placebo group (P = 0.37). Mortality within 60 days of randomization was similar in the two groups (P = 0.40), even after adjustment for factors that were either unbalanced or individually predictive of survival in the two groups (P = 0.70). Pneumonia developed in 59 patients (13 percent) in the intensive care unit within 30 days of enrollment in the study (33 in the placebo group and 26 in the treatment group, P = 0.42). Pneumonia acquired in the intensive care unit and due to gram-negative bacilli was less frequent (P = 0.01) in the treatment group than in the placebo group. The total charges for antibiotics were 2.2 times higher in the treatment group. Conclusions. Selective decontamination of the digestive tract does not improve survival among patients receiving mechanical ventilation in the intensive care unit, although it substantially increases the cost of their care.			GASTINNE, H (corresponding author), HOP UNIV DUPUYTREN,SERV REANIMAT,2 AVE ALEXIS CARREL,F-87042 LIMOGES,FRANCE.		Misset, Benoit/P-7817-2018	Misset, Benoit/0000-0001-6466-0065; chevret, sylvie/0000-0001-6449-4730				ATHERTON ST, 1978, LANCET, V2, P968; BODEY GP, 1981, REV INFECT DIS, V3, pS259; BRUNBUISSON C, 1989, ANN INTERN MED, V110, P873, DOI 10.7326/0003-4819-110-11-873; COX DR, 1972, J R STAT SOC B, V34, P187; CRAVEN DE, 1986, AM REV RESPIR DIS, V133, P792; DEITCH EA, 1990, ARCH SURG-CHICAGO, V125, P403; DUMOULIN GC, 1982, LANCET, V1, P242; FAGON JY, 1989, AM REV RESPIR DIS, V139, P877, DOI 10.1164/ajrccm/139.4.877; FLAHERTY J, 1990, J INFECT DIS, V162, P1393, DOI 10.1093/infdis/162.6.1393; GASTINNE H, 1991, INTENS CARE MED, V17, P215, DOI 10.1007/BF01709880; GODARD J, 1990, INTENS CARE MED, V16, P307, DOI 10.1007/BF01706355; HARTENAUER U, 1991, CRIT CARE MED, V19, P463, DOI 10.1097/00003246-199104000-00003; KERVER AJH, 1988, CRIT CARE MED, V16, P1087, DOI 10.1097/00003246-198811000-00001; KNAUS WA, 1985, ANN SURG, V202, P685, DOI 10.1097/00000658-198512000-00004; KONRAD F, 1988, INTENS CARE MED S, V14, P311; LEDINGHAM IM, 1988, LANCET, V1, P785; LEGALL JR, 1984, CRIT CARE MED, V12, P975; LEU HS, 1989, AM J EPIDEMIOL, V129, P1258, DOI 10.1093/oxfordjournals.aje.a115245; MANSHIP L, 1984, AM SURGEON, V50, P94; MEAKINS JL, 1986, ARCH SURG-CHICAGO, V121, P197; PETO R, 1972, J R STAT SOC SER A-G, V135, P185, DOI 10.2307/2344317; RAUSS A, 1990, MED DECIS MAKING, V10, P155, DOI 10.1177/0272989X9001000302; RODRIGUEZROLDAN JM, 1990, CRIT CARE MED, V18, P1239, DOI 10.1097/00003246-199011000-00011; STOUTENBEEK CP, 1987, J TRAUMA, V27, P357, DOI 10.1097/00005373-198704000-00003; SYDOW M, 1988, INTENS CARE MED S, V14, P310; TETTEROO GWM, 1990, INTENS CARE MED, V16, pS224, DOI 10.1007/BF01709705; THULIG D, 1989, INFECTION CONTROL SE, P120; ULRICH C, 1989, INTENS CARE MED, V15, P424, DOI 10.1007/BF00255597; UNERTL K, 1987, INTENS CARE MED, V13, P106; VANSAENE JJM, 1989, INFECTION CONTROL SE, P128; VANUFFELEN R, 1984, INTENS CARE MED, V10, P233, DOI 10.1007/BF00256259	31	262	269	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 27	1992	326	9					594	599		10.1056/NEJM199202273260903	http://dx.doi.org/10.1056/NEJM199202273260903			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HF633	1734249	Bronze			2023-01-03	WOS:A1992HF63300003
J	LANE, DA; RYAN, K; IRELAND, H; CURTIS, JR; NURMOHAMED, MT; KREDIET, RT; ROGGEKAMP, MC; STEVENS, P; TENCATE, JW				LANE, DA; RYAN, K; IRELAND, H; CURTIS, JR; NURMOHAMED, MT; KREDIET, RT; ROGGEKAMP, MC; STEVENS, P; TENCATE, JW			DERMATAN SULFATE IN HEMODIALYSIS	LANCET			English	Note							HEPARIN	Experimental work suggests that dermatan sulphate has potential as an antithrombotic agent: it can inhibit venous thrombi yet has less effect upon bleeding than heparin. While heparin functions as an anticoagulant primarily by its ability to accelerate the action of the plasma protein inhibitor antithrombin III, dermatan sulphate acts selectively through a structurally related inhibitor, heparin co-factor II, to inhibit thrombin. We have done a series of dose-finding studies of the use of dermatan sulphate as an anticoagulant/antithrombotic agent in patients on maintenance haemodialysis. Dermatan sulphate proved to be an effective anticoagulant in this setting.	UNIV AMSTERDAM, ACAD MED CTR, CTR HAEMOSTASIS THROMBOSIS ATHEROSCLEROSIS & INFLA, 1105 AZ AMSTERDAM, NETHERLANDS; UNIV AMSTERDAM, ACAD MED CTR, DEPT NEPHROL, 1105 AZ AMSTERDAM, NETHERLANDS; DIATEL AMSTERDAM, CTR DIALYSIS, AMSTERDAM, NETHERLANDS; CHARING CROSS & WESTMINSTER HOSP, DEPT HAEMATOL, LONDON, ENGLAND; CHARING CROSS & WESTMINSTER HOSP, DEPT MED, LONDON, ENGLAND; CHARING CROSS & WESTMINSTER MED SCH, DEPT MED, LONDON, ENGLAND	University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; Imperial College London; Imperial College London; Imperial College London	LANE, DA (corresponding author), CHARING CROSS & WESTMINSTER MED SCH, DEPT HAEMATOL, LONDON W6 8RF, ENGLAND.		Ireland, Helen A/B-9868-2008; Krediet, Raymond/GLT-2390-2022; Krediet, Raymond/AAP-3291-2021	Ireland, Helen A/0000-0002-7980-548X; Krediet, Raymond/0000-0002-9851-8507; Nurmohamed, Michael/0000-0002-6274-1934				BJORK I, 1989, HEPARIN CHEM BIOL PR, P229; FERNANDEZ F, 1986, BRIT J HAEMATOL, V64, P309, DOI 10.1111/j.1365-2141.1986.tb04124.x; HIRSH J, 1990, ACTA CHIR SCAND, P42; MCKENNA JV, 1989, THROMB HAEMOSTASIS, V61, P7; OKWUSIDI J, 1990, THROMB HAEMORRH DISO, V1, P77; TOLLEFSEN DM, 1981, J CLIN INVEST, V68, P589, DOI 10.1172/JCI110292; TOLLEFSEN DM, 1983, J BIOL CHEM, V258, P6713	7	29	29	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 8	1992	339	8789					334	335		10.1016/0140-6736(92)91650-W	http://dx.doi.org/10.1016/0140-6736(92)91650-W			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HC771	1346414				2023-01-03	WOS:A1992HC77100007
J	ELFERINK, MGL; DEWIT, JG; DEMEL, R; DRIESSEN, AJM; KONINGS, WN				ELFERINK, MGL; DEWIT, JG; DEMEL, R; DRIESSEN, AJM; KONINGS, WN			FUNCTIONAL RECONSTITUTION OF MEMBRANE-PROTEINS IN MONOLAYER LIPOSOMES FROM BIPOLAR LIPIDS OF SULFOLOBUS-ACIDOCALDARIUS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTON-MOTIVE FORCE; THERMOPHILIC ARCHAEBACTERIA; STREPTOCOCCUS-CREMORIS; BLACK MEMBRANES; ETHER LIPIDS; CYTOCHROME-C; VESICLES; OXIDASE; PURIFICATION; TEMPERATURE	Membranes of Sulfolobus acidocaldarius, an extreme thermophilic archaebacterium, are composed of unusual bipolar lipids. They consist of macrocyclic tetraethers with two polar heads linked by two hydrophobic C40 phytanyl chains which are thought to be arranged as a monolayer in the cytoplasmic membrane. Fractionation of a total lipid-extract from S. acidocaldarius yielded a lipid fraction which forms closed and stable unilamellar liposomes in aqueous media. Beef heart cytochrome c-oxidase could be functionally reconstituted in these liposomes. In the presence of reduced cytochrome c, a protonmotive force (DELTA-p) across the liposomal membrane was generated of up to -92 mV. Upon fusion of these proteoliposomes with membrane vesicles of Lactococcus lactis, the DELTA-p generated by cytochrome c-oxidase activity was capable to drive uphill transport of leucine. Electron microscopic analysis indicated that the tetraether lipids form a single monolayer liposome. The results demonstrate that tetraether lipids of archaebacteria can form a suitable matrix for the function of exogenous membrane proteins originating from a regular lipid bilayer.	UNIV UTRECHT, CTR BIOMEMBRANES & LIPID ENZYMOL, 3584 CH UTRECHT, NETHERLANDS; UNIV UTRECHT, INST MOLEC BIOL & MED BIOTECHNOL, 3584 CH UTRECHT, NETHERLANDS	Utrecht University; Utrecht University	ELFERINK, MGL (corresponding author), UNIV GRONINGEN, DEPT MICROBIOL, 9751 NN HAREN, NETHERLANDS.		Driessen, Arnold J.M./D-1876-2012; Konings, Wilhelmus N./C-7063-2013	Driessen, Arnold J.M./0000-0001-9258-9104				ANEMULLER S, 1990, EUR J BIOCHEM, V191, P297, DOI 10.1111/j.1432-1033.1990.tb19123.x; AUER J, 1991, BIOCHIMIE, V73, P683, DOI 10.1016/0300-9084(91)90048-6; De Rosa M., 1991, LIFE EXTREME CONDITI, P61, DOI [10.1007/978-3-642-76056-3_5, DOI 10.1007/978-3-642-76056-3_5]; Demel R A, 1974, Methods Enzymol, V32, P539; DEMEL RA, 1982, MEMBRANES TRANSPORT, V1, P159; DEROSA M, 1988, PROG LIPID RES, V27, P153, DOI 10.1016/0163-7827(88)90011-2; DEROSA M, 1983, J MEMBRANE SCI, V16, P287, DOI 10.1016/S0376-7388(00)81316-2; DEROSA M, 1986, MICROBIOL REV, V50, P70, DOI 10.1128/MMBR.50.1.70-80.1986; DRIESSEN AJM, 1987, MICROBIOL SCI, V4, P173; DRIESSEN AJM, 1988, BIOCHEMISTRY-US, V27, P865, DOI 10.1021/bi00403a005; DRIESSEN AJM, 1985, P NATL ACAD SCI USA, V82, P7555, DOI 10.1073/pnas.82.22.7555; DRIESSEN AJM, 1991, IN PRESS METHODS ENZ; GLIOZZI A, 1982, BIOPHYS J, V37, P563, DOI 10.1016/S0006-3495(82)84702-4; GLIOZZI A, 1983, J MEMBRANE BIOL, V75, P45, DOI 10.1007/BF01870798; GLIOZZI A, 1983, BIOCHIM BIOPHYS ACTA, V735, P234, DOI 10.1016/0005-2736(83)90298-5; Gliozzi A., 1982, TRANSPORT BIOMEMBRAN, P39; LANGWORTHY TA, 1977, BIOCHIM BIOPHYS ACTA, V487, P37, DOI 10.1016/0005-2760(77)90042-X; LANGWORTHY TA, 1985, BACTERIA, V8; LELKES PI, 1983, BIOCHIM BIOPHYS ACTA, V732, P714, DOI 10.1016/0005-2736(83)90252-3; LO SL, 1990, BIOCHEM BIOPH RES CO, V167, P238, DOI 10.1016/0006-291X(90)91756-I; LOLKEMA JS, 1983, EUR J BIOCHEM, V130, P287, DOI 10.1111/j.1432-1033.1983.tb07149.x; LOLKEMA JS, 1982, BIOCHIM BIOPHYS ACTA, V681, P85, DOI 10.1016/0005-2728(82)90281-X; OTTO R, 1982, J BACTERIOL, V149, P733, DOI 10.1128/JB.149.2.733-738.1982; ROLANDI R, 1986, EUR BIOPHYS J BIOPHY, V14, P19, DOI 10.1007/BF00260399; SCHAFER G, 1990, FEMS MICROBIOL LETT, V75, P335, DOI 10.1016/0378-1097(90)90543-Y; VELD GI, 1991, BIOCHIM BIOPHYS ACTA, V1065, P203, DOI 10.1016/0005-2736(91)90231-V; VERGER R, 1982, CHEM PHYS LIPIDS, V30, P189, DOI 10.1016/0009-3084(82)90052-4; VIITANEN P, 1986, METHOD ENZYMOL, V125, P429; YU CA, 1975, J BIOL CHEM, V250, P1383	29	103	106	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 15	1992	267	2					1375	1381						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY960	1309769				2023-01-03	WOS:A1992GY96000108
J	CONFINOCOHEN, R; LISHNER, M; SAVIN, H; LANG, R; RAVID, M				CONFINOCOHEN, R; LISHNER, M; SAVIN, H; LANG, R; RAVID, M			RESPONSE OF CARPAL-TUNNEL SYNDROME TO HORMONE REPLACEMENT THERAPY	BRITISH MEDICAL JOURNAL			English	Article									MEIR HOSP,DEPT MED,IL-44281 KEFAR SAVA,ISRAEL; TEL AVIV UNIV,SACKLER FAC MED,IL-69978 TEL AVIV,ISRAEL	Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv University; Sackler Faculty of Medicine	LISHNER, M (corresponding author), MEIR HOSP,DEPT MED,IL-44281 KEFAR SAVA,ISRAEL.							AMADIO PC, 1985, J HAND SURG-AM, V10A, P237, DOI 10.1016/S0363-5023(85)80112-X; KULICK MI, 1986, J HAND SURG-AM, V11A, P59, DOI 10.1016/S0363-5023(86)80104-6; MILFORD L, 1987, CAMPBELLS OPERATIVE, P459; STRANSKY M, 1989, SOUTHERN MED J, V82, P841, DOI 10.1097/00007611-198907000-00011	4	11	11	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 14	1991	303	6816					1514	1514		10.1136/bmj.303.6816.1514	http://dx.doi.org/10.1136/bmj.303.6816.1514			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GV476	1838291	Green Published, Bronze			2023-01-03	WOS:A1991GV47600023
J	HJORTDAHL, P; BORCHGREVINK, CF				HJORTDAHL, P; BORCHGREVINK, CF			CONTINUITY OF CARE - INFLUENCE OF GENERAL-PRACTITIONERS KNOWLEDGE ABOUT THEIR PATIENTS ON USE OF RESOURCES IN CONSULTATIONS	BRITISH MEDICAL JOURNAL			English	Article								Objective - To examine the relation between general practitioners' knowledge about their patients and the use of resources in consultations. Design - A cross sectional evaluation of consultations. Setting and subjects - A representative sample of 133 Norwegian general practitioners were each asked to record 30 consecutive consultations. 131 did so, and of 3990 possible registrations, 3918 (98%) were evaluated. Main outcome measures - The influence, as assessed by the doctor, of accumulated knowledge on the use of laboratory tests, expectant management, prescriptions, sickness certification, referrals, and time spent in the consultation. Results - Accumulated knowledge was a substantial factor in saving time, especially in consultations with children, the elderly, patients with psychosocial problems. and those with chronic diseases. It also influenced the overall use of laboratory tests, expectant management, sickness certification, and referrals, and to a lesser degree the use of medication. Conclusion - The findings imply strong but complex associations between accumulated knowledge and the use of resources in the consultation.			HJORTDAHL, P (corresponding author), UNIV OSLO,DEPT GEN PRACTICE,N-0264 OSLO 2,NORWAY.							ANDREWS FM, 1984, PUBLIC OPIN QUART, V48, P409, DOI 10.1086/268840; Bentsen B G, 1986, Scand J Prim Health Care, V4, P43, DOI 10.3109/02813438609013970; CARTWRIGHT A, 1976, J R COLL GEN PRACT, V26, P895; Hjortdahl P, 1990, Fam Med, V22, P361; Hosmer D., 2000, APPL LOGISTIC REGRES, V2; MCWHINNEY I, 1982, J FAM PRACTICE, V15, P847; McWhinney IR, 1989, TXB FAMILY MED; MOSSEY JM, 1982, AM J PUBLIC HEALTH, V72, P800, DOI 10.2105/AJPH.72.8.800; Nylenna M, 1985, Scand J Prim Health Care, V3, P155, DOI 10.3109/02813438509013938; NYLENNA M, 1986, FAM PRACT, V3, P240, DOI 10.1093/fampra/3.4.240; ODOWD TC, 1988, BRIT MED J, V297, P528, DOI 10.1136/bmj.297.6647.528; Polanyi M., 2009, TACIT DIMENSION; ROSENBERG EE, 1985, FAM PRACT, V2, P23, DOI 10.1093/fampra/2.1.23; RUTLE O, 1983, 11983 STAT I FOLK RA; Schon D. A, 2016, REFLECTIVE PRACTITIO; SHELDON M, 1985, DECISION MAKING GENE; YAFFE MJ, 1985, MED CARE, V23, P1276, DOI 10.1097/00005650-198511000-00006; 1989, WORKING PATIENTS; 1988, JAMA-J AM MED ASSOC, V260, P1272	19	119	120	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 9	1991	303	6811					1181	1184		10.1136/bmj.303.6811.1181	http://dx.doi.org/10.1136/bmj.303.6811.1181			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GP488	1747619	Bronze, Green Published			2023-01-03	WOS:A1991GP48800029
J	SMITH, DB; NEWLANDS, ES; RUSTIN, GJS; BEGENT, RHJ; HOWELLS, N; MCQUADE, B; BAGSHAWE, KD				SMITH, DB; NEWLANDS, ES; RUSTIN, GJS; BEGENT, RHJ; HOWELLS, N; MCQUADE, B; BAGSHAWE, KD			COMPARISON OF ONDANSETRON AND ONDANSETRON PLUS DEXAMETHASONE AS ANTIEMETIC PROPHYLAXIS DURING CISPLATIN-CONTAINING CHEMOTHERAPY	LANCET			English	Article							HIGH-DOSE METOCLOPRAMIDE; ANTI-EMETIC EFFICACY; CYTO-TOXIC DRUGS; INDUCED NAUSEA; INDUCED EMESIS; CANCER-CHEMOTHERAPY; DOUBLE-BLIND; ANTAGONIST; PREVENTION; GR38032F	Ondansetron, a serotonin antagonist, is effective in controlling the emesis associated with cancer chemotherapy; however, emesis in patients receiving high-dose cisplatin is poorly controlled by ondansetron alone. Dexamethasone is an effective antiemetic with no known interaction with serotonin receptors and was thus chosen for study in combination with ondansetron. 31 patients (30 male, 1 female; median age 28.5 years, range 18-49) receiving a 4-day course of a chemotherapy regimen containing cisplatin (100-120 mg/m2) for metastatic germ-cell tumours were entered in a randomised, double-blind, cross-over trial comparing oral ondansetron plus placebo with oral ondansetron plus dexamethasone as antiemetic prophylaxis. Ondansetron (8 mg every 8 h) was given to all patients for 8 days from the start of chemotherapy. Patients were given 8 mg of dexamethasone or placebo every 8 h starting 2 h before cisplatin (on day 4) and continuing for six doses (ie, for 2 days only). A second course of chemotherapy began 14 days after the start of the first, during which patients crossed over to the alternative antiemetic regimen. Results were available from 27 patients. In the 24-48 h after cisplatin 78% of patients taking ondansetron plus dexamethasone reported complete or major control of emesis compared with 30% of those taking ondansetron plus placebo (p = 0.001). Cross-over analysis showed a significant advantage for ondansetron plus dexamethasone in the control of nausea (p = 0.013) and emesis (p < 0.001) over the 8-day study. 24 of 26 patients expressed a preference for the combination therapy (p < 0.001). Ondansetron plus dexamethasone is effective antiemetic prophylaxis for high-dose cisplatin chemotherapy, has few side effects, and is active when given orally.	MT VERNON CANC CTR,NORTHWOOD,MIDDX,ENGLAND; GLAXO GRP RES LTD,GREENFORD UB6 0HE,MIDDX,ENGLAND	Mount Vernon Cancer Centre; GlaxoSmithKline	SMITH, DB (corresponding author), CHARING CROSS HOSP,DEPT MED ONCOL,CANC RES CAMPAIGN LABS,LONDON W6 8RF,ENGLAND.		Rustin, Gordon J. S./J-9763-2019					AAPRO MS, 1981, CANCER CHEMOTH PHARM, V7, P11; ALLAN SG, 1984, BRIT MED J, V289, P878, DOI 10.1136/bmj.289.6449.878-a; BATEMAN DN, 1985, BRIT MED J, V291, P920; BLACKWELL SP, 1989, EUR J CLIN ONCOL S1, V25, P21; CASSIDY J, 1988, BRIT J CANCER, V58, P651, DOI 10.1038/bjc.1988.278; COATES A, 1983, EUR J CANCER CLIN ON, V19, P203, DOI 10.1016/0277-5379(83)90418-2; COSTALL B, 1986, NEUROPHARMACOLOGY, V25, P959, DOI 10.1016/0028-3908(86)90030-4; CUBEDDU LX, 1990, NEW ENGL J MED, V322, P810, DOI 10.1056/NEJM199003223221204; CUNNINGHAM D, 1987, LANCET, V1, P1461, DOI 10.1016/S0140-6736(87)92208-2; CUNNINGHAM D, 1989, LANCET, V1, P1323; Demulder PHM, 1990, ANN INTERN MED, V113, P834, DOI 10.7326/0003-4819-113-11-834; FOZARD JR, 1978, EUR J PHARMACOL, V49, P109, DOI 10.1016/0014-2999(78)90228-5; GRALLA RJ, 1981, NEW ENGL J MED, V305, P905, DOI 10.1056/NEJM198110153051601; HAWTHORN J, 1988, Q J EXP PHYSIOL CMS, V73, P7, DOI 10.1113/expphysiol.1988.sp003124; HILLS M, 1979, BRIT J CLIN PHARMACO, V8, P7, DOI 10.1111/j.1365-2125.1979.tb05903.x; KOCH GG, 1972, BIOMETRICS, V28, P577, DOI 10.2307/2556170; KRIS MG, 1985, J CLIN ONCOL, V3, P1379, DOI 10.1200/JCO.1985.3.10.1379; KRIS MG, 1987, CANCER, V60, P2816, DOI 10.1002/1097-0142(19871201)60:11<2816::AID-CNCR2820601137>3.0.CO;2-7; MARTY M, 1990, NEW ENGL J MED, V322, P816, DOI 10.1056/NEJM199003223221205; NEWLANDS ES, 1986, BRIT J UROL, V58, P307, DOI 10.1111/j.1464-410X.1986.tb09061.x; Prescott R. J., 1981, Applied Statistics, V30, P9, DOI 10.2307/2346652; SMITH DB, 1990, BRIT J CANCER, V61, P323, DOI 10.1038/bjc.1990.62; SMITH DB, 1990, CANCER CHEMOTH PHARM, V25, P291, DOI 10.1007/BF00684888; STRUM SB, 1982, JAMA-J AM MED ASSOC, V247, P2683, DOI 10.1001/jama.247.19.2683	24	226	226	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 24	1991	338	8765					487	490		10.1016/0140-6736(91)90555-4	http://dx.doi.org/10.1016/0140-6736(91)90555-4			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GC153	1714532				2023-01-03	WOS:A1991GC15300015
J	FRENKEN, LAM; VANLIER, HJJ; GERLAG, PGG; DENHARTOG, M; KOENE, RAP				FRENKEN, LAM; VANLIER, HJJ; GERLAG, PGG; DENHARTOG, M; KOENE, RAP			ASSESSMENT OF PAIN AFTER SUBCUTANEOUS INJECTION OF ERYTHROPOIETIN IN PATIENTS RECEIVING HEMODIALYSIS	BRITISH MEDICAL JOURNAL			English	Article									UNIV HOSP NIJMEGEN,DEPT NEPHROL,NIJMEGEN,NETHERLANDS; UNIV HOSP NIJMEGEN,DEPT MED STAT,NIJMEGEN,NETHERLANDS; ST JOSEPH HOSP,DEPT MED,VELDHOVEN,NETHERLANDS; HOSP DE GELDERSE VALLEI,WAGENINGEN,NETHERLANDS	Radboud University Nijmegen; Radboud University Nijmegen; Gelderse Vallei Hospital	FRENKEN, LAM (corresponding author), UNIV HOSP NIJMEGEN,DEPT MED,NIJMEGEN,NETHERLANDS.							BOMMER J, 1989, CONTRIB NEPHROL, V76, P149; ESCHBACH JW, 1989, NEW ENGL J MED, V321, P158, DOI 10.1056/NEJM198907203210305; ESCHBACH JW, 1987, NEW ENGL J MED, V316, P73, DOI 10.1056/NEJM198701083160203; MACHIN D, 1988, CLIN J PAIN, V4, P161, DOI 10.1097/00002508-198809000-00006; WINEARLS CG, 1986, LANCET, V2, P75	5	38	38	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 3	1991	303	6797					288	288		10.1136/bmj.303.6797.288	http://dx.doi.org/10.1136/bmj.303.6797.288			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FZ721	1888931	Green Published, Bronze			2023-01-03	WOS:A1991FZ72100023
J	HNATIUK, OW; DILLARD, TA; OSTER, CN				HNATIUK, OW; DILLARD, TA; OSTER, CN			BLEOMYCIN SCLEROTHERAPY FOR BILATERAL PNEUMOTHORACES IN A PATIENT WITH AIDS	ANNALS OF INTERNAL MEDICINE			English	Note											HNATIUK, OW (corresponding author), WALTER REED ARMY MED CTR, DEPT CLIN INVEST, WASHINGTON, DC 20307 USA.							BITRAN JD, 1981, J SURG ONCOL, V16, P273, DOI 10.1002/jso.2930160312; DYNER TS, 1989, ANN INTERN MED, V111, P94, DOI 10.7326/0003-4819-111-1-94; ENG RHK, 1987, ARCH INTERN MED, V147, P746, DOI 10.1001/archinte.147.4.746; FLEISHER AG, 1988, ANN THORAC SURG, V45, P21, DOI 10.1016/S0003-4975(10)62388-0; GOLDSZER RC, 1979, JAMA-J AM MED ASSOC, V241, P724, DOI 10.1001/jama.241.7.724; OSTROWSKI MJ, 1989, J SURG ONCOL, P7; SAHN SA, 1981, AM REV RESPIR DIS, V124, P65; SCANNELL KA, 1990, CHEST, V97, P479, DOI 10.1378/chest.97.2.479; SHERMAN M, 1986, CHEST, V90, P609, DOI 10.1378/chest.90.4.609; TASSI GF, 1983, CHEST, V83, P836, DOI 10.1378/chest.83.5.836a	10	14	14	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 15	1990	113	12					988	990		10.7326/0003-4819-113-12-988	http://dx.doi.org/10.7326/0003-4819-113-12-988			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EM297	1700656				2023-01-03	WOS:A1990EM29700015
J	SIEGERT, W; AGTHE, A; GRIESSER, H; SCHWERDTFEGER, R; BRITTINGER, G; ENGELHARD, M; KUSE, R; TIEMANN, M; LENNERT, K; HUHN, D				SIEGERT, W; AGTHE, A; GRIESSER, H; SCHWERDTFEGER, R; BRITTINGER, G; ENGELHARD, M; KUSE, R; TIEMANN, M; LENNERT, K; HUHN, D			TREATMENT OF ANGIOIMMUNOBLASTIC LYMPHADENOPATHY (AILD)-TYPE T-CELL LYMPHOMA USING PREDNISONE WITH OR WITHOUT THE COPBLAM/IMVP-16 REGIMEN - A MULTICENTER STUDY	ANNALS OF INTERNAL MEDICINE			English	Article						CEREBROVASCULAR DISORDERS; HEPARINOID; ENOXAPARIN; HEPARIN; THROMBOEMBOLISM	ANGIO-IMMUNOBLASTIC LYMPHADENOPATHY; LYMPHOPROLIFERATIVE DISORDERS; CHROMOSOMAL-ABNORMALITIES; COMBINATION CHEMOTHERAPY; REARRANGEMENT; FEATURES; DISEASE	Objective: To describe the clinical course of patients with angioimmunoblastic lymphadenopathy (AILD)-type lymphoma with a sequential treatment with prednisone and COPBLAM/IMVP-16. Design: A multicenter, prospective, nonrandomized trial. Setting: University medical centers and community hospitals. Patients: Sixty-seven patients were registered, 28 were excluded, and 39 patients were evaluable for response (median age, 59 years; range, 25 to 82 years) (stages I and II, 10%; stages III and IV, 90%; B symptoms, 74%). Measurements: Response, survival, and relapse. Intervention: Patients initially received prednisone and no further treatment if a complete remission was achieved. Relapsing or refractory patients were treated with COPBLAM/IMVP-16. Patients with life-threatening tumor progression or extension received COPBLAM/IMVP-16 initially. Treatments were chosen in accordance with tumor extension and response to prednisone. Treatment modalities were not compared. Results: Twenty-eight patients received primary prednisone, 18 received secondary prednisone, and 11 received primary chemotherapy. The complete response rates (with 95% CIs) were 29% (CI, 12% to 46%), 56% (CI, 33% to 79%), and 64% (CI, 36% to 92%), respectively. The median observation time of surviving patients was 28 months (range, 7 to 53). The median overall survival time was 15 months. The probabilities (with 95% CIs) of overall survival, event-free survival, and relapse at 36 months were 40.5% (CI, 24% to 56%), 32.3% (CI, 17% to 47%), and 34.6% (CI, 14% to 56%), respectively. At the time of evaluation, 22 of 39 patients had died, 7 of noninfectious complications and 14 of infections. Conclusions: Prednisone with or without COPBLAM/IMVP-16 treatment in AILD-type lymphoma leads to complete remissions in about half of the patients and in long-term, disease free survival for one third.	UNIV KIEL, INST PATHOL, W-2300 KIEL 1, GERMANY; UNIV ESSEN GESAMTHSCH, MED KLIN, W-4300 ESSEN 1, GERMANY; ALLGEMEINES KRANKENHAUS ST GEORG, W-2000 HAMBURG 1, GERMANY	University of Kiel; University of Duisburg Essen; Asklepios Klinik St. Georg	SIEGERT, W (corresponding author), FREE UNIV BERLIN, KLINIKUM RUDOLF VIRCHOW, STANDORT CHARLOTTENBURG, SPANDAUER DAMM 130, W-1000 BERLIN 19, GERMANY.		Agthe, Alexander/A-3003-2011					ARCHIMBAUD E, 1987, CANCER-AM CANCER SOC, V59, P208, DOI 10.1002/1097-0142(19870115)59:2<208::AID-CNCR2820590205>3.0.CO;2-7; AZEVEDO SJ, 1985, AM J HEMATOL, V20, P301, DOI 10.1002/ajh.2830200314; CABANILLAS F, 1982, BLOOD, V60, P693; ENGELHARD M, 1991, ANN ONCOL, V2, P177, DOI 10.1093/annonc/2.suppl_2.177; FELLER AC, 1988, AM J PATHOL, V133, P549; FRIZZERA G, 1975, AM J MED, V59, P803, DOI 10.1016/0002-9343(75)90466-0; FRIZZERA G, 1989, LEUKEMIA, V3, P1; GANESAN TS, 1987, BRIT J CANCER, V55, P437, DOI 10.1038/bjc.1987.86; GODDESALZ E, 1987, LEUKEMIA RES, V11, P181, DOI 10.1016/0145-2126(87)90024-5; GRIESSER H, 1986, J CLIN INVEST, V78, P1179, DOI 10.1172/JCI112700; GRIESSER H, 1989, BLOOD, V73, P1402; KANEKO Y, 1988, BLOOD, V72, P413; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; LAURENCE J, 1982, ANN INTERN MED, V97, P190, DOI 10.7326/0003-4819-97-2-190; LENNERT K, 1973, LEUKAMIEN MALIGNE LY, P281; Lennert K, 1990, HISTOPATHOLOGIE NONH; LUKES RJ, 1975, NEW ENGL J MED, V292, P1, DOI 10.1056/NEJM197501022920101; NATHWANI BN, 1978, CANCER, V41, P578, DOI 10.1002/1097-0142(197802)41:2<578::AID-CNCR2820410226>3.0.CO;2-8; PANGALIS GA, 1983, CANCER-AM CANCER SOC, V52, P318, DOI 10.1002/1097-0142(19830715)52:2<318::AID-CNCR2820520221>3.0.CO;2-G; RADASZKIEWICZ T, 1975, DEUT MED WOCHENSCHR, V100, P1157, DOI 10.1055/s-0028-1106350; SCHAUER PK, 1981, CANCER, V48, P2493, DOI 10.1002/1097-0142(19811201)48:11<2493::AID-CNCR2820481124>3.0.CO;2-T; SCHLEGELBERGER B, 1990, CANCER GENET CYTOGEN, V50, P15, DOI 10.1016/0165-4608(90)90233-Z; SIEGERT W, 1989, BLOOD S, V74, pA280; SUCHI T, 1987, J CLIN PATHOL, V40, P995, DOI 10.1136/jcp.40.9.995; TOBINAI K, 1988, BLOOD, V72, P1000; WEISS LM, 1986, AM J PATHOL, V122, P392	27	89	92	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 1	1992	117	5					364	370		10.7326/0003-4819-117-5-364	http://dx.doi.org/10.7326/0003-4819-117-5-364			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JK678	1380221				2023-01-03	WOS:A1992JK67800003
J	MAIN, J; WARD, MK				MAIN, J; WARD, MK			POTENTIATION OF ALUMINUM ABSORPTION BY EFFERVESCENT ANALGESIC TABLETS IN A HEMODIALYSIS PATIENT	BRITISH MEDICAL JOURNAL			English	Article							TOXICITY; CITRATE				MAIN, J (corresponding author), ROYAL VICTORIA INFIRM,RENAL OFF,NEWCASTLE TYNE NE1 4LP,TYNE & WEAR,ENGLAND.							KIRSCHBAUM BB, 1989, AM J MED SCI, V297, P9, DOI 10.1097/00000441-198901000-00003; MOLITORIS BA, 1989, KIDNEY INT, V36, P949, DOI 10.1038/ki.1989.286; NOLIN CR, 1990, KIDNEY INT, V38, P937; PARTRIDGE NA, 1989, KIDNEY INT, V35, P1413, DOI 10.1038/ki.1989.142	4	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 27	1992	304	6843					1686	1686		10.1136/bmj.304.6843.1686	http://dx.doi.org/10.1136/bmj.304.6843.1686			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JB939	1633526	Bronze, Green Published			2023-01-03	WOS:A1992JB93900031
J	BERDEN, HJJM; WILLEMS, FF; HENDRICK, JMA; KNAPE, JTA; PIJLS, NHJ				BERDEN, HJJM; WILLEMS, FF; HENDRICK, JMA; KNAPE, JTA; PIJLS, NHJ			VARIATION IN THE QUALITY OF CARDIOPULMONARY-RESUSCITATION	LANCET			English	Note								During instruction in basic cardiopulmonary resuscitation (CPR) skills, cardiac massage and mouth-to-mouth ventilation are applied without interruption for no longer than a few minutes. The aim of this study was to see if the quality of technique during the first 2 min of CPR reflects the resuscitators ability to perform CPR over a 15 min period. Assessments were done with a resuscitation mannequin from which recordings of several variables were made at 2, 5, 10, and 15 min after the start of CPR. 60 lay volunteers who had received CPR training were studied, and six variables that describe the quality of CPR technique were recorded and scored with a predefined scoring system. No deterioration in CPR skills was seen during 15 min. We conclude that the initial 2 min assessment reflects the resuscitators ability to perform CPR over a longer period.	CATHARINA HOSP,DEPT CARDIOL,POB 1350,5602 ZA EINDHOVEN,NETHERLANDS; DUTCH COLL GEN PRACTIONERS,UTRECHT,NETHERLANDS; CATHOLIC UNIV NIJMEGEN,RADBOUD HOSP,DEPT CARDIOL,NIJMEGEN,NETHERLANDS; UNIV UTRECHT HOSP,DEPT ANAESTHESIA,3511 GV UTRECHT,NETHERLANDS	Catharina Hospital; Radboud University Nijmegen; Utrecht University; Utrecht University Medical Center			Berden, Hubert/GQB-0441-2022					BECKER LB, 1991, ANN EMERG MED, V20, P355, DOI 10.1016/S0196-0644(05)81654-3; BERDEN HJJM, 1992, RESUSCITATION, V23, P21, DOI 10.1016/0300-9572(92)90159-A; CUMMINS RO, 1985, AM J EMERG MED, V3, P114, DOI 10.1016/0735-6757(85)90032-4; KALMTHOUT P, 1985, BRIT HEART J, V53, P562; KAYE W, 1991, RESUSCITATION, V21, P67, DOI 10.1016/0300-9572(91)90080-I; ROOS L, 1990, CARDIOLOGISCHE PATIE; SEFRIN P, 1987, ANASTH INTENSIVMED, V28, P129; SILVAST T, 1990, AM J EMERG MED, V8, P359; VANHOEYWEGHEN RJ, 1991, ANN EMERG MED, V20, P279, DOI 10.1016/S0196-0644(05)80940-0; 1986, JAMA-J AM MED ASSOC, V255, P2905	10	6	6	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 25	1992	339	8800					1019	1020		10.1016/0140-6736(92)90539-F	http://dx.doi.org/10.1016/0140-6736(92)90539-F			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HQ435	1349054				2023-01-03	WOS:A1992HQ43500007
J	LEWIN, B; ROBERTSON, IH; CAY, EL; IRVING, JB; CAMPBELL, M				LEWIN, B; ROBERTSON, IH; CAY, EL; IRVING, JB; CAMPBELL, M			EFFECTS OF SELF-HELP POST-MYOCARDIAL-INFARCTION REHABILITATION ON PSYCHOLOGICAL ADJUSTMENT AND USE OF HEALTH-SERVICES	LANCET			English	Article							CARDIAC REHABILITATION; HEART-ATTACK; MORBIDITY; BEHAVIOR; RECOVERY; ILLNESS	A home-based exercise programme has been found to be as useful as a hospital-based one in improving cardiovascular fitness after an acute myocardial infarction. To find out whether a comprehensive home-based programme would reduce psychological distress, 176 patients with an acute myocardial infarction were randomly allocated to a self-help rehabilitation programme based on a heart manual or to receive standard care plus a placebo package of information and informal counselling. Psychological adjustment, as assessed by the Hospital Anxiety and Depression Scale, was better in the rehabilitation group at 1 year. They also had significantly less contact with their general practitioners during the following year and significantly fewer were readmitted to hospital in the first 6 months. The improvement was greatest among patients who were clinically anxious or depressed at discharge from hospital. The cost-effectiveness of the home-based programme has yet to be compared with that of a hospital-based programme, but the findings of this study indicate that it might be worth offering such a package to all patients with acute myocardial infarction.	ASTLEY AINSLIE HOSP,REHABIL MED UNIT,EDINBURGH EH9 2HL,SCOTLAND		LEWIN, B (corresponding author), ASTLEY AINSLIE HOSP,DEPT CLIN PSYCHOL,EDINBURGH EH9 2HL,SCOTLAND.							BERWICK DM, 1987, J CHRON DIS, V40, pS71, DOI 10.1016/S0021-9681(87)80035-8; BRYNE DG, 1978, J PSYCHOSOM RES, V22, P485; BYRNE DG, 1981, J PSYCHOSOM RES, V25, P97, DOI 10.1016/0022-3999(81)90096-9; CAY EL, 1972, J PSYCHOSOM RES, V16, P425, DOI 10.1016/0022-3999(72)90068-2; DEBUSK F, 1985, AM J CARDIOL, V85, P251; DELLIPIANI AW, 1976, BRIT HEART J, V38, P752; DOEHRMAN SR, 1977, SOC SCI MED, V11, P199, DOI 10.1016/0037-7856(77)90094-4; FRASURESMITH N, 1991, AM J CARDIOL, V67, P121, DOI 10.1016/0002-9149(91)90432-K; GLASGOW RE, 1978, PSYCHOL BULL, V85, P1, DOI 10.1037/0033-2909.85.1.1; GLOAG D, 1985, BRIT MED J, V290, P617, DOI 10.1136/bmj.290.6468.617; GOLDBERG DP, 1970, BMJ-BRIT MED J, V2, P439, DOI 10.1136/bmj.2.5707.439; GREEN V, 1988, PHYSIOTHERAPY, V74, P363; HEDBACK B, 1987, EUR HEART J, V8, P234, DOI 10.1093/oxfordjournals.eurheartj.a062265; HEDBACK B, 1985, J CARDIOPULM REHABIL, V5, P576; HOEPER EW, 1980, AM J PSYCHIAT, V137, P207; LLOYD GG, 1982, Q J MED, V51, P33; MAELAND JG, 1989, SCAND J SOC MED, V17, P93, DOI 10.1177/140349488901700114; MAYOU R, 1984, J PSYCHOSOM RES, V28, P17, DOI 10.1016/0022-3999(84)90036-9; MILLER NH, 1984, CIRCULATION, V4, P645; OBERMAN A, 1989, CIRCULATION, V80, P416, DOI 10.1161/01.CIR.80.2.416; OCONNOR GT, 1989, CIRCULATION, V80, P234, DOI 10.1161/01.CIR.80.2.234; OLDRIDGE NB, 1988, JAMA-J AM MED ASSOC, V260, P945, DOI 10.1001/jama.260.7.945; Parmley W W, 1986, J Am Coll Cardiol, V7, P451; STERN MJ, 1977, ARCH INTERN MED, V137, P1680, DOI 10.1001/archinte.137.12.1680; Vieweg B. W., 1983, J OPER PSYCHIATR, V14, P74; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x; 1988, ANN INTERN MED, V109, P671; 1975, J R COLL PHYSICIANS, V9, P281; 1981, BRIT MED J, V282, P894	29	211	214	2	17	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 25	1992	339	8800					1036	1040		10.1016/0140-6736(92)90547-G	http://dx.doi.org/10.1016/0140-6736(92)90547-G			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HQ435	1349062				2023-01-03	WOS:A1992HQ43500015
J	BOS, AP; BROERS, CJM; HAZEBROEK, FWJ; VANHEMEL, JO; TIBBOEL, D; WESBYVANSWAAY, E; MOLENAAR, JC				BOS, AP; BROERS, CJM; HAZEBROEK, FWJ; VANHEMEL, JO; TIBBOEL, D; WESBYVANSWAAY, E; MOLENAAR, JC			AVOIDANCE OF EMERGENCY-SURGERY IN NEWBORN-INFANTS WITH TRISOMY-18	LANCET			English	Article							DIE	Trisomy 18 (Edwards' syndrome) presents with characteristic external features as well as life-threatening abnormalities; many of these abnormalities require surgical correction during the neonatal period. Children with trisomy 18 have a very short life expectancy, and all long-term survivors have severe mental retardation. Difficult medical and ethical issues arise over whether or not to institute treatment when a newborn infant with suspected trisomy 18 has a life-threatening anomaly. We studied the policy of treatment in seven patients with clinical Edwards' syndrome. For three, the period of uncertainty was shortened because trisomy 18 was rapidly diagnosed by karyotyping of a bone-marrow aspirate. Four of the patients underwent surgery before the diagnosis of trisomy 18 was confirmed by routine karyotyping in lymphocytes; karyotyping in bone marrow might have allowed invasive treatment to be avoided in three of these. Rapid confirmation of clinically suspected Edwards' syndrome is very important because surgery may then be withheld. A newborn infant with trisomy 18 should be considered as a patient with a hopeless outlook who ought not to be subjected to invasive procedures. The decision to withdraw or withhold treatment should be discussed frankly with the parents. The period of uncertainty can be reduced to a minimum by the use of karyotyping in bone marrow.	ERASMUS UNIV,SCH MED,SOPHIA CHILDRENS HOSP,DEPT CLIN GENET,3000 LL ROTTERDAM,NETHERLANDS	Erasmus University Rotterdam; Erasmus MC - Sophia Children's Hospital	BOS, AP (corresponding author), ERASMUS UNIV,SCH MED,SOPHIA CHILDRENS HOSP,DEPT PAEDIAT SURG,POB 70029,3000 LL ROTTERDAM,NETHERLANDS.							CARTER PE, 1985, CLIN GENET, V27, P59; EDWARDS JH, 1960, LANCET, V1, P787; MARION RW, 1988, J PEDIATR-US, V113, P45, DOI 10.1016/S0022-3476(88)80526-2; MIRAIE ED, 1988, J PEDIATR-US, V113, P262, DOI 10.1016/S0022-3476(88)80262-2; SAFAR P, 1990, CRIT CARE MED, V18, P788; SMITH DW, 1988, RECOGNIZABLE PATTERN, P16; TRUOG RD, 1990, CRIT CARE MED, V18, P790; VANDYKE DC, 1990, PEDIATRICS, V85, P753; WALDSTEIN G, 1987, ARCH PATHOL LAB MED, V111, P703; WALTERS JW, 1988, AM J DIS CHILD, V142, P825, DOI 10.1001/archpedi.1988.02150080031015	10	42	42	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 11	1992	339	8798					913	915		10.1016/0140-6736(92)90940-5	http://dx.doi.org/10.1016/0140-6736(92)90940-5			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HN483	1348308				2023-01-03	WOS:A1992HN48300014
J	HOLLENBERG, PF				HOLLENBERG, PF			MECHANISMS OF CYTOCHROME-P450 AND PEROXIDASE-CATALYZED XENOBIOTIC METABOLISM	FASEB JOURNAL			English	Article						CYTOCHROME-P450; PEROXIDASE; MONOOXYGENASE; MIXED-FUNCTION OXIDASE; HYDROXYLATION	N-DEMETHYLATION REACTIONS; LIVER MICROSOMAL CYTOCHROME-P-450; HORSERADISH-PEROXIDASE; ELECTRON-TRANSFER; CHLOROPEROXIDASE; OXIDATION; HYDROXYLATION; AMINE; DEPROTONATION; CARBINOLAMINE	The cytochrome P450 enzyme systems catalyze the metabolism of a wide variety of naturally occurring and foreign compounds by reactions requiring NADPH and O2. Cytochrome P450 also catalyzes peroxide-dependent hydroxylation of substrates in the absence of NADPH and O2. Peroxidases such as chloroperoxidase and horseradish peroxidase catalyze peroxide-dependent reactions similar to those catalyzed by cytochrome P450. The kinetic and chemical mechanisms of the NADPH and O2-supported dealkylation reactions catalyzed by P450 have been investigated and compared with those catalyzed by P450 and peroxidases when the reactions are supported by peroxides. Detailed kinetic studies demonstrated that chloroperoxidase- and horseradish peroxidase-catalyzed N-demethylations proceed by a Ping Pong Bi Bi mechanism whereas P450-catalyzed O-dealkylations proceed by sequential mechanisms. Intramolecular isotope effect studies demonstrated that N-demethylations catalyzed by P450s and peroxidases proceed by different mechanisms. Most hemeproteins investigated catalyzed these reactions via abstraction of an alpha-carbon hydrogen whereas reactions catalyzed by P-450 and chloroperoxidase proceeded via an initial one-electron oxidation followed by alpha-carbon deprotonation. O-18-Labeling studies of the metabolism of NMC also demonstrated differences between the peroxidases and P450s. Because the hemeprotein prosthetic groups of P450, chloroperoxidase, and horseradish peroxidase are identical, the differences in the catalytic mechanisms result from differences in the environments provided by the proteins for the heme active site. It is suggested that the axial heme-iron thiolate moiety in P450 and chloroperoxidase may play a critical role in determining the mechanism of N-demethylation reactions catalyzed by these proteins.			HOLLENBERG, PF (corresponding author), WAYNE STATE UNIV,SCH MED,DEPT PHARMACOL,DETROIT,MI 48201, USA.		Hollenberg, Paul F/A-7538-2009		NCI NIH HHS [CA 16954] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA016954, R01CA016954] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABDELMONEM MM, 1975, J MED CHEM, V18, P427, DOI 10.1021/jm00238a021; BLACK SD, 1986, CYTOCHROME P450 STRU, P161; BLANKE SR, 1988, J BIOL CHEM, V263, P18739; CHEN CD, 1985, ARCH BIOCHEM BIOPHYS, V238, P195, DOI 10.1016/0003-9861(85)90156-0; CROWLEY JR, 1991, FASEB J, V5, pA1517; DAWSON JH, 1988, SCIENCE, V240, P433, DOI 10.1126/science.3358128; DAWSON JH, 1987, CHEM REV, V87, P1255, DOI 10.1021/cr00081a015; DINNOCENZO JP, 1989, J AM CHEM SOC, V111, P8646, DOI 10.1021/ja00205a014; GROVES JT, 1978, BIOCHEM BIOPH RES CO, V81, P154, DOI 10.1016/0006-291X(78)91643-1; GUENGERICH FP, 1984, J MED CHEM, V27, P1101, DOI 10.1021/jm00375a002; GUENGERICH FP, 1990, CHEM RES TOXICOL, V3, P21, DOI 10.1021/tx00013a004; GUENGERICH FP, 1990, CRIT REV BIOCHEM MOL, V25, P97; GUENGERICH FP, 1991, CHEM RES TOXICOL, V4, P391, DOI 10.1021/tx00022a001; HEWSON WD, 1979, PORPHYRINS, V7, P295; HOLLENBERG PF, 1973, J BIOL CHEM, V248, P2630; HOLLENBERG PF, 1974, J BIOL CHEM, V249, P5816; HOLLENBERG PF, 1985, DRUG METAB DISPOS, V13, P272; JONES JP, 1990, J MED CHEM, V33, P1242, DOI 10.1021/jm00166a024; KADLUBAR FF, 1973, BIOCHEM BIOPH RES CO, V54, P1225; KEDDERIS GL, 1986, J BIOL CHEM, V261, P5910; KEDDERIS GL, 1983, J BIOL CHEM, V258, P2413; KEDDERIS GL, 1983, MOL PHARMACOL, V23, P758; KEDDERIS GL, 1980, J BIOL CHEM, V255, P174; KEDDERIS GL, 1983, J BIOL CHEM, V258, P8129; KOOP DR, 1980, J BIOL CHEM, V255, P9685; LEWIS FD, 1980, J AM CHEM SOC, V102, P1751, DOI 10.1021/ja00525a061; Marnett L.J., 1986, CYTOCHROME P 450 STR, P29; MIWA GT, 1980, J BIOL CHEM, V255, P6049; MIWA GT, 1983, J BIOL CHEM, V258, P4445; MIWA GT, 1980, MICROSOMES DRUG OXID, V1, P363; NORDBLOM GD, 1976, ARCH BIOCHEM BIOPHYS, V175, P524, DOI 10.1016/0003-9861(76)90541-5; Northrop D. B., 1977, ISOTOPE EFFECTS ENZY, P122; Ortiz de Montellano PR, 1986, CYTOCHROME P450 STRU, P217; PANDEY RN, 1989, BIOCHEM PHARMACOL, V38, P2181, DOI 10.1016/0006-2952(89)90074-9; PORTER TD, 1991, J BIOL CHEM, V266, P13469; POTTER DW, 1987, J BIOL CHEM, V262, P974; RAHIMTULA AD, 1974, BIOCHEM BIOPH RES CO, V60, P440, DOI 10.1016/0006-291X(74)90223-X; ROMAN R, 1972, BIOCHEMISTRY-US, V11, P2076, DOI 10.1021/bi00761a013; ROSENBLATT DH, 1968, J ORG CHEM, V33, P1649, DOI 10.1021/jo01268a076; SHEA JP, 1982, BIOCHEM BIOPH RES CO, V109, P231, DOI 10.1016/0006-291X(82)91589-3; SHONO T, 1982, J AM CHEM SOC, V104, P2639, DOI 10.1021/ja00373a053; THOMAS JA, 1970, J BIOL CHEM, V245, P3129; WHITE RE, 1980, ANNU REV BIOCHEM, V49, P315, DOI 10.1146/annurev.bi.49.070180.001531; WISLOCKI PG, 1980, ENZYMATIC BASIS DETO, V1, P135; ZIEGLER DM, 1964, BIOCHEM BIOPH RES CO, V15, P188, DOI 10.1016/0006-291X(64)90322-5	45	82	85	2	19	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JAN 6	1992	6	2					686	694		10.1096/fasebj.6.2.1537457	http://dx.doi.org/10.1096/fasebj.6.2.1537457			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	GZ440	1537457				2023-01-03	WOS:A1992GZ44000007
J	BREO, DL				BREO, DL			BLOOD, MONEY, AND HEMOPHILIACS - THE FATAL STORY OF FRANCES AIDSGATE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																		DESFORGES J, 1983, NEW ENGLAND J MED	1	3	3	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 25	1991	266	24					3477	3482		10.1001/jama.266.24.3477	http://dx.doi.org/10.1001/jama.266.24.3477			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GV878	1744965				2023-01-03	WOS:A1991GV87800037
J	NELSON, SR; HAWKINS, PN; RICHARDSON, S; LAVENDER, JP; SETHI, D; GOWER, PE; PUGH, CW; WINEARLS, CG; OLIVER, DO; PEPYS, MB				NELSON, SR; HAWKINS, PN; RICHARDSON, S; LAVENDER, JP; SETHI, D; GOWER, PE; PUGH, CW; WINEARLS, CG; OLIVER, DO; PEPYS, MB			IMAGING OF HEMODIALYSIS-ASSOCIATED AMYLOIDOSIS WITH I-123 SERUM AMYLOID-P COMPONENT	LANCET			English	Article							LONG-TERM HEMODIALYSIS; SYSTEMIC AMYLOIDOSIS; BETA-2-MICROGLOBULIN AMYLOIDOSIS; RENAL-TRANSPLANTATION; DEPOSITS; PROTEIN	Long-term haemodialysis is frequently complicated by amyloid deposition in which the fibrils consist of beta-2-microglobulin. Dialysis-related amyloid disease causes extensive morbidity and has been associated with deaths in some cases. All amyloid deposits contain amyloid P component that is derived from the normal circulating protein, serum amyloid P component (SAP). We have used scintigraphic imaging after injection of I-123-labelled SAP to assess the distribution of amyloidosis in 38 patients receiving long-term haemodialysis for end-stage renal failure. There was focal localisation of tracer at all sites where histological examination confirmed amyloid deposition. Splenic uptake was seen in 12 patients, indicating splenic amyloidosis, but there was no evidence of other visceral involvement. 6 control subjects who had been dialysed for under 1.5 years showed no localisation of tracer, nor was there any uptake of I-123-labelled human serum albumin in 3 long-term dialysis patients with histologically confirmed amyloidosis and positive I-123-SAP images. Negative scans were also obtained in 5 patients who had been transplanted 0.8-2.4 years previously, despite past evidence of dialysis arthropathy (5) and histologically proven amyloidosis (4). I-123-SAP scintigraphy may be helpful as a non-invasive method for both the diagnosis and monitoring of dialysis-associated amyloidosis.	HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,DEPT MED,IMMUNOL MED UNIT,DU CANE RD,LONDON W12 0NN,ENGLAND; HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,DEPT RADIOL,LONDON W12 0NN,ENGLAND; CHARING CROSS HOSP,DEPT MED,RENAL UNIT,LONDON W6 8RP,ENGLAND; CHURCHILL HOSP,RENAL UNIT,OXFORD OX3 7LJ,ENGLAND	Imperial College London; Imperial College London; Imperial College London; University of Oxford			Hawkins, Philip N/C-5573-2008	Pugh, Chris/0000-0002-5170-1662				BALTZ ML, 1986, CLIN EXP IMMUNOL, V66, P691; CHOI HSH, 1989, GASTROENTEROLOGY, V96, P230, DOI 10.1016/0016-5085(89)90785-3; DESTRIHOU CV, 1990, INT YB NEPHROLOGY, P217; FLOEGE J, 1989, NEPHRON, V51, P444, DOI 10.1159/000185351; FLOEGE J, 1990, KIDNEY INT, V38, P1169, DOI 10.1038/ki.1990.329; FUCHS A, 1987, AM J CLIN PATHOL, V88, P302, DOI 10.1093/ajcp/88.3.302; GEJYO F, 1985, BIOCHEM BIOPH RES CO, V129, P701, DOI 10.1016/0006-291X(85)91948-5; GOREVIC PD, 1985, J CLIN INVEST, V76, P2425, DOI 10.1172/JCI112257; HAWKINS PN, 1988, J EXP MED, V167, P903, DOI 10.1084/jem.167.3.903; HAWKINS PN, 1988, LANCET, V1, P1413; HAWKINS PN, 1990, J CLIN INVEST, V86, P1862, DOI 10.1172/JCI114917; HAWKINS PN, 1990, NEW ENGL J MED, V323, P508, DOI 10.1056/NEJM199008233230803; JADOUL M, 1989, CLIN NEPHROL, V32, P194; MAHER ER, 1988, BRIT MED J, V297, P265, DOI 10.1136/bmj.297.6643.265; MANTZOURANIS EC, 1985, J BIOL CHEM, V280, P7752; OHNISHI S, 1986, J BIOCHEM-TOKYO, V100, P849, DOI 10.1093/oxfordjournals.jbchem.a121797; ORFILA C, 1987, NEPHROL DIAL TRANSPL, V2, P448; Pepys M. B, 1988, IMMUNOLOGICAL DISEAS, V1, P631; PEPYS MB, CLIN EXP; PRELLI F, 1985, J BIOL CHEM, V260, P12865; SETHI D, 1989, AM J NEPHROL, V9, P173, DOI 10.1159/000167959; SHINODA T, 1989, CLIN NEPHROL, V32, P284; STONE WJ, 1989, AM J NEPHROL, V9, P177, DOI 10.1159/000167962; THEAKER JM, 1987, J CLIN PATHOL, V40, P1247, DOI 10.1136/jcp.40.10.1247	24	98	99	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 10	1991	338	8763					335	339		10.1016/0140-6736(91)90478-8	http://dx.doi.org/10.1016/0140-6736(91)90478-8			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GA607	1677697				2023-01-03	WOS:A1991GA60700003
J	SMITH, DW; FRANKEL, LR; MATHERS, LH; TANG, ATS; ARIAGNO, RL; PROBER, CG				SMITH, DW; FRANKEL, LR; MATHERS, LH; TANG, ATS; ARIAGNO, RL; PROBER, CG			A CONTROLLED TRIAL OF AEROSOLIZED RIBAVIRIN IN INFANTS RECEIVING MECHANICAL VENTILATION FOR SEVERE RESPIRATORY SYNCYTIAL VIRUS-INFECTION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SPECTRUM ANTIVIRAL ACTIVITY; VIRAL-INFECTION; BRONCHIOLITIS; DISEASE; 1-BETA-D-RIBOFURANOSYL-1,2,4-TRIAZOLE-3-CARBOXAMIDE; VIRAZOLE	Background. Although the antiviral agent ribavirin improves the course of lower respiratory tract disease in spontaneously breathing infants with respiratory syncytial virus infection, it is not known whether ribavirin can benefit infants with severe respiratory syncytial virus disease who require mechanical ventilation. Methods. We conducted a randomized, double-blind, placebo-controlled evaluation of ribavirin (20 mg per milliliter) administered continuously in aerosolized form to infants receiving mechanical ventilation for respiratory failure that was caused by documented respiratory syncytial virus infection. Results. Of the 28 infants (mean [+/- SD] age, 1.4 +/- 1.7 months) enrolled, 7 had underlying diseases predisposing them to severe infection (mean age, 3.0 +/- 2.6 months), and 21 were previously normal (mean age, 0.8 +/- 0.9 month). Among the 14 infants who received ribavirin, the mean duration of mechanical ventilation was 4.9 days (as compared with 9.9 days among the 14 who received placebo; P = 0.01), and the mean length of supplemental oxygen use was 8.7 days (as compared with 13.5 days; P = 0.01). The mean length of the hospital stay was 13.3 days after treatment with ribavirin and 15.0 with placebo (P = 0.04). When only the 21 previously normal infants were considered, the mean length of the hospital stay was 9.0 days for the ribavirin recipients and 15.3 days for those who received placebo (P = 0.005). Conclusions. In infants who require mechanical ventilation because of severe respiratory syncytial virus infection, treatment with aerosolized ribavirin decreases the duration of mechanical ventilation, oxygen treatment, and the hospital stay.	STANFORD UNIV, MED CTR, SCH MED, DIV INTENS CARE, STANFORD, CA 94305 USA; STANFORD UNIV, MED CTR, SCH MED, DIV INFECT DIS, STANFORD, CA 94305 USA; STANFORD UNIV, MED CTR, SCH MED, DIV NEONATAL, STANFORD, CA 94305 USA; STANFORD UNIV, MED CTR, SCH MED, DEPT PEDIAT, STANFORD, CA 94305 USA	Stanford University; Stanford University; Stanford University; Stanford University			Ariagno, Ronald/ABG-5884-2020		NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000081] Funding Source: NIH RePORTER; NCRR NIH HHS [RR-00081] Funding Source: Medline; NIAID NIH HHS [AI 008844] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		[Anonymous], 1987, PEDIATRICS, V79, P475; BARRY W, 1986, ARCH DIS CHILD, V61, P593, DOI 10.1136/adc.61.6.593; CONRAD DA, 1987, PEDIATR INFECT DIS J, V6, P152, DOI 10.1097/00006454-198702000-00003; EDELSON PJ, 1990, PEDIATR INFECT DIS J, V9, pS71, DOI 10.1097/00006454-199009001-00002; FRANKEL LR, 1987, CRIT CARE MED, V15, P1051, DOI 10.1097/00003246-198711000-00012; FRANKEL LR, 1986, PEDIATR PULM, V2, P307, DOI 10.1002/ppul.1950020511; GREEN M, 1989, PEDIATR INFECT DIS J, V8, P601, DOI 10.1097/00006454-198909000-00007; HALL CB, 1985, JAMA-J AM MED ASSOC, V254, P3047, DOI 10.1001/jama.254.21.3047; HALL CB, 1983, NEW ENGL J MED, V308, P1443, DOI 10.1056/NEJM198306163082403; HUFFMAN JH, 1973, ANTIMICROB AGENTS CH, V3, P235, DOI 10.1128/AAC.3.2.235; KWONG MS, 1985, PEDIATRICS, V76, P585; MANSELL A, 1972, J APPL PHYSIOL, V33, P711, DOI 10.1152/jappl.1972.33.6.711; RODRIGUEZ WJ, 1987, PEDIATR INFECT DIS J, V6, P159, DOI 10.1097/00006454-198702000-00004; ROSENFELD W, 1988, BRONCHOPULMONARY DYS, P366; SIDWELL RW, 1972, SCIENCE, V177, P705, DOI 10.1126/science.177.4050.705; TABER LH, 1983, PEDIATRICS, V72, P613; WALD ER, 1988, J PEDIATR-US, V112, P154, DOI 10.1016/S0022-3476(88)80143-4; WITKOWSKI JT, 1972, J MED CHEM, V15, P1150, DOI 10.1021/jm00281a014; 1986, VIRAZOLE	19	200	220	0	7	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 4	1991	325	1					24	29		10.1056/NEJM199107043250105	http://dx.doi.org/10.1056/NEJM199107043250105			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FU342	1904551				2023-01-03	WOS:A1991FU34200005
J	FAVREAU, LV; PICKETT, CB				FAVREAU, LV; PICKETT, CB			TRANSCRIPTIONAL REGULATION OF THE RAT NAD(P)H-QUINONE REDUCTASE GENE - IDENTIFICATION OF REGULATORY ELEMENTS CONTROLLING BASAL LEVEL EXPRESSION AND INDUCIBLE EXPRESSION BY PLANAR AROMATIC-COMPOUNDS AND PHENOLIC ANTIOXIDANTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID SEQUENCE; AH RECEPTOR COMPLEX; QUINONE REDUCTASE; NUCLEOTIDE-SEQUENCE; ESCHERICHIA-COLI; STRUCTURAL GENE; DT-DIAPHORASE; MESSENGER-RNA; CDNA CLONE; LIVER	We have identified two regions in the 5'-flanking sequence of the rat quinone reductase gene that contain xenobiotic responsive elements. The DNA sequence of the first region spans nucleotides -393 to -352 of the 5'-flanking region and shares sequence identity with the xenobiotic responsive element (XRE) described for the cytochrome P-450 CYPIA1 gene. The DNA sequence of the second region spans nucleotides -434 to -404 of the 5'-flanking region of the quinone reductase structural gene. When a synthetic oligonucleotide corresponding to nucleotides -434 to -404 was inserted in front of a heterologous promoter linked to the chloramphenicol acetyltransferase structural gene, an increase in basal level expression as well as responsiveness to beta-naphthoflavone and t-butylhydroquinone, but not 2,3,7,8-tetrachlorodibenzo-p-dioxin, was observed. The sequence, -434 to -404, did not have any sequence identity with the XRE but shared a large degree of identity with the antioxidant responsive element recently described for the rat glutathione S-transferase Ya subunit gene (Rushmore, T. H., King, R. G., Paulson, K. E., and Pickett, C. B. (1990) Proc. Natl. Acad. Sci. U. S. A. 87, 3826-3830; Rushmore, T. H., and Pickett, C. B. (1990) J. Biol. Chem. 265, 14648-14653). These results indicate that the antioxidant responsive element can be distinguished functionally from the classical XRE and is also involved in the regulation of the quinone reductase gene by planar aromatic compounds and phenolic antioxidants.			FAVREAU, LV (corresponding author), MERCK FROSST CTR THERAPEUT RES,POB 1005,POINTE CLAIRE H9R 4P8,QUEBEC,CANADA.							BAYNEY RM, 1988, ARCH BIOCHEM BIOPHYS, V260, P847, DOI 10.1016/0003-9861(88)90516-4; BAYNEY RM, 1987, J BIOL CHEM, V262, P572; BAYNEY RM, 1989, J BIOL CHEM, V264, P21793; CHESIS PL, 1984, P NATL ACAD SCI-BIOL, V81, P1696, DOI 10.1073/pnas.81.6.1696; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHRISTMAN MF, 1989, P NATL ACAD SCI USA, V86, P3484, DOI 10.1073/pnas.86.10.3484; CLEWELL DB, 1972, J BACTERIOL, V110, P667, DOI 10.1128/JB.110.2.667-676.1972; COURTOIS G, 1988, P NATL ACAD SCI USA, V85, P7937, DOI 10.1073/pnas.85.21.7937; DELONG MJ, 1986, P NATL ACAD SCI USA, V83, P787; DENISON MS, 1989, J BIOL CHEM, V264, P16478; DENISON MS, 1988, J BIOL CHEM, V263, P17221; ERNSTER L, 1960, BIOCHEM BIOPH RES CO, V2, P88, DOI 10.1016/0006-291X(60)90193-5; ERNSTER L, 1967, METHOD ENZYMOL, V10, P309, DOI DOI 10.1016/0076-6879(67)10059-1; FUJISAWASEHARA A, 1988, P NATL ACAD SCI USA, V85, P5859, DOI 10.1073/pnas.85.16.5859; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HUANG MT, 1979, J BIOL CHEM, V254, P1223; KUMAKI K, 1977, J BIOL CHEM, V252, P157; LIND C, 1985, ARCH BIOCHEM BIOPHYS, V240, P226, DOI 10.1016/0003-9861(85)90027-X; LIND C, 1982, ARCH BIOCHEM BIOPHYS, V216, P178, DOI 10.1016/0003-9861(82)90202-8; Maniatis T., 1982, MOL CLONING; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; NEUHOLD LA, 1989, MOL CELL BIOL, V9, P2378, DOI 10.1128/MCB.9.6.2378; PAULSON KE, 1990, MOL CELL BIOL, V10, P1841, DOI 10.1128/MCB.10.5.1841; PROCHASKA HJ, 1988, CANCER RES, V48, P4776; PROCHASKA HJ, 1985, P NATL ACAD SCI USA, V82, P8232, DOI 10.1073/pnas.82.23.8232; ROBERTSON JA, 1986, J BIOL CHEM, V261, P5794; RUSHMORE TH, 1990, J BIOL CHEM, V265, P14648; RUSHMORE TH, 1990, P NATL ACAD SCI USA, V87, P3826, DOI 10.1073/pnas.87.10.3826; STORZ G, 1990, SCIENCE, V248, P189, DOI 10.1126/science.2183352; TALALAY P, 1988, P NATL ACAD SCI USA, V85, P8261, DOI 10.1073/pnas.85.21.8261; TARTAGLIA LA, 1989, J MOL BIOL, V210, P709, DOI 10.1016/0022-2836(89)90104-6; TELAKOWSKIHOPKINS CA, 1988, P NATL ACAD SCI USA, V85, P1000, DOI 10.1073/pnas.85.4.1000; THOR H, 1982, J BIOL CHEM, V257, P2419; WHITLOCK JP, 1987, PHARMACOL REV, V39, P147; WILLIAMS JB, 1986, J BIOL CHEM, V261, P5524; WILLIAMS JB, 1984, ARCH BIOCHEM BIOPHYS, V232, P408, DOI 10.1016/0003-9861(84)90556-3	36	462	474	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1991	266	7					4556	4561						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FA694	1900296				2023-01-03	WOS:A1991FA69400082
J	MOULIN, DE; KREEFT, JH; MURRAYPARSONS, N; BOUQUILLON, AI				MOULIN, DE; KREEFT, JH; MURRAYPARSONS, N; BOUQUILLON, AI			COMPARISON OF CONTINUOUS SUBCUTANEOUS AND INTRAVENOUS HYDROMORPHONE INFUSIONS FOR MANAGEMENT OF CANCER PAIN	LANCET			English	Article							TERMINAL MALIGNANCY; MORPHINE	To compare the safety and efficacy of subcutaneous and intravenous infusion of opioid analgesics, a randomised, double-blind, crossover trial was carried out in inpatients. 15 patients with severe cancer pain received two 48 h infusions of hydromorphone- one subcutaneously and one intravenously in randomly allocated order. The study was made double-blind by the use of two infusion pumps throughout; during the active subcutaneous infusion the intravenous pump delivered saline and vice versa. Serial measurements of pain intensity, pain relief, mood, and sedation by means of visual analogue scales showed no clinically or statistically significant difference between the two infusion routes. Side-effects were slight, and the mean number of morphine injections for breakthrough pain did not differ significantly between the routes (4.8 [SD 4.5] for intravenous vs 5.3 [5.6] for subcutaneous). Plasma hydromorphone concentrations measured at 24 h and 48 h of infusion showed stable steady-state pharmacokinetics; the mean bioavailability from subcutaneous infusion was 78% of that with intravenous infusion. Because of the simplicity, technical advantages, and cost-effectiveness of continuous subcutaneous opioid infusion into the chest wall or trunk, intravenous opioid infusion for the management of severe cancer pain should be abandoned.	UNIV WESTERN ONTARIO,DEPT CLIN NEUROL SCI & ONCOL,LONDON N6A 3K7,ONTARIO,CANADA; UNIV WESTERN ONTARIO,DEPT MED CLIN PHARMACOL,LONDON N6A 3K7,ONTARIO,CANADA	Western University (University of Western Ontario); Western University (University of Western Ontario)								BRUERA E, 1988, J NATL CANCER I, V80, P1152, DOI 10.1093/jnci/80.14.1152; BRUERA E, 1988, CANCER-AM CANCER SOC, V62, P407, DOI 10.1002/1097-0142(19880715)62:2<407::AID-CNCR2820620227>3.0.CO;2-T; CAMPBELL CF, 1983, ANN INTERN MED, V98, P51, DOI 10.7326/0003-4819-98-1-51; CITRON ML, 1984, AM J MED, V77, P199, DOI 10.1016/0002-9343(84)90691-0; FERRIS FD, IN PRESS J CLIN EPID; FISHMAN B, 1987, CANCER-AM CANCER SOC, V60, P1151, DOI 10.1002/1097-0142(19870901)60:5<1151::AID-CNCR2820600538>3.0.CO;2-G; FOLEY KM, 1985, NEW ENGL J MED, V313, P84, DOI 10.1056/NEJM198507113130205; HOUDE RAYMOND W., 1966, INT ENCYCL PHARMACOL THER, V1, P59; JAFFE JH, 1985, GOODMAN GILMANS PHAR, P494; KERR IG, 1988, ANN INTERN MED, V108, P554, DOI 10.7326/0003-4819-108-4-554; LACHIN JM, 1981, CONTROL CLIN TRIALS, V2, P93, DOI 10.1016/0197-2456(81)90001-5; MISER AW, 1980, J PEDIATR-US, V96, P930, DOI 10.1016/S0022-3476(80)80585-3; PENN RD, 1984, J NEUROSURG, V61, P302, DOI 10.3171/jns.1984.61.2.0302; PORTENOY RK, 1986, CANCER TREAT REP, V70, P575; SAWE J, 1981, CLIN PHARMACOL THER, V30, P629; SAWE J, 1983, BRIT J CLIN PHARMACO, V16, P85, DOI 10.1111/j.1365-2125.1983.tb02148.x; SVENSSON JO, 1986, J CHROMATOGR, V375, P174, DOI 10.1016/S0378-4347(00)83707-X; URQUHART ML, 1988, ANESTHESIOLOGY, V69, P428, DOI 10.1097/00000542-198809000-00029; VALLNER JJ, 1981, J CLIN PHARMACOL, V21, P152, DOI 10.1002/j.1552-4604.1981.tb05693.x; WALDMANN CS, 1984, ANAESTHESIA, V39, P768, DOI 10.1111/j.1365-2044.1984.tb06520.x; WEINBERG DS, 1988, CLIN PHARMACOL THER, V44, P335, DOI 10.1038/clpt.1988.159; Winer BJ., 1971, STAT PRINCIPLES EXPT, V2nd ed	22	83	85	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 23	1991	337	8739					465	468		10.1016/0140-6736(91)93401-T	http://dx.doi.org/10.1016/0140-6736(91)93401-T			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EY887	1704089				2023-01-03	WOS:A1991EY88700012
J	WOLFF, K; HONIGSMANN, H				WOLFF, K; HONIGSMANN, H			GENITAL CARCINOMAS IN PSORIASIS PATIENTS TREATED WITH PHOTOCHEMOTHERAPY	LANCET			English	Letter							LONG-TERM PHOTOCHEMOTHERAPY; FOLLOW-UP; PUVA TREATMENT; EUROPEAN PUVA; SKIN-CANCER; TUMORS				WOLFF, K (corresponding author), UNIV VIENNA,SCH MED,DEPT DERMATOL 1,A-1090 VIENNA,AUSTRIA.		Hoenigsmann, Herbert/H-9045-2019; Hoenigsmann, Herbert/H-9540-2019	Honigsmann, Herbert/0000-0001-6401-6966				GIBBS NK, 1986, LANCET, V1, P150; HENSELER T, 1987, J AM ACAD DERMATOL, V16, P108, DOI 10.1016/S0190-9622(87)70010-3; HONIGSMANN H, 1980, J AM ACAD DERMATOL, V3, P406, DOI 10.1016/S0190-9622(80)80336-7; LASSUS A, 1981, ACTA DERM-VENEREOL, V61, P141; LINDSKOV R, 1983, ACTA DERM-VENEREOL, V63, P223; PERKINS, 1990, LANCET, V336, P1248; ROS AM, 1983, ACTA DERM-VENEREOL, V63, P215; STERN RS, 1990, NEW ENGL J MED, V322, P1093, DOI 10.1056/NEJM199004193221601; STERN RS, 1988, J INVEST DERMATOL, V91, P120, DOI 10.1111/1523-1747.ep12464137; TANEW A, 1986, J AM ACAD DERMATOL, V15, P980	11	4	4	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 16	1991	337	8738					439	439		10.1016/0140-6736(91)91226-K	http://dx.doi.org/10.1016/0140-6736(91)91226-K			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EX605	1671465				2023-01-03	WOS:A1991EX60500065
J	DENTON, M; MORGAN, MS; WHITE, RR				DENTON, M; MORGAN, MS; WHITE, RR			QUALITY OF PRESCRIBING OF INTRAVENOUS ANTIBIOTICS IN A DISTRICT GENERAL-HOSPITAL	BRITISH MEDICAL JOURNAL			English	Article									WALTON HOSP,DEPT MICROBIOL,LIVERPOOL L9 1AE,MERSEYSIDE,ENGLAND	University of Liverpool; Walton Centre				morgan, marina/0000-0002-9336-481X				BAIN PG, 1990, BRIT MED J, V300, P1463; BAKKERWOUDENBERG IAJM, 1988, J ANTIMICROB CHEMOTH, V21, P145, DOI 10.1093/jac/21.2.145; BROWN B, 1989, ANN INTERN MED, V110, P247, DOI 10.7326/0003-4819-110-3-247; ZALIN AM, 1989, BRIT MED J, V299, P1279, DOI 10.1136/bmj.299.6710.1279	4	7	7	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 9	1991	302	6772					327	328		10.1136/bmj.302.6772.327-a	http://dx.doi.org/10.1136/bmj.302.6772.327-a			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EX569	2001508	Bronze, Green Published			2023-01-03	WOS:A1991EX56900024
J	COATS, AJS; ADAMOPOULOS, S; MEYER, TE; CONWAY, J; SLEIGHT, P				COATS, AJS; ADAMOPOULOS, S; MEYER, TE; CONWAY, J; SLEIGHT, P			EFFECTS OF PHYSICAL-TRAINING IN CHRONIC HEART-FAILURE	LANCET			English	Article											COATS, AJS (corresponding author), JOHN RADCLIFFE HOSP,DEPT CARDIOVASC MED,OXFORD OX3 9DU,ENGLAND.		Coats, Andrew J Stewart/E-4451-2012	Coats, Andrew J Stewart/0000-0002-2771-4260				ARMITAGE P, 1987, STATISTICAL METHODS; ASTRAND PO, 1987, TXB WORK PHYSL PHYSL; BARRY AJ, 1966, AM J CARDIOL, V17, P1, DOI 10.1016/0002-9149(66)90254-2; BLOMQVIST CG, 1983, ANNU REV PHYSIOL, V45, P169, DOI 10.1146/annurev.ph.45.030183.001125; CLAUSEN JP, 1976, PROG CARDIOVASC DIS, V18, P459, DOI 10.1016/0033-0620(76)90012-8; CONN EH, 1982, AM J CARDIOL, V49, P296, DOI 10.1016/0002-9149(82)90504-5; DETRY JMR, 1971, CIRCULATION, V44, P109, DOI 10.1161/01.CIR.44.1.109; ECKSTEIN RW, 1957, CIRC RES, V5, P230, DOI 10.1161/01.RES.5.3.230; HELLERSTEIN HK, 1967, CAN MED ASSOC J, V96, P901; HILLS M, 1979, BRIT J CLIN PHARMACO, V8, P7, DOI 10.1111/j.1365-2125.1979.tb05903.x; LEE AP, 1979, CIRCULATION, V60, P1519, DOI 10.1161/01.CIR.60.7.1519; LETAC B, 1977, CIRCULATION, V56, P375, DOI 10.1161/01.CIR.56.3.375; LIPKIN DP, 1985, BRIT HEART J, V54, P321; MCHENRY MM, 1974, AM J CARDIOL, V33, P752, DOI 10.1016/0002-9149(74)90216-1; McPherson B D, 1967, J Sports Med Phys Fitness, V7, P95; SCHEUER J, 1977, ANNU REV PHYSIOL, V39, P221, DOI 10.1146/annurev.ph.39.030177.001253; SHABETAI R, 1988, CIRCULATION, V78, P775, DOI 10.1161/01.CIR.78.3.775; SULLIVAN MJ, 1989, CIRCULATION, V79, P324, DOI 10.1161/01.CIR.79.2.324; SULLIVAN MJ, 1988, CIRCULATION, V78, P506, DOI 10.1161/01.CIR.78.3.506; WILLIAMS RS, 1985, CARDIOVASC CLIN, V15, P218; 1988, LANCET, V1, P489	21	330	338	0	10	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 13	1990	335	8681					63	66		10.1016/0140-6736(90)90536-E	http://dx.doi.org/10.1016/0140-6736(90)90536-E			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CH516	1967416				2023-01-03	WOS:A1990CH51600001
J	SALAMA, A; BERGHOFER, H; MUELLERECKHARDT, C				SALAMA, A; BERGHOFER, H; MUELLERECKHARDT, C			RED-BLOOD-CELL TRANSFUSION IN WARM-TYPE AUTOIMMUNE HEMOLYTIC-ANEMIA	LANCET			English	Article							HEMOLYTIC-ANEMIA; AUTOANTIBODIES	Blood transfusions are regarded as hazardous in patients with warm-type autoimmune haemolytic anaemia (AIHA) because of potential intensification of haemolysis and a presumed high incidence of alloimmunisation. We have retrospectively analysed data of 79 multitransfused patients (74 adults, 5 children) with detectable warm autoantibodies and transitory or persisting haemolytic anaemia. All patients had received blood transfusions on at least two occasions. Patients were reexamined at least twice within the first 6 months of transfusion (duration of follow-up 6 months-12 years). 53 patients had received blood transfusions because of decompensated AIHA, all of whom presented with detectable autoantibodies against red blood cells. None of these patients had transfusion-related alloimmunisation or a definite increase in haemolysis, even when the transfused red cells were serologically incompatible because of free serum autoantibodies. The other 26 patients had no signs of AIHA at presentation (negative direct and indirect antiglobulin test), but received blood transfusions for anaemia due to various other causes. 23 of these 26 patients went on to develop alloantibodies as well as autoantibodies upon transfusion, and 3 patients developed autoantibodies alone. Our findings do not support the generally accepted notion that transfusion therapy should be avoided in AIHA patients. Rather, they indicate that the incidence of alloimmunisation as well as adverse haemolytic transfusion reactions are less common in AIHA patients than in other multitransfused patients.	UNIV GIESSEN,INST CLIN IMMUNOL & TRANSFUS MED,LANGHANSSTR 7,W-6300 GIESSEN,GERMANY; UNIV GIESSEN,DEPT INTERNAL MED,W-6300 GIESSEN,GERMANY	Justus Liebig University Giessen; Justus Liebig University Giessen	MUELLERECKHARDT, C (corresponding author), UNIV GIESSEN,INST CLIN IMMUNOL & TRANSFUS MED,LANGHANSSTR 7,W-6300 GIESSEN,GERMANY.							BELL CA, 1973, AM J CLIN PATHOL, V60, P903; BRUNSON ME, 1990, TRANSFUSION, V30, P651, DOI 10.1046/j.1537-2995.1990.30790385527.x; CROOKSTON JH, 1975, ARCH INTERN MED, V135, P1314, DOI 10.1001/archinte.135.10.1314; HABIBI B, 1974, AM J MED, V56, P61, DOI 10.1016/0002-9343(74)90751-7; ISSITT P, 1985, APPLIED BLOOD GROUP; LEDDY JP, 1970, J IMMUNOL, V105, P677; NESS PM, 1990, TRANSFUSION, V30, P688, DOI 10.1046/j.1537-2995.1990.30891020325.x; Petz LD, 1980, ACQUIRED IMMUNE HEMO; PIROFSKY B, 1975, CLIN HAEMATOL, V4, P167; ROSENFIELD RE, 1976, SEMIN HEMATOL, V13, P311; SALAMA A, 1987, BRIT J HAEMATOL, V65, P67, DOI 10.1111/j.1365-2141.1987.tb06137.x; SALAMA A, 1984, TRANSFUSION, V24, P188, DOI 10.1046/j.1537-2995.1984.24384225018.x; WALLHERMFECHTEL MA, 1984, TRANSFUSION, V24, P482, DOI 10.1046/j.1537-2995.1984.24685066805.x	13	53	56	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 19	1992	340	8834-5					1515	1517		10.1016/0140-6736(92)92766-9	http://dx.doi.org/10.1016/0140-6736(92)92766-9			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KD069	1361607				2023-01-03	WOS:A1992KD06900015
J	GREEN, S				GREEN, S			A CRITIQUE OF THE RATIONALE FOR CANCER-TREATMENT WITH COFFEE ENEMAS AND DIET	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							GLUTATHIONE S-TRANSFERASE; IDENTIFICATION; CAFESTOL; KAHWEOL				GREEN, S (corresponding author), ZOL CONSULTANTS INC, NEW YORK, NY USA.				NATIONAL CANCER INSTITUTE [R44CA041953] Funding Source: NIH RePORTER; NCI NIH HHS [2R44CA41953-02] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AGGARWAL BB, 1987, CIBA F SYMP, V131, P39; AISENBERG A, 1961, GLYCOLYSIS RESPIRATI, P150; ARIUS IM, 1982, LIVER BIOL PATHOBIOL, P429; BASERGA R, 1985, BIOL CELL REPRODUCTI, P179; BAUER KH, CITED DIRECTLY; BERK JE, 1985, BOCKUS GASTROENTEROL, V1, P1505; BRYSON PD, 1989, COMPREHENSIVE REV TO, P374; CAREY FA, 1987, ORGANIC CHEM, P1074; CASSILETH BR, 1984, ANN INTERN MED, V101, P105, DOI 10.7326/0003-4819-101-1-105; Chasseaud L F, 1979, Adv Cancer Res, V29, P175, DOI 10.1016/S0065-230X(08)60848-9; Coley W.B, 1893, AM J MED SCI, V105, P487, DOI [DOI 10.1097/00000441-189305000-00001, 10.1097/00000441-189305000-00001]; Dixon M., 1964, ENZYMES, V2d; EISELE JW, 1980, JAMA-J AM MED ASSOC, V244, P1608, DOI 10.1001/jama.244.14.1608; GERSON M, 1978, PHYSIOL CHEM PHYS M, V10, P449; GERSON M, 1977, CANCER THERAPY RESUL, P41; GERSON M, 1977, CANCER THERAPY RESUL; GERSON M, 1977, CANCER THERAPY RESUL, P21; GINSBERG MM, 1981, MMWR-MORBID MORTAL W, V30, P294; HERBERT V, 1991, MOUNT SINAI SCH MED; HESSE CC, 1982, GERSON PRIMER; HILDENBRAND G, 1986, HEALING NEWSLETT MAY, P1; HILDENBRAND G, 1990, HEALING NEWSLETT, V6, P25; ISTRE GR, 1982, NEW ENGL J MED, V307, P339, DOI 10.1056/NEJM198208053070603; JOKLIK WK, 1984, ZINSSER MICROBIOLOGY, P367; Kabat E., 1961, EXPT IMMUNOCHEMISTRY; KLAASSEN CD, 1986, CASSARETT DOULLES TO, P50; KURTJONES EA, 1985, P NATL ACAD SCI USA, V82, P1204, DOI 10.1073/pnas.82.4.1204; LAM LKT, 1982, CANCER RES, V42, P1193; LAM LKT, 1987, J MED CHEM, V30, P1399, DOI 10.1021/jm00391a022; LECHNER P, 1984, JUN P AUSTR SOC SURG; LECHNER P, CITED INDIRECTLY; LEE MD, 1987, P NATL ACAD SCI USA, V84, P2590, DOI 10.1073/pnas.84.9.2590; LICHTENFELT H, CITED INDIRECTLY; LORAND A, CITED INDIRECTLY; MORAHAN PS, 1988, MACROPHAGES CANCER, P12; NAUTS HC, 1953, ACTA MED SCAND, V145, P276; PITOT HC, 1991, FASEB J, V5, P2280, DOI 10.1096/fasebj.5.9.1860619; SHYROCK RH, 1980, DEV MODERN MED; SOLOMON E, 1991, SCIENCE, V254, P1153, DOI 10.1126/science.1957167; STERNSON LA, 1987, ANN NY ACAD SCI, V507, P19, DOI 10.1111/j.1749-6632.1987.tb45788.x; TRACEY KJ, 1990, ANN NY ACAD SCI, V587, P325, DOI 10.1111/j.1749-6632.1990.tb00173.x; VONBERGMANN G, CITED INDIRECTLY; WARREN RS, 1987, ARCH SURG-CHICAGO, V122, P1396; 1990, CA-CANCER J CLIN, V40, P252; [No title captured]; 1990, OTAH405 OFF TECHN AS	46	21	22	0	11	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 9	1992	268	22					3224	3227		10.1001/jama.268.22.3224	http://dx.doi.org/10.1001/jama.268.22.3224			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KA654	1433763				2023-01-03	WOS:A1992KA65400029
J	COCHRANE, RA; MANDAL, AR; LEDGERSCOTT, M; WALKER, R				COCHRANE, RA; MANDAL, AR; LEDGERSCOTT, M; WALKER, R			CHANGES IN DRUG-TREATMENT AFTER DISCHARGE FROM HOSPITAL IN GERIATRIC-PATIENTS	BRITISH MEDICAL JOURNAL			English	Article								Objectives-To ascertain changes in drug treatment of elderly patients after discharge from hospital and to identify areas of communication which may require improvement. Design-Follow up of patients six to 14 days after discharge, when the drugs supplied by the hospital should have run out and a further supply obtained from the general practitioner. Patients were also asked about information supplied to them by health care professionals during their hospital stay. Subjects - 50 elderly patients discharged from five geriatric wards (mean age 76.9 years). Setting- Sunderland District Health Authority. Main outcome measure-Drugs taken after discharge from hospital. Results-After returning home the drug regimen of 45 patients differed from that prescribed on discharge from hospital, with 11 patients taking a different dose, 10 having stopped drugs, and 20 taking new drugs. Possible influencing factors included an incomplete drug history, the continuation of drugs taken before hospital admission, and changes in the prescription not attributable to a conscious clinical decision. Lack of information also contributed; 46 patients could not recall being told when to take drugs before discharge. Conclusion-Closer communication is needed between hospital and community health care professionals to ensure that patients are informed about their discharge prescription and continuation of treatment.	SUNDERLAND DIST GEN HOSP,SUNDERLAND SR4 7TP,ENGLAND; ROYAL INFIRM,SUNDERLAND SR2 7JE,ENGLAND; SUNDERLAND POLYTECH,SCH PHARMACEUT & CHEM SCI,SUNDERLAND SR2 7EE,DURHAM,ENGLAND	Sunderland Royal Hospital; University of Sunderland								Davidson J R, 1974, Nurs Times, V70, P391; Hatch A M, 1982, Nurs Times, V78, P1773; MACDONALD ET, 1977, BMJ-BRIT MED J, V2, P618, DOI 10.1136/bmj.2.6087.618; MOTTRAM DR, 1989, PHARM J, V243, P458; PARKIN DM, 1976, BMJ-BRIT MED J, V2, P686, DOI 10.1136/bmj.2.6037.686; Sweeney SJ, 1989, PHARM J, V242; WALKER CA, 1987, BRIT J PHARM PRACTIC, V9, P47; WINFIELD AJ, 1990, BR J PHARM PRACT, V12, P206	8	86	89	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 19	1992	305	6855					694	696		10.1136/bmj.305.6855.694	http://dx.doi.org/10.1136/bmj.305.6855.694			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JP511	1393119	Bronze, Green Submitted, Green Published			2023-01-03	WOS:A1992JP51100028
J	GATENBY, R; LYONS, K; STEWART, T; TAYLOR, J; SCOTT, J; PAYNE, G; REID, J; GLASS, D; CARROLL, D; MCLEAN, A; MENNIE, G; MAIR, F; BARCLAY, D; MCCRONE, M; MORTON, K; KENNEDY, N; ANDERSON, J; INNES, D; SCOTT, D; GUTHRIE, C; DAWSON, H; KINNON, J; MURRAY, B; FRASER, K; MORRISON, W; BURGESS, C; DONALDSON, A; PUCCI, M; SIMPSON, I; MCKERCHER, D; MACKAY, I; BELL, R; BICHAN, R; GORDON, G; HAYWORTH, A; MASSIE, R; WISLEY, A; TOSH, V; STEELE, W; WILSON, E; LOGAN, R; NICOL, H; MCLEAN, I; TAYLOR, A; ROBERTSON, S; WALLACE, R; CONNELL, D; RAE, J; FERGUSON, G; SANDEMAN, J; COSGROVE, E; SHIRREFFS, G; EASTON, D; SINCLAIR, A; CARTER, G; KAY, M; MACKIE, H; MORRICE, G; JOHNSTON, V; FISKEN, A; BEATTIE, J; BLACK, J; MACDONALD, J; GILL, G; CRUICKSHANK, I; HOOD, D; HARKNESS, S; SMYLIE, D; MORRISON, M; HARRINGTON, J; HERD, G; HUTCHISON, R; THOMASON, J; HAWSON, D; YOUNG, G; GREEN, P; MACK, N; BROOKER, I; BARBOUR, A; MILLER, J; GAULD, A; GOODBRAND, T; MCINNES, R; NICOL, D; ROBERTSON, A; MCLEMAN, D; CROCKETT, S; TAYLOR, I; MORGAN, A; MCINTOSH, G; STEWART, A; HERD, J; SMITH, J; MACCUISH, A; DELAAT, A; SNEDDON, A; CROWLEY, D; DUTHIE, A; FRASER, R; SMITH, A; LIDDELL, R; BEVAN, J; BEWSHER, P; BRUNT, P; BENJAMIN, N; CATTO, G; EDWARD, N; HIMSWORTH, R; JEFFERS, A; JENNINGS, K; JOHNSTON, A; KENMURE, A; MCLEOD, A; MOWAT, A; MURCHISON, L; PEARSON, D; PETRIE, J; POWER, D; RAWLES, J; SINCLAIR, T; SMITH, C; WALTON, S; WEBSTER, J; WILLIAMS, M; LIGHT, J; WATT, M; MCKNIGHT, J; SIMPSON, M; CREE, F; WELLWOOD, M				GATENBY, R; LYONS, K; STEWART, T; TAYLOR, J; SCOTT, J; PAYNE, G; REID, J; GLASS, D; CARROLL, D; MCLEAN, A; MENNIE, G; MAIR, F; BARCLAY, D; MCCRONE, M; MORTON, K; KENNEDY, N; ANDERSON, J; INNES, D; SCOTT, D; GUTHRIE, C; DAWSON, H; KINNON, J; MURRAY, B; FRASER, K; MORRISON, W; BURGESS, C; DONALDSON, A; PUCCI, M; SIMPSON, I; MCKERCHER, D; MACKAY, I; BELL, R; BICHAN, R; GORDON, G; HAYWORTH, A; MASSIE, R; WISLEY, A; TOSH, V; STEELE, W; WILSON, E; LOGAN, R; NICOL, H; MCLEAN, I; TAYLOR, A; ROBERTSON, S; WALLACE, R; CONNELL, D; RAE, J; FERGUSON, G; SANDEMAN, J; COSGROVE, E; SHIRREFFS, G; EASTON, D; SINCLAIR, A; CARTER, G; KAY, M; MACKIE, H; MORRICE, G; JOHNSTON, V; FISKEN, A; BEATTIE, J; BLACK, J; MACDONALD, J; GILL, G; CRUICKSHANK, I; HOOD, D; HARKNESS, S; SMYLIE, D; MORRISON, M; HARRINGTON, J; HERD, G; HUTCHISON, R; THOMASON, J; HAWSON, D; YOUNG, G; GREEN, P; MACK, N; BROOKER, I; BARBOUR, A; MILLER, J; GAULD, A; GOODBRAND, T; MCINNES, R; NICOL, D; ROBERTSON, A; MCLEMAN, D; CROCKETT, S; TAYLOR, I; MORGAN, A; MCINTOSH, G; STEWART, A; HERD, J; SMITH, J; MACCUISH, A; DELAAT, A; SNEDDON, A; CROWLEY, D; DUTHIE, A; FRASER, R; SMITH, A; LIDDELL, R; BEVAN, J; BEWSHER, P; BRUNT, P; BENJAMIN, N; CATTO, G; EDWARD, N; HIMSWORTH, R; JEFFERS, A; JENNINGS, K; JOHNSTON, A; KENMURE, A; MCLEOD, A; MOWAT, A; MURCHISON, L; PEARSON, D; PETRIE, J; POWER, D; RAWLES, J; SINCLAIR, T; SMITH, C; WALTON, S; WEBSTER, J; WILLIAMS, M; LIGHT, J; WATT, M; MCKNIGHT, J; SIMPSON, M; CREE, F; WELLWOOD, M			FEASIBILITY, SAFETY, AND EFFICACY OF DOMICILIARY THROMBOLYSIS BY GENERAL-PRACTITIONERS - GRAMPIAN REGION EARLY ANISTREPLASE TRIAL	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ACUTE MYOCARDIAL-INFARCTION; MOBILE CORONARY-CARE; CARDIAC-ARREST; MORTALITY; REDUCTION; UNIT	Objective-To assess the feasibility, safety, and efficacy of domiciliary thrombolysis by general practitioners. Design-Randomised double blind parallel group trial of anistreplase 30 units intravenously and placebo given either at home or in hospital. Setting-29 rural practices in Grampian admitting patients to teaching hospitals in Aberdeen (average distance 36 (range 16-62) miles). Patients-311 patients with suspected acute myocardial infarction and no contraindications to thrombolytic therapy seen at home within four hours of onset of symptoms. Main outcome measures-Time saving, adverse events, Q wave infarction, left ventricular function. Results-Anistreplase was administered at home 101 minutes after onset of symptoms, while anistreplase was given in hospital 240 minutes after onset of symptoms (median times). Adverse events after thrombolysis were infrequent and, apart from cardiac arrest, not a serious problem when they occurred in the community: seven of 13 patients were resuscitated after cardiac arrest out of hospital. By three months after trial entry the relative reduction of deaths from all causes in patients given thrombolytic therapy at home was 49% (13/163 (8.0%) v 23/148 (15.5%); difference -7.6% (95% confidence interval -14.7% to -0.4%), p=0.04). Full thickness Q wave infarction was less common in patients with confirmed infarction receiving treatment at home (65/122 (53.3%) v 76/112 (67.9%); difference -14.6% (95% confidence interval -27.0% to -2.2%), p=0.02). Conclusions-General practitioners provided rapid pre-hospital coronary care of a high standard. Compared with later administration in hospital, giving anistreplase at home resulted in reduction in mortality, fewer cardiac arrests, fewer Q wave infarcts, and better left ventricular function. Benefits were most marked where thrombolytic therapy was administered within two hours of the onset of symptoms.	UNIV ABERDEEN, MED ASSESSMENT RES UNIT, FORESTERHILL, ABERDEEN AB9 2ZD, SCOTLAND	University of Aberdeen								[Anonymous], 1988, LANCET, V2, P349; [Anonymous], 1986, LANCET, V1, P397; BAUGHMAN KL, 1981, CIRCULATION, V63, P317, DOI 10.1161/01.CIR.63.2.317; BERGMANN SR, 1982, AM J MED, V73, P573, DOI 10.1016/0002-9343(82)90338-2; CHAMBERLAIN DA, 1988, LANCET, V1, P545; COBBE SM, 1991, BRIT MED J, V302, P1517, DOI 10.1136/bmj.302.6791.1517; COLQUHOUN MC, 1992, LANCET, V339, P1167, DOI 10.1016/0140-6736(92)90765-U; CRAMPTON RS, 1975, AM J MED, V58, P151, DOI 10.1016/0002-9343(75)90564-1; DICKINSON RJ, 1991, BRIT MED J, V302, P111; HAITES NE, 1985, BRIT HEART J, V53, P123; LEIZOROVICZ A, 1988, EUR HEART J, V9, P118; MACLENNAN AC, 1989, BMJ-BRIT MED J, V301, P321; MATHEWSON ZM, 1985, LANCET, V1, P441; METCALFE MJ, 1990, BRIT HEART J, V63, P267; METCALFE MJ, 1989, LANCET, V1, P1371; PAI GR, 1987, BRIT MED J, V294, P352, DOI 10.1136/bmj.294.6568.352; PANTRIDG.JF, 1967, LANCET, V2, P271; PANTRIDGE J F, 1970, QJM, V39, P621; PETCH MC, 1991, BMJ-BRIT MED J, V302, P1287, DOI 10.1136/bmj.302.6788.1287; RAWLES JM, 1988, BRIT MED J, V296, P882, DOI 10.1136/bmj.296.6626.882; RAWLES JM, 1987, BRIT MED J, V295, P639, DOI 10.1136/bmj.295.6599.639; ROWLEY JM, 1992, BRIT HEART J, V67, P255; SHAH M, 1990, BRIT MED J, V301, P1219, DOI 10.1136/bmj.301.6762.1219-a; WENNERBLOM B, 1982, EUR HEART J, V3, P504, DOI 10.1093/oxfordjournals.eurheartj.a061345; WILCOX RG, 1988, LANCET, V2, P525	25	235	237	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 5	1992	305	6853					548	553						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JM495	1393033				2023-01-03	WOS:A1992JM49500015
J	ELSNER, RH; ZIEGLER, K				ELSNER, RH; ZIEGLER, K			RADIATION INACTIVATION OF MULTISPECIFIC TRANSPORT-SYSTEMS FOR BILE-ACIDS AND XENOBIOTICS IN BASOLATERAL RAT-LIVER PLASMA-MEMBRANE VESICLES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ISOLATED HEPATOCYTES; CHOLIC-ACID; COMPETITIVE-INHIBITION; TAUROCHOLATE UPTAKE; NAK-ATPASE; BINDING; PHALLOIDIN; CHOLATE; PROTEINS; COTRANSPORTER	The functional molecular mass of the cholate, phallotoxin, iodipamide, and ouabain transport proteins in isolated basolateral plasma membrane vesicles was determined by radiation inactivation. Purified basolateral plasma membrane vesicles were irradiated (- 90 to - 120-degrees-C) with high energy electrons from a 10-MeV linear accelerator at doses from 0 to 30 megarads. After each dose, the initial uptake, the equilibrium binding, and the binding of the substrates at 4-degrees-C were checked. The size of the transporting function was, for cholate, 107 +/- 8.9 kDa; for phallotoxin, 104 +/- 7 kDa; and for ouabain, 120 +/- 4.7 kDa. The target size for the binding proteins was 56 +/- 4.2, 57 +/- 5, and 47.2 +/- 1.95 kDa for cholate, phallotoxin, and taurocholate, respectively. In the case of iodipamide, the functional molecular mass for both the transport and binding proteins was 54 +/- 4.8 kDa.	UNIV GIESSEN,INST PHARMACOL & TOXIKOL,FRANKFURTER STR 107,W-6300 GIESSEN,GERMANY	Justus Liebig University Giessen								AMES BN, 1960, J BIOL CHEM, V235, P769; ANANTHANARAYANAN M, 1988, J BIOL CHEM, V263, P8338; ANWER MS, 1977, H-S Z PHYSIOL CHEM, V358, P543, DOI 10.1515/bchm2.1977.358.1.543; ANWER MS, 1976, H-S Z PHYSIOL CHEM, V357, P1477, DOI 10.1515/bchm2.1976.357.2.1477; BELIVEAU R, 1988, BIOCHEM J, V252, P807, DOI 10.1042/bj2520807; BLITZER BL, 1985, AM J PHYSIOL, V249, pG120, DOI 10.1152/ajpgi.1985.249.1.G120; BLITZER BL, 1986, J BIOL CHEM, V261, P2042; BLITZER BL, 1984, J BIOL CHEM, V259, P9295; CAFLISCH C, 1990, BIOCHIM BIOPHYS ACTA, V1021, P70, DOI 10.1016/0005-2736(90)90386-3; DUFFY MC, 1983, J CLIN INVEST, V72, P1470, DOI 10.1172/JCI111103; ELSNER R, 1989, BIOCHIM BIOPHYS ACTA, V983, P113, DOI 10.1016/0005-2736(89)90387-8; ELSNER RH, 1989, N-S ARCH PHARMACOL, V340, pR69; Fricke H, 1927, AM J ROENTGENOL RADI, V18, P426; FRIMMER M, 1980, N-S ARCH PHARMACOL, V313, P85, DOI 10.1007/BF00505808; FRIMMER M, 1988, BIOCHIM BIOPHYS ACTA, V947, P75, DOI 10.1016/0304-4157(88)90020-2; HAGENBUCH B, 1990, J BIOL CHEM, V265, P5357; HARPER AE, 1962, METHODEN ENZYMATISCH, P788; INOUE M, 1982, HEPATOLOGY, V2, P572; JUNG CY, 1984, MOL CHEM CHARACTERIZ, P193; KEEFFE EB, 1979, J CLIN INVEST, V64, P1590, DOI 10.1172/JCI109620; KEMPNER ES, 1982, J BIOL CHEM, V257, P13297; KEPNER GR, 1968, BIOCHIM BIOPHYS ACTA, V163, P188, DOI 10.1016/0005-2736(68)90097-7; KRAMER W, 1982, EUR J BIOCHEM, V129, P13, DOI 10.1111/j.1432-1033.1982.tb07015.x; LUTZ F, 1972, N-S ARCH PHARMACOL, V273, P341, DOI 10.1007/BF00499668; MICHELL RH, 1965, BIOCHEM BIOPH RES CO, V21, P333, DOI 10.1016/0006-291X(65)90198-1; PETZINGER E, 1983, N-S ARCH PHARMACOL, V322, P174, DOI 10.1007/BF00512393; PETZINGER E, 1981, N-S ARCH PHARMACOL, V316, P345, DOI 10.1007/BF00501368; PETZINGER E, 1985, BIOCHIM BIOPHYS ACTA, V815, P334, DOI 10.1016/0005-2736(85)90359-1; PETZINGER E, 1986, CARDIAC GLYCOSIDES 1, P297; SCHARSCHMIDT BF, 1979, J LAB CLIN MED, V93, P790; SCHWENK M, 1981, N-S ARCH PHARMACOL, V316, P340, DOI 10.1007/BF00501367; STEVENS BR, 1990, P NATL ACAD SCI USA, V87, P1456, DOI 10.1073/pnas.87.4.1456; TAFLER M, 1986, BIOCHIM BIOPHYS ACTA, V855, P157, DOI 10.1016/0005-2736(86)90200-2; TAFLER M, 1988, N-S ARCH PHARMACOL, V337, P231; VONDIPPE P, 1983, J BIOL CHEM, V258, P8896; WIELAND T, 1984, P NATL ACAD SCI-BIOL, V81, P5232, DOI 10.1073/pnas.81.16.5232; ZIEGLER K, 1982, N-S ARCH PHARMACOL, V319, P254, DOI 10.1007/BF00495875; ZIEGLER K, 1984, BIOCHIM BIOPHYS ACTA, V773, P11, DOI 10.1016/0005-2736(84)90545-5; ZIEGLER K, 1988, BIOCHIM BIOPHYS ACTA, V945, P263, DOI 10.1016/0005-2736(88)90488-9; ZIEGLER K, 1989, BIOCHIM BIOPHYS ACTA, V980, P161, DOI 10.1016/0005-2736(89)90395-7; ZIEGLER K, 1985, BIOCHIM BIOPHYS ACTA, V845, P86, DOI 10.1016/0167-4889(85)90058-8; ZIMMERLI B, 1989, J PHARMACOL EXP THER, V250, P301	42	14	14	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1992	267	14					9788	9793						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HT965	1577813				2023-01-03	WOS:A1992HT96500055
J	ORENTLICHER, D				ORENTLICHER, D			THE ILLUSION OF PATIENT CHOICE IN END-OF-LIFE DECISIONS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							CRITICALLY ILL; RESUSCITATION; INFORMATION; PREFERENCES; PHYSICIANS; DOCTORS				ORENTLICHER, D (corresponding author), AMER MED ASSOC,ETH & HLTH POLICY COUNSEL,CHICAGO,IL 60610, USA.							BEDELL SE, 1986, JAMA-J AM MED ASSOC, V256, P233, DOI 10.1001/jama.256.2.233; CALLAHAN D, 1983, HASTINGS CENT REP, V20, P22; DANIS M, 1991, NEW ENGL J MED, V324, P882, DOI 10.1056/NEJM199103283241304; DAVIDSON KW, 1989, JAMA-J AM MED ASSOC, V262, P2415, DOI 10.1001/jama.262.17.2415; EMANUEL LL, 1991, NEW ENGL J MED, V324, P889, DOI 10.1056/NEJM199103283241305; ENDE J, 1989, J GEN INTERN MED, V4, P23, DOI 10.1007/BF02596485; EVANS AL, 1985, JAMA-J AM MED ASSOC, V253, P2236, DOI 10.1001/jama.253.15.2236; GOYERT GL, 1989, NEW ENGL J MED, V320, P706, DOI 10.1056/NEJM198903163201106; HELD PJ, 1988, ARCH INTERN MED, V148, P2594, DOI 10.1001/archinte.148.12.2594; KATZ J, 1984, SILENT WORLD DOCTOR, P48; KODISH E, 1991, NEW ENGL J MED, V325, P1349, DOI 10.1056/NEJM199111073251905; LAPUMA J, 1991, JAMA-J AM MED ASSOC, V266, P402, DOI 10.1001/jama.266.3.402; LEVY DR, 1985, PEDIATRICS, V75, P639; LOCALIO AR, 1991, NEW ENGL J MED, V325, P245, DOI 10.1056/NEJM199107253250405; LOUISELL DW, 1989, MED MALPRACTICE; MALLOY TR, 1991, AM GERIATRIC SOC AM; MARTEAU TM, 1989, BRIT J SOC PSYCHOL, V28, P89, DOI 10.1111/j.2044-8309.1989.tb00849.x; MCNEIL BJ, 1978, NEW ENGL J MED, V299, P1397, DOI 10.1056/NEJM197812212992506; MILES SH, 1991, NEW ENGL J MED, V325, P512, DOI 10.1056/NEJM199108153250713; SECKLER AB, 1991, ANN INTERN MED, V115, P92, DOI 10.7326/0003-4819-115-2-92; SEHGAL A, 1992, JAMA-J AM MED ASSOC, V267, P59, DOI 10.1001/jama.267.1.59; SMEDIRA NG, 1990, NEW ENGL J MED, V322, P309, DOI 10.1056/NEJM199002013220506; TOMLINSON T, 1990, JAMA-J AM MED ASSOC, V264, P1276, DOI 10.1001/jama.264.10.1276; UHLMANN RF, 1988, J GERONTOL, V43, pM115, DOI 10.1093/geronj/43.5.M115; WACHTER RM, 1989, ANN INTERN MED, V111, P525, DOI 10.7326/0003-4819-111-6-525; WAITZKIN H, 1984, JAMA-J AM MED ASSOC, V252, P2441, DOI 10.1001/jama.252.17.2441; WALLACE LM, 1986, SOC SCI MED, V22, P29, DOI 10.1016/0277-9536(86)90305-9; WENNEKER MB, 1989, JAMA-J AM MED ASSOC, V261, P253, DOI 10.1001/jama.261.2.253; YOUNGNER SJ, 1983, ANN INTERN MED, V99, P252, DOI 10.7326/0003-4819-99-2-252; 1987, GUIDELINES TERMINATI, P26; 1982, MAKING HLTH CARE DEC, P1; 1990, JAMA-J AM MED ASSOC, V263, P2344; 1983, DECIDING FOREGO LIFE, P43; 1991, JAMA-J AM MED ASSOC, V265, P1868; 1992, CURRENT OPINIONS 199	35	81	81	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 15	1992	267	15					2101	2104		10.1001/jama.267.15.2101	http://dx.doi.org/10.1001/jama.267.15.2101			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HM650	1552646				2023-01-03	WOS:A1992HM65000038
J	DUFFY, TP				DUFFY, TP			WHEN TO LET GO	NEW ENGLAND JOURNAL OF MEDICINE			English	Article											DUFFY, TP (corresponding author), YALE UNIV,SCH MED,DEPT INTERNAL MED,HEMATOL SECT,WWW4,POB 3333,NEW HAVEN,CT 06510, USA.							ANNAS GJ, 1991, NEW ENGL J MED, V324, P1210, DOI 10.1056/NEJM199104253241711; Katz J., 1984, SILENT WORLD DOCTOR; WOLF SM, 1991, NEW ENGL J MED, V325, P1666, DOI 10.1056/NEJM199112053252334	3	6	6	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 2	1992	326	14					933	935		10.1056/NEJM199204023261406	http://dx.doi.org/10.1056/NEJM199204023261406			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HL261	1542343				2023-01-03	WOS:A1992HL26100006
J	MCADAMS, AL				MCADAMS, AL			A RIGHT-TO-DIE	BRITISH MEDICAL JOURNAL			English	Article																			0	2	2	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 21	1992	304	6829					765	766		10.1136/bmj.304.6829.765	http://dx.doi.org/10.1136/bmj.304.6829.765			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HK800	1571685	Bronze, Green Published			2023-01-03	WOS:A1992HK80000027
J	KJELDSENKRAGH, J; HAUGEN, M; FFORRE, O				KJELDSENKRAGH, J; HAUGEN, M; FFORRE, O			DIET THERAPY IN RHEUMATOID-ARTHRITIS	LANCET			English	Letter									OSLO SANITETSFORENING REUMATISM HOSP,OSLO,NORWAY		KJELDSENKRAGH, J (corresponding author), NATL HOSP,INST IMMUNOL & RHEUMATOL,N-0172 OSLO,NORWAY.		Kjeldsen-Kragh, Jens/A-4472-2008; Haugen, Margaretha/H-7007-2016	Haugen, Margaretha/0000-0001-5924-5000				OFARRELLY, 1992, LANCET, V339, P68	1	4	4	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 25	1992	339	8787					250	250		10.1016/0140-6736(92)90059-C	http://dx.doi.org/10.1016/0140-6736(92)90059-C			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HA589	1346210				2023-01-03	WOS:A1992HA58900051
J	MISBIN, RI				MISBIN, RI			PHYSICIANS AID IN DYING	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							ASSISTED SUICIDE; EUTHANASIA				MISBIN, RI (corresponding author), UNIV FLORIDA, GAINESVILLE, FL 32610 USA.							ALTMAN LK, 1991, NY TIMES        0724, pA10; ANGELL M, 1988, NEW ENGL J MED, V319, P1348, DOI 10.1056/NEJM198811173192010; ANNAS GJ, 1990, NEW ENGL J MED, V323, P686, DOI 10.1056/NEJM199009063231020; BEAUCHAMP TL, 1989, PRINCIPLES BIOMEDICA, P151; BEAUCHAMP TL, PRINCIPLES BIOMEDICA, V127, P89; CALLAHAN D, 1990, WHAT KIND LIFE LIMIT, P233; CASSEL CK, 1990, NEW ENGL J MED, V323, P750, DOI 10.1056/NEJM199009133231110; DEWACHTER MAM, 1989, JAMA-J AM MED ASSOC, V262, P3316, DOI 10.1001/jama.262.23.3316; Doerflinger R, 1989, Hastings Cent Rep, V19, P16, DOI 10.2307/3561965; GAYLIN W, 1988, JAMA-J AM MED ASSOC, V259, P2139; GIANELLI DM, 1991, WASHINGTON STATE PHY, P1; GIANELLI DM, 1991, AM MED NEWS     0107, P9; HECHINGER FM, 1991, NY TIMES        0124, pA22; HORAN DJ, 1980, DEATH DYING EUTHANAS, P127; JAKOBOVITS I, 1961, Harofe Haivri Heb Med J, V2, P242; ORENTLICHER D, 1989, JAMA-J AM MED ASSOC, V262, P1844, DOI 10.1001/jama.262.13.1844; QUILL TE, 1991, NEW ENGL J MED, V324, P691, DOI 10.1056/NEJM199103073241010; ROSNER F, 1986, MODERN MED JEWISH ET, P189; SINGER PA, 1990, NEW ENGL J MED, V322, P1881, DOI 10.1056/NEJM199006283222610; THOMASMA DC, 1990, EUTHANASIA ETHICAL S; WANZER SH, 1989, NEW ENGL J MED, V320, P844, DOI 10.1056/NEJM198903303201306; WEIR RF, 1989, ABATING TREATMENT CR; WERTHAM F, 1980, DEATH DYING EUTHANAS, P610; Wolf S M, 1989, Hastings Cent Rep, V19, P13, DOI 10.2307/3561964; 1988, JAMA-J AM MED ASSOC, V259, P272	25	37	37	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 31	1991	325	18					1307	1311		10.1056/NEJM199110313251811	http://dx.doi.org/10.1056/NEJM199110313251811			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GM041	1922229				2023-01-03	WOS:A1991GM04100011
J	WALSH, MT; SEN, AC; CHAKRABARTI, B				WALSH, MT; SEN, AC; CHAKRABARTI, B			MICELLAR SUBUNIT ASSEMBLY IN A 3-LAYER MODEL OF OLIGOMERIC ALPHA-CRYSTALLIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE LENS CRYSTALLINS; STATISTICAL MECHANICAL DECONVOLUTION; HEAT-SHOCK PROTEINS; CIRCULAR-DICHROISM; MOLECULAR-WEIGHT; THERMAL TRANSITIONS; SPECTROSCOPIC INVESTIGATIONS; EXCIMER FLUORESCENCE; QUATERNARY STRUCTURE; SULFHYDRYL-GROUP	Differential scanning calorimetry was performed to monitor the heat-induced changes that occur in the structural domain of lens alpha-crystallin. Circular dichroism and fluorescence also were used to resolve the controversial issue of the quaternary structure of alpha-crystallin. Based on the thermal behavior as monitored by these techniques, a model is proposed that can account for all previous data as well as the currently reported thermal data. The proposed model of native alpha-crystallin has a three-layer structure in which the inner layer (core) is a micelle containing 12 subunits arranged in cuboctahedral symmetry. The apolar region is directed inward constituting a hydrophobic core similar to a micelle and adding structural stability. A second layer of six subunits has a similar but not identical structure to the first layer, directing its apolar face toward the hydrophobic core. Thus, these two layers constitute a micelle-like structure with octahedral symmetry. The third layer adds more subunits for a total of not more than 24. Differential scanning calorimetry, circular dichroism, and fluorescence studies indicated that the inner two-layer structure of molecular mass 360 kDa is highly stable and is most likely of the alpha-m form. The three-layer structure of the native protein, however, is rather unstable. At 35-45-degrees-C the outer layer dissociates from the inner two layers, and at higher temperatures rapidly reassociates to a slightly modified two-layer structure with a stability similar to that of alpha-m. The proposed model does not require any specific assembly of the alpha-A and alpha-B subunits in each layer, but the fluorescence results suggest that the native inner two layers probably contain mostly alpha-A.	HARVARD UNIV,SCH MED,EYE RES INST,20 STANIFORD ST,BOSTON,MA 02114; HARVARD UNIV,SCH MED,DEPT OPHTHALMOL,BOSTON,MA 02114; BOSTON UNIV,SCH MED,DEPT BIOPHYS,BOSTON,MA 02118	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Boston University					NEI NIH HHS [EY04161] Funding Source: Medline; NHLBI NIH HHS [HL26335] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY004161] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL026335] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDLEY UP, 1982, BIOCHEMISTRY-US, V21, P1853, DOI 10.1021/bi00537a023; AUGUSTEYN RC, 1987, FEBS LETT, V222, P1, DOI 10.1016/0014-5793(87)80180-1; BETTELHEIM F A, 1982, Current Eye Research, V2, P803, DOI 10.3109/02713688209020015; BETTELHEIM FA, 1990, EXP EYE RES, V50, P715, DOI 10.1016/0014-4835(90)90119-F; BHAT S P, 1990, Investigative Ophthalmology and Visual Science, V31, P52; BINDELS JG, 1979, OPHTHALMIC RES, V11, P441, DOI 10.1159/000265048; COOPMAN S, 1984, EXP EYE RES, V38, P463, DOI 10.1016/0014-4835(84)90124-6; De Jong W.W., 1981, MOL CELLULAR BIOL EY, P221, DOI DOI 10.1146/ANNUREV.ECOLSYS.33.020602.095451; DEJONG WW, 1984, EUR J BIOCHEM, V141, P131; FREIRE E, 1978, BIOPOLYMERS, V17, P481, DOI 10.1002/bip.1978.360170213; FREIRE E, 1978, BIOPOLYMERS, V17, P497, DOI 10.1002/bip.1978.360170214; FREIRE E, 1978, BIOPOLYMERS, V17, P463, DOI 10.1002/bip.1978.360170212; FUKUDA H, 1983, J BIOL CHEM, V258, P13193; GRACEFFA P, 1980, J BIOL CHEM, V255, P1296; HARDING JJ, 1976, EXP EYE RES, V22, P1, DOI 10.1016/0014-4835(76)90033-6; HELENIUS A, 1975, BIOCHIM BIOPHYS ACTA, V415, P29, DOI 10.1016/0304-4157(75)90016-7; HOENDERS HJ, 1981, MOL CELLULAR BIOL EY, P279; HORWITZ J, 1976, EXP EYE RES, V23, P471, DOI 10.1016/0014-4835(76)90156-1; INGOLIA TD, 1982, P NATL ACAD SCI-BIOL, V79, P2360, DOI 10.1073/pnas.79.7.2360; KONO M, 1988, PHOTOCHEM PHOTOBIOL, V47, P593, DOI 10.1111/j.1751-1097.1988.tb08849.x; KONO M, 1990, BIOCHEMISTRY-US, V29, P464, DOI 10.1021/bi00454a022; KRESHECK GC, 1988, BIOCHEMISTRY-US, V27, P2490, DOI 10.1021/bi00407a035; Krishinan K S, 1978, Methods Enzymol, V49, P3; LAWSON EQ, 1981, J BIOL CHEM, V256, P6523; LERMAN S, 1976, DOC OPHTHALMOL, V8, P241; LI LK, 1974, EXP EYE RES, V18, P383, DOI 10.1016/0014-4835(74)90116-X; LI LK, 1974, EXP EYE RES, V19, P49, DOI 10.1016/0014-4835(74)90071-2; LIANG JN, 1982, BIOCHEMISTRY-US, V21, P1847, DOI 10.1021/bi00537a022; MAITI M, 1988, FEBS LETT, V236, P109, DOI 10.1016/0014-5793(88)80295-3; MESSMER M, 1988, EXP EYE RES, V47, P173, DOI 10.1016/0014-4835(88)90001-2; PRIVALOV PL, 1982, ADV PROTEIN CHEM, V35, P1, DOI 10.1016/S0065-3233(08)60468-4; RIGELL CW, 1985, BIOCHEMISTRY-US, V24, P5638, DOI 10.1021/bi00341a053; RUSSNAK RH, 1983, NUCLEIC ACIDS RES, V11, P3187, DOI 10.1093/nar/11.10.3187; SEN AC, 1990, EXP EYE RES, V51, P701, DOI 10.1016/0014-4835(90)90055-Y; SEN AC, 1990, J BIOL CHEM, V265, P14277; SIEZEN RJ, 1982, EXP EYE RES, V34, P969, DOI 10.1016/0014-4835(82)90077-X; SIEZEN RJ, 1978, BIOCHIM BIOPHYS ACTA, V537, P456, DOI 10.1016/0005-2795(78)90530-5; SIEZEN RJ, 1980, EUR J BIOCHEM, V111, P435, DOI 10.1111/j.1432-1033.1980.tb04958.x; SIEZEN RJ, 1983, BIOCHIM BIOPHYS ACTA, V748, P56, DOI 10.1016/0167-4838(83)90027-4; SPECTOR A, 1967, J BIOL CHEM, V242, P3594; STEADMAN BL, 1989, BIOCHEMISTRY-US, V28, P9653, DOI 10.1021/bi00451a017; STURTEVANT JM, 1974, ANNU REV BIOPHYS BIO, V3, P35, DOI 10.1146/annurev.bb.03.060174.000343; TARDIEU A, 1986, J MOL BIOL, V192, P711, DOI 10.1016/0022-2836(86)90023-9; THOMSON JA, 1989, BIOCHIM BIOPHYS ACTA, V994, P246, DOI 10.1016/0167-4838(89)90300-2; THOMSON JA, 1984, J BIOL CHEM, V259, P4339; THOMSON JA, 1983, EXP EYE RES, V37, P367, DOI 10.1016/0014-4835(83)90173-2; VANDENOETELAAR PJM, 1985, J BIOL CHEM, V260, P4030; WALSH M T, 1990, Investigative Ophthalmology and Visual Science, V31, P51; WALSH MT, 1990, J LIPID RES, V31, P1051; WISTOW G, 1987, SCIENCE, V236, P1554, DOI 10.1126/science.3589669; WISTOW G, 1985, FEBS LETT, V181, P1, DOI 10.1016/0014-5793(85)81102-9	51	127	129	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1991	266	30					20079	20084						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GM039	1939070				2023-01-03	WOS:A1991GM03900034
J	DELUZE, C; BOSIA, L; ZIRBS, A; CHANTRAINE, A; VISCHER, TL				DELUZE, C; BOSIA, L; ZIRBS, A; CHANTRAINE, A; VISCHER, TL			ELECTROACUPUNCTURE IN FIBROMYALGIA - RESULTS OF A CONTROLLED TRIAL	BRITISH MEDICAL JOURNAL			English	Article							ACUPUNCTURE ANALGESIA; CEREBROSPINAL-FLUID; PAIN PATIENTS; DOUBLE-BLIND; STIMULATION; RELIEF; REHABILITATION; FIBROSITIS; INHIBITION; RESPONSES	Objective-To determine the efficacy of electroacupuncture in patients with fibromyalgia, a syndrome of unknown origin causing diffuse musculoskeletal pain. Design-Three weeks' randomised study with blinded patients and evaluating physician. Setting-University divisions of physical medicine and rehabilitation and rheumatology, Geneva. Patients-70 patients (54 women) referred to the division for fibromyalgia as defined by the American College of Rheumatology. Interventions-Patients were randomised to electroacupuncture (n=36) or a sham procedure (n=34) by means of an electronic numbers generator. Main outcome measures-Pain threshold, number of analgesic tablets used, regional pain score, pain recorded on visual analogue scale, sleep quality, morning stiffness, and patient's and evaluating physician's appreciation. Results-Seven of the eight outcome parameters showed a significant improvement in the active treatment group whereas none were improved in the sham treatment group. Differences between the groups were significant for five of the eight outcome measures after treatment. Conclusions-Electroacupuncture is effective in relieving symptoms of fibromyalgia. Its potential in long term management should now be studied.	UNIV HOSP GENEVA,DIV RHEUMATOL,CH-1211 GENEVA 14,SWITZERLAND; UNIV HOSP GENEVA,DIV PHYS MED & REHABIL,CH-1211 GENEVA 14,SWITZERLAND	University of Geneva; University of Geneva								BENNETT RM, 1988, ARTHRITIS RHEUM, V31, P1535, DOI 10.1002/art.1780311210; BENNETT RM, 1989, TXB RHEUMATOLOGY, P541; BING Z, 1991, PAIN, V47, P71, DOI 10.1016/0304-3959(91)90013-N; BUCKELEW SP, 1989, AM J PHYS MED REHAB, V68, P37, DOI 10.1097/00002060-198902000-00010; CARETTE S, 1986, ARTHRITIS RHEUM-US, V29, P655, DOI 10.1002/art.1780290510; CHENG RSS, 1989, SCI BASES ACUPUNCTUR, P119; CLEMENTJONES V, 1980, LANCET, V2, P946; EADIE MJ, 1990, MED J AUSTRALIA, V153, P180, DOI 10.5694/j.1326-5377.1990.tb136855.x; Fields H.L., 1989, TXB PAIN, P206; HAN JS, 1986, INT J NEUROSCI, V29, P79; HAN JS, 1989, SCI BASES ACUPUNCTUR, P7; HANSEN PE, 1983, HEADACHE, V23, P66, DOI 10.1111/j.1526-4610.1983.hed2302066.x; HE LF, 1991, PAIN, V44, P89; HO WKK, 1989, NEUROPHARMACOLOGY, V28, P961, DOI 10.1016/0028-3908(89)90196-2; KISER RS, 1983, LANCET, V2, P1394; LAUTENSCHAGER J, 1989, DTSCH ZSCHR AKUP, V6, P122; Le Bars D., 1989, SCI BASES ACUPUNCTUR, P79, DOI 10.1007/978-3-642-73757-2_5; LEE KH, 1985, J NEUROSURG, V62, P276, DOI 10.3171/jns.1985.62.2.0276; LEHMANN TR, 1986, PAIN, V26, P277, DOI 10.1016/0304-3959(86)90057-6; LEWIT K, 1979, PAIN, V6, P83, DOI 10.1016/0304-3959(79)90142-8; MacDonald A., 1989, TXB PAIN, P906; MAYER DJ, 1977, BRAIN RES, V121, P368, DOI 10.1016/0006-8993(77)90161-5; MELZACK R, 1977, PAIN, V3, P2; MOORE ME, 1976, ANN INTERN MED, V84, P381, DOI 10.7326/0003-4819-84-4-381; PAIK KS, 1988, EXP NEUROL, V99, P498, DOI 10.1016/0014-4886(88)90166-5; POMMERANZ B, 1979, EXP NEUROL, V64, P327; PRICE DD, 1984, PAIN, V19, P27, DOI 10.1016/0304-3959(84)90062-9; REEVES JL, 1986, PAIN, V24, P313, DOI 10.1016/0304-3959(86)90117-X; RIET GT, 1990, J CLIN EPIDEMIOL, V43, P1191; TODA K, 1978, EXP NEUROL, V61, P465, DOI 10.1016/0014-4886(78)90261-3; VINCENT CA, 1986, PAIN, V24, P1, DOI 10.1016/0304-3959(86)90022-9; Waylonis G W, 1977, Ohio State Med J, V73, P299; WILLER JC, 1982, PAIN, V14, P267, DOI 10.1016/0304-3959(82)90133-6; 1990, ARTHRITIS RHEUM, V33, P160	34	167	171	0	27	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 21	1992	305	6864					1249	1252		10.1136/bmj.305.6864.1249	http://dx.doi.org/10.1136/bmj.305.6864.1249			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JZ521	1477566	Green Submitted, Bronze, Green Published			2023-01-03	WOS:A1992JZ52100020
J	QUILL, TE; CASSEL, CK; MEIER, DE				QUILL, TE; CASSEL, CK; MEIER, DE			CARE OF THE HOPELESSLY ILL - PROPOSED CLINICAL-CRITERIA FOR PHYSICIAN-ASSISTED SUICIDE	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							EUTHANASIA; DEATH; RESPONSIBILITY; NETHERLANDS		UNIV ROCHESTER, SCH MED, ROCHESTER, NY 14607 USA; UNIV CHICAGO, CHICAGO, IL 60637 USA; CUNY MT SINAI SCH MED, NEW YORK, NY 10029 USA	University of Rochester; University of Chicago; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai								ANGELL M, 1988, NEW ENGL J MED, V319, P1348, DOI 10.1056/NEJM198811173192010; ARIES P, 1982, HOUR OF OUR DEATH; BENRUBI GI, 1992, NEW ENGL J MED, V326, P197, DOI 10.1056/NEJM199201163260311; BRAHAMS D, 1990, LANCET, V335, P591; Broadfield L, 1988, J Palliat Care, V4, P21; CASSEL CK, 1990, NEW ENGL J MED, V323, P750, DOI 10.1056/NEJM199009133231110; CHARLSON ME, 1987, J GEN INTERN MED, V2, P359, DOI 10.1007/BF02596176; CONWELL Y, 1991, NEW ENGL J MED, V325, P1100, DOI 10.1056/NEJM199110103251511; GAYLIN W, 1988, JAMA-J AM MED ASSOC, V259, P2139; GEST T, 1990, US NEWS WORLD R 0709, P22; Glantz L H, 1987, Law Med Health Care, V15, P231; GLOVER J, 1977, CAUSING DEATH SAVING, P182; Gomez Carlos F., 1991, REGULATING DEATH EUT; HEILIG S, 1988, SAN FRANCISCO MED, V24, P34; JECKER NS, 1991, J AM GERIATR SOC, V39, P831, DOI 10.1111/j.1532-5415.1991.tb02708.x; LACHS J, 1976, NEW ENGL J MED, V294, P838, DOI 10.1056/NEJM197604082941513; LEENEN HJJ, 1990, BRIT MED J, V300, P69; MALCOLM A, 1990, NY TIMES        0614, pA6; MEIER DE, 1983, J AM GERIATR SOC, V31, P294, DOI 10.1111/j.1532-5415.1983.tb04874.x; MISBIN RI, 1991, NEW ENGL J MED, V325, P1307, DOI 10.1056/NEJM199110313251811; NEWMAN SA, 1991, U PITT LAW REV, V53, P153; ORENTLICHER D, 1992, JAMA-J AM MED ASSOC, V267, P2229; ORENTLICHER D, 1989, JAMA-J AM MED ASSOC, V262, P1844, DOI 10.1001/jama.262.13.1844; OVERMYER M, 1991, PHYSICIANS MANAGE, V31, P40; POSES RM, 1989, CRIT CARE MED, V17, P827, DOI 10.1097/00003246-198908000-00021; QUILL TE, 1991, NEW ENGL J MED, V324, P691, DOI 10.1056/NEJM199103073241010; RACHELS J, 1975, NEW ENGL J MED, V292, P78, DOI 10.1056/NEJM197501092920206; REICHEL W, 1989, LANCET, V2, P1321; RHYMES J, 1990, JAMA-J AM MED ASSOC, V264, P369, DOI 10.1001/jama.264.3.369; Schonwetter R S, 1990, Hosp J, V6, P65; SINGER PA, 1990, NEW ENGL J MED, V322, P1881, DOI 10.1056/NEJM199006283222610; van der Maas PJ, 1991, LANCET, V338, P669, DOI 10.1016/0140-6736(91)91241-L; VAUX KL, 1988, JAMA-J AM MED ASSOC, V259, P2140, DOI 10.1001/jama.259.14.2140; WALLSTON KA, 1988, MED CARE, V26, P177, DOI 10.1097/00005650-198802000-00008; WANZER SH, 1984, NEW ENGL J MED, V310, P955, DOI 10.1056/NEJM198404123101505; WANZER SH, 1989, NEW ENGL J MED, V320, P844, DOI 10.1056/NEJM198903303201306; Weir R F, 1992, Law Med Health Care, V20, P116, DOI 10.1111/j.1748-720X.1992.tb01178.x; WOLF SM, 1989, HASTINGS CENT REP, V19, pS13; 1988, WITHHOLDING WITHDRAW; 1990, 1990 ROPER POLL PHYS; 1988, 1987 SURVEY CALIFORN; 1991, 1991 ROPER POLL W CO	42	221	220	0	12	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 5	1992	327	19					1380	1384		10.1056/NEJM199211053271911	http://dx.doi.org/10.1056/NEJM199211053271911			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JW077	1406842				2023-01-03	WOS:A1992JW07700011
J	SONNEVELD, P; DURIE, BGM; LOKHORST, HM; MARIE, JP; SOLBU, G; SUCIU, S; ZITTOUN, R; LOWENBERG, B; NOOTER, K				SONNEVELD, P; DURIE, BGM; LOKHORST, HM; MARIE, JP; SOLBU, G; SUCIU, S; ZITTOUN, R; LOWENBERG, B; NOOTER, K			MODULATION OF MULTIDRUG-RESISTANT MULTIPLE-MYELOMA BY CYCLOSPORINE	LANCET			English	Article							ACUTE MYELOCYTIC-LEUKEMIA; PLASMA-CELL MYELOMA; P-GLYCOPROTEIN; DRUG-RESISTANCE; MDR1 GENE; ACCUMULATION; EXPRESSION; CANCER; ANTHRACYCLINES; DOXORUBICIN	Resistance to chemotherapy in refractory multiple myeloma is frequently associated with expression of multidrug resistance (MDR). In resistant cells, intracellular accumulation of doxorubicin and vincristine does not occur because the MDR-1 gene product, a membrane glycoprotein (PgP), is an energy-dependent efflux pump. Cyclosporin is one of several non-cytotoxic drugs that can block the function of PgP. In a prospective study, we assessed the possibility that cyclosporin could be used clinically to modulate MDR. We studied 21 patients with multiple myeloma; disease had progressed during primary chemotherapy in 6 and was resistant to VAD (vincristine, doxorubicin, dexamethasone) in 15, The patients received cyclosporin by continuous infusion during VAD treatment; there were three cyclosporin dosage groups (5, 7.5, 10 mg/kg daily). Serum cyclosporin concentrations adequate for MDR modulation were reached in all patients receiving 7.5 or 10 mg/kg daily. 47% (7) of the VAD-refractory patients and 48% (10) of the whole group responded to VAD. Before treatment, MDR-1 expression was present in 12 patients. After VAD plus cyclosporin, no MDR-1-positive plasma cells were present in 6 of 8 patients tested. The response rate in MDR-1-positive patients was 58% compared with 33% in all our patients. Toxic effects were mild and reversible and did not include nephrotoxic or serious cardiovascular side-effects. 12 months after the start of treatment, survival was 85%, and disease-free survival at a median of 9 months after the response was 65%. Thus, in multiple myeloma clinical resistance to VAD can be circumvented by cyclosporin, which enables the cytotoxic drugs to eliminate resistant myeloma cells.	EUROPEAN ORG RES TREATMENT CANC,CTR DATA,DEPT HAEMATOL,BRUSSELS,BELGIUM; WESTMINSTER & CHARING CROSS MED SCH,DEPT HAEMATOL,LONDON,ENGLAND; INST APPL IMMUNOL & RADIOBIOL,DEPT HAEMATOL,RIJSWIJK,NETHERLANDS; UNIV UTRECHT HOSP,DEPT HAEMATOL,3511 GV UTRECHT,NETHERLANDS; HOP HOTEL DIEU,DEPT HAEMATOL,F-75181 PARIS 04,FRANCE	European Organisation for Research & Treatment of Cancer; Imperial College London; Utrecht University; Utrecht University Medical Center; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Hotel-Dieu - APHP; UDICE-French Research Universities; Universite Paris Cite	SONNEVELD, P (corresponding author), ERASMUS UNIV,HOSP DIJKZIGT,DEPT HAEMATOL,ROOM L407,DR MOLEWARTERPLEIN 40,3015 GD ROTTERDAM,NETHERLANDS.							ALEXANIAN R, 1990, AM J HEMATOL, V33, P86, DOI 10.1002/ajh.2830330203; ALEXANIAN R, 1985, ARCH INTERN MED, V145, P2073, DOI 10.1001/archinte.145.11.2073; BARLOGIE B, 1986, BLOOD, V67, P1298; BARLOGIE B, 1984, NEW ENGL J MED, V310, P1353, DOI 10.1056/NEJM198405243102104; BELCH A, 1988, BRIT J CANCER, V57, P94, DOI 10.1038/bjc.1988.17; BUZAID AC, 1988, J CLIN ONCOL, V6, P889, DOI 10.1200/JCO.1988.6.5.889; DALTON WS, 1989, BLOOD, V73, P747; DURIE BGM, 1975, CANCER, V36, P842, DOI 10.1002/1097-0142(197509)36:3<842::AID-CNCR2820360303>3.0.CO;2-U; EPSTEIN J, 1989, BLOOD, V74, P913; GORE ME, 1989, LANCET, V2, P879; GOSLAND MP, 1991, P AM ASSOC CANC RES, P82; GROGAN T, 1990, LAB INVEST, V63, P815; HERWEIJER H, 1990, JNCI-J NATL CANCER I, V82, P1133, DOI 10.1093/jnci/82.13.1133; KYLE RA, 1986, PROG HEMATOL, V14, P257; NOOTER K, 1990, INT J CANCER, V45, P263, DOI 10.1002/ijc.2910450210; PASTAN I, 1987, NEW ENGL J MED, V316, P1388; SALMON SE, 1991, BLOOD, V78, P44; SALMON SE, 1989, J NATL CANCER I, V81, P696, DOI 10.1093/jnci/81.9.696; SONNEVELD P, 1990, BRIT J HAEMATOL, V75, P208, DOI 10.1111/j.1365-2141.1990.tb02650.x; SPETH PAJ, 1986, J CHROMATOGR, V377, P415, DOI 10.1016/S0378-4347(00)80803-8; TSURUO T, 1981, CANCER RES, V41, P1967; UEDA K, 1987, P NATL ACAD SCI USA, V84, P3004, DOI 10.1073/pnas.84.9.3004; VANKALKEN CK, 1991, EUR J CANCER, V27, P739, DOI 10.1016/0277-5379(91)90178-G	23	369	378	0	11	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 1	1992	340	8814					255	259		10.1016/0140-6736(92)92353-H	http://dx.doi.org/10.1016/0140-6736(92)92353-H			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JG665	1353189				2023-01-03	WOS:A1992JG66500001
J	SCHOR, JD; LEVKOFF, SE; LIPSITZ, LA; REILLY, CH; CLEARY, PD; ROWE, JW; EVANS, DA				SCHOR, JD; LEVKOFF, SE; LIPSITZ, LA; REILLY, CH; CLEARY, PD; ROWE, JW; EVANS, DA			RISK-FACTORS FOR DELIRIUM IN HOSPITALIZED ELDERLY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACUTE CONFUSIONAL STATES; BACTERIAL-MENINGITIS; DEMENTIA; AGE	Objective. - To determine risk factors for delirium in elderly hospitalized patients. Design. - Cohort analytic study. Using a reliable and valid instrument for detection of delirium, we prospectively followed up a cohort of elderly patients admitted to an acute care hospital. Using standardized criteria, we collected risk factor data from patient medical records. Setting. - General medical and surgical wards of a tertiary-care hospital. Patients. - Patients (n = 325) were 65 years of age or older, from either a geographically defined community or a long-term-care institution. We studied those patients (n = 291) not delirious on first evaluation. Fifty-seven patients or their families refused participation. Main Outcome Measures. - Incidence of delirium and risk factors calculated as adjusted odds ratios (ORs). Main Results. - Delirium developed in 91 patients. By stepwise logistic regression, the independent risk factors for in-hospital delirium included prior cognitive impairment (OR, 8.97; 95% confidence interval [Cl], 3.99 to 20.14), age over 80 years (OR, 5.22; 95% Cl, 2.60 to 10.46), fracture on admission (OR, 6.57; 95% Cl, 2.23 to 19.33), symptomatic infection (OR, 2.96; 95% Cl, 1.42 to 6.15), and male sex (OR, 2.40; 95% Cl, 1.19 to 4.84). Among medication groups, only neuroleptic use (OR, 4.48; 95% Cl, 1.82 to 10.45) and narcotic use (OR, 2.54; 955 Cl, 1.24 to 5.18) were independently associated with delirium. Anticholinergic use was not associated with delirium. Conclusions. - Delirium in hospitalized patients is most closely associated with factors already present on admission such as prior cognitive impairment, advanced age, and fracture. In the hospital, use of neuroleptics and narcotics and the presence of infection are less strongly associated with this syndrome.	HEBREW REHABIL CTR AGED, BOSTON, MA USA; RUSH PRESBYTERIAN ST LUKES MED CTR, CTR RES HLTH & AGING, CHICAGO, IL 60612 USA; HARVARD UNIV, SCH MED, DIV AGING, BOSTON, MA 02115 USA; BETH ISRAEL HOSP, BOSTON, MA 02215 USA; MT SINAI MED CTR, NEW YORK, NY 10029 USA	Rush University; Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Icahn School of Medicine at Mount Sinai			Cleary, Paul/AAF-7048-2019					ALBERT MS, IN PRESS J GERIATR P; BERGMANN K, 1974, Age and Ageing, V3, P174, DOI 10.1093/ageing/3.3.174; BERNSTEIN S, 1967, NEW ENGL J MED, V277, P638, DOI 10.1056/NEJM196709212771206; BILBERT VE, 1968, METABOLISM, V17, P943; BOHR V, 1983, J INFECTION, V7, P21, DOI 10.1016/S0163-4453(83)90894-0; BRIZER DA, 1982, AM J PSYCHIAT, V139, P1343; DINARELLO CA, 1984, NEW ENGL J MED, V311, P1413; DJOKOVIC JL, 1979, JAMA-J AM MED ASSOC, V242, P2301, DOI 10.1001/jama.242.21.2301; DRACHMAN DA, 1974, ARCH NEUROL-CHICAGO, V30, P113, DOI 10.1001/archneur.1974.00490320001001; ENGEL G L, 1959, J Chronic Dis, V9, P260, DOI 10.1016/0021-9681(59)90165-1; ERKINJUNTTI T, 1986, ARCH INTERN MED, V146, P1923, DOI 10.1001/archinte.146.10.1923; FRANCIS J, 1990, JAMA-J AM MED ASSOC, V263, P1097, DOI 10.1001/jama.263.8.1097; GILLICK MR, 1982, SOC SCI MED, V16, P1033, DOI 10.1016/0277-9536(82)90175-7; GORSE GJ, 1984, ARCH INTERN MED, V144, P1603, DOI 10.1001/archinte.144.8.1603; GREENFIELD S, 1988, JAMA-J AM MED ASSOC, V260, P2253, DOI 10.1001/jama.260.15.2253; GREENFIELD S, 1987, JAMA-J AM MED ASSOC, V257, P2766, DOI 10.1001/jama.257.20.2766; Hodkinson H M, 1973, J R Coll Physicians Lond, V7, P305; JOHNSON JC, 1990, J GERONTOL, V45, pM113, DOI 10.1093/geronj/45.3.M113; KADLECOVA O, 1974, J HYG EPID MICROB IM, V18, P472; LEVKOFF SE, IN PRESS ARCH INTERN; LIPOWSKI ZJ, 1989, NEW ENGL J MED, V320, P578; LIPOWSKI ZJ, 1987, JAMA-J AM MED ASSOC, V258, P1789, DOI 10.1001/jama.258.13.1789; LIPOWSKI ZJ, 1983, AM J PSYCHIAT, V140, P1426; LIPOWSKI ZJ, 1990, DELIRIUM ACUTE CONFU, P229; NORMAN DC, 1983, J AM GERIATR SOC, V31, P677, DOI 10.1111/j.1532-5415.1983.tb04154.x; SEYMOUR DG, 1980, AGE AGEING, V9, P137, DOI 10.1093/ageing/9.3.137; SIESJO BK, 1976, CRIT CARE MED, V4, P283, DOI 10.1097/00003246-197611000-00001; SIMON ALEXANDER, 1963, PSYCHIAT RES REPTS, V16, P8; SUNDERLAND T, 1987, ARCH GEN PSYCHIAT, V44, P418; SUNDERLAND T, 1988, BRAIN RES REV, V13, P371, DOI 10.1016/0165-0173(88)90013-6; THOMAS RI, 1988, ARCH GEN PSYCHIAT, V45, P937; VERGHESE A, 1983, MEDICINE, V62, P271, DOI 10.1097/00005792-198309000-00002; VERGHESE A, 1985, AM J MED, V79, P370, DOI 10.1016/0002-9343(85)90316-X; 1987, DIAGNOSTIC STATISTIC, P100	34	344	351	0	14	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 12	1992	267	6					827	831		10.1001/jama.267.6.827	http://dx.doi.org/10.1001/jama.267.6.827			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HC484	1732655				2023-01-03	WOS:A1992HC48400028
J	CUNDY, T; EVANS, M; ROBERTS, H; WATTIE, D; AMES, R; REID, IR				CUNDY, T; EVANS, M; ROBERTS, H; WATTIE, D; AMES, R; REID, IR			BONE-DENSITY IN WOMEN RECEIVING DEPOT MEDROXYPROGESTERONE ACETATE FOR CONTRACEPTION	BRITISH MEDICAL JOURNAL			English	Article							POST-MENOPAUSAL WOMEN; MINERAL-CONTENT; RELATIVE CONTRIBUTIONS; POSTMENOPAUSAL WOMEN; HORMONE-REPLACEMENT; ESTROGENS; AGE; NORETHISTERONE; PROVERA; MPA	Objective-To determine if the use of the injectable contraceptive depot medroxyprogesterone (DMPA), which reduces ovarian oestrogen production, is associated with changes in bone density. Design-Population study. DMPA users were compared with two control groups selected from larger population studies and individually matched for several putative determinants of bone density (age, race, body mass index, and years of oestrogen deficiency). Controls and DMPA users were matched without prior knowledge of their bone density measurements. Setting- Teaching hospital and community family planning clinics. Subjects-30 current users of DMPA with a minimum five years' previous use, 30 premenopausal controls, and 30 postmenopausal controls. Main outcome measure-Lumbar spine and femoral neck bone mineral density assessed by dual energy x ray absorptiometry. Results-Compared with premenopausal controls matched for age, race, and body mass index, DMPA users had significantly reduced bone density in the lumbar spine (mean difference 7.5% (95% confidence interval 1.9% to 13.1%), p = 0.002) and in the femoral neck (6.6%, (0.8% to 12.3%), p = 0.007). Compared with postmenopausal controls matched for body mass index and duration of oestrogen deficiency, DMPA users had greater bone density in the lumbar spine (8.9% (4.3% to 13.5%), p = 0.001), but in the femoral neck the difference in bone density was less (4.0% (-0.4% to 8.5%), p = 0.04). Conclusions-Women using DMPA have bone density values intermediate between those of normal premenopausal and postmenopausal controls; thus, the degree of oestrogen deficiency induced by DMPA may have an adverse effect on bone density.	FAMILY PLANNING ASSOC NEW ZEALAND,AUCKLAND 1,NEW ZEALAND		CUNDY, T (corresponding author), AUCKLAND HOSP,DEPT MED,AUCKLAND 1,NEW ZEALAND.			Cundy, Timothy/0000-0003-4890-9400; Roberts, Helen/0000-0002-8107-5746				ABDALLA HI, 1985, OBSTET GYNECOL, V66, P789; ADAMI S, 1989, BONE MINER, V7, P79, DOI 10.1016/0169-6009(89)90064-0; CANN CE, 1980, JAMA-J AM MED ASSOC, V244, P2056; CANN CE, 1984, JAMA-J AM MED ASSOC, V251, P626, DOI 10.1001/jama.251.5.626; CRILLY RG, 1980, CLIN SCI, V58, P341, DOI 10.1042/cs0580341; DRINKWATER BL, 1984, NEW ENGL J MED, V311, P277, DOI 10.1056/NEJM198408023110501; GALLAGHER JC, 1991, AM J MED, V90, P171; HODGKINSON A, 1982, J CLIN PATHOL, V35, P807, DOI 10.1136/jcp.35.8.807; HORSMAN A, 1983, NEW ENGL J MED, V309, P1405, DOI 10.1056/NEJM198312083092301; JARMAN H, 1990, AUST NZ J OBSTET GYN, V30, P74, DOI 10.1111/j.1479-828X.1990.tb03202.x; JENSEN J, 1985, NEW ENGL J MED, V313, P973, DOI 10.1056/NEJM198510173131602; JEPPSSON S, 1973, CONTRACEPTION, V8, P165, DOI 10.1016/0010-7824(73)90122-4; JEPPSSON S, 1982, ACTA ENDOCRINOL-COP, V99, P339, DOI 10.1530/acta.0.0990339; KLIBANSKI A, 1986, NEW ENGL J MED, V315, P542, DOI 10.1056/NEJM198608283150903; KOPPELMAN MCS, 1984, J CLIN ENDOCR METAB, V59, P1050, DOI 10.1210/jcem-59-6-1050; LOBO RA, 1984, OBSTET GYNECOL, V63, P1; MANDEL FP, 1982, J REPROD MED, V27, P511; MATTA WH, 1988, CLIN ENDOCRINOL, V29, P45, DOI 10.1111/j.1365-2265.1988.tb00248.x; MAZESS R, 1989, CALCIFIED TISSUE INT, V44, P228, DOI 10.1007/BF02556569; MELTON LJ, 1988, J CLIN EPIDEMIOL, V41, P985; NORDIN BEC, 1990, J CLIN ENDOCR METAB, V70, P83, DOI 10.1210/jcem-70-1-83; ORTIZ A, 1977, J CLIN ENDOCR METAB, V44, P32, DOI 10.1210/jcem-44-1-32; POWERS MS, 1985, AM J OBSTET GYNECOL, V152, P1099, DOI 10.1016/0002-9378(85)90569-1; PRIOR JC, 1990, NEW ENGL J MED, V323, P1221, DOI 10.1056/NEJM199011013231801; PRIOR JC, 1990, ENDOCR REV, V11, P386, DOI 10.1210/edrv-11-2-386; REDMAN JR, 1988, AM J MED, V85, P65, DOI 10.1016/0002-9343(88)90504-9; REID IR, 1986, BRIT MED J, V292, P1547, DOI 10.1136/bmj.292.6535.1547; RICHELSON LS, 1984, NEW ENGL J MED, V311, P1273, DOI 10.1056/NEJM198411153112002; RIGOTTI NA, 1984, NEW ENGL J MED, V311, P1601, DOI 10.1056/NEJM198412203112503; RIIS BJ, 1990, J CLIN ENDOCR METAB, V70, P920, DOI 10.1210/jcem-70-4-920; SELBY PL, 1985, CLIN SCI, V69, P265, DOI 10.1042/cs0690265; YOUNG MM, 1967, LANCET, V2, P118	32	212	213	0	7	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 6	1991	303	6793					13	16		10.1136/bmj.303.6793.13	http://dx.doi.org/10.1136/bmj.303.6793.13			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FW128	1830502	Bronze, Green Published			2023-01-03	WOS:A1991FW12800018
J	HELEWA, A; GOLDSMITH, CH; LEE, P; BOMBARDIER, C; HANES, B; SMYTHE, HA; TUGWELL, P				HELEWA, A; GOLDSMITH, CH; LEE, P; BOMBARDIER, C; HANES, B; SMYTHE, HA; TUGWELL, P			EFFECTS OF OCCUPATIONAL-THERAPY HOME SERVICE ON PATIENTS WITH RHEUMATOID-ARTHRITIS	LANCET			English	Article								Because there is little information about the efficacy of home occupational therapy, we decided to assess the effects of a home service on patients with rheumatoid arthritis. 105 patients aged 18-70 years, on stable medical therapy, were randomised to receive a 6-week comprehensive programme of occupational therapy (experimental group, 53 patients) or to receive no such treatment (control group, 52). At 6 weeks, control patients received the experimental regimen, and experimental patients were continued on treatment as needed up to 12 weeks. Outcomes were measured at baseline, 6, and 12 weeks with a global functional capacity score (functional score). At 6 weeks the functional score for the experimental group was significantly higher than that for the control group (mean difference = 8.1, 95% Cl 1-7 to 15.8, p = 0.012). Control patients at 12 weeks showed a similar improvement to experimental patients at 6 weeks, and between 6 and 12 weeks the experimental patients were stable. Occupational therapy leads to a statistically significant and clinically important improvement in function in patients with rheumatoid arthritis.	MCMASTER UNIV, DEPT CLIN EPIDEMIOL & BIOSTAT, HAMILTON L8S 4L8, ONTARIO, CANADA; ARTHRITIS SOC OCCUPAT THERAPY SERV, ONTARIO DIV, TORONTO, ONTARIO, CANADA; WELLESLEY COLL HOSP, DEPT RHEUMATOL, TORONTO M4Y 1J3, ONTARIO, CANADA	McMaster University; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto	HELEWA, A (corresponding author), UNIV WESTERN ONTARIO, ELBORN COLL, DEPT PHYS THERAPY, LONDON N6G 1H1, ONTARIO, CANADA.		Tugwell, Peter/AFD-8076-2022	Tugwell, Peter/0000-0001-5062-0556				ALTMAN DG, 1985, STATISTICIAN, V34, P125; Beck A. T., 1960, ARCH GEN PSYCHIAT, V4, P53, DOI DOI 10.1001/ARCHPSYC.1961.01710120031004; COHEN S, 1966, J CHRON DIS, V19, P631; DEBBECQ AL, GUIDE NOMINAL GROUP; EBERL DR, 1976, ARTHRITIS RHEUM, V19, P1278, DOI 10.1002/art.1780190608; FRIES JF, 1980, ARTHRITIS RHEUM, V23, P137, DOI 10.1002/art.1780230202; GOLDSMITH C H, 1987, Arthritis and Rheumatism, V30, pS101; HELEWA A, 1987, J RHEUMATOL, V14, P87; HUSKISSON EC, 1982, J RHEUMATOL, V9, P768; MEENAN RF, 1980, ARTHRITIS RHEUM, V23, P146, DOI 10.1002/art.1780230203; MOWAT AG, 1980, ANN RHEUM DIS, V39, P12, DOI 10.1136/ard.39.1.12; ROPES M W, 1958, Bull Rheum Dis, V9, P175; SMYTHE HA, 1977, J RHEUMATOL, V4, P144; 1955, ANN RHEUM DIS, V14, P353	14	48	48	0	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 15	1991	337	8755					1453	1456		10.1016/0140-6736(91)93138-Y	http://dx.doi.org/10.1016/0140-6736(91)93138-Y			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FR060	1675329				2023-01-03	WOS:A1991FR06000015
J	VERRESEN, L; WAER, M; VANRENTERGHEM, Y; MICHIELSEN, P				VERRESEN, L; WAER, M; VANRENTERGHEM, Y; MICHIELSEN, P			ANGIOTENSIN-CONVERTING-ENZYME INHIBITORS AND ANAPHYLACTOID REACTIONS TO HIGH-FLUX MEMBRANE DIALYSIS	LANCET			English	Article											VERRESEN, L (corresponding author), UNIV ZIEKENHUIS GASTHUISBERG,DEPT NEPHROL,HERESTR 49,B-3000 LOUVAIN,BELGIUM.							BIGAZZI R, 1989, 7TH P ANN M INT SOC; BINGEL M, 1986, NEPHRON, V43, P161, DOI 10.1159/000183822; BOUVIER P, 1989, NEPHROLOGIE, V10, P40; GEJYO F, 1986, KIDNEY INT, V30, P385, DOI 10.1038/ki.1986.196; GOLDMAN M, 1989, INT J ARTIF ORGANS, V12, P373, DOI 10.1177/039139888901200605; GOREVIC PD, 1986, P NATL ACAD SCI USA, V83, P7908, DOI 10.1073/pnas.83.20.7908; HAUGLUSTAINE D, 1986, LANCET, V1, P1211; KOZIN F, 1988, INFLAMMATION BASIC P, P101; Lindgren B R, 1988, Acta Physiol Scand Suppl, V573, P1; LONNEMANN G, 1988, KIDNEY INT, V33, P29, DOI 10.1038/ki.1988.5; Man N K, 1988, Contrib Nephrol, V62, P24; MARTINMALO A, 1989, INT J ARTIF ORGANS, V12, P509, DOI 10.1177/039139888901200805; MONTAGNAC R, 1988, NEPHROLOGIE, V9, P29; NORN S, 1985, AGENTS ACTIONS, V16, P273, DOI 10.1007/BF01983158; NORN S, 1986, AGENTS ACTIONS, V18, P149, DOI 10.1007/BF01988007; PORT FK, 1987, AM J KIDNEY DIS, V10, P118, DOI 10.1016/S0272-6386(87)80043-4; WILLIAMS GH, 1977, NEW ENGL J MED, V297, P184, DOI 10.1056/NEJM197707282970404; Yamagami S, 1989, ASAIO Trans, V35, P331, DOI 10.1097/00002480-198907000-00050	18	101	102	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 1	1990	336	8727					1360	1362		10.1016/0140-6736(90)92904-V	http://dx.doi.org/10.1016/0140-6736(90)92904-V			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EL365	1978172				2023-01-03	WOS:A1990EL36500012
J	TWYCROSS, RG				TWYCROSS, RG			ASSISTED DEATH - A REPLY	LANCET			English	Editorial Material											TWYCROSS, RG (corresponding author), SIR MICHAEL SOBELL HOUSE, CHURCHILL HOUSE, OXFORD OX3 7LJ, ENGLAND.							ANGELL M, 1988, NEW ENGL J MED, V319, P1348, DOI 10.1056/NEJM198811173192010; DRAIN G, 1990, LANCET, V2, P610; FENIGSEN R, 1989, HASTINGS CENT REP, V19, pS22; GAYLIN W, 1988, JAMA-J AM MED ASSOC, V259, P2139; RAGLAN, 1972, CONTACT, V39, P9; Roy D J, 1990, J Palliat Care, V6, P3	6	11	11	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 29	1990	336	8718					796	798		10.1016/0140-6736(90)93253-L	http://dx.doi.org/10.1016/0140-6736(90)93253-L			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EB077	1698235				2023-01-03	WOS:A1990EB07700016
J	STEVENSON, JC; CUST, MP; GANGAR, KF; HILLARD, TC; LEES, B; WHITEHEAD, MI				STEVENSON, JC; CUST, MP; GANGAR, KF; HILLARD, TC; LEES, B; WHITEHEAD, MI			EFFECTS OF TRANSDERMAL VERSUS ORAL HORMONE REPLACEMENT THERAPY ON BONE-DENSITY IN SPINE AND PROXIMAL FEMUR IN POSTMENOPAUSAL WOMEN	LANCET			English	Article									UNIV LONDON KINGS COLL,SCH MED & DENT,DEPT OBSTET & GYNAECOL,LONDON WC2R 2LS,ENGLAND	University of London; King's College London	STEVENSON, JC (corresponding author), WYNN INST METAB RES,21 WELLINGTON RD,LONDON NW8 9SQ,ENGLAND.							ADAMI S, 1989, BONE MINER, V7, P79, DOI 10.1016/0169-6009(89)90064-0; ALAZZAWI F, 1987, BRIT MED J, V298, P924; CHRISTENSEN MS, 1982, AM J OBSTET GYNECOL, V144, P873, DOI 10.1016/0002-9378(82)90176-4; ETTINGER B, 1987, ANN INTERN MED, V106, P40, DOI 10.7326/0003-4819-106-1-40; GENANT HK, 1982, ANN INTERN MED, V97, P699, DOI 10.7326/0003-4819-97-5-699; HEDLUND LR, 1989, J BONE MINER RES, V4, P639; HODGKINSON A, 1982, J CLIN PATHOL, V35, P807, DOI 10.1136/jcp.35.8.807; HUTCHINSON TA, 1979, LANCET, V2, P706; LINDSAY R, 1976, LANCET, V1, P1038; LINDSAY R, 1984, OBSTET GYNECOL, V63, P759; MACINTYRE I, 1988, LANCET, V1, P900; MAZESS RB, 1987, BONE MINER, V2, P211; MELTON LJ, 1986, AM J EPIDEMIOL, V124, P254, DOI 10.1093/oxfordjournals.aje.a114383; MELTON LJ, 1985, J NUCL MED, V26, P24; MUNKJENSEN N, 1988, BRIT MED J, V296, P1150, DOI 10.1136/bmj.296.6630.1150; RIBOT C, 1987, OSTEOPOROSIS 1987, P546; RIIS BJ, 1987, AM J OBSTET GYNECOL, V156, P61, DOI 10.1016/0002-9378(87)90203-1; STEVENSON JC, 1982, BRIT MED J, V285, P585, DOI 10.1136/bmj.285.6342.585; STEVENSON JC, 1987, J CLIN INVEST, V80, P258, DOI 10.1172/JCI113056; STEVENSON JC, 1989, BRIT MED J, V298, P924, DOI 10.1136/bmj.298.6678.924; STEVENSON JC, 1988, BRIT MED J, V297, P15, DOI 10.1136/bmj.297.6640.15; WEISS NS, 1980, NEW ENGL J MED, V303, P1195, DOI 10.1056/NEJM198011203032102; WHITEHEAD MI, 1990, LANCET, V335, P310, DOI 10.1016/0140-6736(90)90605-5	23	222	225	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 4	1990	336	8710					265	269		10.1016/0140-6736(90)91801-G	http://dx.doi.org/10.1016/0140-6736(90)91801-G			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DT007	1973969				2023-01-03	WOS:A1990DT00700002
J	JOHNSTONE, SA; HUBAISHY, I; WAISMAN, DM				JOHNSTONE, SA; HUBAISHY, I; WAISMAN, DM			PHOSPHORYLATION OF ANNEXIN-II TETRAMER BY PROTEIN-KINASE-C INHIBITS AGGREGATION OF LIPID VESICLES BY THE PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA-2+-DEPENDENT PHOSPHOLIPID-BINDING; DEPENDENT 35-KILODALTON SUBSTRATE; AFFINITY COLUMN CHROMATOGRAPHY; FACTOR RECEPTOR KINASE; AMINO-ACID-SEQUENCE; LIPOCORTIN-I; CHROMAFFIN CELLS; TYROSINE KINASE; CALPACTIN-I; DOMAIN-STRUCTURE	Annexin II tetramer (A-IIt) is a member of the annexin family of Ca2+ and phospholipid-binding proteins. The ability of this protein to aggregate both phospholipid vesicles and chromaffin granules has suggested a role for the protein in membrane trafficking events such as exocytosis. A-IIt is also a major intracellular substrate of both pp60src and protein kinase C; however, the effect of phosphorylation on the activity of this protein is unknown. In the current report we have examined the effect of phosphorylation on the lipid vesicle aggregation activity of the protein,Protein kinase C catalyzed the incorporation of 2.1 +/- 0.8 mol of phosphate/mol of A-IIt. Phosphorylation of A-IIt caused a dramatic decrease in the rate and extent of lipid vesicle aggregation without significantly effecting Ca2+-dependent lipid binding by the phosphorylated protein. Phosphorylation of A-IIt increased the A50%(Ca2+) of lipid vesicle aggregation from 0.18 muM to 0.65 mM. Activation of A-IIt phosphorylation, concomitant with activation of lipid vesicle aggregation, inhibited both the rate and extent of lipid vesicle aggregation but did not cause disassembly of the aggregated lipid vesicles. These results suggest that protein kinase C-dependent phosphorylation of A-IIt blocks the ability of the protein to aggregate phospholipid vesicles without affecting the lipid vesicle binding properties of the protein.	UNIV CALGARY, DEPT MED BIOCHEM, MRC, SIGNAL TRANSDUCT GRP, CALGARY T2N 4N1, ALBERTA, CANADA	University of Calgary	WAISMAN, DM (corresponding author), UNIV CALGARY, DEPT MED BIOCHEM, MRC, SIGNAL TRANSDUCT GRP, CALGARY T2N 4N1, ALBERTA, CANADA.			Waisman, David/0000-0002-5097-9662				ALI SM, 1989, NATURE, V340, P313, DOI 10.1038/340313a0; ALI SM, 1990, CELL SIGNAL, V2, P265, DOI 10.1016/0898-6568(90)90054-E; ANDO Y, 1989, J BIOL CHEM, V264, P6948; BLACKWOOD RA, 1990, BIOCHEM J, V266, P195, DOI 10.1042/bj2660195; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURGOYNE RD, 1989, CELL CALCIUM, V10, P1, DOI 10.1016/0143-4160(89)90038-9; BURGOYNE RD, 1990, ANNU REV PHYSIOL, V52, P647; DE BK, 1986, J BIOL CHEM, V261, P3784; DEDMAN JR, 1986, CELL CALCIUM, V7, P297, DOI 10.1016/0143-4160(86)90034-5; DRUST DS, 1988, NATURE, V331, P88, DOI 10.1038/331088a0; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; FAVA RA, 1984, J BIOL CHEM, V259, P2636; GEISOW MJ, 1990, PROG CLIN BIOL RES, V349, P111; GEISOW MJ, 1986, NATURE, V320, P636, DOI 10.1038/320636a0; GEISOW MJ, 1986, FEBS LETT, V203, P99, DOI 10.1016/0014-5793(86)81445-4; GERKE V, 1984, EMBO J, V3, P227, DOI 10.1002/j.1460-2075.1984.tb01789.x; GERKE V, 1985, J BIOL CHEM, V260, P1688; GLENNEY J, 1986, J BIOL CHEM, V261, P7247; GLENNEY JR, 1985, P NATL ACAD SCI USA, V82, P7884, DOI 10.1073/pnas.82.23.7884; GLENNEY JR, 1985, FEBS LETT, V192, P79, DOI 10.1016/0014-5793(85)80047-8; GLENNEY JR, 1987, BIOESSAYS, V7, P173, DOI 10.1002/bies.950070408; GOULD KL, 1986, MOL CELL BIOL, V6, P2738, DOI 10.1128/MCB.6.7.2738; HANNUN YA, 1986, J BIOL CHEM, V261, P7184; IKEBUCHI NW, 1990, J BIOL CHEM, V265, P3392; JOHNSSON N, 1990, PROG CLIN BIOL RES, V349, P123; JOHNSSON N, 1986, FEBS LETT, V198, P361, DOI 10.1016/0014-5793(86)80437-9; KHANNA N, 1987, BIOCHEM BIOPH RES CO, V137, P397; KHANNA NC, 1986, BIOCHEM BIOPH RES CO, V141, P547, DOI 10.1016/S0006-291X(86)80208-X; KHANNA NC, 1990, BIOCHEMISTRY-US, V29, P4852, DOI 10.1021/bi00472a015; KHANNA NC, 1987, CELL CALCIUM, V8, P217, DOI 10.1016/0143-4160(87)90020-0; Kitano T, 1986, Methods Enzymol, V124, P349; KLEE CB, 1988, BIOCHEMISTRY-US, V27, P6645, DOI 10.1021/bi00418a001; KRETSINGER RH, 1986, NATURE, V320, P573, DOI 10.1038/320573a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MICHENER ML, 1986, J BIOL CHEM, V261, P6548; MOSS SE, 1990, TRENDS BIOCHEM SCI, V15, P11, DOI 10.1016/0968-0004(90)90118-U; PEPINSKY RB, 1988, J BIOL CHEM, V263, P10799; PIGAULT C, 1990, BIOCHIM BIOPHYS ACTA, V1037, P106, DOI 10.1016/0167-4838(90)90108-R; POWELL MA, 1987, BIOCHEM J, V247, P321, DOI 10.1042/bj2470321; REEVES JP, 1969, J CELL PHYSIOL, V73, P49, DOI 10.1002/jcp.1040730108; RUSSOMARIE F, 1986, PATHOL BIOL, V34, P227; SARAFIAN T, 1991, J CELL BIOL, V114, P1135, DOI 10.1083/jcb.114.6.1135; SARIS CJM, 1986, CELL, V46, P210; SCHLAEPFER DD, 1988, BIOCHEMISTRY-US, V27, P4253, DOI 10.1021/bi00412a008; SCHLAEPFER DD, 1987, J BIOL CHEM, V262, P6931; SHARMA RK, 1986, J BIOL CHEM, V261, P1322; SUDHOF TC, 1988, P NATL ACAD SCI USA, V85, P664, DOI 10.1073/pnas.85.3.664; VARTICOVSKI L, 1988, BIOCHEMISTRY-US, V27, P3682, DOI 10.1021/bi00410a024; WEBER K, 1986, FEBS LETT, V203, P95, DOI 10.1016/0014-5793(86)81444-2; WEBER K, 1987, EMBO J, V6, P1599, DOI 10.1002/j.1460-2075.1987.tb02406.x; WOOTEN MW, 1987, EUR J BIOCHEM, V164, P461, DOI 10.1111/j.1432-1033.1987.tb11079.x; WU YN, 1991, FEBS LETT, V282, P197, DOI 10.1016/0014-5793(91)80476-J; ZAKS WJ, 1991, BIOCHEMISTRY-US, V30, P9607, DOI 10.1021/bi00104a007	53	89	90	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 25	1992	267	36					25976	25981						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KD073	1464610				2023-01-03	WOS:A1992KD07300059
J	GRADY, D; RUBIN, SM; PETITTI, DB; FOX, CS; BLACK, D; ETTINGER, B; ERNSTER, VL; CUMMINGS, SR				GRADY, D; RUBIN, SM; PETITTI, DB; FOX, CS; BLACK, D; ETTINGER, B; ERNSTER, VL; CUMMINGS, SR			HORMONE-THERAPY TO PREVENT DISEASE AND PROLONG LIFE IN POSTMENOPAUSAL WOMEN	ANNALS OF INTERNAL MEDICINE			English	Review						MENOPAUSE; ESTROGEN REPLACEMENT THERAPY; OSTEOPOROSIS, POSTMENOPAUSAL; CORONARY DISEASE; PROGESTATIONAL HORMONES	ESTROGEN REPLACEMENT THERAPY; POST-MENOPAUSAL WOMEN; CORONARY HEART-DISEASE; LONG-TERM ESTROGEN; BREAST-CANCER RISK; NON-CONTRACEPTIVE ESTROGENS; DENSITY-LIPOPROTEIN SUBFRACTIONS; ACUTE MYOCARDIAL-INFARCTION; ENDOMETRIAL CANCER; EXOGENOUS ESTROGENS	Purpose:To critically review the risks and benefits of hormone therapy for asymptomatic postmenopausal women who are considering long-term hormone therapy to prevent disease or to prolong life. Data Sources: Review of the English-language literature since 1970 on the effect of estrogen therapy and estrogen plus progestin therapy on endometrial cancer, breast cancer, coronary heart disease, osteoporosis, and stroke. We used standard meta-analytic statistical methods to pool estimates from studies to determine summary relative risks for these diseases in hormone users and modified lifetable methods to estimate changes in lifetime probability and life expectancy due to use of hormone regimens. Results: There is evidence that estrogen therapy decreases risk for coronary heart disease and for hip fracture, but long-term estrogen therapy increases risk for endometrial cancer and may be associated with a small increase in risk for breast cancer. The increase in endometrial cancer risk can probably be avoided by adding a progestin to the estrogen regimen for women who have a uterus, but the effects of combination hormones on risk for other diseases has not been adequately studied. We present estimates for changes in lifetime probabilities of disease and life expectancy due to hormone therapy in women who have had a hysterectomy; with coronary heart disease; and at increased risk for coronary heart disease, hip fracture, and breast cancer. Conclusions: Hormone therapy should probably be recommended for women who have had a hysterectomy and for those with coronary heart disease or at high risk for coronary heart disease. For other women, the best course of action is unclear.	AMER COLL PHYSICIANS, SCI POLICY, PHILADELPHIA, PA 19106 USA; UNIV CALIF SAN FRANCISCO, SAN FRANCISCO, CA 94143 USA; VET AFFAIRS MED CTR, SAN FRANCISCO, CA USA; KAISER PERMANENTE MED CTR, SAN FRANCISCO, CA USA	American College of Physicians; University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA); Kaiser Permanente								ADAM S, 1981, BRIT MED J, V282, P1277, DOI 10.1136/bmj.282.6272.1277; ADAMI HO, 1989, INT J CANCER, V44, P833, DOI 10.1002/ijc.2910440515; ADAMS MR, 1990, ARTERIOSCLEROSIS, V10, P1051, DOI 10.1161/01.ATV.10.6.1051; [Anonymous], 1974, N Engl J Med, V290, P15; ANTUNES CMF, 1979, NEW ENGL J MED, V300, P9, DOI 10.1056/NEJM197901043000103; ARMSTRONG BK, 1988, MED J AUSTRALIA, V148, P213, DOI 10.5694/j.1326-5377.1988.tb99424.x; ARTHES FG, 1971, CANCER, V28, P1391, DOI 10.1002/1097-0142(197112)28:6<1391::AID-CNCR2820280609>3.0.CO;2-S; AVILA MH, 1990, EPIDEMIOLOGY, V1, P128; BAIN C, 1981, CIRCULATION, V64, P42, DOI 10.1161/01.CIR.64.1.42; BARRETTCONNOR E, 1989, JAMA-J AM MED ASSOC, V261, P2095, DOI 10.1001/jama.261.14.2095; BARRETTCONNOR E, 1990, SERONO S, P199; BEARD CM, 1989, MAYO CLIN PROC, V64, P1471, DOI 10.1016/S0025-6196(12)65702-4; BERGKVIST L, 1988, INT J EPIDEMIOL, V17, P732, DOI 10.1093/ije/17.4.732; BERGKVIST L, 1989, NEW ENGL J MED, V321, P293, DOI 10.1056/NEJM198908033210505; BEWTRA C, 1988, J REPROD MED, V33, P205; BHATIA NN, 1989, AM J OBSTET GYNECOL, V160, P176, DOI 10.1016/0002-9378(89)90114-2; BLAND KI, 1980, CANCER, V45, P3027, DOI 10.1002/1097-0142(19800615)45:12<3027::AID-CNCR2820451225>3.0.CO;2-2; BOURNE TH, 1990, BRIT MED J, V301, P369, DOI 10.1136/bmj.301.6748.369; BOYSEN G, 1988, STROKE, V19, P1345, DOI 10.1161/01.STR.19.11.1345; BRADLEY DD, 1978, NEW ENGL J MED, V299, P17, DOI 10.1056/NEJM197807062990104; BRINCAT M, 1983, BRIT MED J, V287, P1337, DOI 10.1136/bmj.287.6402.1337; BRINCAT M, 1985, BRIT J OBSTET GYNAEC, V92, P256, DOI 10.1111/j.1471-0528.1985.tb01091.x; BRINCAT M, 1987, OBSTET GYNECOL, V70, P123; BRINTON LA, 1986, BRIT J CANCER, V54, P825, DOI 10.1038/bjc.1986.246; BRINTON LA, 1979, J NATL CANCER I, V62, P37; BRINTON LA, 1981, CANCER-AM CANCER SOC, V47, P2517, DOI 10.1002/1097-0142(19810515)47:10<2517::AID-CNCR2820471035>3.0.CO;2-L; BROWN MA, 1989, ENERG BUILDINGS, V13, P51, DOI 10.1016/0378-7788(89)90017-0; BUCHMAN MI, 1978, OBSTET GYNECOL, V51, P339, DOI 10.1097/00006250-197803000-00018; BURCH JC, 1974, AM J OBSTET GYNECOL, V118, P778, DOI 10.1016/0002-9378(74)90487-6; BURCH JC, 1971, ANN SURG, V174, P414, DOI 10.1097/00000658-197109000-00010; BURING JE, 1987, AM J EPIDEMIOL, V125, P939, DOI 10.1093/oxfordjournals.aje.a114632; BURING JE, 1986, AM J EPIDEMIOL, V124, P434, DOI 10.1093/oxfordjournals.aje.a114414; BUSH TL, 1987, CIRCULATION, V75, P1102, DOI 10.1161/01.CIR.75.6.1102; BUSH TL, 1990, MENOPAUSE BIOL CLIN, P211; BYRD BF, 1977, ANN SURG, V185, P574, DOI 10.1097/00000658-197705000-00010; BYRD BF, 1973, ANN SURG, V177, P626; CAMPBELL S, 1977, CLIN OBSTET GYNAECOL, V4, P31; CAMPBELL S, 1976, MANAGEMENT MENOPAUSE, P227; CASAGRANDE J, 1976, J NATL CANCER I, V56, P839, DOI 10.1093/jnci/56.4.839; CAULEY JA, 1983, ATHEROSCLEROSIS, V49, P31, DOI 10.1016/0021-9150(83)90005-9; Chiang C., 1968, INTRO STOCHASTIC PRO; CHRISTIANSEN C, 1985, LANCET, V2, P800; CHRISTIANSEN C, 1981, LANCET, V1, P459; CHU J, 1982, AM J OBSTET GYNECOL, V143, P569, DOI 10.1016/0002-9378(82)90549-X; CLARKSON TB, 1990, OBSTET GYNECOL, V75, P217; COLDITZ GA, 1990, JAMA-J AM MED ASSOC, V264, P2648, DOI 10.1001/jama.264.20.2648; COLLINS J, 1980, LANCET, V2, P961; CRILLY RG, 1978, POSTGRAD MED J, V54, P47; CRIQUI MH, 1988, AM J EPIDEMIOL, V128, P606, DOI 10.1093/oxfordjournals.aje.a115008; CROFT P, 1989, BRIT MED J, V298, P165, DOI 10.1136/bmj.298.6667.165; CUMMINGS SR, 1990, ANN INTERN MED, V113, P565, DOI 10.7326/0003-4819-113-8-565; CUMMINGS SR, 1989, ARCH INTERN MED, V149, P2445, DOI 10.1001/archinte.149.11.2445; CUMMINGS SR, 1985, EPIDEMIOL REV, V7, P178, DOI 10.1093/oxfordjournals.epirev.a036281; CUMMINGS SR, 1987, OSTEOPOROSIS 1987, P1193; DELIGNIERES B, 1982, MATURITAS, V4, P67, DOI 10.1016/0378-5122(82)90021-4; DENNERSTEIN L, 1986, MATURITAS, V8, P101, DOI 10.1016/0378-5122(86)90016-2; DENNERSTEIN L, 1980, OBSTET GYNECOL, V56, P316; DEQUEKER J, 1982, MATURITAS, V4, P309, DOI 10.1016/0378-5122(82)90063-9; DEVOR M, 1992, AM J MED, V92, P275, DOI 10.1016/0002-9343(92)90077-O; DITKOFF EC, 1991, OBSTET GYNECOL, V78, P991; DUPONT WD, 1991, ARCH INTERN MED, V151, P67, DOI 10.1001/archinte.151.1.67; DUPONT WD, 1989, CANCER-AM CANCER SOC, V63, P948, DOI 10.1002/1097-0142(19890301)63:5<948::AID-CNCR2820630527>3.0.CO;2-U; EAKER ED, 1987, CORONARY HEART DISEA, P122; ELWOOD JM, 1977, J NATL CANCER I, V59, P1055, DOI 10.1093/jnci/59.4.1055; ERNSTER VL, 1986, OBSTET GYNECOL, V68, P715; ETTINGER B, 1985, ANN INTERN MED, V102, P319, DOI 10.7326/0003-4819-102-3-319; ETTINGER B, 1988, MATURITAS, V10, P271, DOI 10.1016/0378-5122(88)90063-1; EWERTZ M, 1988, INT J CANCER, V42, P832, DOI 10.1002/ijc.2910420606; EWERTZ M, 1988, EUR J CANCER CLIN ON, V24, P189, DOI 10.1016/0277-5379(88)90251-9; FABER P, 1977, UROL INT, V32, P221, DOI 10.1159/000280134; FAHRAEUS L, 1986, FERTIL STERIL, V45, P503; FAHRAEUS L, 1983, J CLIN ENDOCR METAB, V56, P797, DOI 10.1210/jcem-56-4-797; FARMER ME, 1984, AM J PUBLIC HEALTH, V74, P1374, DOI 10.2105/AJPH.74.12.1374; Fedor-Freybergh P, 1977, Acta Obstet Gynecol Scand Suppl, V64, P1; FERENCZY A, 1978, CONT OB GYN, V11, P137; FINUCANE F, 1991, CIRCULATION, V83, pP23; FINUCANE F, 1993, IN PRESS ARCH INTERN; Fisher E S, 1991, Epidemiology, V2, P116, DOI 10.1097/00001648-199103000-00005; Gambrell R D Jr, 1981, Acta Obstet Gynecol Scand Suppl, V106, P37; GAMBRELL RD, 1980, OBSTET GYNECOL, V55, P732; GAMBRELL RD, 1986, MATURITAS, V8, P159, DOI 10.1016/0378-5122(86)90022-8; GAMBRELL RD, 1984, SOUTHERN MED J, V77, P1509, DOI 10.1097/00007611-198412000-00009; GAMBRELL RD, 1978, MATURITAS, V1, P107, DOI 10.1016/0378-5122(78)90017-8; GAMBRELL RD, 1982, J REPROD MED, V27, P531; GAMBRELL RD, 1984, AM J OBSTET GYNECOL, V150, P119; GAMBRELL RD, 1978, MATURITAS, V1, P99, DOI 10.1016/0378-5122(78)90016-6; GAMBRELL RD, 1983, OBSTET GYNECOL, V62, P435; GELFAND MM, 1989, OBSTET GYNECOL, V74, P398; GOLDSTEIN SR, 1990, AM J OBSTET GYNECOL, V163, P119, DOI 10.1016/S0002-9378(11)90683-8; GORDON T, 1978, ANN INTERN MED, V89, P157, DOI 10.7326/0003-4819-89-2-157; GRADY D, 1991, AM J EPIDEMIOL, V134, P1396, DOI 10.1093/oxfordjournals.aje.a116043; GRANBERG S, 1991, AM J OBSTET GYNECOL, V164, P47, DOI 10.1016/0002-9378(91)90622-X; GRAY LA, 1977, OBSTET GYNECOL, V49, P385; GREENLAND S, 1987, EPIDEMIOL REV, V9, P1; GRUCHOW HW, 1988, AM HEART J, V115, P954, DOI 10.1016/0002-8703(88)90063-4; GUSBERG SB, 1976, AM J OBSTET GYNECOL, V126, P535, DOI 10.1016/0002-9378(76)90744-4; HAMMOND CB, 1979, AM J OBSTET GYNECOL, V133, P525, DOI 10.1016/0002-9378(79)90288-6; HAMMOND CB, 1979, AM J OBSTET GYNECOL, V133, P537, DOI 10.1016/0002-9378(79)90289-8; HARGROVE JT, 1989, OBSTET GYNECOL, V73, P606; HELLBERG D, 1987, MATURITAS, V9, P103, DOI 10.1016/0378-5122(87)90058-2; HENDERSO.BE, 1974, J NATL CANCER I, V53, P609, DOI 10.1093/jnci/53.3.609; HENDERSON BE, 1988, AM J OBSTET GYNECOL, V159, P312, DOI 10.1016/S0002-9378(88)80074-7; HENDERSON BE, 1983, BRIT J CANCER, V47, P749, DOI 10.1038/bjc.1983.127; HENDERSON BE, 1991, ARCH INTERN MED, V151, P75, DOI 10.1001/archinte.151.1.75; HIATT RA, 1984, CANCER, V54, P139, DOI 10.1002/1097-0142(19840701)54:1<139::AID-CNCR2820540128>3.0.CO;2-X; HOLST J, 1987, MATURITAS, V9, P63, DOI 10.1016/0378-5122(87)90053-3; HOLST J, 1989, MATURITAS, V11, P13, DOI 10.1016/0378-5122(89)90116-3; HOOGERLAND DL, 1978, GYNECOL ONCOL, V6, P451, DOI 10.1016/0090-8258(78)90054-9; HOOVER R, 1976, NEW ENGL J MED, V295, P401, DOI 10.1056/NEJM197608192950801; HOOVER R, 1976, LANCET, V1, P885; HOOVER R, 1981, J NATL CANCER I, V67, P815; HORWITZ RI, 1978, NEW ENGL J MED, V299, P1089, DOI 10.1056/NEJM197811162992001; HORWITZ RI, 1984, AM J MED, V76, P192, DOI 10.1016/0002-9343(84)90773-3; HULKA BS, 1982, AM J OBSTET GYNECOL, V143, P638, DOI 10.1016/0002-9378(82)90108-9; HULKA BS, 1980, AM J OBSTET GYNECOL, V137, P92, DOI 10.1016/0002-9378(80)90391-9; HULKA BS, 1980, JAMA-J AM MED ASSOC, V244, P2419; HUNT K, 1990, BRIT J OBSTET GYNAEC, V97, P1080, DOI 10.1111/j.1471-0528.1990.tb02494.x; HUNT K, 1987, BRIT J OBSTET GYNAEC, V94, P620, DOI 10.1111/j.1471-0528.1987.tb03166.x; HUTCHINSON TA, 1979, LANCET, V2, P705; Iversen O E, 1985, Obstet Gynecol Surv, V40, P14, DOI 10.1097/00006254-198501000-00002; JABER R, 1988, J FAM PRACTICE, V26, P67; JELOVSEK FR, 1980, AM J OBSTET GYNECOL, V137, P85, DOI 10.1016/0002-9378(80)90390-7; JENSEN J, 1986, BRIT J OBSTET GYNAEC, V93, P613, DOI 10.1111/j.1471-0528.1986.tb08035.x; JENSEN J, 1987, AM J OBSTET GYNECOL, V156, P66, DOI 10.1016/0002-9378(87)90204-3; JICK H, 1980, AM J EPIDEMIOL, V112, P586, DOI 10.1093/oxfordjournals.aje.a113031; JICK H, 1979, NEW ENGL J MED, V300, P218, DOI 10.1056/NEJM197902013000502; JICK H, 1978, JAMA-J AM MED ASSOC, V239, P1407, DOI 10.1001/jama.239.14.1407; JICK H, 1978, JAMA-J AM MED ASSOC, V240, P2548, DOI 10.1001/jama.240.23.2548; JOHNSON RE, 1981, AM J PUBLIC HEALTH, V71, P138, DOI 10.2105/AJPH.71.2.138; KABLE WT, 1990, J REPROD MED, V35, P512; KANNEL WB, 1987, NIH872703 PUBL; KAUFMAN DW, 1984, JAMA-J AM MED ASSOC, V252, P63, DOI 10.1001/jama.252.1.63; KAUFMAN DW, 1991, AM J EPIDEMIOL, V134, P1375, DOI 10.1093/oxfordjournals.aje.a116041; KELSEY JL, 1981, JNCI-J NATL CANCER I, V67, P327; KELSEY JL, 1982, AM J EPIDEMIOL, V116, P333, DOI 10.1093/oxfordjournals.aje.a113417; KENNEDY DL, 1985, OBSTET GYNECOL, V65, P441; KEY TJA, 1988, EUR J CANCER CLIN ON, V24, P29, DOI 10.1016/0277-5379(88)90173-3; KIEL DP, 1987, NEW ENGL J MED, V317, P1169, DOI 10.1056/NEJM198711053171901; KNOPP RH, 1988, AM J OBSTET GYNECOL, V158, P1630, DOI 10.1016/0002-9378(88)90201-3; KOSS LG, 1984, OBSTET GYNECOL, V64, P1; KRAUSS RM, 1988, AM J OBSTET GYNECOL, V158, P1606, DOI 10.1016/0002-9378(88)90198-6; KREIGER N, 1982, AM J EPIDEMIOL, V116, P141, DOI 10.1093/oxfordjournals.aje.a113388; LAFFERTY FW, 1985, MATURITAS, V7, P147, DOI 10.1016/0378-5122(85)90021-0; LAROSA JC, 1985, J REPROD MED, V30, P811; LAVECCHIA C, 1987, AM J EPIDEMIOL, V125, P832, DOI 10.1093/oxfordjournals.aje.a114599; LAVECCHIA C, 1986, BRIT J CANCER, V54, P311, DOI 10.1038/bjc.1986.178; LAVECCHIA C, 1986, INT J CANCER, V38, P853, DOI 10.1002/ijc.2910380612; LAVECCHIA C, 1984, J NATL CANCER I, V73, P667; LAWSON DH, 1981, AM J EPIDEMIOL, V114, P710, DOI 10.1093/oxfordjournals.aje.a113242; LINDSAY R, 1980, LANCET, V2, P1151; LINDSAY R, 1978, LANCET, V1, P1325; LINDSAY R, 1978, CLIN SCI MOL MED, V54, P193, DOI 10.1042/cs0540193; LUCIANO AA, 1988, OBSTET GYNECOL, V71, P39; LUFKIN EG, 1992, ANN INTERN MED, V117, P1, DOI 10.7326/0003-4819-117-1-1; MACK TM, 1976, NEW ENGL J MED, V294, P1262, DOI 10.1056/NEJM197606032942304; MACK TM, 1975, NEW ENGL J MED, V292, P1366, DOI 10.1056/NEJM197506262922603; MACMAHON B, 1978, CORONARY HEART DISEA, P197; MAGAZINER J, 1989, AM J PUBLIC HEALTH, V79, P274, DOI 10.2105/AJPH.79.3.274; MAGOS AL, 1985, OBSTET GYNECOL, V65, P496; MASHCHAK CA, 1985, J REPROD MED, V30, P805; MATTSSON LA, 1982, MATURITAS, V4, P95, DOI 10.1016/0378-5122(82)90035-4; MCBRIDE JM, 1959, J OBSTET GYN BR COMM, V54, P521; MCDONALD JA, 1986, BREAST CANCER RES TR, V7, P193, DOI 10.1007/BF01806250; MCDONALD TW, 1977, AM J OBSTET GYNECOL, V127, P572, DOI 10.1016/0002-9378(77)90351-9; MCFARLAND KF, 1989, AM HEART J, V117, P1209, DOI 10.1016/0002-8703(89)90398-0; MCGILL HC, 1989, POSTGRAD MED     APR, P64; MILLER CW, 1978, J BONE JOINT SURG AM, V60, P930, DOI 10.2106/00004623-197860070-00010; MILLER V, 1990, BIOMEDICAL ADV AGING, P531; MILLER VT, 1991, OBSTET GYNECOL, V77, P235, DOI 10.1097/00006250-199102000-00014; MILLS PK, 1989, CANCER, V64, P591, DOI 10.1002/1097-0142(19890801)64:3<591::AID-CNCR2820640305>3.0.CO;2-U; MUSIANI U, 1972, UROL INT, V27, P405, DOI 10.1159/000279809; MYERS LS, 1990, J CLIN ENDOCR METAB, V70, P1124, DOI 10.1210/jcem-70-4-1124; NACHTIGALL LE, 1979, OBSTET GYNECOL, V53, P277; NACHTIGALL LE, 1979, OBSTET GYNECOL, V54, P74, DOI 10.1097/00006250-197907000-00017; NAESSEN T, 1990, ANN INTERN MED, V113, P95, DOI 10.7326/0003-4819-113-2-95; NASRI MN, 1989, BRIT J OBSTET GYNAEC, V96, P1333, DOI 10.1111/j.1471-0528.1989.tb03233.x; NOMURA AMY, 1986, INT J CANCER, V37, P49, DOI 10.1002/ijc.2910370109; OSMERS R, 1990, LANCET, V335, P1569, DOI 10.1016/0140-6736(90)91387-P; Paganini-Hill A, 1991, Epidemiology, V2, P16; PAGANINIHILL A, 1981, ANN INTERN MED, V95, P28, DOI 10.7326/0003-4819-95-1-28; PAGANINIHILL A, 1988, BMJ-BRIT MED J, V297, P519, DOI 10.1136/bmj.297.6647.519; PAGANINIHILL A, 1989, BRIT J CANCER, V59, P445, DOI 10.1038/bjc.1989.91; PAGANINIHILL A, 1988, INT J CANCER, V42, P832; PALMER JR, 1991, AM J EPIDEMIOL, V134, P1386, DOI 10.1093/oxfordjournals.aje.a116042; PATERSON MEL, 1980, BRIT MED J, V280, P822, DOI 10.1136/bmj.280.6217.822; PERSSON I, 1989, BRIT MED J, V298, P147, DOI 10.1136/bmj.298.6667.147; PERSSON IR, 1986, ACTA OBSTET GYN SCAN, V65, P211, DOI 10.3109/00016348609155173; PETITTI DB, 1979, JAMA-J AM MED ASSOC, V242, P1150, DOI 10.1001/jama.242.11.1150; PETITTI DB, 1988, GASTROENTEROLOGY, V94, P91, DOI 10.1016/0016-5085(88)90614-2; PETITTI DB, 1987, OBSTET GYNECOL, V70, P289; PETITTI DB, 1986, NEW ENGL J MED, V315, P131; PETITTI DB, 1978, AM J EPIDEMIOL, V108, P480, DOI 10.1093/oxfordjournals.aje.a112646; PFEFFER RI, 1978, AM J EPIDEMIOL, V107, P479, DOI 10.1093/oxfordjournals.aje.a112567; PFEFFER RI, 1976, AM J EPIDEMIOL, V103, P445, DOI 10.1093/oxfordjournals.aje.a112246; PROUGH SG, 1987, AM J OBSTET GYNECOL, V157, P1449, DOI 10.1016/S0002-9378(87)80242-9; PUNNONEN R, 1981, MATURITAS, V3, P309, DOI 10.1016/0378-5122(81)90039-6; PUNNONEN R, 1984, MATURITAS, V5, P259, DOI 10.1016/0378-5122(84)90019-7; PUNNONEN R, 1987, ANN CHIR GYNAECOL FE, V76, P39; PUNNONEN R, 1972, ACTA OBSTET GYNECO S, V21, P1; RAVNIHAR B, 1979, EUR J CANCER, V15, P395, DOI 10.1016/0014-2964(79)90074-4; ROBBOY SJ, 1979, OBSTET GYNECOL, V54, P269; ROBIN JC, 1983, STEROIDS, V42, P669, DOI 10.1016/0039-128X(83)90130-7; ROHAN TE, 1988, MED J AUSTRALIA, V148, P217; ROSENBERG L, 1976, NEW ENGL J MED, V294, P1256, DOI 10.1056/NEJM197606032942302; ROSENBERG L, 1980, JAMA-J AM MED ASSOC, V244, P339, DOI 10.1001/jama.244.4.339; ROSENBERG SH, 1980, WESTERN J MED, V133, P292; ROSS RK, 1980, JAMA-J AM MED ASSOC, V243, P1635, DOI 10.1001/jama.243.16.1635; ROSS RK, 1981, LANCET, V1, P858; RUBIN GL, 1990, AM J OBSTET GYNECOL, V162, P148, DOI 10.1016/0002-9378(90)90838-X; SALKEBORN M, 1992, IN PRESS BR J OBST G, V99; Salmi T, 1980, Acta Endocrinol Suppl (Copenh), V233, P37; SARTWELL PE, 1977, JNCI-J NATL CANCER I, V59, P1589, DOI 10.1093/jnci/59.6.1589; SCHIFF I, 1982, FERTIL STERIL, V37, P79; SCHLEYERSAUNDERS E, 1976, J AM GERIATR SOC, V24, P337, DOI 10.1111/j.1532-5415.1976.tb03308.x; SELBY PL, 1985, CLIN SCI, V69, P265, DOI 10.1042/cs0690265; SHAPIRO S, 1980, NEW ENGL J MED, V303, P485, DOI 10.1056/NEJM198008283030903; SHAPIRO S, 1985, NEW ENGL J MED, V313, P969, DOI 10.1056/NEJM198510173131601; SHERMAN B, 1983, CANCER, V51, P1527, DOI 10.1002/1097-0142(19830415)51:8<1527::AID-CNCR2820510828>3.0.CO;2-T; SHERWIN BB, 1989, OBSTET GYNECOL, V73, P759; SMITH DC, 1975, NEW ENGL J MED, V293, P1164, DOI 10.1056/NEJM197512042932302; SPENGLER RF, 1981, AM J EPIDEMIOL, V114, P497, DOI 10.1093/oxfordjournals.aje.a113215; SPORRONG T, 1988, BRIT J OBSTET GYNAEC, V95, P1042, DOI 10.1111/j.1471-0528.1988.tb06511.x; STALAND B, 1981, MATURITAS, V3, P145, DOI 10.1016/0378-5122(81)90006-2; STAMPFER MJ, 1986, AM J EPIDEMIOL, V124, P520; STAMPFER MJ, 1991, NEW ENGL J MED, V325, P756, DOI 10.1056/NEJM199109123251102; STAMPFER MJ, 1991, PREV MED, V20, P47, DOI 10.1016/0091-7435(91)90006-P; STAMPFER MJ, 1985, NEW ENGL J MED, V313, P1044, DOI 10.1056/NEJM198510243131703; STAVRAKY KM, 1981, AM J OBSTET GYNECOL, V141, P547, DOI 10.1016/S0002-9378(15)33276-2; STEINBERG KK, 1991, JAMA-J AM MED ASSOC, V265, P1985, DOI 10.1001/jama.265.15.1985; SULLIVAN JM, 1990, ARCH INTERN MED, V150, P2557, DOI 10.1001/archinte.150.12.2557; SULLIVAN JM, 1988, ANN INTERN MED, V108, P358, DOI 10.7326/0003-4819-108-3-358; SZKLO M, 1984, PREV MED, V13, P510, DOI 10.1016/0091-7435(84)90019-7; TALBOTT E, 1977, AM J CARDIOL, V39, P858, DOI 10.1016/S0002-9149(77)80040-4; TELINDE RW, 1985, OPERATIVE GYNECOLOGY, P245; THOM MH, 1979, LANCET, V2, P455; THOMAS DB, 1982, JNCI-J NATL CANCER I, V69, P1017; THOMPSON SG, 1989, J EPIDEMIOL COMMUN H, V43, P173, DOI 10.1136/jech.43.2.173; TSEVAT J, 1991, CIRCULATION, V83, P1194, DOI 10.1161/01.CIR.83.4.1194; VAKIL DV, 1983, CANCER DETECT PREV, V6, P415; VARNER RE, 1991, OBSTET GYNECOL, V78, P195; VOIGT LF, 1991, LANCET, V338, P274, DOI 10.1016/0140-6736(91)90417-N; WALTER S, 1978, UROL INT, V33, P135, DOI 10.1159/000280190; WEINSTEIN L, 1987, OBSTET GYNECOL, V69, P929; WEINSTEIN L, 1990, AM J OBSTET GYNECOL, V162, P1534, DOI 10.1016/0002-9378(90)90917-V; WEISS NS, 1980, NEW ENGL J MED, V303, P1195, DOI 10.1056/NEJM198011203032102; WEISS NS, 1979, JAMA-J AM MED ASSOC, V242, P261, DOI 10.1001/jama.242.3.261; WEISS NS, 1980, MATURITAS, V2, P185, DOI 10.1016/0378-5122(80)90003-1; WEISS NS, 1983, J CHRON DIS, V36, P879, DOI 10.1016/0021-9681(83)90009-7; WHITEHEAD MI, 1987, OBSTET GYN CLIN N AM, V14, P299; WHITEHEAD MI, 1990, OBSTET GYNECOL, V75, pS59; WHITEHEAD MI, 1981, NEW ENGL J MED, V305, P1599, DOI 10.1056/NEJM198112313052701; WHITEHEAD MI, 1978, MATURITAS, V1, P87, DOI 10.1016/0378-5122(78)90015-4; WHITEHEAD MI, 1982, J REPROD MED, V27, P539; WIGLE DT, 1978, CAN MED ASSOC J, V118, P1276; WILLIAMS AR, 1982, OBSTET GYNECOL, V60, P695; WILSON PD, 1987, BRIT J OBSTET GYNAEC, V94, P568, DOI 10.1111/j.1471-0528.1987.tb03152.x; WILSON PWF, 1985, NEW ENGL J MED, V313, P1038, DOI 10.1056/NEJM198510243131702; WINGO PA, 1987, JAMA-J AM MED ASSOC, V257, P209, DOI 10.1001/jama.257.2.209; WOLF PH, 1991, AM J OBSTET GYNECOL, V164, P489, DOI 10.1016/S0002-9378(11)80006-2; WYNDER EL, 1978, CANCER-AM CANCER SOC, V41, P2341, DOI 10.1002/1097-0142(197806)41:6<2341::AID-CNCR2820410637>3.0.CO;2-N; YLIKORKALA O, 1987, J CLIN ENDOCR METAB, V65, P1238, DOI 10.1210/jcem-65-6-1238; ZIEL HK, 1975, NEW ENGL J MED, V293, P1167, DOI 10.1056/NEJM197512042932303; 1988, CANCER 1987 A 882789; 1992, ACOG TECHNICAL B, V166, P1; 1990, VITAL STATISTICS U A, V2	265	1975	2017	1	107	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 15	1992	117	12					1016	1037		10.7326/0003-4819-117-12-1016	http://dx.doi.org/10.7326/0003-4819-117-12-1016			22	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KB980	1443971				2023-01-03	WOS:A1992KB98000008
J	KINMONTH, AL; FULTON, Y; CAMPBELL, MJ				KINMONTH, AL; FULTON, Y; CAMPBELL, MJ			MANAGEMENT OF FEVERISH CHILDREN AT HOME	BRITISH MEDICAL JOURNAL			English	Article							YOUNG-CHILDREN	Objectives-To compare the acceptability and effects on temperature of advice to unwrap children and give paracetamol or warm sponging treatments in the management of feverish illness at home. Design-A randomised, open, parallel group study using factorial design comparison of unwrapping, warm sponging plus unwrapping, paracetamol plus unwrapping, and paracetamol and warm sponging plus unwrapping. Setting-Homes of willing families with a feverish child recruited after consulting one of 21 participating general practitioners in Southampton. Subjects-52 children aged from 3 months to 5 years with axillary temperatures before treatment of greater-than-or-equal-to 37.8-degrees-C and < 40-degrees-C. Main outcome measures-Response to advice assessed over four hours; temperature assessed by continuous data logging from an axillary thermistor; acceptability of treatment to child and parent scored on Likert scales immediately after treatment and on return to health. Results-Response to treatment advice varied; unwrapping alone had little effect on temperature. Paracetamol increased the time below 37.2-degrees-C in four hours by 109 (95% confidence interval 74 to 145) minutes compared with unwrapping; warm sponging caused the fastest reduction in temperature. Parents discriminated between treatments, preferring paracetamol. Conclusion-Advice to give paracetamol is more effective than sponging or unwrapping in controlling temperature in children at home and is more acceptable to parents. Warm sponging has an additive effect and reduces fever more quickly than paracetamol.	SOUTHAMPTON GEN HOSP,COLL NURSING,SOUTHAMPTON SO9 4XY,HANTS,ENGLAND; UNIV SOUTHAMPTON,SOUTHAMPTON GEN HOSP,SOUTHAMPTON S09 4XY,ENGLAND	University of Southampton; University of Southampton	KINMONTH, AL (corresponding author), UNIV SOUTHAMPTON,ALDERMOOR HEALTH CTR,SOUTHAMPTON SO1 6ST,ENGLAND.							AYRES R, 1986, THESIS U SOUTHAMPTON; BAIN J, 1986, THESIS U ABERDEEN; HUNTER J, 1973, ARCH DIS CHILD, V48, P313, DOI 10.1136/adc.48.4.313; ILLINGWORTH RS, 1971, TREATMENT CHILD HOME, P171; KLUGER MJ, 1980, PEDIATRICS, V66, P720; KRAMER MS, 1991, LANCET, V337, P591, DOI 10.1016/0140-6736(91)91648-E; MATTHEWS JNS, 1990, BRIT MED J, V300, P230, DOI 10.1136/bmj.300.6719.230; NEWMAN J, 1985, CAN MED ASSOC J, V132, P641; PANTELL RH, 1980, CLIN PEDIATR, V19, P77, DOI 10.1177/000992288001900201; RYLANCE GW, 1988, BMJ-BRIT MED J, V297, P445, DOI 10.1136/bmj.297.6646.445; SCHWARTZ D, 1967, J CHRON DIS, V20, P637, DOI 10.1016/0021-9681(67)90041-0; SOMAN M, 1985, J FAM PRACTICE, V21, P117; STEELE RW, 1970, J PEDIATR-US, V77, P824, DOI 10.1016/S0022-3476(70)80242-6; TAYLOR JP, 1985, AM J DIS CHILD, V139, P486, DOI 10.1001/archpedi.1985.02140070060034; 1986, MORBIDITY STATISTICS	15	31	32	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 7	1992	305	6862					1134	1136		10.1136/bmj.305.6862.1134	http://dx.doi.org/10.1136/bmj.305.6862.1134			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JX841	1463951	Bronze, Green Submitted, Green Published			2023-01-03	WOS:A1992JX84100025
J	BRODY, H				BRODY, H			ASSISTED DEATH - A COMPASSIONATE RESPONSE TO A MEDICAL FAILURE	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							EUTHANASIA; SUICIDE; ETHICS				BRODY, H (corresponding author), MICHIGAN STATE UNIV, DEPT FAMILY PRACTICE, CTR CLIN B100, E LANSING, MI 48824 USA.		Brody, Howard/GQA-6310-2022					ADMIRAAL PV, 1984, JUSTIFIED EUTHANASIA; [Anonymous], 1992, HARVARD LAW REV, V105, P2021; ARRAS JD, 1991, J MED PHILOS, V16, P29, DOI 10.1093/jmp/16.1.29; Battin M, 1992, Law Med Health Care, V20, P133; Benjamin Martin, 1990, SPLITTING DIFFERENCE; BENRUBI GI, 1992, NEW ENGL J MED, V326, P197, DOI 10.1056/NEJM199201163260311; Brody H., 1987, STORIES SICKNESS; BRODY H, 1992, HEALERS POWER; CALLAHAN D, 1977, HASTINGS CENT REP, V7, P32, DOI 10.2307/3560692; Callahan D., 1987, SETTING LIMITS MED G; CALLAHAN D, 1991, COMMONWEAL S    0809, P12; CASSEL CK, 1990, NEW ENGL J MED, V323, P750, DOI 10.1056/NEJM199009133231110; CONWELL Y, 1991, NEW ENGL J MED, V325, P1100, DOI 10.1056/NEJM199110103251511; CRANFORD RE, 1984, I ETHICS COMMITTEES; DEWACHTER MAM, 1989, JAMA-J AM MED ASSOC, V262, P3316, DOI 10.1001/jama.262.23.3316; Drane JF, 1988, BECOMING GOOD DOCTOR; DUFFY TP, 1992, NEW ENGL J MED, V326, P933, DOI 10.1056/NEJM199204023261406; FENIGSEN R, 1991, ISSUES LAW MED, V7, P339; FOLEY KM, 1991, J PAIN SYMPTOM MANAG, V6, P289, DOI 10.1016/0885-3924(91)90052-6; GAYLIN W, 1988, JAMA-J AM MED ASSOC, V259, P2139; Gomez Carlos F., 1991, REGULATING DEATH EUT; GOMEZ CF, 1991, COMMONWEAL S, P5; Hampshire Stuart., 1983, MORALITY CONFLICT; Humphry, 1991, FINAL EXIT PRACTICAL; Jonsen Albert R., 1988, ABUSE CASUISTRY HIST; JONSEN AR, 1991, THEOR MED, V12, P295, DOI 10.1007/BF00489890; JONSEN AR, 1991, COMMONWEAL S, P2; KANOTI GA, 1987, HLTH CARE ETHICS GUI, P293; KASS LR, 1989, PUBLIC INTEREST, P25; KASS LR, 1991, COMMONWEAL S, P8; KEVORKIAN J, 1991, PRESCRIPTION MEDICID; LADD J, 1980, LANCET, V2, P1127; LO B, 1987, NEW ENGL J MED, V317, P46, DOI 10.1056/NEJM198707023170110; May W E, 1987, Issues Law Med, V3, P203; Miller R J, 1992, Law Med Health Care, V20, P127, DOI 10.1111/j.1748-720X.1992.tb01179.x; MISBIN RI, 1991, NEW ENGL J MED, V325, P1307, DOI 10.1056/NEJM199110313251811; ORENTLICHER D, 1990, JAMA-J AM MED ASSOC, V263, P2365, DOI 10.1001/jama.263.17.2365; Pellegrino E., 1981, PHILOS BASIS MED PRA; Pellegrino E., 1988, PATIENTS GOOD RESTOR; Pellegrino E D, 1992, J Clin Ethics, V3, P95; PENCE GE, 1988, AM J MED, V84, P139, DOI 10.1016/0002-9343(88)90022-8; PUTNAM H, 1983, NOT SOLVE ETHICAL PR; QUILL TE, 1991, NEW ENGL J MED, V324, P691, DOI 10.1056/NEJM199103073241010; RACHELS J., 1986, END LIFE EUTHANASIA; SHAFFER CD, 1986, COLUMBIA LAW REV, V86, P348, DOI 10.2307/1122707; Shelp E. E., 1985, VIRTUE MED EXPLORATI; SINGER PA, 1990, NEW ENGL J MED, V322, P1881, DOI 10.1056/NEJM199006283222610; van der Maas PJ, 1991, LANCET, V338, P669, DOI 10.1016/0140-6736(91)91241-L; VANCE R, 1985, PERSPECT BIOL MED, V28, P282; WANZER SH, 1989, NEW ENGL J MED, V320, P844, DOI 10.1056/NEJM198903303201306; Weir R F, 1992, Law Med Health Care, V20, P116, DOI 10.1111/j.1748-720X.1992.tb01178.x; WILSON WC, 1992, JAMA-J AM MED ASSOC, V267, P949; WOLF SM, 1989, HASTINGS CENT REP, V19, pS13; 1988, EUTHANASIA REPORT RE	54	108	108	0	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 5	1992	327	19					1384	1388		10.1056/NEJM199211053271912	http://dx.doi.org/10.1056/NEJM199211053271912			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JW077	1383820				2023-01-03	WOS:A1992JW07700012
J	DAYSON, D; GOOCH, C; THORNICROFT, G				DAYSON, D; GOOCH, C; THORNICROFT, G			THE TAPS PROJECT .16. DIFFICULT TO PLACE, LONG-TERM PSYCHIATRIC-PATIENTS - RISK-FACTORS FOR FAILURE TO RESETTLE LONG STAY PATIENTS IN COMMUNITY FACILITIES	BRITISH MEDICAL JOURNAL			English	Article								Objective-To identify patients who could not be resettled in the community as part of the closure plans of two psychiatric hospitals and to determine their numbers and risk factors for failure. Design and setting-Prospective study of the closure of Friern and Claybury psychiatric hospitals. Patients-The first third (369) of long stay psychiatric patients to be resettled. Outcome measures-Reasons for patients being readmitted to hospital and not leaving the patients' service needs. Results-22-6% of both hospitals' long stay patients-were not successfully resettled in the community. Eighteen continuing care places per 100 000 of catchment area population seem to be required for this group. Patients whose placements were unsuccessful were usually readmitted because of a deterioration of their mental state and aggressive behavior, both of which persisted and necessitated their continuing stay in hospital, often in a locked ward. Risk factors associated with failure were a high level of psychosis; a diagnosis of paranoid psychosis; incontinence; and being male. But having a social network, especially a large one, seemed to aid successful placement in the community. Conclusion-Rehabilitation efforts should be focused on the characteristics of these patients that put them at risk of failing to succeed in community placements.	INST PSYCHIAT,LONDON SE5 8AF,ENGLAND	University of London; King's College London	DAYSON, D (corresponding author), FRIERN HOSP,TAPS RES UNIT,LONDON N11 3BP,ENGLAND.		Thornicroft, Graham/B-4027-2010	Thornicroft, Graham/0000-0003-0662-0879				ANDERSON J, IN PRESS BR J PSYCHI; CHRISTIEBROWN JRW, 1977, PSYCHOL MED, V7, P113; COID JW, 1991, BRIT MED J, V302, P603, DOI 10.1136/bmj.302.6777.603; DAYSON D, IN PRESS BR J PSYCHI; DUNN M, 1990, BRIT J PSYCHIAT, V157, P842, DOI 10.1192/bjp.157.6.842; HERXHEIMER A, 1991, DRUG THERAPEUTIC B, V29, P41; KENDELL RE, 1989, BRIT MED J, V299, P1237, DOI 10.1136/bmj.299.6710.1237; LEFF J, 1990, BRIT J PSYCHIAT, V157, P848, DOI 10.1192/bjp.157.6.848; STURT E, 1986, BRIT J PSYCHIAT, V148, P1; THORNICROFT G, 1989, BRIT J PSYCHIAT, V155, P739, DOI 10.1192/bjp.155.6.739; THORNICROFT G, IN PRESS TAPS PROJEC; WING JK, 1990, BRIT J PSYCHIAT, V157, P822, DOI 10.1192/bjp.157.6.822; Wing JK, 1974, DESCRIPTION CLASSIFI; 1992, HLTH NATION; 1991, HLTH NATION	15	26	27	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 24	1992	305	6860					993	995		10.1136/bmj.305.6860.993	http://dx.doi.org/10.1136/bmj.305.6860.993			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	JV776	1458147	Green Published, Bronze, Green Submitted			2023-01-03	WOS:A1992JV77600027
J	SIMONS, FER; GILLESPIE, CA; SIMONS, KJ				SIMONS, FER; GILLESPIE, CA; SIMONS, KJ			LOCAL-ANESTHETIC CREAMS AND INTRADERMAL SKIN-TESTS	LANCET			English	Letter							HISTAMINE; ANESTHESIA; FLARE				SIMONS, FER (corresponding author), UNIV MANITOBA,FAC MED,DEPT PEDIAT & CHILD HLTH,WINNIPEG R3A 1S1,MANITOBA,CANADA.							BJERRING P, 1990, BRIT J ANAESTH, V64, P173, DOI 10.1093/bja/64.2.173; BOUSQUET J, 1988, ALLERGY PRINCIPLES P, P419; HARPER EI, 1989, AGENTS ACTIONS, V28, P192, DOI 10.1007/BF01967400; PIPKORN U, 1987, CLIN ALLERGY, V17, P307, DOI 10.1111/j.1365-2222.1987.tb02019.x; SHUTTLEWORTH D, 1988, BRIT J DERMATOL, V119, P535, DOI 10.1111/j.1365-2133.1988.tb03259.x; SIMONS FER, 1990, J ALLERGY CLIN IMMUN, V86, P540	6	15	16	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 30	1992	339	8805					1351	1352		10.1016/0140-6736(92)91994-J	http://dx.doi.org/10.1016/0140-6736(92)91994-J			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HW837	1350007				2023-01-03	WOS:A1992HW83700026
J	ZARDENETA, G; HOROWITZ, PM				ZARDENETA, G; HOROWITZ, PM			MICELLE-ASSISTED PROTEIN FOLDING - DENATURED RHODANESE BINDING TO CARDIOLIPIN-CONTAINING LAURYL MALTOSIDE MICELLES RESULTS IN SLOWER REFOLDING KINETICS BUT GREATER ENZYME REACTIVATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANIDINIUM CHLORIDE; MITOCHONDRIA; DETERGENT	Unfolded (inactive) rhodanese (thiosulfate:cyanide sulfurtransferase, EC 2.8.1.1) can be reactivated in the presence of detergents, e.g. lauryl maltoside (LM). Here, we report the reactivation of urea-unfolded rhodanese in the presence of mixed micelles containing LM and the anionic mitochondrial phospholipid, cardiolipin (CL). Reactivation times increased as the number of CL molecules/micelle was increased. A maximum of 94% of the activity was recovered at 2.2 CL/micelle. Only 71% of the activity was recovered in the absence of CL. The major zwitterionic mitochondrial phospholipid, phosphatidylcholine (PC), had no effect on the LM-assisted reactivation of rhodanese. Size exclusion chromatography showed that denatured, but not native, rhodanese apparently binds to micellar amounts of LM and CL/LM, but not to PC/LM micelles. The lifetime of the enzyme-micelle complex increased with the number of CL molecules/micelle. Furthermore, chromatographic fractions containing micelle-bound enzyme had no activity, while renatured rhodanese-containing fractions were active. These results suggest that transient complexes form between enzyme and both LM and CL/LM micelles, and that this complex formation may be necessary for reactivation. For CL/LM micelles, interactions may occur between the positively charged amino-terminal sequence of rhodanese and the negatively charged CL phosphate. Finally, this work shows that there are similarities between "micelle-assisted" and chaperonin-assisted rhodanese refolding.	UNIV TEXAS,HLTH SCI CTR,DEPT BIOCHEM,7703 FLOYD CURL DR,SAN ANTONIO,TX 78284	University of Texas System; University of Texas Health San Antonio					NIEHS NIH HHS [ES05729] Funding Source: Medline; NIGMS NIH HHS [GM25177] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES005729] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025177] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOGGARAM V, 1985, BIOCHEM BIOPH RES CO, V130, P407, DOI 10.1016/0006-291X(85)90431-0; FISCHER G, 1990, BIOCHEMISTRY-US, V29, P2205, DOI 10.1021/bi00461a001; HOROWITZ PM, 1989, J BIOL CHEM, V264, P3311; HOROWITZ PM, 1986, J BIOL CHEM, V261, P13887; HOROWITZ PM, 1978, ANAL BIOCHEM, V86, P751, DOI 10.1016/0003-2697(78)90803-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUBBEN TH, 1990, P NATL ACAD SCI USA, V87, P7683, DOI 10.1073/pnas.87.19.7683; MCMULLIN TW, 1988, MOL CELL BIOL, V8, P371, DOI 10.1128/MCB.8.1.371; MENDOZA JA, 1991, J BIOL CHEM, V266, P13587; MENDOZA JA, 1991, J BIOL CHEM, V266, P13044; MILLER DM, 1991, J BIOL CHEM, V266, P4686; Pain D, 1991, Genet Eng (N Y), V13, P153; PLOEGMAN JH, 1978, NATURE, V273, P124, DOI 10.1038/273124a0; ROBINSON NC, 1980, BIOCHEMISTRY-US, V19, P3656, DOI 10.1021/bi00557a003; ROUSER G, 1968, BIOL MEMBR, V1, P37; SCHLEYER M, 1985, CELL, V43, P339, DOI 10.1016/0092-8674(85)90039-X; SORBO BH, 1953, ACTA CHEM SCAND, V7, P1123; TANDON S, 1989, J BIOL CHEM, V264, P9859; TANDON S, 1986, J BIOL CHEM, V261, P5615; TANDON S, 1987, J BIOL CHEM, V262, P4486; THOMPSON DA, 1983, BIOCHEMISTRY-US, V22, P3178, DOI 10.1021/bi00282a022	21	75	78	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1992	267	9					5811	5816						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HK318	1556097				2023-01-03	WOS:A1992HK31800017
J	BALLARD, RA; BALLARD, PL; CREASY, RK; PADBURY, J; POLK, DH; BRACKEN, M; MOYA, FR; GROSS, I				BALLARD, RA; BALLARD, PL; CREASY, RK; PADBURY, J; POLK, DH; BRACKEN, M; MOYA, FR; GROSS, I			RESPIRATORY-DISEASE IN VERY-LOW-BIRTH-WEIGHT INFANTS AFTER PRENATAL THYROTROPIN-RELEASING-HORMONE AND GLUCOCORTICOID	LANCET			English	Article							FETAL RABBIT LUNG; PITUITARY-THYROID AXIS; PREMATURE-INFANTS; SURFACTANT; MATURATION; CORTICOSTEROIDS; STIMULATION; PREVENTION; THERAPY; TRH	Although prenatal glucocorticoid treatment reduces neonatal respiratory morbidity, respiratory distress syndrome and chronic lung disease (CLD) develop in many very-low-birthweight infants despite therapy. To investigate the effect of additional prenatal treatment with thyrotropin-releasing hormone (TRH), we did a multicentre, blinded, randomised trial. 404 women with threatened preterm delivery at less than 32 weeks' gestation received betamethasone plus TRH (4 doses of 400-mu-g 8-hourly) or betamethasone plus placebo. 103 infants who were fully treated and of less than 1500 g birthweight were evaluated during the neonatal period. TRH treatment (55 infants) did not affect the total incidence of respiratory distress syndrome (47% vs 58% in controls) or of severe respiratory distress syndrome (13% vs 25% in controls, p = 0.11). CLD (defined as requirement for supplemental oxygen at 28 days after birth) developed in significantly fewer TRH-treated infants (18% vs 44% of controls, p < 0.01). The unadjusted relative risk of CLD with TRH therapy was 0.40 (95% Cl 0.26-0-80, p < 0.05), and this was not materially changed after adjustment for potentially modifying variables. There were significantly fewer adverse outcomes, defined as death or continuing oxygen requirement, in the TRH group than in the steroid-alone group both at 28 days and when infants reached 36 weeks' postconceptional age. The incidence of other complications of prematurity was similar in the two groups. Prenatal TRH reduces the incidence of chronic lung disease among betamethasone-treated infants.	MT ZION HOSP & MED CTR,DEPT PEDIAT,SAN FRANCISCO,CA 94120; MT ZION HOSP & MED CTR,DEPT OBSTET & GYNECOL,SAN FRANCISCO,CA 94120; UNIV CALIF SAN FRANCISCO,SAN FRANCISCO,CA 94143; YALE UNIV,SCH MED,NEW HAVEN,CT 06510; YALE UNIV,SCH EPIDEMIOL & PUBL HLTH,NEW HAVEN,CT 06520; UNIV TEXAS,HLTH SCI CTR,HOUSTON,TX 77225; UNIV CALIF LOS ANGELES,LOS ANGELES CTY HARBOR MED CTR,TORRANCE,CA 90509	University of California System; University of California San Francisco; UCSF Medical Center; UCSF Medical Center at Mount Zion; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Medical Center at Mount Zion; University of California System; University of California San Francisco; Yale University; Yale University; University of Texas System; University of Texas Health Science Center Houston; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center					NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000425, M01RR000125] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL024075] Funding Source: NIH RePORTER; NCRR NIH HHS [GCRC-RR-00425, M01 RR00125] Funding Source: Medline; NHLBI NIH HHS [HL-24075] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALTHABE F, 1991, PEDIATR RES, V29, pA200; BALLARD JL, 1979, J PEDIATR-US, V95, P769, DOI 10.1016/S0022-3476(79)80734-9; BALLARD PL, 1984, J CLIN INVEST, V74, P898, DOI 10.1172/JCI111507; BALLARD PL, 1991, PEDIATR RES, V29, pA307; BALLARD PL, 1986, MONOGR ENDOCRINOL, V28, P197; BALLARD RA, 1991, PEDIATR RES, V29, pA307; BALLARD RA, 1986, MONOGRAPHS ENDOCRINO, V28, P173; BARKER PM, 1990, PEDIATR RES, V27, P588, DOI 10.1203/00006450-199006000-00010; BAUER CR, 1984, PEDIATRICS, V73, P682; Bracken M. B., 1992, EFFECTIVE CARE NEWBO; CLYMAN RI, 1981, J PEDIATR-US, V98, P123, DOI 10.1016/S0022-3476(81)80557-4; CROWLEY P, 1989, EFFECTIVE CARE PREGN, V1, P746; DEVASKAR U, 1987, AM J OBSTET GYNECOL, V157, P460, DOI 10.1016/S0002-9378(87)80195-3; GONZALES LW, 1986, J CLIN ENDOCR METAB, V62, P687; IKEGAMI M, 1987, AM REV RESPIR DIS, V136, P892, DOI 10.1164/ajrccm/136.4.892; JIKIHARA H, 1990, 6TH P C FED AS OC PE; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; LIGGINS GC, 1972, PEDIATRICS, V50, P515; MANTEL N, 1959, J NATL CANCER I, V22, P719; MORALES WJ, 1989, OBSTET GYNECOL, V73, P111; MOYA F, 1986, PEDIATR RES, V20, P982, DOI 10.1203/00006450-198610000-00018; MOYA FR, 1990, PEDIATR RES, V27, pA81; OHLSSON A, 1989, AM J OBSTET GYNECOL, V160, P890, DOI 10.1016/0002-9378(89)90306-2; OULTON M, 1989, AM J OBSTET GYNECOL, V160, P961, DOI 10.1016/0002-9378(89)90317-7; ROTI E, 1981, J CLIN ENDOCR METAB, V53, P813, DOI 10.1210/jcem-53-4-813; SHELLENBERG JC, 1988, J APPL PHYSIOL, V65, P94; SHENNAN AT, 1988, PEDIATRICS, V82, P527; VANMARTER LJ, 1990, PEDIATRICS, V86, P331; WARBURTON D, 1988, PEDIATR RES, V24, P166, DOI 10.1203/00006450-198808000-00005	29	102	103	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 29	1992	339	8792					510	515		10.1016/0140-6736(92)90337-3	http://dx.doi.org/10.1016/0140-6736(92)90337-3			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HF631	1346877				2023-01-03	WOS:A1992HF63100002
J	NIGHTINGALE, ST				NIGHTINGALE, ST			3 ADDITIONAL DRUGS AVAILABLE UNDER TREATMENT IND	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, ST (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LANE,ROCKVILLE,MD 20857, USA.								0	1	2	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 15	1992	267	3					339	339		10.1001/jama.267.3.339	http://dx.doi.org/10.1001/jama.267.3.339			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GY437	1727943				2023-01-03	WOS:A1992GY43700004
J	VALENZUELA, TD; SPAITE, DW; MEISLIN, HW; CLARK, LL; WRIGHT, AL; EWY, GA				VALENZUELA, TD; SPAITE, DW; MEISLIN, HW; CLARK, LL; WRIGHT, AL; EWY, GA			CASE AND SURVIVAL DEFINITIONS IN OUT-OF-HOSPITAL CARDIAC-ARREST - EFFECT ON SURVIVAL RATE CALCULATION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							RESUSCITATION; DEATH	Objective. - To determine the effect of different case and survival definitions of out-of-hospital cardiac arrest on survival rate calculations. Design. - A 22-month case series of nontraumatic, out-of-hospital cardiac arrests. Setting. - Southwestern city (population, 400000; area, 390 km2) with a two-tiered emergency response system consisting of emergency medical technicians and paramedics. Patients. - A consecutive sample of 372 patients found without palpable pulse or spontaneous respiration. Main Outcome Measures. - Survival rate after cardiac arrest was calculated using three case definitions of arrest and two definitions of survival. Results. - Twenty percent of all patients survived to hospital admission and 6% survived to hospital discharge. Twenty-six percent of adults whose collapse was witnessed survived to hospital admission, and 10% survived to hospital discharge. Patients whose collapse was witnessed and who experienced initial ventricular fibrillation survived to hospital admission in 38% and to hospital discharge in 15% of cases. Conclusions. - The survival rate after out-of-hospital cardiac arrest varies widely depending on the case and survival definitions selected. To facilitate intersystem comparison and assessment of interventions designed to improve outcome, the Utstein Consensus Conference recommended that case and survival definitions should be adopted by all prehospital emergency systems.	ARIZONA EMERGENCY MED RES CTR,TUCSON,AZ; UNIV ARIZONA,COLL MED,CARDIOL SECT,TUCSON,AZ 85721; UNIV ARIZONA,DEPT MATH,TUCSON,AZ 85721	University of Arizona; University of Arizona				Spaite, Daniel/0000-0003-2601-6476				COBB LA, 1980, MOD CONC CARDIOV DIS, V49, P31; Colton T., 1974, STAT MED, P128; CUMMINS RO, 1991, ANN EMERG MED, V20, P861; DAWSONSAUNDERS E, 1990, BASIC CLIN BIOSTATIS, P148; EISENBERG M, 1979, AM J PUBLIC HEALTH, V69, P30, DOI 10.2105/AJPH.69.1.30; EISENBERG MS, 1990, ANN EMERG MED, V19, P179, DOI 10.1016/S0196-0644(05)81805-0; EISENBERG MS, 1990, ANN EMERG MED, V19, P1249, DOI 10.1016/S0196-0644(05)82283-8; HUNT RC, 1989, AM J EMERG MED, V7, P68, DOI 10.1016/0735-6757(89)90089-2; PANTRIDG.JF, 1967, LANCET, V2, P271; VALENZUELA TD, 1989, ANN EMERG MED, V18, P573, DOI 10.1016/S0196-0644(89)80847-9; WEAVER WD, 1986, ANN EMERG MED, V15, P1181; WEAVER WD, 1986, J AM COLL CARDIOL, V7, P752, DOI 10.1016/S0735-1097(86)80332-1	12	52	52	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 8	1992	267	2					272	274		10.1001/jama.267.2.272	http://dx.doi.org/10.1001/jama.267.2.272			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GY046	1727526				2023-01-03	WOS:A1992GY04600033
J	RUBENS, RD; TOWLSON, KE; RAMIREZ, AJ; COLTART, S; SLEVIN, ML; TERRELL, C; TIMOTHY, AR				RUBENS, RD; TOWLSON, KE; RAMIREZ, AJ; COLTART, S; SLEVIN, ML; TERRELL, C; TIMOTHY, AR			APPROPRIATE CHEMOTHERAPY FOR PALLIATING ADVANCED CANCER	BRITISH MEDICAL JOURNAL			English	Article									KENT & CANTERBURY HOSP,DEPT RADIOTHERAPY,CANTERBURY CT1 3NG,ENGLAND; ST BARTHOLOMEWS HOSP,DEPT MED ONCOL,LONDON EC1,ENGLAND; ST ELIZABETHS HOSPICE,IPSWICH IP3 8LX,SUFFOLK,ENGLAND; ST THOMAS HOSP,DEPT RADIOTHERAPY,LONDON SE1 7EW,ENGLAND	University of Kent; Guy's & St Thomas' NHS Foundation Trust	RUBENS, RD (corresponding author), GUYS HOSP,IMPERIAL CANC RES FUND,CLIN ONCOL UNIT,LONDON SE1 9RT,ENGLAND.							BLACKLEDGE G, 1989, BRIT J CANCER, V59, P650, DOI 10.1038/bjc.1989.132; Holland JC, 1989, HDB PSYCHOONCOLOGY P; PINEDO HM, 1990, CANCER CHEMOTHERAPY; RUBENS RD, 1990, EUR J CANCER, V26, P1023; SLEVIN ML, 1988, BRIT MED J, V297, P669, DOI 10.1136/bmj.297.6649.669; 1989, WORKING PATIENTS	6	31	31	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 4	1992	304	6818					35	40		10.1136/bmj.304.6818.35	http://dx.doi.org/10.1136/bmj.304.6818.35			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GY909	1370911	Green Published, Bronze			2023-01-03	WOS:A1992GY90900034
J	NANKHONYA, JM; TURNBULL, CJ; NEWTON, JT				NANKHONYA, JM; TURNBULL, CJ; NEWTON, JT			SOCIAL AND FUNCTIONAL IMPACT OF MINOR FRACTURES IN ELDERLY PEOPLE	BRITISH MEDICAL JOURNAL			English	Article									ARROWE PK HOSP,DEPT GERIATR MED,WIRRAL L49 5PE,ENGLAND; SALFORD UNIV,DEPT BEHAV SCI,SALFORD M6 6PU,ENGLAND	University of Salford	NANKHONYA, JM (corresponding author), 24 COLMORE AVE,WIRRAL L63 9NL,ENGLAND.		Newton, Jonathon T/B-7015-2009					ANDREWS K, 1989, CLIN NEUROLOGY OLD A, P479; Dove A F, 1986, Health Trends, V18, P86; Roberts NA, 1990, CLIN REHABIL, V4, P37; ROWLAND K, 1990, AGE AGEING, V19, P415, DOI 10.1093/ageing/19.6.415; 1989, FRACTURED NECK FEMUR	5	7	7	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 14	1991	303	6816					1514	1515		10.1136/bmj.303.6816.1514-a	http://dx.doi.org/10.1136/bmj.303.6816.1514-a			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GV476	1782491	Bronze, Green Published			2023-01-03	WOS:A1991GV47600024
J	LEFRAK, S				LEFRAK, S			TUBERCULOSIS SCREENING IN A NURSING-HOME - INDICATIONS FOR PREVENTIVE THERAPY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											LEFRAK, S (corresponding author), WASHINGTON UNIV,JEWISH HOSP ST LOUIS,MED CTR,ST LOUIS,MO 63110, USA.							1990, MMWR, V39, P7; [No title captured]; 1990, MMWR, V39, P1	3	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 9	1991	266	14					2000	&						0	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GH406	1895483				2023-01-03	WOS:A1991GH40600032
J	GITTER, MJ; GOLDSMITH, SR; DUNBAR, DN; SHARKEY, SW				GITTER, MJ; GOLDSMITH, SR; DUNBAR, DN; SHARKEY, SW			COCAINE AND CHEST PAIN - CLINICAL-FEATURES AND OUTCOME OF PATIENTS HOSPITALIZED TO RULE OUT MYOCARDIAL-INFARCTION	ANNALS OF INTERNAL MEDICINE			English	Article							ABUSE; ISCHEMIA	Objective: To investigate the clinical features, electrocardiographic findings, and hospital course in patients admitted with acute chest pain temporally related to cocaine use. Design: Retrospective data analysis. Setting: A 485-bed county hospital. Patients: One hundred and one consecutive patients with cocaine-related chest pain admitted to the hospital to rule out myocardial infarction. Measurements and Main Results: The quality of the chest pain frequently suggested myocardial ischemia. Dyspnea was common (56%). The onset of chest pain occurred during cocaine use in 21% of patients, within 1 hour of use in 37%, and after 1 hour of use in 42%. Admission electrocardiographic findings were interpreted as normal in 32% of patients; as acute myocardial injury in 8%; as early repolarization variant in 32%; as left ventricular hypertrophy in 16%; and as "other" in 12%. Forty-three percent of patients had ST-segment elevation meeting the electrocardiographic criteria for use of thrombolytic therapy, but such elevation was usually due to the early repolarization variant. The initial total creatine kinase was elevated more than 3.3-mu-kat/L (200 U/L) in 43% of patients, and an elevated total creatine kinase was recorded at some time during the hospital course in 47% of patients. The creatine kinase MB fraction was less than 0.02 in all patients. Myocardial infarction was ruled out in all patients. No patient experienced in-hospital cardiovascular complications. Conclusion: The quality of acute chest pain related to cocaine use is indistinguishable from that experienced in acute myocardial ischemia. Abnormal or normal variant electrocardiographic findings are common in patients with chest pain related to cocaine use, but nevertheless the incidence of acute myocardial infarction is low. The ST-segment and T-wave changes can mimic acute myocardial injury and are most likely normal findings in young black men that can be readily recognized in the emergency department. Most of these patients do not require admission to an intensive	HENNEPIN CTY MED CTR, DIV CARDIOL, 701 PK AVE, MINNEAPOLIS, MN 55415 USA; UNIV MINNESOTA, MINNEAPOLIS, MN 55455 USA	Hennepin County Medical Center; University of Minnesota System; University of Minnesota Twin Cities								AMIN M, 1990, AM J CARDIOL, V66, P1434, DOI 10.1016/0002-9149(90)90529-A; BLACKMAN NS, 1964, AM HEART J, V67, P304, DOI 10.1016/0002-8703(64)90004-3; BRODY SL, 1990, AM J MED, V88, P325, DOI 10.1016/0002-9343(90)90484-U; CHELTON LG, 1955, AM J MED SCI, V230, P54, DOI 10.1097/00000441-195507000-00008; CREGLER LL, 1986, NEW ENGL J MED, V315, P1495, DOI 10.1056/NEJM198612043152327; CREGLER LL, 1985, AM J CARDIOL, V56, P794, DOI 10.1016/0002-9149(85)91140-3; GOLDBERGER AL, 1980, MOD CONC CARDIOV DIS, V49, P13; GOLDBERGER AL, 1984, MYOCARDIAL INFARCTIO, P167; GOLDMAN MJ, 1953, AM HEART J, V46, P817, DOI 10.1016/0002-8703(53)90080-5; HERZLICH BC, 1988, ANN INTERN MED, V109, P335, DOI 10.7326/0003-4819-109-4-335; ISNER JM, 1986, NEW ENGL J MED, V315, P1438, DOI 10.1056/NEJM198612043152302; LANGE RA, 1989, NEW ENGL J MED, V321, P1557, DOI 10.1056/NEJM198912073212301; LANGE RA, 1990, CARDIOLOGY, V8, P74; LEE TH, 1986, ANN INTERN MED, V105, P221, DOI 10.7326/0003-4819-105-2-221; LEE TH, 1987, AM J CARDIOL, V60, P219, DOI 10.1016/0002-9149(87)90217-7; LEE TH, 1987, ANN INTERN MED, V106, P181, DOI 10.7326/0003-4819-106-2-181; LITTMANN D, 1946, AM HEART J, V32, P370, DOI 10.1016/0002-8703(46)90797-1; MATHIAS DW, 1986, AM J MED, V81, P675, DOI 10.1016/0002-9343(86)90556-5; OSHER HL, 1953, AM J MED SCI, V226, P541, DOI 10.1097/00000441-195322650-00011; PASCUALLEONE A, 1990, NEUROLOGY, V40, P404, DOI 10.1212/WNL.40.3_Part_1.404; PASTERNACK PF, 1985, AM J CARDIOL, V55, P847, DOI 10.1016/0002-9149(85)90172-9; ROTH D, 1988, NEW ENGL J MED, V319, P673, DOI 10.1056/NEJM198809153191103; RUBIN RB, 1989, AM J MED, V86, P551, DOI 10.1016/0002-9343(89)90383-5; SMITH HWB, 1987, ANN INTERN MED, V107, P13, DOI 10.7326/0003-4819-107-1-13; THOMAS J, 1960, AM J CARDIOL, V5, P468, DOI 10.1016/0002-9149(60)90102-8; Thompson WP, 1943, AM HEART J, V25, P372, DOI 10.1016/S0002-8703(43)90831-2; TOKARSKI GF, 1990, ANN EMERG MED, V19, P1088, DOI 10.1016/S0196-0644(05)81509-4; WIENER L, 1964, AM HEART J, V67, P684, DOI 10.1016/0002-8703(64)90340-0; ZIMMERMAN FH, 1987, J AM COLL CARDIOL, V9, P964, DOI 10.1016/S0735-1097(87)80256-5	29	96	99	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 15	1991	115	4					277	282		10.7326/0003-4819-115-4-277	http://dx.doi.org/10.7326/0003-4819-115-4-277			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GA764	1854111				2023-01-03	WOS:A1991GA76400006
J	VANDENBROUCKE, JP				VANDENBROUCKE, JP			POSTMENOPAUSAL ESTROGEN AND CARDIOPROTECTION	LANCET			English	Editorial Material							ESTROGEN USE; MORTALITY; DISEASE; THERAPY; WOMEN				VANDENBROUCKE, JP (corresponding author), LEIDEN UNIV HOSP,DEPT CLIN EPIDEMIOL,POB 9600,2300 RC LEIDEN,NETHERLANDS.		Vandenbroucke, Jan/AAM-3928-2020	Vandenbroucke, Jan/0000-0001-5668-6716				BUSH TL, 1985, EPIDEMIOL REV, V7, P80, DOI 10.1093/oxfordjournals.epirev.a036287; BUSH TL, 1987, CIRCULATION, V75, P1102, DOI 10.1161/01.CIR.75.6.1102; BUSH TL, 1990, MENOPAUSE BIOL CLIN, P211; COLDITZ GA, 1990, JAMA-J AM MED ASSOC, V264, P2648, DOI 10.1001/jama.264.20.2648; CRIQUI MH, 1988, AM J EPIDEMIOL, V128, P606, DOI 10.1093/oxfordjournals.aje.a115008; CUMMINGS SR, 1990, ANN INTERN MED, V113, P565, DOI 10.7326/0003-4819-113-8-565; DAVIS ME, 1964, CLIN OBSTET GYNECOL, V7, P558; GAMBRELL RD, 1982, ACTA OBSTET GYNECO S, V106, P37; KNOPP RH, 1988, OBSTET GYNECOL, V72, pS23; NACHTIGALL LE, 1979, OBSTET GYNECOL, V54, P74, DOI 10.1097/00006250-197907000-00017; NORDIN BEC, 1990, LANCET, V336, P1327, DOI 10.1016/0140-6736(90)93018-K; STAMPFER MJ, 1991, PREV MED, V20, P47, DOI 10.1016/0091-7435(91)90006-P; STAMPFER MJ, 1985, NEW ENGL J MED, V313, P1044, DOI 10.1056/NEJM198510243131703; STEVENSON JC, 1990, LANCET, V336, P1121, DOI 10.1016/0140-6736(90)92590-E; TOSTESON ANA, 1990, ANN INTERN MED, V113, P594, DOI 10.7326/0003-4819-113-8-594; WEINSTEIN MC, 1980, NEW ENGL J MED, V303, P308, DOI 10.1056/NEJM198008073030604; WILSON RA, 1963, J AM GERIATR SOC, V11, P347, DOI 10.1111/j.1532-5415.1963.tb00068.x; 1970, JAMA-J AM MED ASSOC, V214, P1303; 1977, BRIT MED J, V1, P862	19	32	33	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 6	1991	337	8745					833	834		10.1016/0140-6736(91)92526-8	http://dx.doi.org/10.1016/0140-6736(91)92526-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FF228	1672923				2023-01-03	WOS:A1991FF22800014
J	EMANUEL, LL; BARRY, MJ; STOECKLE, JD; ETTELSON, LM; EMANUEL, EJ				EMANUEL, LL; BARRY, MJ; STOECKLE, JD; ETTELSON, LM; EMANUEL, EJ			ADVANCE DIRECTIVES FOR MEDICAL-CARE - A CASE FOR GREATER USE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LIFE-SUSTAINING TREATMENT; CARDIOPULMONARY RESUSCITATION; ELDERLY OUTPATIENTS; PHYSICIANS; DECISIONS; PREFERENCES; ATTITUDES; CHOICES; END	Background. Advance directives for medical care and the designation of proxy decision makers to guide medical care after a patient has become incompetent have been widely advocated but little studied. We investigated the attitudes of patients toward planning, perceived barriers to such planning, treatment preferences in four hypothetical scenarios, and the feasibility of using a particular document (the Medical Directive) in the outpatient setting to specify advance directives. Methods. We surveyed 405 outpatients of 30 primary care physicians at Massachusetts General Hospital and 102 members of the general public in Boston and asked them as part of the survey to complete the Medical Directive. Results. Advance directives were desired by 93 percent of the outpatients and 89 percent of the members of the general public (P > 0.2). Both the young and the healthy subgroups expressed at least as much interest in planning as those older than 65 and those in fair-to-poor health. Of the perceived barriers to issuing advance directives, the lack of physician initiative was among the most frequently mentioned, and the disturbing nature of the topic was among the least. The outpatients refused life-sustaining treatments in 71 percent of their responses to options in the four scenarios (coma with chance of recovery, 57 percent; persistent vegetative state, 85 percent; dementia, 79 percent; and dementia with a terminal illness, 87 percent), with small differences between widely differing types of treatments. Specific treatment preferences could not be usefully predicted according to age, self-rated state of health, or other demographic features. Completing the Medical Directive took a median of 14 minutes. Conclusions. When people are asked to imagine themselves incompetent with a poor prognosis, they decide against life-sustaining treatments about 70 percent of the time. Health, age, or other demographic features cannot be used, however, to predict specific preferences. Advance directives as part of a comprehensive approach such as that provided by the Medical Directive are desired by most people, require physician initiative, and can be achieved during a regular office visit.	BETH ISRAEL HOSP,BOSTON,MA 02215; HARVARD UNIV,PROGRAM ETH & PROFESS,CAMBRIDGE,MA 02138	Harvard University; Beth Israel Deaconess Medical Center; Harvard University	EMANUEL, LL (corresponding author), MASSACHUSETTS GEN HOSP,GEN INTERNAL MED UNIT,BOSTON,MA 02114, USA.				AHRQ HHS [R01 HS06120] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		BEDELL SE, 1984, NEW ENGL J MED, V310, P1089, DOI 10.1056/NEJM198404263101706; BOK S, 1976, NEW ENGL J MED, V295, P367, DOI 10.1056/NEJM197608122950706; BRENNAN TA, 1988, JAMA-J AM MED ASSOC, V260, P803, DOI 10.1001/jama.260.6.803; BUCHANAN A, 1988, PHILOS PUBLIC AFF, V17, P277; COLTON T, 1974, STAT MED, P120; DAVIDSON KW, 1989, JAMA-J AM MED ASSOC, V262, P2415, DOI 10.1001/jama.262.17.2415; EMANUEL EJ, 1988, AM J MED, V84, P291, DOI 10.1016/0002-9343(88)90428-7; EMANUEL LL, 1989, JAMA-J AM MED ASSOC, V261, P3288, DOI 10.1001/jama.261.22.3288; EMANUEL LL, 1989, AM J MED, V86, P87, DOI 10.1016/0002-9343(89)90234-9; FINUCANE TE, 1988, J GEN INTERN MED, V3, P322, DOI 10.1007/BF02595788; LO B, 1986, ARCH INTERN MED, V146, P1613, DOI 10.1001/archinte.146.8.1613; Lubitz J, 1984, Health Care Financ Rev, V5, P117; ORENTLICHER D, 1990, JAMA-J AM MED ASSOC, V263, P2365, DOI 10.1001/jama.263.17.2365; President's Commission for the Study of Ethical Problems in Medicine and Biomedical and Behavioral Research, 1983, DECIDING FOREGO LIFE; READLEAF DL, 1979, STANFORD LAW REV, V31, P913; SCHNEIDERMAN LJ, 1985, ANN INTERN MED, V102, P693, DOI 10.7326/0003-4819-102-5-693; Shapiro R S, 1986, Wis Med J, V85, P17; SHMERLING RH, 1988, J GEN INTERN MED, V3, P317, DOI 10.1007/BF02595786; STARR TJ, 1986, J GEN INTERN MED, V1, P373, DOI 10.1007/BF02596420; STEIBER SR, 1987, HOSPITALS, V61, P72; STEINBROOK R, 1986, NEW ENGL J MED, V314, P457, DOI 10.1056/NEJM198602133140730; UHLMANN RF, 1988, J GERONTOL, V43, pM115, DOI 10.1093/geronj/43.5.M115; ZWEIBEL NR, 1989, GERONTOLOGIST, V29, P615, DOI 10.1093/geront/29.5.615; 1989, RESOLUTION LEGISLATI; 1989, CURRENT OPINIONS COU; 1987, HDB LIVING WILL LAWS	26	595	598	0	31	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 28	1991	324	13					889	895		10.1056/NEJM199103283241305	http://dx.doi.org/10.1056/NEJM199103283241305			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FD111	2000111				2023-01-03	WOS:A1991FD11100005
J	MCGUIRE, P; FAHY, T				MCGUIRE, P; FAHY, T			CHRONIC PARANOID PSYCHOSIS AFTER MISUSE OF MDMA (ECSTASY)	BRITISH MEDICAL JOURNAL			English	Article									INST PSYCHIAT,LONDON SE5,ENGLAND; UNIV LONDON KINGS COLL HOSP,LONDON SE5 8RX,ENGLAND	King's College Hospital NHS Foundation Trust; King's College Hospital; University of London; King's College London	MCGUIRE, P (corresponding author), MAUDSLEY HOSP & INST PSYCHIAT,PSYCHIAT,LONDON SE5 8SJ,ENGLAND.			McGuire, Philip/0000-0003-4381-0532; Fahy, Thomas/0000-0003-3019-3547				Connell PH, 1958, MAUDSLEY MONOGRAPH, V5; GREER G, 1985, AM J PSYCHIAT, V142, P1391; MCKENNA DJ, 1990, J NEUROCHEM, V54, P14, DOI 10.1111/j.1471-4159.1990.tb13277.x; PRICE LH, 1989, ARCH GEN PSYCHIAT, V46, P20; RICAURTE GA, 1988, BRAIN RES, V446, P165, DOI 10.1016/0006-8993(88)91309-1	5	102	104	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 23	1991	302	6778					697	697		10.1136/bmj.302.6778.697	http://dx.doi.org/10.1136/bmj.302.6778.697			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FE333	1673631	Bronze, Green Published			2023-01-03	WOS:A1991FE33300024
J	RUZE, P				RUZE, P			KAVA-INDUCED DERMOPATHY - A NIACIN DEFICIENCY	LANCET			English	Article									DARTMOUTH COLL, HITCHCOCK MED CTR, DARTMOUTH MED SCH, HANOVER, NH 03756 USA	Dartmouth College								ANDERSON PC, 1965, ARCH DERMATOL, V92, P181; BOTT E, 1972, INTERPRETATION RITUA, P215; CAWTE J, 1986, AUST NZ J PSYCHIAT, V20, P70, DOI 10.3109/00048678609158867; DILORENZO PA, 1967, ACTA DERM-VENEREOL, V47, P318; DUFFIELD AM, 1988, NATL DRUG ALCOHOL RE, V5, P1; FRATER AS, 1976, FIJI MED J, V4, P526; GARNER LF, 1985, J ETHNOPHARMACOL, V13, P307, DOI 10.1016/0378-8741(85)90076-5; GILLMAN AG, 1985, GOODMAN GILLMANS PHA, P1559; HANSEL R, 1968, PAC SCI, V22, P293; KLOHS MW, 1967, ETHNOPHARMACOLOGIC S, P126; LEBOT V, 1988, 195 S PAC COMM TECHN, P18; LUDWIG GD, 1960, CLIN RES, V8, P212; MATHEWS JD, 1988, MED J AUSTRALIA, V148, P548, DOI 10.5694/j.1326-5377.1988.tb93809.x; MILLER SJ, 1989, J AM ACAD DERMATOL, V21, P1, DOI 10.1016/S0190-9622(89)70144-4; MOCHELLA SL, 1985, DERMATOLOGY, V2, P1430; PARSONS WB, 1959, ARCH INTERN MED, V103, P783, DOI 10.1001/archinte.1959.00270050105016; ROOK A, 1986, TXB DERMATOLOGY, V3, P2327; SCHUCKIT MA, 1989, DRUG ALCOHOL ABUSE C, V18; SIMPSON GM, 1964, CLIN PHARMACOL THER, V5, P310; SINGH YN, 1983, J ETHNOPHARMACOL, V7, P267, DOI 10.1016/0378-8741(83)90002-8; STRATIGOS JD, 1977, BRIT J DERMATOL, V96, P99, DOI 10.1111/j.1365-2133.1977.tb05197.x; WILLIAMS ML, 1987, ARCH DERMATOL, V123, P1535, DOI 10.1001/archderm.123.11.1535; WINKELMANN RK, 1963, ARCH DERMATOL, V87, P372, DOI 10.1001/archderm.1963.01590150088016	23	36	36	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 16	1990	335	8703					1442	1445						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DJ234	1972218	hybrid			2023-01-03	WOS:A1990DJ23400013
J	MARKOWITZ, N; QUINN, EL; SARAVOLATZ, LD				MARKOWITZ, N; QUINN, EL; SARAVOLATZ, LD			TRIMETHOPRIM-SULFAMETHOXAZOLE COMPARED WITH VANCOMYCIN FOR THE TREATMENT OF STAPHYLOCOCCUS-AUREUS INFECTION	ANNALS OF INTERNAL MEDICINE			English	Article						TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION; VANCOMYCIN; STAPHYLOCOCCUS-AUREUS; SUBSTANCE ABUSE	IMPAIRED RENAL-FUNCTION; METHICILLIN-RESISTANT; ANTIBIOTIC-TREATMENT; PLUS RIFAMPIN; THERAPY; ENDOCARDITIS; COMBINATION; CIPROFLOXACIN; MENINGITIS; OXACILLIN	Objective: To compare trimethoprim-sulfamethoxazole (TMP-SMZ) and vancomycin regarding efficacy and safety in the therapy of serious Staphylococcus aureus infections. Design: Randomized, double-blind comparative trial. Setting: A tertiary-care hospital. Patients: One hundred and one intravenous drug users hospitalized with S. aureus infection. Measurements: Cure and failure rates; blood and wound cultures; minimum inhibitory and bactericidal concentrations; serum inhibitory and bactericidal titers; temperature; leukocyte count; durations of treatment and hospitalization; and toxicity. Results: Of 228 intravenous drug users, 101 had S. aureus infection and were included in the efficacy analysis (43 received TMP-SMZ and 58 received vancomycin). Methicillin-resistant S. aureus (MRSA) accounted for 47% of S. aureus isolates, and 65% of patients were bacteremic. Infections were cured in 57 of 58 vancomycin recipients and in 37 of 43 TMP-SMZ recipients (P < 0.02). Failure occurred mostly in patients with tricuspid valve endocarditis and only in those with infection caused by methicillin-sensitive S. aureus (MSSA). The mean duration of bacteremia was 6.7 days in TMP-SMZ recipients and 4.3 days in vancomycin recipients. Among 222 subjects hospitalized for at least 24 hours, toxicity rates were similar for TMP-SMZ (23%) and vancomycin (20%) recipients; nausea and vomiting were associated with TMP-SMZ and inflammation at the intravenous site was associated with vancomycin. Forty-four percent of TMP-SMZ recipients and 29% of vancomycin recipients experienced side effects in the efficacy cohort (P > 0.05). Conclusions: Vancomycin is superior to TMP-SMZ in efficacy and safety when treating intravenous drug users who have staphylococcal infections. However, all treatment failures occurred in patients with MSSA infection at any site. Therefore, TMP-SMZ may be considered as an alternative to vancomycin in selected cases of MRSA infection.			MARKOWITZ, N (corresponding author), HENRY FORD HOSP, DIV INFECT DIS, 2799 W GRAND BLVD, DETROIT, MI 48202 USA.							ARCHER GL, 1986, ANTIMICROB AGENTS CH, V29, P733, DOI 10.1128/AAC.29.5.733; ARDATI KO, 1979, J PEDIATR-US, V95, P801, DOI 10.1016/S0022-3476(79)80740-4; BAJPAI J, 1977, INT SURG, V62, P172; BENGTSSON E, 1974, SCAND J INFECT DIS, V6, P177, DOI 10.3109/inf.1974.6.issue-2.13; Bernstein-Hahn L, 1969, Paraplegia, V7, P96; BERNSTEINHAHN L, 1971, INT SURG, V46, P8; BRAINE HG, 1982, REV INFECT DIS, V4, P586; BUSHBY SRM, 1973, J INFECT DIS, V128, pS442, DOI 10.1093/infdis/128.Supplement_3.S442; CRAIG WA, 1973, ANN INTERN MED, V78, P491, DOI 10.7326/0003-4819-78-4-491; CRAVEN DE, 1983, J INFECT DIS, V147, P137, DOI 10.1093/infdis/147.1.137; CRAVEN JL, 1970, BRIT MED J, V3, P201, DOI 10.1136/bmj.3.5716.201; CROSSLEY K, 1979, J INFECT DIS, V139, P273, DOI 10.1093/infdis/139.3.273; DAUM TE, 1990, ANTIMICROB AGENTS CH, V34, P1862, DOI 10.1128/AAC.34.9.1862; FARBER BF, 1983, ANTIMICROB AGENTS CH, V23, P138, DOI 10.1128/AAC.23.1.138; FRIMODTMOLLER N, 1987, ACTA MED SCAND, V222, P175; Gavan T. L., 1980, MANUAL CLIN MICROBIO, P459; GOODWIN NM, 1973, S AFR MED J, V47, P2159; HALEY RW, 1982, ANN INTERN MED, V97, P297, DOI 10.7326/0003-4819-97-3-297; HUGHES DTD, 1973, J INFECT DIS, V128, pS701, DOI 10.1093/infdis/128.Supplement_3.S701; KIANI R, 1983, JAMA-J AM MED ASSOC, V249, P2812; KOCH UJ, 1973, CHEMOTHERAPY, V19, P314, DOI 10.1159/000221470; KORZENIOWSKI O, 1982, ANN INTERN MED, V97, P496, DOI 10.7326/0003-4819-97-4-496; LAMBERTUS MW, 1990, ANTIMICROB AGENTS CH, V34, P1453, DOI 10.1128/AAC.34.7.1453; LEGGETT JE, 1989, J INFECT DIS, V160, P616, DOI 10.1093/infdis/160.4.616; LEVINE DP, 1991, ANN INTERN MED, V115, P674, DOI 10.7326/0003-4819-115-9-674; LEVITZ RE, 1984, ANN INTERN MED, V100, P881, DOI 10.7326/0003-4819-100-6-881; LEWIS E, 1985, AM J INFECT CONTROL, V13, P109, DOI 10.1016/S0196-6553(85)80011-0; MARKOWITZ N, 1987, REV INFECT DIS, V9, pS218; MARKOWITZ N, 1983, ANTIMICROB AGENTS CH, V23, P450, DOI 10.1128/AAC.23.3.450; MOELLERING RC, 1981, ANN INTERN MED, V94, P343, DOI 10.7326/0003-4819-94-3-343; MOELLERING RC, 1984, J ANTIMICROB CHEMOTH, V14, P43, DOI 10.1093/jac/14.suppl_D.43; MUANGMAN V, 1973, J MED ASSOC THAILAND, V56, P448; PEACOCK JE, 1980, ANN INTERN MED, V93, P526, DOI 10.7326/0003-4819-93-4-526; PELLETIER LL, 1988, ANTIMICROB AGENTS CH, V32, P374, DOI 10.1128/AAC.32.3.374; PETERSON LR, 1990, ARCH INTERN MED, V150, P2151, DOI 10.1001/archinte.150.10.2151; PINES A, 1973, J INFECT DIS, V128, pS706, DOI 10.1093/infdis/128.Supplement_3.S706; POLK RE, 1988, J INFECT DIS, V157, P502, DOI 10.1093/infdis/157.3.502; PUGSLEY DJ, 1969, POSTGRAD MED J, VS, P95; QUICK CA, 1973, J INFECT DIS, V128, pS696, DOI 10.1093/infdis/128.Supplement_3.S696; RAVIGLIONE MC, 1990, ANTIMICROB AGENTS CH, V34, P2050, DOI 10.1128/AAC.34.11.2050; ROSASCHINO F, 1973, TRIMETHOPRIM SULPHAM, P165; RUTENBURG AM, 1960, NEW ENGL J MED, V263, P1174, DOI 10.1056/NEJM196012082632305; SABEL KG, 1975, ACTA PAEDIATR SCAND, V64, P25; SALTER AJ, 1982, REV INFECT DIS, V4, P338; SARAVOLATZ LD, 1982, ANN INTERN MED, V96, P11, DOI 10.7326/0003-4819-96-1-11; SCHELD WM, 1987, J ANTIMICROB CHEMOTH, V19, P647, DOI 10.1093/jac/19.5.647; SCHMIDT U, 1982, REV INFECT DIS, V4, P332; SELIGMAN SJ, 1973, J INFECT DIS, V128, pS754, DOI 10.1093/infdis/128.Supplement_3.S754; SHAFQAT SH, 1971, BRIT HEART J, V33, P974; SMALL PM, 1990, ANTIMICROB AGENTS CH, V34, P1227, DOI 10.1128/AAC.34.6.1227; SORRELL TC, 1982, ANN INTERN MED, V97, P344, DOI 10.7326/0003-4819-97-3-344; STRATFORD BC, 1978, MED J AUSTRALIA, V2, P37, DOI 10.5694/j.1326-5377.1978.tb131329.x; TAMER MA, 1982, CLIN PEDIATR, V21, P125, DOI 10.1177/000992288202100211; WOLFSON JS, 1985, NEW ENGL J MED, V312, P968, DOI 10.1056/NEJM198504113121507; WORMSER GP, 1979, ANN INTERN MED, V91, P420, DOI 10.7326/0003-4819-91-3-420; 1973, J INFECT DIS, V128, pS629	57	267	273	0	18	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 1	1992	117	5					390	398		10.7326/0003-4819-117-5-390	http://dx.doi.org/10.7326/0003-4819-117-5-390			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JK678	1503330				2023-01-03	WOS:A1992JK67800007
J	COWELL, R				COWELL, R			AFTER ISIS-3	LANCET			English	Letter											COWELL, R (corresponding author), HAREFIELD HOSP,DEPT CARDIOL,HAREFIELD UB9 6JH,ENGLAND.							URBAN, 1992, LANCET, V339, P817	1	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 16	1992	339	8803					1227	1227						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HU684	1349952				2023-01-03	WOS:A1992HU68400024
J	SOBEL, BE; COLLEN, D				SOBEL, BE; COLLEN, D			AFTER ISIS-3	LANCET			English	Letter							TISSUE PLASMINOGEN-ACTIVATOR; ACUTE MYOCARDIAL-INFARCTION; HEPARIN; THROMBOLYSIS		WASHINGTON UNIV,SCH MED,CTR CARDIOVASC RES,ST LOUIS,MO 63110; CATHOLIC UNIV LEUVEN,CTR THROMBOSIS & VASC RES,B-3000 LOUVAIN,BELGIUM	Washington University (WUSTL); KU Leuven	SOBEL, BE (corresponding author), WASHINGTON UNIV,SCH MED,DEPT MED,DIV CARDIOVASC,ST LOUIS,MO 63110, USA.							BLEICH SD, 1990, AM J CARDIOL, V66, P1412, DOI 10.1016/0002-9149(90)90525-6; BRAUNWALD E, 1987, J AM COLL CARDIOL, V9, P467, DOI 10.1016/S0735-1097(87)80407-2; CHESEBRO JH, 1988, NEW ENGL J MED, V319, P1544; DEBONO DP, 1992, BRIT HEART J, V67, P122; GORE JM, 1991, CIRCULATION, V83, P448, DOI 10.1161/01.CIR.83.2.448; HSIA J, 1990, NEW ENGL J MED, V323, P1433, DOI 10.1056/NEJM199011223232101; TURPIE AGG, 1989, NEW ENGL J MED, V320, P352, DOI 10.1056/NEJM198902093200604; WHITE HD, 1989, NEW ENGL J MED, V320, P817, DOI 10.1056/NEJM198903303201301; 1990, LANCET, V336, P71	9	2	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 16	1992	339	8803					1225	1226						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HU684	1349951				2023-01-03	WOS:A1992HU68400022
J	OXNER, RBG; SIMMONDS, NJ; GERTNER, DJ; NIGHTINGALE, JMD; BURNHAM, WR				OXNER, RBG; SIMMONDS, NJ; GERTNER, DJ; NIGHTINGALE, JMD; BURNHAM, WR			CONTROLLED TRIAL OF ENDOSCOPIC INJECTION TREATMENT FOR BLEEDING FROM PEPTIC-ULCERS WITH VISIBLE VESSELS	LANCET			English	Article							UPPER GASTROINTESTINAL-TRACT; THERAPY; HEMORRHAGE; SCLEROSIS; NECROSIS	Controlled trials have shown that bleeding peptic ulcers can be successfully treated by endoscopy and injection of adrenaline, with or without sclerosant. However, these trials have been done in major research centres, and endoscopic treatment of upper gastrointestinal bleeding has not yet become routine in general hospitals. We have done a prospective, randomised, controlled trial of injection treatment for bleeding peptic ulcers in a district general hospital. Between April, 1989, and June, 1991, all patients with acute upper gastrointestinal bleeding (n = 555) underwent endoscopy by an experienced endoscopist within 24 h of admission. 98 patients were found to have an ulcer with a visible vessel, of whom 93 were randomised to injection (n = 48) or standard treatment alone (n = 45). Injection treatment consisted of 1-2 ml of 1 in 10000 adrenaline injected at four to six sites around the ulcer. Adrenaline and 5% ethanolamine oleate (1-2 ml) were then injected directly into the vessel. The medical team managing the patient was unaware of the endoscopic treatment given. The two groups were similar for age, initial haemoglobin concentration, shock, and ulcer site. Rebleeding (injected 8 [16.7%] vs control 21 [46.7%], p = 0.011) was significantly reduced in treated patients. The treated group also had lower mortality (4 [8.3%] vs 9 [20%]), requirement for surgery (4 [8.3%] vs 8 [17.8%]), and mean blood-transfusion requirement (5 vs 7.5 units). Endoscopic injection treatment in our patients significantly reduced rebleeding rate and may have other benefits. This cheap and widely applicable treatment can be used routinely in the management of patients with bleeding peptic ulcers who are at high risk of rebleeding.	OLDCHURCH HOSP,DEPT GASTROENTEROL,ROMFORD RM7 0BE,ESSEX,ENGLAND									BLANZO J, 1988, ENDOSCOPY, V20, P289; CHESTER JF, 1990, ENDOSCOPY, V22, P287, DOI 10.1055/s-2007-1012873; DIFELICE G, 1987, ENDOSCOPY, V19, P185, DOI 10.1055/s-2007-1018278; HENRY D, 1991, GASTROENTEROLOGY, V100, P1481; HIRAO M, 1985, GASTROINTEST ENDOSC, V31, P313, DOI 10.1016/S0016-5107(85)72213-4; LOPERFIDO S, 1990, ENDOSCOPY, V22, P285, DOI 10.1055/s-2007-1010728; PANES J, 1987, LANCET, V2, P1292; RAJGOPAL C, 1991, GUT, V32, P727, DOI 10.1136/gut.32.7.727; RUTGEERTS P, 1989, LANCET, V1, P1164; SACKS HS, 1990, JAMA-J AM MED ASSOC, V264, P494, DOI 10.1001/jama.264.4.494; SOEHENDRA N, 1985, ENDOSCOPY, V17, P129, DOI 10.1055/s-2007-1018481; Steele R J, 1989, J R Coll Surg Edinb, V34, P133; SWAIN C P, 1991, Gastroenterology, V100, pA170	13	75	76	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 18	1992	339	8799					966	968		10.1016/0140-6736(92)91537-I	http://dx.doi.org/10.1016/0140-6736(92)91537-I			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HP036	1348805				2023-01-03	WOS:A1992HP03600010
J	GULATI, SC; BENNETT, CL				GULATI, SC; BENNETT, CL			GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR (GM-CSF) AS ADJUNCT THERAPY IN RELAPSED HODGKIN DISEASE	ANNALS OF INTERNAL MEDICINE			English	Article						GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HODGKINS DISEASE; CHEMOTHERAPY, ADJUVANT; COST-BENEFIT ANALYSIS; NEUTROPENIA	BONE-MARROW TRANSPLANTATION; HIGH-DOSE CHEMOTHERAPY; ACQUIRED IMMUNODEFICIENCY SYNDROME; MULTIVARIATE PREDICTION MODEL; HEMATOPOIETIC RECONSTITUTION; HOSPITAL CHARGES; RAPID ESTIMATION; CYCLOPHOSPHAMIDE; MALIGNANCIES; MORTALITY	Objective: To determine the clinical and economic effects of granulocyte macrophage colony-stimulating factor (GM-CSF) as adjunct therapy in relapsed or refractory Hodgkin disease. Design: A randomized, double-blind, phase III clinical trial. Setting: A tertiary referral center. Patients: Twenty-four patients (twelve of whom were controls) treated with high-dose chemotherapy and autologous bone marrow transplantation. Main Results: The 12 patients treated with GM-CSF, when compared with placebo recipients, had shorter periods of neutropenia (median duration of an absolute neutrophil count of less than 1000 cells/mm3, 16 days compared with 27 days; P = 0.02), shorter periods of platelet-transfusion dependency (median duration, 13.5 days compared with 21 days; P = 0.03), and shorter hospitalizations (median hospital stay, 32 days compared with 40.5 days; P = 0.004). Other clinical outcomes, such as frequency and severity of toxicities, development of pneumonia or infection, in-hospital death, and response rate were similar in the two groups. Actuarial long-term disease-free survival was 64% for patients treated with GM-CSF and 58% for patients who received placebo after 32 months of follow-up (P = 0.1 5). The group treated with GM-CSF had lower total charges after infusion of autologous marrow than the placebo group (median in-hospital charges, $39800 compared with $62500; P = 0.005) because of lower post-infusion charges for room and board, antibiotic therapy, transfusions, laboratory tests, and physical therapy visits. Conclusions: Administration of GM-CSF was associated with acceleration of myeloid and platelet recovery and was cost effective in the treatment of patients with relapsed Hodgkin disease who received intensive chemotherapy.	VET AFFAIRS HOSP, DURHAM, NC USA; MEM SLOAN KETTERING CANC CTR, NEW YORK, NY 10021 USA; DUKE UNIV, SCH MED, DURHAM, NC 27706 USA; RAND CORP, SANTA MONICA, CA 90406 USA	Memorial Sloan Kettering Cancer Center; Duke University; RAND Corporation			Bennett, Charles L/C-2050-2008					ANTMAN KS, 1988, NEW ENGL J MED, V319, P593, DOI 10.1056/NEJM198809083191001; ARMITAGE JO, 1989, AM J MED, V86, P203, DOI 10.1016/0002-9343(89)90270-2; BENNETT CL, 1990, ARCH INTERN MED, V150, P1447, DOI 10.1001/archinte.150.7.1447; BRANDT SJ, 1988, NEW ENGL J MED, V318, P869, DOI 10.1056/NEJM198804073181401; CARELLA AM, 1988, J CLIN ONCOL, V6, P1411, DOI 10.1200/JCO.1988.6.9.1411; CHESON BD, 1989, ANN INTERN MED, V110, P51, DOI 10.7326/0003-4819-110-1-51; COLLINS C, 1989, CANCER, V63, P228, DOI 10.1002/1097-0142(19890115)63:2<228::AID-CNCR2820630204>3.0.CO;2-3; CRAWFORD J, 1991, NEW ENGL J MED, V325, P164, DOI 10.1056/NEJM199107183250305; DEMETRI GD, 1990, J CLIN ONCOL, V8, P761, DOI 10.1200/JCO.1990.8.5.761; DEVITA VT, 1990, MONOGR NCI, V10, P19; FINKLER SA, 1982, ANN INTERN MED, V96, P102, DOI 10.7326/0003-4819-96-1-102; GABRILOVE JL, 1988, NEW ENGL J MED, V318, P1414, DOI 10.1056/NEJM198806023182202; GIANNI AM, 1989, HEMATOL ONCOL, V7, P139, DOI 10.1002/hon.2900070205; GIANNI AM, 1990, J CLIN ONCOL, V8, P768, DOI 10.1200/JCO.1990.8.5.768; GROOPMAN JE, 1987, NEW ENGL J MED, V317, P593, DOI 10.1056/NEJM198709033171003; GULATI SC, 1991, ANN ONCOL, V2, P51, DOI 10.1093/annonc/2.suppl_1.51; GULATI SC, 1991, CURR PROB CANCER, V15, P5; HANNAN EL, 1989, JAMA-J AM MED ASSOC, V262, P503, DOI 10.1001/jama.262.4.503; JACOBS J, 1987, DRUG INTEL CLIN PHAR, V21, P373, DOI 10.1177/106002808702100415; JAGANNATH S, 1989, J CLIN ONCOL, V7, P179, DOI 10.1200/JCO.1989.7.2.179; JONES RJ, 1990, J CLIN ONCOL, V8, P527, DOI 10.1200/JCO.1990.8.3.527; KLINGEMANN HG, 1991, EXP HEMATOL, V19, P558; KUKULL WA, 1986, MED CARE, V24, P961, DOI 10.1097/00005650-198610000-00009; MCCUE JD, 1985, REV INFECT DIS, V7, P643; MORTSYN G, 1988, LANCET, V1, P667; NEMUNAITIS J, 1991, NEW ENGL J MED, V324, P1773, DOI 10.1056/NEJM199106203242504; NEMUNAITIS J, 1988, BLOOD, V72, P834; PHILIP T, 1987, NEW ENGL J MED, V316, P1493, DOI 10.1056/NEJM198706113162401; PHILLIPS GL, 1989, BLOOD, V73, P2086; TAKVORIAN T, 1987, NEW ENGL J MED, V316, P1499, DOI 10.1056/NEJM198706113162402; WELCH HG, 1989, MED CARE, V27, P900, DOI 10.1097/00005650-198909000-00005; WELCH HG, 1989, NEW ENGL J MED, V321, P807, DOI 10.1056/NEJM198909213211207; 1990, REDBOOK 1990; 1991, MED LETT DRUGS THER, V33, P61	34	172	172	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 1	1992	116	3					177	182		10.7326/0003-4819-116-3-177	http://dx.doi.org/10.7326/0003-4819-116-3-177			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HB356	1728202				2023-01-03	WOS:A1992HB35600001
J	MALONE, S; LIU, PP; HOLLOWAY, R; RUTHERFORD, R; XIE, A; BRADLEY, TD				MALONE, S; LIU, PP; HOLLOWAY, R; RUTHERFORD, R; XIE, A; BRADLEY, TD			OBSTRUCTIVE SLEEP-APNEA IN PATIENTS WITH DILATED CARDIOMYOPATHY - EFFECTS OF CONTINUOUS POSITIVE AIRWAY PRESSURE	LANCET			English	Article							CONGESTIVE HEART-FAILURE; INTRA-THORACIC PRESSURE; APNEA SYNDROME; ANGINA-PECTORIS; RISK FACTOR; DISEASE; HYPERTENSION; PATHOGENESIS; STROKE; MEN	The combined effects of negative intrathoracic pressure swings during obstructive sleep apnoeas (OSAs) and increased sympathetic nervous system tone associated with hypoxia and sleep arousal may lead to pulmonary oedema or left-ventricular hypertrophy. Therefore, we have done a study of patients with congestive heart failure secondary to idiopathic dilated cardiomyopathy to see whether OSA could contribute to impaired left-ventricular function and to assess nasal continuous positive airway pressure (NCPAP) for treatment. Eight men (aged 29-69 years) took part in the study, all were obese. Left-ventricular ejection fraction (LVEF) was measured while on stable medication and then 4 weeks after the start of nocturnal NCPAP. NCPAP was associated with abolition of OSA (mean [SE] number of apnoeas and hypopnoeas per hour of sleep 54.1 [7.2] and 1.0 [0.4] for pretreatment and NCPAP nights, respectively, p < 0.0001). Mean (SE) LVEF increased from 37 (4)% pretreatment to 49 (5)% after four weeks' NCPAP therapy (p < 0.0001). Withdrawal of NCPAP for 1 week in four patients was associated with a reduction in LVEF from 53 (6)% to 45 (5)% (p < 0.001). OSA may contribute to impaired left-ventricular function in some patients with dilated cardiomyopathy of otherwise unknown origin, and reversal of OSA by NCPAP can lead to significant improvement in LVEF.	TORONTO GEN HOSP,DEPT MED,200 ELIZABETH ST,TORONTO M5G 2C4,ONTARIO,CANADA; QUEEN ELIZABETH HOSP,SLEEP RES LAB,TORONTO,ONTARIO,CANADA; MT SINAI HOSP,DEPT MED,TORONTO M5G 1X5,ONTARIO,CANADA; UNIV TORONTO,DEPT MED,TORONTO M5S 1A1,ONTARIO,CANADA	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital; McGill University; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto	BRADLEY, TD (corresponding author), TORONTO GEN HOSP,DEPT MED,200 ELIZABETH ST,TORONTO M5G 2C4,ONTARIO,CANADA.							ABT K, 1981, CONTROL CLIN TRIALS, V1, P377, DOI 10.1016/0197-2456(81)90042-8; ALLEN DG, 1987, CIRC RES, V60, P153, DOI 10.1161/01.RES.60.2.153; BARRUZZI A, 1991, SLEEP, V14, P83; BRADLEY TD, 1985, MED CLIN N AM, V69, P1169; BRADLEY TD, 1985, AM REV RESPIR DIS, V131, P835; BRADLEY TD, IN PRESS AM REV RESP; BUDA AJ, 1979, NEW ENGL J MED, V301, P453, DOI 10.1056/NEJM197908303010901; BUDA AJ, 1981, INT J CARDIOL, V1, P67, DOI 10.1016/0167-5273(81)90050-4; CAMPEAU L, 1976, CIRCULATION, V54, P522, DOI 10.1161/circ.54.3.947585; CHADHA TS, 1982, AM REV RESPIR DIS, V125, P644; CHAN HS, 1991, CHEST, V99, P1023, DOI 10.1378/chest.99.4.1023; CHAUDHARY BA, 1982, CHEST, V82, P122, DOI 10.1378/chest.82.1.122; GOULD GA, 1988, AM REV RESPIR DIS, V137, P895, DOI 10.1164/ajrccm/137.4.895; HEDNER J, 1990, J HYPERTENS, V8, P941, DOI 10.1097/00004872-199010000-00009; HEDNER J, 1988, HYPERTENSION DALL S4, V6, pS529; HUNG J, 1990, LANCET, V336, P261, DOI 10.1016/0140-6736(90)91799-G; KATZ AM, 1990, NEW ENGL J MED, V322, P100; KOSKENVUO M, 1987, BRIT MED J, V294, P16, DOI 10.1136/bmj.294.6563.16; KOSKENVUO M, 1985, LANCET, V1, P893; MILICEMILI J, 1964, J APPL PHYSIOL, V19, P207, DOI 10.1152/jappl.1964.19.2.207; Rechtschaffen A., 1968, MANUAL STANDARDIZED; RINGLER J, 1990, J APPL PHYSIOL, V69, P2143, DOI 10.1152/jappl.1990.69.6.2143; SCHARF SM, 1981, CIRCULATION, V63, P871, DOI 10.1161/01.CIR.63.4.871; Schroeder JS, 1978, SLEEP APNEA SYNDROME, P177; SULLIVAN CE, 1981, LANCET, V1, P862; TAKASAKI Y, 1989, AM REV RESPIR DIS, V140, P1578, DOI 10.1164/ajrccm/140.6.1578; TOLLE FA, 1983, J APPL PHYSIOL, V55, P1718, DOI 10.1152/jappl.1983.55.6.1718; WALLER PC, 1989, LANCET, V1, P143; WEBER KT, 1984, CLIN CHEST MED, V5, P173	29	276	292	0	10	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 14	1991	338	8781					1480	1484						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GV077	1683918				2023-01-03	WOS:A1991GV07700003
J	SILVERMAN, NS; DARBY, MJ; RONKIN, SL; WAPNER, RJ				SILVERMAN, NS; DARBY, MJ; RONKIN, SL; WAPNER, RJ			HEPATITIS-B PREVALENCE IN AN UNREGISTERED PRENATAL POPULATION - IMPLICATIONS FOR NEONATAL THERAPY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MUNICIPAL OBSTETRICAL POPULATION; PASSIVE-ACTIVE IMMUNIZATION; POSITIVE CARRIER MOTHERS; ENDEMIC AREA SENEGAL; SURFACE-ANTIGEN; PERINATAL TRANSMISSION; VERTICAL TRANSMISSION; UNITED-STATES; INFANTS BORN; IMMUNE GLOBULIN	Study Objective. -To evaluate the risk and associated cofactors for hepatitis B infection in inner-city pregnant women not registered for prenatal care. Design. - Fifteen-month survey of 208 patients not registered for prenatal care, compared with 1555 women registered for prenatal care during the same period. Setting. - An urban university hospital prenatal clinic and labor unit. Results. - Unregistered patients had a significantly higher rate of hepatitis B surface antigen positivity than patients who had registered with the clinic (6.7% vs 0.8%; P < .0001). Unregistered patients with positive results of urine drug screening (46%) had a relative risk for seropositivity of 29.2%, compared with registered patients who did not have histories of illicit drug use (95% confidence interval, 25.9% to 32.4%), while registered patients with past histories of drug use had a relative risk of 6.7%, compared with the reference group that did not have histories of drug use (95% confidence interval, 1.8% to 24.0%). Conclusions. - Among inner-city pregnant women not registered for prenatal care, a positive result of urine drug screening is a rapidly available marker for increased risk of hepatitis B surface antigen positivity. Infants born to unregistered women with positive results of urine drug screening before maternal hepatitis B surface antigen results are available may warrant empiric initiation of hepatitis B virus-specific prophylaxis.	THOMAS JEFFERSON UNIV, JEFFERSON MED COLL, DEPT OBSTET & GYNECOL, DIV MATERNAL FETAL MED, PHILADELPHIA, PA 19107 USA	Jefferson University				Wapner, Ronald/0000-0003-0727-1244				AREVALO JA, 1988, JAMA-J AM MED ASSOC, V259, P365, DOI 10.1001/jama.259.3.365; BEASLEY RP, 1977, AM J EPIDEMIOL, V105, P94, DOI 10.1093/oxfordjournals.aje.a112370; BEASLEY RP, 1983, LANCET, V2, P1099; BEASLEY RP, 1981, LANCET, V2, P388; BEASLEY RP, 1981, LANCET, V2, P1129; Beasley RP, 1978, VIRAL HEPATITIS, P333; BISWAS SC, 1989, T ROY SOC TROP MED H, V83, P698, DOI 10.1016/0035-9203(89)90401-X; CHRISTIAN SS, 1989, OBSTET GYNECOL, V74, P259; COURSAGET P, 1987, J MED VIROL, V22, P1, DOI 10.1002/jmv.1890220102; DELAPLANE D, 1983, PEDIATRICS, V72, P176; FARMER K, 1987, NEW ZEAL MED J, V100, P412; FRANKS AL, 1989, NEW ENGL J MED, V321, P1301, DOI 10.1056/NEJM198911093211905; JONAS MM, 1990, AM J GASTROENTEROL, V85, P277; JONAS MM, 1987, ANN INTERN MED, V107, P335, DOI 10.7326/0003-4819-107-2-335; KANE MA, 1988, JAMA-J AM MED ASSOC, V259, P408, DOI 10.1001/jama.259.3.408; KORETZ RL, 1989, OBSTET GYNECOL, V74, P808; KUMAR ML, 1987, ANN INTERN MED, V107, P273, DOI 10.7326/0003-4819-107-2-273; LO KJ, 1985, J INFECT DIS, V152, P817, DOI 10.1093/infdis/152.4.817; MALECKI JM, 1986, AM J OBSTET GYNECOL, V154, P625, DOI 10.1016/0002-9378(86)90615-0; MAUPAS P, 1981, LANCET, V1, P289; MAUPAS P, 1976, LANCET, V1, P1367; MAYNARD JE, 1989, REV INFECT DIS, V11, pS574; MCMAHON BJ, 1985, J INFECT DIS, V151, P599, DOI 10.1093/infdis/151.4.599; OKADA K, 1976, NEW ENGL J MED, V294, P746, DOI 10.1056/NEJM197604012941402; ROSS JW, 1989, JAMA-J AM MED ASSOC, V261, P1727; ROTHMAN KJ, 1986, MODERN EPIDEMIOLOGY, P37; SCHALM SW, 1989, PEDIATRICS, V83, P1041; SCHWEITZER IL, 1975, AM J MED SCI, V270, P287, DOI 10.1097/00000441-197509000-00008; SINATRA FR, 1982, PEDIATRICS, V70, P557; STEVENS CE, 1985, JAMA-J AM MED ASSOC, V253, P1740, DOI 10.1001/jama.253.12.1740; STEVENS CE, 1975, NEW ENGL J MED, V292, P771, DOI 10.1056/NEJM197504102921503; STEVENS CE, 1983, NEW ENGL J MED, V308, P1163; SZMUNESS W, 1981, LANCET, V1, P575; SZMUNESS W, 1980, NEW ENGL J MED, V303, P833, DOI 10.1056/NEJM198010093031501; TADA H, 1982, PEDIATRICS, V70, P613; WILLIAMS BC, 1989, ANN INTERN MED, V111, P444, DOI 10.7326/0003-4819-111-5-444; WONG VCW, 1984, LANCET, V1, P921; XU ZY, 1985, PEDIATRICS, V76, P713; 1990, VITAL STATISTICS REP; 1988, MMWR, V37, P341; 1984, MMWR, V33, P285	41	15	15	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 27	1991	266	20					2852	2855		10.1001/jama.266.20.2852	http://dx.doi.org/10.1001/jama.266.20.2852			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GQ722	1834870				2023-01-03	WOS:A1991GQ72200033
J	CLEAVELAND, CR				CLEAVELAND, CR			CPR	ANNALS OF INTERNAL MEDICINE			English	Editorial Material						PHYSICIAN-PATIENT RELATIONS; RESUSCITATION; MORTALITY; BURNOUT, PROFESSIONAL; STRESS, PSYCHOLOGICAL		A doctor, after a discouraging week at work, seeks respite in the new film version of Hamlet. However, real tragedy intervenes. In an adjoining theater, an old man collapses, the victim of an apparent cardiac arrest. The doctor responds to the appeal for medical help and does all he can to save the man. The intensity and cathartic nature of this experience lead to revelations and insights of interest to all doctors.											0	4	4	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 1	1991	115	7					570	571		10.7326/0003-4819-115-7-570	http://dx.doi.org/10.7326/0003-4819-115-7-570			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GG283	1810284				2023-01-03	WOS:A1991GG28300011
J	KESSLER, M; NETTER, P; MAHEUT, H; WOLF, C; PRENAT, E; HUU, TC; GAUCHER, A				KESSLER, M; NETTER, P; MAHEUT, H; WOLF, C; PRENAT, E; HUU, TC; GAUCHER, A			HIGHLY PERMEABLE AND BIOCOMPATIBLE MEMBRANES AND PREVALENCE OF DIALYSIS-ASSOCIATED ARTHROPATHY	LANCET			English	Letter							BETA-2-MICROGLOBULIN AMYLOIDOSIS; OSTEOARTHROPATHY		CTR HOSP REG UNIV NANCY,DEPT RHEUMATOL,CNRS,URA 1288,F-54500 VANDOEUVRE NANCY,FRANCE	Centre National de la Recherche Scientifique (CNRS); CHU de Nancy	KESSLER, M (corresponding author), CTR HOSP REG UNIV NANCY,DEPT NEPHROL,CNRS,URA 1288,F-54500 VANDOEUVRE NANCY,FRANCE.							CHANARD J, 1989, BRIT MED J, V298, P867, DOI 10.1136/bmj.298.6677.867; CORNELIS F, 1989, ARTHRITIS RHEUM, V32, P785, DOI 10.1002/anr.1780320619; DESTRIHOU CV, 1988, NEPHROL DIAL TRANSPL, V3, P552; KESSLER M, IN PRESS BR J RHEUMA; KUNTZ D, 1984, ARTHRITIS RHEUM-US, V27, P369, DOI 10.1002/art.1780270402; RENAUD H, 1988, NEPHROL DIAL TRANSPL, V3, P820; VANDENBROUCKE JM, 1986, LANCET, V1, P1210; ZINGRAFF JJ, 1990, NEW ENGL J MED, V323, P1070	8	24	25	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 4	1991	337	8749					1092	1093		10.1016/0140-6736(91)91736-E	http://dx.doi.org/10.1016/0140-6736(91)91736-E			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FK204	1673510				2023-01-03	WOS:A1991FK20400030
J	HALL, JC; TARALA, R; HARRIS, J; TAPPER, J; CHRISTIANSEN, K				HALL, JC; TARALA, R; HARRIS, J; TAPPER, J; CHRISTIANSEN, K			INCENTIVE SPIROMETRY VERSUS ROUTINE CHEST PHYSIOTHERAPY FOR PREVENTION OF PULMONARY COMPLICATIONS AFTER ABDOMINAL-SURGERY	LANCET			English	Article							DIAPHRAGMATIC FUNCTION; ATELECTASIS; CARE	We entered 876 patients into a clinical trial aimed at preventing pulmonary complications after abdominal surgery. Patients either received conventional chest physiotherapy or were encouraged to perform maximal inspiratory manoeuvres for 5 min during each hour while awake, using an incentive spirometer. The incidence of pulmonary complications did not differ significantly between the groups: incentive spirometry 68 of 431 (15.8%, 95% Cl 14.0-17.6%), and chest physiotherapy 68 of 445 (15.3%, Cl 13.6-17.0%). Nor was there a difference between the groups in the incidence of positive clinical signs, pyrexia, abnormal chest radiographs, pathogens in sputum, respiratory failure (PO2 < 60 mm Hg), or length of stay in hospital. We conclude that prophylactic incentive spirometry and chest physiotherapy are of equivalent clinical efficacy in the general management of patients undergoing abdominal surgery.	UNIV WESTERN AUSTRALIA, ROYAL PERTH HOSP, DEPT MICROBIOL, PERTH, WA 6000, AUSTRALIA; UNIV WESTERN AUSTRALIA, ROYAL PERTH HOSP, DEPT PHYSIOTHERAPY, PERTH, WA 6000, AUSTRALIA; UNIV WESTERN AUSTRALIA, ROYAL PERTH HOSP, DEPT RES MED, PERTH, WA 6000, AUSTRALIA	Royal Perth Hospital; University of Western Australia; Royal Perth Hospital; University of Western Australia; Royal Perth Hospital; University of Western Australia	HALL, JC (corresponding author), UNIV WESTERN AUSTRALIA, ROYAL PERTH HOSP, DEPT SURG, WELLINGTON ST, PERTH, WA 6000, AUSTRALIA.							[Anonymous], 1965, LANCET, V1, P775; BARTLETT RH, 1973, JAMA-J AM MED ASSOC, V224, P1017, DOI 10.1001/jama.224.7.1017; BARTLETT RH, 1973, SURG GYNECOL OBSTET, V137, P925; CELLI BR, 1984, AM REV RESPIR DIS, V130, P12; CHUTER TAM, 1989, SURGERY, V105, P488; COLEMAN DL, 1987, CHEST, V92, P520, DOI 10.1378/chest.92.3.520; CRAVEN JL, 1974, BRIT J SURG, V61, P793, DOI 10.1002/bjs.1800611012; DEMERS RR, 1976, RESP CARE, V21, P234; DUREUIL B, 1987, BRIT J ANAESTH, V59, P1230, DOI 10.1093/bja/59.10.1230; FRISANCHO AR, 1981, AM J CLIN NUTR, V34, P2540, DOI 10.1093/ajcn/34.11.2540; GARDNER MJ, 1986, BMJ-BRIT MED J, V292, P746, DOI 10.1136/bmj.292.6522.746; GRACEY DR, 1979, CHEST, V76, P123, DOI 10.1378/chest.76.2.123; JACKSON CV, 1988, ARCH INTERN MED, V148, P2120, DOI 10.1001/archinte.148.10.2120; JONES JG, 1987, BRIT J ANAESTH, V59, P949, DOI 10.1093/bja/59.8.949; JUNG R, 1980, CHEST, V78, P31, DOI 10.1378/chest.78.1.31; KIRILOFF LH, 1985, CHEST, V88, P436, DOI 10.1378/chest.88.3.436; LATIMER RG, 1971, AM J SURG, V122, P622, DOI 10.1016/0002-9610(71)90290-X; LYAGER S, 1979, ACTA ANAESTH SCAND, V23, P312, DOI 10.1111/j.1399-6576.1979.tb01456.x; MACHIN D, 1987, STATISTICAL TABLES D, P20; MITCHELL C, 1982, AUST NZ J SURG, V52, P203, DOI 10.1111/j.1445-2197.1982.tb06103.x; MORRIS JF, 1971, AM REV RESPIR DIS, V103, P57; ODONOHUE WJ, 1985, CHEST, V87, P76, DOI 10.1378/chest.87.1.76; ROUKEMA JA, 1988, ARCH SURG-CHICAGO, V123, P30; SCHWIEGER I, 1986, CHEST, V89, P652, DOI 10.1378/chest.89.5.652; SELSBY DS, 1989, BMJ-BRIT MED J, V298, P541, DOI 10.1136/bmj.298.6673.541; THOREN L, 1954, ACTA CHIR SCAND, V107, P193; TORRINGTON KG, 1988, CHEST, V93, P946, DOI 10.1378/chest.93.5.946; VACANTI CJ, 1970, ANESTH ANAL CURR RES, V49, P564; WIGHTMAN JAU, 1954, ACTA CHIR SCAND, V107, P193; 1989, PRINCIPLES ANALGESIC, P10	30	76	78	0	6	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 20	1991	337	8747					953	956		10.1016/0140-6736(91)91580-N	http://dx.doi.org/10.1016/0140-6736(91)91580-N			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FH131	1678039				2023-01-03	WOS:A1991FH13100013
J	HUNT, RC; BRYAN, DM; BRINKLEY, VS; WHITLEY, TW; BENSON, NH				HUNT, RC; BRYAN, DM; BRINKLEY, VS; WHITLEY, TW; BENSON, NH			INABILITY TO ASSESS BREATH SOUNDS DURING AIR MEDICAL TRANSPORT BY HELICOPTER	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note								This study assessed the capabilities of a traditional and an amplified stethoscope used by flight nurses to assess breath sounds during air medical transport in an MBB BO-105 helicopter. We developed a normal breath sound model using a prerecorded tape of breath sounds interspersed with segments without breath sounds; the recorder had been placed in the chest wall of a resuscitation training manikin. Flight nurses completed control listening sessions in a quiet environment and experimental sessions during flight using a traditional stethoscope for half of the sessions and an amplified stethoscope for the remaining half. In the quiet environment, flight nurses accurately reported the presence or absence of breath sounds in 110 (92%) of 120 trials. During helicopter flight, none of the flight nurses heard breath sounds during any of the recorded segments with either the traditional stethoscope or the amplified stethoscope. We conclude that flight nurses are unable to hear normal breath sounds using a traditional or amplified stethoscope during flight in a medically configured MBB BO-105 helicopter. Improved stethoscopes, innovative methods of listening, and reduction of aircraft noise are potential solutions to the problems of breath sound assessment during air medical transport.	PITT CTY MEM HOSP,EASTCARE EMERGENCY AIR MED SERV,GREENVILLE,NC		HUNT, RC (corresponding author), E CAROLINA UNIV,SCH MED,DEPT EMERGENCY MED,MOYE BLVD,GREENVILLE,NC 27858, USA.							BISHOP LC, 1990, JAMA-J AM MED ASSOC, V263, P233, DOI 10.1001/jama.1990.03440020067017; COLLETT HM, 1990, J AIR MED TRANSP JUL, P20; DICK T, 1986, JEMS, V11, P77; GASAWAY DC, 1986, AVIAT SPACE ENVIR MD, V57, P103; HARMS T, 1990, J AIR MED TRANSP OCT, P76; HUNT RC, 1990, 1990 ROCK MOUNT C EM; PASIC TB, 1985, ARCH OTOLARYNGOL, V111, P507; WILKINS RL, 1988, LUNG SOUNDS PRACTICA; 1990, J AIR MED TRANSP MAR, P6	9	46	47	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 17	1991	265	15					1982	1984		10.1001/jama.265.15.1982	http://dx.doi.org/10.1001/jama.265.15.1982			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FF768	2008028				2023-01-03	WOS:A1991FF76800025
J	GURWITZ, JH; GOLDBERG, RJ; GORE, JM				GURWITZ, JH; GOLDBERG, RJ; GORE, JM			CORONARY THROMBOLYSIS FOR THE ELDERLY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACUTE MYOCARDIAL-INFARCTION; TISSUE PLASMINOGEN-ACTIVATOR; INTRAVENOUS STREPTOKINASE; ARTERY SURGERY; PHASE-I; MORTALITY; AGE; TRIAL; ANGIOPLASTY; PROGNOSIS		HEBREW REHABIL CTR AGED, BOSTON, MA USA; HARVARD UNIV, SCH MED, CTR GERIATR RES & TRAINING, BOSTON, MA 02115 USA; UNIV MASSACHUSETTS, SCH MED, DEPT MED, WORCESTER, MA 01605 USA	Harvard University; Harvard Medical School; University of Massachusetts System; University of Massachusetts Worcester	GURWITZ, JH (corresponding author), HARVARD UNIV, SCH MED, DEPT MED, PROGRAM ANAL CLIN STRATEGIES, 333 LONGWOOD AVE, BOSTON, MA 02115 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035434] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL-35434] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		[Anonymous], 1990, LANCET, V336, P65; [Anonymous], 1986, LANCET, V1, P397; [Anonymous], 1989, NEW ENGL J MED, V320, P618; APPLEGATE WB, 1989, ANN INTERN MED, V110, P901, DOI 10.7326/0003-4819-110-11-901; CALIFF RM, 1988, AM J MED, V85, P353, DOI 10.1016/0002-9343(88)90586-4; CHAITMAN BR, 1989, J AM COLL CARDIOL, V14, P1159, DOI 10.1016/0735-1097(89)90410-5; CHAMBERLAIN DA, 1988, LANCET, V1, P545; FISHER LD, 1989, INT J CARDIOL, V24, P317, DOI 10.1016/0167-5273(89)90011-9; GERSH BJ, 1983, CIRCULATION, V67, P483, DOI 10.1161/01.CIR.67.3.483; GOLDBERG RJ, 1989, AM HEART J, V117, P543, DOI 10.1016/0002-8703(89)90727-8; GORE JM, 1991, CIRCULATION, V83, P448, DOI 10.1161/01.CIR.83.2.448; GRINES CL, 1990, J AM COLL CARDIOL, V16, P223, DOI 10.1016/0735-1097(90)90482-5; GUERCI AD, 1987, NEW ENGL J MED, V317, P1613, DOI 10.1056/NEJM198712243172601; HACKETT TP, 1969, AM J CARDIOL, V24, P651, DOI 10.1016/0002-9149(69)90452-4; HOLLAND KJ, 1989, AM J CARDIOL, V63, P399, DOI 10.1016/0002-9149(89)90307-X; KANNEL WB, 1984, NEW ENGL J MED, V311, P1144, DOI 10.1056/NEJM198411013111802; KAPANTAIS G, 1989, CHARACTERISTICS PERS; KLINKENBERGKNOL EC, 1987, LANCET, V1, P349; KNATTERUD G, 1988, JAMA-J AM MED ASSOC, V260, P2849; KOREN G, 1985, NEW ENGL J MED, V313, P1384, DOI 10.1056/NEJM198511283132204; LEE TC, 1990, AM J CARDIOL, V66, P663, DOI 10.1016/0002-9149(90)91126-Q; LEW AS, 1987, AM J CARDIOL, V59, P1, DOI 10.1016/S0002-9149(87)80059-0; MAGGIONI AP, 1990, CHEST, V97, pS146; MATHEY DG, 1985, J AM COLL CARDIOL, V6, P518, DOI 10.1016/S0735-1097(85)80107-8; MEDALIE JH, 1976, ANN INTERN MED, V84, P526, DOI 10.7326/0003-4819-84-5-526; MOSS AJ, 1969, AM J CARDIOL, V24, P659, DOI 10.1016/0002-9149(69)90453-6; MULLER DWM, 1990, ANN INTERN MED, V113, P949, DOI 10.7326/0003-4819-113-12-949; NADELMANN J, 1990, AM J CARDIOL, V66, P533, DOI 10.1016/0002-9149(90)90477-I; NAYLOR CD, 1990, JAMA-J AM MED ASSOC, V264, P697, DOI 10.1001/jama.264.6.697; OCONNOR CM, 1990, J AM COLL CARDIOL, V16, P533, DOI 10.1016/0735-1097(90)90338-P; PETO R, 1990, AM J CARDIOL, V66, P771, DOI 10.1016/0002-9149(90)91149-Z; PODGOR MJ, 1983, AM J EPIDEMIOL, V118, P206, DOI 10.1093/oxfordjournals.aje.a113628; POWELLGRINER E, 1990, CHARACTERISTIC PERSO; RAO AK, 1988, J AM COLL CARDIOL, V11, P1; ROGERS WJ, 1990, CIRCULATION, V81, P1457, DOI 10.1161/01.CIR.81.5.1457; ROWE JW, 1985, NEW ENGL J MED, V312, P827, DOI 10.1056/NEJM198503283121305; RUTHERFORD JD, 1990, CHEST, V97, pS136; SLEIGHT P, 1990, CIRCULATION, V81, P1706; SMITH SC, 1990, J AM COLL CARDIOL, V16, P784, DOI 10.1016/S0735-1097(10)80322-5; SOLDO BJ, 1988, GERIATRIC MED, P12; TIEFENBRUNN AJ, 1989, JAMA-J AM MED ASSOC, V261, P2107; WARNES CA, 1984, AM HEART J, V108, P431, DOI 10.1016/0002-8703(84)90404-6; WILCOX RG, 1988, LANCET, V2, P525; YANG XS, 1987, ACTA CARDIOL, V42, P59; YUSUF S, 1985, EUR HEART J, V6, P556, DOI 10.1093/oxfordjournals.eurheartj.a061905	45	91	91	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 3	1991	265	13					1720	1723		10.1001/jama.265.13.1720	http://dx.doi.org/10.1001/jama.265.13.1720			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FD659	2002574				2023-01-03	WOS:A1991FD65900029
J	GARRARD, J; MAKRIS, L; DUNHAM, T; HESTON, LL; COOPER, S; RATNER, ER; ZELTERMAN, D; KANE, RL				GARRARD, J; MAKRIS, L; DUNHAM, T; HESTON, LL; COOPER, S; RATNER, ER; ZELTERMAN, D; KANE, RL			EVALUATION OF NEUROLEPTIC DRUG-USE BY NURSING-HOME ELDERLY UNDER PROPOSED MEDICARE AND MEDICAID REGULATIONS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PSYCHOACTIVE MEDICATION; CARE; RESIDENTS; FACILITIES	Federal regulations for use of neuroleptic drugs in Medicare- and Medicaid-certified nursing homes throughout the United States were implemented October 1, 1990. These regulations constitute the first time that prescription drugs are required, by law, to be justified by indications documented in the medical chart. This study used extant data to estimate ineligible neuroleptic use at the individual and nursing home levels had these regulations been in effect in 1976 through 1985. Subjects, randomly sampled admissions (N = 5752) and residents (N = 3191), were followed up for up to 24 months in 60 nursing homes. One half of neuroleptic use in each cohort could be considered ineligible under the regulations; all but one of the nursing homes had one or more individuals who were treated with the ineligible use of neuroleptics. Improvements in documentation and/or prescription of neuroleptic drugs for nursing home elderly will be needed to ensure compliance with these new regulations.	UNIV MINNESOTA,SCH STAT,DEPT APPL STAT,MINNEAPOLIS,MN 55455; UNIV MINNESOTA,COLL EDUC,DEPT EDUC PSYCHOL,MINNEAPOLIS,MN 55455; UNIV MINNESOTA,COLL PHARM,DEPT PHARM PRACTICE,MINNEAPOLIS,MN 55455; ST PAUL RAMSEY MED CTR,DEPT CLIN PHARM,ST PAUL,MN 55101; UNIV MINNESOTA,DIV BIOSTAT,MINNEAPOLIS,MN 55455; ABBOTT NW HOSP,MINNEAPOLIS,MN; UNIV WASHINGTON,WASHINGTON INST MENTAL ILLNESS TRAINING & RES,SEATTLE,WA 98195	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; Saint Paul Ramsey Medical Center; University of Minnesota System; University of Minnesota Twin Cities; University of Washington; University of Washington Seattle	GARRARD, J (corresponding author), UNIV MINNESOTA,SCH PUBL HLTH,DIV HLTH SERV RES & POLICY,420 DELAWARE ST SE,BOX 729 MAYO,MINNEAPOLIS,MN 55455, USA.			Zelterman, Daniel/0000-0003-0711-8688	NATIONAL INSTITUTE ON AGING [K01AG000434] Funding Source: NIH RePORTER; NIA NIH HHS [1KO1-AG 000434-02] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		[Anonymous], 1978, INT CLASSIFICATION D; AVORN J, 1989, NEW ENGL J MED, V320, P227, DOI 10.1056/NEJM198901263200406; BEARDSLEY RS, 1989, J AM GERIATR SOC, V37, P327, DOI 10.1111/j.1532-5415.1989.tb05499.x; BEERS M, 1988, JAMA-J AM MED ASSOC, V260, P3016, DOI 10.1001/jama.260.20.3016; BUCK JA, 1988, J AM GERIATR SOC, V36, P409, DOI 10.1111/j.1532-5415.1988.tb02379.x; BUCK JA, 1989, AM J MENT RETARD, V93, P618; BURNS BJ, 1988, J FAM PRACTICE, V26, P155; DOANE KW, 1989, CONSULTANT PHARM, V4, P367; Goodman L.S., 1980, PHARM BASIS THERAPEU, V6th; HILL BK, 1985, PSYCHOPHARMACOL BULL, V21, P279; Institute of Medicine report, 1986, IMPROVING QUALITY CA; KANE RL, 1989, AM J PUBLIC HEALTH, V79, P1271, DOI 10.2105/AJPH.79.9.1271; KANE RL, 1989, NURSING HOMES NURSIN, P37; Kepferle L, 1983, J Long Term Care Adm, V11, P54; RAY WA, 1987, NEW ENGL J MED, V316, P363, DOI 10.1056/NEJM198702123160702; RAY WA, 1980, AM J PUBLIC HEALTH, V70, P485, DOI 10.2105/AJPH.70.5.485; 1976, US DHEW MONOGRAPH, V2; 1988, ADVERSE DRUG REACT, P100; 1989, FED REG         0202, V54, P5316; 1986, DRUG EVALUATIONS	20	82	82	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 23	1991	265	4					463	467		10.1001/jama.265.4.463	http://dx.doi.org/10.1001/jama.265.4.463			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ET377	1670645				2023-01-03	WOS:A1991ET37700023
J	SOUVIGNET, C; PELOSIN, JM; DANIEL, S; CHAMBAZ, EM; RANSAC, S; VERGER, R				SOUVIGNET, C; PELOSIN, JM; DANIEL, S; CHAMBAZ, EM; RANSAC, S; VERGER, R			ACTIVATION OF PROTEIN-KINASE-C IN LIPID MONOLAYERS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPID MONOLAYERS; PHORBOL ESTER; MIXED MICELLES; RAT-BRAIN; CALCIUM; DIACYLGLYCEROL; ASSOCIATION; MEMBRANES; PURIFICATION; SPECIFICITY	The potential of lipid monolayers spread at an air-water interface was investigated as a well defined membrane model able to support protein kinase C (PKC) association and activation. PKC association to a mixed phospholipid from (phosphatidylcholine, phosphatidylserine) could be detected by an increase of the monolayer surface pressure. This association was strikingly dependent upon the presence of submicromolar concentrations of Ca2+. The effect of Ca2+ resulted in an increase of the PKC penetration into the lipid core at a given permissive surface pressure as well as in a marked increase of the critical surface pressure (29-38 dynes/cm) above which the enzyme was excluded from the membrane. Inclusion of diacylglycerol or tetradecanoate phorbol acetate (TPA) did not modify the PKC-monolayer association in a detectable manner. PKC associated to the lipid layer exhibited the expected catalytic property and was fully activated when diacylglycerol or TPA was included in the membrane. PKC activity was highly dependent upon the surface pressure of the lipid monolayer, being optimal between 30 and 25 dynes/cm. Study of the compression isotherm of various diacylglycerol structures revealed that all potent PKC agonists exhibited an expanded liquid phase behavior with collapse pressure below 40 dynes/cm, in contrast to weak activators which showed condensed isotherms with high collapse pressure (almost-equal-to 60 dynes/cm). These observations showed that the lipid monolayer system is well adapted to the study of the molecular mechanisms involved in the regulation of PKC activity at a model membrane interface. They are in line with the suggestion of a major role of Ca2+ in the association (translocation ) of PKC to membrane in living cell and suggest that diacylglycerol (and TPA) might activate membrane-associated PKC through local change in the surrounding lipid phase organization.	CNRS,CTR BIOCHIM & BIOL MOLEC,F-13009 MARSEILLE,FRANCE	Centre National de la Recherche Scientifique (CNRS)	SOUVIGNET, C (corresponding author), CEN,CEA,DBMS,LBIO,BIOCHIM REGULAT CELLULAIRES ENDOCRINES LAB,INSERM,F-38041 GRENOBLE,FRANCE.			, Stephane Ransac/0000-0003-2597-4584				ALKON DL, 1988, SCIENCE, V239, P998, DOI 10.1126/science.2830669; ASHENDEL CL, 1986, CARCINOGENESIS, V7, P517, DOI 10.1093/carcin/7.4.517; BAZZI MD, 1987, BIOCHEMISTRY-US, V26, P5002, DOI 10.1021/bi00390a018; BAZZI MD, 1988, BIOCHEMISTRY-US, V27, P6776, DOI 10.1021/bi00418a020; BAZZI MD, 1987, BIOCHEMISTRY-US, V26, P115, DOI 10.1021/bi00375a017; BAZZI MD, 1987, BIOCHEMISTRY-US, V26, P1974, DOI 10.1021/bi00381a029; BELL RM, 1986, CELL, V45, P631, DOI 10.1016/0092-8674(86)90774-9; BLUME A, 1979, BIOCHIM BIOPHYS ACTA, V557, P32, DOI 10.1016/0005-2736(79)90087-7; BONI LT, 1985, J BIOL CHEM, V260, P819; BOUGIS P, 1981, BIOCHEMISTRY-US, V20, P4915, DOI 10.1021/bi00520a017; CASTAGNA M, 1982, J BIOL CHEM, V257, P7847; DEMEL RA, 1975, BIOCHIM BIOPHYS ACTA, V406, P97, DOI 10.1016/0005-2736(75)90045-0; EPAND RM, 1988, BIOSCIENCE REP, V8, P49, DOI 10.1007/BF01128971; EPAND RM, 1987, CHEM-BIOL INTERACT, V63, P239, DOI 10.1016/0009-2797(87)90044-5; GO M, 1987, BIOCHEM BIOPH RES CO, V144, P598; GOPALAKRISHNA R, 1986, J BIOL CHEM, V261, P6438; GRAHAM DE, 1979, J COLLOID INTERF SCI, V70, P403, DOI 10.1016/0021-9797(79)90048-1; HANNUN YA, 1986, J BIOL CHEM, V261, P7184; HANNUN YA, 1985, J BIOL CHEM, V260, P39; HARAFUJI H, 1980, J BIOCHEM, V87, P1305, DOI 10.1093/oxfordjournals.jbchem.a132868; INAGAKI M, 1986, FEBS LETT, V202, P277, DOI 10.1016/0014-5793(86)80701-3; INOUE M, 1977, J BIOL CHEM, V252, P7610; KIKKAWA U, 1982, J BIOL CHEM, V257, P13341; KIMELBERG H, 1971, J BIOL CHEM, V252, P4313; KIMELBERG HK, 1971, BIOCHIM BIOPHYS ACTA, V233, P805, DOI 10.1016/0005-2736(71)90181-7; KISHIMOTO A, 1980, J BIOL CHEM, V255, P2273; Macritchie F, 1978, Adv Protein Chem, V32, P283, DOI 10.1016/S0065-3233(08)60577-X; MAYER LD, 1983, BIOCHEMISTRY-US, V22, P316, DOI 10.1021/bi00271a013; SIEGEL DP, 1989, BIOCHEMISTRY-US, V28, P3703, DOI 10.1021/bi00435a012; TAKAI Y, 1979, J BIOL CHEM, V254, P3692; VERGER R, 1982, CHEM PHYS LIPIDS, V30, P189, DOI 10.1016/0009-3084(82)90052-4; WALTON GM, 1987, ANAL BIOCHEM, V161, P425, DOI 10.1016/0003-2697(87)90471-4; WOLF M, 1985, J BIOL CHEM, V260, P5718	33	54	54	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1991	266	1					40	44						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	EQ339	1985909				2023-01-03	WOS:A1991EQ33900008
J	ATZPODIEN, J; KORFER, A; FRANKS, CR; POLIWODA, H; KIRCHNER, H				ATZPODIEN, J; KORFER, A; FRANKS, CR; POLIWODA, H; KIRCHNER, H			HOME THERAPY WITH RECOMBINANT INTERLEUKIN-2 AND INTERFERON-ALPHA-2B IN ADVANCED HUMAN MALIGNANCIES	LANCET			English	Article									MED HSCH HANOVER,MED CTR,DEPT HAEMATOL & ONCOL,W-3000 HANOVER 61,GERMANY; EUROCETUS BV,AMSTERDAM,NETHERLANDS									ATZPODIEN J, 1990, Molecular Biotherapy, V2, P18; ATZPODIEN J, 1988, LEUKAMIEN LYMPHOME, P211; ENGVALL E, 1971, IMMUNOCHEMISTRY, V8, P871, DOI 10.1016/0019-2791(71)90454-X; FISHER RI, 1988, ANN INTERN MED, V108, P518, DOI 10.7326/0003-4819-108-4-518; GILLIS S, 1978, J IMMUNOL, V120, P2027; HUBERMAN M, 1988, P AM SOC CLIN ONCOL, V7, P653; KOLITZ JE, 1988, J BIOL RESP MODIF, V7, P457; LEE KH, 1989, J CLIN ONCOL, V7, P1726, DOI 10.1200/JCO.1989.7.11.1726; LEE RE, 1989, J CLIN ONCOL, V7, P7, DOI 10.1200/JCO.1989.7.1.7; LEGHA SS, 1986, CANCER, V57, P1675, DOI 10.1002/1097-0142(19860415)57:8+<1675::AID-CNCR2820571307>3.0.CO;2-I; MUSS HB, 1987, SEMIN ONCOL, V14, P36; NEGRIER S, 1989, EUR J CANCER CLIN S3, V25, P21; ROSENBERG SA, 1989, J CLIN ONCOL, V7, P1863, DOI 10.1200/JCO.1989.7.12.1863; ROSENBERG SA, 1988, NEW ENGL J MED, V319, P1676, DOI 10.1056/NEJM198812223192527; ROSENBERG SA, 1988, ANN INTERN MED, V108, P853, DOI 10.7326/0003-4819-108-6-853; ROSENBERG SA, 1987, NEW ENGL J MED, V316, P880; ROSENSTEIN M, 1986, J IMMUNOL, V137, P1735; WEST WH, 1987, NEW ENGL J MED, V316, P898, DOI 10.1056/NEJM198704093161502	18	324	326	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 23	1990	335	8704					1509	1512		10.1016/0140-6736(90)93039-R	http://dx.doi.org/10.1016/0140-6736(90)93039-R			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DK586	1972442				2023-01-03	WOS:A1990DK58600013
J	SMALLEY, RV; ANDERSEN, JW; HAWKINS, MJ; BHIDE, V; OCONNELL, MJ; OKEN, MM; BORDEN, EC				SMALLEY, RV; ANDERSEN, JW; HAWKINS, MJ; BHIDE, V; OCONNELL, MJ; OKEN, MM; BORDEN, EC			INTERFERON ALFA COMBINED WITH CYTOTOXIC CHEMOTHERAPY FOR PATIENTS WITH NON-HODGKINS-LYMPHOMA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CHRONIC LYMPHOCYTIC-LEUKEMIA; HUMAN-LEUKOCYTE INTERFERON; COOPERATIVE-ONCOLOGY-GROUP; SINGLE-AGENT CHEMOTHERAPY; METASTATIC BREAST-CANCER; HAIRY-CELL LEUKEMIA; MALIGNANT-LYMPHOMA; MULTIPLE-MYELOMA; COMBINATION CHEMOTHERAPY; RECOMBINANT LEUKOCYTE	Background. Interferon alfa has been found to be effective as an antitumor agent (with a response rate of 30 percent) in patients with low-grade non-Hodgkin's lymphoma, but its effectiveness in those with intermediate-grade non-Hodgkin's lymphoma has been less adequately tested. In a prospective randomized study we evaluated the effectiveness of adding interferon alfa to cytotoxic chemotherapy in patients with clinically aggressive, low-grade non-Hodgkin's lymphoma and certain histologic variants of intermediate-grade non-Hodgkin's lymphoma, not including diffuse histiocytic lymphoma. Methods. The patients were randomly assigned to a regimen of cyclophosphamide, vincristine, prednisone, and doxorubicin or to this regimen combined with recombinant interferon alfa. Treatment was administered every four weeks, for 8 to 10 cycles. Results. The two regimens produced comparable objective responses, but the regimen including interferon had a greater effect in prolonging the time to treatment failure (P<0.001) and the duration of complete response (P = 0.03). Interferon alfa also had a greater effect on overall survival (P = 0.014) when the results were adjusted for important covariates. Conclusions. Interferon alfa, when added to a four-drug doxorubicin-based chemotherapy regimen, is an effective antitumor agent in patients with clinically aggressive low-grade or intermediate-grade non-Hodgkin's lymphoma.	UNIV WISCONSIN,CTR CLIN CANC,MADISON,WI 53706; HARVARD UNIV,SCH MED,DANA FARBER CANC INST,CTR BIOSTAT,BOSTON,MA 02115; VIRGINIA PIPER CANC INST,MINNEAPOLIS,MN; GEORGETOWN UNIV,WASHINGTON,DC 20057; MAYO CLIN & MAYO FDN,ROCHESTER,MN 55905; MED COLL WISCONSIN,MILWAUKEE,WI 53226	University of Wisconsin System; University of Wisconsin Madison; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Georgetown University; Mayo Clinic; Medical College of Wisconsin	SMALLEY, RV (corresponding author), SYNERTRON INC,575 SCI DR,MADISON,WI 53711, USA.				NCI NIH HHS [CA-06594, CA-14548, CA-14958] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U10CA014548, U10CA006594, U10CA014958] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSON T, 1982, CANCER, V50, P2699, DOI 10.1002/1097-0142(19821215)50:12<2699::AID-CNCR2820501202>3.0.CO;2-A; BALKWILL FR, 1984, CANCER RES, V44, P904; Bishop YM., 2007, DISCRETE MULTIVARIAT; CABANILLAS F, 1979, CANCER, V44, P1983, DOI 10.1002/1097-0142(197912)44:6<1983::AID-CNCR2820440604>3.0.CO;2-4; CHIRIGOS MA, 1973, J NATL CANCER I, V51, P1367, DOI 10.1093/jnci/51.4.1367; CHISESI T, 1987, INVEST NEW DRUG, V5, pS35; CLARK RH, 1989, AM J CLIN ONCOL-CANC, V12, P75, DOI 10.1097/00000421-198902000-00017; EZDINLI EZ, 1985, J CLIN ONCOL, V3, P769, DOI 10.1200/JCO.1985.3.6.769; FOON KA, 1986, SEMIN ONCOL, V13, P35; FOON KA, 1984, NEW ENGL J MED, V311, P1148, DOI 10.1056/NEJM198411013111803; GALLAGHER CJ, 1986, J CLIN ONCOL, V4, P1470, DOI 10.1200/JCO.1986.4.10.1470; GAMS R, 1984, P AN M AM SOC CLIN, V3, P65; GRESSER I, 1976, INT J CANCER, V17, P647, DOI 10.1002/ijc.2910170514; GRESSER I, 1978, EUR J CANCER, V14, P97, DOI 10.1016/0014-2964(78)90143-3; GUTTERMAN JU, 1980, ANN INTERN MED, V93, P399, DOI 10.7326/0003-4819-93-3-399; HOPPE RT, 1981, BLOOD, V58, P592; HORNING SJ, 1985, CANCER-AM CANCER SOC, V56, P1305, DOI 10.1002/1097-0142(19850915)56:6<1305::AID-CNCR2820560614>3.0.CO;2-N; LEAVITT RD, 1985, DEV ONCOLOGY, V27, P57; LISTER TA, 1978, BRIT MED J, V1, P533, DOI 10.1136/bmj.1.6112.533; LOUIE AC, 1981, BLOOD, V58, P712; MANDELLI F, 1990, NEW ENGL J MED, V322, P1430, DOI 10.1056/NEJM199005173222005; MEHTA CR, 1983, J AM STAT ASSOC, V78, P427, DOI 10.2307/2288652; MERIGAN TC, 1978, NEW ENGL J MED, V299, P1449, DOI 10.1056/NEJM197812282992608; MOWSHOWITZ SL, 1982, J INTERFERON RES, V2, P587, DOI 10.1089/jir.1982.2.587; Oakes, 1984, ANAL SURVIVAL DATA, DOI DOI 10.1201/9781315137438; OCONNELL MJ, 1986, J CLIN ONCOL, V4, P128, DOI 10.1200/JCO.1986.4.2.128; OCONNELL MJ, 1987, J CLIN ONCOL, V5, P1329, DOI 10.1200/JCO.1987.5.9.1329; OKEN MM, 1982, AM J CLIN ONCOL-CANC, V5, P649, DOI 10.1097/00000421-198212000-00014; OZER H, 1987, INVEST NEW DRUG, V5, pS27; QAZI R, 1976, CANCER, V37, P1923, DOI 10.1002/1097-0142(197604)37:4<1923::AID-CNCR2820370443>3.0.CO;2-D; QUESADA JR, 1984, NEW ENGL J MED, V310, P15, DOI 10.1056/NEJM198401053100104; QUESADA JR, 1984, AM J MED, V77, P427, DOI 10.1016/0002-9343(84)90097-4; ROHATINER AZS, 1987, BRIT J CANCER, V55, P225, DOI 10.1038/bjc.1987.42; SCHILLER JH, 1989, J BIOL RESP MODIF, V8, P252; SLATER LM, 1981, CANCER, V48, P5, DOI 10.1002/1097-0142(19810701)48:1<5::AID-CNCR2820480103>3.0.CO;2-C; SMALLEY RV, 1991, BLOOD, V78, P3133; SOLALCELIGNY P, 1991, P AN M AM SOC CLIN, V10, P275; STEWARD WP, 1988, CANCER-AM CANCER SOC, V61, P441, DOI 10.1002/1097-0142(19880201)61:3<441::AID-CNCR2820610306>3.0.CO;2-N; STRAUS DJ, 1987, AM J MED, V82, P247, DOI 10.1016/0002-9343(87)90064-7; SULLIVAN KM, 1983, BLOOD, V62, P51; VANDERMOLEN LA, 1990, JNCI-J NATL CANCER I, V82, P235, DOI 10.1093/jnci/82.3.235; WAGSTAFF J, 1986, CANCER CHEMOTH PHARM, V18, P54, DOI 10.1007/BF00253065; WAGSTAFF K, 1985, DEV ONCOLOGY, V27, P51	43	179	182	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 5	1992	327	19					1336	1341		10.1056/NEJM199211053271902	http://dx.doi.org/10.1056/NEJM199211053271902			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JW077	1406835	Bronze			2023-01-03	WOS:A1992JW07700002
J	NIGHTINGALE, SL				NIGHTINGALE, SL			FDA PROPOSES TO PROHIBIT 415 INGREDIENTS FROM OTC DRUG PRODUCTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	6	6	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 14	1992	268	14					1828	1828		10.1001/jama.268.14.1828	http://dx.doi.org/10.1001/jama.268.14.1828			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JR439	1404696				2023-01-03	WOS:A1992JR43900009
J	GREGORY, R; TATTERSALL, RB				GREGORY, R; TATTERSALL, RB			ARE DIABETIC PREPREGNANCY CLINICS WORTH WHILE	LANCET			English	Editorial Material							CONGENITAL-MALFORMATIONS; WOMEN; MANAGEMENT; MOTHERS; INFANTS; CONCEPTION; ANOMALIES; BABIES; RISK; CARE		UNIV NOTTINGHAM HOSP,DIABET UNIT,NOTTINGHAM NG7 2UH,ENGLAND	University of Nottingham								BRYCE FC, 1991, DIABETIC MED, V8, P382, DOI 10.1111/j.1464-5491.1991.tb01614.x; CULLIMORE J, 1990, J OBSTET GYNAECOL, V10, P171; DAMM P, 1989, AM J OBSTET GYNECOL, V161, P1163, DOI 10.1016/0002-9378(89)90656-X; DRURY MI, 1989, DIABETIC MED, V6, P291, DOI 10.1111/j.1464-5491.1989.tb01167.x; FURHMAN K, 1983, DIABETES CARE, V6, P219; Greene MF, 1989, DIABETES COMPLICATIN, P147; GREGORY R, 1992, J ROY COLL PHYS LOND, V26, P162; Heller S R, 1984, Diabet Med, V1, P199; JOVANOVIC L, 1981, AM J MED, V71, P921, DOI 10.1016/0002-9343(81)90301-6; KITZMILLER JL, 1991, JAMA-J AM MED ASSOC, V265, P731, DOI 10.1001/jama.265.6.731; Lawrence RD, 1942, Q J MED, V11, P45; LESLIE RDG, 1978, LANCET, V2, P958; LOWY C, 1986, DIABETIC MED, V3, P458, DOI 10.1111/j.1464-5491.1986.tb00791.x; MILLER E, 1981, NEW ENGL J MED, V304, P1331, DOI 10.1056/NEJM198105283042204; MILLS JL, 1979, DIABETES, V28, P292, DOI 10.2337/diabetes.28.4.292; MILLS JL, 1988, NEW ENGL J MED, V319, P1617, DOI 10.1056/NEJM198812223192501; MIODOVNIK M, 1988, DIABETES CARE, V11, P714; MOLSTEDPEDERSEN L, 1985, DIABETES ANN, V1, P238; OAKLEY WG, 1968, CLIN DIABETES ITS BI, P643; ROSENN B, 1991, OBSTET GYNECOL, V77, P846; STEEL JM, 1990, BRIT MED J, V301, P1070, DOI 10.1136/bmj.301.6760.1070; STEEL JM, 1980, DIABETES CARE, V3, P371, DOI 10.2337/diacare.3.2.371; TCHOBROUTSKY C, 1971, DIABETES METAB, V17, P287; YLINEN K, 1984, BRIT MED J, V289, P345, DOI 10.1136/bmj.289.6441.345; 1990, DIABETES CARE, V14, P994	25	15	15	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 12	1992	340	8820					656	658		10.1016/0140-6736(92)92181-E	http://dx.doi.org/10.1016/0140-6736(92)92181-E			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JM851	1355220				2023-01-03	WOS:A1992JM85100013
J	COCCONI, G; BELLA, M; CALABRESI, F; TONATO, M; CANALETTI, R; BONI, C; BUZZI, F; CECI, G; CORGNA, E; COSTA, P; LOTTICI, R; PAPADIA, F; SOFRA, MC; BACCHI, M				COCCONI, G; BELLA, M; CALABRESI, F; TONATO, M; CANALETTI, R; BONI, C; BUZZI, F; CECI, G; CORGNA, E; COSTA, P; LOTTICI, R; PAPADIA, F; SOFRA, MC; BACCHI, M			TREATMENT OF METASTATIC MALIGNANT-MELANOMA WITH DACARBAZINE PLUS TAMOXIFEN	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							GROWTH-FACTOR-BETA; ADVANCED BREAST-CANCER; KILLER CELL-ACTIVITY; HUMAN LYMPHOCYTES-T; ESTROGEN-RECEPTORS; COMBINATION CHEMOTHERAPY; TRANSFORMED PHENOTYPE; ENDOCRINE THERAPY; IMMUNE-RESPONSE; NK ACTIVITY	Background. Endocrine factors may affect the clinical course of malignant melanoma and the response to the treatment of this disease. The presence of estrogen receptors in melanomas has been suggested, and occasional responses to antiestrogen therapy have been reported. Methods and Results. We randomly assigned 117 patients with metastatic malignant melanoma to treatment with dacarbazine alone or dacarbazine in combination with tamoxifen. The overall rate of response, measured objectively, was higher (28 percent vs. 12 percent, P = 0.03) and survival was longer (median, 48 vs. 29 weeks, P = 0.02) among the patients who received dacarbazine plus tamoxifen than among those who received dacarbazine alone. Among women, both the response rate (38 percent vs. 10 percent, P = 0.04) and the median survival (69 vs. 30 weeks, P = 0.008) were better with dacarbazine plus tamoxifen than with dacarbazine alone, whereas among men the differences were smaller and not statistically significant. Among the patients given dacarbazine alone, there were no significant differences between women and men in response rate (10 percent vs. 13 percent) or survival (30 vs. 27 weeks), whereas among those given dacarbazine plus tamoxifen, women had better outcomes, as indicated by both response rate (38 percent vs. 19 percent, P = 0.15) and survival (69 vs. 31 weeks, P = 0.02). When we analyzed the Quetelet body-mass index (the weight in kilograms divided by the square of the height in meters) as an indirect indicator of the levels of endogenous estrogens in postmenopausal women and in men, survival was not affected by the body-mass index in the group given dacarbazine alone, whereas in the group given dacarbazine plus tamoxifen, survival was longer among patients whose Quetelet index was above the median value than among those with a Quetelet index lower than the median value (60 vs. 26 weeks, P<0.001). Conclusions. In the treatment of metastatic malignant melanoma, dacarbazine plus tamoxifen is more effective than dacarbazine alone, as indicated by both the response rate and the median survival; the difference in efficacy occurs mainly among women.	OSPED MAGGIORE PARMA,ITALIAN ONCOL GRP CLIN RES,ONCOL SERV,PARMA UNIT,PARMA,ITALY; IST REGINA ELENA,I-00161 ROME,ITALY; POLICLIN MONTELUCE,DIV MED ONCOL,PERUGIA UNIT,PERUGIA,ITALY; OSPED S MARIA,ONCOL SERV,TERNI UNIT,TERNI,ITALY; OSPED CIVILE,ONCOL SERV,PIACENZA UNIT,PIACENZA,ITALY; UNIV PARMA,DIV PLAST SURG,I-43100 PARMA,ITALY	University of Parma; University Hospital of Parma; IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; University of Parma								ADAMI HO, 1990, JAMA-J AM MED ASSOC, V263, P2189, DOI 10.1001/jama.263.16.2189; BALCH CM, 1983, J CLIN ONCOL, V1, P126, DOI 10.1200/JCO.1983.1.2.126; BALCH CM, 1991, CUTANEOUS MELANOMA, P40; BEHL C, 1990, Proceedings of the American Association for Cancer Research Annual Meeting, V31, P59; BENASSAYAG C, 1986, ENDOCRINOLOGY, V118, P1; BERD D, 1991, P AN M AM SOC CLIN, V10, P291; BLATT J, 1984, BRIT J CANCER, V50, P837, DOI 10.1038/bjc.1984.264; BLATT J, 1984, P AM SOC CLIN ONCOL, V3, P77; BONMASSAR A, 1979, EUR J CANCER, V15, P933, DOI 10.1016/0014-2964(79)90276-7; BROWN TJ, 1987, J IMMUNOL, V139, P2977; CECI G, 1988, CANCER, V61, P1988, DOI 10.1002/1097-0142(19880515)61:10<1988::AID-CNCR2820611010>3.0.CO;2-5; COCCONI G, 1983, CANCER, V51, P581, DOI 10.1002/1097-0142(19830215)51:4<581::AID-CNCR2820510404>3.0.CO;2-G; COHEN JHM, 1983, J IMMUNOL, V131, P2767; COLLETTA AA, 1990, BRIT J CANCER, V62, P405, DOI 10.1038/bjc.1990.307; CREAGAN ET, 1980, CANCER, V46, P1785, DOI 10.1002/1097-0142(19801015)46:8<1785::AID-CNCR2820460815>3.0.CO;2-0; DELARCO JE, 1985, P NATL ACAD SCI USA, V82, P5015; DELPRETE SA, 1984, CANCER TREAT REP, V68, P1403; DERYNCK R, 1985, NATURE, V316, P701, DOI 10.1038/316701a0; DESLYPERE JP, 1985, J CLIN ENDOCR METAB, V61, P564, DOI 10.1210/jcem-61-3-564; FEUCHT KA, 1988, CANCER RES, V48, P7093; FIORETTI MC, 1975, PHARMACOL RES COMMUN, V7, P481, DOI 10.1016/0031-6989(75)90009-0; FISHER RI, 1976, LANCET, V2, P337; FOLKERD EJ, 1983, J STEROID BIOCHEM, V19, P687, DOI 10.1016/0022-4731(83)90236-4; GULINO A, 1985, J LEUKOCYTE BIOL, V38, P159; HANNA N, 1983, J IMMUNOL, V130, P974; HERSEY P, 1982, CANCER RES, V42, P363; HRUSHESKY WJM, 1988, J NATL CANCER I, V80, P1232, DOI 10.1093/jnci/80.15.1232; KALLAND T, 1980, J IMMUNOL, V124, P194; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KARAKOUSIS CP, 1980, CANCER TREAT REP, V64, P819; KEHRL JH, 1986, J EXP MED, V163, P1037, DOI 10.1084/jem.163.5.1037; KNABBE C, 1987, CELL, V48, P417, DOI 10.1016/0092-8674(87)90193-0; LEGHA SS, 1989, SEMIN ONCOL, V16, P34; LUIKART SD, 1984, J CLIN ONCOL, V2, P164, DOI 10.1200/JCO.1984.2.3.164; LUSTER MI, 1981, BIOL RELEVANCE IMMUN, P153; MANDEVILLE R, 1984, EUR J CANCER CLIN ON, V20, P983, DOI 10.1016/0277-5379(84)90174-3; MARELLI O, 1988, BRIT J CANCER, V58, P171, DOI 10.1038/bjc.1988.186; MCCARTY KS, 1986, CANCER RES, V46, P4244; MCCLAY EF, 1987, CANCER TREAT REP, V71, P465; MCCLAY EF, 1988, SEMIN ONCOL, V15, P569; MCCLAY EF, 1989, CANCER, V63, P1292, DOI 10.1002/1097-0142(19890401)63:7<1292::AID-CNCR2820630711>3.0.CO;2-I; MEYSKENS FL, 1980, CANCER TREAT REP, V64, P171; MILLER AB, 1981, CANCER, V47, P207, DOI 10.1002/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6; MOURIDSEN HT, 1985, EUR J CANCER CLIN ON, V21, P291, DOI 10.1016/0277-5379(85)90128-2; NESBIT RA, 1979, NEW ENGL J MED, V301, P1241; PAAVONEN T, 1981, J EXP MED, V154, P1935, DOI 10.1084/jem.154.6.1935; PARMIANI G, 1990, J NATL CANCER I, V82, P361, DOI 10.1093/jnci/82.5.361; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; ROBERTS AB, 1990, ADV CLIN ONCOL, V1, P283; SPORN MB, 1986, SCIENCE, V233, P532, DOI 10.1126/science.3487831; TORMEY DC, 1982, AM J CLIN ONCOL-CANC, V5, P33; VILADIU P, 1985, CANCER, V56, P2745, DOI 10.1002/1097-0142(19851215)56:12<2745::AID-CNCR2820561204>3.0.CO;2-G; WALKER MJ, 1988, SEMIN ONCOL, V15, P512; WALKER MJ, 1987, J CLIN ONCOL, V5, P1256, DOI 10.1200/JCO.1987.5.8.1256; WIELAND I, 1986, CELL, V47, P675, DOI 10.1016/0092-8674(86)90510-6; ZAVA DT, 1983, EUR J CANCER CLIN ON, V19, P1151, DOI 10.1016/0277-5379(83)90041-X; 1985, SAS USERS GUIDE STAT; 1984, J CLIN ONCOL, V2, P131	58	221	231	0	8	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 20	1992	327	8					516	523		10.1056/NEJM199208203270803	http://dx.doi.org/10.1056/NEJM199208203270803			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JJ457	1635566				2023-01-03	WOS:A1992JJ45700003
J	BLENDON, RJ; SZALAY, US; KNOX, RA				BLENDON, RJ; SZALAY, US; KNOX, RA			SHOULD PHYSICIANS AID THEIR PATIENTS IN DYING - THE PUBLIC PERSPECTIVE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									BOSTON GLOBE,BOSTON,MA		BLENDON, RJ (corresponding author), HARVARD UNIV,SCH PUBL HLTH,DEPT HLTH POLICY & MANAGEMENT,PROGRAM PUBL OPIN & HLTH CARE,BOSTON,MA 02115, USA.							KENT C, 1991, MED HLTH        1202, V45, pA2; OUSLANDER JG, 1989, ARCH INTERN MED, V149, P1367, DOI 10.1001/archinte.149.6.1367; QUILL TE, 1991, NEW ENGL J MED, V324, P691, DOI 10.1056/NEJM199103073241010; UHLMANN RF, 1988, J GERONTOL, V43, pM115, DOI 10.1093/geronj/43.5.M115; WOOD F, 1990, AM PROFILE OPINIONS, P627; 1991, AM VIEW ANGING RESUL; 1989, PHYSICIAN PUBLIC ATT; 1991, NY TIMES        1107, pB14; 1990, GENERAL SOCIAL SURVE	9	181	182	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 20	1992	267	19					2658	2662		10.1001/jama.267.19.2658	http://dx.doi.org/10.1001/jama.267.19.2658			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HT823	1573758				2023-01-03	WOS:A1992HT82300038
J	HANNAFORD, PC; KAY, CR				HANNAFORD, PC; KAY, CR			AFTER ISIS-3	LANCET			English	Letter											HANNAFORD, PC (corresponding author), ROYAL COLL GEN PRACTIT,MANCHESTER RES UNIT,MANCHESTER M20 0TR,ENGLAND.		Hannaford, Philip C/B-7867-2012					1992, LANCET, V339, P753	1	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 16	1992	339	8803					1225	1225		10.1016/0140-6736(92)91161-Z	http://dx.doi.org/10.1016/0140-6736(92)91161-Z			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HU684	1349950				2023-01-03	WOS:A1992HU68400021
J	GILL, TM				GILL, TM			WHAT HAVE I DONE	ANNALS OF INTERNAL MEDICINE			English	Editorial Material						RESUSCITATION; HEART ARREST; ETHICS, MEDICAL		This short tale deals with a timely subject of general concern to internists and to most clinicians-that awful moment of hesitation when embarking on the urgent resuscitation of a patient whose previous health status is unknown. The exhilaration of a successful effort is supplanted by the dismay of a dismal outcome.			GILL, TM (corresponding author), YALE UNIV, SCH MED, RM IE-61 SHM, POB 3333, NEW HAVEN, CT 06510 USA.			Gill, Thomas/0000-0002-6450-0368				MURPHY DJ, 1989, ANN INTERN MED, V111, P199, DOI 10.7326/0003-4819-111-3-199	1	0	0	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 15	1992	116	8					691	691		10.7326/0003-4819-116-8-691	http://dx.doi.org/10.7326/0003-4819-116-8-691			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HN844	1546871				2023-01-03	WOS:A1992HN84400014
J	HORINA, JH; HOLZER, H; REISINGER, EC; KREJS, GJ; NEUGEBAUER, JS				HORINA, JH; HOLZER, H; REISINGER, EC; KREJS, GJ; NEUGEBAUER, JS			ELDERLY PATIENTS AND CHRONIC-HEMODIALYSIS	LANCET			English	Letter									KRANKENHAUS WIENER NEUSTADT,WIENER NEUSTADT,GERMANY		HORINA, JH (corresponding author), GRAZ UNIV,DEPT MED,A-8036 GRAZ,AUSTRIA.							HORINA JH, 1991, NEPHRON, V58, P407, DOI 10.1159/000186471; Karnofsky DA, 1949, CLIN EVALUATION CHEM, P191; KILNER JF, 1990, AM J KIDNEY DIS, V15, P218, DOI 10.1016/S0272-6386(12)80766-9; Kjellstrand C M, 1988, Acta Med Scand Suppl, V725, P1; NEU S, 1986, NEW ENGL J MED, V314, P14, DOI 10.1056/NEJM198601023140103; 1984, LANCET, V1, P717	6	16	17	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 18	1992	339	8786					183	183		10.1016/0140-6736(92)90251-W	http://dx.doi.org/10.1016/0140-6736(92)90251-W			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GZ968	1346036				2023-01-03	WOS:A1992GZ96800039
J	TOBIAS, JS				TOBIAS, JS			CLINICAL-PRACTICE OF RADIOTHERAPY	LANCET			English	Article							CELL LUNG-CANCER; RANDOMIZED TRIAL; RADIATION; THERAPY; CARCINOMA; TUMORS; SCHEDULES; HEAD				TOBIAS, JS (corresponding author), UNIV COLL HOSP LONDON,DEPT RADIOTHERAPY & ONCOL,GOWER ST,LONDON WC1E 6AU,ENGLAND.							ARRIAGADA R, 1985, INT J RADIAT ONCOL, V11, P1461, DOI 10.1016/0360-3016(85)90333-5; BLOOM HJG, 1982, BRIT J UROL, V54, P136, DOI 10.1111/j.1464-410X.1982.tb13537.x; BLOOM HJG, 1986, CANCER CHILDREN CLIN, P197; BUXTON EJ, 1990, CANCER CHEMOTHER PHA, V26, P59; DILLMAN RO, 1990, NEW ENGL J MED, V323, P940, DOI 10.1056/NEJM199010043231403; DUNCAN W, 1987, INT J RADIAT ONCOL, V13, P171, DOI 10.1016/0360-3016(87)90124-6; ERRINGTON RD, 1991, BRIT MED J, V302, P1045, DOI 10.1136/bmj.302.6784.1045; FISHER B, 1985, NEW ENGL J MED, V312, P665, DOI 10.1056/NEJM198503143121101; GAHRTON G, 1991, NEW ENGL J MED, V325, P1267, DOI 10.1056/NEJM199110313251802; GUPTA NK, 1987, CLIN RADIOL, V38, P575, DOI 10.1016/S0009-9260(87)80327-6; Hellman S., 1989, CANCER PRINCIPLES PR, P247; HETZEL MR, 1985, THORAX, V40, P341, DOI 10.1136/thx.40.5.341; HORIOT JC, 1990, EUR J CANCER, V26, P779, DOI 10.1016/0277-5379(90)90150-R; HORWICH A, 1990, RADIOTHER ONCOL, V19, P353, DOI 10.1016/0167-8140(90)90036-V; KJELLBERG RN, 1983, NEW ENGL J MED, V309, P269, DOI 10.1056/NEJM198308043090503; KROOK JE, 1991, NEW ENGL J MED, V324, P709, DOI 10.1056/NEJM199103143241101; LIVESEY EA, 1990, BRIT J CANCER, V61, P622, DOI 10.1038/bjc.1990.138; PEREZ CA, 1986, GYNECOL ONCOL, V23, P127, DOI 10.1016/0090-8258(86)90216-7; PETERMAN SB, 1985, NEURORADIOLOGY, V27, P202, DOI 10.1007/BF00344488; PRICE P, 1986, RADIOTHER ONCOL, V6, P247, DOI 10.1016/S0167-8140(86)80191-8; ROWELL NP, 1991, BLOOD REV, V5, P84, DOI 10.1016/0268-960X(91)90039-F; SAUNDERS MI, 1989, INT J RADIAT ONCOL, V17, P1287, DOI 10.1016/0360-3016(89)90538-5; Sheline G E, 1986, Clin Neurosurg, V33, P563; SUIT HD, 1985, CANCER-AM CANCER SOC, V55, P2659, DOI 10.1002/1097-0142(19850601)55:11<2659::AID-CNCR2820551122>3.0.CO;2-Q; TAIT DM, 1990, EUR J CANCER, V26, P750, DOI 10.1016/0277-5379(90)90135-G; TANNOCK IF, 1989, RADIOTHER ONCOL, V16, P81; Tobias J, 1990, NEUROONCOLOGY PRIMAR, P164; TOBIAS JS, 1991, EUR J CANCER, V27, P1350, DOI 10.1016/0277-5379(91)90007-Z; WILLIAMS SF, 1990, SEMIN ONCOL, V17, P88; 1991, REPORT MEDICAL MANPO; IN PRESS BR J CANCER	31	21	23	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 18	1992	339	8786					159	163		10.1016/0140-6736(92)90219-S	http://dx.doi.org/10.1016/0140-6736(92)90219-S			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GZ968	1370338				2023-01-03	WOS:A1992GZ96800012
J	JACK, DB; SOPPITT, AJ				JACK, DB; SOPPITT, AJ			GIVE A DRUG A BAD NAME	BRITISH MEDICAL JOURNAL			English	Article									DUDLEY RD GEN HOSP,DEPT GASTROENTEROL,BIRMINGHAM B18 7QH,W MIDLANDS,ENGLAND		JACK, DB (corresponding author), FIDIA RES LABS,SCI INFORMAT SERV,I-35031 ABANO TERME,ITALY.							BLAIN J, 1990, REV PRESCRIRE    OCT; Eliot T. S., 1939, OLD POSSUMS BOOK PRA; FABER J, 1991, LANCET, V337, P1286, DOI 10.1016/0140-6736(91)92954-Z; Heller J., 1962, CATCH 22; HOFFMAN JP, 1990, NEW ENGL J MED, V323, P1428; KURTH MC, 1990, NEW ENGL J MED, V323, P1776; TOLSTOI LN, 1954, ANNA KARENINA; 1990, INDEX NOMINUM; 1991, BRIT NATIONAL FORMUL, V21	9	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 21	1991	303	6817					1606	1608		10.1136/bmj.303.6817.1606	http://dx.doi.org/10.1136/bmj.303.6817.1606			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GX956	1773189	Green Published, Bronze			2023-01-03	WOS:A1991GX95600022
J	STERN, RS; WEISSMAN, JS; EPSTEIN, AM				STERN, RS; WEISSMAN, JS; EPSTEIN, AM			THE EMERGENCY DEPARTMENT AS A PATHWAY TO ADMISSION FOR POOR AND HIGH-COST PATIENTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HOSPITALS; SYSTEMS; RATES; RISK	Background. - To determine the importance of the emergency department as the means of access to the hospital for the poor and the fiscal implications of providing these services, we examined the relationship between patients' socioeconomic status and admission via the emergency department. We also determined the association between entering the hospital via the emergency department and hospital resource use. Methods. - We conducted a study of 20 089 patients admitted to five Massachusetts hospitals (three community, two tertiary care) during a 6-month period. We determined the proportions of patients within various socioeconomic and disease groupings who entered through the emergency department. We compared length ot stay and charges for patients admitted through the emergency department with those for patients admitted through other routes. Results. - Overall, 51% of patients entered via the emergency department. Elderly patients (age > 65 years; odds ratio, 1.87) and patients with lower socioeconomic status as measured by income, occupation, and education (odds ratios, 2.38. 1.47, and 1.69, respectively) were more likely to enter the hospital via the emergency department than other patients. After adjustment for diagnosis related group, severity as measured by DRGSCALE, and socioeconomic status as measured by income. and excluding outliers, patients admitted via the emergency department stayed 27% longer and incurred 13% higher charges than other patients (P < .001). Conclusions. - Our data indicate that patients with lower socioeconomic status are more likely than other patients to use the emergency department as their means of access to the hospital and that patients admitted via the emergency department use far more resources than patients in the same diagnosis related group admitted by other means. Hospitals that make emergency department services more available may be more likely to hospitalize socioeconomically disadvantaged patients and may be at a substantial financial disadvantage under per-case reimbursement systems such as Medicare.	HARVARD UNIV,BETH ISRAEL HOSP,SCH MED,CHARLES A DANA RES INST,BOSTON,MA 02215; BRIGHAM & WOMENS HOSP,DEPT MED,DIV GEN MED,HLTH SERV & POLICY RES SECT,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT HLTH CARE POLICY,BOSTON,MA 02115; HARVARD UNIV,SCH PUBL HLTH,DEPT HLTH POLICY & MANAGEMENT,BOSTON,MA 02115	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health	STERN, RS (corresponding author), HARVARD UNIV,BETH ISRAEL HOSP,SCH MED,DEPT DERMATOL,330 BROOKLINE AVE,BOSTON,MA 02215, USA.				AHRQ HHS [1 F32 HS00024] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		ANDREN KG, 1987, SOC SCI MED, V25, P1121, DOI 10.1016/0277-9536(87)90353-4; BRESLOW NE, 1980, STATISTICAL METHODS, P1; CONKLIN JE, 1984, DRG REFINEMENT FEASI; CONKLIN JE, 1987, DRG REFINEMENT USING; EPSTEIN AM, 1990, NEW ENGL J MED, V322, P1122, DOI 10.1056/NEJM199004193221606; HELLINGER FJ, 1985, INQUIRY-J HEALTH CAR, V22, P78; Melnick G A, 1989, Health Care Financ Rev, V10, P29; MUNOZ E, 1985, JAMA-J AM MED ASSOC, V254, P1763, DOI 10.1001/jama.254.13.1763; MUNOZ E, 1986, AM J PUBLIC HEALTH, V76, P696, DOI 10.2105/AJPH.76.6.696; MUNOZ E, 1989, J CARDIOVASC SURG, V30, P58; MUNOZ E, 1988, J THORAC CARDIOV SUR, V96, P376; OGRADY KF, 1985, NEW ENGL J MED, V313, P484, DOI 10.1056/NEJM198508223130806; SLOAN FA, 1988, AM J PUBLIC HEALTH, V78, P553, DOI 10.2105/AJPH.78.5.553; 1990, MEDICARES DISPROPORT; [No title captured]	15	94	94	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 23	1991	266	16					2238	2243		10.1001/jama.266.16.2238	http://dx.doi.org/10.1001/jama.266.16.2238			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GK661	1920722				2023-01-03	WOS:A1991GK66100031
J	HOWARD, NJ; LAING, RO				HOWARD, NJ; LAING, RO			CHANGES IN THE WORLD-HEALTH-ORGANIZATION ESSENTIAL DRUG LIST	LANCET			English	Review								The World Health Organisation Model List of Essential Drugs is an attempt to provide guidelines for selection of essential pharmaceuticals. Analysis of the six lists produced between 1977 and 1990 shows an increase in the number of items from 205 to 268. 120 drugs have been added and 57 deleted; however, only 16 of the additional drugs can be considered new clinical entities or to have new indications. The original purpose of the essential drug list was to itemise the minimum number of essential drugs. Many additions were due to a change in perception about the usefulness of a particular drug, not scientific advances. Nevertheless, the list remains a useful guide for countries selecting their own national lists.	MANAGEMENT SCI HLTH,165 ALLANDALE RD,BOSTON,MA 02130									[Anonymous], 1989, WHO MODEL PRESCRIBIN; 1985, TECHNIAL REPORT SERI, V722; 1990, LANCET, V335, P1003; 1988, TECHNICAL REPORT SER, V770; 1990, WHO MODEL PRESCRIBIN; 1987, 1986 INT WORKSH NORD, P3; 1990, TECHNICAL REPORT SER, V796; 1983, TECHNICAL REPORT SER, V685; 1979, TECHNICAL REPORT SER, V641; 1977, TECHICAL REPORT SERI, V615	10	13	13	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 21	1991	338	8769					743	745		10.1016/0140-6736(91)91455-4	http://dx.doi.org/10.1016/0140-6736(91)91455-4			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GG104	1679879				2023-01-03	WOS:A1991GG10400016
J	BOVILL, EG; TERRIN, ML; STUMP, DC; BERKE, AD; FREDERICK, M; COLLEN, D; FEIT, F; GORE, JM; HILLIS, LD; LAMBREW, CT; LEIBOFF, R; MANN, KG; MARKIS, JE; PRATT, CM; SHARKEY, SW; SOPKO, G; TRACY, RP; CHESEBRO, JH				BOVILL, EG; TERRIN, ML; STUMP, DC; BERKE, AD; FREDERICK, M; COLLEN, D; FEIT, F; GORE, JM; HILLIS, LD; LAMBREW, CT; LEIBOFF, R; MANN, KG; MARKIS, JE; PRATT, CM; SHARKEY, SW; SOPKO, G; TRACY, RP; CHESEBRO, JH			HEMORRHAGIC EVENTS DURING THERAPY WITH RECOMBINANT TISSUE-TYPE PLASMINOGEN-ACTIVATOR, HEPARIN, AND ASPIRIN FOR ACUTE MYOCARDIAL-INFARCTION - RESULTS OF THE THROMBOLYSIS IN MYOCARDIAL-INFARCTION (TIMI), PHASE-II TRIAL	ANNALS OF INTERNAL MEDICINE			English	Article							LEFT-VENTRICULAR FUNCTION; INTRAVENOUS STREPTOKINASE; REPERFUSION; SURVIVAL	Objectives: To assess the effects of invasive procedures, hemostatic and clinical variables, the timing of beta-blocker therapy, and the doses of recombinant plasminogen activator (rt-PA) on hemorrhagic events. Design: A multicenter, randomized, controlled trial. Setting: Hospitals participating in the Thrombolysis in Myocardial Infarction, Phase II trial (TIMI II). Interventions: Patients received rt-PA, heparin, and aspirin. The total dose of rt-PA was 150 mg for the first 520 patients and 100 mg for the remaining 2819 patients. Patients were randomly assigned to an invasive strategy (coronary arteriography with percutaneous angioplasty [if feasible] done routinely 18 to 48 hours after the start of thrombolytic therapy) or to a conservative strategy (coronary arteriography done for recurrent spontaneous or exercise-induced ischemia). Eligible patients were also randomly assigned to either immediate intravenous or deferred beta-blocker therapy. Measurements: Patients were monitored for hemorrhagic events during hospitalization. Main Results: In patients on the 100-mg rt-PA regimen, major and minor hemorrhagic events were more common among those assigned to the invasive than among those assigned to the conservative strategy (18.5% versus 12.8%, P < 0.001). Major or minor hemorrhagic events were associated with the extent of fibrinogen breakdown, peak rt-PA levels, thrombocytopenia, prolongation of the activated partial thromboplastin time (APTT) to more than 90 seconds, weight of 70 kg or less, female gender, and physical signs of cardiac decompensation. Immediate intravenous beta-blocker therapy had no important effect on hemorrhagic events when compared with delayed beta-blocker therapy. Intracranial hemorrhages were more frequent among patients treated with the 150-mg rt-PA dose than with the 100-mg rt-PA dose (2.1% versus 0.5%, P < 0.001). The extent of the plasmin-mediated hemostatic defect was also greater in patients receiving the 150-mg dose. Conclusions: Increased morbidity due to hemorrhagic complications is associated with an invasive management strategy in patients with acute myocardial infarction. Our findings show the complex interaction of several factors in the occurrence of hemorrhagic events during thrombolytic therapy.	UNIV VERMONT, BURLINGTON, VT 05405 USA; COLUMBIA UNIV, NEW YORK, NY 10027 USA; NYU, NEW YORK, NY 10003 USA; UNIV MASSACHUSETTS, SCH MED, WORCESTER, MA 01605 USA; UNIV TEXAS, SW MED CTR, DALLAS, TX 75230 USA; MAINE MED CTR, PORTLAND, ME 04102 USA; GEORGE WASHINGTON UNIV, WASHINGTON, DC 20052 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA; BAYLOR COLL MED, HOUSTON, TX 77030 USA; UNIV MINNESOTA, MINNEAPOLIS, MN 55455 USA; NHLBI, BETHESDA, MD 20892 USA; MAYO CLIN & MAYO FDN, ROCHESTER, MN 55905 USA	University of Vermont; Columbia University; New York University; University of Massachusetts System; University of Massachusetts Worcester; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Maine Medical Center; George Washington University; Harvard University; Harvard Medical School; Baylor College of Medicine; University of Minnesota System; University of Minnesota Twin Cities; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Mayo Clinic	BOVILL, EG (corresponding author), MARYLAND MED RES INST, TIMI COORDINATING CTR, 600 WYNDHURST AVE, BALTIMORE, MD 21210 USA.		Burkle, Frederick/AAE-5423-2020		NHLBI NIH HHS [HL38460, HL35058] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038460, P50HL035058] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSON JL, 1988, J AM COLL CARDIOL, V11, P1153, DOI 10.1016/0735-1097(88)90276-8; [Anonymous], 1988, LANCET, V2, P349; [Anonymous], 1986, LANCET, V1, P397; [Anonymous], 1989, NEW ENGL J MED, V320, P618; BOVILL E, 1987, BLOOD S, V760, pA1323; BRAUNWALD E, 1987, J AM COLL CARDIOL, V10, P970, DOI 10.1016/S0735-1097(87)80296-6; BRAUNWALD E, 1987, J AM COLL CARDIOL, V9, P467, DOI 10.1016/S0735-1097(87)80407-2; CALIFF RM, 1988, AM J MED, V85, P353, DOI 10.1016/0002-9343(88)90586-4; CHAITMAN BR, 1989, J AM COLL CARDIOL, V14, P1159, DOI 10.1016/0735-1097(89)90410-5; CHAMBERLAIN DA, 1988, LANCET, V1, P545; CLAUSS A., 1957, ACTA HAEMATOL, V17, P237; COLLEN D, 1986, CIRCULATION, V73, P511, DOI 10.1161/01.CIR.73.3.511; DIXON WJ, 1985, BMDP STATISTICAL SOF; Fleiss JL, 1981, STATISTICAL METHODS, P19; GARABEDIAN HD, 1986, AM J CARDIOL, V58, P673, DOI 10.1016/0002-9149(86)90336-X; GORE JM, 1991, CIRCULATION, V83, P448, DOI 10.1161/01.CIR.83.2.448; HOLVOET P, 1985, THROMB HAEMOSTASIS, V54, P684; HOSMER DW, 1989, APPL LOGISTIC REGRES, P25; JAN KM, 1975, CIRCULATION, V51, P1079, DOI 10.1161/01.CIR.51.6.1079; KALBFLEISCH JD, 1980, STATISTICAL ANAL FAI, P122; KELTON J, 1991, PROGR HEMOSTASIS THR, V10, P1; KENNEDY JW, 1988, CIRCULATION, V77, P345, DOI 10.1161/01.CIR.77.2.345; MERSKEY C, 1969, P SOC EXP BIOL MED, V131, P871; MUELLER HS, 1987, J AM COLL CARDIOL, V10, P479, DOI 10.1016/S0735-1097(87)80188-2; RAO AK, 1988, J AM COLL CARDIOL, V11, P1; ROBERTS R, 1991, CIRCULATION, V83, P422, DOI 10.1161/01.CIR.83.2.422; ROGERS WJ, 1990, CIRCULATION, V81, P1457, DOI 10.1161/01.CIR.81.5.1457; SCHRODER R, 1986, NEW ENGL J MED, V314, P1465; Snedecor G. W., 1967, STATISTICAL METHODS, P91; STUMP DC, 1988, THROMB HAEMOSTASIS, V59, P133; STUMP DC, 1989, CIRCULATION, V80, P1222, DOI 10.1161/01.CIR.80.5.1222; TRACY RP, 1988, BLOOD, V72, P1415; VANDEWERF F, 1988, BMJ-BRIT MED J, V297, P1374, DOI 10.1136/bmj.297.6660.1374; WHITE HD, 1987, NEW ENGL J MED, V317, P850, DOI 10.1056/NEJM198710013171402; WILCOX RG, 1988, LANCET, V2, P525; 1990, LANCET, P65; 1985, SAS USERS GUIDE BASI	37	415	428	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 15	1991	115	4					256	265		10.7326/0003-4819-115-4-256	http://dx.doi.org/10.7326/0003-4819-115-4-256			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GA764	1906692				2023-01-03	WOS:A1991GA76400003
J	WOOD, PD; STEFANICK, ML; WILLIAMS, PT; HASKELL, WL				WOOD, PD; STEFANICK, ML; WILLIAMS, PT; HASKELL, WL			THE EFFECTS ON PLASMA-LIPOPROTEINS OF A PRUDENT WEIGHT-REDUCING DIET, WITH OR WITHOUT EXERCISE, IN OVERWEIGHT MEN AND WOMEN	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CORONARY HEART-DISEASE; CARDIOVASCULAR-DISEASE; ADIPOSE-TISSUE; CHOLESTEROL; PARTICIPANTS; OBESITY; FOLLOW; RISK; PRECIPITATION; QUANTITATION	Background. The National Cholesterol Education Program (NCEP) recommends a low-saturated-fat, low-cholesterol diet, with weight loss if indicated, to correct elevated plasma cholesterol levels. Weight loss accomplished by simple caloric restriction or increased exercise typically increases the level of high-density lipoprotein (HDL) cholesterol. Little is known about the effects on plasma lipoproteins of a hypocaloric NCEP diet with or without exercise in overweight people. Methods. We tested the hypothesis that exercise (walking or jogging) will increase HDL cholesterol levels in moderately overweight, sedentary people who adopt a hypocaloric NCEP diet. We randomly assigned 132 men and 132 women 25 to 49 years old to one of three groups: control, hypocaloric NCEP diet, or hypocaloric NCEP diet with exercise. One hundred nineteen of the men and 112 of the women returned for testing after one year. Results. After one year, the subjects in both intervention groups had reached or closely approached NCEP Step 1 dietary goals and reduced their mean body fat significantly (range of reduction in mean fat weight, 4.0 to 7.8 kg). Weight loss on the NCEP diet alone did not significantly change HDL cholesterol levels in either the men or the women as compared with the subjects in the control group. Plasma levels of HDL cholesterol increased significantly more in the men who exercised and dieted (mean [+/- SE] change, +13 +/- 3 percent) than in the men who only dieted (+2 +/- 3 percent, P < 0.01) or the men who acted as controls (-4 +/- 2 percent, P < 0.001). HDL cholesterol levels remained about the same in the women who exercised and dieted (+1 +/- 2 percent); they were higher than in the women who only dieted (-10 +/- 3 percent, P < 0.01), but not higher than in the controls (-3 +/- 3 percent). Conclusions. Regular exercise in overweight men and women enhances the improvement in plasma lipoprotein levels that results from the adoption of a low-saturated-fat, low-cholesterol diet.			WOOD, PD (corresponding author), STANFORD UNIV,SCH MED,STANFORD CTR RES DIS PREVENT,730 WELCH RD,PALO ALTO,CA 94304, USA.		González, Adela M Gómez/D-2863-2012		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL024462, K04HL002183] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-24462, HL-02183] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALLAIN CC, 1974, CLIN CHEM, V20, P470; ANDERSON KM, 1991, CIRCULATION, V83, P356, DOI 10.1161/01.CIR.83.1.356; BLAIR SN, 1989, JAMA-J AM MED ASSOC, V262, P2395, DOI 10.1001/jama.262.17.2395; BUSH TL, 1988, CLIN CHEM, V34, pB60; FORTMANN SP, 1988, AM J CARDIOL, V62, P89, DOI 10.1016/0002-9149(88)91370-7; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; HAGBERG JM, 1990, EXERCISE, FITNESS, AND HEALTH, P455; HUBERT HB, 1983, CIRCULATION, V67, P968, DOI 10.1161/01.CIR.67.5.968; KRAUSS RM, 1982, MED CLIN N AM, V66, P403, DOI 10.1016/S0025-7125(16)31427-4; LAPIDUS L, 1984, BMJ-BRIT MED J, V289, P1257, DOI 10.1136/bmj.289.6454.1257; LARSSON B, 1984, BRIT MED J, V288, P1401, DOI 10.1136/bmj.288.6428.1401; MACIEJKO JJ, 1987, CLIN CHEM, V33, P2065; MANSON JAE, 1990, NEW ENGL J MED, V322, P882, DOI 10.1056/NEJM199003293221303; NAITO HK, 1985, ANN NY ACAD SCI, V454, P230, DOI 10.1111/j.1749-6632.1985.tb11862.x; POWELL KE, 1987, ANNU REV PUBL HEALTH, V8, P253, DOI 10.1146/annurev.publhealth.8.1.253; SAMPSON EJ, 1975, CLIN CHEM, V21, P1983; SAVIN WM, 1980, CIRCULATION, V62, P55, DOI 10.1161/01.CIR.62.1.55; Siri W., 1961, TECHNIQUES MEASURING, P223; THOMPSON JK, 1982, PSYCHOL BULL, V91, P55, DOI 10.1037/0033-2909.91.1.55; WARNICK GR, 1982, CLIN CHEM, V28, P1574; WARNICK GR, 1982, CLIN CHEM, V28, P1379; WOOD PD, 1988, NEW ENGL J MED, V319, P1173, DOI 10.1056/NEJM198811033191801; 1982, DHEW NIH75628 PUBL; 1990, MMWR, V39, P541; 1986, NUTRIENT DATA BASE V; 1987, DHHS NIH882926 PUBL; [No title captured]; 1989, DHHS NIH892925 PUBL; 1984, JAMA-J AM MED ASSOC, V251, P351	29	459	472	0	20	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 15	1991	325	7					461	466		10.1056/NEJM199108153250703	http://dx.doi.org/10.1056/NEJM199108153250703			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GA763	1852180				2023-01-03	WOS:A1991GA76300003
J	SHORT, RV; LEWIS, PR; RENFREE, MB; SHAW, G				SHORT, RV; LEWIS, PR; RENFREE, MB; SHAW, G			CONTRACEPTIVE EFFECTS OF EXTENDED LACTATIONAL AMENORRHEA - BEYOND THE BELLAGIO CONSENSUS	LANCET			English	Article								We have recorded the duration of lactational anovulation and amenorrhoea in a well-nourished group of Australian women who breastfed their babies throughout the study. The data enabled us to compare the theoretical cumulative probability of conception among breastfeeding women who had unprotected intercourse irrespective of their menstrual status with that of those who had unprotected intercourse only during lactational amenorrhoea. Breastfeeding alone is not an effective form of contraception, since all the women in our study resumed normal ovulation while still breastfeeding. However, among women who have unprotected intercourse only during lactational amenorrhoea but adopt other contraceptive measures when they resume menstruation, only 1.7% would have become pregnant during the first 6 months of amenorrhoea, only 7% after 12 months, and only 13% after 24 months. Thus for our women it would be possible to extend the Bellagio Consensus Conference guidelines which stated that lactational amenorrhoea can only be relied on as a contraceptive for the first 6 months post-partum in women who are fully or almost fully breastfeeding. The lactational amenorrhoea method can be relied on for excellent contraceptive protection in the first 6 months of breastfeeding, irrespective of when supplements are introduced into the baby's diet; for women who continue to breastfeed the method can also give good protection for up to 12 months post partum. Once menstruation has returned, other forms of contraception are essential to prevent pregnancy.	NURSING MOTHERS ASSOC AUSTRALIAL,NUNAWADING,AUSTRALIA; MONASH UNIV,DEPT ANAT,MELBOURNE,VIC 3004,AUSTRALIA	Monash University	SHORT, RV (corresponding author), MONASH UNIV,DEPT PHYSIOL,MELBOURNE 3168,AUSTRALIA.		Shaw, Geoff/A-6916-2012	Shaw, Geoff/0000-0002-7421-7136; Renfree, Marilyn/0000-0002-4589-0436				GRAY RH, 1990, LANCET, V335, P25, DOI 10.1016/0140-6736(90)90147-W; KENNEDY KI, 1989, CONTRACEPTION, V39, P477, DOI 10.1016/0010-7824(89)90103-0; LEWIS PR, IN PRESS FERTIL STER; RODRIGUEZ G, 1988, BREASTFEEDING LENGTH; SIMPSONHEBERT M, 1981, STUD FAMILY PLANN, V12, P125, DOI 10.2307/1965593; THAPA S, 1988, NATURE, V335, P679, DOI 10.1038/335679a0; WOOD JW, 1989, OXFORD REV REPROD B, V11, P61; 1988, LANCET, V2, P1204	8	75	75	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 23	1991	337	8743					715	717		10.1016/0140-6736(91)90288-Z	http://dx.doi.org/10.1016/0140-6736(91)90288-Z			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FD367	1672186				2023-01-03	WOS:A1991FD36700018
J	SOMA, M; FUMAGALLI, R; PAOLETTI, R; MESCHIA, M; MAINI, MC; CROSIGNANI, P; GHANEM, K; GAUBATZ, J; MORRISETT, JD				SOMA, M; FUMAGALLI, R; PAOLETTI, R; MESCHIA, M; MAINI, MC; CROSIGNANI, P; GHANEM, K; GAUBATZ, J; MORRISETT, JD			PLASMA LP(A) CONCENTRATION AFTER ESTROGEN AND PROGESTAGEN IN POSTMENOPAUSAL WOMEN	LANCET			English	Letter							LIPOPROTEIN LP(A)		UNIV MILAN,DEPT OBSTET & GYNAECOL,I-20122 MILAN,ITALY; BAYLOR UNIV,METHODIST HOSP,HOUSTON,TX 77030	University of Milan; Baylor University; The Methodist Hospital System; The Methodist Hospital - Houston	SOMA, M (corresponding author), UNIV MILAN,INST PHARMACOL SCI,I-20133 MILAN,ITALY.							DAHLEN GH, 1986, CIRCULATION, V74, P758, DOI 10.1161/01.CIR.74.4.758; Gaubatz J W, 1986, Methods Enzymol, V129, P167; GUYTON JR, 1985, ARTERIOSCLEROSIS, V5, P265, DOI 10.1161/01.ATV.5.3.265; HOEFLER G, 1988, ARTERIOSCLEROSIS, V8, P398, DOI 10.1161/01.ATV.8.4.398; MESCHIA M, 1989, 45TH ANN M AM FERT S, P1068; Sandkamp M, 1990, LIPOPROTEIN A, P205	6	127	129	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 9	1991	337	8741					612	612		10.1016/0140-6736(91)91674-J	http://dx.doi.org/10.1016/0140-6736(91)91674-J			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FA702	1671962				2023-01-03	WOS:A1991FA70200029
J	BERRY, GT; HEIDENREICH, R; KAPLAN, P; LEVINE, F; MAZUR, A; PALMIERI, MJ; YUDKOFF, M; SEGAL, S				BERRY, GT; HEIDENREICH, R; KAPLAN, P; LEVINE, F; MAZUR, A; PALMIERI, MJ; YUDKOFF, M; SEGAL, S			BRANCHED-CHAIN AMINO-ACID FREE PARENTERAL-NUTRITION IN THE TREATMENT OF ACUTE METABOLIC DECOMPENSATION IN PATIENTS WITH MAPLE SYRUP URINE DISEASE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									UNIV PENN,SCH MED,DEPT PEDIAT & MED,PHILADELPHIA,PA 19104	University of Pennsylvania	BERRY, GT (corresponding author), CHILDRENS HOSP PHILADELPHIA,DIV BIOCHEM DEV & MOLEC DIS,34TH ST & CIVIC CTR BLVD,PHILADELPHIA,PA 19104, USA.		Levine, Fred/L-2693-2013	Levine, Fred/0000-0002-7336-2526; Berry, Gerard/0000-0001-5299-3313	NCRR NIH HHS [RR240] Funding Source: Medline	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Danner DJ, 1989, METABOLIC BASIS INHE, P671; ELSAS LJ, 1988, MODERN NUTRITION HLT, P1337; RUTLEDGE SL, 1990, J PEDIATR-US, V116, P125, DOI 10.1016/S0022-3476(05)81661-0; TOWNSEND I, 1982, AM J CLIN NUTR, V36, P359, DOI 10.1093/ajcn/36.2.359; WENDEL U, 1982, J INHERIT METAB DIS, V5, P25, DOI 10.1007/BF01799811; 1985, WHO TECH REP SER, V724, P71; 1989, RECOMMENDED DIETARY	7	25	27	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 17	1991	324	3					175	179		10.1056/NEJM199101173240307	http://dx.doi.org/10.1056/NEJM199101173240307			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ER471	1898534				2023-01-03	WOS:A1991ER47100007
J	POTTS, M; ROSENFIELD, A				POTTS, M; ROSENFIELD, A			THE 5TH FREEDOM REVISITED .1. BACKGROUND AND EXISTING PROGRAMS	LANCET			English	Review									COLUMBIA SCH PUBL HLTH,NEW YORK,NY	Columbia University	POTTS, M (corresponding author), FAMILY HLTH INT,POB 13950,RES TRIANGLE PK,NC 27709, USA.							BAIRD D, 1965, BMJ-BRIT MED J, V2, P1141, DOI 10.1136/bmj.2.5471.1141; BLACK T, 1972, NEW CONCEPTS CONTRAC, P43; BONGAARTS J, 1984, POPUL DEV REV, V10, P341, DOI 10.2307/1973086; Bongaarts J, 1983, FERTILITY BIOL BEHAV; CAMP SL, 1989, WORLD BANKS ROLE GLO; Chayovan N., 1988, International Family Planning Perspectives, V14, P86, DOI 10.2307/2947738; CHAYOVAN N, 1988, INT FAM PLANN PERSPE, V14, P102; CUTRIGHT P, 1983, INT FAMILY PLANNING, V9, P101; HUBER SC, 1989, J BIOSOC SCI, V21, P267, DOI 10.1017/S0021932000017971; HUG MN, 1989, PRELIMINARY REPORT B; JANOWITZ BS, 1990, INVESTING FUTURE; MAINE D, 1981, FAMILY PLANNING ITS; MOSHER WD, 1988, FAM PLANN PERSPECT, V20, P207, DOI 10.2307/2135622; MUMFORD SD, 1980, LANCET, V2, P1066; Murphy F X, 1981, Popul Bull, V35, P1; NESS GD, 1989, POPULI, V16, P4; POTTS M, 1977, ABORTION; ROSENFIELD A., 1982, International Family Planning Perspectives, V8, P43, DOI 10.2307/2948087; ROSENFIELD A, 1989, JAMA-J AM MED ASSOC, V262, P376, DOI 10.1001/jama.262.3.376; ROSENFIELD AG, 1972, AM J OBSTET GYNECOL, V114, P942, DOI 10.1016/0002-9378(72)90103-2; ROSENFIELD AG, 1974, AM J OBSTET GYNECOL, V118, P1104, DOI 10.1016/0002-9378(74)90690-5; ROSS JA, 1989, FAM PLANN PERSPECT, V21, P275, DOI 10.2307/2135382; THAPA S, 1988, NATURE, V335, P679, DOI 10.1038/335679a0; Tietze C, 1986, INDUCED ABORTION WOR; ZAVALA AS, 1987, STUD FAMILY PLANN, V18, P284, DOI 10.2307/1966857; 1990, UNFPA1989 ANN REP; 1990, INT FORUM POPULATION	27	13	13	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 17	1990	336	8725					1227	1231		10.1016/0140-6736(90)92843-7	http://dx.doi.org/10.1016/0140-6736(90)92843-7			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	EJ064	1978080				2023-01-03	WOS:A1990EJ06400013
J	SINGH, V; WISNIEWSKI, A; BRITTON, J; TATTERSFIELD, A				SINGH, V; WISNIEWSKI, A; BRITTON, J; TATTERSFIELD, A			EFFECT OF YOGA BREATHING EXERCISES (PRANAYAMA) ON AIRWAY REACTIVITY IN SUBJECTS WITH ASTHMA	LANCET			English	Article											SINGH, V (corresponding author), CITY HOSP NOTTINGHAM, RESP MED UNIT, NOTTINGHAM NG5 1PB, ENGLAND.		Britton, John R/G-9705-2011					BANDOUVAKIS J, 1981, BRIT J DIS CHEST, V75, P295, DOI 10.1016/0007-0971(81)90009-7; BENSON H, 1982, NATURE, V295, P234, DOI 10.1038/295234a0; BRITTON J, 1988, THORAX, V43, P300, DOI 10.1136/thx.43.4.300; CASTERLINE CL, 1976, J ALLERGY CLIN IMMUN, V58, P607, DOI 10.1016/0091-6749(76)90207-4; CHINN S, 1987, THORAX, V42, P45, DOI 10.1136/thx.42.1.45; CHUNG KF, 1982, AM REV RESPIR DIS, V126, P849; COCKCROFT DW, 1977, THORAX, V32, P429, DOI 10.1136/thx.32.4.429; EWER TC, 1986, BMJ-BRIT MED J, V293, P1129, DOI 10.1136/bmj.293.6555.1129; GOYECHE JRM, 1982, J ASTHMA, V19, P189, DOI 10.3109/02770908209104756; HILLS M, 1979, BRIT J CLIN PHARMACO, V8, P7, DOI 10.1111/j.1365-2125.1979.tb05903.x; KERREBIJN KF, 1987, J ALLERGY CLIN IMMUN, V79, P653, DOI 10.1016/S0091-6749(87)80163-X; KRAAN J, 1988, AM REV RESPIR DIS, V137, P44, DOI 10.1164/ajrccm/137.1.44; KRAAN J, 1985, J ALLERGY CLIN IMMUN, V76, P628, DOI 10.1016/0091-6749(85)90786-9; Murthy KJR, 1984, LUNG INDIA, V2, P187; NAGARATHNA R, 1985, BRIT MED J, V291, P1077, DOI 10.1136/bmj.291.6502.1077; NAGENDRA HR, 1986, J ASTHMA, V23, P123, DOI 10.3109/02770908609077486; NAIR N, 1977, ANN ALLERGY, V38, P297; RYAN G, 1985, J ALLERGY CLIN IMMUN, V75, P25, DOI 10.1016/0091-6749(85)90007-7; SCHULTE HJ, 1979, ARIZ MED, V36, P681; SINGH V, 1987, J ASTHMA, V24, P355, DOI 10.3109/02770908709070967; SINGH V, 1987, J ASTHMA, V24, P183, DOI 10.3109/02770908709070936; TANDON MK, 1978, THORAX, V33, P514, DOI 10.1136/thx.33.4.514; UDUPA KN, 1972, J AMER MED ASSOC, V220, P1365, DOI 10.1001/jama.1972.03200100075029; YAN K, 1983, THORAX, V38, P760, DOI 10.1136/thx.38.10.760	24	112	118	1	21	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 9	1990	335	8702					1381	1383		10.1016/0140-6736(90)91254-8	http://dx.doi.org/10.1016/0140-6736(90)91254-8			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DH145	1971670				2023-01-03	WOS:A1990DH14500013
J	HECKMATT, JZ; LOH, L; DUBOWITZ, V				HECKMATT, JZ; LOH, L; DUBOWITZ, V			NIGHT-TIME NASAL VENTILATION IN NEUROMUSCULAR DISEASE	LANCET			English	Article									RADCLIFFE INFIRM,DEPT ANAESTHET,OXFORD OX2 6HE,ENGLAND	Radcliffe Infirmary	HECKMATT, JZ (corresponding author), HAMMERSMITH HOSP,DEPT PAEDIAT,LONDON W12 0NN,ENGLAND.							BACH J, 1981, ARCH PHYS MED REHAB, V62, P328; BACH JR, 1987, CHEST, V92, P169; CARROLL N, 1988, THORAX, V43, P349, DOI 10.1136/thx.43.5.349; DAVIS JN, 1976, Q J MED, V45, P87; ELLIS ER, 1987, AM REV RESPIR DIS, V136, P188, DOI 10.1164/ajrccm/136.1.188; ELLIS ER, 1987, AM REV RESPIR DIS, V135, P148; GODFREY S, 1970, British Journal of Diseases of the Chest, V64, P15, DOI 10.1016/S0007-0971(70)80045-6; HECKMATT JZ, 1987, BRIT MED J, V295, P1014, DOI 10.1136/bmj.295.6605.1014; HECKMATT JZ, 1989, PEDIATRICS, V83, P250; KERBY GR, 1987, AM REV RESPIR DIS, V135, P738; MILLER JR, 1988, DEV MED CHILD NEUROL, V30, P200; NOBLEJAMIESON CM, 1986, ARCH DIS CHILD, V61, P178, DOI 10.1136/adc.61.2.178; Rideau Y, 1983, Acta Neurol (Napoli), V5, P118; SEGALL D, 1988, CHEST, V93, P1299	14	80	80	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 10	1990	335	8689					579	582		10.1016/0140-6736(90)90357-B	http://dx.doi.org/10.1016/0140-6736(90)90357-B			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CT653	1968582				2023-01-03	WOS:A1990CT65300011
J	PHIPPS, JH; LEWIS, BV; ROBERTS, T; PRIOR, MV; HAND, JW; ELDER, M; FIELD, SB				PHIPPS, JH; LEWIS, BV; ROBERTS, T; PRIOR, MV; HAND, JW; ELDER, M; FIELD, SB			TREATMENT OF FUNCTIONAL MENORRHAGIA BY RADIOFREQUENCY-INDUCED THERMAL ENDOMETRIAL ABLATION	LANCET			English	Article									HAMMERSMITH HOSP,MRC,CYCLOTRON UNIT,HYPERTHERMIA SECT,LONDON W12 0HS,ENGLAND; ROYAL POSTGRAD MED SCH,INST OBSTET & GYNAECOL,LONDON W12 0HS,ENGLAND	Imperial College London; Imperial College London	PHIPPS, JH (corresponding author), WATFORD DIST GEN HOSP,DEPT OBSTET & GYNAECOL,VICARAGE RD,WATFORD WD1 8HB,HERTS,ENGLAND.		Hand, Jeff/AAF-1503-2020	Hand, Jeffrey/0000-0002-4898-9511				ASHERMAN JG, 1948, J OBSTET GYN BRIT EM, V55, P23; ASTRAHAN MA, 1989, INT J HYPERTHER, V5, P383; COAKLEY WT, 1979, J THERM BIOL, V4, P85, DOI 10.1016/0306-4565(79)90051-2; DAVIS J, 1987, BAILLIERE CLIN OB GY, V1, P331, DOI 10.1016/S0950-3552(87)80058-5; DECHERNEY A, 1983, OBSTET GYNECOL, V61, P392; DROEGEMUELLER W, 1971, OBSTET GYNECOL, V38, P256; GOLDRATH MH, 1987, GYNAECOLOGICAL LASER, P253; LOMANO JM, 1988, AM J OBSTET GYNECOL, V159, P152, DOI 10.1016/0002-9378(88)90512-1; SUGAHARA T, 1989, HYPERTHERMIC ONCOLOG	9	77	86	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 17	1990	335	8686					374	376		10.1016/0140-6736(90)90207-L	http://dx.doi.org/10.1016/0140-6736(90)90207-L			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CN988	1968117				2023-01-03	WOS:A1990CN98800004
J	TAI, YT; BUT, PPH; YOUNG, K; LAU, CP				TAI, YT; BUT, PPH; YOUNG, K; LAU, CP			CARDIOTOXICITY AFTER ACCIDENTAL HERB-INDUCED ACONITE POISONING	LANCET			English	Note								Aconitine and its related alkaloids are known cardiotoxins with no therapeutic role in modern western medicine. The rootstocks of Aconitum plants, which contain aconite alkaloids, have been common components of Chinese herbal recipes. We have documented life-threatening intoxication in 17 Chinese subjects after accidental herb-induced aconite poisoning. All patients developed symptoms of aconite toxicity within 2 h of herb ingestion. Most developed tachyarrhythmias, including ventricular tachycardia and fibrillation from which 2 patients died. Toxicological evaluation revealed that aconites from the Aconitum rootstocks were the only plausible casual factor for intoxication. These cases point to the need for strict surveillance of herbal substances with low safety margins.	UNIV HONG KONG,DEPT MED,HONG KONG,HONG KONG; CHINESE UNIV HONG KONG,CHINESE MED MAT RES CTR,SHA TIN,HONG KONG; CHINESE UNIV HONG KONG,DEPT ANAESTHESIA & INTENS CARE,SHA TIN,HONG KONG; CHINESE UNIV HONG KONG,DEPT BIOL,SHA TIN,HONG KONG	University of Hong Kong; Chinese University of Hong Kong; Chinese University of Hong Kong; Chinese University of Hong Kong								BISSET NG, 1981, J ETHNOPHARMACOL, V4, P247, DOI 10.1016/0378-8741(81)90001-5; CHANG HM, 1987, PHARM APPLICATIONS C, V1; CHANG HM, 1987, PHARM APPLICATIONS C, V2; FATOVICH DM, 1992, ANN EMERG MED, V21, P309, DOI 10.1016/S0196-0644(05)80894-7; FIDDES FS, 1958, BRIT MED J, V2, P779, DOI 10.1136/bmj.2.5099.779; Hartung EF, 1930, J AMER MED ASSOC, V95, P1265, DOI 10.1001/jama.1930.27210170005010c; KAPOOR SC, 1969, INDIAN HEART J, V25, P329; PEPPER K, 1967, PFLUGGERS ARCH, V296, P328; REYNOLDS JEF, 1989, MARTINDALE EXTRA PHA, P1538; 1990, PHARMACOPOEIA PEOPLE, V1, P26; 1983, BRIT HERBAL PHARMACO, P12	11	148	154	3	7	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 21	1992	340	8830					1254	1256		10.1016/0140-6736(92)92951-B	http://dx.doi.org/10.1016/0140-6736(92)92951-B			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JZ237	1359321				2023-01-03	WOS:A1992JZ23700005
J	JANKNEGT, RA; BAETEN, CGMI; WEIL, EHJ; SPAANS, F				JANKNEGT, RA; BAETEN, CGMI; WEIL, EHJ; SPAANS, F			ELECTRICALLY STIMULATED GRACILIS SPHINCTER FOR TREATMENT OF BLADDER SPHINCTER INCONTINENCE	LANCET			English	Note							MUSCLE	Correction of total urinary incontinence due to sphincter damage is done with an artificial sphincter prosthesis or urinary diversion. In this pilot study we used graciloplasty around the bladder neck followed by electrical stimulation of this muscle with an implanted stimulator, which could be switched off and on by a magnet. Stimulus variables could be changed externally. With the stimulator on, urethral pressures of about 50 cm H2O were obtained. Of three patients who underwent the procedure, two became continent and one improved but remained incontinent. Dynamic graciloplasty can restore urinary incontinence.	ACAD HOSP MAASTRICHT,DEPT UROL,MAASTRICHT,NETHERLANDS; ACAD HOSP MAASTRICHT,DEPT GEN SURG,MAASTRICHT,NETHERLANDS; ACAD HOSP MAASTRICHT,DEPT CLIN NEUROPHYSIOL,MAASTRICHT,NETHERLANDS	Maastricht University; Maastricht University Medical Centre (MUMC); Maastricht University; Maastricht University Medical Centre (MUMC); Maastricht University; Maastricht University Medical Centre (MUMC)								ACKER MA, 1986, BIOMECHANICAL CARDIA, P19; BAETEN C, 1988, DIS COLON RECTUM, V31, P134, DOI 10.1007/BF02562646; BAETEN CGMI, 1991, LANCET, V338, P1163, DOI 10.1016/0140-6736(91)92030-6; BOBECHKO WP, 1979, ORTHOP CLIN N AM, V10, P927; CHACHQUES JC, 1986, BIOMECHANICAL CARDIA, P59; HALLAN RI, 1990, BRIT J SURG, V77, P208, DOI 10.1002/bjs.1800770226; Mortimer JT, 1981, HDB PHYSL NERVOUS SY, VII, P155; MUNSAT TL, 1976, ARCH NEUROL-CHICAGO, V33, P608, DOI 10.1001/archneur.1976.00500090014004	8	37	41	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 7	1992	340	8828					1129	1130		10.1016/0140-6736(92)93153-E	http://dx.doi.org/10.1016/0140-6736(92)93153-E			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JX134	1359213				2023-01-03	WOS:A1992JX13400006
J	MITCHELL, JM; SCOTT, E				MITCHELL, JM; SCOTT, E			PHYSICIAN OWNERSHIP OF PHYSICAL THERAPY SERVICES - EFFECTS ON CHARGES, UTILIZATION, PROFITS, AND SERVICE CHARACTERISTICS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CONFLICTS	Objective.-To evaluate the effects of physician ownership of freestanding physical therapy and rehabilitation facilities on utilization, charges, profits, and three measures of service characteristics for physical therapy treatments. Design.-Statistical comparison by physician joint venture ownership status of freestanding physical therapy and comprehensive rehabilitation facilities providing physical therapy treatments in Florida. Participants.-A total of 118 outpatient physical therapy facilities and 63 outpatient comprehensive rehabilitation facilities providing services in Florida during 1989. The data from the facilities were collected under a legislative mandate. Main Outcome Measures.-Visits per patient, average revenue per patient, percent operating income, percent markup, profits per patient, licensed therapist time per visit, and licensed and nonlicensed medical worker time per visit. Results.-Visits per patient were 39% to 45% higher in joint venture facilities. Both gross and net revenue per patient were 30% to 40% higher in facilities owned by referring physicians. Percent operating income and percent markup were significantly higher in joint venture physical therapy and rehabilitation facilities. Licensed physical therapists and licensed therapist assistants employed in nonjoint venture facilities spend about 60% more time per visit treating physical therapy patients than licensed therapists and licensed therapist assistants working in joint venture facilities. Joint ventures also generate more of their revenues from patients with well-paying insurance. Conclusion.-Our results indicate that utilization, charges per patient, and profits are higher when physical therapy and rehabilitation facilities are owned by referring physicians. With respect to service characteristics, joint venture firms employ proportionately fewer licensed therapists and licensed therapist assistants to perform physical therapy, so that licensed professionals employed in joint venture businesses spend significantly less time per visit treating patients. These results should be of interest to the medical profession, third-party payers, and policymakers, all of whom are concerned about the consequences of physician self-referral arrangements.	FLORIDA STATE UNIV,DEPT ECON,TALLAHASSEE,FL 32306; FLORIDA STATE UNIV,DEPT FINANCE,TALLAHASSEE,FL 32306	State University System of Florida; Florida State University; State University System of Florida; Florida State University								BURDA D, 1992, MOD HEALTHCARE  0629, V23, P3; CRANE TS, 1992, JAMA-J AM MED ASSOC, V268, P85, DOI 10.1001/jama.268.1.85; DOBSON R, 1986, NEW ENGL J MED, V314, P250; IGLEHART JK, 1990, NEW ENGL J MED, V322, P1682, DOI 10.1056/NEJM199006073222327; MITCHELL JM, 1992, JAMA-J AM MED ASSOC, V268, P80, DOI 10.1001/jama.268.1.80; MITCHELL JM, 1991, JOINT VENTURES HLTH, V2; MORREIM EH, 1989, JAMA-J AM MED ASSOC, V262, P390, DOI 10.1001/jama.262.3.390; PEAR R, 1992, NY TIMES        0406, pA2; PEAR R, 1991, NY TIMES        1118, pA1; RELMAN AS, 1985, NEW ENGL J MED, V313, P749, DOI 10.1056/NEJM198509193131209; Rosenfeld R.H., 1984, MOD HEATHCARE, V14, P60; TODD JS, 1992, JAMA-J AM MED ASSOC, V268, P98, DOI 10.1001/jama.268.1.98; Waldholz Michael, 1989, WALL STREET J   0301, pA6; Waldholz Michael, 1989, WALL STREET J   0301, pA1; ZIMMERMAN M, 1989, COMMUNICATION    MAY; 1989, FINANCIAL ARRANGEMEN; 1991, FINAL OCCUPATIONAL S; 1991, 91390 US DEP LAB PUB; 1992, JAMA-J AM MED ASSOC, V267, P2366; 1986, FOR PROFIT ENTERPRIS, P153; 1992, SOURCES HLTH INSURAN	21	89	89	0	9	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 21	1992	268	15					2055	2059		10.1001/jama.268.15.2055	http://dx.doi.org/10.1001/jama.268.15.2055			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JT520	1404742				2023-01-03	WOS:A1992JT52000029
J	COOPER, JR; CZECHOWICZ, DJ; PETERSEN, RC; MOLINARI, SP				COOPER, JR; CZECHOWICZ, DJ; PETERSEN, RC; MOLINARI, SP			PRESCRIPTION DRUG DIVERSION CONTROL AND MEDICAL-PRACTICE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CATCHMENT-AREA SITES; UNITED-STATES; CHRONIC PAIN; BENZODIAZEPINES; ABUSE; PREVALENCE; DEPRESSION; DISORDER; PROGRAM; QUALITY	Concern about the role of prescription drug diversion in drug abuse has led to demands for more stringent regulation and for better ways to detect prescription drug diversion. Advances in technology now allow point-of-sale computer systems to report prescriptions filled by pharmacies to state agencies rapidly and possibly more economically. However, the advantages of more comprehensive control systems must be balanced against their possible effects on medical practice and patient care. Our limited knowledge about prescription drug diversion and the impact of diversion control systems on medical practice is summarized. Needed research is outlined together with the components of a diversion control program that balances reducing drug diversion with minimizing adverse effects on medical practice and patient care. We stress the need for broadly defined practice parameters and peer review by medical experts thoroughly familiar with the complexities of medical practice.	NIDA,ROCKVILLE,MD	National Institutes of Health (NIH) - USA; NIH National Institute on Drug Abuse (NIDA)								ADAMS EH, 1991, NEW YORK STATE J MED, V91, P337; AMBRE JJ, 1991, MAY NAT I DRUG AB TE; BAIRD WP, 1990, BALANCING RESPONSE P, P65; BALTER MB, 1992, J PSYCHOACTIVE DRUGS, V24, P63, DOI 10.1080/02791072.1992.10471620; BARNETT GO, 1978, MED CARE, V16, P962, DOI 10.1097/00005650-197811000-00007; BATTEN HL, 1991, DRUG SERVICES RES SO; BERINA LF, 1985, AM J HOSP PHARM, V42, P857, DOI 10.1093/ajhp/42.4.857; Burton B T, 1991, NIDA Res Monogr, V115, P47; CHIARELLO RJ, 1987, ARCH GEN PSYCHIAT, V44, P286; CLEELAND CS, 1989, ADV PAIN RES THER, P81; COLE JO, 1990, J PSYCHIAT RES, V24, P135, DOI 10.1016/0022-3956(90)90045-R; DAHL J, 1991, MAY NAT I DRUG AB TE; Du Pont R.L., 1988, AM J DRUG ALCOHOL S1, V14, P1; DUBE CE, 1990, CURRICULUM PRIMARY C; EDWARDS CC, 1972, FED REG         0815, V37, P16503; FARNSWORTH P, 1990, BALANCING RESPONSE P, P103; FDA Drug Bulletin, 1982, FDA DRUG B, V12, P4; FRANCE RD, 1984, SOC SCI MED, V19, P1379, DOI 10.1016/0277-9536(84)90027-3; GARVEY MJ, 1986, AM J PSYCHIAT, V143, P1601; GLASS RM, 1991, JAMA-J AM MED ASSOC, V266, P2431, DOI 10.1001/jama.266.17.2431; Green J, 1989, PAIN MANAGE, V2, P241; HAISLIP GR, 1982, SUBST ABUS, V4, P4; HASH BM, 1984, J CLIN PSYCHOPHARM, V4, P298, DOI 10.1097/00004714-198410000-00022; HECHTMAN L, 1984, AM J ORTHOPSYCHIAT, V54, P415, DOI 10.1111/j.1939-0025.1984.tb01507.x; HILL CS, 1987, JAMA-J AM MED ASSOC, V257, P2081; HOLLISTER AS, 1991, SCIENCE, V252, P11, DOI 10.1126/science.252.5002.11-a; HOLLISTER AS, 1990, SUBST ABUSE, V11, P69; HORGAN C, 1991, REV PRESCRIPTION DRU; HUGHES PH, 1991, JAMA-J AM MED ASSOC, V265, P2069, DOI 10.1001/jama.265.16.2069; IRVINE GD, 1991, METHAMPHETAMINE ABUS, P33; Joranson D E, 1990, J Pain Symptom Manage, V5, pS12; JORANSON DE, 1992, B J MED LICENSURE DI, V79, P15; KALES A, 1983, J CLIN PSYCHOPHARM, V3, P140, DOI 10.1097/00004714-198304000-00038; KLEIN LE, 1981, J MED EDUC, V56, P504; LEVIN AA, 1992, JAMA-J AM MED ASSOC, V268, P473, DOI 10.1001/jama.268.4.473; LONEY J, 1988, ADOLESCENT DRUG ABUS, P19; LURIE P, 1992, JAMA-J AM MED ASSOC, V268, P472; MARKOWITZ JS, 1989, ARCH GEN PSYCHIAT, V46, P984; MAX MB, 1990, ANN INTERN MED, V113, P885, DOI 10.7326/0003-4819-113-11-885; MELLINGER GD, 1984, JAMA-J AM MED ASSOC, V251, P375, DOI 10.1001/jama.251.3.375; Mellinger Glen, 1981, EPIDEMIOLOGICAL IMPA, P117; MORGAN JP, 1986, AM OPIOPHOBIA CUSTOM, P163; NAGY A, 1987, ACTA PSYCHIAT SCAND, V765, P47; Nemeroff C B, 1990, N C Med J, V51, P240; PERRY S, 1982, PAIN, V13, P267, DOI 10.1016/0304-3959(82)90016-1; PISCOPO JA, 1991, MAY NAT I DRUG AB TE; PORTENOY R, 1990, J PAIN SYMPTOM MA S1, V5, P546; PORTER J, 1980, NEW ENGL J MED, V302, P123; PROTTAS J, 1991, MAY NAT I DRUG AB TE; PUDER KS, 1988, AM J DRUG ALCOHOL AB, V14, P463, DOI 10.3109/00952998809001564; REGIER DA, 1988, ARCH GEN PSYCHIAT, V45, P977; RICHARD BW, 1988, J CLIN PHARMACOL, V28, P395, DOI 10.1002/j.1552-4604.1988.tb05747.x; RICKELS K, 1972, CLIN PHARMACOL THER, V13, P595; RICKELS K, 1991, MAY NAT I DRUG AB TE; ROCK N, 1991, MAY AM AC CHILD AD P; SALZMAN C, 1991, NOV NIH CONS DEV C D; Sanders J H Jr, 1989, N C Med J, V50, P105; SATEL SL, 1989, J CLIN PSYCHIAT, V50, P241; SCHWARTZ HI, 1991, GEN HOSP PSYCHIAT, V13, P219, DOI 10.1016/0163-8343(91)90122-D; SCHWEIZER E, 1990, ARCH GEN PSYCHIAT, V47, P908; SHADER RI, 1991, J CLIN PHARMACOL, V31, P781, DOI 10.1002/j.1552-4604.1991.tb01910.x; SHAPIRO S, 1984, ARCH GEN PSYCHIAT, V41, P971; SIGLER KA, 1984, AM J HOSP PHARM, V41, P108, DOI 10.1093/ajhp/41.1.108; SMITH MC, 1983, SOC MED CONFLICTING, P259; STROSS JK, 1980, ARTHRITIS RHEUM, V23, P846, DOI 10.1002/art.1780230711; TEMIN P, 1981, DRUGS HLTH, P173; TENNANT FS, 1983, POSTGRAD MED, V73, P81, DOI 10.1080/00325481.1983.11698315; UHLENHUTH EH, 1988, J CLIN PSYCHOPHARM, V8, P161; UHLENHUTH EH, 1987, CURR MED RES OPIN, V765, P47; UNGERLEIDER JT, 1980, ARCH GEN PSYCHIAT, V37, P106; WEBB CE, 1991, MAY NAT I DRUG AB TE; WEINTRAUB M, 1991, JAMA-J AM MED ASSOC, V266, P2392, DOI 10.1001/jama.266.17.2392; WEINTRAUB M, 1992, CLIN PHARMACOL THER, V51, P642, DOI 10.1038/clpt.1992.76; Weissman D E, 1991, Wis Med J, V90, P671; WILFORD BB, 1991, J PSYCHOACTIVE DRUGS, V23, P343, DOI 10.1080/02791072.1991.10471605; WILFORD BB, 1983, NEW ENGL J MED, V308, P1457; WOLFE SM, 1990, HLTH LETT, V6, P6; WOODS JH, 1991, LANCET, V337, P295, DOI 10.1016/0140-6736(91)90902-2; WOODS JH, 1988, JAMA-J AM MED ASSOC, V260, P3476, DOI 10.1001/jama.260.23.3476; ZULLICH SG, 1992, ANN PHARMACOTHER, V26, P539; 1991, US DHHS ADM901839 PU; 1985, FED REG         1018, V50, P42184; 1991, J AM ACAD CHILD ADOL, V30, P1; 1991, US DHHS ADM911732 PU; 1982, GAOGGD832 GEN ACC OF; 1978, GAOGGD7822 GEN ACC O; 1990, PLAN CURB PRESCRIPTI; 1986, FED REG         0513, V51, P17476; 1992, OHIO STATE BOARD FEB, V13, P3; 1992, J NIH RES, V4, P27; 1990, EPIDEMIOL NOTES, V5, P1; 1990, BENZODIAZEPINE DEPEN; 1992, GAOHRD92115 GEN ACC	93	26	26	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 9	1992	268	10					1306	1310		10.1001/jama.268.10.1306	http://dx.doi.org/10.1001/jama.268.10.1306			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	JL608	1507377				2023-01-03	WOS:A1992JL60800032
J	GOLDING, J; GREENWOOD, R; BIRMINGHAM, K; MOTT, M				GOLDING, J; GREENWOOD, R; BIRMINGHAM, K; MOTT, M			CHILDHOOD-CANCER, INTRAMUSCULAR VITAMIN-K, AND PETHIDINE GIVEN DURING LABOR	BRITISH MEDICAL JOURNAL			English	Article							BENZO(A)PYRENE METABOLISM; DEFICIENCY; LEUKEMIA	Objective-To assess unexpected associations between childhood cancer and pethidine given in labour and the neonatal administration of vitamin K that had emerged in a study performed in the 1970 national birth cohort. Design and setting-195 children with cancer diagnosed in 1971-March 1991 and born in the two major Bristol maternity hospitals in 1965-87 were compared with 558 controls identified from the delivery books for the use of pethidine during labour and administration of vitamin K. Main outcome measures-Odds ratios for cancer in the presence of administration of pethidine or of intramuscular vitamin K. Both logistic regression and Mantel-Haenszel techniques were used for statistical analyses. Results-Children of mothers given pethidine in labour were not at increased risk of cancer (odds ratio 1.05, 95% confidence interval 0.7 to 1.5) after allowing for year and hospital of delivery, but there was a significant association (p=0.002) with intramuscular vitamin K (odds ratio 1.97, 95% confidence interval 1.3 to 3.0) when compared with oral vitamin K or no vitamin K. There was no significantly increased risk for children who had been given oral vitamin K when compared with no vitamin K (odds ratio 1.15, 95% confidence interval 0.5 to 2.7). These results could not be accounted for by other factors associated with administration of intramuscular vitamin K, such as type of delivery or admission to a special care baby unit. Conclusions-The only two studies so far to have examined the relation between childhood cancer and intramuscular vitamin K have shown similar results, and the relation is biologically plausible. The prophylactic benefits against haemorrhagic disease are unlikely to exceed the potential adverse effects from intramuscular vitamin K. Since oral vitamin K has major benefits but no obvious adverse effects this could be the prophylaxis of choice.			GOLDING, J (corresponding author), ROYAL HOSP SICK CHILDREN,INST CHILD HLTH,BRISTOL BS2 8BJ,ENGLAND.			Golding, Jean/0000-0003-2826-3307				BUTLER NR, 1982, J ROY SOC MED, V75, P781; Butler NR, 1986, BIRTH 5 STUDY HLTH B; Chamberlain R., 1975, BRIT BIRTHS, V1; CORNELISSEN M, 1991, PEDIATR RES, V30, P550, DOI 10.1203/00006450-199112000-00011; DOGRA SC, 1987, INT J BIOCHEM, V19, P471, DOI 10.1016/0020-711X(87)90070-X; Elwood M, 1988, CAUSAL RELATIONSHIPS; Gilman E A, 1989, Paediatr Perinat Epidemiol, V3, P66, DOI 10.1111/j.1365-3016.1989.tb00371.x; GILMAN EA, 1988, J SOC RADIOLOGICAL P, V3, P3; Golding J, 1990, West Engl Med J, V105, P80; GOLDING J, 1990, BRIT J CANCER, V62, P304, DOI 10.1038/bjc.1990.283; HILGARD P, 1977, BRIT J CANCER, V35, P891, DOI 10.1038/bjc.1977.135; ISRAELS LG, 1987, PEDIATR RES, V22, P405, DOI 10.1203/00006450-198710000-00008; ISRAELS LG, 1983, J CLIN INVEST, V71, P1130, DOI 10.1172/JCI110863; KNEALE GW, 1976, J NATL CANCER I, V56, P879, DOI 10.1093/jnci/56.5.879; MCKINNEY PA, 1987, ARCH DIS CHILD, V62, P279, DOI 10.1136/adc.62.3.279; MCNINCH AW, 1985, ARCH DIS CHILD, V60, P814, DOI 10.1136/adc.60.9.814; MCNINCH AW, 1991, BRIT MED J, V303, P1105, DOI 10.1136/bmj.303.6810.1105; ROBINS J, 1986, AM J EPIDEMIOL, V124, P719, DOI 10.1093/oxfordjournals.aje.a114447; STILLER CA, 1982, BRIT J CANCER, V45, P543, DOI 10.1038/bjc.1982.90; STJERNFELDT M, 1986, LANCET, V2, P687; von Kries R, 1992, Paediatr Perinat Epidemiol, V6, P7	21	224	229	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 8	1992	305	6849					341	346		10.1136/bmj.305.6849.341	http://dx.doi.org/10.1136/bmj.305.6849.341			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JJ032	1392886	Green Published, Green Submitted, Bronze			2023-01-03	WOS:A1992JJ03200022
J	WIERTELAK, EP; MAIER, SF; WATKINS, LR				WIERTELAK, EP; MAIER, SF; WATKINS, LR			CHOLECYSTOKININ ANTIANALGESIA - SAFETY CUES ABOLISH MORPHINE ANALGESIA	SCIENCE			English	Article							SPINAL-CORD; OPIATE ANALGESIA; BINDING-SITES; ANTAGONIST; PAIN; CCK; NEUROPEPTIDE; NOCICEPTION; INHIBITION; L-365,260	Environmental stimuli that signal the occurrence of aversive or dangerous events activate endogenous opiate analgesia systems. Signals for safety (the nonoccurrence of aversive events) produce the opposite and inhibit environmentally produced analgesia. Stimuli that signal safety are now shown to abolish the analgesic effect of morphine, even when morphine is applied directly to spinal cord. Further, this antiopiate effect occurs because the environmental stimulus leads to release of the neuropeptide cholecystokinin in the spinal cord. This process may contribute to the regulation of pain and the development of opiate tolerance.			WIERTELAK, EP (corresponding author), UNIV COLORADO, DEPT PSYCHOL, BOULDER, CO 80309 USA.				NATIONAL INSTITUTE OF MENTAL HEALTH [T32MH014617] Funding Source: NIH RePORTER; NIMH NIH HHS [5T32MH14617-15] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ALLARD M, 1991, NEUROSCIENCE, V40, P81, DOI 10.1016/0306-4522(91)90176-O; ALLARD M, 1989, BRAIN RES, V500, P169, DOI 10.1016/0006-8993(89)90311-9; BABER NS, 1989, PAIN, V39, P307, DOI 10.1016/0304-3959(89)90045-6; BELL JA, 1977, EUR J PHARMACOL, V42, P147, DOI 10.1016/0014-2999(77)90354-5; BOLLES RC, 1980, BEHAV BRAIN SCI, V3, P291, DOI 10.1017/S0140525X0000491X; CHANG RSL, 1986, P NATL ACAD SCI USA, V83, P4923, DOI 10.1073/pnas.83.13.4923; D'amour FE, 1941, J PHARMACOL EXP THER, V72, P74; FARIS PL, 1983, SCIENCE, V219, P310, DOI 10.1126/science.6294831; HARRO J, 1991, EUR J PHARMACOL, V193, P379, DOI 10.1016/0014-2999(91)90156-K; HILL DR, 1990, BRAIN RES, V526, P276, DOI 10.1016/0006-8993(90)91232-6; HILL DR, 1988, NEUROSCI LETT, V89, P133, DOI 10.1016/0304-3940(88)90369-2; KELLY DD, 1986, ANN NY ACAD SCI, V467; LOTTI VJ, 1989, EUR J PHARMACOL, V162, P273, DOI 10.1016/0014-2999(89)90290-2; MAIER SF, 1976, ANIM LEARN BEHAV, V4, P217, DOI 10.3758/BF03214039; MELZACK R, 1988, 5TH P WORLD C PAIN, P4; MILLAN MJ, 1986, PAIN, V27, P303, DOI 10.1016/0304-3959(86)90158-2; PASTERNAK GW, 1988, JAMA-J AM MED ASSOC, V259, P1362, DOI 10.1001/jama.259.9.1362; RATAUD J, 1991, BRAIN RES, V548, P315, DOI 10.1016/0006-8993(91)91139-R; SIEGEL S, 1979, PSYCHOPATHOLOGY ANIM, P143; SOLOMON RL, 1974, PSYCHOL REV, V81, P119, DOI 10.1037/h0036128; TANG J, 1984, P NATL ACAD SCI-BIOL, V81, P5002, DOI 10.1073/pnas.81.15.5002; TWYCROSS RG, 1984, TXB PAIN, P516; WATKINS LR, 1986, BRAIN RES, V362, P308, DOI 10.1016/0006-8993(86)90455-5; WATKINS LR, 1984, SCIENCE, V224, P395, DOI 10.1126/science.6546809; WESTBROOK RF, 1990, Q J EXP PSYCHOL-B, V42, P1; WIERTELAK E P, 1991, Society for Neuroscience Abstracts, V17, P109; WIERTELAK EP, UNPUB; YAKSH TL, 1977, J PHARMACOL EXP THER, V202, P411; YAKSH TL, 1985, ANNU REV PHARMACOL, V25, P433, DOI 10.1146/annurev.pa.25.040185.002245; YAKSH TL, 1976, PHYSIOL BEHAV, V17, P1031, DOI 10.1016/0031-9384(76)90029-9; ZADINA JE, 1987, BRAIN RES, V409, P10, DOI 10.1016/0006-8993(87)90736-0; ZINBERG NE, 1984, DRUG SET SETTING, P12	32	127	128	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 8	1992	256	5058					830	833		10.1126/science.1589765	http://dx.doi.org/10.1126/science.1589765			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HT235	1589765				2023-01-03	WOS:A1992HT23500043
J	YOUNG, JB; FORSTER, A				YOUNG, JB; FORSTER, A			THE BRADFORD COMMUNITY STROKE TRIAL - RESULTS AT 6 MONTHS	BRITISH MEDICAL JOURNAL			English	Article								Objective - Comparison of day hospital attendance and home physiotherapy for stroke patients leaving hospital to determine which service produces greater functional and social improvement for the patient, reduces emotional stress for the care giver, and lessens the need for community support. Design - Stratified, randomised trial of stroke patients attending day hospital two days a week or receiving home treatment from a community physiotherapist. The six month assessment results are reported in this paper. Subjects - Patients over 60 years old resident within the Bradford metropolitan district discharged home after a new stroke with residual disability. Setting - Four day hospitals in two health authorities and domiciliary work undertaken by experienced community physiotherapists. Main outcome measures - Barthel index, functional ambulatory categories, Motor Club assessment, Frenchay activities index, and Nottingham health profile were used. Carers' stress was indicated by the general health questionnaire. Treatment given and community care provided were recorded. Results - Of 124 patients recruited, 108 were available for reassessment at six months. Both treatment groups had significantly improved in functional abilities between discharge and six months. The improvements were significantly greater for patients treated at home (Mann-Whitney test; Barthel index, median difference 2 (95% confidence interval 0 to 3) p = 0.01; Motor Club assessment, median difference 2 (1 to 5), p = 0.01). The home treated patients received less treatment (median difference 16 (11 to 21) treatments, p < 0.001). More than a third of patients in both groups showed depressed mood, and a quarter of care givers were emotionally distressed. Conclusions - Home physiotherapy seems to be slightly more effective and more resource efficient than day hospital attendance and should be the preferred rehabilitation method for aftercare of stroke patients. New strategies are needed to address psychosocial function for both patients and care givers.			YOUNG, JB (corresponding author), ST LUKES HOSP,DEPT HLTH CARE ELDERLY,BRADFORD BD5 0NA,ENGLAND.			Forster, Anne/0000-0001-7466-4414; young, john/0000-0003-4085-9306				AHLSIO B, 1984, STROKE, V15, P886, DOI 10.1161/01.STR.15.5.886; Altman DG., 1982, STATISTICS PRACTICE, P6; Ashburn A, 1982, Physiotherapy, V68, P109; BROCKLEHURST JC, 1981, SOC SCI MED-MED SOC, V15, P35, DOI 10.1016/0271-7123(81)90043-2; BURNARD S, 1988, PHYSIOTHERAPY, V74, P4; CAMPBELL MJ, 1989, STATISTICS CONFIDENC, P71; EAGLE DJ, 1991, CAN MED ASSOC J, V144, P699; EBRAHIM S, 1986, J EPIDEMIOL COMMUN H, V40, P166, DOI 10.1136/jech.40.2.166; Forster A, 1989, Int Disabil Stud, V11, P181; FORSTER A, 1990, PHYSIOTHERAPY, V76, P495; GARRAWAY WM, 1980, BRIT MED J, V281, P827, DOI 10.1136/bmj.281.6244.827; GLOSSOP ES, 1981, PHYSIOTHERAPY, V67, P79; GOLDBERG DP, 1979, PSYCHOL MED, V9, P139, DOI 10.1017/S0033291700021644; GOLDBERG DP, 1988, USERSS GUIDE GENERAL; GORE SM, 1982, STATISTICS PRACTICE, P44; Hildick-Smith M, 1985, Int Rehabil Med, V7, P120; HOLBROOK M, 1982, J ROY COLL PHYS LOND, V16, P100; Hunt SM, 1986, MEASURING HLTH STATU; KETTLE M, 1989, CLIN REHABIL, V3, P131; MAHONEY F I, 1965, Md State Med J, V14, P61; SCHMIDT SM, 1986, ARCH PHYS MED REHAB, V67, P99, DOI 10.1016/0003-9993(86)90110-3; STOKOE D, 1985, AGE AGEING, V14, P308, DOI 10.1093/ageing/14.5.308; TUCKER MA, 1984, BRIT MED J, V289, P1209, DOI 10.1136/bmj.289.6453.1209; Wade D T, 1985, Int Rehabil Med, V7, P176; WADE DT, 1985, LANCET, V1, P323; WADE DT, 1987, SCAND J REHABIL MED, V19, P25; YOUNG J, 1991, CLIN REHABILITATION, V5, P127; Young J, 1991, CLIN REHABIL, V5, P283	28	126	126	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 25	1992	304	6834					1085	1089		10.1136/bmj.304.6834.1085	http://dx.doi.org/10.1136/bmj.304.6834.1085			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HR136	1586821	Green Published, Bronze			2023-01-03	WOS:A1992HR13600016
J	TASAKI, T; OHTO, H; HASHIMOTO, C; ABE, R; SAITOH, A; KIKUCHI, S				TASAKI, T; OHTO, H; HASHIMOTO, C; ABE, R; SAITOH, A; KIKUCHI, S			RECOMBINANT-HUMAN-ERYTHROPOIETIN FOR AUTOLOGOUS BLOOD DONATION - EFFECTS ON PERIOPERATIVE RED-BLOOD-CELL AND SERUM ERYTHROPOIETIN PRODUCTION	LANCET			English	Article							TRANSFUSION; ANTIBODY; VIRUS	To speed collection of blood for autologous transfusion during elective surgery, patients may be given recombinant human erythropoietin (r-HuEPO). In a controlled trial, we evaluated the effects of r-HuEPO on perioperative red-blood-cell and serum erythropoietin (s-EPO) production in patients, donating blood before elective orthopaedic surgery. Patients were assigned randomly to receive no r-HuEPO (1 2 patients), or 3000 U (4), 6000 U (5), or 9000 U (4) of r-HuEPO intravenously twice a week from the time of the first blood donation. All patients received iron sulphate. 1200 ml blood was collected from each patient in three weekly donations of 400 ml. The 3000, 6000, and 9000 U treatment groups produced 284, 350, and 383 ml, respectively, of red cells during donation, and the untreated controls produced 211 ml. s-EPO concentrations were within the normal range during donation. After surgery, s-EPO concentrations peaked on postoperative day 1 in untreated patients and on day 7 in treated patients; therefore, r-HuEPO may suppress endogenous erythropoietin secretion. Although administration of r-HuEPO increases production of red blood cells, the preoperative anaemia induced by repeated phlebotomy without r-HuEPO may accelerate the postoperative secretion of endogenous erythropoietin.	FUKUSHIMA MED SCH,DEPT ORTHOPAED SURG,FUKUSHIMA 96012,JAPAN	Fukushima Medical University	TASAKI, T (corresponding author), FUKUSHIMA MED SCH,BLOOD TRANSFUS SERV,HIKARIGA OKA,FUKUSHIMA 96012,JAPAN.							ALTER HJ, 1989, NEW ENGL J MED, V321, P1494, DOI 10.1056/NEJM198911303212202; ANDERSON KC, 1990, NEW ENGL J MED, V323, P315; CUMMING PD, 1989, NEW ENGL J MED, V321, P914; ERSLEV AJ, 1991, NEW ENGL J MED, V324, P1339, DOI 10.1056/NEJM199105093241907; GOODNOUGH LT, 1989, NEW ENGL J MED, V321, P1163, DOI 10.1056/NEJM198910263211705; HOWARD JE, 1978, TRANSFUSION, V18, P496, DOI 10.1046/j.1537-2995.1978.18478251250.x; INABA S, 1989, TRANSFUSION, V29, P7, DOI 10.1046/j.1537-2995.1989.29189101168.x; JACOBS K, 1985, NATURE, V313, P806, DOI 10.1038/313806a0; KICKLER TS, 1988, JAMA-J AM MED ASSOC, V260, P65, DOI 10.1001/jama.260.1.65; LEVINE E, 1990, TRANSFUSION, V30, P295, DOI 10.1046/j.1537-2995.1990.30490273433.x; MAEDA H, 1989, LANCET, V2, P284; NADLER SB, 1962, SURGERY, V51, P224; OWINGS DV, 1989, JAMA-J AM MED ASSOC, V262, P1963	13	47	47	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 28	1992	339	8796					773	775		10.1016/0140-6736(92)91895-F	http://dx.doi.org/10.1016/0140-6736(92)91895-F			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HL501	1347803				2023-01-03	WOS:A1992HL50100003
J	FAYAD, IM; HIRSCHHORN, N; ABUZIKRY, M; KAMEL, M				FAYAD, IM; HIRSCHHORN, N; ABUZIKRY, M; KAMEL, M			HYPERNATREMIA SURVEILLANCE DURING A NATIONAL DIARRHEAL DISEASES CONTROL PROJECT IN EGYPT	LANCET			English	Article							ORAL REHYDRATION SOLUTION; INFANTILE DIARRHEA; CHILDREN	The nationwide introduction of oral rehydration therapy to Egypt has led to improvement in diarrhoea case management and a fall in infant and child mortality. With the wider use of oral rehydration solution (ORS) prepared from packets, the incidence of hypernatraemia (serum sodium > 150 mmol/l) in inpatients with dehydration seen at Abu El-Reeche Hospital, Cairo, increased between 1980 and 1984. Systematic surveillance of hypernatraemia in the outpatient rehydration unit began in late 1984, and we report trends in hypernatraemia and analyses of key variables affecting its incidence in dehydrated children. In 1980, 17 of 100 children sampled had hypernatraemia and 2 had severe hypernatraemia (ie, serum sodium > 165 mmol/l). The frequency in inpatients peaked at 49% of 222 children in 1984 (19% with severe hypernatraemia). Between 1 986 and 1 989, at least 1 000 dehydrated outpatients were surveyed each year; by 1989 the incidence of hypernatraemia had fallen to around 10% (2% severe hypernatraemia). The rise and decline coincided with increasing use of ORS and then increasing ability of mothers to mix the solution correctly. Hypernatraemia was positively related to the quantity of ORS taken, severity of dehydration, nutritional status, and the cooler season, and negatively related to age and duration of diarrhoea. Explanations for our findings include improved use of ORS and better case-management. Good practice promoted through the mass media has facilitated these changes, if the standard of ORS use is not maintained, there may be a case for reducing the sodium content of ORS.	JOHN SNOW INC, BOSTON, MA USA; MINIST HLTH CAIRO, NATL CONTROL DIARRHEAL DIS PROJECT, CAIRO, EGYPT	Egyptian Knowledge Bank (EKB); Ministry of Health & Population - Egypt	FAYAD, IM (corresponding author), UNIV CAIRO, CHILDRENS HOSP, ABU EL REECHE HOSP, FAC MED, GASTROENTERITIS UNIT, CAIRO, EGYPT.							BLACK RE, 1984, PEDIATRICS, V73, P799; CLEARY TG, 1981, J PEDIATR-US, V99, P739, DOI 10.1016/S0022-3476(81)80397-6; ELMOUGI M, 1989, J TROP PEDIATRICS, V35, P230, DOI 10.1093/tropej/35.5.230; ELRAFIE M, 1990, LANCET, V335, P334; FARTHING MJG, 1988, DRUGS, V36, P80, DOI 10.2165/00003495-198800364-00011; FORTIN J, 1978, J TROP PED ENV CH H, V24, P110, DOI 10.1093/tropej/24.3.110; HELMY N, 1988, J PEDIATR GASTR NUTR, V7, P417, DOI 10.1097/00005176-198805000-00018; HIRSCHHORN N, 1980, AM J CLIN NUTR, V33, P637, DOI 10.1093/ajcn/33.3.637; PANETH N, 1980, AM J DIS CHILD, V134, P785, DOI 10.1001/archpedi.1980.02130200053017; PIZARRO D, 1984, J PEDIATR-US, V104, P316, DOI 10.1016/S0022-3476(84)81023-9; SANTOSHAM M, 1990, J PEDIATR-US, V116, P868, DOI 10.1016/S0022-3476(05)80642-0; 1988, LANCET, V2, P145; 1977, B WORLD HEALTH ORGAN, V55, P87	13	19	19	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 15	1992	339	8790					389	393		10.1016/0140-6736(92)90079-I	http://dx.doi.org/10.1016/0140-6736(92)90079-I			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HD659	1346660				2023-01-03	WOS:A1992HD65900004
J	HARRINGTON, C; CASSEL, C; ESTES, CL; WOOLHANDLER, S; HIMMELSTEIN, DU				HARRINGTON, C; CASSEL, C; ESTES, CL; WOOLHANDLER, S; HIMMELSTEIN, DU			A NATIONAL LONG-TERM CARE PROGRAM FOR THE UNITED-STATES - A CARING VISION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HEALTH; FUTURE	The financing and delivery of long-term care (LTC) need substantial reform. Many cannot afford essential services; age restrictions often arbitrarily limit access for the nonelderly, although more than a third of those needing care are under 65 years old; Medicaid, the principal third-party payer for LTC, is biased toward nursing home care and discourages independent living; informal care provided by relatives and friends, the only assistance used by 70% of those needing LTC, is neither supported nor encouraged; and insurance coverage often excludes critically important services that fall outside narrow definitions of medically necessary care. We describe an LTC program designed as an integral component of the national health program advanced by Physicians for a National Health Program. Everyone would be covered for all medically and socially necessary services under a single public plan, federally mandated and funded but administered locally. An LTC payment board in each state would contract directly with providers through a network of local public agencies responsible for eligibility determination and care coordination. Nursing homes, home care agencies, and other institutional providers would be paid a global budget to cover all operating costs and would not bill on a per-patient basis. Alternatively, integrated provider organizations could receive a capitation fee to cover a broad range of LTC and acute care services. Individual practitioners could continue to be paid on a fee-for-service basis or could receive salaries from institutional providers. Support for innovation, training of LTC personnel, and monitoring of the quality of care would be greatly augmented. For-profit providers would be compensated for past investments and phased out. Our program would add between $18 billion and $23.5 billion annually to current spending on LTC. Polls indicate that a majority of Americans want such a program and are willing to pay earmarked taxes to support it.	HARVARD UNIV,CAMBRIDGE HOSP,SCH MED,NATL HLTH PROGRAM,1493 CAMBRIDGE ST,CAMBRIDGE,MA 02139	Harvard University; Cambridge Health Alliance; Cambridge Hospital								BALL R, 1989, BECAUSE WERE ALL THI; BARKER WH, 1987, ADDING LIFE YEARS OR; BLENDON RJ, 1988, JAMA-J AM MED ASSOC, V259, P3587, DOI 10.1001/jama.259.24.3587; BLUMENTHAL D, 1988, RENEWING PROMISE MED; BODENHEIMER T, 1990, INT J HEALTH SERV, V20, P199, DOI 10.2190/DAKX-ULL1-R1EF-X5NR; CALLAHAN JJ, 1989, J AGING SOC POLICY, V1, P181; Campbell L J, 1987, Clin Geriatr Med, V3, P99; ESTES CL, 1989, GERONTOLOGIST, V29, P587, DOI 10.1093/geront/29.5.587; ESTES CL, 1990, LONG TERM CARE REQUI; ESTES CL, 1985, INT PERSPECTIVES LON, P315; ESTES CL, 1983, FISCAL AUSTERITY AGI; EVANS RG, 1989, NEW ENGL J MED, V320, P571, DOI 10.1056/NEJM198903023200906; FIRMAN JP, 1988, PRIVATE LONG TERM CA; FREIDSON F, 1970, PROFESSIONAL DOMINAN; HARRINGTON C, 1985, LONG TERM CARE ELDER; HARRINGTON C, 1987, SOCIAL HLTH MAINTENA, pCH4; HARRIS L, 1988, MAJORITIES FAVOR PAS; HAWES C, 1986, FOR PROFIT ENTERPRIS, P492; HAZZARD WR, 1991, ANN INTERN MED, V115, P229, DOI 10.7326/0003-4819-115-3-229; HIMMELSTEIN DU, 1989, NEW ENGL J MED, V320, P102, DOI 10.1056/NEJM198901123200206; HIMMELSTEIN DU, 1991, JAMA-J AM MED ASSOC, V266, P399, DOI 10.1001/jama.266.3.399; HOLAHAN J, 1989, MILBANK Q, V67, P137, DOI 10.2307/3350072; Institute of Medicine report, 1986, IMPROVING QUALITY CA; JUSTICE D, 1988, STATE LONG TERM CARE; KANE R, 1980, NEW ENGL J MED, V302, P1327, DOI 10.1056/NEJM198006123022402; Kane RA, 1987, LONG TERM CARE PRINC; KANE RL, 1991, NEW ENGL J MED, V324, P627, DOI 10.1056/NEJM199102283240910; Kane Robert L., 1985, WILL WAY WHAT US CAN; KUSSEROW RP, 1987, OA1018600010 US DEP; LAPLANTE MP, 1988, DATA DISABILITY NATI; LEVIT KR, 1988, HEALTH AFFAIR, V7, P124, DOI 10.1377/hlthaff.7.5.124; Liu K, 1985, Health Care Financ Rev, V7, P51; NEWCOMER RJ, 1989, 03283 US DEP HLTH HU; PRICE RJ, 1990, LONG TERM CARE ELDER; RIVLIN AM, 1988, CARING DISABLED ELDE; ROWE JW, 1987, NEW ENGL J MED, V316, P1425, DOI 10.1056/NEJM198705283162229; STONE R, 1987, GERONTOLOGIST, V27, P616, DOI 10.1093/geront/27.5.616; STONE R, 1986, NCHS ADV DATA, P124; WOOLHANDLER S, 1991, NEW ENGL J MED, V324, P1253, DOI 10.1056/NEJM199105023241805; ZAWADSKI RT, 1983, HOME HEALTH CARE SER, V4, P3; 1988, INTERSTUDYS LONG TER, P2; 1987, VITAL HLTH STAT 13, V97; 1987, MEDICARE MEDICAID ST; 1987, AM PUBLIC VIEWS LONG; 1990, CALL ACTION FINAL RE; 1989, ISSUES FINANCING DEL; 1986, HOSPITAL STATISTICS; 1989, DEV AGING 1988 REPOR, P1; 1990, HLTH MED SERVICES US; 1986, MEDIGAP INSURANCE LA; 1987, LONG TERM CARE C; 1987, NATIONAL HLTH EXPEND, V8, P1; 1988, INTERSTUDYS LONG TER, P1; 1989, PRIVATE LONG TERM CA; 1987, VITAL HLTH STAT 10, V166; 1988, SOURCE BOOK HLTH INS	56	25	25	0	10	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 4	1991	266	21					3023	3029		10.1001/jama.266.21.3023	http://dx.doi.org/10.1001/jama.266.21.3023			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GR775	1820477				2023-01-03	WOS:A1991GR77500037
J	GARNICK, DW; HENDRICKS, AM; BRENNAN, TA				GARNICK, DW; HENDRICKS, AM; BRENNAN, TA			CAN PRACTICE GUIDELINES REDUCE THE NUMBER AND COSTS OF MALPRACTICE CLAIMS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PROFESSIONAL LIABILITY; PHYSICIANS; STANDARDS; SYSTEM; CARE	Practice guidelines have the potential to reduce the number of malpractice cases and the costs of settling them. However, for practice guidelines to exert any influence, they must be assumed to be (1) developed for conditions or procedures that frequently lead to events for which negligence claims are filed; (2) widely accepted in the medical profession; (3) fully integrated into clinical practice; and (4) straightforward and readily interpreted in a litigation setting. Because the validity of each of these assumptions can be questioned, the idea that inserting practice guidelines into the existing litigation process will generate large savings in the near future is overly optimistic.	BRIGHAM & WOMENS HOSP, DIV GEN MED, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	GARNICK, DW (corresponding author), HARVARD UNIV, SCH PUBL HLTH, PROGRAM HLTH CARE FINANCING & INSURANCE, BOSTON, MA 02115 USA.		Garnick, Deborah w/I-9009-2012					ABRAHAM KS, 1988, JAMA-J AM MED ASSOC, V260, P68, DOI 10.1001/jama.260.1.68; [Anonymous], 1986, COSTS COMPENSATION P; BIERIG JR, 1990, MAR CAP CONS C APPR; BRENNAN TA, 1991, NEW ENGL J MED, V324, P370, DOI 10.1056/NEJM199102073240604; BRENNAN TA, 1989, U PITT LAW REV, V51, P1; BRENNAN TA, 1991, J HEALTH POLIT POLIC, V16, P67, DOI 10.1215/03616878-16-1-67; CHASSIN MR, 1988, INQUIRY-J HEALTH CAR, V25, P437; DANZON P, 1989, LIABILITY PERSPECTIV; Danzon P.M, 1985, MED MALPRACTICE; EDDY DM, 1990, JAMA-J AM MED ASSOC, V263, P3077, DOI 10.1001/jama.263.22.3077; EDDY DM, 1988, HEALTH AFFAIR, V7, P19, DOI 10.1377/hlthaff.7.1.19; EICHHORN JH, 1989, ANESTHESIOLOGY, V70, P572, DOI 10.1097/00000542-198904000-00002; FEILD DJ, 1987, J AM COLL CARDIOL, V10, P935, DOI 10.1016/S0735-1097(87)80294-2; Field MJ, 1990, CLIN PRACTICE GUIDEL; FRANKLIN M, 1987, TORT LAW ALTERNATIVE; GRILLI R, 1991, MED CARE, V29, P50, DOI 10.1097/00005650-199101000-00005; HARVEY IM, 1987, LANCET, V1, P145; HAYWARD RSA, 1991, ANN INTERN MED, V114, P758, DOI 10.7326/0003-4819-114-9-758; HENDERSON JA, 1986, LAW CONTEMP PROBL, V49, P243, DOI 10.2307/1191425; HIRSHFELD EB, 1990, JAMA-J AM MED ASSOC, V263, P1556; Holzer J F, 1990, QRB Qual Rev Bull, V16, P71; HUGHES D, 1990, MED PROFESSIONAL LIA, P2; Kelly J T, 1990, QRB Qual Rev Bull, V16, P54; KOSECOFF J, 1987, JAMA-J AM MED ASSOC, V258, P2708, DOI 10.1001/jama.258.19.2708; Leape L L, 1990, QRB Qual Rev Bull, V16, P42; LEAPE LL, 1991, NEW ENGL J MED, V324, P377, DOI 10.1056/NEJM199102073240605; LOMAS J, 1989, NEW ENGL J MED, V321, P1306, DOI 10.1056/NEJM198911093211906; MANUEL BM, 1990, NEW ENGL J MED, V322, P627, DOI 10.1056/NEJM199003013220912; PUSEY A, 1991, ANNOTATED DIRECTORY, P2; RELMAN AS, 1990, NEW ENGL J MED, V322, P626, DOI 10.1056/NEJM199003013220911; REYNOLDS RA, 1987, JAMA-J AM MED ASSOC, V257, P2776, DOI 10.1001/jama.257.20.2776; ROBINSON GO, 1986, LAW CONTEMP PROBL, V49, P5, DOI 10.2307/1191413; ROPER WL, 1988, NEW ENGL J MED, V319, P1197, DOI 10.1056/NEJM198811033191805; SALES P, 1987, TECH REV, V10, P43; STEPHENSON GM, 1990, REP MED GUIDELINES O, V1, P7; WEILER P, 1990, CALL ACTION, V2; WESSEL, 1988, JURIMETRICS J, V28, P379; 1988, MONITORING HLTH CARE; 1990, GAOTHRD9024 GEN ACC; 1988, PROFESSIONAL LIABILI; 1990, PATIENTS DOCTORS LAW; 1989, LISTING PRACTICE GUI	42	56	57	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 27	1991	266	20					2856	2860		10.1001/jama.266.20.2856	http://dx.doi.org/10.1001/jama.266.20.2856			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GQ722	1942453				2023-01-03	WOS:A1991GQ72200034
J	WALSH, BW; SCHIFF, I; ROSNER, B; GREENBERG, L; RAVNIKAR, V; SACKS, FM				WALSH, BW; SCHIFF, I; ROSNER, B; GREENBERG, L; RAVNIKAR, V; SACKS, FM			EFFECTS OF POSTMENOPAUSAL ESTROGEN REPLACEMENT ON THE CONCENTRATIONS AND METABOLISM OF PLASMA-LIPOPROTEINS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LOW-DENSITY LIPOPROTEIN; POST-MENOPAUSAL WOMEN; APOLIPOPROTEIN-B; HEART-DISEASE; TRIGLYCERIDE KINETICS; SERUM-LIPOPROTEINS; LONG-TERM; ESTRADIOL; HORMONE; CHOLESTEROL	Background. Postmenopausal estrogen-replacement therapy may reduce the risk of cardiovascular disease, and this beneficial effect may be mediated in part by favorable changes in plasma lipid levels. However, the effects on plasma lipoprotein levels of postmenopausal estrogens in the low doses currently used have not been precisely quantified, and the mechanism of these effects is unknown. Methods. We conducted two randomized, double-blind crossover studies in healthy postmenopausal women who had normal lipid values at base line. In study 1, 31 women received placebo and conjugated estrogens at two doses (0.625 mg and 1.25 mg per day), each treatment for three months. In study 2, nine women received placebo, oral micronized estradiol (2 mg per day), and transdermal estradiol (0.1 mg twice a week), each treatment for six weeks. The metabolism of very-low-density lipoprotein (VLDL) and low-density lipoprotein (LDL) was measured by endogenously labeling their protein component, apolipoprotein B. Results. In study 1, the conjugated estrogens at doses of 0.625 mg per day and 1.25 mg per day decreased the mean LDL cholesterol level by 15 percent (95 percent confidence interval, 11 to 19 percent; P < 0.0001) and 19 percent (95 percent confidence interval, 15 to 23 percent; P < 0.0001), respectively; increased the HDL cholesterol level by 16 percent (95 percent confidence interval, 12 to 20 percent; P < 0.0001) and 18 percent (95 percent confidence interval, 14 to 22 percent; P < 0.0001), respectively; and increased VLDL triglyceride levels by 24 percent (95 percent confidence interval, 8 to 40 percent; P < 0.003) and 42 percent (95 percent confidence interval, 26 to 58 percent; P < 0.0001), respectively. In study 2, oral estradiol increased the mean concentration of large VLDL apolipoprotein B by 30 +/- 10 percent (P = 0.05) by increasing its production rate by 82 +/- 18 percent P < 0.01). Most of this additional large VLDL was cleared directly from the circulation and was not converted to small VLDL or LDL. Oral estradiol reduced LDL cholesterol concentrations by 14 +/- 3 percent (P < 0.005), because LDL catabolism increased by 36 +/- 7 percent (P < 0.005). The oral estradiol increased the HDL cholesterol level by 15 +/- 2 percent (P < 0.0001). Transdermal estradiol had no effect. Conclusions. The postmenopausal use of oral estrogens in low doses favorably alters LDL and HDL levels that may protect women against atherosclerosis, while minimizing potentially adverse effects on triglyceride levels. The decrease in LDL levels results from accelerated LDL catabolism; the increase in triglyceride levels results from increased production of large, triglyceride-rich VLDL.	BRIGHAM & WOMENS HOSP, DEPT MED, CHANNING LAB, 180 LONGWOOD AVE, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT CLIN EPIDEMIOL & BIOSTAT, BOSTON, MA 02115 USA; BRIGHAM & WOMENS HOSP, DEPT GYNECOL, BOSTON, MA 02115 USA; BRIGHAM & WOMENS HOSP, CLIN RES CTR, BOSTON, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital					NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR002635] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL034980] Funding Source: NIH RePORTER; NCRR NIH HHS [RR-02635] Funding Source: Medline; NHLBI NIH HHS [HL-34980] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bachorik P S, 1986, Methods Enzymol, V129, P78; BARBARAS R, 1987, BIOCHEM BIOPH RES CO, V142, P63, DOI 10.1016/0006-291X(87)90451-7; BARRETTCONNOR E, 1989, JAMA-J AM MED ASSOC, V261, P2095, DOI 10.1001/jama.261.14.2095; BUSH TL, 1987, CIRCULATION, V75, P1102, DOI 10.1161/01.CIR.75.6.1102; CHETKOWSKI RJ, 1986, NEW ENGL J MED, V314, P1615, DOI 10.1056/NEJM198606193142505; CRYER DR, 1986, J LIPID RES, V27, P508; EGUSA G, 1983, J LIPID RES, V24, P1261; ERIKSSON M, 1989, J CLIN INVEST, V84, P802, DOI 10.1172/JCI114239; GLUECK CJ, 1975, METABOLISM, V24, P537, DOI 10.1016/0026-0495(75)90078-5; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; HENDERSON BE, 1986, AM J OBSTET GYNECOL, V154, P1181, DOI 10.1016/0002-9378(86)90696-4; HENDERSON BE, 1991, ARCH INTERN MED, V151, P75, DOI 10.1001/archinte.151.1.75; JENSEN J, 1987, AM J OBSTET GYNECOL, V156, P66, DOI 10.1016/0002-9378(87)90204-3; KISSEBAH AH, 1973, HORM METAB RES, V5, P184, DOI 10.1055/s-0028-1093969; KLETZKY OA, 1975, AM J OBSTET GYNECOL, V121, P688, DOI 10.1016/0002-9378(75)90474-3; LINDGREN FT, 1972, BLOOD LIPIDS LIPOPRO, P181; LINDSAY R, 1984, OBSTET GYNECOL, V63, P759; LOBO RA, 1980, AM J OBSTET GYNECOL, V138, P714, DOI 10.1016/0002-9378(80)90094-0; MANDEL FP, 1983, J CLIN ENDOCR METAB, V57, P133, DOI 10.1210/jcem-57-1-133; MANNINEN V, 1988, JAMA-J AM MED ASSOC, V260, P641, DOI 10.1001/jama.260.5.641; MASHCHAK CA, 1982, AM J OBSTET GYNECOL, V144, P511, DOI 10.1016/0002-9378(82)90218-6; MILLER KW, 1984, J BIOL CHEM, V259, P5277; OHTA T, 1988, J LIPID RES, V29, P721; OHTA T, 1989, ARTERIOSCLEROSIS, V9, P90, DOI 10.1161/01.ATV.9.1.90; PACKARD CJ, 1984, J CLIN INVEST, V74, P2178, DOI 10.1172/JCI111644; PUCHOIS P, 1987, ATHEROSCLEROSIS, V68, P35, DOI 10.1016/0021-9150(87)90091-8; RIFKIND BM, 1984, JAMA-J AM MED ASSOC, V251, P365; ROSNER B, 1989, J AM STAT ASSOC, V84, P373, DOI 10.2307/2289920; ROSNER B, 1982, FUNDAMENTALS BIOSTAT, P189; ROSS RK, 1981, LANCET, V1, P858; ROSS RK, 1988, AM J PUBLIC HEALTH, V78, P516, DOI 10.2105/AJPH.78.5.516; SACKS FM, 1990, ANN NY ACAD SCI, V592, P272; SHARF M, 1985, GYNECOL OBSTET INVES, V19, P207, DOI 10.1159/000299035; SIMONS LA, 1983, J LIPID RES, V24, P192; STAMPFER MJ, 1991, NEW ENGL J MED, V325, P756, DOI 10.1056/NEJM199109123251102; STANCZYK FZ, 1988, AM J OBSTET GYNECOL, V159, P1540, DOI 10.1016/0002-9378(88)90591-1; TASKINEN MR, 1987, LIPOPROTEIN LIPASE, P201; TIKKANEN MJ, 1985, FEBS LETT, V181, P160, DOI 10.1016/0014-5793(85)81134-0; VAITUKAITIS JL, 1973, J CLIN ENDOCR METAB, V37, P653, DOI 10.1210/jcem-37-5-653; VELDHUIS JD, 1985, ENDOCRINOLOGY, V117, P1321, DOI 10.1210/endo-117-4-1321; WEISS NS, 1980, NEW ENGL J MED, V303, P1195, DOI 10.1056/NEJM198011203032102; WINDLER EET, 1980, J BIOL CHEM, V255, P464; WOLFE BM, 1989, J CLIN INVEST, V83, P40, DOI 10.1172/JCI113882; ZILVERSMIT DB, 1960, AM J MED, V29, P832, DOI 10.1016/0002-9343(60)90117-0; NIH801527 DIV HEART, V1; 1988, SAS USERS GUIDE STAT	46	1056	1085	1	14	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 24	1991	325	17					1196	1204		10.1056/NEJM199110243251702	http://dx.doi.org/10.1056/NEJM199110243251702			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GL282	1922206				2023-01-03	WOS:A1991GL28200002
J	MUSHLIN, AI; BLACK, ER; CONNOLLY, CA; BUONACCORSO, KM; EBERLY, SW				MUSHLIN, AI; BLACK, ER; CONNOLLY, CA; BUONACCORSO, KM; EBERLY, SW			THE NECESSARY LENGTH OF HOSPITAL STAY FOR CHRONIC PULMONARY-DISEASE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CARE	Objective. - To determine the necessary length of stay for patients admitted to the hospital with an exacerbation of chronic pulmonary disease and to compare this with the length of stay assigned by the diagnosis related group system. Design. - A cohort of patients were followed up prospectively after hospital admission to determine when complications, critical incidents, and the need for monitoring occurred. The medically derived necessary lengths of stay were statistically compared with the lengths of stay assigned by the diagnosis related group. Clinical factors were used to predict long vs short necessary lengths of stay. Setting. - Two acute care hospitals: one was the principal and the other a major community teaching hospital. Patients. - A consecutive sample of 83 patients who were 45 years of age or older and who required admission for treatment of chronic pulmonary disease. Main Outcome Measures. - The occurrence and time of complications, critical interventions, and monitoring. Results. - After 6 days in the hospital, 90% of patients were free of complications or the need for monitoring. However, 16 days elapsed before 90% of patients had been discharged from the hospital. The length of stay that was considered necessary for care averaged 6.9 days; the actual mean length of stay was 8.7 days. The correlation between each patient's ideal length of stay and the length of stay assigned by the diagnosis related group was low and was not statistically significant. Three clinical variables at the time of admission (high PCO2 levels, symptoms that were present for more than 1 day, and antibiotic treatment) were associated with the need for longer hospital stays. Conclusions. - The medically required length of stay for patients with an exacerbation of chronic pulmonary disease was between 6 and 7 days, on average. This length of stay, which was based on clinical events, differs from the length of stay that was calculated as a statistical norm by the diagnosis related group system. Clinical characteristics may help to identify patients who require a longer length of stay.	UNIV ROCHESTER,SCH MED & DENT,DEPT COMMUNITY & PREVENT MED,ROCHESTER,NY 14642; UNIV ROCHESTER,SCH MED & DENT,DEPT BIOSTAT,ROCHESTER,NY 14642; STRONG MEM HOSP,OFF CLIN PRACTICE EVALUAT,ROCHESTER,NY 14642	University of Rochester; University of Rochester; University of Rochester	MUSHLIN, AI (corresponding author), UNIV ROCHESTER,SCH MED & DENT,DEPT MED,ROCHESTER,NY 14642, USA.				AHRQ HHS [HS 05386] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		DIXON WJ, 1990, BMDP STATISTICAL SOF, V2; FITZGERALD JF, 1987, JAMA-J AM MED ASSOC, V258, P218; GERTMAN PM, 1981, MED CARE, V19, P855, DOI 10.1097/00005650-198108000-00005; GOLDMAN L, 1981, CIRCULATION, V64, P1227, DOI 10.1161/01.CIR.64.6.1227; HORN SD, 1985, NEW ENGL J MED, V313, P20, DOI 10.1056/NEJM198507043130105; Mushlin A I, 1985, QRB Qual Rev Bull, V11, P378; Ryan B. F., 1985, MINITAB HDB; 1988, ROCHESTER AREA HOSPI; 1977, US DHEW NIH771248; 1983, SOCIAL SECURITY AMEN; 1980, US DHEW NIH812019	11	72	74	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 3	1991	266	1					80	83						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FT934	1904506				2023-01-03	WOS:A1991FT93400031
J	NIGHTINGALE, SL				NIGHTINGALE, SL			CORRECTION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Correction, Addition																		NIGHTINGALE SL, 1991, JAMA-J AM MED ASSOC, V265, P847, DOI 10.1001/jama.265.7.847	1	32	33	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 10	1991	265	14					1802	1802		10.1001/jama.265.14.1802	http://dx.doi.org/10.1001/jama.265.14.1802			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FE862	1848642				2023-01-03	WOS:A1991FE86200004
J	OLIVIERI, NF; KOREN, G; HERMANN, C; BENTUR, Y; CHUNG, D; KLEIN, J; STLOUIS, P; FREEDMAN, MH; MCCLELLAND, RA; TEMPLETON, DM				OLIVIERI, NF; KOREN, G; HERMANN, C; BENTUR, Y; CHUNG, D; KLEIN, J; STLOUIS, P; FREEDMAN, MH; MCCLELLAND, RA; TEMPLETON, DM			COMPARISON OF ORAL IRON CHELATOR L1 AND DESFERRIOXAMINE IN IRON-LOADED PATIENTS	LANCET			English	Article									UNIV TORONTO,DEPT CHEM,TORONTO M5S 1A1,ONTARIO,CANADA; UNIV TORONTO,DEPT CLIN BIOCHEM,TORONTO M5S 1A1,ONTARIO,CANADA; HOSP SICK CHILDREN,DIV CLIN PHARMACOL,TORONTO M5G 1X8,ONTARIO,CANADA; HOSP SICK CHILDREN,DEPT PAEDIAT,TORONTO M5G 1X8,ONTARIO,CANADA; HOSP SICK CHILDREN,DEPT CLIN BIOCHEM,TORONTO M5G 1X8,ONTARIO,CANADA; HOSP SICK CHILDREN,DEPT BIOCHEM,TORONTO M5G 1X8,ONTARIO,CANADA	University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)	OLIVIERI, NF (corresponding author), HOSP SICK CHILDREN,DIV HAEMATOL ONCOL,555 UNIV AVE,TORONTO M5G 1X8,ONTARIO,CANADA.		Olivieri, Nancy/AAI-2250-2020	Templeton, Douglas/0000-0003-0693-662X				BORGNAPIGNATTI C, 1985, J PEDIATR-US, V106, P150, DOI 10.1016/S0022-3476(85)80488-1; COHEN A, 1984, BRIT J HAEMATOL, V58, P369, DOI 10.1111/j.1365-2141.1984.tb06096.x; COHEN A, 1987, PEDIATRIC HEMATOLOGY, V1, P521; GRADY RW, 1987, BLOOD, V70, pA47; GRADY RW, 1986, BLOOD, V68, pA46; GYPARAKI M, 1987, ACTA HAEMATOL-BASEL, V78, P217, DOI 10.1159/000205878; HERSHKO C, 1988, CRC CR REV CL LAB SC, V26, P303, DOI 10.3109/10408368809105894; HERSHKO C, 1988, BRIT MED J, V296, P1081, DOI 10.1136/bmj.296.6629.1081; HILLIARD EP, 1979, ANALYST, V104, P312; HOFFBRAND AV, 1989, LANCET, V2, P457; KONTOGHIORGHES GJ, 1987, BRIT MED J, V295, P1509, DOI 10.1136/bmj.295.6612.1509; KONTOGHIORGHES GJ, 1989, LANCET, V2, P1516; KONTOGHIORGHES GJ, 1987, INORG CHIM A-BIOINOR, V136, pL11, DOI 10.1016/S0020-1693(00)85549-8; KONTOGHIORGHES GJ, 1987, LANCET, V1, P1294; KONTOGHIORGHES GJ, 1989, LANCET, V2, P457; KONTOGHIORGHES GJ, 1986, BRIT J HAEMATOL, V62, P607, DOI 10.1111/j.1365-2141.1986.tb04082.x; MARCUS RE, 1984, LANCET, V1, P392; MCGEE A, 1989, BLOOD, V74, pA311; MODELL B, 1982, BRIT MED J, V284, P1081, DOI 10.1136/bmj.284.6322.1081; OLIVIERI NF, 1986, NEW ENGL J MED, V314, P869, DOI 10.1056/NEJM198604033141402; PIPPARD MJ, 1982, BLOOD, V60, P288; PORTER JB, 1986, BIOCHEM SOC T, V14, P1180, DOI 10.1042/bst0141180; PORTER JB, 1989, LANCET, V2, P156; TESARO A, 1989, THER DRUG MONIT, V11, P463; WOLFE L, 1985, NEW ENGL J MED, V312, P1600, DOI 10.1056/NEJM198506203122503; WOLFE LC, 1989, BRIT J HAEMATOL, V72, P456, DOI 10.1111/j.1365-2141.1989.tb07732.x; WOOLF GM, 1983, GASTROENTEROLOGY, V84, P823; 1989, LANCET, V2, P1016	28	168	173	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 24	1990	336	8726					1275	1279		10.1016/0140-6736(90)92962-H	http://dx.doi.org/10.1016/0140-6736(90)92962-H			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EJ943	1978115				2023-01-03	WOS:A1990EJ94300003
J	TETTEROO, GWM; WAGENVOORT, JHT; CASTELEIN, A; TILANUS, HW; INCE, C; BRUINING, HA				TETTEROO, GWM; WAGENVOORT, JHT; CASTELEIN, A; TILANUS, HW; INCE, C; BRUINING, HA			SELECTIVE DECONTAMINATION TO REDUCE GRAM-NEGATIVE COLONIZATION AND INFECTIONS AFTER ESOPHAGEAL RESECTION	LANCET			English	Article									ERASMUS UNIV,HOSP DIJKZIGT,DEPT SURG,ROTTERDAM,NETHERLANDS; ERASMUS UNIV,HOSP DIJKZIGT,DEPT CLIN MICROBIOL,ROTTERDAM,NETHERLANDS	Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC								BRYANT LR, 1972, ARCH SURG-CHICAGO, V104, P647; CAPLAN ES, 1981, AM J MED, V70, P638, DOI 10.1016/0002-9343(81)90587-8; CHOW AW, 1979, J INFECT DIS, V139, P621, DOI 10.1093/infdis/139.6.621; CRAVEN DE, 1986, AM REV RESPIR DIS, V133, P792; DASCHNER F, 1985, INTENS CARE MED, V11, P284, DOI 10.1007/BF00273537; DONOWITZ GR, 1988, NEW ENGL J MED, V318, P490; DONOWITZ LG, 1982, CRIT CARE MED, V10, P355, DOI 10.1097/00003246-198206000-00001; EICKHOFF TC, 1982, NEW ENGL J MED, V306, P1545, DOI 10.1056/NEJM198206243062508; GROSS PA, 1980, AM J MED, V68, P219, DOI 10.1016/0002-9343(80)90357-5; GUGLIELMO BJ, 1983, ARCH SURG-CHICAGO, V118, P943; GUIOT HFL, 1981, J INFECT DIS, V143, P644, DOI 10.1093/infdis/143.5.644; Hughes J M, 1988, Curr Clin Top Infect Dis, V9, P241; KERVER AJH, 1987, INTENS CARE MED, V13, P347; KERVER AJH, 1988, CRIT CARE MED, V16, P1087, DOI 10.1097/00003246-198811000-00001; LEDINGHAM IM, 1988, LANCET, V1, P785; MANDELLI M, 1989, CRIT CARE MED, V17, P501, DOI 10.1097/00003246-198906000-00003; NORD CE, 1984, AM J MED, V76, P99, DOI 10.1016/0002-9343(84)90250-X; NORTHEY D, 1974, SURG GYNECOL OBSTET, V139, P321; ROSE HD, 1975, AM J EPIDEMIOL, V101, P495, DOI 10.1093/oxfordjournals.aje.a112120; SLEYFER DT, 1980, EUR J CANCER, V16, P859; STOUTENBEEK CP, 1984, INTENS CARE MED, V10, P185, DOI 10.1007/BF00259435; TURCK M, 1981, AM J MED, V70, P651, DOI 10.1016/0002-9343(81)90590-8; VANDERWAAIJ D, 1984, A VAN LEEUW J MICROB, V50, P745, DOI 10.1007/BF02386238; VANDERWAAIJ D, 1971, J HYG-CAMB, V69, P405, DOI 10.1017/S0022172400021653; VANUFFELEN R, 1984, INTENS CARE MED, V10, P233, DOI 10.1007/BF00256259	25	84	87	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 24	1990	335	8691					704	707		10.1016/0140-6736(90)90813-K	http://dx.doi.org/10.1016/0140-6736(90)90813-K			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CV305	1969068	Green Submitted			2023-01-03	WOS:A1990CV30500011
J	WILLIAMS, RW; WEAVER, JL				WILLIAMS, RW; WEAVER, JL			SECONDARY STRUCTURE OF SUBSTANCE-P BOUND TO LIPOSOMES IN ORGANIC-SOLVENTS AND IN SOLUTION FROM RAMAN AND CD SPECTROSCOPY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article											WILLIAMS, RW (corresponding author), UNIFORMED SERV UNIV HLTH SCI,DEPT BIOCHEM,BETHESDA,MD 20814, USA.				NIGMS NIH HHS [GM7160] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aronin N., 1983, P783; BANDEKAR J, 1988, BIOPOLYMERS, V27, P885, DOI 10.1002/bip.360270602; BARUCH P, 1987, SUBSTANCE P NEUROKIN, P308; CANDY JM, 1981, J PHYSIOL-LONDON, V320, pP112; CHANG MM, 1971, NATURE-NEW BIOL, V232, P86, DOI 10.1038/newbio232086a0; CHASSAING G, 1986, EUR J BIOCHEM, V154, P77, DOI 10.1111/j.1432-1033.1986.tb09361.x; Chassaing G., 1987, SUBSTANCE P NEUROKIN, P63; DEYOUNG LR, 1988, BIOPHYS J, V53, P497; ERNE D, 1986, HELV CHIM ACTA, V69, P1807, DOI 10.1002/hlca.19860690804; GABER BP, 1978, BIOPHYS J, V21, P161, DOI 10.1016/S0006-3495(78)85516-7; GIERASCH LM, 1982, BIOPHYS J, V37, P275, DOI 10.1016/S0006-3495(82)84676-6; GREENFIE.N, 1969, BIOCHEMISTRY-US, V8, P4108, DOI 10.1021/bi00838a031; HAN SL, 1980, INT J PEPT PROT RES, V16, P173; HOLLOSI M, 1987, BIOPOLYMERS, V26, P1555, DOI 10.1002/bip.360260908; HOLLOSI M, 1985, BIOPOLYMERS, V24, P211, DOI 10.1002/bip.360240117; HOLZER P, 1987, SUBSTANCE P NEUROKIN, P187; Jardetzky O., 1981, NMR MOL BIOL; KARLE IL, 1978, ACTA CRYSTALLOGR B, V34, P3237, DOI 10.1107/S0567740878010572; KARLE IL, 1981, PERSPECTIVES PEPTIDE; KIM PS, 1982, J MOL BIOL, V162, P187, DOI 10.1016/0022-2836(82)90168-1; KOZIEJ P, 1985, Z NATURFORSCH B, V40, P1570; KRIMM S, 1986, ADV PROTEIN CHEM, V38, P181, DOI 10.1016/S0065-3233(08)60528-8; MEHLIS B, 1975, BIOCHEM BIOPH RES CO, V66, P1447, DOI 10.1016/0006-291X(75)90521-5; MEHLIS B, 1980, INT J PEPT PROT RES, V15, P20; MINTON AP, 1981, BIOPOLYMERS, V20, P2093, DOI 10.1002/bip.1981.360201006; MINTON AP, 1987, IIGBT SCI NEWSLETTER, V2, P2; MULLER MJ, 1987, SUBSTANCE P NEUROKIN, P78; NEVSKAYA NA, 1976, BIOPOLYMERS, V15, P637, DOI 10.1002/bip.1976.360150404; OHLEN A, 1987, SUBSTANCE P NEUROKIN, P192; PLOUX O, 1987, SUBSTANCE P NEUROKIN, P60; ROLKA K, 1986, HELV CHIM ACTA, V69, P1798, DOI 10.1002/hlca.19860690803; ROSE GD, 1985, ADV PROTEIN CHEM, V37, P1, DOI 10.1016/S0065-3233(08)60063-7; RUEGER M, 1984, BIOPOLYMERS, V23, P747, DOI 10.1002/bip.360230413; RUEGER M, 1979, PEPTIDES 1978, P465; SANDBERG BEB, 1982, J MED CHEM, V25, P1009, DOI 10.1021/jm00351a001; SARGENT DF, 1986, P NATL ACAD SCI USA, V83, P5774, DOI 10.1073/pnas.83.16.5774; SCHWYZER R, 1987, EMBO J, V6, P2255, DOI 10.1002/j.1460-2075.1987.tb02498.x; SCHWYZER R, 1986, HELV CHIM ACTA, V69, P1789, DOI 10.1002/hlca.19860690802; SEELIG A, 1989, BIOCHEMISTRY-US, V28, P2490, DOI 10.1021/bi00432a021; SHIH LB, 1986, J PHYS CHEM-US, V90, P1615, DOI 10.1021/j100399a032; SMITH GD, 1978, SCIENCE, V199, P1214, DOI 10.1126/science.204006; SUGIHARA T, 1982, BIOCHEMISTRY-US, V21, P3444, DOI 10.1021/bi00257a030; VAUGHT JL, 1987, SUBSTANCE P NEUROKIN, P176; WALLACE BA, 1983, BIOPOLYMERS, V22, P397, DOI 10.1002/bip.360220152; WATKINS DJ, 1987, SUBSTANCE P NEUROKIN, P87; WILLIAMS RW, 1983, J MOL BIOL, V166, P581, DOI 10.1016/S0022-2836(83)80285-X; WILLIAMS RW, 1987, BIOCHIM BIOPHYS ACTA, V916, P200, DOI 10.1016/0167-4838(87)90109-9; WILLIAMS RW, 1986, J BIOL CHEM, V261, P2408; WILLIAMS RW, 1986, METHOD ENZYMOL, V130, P311; WILLIAMS RW, 1981, J MOL BIOL, V152, P783, DOI 10.1016/0022-2836(81)90127-3; WOOLLEY GA, 1987, BIOPOLYMERS, V26, pS109, DOI 10.1002/bip.360260012; WU CSC, 1978, BIOCHEM BIOPH RES CO, V82, P85, DOI 10.1016/0006-291X(78)90580-6; WU CSC, 1981, MOL CELL BIOCHEM, V40, P109; WU CSC, 1982, BIOCHEMISTRY-US, V21, P4556, DOI 10.1021/bi00262a007; YANG JT, 1986, METHOD ENZYMOL, V130, P208	55	41	42	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 15	1990	265	5					2505	2513						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	CM848	1689289				2023-01-03	WOS:A1990CM84800020
J	MANN, MC; VOTTO, J; KAMBE, J; MCNAMEE, MJ				MANN, MC; VOTTO, J; KAMBE, J; MCNAMEE, MJ			MANAGEMENT OF THE SEVERELY ANEMIC PATIENT WHO REFUSES TRANSFUSION - LESSONS LEARNED DURING THE CARE OF A JEHOVAH WITNESS	ANNALS OF INTERNAL MEDICINE			English	Editorial Material						JEHOVAH WITNESSES; ANEMIA; BLOOD TRANSFUSION; ETHICS, MEDICAL; TREATMENT REFUSAL	RECOMBINANT-HUMAN-ERYTHROPOIETIN; PROLONGED NEUROMUSCULAR BLOCKADE; CRITICALLY ILL PATIENTS; FLUOSOL-DA; BLOOD CONSERVATION; SURGERY; FLUID; HEMODILUTION; DESMOPRESSIN; SUBSTITUTES	Objective: To present the case of a Jehovah's Witness with severe anemia and to review the religious philosophy of such patients, the ethical and medicolegal aspects of their care, and the therapeutic options available to clinicians. Data Sources: A MEDLINE literature search (1980 to 1992) identified most studies. Other studies were selected from the bibliographies of identified articles. Study Selection: Selection of articles was limited to the history, philosophy, medicolegal and ethical issues, and clinical management of anemic Jehovah's Witnesses; a recent article on recommendations for red cell transfusion was also reviewed. Conclusions: A clear understanding of the philosophy of the Jehovah's Witnesses regarding blood transfusion and of the medicolegal and ethical aspects of their care is essential to clinicians who care for such patients. One must also be aware of the many alternative therapeutic options that can maximize oxygen delivery and minimize oxygen consumption. The insights gained from this review are applicable to any severely anemic patient who refuses blood transfusion.	NEW BRITAIN GEN HOSP, NEW BRITAIN, CT 06050 USA; UNIV CONNECTICUT, CTR HLTH, FARMINGTON, CT 06032 USA; NEW BRITAIN MEM HOSP, DIV PULM, 2150 CORBIN AVE, NEW BRITAIN, CT 06053 USA	University of Connecticut								ALSOP KS, 1987, LAB MED, V18, P444, DOI 10.1093/labmed/18.7.444; ANAGNOSTOU A, 1977, BLOOD, V50, P1093; AUERBACH M, 1988, J LAB CLIN MED, V111, P566; Boerema I, 1960, J CARDIOVASC SURG TO, V1, P133; BOSHKOV LK, 1991, AM J HEMATOL, V37, P53, DOI 10.1002/ajh.2830370113; CHERNOW B, 1991, CRIT CARE MED, V19, P313; CHERVENAK FA, HASTINGS CTR REP; COOPER JR, 1990, INT ANESTHESIOL CLIN, V28, P210, DOI 10.1097/00004311-199002840-00006; DAVIS NJ, 1974, CLIN ORTHOP RELAT R, V101, P93; DECOUL AAWO, 1985, CLIN NEUROL NEUROSUR, V87, P17, DOI 10.1016/0303-8467(85)90060-5; DUDRICK SJ, 1985, ARCH SURG-CHICAGO, V120, P721; EDWARDS JD, 1989, CRIT CARE MED, V17, P996, DOI 10.1097/00003246-198910000-00006; ENDERBY GE, 1961, BRIT J ANAESTH, V33, P109, DOI 10.1093/bja/33.2.109; ERSLEV AJ, 1991, NEW ENGL J MED, V324, P1339, DOI 10.1056/NEJM199105093241907; FAITHFULL NS, 1992, ADV EXP MED BIOL, V317, P55; Gonzalez E R, 1980, JAMA, V243, P724, DOI 10.1001/jama.243.8.720; GOOCH JL, 1991, CRIT CARE MED, V19, P1125, DOI 10.1097/00003246-199109000-00006; GOULD SA, 1986, NEW ENGL J MED, V314, P1653, DOI 10.1056/NEJM198606263142601; GREEN D, 1990, ANN INTERN MED, V113, P720, DOI 10.7326/0003-4819-113-9-720_2; HAMPTON HJ, 1953, ARCH SURG-CHICAGO, V67, P549; Jim R T, 1990, Hawaii Med J, V49, P209; JOHNSON PWM, 1991, BRIT J CANCER, V63, P476, DOI 10.1038/bjc.1991.111; Jonsen A R, 1986, Crit Care Clin, V2, P91; KHINE HH, 1978, ANESTH ANALG, V57, P279; KOESTNER JA, 1990, J TRAUMA, V30, P1406, DOI 10.1097/00005373-199011000-00016; KUPFER Y, 1987, CRIT CARE MED, V15, P795, DOI 10.1097/00003246-198708000-00019; LARSON AG, 1964, ANESTHESIOLOGY, V25, P682, DOI 10.1097/00000542-196409000-00018; LAW EJ, 1991, BURNS, V17, P75, DOI 10.1016/0305-4179(91)90020-H; LEWIS CTP, 1991, ANN THORAC SURG, V51, P448, DOI 10.1016/0003-4975(91)90862-K; LICHTENSTEIN A, 1988, ANESTHESIOLOGY, V69, P119, DOI 10.1097/00000542-198807000-00022; LICHTIGER B, 1982, ANESTH ANALG, V61, P618; LOCKWOOD DNJ, 1988, ANAESTHESIA, V43, P391, DOI 10.1111/j.1365-2044.1988.tb09021.x; LONGMUIR IS, 1962, LIFE SCI, P297, DOI 10.1016/0024-3205(62)90121-2; MARGOLIS BD, 1991, CHEST, V100, P877, DOI 10.1378/chest.100.3.877; MARTENS PR, 1989, LANCET, V1, P1322; MESSMER K, 1975, SURG CLIN N AM, V55, P659; MICHENFELDER JD, 1965, BRIT J ANAESTH, V37, P738; MISHLER JM, 1984, CLIN HAEMATOL, V13, P75; MOFFAT AS, 1991, SCIENCE, V253, P32, DOI 10.1126/science.2063203; NEARMAN HS, 1983, CRIT CARE MED, V11, P142, DOI 10.1097/00003246-198302000-00018; NELSON CL, 1986, J BONE JOINT SURG AM, V68A, P350, DOI 10.2106/00004623-198668030-00006; OHYANAGI H, 1984, ARTIF ORGANS, V8, P10, DOI 10.1111/j.1525-1594.1984.tb04238.x; OLSEN JB, 1990, SCAND J THORAC CARD, V24, P165, DOI 10.3109/14017439009098063; ONESON R, 1985, TRANSFUSION, V25, P179, DOI 10.1046/j.1537-2995.1985.25285169218.x; PARTRIDGE BL, 1990, CRIT CARE MED, V18, P1177, DOI 10.1097/00003246-199010000-00025; POOL R, 1990, SCIENCE, V250, P1655, DOI 10.1126/science.2270476; SALZMAN EW, 1986, NEW ENGL J MED, V314, P1402, DOI 10.1056/NEJM198605293142202; SEGREDO V, 1990, ANESTHESIOLOGY, V72, P566, DOI 10.1097/00000542-199003000-00030; SMOLLER BR, 1986, NEW ENGL J MED, V314, P1233, DOI 10.1056/NEJM198605083141906; SPENCE RK, 1990, CRIT CARE MED, V18, P1227, DOI 10.1097/00003246-199011000-00008; STONE DJ, 1988, ANESTHESIOLOGY, V69, P1028, DOI 10.1097/00000542-198812000-00056; STONE WJ, 1988, AM J MED SCI, V296, P171, DOI 10.1097/00000441-198809000-00005; THOMPSON R, 1977, J ELECTROCARDIOL, V10, P67, DOI 10.1016/S0022-0736(77)80034-4; TREMPER KK, 1980, CRIT CARE MED, V8, P738, DOI 10.1097/00003246-198012000-00009; TREMPER KK, 1982, NEW ENGL J MED, V307, P277, DOI 10.1056/NEJM198207293070503; TROUWBORST A, 1990, BRIT J ANAESTH, V64, P646, DOI 10.1093/bja/64.5.646; VINCENT JL, 1991, EUR J ANAESTH, V8, P297; WAXMAN K, 1984, ARCH SURG-CHICAGO, V119, P721; WELCH HG, 1992, ANN INTERN MED, V116, P393, DOI 10.7326/0003-4819-116-5-393; Whipple GH, 1940, J EXP MED, V71, P569, DOI 10.1084/jem.71.4.569; 1977, JEHOVAHS WITNESSES Q; 1945, WATCHTOWER, V66, P195	62	65	65	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 15	1992	117	12					1042	1048		10.7326/0003-4819-117-12-1042	http://dx.doi.org/10.7326/0003-4819-117-12-1042			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KB980	1307705				2023-01-03	WOS:A1992KB98000010
J	ADDINGTONHALL, JM; MACDONALD, LD; ANDERSON, HR; CHAMBERLAIN, J; FREELING, P; BLAND, JM; RAFTERY, J				ADDINGTONHALL, JM; MACDONALD, LD; ANDERSON, HR; CHAMBERLAIN, J; FREELING, P; BLAND, JM; RAFTERY, J			RANDOMIZED CONTROLLED TRIAL OF EFFECTS OF COORDINATING CARE FOR TERMINALLY ILL CANCER-PATIENTS	BRITISH MEDICAL JOURNAL			English	Article							DEPRESSION; FAMILIES; ANXIETY	Objectives-To measure effects on terminally ill cancer patients and their families of coordinating the services available within the NHS and from local authorities and the voluntary sector. Design-Randomised controlled trial. Setting-Inner London health district. Patients-Cancer patients were routinely notified from 1987 to 1990. 554 patients expected to survive less than one year entered the trial and were randomly allocated to a coordination or a control group. Intervention-All patients received routinely available services. Coordination group patients received the assistance of two nurse coordinators, whose role was to ensure that patients received appropriate and well coordinated services, tailored to their individual needs and circumstances. Main outcome measures-Patients and carers were interviewed at home on entry to the trial and at intervals until death. Interviews after bereavement were also conducted. Outcome measures included the presence and severity of physical symptoms, psychiatric morbidity, use of and satisfaction with services, and carers' problems. Results from the baseline interview, the interview closest to death, and the interview after bereavement were analysed. Results-Few differences between groups were significant. Coordination group patients were less likely to suffer from vomiting, were more likely to report effective treatment for it, and less likely to be concerned about having an itchy skin. Their carers were more likely to report that in the last week of life the patient had had a cough and had had effective treatinent for constipation, and they were less likely to rate the patient's difficulty swallowing as severe or to report effective treatment for anxiety. Coordination group patients were more likely to have seen a chiropodist and their carers were more likely to contact a specialist nurse in a night time emergency. These carers were less likely to feel angry about the death of the patient. Conclusions-This coordinating service made little difference to patiept or family outcomes, perhaps because the service did not have a budget with which it could obtain services or because the professional skills of the nurse-coordinators may have conflicted with the requirements of the coordinating role.	ST GEORGE HOSP,SCH MED,DEPT PUBL HLTH SCI,LONDON SW17 0RE,ENGLAND; ROYAL MARSDEN HOSP,S W THAMES REG CANC ORG,SUTTON SM2 5PT,SURREY,ENGLAND; ST GEORGE HOSP,SCH MED,DIV GEN PRACTICE & PRIMARY CARE,LONDON SW17 0RE,ENGLAND	St Georges University London; Royal Marsden NHS Foundation Trust; St Georges University London								ADDINGTON-HALL J M, 1991, Palliative Medicine, V5, P207, DOI 10.1177/026921639100500305; Altman DG, 1991, PRACTICAL STATISTICS; ARMITAGE P, 1987, STATISTICAL METHODS; CARTWRIGHT A, 1973, LIFE DEATH; HIGGINSON I, 1990, BRIT MED J, V301, P277, DOI 10.1136/bmj.301.6746.277; HOCKLEY JM, 1988, BRIT MED J, V296, P1715, DOI 10.1136/bmj.296.6638.1715; HOUTS PS, 1988, CANCER, V62, P627, DOI 10.1002/1097-0142(19880801)62:3<627::AID-CNCR2820620331>3.0.CO;2-1; HURLEY RE, 1986, SOC SCI MED, V23, P82; KANE RL, 1984, LANCET, V1, P890; LUNT B, 1981, BRIT MED J, V283, P595, DOI 10.1136/bmj.283.6291.595; MORRIS JN, 1987, J CHRON DIS, V40, P545, DOI 10.1016/0021-9681(87)90012-9; RAPP CA, 1985, SOC WORK, V30, P417; SEALE CF, 1989, SOC SCI MED, V28, P551, DOI 10.1016/0277-9536(89)90249-9; Shepherd G, 1990, Health Trends, V22, P59; SMILKSTEIN G, 1982, J FAM PRACTICE, V15, P303; SNAITH RP, 1976, BRIT J PSYCHIAT, V128, P156, DOI 10.1192/bjp.128.2.156; SPITZER WO, 1981, J CHRON DIS, V34, P585, DOI 10.1016/0021-9681(81)90058-8; WILKES E, 1984, LANCET, V1, P950; WILKES E, 1980, TERMINAL CARE REPORT; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x; 1992, DIRECTORY HOSPICE SE	21	142	143	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 28	1992	305	6865					1317	1322		10.1136/bmj.305.6865.1317	http://dx.doi.org/10.1136/bmj.305.6865.1317			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KA773	1483075	Green Published, Green Submitted, Bronze			2023-01-03	WOS:A1992KA77300019
J	KAYE, SB; LEWIS, CR; PAUL, J; DUNCAN, ID; GORDON, HK; KITCHENER, HC; CRUICKSHANK, DJ; ATKINSON, RJ; SOUKOP, M; RANKIN, EM; CASSIDY, J; DAVIS, JA; REED, NS; CRAWFORD, SM; MACLEAN, A; SWAPP, GA; SARKAR, TK; KENNEDY, JH; SYMONDS, RP				KAYE, SB; LEWIS, CR; PAUL, J; DUNCAN, ID; GORDON, HK; KITCHENER, HC; CRUICKSHANK, DJ; ATKINSON, RJ; SOUKOP, M; RANKIN, EM; CASSIDY, J; DAVIS, JA; REED, NS; CRAWFORD, SM; MACLEAN, A; SWAPP, GA; SARKAR, TK; KENNEDY, JH; SYMONDS, RP			RANDOMIZED STUDY OF 2 DOSES OF CISPLATIN WITH CYCLOPHOSPHAMIDE IN EPITHELIAL OVARIAN-CANCER	LANCET			English	Article							COMBINATION CHEMOTHERAPY; CARCINOMA; CARBOPLATIN; REGIMENS; TRIAL	Cisplatin is generally accepted to be the most active cytotoxic agent for the treatment of ovarian cancer but the optimum dose remains unclear. We have performed a randomised trial to assess the importance of cisplatin dose in the treatment of advanced epithelial ovarian cancer. Patients were randomly assigned treatment with 50 mg/m2 (low dose) or 100 mg/m2 (high dose) cisplatin plus 750 mg/m2 cyclophosphamide, for a maximum of six cycles with intervals of 3 weeks. We planned to recruit 300 patients, but an interim analysis on the first 165 indicated a highly significant survival difference (p = 0.0008). Recruitment was therefore stopped and the trial patients were followed-up for 12 months longer. The relative progression rate (high-dose/low-dose) after 12 months' extra follow-up was 0.55 (95% confidence interval 0.37-0.81, p = 0.003) and the relative death rate 0.53 (0.34-0.81, p = 0.003). Overall median survival was 69 weeks in the low-dose group and 114 weeks in the high-dose group. Residual disease extent before chemotherapy had an important influence-patients with lesions of less than 2 cm did best; if given high-dose cisplatin their median survival was 3 years. 56 low-dose and 45 high-dose patients completed six cycles of chemotherapy; 15 and 9 patients, respectively, were withdrawn early because of progressive disease and treatment was stopped in 6 and 25, respectively, because of unacceptable side-effects or patient refusal. Toxic effects were significantly greater in the high-dose group, especially those on the nervous system and ears, alopecia, vomiting, and anaemia. Although the higher dose of cisplatin clearly leads to better results in terms of survival, its overall clinical benefit in the management of ovarian cancer will depend on further improvements in measures to alleviate toxic effects.	GLASGOW ROYAL INFIRM, GLASGOW G4 0SF, SCOTLAND; STOBHILL GEN HOSP, GLASGOW G21 3UW, SCOTLAND; UNIV DUNDEE, NINEWELLS HOSP & MED SCH, DUNDEE DD1 9SY, SCOTLAND; ABERDEEN ROYAL INFIRM, ABERDEEN AB9 2ZB, SCOTLAND; BELFAST CITY HOSP, BELFAST BT9 7AD, ANTRIM, NORTH IRELAND; AIREDALE HOSP, W YORKSHIRE, ENGLAND	University of Glasgow; University of Dundee; University of Aberdeen; Belfast City Hospital	KAYE, SB (corresponding author), WESTERN INFIRM & ASSOCIATED HOSP, BEATSON ONCOL CTR, GLASGOW G11 6NT, SCOTLAND.			Paul, James/0000-0001-7367-5816				AAPRO MS, 1991, EUR J CANCER, V27, P356, DOI 10.1016/0277-5379(91)90545-O; BLAND M, 1987, INTRO MED STATISTICS; COX DR, 1972, J R STAT SOC B, V34, P187; DEMBO AJ, 1986, J CLIN ONCOL, V4, P1573, DOI 10.1200/JCO.1986.4.11.1573; DIRE F, 1990, CANCER CHEMOTH PHARM, V25, P355, DOI 10.1007/BF00686237; EHRLICH CE, 1983, CLIN OBSTET GYNAECOL, V10, P325; EINHORN L, 1990, P AN M AM SOC CLIN, V9, P132; HAMERS FD, 1990, P AN M AM SOC CLIN, V9, P140; HUGHES MD, 1988, STAT MED, V7, P1231, DOI 10.1002/sim.4780071204; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; LAMBERT HE, 1985, BRIT MED J, V290, P889, DOI 10.1136/bmj.290.6472.889; LEVIN L, 1987, J CLIN ONCOL, V5, P756, DOI 10.1200/JCO.1987.5.5.756; MANGIONI C, 1989, J NATL CANCER I, V81, P1464, DOI 10.1093/jnci/81.19.1464; MCGUIRE WP, 1989, J NATL CANCER I, V81, P1438, DOI 10.1093/jnci/81.19.1438; MCGUIRE WP, 1992, P AN M AM SOC CLIN, V11, P226; MOLLMAN JE, 1988, CANCER, V61, P2192, DOI 10.1002/1097-0142(19880601)61:11<2192::AID-CNCR2820611110>3.0.CO;2-A; NEIJT JP, 1987, J CLIN ONCOL, V5, P1157, DOI 10.1200/JCO.1987.5.8.1157; NGAN HYS, 1989, CHEMOTHERAPY, V35, P221, DOI 10.1159/000238673; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; RANKIN EM, 1992, BRIT J CANCER, V65, P275, DOI 10.1038/bjc.1992.55; SAMSON MK, 1984, CANCER, V53, P1029, DOI 10.1002/1097-0142(19840301)53:5<1029::AID-CNCR2820530503>3.0.CO;2-Z; STEWART LA, 1991, BRIT MED J, V303, P884; VANDERHOOP RG, 1990, NEW ENGL J MED, V322, P89, DOI 10.1056/NEJM199001113220204; 1979, HDB REPORTING RESULT	24	198	200	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 8	1992	340	8815					329	333		10.1016/0140-6736(92)91404-V	http://dx.doi.org/10.1016/0140-6736(92)91404-V			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JH125	1353804				2023-01-03	WOS:A1992JH12500003
J	KOVAR, PA; ALLEGRANTE, JP; MACKENZIE, CR; PETERSON, MGE; GUTIN, B; CHARLSON, ME				KOVAR, PA; ALLEGRANTE, JP; MACKENZIE, CR; PETERSON, MGE; GUTIN, B; CHARLSON, ME			SUPERVISED FITNESS WALKING IN PATIENTS WITH OSTEOARTHRITIS OF THE KNEE - A RANDOMIZED, CONTROLLED TRIAL	ANNALS OF INTERNAL MEDICINE			English	Article						WALKING; OSTEOARTHRITIS; KNEE INJURIES; EXERCISE THERAPY; PATIENT EDUCATION	CONTROLLED LONG-TERM; ALL-CAUSE MORTALITY; RHEUMATOID-ARTHRITIS; OSTEO-ARTHRITIS; PHYSICAL-ACTIVITY; AEROBIC EXERCISE; HEART-DISEASE; HEALTHY-MEN; WOMEN; EPIDEMIOLOGY	Objective: To assess the effect of a program of supervised fitness walking and patient education on functional status, pain, and use of medication in patients with osteoarthritis of the knee. Design: An 8-week randomized, controlled trial. Setting: Inpatient and outpatient services of an orthopedic hospital in an academic medical center. Patients: A total of 102 patients with a documented diagnosis of primary osteoarthritis of one or both knees participated in the study. Data were obtained on 47 of 51 intervention patients and 45 of 51 control patients. Interventions: An 8-week program of supervised fitness walking and patient education or standard routine medical care. Measurements: Patients were evaluated and outcomes assessed before and after the intervention using a 6-minute test of walking distance and scores on the physical activity, arthritis impact, pain, and medication subscales of the Arthritis Impact Measurement Scale (AIMS). Results: Patients randomly assigned to the walking program had a 70-meter increase in walking distance relative to their baseline assessment, which represents an improvement of 18.4% (95% CI, 9.8% to 27.0%). In contrast, controls showed a 17-meter decrease in walking distance relative to their baseline assessment (P < 0.001). Improvements in functional status as measured by the AIMS physical activity subscale were also observed in the walking group but not in the control group (P < 0.001); patients assigned to the walking program improved 39% (CI, 15.6% to 60.4%). Although changes in scores on the arthritis impact subscale were similar in the two groups (P = 0.093), the walking group experienced a decrease in arthritis pain of 27% (CI, 9.6% to 41.4%) (P = 0.003). Medication use was less frequent in the walking group than in the control group at the post-test (P = 0.08). Conclusions: A program of supervised fitness walking and patient education can improve functional status without worsening pain or exacerbating arthritis-related symptoms in patients with osteoarthritis of the knee.	HOSP SPECIAL SURG, CORNELL ARTHRIT & MUSCULOSKELETAL DIS CTR, 535 E 70TH ST, NEW YORK, NY 10021 USA; COLUMBIA UNIV, NEW YORK, NY 10027 USA; MED COLL GEORGIA, DEPT PEDIAT, AUGUSTA, GA 30912 USA; MED COLL GEORGIA, GEORGIA PREVENT INST, AUGUSTA, GA 30912 USA	Columbia University; University System of Georgia; Augusta University; University System of Georgia; Augusta University				Allegrante, John/0000-0002-6281-3037	NIAMS NIH HHS [1 P60 AR38520-01A1] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P60AR038520] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ACHTERBERGLAWLIS J, 1982, J CONSULT CLIN PSYCH, V50, P984, DOI 10.1037/0022-006X.50.6.984; ALLEGRANTE JP, IN PRESS HLTH ED Q; ALLEN ME, 1990, RHEUMATIC DISEASES C, P887; ALOIA JF, 1978, ANN INTERN MED, V89, P356, DOI 10.7326/0003-4819-89-3-356; BEALS CA, 1985, J RHEUMATOL, V12, P458; BLAIR SN, 1989, JAMA-J AM MED ASSOC, V262, P2395, DOI 10.1001/jama.262.17.2395; EKBLOM B, 1974, SCAND J RHEUMATOL, V3, P121, DOI 10.3109/03009747409097136; EKBLOM B, 1975, SCAND J RHEUMATOL, V4, P87, DOI 10.3109/03009747509095620; EKBLOM B, 1975, J SCAND J RHEUMATOL, V41, P80; FELSON DT, 1988, ANN INTERN MED, V109, P18, DOI 10.7326/0003-4819-109-1-18; FELSON DT, 1988, EPIDEMIOL REV, V10, P1; FELSON DT, 1987, ARTHRITIS RHEUM, V30, P914, DOI 10.1002/art.1780300811; GUYATT GH, 1985, CAN MED ASSOC J, V132, P919; HARKCOM TM, 1985, ARTHRITIS RHEUM, V28, P32, DOI 10.1002/art.1780280106; IKE RW, 1989, PHYSICIAN SPORTSMED, V17, P128, DOI 10.1080/00913847.1989.11709710; KELLEY WN, 1978, TXB RHEUMATOLOGY, V89, P356; KOHL HW, 1988, SPORTS MED, V6, P222, DOI 10.2165/00007256-198806040-00004; LUBECK DP, 1982, 1982 ANN M AM PUBL H; Mason J H, 1989, Arthritis Care Res, V2, P89, DOI 10.1002/anr.1790020303; MEENAN RF, 1982, J RHEUMATOL, V9, P785; MINOR MA, 1989, ARTHRITIS RHEUM, V32, P1396, DOI 10.1002/anr.1780321108; MINOR MA, 1988, J RHEUMATOL, V15, P905; MOSCOWITZ RW, 1986, ARTHRITIS ELDERLY; MOSKOWITZ RW, 1987, AM J MED, V83, P5, DOI 10.1016/0002-9343(87)90844-8; NORDEMAR R, 1976, SCAND J RHEUMATOL, V5, P233, DOI 10.3109/03009747609099911; NORDEMAR R, 1981, SCAND J RHEUMATOL, V10, P25; NORDEMAR R, 1981, SCAND J RHEUMATOL, V10, P17; NORDESJO LO, 1983, SCAND J RHEUMATOL, V12, P152, DOI 10.3109/03009748309102902; PAFFENBARGER RS, 1986, NEW ENGL J MED, V314, P605, DOI 10.1056/NEJM198603063141003; POLLOCK ML, 1971, J APPL PHYSIOL, V30, P126, DOI 10.1152/jappl.1971.30.1.126; PORCARI J, 1987, PHYSICIAN SPORTSMED, V15, P119, DOI 10.1080/00913847.1987.11709285; POWELL KE, 1987, ANNU REV PUBL HEALTH, V8, P253, DOI 10.1146/annurev.publhealth.8.1.253; PRICE LG, 1988, ARTHRIT CARE RES, V1, P33; RIPPE JM, 1988, JAMA-J AM MED ASSOC, V259, P2720, DOI 10.1001/jama.259.18.2720; RIPPE JM, 1989, PRAC CARDIOL, V15, P66; SHOENFELD Y, 1980, JAMA-J AM MED ASSOC, V243, P2062, DOI 10.1001/jama.243.20.2062; SISCOVICK DS, 1985, PUBLIC HEALTH REP, V100, P180; SPIEGEL D, 1989, LANCET, V2, P888; STERN MJ, 1981, ARCH INTERN MED, V141, P1463, DOI 10.1001/archinte.141.11.1463; SUMMERS MN, 1988, ARTHRITIS RHEUM, V31, P204, DOI 10.1002/art.1780310208; TAYLOR CB, 1985, PUBLIC HEALTH REP, V100, P195; TINETTI ME, 1988, NEW ENGL J MED, V319, P1701, DOI 10.1056/NEJM198812293192604; VANSAASE JLCM, 1989, ANN RHEUM DIS, V48, P271, DOI 10.1136/ard.48.4.271	43	377	382	3	33	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 1	1992	116	7					529	534		10.7326/0003-4819-116-7-529	http://dx.doi.org/10.7326/0003-4819-116-7-529			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HL258	1543305				2023-01-03	WOS:A1992HL25800001
J	WELCH, HG; MEEHAN, KR; GOODNOUGH, LT				WELCH, HG; MEEHAN, KR; GOODNOUGH, LT			PRUDENT STRATEGIES FOR ELECTIVE RED-BLOOD-CELL TRANSFUSION	ANNALS OF INTERNAL MEDICINE			English	Review							RECOMBINANT-HUMAN-ERYTHROPOIETIN; OPEN-HEART SURGERY; ACUTE NORMOVOLEMIC ANEMIA; STAGE RENAL-DISEASE; AUTOLOGOUS BLOOD; CARDIAC-SURGERY; CARDIOPULMONARY BYPASS; OXYGEN-TRANSPORT; CLINICAL-TRIAL; FIBRIN GLUE	Objective: To review the literature on the appropriateness of red blood cell transfusion and current physician practice, with emphasis on the physiologic and symptomatic implications of elective transfusion in the treatment of anemia. Data Sources: Studies on the therapeutic use of red blood cell transfusion were identified through a search of MEDLINE (1966 to the present) and through a manual review of bibliographies of identified articles. In addition, evidence was solicited from selected experts in the field and recent consensus panels that have developed transfusion guidelines. Data Synthesis: No controlled trials of blood transfusion were identified, but data were available on four issues relevant to transfusion practice: current physician practice and evidence for excessive use of red blood cell transfusion; physiologic adaptation to anemia; human tolerance of low hemoglobin levels; and strategies for reducing homologous transfusion requirements. Conclusions: Despite the recent decline in red blood cell use because of concerns about infection, current transfusion practice remains variable because physicians have disparate views about its appropriateness. The remarkable human tolerance of anemia suggests that clinicians can accept hemoglobin levels above 70 g/L (7 g/dL) in most patients with self-limited anemia. In patients with impaired cardiovascular status or with anemias that will not resolve spontaneously, however, the data are insufficient to determine minimum acceptable hemoglobin levels, and therapy must be guided by the clinical situation. Several therapeutic strategies and pharmacologic interventions are available in the peri-operative and non-operative settings to further reduce red blood cell use.	DARTMOUTH COLL, HITCHCOCK MED CTR, DARTMOUTH MED SCH, HANOVER, NH 03756 USA; UNIV HOSP CLEVELAND, CLEVELAND, OH 44106 USA; CASE WESTERN RESERVE UNIV, SCH MED, CLEVELAND, OH 44106 USA	Dartmouth College; University Hospitals of Cleveland; Case Western Reserve University	WELCH, HG (corresponding author), VET AFFAIRS HOSP, MED SERV, N HARTLAND RD, WHITE RIVER JCT, VT 05001 USA.							ALEXIU O, 1975, ANAESTHESIA, V30, P609, DOI 10.1111/j.1365-2044.1975.tb00920.x; ALLEN JB, 1982, INT ANESTHESIOL CLIN, V20, P1, DOI 10.1097/00004311-198220040-00003; ALLEN JG, 1972, NEW ENGL J MED, V287, P984, DOI 10.1056/NEJM197211092871914; Allen JR, 1987, TRANSFUSION TRANSMIT, P37; ALTER HJ, 1989, NEW ENGL J MED, V321, P1494, DOI 10.1056/NEJM198911303212202; BAKER JW, 1987, ANN THORAC SURG, V43, P564, DOI 10.1016/S0003-4975(10)60214-7; BARRY MJ, 1988, JAMA-J AM MED ASSOC, V259, P3010, DOI 10.1001/jama.259.20.3010; BAYER WL, 1980, ANN THORAC SURG, V29, P117, DOI 10.1016/S0003-4975(10)61648-7; BERNE RM, 1986, CARDIOVASCULAR PHYSL, P204; BERNSTEIN MJ, 1987, JAMA-J AM MED ASSOC, V257, P1777; BERNSTEIN MJ, 1985, JAMA-J AM MED ASSOC, V253, P551; BERNSTEIN MJ, 1988, JAMA-J AM MED ASSOC, V260, P2700; BIDSTRUP BP, 1989, J THORAC CARDIOV SUR, V97, P364; BLUM L, 1955, Bull N Y Acad Med, V31, P671; BRANNON ES, 1945, J CLIN INVEST, V24, P332, DOI 10.1172/JCI101610; BRAZIER J, 1974, SURGERY, V75, P508; CARSON JL, 1988, LANCET, V1, P727; CHAPLER CK, 1986, CAN J PHYSIOL PHARM, V64, P7, DOI 10.1139/y86-002; CHAPLIN H, 1969, NEW ENGL J MED, V281, P364, DOI 10.1056/NEJM196908142810707; CICERO JL, 1991, AM SURGEON, V57, P165; COFFIN C, 1989, TRANSFUSION, V29, P298, DOI 10.1046/j.1537-2995.1989.29489242793.x; CORDELL AR, 1981, ANN THORAC SURG, V31, P421, DOI 10.1016/S0003-4975(10)60992-7; Deniston O L, 1990, ASAIO Trans, V36, pM157; DIETHRICH EB, 1965, TRANSFUSION, V5, P82, DOI 10.1111/j.1537-2995.1965.tb01138.x; DUKE M, 1969, CIRCULATION, V39, P503, DOI 10.1161/01.CIR.39.4.503; EEROLA R, 1979, ANN CHIR GYNAECOL, V68, P109; ESCHBACH JW, 1989, NEW ENGL J MED, V321, P158, DOI 10.1056/NEJM198907203210305; ESCHBACH JW, 1987, NEW ENGL J MED, V316, P73, DOI 10.1056/NEJM198701083160203; ESCHBACH JW, 1989, ANN INTERN MED, V111, P992, DOI 10.7326/0003-4819-111-12-992; ESCOBAR E, 1966, AM J PHYSIOL, V211, P877, DOI 10.1152/ajplegacy.1966.211.4.877; EVANS RW, 1990, JAMA-J AM MED ASSOC, V263, P825; FINCH CA, 1972, NEW ENGL J MED, V286, P407, DOI 10.1056/NEJM197202242860806; FISCHL M, 1990, NEW ENGL J MED, V322, P1488, DOI 10.1056/NEJM199005243222103; FOWLER NO, 1975, J APPL PHYSIOL, V39, P453, DOI 10.1152/jappl.1975.39.3.453; FRIEDMAN BA, 1978, TRANSFUSION, V18, P193, DOI 10.1046/j.1537-2995.1978.18278160583.x; FRIEDMAN BA, 1980, TRANSFUSION, V20, P179, DOI 10.1046/j.1537-2995.1980.20280169958.x; FULLERTON WT, 1962, LANCET, V1, P75; GEHA AS, 1976, SURGERY, V80, P47; GIBBLE JW, 1990, TRANSFUSION, V30, P741, DOI 10.1046/j.1537-2995.1990.30891020337.x; GOLLUB S, 1966, JAMA-J AM MED ASSOC, V198, P149; GOODNOUGH L T, 1990, Transfusion Medicine Reviews, V4, P288, DOI 10.1016/S0887-7963(90)70271-4; GOODNOUGH LT, 1990, AM J SURG, V159, P602, DOI 10.1016/S0002-9610(06)80079-6; GOODNOUGH LT, 1991, ANN THORAC SURG, V51, P703, DOI 10.1016/0003-4975(91)90108-3; GOODNOUGH LT, 1991, JAMA-J AM MED ASSOC, V265, P86, DOI 10.1001/jama.265.1.86; GOODNOUGH LT, 1989, NEW ENGL J MED, V321, P1163, DOI 10.1056/NEJM198910263211705; GOODNOUGH LT, 1990, J LAB CLIN MED, V115, P28; GOODNOUGH LT, 1990, VOX SANG, V59, P65, DOI 10.1111/j.1423-0410.1990.tb05010.x; GOULD SA, 1986, NEW ENGL J MED, V314, P1653, DOI 10.1056/NEJM198606263142601; GRINDON AJ, 1985, JAMA-J AM MED ASSOC, V253, P540, DOI 10.1001/jama.253.4.540; HACKMANN T, 1989, NEW ENGL J MED, V321, P1437, DOI 10.1056/NEJM198911233212104; HAGL S, 1977, BASIC RES CARDIOL, V72, P344, DOI 10.1007/BF02023594; HEDDERICH GS, 1990, CAN J SURG, V33, P33; HILLMAN RS, 1985, RED CELL MANUAL, P22; JAMIESON WRE, 1982, CAN J SURG, V25, P538; JESSEN C, 1985, ANN THORAC SURG, V39, P521, DOI 10.1016/S0003-4975(10)61991-1; KAFER ER, 1986, ANESTH ANALG       S, V65, pS76; KAHN RC, 1986, INTENS CARE MED, V12, P22, DOI 10.1007/BF00315364; KANDEL G, 1983, ARCH INTERN MED, V143, P1400, DOI 10.1001/archinte.143.7.1400; KAWAGUCHI A, 1984, CIRCULATION, V70, P30; KEELING MM, 1983, ANN SURG, V197, P536, DOI 10.1097/00000658-198305000-00006; KEITT AS, 1985, CECIL TXB MED, P870; KENNEDY AC, 1954, J CLIN INVEST, V33, P1372, DOI 10.1172/JCI103014; KICKLER TS, 1988, JAMA-J AM MED ASSOC, V260, P65, DOI 10.1001/jama.260.1.65; KLEINMAN KS, 1989, AM J KIDNEY DIS, V14, P486, DOI 10.1016/S0272-6386(89)80149-0; KOBRINSKY NL, 1987, ANN INTERN MED, V107, P446, DOI 10.7326/0003-4819-107-4-446; KOWALYSHYN TJ, 1972, ANESTH ANAL CURR RES, V51, P75; LAUPACIS A, 1990, BMJ-BRIT MED J, V300, P573; LENFANT C, 1990, TRANSFUSION, V30, P97, DOI 10.1046/j.1537-2995.1990.30290162913.x; LEVINE E, 1990, TRANSFUSION, V30, P11, DOI 10.1046/j.1537-2995.1990.30190117621.x; LEVINE EA, 1991, ANN THORAC SURG, V51, P764, DOI 10.1016/0003-4975(91)90121-6; LILLEAASEN P, 1978, ANN THORAC SURG, V25, P127, DOI 10.1016/S0003-4975(10)63505-9; LUDWIG H, 1990, NEW ENGL J MED, V322, P1693, DOI 10.1056/NEJM199006143222402; MESSMER K, 1973, RES EXP MED, V159, P152, DOI 10.1007/BF01851543; MILLER CB, 1990, NEW ENGL J MED, V322, P1689, DOI 10.1056/NEJM199006143222401; MOZES B, 1989, TRANSFUSION, V29, P473, DOI 10.1046/j.1537-2995.1989.29689318442.x; MURRAY JF, 1969, AM J PHYSIOL, V216, P638, DOI 10.1152/ajplegacy.1969.216.3.638; MYHRE BA, 1980, JAMA-J AM MED ASSOC, V244, P1333; OWINGS DV, 1989, JAMA-J AM MED ASSOC, V262, P1963; PALERMO G, 1980, TRANSFUSION, V20, P704, DOI 10.1046/j.1537-2995.1980.20681057160.x; PINCUS T, 1990, AM J MED, V89, P161, DOI 10.1016/0002-9343(90)90294-N; POPOVSKY MA, 1985, MAYO CLIN PROC, V60, P125, DOI 10.1016/S0025-6196(12)60299-7; RAINE AEG, 1988, LANCET, V1, P97; REECE RL, 1966, JAMA-J AM MED ASSOC, V195, P113; RODMAN T, 1960, ANN INTERN MED, V52, P295, DOI 10.7326/0003-4819-52-2-295; ROY SB, 1963, CIRCULATION, V28, P346, DOI 10.1161/01.CIR.28.3.346; Royston D, 1990, Blood Coagul Fibrinolysis, V1, P55, DOI 10.1097/00001721-199003000-00009; SALEMSCHATZ SR, 1990, JAMA-J AM MED ASSOC, V264, P476, DOI 10.1001/jama.264.4.476; SALZMAN EW, 1986, NEW ENGL J MED, V314, P1402, DOI 10.1056/NEJM198605293142202; SEHGAL LR, 1984, SURGERY, V95, P433; SHAH DM, 1982, J TRAUMA, V22, P741, DOI 10.1097/00005373-198209000-00004; SILBERSTEIN LE, 1989, JAMA-J AM MED ASSOC, V262, P1993, DOI 10.1001/jama.262.14.1993; SMOLLER BR, 1986, NEW ENGL J MED, V314, P1233, DOI 10.1056/NEJM198605083141906; SOHMER PR, 1979, CRC CR REV CL LAB SC, V11, P107, DOI 10.3109/10408367909105855; STARK J, 1984, ANN THORAC SURG, V38, P411, DOI 10.1016/S0003-4975(10)62298-9; STEHLING L, 1990, TRANSFUSION, V30, P1, DOI 10.1046/j.1537-2995.1990.30190117620.x; STEHLING LC, 1987, VOX SANG, V52, P60, DOI 10.1111/j.1423-0410.1987.tb02990.x; STUDZINSKI T, 1980, Acta Physiologica Polonica, V31, P365; SURGENOR DM, 1990, NEW ENGL J MED, V322, P1646, DOI 10.1056/NEJM199006073222306; SURGENOR DM, 1989, TRANSFUSION, V29, P761, DOI 10.1046/j.1537-2995.1989.29990070178.x; SURGENOR DM, 1988, TRANSFUSION, V28, P513, DOI 10.1046/j.1537-2995.1988.28689059022.x; SURGENOR DM, 1991, TRANSFUSION, V31, P531, DOI 10.1046/j.1537-2995.1991.31691306252.x; THALER M, 1989, NEW ENGL J MED, V321, P25, DOI 10.1056/NEJM198907063210105; TOY PTCY, 1987, NEW ENGL J MED, V316, P517, DOI 10.1056/NEJM198702263160906; TYSON GS, 1989, ANN SURG, V209, P736, DOI 10.1097/00000658-198906000-00011; VARAT MA, 1972, AM HEART J, V83, P415, DOI 10.1016/0002-8703(72)90445-0; VERSKA JJ, 1974, ANN THORAC SURG, V18, P72, DOI 10.1016/S0003-4975(10)65720-7; WASMAN J, 1987, JAMA-J AM MED ASSOC, V258, P3135, DOI 10.1001/jama.258.21.3135; WHITAKER W, 1956, Q J MED, V25, P175; WILHELM JA, 1986, J INFECT DIS, V154, P169, DOI 10.1093/infdis/154.1.169; WILKERSON DK, 1988, SURGERY, V103, P665; WINSLOW RM, 1989, TRANSFUSION, V29, P753, DOI 10.1046/j.1537-2995.1989.29990070175.x; WOODMAN RC, 1990, BLOOD, V76, P1680; WOODSON RD, 1982, J APPL PHYSIOL, V53, P1299, DOI 10.1152/jappl.1982.53.5.1299; WRIGHT CJ, 1976, SURGERY, V79, P299; ZUCK TF, 1987, TRANSFUSION, V27, P447, DOI 10.1046/j.1537-2995.1987.27688071691.x; ZUCK TF, 1990, ARCH PATHOL LAB MED, V114, P309; 1989, TRANSFUSION, V29, P711; 1988, ACCREDITATION MANUAL, P120; 1983, NATIONAL I HLTH GUID; 1986, JAMA-J AM MED ASSOC, V256, P2378	120	283	292	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 1	1992	116	5					393	402		10.7326/0003-4819-116-5-393	http://dx.doi.org/10.7326/0003-4819-116-5-393			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HF268	1736773				2023-01-03	WOS:A1992HF26800009
J	BRADLEY, CP				BRADLEY, CP			UNCOMFORTABLE PRESCRIBING DECISIONS - A CRITICAL INCIDENT STUDY	BRITISH MEDICAL JOURNAL			English	Article								Objective - To explore the discomfort experienced by general practitioners in relation to decisions about whether or not to prescribe. Design - Focused interviews of general practitioners about prescribing decisions that made them uncomfortable. Analysis based on the critical incident technique. Setting - One family practitioner committee area in the north of England. Respondents - 69 principals and five trainee general practitioners. Main outcome measures - Drugs and clinical problems associated with prescribing discomfort. Reasons given by doctors for making the prescribing decisions they did and reasons for feeling uncomfortable. Results - Antibiotics, tranquillisers, hypnotics, and symptomatic remedies were most often associated with discomfort, but any prescribeable item could be associated with discomfort. Respiratory diseases, musculoskeletal problems, and anxiety were most often associated with discomfort, but again any condition could be associated. The main reasons given for the decisions made were patient expectation, clinical appropriateness, factors related to the doctor-patient relationship, and precedents. The main reasons given for feeling uncomfortable were concern about drug toxicity, failure to live up to the general practitioner's own expectations, concern about the appropriateness of treatment, and ignorance or uncertainty. Conclusions - Many considerations, including medical, social, and logistic ones, influence the decision to prescribe in general practice. The final action taken depends on a complex interaction of these disparate influences.			BRADLEY, CP (corresponding author), UNIV MANCHESTER,RUSHOLME HLTH CTR,DEPT GEN PRACTICE,MANCHESTER M14 5NP,ENGLAND.			Bradley, Colin/0000-0002-3595-9567				BRADLEY CP, 1991, FAM PRACT, V8, P276, DOI 10.1093/fampra/8.3.276; BRADLEY CP, IN PRESS FAM PRACT; BRADLEY CP, 1990, THESIS U DUBLIN; FLANAGAN JC, 1954, PSYCHOL BULL, V51, P327, DOI 10.1037/h0061470; Glaster B. G., 1967, THEORETICAL SENSITIV; HARRIS CM, 1980, BRIT MED J, V281, P57; HEMMINKI E, 1975, MED CARE, V13, P150, DOI 10.1097/00005650-197502000-00006; HOWIE JGR, 1976, BRIT MED J, V2, P1061, DOI 10.1136/bmj.2.6043.1061; PARISH PA, 1973, ROY SOC HEALTH J, V93, P213, DOI 10.1177/146642407309300414; 1986, 1981 1982 MORBIDITY; 1989, HLTH PERSONAL SOCIAL; 1987, BMA GUIDE LIVING RIS	12	145	146	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 1	1992	304	6822					294	296		10.1136/bmj.304.6822.294	http://dx.doi.org/10.1136/bmj.304.6822.294			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HC708	1739831	Green Published, Bronze			2023-01-03	WOS:A1992HC70800024
J	YANG, CS; BRADY, JF; HONG, JY				YANG, CS; BRADY, JF; HONG, JY			DIETARY-EFFECTS ON CYTOCHROMES-P450, XENOBIOTIC METABOLISM, AND TOXICITY	FASEB JOURNAL			English	Article						DIET; NUTRITION; CYTOCHROME-P450; ENZYME REGULATION; XENOBIOTICS; DRUG METABOLISM; TOXICITY; CARCINOGENS	N-NITROSODIMETHYLAMINE DEMETHYLASE; DRUG-NUTRIENT INTERACTIONS; RAT-LIVER; ISOZYME 3A; CYTOCHROME-P-450; INDUCTION; ETHANOL; CARCINOGENESIS; MECHANISMS; MICROSOMES	The levels and activities of cytochrome P450 enzymes are influenced by a variety of factors, including the diet. In this article, the effects of selected non-nutritive dietary chemicals, macronutrients, micronutrients, and ethanol on cytochromes P450 and xenobiotic metabolism are reviewed in the light of our current understanding of the multiplicity and substrate specificity of cytochrome P450 enzymes. Although the mechanisms of action of several dietary chemicals on specific cytochrome P450 isozymes have been established, those for macro- and micronutrients are largely unknown. It is known, however, that specific nutrients may have varied effects on different cytochrome P450 forms and thus may affect the metabolism of various drugs differently. Nutritional deficiencies generally cause lowered rates of xenobiotic metabolism. In certain cases, such as thiamin deficiency and mild riboflavin deficiency, however, enhanced rates of metabolism of xenobiotics were observed. The effects of dietary modulation of xenobiotic metabolism on chemical toxicity and carcinogenicity are discussed.			YANG, CS (corresponding author), RUTGERS STATE UNIV,COLL PHARM,DEPT CHEM BIOL & PHARMACOGNOSY,CANC RES LAB,PISCATAWAY,NJ 08855, USA.				NCI NIH HHS [CA37037, CA46535] Funding Source: Medline; NIEHS NIH HHS [ES03938] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA037037, R37CA037037] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES003938] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ANDERSON KE, 1985, FED PROC, V44, P130; ANDERSON LM, 1988, CARCINOGENESIS, V9, P1717, DOI 10.1093/carcin/9.9.1717; BAILEY DG, 1990, CLIN PHARMACOL THER, V47, P180; BAILEY GS, 1978, J NATL CANCER I, P931; BIDLACK WR, 1986, FASEB J, V45, P142; BIRT DF, 1983, TOXICOL APPL PHARM, V68, P77, DOI 10.1016/0041-008X(83)90356-3; BRADFIELD CA, 1987, J TOXICOL ENV HEALTH, V21, P311, DOI 10.1080/15287398709531021; BRADY JF, 1991, TOXICOL APPL PHARM, V108, P342, DOI 10.1016/0041-008X(91)90123-V; BRADY JF, 1991, CHEM RES TOXICOL, V4, P642, DOI 10.1021/tx00024a008; CAMPBELL TC, 1974, PHARMACOL REV, V26, P171; CONNEY AH, 1982, CANCER RES, V42, P4875; CORREA P, 1981, CANCER RES, V41, P3685; DING XX, 1986, MOL PHARMACOL, V30, P370; DONG ZG, 1988, ARCH BIOCHEM BIOPHYS, V263, P29, DOI 10.1016/0003-9861(88)90610-8; EKSTROM G, 1989, BIOCHEM PHARMACOL, V38, P1313, DOI 10.1016/0006-2952(89)90338-9; FARINATI F, 1984, GASTROENTEROLOGY, V86, P1073; FONG AT, 1990, BIOCHEM PHARMACOL, V39, P19, DOI 10.1016/0006-2952(90)90643-Y; GIGER U, 1981, J BIOL CHEM, V256, P1182; GILLNER M, 1985, MOL PHARMACOL, V28, P357; GRICIUTE L, 1981, CANCER LETT, V13, P345, DOI 10.1016/0304-3835(81)90063-X; GUENGERICH FP, 1990, CARCINOGENESIS, V11, P2275, DOI 10.1093/carcin/11.12.2275; GUENGERICH FP, 1984, ANNU REV NUTR, V4, P207, DOI 10.1146/annurev.nu.04.070184.001231; GUENGERICH FP, 1991, CHEM RES TOXICOL, V4, P391, DOI 10.1021/tx00022a001; GUENGERICH FP, 1991, CHEM RES TOXICOL, V4, P168, DOI 10.1021/tx00020a008; HATHCOCK JN, 1985, FED PROC, V44, P124; HONG JY, 1987, BIOCHEM BIOPH RES CO, V142, P1077, DOI 10.1016/0006-291X(87)91525-7; HONG JY, 1987, CANCER RES, V47, P5948; IMAIDA K, 1983, CARCINOGENESIS, V4, P895, DOI 10.1093/carcin/4.7.895; ISHIZAKI H, 1990, XENOBIOTICA, V20, P255, DOI 10.3109/00498259009046845; KATO R, 1965, J PHARMACOL EXP THER, V150, P279; KOOP DR, 1982, J BIOL CHEM, V257, P8472; KOOP DR, 1985, J BIOL CHEM, V260, P3607; LIEBER CS, 1986, NEW YORK STATE J MED, V86, P297; MA Q, 1989, BIOCHEM PHARMACOL, V38, P3179; MICHNOVICZ JJ, 1990, J NATL CANCER I, V82, P947, DOI 10.1093/jnci/82.11.947; MILLER KW, 1984, ARCH BIOCHEM BIOPHYS, V229, P483, DOI 10.1016/0003-9861(84)90179-6; MORSE MA, 1989, CANCER RES, V49, P2894; NELSON DR, 1987, MOL BIOL EVOL, V4, P572; PAN JM, 1991, FASEB J, V5, pA1161; PERROT N, 1989, EUR J CLIN INVEST, V19, P549, DOI 10.1111/j.1365-2362.1989.tb00273.x; SEITZ HK, 1985, DRUG NUTR INTERACT, V4, P143; SMITH TJ, 1990, CANCER RES, V50, P6817; SONG BJ, 1986, J BIOL CHEM, V261, P6689; STONER GD, 1991, CANCER RES, V51, P2063; STROTHER A, 1971, J PHARMACOL EXP THER, V179, P490; TINEL M, 1987, BIOCHEM PHARMACOL, V36, P951, DOI 10.1016/0006-2952(87)90190-0; VANG O, 1990, CARCINOGENESIS, V11, P1259, DOI 10.1093/carcin/11.8.1259; WADE AE, 1986, J ENVIRON PATHOL TOX, V6, P161; WANG TY, 1985, J NATL CANCER I, V74, P1291; WARGOVICH MJ, 1988, CANCER RES, V48, P6872; WATTENBERG LW, 1978, JNCI-J NATL CANCER I, V60, P11, DOI 10.1093/jnci/60.1.11; WATTENBERG LW, 1971, CANCER-AM CANCER SOC, V28, P99, DOI 10.1002/1097-0142(197107)28:1<99::AID-CNCR2820280118>3.0.CO;2-M; WORTELBOER HM, 1990, DRUG METABOLIZING EN; YANG CS, 1988, PHARMACOL THERAPEUT, V38, P53, DOI 10.1016/0163-7258(88)90102-7; YANG CS, 1990, DRUG METAB REV, V22, P147, DOI 10.3109/03602539009041082; YANG CS, 1991, IN PRESS NUTRITION T; YOO JSH, 1991, J NUTR, V121, P959, DOI 10.1093/jn/121.7.959; YOO JSH, 1990, J NUTR, V120, P1718, DOI 10.1093/jn/120.12.1718; YOO JSH, 1990, BIOCHEM PHARMACOL, V39, P519, DOI 10.1016/0006-2952(90)90059-T; YOU WC, 1989, J NATL CANCER I, V81, P162, DOI 10.1093/jnci/81.2.162	60	194	197	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JAN 6	1992	6	2					737	744		10.1096/fasebj.6.2.1537464	http://dx.doi.org/10.1096/fasebj.6.2.1537464			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	GZ440	1537464				2023-01-03	WOS:A1992GZ44000015
J	ABDELMAEBOUD, KH; ELNAGGAR, T; ELHAWI, EMM; MAHMOUD, SAR; ABDELHAY, S				ABDELMAEBOUD, KH; ELNAGGAR, T; ELHAWI, EMM; MAHMOUD, SAR; ABDELHAY, S			RECTAL SUPPOSITORY - COMMONSENSE AND MODE OF INSERTION	LANCET			English	Article								Rectal suppository is a well-known form of medication and its use is increasing. The commonest shape is one with an apex (pointed end) tapering to a base (blunt end). Because of a general lack of information about mode of insertion, we asked 360 lay subjects (Egyptians and non-Egyptians) and 260 medical personnel (physicians, pharmacists, and nurses) by questionnaire which end they inserted foremost. Apart from 2 individuals, all subjects suggested insertion with the apex foremost. Commonsense was the most frequent basis for this practice (86.9% of lay subjects and 84.6% of medical personnel) followed by information from a relative, a friend, or medical personnel, or from study at medical school. Suppository insertion with the base or apex foremost was compared in 100 subjects (60 adults, 40 infants and children). Retention with the former method was more easily achieved in 98% of the cases, with no need to introduce a finger in the anal canal (1% vs 83%), and lower expulsion rate (0% vs 3%). The designer of the "torpedo-shaped" suppository suggested its insertion with apex foremost. Our data suggest that a suppository is better inserted with the base foremost. Reversed vermicular contractions or pressure gradient of the anal canal might press it inwards.	AIN SHAMS UNIV HOSP,CAIRO,EGYPT	Egyptian Knowledge Bank (EKB); Ain Shams University								ANSET HC, 1981, INTRO PHARMACEUTICAL, P328; Avouac B, 1988, J Clin Pharmacol, V28, pS2; BENNETT RC, 1964, BRIT J SURG, V51, P355, DOI 10.1002/bjs.1800510514; BENTLEY AO, 1936, TXB PHARMACEUTICS, P565; BERGSTROM BKV, 1988, J INT MED RES, V16, P376, DOI 10.1177/030006058801600507; CARTER SJ, 1975, DISPENSING PHARM STU, P232; COLLINS CD, 1967, GUT, V8, P354, DOI 10.1136/gut.8.4.354; DUTHIE HL, 1963, GUT, V4, P179, DOI 10.1136/gut.4.2.179; DUTHIE LH, 1965, GUT, V6, P64; GOLIGHER JC, 1980, SURGERY ANUS RECTUM, P1; HANCOCK BD, 1976, GUT, V17, P645, DOI 10.1136/gut.17.8.645; HILL J R, 1960, Dis Colon Rectum, V3, P203, DOI 10.1007/BF02616555; KAPOOR DA, 1989, J UROLOGY, V142, P1428, DOI 10.1016/S0022-5347(17)39117-6; KUROSAWA S, 1987, J INT MED RES, V15, P121, DOI 10.1177/030006058701500301; NEWRICK PG, 1990, LANCET, V335, P212, DOI 10.1016/0140-6736(90)90289-H; NISHIHATA T, 1989, J PHARM PHARMACOL, V41, P799, DOI 10.1111/j.2042-7158.1989.tb06372.x; ODIGIE EA, 1988, INT J GYNECOL OBSTET, V26, P57, DOI 10.1016/0020-7292(88)90196-8; SENIOR N, 1969, PHARM J, V203, P703; SHAFIK A, 1975, INVEST UROL, V12, P412; SONANDER H, 1985, BRIT J ANAESTH, V57, P578, DOI 10.1093/bja/57.6.578; WELLCOME HS, 1893, 41ST P ANN M AM PHAR, P103; 1979, PHARMACEUTICAL CODEX, P890	22	17	17	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 28	1991	338	8770					798	800		10.1016/0140-6736(91)90676-G	http://dx.doi.org/10.1016/0140-6736(91)90676-G			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GG979	1681170				2023-01-03	WOS:A1991GG97900014
J	WRENN, K; SLOVIS, CM; MURPHY, F; GREENBERG, RS				WRENN, K; SLOVIS, CM; MURPHY, F; GREENBERG, RS			AMINOPHYLLINE THERAPY FOR ACUTE BRONCHOSPASTIC DISEASE IN THE EMERGENCY ROOM	ANNALS OF INTERNAL MEDICINE			English	Article							INTRAVENOUSLY ADMINISTERED AMINOPHYLLINE; OBSTRUCTIVE PULMONARY-DISEASE; SERUM THEOPHYLLINE LEVELS; BETA-ADRENERGIC AGONIST; ACUTE ASTHMA; BRONCHODILATOR THERAPY; ORAL THEOPHYLLINE; FATAL ASTHMA; HISTAMINE; BRONCHOCONSTRICTION	Objective: To assess the role of aminophylline in the treatment of acute exacerbations of bronchospastic disease when used in addition to inhaled beta-agonists and intravenous corticosteroids. Design: Randomized, double-blind, placebo-controlled intervention study. Patients: One hundred thirty-three adult patients with either asthma or chronic obstructive pulmonary disease who presented to the emergency department with asthma or wheezing. Interventions: All patients received therapy with both aerosolized metaproterenol and intravenous methylprednisolone. Patients were randomly assigned to receive either a loading dose of aminophylline followed by a routine infusion (n = 65) or an equal volume of placebo as a loading dose and infusion (n = 68). Measurements and Main Results: At discharge from the emergency department, the median serum theophylline concentration for the aminophylline group was 54-mu-mol/L (9.7 mg/L). The two groups showed no differences (P > 0.2) in measurements of forced expiratory volume at 1 second (FEV1), forced vital capacity (FVC), or peak expiratory flow rate (PEFR) at baseline or at 60 or 120 minutes after aminophylline administration. Neither patient satisfaction nor physician assessment of response to therapy differed between the two groups. There was no difference (P > 0.2) in the frequency of side effects, except for a trend toward a higher frequency of nausea (P = 0.13) in the aminophylline group. There was, however, a threefold decrease in the hospital admission rate for patients treated with aminophylline (6%) compared with placebo recipients (21%) (P = 0.016). Conclusion: Aminophylline, in doses producing levels just below the commonly accepted therapeutic range, appears to decrease hospital admissions in patients with acute exacerbation of asthma or chronic obstructive pulmonary disease. This finding, if confirmed in larger studies, may represent a substantial cost savings.	EMORY UNIV, SCH MED, ATLANTA, GA 30322 USA; EMORY UNIV, SCH PUBL HLTH, ATLANTA, GA 30322 USA	Emory University; Emory University	WRENN, K (corresponding author), UNIV ROCHESTER, MED CTR, DEPT EMERGENCY, BOX 655, 601 ELMWOOD AVE, ROCHESTER, NY 14642 USA.		Wrenn, Keith/AAI-7651-2020					AHRENS RC, 1987, CHEST, V92, pS15; AUBIER M, 1981, NEW ENGL J MED, V305, P249, DOI 10.1056/NEJM198107303050503; BARKER AF, 1989, WESTERN J MED, V150, P303; BENATAR SR, 1986, NEW ENGL J MED, V314, P423, DOI 10.1056/NEJM198602133140706; BILLING B, 1987, EUR J RESPIR DIS, V70, P35; BRADY HR, 1989, ARCH INTERN MED, V149, P2367, DOI 10.1001/archinte.149.10.2367; CARTIER A, 1986, J ALLERGY CLIN IMMUN, V77, P570, DOI 10.1016/0091-6749(86)90347-7; COLEMAN JJ, 1986, CHEST, V90, P45, DOI 10.1378/chest.90.1.45; DOWELL AR, 1965, NEW ENGL J MED, V273, P1447, DOI 10.1056/NEJM196512302732702; FANTA CH, 1986, AM J MED, V80, P5, DOI 10.1016/0002-9343(86)90041-0; FLETCHER RH, 1988, CLIN EPIDEMIOLOGY ES, P172; GLANTZ SA, 1987, PRIMER BIOSTATISTICS, P88; GUYATT GH, 1988, ARCH INTERN MED, V148, P1949, DOI 10.1001/archinte.148.9.1949; HILL NS, 1988, ARCH INTERN MED, V148, P2579, DOI 10.1001/archinte.148.12.2579; IRAVANI J, 1975, RESPIRATION, V32, P157, DOI 10.1159/000193645; JENNE JW, 1987, CHEST, V92, pS7, DOI 10.1378/chest.92.1.7S; KLEIN JJ, 1983, AM REV RESPIR DIS, V127, P413, DOI 10.1164/arrd.1983.127.4.413; KOETER GH, 1984, RESPIRATION, V45, P139, DOI 10.1159/000194610; LITTENBERG B, 1988, JAMA-J AM MED ASSOC, V259, P1678, DOI 10.1001/jama.259.11.1678; LITTENBERG B, 1986, NEW ENGL J MED, V314, P150, DOI 10.1056/NEJM198601163140304; LUNELL E, 1984, EUR J RESPIR DIS, V65, P28; MATTHAY RA, 1978, AM J MED, V65, P903, DOI 10.1016/0002-9343(78)90741-6; MCWILLIAMS BC, 1986, AM REV RESPIR DIS, V133, P744; MCWILLIAMS BC, 1984, AM REV RESPIR DIS, V130, P193; MITENKO PA, 1973, NEW ENGL J MED, V289, P600, DOI 10.1056/NEJM197309202891202; MURCIANO D, 1989, NEW ENGL J MED, V320, P1521, DOI 10.1056/NEJM198906083202304; NASSIF EG, 1981, NEW ENGL J MED, V304, P71, DOI 10.1056/NEJM198101083040202; PASSAMONTE PM, 1984, CHEST, V85, P610, DOI 10.1378/chest.85.5.610; PAUWELS R, 1985, J ALLERGY CLIN IMMUN, V76, P583, DOI 10.1016/0091-6749(85)90779-1; POLSON JB, 1978, CLIN EXP PHARMACOL P, V5, P535; REBUCK AS, 1987, CAN MED ASSOC J, V136, P483; ROBERTSON C, 1985, CHEST, V87, pS64; ROSSING TH, 1989, ANN INTERN MED, V110, P502, DOI 10.7326/0003-4819-110-7-502; ROSSING TH, 1980, AM REV RESPIR DIS, V122, P365; SIEGEL D, 1985, AM REV RESPIR DIS, V132, P283; SMITH SR, 1986, BRIT J CLIN PHARMACO, V21, P451, DOI 10.1111/j.1365-2125.1986.tb05221.x; SUMMER WR, 1985, CHEST, V87, pS87; TAGER I, 1975, NEW ENGL J MED, V292, P563, DOI 10.1056/NEJM197503132921105; TURNERWARWICK M, 1957, BRIT MED J, V2, P67, DOI 10.1136/bmj.2.5036.67; VOZEH S, 1982, AM REV RESPIR DIS, V125, P181; WEISS KB, 1990, JAMA-J AM MED ASSOC, V263, P2323; WEISSERT WG, 1986, J HEALTH POLIT POLIC, V11, P463, DOI 10.1215/03616878-11-3-463; WELSH MJ, 1980, J APPL PHYSIOL, V49, P905, DOI 10.1152/jappl.1980.49.5.905; WILSON JD, 1981, LANCET, V1, P1235; WOLFE JD, 1978, NEW ENGL J MED, V298, P363, DOI 10.1056/NEJM197802162980703	45	101	103	0	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 15	1991	115	4					241	247		10.7326/0003-4819-115-4-241	http://dx.doi.org/10.7326/0003-4819-115-4-241			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GA764	1854108				2023-01-03	WOS:A1991GA76400001
J	STEVENSON, FK				STEVENSON, FK			TUMOR VACCINES	FASEB JOURNAL			English	Review						TUMOR; VACCINE; IMMUNOTHERAPY; IDIOTYPE; DORMANCY	ANTI-IDIOTYPIC ANTIBODIES; B-CELL LYMPHOMA; INTERNAL IMAGE; INFILTRATING LYMPHOCYTES; ADOPTIVE IMMUNOTHERAPY; KILLER CELLS; CANCER; TARGET; VIRUS; VACCINATION	Vaccination against tumor, either as a prophylactic procedure or as a mode of treatment, has been a distant goal of immunologists for many years. Ideally, the less specific therapies such as chemotherapy would be replaced by an anti-tumor immune response in the host that would be present on a continuing basis.. However, progress has been hampered by a lack of understanding of the role of viruses in human tumor development and the molecular nature of tumor-associated antigens. Recent developments using the techniques of molecular biology and monoclonal antibody reagents are beginning to remedy this deficiency so that vaccination has become a real possibility for certain human cancers. The natural fluctuations in growth rates of some human tumors, and the observation that tumors can occasionally remain dormant for years, has led to the idea that the host has an intrinsic ability to control tumor growth, and that this ability is a property of the immune system. Attempts to enhance this putative control are being made by treating the host with defined biological modifiers that stimulate cells involved in immunity in vivo, and by seeking and expanding such cells in vitro before reinfusing them into the host. These attempts to harness the immune system to attack tumor cells that have evaded the host's defenses might be considered optimistic, but they will at least tell us a great deal about tumor cell behavior and the ability of the host to influence it.			STEVENSON, FK (corresponding author), SOUTHAMPTON GEN HOSP, TENOVUS LAB, LYMPHOMA RES UNIT, HOST IMMUN TUMOR GRP, SOUTHAMPTON SO9 4XY, HANTS, ENGLAND.			Stevenson, Freda/0000-0002-0933-5021				BERENDT MJ, 1980, J EXP MED, V151, P69, DOI 10.1084/jem.151.1.69; BERNARDS R, 1987, P NATL ACAD SCI USA, V84, P6854, DOI 10.1073/pnas.84.19.6854; BISHOP JM, 1987, SCIENCE, V235, P305, DOI 10.1126/science.3541204; BLUMBERG BS, 1985, JNCI-J NATL CANCER I, V74, P267; BYSTRYN JC, 1988, CANCER, V61, P1065, DOI 10.1002/1097-0142(19880315)61:6<1065::AID-CNCR2820610602>3.0.CO;2-L; CHURCHILL AE, 1969, NATURE, V221, P744, DOI 10.1038/221744a0; DALGLEISH AG, 1988, VACCINE, V6, P215, DOI 10.1016/0264-410X(88)90213-7; DYKE RJ, IN PRESS CELL IMMUNO; EHRLICH P, 1957, IMMUNOLOGY CANCER RE, P550; ESTIN CD, 1988, P NATL ACAD SCI USA, V85, P1052, DOI 10.1073/pnas.85.4.1052; George A J, 1989, Int Rev Immunol, V4, P271, DOI 10.3109/08830188909044783; GEORGE AJT, 1988, J IMMUNOL, V141, P2168; GULLICK WJ, 1990, INT J CANCER, P55; HEARING VJ, 1986, J IMMUNOL, V137, P379; HELLSTROM KE, 1989, FASEB J, V3, P1715, DOI 10.1096/fasebj.3.6.2649402; HERLYN D, 1986, SCIENCE, V232, P100, DOI 10.1126/science.3952496; HIRAI H, 1975, ANN NY ACAD SCI, V259, P5, DOI 10.1111/j.1749-6632.1975.tb25396.x; HOOVER HC, 1985, CANCER, V55, P1236, DOI 10.1002/1097-0142(19850315)55:6<1236::AID-CNCR2820550616>3.0.CO;2-#; HUI K, 1984, NATURE, V311, P750, DOI 10.1038/311750a0; JERNE NK, 1974, ANN INST PASTEUR IMM, VC125, P373; KAMINSKI MS, 1987, J IMMUNOL, V138, P1289; LAMM DL, 1989, J UROLOGY, V141, pA249; LENNOX ES, 1981, TRANSPLANT P, V13, P1759; LYNCH RG, 1979, IMMUNOL REV, V48, P45, DOI 10.1111/j.1600-065X.1979.tb00298.x; MEEKER T, 1985, NEW ENGL J MED, V312, P1658, DOI 10.1056/NEJM198506273122602; NISONOFF A, 1981, CLIN IMMUNOL IMMUNOP, V21, P397, DOI 10.1016/0090-1229(81)90228-2; OJO E, 1978, SCAND J IMMUNOL, V7, P297, DOI 10.1111/j.1365-3083.1978.tb00457.x; OLD LJ, 1964, ANNU REV MED, V15, P167, DOI 10.1146/annurev.me.15.020164.001123; OSTERHAUS A, 1985, J IMMUNOL, V135, P591; PARHAM P, 1989, IMMUNOL TODAY, V10, P206, DOI 10.1016/0167-5699(89)90326-5; RAYCHAUDHURI S, 1986, J IMMUNOL, V137, P1743; ROSENBERG SA, 1985, NEW ENGL J MED, V313, P1485, DOI 10.1056/NEJM198512053132327; ROSENBERG SA, 1986, SCIENCE, V233, P1318, DOI 10.1126/science.3489291; ROSENSTEIN M, 1984, J IMMUNOL, V132, P2117; SMITH MEF, 1988, LANCET, V1, P823; SPRINGER GF, 1976, CANCER, V37, P169, DOI 10.1002/1097-0142(197601)37:1<169::AID-CNCR2820370124>3.0.CO;2-#; STEVENSON FK, 1990, CHEM IMMUNOL, V48, P126; STEVENSON GT, 1985, CANCER SURV, V4, P213; STORKUS WJ, 1987, J IMMUNOL, V138, P1657; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; ULLRICH SJ, 1986, P NATL ACAD SCI USA, V83, P3121, DOI 10.1073/pnas.83.10.3121; VOSE BM, 1985, SEMIN HEMATOL, V22, P27; WHEELOCK EF, 1983, LAB INVEST, V48, P120; ZIEGLER JL, 1982, LANCET, V2, P631	44	23	32	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	1991	5	9					2250	2257		10.1096/fasebj.5.9.1860616	http://dx.doi.org/10.1096/fasebj.5.9.1860616			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	FP872	1860616				2023-01-03	WOS:A1991FP87200005
J	CLINTON, JJ				CLINTON, JJ			PHYSICIAN INPUT INVITED ON CLINICAL GUIDELINE DEVELOPMENT	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									AGCY HLTH CARE POLICY & RES,ROCKVILLE,MD 20857	Agency for Healthcare Research & Quality								1990, FED REG         1210, P55	1	5	5	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 27	1991	265	12					1508	1508		10.1001/jama.265.12.1508	http://dx.doi.org/10.1001/jama.265.12.1508			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FC604	1999893				2023-01-03	WOS:A1991FC60400005
J	STREET, P; GANNON, MJ; HOLT, EM				STREET, P; GANNON, MJ; HOLT, EM			COMMUNITY OBSTETRIC CARE IN WEST BERKSHIRE	BRITISH MEDICAL JOURNAL			English	Article							GENERAL-PRACTITIONER OBSTETRICS; PAPER	Objective-To assess the effects of a revised obstetric booking policy whereby all low risk pregnant women received their antenatal care entirely in the community. Design-Comparison of the distribution of antenatal clinic attendances, transfers, and perinatal mortality rates for 1987 and 1989, before and after introduction of the revised policy. Setting-West Berkshire Health District. Subjects-All women who delivered with a registrable birth in the district in 1987 (5817 women) and 1989 (5372). Main outcome measures-Attendances at community and consultant antenatal clinics; bookings transferred from community care to consultant care; perinatal mortality rates. Results-Of 5372 women delivering in West Berkshire in 1989, 3185 (58.3%) were originally booked for general practitioner-midwife care, of whom 1567 (49.2% of general practitioner-midwife bookings) were transferred to consultant care. 1618 women (30.1% of all women delivered) received their entire obstetric care from general practitioners and midwives. Attendance at hospital antenatal clinics was reduced by 16%. In 1989 the perinatal mortality rates (1987 values) for the district were 6.3 (7.6) per 1000 births overall; 8.2 (8.3) per 1000 consultant bookings; 5.0 (4.7) per 1000 for community bookings; and 10.2 (14.4) per 1000 for women transferred to consultant care. Conclusion-Antenatal care of low risk pregnant women may safely be provided by their general practitioner and midwife.			STREET, P (corresponding author), ROYAL BERKSHIRE HOSP,DEPT OBSTET & GYNAECOL,READING RG1 5AN,BERKS,ENGLAND.							BRUDENELL JM, 1983, J ROY SOC MED, V76, P197, DOI 10.1177/014107688307600309; BRYCE FC, 1990, BRIT MED J, V300, P725, DOI 10.1136/bmj.300.6726.725; BULL M, 1989, PRACTITIONER, V233, P211; CHAMBERLAIN G, 1989, BRIT MED J, V298, P1702, DOI 10.1136/bmj.298.6689.1702; DRIFE JO, 1988, BRIT MED J, V297, P1208; LOUDON I, 1990, BRIT MED J, V301, P703, DOI 10.1136/bmj.301.6754.703; MARSH GN, 1985, BRIT MED J, V290, P901, DOI 10.1136/bmj.290.6472.901; REYNOLDS JL, 1988, J ROY COLL GEN PRACT, V38, P307; SANGALA V, 1990, BRIT MED J, V301, P418, DOI 10.1136/bmj.301.6749.418; TAYLOR A, 1986, J ROY COLL GEN PRACT, V36, P157; TAYLOR GW, 1980, LANCET, V2, P1287; 1990, WOMENS HLTH CHARTER	12	17	17	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 23	1991	302	6778					698	700		10.1136/bmj.302.6778.698	http://dx.doi.org/10.1136/bmj.302.6778.698			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FE333	1878023	Green Published, Bronze			2023-01-03	WOS:A1991FE33300026
J	ROBINSON, GE; BURREN, T; MACKIE, IJ; BOUNDS, W; WALSHE, K; FAINT, R; GUILLEBAUD, J; MACHIN, SJ				ROBINSON, GE; BURREN, T; MACKIE, IJ; BOUNDS, W; WALSHE, K; FAINT, R; GUILLEBAUD, J; MACHIN, SJ			CHANGES IN HEMOSTASIS AFTER STOPPING THE COMBINED CONTRACEPTIVE PILL - IMPLICATIONS FOR MAJOR SURGERY	BRITISH MEDICAL JOURNAL			English	Article							ORAL-CONTRACEPTIVES; COAGULATION; THROMBOSIS; DISEASE	Objective-To investigate the changes in haemostasis in the three months immediately after stopping the combined contraceptive pill. Design-Prospective randomised study. Setting-Family planning centre in London. Subjects-24 women aged 35-45 investigated before, during, and after six months' use of combined oral contraceptives containing 30-mu-g ethinyl oestradiol together with the progestogens desogestrel or gestodene. Main outcome measures and results-Blood samples were taken immediately before and after six months of oral contraceptive use and one, two, four, six, eight, and 12 weeks after the pill had been stopped. During the six months of oral contraceptive use the plasma concentration of factor X and fibrinogen increased and that of antithrombin III decreased. Between two and six weeks after stopping the pill a rebound phenomenon occurred with plasma concentrations of antithrombin III increasing (mean change from baseline at two weeks 0.06 IU/l and at six weeks 0.10 IU/l) and fibrinogen decreasing (0.26 g/l change at two weeks and 0.40 g/l at six weeks). Factor X concentrations fell gradually and the values at eight weeks were not significantly different from those found before the combined pill was started. Conclusion-The combined pill should be stopped at least four weeks before major surgery, which carries the risk of postoperative thrombosis, to allow the potentially prothrombotic haemostatic changes that occur during its use to be corrected.	MARGARET PYKE CTR STUDY & TRAINING FAMILY PLANNING,15 BATEMANS BLDG,SOHO SQ,LONDON W1V 5TW,ENGLAND; UNIV COLL & MIDDLESEX SCH MED,DEPT HAEMATOL,LONDON W1,ENGLAND	University of London; University College London			MACKIE, Ian J/C-1587-2008					BONNAR J, 1987, AM J OBSTET GYNECOL, V157, P1042, DOI 10.1016/S0002-9378(87)80129-1; BOTTIGER LE, 1980, LANCET, V1, P1097; COHEN H, 1988, BRIT J HAEMATOL, V69, P259, DOI 10.1111/j.1365-2141.1988.tb07631.x; GALLUS AS, 1984, THROMB RES, V35, P513, DOI 10.1016/0049-3848(84)90283-4; GIDDINGS JC, 1980, BLOOD COAGULATION HA, P138; GUILLEBAUD J, 1988, BRIT MED J, V296, P786, DOI 10.1136/bmj.296.6624.786-a; GUILLEBAUD J, 1985, BRIT MED J, V291, P498, DOI 10.1136/bmj.291.6494.498; HAWKINS DF, 1979, HUMAN FERTILITY CONT; KOCH GG, 1980, INT STAT REV, V48, P249, DOI 10.2307/1402940; MACHIN SJ, 1989, LABORATORY HAEMATOLO, P263; MAMMEN EF, 1982, AM J OBSTET GYNECOL, V142, P781; Mancini G, 1965, Immunochemistry, V2, P235, DOI 10.1016/0019-2791(65)90004-2; REALINI JP, 1985, AM J OBSTET GYNECOL, V152, P729, DOI 10.1016/S0002-9378(85)80001-6; SAGAR S, 1976, LANCET, V1, P509; SUELING H, 1988, BRIT MED J, V296, P447, DOI 10.1136/bmj.296.6620.447; VESSEY M, 1986, BRIT MED J, V292, P526, DOI 10.1136/bmj.292.6519.526; VONCLAUSS A, 1957, ACTA HAEMAT, V17, P237; 1989, OUTLOOK, V7, P10	18	49	51	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 2	1991	302	6771					269	271		10.1136/bmj.302.6771.269	http://dx.doi.org/10.1136/bmj.302.6771.269			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EX919	1998792	Green Published, Bronze			2023-01-03	WOS:A1991EX91900020
J	CONFORTI, G; ZANETTI, A; PASQUALIRONCHETTI, I; QUAGLINO, D; NEYROZ, P; DEJANA, E				CONFORTI, G; ZANETTI, A; PASQUALIRONCHETTI, I; QUAGLINO, D; NEYROZ, P; DEJANA, E			MODULATION OF VITRONECTIN RECEPTOR-BINDING BY MEMBRANE LIPID-COMPOSITION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article									UNIV MODENA,IST PATOL GEN,I-41100 MODENA,ITALY; UNIV PARMA,IST CHIM BIOL,I-43100 PARMA,ITALY	Universita di Modena e Reggio Emilia; University of Parma	CONFORTI, G (corresponding author), MARIO NEGRI INST PHARMACOL RES,I-20157 MILAN,ITALY.		Quaglino, Daniela/A-9381-2010	Quaglino, Daniela/0000-0002-4302-5078; adriana, zanetti/0000-0002-5825-9707; NEYROZ, PAOLO/0000-0002-9790-4027; DEJANA, ELISABETTA/0000-0002-0007-0426				ALBELDA SM, 1989, J CLIN INVEST, V83, P1992, DOI 10.1172/JCI114109; ALOJ SM, 1982, HORMONE RECEPTORS, P83; ASCH AS, 1987, J CLIN INVEST, V79, P1054, DOI 10.1172/JCI112918; AZUMI T, 1962, J CHEM PHYS, V37, P2413, DOI 10.1063/1.1733019; BERLINER S, 1988, J BIOL CHEM, V263, P7500; CHARO IF, 1987, J BIOL CHEM, V262, P9935; CHERESH DA, 1989, CELL, V57, P59, DOI 10.1016/0092-8674(89)90172-4; CHERESH DA, 1987, P NATL ACAD SCI USA, V84, P6471, DOI 10.1073/pnas.84.18.6471; CHERESH DA, 1987, J BIOL CHEM, V262, P17703; COLLER BS, 1983, J CLIN INVEST, V72, P325, DOI 10.1172/JCI110973; CONFORTI G, 1989, BLOOD, V73, P1576; DEJANA E, 1989, J CELL BIOL, V109, P367, DOI 10.1083/jcb.109.1.367; DEJANA E, 1988, BLOOD, V71, P566; DEJANA E, 1987, J CELL BIOL, V104, P1403, DOI 10.1083/jcb.104.5.1403; DEJANA E, 1988, J CELL BIOL, V107, P1215, DOI 10.1083/jcb.107.3.1215; DEJANA E, 1990, IN PRESS BLOOD; DEMARCO L, 1981, J CLIN INVEST, V68, P321, DOI 10.1172/JCI110259; FITZGERALD LA, 1987, J BIOL CHEM, V262, P3936; GAILIT J, 1988, J BIOL CHEM, V263, P12927; GALVIN JB, 1987, J BIOL CHEM, V262, P2199; GINSBERG MH, 1987, J BIOL CHEM, V262, P5437; GINSBERG MH, 1986, J CLIN INVEST, V78, P1103, DOI 10.1172/JCI112667; HEMLER ME, 1987, J BIOL CHEM, V262, P3300; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; KAJIJI S, 1989, EMBO J, V8, P673, DOI 10.1002/j.1460-2075.1989.tb03425.x; KANTOR RRS, 1987, J BIOL CHEM, V262, P15158; LAWLER J, 1988, J CELL BIOL, V107, P2351, DOI 10.1083/jcb.107.6.2351; MARGUERIE GA, 1982, J BIOL CHEM, V257, P1872; MIMMS LT, 1981, BIOCHEMISTRY-US, V20, P833, DOI 10.1021/bi00507a028; MULLER WA, 1983, METHOD ENZYMOL, V98, P404; MURPHYULLRICH JE, 1985, BLOOD, V66, P1098; MURPHYULLRICH JE, 1987, J CELL BIOL, V105, P1603, DOI 10.1083/jcb.105.4.1603; PARISE LV, 1985, J BIOL CHEM, V260, P1750; PARISE LV, 1987, J BIOL CHEM, V262, P12597; PISCHEL KD, 1987, J IMMUNOL, V138, P226; POLACK B, 1989, BLOOD, V73, P1519; PREISSNER KT, 1985, BIOCHEM J, V231, P349, DOI 10.1042/bj2310349; PYTELA R, 1985, P NATL ACAD SCI USA, V82, P5766, DOI 10.1073/pnas.82.17.5766; PYTELA R, 1987, METHOD ENZYMOL, V144, P475; PYTELA R, 1986, SCIENCE, V231, P1559, DOI 10.1126/science.2420006; PYTELA R, 1985, CELL, V40, P91; RUOSLAHTI E, 1986, CELL, V44, P517, DOI 10.1016/0092-8674(86)90259-X; RUOSLAHTI E, 1988, ANNU REV BIOCHEM, V57, P375, DOI 10.1146/annurev.bi.57.070188.002111; SAKARIASSEN KS, 1979, NATURE, V279, P636, DOI 10.1038/279636a0; SMITH JW, 1988, J CELL BIOL, V106, P153; SUZUKI S, 1987, J BIOL CHEM, V262, P14080; WAGNER DD, 1983, J BIOL CHEM, V258, P2065; WAYNER EA, 1987, J CELL BIOL, V105, P1873, DOI 10.1083/jcb.105.4.1873	48	180	181	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1990	265	7					4011	4019						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	CQ480	1689312				2023-01-03	WOS:A1990CQ48000067
J	CANELLOS, GP; ANDERSON, JR; PROPERT, KJ; NISSEN, N; COOPER, MR; HENDERSON, ES; GREEN, MR; GOTTLIEB, A; PETERSON, BA				CANELLOS, GP; ANDERSON, JR; PROPERT, KJ; NISSEN, N; COOPER, MR; HENDERSON, ES; GREEN, MR; GOTTLIEB, A; PETERSON, BA			CHEMOTHERAPY OF ADVANCED HODGKINS-DISEASE WITH MOPP, ABVD, OR MOPP ALTERNATING WITH ABVD	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							TERM FOLLOW-UP; COMBINATION CHEMOTHERAPY; PROGNOSTIC FACTORS; DACARBAZINE ABVD; BLEOMYCIN; VINBLASTINE; SURVIVAL; ADRIAMYCIN; TOXICITY; THERAPY	Background and Methods. MOPP (mechlorethamine, vincristine, procarbazine, and prednisone) has been the standard treatment for Hodgkin's disease for almost 20 years. In a randomized, multicenter trial, we compared three regimens of primary systemic therapy for newly diagnosed advanced Hodgkin's disease in Stages IIIA2, IIIB, and IVA or IVB: (1) MOPP alone given for 6 to 8 cycles, (2) MOPP alternating with ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) for 12 cycles, and (3) ABVD alone for 6 to 8 cycles. Patients in a first relapse after radiation therapy were eligible. No additional radiation therapy was given. Patients who did not have a complete response or who had a relapse with either MOPP alone or ABVD alone were switched to the opposite regimen. Results. Of 361 eligible patients, 123 received MOPP, 123 received MOPP alternating with ABVD, and 115 received ABVD alone. The patients were stratified according to age, stage, previous radiation, histologic features, and performance status. The overall response rate was 93 percent, with complete responses in 77 percent: 67 percent in the MOPP group, 82 percent in the ABVD group, and 83 percent in the MOPP-ABVD group (P = 0.006 for the comparison of MOPP with the other two regimens, both of which contained doxorubicin). The rates of failure-free survival at five years were 50 percent for MOPP, 61 percent for ABVD, and 65 percent for MOPP-ABVD. Age, stage (III vs. IV), and regimen influenced failure-free survival significantly. Overall survival at five years was 66 percent for MOPP, 73 percent for ABVD, and 75 percent for MOPP-ABVD (P = 0.28 for the comparison of MOPP with the doxorubicin regimens). MOPP had more severe toxic effects on bone marrow than ABVD and was associated with greater reductions in the prescribed dose. Conclusions. In this trial, ABVD therapy for 6 to 8 months was as effective as 12 months of MOPP alternating with ABVD, and both were superior to MOPP alone in the treatment of advanced Hodgkin's disease. ABVD was less myelotoxic than MOPP or ABVD alternating with MOPP.	SUNY HLTH SCI CTR,DEPT MED,SYRACUSE,NY; UNIV MINNESOTA,DEPT MED,MINNEAPOLIS,MN 55455; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115; UNIV NEBRASKA,MED CTR,OMAHA,NE 68105; HARVARD UNIV,SCH PUBL HLTH,DEPT BIOSTAT,BOSTON,MA 02115; RIGSHOSP,DEPT HEMATOL,DK-2100 COPENHAGEN,DENMARK; WAKE FOREST UNIV,BOWMAN GRAY SCH MED,DEPT MED,WINSTON SALEM,NC 27103; US FDA,ROCKVILLE,MD 20857; UNIV CALIF SAN DIEGO,DEPT MED,LA JOLLA,CA 92093	State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center; University of Minnesota System; University of Minnesota Twin Cities; Harvard University; Harvard Medical School; University of Nebraska System; University of Nebraska Medical Center; Harvard University; Harvard T.H. Chan School of Public Health; Rigshospitalet; University of Copenhagen; Wake Forest University; Wake Forest Baptist Medical Center; US Food & Drug Administration (FDA); University of California System; University of California San Diego	CANELLOS, GP (corresponding author), HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV MED ONCOL,44 BINNEY ST,BOSTON,MA 02115, USA.				NATIONAL CANCER INSTITUTE [U10CA031946] Funding Source: NIH RePORTER; NCI NIH HHS [CA 31946] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAKEMEIER RF, 1984, ANN INTERN MED, V101, P447, DOI 10.7326/0003-4819-101-4-447; BONADONNA G, 1986, ANN INTERN MED, V104, P739, DOI 10.7326/0003-4819-104-6-739; BONADONNA G, 1975, CANCER, V36, P252, DOI 10.1002/1097-0142(197507)36:1<252::AID-CNCR2820360128>3.0.CO;2-7; BURGERS JMV, 1991, ANN ONCOL, V2, P63, DOI 10.1093/annonc/2.suppl_2.63; CARDE P, 1983, J CLIN ONCOL, V1, P146, DOI 10.1200/JCO.1983.1.2.146; DEVITA VT, 1970, ANN INTERN MED, V73, P881, DOI 10.7326/0003-4819-73-6-881; FLEISS JL, 1973, STATISTICAL METHODS; GLICK J, 1991, P AN M AM SOC CLIN, V10, P271; HARKER WG, 1984, ANN INTERN MED, V101, P440, DOI 10.7326/0003-4819-101-4-440; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KLIMO P, 1985, J CLIN ONCOL, V3, P1174, DOI 10.1200/JCO.1985.3.9.1174; LISTER TA, 1989, J CLIN ONCOL, V7, P1630, DOI 10.1200/JCO.1989.7.11.1630; Lister TA, 1990, J CLIN ONCOL, V8, P1602; LONGO DL, 1986, J CLIN ONCOL, V4, P1295, DOI 10.1200/JCO.1986.4.9.1295; PAPA G, 1982, EUR J CANCER CLIN ON, V18, P803, DOI 10.1016/0277-5379(82)90188-2; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; PIGA A, 1984, CANCER TREAT REP, V68, P947; PILLAI GN, 1985, CANCER, V55, P691, DOI 10.1002/1097-0142(19850215)55:4<691::AID-CNCR2820550403>3.0.CO;2-Q; SANTORO A, 1987, J CLIN ONCOL, V5, P27, DOI 10.1200/JCO.1987.5.1.27; SCHILSKY RL, 1981, AM J MED, V71, P552, DOI 10.1016/0002-9343(81)90205-9; SELBY P, 1990, BRIT J CANCER, V62, P279, DOI 10.1038/bjc.1990.278; STRAUS DJ, 1990, J CLIN ONCOL, V8, P1173, DOI 10.1200/JCO.1990.8.7.1173; SUTCLIFFE SB, 1979, CANCER CHEMOTH PHARM, V2, P209; TUCKER MA, 1988, NEW ENGL J MED, V318, P76, DOI 10.1056/NEJM198801143180203; VALAGUSSA P, 1986, J CLIN ONCOL, V4, P830, DOI 10.1200/JCO.1986.4.6.830; VANRIJSWIJK REN, 1989, J CLIN ONCOL, V7, P1776, DOI 10.1200/JCO.1989.7.12.1776; VIVIANI S, 1985, EUR J CANCER CLIN ON, V21, P601, DOI 10.1016/0277-5379(85)90088-4; WAGSTAFF J, 1988, BRIT J CANCER, V58, P487, DOI 10.1038/bjc.1988.246; WAXMAN JHX, 1982, BRIT MED J, V285, P1612, DOI 10.1136/bmj.285.6355.1612	29	810	832	1	7	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 19	1992	327	21					1478	1484		10.1056/NEJM199211193272102	http://dx.doi.org/10.1056/NEJM199211193272102			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JY165	1383821				2023-01-03	WOS:A1992JY16500002
J	BAIRD, EA; MCHENRY, PM; MACKIE, RM				BAIRD, EA; MCHENRY, PM; MACKIE, RM			EFFECT OF MAINTENANCE CHEMOTHERAPY IN CHILDHOOD ON NUMBERS OF MELANOCYTIC NEVI	BRITISH MEDICAL JOURNAL			English	Article							MALIGNANT-MELANOMA; RISK-FACTOR; NEVI	Objective-(a) To determine whether children given chemotherapy for haematological malignancy have significantly more melanocytic naevi than age matched children in the local population; (b) to establish whether any observed variation in naevus counts from normal is seen at the start of maintenance chemotherapy. Design-Follow up of 29 consecutive children starting maintenance chemotherapy, with parental interview and count of all melanocytic naevi greater-than-or-equal-to 2 mm on the child's skin. Assessment repeated three years later after completion of maintenance chemotherapy. Other dermatological problems identified at either visit were also recorded. Setting-Royal Hospital for Sick Children, Glasgow. Results-At the start of maintenance chemotherapy all children had total body counts of melanocytic naevi within the normal range established for age matched children in the local population. Three years later total body naevus counts were significantly increased, the median increase being 66 naevi per child (95% confidence interval 57 to 94). The only other problem noted in these children was relatively poor regrowth of scalp hair. Conclusion-Children on maintenance chemotherapy for haematological malignancies develop an excessive number of melanocytic naevi. Excessive numbers of melanocytic naevi are the most important risk factor for melanoma in the general population. These children should have periodic skin examinations at their follow up visits, and both child and parent should be educated about clinical features of early melanoma.	UNIV GLASGOW,ROYAL HOSP SICK CHILDREN,DEPT DERMATOL,GLASGOW G12 8QQ,SCOTLAND	University of Glasgow								DEWIT PEJ, 1990, MED PEDIATR ONCOL, V18, P336, DOI 10.1002/mpo.2950180417; GALLAGHER RP, 1990, ARCH DERMATOL, V126, P770, DOI 10.1001/archderm.126.6.770; HOLLY EA, 1987, J AM ACAD DERMATOL, V17, P459, DOI 10.1016/S0190-9622(87)70230-8; HUGHES BR, 1989, BMJ-BRIT MED J, V299, P88, DOI 10.1136/bmj.299.6691.88; MACKIE RM, 1985, BRIT J DERMATOL, V113, P167, DOI 10.1111/j.1365-2133.1985.tb02060.x; MACKIE RM, 1989, LANCET, V2, P487; OSTERLIND A, 1988, INT J CANCER, V42, P200, DOI 10.1002/ijc.2910420210; SWERDLOW AJ, 1986, BRIT MED J, V292, P1555, DOI 10.1136/bmj.292.6535.1555	8	39	39	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 3	1992	305	6857					799	801		10.1136/bmj.305.6857.799	http://dx.doi.org/10.1136/bmj.305.6857.799			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JT256	1422359	Green Submitted, Green Published, Bronze			2023-01-03	WOS:A1992JT25600019
J	LASIC, DD				LASIC, DD			MIXED MICELLES IN DRUG DELIVERY	NATURE			English	Article							AMPHOTERICIN-B				LASIC, DD (corresponding author), LIPOSOME TECHNOL INC,1050 HAMILTON COURT,MENLO PK,CA 94025, USA.							BRODIN A, 1982, ACTA PHARM SUEC, V19, P267; CANTU L, 1990, EUROPHYS LETT, V13, P561, DOI 10.1209/0295-5075/13/6/015; FIELDING RM, 1991, ANTIMICROB AGENTS CH, V35, P1208, DOI 10.1128/AAC.35.6.1208; FIELDING RM, IN PRESS ANTIMICROB; GUENTERT TW, 1987, BRIT J CLIN PHARMACO, V23, P569, DOI 10.1111/j.1365-2125.1987.tb03093.x; GUO LSS, 1991, INT J PHARM, V75, P45, DOI 10.1016/0378-5173(91)90249-N; JANOFF AS, 1988, P NATL ACAD SCI USA, V85, P6122, DOI 10.1073/pnas.85.16.6122; LASIC DD, 1982, BIOCHIM BIOPHYS ACTA, V692, P501, DOI 10.1016/0005-2736(82)90404-7; LASIC DD, 1988, BIOCHEM J, V256, P1; LASIC DD, 1991, BIOCHIM BIOPHYS ACTA, V1070, P187, DOI 10.1016/0005-2736(91)90162-2; LASIC DD, 1991, PERIOD BIOL, V93, P287; LOPEZBERESTEIN G, 1985, J INFECT DIS, V151, P704, DOI 10.1093/infdis/151.4.704; PAPAHADJOPOULOS P, 1991, P NATL ACAD SCI USA, V88, P11460; Prescott L.F., 1989, NOVEL DRUG DELIVERY; YOKOYAMA M, 1990, CANCER RES, V50, P1693	15	151	165	2	26	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 16	1992	355	6357					279	280		10.1038/355279a0	http://dx.doi.org/10.1038/355279a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GZ694	1731228				2023-01-03	WOS:A1992GZ69400077
J	MURRAY, RH; RUBEL, AJ				MURRAY, RH; RUBEL, AJ			PHYSICIANS AND HEALERS - UNWITTING PARTNERS IN HEALTH-CARE	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							MEDICINE; CANCER; PRACTITIONERS; SURVIVAL; TRIAL		UNIV CALIF IRVINE,IRVINE,CA 92717	University of California System; University of California Irvine	MURRAY, RH (corresponding author), MICHIGAN STATE UNIV,E LANSING,MI 48824, USA.							CASSILETH BR, 1991, NEW ENGL J MED, V324, P1180, DOI 10.1056/NEJM199104253241706; CASSILETH BR, 1984, ANN INTERN MED, V101, P105, DOI 10.7326/0003-4819-101-1-105; CHLEBOWSKI RT, 1990, J CLIN ONCOL, V8, P9, DOI 10.1200/JCO.1990.8.1.9; COOK C, 1986, SOUTH MED J, V79, P1098, DOI 10.1097/00007611-198609000-00014; FISHER P, 1989, BRIT MED J, V299, P365, DOI 10.1136/bmj.299.6695.365; FULDER SJ, 1985, LANCET, V2, P542; GIBSON RG, 1980, BRIT J CLIN PHARMACO, V9, P453, DOI 10.1111/j.1365-2125.1980.tb05840.x; MADDOCKS I, 1985, MED J AUSTRALIA, V142, P547, DOI 10.5694/j.1326-5377.1985.tb113490.x; McGuire Meredith, 1988, RITUAL HEALING SUBUR; SHEKELLE PG, 1991, RAND R40252CCRFLER; SHIPLEY M, 1983, LANCET, V1, P97; SPIEGEL D, 1989, LANCET, V2, P888; WATT J, 1988, TALKING HLTH CONVENT; 1981, ALTERNATIVE MED NETH; 1986, ALTERNATIVE THERAPY; 1987, N Z MED J, V100, P110; 1986, AM MED NEWS     0411, P46; 1990, OTAH405 OFF TECHN AS; 1987, ENCY MED ORG AGENCIE, P93	19	104	105	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 2	1992	326	1					61	64		10.1056/NEJM199201023260113	http://dx.doi.org/10.1056/NEJM199201023260113			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GX315	1727068				2023-01-03	WOS:A1992GX31500013
J	BERSTEN, AD; HOLT, AW; VEDIG, AE; SKOWRONSKI, GA; BAGGOLEY, CJ				BERSTEN, AD; HOLT, AW; VEDIG, AE; SKOWRONSKI, GA; BAGGOLEY, CJ			TREATMENT OF SEVERE CARDIOGENIC PULMONARY-EDEMA WITH CONTINUOUS POSITIVE AIRWAY PRESSURE DELIVERED BY FACE MASK	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ACUTE RESPIRATORY-FAILURE; CONGESTIVE HEART-FAILURE; MYOCARDIAL-INFARCTION; FUROSEMIDE; PEEP	Background. Severe cardiogenic pulmonary edema is a frequent cause of respiratory failure, and many patients with this condition require endotracheal intubation and mechanical ventilation. We investigated whether continuous positive airway pressure delivered by means of a face mask had physiologic benefit and would reduce the need for intubation and mechanical ventilation. Methods. We randomly assigned 39 consecutive patients with respiratory failure due to severe cardiogenic pulmonary edema to receive either oxygen alone or oxygen plus continuous positive airway pressure delivered through a face mask. It was not possible to blind the investigators to the assigned treatment. Physiologic measurements were made over the subsequent 24 hours, and the patients were followed to hospital discharge. Results. After 30 minutes, both respiratory rate and arterial carbon dioxide tension had decreased more in the patients who received oxygen plus continuous positive airway pressure. The mean (+/- SD) respiratory rate at 30 minutes decreased from 32 +/- 6 to 33 +/- 9 breaths per minute in the patients receiving oxygen alone and from 35 +/- 8 to 27 +/- 6 breaths per minute in those receiving oxygen plus continuous positive airway pressure (P = 0.008); the arterial carbon dioxide tension decreased from 64 +/- 17 to 62 +/- 14 mm Hg in those receiving oxygen alone and from 58 +/- 8 to 46 +/- 4 mm Hg in those receiving oxygen plus continuous positive airway pressure (P < 0.001). The patients receiving continuous positive airway pressure also had a greater increase in the arterial pH (oxygen alone, from 7.15 +/- 0.11 to 7.18 +/- 0.18; oxygen plus continuous positive airway pressure, from 7.18 +/- 0.08 to 7.28 +/- 0.06; P < 0.001) and in the ratio of arterial oxygen tension to the fraction of inspired oxygen (oxygen alone, from 136 +/- 4 to 126 +/- 47; oxygen plus continuous positive airway pressure, from 138 +/- 32 to 206 +/- 126; P = 0.01). After 24 hours, however, there were no significant differences between the two treatment groups in any of these respiratory indexes. Seven (35 percent) of the patients who received oxygen alone but none who received oxygen plus continuous positive airway pressure required intubation and mechanical ventilation (P = 0.005). However, no significant difference was found in in-hospital mortality (oxygen alone, 4 of 20 patients; oxygen plus continuous positive airway pressure, 2 of 19; P = 0.36) or the length of the hospital stay. Conclusions. Continuous positive airway pressure delivered by face mask in patients with severe cardiogenic pulmonary edema can result in early physiologic improvement and reduce the need for intubation and mechanical ventilation. This short-term study could not establish whether continuous positive airway pressure has any long-term benefit or whether a larger study would have shown a difference in mortality between the treatment groups.	FLINDERS UNIV,MED CTR,DEPT EMERGENCY MED,BEDFORD PK,SA 5042,AUSTRALIA	Flinders University South Australia	BERSTEN, AD (corresponding author), FLINDERS UNIV,MED CTR,DEPT INTENS CARE,INTENS CARE UNIT,BEDFORD PK,SA 5042,AUSTRALIA.			Bersten, Andrew/0000-0001-9908-394X				BERSTEN AD, 1991, CRIT CARE MED, V19, P266, DOI 10.1097/00003246-199102000-00024; BROSEGHINI C, 1988, AM REV RESPIR DIS, V138, P355, DOI 10.1164/ajrccm/138.2.355; BUDA AJ, 1979, NEW ENGL J MED, V301, P453, DOI 10.1056/NEJM197908303010901; BUSSMANN WD, 1978, AM J CARDIOL, V41, P931, DOI 10.1016/0002-9149(78)90736-1; CALVIN JE, 1981, AM REV RESPIR DIS, V124, P121; DIKSHIT K, 1973, NEW ENGL J MED, V288, P1087, DOI 10.1056/NEJM197305242882102; FRANCIS GS, 1985, ANN INTERN MED, V103, P1, DOI 10.7326/0003-4819-103-1-1; KATZ JA, 1985, ANESTHESIOLOGY, V63, P598, DOI 10.1097/00000542-198512000-00008; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; LESCH M, 1968, NEW ENGL J MED, V279, P115, DOI 10.1056/NEJM196807182790301; LIGHT RW, 1983, ARCH INTERN MED, V143, P429, DOI 10.1001/archinte.143.3.429; NELSON GIC, 1983, LANCET, V1, P730; PINGLETON SK, 1988, AM REV RESPIR DIS, V137, P1463, DOI 10.1164/ajrccm/137.6.1463; POULTON PE, 1936, LANCET, V2, P981; RASANEN J, 1985, AM J CARDIOL, V55, P296, DOI 10.1016/0002-9149(85)90364-9; RIZK NW, 1982, AM J MED, V72, P381, DOI 10.1016/0002-9343(82)90491-0; ROUSSOS C, 1982, NEW ENGL J MED, V307, P786, DOI 10.1056/NEJM198209233071304; SHARP JT, 1958, J CLIN INVEST, V37, P111, DOI 10.1172/JCI103577	18	386	402	0	4	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 26	1991	325	26					1825	1830		10.1056/NEJM199112263252601	http://dx.doi.org/10.1056/NEJM199112263252601			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GW528	1961221				2023-01-03	WOS:A1991GW52800001
J	WILLIAMS, NS; PATEL, J; GEORGE, BD; HALLAN, RI; WATKINS, ES				WILLIAMS, NS; PATEL, J; GEORGE, BD; HALLAN, RI; WATKINS, ES			DEVELOPMENT OF AN ELECTRICALLY STIMULATED NEOANAL SPHINCTER	LANCET			English	Article							FECAL INCONTINENCE; GRACILIS MUSCLE; SKELETAL-MUSCLE; CONSTRUCTION; CONTINENCE	In early surgical attempts to create a neoanal sphincter for patients who are faecally incontinent, skeletal muscle (usually the gracilis) has been transposed around the anal canal. Despite modifications, such as intermittent electrical stimulation, this procedure is likely to fail because the fast-twitch gracilis muscle is incapable of prolonged contraction without fatigue. Long-term electrical stimulation to convert such a muscle to a slow-twitch, fatigue-resistant muscle, though practicable, has yielded inconsistent results. We describe further modifications of this technique. A neoanal sphincter was constructed with an electrically stimulated transposed gracilis muscle in 20 incontinent patients with a deficient anal sphincter, and as part of a reconstruction in 12 patients in whom the anorectum had been excised or was congenitally absent. A totally implanted stimulator was used to convert the muscle from a fast-twitch to a slow-twitch muscle. Other modifications included vascular delay 4-6 weeks before transposition of the muscle, stimulation of the main nerve to the gracilis rather than its peripheral branches, and intermittent higher frequency stimulation. 2-4 of these modifications gave significantly fewer failures than did 0-1. With the new technique, continence has been restored in patients whose only other treatment option was a permanent stoma.	ROYAL LONDON HOSP,NEUROSURG UNIT,LONDON E1 1BB,ENGLAND	Barts Health NHS Trust; Royal London Hospital	WILLIAMS, NS (corresponding author), ROYAL LONDON HOSP,SURG UNIT,LONDON E1 1BB,ENGLAND.							BAETEN C, 1988, DIS COLON RECTUM, V31, P134, DOI 10.1007/BF02562646; CAVINA E, 1987, Italian Journal of Surgical Sciences, V17, P305; HALLAN RI, 1990, BRIT J SURG, V77, P208, DOI 10.1002/bjs.1800770226; PATEL J, 1991, CLIN ANAT, V4, P385; PATEL J, 1991, J ANAT, V176, P270; PICKRELL KL, 1952, ANN SURG, V135, P853, DOI 10.1097/00000658-195206000-00010; SALMONS S, 1981, MUSCLE NERVE, V4, P94, DOI 10.1002/mus.880040204; SIMONSEN SO, 1976, BRIT J SURG, V63, P389; WILLIAMS NS, 1990, DIS COLON RECTUM, V33, P561, DOI 10.1007/BF02052207; WILLIAMS NS, 1989, BRIT J SURG, V76, P1191, DOI 10.1002/bjs.1800761124; WILLIAMS NS, 1990, ANN ROY COLL SURG, V72, P108; WILLIAMS NS, 1991, CLIN MEASUREMENT COL, P109; WOMACK NR, 1988, BRIT J SURG, V75, P48, DOI 10.1002/bjs.1800750118; WONG SKC, 1984, AUST NZ J SURG, V54, P575, DOI 10.1111/j.1445-2197.1984.tb05450.x; YOSHIOKA K, 1988, DIS COLON RECTUM, V31, P767, DOI 10.1007/BF02560102	15	229	244	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 9	1991	338	8776					1166	1169						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GP034	1682591				2023-01-03	WOS:A1991GP03400003
J	TOMA, E; FOURNIER, S				TOMA, E; FOURNIER, S			ADVERSE REACTIONS TO COTRIMOXAZOLE IN HIV-INFECTION	LANCET			English	Letter							PNEUMOCYSTIS-CARINII PNEUMONIA		HOP HOTEL DIEU,DEPT PHARM,MONTREAL H2W 1T8,QUEBEC,CANADA	Universite de Montreal	TOMA, E (corresponding author), HOP HOTEL DIEU,DIV MICROBIOL & INFECT DIS,MONTREAL H2W 1T8,QUEBEC,CANADA.							BLACK JR, 1991, EUR J CLIN MICROBIOL, V10, P204, DOI 10.1007/BF01964465; MEDINA I, 1990, NEW ENGL J MED, V323, P776, DOI 10.1056/NEJM199009203231202; PERREAULT S, 1986, JUN INT C AIDS PAR; RUF B, 1991, EUR J CLIN MICROBIOL, V10, P207, DOI 10.1007/BF01964466; TOMA E, 1991, EUR J CLIN MICROBIOL, V10, P210, DOI 10.1007/BF01964467; TOMA E, 1989, LANCET, V1, P1046, DOI 10.1016/S0140-6736(89)92446-X; VANDERVEN, 1991, LANCET, V338, P431	7	10	10	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 12	1991	338	8772					954	954		10.1016/0140-6736(91)91827-H	http://dx.doi.org/10.1016/0140-6736(91)91827-H			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GJ899	1681303				2023-01-03	WOS:A1991GJ89900055
J	ALBRIGHT, GA; COHEN, H; FORSTER, RM; GLASSENBERG, R; BRUNNER, EA				ALBRIGHT, GA; COHEN, H; FORSTER, RM; GLASSENBERG, R; BRUNNER, EA			ANESTHESIA FOR PATIENTS WITH PREECLAMPSIA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter									NORTHWESTERN UNIV,SCH MED,CHICAGO,IL 60611	Northwestern University	ALBRIGHT, GA (corresponding author), NW MEM HOSP,CHICAGO,IL 60611, USA.							1986, SURV ANESTHESIOL, V30, P306	1	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 27	1991	265	12					1587	1587		10.1001/jama.265.12.1587	http://dx.doi.org/10.1001/jama.265.12.1587			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FC604	1999909				2023-01-03	WOS:A1991FC60400038
J	KALK, WJ; VERIAVA, Y				KALK, WJ; VERIAVA, Y			HOSPITAL MANAGEMENT OF VOLUNTARY TOTAL FASTING AMONG POLITICAL PRISONERS	LANCET			English	Editorial Material								In 1989 20 political detainees, held without trial for up to 32 months, were admitted, on hunger strike, to the Johannesburg Hospital, South Africa. Most were held under the regulations of the State of Emergency (since revoked) and 5 were held incommunicado under section 29 of the Internal Security Act (still in force). Guidelines for ethical management were based on the Declaration of Tokyo, which included the understanding that such detentions constituted mental torture. Conditions of detention in hospital were complicated by police interference in medical and nursing care, and by the chaining of some prisoners to their beds. Doctors are in a unique position to protest against inhuman treatment of prisoners, and should use this authority.	CORONAT HOSP,DEPT MED,JOHANNESBURG,SOUTH AFRICA; NATL & MED DENT ASSOC DETAINEES SERV,PARKTOWN 2193,SOUTH AFRICA; UNIV WITWATERSRAND,SCH MED,JOHANNESBURG 2001,SOUTH AFRICA	University of Witwatersrand; University of Witwatersrand	KALK, WJ (corresponding author), UNIV WITWATERSRAND,SCH MED,DEPT MED,PARKTOWN 2193,SOUTH AFRICA.							FROMMEL D, 1984, LANCET, V1, P1451, DOI 10.1016/S0140-6736(84)91941-X; HARDING TW, 1989, LANCET, V1, P1191; LEVIN J, 1988, S AFR MED J, V74, P460; VERIAVA Y, 1989, CRITICAL HLTH, V26, P39; 1975, WORLD MED J, V22, P87; 1989, S89278 U WITW FM DOC; 1989, WEEKLY MAIL     0303; 1988, LANCET, V2, P1402; 1989, NATAL MERCURY   1028; 1981, HDB MED ETHICS	10	21	21	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 16	1991	337	8742					660	662		10.1016/0140-6736(91)92465-E	http://dx.doi.org/10.1016/0140-6736(91)92465-E			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FB730	1672002				2023-01-03	WOS:A1991FB73000015
J	MORRIS, F; TORDOFF, SG; WALLIS, D; SKINNER, DV				MORRIS, F; TORDOFF, SG; WALLIS, D; SKINNER, DV			CARDIOPULMONARY-RESUSCITATION SKILLS OF PREREGISTRATION HOUSE OFFICERS - 5 YEARS ON	BRITISH MEDICAL JOURNAL			English	Article									ST BARTHOLOMEWS HOSP,DEPT ANAESTHESIA,LONDON EC1A 7BE,ENGLAND	University of London; Queen Mary University London	MORRIS, F (corresponding author), ST BARTHOLOMEWS HOSP,DEPT ACCID & EMERGENCY,LONDON EC1A 7BE,ENGLAND.							BASKETT PJF, 1985, BRIT MED J, V290, P1531, DOI 10.1136/bmj.290.6481.1531; CASEY WF, 1984, J ROY SOC MED, V77, P921, DOI 10.1177/014107688407701105; CURRY L, 1987, CAN MED ASSOC J, V137, P491; SKINNER DV, 1985, BRIT MED J, V290, P1549, DOI 10.1136/bmj.290.6481.1549; 1987, J R COLL PHYSICIANS, V21, P175	5	34	35	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 16	1991	302	6777					626	627		10.1136/bmj.302.6777.626	http://dx.doi.org/10.1136/bmj.302.6777.626			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FC071	1878021	Green Published, Bronze			2023-01-03	WOS:A1991FC07100022
J	PORRECO, RP; BARTON, SM; HAVERKAMP, AD				PORRECO, RP; BARTON, SM; HAVERKAMP, AD			OCCLUSION OF UMBILICAL ARTERY IN ACARDIAC, ACEPHALIC TWIN	LANCET			English	Note								In the acardiac, acephalic twin malformation the normal co-twin is put at risk because of the extra cardiac work-load. Surgical procedures may be hazardous to the mother. We describe a novel approach - the insertion of a helical metal coil to induce thrombosis in the umbilical artery of the acardiac twin - which immediately interrupted flow. The co-twin was delivered at 39 weeks and his neonatal course has been normal.	COLORADO PERMANENTE MED GRP PC,DENVER,CO; UNIV COLORADO,HLTH SERV CTR,DEPT OBSTET & GYNECOL,DENVER,CO 80203	Permanente Medical Groups; University of Colorado System; University of Colorado Denver	PORRECO, RP (corresponding author), UNIV COLORADO,HLTH SERV CTR,AMI ST LUKES PERINATAL PROGRAM,DENVER,CO 80203, USA.							ROBIE GF, 1989, NEW ENGL J MED, V320, P512, DOI 10.1056/NEJM198902233200808; VANALLEN MI, 1983, SEMIN PERINATOL, V7, P285	2	85	87	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 9	1991	337	8737					326	327		10.1016/0140-6736(91)90946-M	http://dx.doi.org/10.1016/0140-6736(91)90946-M			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EX362	1671233				2023-01-03	WOS:A1991EX36200005
J	VERNON, CC; HARRISON, M				VERNON, CC; HARRISON, M			HYPERTHERMIA WITH LOW-DOSE RADIOTHERAPY FOR RECURRENT BREAST-CARCINOMA	LANCET			English	Letter									HAMMERSMITH HOSP,DEPT RADIOTHERAPY & ONCOL,LONDON W12 0HS,ENGLAND	Imperial College London	VERNON, CC (corresponding author), HAMMERSMITH HOSP,CYCLOTRON UNIT,MRC,HYPERTHERMIA CLIN,LONDON W12 0HS,ENGLAND.							DUNLOP P R C, 1986, International Journal of Hyperthermia, V2, P39, DOI 10.3109/02656738609019992; Egawa S., 1989, J JPN SOC THER RADIO, V1, P135; GONZALEZ DG, 1988, RADIOTHER ONCOL, V12, P95, DOI 10.1016/0167-8140(88)90163-6; LINDHOLM CE, 1987, INT J HYPERTHER, V3, P393, DOI 10.3109/02656738709140410; NOVELL, 1990, LANCET, V336, P1383; PEREZ CA, IN PRESS AM J CLIN O; VANDERZEE J, 1988, INT J RADIAT ONCOL, V15, P1407, DOI 10.1016/0360-3016(88)90237-4	7	1	1	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 5	1991	337	8732					59	59		10.1016/0140-6736(91)93384-L	http://dx.doi.org/10.1016/0140-6736(91)93384-L			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EQ604	1670685				2023-01-03	WOS:A1991EQ60400062
J	BISACCIA, E; BERGER, C; KLAINER, AS				BISACCIA, E; BERGER, C; KLAINER, AS			EXTRACORPOREAL PHOTOPHERESIS IN THE TREATMENT OF AIDS-RELATED COMPLEX - A PILOT-STUDY	ANNALS OF INTERNAL MEDICINE			English	Article									COLUMBIA UNIV COLL PHYS & SURG, NEW YORK, NY 10032 USA	Columbia University	BISACCIA, E (corresponding author), MORRISTOWN MEM HOSP, PHOTOPHERESIS UNIT, 100 MADISON AVE, MORRISTOWN, NJ 07962 USA.							AMMANN AJ, 1984, JAMA-J AM MED ASSOC, V251, P1447, DOI 10.1001/jama.251.11.1447; ANDREWS CA, 1987, J PEDIATR-US, V111, P672, DOI 10.1016/S0022-3476(87)80241-X; COHEN IR, 1984, ADV INTERNAL MED, V29, P147; COOMBS RW, 1989, NEW ENGL J MED, V321, P1626, DOI 10.1056/NEJM198912143212402; EDELSON R, 1987, NEW ENGL J MED, V316, P297, DOI 10.1056/NEJM198702053160603; EDELSON RL, 1988, SCI AM, V259, P68, DOI 10.1038/scientificamerican0888-68; FAHEY JL, 1990, NEW ENGL J MED, V322, P166, DOI 10.1056/NEJM199001183220305; GALLO RC, 1988, J ACQ IMMUN DEF SYND, V1, P521; JACKSON GG, 1988, ANN INTERN MED, V108, P175, DOI 10.7326/0003-4819-108-2-175; KHAVARI PA, 1988, CLIN RES, V36, pA662; KUNG PC, 1981, BLOOD, V57, P261; LACEY CJN, 1987, AIDS, V1, P123; LEVY JA, 1985, J INFECT DIS, V152, P734, DOI 10.1093/infdis/152.4.734; MASUR H, 1989, ANN INTERN MED, V111, P223, DOI 10.7326/0003-4819-111-3-223; MCDOUGAL JS, 1987, J CLIN INVEST, V80, P316, DOI 10.1172/JCI113075; MURRAY HW, 1989, AM J MED, V86, P533, DOI 10.1016/0002-9343(89)90380-X; MUSAJO L, 1965, EXPERIENTIA, V21, P22, DOI 10.1007/BF02136362; NAKASHIMA K, 1978, J BIOL CHEM, V253, P8680; NG VL, 1989, J CLIN MICROBIOL, V27, P977, DOI 10.1128/JCM.27.5.977-982.1989; QUINNAN GV, 1986, TRANSFUSION, V26, P481, DOI 10.1046/j.1537-2995.1986.26587020131.x; REDFIELD DC, 1981, INFECT IMMUN, V32, P1216, DOI 10.1128/IAI.32.3.1216-1226.1981; REDFIELD RR, 1986, NEW ENGL J MED, V314, P131, DOI 10.1056/NEJM198601093140232; ROTHENBERG R, 1987, NEW ENGL J MED, V317, P1297, DOI 10.1056/NEJM198711193172101; VELLECA WN, 1986, TRAINING MANUAL CTR, V3	24	57	66	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 15	1990	113	4					270	275		10.7326/0003-4819-113-4-270	http://dx.doi.org/10.7326/0003-4819-113-4-270			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DU081	1973885				2023-01-03	WOS:A1990DU08100004
J	VANDEWERF, F				VANDEWERF, F			IN-HOSPITAL MORTALITY AND CLINICAL COURSE OF 20891 PATIENTS WITH SUSPECTED ACUTE MYOCARDIAL-INFARCTION RANDOMIZED BETWEEN ALTEPLASE AND STREPTOKINASE WITH OR WITHOUT HEPARIN	LANCET			English	Article											VANDEWERF, F (corresponding author), CATHOLIC UNIV LEUVEN, HOSP GASTHUISBERG, DIV CARDIOL, HERESTR 49, B-3000 LOUVAIN, BELGIUM.		Simes, Robert John/P-1497-2014					[Anonymous], 1988, LANCET, V2, P349; [Anonymous], 1990, Lancet, V336, P65; [Anonymous], 1986, Lancet, V1, P397; BENTLEY PG, 1980, THROMB RES, V18, P177, DOI 10.1016/0049-3848(80)90182-6; BLEICH SD, 1989, CIRCULATION S2, V80, P13; CHAMBERLAIN DA, 1988, LANCET, V1, P545; CHESEBRO JH, 1987, CIRCULATION, V76, P142, DOI 10.1161/01.CIR.76.1.142; DEVITA C, 1990, LANCET, V335, P289, DOI 10.1016/0140-6736(90)90104-D; DOYLE DJ, 1987, ANN INTERN MED, V107, P441, DOI 10.7326/0003-4819-107-4-441; FLEISS JL, 1981, STATISTICAL METHODS, P56; GAIL M, 1985, BIOMETRICS, V41, P361, DOI 10.2307/2530862; ROSS A M, 1990, Journal of the American College of Cardiology, V15, p64A; TAVAZZI L, 1989, LANCET, V2, P182; TOPOL EJ, 1989, CIRCULATION, V79, P281, DOI 10.1161/01.CIR.79.2.281; TURPIE AGG, 1989, NEW ENGL J MED, V320, P352, DOI 10.1056/NEJM198902093200604; VERSTRAETE M, 1985, LANCET, V1, P842, DOI 10.1016/S0140-6736(85)92208-1; WILCOX RG, 1988, LANCET, V2, P525	17	509	516	1	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 14	1990	336	8707					71	75						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DN793	1975322				2023-01-03	WOS:A1990DN79300002
J	MIKL, J; CZERWENKA, K; SALZER, H; SPONA, J; AIGINGER, P; KUBISTA, E; SEVELDA, P; STAFFEN, A; ZIELINSKI, CC				MIKL, J; CZERWENKA, K; SALZER, H; SPONA, J; AIGINGER, P; KUBISTA, E; SEVELDA, P; STAFFEN, A; ZIELINSKI, CC			ADJUVANT TAMOXIFEN IN POSTMENOPAUSAL STAGE-II BREAST-CANCER 5 YEARS ON	LANCET			English	Letter									UNIV HOSP VIENNA,DEPT OBSTET & GYNAECOL,A-1090 VIENNA,AUSTRIA; UNIV HOSP VIENNA,DEPT SURG 2,A-1090 VIENNA,AUSTRIA	University Hospital Vienna; University Hospital Vienna	MIKL, J (corresponding author), UNIV HOSP VIENNA,DEPT MED 2,A-1090 VIENNA,AUSTRIA.							BONADONNA G, 1985, LANCET, V1, P976; ZIELINSKI CC, 1986, LANCET, V2, P1164; ZIELINSKI CC, 1989, CANCER, V63, P113	3	3	3	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 3	1990	335	8688					541	541		10.1016/0140-6736(90)90775-Z	http://dx.doi.org/10.1016/0140-6736(90)90775-Z			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CT015	1968551				2023-01-03	WOS:A1990CT01500037
J	ZARDENETA, G; HOROWITZ, PM				ZARDENETA, G; HOROWITZ, PM			ANALYSIS OF THE PERTURBATION OF PHOSPHOLIPID MODEL MEMBRANES BY RHODANESE AND ITS PRESEQUENCE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMPORTED MITOCHONDRIAL PROTEIN; GUANIDINIUM CHLORIDE; DENATURED RHODANESE; PRECURSOR PROTEIN; SIGNAL SEQUENCES; PRE-SEQUENCE; PEPTIDE; BINDING; HELIX; FORM	The ability of the cytoplasmically synthesized mitochondrial enzyme rhodanese and its putative import signal sequence to interact with model phospholipid membranes was characterized. Membrane perturbation assays were used to test a current hypothesis that the initial step in protein translocation may involve binding of signal sequences with membrane lipids. Here we show comparative studies on the effect of native and various forms of denatured rhodanese, as well as two peptides, rho(1-23) and rho(11-23), derived from its NH2-terminal sequence, on the perturbation of 6-carboxyfluorescein-containing large unilamellar vesicles composed of either cardiolipin, phosphatidylcholine, or phosphatidylserine. We monitored the degree of perturbation by measuring dye leakage and found differential perturbation by either peptide or protein. Unfolded rhodanese perturbed vesicles in the order phosphatidylserine > cardiolipin >> phosphatidylcholine. Denatured rhodanese was approximately 25 times more effective (on a molar basis) than rho(1-23) in the disruption of anionic liposomes. Rho(11-23) was unable to perturb liposomes. We found an inverse correlation between degree of activity of rhodanese folding intermediates and their ability to perturb liposomes. On urea denaturation, enzymatic activity was completely lost before membrane perturbation ability reached significant levels. Analysis of the peptides by circular dichroism showed that anionic liposomes can induce alpha-helical structure only in rho(1-23) and denatured rhodanese. Intrinsic peptide fluorescence studies showed that only rho(1-23) and denatured rhodanese partitioned into these model membranes. Results obtained here imply that peptides from naturally occurring alpha-helical structures may need adjacent motifs for helical structure induction in lipid environments, and the subsequent secondary structure may, in turn, promote partitioning of these segments into the lipid phase and ultimately lead to membrane perturbation.	UNIV TEXAS,HLTH SCI CTR,DEPT BIOCHEM,7703 FLOYD CURL DR,SAN ANTONIO,TX 78284	University of Texas System; University of Texas Health San Antonio					NIEHS NIH HHS [ES05729] Funding Source: Medline; NIGMS NIH HHS [GM25177] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES005729] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025177] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ames B.N., 1966, METHOD ENZYMOL, V8, P115, DOI DOI 10.1016/0076-6879(66)08014-5; BRIGGS MS, 1986, SCIENCE, V233, P206, DOI 10.1126/science.2941862; BRUCH MD, 1990, J BIOL CHEM, V265, P3851; BURSTEIN EA, 1973, PHOTOCHEM PHOTOBIOL, V18, P263, DOI 10.1111/j.1751-1097.1973.tb06422.x; CHEN WJ, 1987, J BIOL CHEM, V262, P15605; CHEN YH, 1974, BIOCHEMISTRY-US, V13, P3350, DOI 10.1021/bi00713a027; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P222, DOI 10.1021/bi00699a002; DAUM G, 1985, BIOCHIM BIOPHYS ACTA, V822, P1, DOI 10.1016/0304-4157(85)90002-4; DEKROON AIP, 1990, BIOCHEMISTRY-US, V29, P8229, DOI 10.1021/bi00488a006; DEKROON AIPM, 1989, BIOCHIM BIOPHYS ACTA, V981, P371, DOI 10.1016/0005-2736(89)90051-5; EILERS M, 1986, NATURE, V322, P228, DOI 10.1038/322228a0; GIERASCH LM, 1989, BIOCHEMISTRY-US, V28, P923, DOI 10.1021/bi00429a001; HACKENBR.CR, 1968, P NATL ACAD SCI USA, V61, P598, DOI 10.1073/pnas.61.2.598; HARTL FU, 1989, BIOCHIM BIOPHYS ACTA, V988, P1, DOI 10.1016/0304-4157(89)90002-6; HAY R, 1984, BIOCHIM BIOPHYS ACTA, V779, P65, DOI 10.1016/0304-4157(84)90004-2; HOROWITZ PM, 1986, J BIOL CHEM, V261, P13887; HOROWITZ PM, 1978, ANAL BIOCHEM, V86, P751, DOI 10.1016/0003-2697(78)90803-5; HOROWITZ PM, 1990, J BIOL CHEM, V265, P2576; HORWICH AL, 1985, EMBO J, V4, P1129, DOI 10.1002/j.1460-2075.1985.tb03750.x; HURT EC, 1985, EMBO J, V4, P2061, DOI 10.1002/j.1460-2075.1985.tb03892.x; KURABAN GP, 1991, PROTEIN EXP PURIF, V2, P379; LANDRY SJ, 1991, BIOCHEMISTRY-US, V30, P7359, DOI 10.1021/bi00244a001; LIN KC, 1982, NATURE, V296, P164, DOI 10.1038/296164a0; MACDONALD RC, 1991, BIOCHIM BIOPHYS ACTA, V1061, P297, DOI 10.1016/0005-2736(91)90295-J; MENDOZA JA, 1991, J BIOL CHEM, V266, P13587; MENDOZA JA, 1991, J BIOL CHEM, V266, P13044; MILLER DM, 1992, BIOCHIM BIOPHYS ACTA, V1121, P286, DOI 10.1016/0167-4838(92)90158-A; MILLER DM, 1991, J BIOL CHEM, V266, P4686; OU WJ, 1988, J BIOCHEM-TOKYO, V103, P589, DOI 10.1093/oxfordjournals.jbchem.a122312; PLOEGMAN JH, 1978, NATURE, V273, P124, DOI 10.1038/273124a0; RIEZMAN H, 1983, EMBO J, V2, P1113, DOI 10.1002/j.1460-2075.1983.tb01554.x; ROISE D, 1992, P NATL ACAD SCI USA, V89, P608, DOI 10.1073/pnas.89.2.608; ROISE D, 1986, EMBO J, V5, P1327, DOI 10.1002/j.1460-2075.1986.tb04363.x; ROISE D, 1988, J BIOL CHEM, V263, P4509; SCHERER PE, 1990, EMBO J, V9, P4315, DOI 10.1002/j.1460-2075.1990.tb07880.x; SCHIFFER M, 1967, BIOPHYS J, V7, P121, DOI 10.1016/S0006-3495(67)86579-2; SORBO BH, 1953, ACTA CHEM SCAND, V7, P1123; TAMM LK, 1986, BIOCHEMISTRY-US, V25, P7470, DOI 10.1021/bi00371a032; TANDON S, 1989, J BIOL CHEM, V264, P9859; TANDON S, 1987, J BIOL CHEM, V262, P4486; VERNER K, 1988, SCIENCE, V241, P1307, DOI 10.1126/science.2842866; VONHEIJNE G, 1986, EMBO J, V5, P1335, DOI 10.1002/j.1460-2075.1986.tb04364.x; ZAMBRANO F, 1975, BIOCHIM BIOPHYS ACTA, V380, P357, DOI 10.1016/0005-2760(75)90104-6; ZARDENETA G, 1992, J BIOL CHEM, V267, P5811	44	25	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1992	267	34					24193	24198						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KA263	1447169				2023-01-03	WOS:A1992KA26300011
J	MITCHELL, JM; SUNSHINE, JH				MITCHELL, JM; SUNSHINE, JH			CONSEQUENCES OF PHYSICIANS OWNERSHIP OF HEALTH-CARE FACILITIES - JOINT VENTURES IN RADIATION-THERAPY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							FINANCIAL INCENTIVES; OFFICE PRACTICE; PREPAID; DEMAND	Background. Physicians are increasingly the owners of health care facilities to which they refer patients for services but at which they do not practice. We studied such ownership arrangements, known as "joint ventures," in the field of radiation therapy, examining their effects on access, use of services, costs, and quality. Methods. Because 44 percent of free-standing facilities providing radiation therapy in Florida in 1989 were joint ventures, as compared with 7 percent elsewhere (95 percent confidence interval, 3 to 10 percent), we compared data for Florida with comparable data for the remainder of the United States. We also compared radiation-therapy facilities in Florida that were established as joint ventures with those that were not. Since most data were derived from entire populations rather than from samples, any differences found were of necessity statistically significant. Results. No joint-venture facilities providing radiation therapy were located in inner-city neighborhoods or rural areas, but 11 percent of other free-standing facilities and hospital-based facilities were located in such areas. Among free-standing facilities, joint ventures received 39 percent of their revenues from patients with well-paying insurance coverage, as compared with 31 percent for facilities that were not joint ventures (P<0.01). The frequency and costs of radiation-therapy treatments at free-standing centers were 40 to 60 percent higher in Florida than in the rest of the United States; there was no below-average use of radiation therapy at hospitals or higher cancer rates that explained the higher rates of use or higher costs in Florida. Radiation physicists at joint-venture facilities (the principal personnel involved in quality control other than physicians) spent 18 percent less time with each patient over the course of treatment than did their counterparts at free-standing facilities that were not joint ventures (P<0.05). Mortality among patients with cancer in Florida was not lower than the U.S. average, even though joint ventures are much more common in that state. Conclusions. Joint ventures in radiation therapy appear to have adverse effects on patients' access to care. They also appear to increase the use of services and costs substantially. Some indicators show that joint ventures cause either no improvement in quality or a decline. Our results add to the evidence indicating that physicians' self-referral generally has negative consequences. We recommend legislation to ban ownership of joint ventures by referring physicians. Such legislation needs to be carefully designed in order to achieve its objectives and forestall new, financially abusive arrangements.	AMER COLL RADIOL,RES DEPT,RESTON,VA; FLORIDA STATE UNIV,DEPT ECON,TALLAHASSEE,FL 32306	American College of Radiology; State University System of Florida; Florida State University	MITCHELL, JM (corresponding author), GEORGETOWN UNIV,GRAD PUBL POLICY PROGRAM,3600 N ST NW,SUITE 200,WASHINGTON,DC 20007, USA.							EPSTEIN AM, 1986, NEW ENGL J MED, V314, P1089, DOI 10.1056/NEJM198604243141706; FUCHS VR, 1978, J HUM RESOUR, V13, P35, DOI 10.2307/145247; GRAY BH, 1986, FOR PROFIT ENTERPRIS, P151; HANKS G E, 1984, International Journal of Radiation Oncology, Biology, Physics, V10, P87; HEMENWAY D, 1990, NEW ENGL J MED, V322, P1059, DOI 10.1056/NEJM199004123221507; HILLMAN BJ, 1990, NEW ENGL J MED, V323, P1604, DOI 10.1056/NEJM199012063232306; IGLEHART JK, 1990, NEW ENGL J MED, V322, P1682, DOI 10.1056/NEJM199006073222327; IGLEHART JK, 1989, NEW ENGL J MED, V321, P198, DOI 10.1056/NEJM198907203210327; KRAMER S, 1984, STAT MED, V3, P353, DOI 10.1002/sim.4780030411; KRAMER S, 1984, International Journal of Radiation Oncology, Biology, Physics, V10, P49; MANNING WG, 1984, NEW ENGL J MED, V310, P1505, DOI 10.1056/NEJM198406073102305; MITCHELL JM, 1992, JAMA-J AM MED ASSOC, V268, P80, DOI 10.1001/jama.268.1.80; MITCHELL JM, 1991, 1991 FLOR HLTH CAR C; Morrison D.E., 1970, SIGNIFICANCE TEST CO; PEAR R, 1991, NY TIMES        1105, pA17; PEAR R, 1991, NY TIMES        1118, pA1; RELMAN AS, 1985, NEW ENGL J MED, V313, P749, DOI 10.1056/NEJM198509193131209; RIES LAG, 1991, NCI NIH912789 PUBL; Rosenfeld R.H., 1984, MOD HEATHCARE, V14, P60; SCHROEDER SA, 1978, MED CARE, V16, P289, DOI 10.1097/00005650-197804000-00002; SUNSHINE JH, 1992, RADIOLOGY, V183, P535, DOI 10.1148/radiology.183.2.1561364; Waldholz Michael, 1989, WALL STREET J   0301, pA1; WILENSKY GR, 1983, MILBANK FUND Q, V61, P252, DOI 10.2307/3349907; 1990, PHYSICIANS CURRENT P; 1989, FINANCIAL ARRANGEMEN; 1989, FED REGISTER, V54, P8894; 1992, JAMA-J AM MED ASSOC, V267, P2366; 1992, PRESIDENTS COMPREHEN, P68	28	99	99	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 19	1992	327	21					1497	1501		10.1056/NEJM199211193272106	http://dx.doi.org/10.1056/NEJM199211193272106			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JY165	1406881				2023-01-03	WOS:A1992JY16500006
J	NIGHTINGALE, SL				NIGHTINGALE, SL			FDAS ELECTRONIC BULLETIN BOARD	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	6	6	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 14	1992	268	14					1828	1828		10.1001/jama.268.14.1828	http://dx.doi.org/10.1001/jama.268.14.1828			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JR439	1404696				2023-01-03	WOS:A1992JR43900010
J	LABRAKE, CC; FUNG, LWM				LABRAKE, CC; FUNG, LWM			PHOSPHOLIPID-VESICLES PROMOTE HUMAN HEMOGLOBIN OXIDATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RED-CELL MEMBRANE; LIPID-PEROXIDATION; PHOSPHATIDYLSERINE VESICLES; ERYTHROCYTE-MEMBRANE; SUPEROXIDE-DISMUTASE; AUTOXIDATION; MECHANISM; LIPOSOMES; HEME; FUSION	We have studied the heme oxidation kinetics of purified human hemoglobin (Hb) in the presence of lipid vesicles of dipalmitoyl phosphatidylcholine and bovine brain phosphatidylserine that exhibited minimal lipid peroxidation. We showed that the lipid vesicles enhanced Hb oxidation and that small unilamellar vesicles (SUVs) exerted a larger effect than large unilamellar vesicles (LUVs). We have determined pseudo first-order rate constants for the initial disappearance of oxygenated ferrous Hb (k0) and for the initial formation of several ferric Hb species (methemoglobin, hemichrome, and choleglobin) in the presence of SUVs and LUVs. k0 and other rate constants depended linearly on lipid-to-hemoglobin molar ratio (lipid/Hb), with k0SUV (h-1) = k0auto (h-1) + 3.7 x 10(-3) x lipid/Hb, and k0LUV (h-1) = k0auto (h-1) + 0.2 x 10(-3) x lipid/Hb, where k0auto is the rate constant for Hb autoxidation in the absence of vesicles. Thus, in the absence of lipid peroxidation products, lipid vesicles themselves promote Hb oxidation by enhancing the rate of Hb oxidation. The enhanced oxidation was inhibited by catalase, but not by butylated hydroxytoluene. The rate constants were independent of Hb concentration, in the range of about 3.1 to 100-mu-M. We suggest that the lipid surface properties, including surface curvature, surface energy, and hydrophobicity, promote hemoglobin oxidation.	LOYOLA UNIV, DEPT CHEM, 6525 N SHERIDAN RD, CHICAGO, IL 60626 USA	Loyola University Chicago					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038361, S15HL041756] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALMOG R, 1991, CHEM PHYS LIPIDS, V60, P93, DOI 10.1016/0009-3084(91)90031-6; ANTONINI E, 1971, HEMOGLOBIN MYOGLOBIN, P18; Aust SD, 1985, CRC HDB METHODS OXYG, P203; BENESCH RE, 1990, J BIOL CHEM, V265, P14881; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BRANDL M, 1989, DRUG DEV IND PHARM, V15, P655, DOI 10.3109/03639048909058524; Buege J A, 1978, Methods Enzymol, V52, P302; CALISSANO P, 1972, BIOCHIM BIOPHYS ACTA, V255, P1009, DOI 10.1016/0005-2736(72)90414-2; CANNON JB, 1984, BIOCHEMISTRY-US, V23, P3715, DOI 10.1021/bi00311a022; CAUGHEY WS, 1985, HDB METHODS OXYGEN R, P95; CHIESI M, 1980, BIOCHEMISTRY-US, V19, P2912, DOI 10.1021/bi00554a015; Claiborne A.L., 1985, HDB METHODS OXYGEN R; CULLIS PR, 1985, BIOCH LIPIDS MEMBRAN, P25; DAS SK, 1980, BRIT J HAEMATOL, V44, P87, DOI 10.1111/j.1365-2141.1980.tb01186.x; DEISSEROTH A, 1970, PHYSIOL REV, V50, P319, DOI 10.1152/physrev.1970.50.3.319; DUNN MF, 1980, BIOCHEMISTRY-US, V19, P718, DOI 10.1021/bi00545a017; DUZGUNES N, 1988, SPECTROSCOPIC MEMBRA; Fridovich I, 1985, CRC HDB METHODS OXYG, P213; FUNG LWM, 1981, BIOCHEMISTRY-US, V20, P7162, DOI 10.1021/bi00528a017; GRAY A, 1991, BLOOD REV, V5, P258, DOI 10.1016/0268-960X(91)90017-7; GUTTERIDGE JMC, 1990, TRENDS BIOCHEM SCI, V15, P129, DOI 10.1016/0968-0004(90)90206-Q; HEBBEL RP, 1988, P NATL ACAD SCI USA, V85, P237, DOI 10.1073/pnas.85.1.237; ITABE H, 1988, BIOCHIM BIOPHYS ACTA, V961, P13; KAUL RK, 1983, KLIN WOCHENSCHR, V61, P831, DOI 10.1007/BF01537457; KAWANISHI S, 1985, J BIOL CHEM, V260, P4622; KIKUGAWA K, 1981, CHEM PHARM BULL, V29, P1382; KIMELBERG HK, 1976, MOL CELL BIOCHEM, V10, P171, DOI 10.1007/BF01731688; KLEIN RA, 1970, BIOCHIM BIOPHYS ACTA, V210, P486, DOI 10.1016/0005-2736(70)90231-2; LIGHT WR, 1990, J BIOL CHEM, V265, P15623; LIGLER FS, 1989, RED CELL, P435; LILLEY GL, 1987, LIFE SCI, V41, P2429, DOI 10.1016/0024-3205(87)90668-0; LORIMER JP, 1987, CHEM SOC REV, V16, P239, DOI 10.1039/cs9871600239; LOUGHREY HC, 1990, BIOCHIM BIOPHYS ACTA, V1028, P73, DOI 10.1016/0005-2736(90)90267-R; MACDONALD RC, 1988, J BIOL CHEM, V263, P10052; MACDONALD RC, 1990, HEPATOLOGY, V4, P1; MACDONALD RC, 1988, MOL MECHANISMS MEMBR, P101; MACDONALD VW, 1982, BIOCHIM BIOPHYS ACTA, V701, P39, DOI 10.1016/0167-4838(82)90309-0; MANSOURI A, 1974, BIOCHEMISTRY-US, V13, P3311, DOI 10.1021/bi00713a021; MARINETTI GV, 1978, J SUPRAMOL STR CELL, V8, P191, DOI 10.1002/jss.400080208; MAYER LD, 1986, BIOCHIM BIOPHYS ACTA, V858, P161, DOI 10.1016/0005-2736(86)90302-0; MISRA HP, 1972, J BIOL CHEM, V247, P6960; MORRISON GR, 1965, ANAL CHEM, V37, P1124, DOI 10.1021/ac60228a014; OHKI S, 1986, BIOCHIM BIOPHYS ACTA, V861, P177, DOI 10.1016/0005-2736(86)90577-8; OHKI S, 1984, J MEMBRANE BIOL, V77, P265, DOI 10.1007/BF01870574; PAPAHADJOPOULOS D, 1973, Biochimica et Biophysica Acta, V330, P8, DOI 10.1016/0005-2736(73)90280-0; PROTTER MH, 1970, COLLEGE CALCULUS ANA; RABINOVICI R, 1990, CIRC SHOCK, V32, P1; RAUENBUEHLER PB, 1982, BIOCHIM BIOPHYS ACTA, V692, P361, DOI 10.1016/0005-2736(82)90385-6; Riggs A., 1981, Methods in Enzymology, V76, P5; ROSE MY, 1985, J BIOL CHEM, V260, P6632; SADRZADEH SMH, 1984, J BIOL CHEM, V259, P4354; SCHERPHOF G, 1979, BIOCHIM BIOPHYS ACTA, V556, P196, DOI 10.1016/0005-2736(79)90042-7; SHAKLAI N, 1985, BIOCHIM BIOPHYS ACTA, V821, P355, DOI 10.1016/0005-2736(85)90106-3; SHIKAMA K, 1990, BIOL REV, V65, P517, DOI 10.1111/j.1469-185X.1990.tb01236.x; SHIKAMA K, 1984, BIOCHEM J, V223, P279, DOI 10.1042/bj2230279; SHVIRO Y, 1982, BIOCHIM BIOPHYS ACTA, V687, P63, DOI 10.1016/0005-2736(82)90170-5; STEWART JCM, 1980, ANAL BIOCHEM, V104, P10, DOI 10.1016/0003-2697(80)90269-9; SUBBARAO NK, 1991, BIOCHIM BIOPHYS ACTA, V1063, P147, DOI 10.1016/0005-2736(91)90364-E; SZEBENI J, 1988, BIOCHEMISTRY-US, V27, P6425, DOI 10.1021/bi00417a034; SZEBENI J, 1985, BIOCHEMISTRY-US, V24, P2827, DOI 10.1021/bi00333a003; SZEBENI J, 1986, BIOCHIM BIOPHYS ACTA, V857, P139, DOI 10.1016/0005-2736(86)90341-X; SZEBENI J, 1984, BIOCHEM J, V220, P685, DOI 10.1042/bj2200685; SZOKA FC, 1987, CELL FUSION; SZUNDI I, 1980, BIOCHIM BIOPHYS ACTA, V595, P41, DOI 10.1016/0005-2736(80)90245-X; TITOV VY, 1991, B EXP BIOL MED+, V112, P957, DOI 10.1007/BF00841142; VANDENBERG JJM, 1988, BIOCHIM BIOPHYS ACTA, V944, P29, DOI 10.1016/0005-2736(88)90313-6; WALDER JA, 1984, J BIOL CHEM, V259, P238; WALLACE WJ, 1982, J BIOL CHEM, V257, P4966; WALLACE WJ, 1974, FEBS LETT, V43, P33, DOI 10.1016/0014-5793(74)81099-9; WATKINS JA, 1985, BIOCHEM BIOPH RES CO, V132, P742, DOI 10.1016/0006-291X(85)91195-7; WAYS P, 1964, J LIPID RES, V5, P318; WEISS JJ, 1964, NATURE, V202, P83, DOI 10.1038/202083b0; WILSCHUT J, 1981, BIOCHEMISTRY-US, V20, P3126, DOI 10.1021/bi00514a022; WINTERBOURN CC, 1985, ENVIRON HEALTH PERSP, V64, P321, DOI 10.2307/3430020; WINTERBOURN CC, 1975, J LAB CLIN MED, V85, P337; WINTERBOURN CC, 1985, HDB METHODS OXYGEN R, P137; YAMAMOTO Y, 1985, BIOCHIM BIOPHYS ACTA, V819, P29, DOI 10.1016/0005-2736(85)90192-0; ZHANG L, 1991, J BIOL CHEM, V266, P24698	78	24	24	0	5	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1992	267	23					16703	16711						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JJ458	1644843				2023-01-03	WOS:A1992JJ45800108
J	MERRILL, JM				MERRILL, JM			ESTROGEN REPLACEMENT THERAPY AFTER BREAST-CANCER	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							RISK				MERRILL, JM (corresponding author), NORTHWESTERN UNIV,CTR CANC,CHICAGO,IL 60611, USA.							BERGKVIST L, 1989, NEW ENGL J MED, V321, P293, DOI 10.1056/NEJM198908033210505; CARBONE PP, 1989, JAMA-J AM MED ASSOC, V261, P3616; ESKIN BA, 1991, JAMA-J AM MED ASSOC, V266, P1146; HAYES DF, 1990, JAMA-J AM MED ASSOC, V263, P1145; HULKA BS, 1990, CA-CANCER J CLIN, V40, P289, DOI 10.3322/canjclin.40.5.289; KELSEY JL, 1988, CANCER RES, V48, P5616	6	3	3	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 22	1992	267	4					568	568						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GZ439	1309584				2023-01-03	WOS:A1992GZ43900037
J	NIGHTINGALE, SL				NIGHTINGALE, SL			FINAL RULE ELIMINATES USE OF 111 WEIGHT-CONTROL INGREDIENTS FROM OVER-THE-COUNTER DRUG PRODUCTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LANE,ROCKVILLE,MD 20857, USA.							1991, FED REG         0808, V56, P37792	1	1	2	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 15	1992	267	3					339	339		10.1001/jama.267.3.339	http://dx.doi.org/10.1001/jama.267.3.339			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GY437	1727943				2023-01-03	WOS:A1992GY43700009
J	LAETZ, T; SILBERMAN, G				LAETZ, T; SILBERMAN, G			REIMBURSEMENT POLICIES CONSTRAIN THE PRACTICE OF ONCOLOGY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Objective. -To determine the prevalence of off-label anticancer drug use (ie, using drugs to treat conditions other than those listed on the Food and Drug Administration's approved drug label), the extent of reimbursement denials for these uses, and the effect of denials on the treatment of cancer patients. Design, Setting, and Participants. - A three-part questionnaire was sent to a randomized sample of oncologists taken from the 1990 membership of the American Society of Clinical Oncology in March 1990. A response rate of 56% yielded information from 681 oncologists on the drugs they prescribed to 2018 new cancer patients and on those they frequently use in treating 11 specific types of cancer. Main Outcome Measures. - The labeled uses of the drugs prescribed and frequently used in chemotherapies were checked against the indications treated to determine whether they were prescribed for off-label uses. Three drug compendia were used as cited sources of off-label drug uses. The extent of reimbursement denials over the last 12 months and their effects on treatments were based on respondent opinions. Main Results. - Off-label drug use is prevalent and dominates the chemotherapy regimens of cancers that are more difficult to treat and for which there are no cures or agreements on standardized treatment. Most oncologists reported frustration with shifting reimbursement policies in general and with an increasing rate of denials for some off-label drug uses. Indeed, a surprising number of oncologists claimed that these policies caused them to alter preferred treatments and site of care. Conclusion. - These findings suggest the need for public discussion of off-label drug use issues so that appropriate policies can be developed.	US GEN ACCOUNTING OFF,PROGRAM EVALUAT & METHODOL,441 G ST NW,WASHINGTON,DC 20548									DEVITA VT, 1985, PRINCIPLES PRACTICE, P282; 1991, PEMD9114 US GEN ACC; 1989, FED REG         0130, V54, P4302	3	51	53	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 4	1991	266	21					2996	2999		10.1001/jama.266.21.2996	http://dx.doi.org/10.1001/jama.266.21.2996			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GR775	1820471				2023-01-03	WOS:A1991GR77500030
J	WEINTRAUB, M; SINGH, S; BYRNE, L; MAHARAJ, K; GUTTMACHER, L				WEINTRAUB, M; SINGH, S; BYRNE, L; MAHARAJ, K; GUTTMACHER, L			CONSEQUENCES OF THE 1989 NEW-YORK-STATE TRIPLICATE BENZODIAZEPINE PRESCRIPTION REGULATIONS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ABUSE	Objective. - Comparison of psychoactive medication prescribing and Medicaid expenditures before (1987 through 1988) and after (1989 through 1990) institution of the New York State triplicate benzodiazepine regulations. Data Sources. - The National Prescription Audit (IMS America, Plymouth Meeting, Pa), New York State Medicaid, and Blue Cross/Blue Shield of the Rochester (NY) Area. Results. - From 1988 to 1989, New York State benzodiazepine prescribing decreased by 44%, 60%, and 30% as assessed by IMS America, Medicaid, and Blue Cross/Blue Shield, respectively. Prescribing of the following alternative sedative-hypnotics increased in New York State compared with decreases nationally (IMS America data): meprobamate, + 125% vs - 9%; methyprylon, + 84% vs - 15%; ethchlorvynol, + 29% vs - 18%; butabarbital, + 31 % vs - 15%; hydroxyzine, + 15% vs - 1.1 %; and chloral hydrate, + 136% vs - 0.4%. increased prescribing of alternatives was also seen in the Medicaid and Blue Cross/Blue Shield data. Medicaid benzodiazepine expenditures decreased 52% from 1988 to 1989 ($21.7 million to $10.4 million). Alternative sedative expenditures increased 115% ($3.9 million to $8.4 million). Total Medicaid psychoactive medication expenditures remained nearly constant ($46.7 million to $45.6 million). Conclusion. - Although the triplicate regulations have decreased benzodiazepine prescribing, an undesirable increase has occurred in the prescribing of less acceptable medications. The wider public health, patient care, and financial implications of triplicate benzodiazepine regulations are of concern and require further study before other jurisdictions undertake similar programs.	UNIV ROCHESTER,SCH MED & DENT,DEPT PSYCHIAT,ROCHESTER,NY 14642	University of Rochester	WEINTRAUB, M (corresponding author), UNIV ROCHESTER,SCH MED & DENT,DEPT COMMUNITY & PREVENT MED,BOX 644,601 ELMWOOD AVE,ROCHESTER,NY 14642, USA.							BLACKWELL B, 1973, JAMA-J AM MED ASSOC, V223, P798, DOI 10.1001/jama.1973.03220070052017; BRAHAMS D, 1990, LANCET, V336, P1372, DOI 10.1016/0140-6736(90)92914-4; EADIE JL, 1988, DEC AM MED ASS NAT S; FINKLE BS, 1979, JAMA-J AM MED ASSOC, V242, P429, DOI 10.1001/jama.242.5.429; KAUFMAN A, 1972, J AMER MED ASSOC, V221, P1504, DOI 10.1001/jama.221.13.1504; KUNIN CM, 1973, ANN INTERN MED, V79, P555, DOI 10.7326/0003-4819-79-4-555; MADDALONI M A, 1990, Veterinary and Human Toxicology, V32, P355; MARKS J, 1985, BENZODIAZEPINES USE; PRESCOTT LP, 1983, BENZODIAZEPINES MOL, P252; RALL T W, 1990, P345; ROACHE JD, 1987, J PHARMACOL EXP THER, V243, P978; RODOS JJ, 1990, J AM OSTEOPATH ASSOC, V90, P26; SHENFIELD GM, 1980, BRIT MED J, V281, P651, DOI 10.1136/bmj.281.6241.651; WOODS JH, 1988, JAMA-J AM MED ASSOC, V260, P3476, DOI 10.1001/jama.260.23.3476; 1987, NEW YORK STAT R 0831; 1990, NEW YORK STATES REGU; 1989, EPIDEMIOL NOTES, P4; 1982, WHO6TH REP; 1990, EPIDEMIOL NOTES, P5; 1990, BENZODIAZEPINE DEPEN	20	123	127	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 6	1991	266	17					2392	2397		10.1001/jama.266.17.2392	http://dx.doi.org/10.1001/jama.266.17.2392			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GM790	1681121				2023-01-03	WOS:A1991GM79000025
J	DETSKY, AS				DETSKY, AS			PARENTERAL-NUTRITION - IS IT HELPFUL	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							META-ANALYSIS				DETSKY, AS (corresponding author), UNIV TORONTO,TORONTO M5G 2C4,ONTARIO,CANADA.							DETSKY AS, 1987, ANN INTERN MED, V107, P195, DOI 10.7326/0003-4819-107-2-195; DETSKY AS, 1987, JPEN-PARENTER ENTER, V11, P440, DOI 10.1177/0148607187011005440; DETSKY AS, 1987, JPEN-PARENTER ENTER, V11, P8, DOI 10.1177/014860718701100108; MCGEER AJ, 1990, NUTRITION, V6, P233; NAYLOR C D, 1987, Renal Failure, V10, P141, DOI 10.3109/08860228709047649; NAYLOR CD, 1989, GASTROENTEROLOGY, V97, P1033, DOI 10.1016/0016-5085(89)91517-5; 1987, ANN INTERN MED, V107, P252; 1991, NEW ENGL J MED, V325, P525; 1990, INT J TECHNOL ASSESS, V6, P655; 1989, ANN INTERN MED, V110, P734	10	18	18	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 22	1991	325	8					573	575		10.1056/NEJM199108223250808	http://dx.doi.org/10.1056/NEJM199108223250808			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GB447	1830369				2023-01-03	WOS:A1991GB44700008
J	CASTELLANO, AR; NETTLEMAN, MD				CASTELLANO, AR; NETTLEMAN, MD			COST AND BENEFIT OF SECONDARY PROPHYLAXIS FOR PNEUMOCYSTIS-CARINII PNEUMONIA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACQUIRED IMMUNODEFICIENCY SYNDROME; TRIMETHOPRIM-SULFAMETHOXAZOLE; AIDS; PENTAMIDINE; PREVENTION	Objective.-To determine the relative cost and benefit of aerosolized pentamidine and the combination product of sulfamethoxazole and trimethoprim sulfate as secondary prophylaxis for Pneumocystis carinii pneumonia. Design.-A Markov-based cost-benefit analysis was performed. Drug efficacies, toxicities, and mortality rates were drawn from the current literature. Setting.-Hypothetical. Patient Population.-Patients infected with the human immunodeficiency virus who had had at least one episode of P carinii pneumonia. Interventions.-Regimen 1 required the use of aerosolized pentamidine as the sole first-line prophylactic agent in all patients. Regimen 2 required the use of sulfamethoxazole-trimethoprim in all patients who had no history of a toxic reaction to the drug; only patients with a history of toxic effects and those who developed toxic effects while receiving the drug would receive aerosolized pentamidine. Regimen 3 required that no secondary prophylaxis be given. Main Outcome Measures.-Net cost, median patient survival, and 5-year survival for each regimen and for regimens 1 and 2 compared with regimen 3. Main Results.-Regimen 2 was dominant, with a net cost of $6332 per patient and a median survival of 2.050 years. Compared with no prophylaxis, regimen 2 resulted in a savings of $16 503 per patient and a 0.696-year increase in median survival. Compared with regimen 1, regimen 2 resulted in a savings of $2904 and a 0.067-year increase in median survival. Conclusions.-Secondary prophylaxis for P carinii saves money and extends survival. Current data suggest that sulfamethoxazole-trimethoprim should be given whenever it can be tolerated. Use of aerosolized pentamidine as a first-line agent would result in a modest increase in cost and a decrease in life expectancy.	UNIV IOWA,COLL MED,IOWA CITY,IA 52242	University of Iowa								BECK JR, 1983, MED DECIS MAKING, V3, P419, DOI 10.1177/0272989X8300300403; BERNARD E, 1988, 4TH INT C AIDS STOCK, P420; BERNARD EM, 1987, CLIN RES, V35, pA468; BIRGITTE NJ, 1989, 5TH INT C AIDS MONTR, P296; BRENNER M, 1987, AM REV RESPIR DIS, V136, P1199, DOI 10.1164/ajrccm/136.5.1199; CLOTET B, 1990, 6TH INT C AIDS SAN F, P225; CONTE JE, 1988, 4TH INT C AIDS STOCK, P419; CORCKERY KJ, 1988, RESPIR CARE, V33, P676; CREIGHKIRK T, 1988, JAMA-J AM MED ASSOC, V260, P3009; FISCHL MA, 1988, JAMA-J AM MED ASSOC, V259, P1185, DOI 10.1001/jama.259.8.1185; Friedberg G, 1988, J Palliat Care, V4, P38; GABIN SJ, 1988, 4TH INT C AIDS STOCK, P419; GOLDEN JA, 1989, LANCET, V1, P654; GORDIN FM, 1984, ANN INTERN MED, V100, P495, DOI 10.7326/0003-4819-100-4-495; GREEN J, 1990, JAMA-J AM MED ASSOC, V264, P1261, DOI 10.1001/jama.264.10.1261; KAPLAN LD, 1985, CLIN RES, V33, pA406; KELLY J, 1990, 6TH INT C AIDS SAN F, P225; KEYES C, 1989, 5TH INT C AIDS MONTR, P295; KOVACS JA, 1988, J INFECT DIS, V158, P254, DOI 10.1093/infdis/158.1.254; KOVACS JA, 1984, ANN INTERN MED, V100, P663, DOI 10.7326/0003-4819-100-5-663; LANG OS, 1989, 5TH INT C AIDS MONTR, P196; LEOUNG GS, 1988, 4TH INT C AIDS STOCK, P419; LEOUNG GS, 1989, 5TH INT C AIDS MONTR, P299; MASUR H, 1989, PRINCIPLES PRACTICE, P3; MEDINA I, 1987, 27TH INT C ANT AG CH, P261; METROKA CE, 1989, 5TH INT C AIDS MONTR, P196; MOON MW, 1989, 5TH INT C AIDS MONTR, P298; NETTLEMAN MD, 1988, INFECT CONT HOSP EP, V9, P88, DOI 10.2307/30144149; NIELSEN TL, 1990, 6TH INT C AIDS SAN F, P225; PAUKER SG, 1987, NEW ENGL J MED, V316, P250, DOI 10.1056/NEJM198701293160505; RUSKIN J, 1991, LANCET, V337, P468, DOI 10.1016/0140-6736(91)93402-U; SATTLER FR, 1988, ANN INTERN MED, V109, P280, DOI 10.7326/0003-4819-109-4-280; SHAFER RW, 1989, J ACQ IMMUN DEF SYND, V2, P389; SMITH DE, 1988, 4TH INT C AIDS STOCK, P418; STASZEWSKI S, 1989, 5TH INT C AIDS MONTR, P299; TORRES R, 1990, 6TH INT AIDS C SAN F, P223; TORRES RA, 1989, 5TH INT C AIDS MONTR, P299; VANGUNDY KP, 1988, 4TH INT C AIDS STOCK, P420; WEINKE T, 1988, 4TH INT C AIDS STOCK, P421; Weinstein MC, 1980, CLIN DECISION ANAL; WEISMAN J, 1989, 5TH INT C AIDS MONTR, P219; WHARTON JM, 1986, ANN INTERN MED, V105, P37, DOI 10.7326/0003-4819-105-1-37; WOFSY CB, 1987, REV INFECT DIS, V9, pS184; 1989, MMWR SS5, V38, P1	44	44	44	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 14	1991	266	6					820	824		10.1001/jama.266.6.820	http://dx.doi.org/10.1001/jama.266.6.820			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GA073	1907671				2023-01-03	WOS:A1991GA07300034
J	RUSKIN, J; LARIVIERE, M				RUSKIN, J; LARIVIERE, M			LOW-DOSE COTRIMOXAZOLE FOR PREVENTION OF PNEUMOCYSTIS-CARINII PNEUMONIA IN HUMAN-IMMUNODEFICIENCY-VIRUS DISEASE	LANCET			English	Article							SULFAMETHOXAZOLE; CHEMOPROPHYLAXIS; PENTAMIDINE; AIDS	The efficacy and tolerability of low, intermittent doses of co-trimoxazole (160 mg trimethoprim and 800 mg sulfamethoxazole given Monday, Wednesday, Friday) for prophylaxis against Pneumocystis carinii pneumonia (PCP) was assessed retrospectively in 116 patients with the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex at high risk of PCP. 92% were receiving concomitant zidovudine. 71 with previous episode(s) of PCP were followed a mean of 18.5 months (range 3-42). 45 without past PCP but with depletion of CD4 cells to < 200/mu-l were observed for a mean of 24.2 months (range 9-40). PCP did not develop in any patient on co-trimoxazole. 33 (28%) had side-effects, mainly rash, pruritus, and nausea. 15 discontinued co-trimoxazole, but only 11 (9%), who withdrew in the first month, were clearly drug-intolerant. Thus, low-dose, thrice weekly cotrimoxazole completely prevents AIDS-associated PCP, is cost-effective, and well tolerated by more than 85% of patients. Controlled comparisons of this regimen with other prophylactic agents are warranted.			RUSKIN, J (corresponding author), KAISER PERMANENTE MED CTR,DEPT INTERNAL MED,DIV INFECT DIS,1505 N EDGEMONT ST,LOS ANGELES,CA 90027, USA.							BERNARD EM, 1989, 5 INT C AIDS MONTR; BIGBY TD, 1986, AM REV RESPIR DIS, V133, P515; FISCHL MA, 1988, JAMA-J AM MED ASSOC, V259, P1185, DOI 10.1001/jama.259.8.1185; FISCHL MA, 1990, NEW ENGL J MED, V323, P1009, DOI 10.1056/NEJM199010113231501; GIRARD PM, 1989, LANCET, V1, P1348; GLUCKSTEIN D, 1988, 4 INT C AIDS STOCKH; GOLDEN JA, 1989, LANCET, V1, P654; HUGHES WT, 1977, NEW ENGL J MED, V297, P1419, DOI 10.1056/NEJM197712292972602; HUGHES WT, 1987, NEW ENGL J MED, V316, P1627, DOI 10.1056/NEJM198706253162604; HUGHES WT, 1979, ANTIMICROB AGENTS CH, V16, P333, DOI 10.1128/AAC.16.3.333; JULESELYSEE KM, 1990, ANN INTERN MED, V112, P750, DOI 10.7326/0003-4819-112-10-750; LEOUNG GS, 1990, NEW ENGL J MED, V323, P769, DOI 10.1056/NEJM199009203231201; NICHOLAS P, 1990, 6 INT C AIDS SAN FRA; PESANTI EL, 1980, J INFECT DIS, V141, P775, DOI 10.1093/infdis/141.6.775; PHAIR J, 1990, NEW ENGL J MED, V322, P161, DOI 10.1056/NEJM199001183220304; SATTLER FR, 1988, ANN INTERN MED, V109, P280, DOI 10.7326/0003-4819-109-4-280; TELZAK EE, 1990, REV INFECT DIS, V12, P380; [No title captured]; 1989, AIDS WKLY SURV  0130, P1; 1989, MMWR, V38, P1	20	126	126	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 23	1991	337	8739					468	471		10.1016/0140-6736(91)93402-U	http://dx.doi.org/10.1016/0140-6736(91)93402-U			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EY887	1671479				2023-01-03	WOS:A1991EY88700013
J	GOLDHIRSCH, A; CASTIGLIONE, M; GELBER, RD				GOLDHIRSCH, A; CASTIGLIONE, M; GELBER, RD			ADJUVANT CHEMOENDOCRINE THERAPY IN POSTMENOPAUSAL WOMEN WITH BREAST-CANCER AND AXILLARY-NODE METASTASES	LANCET			English	Letter									HARVARD UNIV,SCH MED,DANA FARBER CANC INST,BOSTON,MA 02115	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	GOLDHIRSCH, A (corresponding author), INT BREAST CANC STUDY GRP,KONSUMSTR 13,CH-3007 BERN,SWITZERLAND.							GOLDHIRSCH A, 1989, J CLIN ONCOL, V7, P36, DOI 10.1200/JCO.1989.7.1.36; MIKL, 1990, LANCET, V335, P541; 1988, NEW ENGL J MED, V319, P1681	3	4	4	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 5	1990	335	8697					1099	1100		10.1016/0140-6736(90)92675-8	http://dx.doi.org/10.1016/0140-6736(90)92675-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DC568	1970400				2023-01-03	WOS:A1990DC56800036
J	ALEXANDERWILLIAMS, J				ALEXANDERWILLIAMS, J			ADVANCED RECTAL-CANCER	BRITISH MEDICAL JOURNAL			English	Editorial Material											ALEXANDERWILLIAMS, J (corresponding author), GEN HOSP,GASTROINTESTINAL SURG,BIRMINGHAM B4 6NH,W MIDLANDS,ENGLAND.							BERRY AR, IN PRESS BR J SURG; CRILE G, 1972, SURG GYNECOL OBSTETR, V135, P391; EISENBERG HW, 1984, SURG GYNECOL OBSTET, V159, P471; GUNDERSON LL, 1988, ANN SURG, V207, P52; Mason A Y, 1972, Ann R Coll Surg Engl, V51, P320; MELLOW MH, 1989, GASTROINTEST ENDOSC, V35, P283, DOI 10.1016/S0016-5107(89)72792-9; PAPILLON J, 1982, RECTAL ANAL CANCERS; PARKS AG, 1973, BRIT J SURG, V60, P688, DOI 10.1002/bjs.1800600908; ZINKIN LD, 1979, SURG GYNECOL OBSTET, V148, P427	9	6	6	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 3	1990	300	6720					276	277		10.1136/bmj.300.6720.276	http://dx.doi.org/10.1136/bmj.300.6720.276			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CM195	1690034	Bronze, Green Published			2023-01-03	WOS:A1990CM19500002
J	KRISHNASWAMY, S; FIELD, KA; EDGINGTON, TS; MORRISSEY, JH; MANN, KG				KRISHNASWAMY, S; FIELD, KA; EDGINGTON, TS; MORRISSEY, JH; MANN, KG			ROLE OF THE MEMBRANE-SURFACE IN THE ACTIVATION OF HUMAN COAGULATION FACTOR-X	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE FACTOR PATHWAY; K-DEPENDENT PROTEINS; BOVINE FACTOR-V; FACTOR-VII; PHOSPHOLIPID-VESICLES; BLOOD-COAGULATION; HUMAN-PROTHROMBIN; PROCOAGULANT ACTIVITY; PARA-AMINOBENZAMIDINE; EXTRINSIC PATHWAY	Coagulation factor X is activated by the extrinsic Xase complex composed of factor VIIa associated with the integral membrane protein tissue factor. The kinetics of human factor X activation was studied following reconstitution of this reaction system using purified human proteins and synthetic phospholipid vesicles composed of phosphatidylcholine and phosphatidylserine (PCPS) or phosphatidylcholine alone (PC). Factor X activation was evaluated by discontinuous measurements of the amidolytic activity of the product, factor Xa, or continuously monitored using the fluorescent serine protease inhibitor 4-aminobenzamidine. The results of both techniques were verified by direct physical measurements of zymogen activation using SDS-polyacrylamide gel electrophoresis. The rate of factor X activation with PC vesicles was less than 5% of that observed with PCPS vesicles. Since factor X does not bind to vesicles containing only PC, these data suggested an important role for the substrate-membrane interaction in the catalytic cycle. The importance of the substrate-membrane interaction in the activation process was investigated by using membrane-binding proteins to compete with the substrate for combining sites on PCPS vesicles. Prothrombin fragment 1 was an inhibitor of factor X activation. The dependence of inhibition by fragment 1 on PCPS and factor X was consistent with a significant reduction in initial velocity due to the displacement of factor X from the membrane surface. The inhibition data also suggested that the membrane-bound pool of factor X was the preferred substrate for the human extrinsic Xase complex. The influence of PCPS concentrations on the rate of factor X activation was systematically investigated. Increasing concentrations of PCPS resulted in a modest change in the K(m,app) and a dramatic change in the V(max,app) for the reaction. The initial velocity data could be globally analyzed according to the preferential utilization of membrane-bound factor X with the intrinsic kinetic constants: K(m) congruent-to 1 muM and k(cat) = 37 s-1 at saturating PCPS. In addition, the equilibrium parameters for the factor X-membrane interaction inferred from these studies were in excellent agreement with the directly determined values. Collectively, the data suggest that the substrate-membrane interaction must precede catalysis for the efficient activation of human factor X by the extrinsic Xase complex.	UNIV VERMONT, DEPT BIOCHEM, BURLINGTON, VT 05405 USA; SCRIPPS CLIN & RES FDN, DEPT IMMUNOL, VASC BIOL GRP, LA JOLLA, CA 92037 USA	University of Vermont; Scripps Research Institute	KRISHNASWAMY, S (corresponding author), EMORY UNIV, SCH MED, DEPT MED, DIV HAEMATOL, DRAWER AR, ATLANTA, GA 30322 USA.		Morrissey, James H./GLR-5645-2022; Morrissey, James H/H-4933-2011	Morrissey, James H/0000-0002-1570-1569; Field, Kenneth/0000-0001-7417-4386	NHLBI NIH HHS [HL-34575, HL-35058, HL-38337] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL035058, R37HL034575, R29HL038337, R01HL034575] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BACH R, 1986, BIOCHEMISTRY-US, V25, P4007, DOI 10.1021/bi00362a005; BACH R, 1988, BIOCHEMISTRY-US, V27, P4227, DOI 10.1021/bi00412a004; BACH R, 1990, P NATL ACAD SCI USA, V87, P6995, DOI 10.1073/pnas.87.18.6995; BAJAJ SP, 1981, J BIOL CHEM, V256, P253; BAJAJ SP, 1981, PREP BIOCHEM, V11, P397, DOI 10.1080/00327488108065531; BERG OG, 1985, BIOPHYS J, V47, P1, DOI 10.1016/S0006-3495(85)83870-4; BERG OG, 1985, ANNU REV BIOPHYS BIO, V14, P131, DOI 10.1146/annurev.biophys.14.1.131; BEVILACQUA MP, 1984, J EXP MED, V160, P618, DOI 10.1084/jem.160.2.618; Bevington P. R, 1969, DATA REDUCTION ERROR; BLOOM JW, 1979, BIOCHEMISTRY-US, V18, P4419, DOI 10.1021/bi00587a023; BOM VJJ, 1990, BIOCHEM J, V265, P327, DOI 10.1042/bj2650327; CARSON SD, 1980, SCIENCE, V208, P307, DOI 10.1126/science.7367861; CRAIG PA, 1989, J BIOL CHEM, V264, P5452; DISCIPIO RG, 1977, BIOCHEMISTRY-US, V16, P698, DOI 10.1021/bi00623a022; DRAKE TA, 1989, AM J PATHOL, V134, P1087; DUGGLEBY RG, 1986, BIOCHEM J, V235, P613, DOI 10.1042/bj2350613; DURBIN J, 1951, BIOMETRIKA, V38, P159, DOI 10.1093/biomet/38.1-2.159; EVANS SA, 1982, J BIOL CHEM, V257, P3014; FORMAN SD, 1986, P NATL ACAD SCI USA, V83, P4675, DOI 10.1073/pnas.83.13.4675; GALVIN JB, 1987, J BIOL CHEM, V262, P2199; GREGORY SA, 1985, J CLIN INVEST, V76, P2440, DOI 10.1172/JCI112260; HIGGINS DL, 1983, J BIOL CHEM, V258, P6503; JACKSON CM, 1984, PROG HEMOST THROMB, V7, P55; JACKSON CM, 1975, THROMB DIATH HAEMOST, V34, P561; JENNY R, 1986, PREP BIOCHEM, V16, P227, DOI 10.1080/00327488608062468; KRISHNASWAMY S, 1988, J BIOL CHEM, V263, P5714; KRISHNASWAMY S, 1992, J BIOL CHEM, V267, P23696; KRISHNASWAMY S, 1988, J BIOL CHEM, V263, P3823; KRISHNASWAMY S, 1987, J BIOL CHEM, V262, P3291; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWSON JH, 1992, J BIOL CHEM, V267, P4834; MACKMAN N, 1990, P NATL ACAD SCI USA, V87, P2254, DOI 10.1073/pnas.87.6.2254; MANN KG, 1981, METHOD ENZYMOL, V80, P286; MANN KG, 1988, ANNU REV BIOCHEM, V57, P915, DOI 10.1146/annurev.bi.57.070188.004411; MATHESON IBC, 1987, ANAL INSTRUM, V16, P345; MERTENS K, 1984, BIOCHEM J, V223, P599, DOI 10.1042/bj2230599; MONROE DM, 1988, ANAL BIOCHEM, V172, P427, DOI 10.1016/0003-2697(88)90465-4; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; MORRISSEY JH, 1987, CELL, V50, P129, DOI 10.1016/0092-8674(87)90669-6; MORRISSEY JH, 1988, THROMB RES, V50, P481, DOI 10.1016/0049-3848(88)90197-1; NAKAGAKI T, 1991, BIOCHEMISTRY-US, V30, P10819, DOI 10.1021/bi00109a001; NELSESTUEN GL, 1978, BIOCHEMISTRY-US, V17, P2134, DOI 10.1021/bi00604a017; NEMERSON Y, 1986, BIOCHEMISTRY-US, V25, P4020, DOI 10.1021/bi00362a006; NEMERSON Y, 1985, THROMB RES, V40, P351, DOI 10.1016/0049-3848(85)90270-1; NEMERSON Y, 1982, PROG HEMOST THROMB, V6, P237; NEMERSON Y, 1969, J CLIN INVEST, V48, P322, DOI 10.1172/JCI105988; NEMERSON Y, 1988, BLOOD, V71, P1; RAO LVM, 1988, P NATL ACAD SCI USA, V85, P6687, DOI 10.1073/pnas.85.18.6687; RICHTER PH, 1974, BIOPHYS CHEM, V2, P255, DOI 10.1016/0301-4622(74)80050-5; RUF W, 1991, J BIOL CHEM, V266, P2158; SILVERBERG SA, 1977, J BIOL CHEM, V252, P8481; VANDEWAART P, 1984, BIOCHEMISTRY-US, V23, P2838, DOI 10.1021/bi00307a047; VANDIEIJEN G, 1981, BIOCHEMISTRY-US, V20, P7096, DOI 10.1021/bi00528a007; ZAKIM D, 1989, METHOD ENZYMOL, V171, P253; ZUR M, 1982, J BIOL CHEM, V257, P5623; [No title captured]	56	135	145	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 25	1992	267	36					26110	26120						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KD073	1464622				2023-01-03	WOS:A1992KD07300079
J	HARDY, WD; FEINBERG, J; FINKELSTEIN, DM; POWER, ME; HE, W; KACZKA, C; FRAME, PT; HOLMES, M; WASKIN, H; FASS, RJ; POWDERLY, WG; STEIGBIGEL, RT; ZUGER, A; HOLZMAN, RS				HARDY, WD; FEINBERG, J; FINKELSTEIN, DM; POWER, ME; HE, W; KACZKA, C; FRAME, PT; HOLMES, M; WASKIN, H; FASS, RJ; POWDERLY, WG; STEIGBIGEL, RT; ZUGER, A; HOLZMAN, RS			A CONTROLLED TRIAL OF TRIMETHOPRIM SULFAMETHOXAZOLE OR AEROSOLIZED PENTAMIDINE FOR SECONDARY PROPHYLAXIS OF PNEUMOCYSTIS-CARINII PNEUMONIA IN PATIENTS WITH THE ACQUIRED-IMMUNODEFICIENCY-SYNDROME - AIDS CLINICAL-TRIALS GROUP PROTOCOL-021	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							VIRUS INFECTION; CHEMOPROPHYLAXIS; ZIDOVUDINE	Background. Pneumocystis carinii pneumonia (PCP) continues to be the most common index diagnosis in the acquired immunodeficiency syndrome (AIDS), but it is not clear which of several available agents is the most effective in preventing a recurrence of PCP. Methods. We conducted a comparative, open-label trial in 310 adults with AIDS who had recently recovered from an initial episode of PCP and had no treatment-limiting toxic effects of trimethoprim-sulfamethoxazole or pentamidine. All the patients were treated with zidovudine and were randomly assigned to receive either 800 mg of sulfamethoxazole and 160 mg of trimethoprim once daily or 300 mg of aerosolized pentamidine administered every four weeks by jet nebulizer. The participants were followed for a median of 17.4 months. Results. In the trimethoprim-sulfamethoxazole group (n = 154) there were 14 recurrences of PCP, as compared with 36 recurrences (including 1 extrapulmonary recurrence) in the aerosolized-pentamidine group (n = 156). The estimated recurrence rates at 18 months were 11.4 percent with trimethoprim-sulfamethoxazole and 27.6 percent with pentamidine (P<0.001). The risk of a recurrence (adjusted for initial CD4 cell count) was 3.25 times higher in the pentamidine group (P<0.001; 95 percent confidence interval, 1.72 to 6.16). There were no significant differences between the groups in survival or in hematologic or hepatic toxicity. Crossovers from trimethoprim-sulfamethoxazole to aerosolized pentamidine were more common than the reverse (27 vs. 4 percent), partly because of the study protocols for the management of leukopenia. There were 19 serious bacterial infections in the trimethoprim-sulfamethoxazole group and 38 in the pentamidine group. The time to a first bacterial infection was significantly greater for those assigned to trimethoprim-sulfamethoxazole (P = 0.017). Conclusions. In patients with AIDS who are receiving zidovudine, trimethoprim-sulfamethoxazole is more effective than aerosolized pentamidine in conventional doses for the prevention of recurrent pneumocystis infection.	NYU,SCH MED,DEPT MED,550 1ST AVE,NEW YORK,NY 10016; UNIV CALIF LOS ANGELES,DEPT MED,LOS ANGELES,CA 90024; HARVARD UNIV,SCH PUBL HLTH,DEPT BIOSTAT,BOSTON,MA 02115; NIAID,DIV AIDS,BETHESDA,MD 20892; FRONTIER SCI TECHNOL & RES FDN,AMHERST,NY; UNIV CINCINNATI,SCH MED,DEPT MED,CINCINNATI,OH 45221; UNIV SO CALIF,DEPT MED,LOS ANGELES,CA 90089; DUKE UNIV,SCH MED,DEPT MED,DURHAM,NC 27706; OHIO STATE UNIV,COLL MED,DEPT MED,COLUMBUS,OH 43210; WASHINGTON UNIV,SCH MED,DEPT MED,ST LOUIS,MO 63110; SUNY STONY BROOK,DEPT MED,STONY BROOK,NY 11794; YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT MED,BRONX,NY 10461	New York University; University of California System; University of California Los Angeles; Harvard University; Harvard T.H. Chan School of Public Health; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Frontier Science Foundation; University System of Ohio; University of Cincinnati; University of Southern California; Duke University; University System of Ohio; Ohio State University; Washington University (WUSTL); State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Yeshiva University; Albert Einstein College of Medicine	HOLZMAN, RS (corresponding author), NYU,SCH MED,DEPT MED,550 1ST AVE,NEW YORK,NY 10016, USA.			Powderly, William/0000-0001-7808-3086; feinberg, judith/0000-0003-4206-7214	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [N01AI052607, N01AI095030] Funding Source: NIH RePORTER; NIAID NIH HHS [N01-AI-52607, N0-AI-95030] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		CASTELLANO AR, 1991, JAMA-J AM MED ASSOC, V266, P820, DOI 10.1001/jama.266.6.820; COLLIER AC, 1990, NEW ENGL J MED, V323, P1015, DOI 10.1056/NEJM199010113231502; COX DR, 1972, J R STAT SOC B, V34, P187; FAUCI AS, 1985, ANN INTERN MED, V102, P800, DOI 10.7326/0003-4819-102-6-800; FISCHL MA, 1988, JAMA-J AM MED ASSOC, V259, P1185, DOI 10.1001/jama.259.8.1185; FISCHL MA, 1990, NEW ENGL J MED, V323, P1009, DOI 10.1056/NEJM199010113231501; Fleiss JL, 1981, STAT METHODS RATES P; HARDY WD, 1987, 3RD P INT C AIDS WAS, P232; HUGHES WT, 1977, NEW ENGL J MED, V297, P1419, DOI 10.1056/NEJM197712292972602; HUGHES WT, 1987, NEW ENGL J MED, V316, P1627, DOI 10.1056/NEJM198706253162604; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; LEOUNG GS, 1990, NEW ENGL J MED, V323, P769, DOI 10.1056/NEJM199009203231201; MANN HB, 1947, ANN MATH STAT, V18, P50, DOI 10.1214/aoms/1177730491; METROKA CE, 1989, 5TH INT C AIDS MONTR, P196; OBRIEN PC, 1979, BIOMETRICS, V35, P549, DOI 10.2307/2530245; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; VOLBERDING PA, 1990, NEW ENGL J MED, V322, P941, DOI 10.1056/NEJM199004053221401; 1989, MMWR MORB MORTAL SS5, V38, P1	18	349	353	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 24	1992	327	26					1842	1848		10.1056/NEJM199212243272604	http://dx.doi.org/10.1056/NEJM199212243272604			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KD714	1448121	Bronze			2023-01-03	WOS:A1992KD71400004
J	KLEIJNEN, J; KNIPSCHILD, P				KLEIJNEN, J; KNIPSCHILD, P			GINKGO-BILOBA	LANCET			English	Article							DOUBLE-BLIND; EXTRACT; PLACEBO; DRUG; MULTICENTER				KLEIJNEN, J (corresponding author), UNIV LIMBURG,DEPT EPIDEMIOL,POB 616,6200 MD MAASTRICHT,NETHERLANDS.							BAUER U, 1984, ARZNEIMITTEL-FORSCH, V34-1, P716; BRAQUET P, 1991, J ETHNOPHARMACOL, V32, P135, DOI 10.1016/0378-8741(91)90111-P; BRAQUET P, 1989, GINKGOLIDES CHEM BIO, V2; BRAQUET P, 1988, GINKGOLIDES CHEM BIO, V1; BRUCHERT E, 1991, MUNCH MED WOCHENS S1, V133, pS9; CHUNG KF, 1987, LANCET, V1, P248; De Feudis F.V., 1991, GINKGO BILOBA EXTRAC, P68; DEFEUDIS FV, 1991, GINKGO BILOBA EXTRAC, P143; Eckmann F, 1990, Fortschr Med, V108, P557; HAGUENAUER JP, 1986, PRESSE MED, V15, P1569; HARTMANN A, 1991, MUNCHEN MED WOCHEN, V133, pS23; HOFFERBERTH B, 1989, ARZNEIMITTEL-FORSCH, V39-2, P918; HOFFERBERTH B, 1991, MUNCHEN MED WOCHEN, V133, pS30; JUNG F, 1990, ARZNEIMITTELFORSCH, V40-1, P589; KLEIJNEN J, 1992, BRIT J CLIN PHARMACO, V34, P352, DOI 10.1111/j.1365-2125.1992.tb05642.x; KLEIJNEN J, 1991, FOOD SUPPLEMENTS THE; KOLTRINGER P, 1989, PERFUSION, V1, P28; MEYER B, 1986, PRESSE MED, V15, P1562; MOREAU JP, 1986, PRESSE MED, V15, P1458; Nieder M., 1991, MUNCHEN MED WOCHEN, V133, pS61; PINCEMAIL J, 1989, EXPERIENTIA, V45, P708, DOI 10.1007/BF01974564; Rabinovici K, 1991, MUNCH MED WOCHENS S1, V133, pS15; ROBAK J, 1988, BIOCHEM PHARMACOL, V37, P837, DOI 10.1016/0006-2952(88)90169-4; SAUDREAU F, 1989, J MAL VASCUL, V14, P177; TAILLANDIER J, 1986, PRESSE MED, V15, P1583; VORBERG G, 1989, HERZ GEFASSE, V9, P936; Wesnes K., 1987, HUMAN PSYCHOPHARMACO, V2, P159, DOI [10.1002/hup.470020305, DOI 10.1002/HUP.470020305]	27	439	458	1	60	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 7	1992	340	8828					1136	1139		10.1016/0140-6736(92)93158-J	http://dx.doi.org/10.1016/0140-6736(92)93158-J			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JX134	1359218	Bronze			2023-01-03	WOS:A1992JX13400011
J	MCCLELLAN, WM; FLANDERS, WD; GUTMAN, RA				MCCLELLAN, WM; FLANDERS, WD; GUTMAN, RA			VARIABLE MORTALITY-RATES AMONG DIALYSIS TREATMENT CENTERS	ANNALS OF INTERNAL MEDICINE			English	Article						KIDNEY FAILURE, CHRONIC; DIALYSIS; AGE FACTORS; DIABETIC NEPHROPATHY	STAGE RENAL-DISEASE; LONG-TERM DIALYSIS; SURVIVAL; HEMODIALYSIS; PATIENT; RISK	Objective: To examine the variation in the risk for mortality among patients treated at renal dialysis facilities within a defined geographic area. Setting: All free-standing and hospital-based dialysis facilities in a single southeastern state reported to the registry. Design: Cohort of dialysis patients followed for 1 year by an end-stage renal disease registry. Patients: Patients (n = 3612) aged 20 years and older receiving treatment at the dialysis facilities reporting to the registry during 1987. Measurements: Demographic, comorbid, and severity of illness indicators were abstracted from patient records. Facility-specific risk estimates were derived from a Cox proportional hazards model. Results: Facility-specific mortality rates ranged between 2.0 and 10.5 deaths per 10 000 patient days. Mortality rates were higher among older persons; whites; those with a history of diabetic nephropathy, angina, or congestive heart failure; and patients with either nutritional or functional status impairment. Facility-specific prevalence of each mortality risk factor varied widely. The unadjusted risk for death in a facility at the 75th percentile of risk was 1.3 times that of a facility at the median, whereas at the 25th percentile, it was 0.68 times as likely-a twofold range of risk. Controlling for differences in the prevalence of patient characteristics did not change the interquartile range in risks, and a facility's adjusted risk estimate showed a strong correlation with its unadjusted estimate (R2, 0.566; P < 0.0001). Conclusions: Patient attributes associated with increased risk for mortality vary widely among dialysis facilities. Adjustment for these differences did not, however, substantially change either the degree of variation in mortality risks or the relative ranking of a facility's mortality.	EMORY UNIV, SCH MED, ATLANTA, GA 30322 USA; EMORY UNIV, SCH PUBL HLTH, DIV EPIDEMIOL, ATLANTA, GA 30322 USA; DURHAM REG HOSP, DURHAM, NC USA; DUKE UNIV, SCH MED, DURHAM, NC 27706 USA	Emory University; Emory University; Duke University	MCCLELLAN, WM (corresponding author), CLARK HOLDER CLIN, 303 SMITH ST, LA GRANGE, GA 30240 USA.							Acchiardo S R, 1983, Kidney Int Suppl, V16, pS199; BURTON BT, 1971, J AMER MED ASSOC, V218, P718, DOI 10.1001/jama.218.5.718; Degoulet P, 1980, Proc Eur Dial Transplant Assoc, V17, P149; GARCIAGARCIA G, 1985, AM J KIDNEY DIS, V5, P10, DOI 10.1016/S0272-6386(85)80129-3; GROSS JB, 1973, ANN INTERN MED, V78, P341, DOI 10.7326/0003-4819-78-3-341; GUTMAN RA, 1981, NEW ENGL J MED, V304, P309, DOI 10.1056/NEJM198102053040601; HELD PJ, 1991, JAMA-J AM MED ASSOC, V265, P871, DOI 10.1001/jama.265.7.871; HELD PJ, 1987, JAMA-J AM MED ASSOC, V257, P645, DOI 10.1001/jama.257.5.645; HELLERSTEDT WL, 1984, MAYO CLIN PROC, V59, P776, DOI 10.1016/S0025-6196(12)65589-X; HUSEBYE DG, 1987, ARCH INTERN MED, V147, P1921, DOI 10.1001/archinte.147.11.1921; HUTCHINSON TA, 1982, ANN INTERN MED, V96, P417, DOI 10.7326/0003-4819-96-4-417; HUTCHINSON TA, 1984, KIDNEY INT, V26, P44, DOI 10.1038/ki.1984.132; LEWIS EJ, 1969, ANN INTERN MED, V70, P311, DOI 10.7326/0003-4819-70-2-311; LOWRIE EG, 1990, AM J KIDNEY DIS, V15, P458, DOI 10.1016/S0272-6386(12)70364-5; MAIORCA R, 1988, KIDNEY INT, V34, P518, DOI 10.1038/ki.1988.212; MCCLELLAN WM, 1991, J CLIN EPIDEMIOL, V44, P83, DOI 10.1016/0895-4356(91)90204-M; PROWANT B, 1983, AM J KIDNEY DIS, V3, P27, DOI 10.1016/S0272-6386(83)80006-7; RADECKI SE, 1988, AM J KIDNEY DIS, V11, P7, DOI 10.1016/S0272-6386(88)80167-7; ROBERTS JL, 1976, KIDNEY INT, V9, P363, DOI 10.1038/ki.1976.43; UMEN AJ, 1986, STAT MED, V5, P637, DOI 10.1002/sim.4780050611; WALKER JV, 1988, AM J NEPHROL, V8, P40, DOI 10.1159/000167551; WELLER JM, 1982, KIDNEY INT, V21, P78, DOI 10.1038/ki.1982.11; 1991, USRDS1991  NAT I DIA; 1985, EGRET MANUAL STATIST; 1991, USRDS1991 NAT I DIAB	25	73	73	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 15	1992	117	4					332	336		10.7326/0003-4819-117-4-332	http://dx.doi.org/10.7326/0003-4819-117-4-332			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JH464	1637029				2023-01-03	WOS:A1992JH46400011
J	JADAD, AR; CARROLL, D; GLYNN, CJ; MOORE, RA; MCQUAY, HJ				JADAD, AR; CARROLL, D; GLYNN, CJ; MOORE, RA; MCQUAY, HJ			MORPHINE RESPONSIVENESS OF CHRONIC PAIN - DOUBLE-BLIND RANDOMIZED CROSSOVER STUDY WITH PATIENT-CONTROLLED ANALGESIA	LANCET			English	Article								There is controversy about whether the lack of response of some chronic pain to opioid treatment is absolute or relative. It is widely believed that nociceptive pain is responsive to opioids whereas neuropathic pain tends not to be. We have used a method of patient-controlled analgesia (PCA) with simultaneous nurse-observer measurement of analgesia, mood, and adverse effects to address these issues. Ten patients with chronic pain were given morphine at two concentrations (10 and 30 mg/ml) by PCA in two separate sessions in a double-blind randomised crossover study. Before the study a clinical judgment was made as to whether each pain was nociceptive or neuropathic. Seven patients showed good analgesic responses (more than 70 mm pain relief on a visual-analogue scale) of pain at rest, two patients poor responses (less than 30 mm pain relief), and one a moderate response with both concentrations (30-70 mm pain relief). The response to morphine was consistent (greater and faster relief with the higher concentration) in nine patients. Two patients had pain on movement that responded moderately to low-concentration morphine and well to the higher concentration. All patients with pains judged to be nociceptive showed good analgesic responses compared with half of those with neuropathic pain. There was no evidence that analgesic responses in patients with neuropathic pain were due to changes in mood. This PCA method is a quick and efficient tool to determine the consistency of the analgesic response. Such consistency can guide the clinician as to whether continued or higher-dose opioid treatment will produce good analgesia. An inconsistent response points to the use of other pain-relieving strategies.	UNIV OXFORD,NUFFIELD DEPT ANAESTHET,OXFORD,ENGLAND; DIAGNOST PROD CORP,EUROPEAN RES INST,OXFORD,ENGLAND	University of Oxford								ARNER S, 1988, PAIN, V33, P11, DOI 10.1016/0304-3959(88)90198-4; BRENA SF, 1991, CLIN J PAIN, V7, P342, DOI 10.1097/00002508-199112000-00015; BRUERA E, 1991, PAIN, V44, P167, DOI 10.1016/0304-3959(91)90132-H; COOPER SA, 1991, DESIGN ANALGESIC CLI, V18, P117; GLYNN CJ, 1991, CLIN J PAIN, V7, P346, DOI 10.1097/00002508-199112000-00016; HARDY PAJ, 1991, BRIT J HOSP MED, V45, P257; HILL CS, 1989, ADV PAIN RES THERAPY, V11; JACOBS OLR, 1985, AUTOMATICA, V21, P349, DOI 10.1016/0005-1098(85)90072-X; KEERISZANTO M, 1979, PAIN, V6, P217, DOI 10.1016/0304-3959(79)90129-5; KUPERS RC, 1991, PAIN, V47, P5, DOI 10.1016/0304-3959(91)90004-H; MCQUAY HJ, IN PRESS ANAESTHESIA; PORTENOY RK, 1990, PAIN, V43, P273, DOI 10.1016/0304-3959(90)90025-9; ROWBOTHAM MC, 1991, NEUROLOGY, V41, P1024, DOI 10.1212/WNL.41.7.1024; TASKER RR, 1983, ADV PAIN RES THER, V5, P713	14	154	157	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 6	1992	339	8806					1367	1371		10.1016/0140-6736(92)91194-D	http://dx.doi.org/10.1016/0140-6736(92)91194-D			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HX636	1350803				2023-01-03	WOS:A1992HX63600001
J	NIEMIRA, DA				NIEMIRA, DA			A TIME TO DECIDE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 8	1992	267	14					1913	1913		10.1001/jama.267.14.1913	http://dx.doi.org/10.1001/jama.267.14.1913			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HL677	1548814				2023-01-03	WOS:A1992HL67700007
J	TORRES, A; SERRABATLLES, J; ROS, E; PIERA, C; DELABELLACASA, JP; COBOS, A; LOMENA, F; RODRIGUEZROISIN, R				TORRES, A; SERRABATLLES, J; ROS, E; PIERA, C; DELABELLACASA, JP; COBOS, A; LOMENA, F; RODRIGUEZROISIN, R			PULMONARY ASPIRATION OF GASTRIC CONTENTS IN PATIENTS RECEIVING MECHANICAL VENTILATION - THE EFFECT OF BODY POSITION	ANNALS OF INTERNAL MEDICINE			English	Article						RESPIRATION, ARTIFICIAL; PNEUMONIA; SUPINE POSITION; SUCRALFATE; HISTAMINE-H2 RECEPTOR; BLOCKADERS	NOSOCOMIAL PNEUMONIA; GASTROESOPHAGEAL REFLUX; ARTIFICIAL-VENTILATION; RESPIRATORY-TRACT; RISK; COLONIZATION; SUCRALFATE; CIMETIDINE; PROGNOSIS; BACTERIA	Objective: To determine if the semirecumbent position (45-degree angle) decreases aspiration of gastric contents to the airways in intubated and mechanically ventilated patients. Design: A randomized, two-period crossover trial. Setting: Respiratory intensive care unit. Patients: Nineteen patients requiring intubation and mechanical ventilation. Interventions: Patients were studied in the supine and semirecumbent positions on two separate days. Measurements: After technetium (Tc)-99m sulphur colloid labeling of gastric contents, sequential radioactive counts in endobronchial secretions were measured at 30-minute intervals over a 5-hour period. Samples of endobronchial secretions, gastric juice, and pharyngeal contents were obtained for qualitative bacterial cultures. Results: Mean radioactive counts in endobronchial secretions were higher in samples obtained while patients were in the supine position than in those obtained while patients were in the semirecumbent position (4154 cpm compared with 954 cpm; P = 0.036). Moreover, the aspiration pattern was time-dependent for each position: For the supine position, radioactivity was 298 cpm at 30 min and 2592 cpm at 300 min (P = 0.013); for the semirecumbent position, radioactivity was 103 cpm at 30 min and 216 cpm at 300 min (P = 0.04). The same microorganisms were isolated from stomach, pharynx, and endobronchial samples in 32% of studies done while patients were semirecumbent and in 68% of studies done while patients were in the supine position. Conclusions: We conclude that the supine position and length of time the patient is kept in this position are potential risk factors for aspiration of gastric contents. Elevating the head of the bed for patients who can tolerate the semirecumbent position may be a simple, no-cost prophylactic measure.	UNIV BARCELONA, FAC MED REUS, UNITAT BIOESTADIST, E-08036 BARCELONA, SPAIN	University of Barcelona			Torres, Antoni/H-6128-2017	Torres, Antoni/0000-0002-8643-2167; Ros, Emilio/0000-0002-2573-1294				ANDREWS CP, 1981, CHEST, V80, P254, DOI 10.1378/chest.80.3.254; ATHERTON ST, 1978, LANCET, V2, P968; CELIS R, 1988, CHEST, V93, P318, DOI 10.1378/chest.93.2.318; CHERNOW B, 1979, DIGEST DIS SCI, V24, P839, DOI 10.1007/BF01324899; CRAVEN DE, 1986, AM REV RESPIR DIS, V133, P792; CRAVEN DE, 1989, EUR J CLIN MICROBIOL, V8, P40, DOI 10.1007/BF01964119; DONOWITZ LG, 1986, INFECT CONT HOSP EP, V7, P23, DOI 10.1017/S0195941700063748; DRIKS MR, 1987, NEW ENGL J MED, V317, P1376, DOI 10.1056/NEJM198711263172204; DUMOULIN GC, 1982, LANCET, V1, P242; FAGON JY, 1989, AM REV RESPIR DIS, V139, P877, DOI 10.1164/ajrccm/139.4.877; FISHER RS, 1976, GASTROENTEROLOGY, V70, P301; GOULARTE TA, 1986, AM J INFECT CONTROL, V14, P88; HARDY JF, 1988, CAN J ANAESTH, V35, P162, DOI 10.1007/BF03010658; HELM JF, 1983, GASTROENTEROLOGY, V85, P607; HUXLEY EJ, 1978, AM J MED, V64, P564, DOI 10.1016/0002-9343(78)90574-0; Ibanez J, 1988, INTENS CARE MED, V14, P296; JOHANSON WG, 1972, ANN INTERN MED, V77, P701, DOI 10.7326/0003-4819-77-5-701; LAGGNER AN, 1989, AM J MED, V86, P81, DOI 10.1016/0002-9343(89)90164-2; NACHTKAMP J, 1989, LANCET, V1, P160; NORUSIS MJ, 1986, STATISTICAL PACKAGE; REICH SB, 1977, J NUCL MED, V18, P1079; RUDDELL WSJ, 1980, LANCET, V1, P672; SATIANI B, 1978, ARCH SURG-CHICAGO, V113, P721; SCHULZEDELRIEU K, 1982, DISEASES ESOPHAGUS, P35; TORRES A, 1990, AM REV RESPIR DIS, V142, P523, DOI 10.1164/ajrccm/142.3.523; TORRES A, 1988, AM REV RESPIR DIS, V138, P117, DOI 10.1164/ajrccm/138.1.117; TRYBA M, 1987, AM J MED, V83, P117, DOI 10.1016/0002-9343(87)90840-0; WINTERBAUER RH, 1981, ANN INTERN MED, V95, P67, DOI 10.7326/0003-4819-95-1-67	28	455	478	0	8	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 1	1992	116	7					540	543		10.7326/0003-4819-116-7-540	http://dx.doi.org/10.7326/0003-4819-116-7-540			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HL258	1543307				2023-01-03	WOS:A1992HL25800003
J	HECKER, JF				HECKER, JF			REGULAR REVIEW - POTENTIAL FOR EXTENDING SURVIVAL OF PERIPHERAL INTRAVENOUS INFUSIONS	BMJ-BRITISH MEDICAL JOURNAL			English	Review							IN-LINE FILTRATION; TRANSDERMAL GLYCERYL TRINITRATE; PROSPECTIVE CLINICAL-TRIAL; PARENTERAL-NUTRITION; POSTINFUSION PHLEBITIS; SUPERFICIAL PHLEBITIS; VENOUS CATHETERS; THROMBOPHLEBITIS; PREVENTION; COMPLICATIONS		ROYAL POSTGRAD MED SCH, DEPT SURG, LONDON W12 0HS, ENGLAND	Imperial College London								ADAMS SD, 1986, HEART LUNG, V15, P134; ALLCUTT DA, 1983, BRIT J SURG, V70, P111, DOI 10.1002/bjs.1800700219; ALPAN G, 1984, PEDIATRICS, V74, P375; ANDERSON LH, 1951, J LAB CLIN MED, V38, P585; ANSEL HC, 1971, J AMER MED ASSOC, V218, P1052, DOI 10.1001/jama.1971.03190200082033; BAILEY MJ, 1979, BRIT MED J, V1, P1671, DOI 10.1136/bmj.1.6179.1671; BASS J, 1985, CAN J SURG, V28, P124; BASSAN MM, 1983, CHEST, V84, P439, DOI 10.1378/chest.84.4.439; BERGQVIST D, 1967, NORDISK MED SCAND, V182, P93; BIVINS BA, 1979, SURGERY, V85, P388; CARRIZOSA J, 1974, ANTIMICROB AGENTS CH, V5, P192, DOI 10.1128/AAC.5.2.192; CARTER JFB, 1951, LANCET, V261, P20; CARTER JFB, 1952, LANCET, V263, P660; CHAMBERLAND ME, 1977, AM J HOSP PHARM, V34, P1068, DOI 10.1093/ajhp/34.10.1068; CLARK P B, 1960, Postgrad Med J, V36, P55; COLLIN J, 1973, BMJ-BRIT MED J, V4, P456, DOI 10.1136/bmj.4.5890.456; COX DR, 1972, J R STAT SOC B, V34, P187; DANIELL HW, 1973, JAMA-J AM MED ASSOC, V226, P1317, DOI 10.1001/jama.226.11.1317; DECOCK C, 1984, PHARM WEEKBLAD, V6, P88, DOI 10.1007/BF01953960; DELUCA PP, 1975, AM J HOSP PHARM, V32, P1001, DOI 10.1093/ajhp/32.10.1001; EEROLA R, 1964, Ann Chir Gynaecol Fenn, V53, P519; ELFVING G, 1966, LANCET, V1, P953; ENGER E, 1976, ACTA PAEDIATR SCAND, V65, P248, DOI 10.1111/j.1651-2227.1976.tb16545.x; EREMIN O, 1977, MED J AUSTRALIA, V2, P528, DOI 10.5694/j.1326-5377.1977.tb114619.x; EVANS WE, 1976, AM J HOSP PHARM, V33, P1160, DOI 10.1093/ajhp/33.11.1160; FALCHUK KH, 1985, NEW ENGL J MED, V312, P78, DOI 10.1056/NEJM198501103120203; Fleiss JL, 1981, STAT METHODS RATES P; Flores-Vega C H, 1970, Mo Med, V67, P305; FONKALSRUD EW, 1968, SURGERY, V63, P280; FONKALSRUD EW, 1971, SURG GYNECOL OBSTETR, V133, P253; FONKALSRUD EW, 1968, J SURG RES, V8, P539, DOI 10.1016/0022-4804(68)90005-X; Francombe P, 1988, Nurs Times, V84, P34; GAUKROGER PB, 1988, ANAESTH INTENS CARE, V16, P265, DOI 10.1177/0310057X8801600305; GAZITUA R, 1979, ARCH SURG-CHICAGO, V114, P897; HECKER JF, 1991, J PAEDIATR CHILD H, V27, P175, DOI 10.1111/j.1440-1754.1991.tb00381.x; HECKER JF, 1990, BRIT J CANCER, V62, P660, DOI 10.1038/bjc.1990.351; HECKER JF, 1987, BLOOD COMPATIBILITY, V2, P79; HECKER JF, 1990, PEDIATRIC REV COMMUN, V5, P51; HESSOV I, 1976, EUR J INTEN CARE MED, V2, P97, DOI 10.1007/BF01886123; ISAACS JW, 1977, AM J CLIN NUTR, V30, P552, DOI 10.1093/ajcn/30.4.552; JACQUOT C, 1989, ANN FR ANESTH, V8, P620, DOI 10.1016/S0750-7658(89)80178-9; JAKOBSEN CJ, 1986, J HOSP INFECT, V8, P217, DOI 10.1016/0195-6701(86)90116-7; KEELER C, 1987, HEART LUNG, V16, P201; KELSEY MC, 1984, J HOSP INFECT, V5, P313, DOI 10.1016/0195-6701(84)90081-1; KHAWAJA HT, 1988, BRIT J SURG, V75, P1212, DOI 10.1002/bjs.1800751223; KHAWAJA HT, 1991, J ROY SOC MED, V84, P69, DOI 10.1177/014107689108400205; KHAWAJA HT, 1988, BMJ-BRIT MED J, V299, P97; KOVACEVICH DS, 1986, JPEN-PARENTER ENTER, V10, P639, DOI 10.1177/0148607186010006639; LEBOWITZ MH, 1971, J AMER MED ASSOC, V215, P1937, DOI 10.1001/jama.215.12.1937; LEWIS GBH, 1985, BRIT J ANAESTH, V57, P220, DOI 10.1093/bja/57.2.220; LEWIS GBH, 1986, BRIT J ANAESTH, V58, P467, DOI 10.1093/bja/58.4.467-a; LEWIS GBH, 1984, ANAESTH INTENS CARE, V12, P27, DOI 10.1177/0310057X8401200106; LEWIS GBH, 1991, BRIT J SURG, V78, P500, DOI 10.1002/bjs.1800780437; LINARES J, 1985, J CLIN MICROBIOL, V21, P357; LODGE JPA, 1987, BRIT J CLIN PRACT, V41, P816; Lowe G.D., 1981, BR J INTRAVEN THER, V2, P42; MADDOX RR, 1977, AM J HOSP PHARM, V34, P29, DOI 10.1093/ajhp/34.1.29; MADDOX RR, 1983, CLIN PHARMACY, V2, P58; MAKAREWICZ PA, 1986, AM J SURG, V151, P126, DOI 10.1016/0002-9610(86)90022-X; MCNAIR TJ, 1959, LANCET, V2, P365; MESSING B, 1985, NEW ENGL J MED, V312, P1452; Moclair AE, 1991, INT J PHARM PRACT, V1, P38; MORGAN M, 1983, J PERIODONTOL, V54, P680, DOI 10.1902/jop.1983.54.11.680; MOSTERT JW, 1971, J AMER MED ASSOC, V216, P1483, DOI 10.1001/jama.1971.03180350059024; NORDELL K, 1972, ACTA MED SCAND, V192, P263; PAGE BH, 1952, LANCET, V263, P778; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; RUSHO WJ, 1979, AM J HOSP PHARM, V36, P1355, DOI 10.1093/ajhp/36.10.1355; Ryan P B, 1973, Bull Parenter Drug Assoc, V27, P1; RYPINS EB, 1990, AM J SURG, V159, P222, DOI 10.1016/S0002-9610(05)80266-1; SCHAFERMEYER RW, 1974, JAMA-J AM MED ASSOC, V228, P695, DOI 10.1001/jama.1974.03230310017012; SKETCH MH, 1972, CHEST, V62, P684, DOI 10.1378/chest.62.6.684; SMALLMAN L, 1980, BRIT J SURG, V67, P861, DOI 10.1002/bjs.1800671208; STRADLING JR, 1978, BRIT MED J, V2, P1195, DOI 10.1136/bmj.2.6146.1195; SUBRAHAMANYAM M, 1988, Indian Journal of Physiology and Pharmacology, V32, P37; SWIFT RG, 1975, DRUG INTEL CLIN PHAR, V9, P76, DOI 10.1177/106002807500900202; TANNER WA, 1980, BRIT J SURG, V67, P311, DOI 10.1002/bjs.1800670503; THAYSSEN P, 1977, DAN MED BULL, V24, P160; THOMPSON DR, 1983, J HOSP INFECT, V4, P285, DOI 10.1016/0195-6701(83)90029-4; TSE RL, 1971, J AMER MED ASSOC, V215, P642, DOI 10.1001/jama.1971.03180170076025; TULLY JL, 1981, AM J MED, V70, P702, DOI 10.1016/0002-9343(81)90600-8; VERE DW, 1960, LANCET, V2, P627; WOODHOUSE CRJ, 1979, BRIT MED J, V1, P454, DOI 10.1136/bmj.1.6161.454-a; WRIGHT A, 1985, LANCET, V2, P1148; 1957, LANCET, V2, P595	85	29	29	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 7	1992	304	6827					619	624		10.1136/bmj.304.6827.619	http://dx.doi.org/10.1136/bmj.304.6827.619			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HH733	1472179	Bronze, Green Published			2023-01-03	WOS:A1992HH73300026
J	GORE, SM; FONTAINE, O; PIERCE, NF				GORE, SM; FONTAINE, O; PIERCE, NF			IMPACT OF RICE BASED ORAL REHYDRATION SOLUTION ON STOOL OUTPUT AND DURATION OF DIARRHEA - METAANALYSIS OF 13 CLINICAL-TRIALS	BMJ-BRITISH MEDICAL JOURNAL			English	Article							GLUCOSE ELECTROLYTE SOLUTION; ACUTE CHILDHOOD DIARRHEA; DEHYDRATING DIARRHEA; INFANTILE DIARRHEA; SALT SOLUTION; EFFICACY; CHILDREN; THERAPY; POWDER	Objective - To define the benefit of rice oral rehydration salts solution in relation to the glucose based World Health Organisation oral rehydration salts solution for treating and preventing dehydration in patients with severe dehydrating diarrhoea. Design-Meta-analysis using data from 13 available randomised trials that compared these two formulations. Subjects - The studies compared 1367 patients with cholera, severe cholera-like diarrhoea, or acute non-cholera diarrhoea. 668 received the standard WHO solution and 699 the rice based solution. Intervention - Each trial report was reviewed to determine patient eligibility, the number of patients who were randomised and the number of these excluded from analysis, details of the randomisation procedure, and the precise timing of the outcome measurements. Main outcome measures - Stool output during the first 24 hours; weighted estimates of the difference in mean stool output between treatments. Results - The rice solution significantly reduced the rate of stool output during the first 24 hours by 36% (95% confidence interval 28 to 44%) in adults with cholera and by 32% (19 to 45%) in children with cholera. The rate of stool loss in infants and children with acute non-cholera diarrhoea was reduced by only 18% (6 to 30%). Conclusions - The benefit of rice oral rehydration salts solution for patients with cholera is sufficiently great to warrant its use in such patients. The benefit is considerably smaller for children with acute, non-cholera diarrhoea and should be more precisely defined before its practical value can be judged.	WHO, DIARRHOEAL DIS CONTROL PROGRAMME, CH-1211 GENEVA 27, SWITZERLAND; MRC, BIOSTAT UNIT, CAMBRIDGE, ENGLAND	World Health Organization; MRC Biostatistics Unit								ALAM AN, 1987, ARCH DIS CHILD, V62, P440, DOI 10.1136/adc.62.5.440; AVERY ME, 1990, NEW ENGL J MED, V323, P891, DOI 10.1056/NEJM199009273231307; BHAN MK, 1987, J PEDIATR GASTR NUTR, V6, P392, DOI 10.1097/00005176-198705000-00016; DUTTA P, 1988, INDIAN J MED RES, V87, P229; ELMOUGI M, 1988, J PEDIATR GASTR NUTR, V7, P572, DOI 10.1097/00005176-198807000-00016; HIRSCHHORN N, 1968, NEW ENGL J MED, V279, P176, DOI 10.1056/NEJM196807252790402; HIRSCHHORN N, 1980, AM J CLIN NUTR, V33, P637, DOI 10.1093/ajcn/33.3.637; KENYA PR, 1989, ARCH DIS CHILD, V64, P1032, DOI 10.1136/adc.64.7.1032; LEBENTHAL E, 1983, J PEDIATR-US, V103, P29, DOI 10.1016/S0022-3476(83)80770-7; LEBENTHAL E, 1981, TXB GASTROENTEROLOGY, P149; LEPAGE P, 1989, LANCET, V2, P868; Mahalanabis D, 1974, J Trop Pediatr Environ Child Health, V20, P82; MOHAN M, 1986, J PEDIATR GASTR NUTR, V5, P423, DOI 10.1097/00005176-198605000-00015; MOHAN M, 1988, INDIAN J MED RES, V87, P234; MOLLA AM, 1989, LANCET, V2, P429; MOLLA AM, 1985, B WORLD HEALTH ORGAN, V63, P751; MOLLA AM, 1985, CHILD HLTH TROPICS, P65; PATRA F C, 1986, Journal of Diarrhoeal Diseases Research, V4, P16; PATRA FC, 1982, ARCH DIS CHILD, V57, P910, DOI 10.1136/adc.57.12.910; PATRA FC, 1984, ACTA PAEDIATR SCAND, V73, P18, DOI 10.1111/j.1651-2227.1984.tb09891.x; PIERCE NF, 1968, GASTROENTEROLOGY, V55, P333; SACK DA, 1978, LANCET, V2, P280; VESIKARI T, 1986, ARCH DIS CHILD, V61, P372, DOI 10.1136/adc.61.4.372; WAPNIR RA, 1990, J PEDIATR GASTR NUTR, V10, P213, DOI 10.1097/00005176-199002000-00012	24	144	150	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 1	1992	304	6822					287	291		10.1136/bmj.304.6822.287	http://dx.doi.org/10.1136/bmj.304.6822.287			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HC708	1531430	Green Published, Bronze			2023-01-03	WOS:A1992HC70800021
J	KJELDSENKRAGH, J; HAUGEN, M; BORCHGREVINK, CF; LAERUM, E; EEK, M; MOWINKEL, P; HOVI, K; FORRE, O				KJELDSENKRAGH, J; HAUGEN, M; BORCHGREVINK, CF; LAERUM, E; EEK, M; MOWINKEL, P; HOVI, K; FORRE, O			CONTROLLED TRIAL OF FASTING AND ONE-YEAR VEGETARIAN DIET IN RHEUMATOID-ARTHRITIS	LANCET			English	Article							INDUCED ALLERGIC ARTHRITIS; DISEASE-ACTIVITY; FOOD; THERAPY	Fasting is an effective treatment for rheumatoid arthritis, but most patients relapse on reintroduction of food. The effect of fasting followed by one year of a vegetarian diet was assessed in a randomised, single-blind controlled trial. 27 patients were allocated to a four-week stay at a health farm. After an initial 7-10 day subtotal fast, they were put on an individually adjusted gluten-free vegan diet for 3.5 months. The food was then gradually changed to a lactovegetarian diet for the remainder of the study. A control group of 26 patients stayed for four weeks at a convalescent home, but ate an ordinary diet throughout the whole study period. After four weeks at the health farm the diet group showed a significant improvement in number of tender joints, Ritchie's articular index, number of swollen joints, pain score, duration of morning stiffness, grip strength, erythrocyte sedimentation rate, C-reactive protein, white blood cell count, and a health assessment questionnaire score. In the control group, only pain score improved significantly. The benefits in the diet group were still present after one year, and evaluation of the whole course showed significant advantages for the diet group in all measured indices. This dietary regimen seems to be a useful supplement to conventional medical treatment of rheumatoid arthritis.	UNIV OSLO,DEPT GEN PRACTICE,N-0264 OSLO,NORWAY; OSLO SANITETSFORENING REUMATISM HOSP,N-0172 OSLO,NORWAY; MEDSTAT RES,N-2011 STROMMEN,NORWAY; TONSASEN REKREASJONSHEIM,N-2890 ETNEDAL,NORWAY	University of Oslo	KJELDSENKRAGH, J (corresponding author), NATL HOSP,INST IMMUNOL & RHEUMATOL,FREDRIKKE QVAMS GATE 1,N-0172 OSLO,NORWAY.		Kjeldsen-Kragh, Jens/A-4472-2008; Haugen, Margaretha/H-7007-2016	Haugen, Margaretha/0000-0001-5924-5000				[Anonymous], FEAST TOOLBOX; BERI D, 1988, ANN RHEUM DIS, V47, P69, DOI 10.1136/ard.47.1.69; DARLINGTON LG, 1986, LANCET, V1, P236; FRIES JF, 1980, ARTHRITIS RHEUM, V23, P137, DOI 10.1002/art.1780230202; GOOD RA, 1981, J CLIN IMMUNOL, V1, P3, DOI 10.1007/BF00915471; HAFSTROM I, 1988, ARTHRITIS RHEUM, V31, P585, DOI 10.1002/art.1780310502; HAUGEN M, IN PRESS CLIN RHEUMA; KLEINBAUM DG, 1988, APPLIED REGRESSION A, P96; KREMER JM, 1990, ARTHRITIS RHEUM, V33, P810, DOI 10.1002/art.1780330607; LARSEN A, 1977, ACTA RADIOL DIAGN, V18, P481, DOI 10.1177/028418517701800415; MONTGOMERY DC, 1984, DESIGN ANAL EXPT, P117; PANUSH RS, 1983, ARTHRITIS RHEUM, V26, P462, DOI 10.1002/art.1780260403; PANUSH RS, 1986, ARTHRITIS RHEUM, V29, P220, DOI 10.1002/art.1780290210; PANUSH RS, 1990, J RHEUMATOL, V17, P291; PARKE AL, 1981, BRIT MED J, V282, P2027, DOI 10.1136/bmj.282.6281.2027; PHINNEY SD, 1990, AM J CLIN NUTR, V51, P385, DOI 10.1093/ajcn/51.3.385; RITCHIE DM, 1968, Q J MED, V37, P393; ROPES M W, 1958, Bull Rheum Dis, V9, P175; SKOLDSTAM L, 1979, SCAND J RHEUMATOL, V8, P249, DOI 10.3109/03009747909114631; STEINBROCKER O, 1949, JAMA-J AM MED ASSOC, V140, P659, DOI 10.1001/jama.1949.02900430001001; UDEN AM, 1983, ANN RHEUM DIS, V42, P45, DOI 10.1136/ard.42.1.45; 1984, MATVARETABELL	22	268	273	2	52	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 12	1991	338	8772					899	902		10.1016/0140-6736(91)91770-U	http://dx.doi.org/10.1016/0140-6736(91)91770-U			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GJ899	1681264				2023-01-03	WOS:A1991GJ89900001
J	SELLAR, C; FERGUSON, JA; GOLDACRE, MJ				SELLAR, C; FERGUSON, JA; GOLDACRE, MJ			OCCURRENCE AND REPETITION OF HOSPITAL ADMISSIONS FOR ACCIDENTS IN PRESCHOOL-CHILDREN	BRITISH MEDICAL JOURNAL			English	Article							CHILDHOOD INJURIES; EPIDEMIOLOGY; RATES	Objectives - To examine trends over time in the rates of admission to hospital for accidents of preschool children and to study patterns of repeated admissions for accidents in these children. Design - Analysis of linked, routine abstracts of hospital inpatient records for accidents. Setting - Six districts in the Oxford Regional Health Authority covered by the Oxford record linkage study. Subjects - Records for 19 427 children aged 5 years and under at the time of first recorded admission to hospital. Main outcome measure - Number of admissions to hospital. Results - Records were analysed in three groups: person based annual admission rates were calculated for each calendar year; each child's first recorded admission in 1976-85 was identified, and the child's record was followed up by linkage for one year from that admission; each child's first recorded admission in 1976-81 was identified and followed up for five years. Overall, 19 427 children from an average annual resident population of 163 000 children in 1976-86 had 20 657 admissions for accidents before they were 6 years of age. Of these admissions 13 983 were for injuries, 5717 for poisonings, and 957 for burns. Admission rates declined after 1976 for poisoning, but no substantial changes over time were found in admission rates for injuries or burns. A total of 17 724 children were followed up for one year and 10 889 for five years; 470 (2.6%) of the children who were followed up for one year and 926 (8.5%) of those followed up for five years had at least one further admission for an accident. Of those followed up for one year the 4 and 5 year old children were least likely and those under 1 and 1 year old were most likely to have a further admission for an accident. The number of children who had more than one accident was greater than would be expected if accidents were random occurrences. Those who had a poisoning at first admission were more likely to have another poisoning than an injury or burn; and those who had a burn at first admission were more likely to have another burn. Conclusions - Hospital admissions for accidents in children are common: on average 1 child in 88 in this population was admitted each year. Multiple admissions are uncommon but none the less occur more often than would be expected by chance.			SELLAR, C (corresponding author), UNIV OXFORD,DEPT PUBL HLTH & PRIMARY CARE,CLIN EPIDEMIOL UNIT,HEADINGTON,OXFORD OX3 7LF,ENGLAND.							AGASS M, 1990, BRIT J GEN PRACT, V40, P202; ARMITAGE P, 1987, STATISTICAL METHODS, P371; BIJUR P, 1988, AM J DIS CHILD, V142, P1307, DOI 10.1001/archpedi.1988.02150120061041; BIJUR PE, 1988, PEDIATRICS, V82, P707; BIJUR PE, 1986, AM J DIS CHILD, V140, P487, DOI 10.1001/archpedi.1986.02140190097036; BOYCE WT, 1989, AM J DIS CHILD, V143, P338, DOI 10.1001/archpedi.1989.02150150096024; EMINSON CJ, 1986, J EPIDEMIOL COMMUN H, V40, P170, DOI 10.1136/jech.40.2.170; GOLDACRE MJ, 1988, BRIT MED J, V296, P583, DOI 10.1136/bmj.296.6621.583; HUSBAND P, 1973, PRACTITIONER, V211, P335; JACKSON RH, 1983, BRIT MED J, V287, P1468, DOI 10.1136/bmj.287.6403.1468-a; JACKSON RH, 1983, HUM TOXICOL, V2, P285, DOI 10.1177/096032718300200218; RIVARA FP, 1982, AM J DIS CHILD, V136, P399, DOI 10.1001/archpedi.1982.03970410017003; RIVARA FP, 1982, AM J DIS CHILD, V136, P502, DOI 10.1001/archpedi.1982.03970420026004; STEWARTBROWN S, 1986, INT J EPIDEMIOL, V15, P352, DOI 10.1093/ije/15.3.352; 1989, BASIC PRINCIPLES CHI; 1990, ELM901 DEP HLTH; 1967, MANUAL INT STATISTIC; 1990, ACTION ACCIDENT UNIQ; HOSPITAL PATIENT ENQ; MORTALITY STATISTICS; 1989, EL89P96 DEP HLTH SOC; [No title captured]	22	25	25	1	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 5	1991	302	6767					16	19		10.1136/bmj.302.6767.16	http://dx.doi.org/10.1136/bmj.302.6767.16			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	ER372	1991180	Bronze, Green Published			2023-01-03	WOS:A1991ER37200018
J	HOOTON, TM; HILLIER, S; JOHNSON, C; ROBERTS, PL; STAMM, WE				HOOTON, TM; HILLIER, S; JOHNSON, C; ROBERTS, PL; STAMM, WE			ESCHERICHIA-COLI BACTERIURIA AND CONTRACEPTIVE METHOD	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							URINARY-TRACT INFECTION; SEXUAL INTERCOURSE; DIAPHRAGM USE; RISK-FACTORS; YOUNG-WOMEN; COLONIZATION; ASSOCIATION; FLORA	We evaluated the effects of contraceptive method on the occurrence of bacteriuria and vaginal colonization with Escherichia coli in 104 women who were evaluated prior to having sexual intercourse, the morning after intercourse, and 24 hours later. After intercourse, the prevalence of E coli bacteriuria increased slightly in oral contraceptive users but dramatically in both foam and condom users and diaphragm-spermicide users. Twenty-four hours later, the prevalence of bacteriuria remained significantly elevated only in the latter two groups. Similarly, vaginal colonization with E coli was more dramatic and persistent in users of diaphragm-spermicide and foam and condoms. Vaginal colonization with Candida species, enterococci, and staphylococci also increased significantly in diaphragm-spermicide users after intercourse. We conclude that use of the diaphragm with spermicidal jelly or use of a spermicidal foam with a condom markedly alters normal vaginal flora and strongly predisposes users to the development of vaginal colonization and bacteriuria with E coli.	UNIV WASHINGTON,HARBORVIEW MED CTR,SCH MED,DEPT OBSTET & GYNECOL,SEATTLE,WA 98104	Harborview Medical Center; University of Washington; University of Washington Seattle	HOOTON, TM (corresponding author), UNIV WASHINGTON,HARBORVIEW MED CTR,SCH MED,DEPT MED,325 9TH AVE,SEATTLE,WA 98104, USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI012192] Funding Source: NIH RePORTER; NIAID NIH HHS [AI12192] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADATTO K, 1979, JAMA-J AM MED ASSOC, V241, P2525, DOI 10.1001/jama.241.23.2525; BUCKLEY RM, 1978, NEW ENGL J MED, V298, P321, DOI 10.1056/NEJM197802092980607; ELSTER AB, 1981, SOUTHERN MED J, V74, P704, DOI 10.1097/00007611-198106000-00018; EVANS DA, 1978, NEW ENGL J MED, V299, P536, DOI 10.1056/NEJM197809072991009; FIHN SD, 1986, J UROLOGY, V136, P853, DOI 10.1016/S0022-5347(17)45104-4; FIHN SD, 1985, JAMA-J AM MED ASSOC, V254, P240, DOI 10.1001/jama.254.2.240; FOXMAN B, 1985, AM J PUBLIC HEALTH, V75, P1308, DOI 10.2105/AJPH.75.11.1308; HSIAO V, 1986, J ADOLESCENT HEALTH, V7, P381, DOI 10.1016/S0197-0070(86)80238-8; KROHN MA, 1989, J CLIN MICROBIOL, V27, P1266, DOI 10.1128/JCM.27.6.1266-1271.1989; KUNIN CM, 1968, NEW ENGL J MED, V278, P635, DOI 10.1056/NEJM196803212781201; KUNIN CM, 1980, JAMA-J AM MED ASSOC, V243, P134; LEIBOVICI L, 1987, ARCH INTERN MED, V147, P345, DOI 10.1001/archinte.147.2.345; MCGROARTY JA, 1990, CURR MICROBIOL, V21, P219, DOI 10.1007/BF02092159; NICOLLE LE, 1982, J INFECT DIS, V146, P579, DOI 10.1093/infdis/146.5.579; PEDDIE BA, 1984, AUST NZ J OBSTET GYN, V24, P217, DOI 10.1111/j.1479-828X.1984.tb01494.x; PERCIVALSMITH R, 1983, CONTRACEPTION, V27, P497, DOI 10.1016/0010-7824(83)90046-X; REMIS RS, 1987, AM J EPIDEMIOL, V126, P685, DOI 10.1093/oxfordjournals.aje.a114708; Sobel J D, 1987, Infect Dis Clin North Am, V1, P751; STAMM WE, 1982, NEW ENGL J MED, V307, P463, DOI 10.1056/NEJM198208193070802; STONE KM, 1986, AM J OBSTET GYNECOL, V155, P180, DOI 10.1016/0002-9378(86)90108-0; STROM BL, 1987, ANN INTERN MED, V107, P816, DOI 10.7326/0003-4819-107-6-816; Svanborg Eden C, 1987, Infect Dis Clin North Am, V1, P731; VESSEY MP, 1987, INT J EPIDEMIOL, V16, P441, DOI 10.1093/ije/16.3.441; 1988, MMWR, V37, P133; 1985, ADV DATA, V128, P1	25	102	104	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 2	1991	265	1					64	69		10.1001/jama.265.1.64	http://dx.doi.org/10.1001/jama.265.1.64			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EP555	1859519				2023-01-03	WOS:A1991EP55500029
J	AUTIER, P; FERIR, MC; HAIRAPETIEN, A; ALEXANIAN, A; AGOUDJIAN, V; SCHMETS, G; DALLEMAGNE, G; LEVA, MN; PINEL, J				AUTIER, P; FERIR, MC; HAIRAPETIEN, A; ALEXANIAN, A; AGOUDJIAN, V; SCHMETS, G; DALLEMAGNE, G; LEVA, MN; PINEL, J			DRUG SUPPLY IN THE AFTERMATH OF THE 1988 ARMENIAN EARTHQUAKE	LANCET			English	Editorial Material									MED SANS FRONTIERES BRUSSELS,26 DESCHAMPHELEER ST,B-1080 BRUSSELS,BELGIUM; MINIST HLTH ARSSR,YEREVAN,ARMENIA,USSR				Autier, Philippe/A-4402-2014	Autier, Philippe/0000-0003-1538-5321				DEGOYET CD, 1977, EMERG PLANN DIGE JAN, P2; DEGOYET CD, 1976, TROPICAL DOCTOR, V6, P168; DEGOYET D, 1976, B PAN AM HLTH ORG, V10, P95; LECHAT MF, 1976, P ROY SOC MED, V69, P421, DOI 10.1177/003591577606900612; Reynolds J.E.F., 1989, MARTINDALE EXTRA PHA, V29th; ZEBALLOS JL, 1986, DISASTERS, V10, P141, DOI 10.1111/j.1467-7717.1986.tb00579.x; 1989, OFFICE UN DISASTER R; 1989, ESSENTIAL DRUGS POLI; 1983, SCI PUBLICATION PAN, V438	9	37	44	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 9	1990	335	8702					1388	1390						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DH145	1971672				2023-01-03	WOS:A1990DH14500015
J	WERNERMAN, J; HAMMARQVIST, F; VINNARS, E				WERNERMAN, J; HAMMARQVIST, F; VINNARS, E			ALPHA-KETOGLUTARATE AND POSTOPERATIVE MUSCLE CATABOLISM	LANCET			English	Article									KAROLINSKA INST,ST GORANS CHILDRENS HOSP,DEPT SURG,S-11281 STOCKHOLM,SWEDEN; KAROLINSKA INST,ST GORANS CHILDRENS HOSP,METAB RES LAB,S-11281 STOCKHOLM,SWEDEN	Karolinska Institutet; Karolinska Institutet	WERNERMAN, J (corresponding author), KAROLINSKA INST,ST GORANS CHILDRENS HOSP,DEPT ANAESTHESIA & INTENS CARE,S-11281 STOCKHOLM,SWEDEN.							ALBERS S, 1988, CLIN SCI, V75, P463, DOI 10.1042/cs0750463; ALBERS S, 1989, CLIN SCI, V76, P643, DOI 10.1042/cs0760643; ASKANAZI J, 1980, ANN SURG, V192, P78, DOI 10.1097/00000658-198007000-00014; BERGSTROM J, 1974, J APPL PHYSIOL, V36, P693, DOI 10.1152/jappl.1974.36.6.693; CLOWES GHA, 1980, JPEN-PARENTER ENTER, V4, P195, DOI 10.1177/0148607180004002195; ESSEN P, 1988, CLIN NUTR S, V7, P67; HAMMARQVIST F, 1989, ANN SURG, V209, P455, DOI 10.1097/00000658-198904000-00011; HAMMARQVIST F, 1988, CLIN NUTR, V7, P171, DOI 10.1016/0261-5614(88)90021-0; HAMMARQVIST F, 1990, BRIT J SURG, V77, P214, DOI 10.1002/bjs.1800770227; HAMMARQVIST F, IN PRESS SURGERY; HAMMARQVIST F, 1989, CLIN NUTR S, V8, P57; IQBAL K, 1970, BIOCHEM J, V119, P145, DOI 10.1042/bj1190145; JEPSON MM, 1988, AM J PHYSIOL, V255, pE166, DOI 10.1152/ajpendo.1988.255.2.E166; LEANDER U, 1985, CLIN NUTR, V4, P43, DOI 10.1016/0261-5614(85)90037-8; MACLENNAN PA, 1987, FEBS LETT, V215, P187, DOI 10.1016/0014-5793(87)80139-4; NEWSHOLME EA, 1985, Q J EXP PHYSIOL CMS, V70, P473, DOI 10.1113/expphysiol.1985.sp002935; PETERSSON B, 1989, CLIN NUTR S, V8, P103; SOUBA WW, 1985, JPEN-PARENTER ENTER, V9, P608, DOI 10.1177/0148607185009005608; STEHLE P, 1989, LANCET, V1, P231; VESTERBERG K, 1987, CLIN NUTR, V6, P213, DOI 10.1016/0261-5614(87)90035-5; VINNARS E, 1975, ANN SURG, V182, P665, DOI 10.1097/00000658-197512000-00001; Vinnars E, 1983, Clin Nutr, V2, P3, DOI 10.1016/0261-5614(83)90023-7; WERNERMAN J, 1986, JPEN-PARENTER ENTER, V10, P578, DOI 10.1177/0148607186010006578; WERNERMAN J, 1985, METABOLISM, V34, P665, DOI 10.1016/0026-0495(85)90095-2; WERNERMAN J, 1987, ANN SURG, V206, P674	25	96	98	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 24	1990	335	8691					701	703		10.1016/0140-6736(90)90811-I	http://dx.doi.org/10.1016/0140-6736(90)90811-I			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CV305	1969067				2023-01-03	WOS:A1990CV30500010
J	SCHNEIDER, MME; HOEPELMAN, AIM; SCHATTENKERK, JKME; NIELSEN, TL; VANDERGRAAF, Y; FRISSEN, JPHJ; VANDERENDE, IME; KOLSTERS, AFP; BORLEFFS, JCC				SCHNEIDER, MME; HOEPELMAN, AIM; SCHATTENKERK, JKME; NIELSEN, TL; VANDERGRAAF, Y; FRISSEN, JPHJ; VANDERENDE, IME; KOLSTERS, AFP; BORLEFFS, JCC			A CONTROLLED TRIAL OF AEROSOLIZED PENTAMIDINE OR TRIMETHOPRIM SULFAMETHOXAZOLE AS PRIMARY PROPHYLAXIS AGAINST PNEUMOCYSTIS-CARINII PNEUMONIA IN PATIENTS WITH HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INHALED PENTAMIDINE; SECONDARY PROPHYLAXIS; HIV-INFECTION; PREVENTION; AIDS; CHEMOPROPHYLAXIS; AZIDOTHYMIDINE; COTRIMOXAZOLE; ZIDOVUDINE; PULMONARY	Background. Primary prophylaxis against Pneumocystis carinii pneumonia (PCP) is recommended for patients with human immunodeficiency virus (HIV) infection if their CD4 cell counts are below 200 per cubic millimeter (0.2 x 10(9) per liter). Either aerosolized pentamidine or trimethoprim-sulfamethoxazole (co-trimoxazole) is commonly prescribed for prophylaxis, but the relative efficacy and toxicity of these agents are unknown. Methods. We conducted a multicenter trial involving 215 HIV-infected patients with no history of PCP but with CD4 cell counts below 200 per cubic millimeter. The patients were randomly assigned to one of three regimens: aerosolized pentamidine once a month, 480 mg of trimethoprim-sulfamethoxazole once a day (80 mg of trimethoprim and 400 mg of sulfamethoxazole), or 960 mg of trimethoprim-sulfamethoxazole once a day (160 mg and 800 mg, respectively). The cumulative incidence of PCP was estimated by Kaplan-Meier survival analysis. Results. After a mean follow-up of 264 days, 6 of the 71 patients in the pentamidine group had a confirmed first episode of PCP (11 percent), whereas none of the 142 patients in the two trimethoprim-sulfamethoxazole groups had PCP (P = 0.002). However, adverse events that required discontinuation of the medication were much more frequent in the trimethoprim-sulfamethoxazole groups (1 7 and 18 patients) than in the pentamidine group (2 patients). The adverse reactions occurred significantly sooner in the group given 960 mg of trimethoprim-sulfamethoxazole than in the group given 480 mg (mean time, 16 vs. 57 days; P = 0.02). Conclusions. For patients with HIV infection, trimethoprim-sulfamethoxazole taken once a day is more effective as primary prophylaxis against PCP than aerosolized pentamidine administered once a month, although adverse drug reactions are more frequent with trimethoprim-sulfamethoxazole.	UGENE RES,UTRECHT,NETHERLANDS; UNIV HOSP ROTTERDAM,ROTTERDAM,NETHERLANDS; HVIDOVRE UNIV HOSP,KOBENHAVNS KOMMUNES,DEPT INFECT DIS,DK-2650 HVIDOVRE,DENMARK; UNIV AMSTERDAM,ACAD MED CTR,DEPT INTERNAL MED,AIDS UNIT,1105 AZ AMSTERDAM,NETHERLANDS; UNIV UTRECHT HOSP,DEPT CLIN MICROBIOL,3511 GV UTRECHT,NETHERLANDS; UNIV UTRECHT HOSP,INFECT DIS LAB,3511 GV UTRECHT,NETHERLANDS; UNIV UTRECHT,DEPT EPIDEMIOL,UTRECHT,NETHERLANDS; ONZE LIEVE VROUW HOSP,AMSTERDAM,NETHERLANDS	Erasmus University Rotterdam; Erasmus MC; University of Copenhagen; University of Amsterdam; Academic Medical Center Amsterdam; Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center; Utrecht University; Onze Lieve Vrouwe Gasthuis Hospital	SCHNEIDER, MME (corresponding author), UNIV HOSP UTRECHT,DEPT INTERNAL MED,IMMUNOL & INFECT DIS SECT,F02 126,HEIDELBERGLAAN 100,3584 CX UTRECHT,NETHERLANDS.							ABD AG, 1988, CHEST, V94, P329, DOI 10.1378/chest.94.2.329; BRADBURNE RM, 1989, THORAX, V44, P591, DOI 10.1136/thx.44.7.591; BUHL R, 1989, LANCET, V2, P1294; CARR A, 1992, AIDS, V6, P165, DOI 10.1097/00002030-199202000-00004; CASTELLANO AR, 1991, JAMA-J AM MED ASSOC, V266, P820, DOI 10.1001/jama.266.6.820; CROWE SM, 1991, J ACQ IMMUN DEF SYND, V4, P770; FISCHL MA, 1988, JAMA-J AM MED ASSOC, V259, P1185, DOI 10.1001/jama.259.8.1185; FLANIGAN T, 1987, NEW ENGL J MED, V317, P1155; FREEDBERG KA, 1991, NEW ENGL J MED, V325, P735, DOI 10.1056/NEJM199109053251013; GIRARD PM, 1989, LANCET, V1, P1348; GLATT AE, 1988, NEW ENGL J MED, V318, P1439, DOI 10.1056/NEJM198806023182206; GOLDEN JA, 1989, LANCET, V1, P654; GRAHAM NMH, 1991, LANCET, V338, P265, DOI 10.1016/0140-6736(91)90414-K; HIRSCHEL B, 1991, NEW ENGL J MED, V324, P1079, DOI 10.1056/NEJM199104183241602; HUGHES WT, 1987, NEW ENGL J MED, V316, P1627, DOI 10.1056/NEJM198706253162604; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KOVACS JA, 1984, ANN INTERN MED, V100, P663, DOI 10.7326/0003-4819-100-5-663; KOVACS JA, 1989, J INFECT DIS, V160, P882, DOI 10.1093/infdis/160.5.882; LEOUNG GS, 1990, NEW ENGL J MED, V323, P769, DOI 10.1056/NEJM199009203231201; MACHER AM, 1987, NEW ENGL J MED, V316, P1092; MASUR H, 1989, ANN INTERN MED, V111, P223, DOI 10.7326/0003-4819-111-3-223; MILLER R, 1991, J ANTIMICROB CHEMOTH, V27, P153, DOI 10.1093/jac/27.2.153; MONTANER JSG, 1991, ANN INTERN MED, V114, P948, DOI 10.7326/0003-4819-114-11-948; MURRAY JF, 1984, NEW ENGL J MED, V310, P1682, DOI 10.1056/NEJM198406213102529; NORTHFELT DW, 1989, LANCET, V2, P1454, DOI 10.1016/S0140-6736(89)92060-6; PHAIR J, 1990, NEW ENGL J MED, V322, P161, DOI 10.1056/NEJM199001183220304; RICHMAN DD, 1987, NEW ENGL J MED, V317, P192, DOI 10.1056/NEJM198707233170402; RUSKIN J, 1991, LANCET, V337, P468, DOI 10.1016/0140-6736(91)93402-U; STEIN DS, 1991, ANTIMICROB AGENTS CH, V35, P1705, DOI 10.1128/AAC.35.9.1705; TELZAK EE, 1990, REV INFECT DIS, V12, P380; VANDERVEN AJAM, 1991, LANCET, V338, P431, DOI 10.1016/0140-6736(91)91046-W; WORMSER GP, 1991, ARCH INTERN MED, V151, P688, DOI 10.1001/archinte.151.4.688; ZANGERLE R, 1991, LANCET, V337, P1232, DOI 10.1016/0140-6736(91)92910-T; 1989, JAMA-J AM MED ASSOC, V262, P335; 1986, MMWR MORB MORTAL WKL, V35, P17; 1987, MMWR MORB MORTAL SS1, V36, pS1; 1985, SAS STAT GUIDE PERSO; 1990, STATISTICS EPIDEMIOL; 1989, MMWR MORB MORTAL SS5, V38, P1	39	254	258	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 24	1992	327	26					1836	1841		10.1056/NEJM199212243272603	http://dx.doi.org/10.1056/NEJM199212243272603			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KD714	1360145	Bronze			2023-01-03	WOS:A1992KD71400003
J	MATUCHANSKY, C; MESSING, B; JEEJEEBHOY, KN; BEAU, P; BELIAH, M; ALLARD, JP				MATUCHANSKY, C; MESSING, B; JEEJEEBHOY, KN; BEAU, P; BELIAH, M; ALLARD, JP			CYCLICAL PARENTERAL-NUTRITION	LANCET			English	Review							SUBSTRATE UTILIZATION; ENTERAL NUTRITION; ADULT PATIENTS; BONE-DISEASE; HYPERALIMENTATION; CATHETER; PROTEIN; HUMANS		ST LAZARE HOSP,CTR HOME PARENTERAL NUTR,PARIS,FRANCE; ST MICHAELS HOSP,GASTROENTEROL & NUTR UNIT,TORONTO M5B 1W8,ONTARIO,CANADA; ST MICHAELS HOSP,CTR HOME PARENTERAL NUTR,TORONTO M5B 1W8,ONTARIO,CANADA; JEAN BERNARD HOSP,CTR HOME PARENTERAL NUTR,POITIERS,FRANCE; ST LAZARE HOSP,GASTROENTEROL & NUTR SUPPORT UNIT,107 BIS RUE FAUBOURG ST DENIS,F-75010 PARIS,FRANCE; JEAN BERNARD HOSP,GASTROENTEROL UNIT,POITIERS,FRANCE; TORONTO GEN HOSP,DEPT MED,TORONTO M5G 1L7,ONTARIO,CANADA	University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; CHU Poitiers; Universite de Poitiers; CHU Poitiers; Universite de Poitiers; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital	MATUCHANSKY, C (corresponding author), ST LAZARE HOSP,GASTROENTEROL & NUTR SUPPORT UNIT,107 BIS RUE FAUBOURG ST DENIS,F-75010 PARIS,FRANCE.							BAPTISTA RJ, 1984, JPEN-PARENTER ENTER, V8, P708, DOI 10.1177/0148607184008006708; BEAU P, 1987, LANCET, V330, P1095; BEAU P, 1986, LANCET, V327, P1272; BERKELHAMMER CH, 1988, AM J CLIN NUTR, V48, P1482, DOI 10.1093/ajcn/48.6.1482; BYRNE WJ, 1981, GASTROENTEROLOGY, V80, P947; DETSKY AS, 1986, JPEN-PARENTER ENTER, V10, P49, DOI 10.1177/014860718601000149; DETSKY AS, 1991, NEW ENGL J MED, V325, P573, DOI 10.1056/NEJM199108223250808; DEVERNEJOUL MC, 1985, J CLIN ENDOCR METAB, V60, P109, DOI 10.1210/jcem-60-1-109; GOULET O, 1986, JPEN-PARENTER ENTER, V10, P284, DOI 10.1177/0148607186010003284; GOUTTEBEL MC, 1987, JPEN-PARENTER ENTER, V11, P475, DOI 10.1177/0148607187011005475; HOWARD L, 1989, JPEN-PARENTER ENTER, V13, P478, DOI 10.1177/0148607189013005478; HOWARD L, 1986, JPEN-PARENTER ENTER, V10, P416, DOI 10.1177/0148607186010004416; HOWARD L, 1991, JPEN-PARENTER ENTER, V15, P384, DOI 10.1177/0148607191015004384; JUST B, 1991, AM J CLIN NUTR, V54, P560, DOI 10.1093/ajcn/54.3.560; JUST B, 1990, AM J CLIN NUTR, V51, P107, DOI 10.1093/ajcn/51.1.107; KENNEDY G, 1983, TOTAL PARENTERAL NUT, P87; LEREBOURS E, 1988, JPEN-PARENTER ENTER, V12, P360, DOI 10.1177/0148607188012004360; LIPKIN EW, 1988, AM J CLIN NUTR, V47, P515, DOI 10.1093/ajcn/47.3.515; MAINI B, 1976, J SURG RES, V20, P515, DOI 10.1016/0022-4804(76)90085-8; MARTINS FM, 1985, AM J CLIN NUTR, V42, P61, DOI 10.1093/ajcn/42.1.61; MATUCHANSKY C, 1985, AM J CLIN NUTR, V41, P727, DOI 10.1093/ajcn/41.4.727; MATUCHANSKY C, 1981, GASTROENTEROLOGY, V81, P433; MESSING B, 1992, NUTRITION, V8, P30; MESSING B, 1990, NUTRITION, V6, P190; MESSING B, 1989, CLIN NUTR, V8, P3, DOI 10.1016/0261-5614(89)90018-6; MESSING B, 1983, JPEN-PARENTER ENTER, V7, P21, DOI 10.1177/014860718300700121; MESSING B, 1990, CLIN NUTR, V9, P220, DOI 10.1016/0261-5614(90)90023-L; MESSING B, 1991, GASTROENTEROLOGY, V100, P1502, DOI 10.1016/0016-5085(91)90645-2; MESSING B, 1990, AM J CLIN NUTR, V52, P1094, DOI 10.1093/ajcn/52.6.1094; MILLWARD DJ, 1982, FED PROC, V41, P2686; MORICHAUBEAUCHANT M, 1982, AM J CLIN NUTR, V35, P997, DOI 10.1093/ajcn/35.5.997; MUGHAL M, 1986, LANCET, V2, P383; PUTET G, 1984, ARCH FR PEDIATR, V41, P111; SHIKE M, 1986, AM J CLIN NUTR, V44, P89, DOI 10.1093/ajcn/44.1.89; WAKEFIELD A, 1989, GASTROENTEROLOGY, V97, P1210, DOI 10.1016/0016-5085(89)91692-2; WOOD RJ, 1985, AM J CLIN NUTR, V41, P614, DOI 10.1093/ajcn/41.3.614	36	43	44	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 5	1992	340	8819					588	592		10.1016/0140-6736(92)92116-W	http://dx.doi.org/10.1016/0140-6736(92)92116-W			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JM334	1355164				2023-01-03	WOS:A1992JM33400013
J	FAHAL, IH; SALLOMI, DF; YAQOOB, M; BELL, GM				FAHAL, IH; SALLOMI, DF; YAQOOB, M; BELL, GM			ACUTE-RENAL-FAILURE AFTER ECSTASY	BRITISH MEDICAL JOURNAL			English	Letter							RHABDOMYOLYSIS				FAHAL, IH (corresponding author), ROYAL LIVERPOOL UNIV HOSP,LIVERPOOL L7 8XP,ENGLAND.		Fahal, Ibrahim/ABC-1366-2021	Fahal, Ibrahim/0000-0003-4897-6427				EKNOYAN G, 1986, AM J NEPHROL, V6, P117, DOI 10.1159/000167066; FOLEY RJ, 1984, SOUTHERN MED J, V77, P258, DOI 10.1097/00007611-198402000-00035; GINSBERG MD, 1970, ANN INTERN MED, V73, P81, DOI 10.7326/0003-4819-73-1-81; KENDRICK WC, 1977, ANN INTERN MED, V86, P381, DOI 10.7326/0003-4819-86-4-381; KOFFLER A, 1976, ANN INTERN MED, V85, P23, DOI 10.7326/0003-4819-85-1-23; SCANDLING J, 1982, SOUTHERN MED J, V75, P237, DOI 10.1097/00007611-198202000-00033	6	80	81	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 4	1992	305	6844					29	29		10.1136/bmj.305.6844.29	http://dx.doi.org/10.1136/bmj.305.6844.29			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JC799	1353389	Green Published, Bronze, Green Submitted			2023-01-03	WOS:A1992JC79900028
J	BARNES, D; HUGHES, RAC				BARNES, D; HUGHES, RAC			GUILLAIN-BARRE-SYNDROME AFTER TREATMENT WITH STREPTOKINASE	BRITISH MEDICAL JOURNAL			English	Letter							THERAPY				BARNES, D (corresponding author), GUYS HOSP,LONDON SE1 9RT,ENGLAND.							ARROWSMITH JB, 1985, ANN INTERN MED, V103, P302, DOI 10.7326/0003-4819-103-2-302_2; CICALE MJ, 1987, SOUTHERN MED J, V80, P1068, DOI 10.1097/00007611-198708000-00047; EDEN KV, 1983, JAMA-J AM MED ASSOC, V249, P2020, DOI 10.1001/jama.1983.03330390028021; LEAF DA, 1984, ANN INTERN MED, V100, P617, DOI 10.7326/0003-4819-100-4-617_2; MCDONAGH AJG, 1987, BRIT MED J, V294, P213	5	11	11	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 9	1992	304	6836					1225	1225		10.1136/bmj.304.6836.1225-b	http://dx.doi.org/10.1136/bmj.304.6836.1225-b			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HT964	1515794	Green Published, Bronze			2023-01-03	WOS:A1992HT96400027
J	ORENTLICHER, D; MCMURRAY, RJ; CLARKE, OW; BARRASSO, JA; CLOHAN, DB; EPPS, CH; GLASSON, J; MCQUILLAN, R; PLOWS, CW; PUZAK, MA; HALKOLA, KA; SCHWEICKART, AK				ORENTLICHER, D; MCMURRAY, RJ; CLARKE, OW; BARRASSO, JA; CLOHAN, DB; EPPS, CH; GLASSON, J; MCQUILLAN, R; PLOWS, CW; PUZAK, MA; HALKOLA, KA; SCHWEICKART, AK			DECISIONS NEAR THE END OF LIFE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NETHERLANDS; EUTHANASIA; ILL				ORENTLICHER, D (corresponding author), AMER MED ASSOC,COUNCIL ETH & JUDICIAL AFFAIRS,515 N STATE ST,CHICAGO,IL 60610, USA.							BATTIN MP, 1991, FEB U FLOR COLL MED; BEAUCHAMP DW, 1989, MED ETHICS; Beauchamp T, 1989, PRINCIPLES BIOMEDICA; BILLINGS JA, 1985, J AM GERIATR SOC, V33, P808, DOI 10.1111/j.1532-5415.1985.tb04196.x; BROCK D, 1989, MED ETHICS; Buchanan Allen E., 1989, DECIDING OTHERS ETHI; Capron A M, 1986, Law Med Health Care, V14, P141; DEWACHTER MAM, 1989, JAMA-J AM MED ASSOC, V262, P3316, DOI 10.1001/jama.262.23.3316; GELMAN D, 1990, NEWSWEEK        0723, P46; KAMISAR Y, 1958, MINN LAW REV, V42, P969; KASS LR, 1989, PUBLIC INTEREST, V94, P25; Lifton Robert Jay, 1986, NAZI DOCTORS MED KIL; LIPTON HL, 1986, JAMA-J AM MED ASSOC, V256, P1164, DOI 10.1001/jama.256.9.1164; LYNN J, 1983, HASTING CANC RE 1013, P17; MERZ B, 1991, AM MED NEWS     1118, P29; ORENTLICHER D, 1989, JAMA-J AM MED ASSOC, V262, P1844, DOI 10.1001/jama.262.13.1844; QUILL TE, 1991, NEW ENGL J MED, V324, P691, DOI 10.1056/NEJM199103073241010; RAMSEY P, 1970, PATIENT PERSON, P113; RHYMES J, 1990, JAMA-J AM MED ASSOC, V264, P369, DOI 10.1001/jama.264.3.369; RIGTER H, 1989, HASTINGS CENT REP, V19, P31, DOI 10.2307/3561968; SCHMITZ P, 1986, BY NO EXTRAORDINARY; SPRUNG CL, 1990, JAMA-J AM MED ASSOC, V263, P2211, DOI 10.1001/jama.263.16.2211; van der Maas PJ, 1991, LANCET, V338, P669, DOI 10.1016/0140-6736(91)91241-L; WANZER SH, 1989, NEW ENGL J MED, V320, P844, DOI 10.1056/NEJM198903303201306; 1988, LIFE SUSTAINING TECH; 1990, VITAL STATISTICS U A, V2; 1991, JUN P HOUS DEL AMA C, P261; 1987, GUIDELINES TERMINATI; 1989, CURRENT OPINIONS, P13; 1987, DEC P HOUS DEL AMA C, P170; 1990, DEC P HOUS DEL AMA C, P180; 1987, DECIDING FOREGO LIFE; 1989, JUN P HOUS DEL AMA C, P314; 1988, JUN P HOUS DEL AMA C, P258	34	174	175	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 22	1992	267	16					2229	2233						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HN841	1372944				2023-01-03	WOS:A1992HN84100035
J	KENNEDY, KI; VISNESS, CM				KENNEDY, KI; VISNESS, CM			CONTRACEPTIVE EFFICACY OF LACTATIONAL AMENORRHEA	LANCET			English	Article							OVULATION; RETURN; FERTILITY	Pregnancy is rare among breastfeeding women with lactational amenorrhoea. The lactational amenorrhoea method (LAM) is the informed use of breastfeeding as a contraceptive method by a woman who is still amenorrhoeic, and who is not feeding her baby with supplements, for up to 6 months after delivery. Under these three conditions, LAM users are thought to have 98% protection from pregnancy. It can be difficult, however, to determine when supplementation of the baby's diet begins. We have analysed data from nine studies of the recovery of fertility in breastfeeding women to assess the effectiveness of lactational amenorrhoea alone, irrespective of whether supplements have been introduced, as a fertility regulation method post partum. Cumulative probabilities of ovulation during lactational amenorrhoea were 30.9 and 67.3 per 100 women at 6 and 12 months, respectively, compared with 27.2 at 6 months when all three criteria of the LAM were met. Cumulative pregnancy rates during lactational amenorrhoea were 2.9 and 5.9 per 100 women at 6 and 12 months, compared with 0.7 at 6 months for the LAM. The probability of pregnancy during lactational amenorrhoea calculated from these studies is similar to that of other modern contraceptive methods, and it seems reasonable for a woman to rely on lactational amenorrhoea without regard to whether she is fully or partly breastfeeding. So that amenorrhoea and fertility suppression can be maintained, counselling about good breastfeeding and weaning practices remains important.			KENNEDY, KI (corresponding author), FAMILY HLTH INT,RES TRIANGLE PK,NC 27709, USA.							BENITEZ I, IN PRESS J BIOSCI SC; BONGAARTS J, 1983, DETERMINANTS FERTILI, P103; Brown J B, 1988, Prog Clin Biol Res, V285, P119; DIAZ S, 1991, CONTRACEPTION, V43, P335, DOI 10.1016/0010-7824(91)90072-N; GOLDZIEHER JW, 1962, ACTA ENDOCRINOL-COP, V41, P371, DOI 10.1530/acta.0.0410371; GRAY RH, 1990, LANCET, V335, P25, DOI 10.1016/0140-6736(90)90147-W; HOWIE PW, 1982, CLIN ENDOCRINOL, V17, P323, DOI 10.1111/j.1365-2265.1982.tb01597.x; HOWIE PW, 1982, CLIN ENDOCRINOL, V17, P609; ISRANGKURA B, 1989, INT J GYNECOL OBSTET, V30, P335, DOI 10.1016/0020-7292(89)90820-5; KENNEDY KI, 1989, CONTRACEPTION, V39, P477, DOI 10.1016/0010-7824(89)90103-0; KHAN T, 1989, CONTRACEPTION, V40, P365, DOI 10.1016/0010-7824(89)90099-1; LABBOCK M, 1990, LACTATIONAL ED HLTH, P70; RIVERA R, 1988, FERTIL STERIL, V49, P780; Rolland R., 1976, Bibliography of Reproduction, V28, P1; SAVINA G, 1989, STUD FAMILY PLANN, V20, P203, DOI 10.2307/1966838; SHAABAN MM, 1990, J BIOSOC SCI, V22, P19, DOI 10.1017/S0021932000018344; SHORT RV, 1991, LANCET, V337, P715, DOI 10.1016/0140-6736(91)90288-Z; SIMPSONHEBERT M, 1981, STUD FAMILY PLANN, V12, P125, DOI 10.2307/1965593; TRUSSELL J, 1990, STUD FAMILY PLANN, V21, P51, DOI 10.2307/1966591; Trussell J, 1991, Health Transit Rev, V1, P105; VANGINNE.JK, 1974, STUD FAMILY PLANN, V5, P201, DOI 10.2307/1965371; WOOD JW, 1989, OXFORD REV REPROD B, V11, P61; 1989, LIFETAB PROGRAM LIFE; 1988, LANCET, V2, P1204; 1985, SAS USERS GUIDE STAT	25	122	127	0	7	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 25	1992	339	8787					227	230		10.1016/0140-6736(92)90018-X	http://dx.doi.org/10.1016/0140-6736(92)90018-X			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HA589	1346183				2023-01-03	WOS:A1992HA58900015
J	MACLENNAN, ICM; CHAPMAN, C; DUNN, J; KELLY, K				MACLENNAN, ICM; CHAPMAN, C; DUNN, J; KELLY, K			COMBINED CHEMOTHERAPY WITH ABCM VERSUS MELPHALAN FOR TREATMENT OF MYELOMATOSIS	LANCET			English	Article							ALTERNATING COMBINATION CHEMOTHERAPY; REQUIRING PROLONGED OBSERVATION; BONE-MARROW TRANSPLANTATION; SOUTHWEST-ONCOLOGY-GROUP; MULTIPLE-MYELOMA; PREDNISONE; SURVIVAL; TRIALS; LEUKEMIA; FEATURES	Both melphalan and cyclophosphamide increase life expectancy in patients with myelomatosis, but few large randomised studies have compared combination chemotherapy regimens with these single agents. In the Vth MRC myelomatosis trial, the survival of 314 patients randomised to receive ABCM (adriamycin, BCNU, cyclophosphamide, and melphalan) as first-line treatment was significantly longer than that of 316 patients given intermittent melphalan (M7) (p = 0.0003). The 75%, median, and 25% survivals were 7, 24, and 42 months, respectively, with M7 and 10, 32, and 56 months, respectively, with ABCM. Stable disease with few symptoms (plateau) was achieved by 61% of patients given ABCM and 49% of those given M7 (p = 0.004). Myelotoxicity was comparable between regimens. Cross-trial analysis suggests that M7 is comparable to melphalan and prednisone or melphalan, prednisone, and vincristine; that the efficacy of ABCM in the Vth trial and VIth MRC trials is comparable; and that ABCM gave better survival than intermittent melphalan regimens in the prognostic groups analysed. The results indicate that ABCM is an acceptable regimen that is more effective than melphalan, with or without prednisone, for first-line treatment of myelomatosis.	UNIV BIRMINGHAM,SCH MED,CRC TRIALS UNIT,BIRMINGHAM B15 2SZ,ENGLAND	University of Birmingham	MACLENNAN, ICM (corresponding author), UNIV BIRMINGHAM,SCH MED,DEPT IMMUNOL,MRC,MYELOMATOSIS TRIALS OFF,POB 1894,VINCENT DR,BIRMINGHAM B15 2SZ,ENGLAND.							ALBERTS DS, 1975, LANCET, V1, P926; BERGSAGEL DE, 1988, HEMATOL ONCOL, V6, P159, DOI 10.1002/hon.2900060216; BLADE J, 1990, BLUT, V60, P319, DOI 10.1007/BF01737844; BOCCADORO M, 1991, J CLIN ONCOL, V9, P444, DOI 10.1200/JCO.1991.9.3.444; BRANDES LJ, 1982, CANCER TREAT REP, V66, P1413; CUZICK J, 1985, BRIT J CANCER, V52, P1, DOI 10.1038/bjc.1985.140; CUZICK J, 1980, BRIT J CANCER, V43, P831; DIXON WJ, 1985, BMDP STATISTICAL SOF; DURIE BGM, 1986, J CLIN ONCOL, V4, P1227, DOI 10.1200/JCO.1986.4.8.1227; DURIE BGM, 1975, CANCER, V36, P842, DOI 10.1002/1097-0142(197509)36:3<842::AID-CNCR2820360303>3.0.CO;2-U; GAHRTON G, 1989, EUR J HAEMATOL, V43, P182; HJORTH M, 1990, BRIT J HAEMATOL, V74, P185, DOI 10.1111/j.1365-2141.1990.tb02564.x; JAGANNATH S, 1990, BLOOD, V76, P1860; KELLY KA, 1988, HEMATOL ONCOL, V6, P131, DOI 10.1002/hon.2900060213; MACLENNAN ICM, 1988, HEMATOL ONCOL, V6, P145, DOI 10.1002/hon.2900060215; OSGOOD EE, 1960, CANCER CHEMOTH REP, V9, P1; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; PETO R, 1976, BRIT J CANCER, V34, P585, DOI 10.1038/bjc.1976.220; SALMON SE, 1983, J CLIN ONCOL, V1, P453, DOI 10.1200/JCO.1983.1.8.453; SELBY PJ, 1987, BRIT J HAEMATOL, V66, P55, DOI 10.1111/j.1365-2141.1987.tb06890.x; 1985, BRIT J CANCER, V52, P153; 1980, BRIT J CANCER, V42, P813; 1971, BRIT MED J, V1, P640	23	123	123	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 25	1992	339	8787					200	205		10.1016/0140-6736(92)90004-M	http://dx.doi.org/10.1016/0140-6736(92)90004-M			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HA589	1346171				2023-01-03	WOS:A1992HA58900002
J	TAYLOR, D				TAYLOR, D			MEDICINE IN EUROPE - PRESCRIBING IN EUROPE - FORCES FOR CHANGE .8.	BRITISH MEDICAL JOURNAL			English	Article											TAYLOR, D (corresponding author), KINGS FUND INST,HLTH POLICY ANAL,LONDON NW1 7NF,ENGLAND.							BURSTALL ML, 1990, 1992 REGULATION PHAR; DIENER F, 1990, PHARM ZEITUNG, V40, P2631; GRIFFIN JP, 1991, J ROY COLL PHYS LOND, V25, P44; OBRIEN B, 1984, PATTERNS EUROPEAN DI; Payer Lynn, 1989, MED CULTURE; SAUER F, 1990, EUROPEAN COMMUNITY P; Schieber G J, 1991, Health Aff (Millwood), V10, P106, DOI 10.1377/hlthaff.10.1.106; SMITH T, 1985, BRIT MED J, V290, P532, DOI 10.1136/bmj.290.6467.532; Taylor D.G., 1990, MED NHS EUROPE; THOMAS LG, 1989, SPARE ROD SPOIL IND; TROSS J, 1991, SCRIP, V629, P4; 1991, IMPLICATIONS MED DEV; 1991, LANCET, V337, P1571; 1990, HLTH CARE SYSTEMS TR; 1991, PHARMA PIPELINES; 1990, PHARMA FACTS FIGURES; 1991, FINANCIAL TIMES PHAR, V157, P2	17	16	19	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 25	1992	304	6821					239	242		10.1136/bmj.304.6821.239	http://dx.doi.org/10.1136/bmj.304.6821.239			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HA980	1739801	Green Published, Bronze			2023-01-03	WOS:A1992HA98000030
J	KOU, WH; CALKINS, H; LEWIS, RR; BOLLING, SF; KIRSCH, MM; LANGBERG, JJ; DEBUITLEIR, M; SOUSA, J; ELATASSI, R; MORADY, F				KOU, WH; CALKINS, H; LEWIS, RR; BOLLING, SF; KIRSCH, MM; LANGBERG, JJ; DEBUITLEIR, M; SOUSA, J; ELATASSI, R; MORADY, F			INCIDENCE OF LOSS OF CONSCIOUSNESS DURING AUTOMATIC IMPLANTABLE CARDIOVERTER-DEFIBRILLATOR SHOCKS	ANNALS OF INTERNAL MEDICINE			English	Article							COMPLICATIONS; SURVIVAL	Objective: To determine the incidence of loss of consciousness occurring in association with shocks delivered by automatic implantable cardioverter-defibrillators (AICD) in patients who had undergone implantation as treatment for ventricular tachycardia or ventricular fibrillation. Design: Cohort study. Setting: Two major tertiary medical care facilities. Patients: A total of 180 patients who had undergone implantation of an AICD for treatment of ventricular tachycardia or ventricular fibrillation. Intervention: Implantation of an AICD that delivered only high-energy shock. Measurements: During a mean (+/- SD) follow-up period of 16 +/- 12 months, the incidence of loss of consciousness occurring in association with spontaneous AICD shocks was determined. Various clinical factors were analyzed to identify predictors of loss of consciousness that occurred during AICD shocks. Main Results: Of the 180 patients who received an AICD, 106 patients (59%) experienced AICD shocks during follow-up. Sixteen of the 180 patients (9%) experienced loss of consciousness; 13 of these 16 patients had syncope and 3 died suddenly, in association with AICD shocks. The absence of syncope during one AICD shock did not always predict the absence of syncope during subsequent shocks. Syncope could not be predicted by age, sex, history of syncope, left ventricular function, type of underlying heart disease, electrophysiologic findings, rate of ventricular tachycardia, antiarrhythmic medications, and type of pulse generator implanted. Conclusions: Patients with sustained ventricular tachycardia or ventricular fibrillation who receive an AICD that delivers only high-energy shock therapy are at moderate risk for experiencing loss of consciousness during AICD shocks. No clinical variables were found to be predictors of syncope. Therefore, driving and other activities that require patients to be extra vigilant should not be assumed to be safe after implantation of an AICD that delivers only high-energy shock.	UNIV MICHIGAN HOSP, DIV CARDIOL, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN HOSP, DIV THORAC SURG, ANN ARBOR, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	KOU, WH (corresponding author), VET AFFAIRS MED CTR, CARDIOL SECT 111A, 2215 FULLER RD, ANN ARBOR, MI 48105 USA.							AXTELL KA, 1990, CIRCULATION, V82, P211; CRANCER A, 1968, J AMER MED ASSOC, V205, P272, DOI 10.1001/jama.1968.03140310030006; ECHT DS, 1985, CIRCULATION, V71, P289, DOI 10.1161/01.CIR.71.2.289; HANSOTIA P, 1991, NEW ENGL J MED, V324, P22, DOI 10.1056/NEJM199101033240105; KALBFLEISCH KR, 1989, AM J CARDIOL, V64, P199, DOI 10.1016/0002-9149(89)90457-8; KELLY PA, 1988, J AM COLL CARDIOL, V11, P1278, DOI 10.1016/0735-1097(88)90292-6; KOU WH, 1990, AM HEART J, V120, P208, DOI 10.1016/0002-8703(90)90181-V; LEHMANN MH, 1988, AM J CARDIOL, V62, P803, DOI 10.1016/0002-9149(88)91226-X; MIROWSKI M, 1981, AM HEART J, V102, P265, DOI 10.1016/S0002-8703(81)80017-8; STEINBERG JS, 1991, AM J CARDIOL, V67, P95, DOI 10.1016/0002-9149(91)90109-X; WALLER JA, 1965, NEW ENGL J MED, V273, P1413, DOI 10.1056/NEJM196512232732605; YSANDER L, 1966, BRIT J IND MED, V23, P28	12	51	51	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 15	1991	115	12					942	945		10.7326/0003-4819-115-12-942	http://dx.doi.org/10.7326/0003-4819-115-12-942			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GU417	1952491				2023-01-03	WOS:A1991GU41700005
J	LAPORTE, JP; FOUILLARD, L; DOUAY, L; EUGENEJOLCHINE, I; ISNARD, F; STACHOWIAK, J; NAJMAN, A; GORIN, NC				LAPORTE, JP; FOUILLARD, L; DOUAY, L; EUGENEJOLCHINE, I; ISNARD, F; STACHOWIAK, J; NAJMAN, A; GORIN, NC			GM-CSF INSTEAD OF AUTOLOGOUS BONE-MARROW TRANSPLANTATION AFTER THE BEAM REGIMEN	LANCET			English	Note							COLONY-STIMULATING FACTOR; RECOMBINANT; CHEMOTHERAPY; FAILURE	Five patients with resistant non-Hodgkin lymphoma (NHL) were given granulocyte-macrophage colony-stimulating factor (GM-CSF, 250-mu-g/m2 daily) after the BEAM pretransplant chemotherapy regimen (carmustine 300 mg/m2, etoposide 1.2 g/m2, cytarabine 800 mg/m2, melphalan 140 mg/m2) because persistent lymphoma cell infiltration of the bone marrow precluded autologous bone-marrow transplantation (BMT). In three patients full haemopoietic reconstitution occurred, with similar kinetics to that seen after autologous BMT. The other two patients died without sustained haemopoietic recovery. GM-CSF may replace autologous BMT in highly selected cases of NHL with progressive disease and bone-marrow involvement.	HOP ST ANTOINE,SERV MALAD SANG,BONE MARROW TRANSPLANT UNIT,F-75571 PARIS 12,FRANCE; FORMAT ASSOCIEE CLAUDE BERNARD,UNITE RECH GREFFES CELLULES SOUCHES HEMATOPOIET,PARIS,FRANCE; FDN CTR NATL TRANSFUS SANGUINE,PARIS,FRANCE; LAB HOECHST PARIS,PARIS,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; UDICE-French Research Universities; Sorbonne Universite								[Anonymous], 1982, CANCER, V49, P2112; BRANDT SJ, 1988, NEW ENGL J MED, V318, P869, DOI 10.1056/NEJM198804073181401; BROXMEYER HE, 1987, P NATL ACAD SCI USA, V84, P3871, DOI 10.1073/pnas.84.11.3871; FOUILLARD L, 1989, LANCET, V1, P1460; GORIN NC, 1986, BLOOD, V67, P1367; NEMUNAITIS J, 1990, BLOOD, V76, P245; PHILIP T, 1987, NEW ENGL J MED, V316, P1493, DOI 10.1056/NEJM198706113162401; SHUENING FG, 1989, BLOOD, V74, P1308; VADHANRAJ S, 1987, NEW ENGL J MED, V317, P1545, DOI 10.1056/NEJM198712173172501	9	43	43	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 7	1991	338	8767					601	602		10.1016/0140-6736(91)90609-S	http://dx.doi.org/10.1016/0140-6736(91)90609-S			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GD809	1679155				2023-01-03	WOS:A1991GD80900005
J	RILEY, WA; SCHNECKENBURGER, WA				RILEY, WA; SCHNECKENBURGER, WA			THE MARYLAND EXPERIENCE AND A PRACTICAL PROPOSAL TO EXPAND EXISTING MODELS IN AMBULATORY PRIMARY CARE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Two unique models for caring for the uninsured and underinsured are operating in Maryland. The first is a group practice, primary care model with a unique ambulatory Medicare waiver that has had a positive impact on patients and physicians. The second is a financial model - an all-payer prospective rate-setting system for all critical care inpatient hospitals that, during a 13-year period from 1977 through 1989, has saved the citizens of the state approximately $5.361 billion, has allowed hospitals to provide $1.657 billion of charity care and bad debts, and has earned $517 million in net profits. The reasons for the success of each of the models are discussed and form the basis for a practical and politically feasible proposal: merge the best aspects of each model into an ambulatory primary care - based model financed through an all-payer prospective charge system.			RILEY, WA (corresponding author), GREATER BALTIMORE MED CTR,DEPT MED,6701 N CHARLES ST,BALTIMORE,MD 21204, USA.							1986, 5 CITY PROGRAM IMPRO, V1, P13; 1989, HOSPITAL STATISTICS	2	3	3	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 28	1991	266	8					1118	1122		10.1001/jama.266.8.1118	http://dx.doi.org/10.1001/jama.266.8.1118			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GB975	1865546				2023-01-03	WOS:A1991GB97500037
J	ANNAS, GJ				ANNAS, GJ			ADDING INJUSTICE TO INJURY - COMPULSORY PAYMENT FOR UNWANTED TREATMENT	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material														Annas, George/0000-0001-5836-7831				ANNAS GJ, 1988, HASTINGS CENT REP, V18, P31, DOI 10.2307/3563046; ANNAS GJ, 1991, NEW ENGL J MED, V324, P1210, DOI 10.1056/NEJM199104253241711; BELKIN L, 1992, NY TIMES        0924, pA16; MENIKOFF JA, 1992, NEW ENGL J MED, V327, P1165, DOI 10.1056/NEJM199210153271612; 1992, OTHERS MUST CHOOSE D; 1987, LIFE SUSTAINING TREA	6	3	3	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 24	1992	327	26					1885	1887		10.1056/NEJM199212243272615	http://dx.doi.org/10.1056/NEJM199212243272615			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KD714	1448133				2023-01-03	WOS:A1992KD71400026
J	HOWARD, MR; CHAPMAN, CE; DUNSTAN, JA; MITCHELL, C; LLOYD, HL				HOWARD, MR; CHAPMAN, CE; DUNSTAN, JA; MITCHELL, C; LLOYD, HL			REGIONAL TRANSFUSION CENTER PREOPERATIVE AUTOLOGOUS BLOOD DONATION PROGRAM - THE 1ST 2 YEARS	BRITISH MEDICAL JOURNAL			English	Article							RECOMBINANT-HUMAN-ERYTHROPOIETIN	Objective-To assess the efficacy of a regional autologous blood donation programme. Design-Clinical and laboratory data were collected and stored prospectively. Transfusion data were collected retrospectively from hospital blood bank records. Setting-Northern Region Blood Transfusion Service and 14 hospitals within the Northern Regional Health Authority. Subjects-505 patients referred for autologous blood donation before elective surgery. Main outcome measures-Patient eligibility, adverse events from donation, autologous blood units provided, and autologous and allogeneic blood units transfused within 10 days of operation. Results-Of 505 patients referred, 354 donated at least one unit. 78 of 151 referred patients who did not donate were excluded at the autologous clinic, mostly because of anaemia or ischaemic heart disease. In 73 cases the patient, general practitioner, or hospital consultant decided against donation. 363 autologous procedures were undertaken. In 213 (59%) cases all requested units were provided. The most common reasons for incomplete provision were late referral or anaemia. Adverse events accompanied 24 of 928 donations (2.6%). Transfusion data were obtained for 357 of the 363 procedures. 281 donors were transfused; autologous blood only was given to 225, autologous and allogeneic blood was given to 52, and allogeneic blood only was given to four. 648 of 902 (72%) units of autologous blood were transfused. Complete provision of requested autologous units was followed by allogeneic transfusion in 12 of 208 procedures (5.8%). Incomplete provision was followed by allogeneic transfusion in 44 of 149 procedures (30%). Conclusions-This study shows the feasibility of a regional autologous transfusion programme. Autologous donors only infrequently received allogeneic transfusion. Patients should be appropriately selected and referred early.	NO REG BLOOD TRANSFUS CTR,NEWCASTLE TYNE,ENGLAND		HOWARD, MR (corresponding author), ROYAL VICTORIA INFIRM,DEPT HAEMATOL,NEWCASTLE TYNE NE1 4LP,TYNE & WEAR,ENGLAND.							BACHON JPA, 1991, TRANSFUSION, V31, P513; BENOIT P, 1992, TRANSFUSION MED, V2, P75; BUSCH MP, 1991, NEW ENGL J MED, V325, P1, DOI 10.1056/NEJM199107043250101; DODD RY, 1992, NEW ENGL J MED, V327, P419, DOI 10.1056/NEJM199208063270610; DONAHUE JG, 1992, NEW ENGL J MED, V327, P369, DOI 10.1056/NEJM199208063270601; GIBLETT ER, 1977, TRANSFUSION, V17, P299, DOI 10.1046/j.1537-2995.1977.17477216857.x; GOODNOUGH LT, 1989, NEW ENGL J MED, V321, P1163, DOI 10.1056/NEJM198910263211705; GRAF H, 1990, BRIT MED J, V300, P1627, DOI 10.1136/bmj.300.6740.1627; Gunson H H, 1991, CDR (Lond Engl Rev), V1, pR144; HICKMAN M, 1988, LANCET, V1, P1221; KRUSKALL MS, 1986, TRANSFUSION, V26, P335, DOI 10.1046/j.1537-2995.1986.26486262740.x; NELSON K, 1991, Transfusion (Bethesda), V31, p47S; PETERSEN LR, 1992, 5TH NAT FOR AIDS HEP, P37; PINDYCK J, 1987, JAMA-J AM MED ASSOC, V257, P1186, DOI 10.1001/jama.257.9.1186; POPOVSKY MA, 1992, TRANSFUSION, V32, P589, DOI 10.1046/j.1537-2995.1992.32692367207.x; SCHMIDT PJ, 1991, TRANSFUSION, V31, P681, DOI 10.1046/j.1537-2995.1991.31892023489.x; TASAKI T, 1992, LANCET, V339, P773, DOI 10.1016/0140-6736(92)91895-F; TOY PTCY, 1987, NEW ENGL J MED, V316, P517, DOI 10.1056/NEJM198702263160906; WARD JW, 1988, NEW ENGL J MED, V318, P473, DOI 10.1056/NEJM198802253180803; 1989, VOX SANG, V57, P278; 1986, JAMA-J AM MED ASSOC, V256, P2378; 1988, CLIN LAB HAEMATOL, V10, P193	22	18	18	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 12	1992	305	6867					1470	1473		10.1136/bmj.305.6867.1470	http://dx.doi.org/10.1136/bmj.305.6867.1470			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KC918	1493393	Green Published, Bronze, Green Submitted			2023-01-03	WOS:A1992KC91800022
J	ETEMADI, A; FARID, R; STANFORD, JL				ETEMADI, A; FARID, R; STANFORD, JL			IMMUNOTHERAPY FOR DRUG-RESISTANT TUBERCULOSIS	LANCET			English	Letter									MASHAD UNIV MED SCI, MASHHAD, IRAN; UCL, SCH MED, DEPT MED MICROBIOL, DIV BACTERIOL, LONDON W1P 7LD, ENGLAND	Mashhad University Medical Science; University of London; University College London; UCL Medical School	ETEMADI, A (corresponding author), TAHLEGHANI PULM DIS HOSP, MASHHAD, IRAN.							STANFORD JL, 1991, LANCET, V338, P557, DOI 10.1016/0140-6736(91)91113-9	1	48	49	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	NOV 28	1992	340	8831					1360	1361		10.1016/0140-6736(92)92551-P	http://dx.doi.org/10.1016/0140-6736(92)92551-P			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KA262	1360082				2023-01-03	WOS:A1992KA26200058
J	THORNICROFT, G; GOOCH, C; DAYSON, D				THORNICROFT, G; GOOCH, C; DAYSON, D			THE TAPS PROJECT .17. READMISSION TO HOSPITAL FOR LONG-TERM PSYCHIATRIC-PATIENTS AFTER DISCHARGE TO THE COMMUNITY	BRITISH MEDICAL JOURNAL			English	Article							REVOLVING-DOOR PATIENTS; NATION-WIDE COHORT; DEINSTITUTIONALIZATION; PATTERNS; SAMPLE; STAY	Objective-To identify risk factors which increase the likelihood of readmission for long stay psychiatric patients after discharge from hospital. Design-Follow up for five years of all long stay patients discharged from two large psychiatric hospitals to compare patients readmitted and not readmitted. Setting-Friern and Claybury Hospitals in north London and their surrounding catchment areas. Most patients were discharged to staffed or unstaffed group homes. Subjects-357 psychiatric patients who had been in hospital for over one year, of whom 118 were "new" long stay and 239 "old" long stay patients. Main outcome measures-Readmission to hospital and length of subsequent stay. Results-Of all discharged patients 97 (27%) were readmitted at some time during the follow up period, 57 (16%) in the first year after discharge, and 31 (9%) then remained in hospital for over a year. The best explanatory factors for readmission were: male sex, younger age group, high number of previous admissions, higher levels of symptomatic and social behavioural disturbance, a diagnosis of manic-depressive psychosis, and living in a non-staffed group home. Conclusions-During the closure of psychiatric hospitals, facilities need to be preserved for acute relapses among long term, and especially younger, discharged patients. Staffed group homes may help prevent relapse and reduce the number of admission beds required.			THORNICROFT, G (corresponding author), INST PSYCHIAT,LONDON SE5 8AF,ENGLAND.		Thornicroft, Graham/B-4027-2010	Thornicroft, Graham/0000-0003-0662-0879				AVISON WR, 1987, AM J PSYCHIAT, V144, P10; BEISER M, 1985, AM J PSYCHIAT, V142, P1047; BLUMENTAHL S, 1988, PSYCHIATR PRAX, V154, P96; CHAMBERS M, 1990, BRIT MED J, V301, P1134, DOI 10.1136/bmj.301.6761.1134; CLARKE A, 1990, BRIT MED J, V301, P1136, DOI 10.1136/bmj.301.6761.1136; COLENDA C C, 1989, Psychiatric Quarterly (New York), V60, P227, DOI 10.1007/BF01064798; DAYSON D, 1992, BRIT MED J, V305, P993, DOI 10.1136/bmj.305.6860.993; DRAKE RE, 1989, HOSP COMMUNITY PSYCH, V40, P46; FERNANDO MLD, 1990, CAN J PSYCHIAT, V35, P71, DOI 10.1177/070674379003500111; GELLER JL, 1990, AM J PSYCHIAT, V147, P988; HAEFNER H, 1989, BRIT J PSYCHIAT, V155, P12; JONES K, 1986, BRIT J PSYCHIAT, V149, P537, DOI 10.1192/bjp.149.5.537; KASTRUP M, 1987, ACTA PSYCHIAT SCAND, V76, P80, DOI 10.1111/j.1600-0447.1987.tb02865.x; KASTRUP M, 1987, ACTA PSYCHIAT SCAND, V76, P552, DOI 10.1111/j.1600-0447.1987.tb02918.x; LERNER Y, 1989, SOC PSYCH PSYCH EPID, V24, P121, DOI 10.1007/BF01788020; LEWIS T, 1990, ACTA PSYCHIAT SCAND, V82, P130, DOI 10.1111/j.1600-0447.1990.tb01369.x; MILNE R, 1990, BRIT MED J, V301, P1139, DOI 10.1136/bmj.301.6761.1139; OKIN RL, 1990, AM J PSYCHIAT, V147, P1596; POKORNY AD, 1983, AM J PSYCHIAT, V140, P1598; SETZE PJ, 1985, HOSP COMMUNITY PSYCH, V36, P521; THORNICROFT G, 1989, BRIT J PSYCHIAT, V155, P739, DOI 10.1192/bjp.155.6.739; WAN TTH, 1991, COMMUNITY MENT HLT J, V27, P3, DOI 10.1007/BF00752711; Wing J. K. C., 1974, MEASUREMENT CLASSIFI; WYKES T, 1986, BRIT J PSYCHIAT, V148, P1, DOI 10.1192/bjp.148.1.1; ZILBER N, 1990, SOC PSYCH PSYCH EPID, V25, P144, DOI 10.1007/BF00782743; 1990, 5TH ANN TAPS C LOND	26	36	36	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 24	1992	305	6860					996	998		10.1136/bmj.305.6860.996	http://dx.doi.org/10.1136/bmj.305.6860.996			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	JV776	1458148	Green Published, Bronze, Green Submitted			2023-01-03	WOS:A1992JV77600028
J	NGUYENVANTAM, JS; BAKER, DM				NGUYENVANTAM, JS; BAKER, DM			GENERAL-PRACTICE AND ACCIDENT AND EMERGENCY DEPARTMENT CARE - DOES THE PATIENT KNOW BEST	BRITISH MEDICAL JOURNAL			English	Article									UNIV NOTTINGHAM HOSP,DEPT ACCID & EMERGENCY,NOTTINGHAM NG7 2UH,ENGLAND	University of Nottingham			Nguyen-Van-Tam, Jonathan/I-2162-2019	Nguyen-Van-Tam, Jonathan/0000-0003-2579-4655; Baker, Daryll/0000-0002-0098-405X				DAVISON AG, 1983, J ROY SOC MED, V76, P37, DOI 10.1177/014107688307600109	1	14	14	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 18	1992	305	6846					157	158		10.1136/bmj.305.6846.157	http://dx.doi.org/10.1136/bmj.305.6846.157			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JF063	1515831	Green Published, Green Submitted, Bronze			2023-01-03	WOS:A1992JF06300023
J	NISHINO, T; SUGIYAMA, A; TANAKA, A; ISHIKAWA, T				NISHINO, T; SUGIYAMA, A; TANAKA, A; ISHIKAWA, T			EFFECTS OF TOPICAL NASAL ANESTHESIA ON SHIFT OF BREATHING ROUTE IN ADULTS	LANCET			English	Article							RESPIRATORY ACTIVITY; MUSCLE-ACTIVITY; ANESTHESIA; PRESSURE; OBSTRUCTION; RECEPTORS; INFANTS; HUMANS; LAMBS; SLEEP	The position of the soft palate is known to determine the breathing route, but the physiological mechanisms that bring about a shift from nasal to oral breathing are unclear. To test the hypothesis that activation of receptors in the nasal passage may be involved in reflex initiation of oral breathing after nasal obstruction, we investigated respiratory responses to nasal occlusion before and after topical lignocaine anaesthesia of the nasal passages. Eleven volunteers were fitted with custom-made partitioned face masks, which separated nasal and oral passages. Air flow through each passage was detected by changes in airway pressure and carbon dioxide concentration. Nine subjects were habitual nasal breathers both before and after topical anaesthesia with 4% lignocaine. Among these subjects, the time to initiate oral breathing in response to nasal occlusion was significantly shorter before anaesthesia than afterwards (mean 4.4 [SD 2.5] vs 10.8 [7.4] s, p<0.01). Similarly, the time to resume nasal breathing after release of nasal occlusion was significantly shorter before topical anaesthesia than afterwards (6.9 [4.9] vs 12.1 [7.8] s, p<0.01). Topical anaesthesia did not affect respiration rate, end-tidal carbon dioxide concentration, or arterial oxygen saturation. These findings suggest that in human beings sensory information from receptors in the nasal passage has an important role in controlling the shift of breathing route.			NISHINO, T (corresponding author), NATL CANC CTR,DEPT ANESTHESIOL,TSUKIJI 5-1-1,CHUO KU,TOKYO 104,JAPAN.							DEWEESE EL, 1988, J APPL PHYSIOL, V64, P1346, DOI 10.1152/jappl.1988.64.4.1346; HARDING R, 1990, RESP PHYSIOL, V80, P71, DOI 10.1016/0034-5687(90)90007-L; HARDING R, 1987, RESP PHYSIOL, V68, P177, DOI 10.1016/S0034-5687(87)80004-X; HARDING R, 1991, J APPL PHYSIOL, V71, P1574, DOI 10.1152/jappl.1991.71.4.1574; KUNA ST, 1988, AM REV RESPIR DIS, V137, P656, DOI 10.1164/ajrccm/137.3.656; MATHEW OP, 1982, J APPL PHYSIOL, V52, P438, DOI 10.1152/jappl.1982.52.2.438; MATHEW OP, 1984, RESP PHYSIOL, V58, P41, DOI 10.1016/0034-5687(84)90043-4; MATHEW OP, 1984, J APPL PHYSIOL, V56, P500, DOI 10.1152/jappl.1984.56.2.500; MCBRIDE B, 1981, J APPL PHYSIOL, V51, P1189, DOI 10.1152/jappl.1981.51.5.1189; MILLER MJ, 1985, J PEDIATR-US, V107, P465, DOI 10.1016/S0022-3476(85)80535-7; RODENSTEIN DO, 1985, AM REV RESPIR DIS, V131, P343; RODENSTEIN DO, 1984, J APPL PHYSIOL, V57, P651, DOI 10.1152/jappl.1984.57.3.651; SANTAMBROGIO FB, 1985, J APPL PHYSIOL, V58, P1298, DOI 10.1152/jappl.1985.58.4.1298; SANTAMBROGIO G, 1983, RESP PHYSIOL, V54, P317, DOI 10.1016/0034-5687(83)90075-0; SANTAMBROGIO G, 1985, RESPIR PHYSL, V59, P34; Swift DL., 1977, RESPIRATORY DEFENSE, V5, P63; WHITE DP, 1985, AM REV RESPIR DIS, V132, P972; WOLFSDORF J, 1969, PEDIATRICS, V43, P799	18	14	15	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 20	1992	339	8808					1497	1500		10.1016/0140-6736(92)91261-6	http://dx.doi.org/10.1016/0140-6736(92)91261-6			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HZ175	1351184				2023-01-03	WOS:A1992HZ17500002
J	VANDERMEER, JTM; VANWIJK, W; THOMPSON, J; VANDENBROUCKE, JP; VALKENBURG, HA; MICHEL, MF				VANDERMEER, JTM; VANWIJK, W; THOMPSON, J; VANDENBROUCKE, JP; VALKENBURG, HA; MICHEL, MF			EFFICACY OF ANTIBIOTIC-PROPHYLAXIS FOR PREVENTION OF NATIVE-VALVE ENDOCARDITIS	LANCET			English	Article							INFECTIVE ENDOCARDITIS; BACTERIAL-ENDOCARDITIS; DENTAL PROCEDURES; CONTROVERSIES; VIEW	Whether antibiotic prophylaxis can prevent bacterial endocarditis is hotly debated. In an attempt to settle this issue, we have assessed the efficacy of prophylaxis for bacterial endocarditis on native valves in a nationwide, case-control study in the Netherlands. Cases were patients with known cardiac disease in whom endocarditis developed within 180 days of a medical or dental procedure for which prophylaxis was indicated. Of a total of 438 patients with endocarditis diagnosed during 2 years, 48 were eligible for the study. Controls were patients with the same cardiac status in whom endocarditis did not develop within 180 days of a similar procedure; of a total of 889 controls from five hospitals, 200 were eligible. Overall, about 1 in 6 patients in both groups had received prophylaxis. The best estimate of protective efficacy was 49% for first-ever endocarditis occurring within 30 days of a procedure. Endocarditis developed within 30 days of a procedure in only 13% of patients with a previously diagnosed heart lesion which predisposed to the disease. The findings suggest that strict adherence to generally accepted recommendations for prophylaxis might do little to decrease the total number of patients with endocarditis in the community.	UNIV HOSP LEIDEN, DEPT CLIN EPIDEMIOL, 2300 RC LEIDEN, NETHERLANDS; ERASMUS UNIV, DEPT CLIN MICROBIOL, 3000 DR ROTTERDAM, NETHERLANDS; ERASMUS UNIV, DEPT EPIDEMIOL & BIOSTAT, 3000 DR ROTTERDAM, NETHERLANDS	Leiden University; Leiden University Medical Center (LUMC); Erasmus University Rotterdam; Erasmus University Rotterdam	VANDERMEER, JTM (corresponding author), UNIV HOSP LEIDEN, DEPT INFECT DIS, BLDG 1, C5-P, PO 9600, 2300 RC LEIDEN, NETHERLANDS.		Vandenbroucke, Jan/AAM-3928-2020	Vandenbroucke, Jan/0000-0001-5668-6716				[Anonymous], 1990, Lancet, V335, P88; BADDOUR LM, 1988, REV INFECT DIS, V10, P1163; BAYLISS R, 1983, BRIT HEART J, V50, P513, DOI 10.1136/hrt.50.6.513; BROOKS RG, 1988, AM J MED, V18, P74; DAJANI AS, 1990, JAMA-J AM MED ASSOC, V264, P2919, DOI 10.1001/jama.264.22.2919; DENNING DW, 1984, BRIT MED J, V289, P1499, DOI 10.1136/bmj.289.6457.1499; DINMAN BD, 1980, JAMA-J AM MED ASSOC, V244, P1226, DOI 10.1001/jama.244.11.1226; DURACK DT, 1983, JAMA-J AM MED ASSOC, V250, P2318, DOI 10.1001/jama.250.17.2318; DURACK DT, 1984, PRINCIPLES PRACTICES, P539; FEINSTEIN AR, 1979, J CHRON DIS, V32, P35, DOI 10.1016/0021-9681(79)90009-2; FEKETE T, 1990, DENT CLIN N AM, V34, P79; FINCH R, 1990, SCAND J INFECT DIS, P102; GUTSCHIK E, 1990, SCAND J DENT RES, V98, P144; IMPERIALE TF, 1990, AM J MED, V88, P131, DOI 10.1016/0002-9343(90)90461-L; Jaspers M T, 1984, J Dent Educ, V48, P159; KAPLAN EL, 1986, AM J CARDIOL, V57, P478, DOI 10.1016/0002-9149(86)90777-0; KAYE D, 1986, ANN INTERN MED, V104, P419, DOI 10.7326/0003-4819-104-3-419; LAVIE CJ, 1989, JAMA-J AM MED ASSOC, V262, P3308, DOI 10.1001/jama.262.23.3308; MCGOWAN DA, 1987, J ANTIMICROB CHEMOTH, V20, P105, DOI 10.1093/jac/20.suppl_A.105; MCGOWAN DA, 1978, J ANTIMICROB CHEMOTH, V4, P486, DOI 10.1093/jac/4.6.486; MICHEL MF, 1986, GENEESMIDDELEN B, V20, P53; Murrah V A, 1987, J Dent Educ, V51, P229; OAKLEY CM, 1987, J ANTIMICROB CHEMOTH, V20, P99, DOI 10.1093/jac/20.suppl_A.99; PETERSDORF RG, 1978, AM J MED, V65, P220, DOI 10.1016/0002-9343(78)90811-2; SHANSON DC, 1987, J ANTIMICROB CHEMOTH, V20, P119, DOI 10.1093/jac/20.suppl_A.119; STECKELBERG JM, 1990, AM J MED, V88, P582, DOI 10.1016/0002-9343(90)90521-E; VONREYN CF, 1981, ANN INTERN MED, V94, P505, DOI 10.7326/0003-4819-94-4-505; WALKER M P, 1984, Clinical Preventive Dentistry, V6, P17; 1976, LANCET, V1, P519	29	256	260	2	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 18	1992	339	8786					135	139		10.1016/0140-6736(92)90207-J	http://dx.doi.org/10.1016/0140-6736(92)90207-J			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GZ968	1346008				2023-01-03	WOS:A1992GZ96800001
J	AELONY, Y; KING, R; BOUTIN, C				AELONY, Y; KING, R; BOUTIN, C			THORACOSCOPIC TALC POUDRAGE PLEURODESIS FOR CHRONIC RECURRENT PLEURAL EFFUSIONS	ANNALS OF INTERNAL MEDICINE			English	Article							CORYNEBACTERIUM-PARVUM; SYMPTOMATIC TREATMENT; TETRACYCLINE; MESOTHELIOMA; DIAGNOSIS	Objective: To assess the effectiveness of thoracoscopic talc poudrage for the treatment of chronic pleural effusions. Design: Prospective evaluation. Setting: Kaiser-Permanente Hospital. Patients: Forty-seven consecutive patients with recalcitrant pleural effusions, referred for thoracoscopy. Intervention: Patients received general or local anesthesia; 42 had a 7-mm rigid thoracoscopic examination followed by insufflation of 5 mL of talc. Patients then had chest-tube drainage. Measurements: We recorded clinical characteristics, final diagnosis, procedure-related pain and morbidity, days of hospitalization, patient-reported degree of symptom relief, and chest roentgenographic results at 1, 3, and 12 months. All patients were followed for 16 months or until death. Main Results: Of 39 evaluable patients, all reported prolonged relief of effusion-related dyspnea. Radiographic results confirmed the elimination of pleural effusions in 34 patients (87%), including all 11 with benign conditions and 23 of 28 (82%) with malignancies. Treatment failed in three patients because of entrapped lung and in two patients with mesotheliomas whose effusions recurred more than a year after treatment. No procedure-related mortality or morbidity was found. Ambulatory patients required hospitalization for a mean of 3.9 days (range, 2 to 11 days). Mild pain was reported by some patients. The mean duration of chest-tube drainage was 2.7 days (range, 1 to 9 days). Patients with malignant disease lived an average of 12.4 months (range, 1 to 61 months) after the procedure. Conclusions: Thoracoscopic talc poudrage is an effective pleural sclerosing technique and is relatively painless.	HOP CONCEPTION, F-13386 MARSEILLE 5, FRANCE	Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille	AELONY, Y (corresponding author), SO CALIF PERMANENTE MED GRP, DEPT INTERNAL MED, 25825 S VERMONT, HARBOR CITY, CA 90710 USA.							ANTONY VB, 1987, AM REV RESPIR DIS, V135, P775, DOI 10.1164/arrd.1987.135.4.775; BONIFACE E, 1989, REV MAL RESPIR, V6, P133; BOUTIN C, 1981, AM REV RESPIR DIS, V124, P588; Boutin C, 1991, PRACTICAL THORACOSCO; BOUTIN C, 1990, LUNG S, P1113; Boutin C, 1985, REV MAL RESPIR, V2, P374; BOUTIN C, 1985, PLEURA HLTH DISEASE; BRANDT HJ, 1985, ATLAS DIAGNOSTIC THO; CANTO A, 1985, MED CLIN-BARCELONA, V84, P806; CHRETIEN J, 1983, DISEASES PLEURA, P152; DAVIDSON AC, 1988, THORAX, V43, P327, DOI 10.1136/thx.43.4.327; DUNKEL TB, 1986, MINN MED, V69, P717; ELMES PC, 1976, Q J MED, V45, P427; FENTIMAN IS, 1987, CANCER TREAT REV, V14, P107, DOI 10.1016/0305-7372(87)90043-0; Frank W, 1989, Pneumologie, V43, P80; GAENSLER EA, 1964, NEW ENGL J MED, V270, P1319, DOI 10.1056/NEJM196406182702501; Gust R, 1989, Pneumologie, V43, P85; HAUPT GJ, 1960, JAMA-J AM MED ASSOC, V73, P173; HAUSHEER FH, 1985, SEMIN ONCOL, V12, P54; JONES DP, 1989, CHEST S, V96, pS276; LADJIMI S, 1989, REV MAL RESPIR, V6, P147; LANDVATER L, 1988, CHEST, V93, P1196, DOI 10.1378/chest.93.6.1196; LANGE P, 1988, THORAX, V43, P559, DOI 10.1136/thx.43.7.559; LEAHY BC, 1985, EUR J RESPIR DIS, V66, P50; LIGHT RW, 1972, ANN INTERN MED, V77, P507, DOI 10.7326/0003-4819-77-4-507; LIGHT RW, 1983, PLEURAL DISEASES, P84; LIGHT RW, 1983, PLEURAL DISEASES, P86; LIGHT RW, 1983, PLEURAL DISEASES, P77; MARTINI N, 1975, CANCER, V35, P734, DOI 10.1002/1097-0142(197503)35:3<734::AID-CNCR2820350328>3.0.CO;2-N; MUIR J F, 1987, American Review of Respiratory Disease, V135, pA244; NG TK, 1984, MED J AUSTRALIA, V140, P452, DOI 10.5694/j.1326-5377.1984.tb108157.x; RINALDO JE, 1983, J THORAC CARDIOV SUR, V85, P523; ROSSI GA, 1987, AM REV RESPIR DIS, V135, P885, DOI 10.1164/arrd.1987.135.4.885; SHERMAN S, 1988, CHEST, V93, P533, DOI 10.1378/chest.93.3.533; SHERMAN S, 1987, SOUTH MED J, V80, P716, DOI 10.1097/00007611-198706000-00013; TSANG V, 1990, THORAX, V45, P369, DOI 10.1136/thx.45.5.369; TZENG E, 1990, CHEST, V98, P890, DOI 10.1378/chest.98.4.890; Viskum K, 1981, Poumon Coeur, V37, P25; WEISSBERG D, 1980, ANN THORAC SURG, V29, P205, DOI 10.1016/S0003-4975(10)61868-1; Weissberg D, 1981, Poumon Coeur, V37, P291; WOOTEN S A, 1987, American Review of Respiratory Disease, V135, pA245	41	74	75	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 15	1991	115	10					778	782		10.7326/0003-4819-115-10-778	http://dx.doi.org/10.7326/0003-4819-115-10-778			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GP800	1929026				2023-01-03	WOS:A1991GP80000006
J	SOUMERAI, SB; ROSSDEGNAN, D; AVORN, J; MCLAUGHLIN, TJ; CHOODNOVSKIY, I				SOUMERAI, SB; ROSSDEGNAN, D; AVORN, J; MCLAUGHLIN, TJ; CHOODNOVSKIY, I			EFFECTS OF MEDICAID DRUG-PAYMENT LIMITS ON ADMISSION TO HOSPITALS AND NURSING-HOMES	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CONTROLLED TRIAL; EXPERIENCE; THERAPY; CARE	Background. Many state Medicaid programs limit the number of reimbursable medications that a patient can receive. We hypothesized that such limitations may lead to exacerbations of illness or to admissions to institutions where there are no caps on drug reimbursements. Methods. We analyzed 36 months of Medicaid claims data from New Hampshire, which had a three-drug limit per patient for 11 of those months, and from New Jersey, which did not. The study patients in New Hampshire (n = 411) and a matched comparison cohort in New Jersey (n = 1375) were Medicaid recipients 60 years of age or older who in a base-line year had been taking three or more medications per month, including at least one maintenance drug for certain chronic diseases. Survival (defined as remaining in the community) and time-series analyses were conducted to determine the effect of the reimbursement cap on admissions to hospitals and nursing homes. Results. The base-line demographic characteristics of the cohorts were nearly identical. In New Hampshire, the 35 percent decline in the use of study drugs after the cap was applied was associated with an increase in rates of admission to nursing homes; no changes were observed in the comparison cohort (RR = 1.8; 95 percent confidence interval, 1.2 to 2.6). There was no significantly increased risk of hospitalization. Among the patients in New Hampshire who regularly took three or more study medications at base line, the relative risk of admission to a nursing home during the period of the cap was 2.2 (95 percent confidence interval, 1.2 to 4.1), and the risk of hospitalization was 1.2 (95 percent confidence interval, 0.8 to 1.6). When the cap was discontinued after 11 months, the use of medications returned nearly to base-line levels, and the excess risk of admission to a nursing home ceased. In general, the patients who were admitted to nursing homes did not return to the community. Conclusions. Limiting reimbursement for effective drugs puts frail, low-income, elderly patients at increased risk of institutionalization in nursing homes and may increase Medicaid costs.	HARVARD UNIV, SCH MED, PROGRAM ANAL CLIN STRATEGIES, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT MED, BOSTON, MA 02115 USA; BETH ISRAEL HOSP, BOSTON, MA 02215 USA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center	SOUMERAI, SB (corresponding author), HARVARD UNIV, SCH MED, DEPT SOCIAL MED, 643 HUNTINGTON AVE, BOSTON, MA 02115 USA.		Young, Alexander/A-1523-2009	Young, Alexander/0000-0002-9367-9213	AHRQ HHS [HSO5947] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		[Anonymous], 1967, J AMER MED ASSOC, V202, P1028, DOI 10.1001/jama.1967.03130240070013; [Anonymous], 1970, JAMA, V213, P1143; AVORN J, 1983, NEW ENGL J MED, V308, P1457, DOI 10.1056/NEJM198306163082406; COX DR, 1972, J R STAT SOC B, V34, P187; FEDERSPIEL CF, 1976, MED CARE, V14, P166, DOI 10.1097/00005650-197602000-00006; FITZGERALD JF, 1987, JAMA-J AM MED ASSOC, V258, P218; Harrington C, 1988, Health Care Financ Rev, V9, P81; HOLAHAN J, 1986, MEDICAID TRADE COST; Hsiao W C, 1986, Health Aff (Millwood), V5, P32, DOI 10.1377/hlthaff.5.2.32; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; LEVY M, 1982, INT J CLIN PHARM TH, V20, P600; LURIE N, 1984, NEW ENGL J MED, V311, P480, DOI 10.1056/NEJM198408163110735; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; MARONDE RF, 1989, MED CARE, V27, P1159, DOI 10.1097/00005650-198912000-00007; PEDERSEN TR, 1981, NEW ENGL J MED, V304, P801; Ray W A, 1989, Health Care Financ Rev, V10, P51; RAY WA, 1987, MED CARE, V25, P738, DOI 10.1097/00005650-198708000-00007; SCHAFFNER W, 1983, JAMA-J AM MED ASSOC, V250, P1728, DOI 10.1001/jama.250.13.1728; SOUMERAI SB, 1987, NEW ENGL J MED, V317, P550, DOI 10.1056/NEJM198708273170906; STASON WB, 1977, NEW ENGL J MED, V296, P732, DOI 10.1056/NEJM197703312961307; STRANDBERG LR, 1984, AM HLTH CARE ASS J, V10, P20; 1984, MED DATA SOURCE POST, V1; 1987, HCFA03249 PUBL, P87; 1989, DHHS PHS893448 PUBL; 1985, HCFA03204 PUBL	25	416	418	0	11	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 10	1991	325	15					1072	1077		10.1056/NEJM199110103251505	http://dx.doi.org/10.1056/NEJM199110103251505			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GJ108	1891009	Green Published			2023-01-03	WOS:A1991GJ10800005
J	WALLENTIN, L				WALLENTIN, L			RISK OF MYOCARDIAL-INFARCTION AND DEATH DURING TREATMENT WITH LOW-DOSE ASPIRIN AND INTRAVENOUS HEPARIN IN MEN WITH UNSTABLE CORONARY-ARTERY DISEASE	LANCET			English	Article									LINKOPING UNIV, DEPT INTERNAL MED, S-58185 LINKOPING, SWEDEN; LINKOPING UNIV, DEPT CLIN PHYSIOL, S-58185 LINKOPING, SWEDEN	Linkoping University; Linkoping University								[Anonymous], 1988, LANCET, V2, P349; [Anonymous], 1988, BRIT MED J, V296, P320; BALSANO F, 1990, CIRCULATION, V82, P17, DOI 10.1161/01.CIR.82.1.17; BASHOUR TT, 1988, AM HEART J, V115, P850, DOI 10.1016/0002-8703(88)90889-7; BERGLUND U, IN PRESS EUR HEART J; CAIRNS JA, 1985, NEW ENGL J MED, V313, P1369, DOI 10.1056/NEJM198511283132201; EPSTEIN SE, 1984, AM J CARDIOL, V54, P1245, DOI 10.1016/S0002-9149(84)80074-0; FUSTER V, 1987, PROG CARDIOVASC DIS, V29, P325, DOI 10.1016/0033-0620(87)90001-6; FUSTER V, 1988, CIRCULATION, V77, P1213, DOI 10.1161/01.CIR.77.6.1213; HENNEKENS CH, 1989, CIRCULATION, V80, P749, DOI 10.1161/01.CIR.80.4.749; HENNEKENS CH, 1989, NEW ENGL J MED, V321, P129, DOI 10.1056/nejm198907203210301; HUBER K, 1989, THROMB RES, V55, P779, DOI 10.1016/0049-3848(89)90308-3; KLIMT CR, 1986, J AM COLL CARDIOL, V7, P251, DOI 10.1016/S0735-1097(86)80489-2; LEWIS HD, 1983, NEW ENGL J MED, V309, P396, DOI 10.1056/NEJM198308183090703; LORENZ RL, 1989, AM J CARDIOL, V64, P1185, DOI 10.1016/0002-9149(89)90875-8; PRICHARD PJ, 1989, BMJ-BRIT MED J, V298, P493, DOI 10.1136/bmj.298.6672.493; SERNERI GGN, 1990, LANCET, V335, P615; SWAHN E, 1987, AM J CARDIOL, V59, P208, DOI 10.1016/0002-9149(87)90786-7; TAVAZZI L, 1989, LANCET, V2, P182; TELFORD AM, 1981, LANCET, V1, P1225; THEROUX P, 1988, NEW ENGL J MED, V319, P1105, DOI 10.1056/NEJM198810273191701; YUSUF S, 1988, JAMA-J AM MED ASSOC, V260, P2088, DOI 10.1001/jama.260.14.2088	22	719	732	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 6	1990	336	8719					827	830						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EB901	1976875				2023-01-03	WOS:A1990EB90100001
J	BARTSCH, P; BAUMGARTNER, RW; WABER, U; MAGGIORINI, M; OELZ, O				BARTSCH, P; BAUMGARTNER, RW; WABER, U; MAGGIORINI, M; OELZ, O			COMPARISON OF CARBON-DIOXIDE-ENRICHED, OXYGEN-ENRICHED, AND NORMAL AIR IN TREATMENT OF ACUTE MOUNTAIN-SICKNESS	LANCET			English	Article									INSELSPITAL BERN, DEPT MED, CH-3010 BERN, SWITZERLAND; UNIV HOSP ZURICH, DEPT NEUROL, CH-8091 ZURICH, SWITZERLAND; UNIV HOSP ZURICH, DEPT MED, CH-8091 ZURICH, SWITZERLAND	University of Bern; University Hospital of Bern; University of Zurich; University Zurich Hospital; University of Zurich; University Zurich Hospital				Maggiorini, Marco/0000-0001-8180-2117				Aaslid R, 1986, TRANSCRANIAL DOPPLER; BARTSCH P, 1989, J APPL PHYSIOL, V66, P2136, DOI 10.1152/jappl.1989.66.5.2136; BARTSCH P, 1990, WILDERNESS MED, V1, P162; Bartsch P., 1990, HYPOXIA ADAPTATIONS, P241; BORGSTROM L, 1975, ACTA PHYSIOL SCAND, V93, P423, DOI 10.1111/j.1748-1716.1975.tb05832.x; Childs SB, 1935, NATURE, V135, P457, DOI 10.1038/135457a0; FERRAZZINI G, 1987, BRIT MED J, V294, P1380, DOI 10.1136/bmj.294.6584.1380; HACKETT PH, 1989, LANCET, V1, P272; HACKETT PH, 1988, AVIAT SPACE ENVIR MD, V59, P950; HACKETT PH, 1990, HYPOXIA ADAPTATIONS, P295; HARVEY TC, 1988, LANCET, V2, P639; HOUSTON CS, 1975, LANCET, V2, P758; HUANG SY, 1987, J APPL PHYSIOL, V63, P395, DOI 10.1152/jappl.1987.63.1.395; JOHNSON TS, 1988, NEW ENGL J MED, V319, P841, DOI 10.1056/NEJM198809293191306; KOGURE K, 1970, AM J PHYSIOL, V219, P1393, DOI 10.1152/ajplegacy.1970.219.5.1393; LEVINE BD, 1989, NEW ENGL J MED, V321, P1707, DOI 10.1056/NEJM198912213212504; MARKWALDER TM, 1984, J CEREBR BLOOD F MET, V4, P368, DOI 10.1038/jcbfm.1984.54; MOORE LG, 1986, J APPL PHYSIOL, V60, P1407, DOI 10.1152/jappl.1986.60.4.1407; MOSSO A, 1898, LIFE MAN HIGH ALPS, P287; ROCK PB, 1987, AVIAT SPACE ENVIR MD, V58, P668; SAMPSON JB, 1983, AVIAT SPACE ENVIR MD, V54, P1063	21	40	41	0	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 29	1990	336	8718					772	775		10.1016/0140-6736(90)93240-P	http://dx.doi.org/10.1016/0140-6736(90)93240-P			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EB077	1976147				2023-01-03	WOS:A1990EB07700005
J	JACOBS, HS; LOEFFLER, FE				JACOBS, HS; LOEFFLER, FE			REGULAR REVIEW - POSTMENOPAUSAL HORMONE REPLACEMENT THERAPY	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CORONARY HEART-DISEASE; ESTROGEN REPLACEMENT; BREAST-CANCER; HIP FRACTURE; WOMEN; PREVENTION; MENOPAUSE; RISK; OSTEOPOROSIS; ESTRADIOL		ST MARYS HOSP, LONDON W2 1PG, ENGLAND	Imperial College London	JACOBS, HS (corresponding author), UCL, MIDDLESEX HOSP, SCH MED, LONDON W1N 8AA, ENGLAND.		Jacobs, Howard/A-9845-2009					[Anonymous], 1991, Osteoporos Int, V1, P114; ARMSTRONG BK, 1988, MED J AUSTRALIA, V148, P213, DOI 10.5694/j.1326-5377.1988.tb99424.x; BARABAS R, 1987, BIOCHEM BIOPH RES CO, V142, P63; BARRETTCONNOR E, 1992, BRIT MED BULL, V48, P345, DOI 10.1093/oxfordjournals.bmb.a072550; BARRETTCONNOR E, 1991, ANN INTERN MED, V115, P455, DOI 10.7326/0003-4819-115-6-455; BATES SK, 1991, J SOC OBSTETRICS GYN, V12, P9; BEWLEY S, 1992, LANCET, V339, P290, DOI 10.1016/0140-6736(92)91344-8; BOURNE T, 1990, LANCET, V335, P1470, DOI 10.1016/0140-6736(90)91505-5; Bush T L, 1991, Aging (Milano), V3, P3; CHRISTIANSEN C, 1991, BAILIERES CLIN OBSTE, V4, P785; COMPSTON JE, 1992, BRIT MED BULL, V48, P309, DOI 10.1093/oxfordjournals.bmb.a072549; COOPER C, 1992, TRENDS ENDOCRIN MET, V3, P224, DOI 10.1016/1043-2760(92)90032-V; CREASMAN WT, 1991, OBSTET GYNECOL, V77, P308, DOI 10.1097/00006250-199102000-00031; DAVIES MC, 1990, BRIT MED J, V301, P790, DOI 10.1136/bmj.301.6755.790; DEMPSTER DW, 1986, J BONE MINER RES, V1, P15; DEVOR M, 1992, AM J MED, V92, P275, DOI 10.1016/0002-9343(92)90077-O; DUPONT WD, 1991, ARCH INTERN MED, V151, P67, DOI 10.1001/archinte.151.1.67; DUURSMA SA, 1992, GYNECOL ENDOCRINOL, V6, P205, DOI 10.3109/09513599209015556; ERIKSEN EF, 1988, SCIENCE, V241, P84, DOI 10.1126/science.3388021; FARISH E, 1991, BRIT MED J, V303, P694, DOI 10.1136/bmj.303.6804.694; GANGAR K, 1989, BRIT MED J, V299, P601, DOI 10.1136/bmj.299.6699.601-a; GANGAR KF, 1991, LANCET, V338, P839; GARNETT T, 1990, BRIT J OBSTET GYNAEC, V97, P917, DOI 10.1111/j.1471-0528.1990.tb02447.x; GOLDMAN L, 1991, NEW ENGL J MED, V325, P800, DOI 10.1056/NEJM199109123251108; GRUCHOW HW, 1988, AM HEART J, V115, P954, DOI 10.1016/0002-8703(88)90063-4; HEANEY RP, 1978, J LAB CLIN MED, V92, P964; HELLER RF, 1978, BRIT MED J, V1, P472, DOI 10.1136/bmj.1.6111.472; JENSEN J, 1991, BAILLIERE CLIN OB GY, V5, P867, DOI 10.1016/S0950-3552(05)80294-9; KANIS JA, 1992, BRIT MED J, V305, P1124, DOI 10.1136/bmj.305.6862.1124; KEY TJA, 1988, EUR J CANCER CLIN ON, V24, P29, DOI 10.1016/0277-5379(88)90173-3; LAW MR, 1991, BMJ-BRIT MED J, V303, P453, DOI 10.1136/bmj.303.6800.453; LEATHER AT, 1991, OBSTET GYNECOL, V78, P1008; LINDSAY R, 1980, BRIT MED J, V280, P1207, DOI 10.1136/bmj.280.6225.1207; LINDSAY R, 1991, BAILLIERE CLIN OB GY, V5, P837, DOI 10.1016/S0950-3552(05)80291-3; MANN RD, 1992, HORMONE REPLACEMENT; MANNING DL, 1992, RECENT ADV ENDOCRINO, V4, P133; MARSH MS, 1992, BRIT MED BULL, V48, P426, DOI 10.1093/oxfordjournals.bmb.a072554; MCFARLAND KF, 1989, AM HEART J, V117, P1209, DOI 10.1016/0002-8703(89)90398-0; MEADE TW, 1992, BRIT MED BULL, V48, P276, DOI 10.1093/oxfordjournals.bmb.a072548; MELTON LJ, 1991, BAILLIERE CLIN OB GY, V5, P785, DOI 10.1016/S0950-3552(05)80287-1; NAESSEN T, 1990, ANN INTERN MED, V113, P95, DOI 10.7326/0003-4819-113-2-95; NICHOLSON RI, 1992, RECENT ADV ENDOCRINO, V4, P151; PATERSON MEL, 1980, BRIT MED J, V280, P822, DOI 10.1136/bmj.280.6217.822; REES A, 1990, BRIT MED BULL, V46, P873, DOI 10.1093/oxfordjournals.bmb.a072444; RIGGS BL, 1992, NEW ENGL J MED, V327, P620; SILLEROARENAS M, 1992, OBSTET GYNECOL, V79, P286; SLYPER AH, 1992, LANCET, V340, P289, DOI 10.1016/0140-6736(92)92368-P; SOMA M, 1991, LANCET, V337, P612, DOI 10.1016/0140-6736(91)91674-J; STAMPFER MJ, 1991, PREV MED, V20, P47, DOI 10.1016/0091-7435(91)90006-P; STEINBERG KK, 1991, JAMA-J AM MED ASSOC, V265, P1985, DOI 10.1001/jama.265.15.1985; STEVENSON JC, 1990, LANCET, V336, P265, DOI 10.1016/0140-6736(90)91801-G; STOLL BA, 1989, EUR J CANCER CLIN ON, V25, P1909, DOI 10.1016/0277-5379(89)90372-6; STUDD J, 1992, J ROY SOC MED, V85, P376; SULLIVAN JM, 1988, ANN INTERN MED, V108, P358, DOI 10.7326/0003-4819-108-3-358; THAM KT, 1992, BR MED B, V48, P249; TIKKANEN MJ, 1978, LANCET, V2, P490; TUNSTALLPEDOE H, 1992, BRIT MED J, V305, P1096, DOI 10.1136/bmj.305.6861.1096-b; WALSH BW, 1991, NEW ENGL J MED, V325, P1196, DOI 10.1056/NEJM199110243251702; WILKES HC, 1991, BRIT MED J, V302, P1317, DOI 10.1136/bmj.302.6788.1317; 1991, LANCET, V337, P397; 1992, CURRENT PROBLEMS JUN	61	56	56	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 5	1992	305	6866					1403	1408		10.1136/bmj.305.6866.1403	http://dx.doi.org/10.1136/bmj.305.6866.1403			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KB856	1343093	Green Submitted, Bronze, Green Published			2023-01-03	WOS:A1992KB85600024
J	PIETRONI, PC				PIETRONI, PC			PARTNERS IN PRACTICE .7. BEYOND THE BOUNDARIES - RELATIONSHIP BETWEEN GENERAL-PRACTICE AND COMPLEMENTARY MEDICINE	BRITISH MEDICAL JOURNAL			English	Article											PIETRONI, PC (corresponding author), ST MARYS HOSP,SCH MED,LONDON,ENGLAND.							BEIER LM, 1987, SUFFERERS HEALERS EX, P38; DESSER A, IN PRESS J R COLL GE; FULDER S, 1981, STATUS COMPLEMENTARY; MCLEAN J, 1990, SOC SCI MED, V30, P591, DOI 10.1016/0277-9536(90)90157-N; PETERS D, IN PRESS J R COLL GE; PIETRONI PC, 1988, J R SOC ARTS, P791; REASON P, 1992, J ROY SOC MED, V85, P161; REASON P, 1991, J RES COUNCIL COMPLE, V5, P144; REILLY DT, 1983, BRIT MED J, V287, P337, DOI 10.1136/bmj.287.6388.337; WHARTON R, 1986, BRIT MED J, V292, P1498, DOI 10.1136/bmj.292.6534.1498; 1989, TIMES           1113; 1981, WHICH            AUG; 1991, REPORT OSTEOPATHY	13	28	28	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 5	1992	305	6853					564	566		10.1136/bmj.305.6853.564	http://dx.doi.org/10.1136/bmj.305.6853.564			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JM495	1393039	Green Published, Green Submitted, hybrid			2023-01-03	WOS:A1992JM49500021
J	OKAMOTO, Y				OKAMOTO, Y			HEALTH-CARE FOR THE ELDERLY IN JAPAN - MEDICINE AND WELFARE IN AN AGING SOCIETY FACING A CRISIS IN LONG-TERM CARE	BRITISH MEDICAL JOURNAL			English	Article											OKAMOTO, Y (corresponding author), HANNAN CHUO HOSP,DEPT INTERNAL MED & HOME CARE,3-3-28 MINAMISHINMACHI,MATSUBARA,OSAKA 580,JAPAN.							ANDERSEN BR, 1990, KOSEIFUKUSHI J, P2; CHARLTON JRH, 1986, BRIT MED J, V292, P295, DOI 10.1136/bmj.292.6516.295; HASEGAWA T, 1990, J HLTH WELFARE STATI, V36, P23; HENDRICS J, 1986, AGING MASS SOC MYTHS; HIATT HH, 1987, AM HLTH BALANCE CHOI; IGLEHEART JK, 1989, NEW ENGL J MED, V319, P1166; IGLEHEART JK, 1989, NEW ENGL J MED, V319, P807; MARMOT MG, 1989, BMJ, V99, P23; MENDERSON MA, 1975, TENDER LOVING GREED; MUNDINGWER MO, 1983, HOME CARE CONTROVERS; OKAMOTO Y, 1984, AM NO IRYO TO KANGO; PEGLES CC, 1981, HLTH CARE ELDERLY; SHIEBER G, 1989, HLTH AFF         FAL, P169; SHIMAMOTO T, 1989, CIRCULATION, V79, P503, DOI 10.1161/01.CIR.79.3.503; SHIRAISHI M, 1986, J HLTH WELFARE STATI, V33, P200; SUGAYA Y, 1990, J HLTH WELFARE STATI, V137, P8; Vladeck B.C., 1980, UNLOVING CARE NURSIN; YAMAMOTO M, 1989, J HLTH WELFARE STATI, V36, P13; 1987, OECD SOCIAL POLICY S, P37; 1992, ANN REPORT 1990 91; 1989, NETAKIRI ZERO MEZASH; 1989, J HLTH WELFARE STATI, V36, P91; 1992, NIPPON CHARTED SURVE; 1991, SHAKAI HOKEN JUNPO J, P28	24	26	26	1	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 15	1992	305	6850					403	405		10.1136/bmj.305.6850.403	http://dx.doi.org/10.1136/bmj.305.6850.403			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	JK314	1392924	Green Submitted, Bronze, Green Published			2023-01-03	WOS:A1992JK31400020
J	SHEEHAN, MP; RUSTIN, MHA; ATHERTON, DJ; BUCKLEY, C; HARRIS, DJ; BROSTOFF, J; OSTLERE, L; DAWSON, A				SHEEHAN, MP; RUSTIN, MHA; ATHERTON, DJ; BUCKLEY, C; HARRIS, DJ; BROSTOFF, J; OSTLERE, L; DAWSON, A			EFFICACY OF TRADITIONAL CHINESE HERBAL THERAPY IN ADULT ATOPIC-DERMATITIS	LANCET			English	Article							ECZEMA	There has been considerable interest in traditional Chinese herbal therapy (TCHT) as a new treatment for atopic dermatitis. To establish the efficacy and safety of this treatment, a daily decoction of a formula containing ten herbs that has been found to be beneficial in open studies was tested in a double-blind placebo-controlled study. 40 adult patients with longstanding, refractory, widespread, atopic dermatitis were randomised into two groups to receive 2 months' treatment of either the active formulation of herbs (TCHT) or placebo herbs, followed by a crossover to the other treatment after a 4-week washout period. The main outcome measures were extent and severity of erythema and surface damage as judged by standardised body scores. The patients' own assessments of the overall response to treatment were also sought. The geometric mean score for erythema at the end of active treatment was 12.6 (95% confidence interval [CI] 5.9 to 22.0) and at the end of the placebo phase was 113 (65 to 180). The geometric mean score for surface damage was 11.3 (5.8 to 21.8) and 111.0 (68 to 182), respectively. The 95% CI for the mean geometric ratio for the two values with active treatment was 0.04 to 0.22 for erythema (p<0.0005) and 0.04 to 0.27 for surface damage (p<0.0005). Of the 31 patients who completed the study and expressed a preference, 20 preferred that phase of the trial in which they received TCHT whereas 4 patients preferred placebo (p<0.02). There was a subjective improvement in itching (p<0.001) and sleep (p<0.078) during the TCHT treatment phase. No side-effects were reported by the patients although many commented on the unpalatability of the decoction. TCHT seems to benefit patients with atopic dermatitis. Palatability of the treatment needs to be improved and its safety assured.	UNIV LONDON ROYAL FREE HOSP, DEPT DERMATOL, POND ST, LONDON NW3 2QG, ENGLAND; UNIV COLL & MIDDLESEX SCH MED, DEPT IMMUNOL, LONDON, ENGLAND; HOSP SICK CHILDREN, DEPT DERMATOL, LONDON WC1N 3JH, ENGLAND	University of London; University College London; University of London; University College London; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust								ARMITAGE P, 1987, STATISTICAL METHODS; ATHERTON D, 1990, LANCET, V336, P1254, DOI 10.1016/0140-6736(90)92871-E; CARLSSON C, 1990, LANCET, V336, P1068, DOI 10.1016/0140-6736(90)92538-S; CHANG HM, 1987, PHARM APPLICATIONS C, V2, P1; CHANG HM, 1987, PHARM APPLICATIONS C, V1, P1; CRONER S, 1990, PEDIATR ALLERGY IMMU, V1, P14, DOI DOI 10.1111/J.1399-3038.1990.TB00003.X; DAVIES EG, 1990, LANCET, V336, P177; EDWARDS CRW, 1991, NEW ENGL J MED, V325, P1242, DOI 10.1056/NEJM199110243251709; FARESE RV, 1991, NEW ENGL J MED, V325, P1223, DOI 10.1056/NEJM199110243251706; FINLAY A, 1991, BR J DERMATOL S, V38, P16; GALLOWAY JH, 1991, LANCET, V337, P566, DOI 10.1016/0140-6736(91)91364-Z; HANIFIN JM, 1980, ACTA DERM-VENEREOL S, V92, P44, DOI [10.2340/00015555924447, DOI 10.2340/00015555924447]; HEDDLE RJ, 1984, BRIT MED J, V289, P651, DOI 10.1136/bmj.289.6446.651; MACGREGOR FB, 1989, BRIT MED J, V299, P1156, DOI 10.1136/bmj.299.6708.1156; MORISON WL, 1978, BRIT J DERMATOL, V98, P25, DOI 10.1111/j.1365-2133.1978.tb07329.x; POPOCK SJ, 1983, CLIN TRIALS PRACTICA, P222; SASAKI H, 1989, PLANTA MED, P458; SHEEHAN MP, 1992, BRIT J DERMATOL, V126, P179, DOI 10.1111/j.1365-2133.1992.tb07817.x; SOWDEN JM, 1991, LANCET, V338, P137, DOI 10.1016/0140-6736(91)90134-B; STEWART PM, 1987, LANCET, V2, P821; TEELUCKSINGH S, 1990, LANCET, V335, P1060, DOI 10.1016/0140-6736(90)92633-S; WESTON CFM, 1987, BRIT MED J, V295, P183, DOI 10.1136/bmj.295.6591.183; WU G, 1989, CHIN J INTEGR TRAD C, V9, P57	23	203	206	0	16	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 4	1992	340	8810					13	17		10.1016/0140-6736(92)92424-E	http://dx.doi.org/10.1016/0140-6736(92)92424-E			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JC354	1351600				2023-01-03	WOS:A1992JC35400004
J	CALVERLEY, DC; JONES, GW; KELTON, JG				CALVERLEY, DC; JONES, GW; KELTON, JG			SPLENIC RADIATION FOR CORTICOSTEROID-RESISTANT IMMUNE THROMBOCYTOPENIA	ANNALS OF INTERNAL MEDICINE			English	Article						SPLEEN; RADIOTHERAPY; THROMBOCYTOPENIA; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; PREDNISONE	CHRONIC LYMPHOCYTIC-LEUKEMIA; PURPURA; SPLENECTOMY; IRRADIATION	Objective: To determine the role of splenic radiation as a treatment for immune thrombocytopenia. Design: Retrospective analysis of an open, nonrandomized investigation. Setting: A regional cancer center, referred care, and primary care settings. Patients: Eleven older patients with idiopathic thrombocytopenic purpura (ITP) and 8 patients with secondary immune thrombocytopenia refractory to corticosteroid treatment for whom surgery would have posed a high risk. Intervention: A short course (1 to 6 weeks) of radiation therapy to the spleen (total dose, 75 to 1370 cGy) with or without concurrent and postradiation corticosteroid administration. Measurements: Efficacy was assessed by measuring any increase in the platelet count and by monitoring the duration of response and side effects. Results: Of 11 patients with ITP, 8 patients responded. Three patients had a sustained (> 52 weeks) increase in the platelet count to safe levels after therapy was discontinued. An additional patient had a sustained response but required intermittent, low-dose corticosteroids. Four other patients had increases in their platelet counts that lasted from 8 to 25 weeks. Two of the eight patients without ITP had a positive response, whereas four did not respond, and two were not evaluable. Patients had no adverse reactions to the radiation treatment. Conclusion: Splenic radiation can be a safe and effective method to raise the platelet count in older patients with ITP that is refractory to corticosteroids and in whom the risks associated with splenectomy are high.	MCMASTER UNIV, MED CTR, DEPT MED, ROOM 2N34, 1200 MAIN ST W, HAMILTON L8N 3Z5, ONTARIO, CANADA; MCMASTER UNIV, MED CTR, DEPT PATHOL, HAMILTON L8N 3Z5, ONTARIO, CANADA; HAMILTON REG CANC CTR, DEPT RADIAT ONCOL, HAMILTON L8V 1C3, ONTARIO, CANADA; CANADIAN RED CROSS, BLOOD TRANSFUS SERV, HAMILTON, ONTARIO, CANADA	McMaster University; McMaster University; McMaster University								AKWARI OE, 1987, ANN SURG, V206, P529, DOI 10.1097/00000658-198710000-00014; BRENNAN MF, 1975, AM J SURG, V129, P490, DOI 10.1016/0002-9610(75)90197-X; BYHARDT RW, 1975, CANCER, V35, P1621, DOI 10.1002/1097-0142(197506)35:6<1621::AID-CNCR2820350622>3.0.CO;2-U; COLA B, 1986, INT SURG, V71, P195; COMAS FV, 1968, AMER J ROENTGENOL RA, V104, P668, DOI 10.2214/ajr.104.3.668; COON WW, 1987, SURG GYNECOL OBSTET, V164, P225; DAILEY MO, 1980, NEW ENGL J MED, V302, P215, DOI 10.1056/NEJM198001243020406; GUINEY MJ, 1989, INT J RADIAT ONCOL, V16, P225, DOI 10.1016/0360-3016(89)90035-7; JACOBS P, 1986, Q J MED, V58, P153; PIZZUTO J, 1984, BLOOD, V64, P1179; RUSSO D, 1987, HAEMATOLOGICA, V72, P445; SCHWARTZ SI, 1980, SURGERY, V88, P497; STRATTON JR, 1989, J NUCL MED, V30, P629; TERSTAPPEN LWMM, 1988, EUR J HAEMATOL, V41, P496; WARKENTIN TE, 1990, DRUGS, V40, P531, DOI 10.2165/00003495-199040040-00004; WILLIAMS WJ, 1990, HEMATOLOGY, P1381	16	32	34	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 15	1992	116	12	1				977	981		10.7326/0003-4819-116-12-977	http://dx.doi.org/10.7326/0003-4819-116-12-977			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HY793	1586107				2023-01-03	WOS:A1992HY79300004
J	CHAO, NJ; LONG, GD; NEGRIN, RS; SCHRIBER, JR; RAIMONDI, CM; BROWN, SL; BLUME, KG				CHAO, NJ; LONG, GD; NEGRIN, RS; SCHRIBER, JR; RAIMONDI, CM; BROWN, SL; BLUME, KG			G-CSF AND PERIPHERAL-BLOOD PROGENITOR CELLS	LANCET			English	Letter									AMGEN INC,THOUSAND OAKS,CA	Amgen	CHAO, NJ (corresponding author), STANFORD UNIV,MED CTR,BONE MARROW TRANSPLANT PROGRAM,STANFORD,CA 94305, USA.			Leone, Giuseppe/0000-0002-7812-5300				ADVANI R, 1992, ANN INTERN MED, V116, P183, DOI 10.7326/0003-4819-116-3-183; DEMETRI GD, 1991, BLOOD, V78, P2791; NEMUNAITIS J, 1988, BLOOD, V72, P834; SHERIDAN, 1992, LANCET, V339, P640	4	13	13	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 6	1992	339	8806					1410	1410		10.1016/0140-6736(92)91227-Y	http://dx.doi.org/10.1016/0140-6736(92)91227-Y			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HX636	1375969				2023-01-03	WOS:A1992HX63600025
J	MACARTHUR, C; LEWIS, M; KNOX, EG				MACARTHUR, C; LEWIS, M; KNOX, EG			INVESTIGATION OF LONG-TERM PROBLEMS AFTER OBSTETRIC EPIDURAL-ANESTHESIA	BRITISH MEDICAL JOURNAL			English	Article							INTRAMUSCULAR PETHIDINE; MATERNAL OPINION; ANALGESIA; LABOR; ANESTHESIA; BLOCK	Objective-To examine the association between obstetric epidural anaesthesia and subsequent long term problems. Design -Postal questionnaire on heath problems after childbirth linked to maternity case note data. Setting-Maternity hospital in Birmingham. Subjects-11 701 women who delivered their most recent child during 1978-85 and who returned completed questionnaires. Main outcome measures-Frequencies of long term symptoms after childbirth. Results-Compared with the 6935 women who did Dot have epidural anaesthesia the 4766 women who did more commonly experienced backache (903 (18.9%) with epidural v 731 (10.5%) without epidural), frequent headaches 220 (4.6%) v 199 (2.9%)), migraine (92 (1.9%) v 73 (1.1%)), neckache (116 (2.4%) v 112 (1-6%)), and tingling in hands or fingers (143 (3.0%) v 150 (2.2%)). The results could not be explained by correlated social or obstetric factors. The associations with head, neck, and hand symptoms were found only in women who reported backache. An excess of visual disturbances among women who had epidural anaesthesia (83 (1.7%) v 91 (1.3%); was present only in association with migraine, but excess of dizziness or fainting (102 (2.1%) v 109 (1.6%)) was independent of other symptoms. 26 women had numbness or tingling in the lower back, buttocks, and leg, of whom 23 had had epidural anaesthesia. Of 34 women with spinal headache, nine (five after accidental dural puncture; four after spinal block) reported long term headaches. Conclusions-These associations may indicate a causal sequence, although this cannot be proved from this type of study. Randomised trials of epidural anaesthesia are required to determine whether causal relations exist.	BIRMINGHAM MATERN HOSP,DEPT ANAESTHET,BIRMINGHAM B15 2TG,W MIDLANDS,ENGLAND		MACARTHUR, C (corresponding author), UNIV BIRMINGHAM,SCH MED,DEPT PUBL HLTH & EPIDEMIOL,BIRMINGHAM B15 2TJ,W MIDLANDS,ENGLAND.		MacArthur, Christine/ABA-8601-2021	MacArthur, Christine/0000-0003-0434-2158				BROWNRIDGE P, 1983, ANAESTH INTENS CARE, V11, P4, DOI 10.1177/0310057X8301100102; CRAWFORD JS, 1972, BRIT J ANAESTH, V44, P66, DOI 10.1093/bja/44.1.66; CRAWFORD JS, 1985, ANAESTHESIA, V40, P1219, DOI 10.1111/j.1365-2044.1985.tb10664.x; Crawford JS, 1985, PRINCIPLES PRACTICE; HIBBARD BM, 1990, BRIT J OBSTET GYNAEC, V97, P402, DOI 10.1111/j.1471-0528.1990.tb01826.x; KITZINGER S, 1987, SOME WOMENS EXPERIEN; MACARTHUR C, 1990, BRIT MED J, V301, P9, DOI 10.1136/bmj.301.6742.9; MACARTHUR C, 1991, HLTH AFTER CHILDBIRT; MOORE J, 1974, ANAESTHESIA, V29, P537, DOI 10.1111/j.1365-2044.1974.tb00716.x; MORGAN BM, 1982, LANCET, V2, P808; PHILIPSEN T, 1990, EUR J OBSTET GYN R B, V34, P205, DOI 10.1016/0028-2243(90)90072-9; RAMANATHAN S, 1988, OBSTETRIC ANAESTHESI; ROBINSON JO, 1980, ANAESTHESIA, V35, P1173, DOI 10.1111/j.1365-2044.1980.tb05074.x	13	46	46	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 16	1992	304	6837					1279	1282		10.1136/bmj.304.6837.1279	http://dx.doi.org/10.1136/bmj.304.6837.1279			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HV086	1535010	Bronze, Green Published			2023-01-03	WOS:A1992HV08600020
J	SURENDRAKUMAR, D; DUNN, M; ROBERTS, CJC				SURENDRAKUMAR, D; DUNN, M; ROBERTS, CJC			HOSPITAL ADMISSION AND THE START OF BENZODIAZEPINE USE	BRITISH MEDICAL JOURNAL			English	Article									BRISTOL ROYAL INFIRM & GEN HOSP,BRISTOL BS2 8HW,AVON,ENGLAND	Bristol Royal Infirmary								Ashton H, 1986, ADVERSE DRUG REACT, V118, P440; CATALAN J, 1985, BMJ-BRIT MED J, V290, P1374, DOI 10.1136/bmj.290.6479.1374; EDWARDS C, 1991, BRIT J CLIN PHARMACO, V31, P190, DOI 10.1111/j.1365-2125.1991.tb05513.x; SHAN K, 1990, J ROY SOC MED, V83, P306, DOI 10.1177/014107689008300509; TREWIN VF, 1986, BR J PHARM PRACT, V8, P359	5	21	21	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 4	1992	304	6831					881	881		10.1136/bmj.304.6831.881	http://dx.doi.org/10.1136/bmj.304.6831.881			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HM835	1392750	Green Published, Bronze			2023-01-03	WOS:A1992HM83500027
J	BENRUBI, GI				BENRUBI, GI			EUTHANASIA - THE NEED FOR PROCEDURAL SAFEGUARDS	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							KILL				BENRUBI, GI (corresponding author), UNIV FLORIDA,HLTH SCI CTR,JACKSONVILLE,FL 32209, USA.							ANGELL M, 1988, NEW ENGL J MED, V319, P1348, DOI 10.1056/NEJM198811173192010; CASSEL CK, 1990, NEW ENGL J MED, V323, P750, DOI 10.1056/NEJM199009133231110; COLE JJ, 1989, DEATH STUD, V13, P393, DOI 10.1080/07481188908252317; Hunter S F, 1989, JAMA, V262, P3074, DOI 10.1001/jama.262.21.3074; JONSEN AR, 1988, WESTERN J MED, V149, P195; PARKER M, 1990, J MED ETHICS, V16, P28, DOI 10.1136/jme.16.1.28; REICHEL W, 1989, LANCET, V2, P1321; Schoonheim P L, 1989, J Cancer Educ, V4, P109; SINGER PA, 1988, CAN MED ASSOC J, V138, P1000; SINGER PA, 1990, NEW ENGL J MED, V322, P1881, DOI 10.1056/NEJM199006283222610	10	54	54	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 16	1992	326	3					197	199		10.1056/NEJM199201163260311	http://dx.doi.org/10.1056/NEJM199201163260311			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GZ213	1727551				2023-01-03	WOS:A1992GZ21300011
J	TOMASZEWSKI, PJ; SPYT, TJ				TOMASZEWSKI, PJ; SPYT, TJ			AUTOTRANSFUSION IN OPEN-HEART-SURGERY	LANCET			English	Letter							ARTERY				TOMASZEWSKI, PJ (corresponding author), GROBY RD HOSP,CARDIOTHORAC UNIT,LEICESTER LE3 9QE,ENGLAND.							BLAUHUT B, 1991, J THORAC CARDIOV SUR, V101, P958; COSGROVE DM, 1988, J THORAC CARDIOV SUR, V95, P850; COSGROVE DM, 1985, ANN THORAC SURG, V40, P519, DOI 10.1016/S0003-4975(10)60113-0; FOX M A, 1990, Perfusion (London), V5, P21; JOYCE MH, 1990, J CARDIAC SURG, V4, P315; KOUCHOUKOS NT, 1990, ANN THORAC SURG, V49, P210, DOI 10.1016/0003-4975(90)90140-2; SETHI GK, 1990, J AM COLL CARDIOL, V15, P15, DOI 10.1016/0735-1097(90)90168-O; TAGGART DP, 1990, ANN THORAC SURG, V50, P924	8	0	0	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 28	1991	338	8770					820	820		10.1016/0140-6736(91)90704-S	http://dx.doi.org/10.1016/0140-6736(91)90704-S			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GG979	1681185				2023-01-03	WOS:A1991GG97900036
J	SILVESTRE, L; BOUALI, Y; ULMANN, A				SILVESTRE, L; BOUALI, Y; ULMANN, A			POSTCOITAL CONTRACEPTION - MYTH OR REALITY	LANCET			English	Editorial Material							ETHINYL ESTRADIOL; DL-NORGESTREL; ESTROGENS; DIETHYLSTILBESTROL; INTERCEPTION; COMBINATION; WOMEN		ROUSSEL UCLAF,102 ROUTE NOISY,F-93230 ROMAINVILLE,FRANCE									DIXON GW, 1980, JAMA-J AM MED ASSOC, V244, P1336, DOI 10.1001/jama.244.12.1336; DUBOIS C, 1988, FERTIL STERIL, V50, P593; HASPELS AA, 1976, CONTRACEPTION, V14, P375, DOI 10.1016/S0010-7824(76)80052-2; Haspels DA, 1973, EUR J OBSTET GYNECOL, V3, P113; KUCHERA LK, 1974, CONTRACEPTION, V10, P47, DOI 10.1016/0010-7824(74)90131-0; KUCHERA LK, 1971, J AMER MED ASSOC, V218, P562, DOI 10.1001/jama.218.4.562; PERCIVALSMITH RKL, 1987, CONTRACEPTION, V36, P287, DOI 10.1016/0010-7824(87)90098-9; TIETZE C, 1960, FERTIL STERIL, V11, P485; Tully B, 1983, BRIT J FAM PLANN, V8, P119; VANSANTEN MR, 1985, CONTRACEPTION, V31, P275, DOI 10.1016/0010-7824(85)90097-6; YUZPE AA, 1977, FERTIL STERIL, V28, P932; YUZPE AA, 1982, FERTIL STERIL, V37, P508	12	23	23	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 6	1991	338	8758					39	41		10.1016/0140-6736(91)90018-K	http://dx.doi.org/10.1016/0140-6736(91)90018-K			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FV296	1676094				2023-01-03	WOS:A1991FV29600016
J	KOES, BW; BOUTER, LM; BECKERMAN, H; VANDERHEIJDEN, GJMG; KNIPSCHILD, PG				KOES, BW; BOUTER, LM; BECKERMAN, H; VANDERHEIJDEN, GJMG; KNIPSCHILD, PG			PHYSIOTHERAPY EXERCISES AND BACK PAIN - A BLINDED REVIEW	BRITISH MEDICAL JOURNAL			English	Review							OUTPATIENT TREATMENT; CONSERVATIVE TREATMENT; CLINICAL-TRIAL; MANIPULATION; MANAGEMENT; INPATIENT; THERAPY	Objective - To determine the quality of randomised controlled trials of exercise therapy for back pain. Design - Computer aided search of published papers and blinded assessment of the methods of studies. Subjects - 23 randomised controlled trials, of which 16 studied exercise therapy given by physiotherapists to individual patients with back pain. Other conservative treatments could be included. Main outcome measures - Score for quality of methods (based on four main categories: study population, interventions, measurement of effect, and data presentation and analysis) and main conclusion of author(s) with regard to exercise therapy. Results - Only four studies scored more than 50 points (maximum 100), indicating that most were of poor quality. Six studies found that exercise was better than reference treatments and 10 reported it to be no better or worse than the reference treatment. Those reporting positive results tended to have higher methods scores (4/6 positive v 4/10 negative scored greater-than-or-equal-to 42). Conclusions - No conclusion can be drawn about whether exercise therapy is better than other conservative treatments for back pain or whether a specific type of exercise is more effective. Further trials are needed in which greater attention is paid to methods of study.			KOES, BW (corresponding author), STATE UNIV LIMBURG,DEPT EPIDEMIOL & HLTH CARE RES,POB 616,6200 MD MAASTRICHT,NETHERLANDS.		Koes, Bart w/K-4614-2016	Koes, Bart w/0000-0002-0450-9969; Bouter, Lex/0000-0002-2659-5482; Beckerman, Heleen/0000-0002-8421-3630				BUSWELL J, 1982, ZEALAND J PHYSIOTHER, V10, P13; CHALMERS TC, 1981, CONTROL CLIN TRIALS, V2, P31, DOI 10.1016/0197-2456(81)90056-8; COXHEAD CE, 1981, LANCET, V1, P1065; DAVIES JE, 1979, RHEUMATOL REHABIL, V18, P243, DOI 10.1093/rheumatology/18.4.243; DEYO RA, 1990, NEW ENGL J MED, V322, P1627, DOI 10.1056/NEJM199006073222303; DEYO RA, 1983, JAMA-J AM MED ASSOC, V250, P1057; EVANS C, 1987, Physiotherapy Canada, V39, P96; FARRELL JP, 1982, MED J AUSTRALIA, V1, P160, DOI 10.5694/j.1326-5377.1982.tb132242.x; Feinstein A.R., 1985, CLIN EPIDEMIOLOGY; FRYMOYER JW, 1988, NEW ENGL J MED, V318, P291, DOI 10.1056/NEJM198802043180506; GILBERT JR, 1985, BRIT MED J, V291, P791, DOI 10.1136/bmj.291.6498.791; GOLDIE I, 1970, Scandinavian Journal of Rehabilitation Medicine, V2, P117; HARKAPAA K, 1989, SCAND J REHABIL MED, V21, P81; JACKSON CP, 1983, CLIN ORTHOP RELAT R, V179, P39; JACKSON CP, 1983, CLIN ORTHOP RELAT R, V179, P46; KELSEY JL, 1980, SPINE, V5, P133, DOI 10.1097/00007632-198003000-00007; Kendall PH, 1968, PHYSIOTHERAPY, V54, P154; KLABERMOFFETT JA, 1986, SPINE, V11, P120; KLEIJNEN J, 1991, BRIT MED J, V302, P316, DOI 10.1136/bmj.302.6772.316; LANDEN BR, 1987, PHYS THER, V47, P1126; Lidstrom A, 1970, Scand J Rehabil Med, V2, P37; MACDONALD RS, 1990, SPINE, V15, P364, DOI 10.1097/00007632-199005000-00005; MANNICHE C, 1988, LANCET, V2, P1473; MARTIN PR, 1980, INT REHABILITATION M, V8, P34; MEADE TW, 1990, BRIT MED J, V300, P1431, DOI 10.1136/bmj.300.6737.1431; Meinert CL., 1986, CLIN TRIALS DESIGN C; MELLIN G, 1989, SCAND J REHABIL MED, V21, P91; NACHEMSON A, 1979, SCAND J REHABIL MED, V11, P143; NWUGA G, 1985, Physiotherapy Practice, V1, P99; NWUGA VCB, 1982, AM J PHYS MED REHAB, V61, P273; Spitzer WO, 1987, SPINE, V12, P1, DOI DOI 10.1097/00007632-198701000-00001; STANKOVIC R, 1990, SPINE, V15, P120, DOI 10.1097/00007632-199002000-00014; TERRIET G, 1990, J CLIN EPIDEMIOL, V43, P1191, DOI 10.1016/0895-4356(90)90020-P; TYSEN J, 1983, J PEDIATR, V102, P10; WATERWORTH RF, 1985, NZ MED J, V95, P372; WHITE AWM, 1966, CAN MED ASSOC J, V95, P50; ZYLBERGOLD RS, 1981, ARCH PHYS MED REHAB, V62, P176	37	173	177	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 29	1991	302	6792					1572	1576		10.1136/bmj.302.6792.1572	http://dx.doi.org/10.1136/bmj.302.6792.1572			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FU549	1830233	Green Published, Green Submitted, Bronze			2023-01-03	WOS:A1991FU54900025
J	COBBE, SM; REDMOND, MJ; WATSON, JM; HOLLINGWORTH, J; CARRINGTON, DJ				COBBE, SM; REDMOND, MJ; WATSON, JM; HOLLINGWORTH, J; CARRINGTON, DJ			HEARTSTART SCOTLAND - INITIAL EXPERIENCE OF A NATIONAL SCHEME FOR OUT OF HOSPITAL DEFIBRILLATION	BRITISH MEDICAL JOURNAL			English	Article							EMERGENCY MEDICAL TECHNICIANS; AUTOMATIC EXTERNAL DEFIBRILLATOR; CARDIAC-ARREST; CLINICAL-EXPERIENCE; MANAGEMENT; RESUSCITATION; CARE	Objective - To determine the outcome of out of hospital defibrillation in Scotland during the year after the introduction of automated external defibrillators in October 1988. Design - Retrospective analysis of ambulance service reports and hospital records. Setting - Scottish Ambulance Service and acute receiving hospitals throughout Scotland. Main outcome measures - Delay from cardiac arrest to first defibrillator shock; vital state on arrival at hospital accident and emergency department; survival to hospital discharge. Results - During the study period 268 defibrillators were purchased by public subscription and 96% of the 2000 ambulance crew underwent an eight hour training programme in cardiopulmonary resuscitation and defibrillation. A total of 1111 cardiac arrests were recorded, and defibrillation was indicated and undertaken in 602 (54%) patients, mean age 63 (range 14-92) years. A spontaneous pulse was present on arrival at hospital in 180 (30%) of the defibrillated patients, and 75 (12.5%) were subsequently discharged alive. As expected, the likelihood of survival was inversely related to the delay from the onset of cardiac arrest to the time of the first shock and was greater in the case of witnessed arrest. If ventricular fibrillation occurred after the arrival of the ambulance, survival to discharge was 33%. Conclusions - An effective scheme for out of hospital defibrillation can be introduced rapidly, and with limited training implications and costs, by the use of automated external defibrillators in ambulances.	FIFE LOTHIAN & BORDERS SCOTTISH AMBULANCE SERV,EDINBURGH EH10 5SA,SCOTLAND		COBBE, SM (corresponding author), ROYAL INFIRM,DEPT MED CARDIOL,GLASGOW G31 2ER,SCOTLAND.							ANDERSON IWR, 1987, BRIT MED J, V294, P228, DOI 10.1136/bmj.294.6566.228; BEAGLEHOLE R, 1986, BMJ-BRIT MED J, V292, P33, DOI 10.1136/bmj.292.6512.33; COBB LA, 1986, MANAGEMENT ACUTE COR, P105; COBB LA, 1975, CIRCULATION       S3, V51, P223; CUMMINS RO, 1987, JAMA-J AM MED ASSOC, V257, P1605, DOI 10.1001/jama.257.12.1605; CUMMINS RO, 1989, ANN EMERG MED, V18, P1269, DOI 10.1016/S0196-0644(89)80257-4; EISENBERG MS, 1980, NEW ENGL J MED, V302, P1379, DOI 10.1056/NEJM198006193022502; EISENBERG MS, 1990, ANN EMERG MED, V19, P179, DOI 10.1016/S0196-0644(05)81805-0; EISENBERG MS, 1982, NEW ENGL J MED, V306, P1340, DOI 10.1056/NEJM198206033062206; GRAY AJ, 1987, BMJ, V295, P1133; HAMPTON JR, 1978, BRIT MED J, V1, P1118, DOI 10.1136/bmj.1.6120.1118; JAKOBSSON J, 1987, ACTA MED SCAND, V222, P123; MACKINTOSH AF, 1978, BRIT MED J, V1, P1115, DOI 10.1136/bmj.1.6120.1115; MYERBURG RJ, 1980, AM J MED, V68, P568, DOI 10.1016/0002-9343(80)90307-1; PANTRIDG.JF, 1967, LANCET, V2, P271; ROWLEY JM, 1987, BRIT MED J, V295, P1387, DOI 10.1136/bmj.295.6610.1387; STULTS KR, 1986, CIRCULATION, V73, P701, DOI 10.1161/01.CIR.73.4.701; STULTS KR, 1984, NEW ENGL J MED, V310, P219, DOI 10.1056/NEJM198401263100403; VUKOV LF, 1988, ANN EMERG MED, V17, P318, DOI 10.1016/S0196-0644(88)80771-6; WEAVER WD, 1986, AM J CARDIOL, V57, P1017, DOI 10.1016/0002-9149(86)90667-3; WEAVER WD, 1988, NEW ENGL J MED, V319, P661, DOI 10.1056/NEJM198809153191101; 1990, 1989 GEN REG OFF ANN; 1976, HN76204 DHSS DEP HLT; 1987, EXTENDED TRAINING AM; 1984, DA8412 DHSS DEP HLTH	25	78	78	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 22	1991	302	6791					1517	1520		10.1136/bmj.302.6791.1517	http://dx.doi.org/10.1136/bmj.302.6791.1517			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FT505	1855025	Green Published, Bronze			2023-01-03	WOS:A1991FT50500028
J	HELMAN, CG				HELMAN, CG			LIMITS OF BIO-MEDICAL EXPLANATION	LANCET			English	Article							DISORDERS				HELMAN, CG (corresponding author), UNIV COLL & MIDDLESEX SCH MED, WHITTINGTON HOSP, DEPT PRIMARY HLTH CARE, HIGHGATE HILL, LONDON N19 5NF, ENGLAND.							BRABIN L, 1985, AM J EPIDEMIOL, V122, P725, DOI 10.1093/oxfordjournals.aje.a114155; COOPER JE, 1969, AM J PSYCHIAT, V125, P21, DOI 10.1176/ajp.125.10S.21; Eisenberg L, 1977, Cult Med Psychiatry, V1, P9, DOI 10.1007/BF00114808; ELLIOTTBINNS CP, 1986, J ROY COLL GEN PRACT, V36, P542; Goffman E., 1961, ENCOUNTERS 2 STUDIES; Good B J, 1977, Cult Med Psychiatry, V1, P25, DOI 10.1007/BF00114809; Greeley A. M., 1978, MED ANTHROPOL, V2, P31, DOI [10.1080/01459740.1978.9986961, DOI 10.1080/01459740.1978.9986961]; Helman C G, 1981, J R Coll Gen Pract, V31, P548; HELMAN C G, 1978, Culture Medicine and Psychiatry, V2, P107, DOI 10.1007/BF00054580; Helman C. G., 1990, CULTURE HLTH ILLNESS; HELMAN CG, 1981, SOC SCI MED-MED ANTH, V15, P521, DOI 10.1016/0160-7987(81)90026-0; HELMAN CG, 1985, CULT MED PSYCHIAT, V9, P1; HELMAN CG, 1988, ANTHR TODAY, V14, P14; Kark S. L., 1981, PRACTICE COMMUNITY O; Keesing R. M., 1981, CULTURAL ANTHR; Kleinman A., 1980, PATIENTS HEALERS CON; Lock M, 1988, BIOMEDICINE EXAMINED; MULL JD, 1988, SOC SCI MED, V27, P53, DOI 10.1016/0277-9536(88)90163-3; OBrien B., 1984, PATTERNS EUROPEAN DI; Payer Lynn, 1989, MED CULTURE; PEACOCK J, 1986, ANTHR LENS; PICHOT P, 1982, PSYCHOL MED, V12, P475, DOI 10.1017/S0033291700055586; SKULTANS V, 1970, MAN, V5, P639, DOI 10.2307/2799108; Stacey M., 1988, SOCIOLOGY HLTH HEALI; VAYDA E, 1982, ARCH SURG-CHICAGO, V117, P846; WEISS MG, 1988, SOC SCI MED, V27, P5, DOI 10.1016/0277-9536(88)90159-1	26	21	23	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 4	1991	337	8749					1080	1083		10.1016/0140-6736(91)91720-F	http://dx.doi.org/10.1016/0140-6736(91)91720-F			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FK204	1673506				2023-01-03	WOS:A1991FK20400017
J	CASSILETH, BR; LUSK, EJ; GUERRY, D; BLAKE, AD; WALSH, WP; KASCIUS, L; SCHULTZ, DJ				CASSILETH, BR; LUSK, EJ; GUERRY, D; BLAKE, AD; WALSH, WP; KASCIUS, L; SCHULTZ, DJ			SURVIVAL AND QUALITY-OF-LIFE AMONG PATIENTS RECEIVING UNPROVED AS COMPARED WITH CONVENTIONAL CANCER-THERAPY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							AMYGDALIN; MEDICINE	Background. Cancer treatments without proved efficacy have achieved new levels of popularity, particularly among well-educated patients. The value of these therapies is vigorously debated. Methods. We compared the length of survival and quality of life in patients who received treatment at a prominent unorthodox cancer clinic in addition to conventional treatment and in matched control patients from an academic cancer center who received only conventional treatment. All the patients had documented extensive malignant disease associated with a predicted median survival time of less than one year. The study sample consisted of 78 pairs of patients matched according to sex, race, age, diagnosis, and time from the diagnosis of metastatic or recurrent disease, who were enrolled over a period of 3 1/2 years. Periodic follow-up (approximately every two months) continued until death. Results. There was no difference between the two patient groups in length of survival. Median survival for both groups was 15 months (P = 0.22; relative risk, 1.23; 95 percent confidence interval, 0.88 to 1.72). Quality-of-life scores were consistently better among conventionally treated patients from enrollment on. Conclusions. For this sample of patients with extensive disease and for this particular unorthodox treatment regimen, conventional and unorthodox treatments produced similar results.	UNIV PENN,PSYCHOSOCIAL RES PROGRAMS,PHILADELPHIA,PA 19104	University of Pennsylvania					NATIONAL CANCER INSTITUTE [R01CA042260] Funding Source: NIH RePORTER; NCI NIH HHS [CA 42260] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOWMAN BB, 1984, J CLIN ONCOL, V2, P702, DOI 10.1200/JCO.1984.2.6.702; CASSILETH B R, 1989, Journal of Psychosocial Oncology, V7, P47; CASSILETH BR, 1986, CANCER INVEST, V4, P591, DOI 10.3109/07357908609039837; CASSILETH BR, 1984, ANN INTERN MED, V101, P105, DOI 10.7326/0003-4819-101-1-105; CURT GA, 1986, JAMA-J AM MED ASSOC, V255, P505, DOI 10.1001/jama.255.4.505; DEVERELL D, 1978, I HEALED MY CANCER H; DIPALMA JR, 1982, B NEW YORK ACAD MED, V58, P254; EISELE JW, 1980, JAMA-J AM MED ASSOC, V244, P1608, DOI 10.1001/jama.244.14.1608; GERSON M, 1977, CANCER THERAPY RESUL; HERBERT V, 1980, NUTRITION CULTISM FA; HINDMARSH W, 1980, CLIN TOXICOL, V17, P85; ISTRE GR, 1982, NEW ENGL J MED, V307, P339, DOI 10.1056/NEJM198208053070603; LIVINGSTONWHEEL.V, 1984, CONQUEST CANCER; MASTRANGELO MJ, 1985, CANCER PRINCIPLES PR, V2, P1371; MINNA JD, 1985, CANCER PRINCIPLES PR, V1, P507; MOERTEL CG, 1985, NEW ENGL J MED, V312, P137, DOI 10.1056/NEJM198501173120301; MOERTEL CG, 1982, NEW ENGL J MED, V306, P201, DOI 10.1056/NEJM198201283060403; MOERTEL CG, 1981, JAMA-J AM MED ASSOC, V245, P591, DOI 10.1001/jama.245.6.591; MYERS MH, 1989, CA-CANCER J CLIN, V39, P21, DOI 10.3322/canjclin.39.1.21; OBRIEN PC, 1987, BIOMETRICS, V43, P169, DOI 10.2307/2531957; PORTLOCK CS, 1980, MANUAL CLIN PROBLEMS, P168; SCHAUMBURG H, 1983, NEW ENGL J MED, V309, P445, DOI 10.1056/NEJM198308253090801; SCHIPPER H, 1984, J CLIN ONCOL, V2, P472, DOI 10.1200/JCO.1984.2.5.472; SINDELAR WF, 1985, CANCER PRINCIPLES PR, V1, P691; WHEELER VL, 1980, COMPENDIUM MICROBIOL; WUERTHELE-CASPE V, 1947, J Med Soc N J, V44, P256; 1983, CA, V33, P252; 1990, OTAH405 PUBL; 1983, CA, V33, P57; 1984, CA, V34, P232	30	133	137	0	5	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 25	1991	324	17					1180	1185		10.1056/NEJM199104253241706	http://dx.doi.org/10.1056/NEJM199104253241706			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FH572	2011162				2023-01-03	WOS:A1991FH57200006
J	PETITTO, LA; MARENTETTE, PF				PETITTO, LA; MARENTETTE, PF			BABBLING IN THE MANUAL MODE - EVIDENCE FOR THE ONTOGENY OF LANGUAGE	SCIENCE			English	Article							AMERICAN SIGN LANGUAGE; SPEECH-PERCEPTION; CONTINUITY	Infant vocal babbling has been assumed to be a speech-based phenomenon that reflects the maturation of the articulatory apparatus responsible for spoken language production. Manual babbling has now been reported to occur in deaf children exposed to signed languages from birth. The similarities between manual and vocal babbling suggest that babbling is a product of an amodal, brain-based language capacity under maturational control, in which phonetic and syllabic units are produced by the infant as a first step toward building a mature linguistic system. Contrary to prevailing accounts of the neurological basis of babbling in language ontogeny, the speech modality is not critical in babbling. Rather, babbling is tied to the abstract linguistic structure of language and to an expressive capacity capable of processing different types of signals (signed or spoken).			PETITTO, LA (corresponding author), MCGILL UNIV,DEPT PSYCHOL,MONTREAL H3A 1B1,QUEBEC,CANADA.		Marentette, Paula/D-2888-2011	Marentette, Paula/0000-0002-4098-0571				CHOMSKY N, 1980, BEHAV BRAIN SCI, V3, P1, DOI 10.1017/S0140525X00001515; ELBERS L, 1982, COGNITION, V12, P45, DOI 10.1016/0010-0277(82)90029-4; GLEITMAN LR, 1981, COGNITION, V10, P103; HUTTENLOCHER J, 1987, COGNITIVE PSYCHOL, V19, P63, DOI 10.1016/0010-0285(87)90004-1; JUSCZYK PW, 1986, INVARIANCE VARIABILI, P1; Klima E.S., 1979, SIGNS LANGUAGE; LENNEBERG EH, 1967, BIOL F LANGUAGE; LIBERMAN AM, 1989, SCIENCE, V243, P489, DOI 10.1126/science.2643163; LIBERMAN AM, 1985, COGNITION, V21, P1, DOI 10.1016/0010-0277(85)90021-6; LIDDELL SK, 1984, LANGUAGE, V60, P372, DOI 10.2307/413645; Lieberman P., 1984, BIOL EVOLUTION LANGU; Locke J., 1983, PHONOLOGICAL ACQUISI, DOI DOI 10.2307/414500; MARENTETTE PF, UNPUB; MEHLER J, 1986, CR ACAD SCI III-VIE, V303, P637; Oller D. K., 1980, CHILD PHONOLOGY, V1, P93, DOI [10.1016/B978-0-12-770601-6.50011-5, DOI 10.1016/B978-0-12-770601-6.50011-5]; OLLER DK, 1988, CHILD DEV, V59, P441, DOI 10.2307/1130323; PETITTO LA, 1987, COGNITION, V27, P1, DOI 10.1016/0010-0277(87)90034-5; PETITTO LA, 1988, DEV LANGUAGE LANGUAG, P187; SHATZ M, 1985, MERRILL PALMER QUART, V31, P211; Stokoe W. C., 1976, DICT AM SIGN LANGUAG; van der Stelt J. M., 1986, WENNER GREN CTR IN B, P163; VIHMAN MM, 1985, LANGUAGE, V61, P397, DOI 10.2307/414151; VIHMAN MM, 1986, APPL PSYCHOLINGUIST, V7, P3, DOI 10.1017/S0142716400007165	23	242	248	0	50	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 22	1991	251	5000					1493	1496		10.1126/science.2006424	http://dx.doi.org/10.1126/science.2006424			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	FC853	2006424				2023-01-03	WOS:A1991FC85300051
J	TIERNEY, AJ; LEONARD, RCF; TAYLOR, J; CLOSS, SJ; CHETTY, U; RODGER, A				TIERNEY, AJ; LEONARD, RCF; TAYLOR, J; CLOSS, SJ; CHETTY, U; RODGER, A			SIDE-EFFECTS EXPECTED AND EXPERIENCED BY WOMEN RECEIVING CHEMOTHERAPY FOR BREAST-CANCER	BRITISH MEDICAL JOURNAL			English	Article									LONGMORE HOSP,BREAST UNIT,EDINBURGH,SCOTLAND; WESTERN GEN HOSP,CLIN ONCOL,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND	University of Edinburgh	TIERNEY, AJ (corresponding author), UNIV EDINBURGH,DEPT NURSING STUDIES,NURSING RES UNIT,EDINBURGH EH8 9JT,SCOTLAND.			Closs, Susan Jose/0000-0002-3257-5277				TIERNEY AJ, 1989, STUDY INFORM NURSING	1	28	28	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 2	1991	302	6771					272	272		10.1136/bmj.302.6771.272	http://dx.doi.org/10.1136/bmj.302.6771.272			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EX919	1998793	Bronze, Green Published			2023-01-03	WOS:A1991EX91900021
J	FLEISSIG, A				FLEISSIG, A			UNINTENDED PREGNANCIES AND THE USE OF CONTRACEPTION - CHANGES FROM 1984 TO 1989	BRITISH MEDICAL JOURNAL			English	Article											FLEISSIG, A (corresponding author), INSTITUTE SOCIAL STUDIES MED CARE,14 S HILL PK,LONDON NW3 2SB,ENGLAND.							CARTWRIGHT A, 1988, SOC SCI MED, V27, P249, DOI 10.1016/0277-9536(88)90128-1; Griffiths M, 1990, BRIT J FAM PLANN, V16, P16; Guillebaud J, 2017, CONTRACEPTION YOUR Q; SMITH T, 1990, BRIT MED J, V300, P1154, DOI 10.1136/bmj.300.6733.1154	4	50	50	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 19	1991	302	6769					147	147		10.1136/bmj.302.6769.147	http://dx.doi.org/10.1136/bmj.302.6769.147			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	EU020	1995134	Green Published, Bronze			2023-01-03	WOS:A1991EU02000021
J	EWART, MC; WHITWAM, JG				EWART, MC; WHITWAM, JG			PREVENTION OF PAIN DURING INJECTION OF PROPOFOL	LANCET			English	Letter											EWART, MC (corresponding author), HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,DEPT ANAESTHET,LONDON W12 0HS,ENGLAND.							AITKEN HA, 1988, ANAESTHESIA, V43, P170; BRIGGS LP, 1985, POSTGRAD MED J, V61, P35; BROOKER J, 1985, ANAESTHESIA, V40, P91, DOI 10.1111/j.1365-2044.1985.tb10530.x; DOLD M, 1989, ANAESTHESIA, V44, P533, DOI 10.1111/j.1365-2044.1989.tb11422.x; JAMIESON V, 1988, ANAESTHESIA, V43, P70, DOI 10.1111/j.1365-2044.1988.tb05454.x; KENNEDY KS, 1986, ARCH OTOLARYNGOL, V112, P671; KUMAR CM, 1989, ANAESTHESIA, V44, P266, DOI 10.1111/j.1365-2044.1989.tb11264.x; SCOTT RPF, 1988, ANAESTHESIA, V43, P492, DOI 10.1111/j.1365-2044.1988.tb06641.x; STARK RD, 1985, POSTGRAD MED J, V61, P152	9	10	10	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 31	1990	335	8692					798	799		10.1016/0140-6736(90)90921-Q	http://dx.doi.org/10.1016/0140-6736(90)90921-Q			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CW994	1969548				2023-01-03	WOS:A1990CW99400048
J	SKOBELOFF, EM; SPIVEY, WH; STCLAIR, SS; SCHOFFSTALL, JM				SKOBELOFF, EM; SPIVEY, WH; STCLAIR, SS; SCHOFFSTALL, JM			THE INFLUENCE OF AGE AND SEX ON ASTHMA ADMISSIONS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Objective.-To describe demographic data from a large population of asthmatic patients to define the role of age and sex as risk factors for asthma admission. Design.-A retrospective review of all asthma admissions as defined by international Classification of Diseases, Ninth Revision, code 493.0. Source.-All medical-surgical admissions from 67 hospitals in five counties of southeastern Pennsylvania from 1986 through 1989. Results.-Patients admitted for asthma treatment (33 269) were reviewed. In the 0- to 5-year-old and 6- to 10-year-old age groups, males were admitted nearly twice as often as age-identical females. In the 11- to 20-year-old age group, admissions for males and females were nearly identical. Between 20 and 50 years of age, the female-to-male ratio was nearly 3:1. Thereafter, females were admitted for asthma at a rate of about 2.5:1 when compared with their age-equivalent male counterparts. Length of stay increased proportionally as the patient age increased. After 30 years of age, the length of stay was slightly greater for females than males. Conclusions.-There is a much higher rate of admission for prepubertal males than females. However, there is a higher incidence of asthma admissions for adult females than adult male asthmatic patients, and female asthmatic patients experience longer hospital stays per admission as well. These data indicate that adult females are more severely affected by asthma and raise the possibility that hormonal or biochemical differences related to sex may play a role in the pathophysiology of asthma.	MED COLL PENN,DEPT EMERGENCY MED,DIV RES,3300 HENRY AVE,PHILADELPHIA,PA 19129	Drexel University	SPIVEY, WH (corresponding author), MED COLL PENN,DEPT EMERGENCY MED,DIV RES,3300 HENRY AVE,PHILADELPHIA,PA 19129, USA.							ABDULKARIM RW, 1970, AM J OBSTET GYNECOL, V107, P641, DOI 10.1016/S0002-9378(16)33953-9; ABDULKARIM RW, 1970, AM J OBSTET GYNECOL, V108, P1098, DOI 10.1016/0002-9378(70)90459-X; DODGE RR, 1980, AM REV RESPIR DIS, V122, P567; ELIASSON O, 1987, J ALLERGY CLIN IMMUN, V79, P909, DOI 10.1016/0091-6749(87)90240-5; ELIASSON O, 1985, American Review of Respiratory Disease, V131, pA110; JOHANSSON U, 1981, J PHARM PHARMACOL, V33, P353, DOI 10.1111/j.2042-7158.1981.tb13802.x; Kohler Po, 1986, CLIN ENDOCRINOLOGY; KONNO A, 1986, ORL J OTO-RHINO-LARY, V48, P45, DOI 10.1159/000275841; MARTINEZ FD, 1988, NEW ENGL J MED, V319, P1112, DOI 10.1056/NEJM198810273191702; MOAWAD AH, 1982, AM J OBSTET GYNECOL, V144, P608, DOI 10.1016/0002-9378(82)90235-6; ROCHE WR, 1989, LANCET, V1, P52; Rubio RL, 1988, ALLERGOL IMMUNOPATH, V16, P263; VIDIC B, 1978, CYTOBIOLOGIE, V18, P10; WILKINSON L, 1988, SYSTAT SYSTEM STATIS; 1990, 1988 SUMMARY NATIONA, V185, P1; 1991, JAMA-J AM MED ASSOC, V266, P559; 1991, 913042 DEP HLTH HUM; 1991, 1990 GENERAL POPULAT; 1980, PHS801260 DEP HLTH H	19	285	286	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 23	1992	268	24					3437	3440		10.1001/jama.268.24.3437	http://dx.doi.org/10.1001/jama.268.24.3437			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KC839	1460733				2023-01-03	WOS:A1992KC83900030
J	TRUOG, RD; BERDE, CB; MITCHELL, C; GRIER, HE				TRUOG, RD; BERDE, CB; MITCHELL, C; GRIER, HE			BARBITURATES IN THE CARE OF THE TERMINALLY ILL	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							EUTHANASIA; PAIN; ANALGESIA; PATIENT; CANCER; SODIUM				TRUOG, RD (corresponding author), CHILDRENS HOSP MED CTR, BOSTON, MA 02115 USA.							ANGELL M, 1982, NEW ENGL J MED, V306, P98, DOI 10.1056/NEJM198201143060210; ANGELL M, 1988, NEW ENGL J MED, V319, P1348, DOI 10.1056/NEJM198811173192010; ANNAS GJ, 1991, HASTINGS CENT REP, V21, P33, DOI 10.2307/3562337; BEAUCHAMP TL, 1989, PRINCIPLES BIOMEDICA, P127; BEDAU HA, 1982, DEATH PENALTY AM, P17; BERDE CB, 1990, ANESTHESIOLOGY, V72, P1094, DOI 10.1097/00000542-199006000-00025; BROCK DW, 1992, HASTINGS CENT REP, V22, P10, DOI 10.2307/3562560; CARLON GC, 1978, CRIT CARE MED, V6, P311, DOI 10.1097/00003246-197809000-00002; CARTON RW, 1990, JAMA-J AM MED ASSOC, V263, P2221, DOI 10.1001/jama.263.16.2221; CASSEL EJ, 1982, NEW ENGL J MED, V306, P639, DOI 10.1056/NEJM198203183061104; COHEN MH, 1992, CANCER INVEST, V10, P317, DOI 10.3109/07357909209032756; Coyle N, 1990, J Pain Symptom Manage, V5, P83; DEWACHTER MAM, 1989, JAMA-J AM MED ASSOC, V262, P3316, DOI 10.1001/jama.262.23.3316; Edwards B S, 1991, J Clin Ethics, V2, P118; EISENBERG HM, 1988, J NEUROSURG, V69, P15, DOI 10.3171/jns.1988.69.1.0015; FOLEY KM, 1991, J PAIN SYMPTOM MANAG, V6, P289, DOI 10.1016/0885-3924(91)90052-6; FOLEY KM, 1985, NEW ENGL J MED, V313, P84, DOI 10.1056/NEJM198507113130205; FOSBURG MT, 1983, JAMA-J AM MED ASSOC, V250, P511, DOI 10.1001/jama.250.4.511; GAYLIN W, 1988, JAMA-J AM MED ASSOC, V259, P2139; GREENE WR, 1991, SOUTHERN MED J, V84, P332, DOI 10.1097/00007611-199103000-00009; Humphry, 1991, FINAL EXIT PRACTICAL; Kuhse Helga, 1992, Bioethics, V6, P233, DOI 10.1111/j.1467-8519.1992.tb00200.x; LOWENSTEIN DH, 1988, NEUROLOGY, V38, P395, DOI 10.1212/WNL.38.3.395; MERZ B, 1991, AM MED NEWS, V3, P35; Mount B, 1990, J Palliat Care, V6, P5; PINKNEY DS, 1992, AM MED NEWS     0420, P11; QUILL TE, 1991, NEW ENGL J MED, V324, P691, DOI 10.1056/NEJM199103073241010; RACHELS J, 1975, NEW ENGL J MED, V292, P78, DOI 10.1056/NEJM197501092920206; RALL T W, 1990, P345; RASHKIN MC, 1987, NEUROLOGY, V37, P500, DOI 10.1212/WNL.37.3.500; Roy D J, 1990, J Palliat Care, V6, P3; SINGER PA, 1990, NEW ENGL J MED, V322, P1881, DOI 10.1056/NEJM199006283222610; STAVER S, 1992, AM MED NEWS     0316, P4; STRAIN JD, 1986, RADIOLOGY, V161, P105, DOI 10.1148/radiology.161.1.3763851; Truog Robert D, 1991, J Clin Ethics, V2, P127; Ventafridda V, 1990, J Palliat Care, V6, P7; WANZER SH, 1984, NEW ENGL J MED, V310, P955, DOI 10.1056/NEJM198404123101505; WAY WL, 1986, ANESTHESIA, V2, P799; 1992, PRINCIPLES ANALGESIC	39	96	96	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 3	1992	327	23					1678	1682		10.1056/NEJM199212033272311	http://dx.doi.org/10.1056/NEJM199212033272311			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KA260	1279424				2023-01-03	WOS:A1992KA26000011
J	HADDEN, JW; SMITH, DL				HADDEN, JW; SMITH, DL			IMMUNOPHARMACOLOGY - IMMUNOMODULATION AND IMMUNOTHERAPY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CYCLOSPORINE; METHOTREXATE; ARTHRITIS		UNIV SO ALABAMA,COLL MED,DIV ALLERGY,MOBILE,AL 36688; UNIV SO ALABAMA,COLL MED,DIV CLIN IMMUNOL,MOBILE,AL 36688	University of South Alabama; University of South Alabama	HADDEN, JW (corresponding author), UNIV S FLORIDA,COLL MED,IMMUNOPHARMACOL PROGRAM,TAMPA,FL 33612, USA.							BIZZINI B, 1988, ADV IMMUNOMODULATION; BOREL JF, 1989, PHARMACOL REV, V41, P259; BRAUDE AC, 1983, LANCET, V2, P995; BROSTOFF J, 1991, CLIN IMMUNOLOGY, V27; CLAMAN HN, 1983, HOSP PRACT, V18, P123; CORRIGAN JJ, 1992, NELSON TXB PEDIATRIC, P1281; CRUSE JM, 1989, THERAPY AUTOIMMUNE D; FRIEDMAN H, 1991, DRUGS ABUSE IMMUNITY; HADDEN JW, 1991, TRENDS PHARMACOL SCI, V12, P107, DOI 10.1016/0165-6147(91)90517-V; HADDEN JW, 1989, MED ONCOL TUMOR PHAR, V12, P107; HADDEN JW, 1990, IMMUNOPHARMACOLOGY R, P1; HANDSCHUMACHER RE, 1990, PHARMACOL BASIS THER, P1264; JOHNSON WJ, 1988, J RHEUMATOL, V15, P745; KATZ P, 1988, IMMUNOLOGICAL DISEAS, P675; KEIM D, 1990, J RHEUMATOL, V17, P846; KIRKPATRICK CH, 1989, ANN ALLERGY, V62, P170; LEDERER E, 1988, ADV IMMUNOMODULATION, P9; MASIHI KN, 1990, IMMUNOTHERAPEUTIC PR; MIHICH E, 1986, ADV IMMUNOPHARMACOL, V3, P257; OPPENHEIM JJ, 1991, ANNU REV IMMUNOL, V9, P617, DOI 10.1146/annurev.iy.09.040191.003153; RENOUX G, 1980, DRUGS, V19, P89; SCHALLER JG, 1992, NELSON TXB PEDIAT, P629; SIGAL NH, 1992, ANNU REV IMMUNOL, V10, P519, DOI 10.1146/annurev.iy.10.040192.002511; STRATTA RJ, 1988, SURGERY, V104, P606; SUNDAL E, 1985, SURV IMMUNOL RES S4, V1, P1; TAYLOR CW, 1990, IMMUNOPHARMACOLOGY R, P89; TSANG KY, 1984, IMMUNE MODULATION AG, P79; WHITE WB, 1985, NEW ENGL J MED, V312, P198, DOI 10.1056/NEJM198501243120402; WINKELSTEIN A, 1992, TXB PHARM, P964	29	9	18	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 25	1992	268	20					2964	2969		10.1001/jama.268.20.2964	http://dx.doi.org/10.1001/jama.268.20.2964			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JY668	1433716				2023-01-03	WOS:A1992JY66800025
J	NIGHTINGALE, SL				NIGHTINGALE, SL			UPDATE ON EMS AND L-TRYPTOPHAN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	6	6	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 14	1992	268	14					1828	1828		10.1001/jama.268.14.1828	http://dx.doi.org/10.1001/jama.268.14.1828			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JR439	1404696				2023-01-03	WOS:A1992JR43900008
J	GARFINKEL, A; SPANO, ML; DITTO, WL; WEISS, JN				GARFINKEL, A; SPANO, ML; DITTO, WL; WEISS, JN			CONTROLLING CARDIAC CHAOS	SCIENCE			English	Article							DYNAMICS; CELLS	The extreme sensitivity to initial conditions that chaotic systems display makes them unstable and unpredictable. Yet that same sensitivity also makes them highly susceptible to control, provided that the developing chaos can be analyzed in real time and that analysis is then used to make small control interventions. This strategy has been used here to stabilize cardiac arrhythmias induced by the drug ouabain in rabbit ventricle. By administering electrical stimuli to the heart at irregular times determined by chaos theory, the arrhythmia was converted to periodic beating.	USN,CTR SURFACE WARFARE,SILVER SPRING,MD 20903; COLL WOOSTER,DEPT PHYS,WOOSTER,OH 44691; UNIV CALIF LOS ANGELES,DEPT MED CARDIOL,LOS ANGELES,CA 90024	United States Department of Defense; United States Navy; College of Wooster; University of California System; University of California Los Angeles	GARFINKEL, A (corresponding author), UNIV CALIF LOS ANGELES,DEPT PHYSIOL SCI,LOS ANGELES,CA 90024, USA.		Ditto, William/AAK-9827-2020; Spano, Mark L/B-6883-2011; Spano, Mark/HJB-2436-2022	Ditto, William/0000-0002-7416-8012; 	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL044880, R01HL036729, K04HL001890] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL44880, KO4 HL01890, R01 HL36729] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARNSDORF MF, 1991, CURR OPIN CARDIOL, V6, P3, DOI 10.1097/00001573-199102000-00002; BOWEN R, 1971, T AM MATH SOC, V154, P377, DOI 10.2307/1995452; CHIALVO DR, 1990, NATURE, V343, P653, DOI 10.1038/343653a0; COLQUHOUN D, 1981, NATURE, V294, P752, DOI 10.1038/294752a0; CRUTCHFIELD JP, 1986, SCI AM, V255, P46, DOI 10.1038/scientificamerican1286-46; DITTO WL, 1990, PHYS REV LETT, V65, P3211, DOI 10.1103/PhysRevLett.65.3211; FEDIDA D, 1987, J PHYSIOL-LONDON, V392, P523, DOI 10.1113/jphysiol.1987.sp016795; GARFINKEL AJ, 1991, LIFE SCI, V48, P2189, DOI 10.1016/0024-3205(91)90153-3; GOLLUB JP, 1975, PHYS REV LETT, V35, P927, DOI 10.1103/PhysRevLett.35.927; GREBOGI C, 1988, PHYS REV A, V37, P1711, DOI 10.1103/PhysRevA.37.1711; GUCKENHEIMER J, 1983, NONLINEAR OSCILLATIO, P105; GUEVARA MR, 1981, SCIENCE, V214, P1350, DOI 10.1126/science.7313693; HUNT ER, 1991, PHYS REV LETT, V67, P53; Kaplan JL, 1979, LECT NOTES MATH, P228; Moon F.C., 1987, CHAOTIC VIBRATIONS; OLSEN LF, 1990, SCIENCE, V249, P499, DOI 10.1126/science.2382131; OTT E, 1990, PHYS REV LETT, V64, P1196, DOI 10.1103/PhysRevLett.64.1196; ROSSLER OE, 1978, NATURE, V271, P89, DOI 10.1038/271089a0; ROY R, 1992, PHYS REV LETT, V68, P1259, DOI 10.1103/PhysRevLett.68.1259; SHINBROT T, 1992, PHYS REV LETT, V68, P2863, DOI 10.1103/PhysRevLett.68.2863; SHINBROT T, 1990, PHYS REV LETT, V65, P3215, DOI 10.1103/PhysRevLett.65.3215; WEISS J, 1982, AM J PHYSIOL, V243, pH318, DOI 10.1152/ajpheart.1982.243.2.H318; WEISS JN, 1987, CARDIAC ARRHYTHMIAS, P83	23	703	727	3	42	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 28	1992	257	5074					1230	1235		10.1126/science.1519060	http://dx.doi.org/10.1126/science.1519060			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JL050	1519060	Green Submitted			2023-01-03	WOS:A1992JL05000019
J	VETTER, NJ; LEWIS, PA; LLEWELLYN, L				VETTER, NJ; LEWIS, PA; LLEWELLYN, L			SUPPORTING ELDERLY DEPENDENT PEOPLE AT HOME	BRITISH MEDICAL JOURNAL			English	Article							CARE	Objective-To clarify the relation between the dependency of elderly people and the assistance they receive from others by using a detailed but simple measure of dependency. Design - Secondary analysis of data from a survey of people aged 70 and over. Setting-Two general practices in south Wales. Subjects - 1280 people aged 70 and over. Main outcome measures-Dependency on others to perform essential functions; detailed data on who assists with those functions. Results-Increasing dependency was associated with increased use of more than one member of the family or friends and an increase in the provision of statutory services. Conclusion-The complexity of the relation between dependency and those who care for dependent people has previously been underestimated. The presence of providers of statutory services at the household of elderly dependent people suggests that these services can be developed further to help those caring for elderly people at home.	UNIV WALES COLL MED,DEPT PUBL HLTH MED,CARDIFF CF4 4XN,S GLAM,WALES; UNIV WALES COLL MED,DEPT MED COMP,CARDIFF CF4 4XN,S GLAM,WALES	Cardiff University; Cardiff University	VETTER, NJ (corresponding author), UNIV WALES COLL MED,DEPT EPIDEMIOL & COMMUNITY MED,CARDIFF CF4 4XN,S GLAM,WALES.							BOYDEN PGK, 1979, NZ MED J, V89, P265; BRODY EM, 1981, GERONTOLOGIST, V21, P471, DOI 10.1093/geront/21.5.471; ISAACS B, 1971, BRIT MED J, V4, P282, DOI 10.1136/bmj.4.5782.282; JONES DA, 1984, SOC SCI MED, V19, P511, DOI 10.1016/0277-9536(84)90046-7; NISSEL M, 1984, AGEING SOC, V4, P185; SALVAGE AV, 1988, AGE AGEING, V17, P270, DOI 10.1093/ageing/17.4.270; Vetter N J, 1990, Int Disabil Stud, V12, P22; VETTER NJ, 1984, BRIT MED J, V288, P369, DOI 10.1136/bmj.288.6414.369; 1980, EXPERIENCE CARING EL	9	11	11	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 16	1992	304	6837					1290	1292		10.1136/bmj.304.6837.1290	http://dx.doi.org/10.1136/bmj.304.6837.1290			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HV086	1606435	Green Published, Bronze			2023-01-03	WOS:A1992HV08600027
J	MELSKI, JW				MELSKI, JW			PRICE OF TECHNOLOGY - A BLIND SPOT	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							PROGRESSIVE SYSTEMIC-SCLEROSIS				MELSKI, JW (corresponding author), MARSHFIELD CLIN FDN MED RES & EDUC,DEPT DERMATOL 4K5,MARSHFIELD,WI 54449, USA.							ANGELL M, 1991, NEW ENGL J MED, V325, P1371, DOI 10.1056/NEJM199111073251910; BLACK CM, 1990, ANN RHEUM DIS, V49, P735, DOI 10.1136/ard.49.9.735; BLOOM BS, 1988, INQUIRY-J HEALTH CAR, V25, P383; CHARLEY MR, 1983, J INVEST DERMATOL, V80, pA328; EDELSON R, 1991, PROG DERMATOL, V25, P1; EISENBERG JM, 1989, JAMA-J AM MED ASSOC, V262, P2879, DOI 10.1001/jama.262.20.2879; GRAY WA, 1991, NEW ENGL J MED, V325, P1393, DOI 10.1056/NEJM199111143252001; HILLMAN AL, 1989, NEW ENGL J MED, V321, P86, DOI 10.1056/NEJM198907133210205; JAMPEL RM, 1991, ARCH DERMATOL, V127, P1673, DOI 10.1001/archderm.127.11.1673; JOHNSON HA, 1991, JAMA-J AM MED ASSOC, V265, P2229, DOI 10.1001/jama.265.17.2229; KALALEH MB, 1986, CLIN EXP RHEUMATOL, V4, P367; LOHR K, 1986, MED CARE, V24, pS72; RELMAN AS, 1989, NEW ENGL J MED, V320, P33; ROOK AH, 1989, YALE J BIOL MED, V62, P639; ROOK AH, 1992, ARCH DERMATOL, V128, P1517; STEEN VD, 1982, ANN INTERN MED, V97, P652, DOI 10.7326/0003-4819-97-5-652; STERN RS, 1991, JAMA-J AM MED ASSOC, V265, P74, DOI 10.1001/jama.265.1.74; WINSLOW R, 1991, WALL STREET J   1105, P73	18	10	10	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 18	1992	267	11					1516	1518						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HH488	1538542				2023-01-03	WOS:A1992HH48800034
J	EHRENFORTH, S; KREUZ, W; SCHARRER, I; LINDE, R; FUNK, M; GUNGOR, T; KRACKHARDT, B; KORNHUBER, B				EHRENFORTH, S; KREUZ, W; SCHARRER, I; LINDE, R; FUNK, M; GUNGOR, T; KRACKHARDT, B; KORNHUBER, B			INCIDENCE OF DEVELOPMENT OF FACTOR-VIII AND FACTOR-IX INHIBITORS IN HEMOPHILIACS	LANCET			English	Article							HEMOPHILIA-A; CLASSIC HEMOPHILIA; LIFE EXPECTANCY; UNITED-KINGDOM; ANTIBODIES; FINLAND	The development of factor VIII:C inhibitors remains one of the most serious complications of repeated transfusion in patients with haemophilia A. The proportion of patients affected has been reported to range from 3.6% to 25%, but these figures have been derived mainly from retrospective data and from total numbers of known haemophiliacs instead of number at true risk. The assessment here is based on a prospective study, started in 1976, on the incidence of inhibitor development in haemophiliacs born after 1970 whose FVIII or FIX activity was 5% or less, and who had received replacement therapy at least once. 46 of 63 children with haemophilia A and 13 of 17 with haemophilia B fulfilled the enrolment criteria. Inhibitors developed only in haemophilia A patients who had previously been treated with FVIII products-inhibitor concentrations were high in 12 and low in 3. Inhibitors developed in 24% (15/63) of all haemophilia A patients, and in 52% (14/27) of those with severe disease. The incidence of inhibitor development for all haemophilia patients was 39.1 per 1000 patient-years of observation. All inhibitors were first detected when patients were aged 0.08-5.2 years. The cumulative risk was 33% at age 6 years. The findings indicate that previous reports have underestimated the risk of acquiring FVIII inhibitors. Prospective, standardised studies, especially in children, are needed for the assessment of the true risk of this complication.	UNIV HOSP FRANKFURT, DEPT ANGIOL, CTR INTERNAL MED, FRANKFURT, GERMANY	Goethe University Frankfurt; Goethe University Frankfurt Hospital	EHRENFORTH, S (corresponding author), UNIV HOSP FRANKFURT, DEPT HAEMATOL & ONCOL, CTR PAEDIAT, THEODOR STERN KAI 7, W-6000 FRANKFURT, GERMANY.		Scharrer, Inge/N-2999-2013	Gungor, Tayfun/0000-0002-3261-1186				ALLAIN JP, 1976, BLOOD, V47, P973; BIGGS R, 1974, BRIT J HAEMATOL, V26, P313, DOI 10.1111/j.1365-2141.1974.tb00476.x; BLOOM AL, 1991, THROMB HAEMOSTASIS, V66, P166; BRINKHOUS KM, 1972, THROMB DIATH HAEMO, V51, P315; Gill FM, 1984, FACTOR 8 INHIBITORS, P19; IKKALA E, 1982, BRIT J HAEMATOL, V52, P7, DOI 10.1111/j.1365-2141.1982.tb03856.x; IKKALA E, 1971, SCAND J HAEMATOL, V8, P16; KASPER CK, 1973, THROMB DIATH HAEMOST, V30, P263, DOI 10.1055/s-0038-1649073; KASPER CK, 1975, THROMB DIATH HAEMOST, V34, P869; KESTEVEN PJ, 1984, THROMB HAEMOSTASIS, V52, P50; KREUZ W, 1991, ANN HEMATOL, V62, pA46; LANGDELL RD, 1953, J LAB CLIN MED, V41, P637; LARSSON SA, 1985, BRIT J HAEMATOL, V59, P593, DOI 10.1111/j.1365-2141.1985.tb07353.x; MCMILLAN CW, 1988, BLOOD, V71, P344; RASI V, 1990, BRIT J HAEMATOL, V76, P369, DOI 10.1111/j.1365-2141.1990.tb06370.x; RIZZA CR, 1983, BRIT MED J, V286, P929, DOI 10.1136/bmj.286.6369.929; ROSENDAAL FR, 1989, BRIT J HAEMATOL, V71, P71, DOI 10.1111/j.1365-2141.1989.tb06277.x; RUGGERI ZM, 1977, WORKSHOP INHIBITORS, P45; SCHWARTZ RS, 1990, NEW ENGL J MED, V323, P1800, DOI 10.1056/NEJM199012273232604; SCHWARZINGER I, 1987, AM J HEMATOL, V24, P241, DOI 10.1002/ajh.2830240303; SEREMETIS S, 1991, THROMB HAEMOSTASIS, V65, P1160; SHAPIRO S S, 1975, Seminars in Thrombosis and Hemostasis, V1, P336; SHAPIRO SS, 1984, SCAND J HAEMATOL, V33, P181; SHAPIRO SS, 1979, CLIN HAEMATOL, V8, P207; STENBJERG S, 1984, THROMB RES, V34, P533, DOI 10.1016/0049-3848(84)90257-3; STRAUSS HS, 1969, NEW ENGL J MED, V281, P866, DOI 10.1056/NEJM196910162811603	26	517	527	0	20	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 7	1992	339	8793					594	598		10.1016/0140-6736(92)90874-3	http://dx.doi.org/10.1016/0140-6736(92)90874-3			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HH075	1347102				2023-01-03	WOS:A1992HH07500012
J	HENDRA, TJ; MARSHALL, AJ				HENDRA, TJ; MARSHALL, AJ			INCREASED PRESCRIPTION OF THROMBOLYTIC TREATMENT TO ELDERLY PATIENTS WITH SUSPECTED ACUTE MYOCARDIAL-INFARCTION ASSOCIATED WITH AUDIT	BMJ-BRITISH MEDICAL JOURNAL			English	Article							INTRAVENOUS STREPTOKINASE; THERAPY; MORTALITY	Objectives - To assess prescription of thrombolytic treatment to elderly patients with suspected acute myocardial infarction and the incidence of side effects. Design - Retrospective analysis of prescriptions during five months (first audit) followed by prospective analysis of uptake of treatment during five months after interventions in clinical management; prospective assessment of adverse events during thrombolytic treatment. Setting - Coronary care unit of large district general hospital. Patients - 110 patients aged greater-than-or-equal-to 65 with subsequently proved acute myocardial infarction admitted in first audit and 119 admitted in the second. Main outcome measures - Site of infarct, prescription of thrombolysis treatment, reasons for nonprescription, complications. Results - Before intervention thrombolytic treatment was prescribed to 13/110 (12%) patients with subsequently confirmed myocardial infarction and after intervention to 55/119 (46%) patients (p < 0.01). In the first audit no patients with angina received thrombolytic treatment whereas 13/79 (16%) were treated in the second audit. Increased prescription of thrombolytic treatment in the second audit was associated with significantly fewer exclusions owing to dyspepsia (p < 0.05) and unstated or unsatisfactory reasons (p < 0.01) Streptokinase infusions were completed uneventfully in 75% (48/64) and 77% (10/13) of patients with infarction and angina respectively. Side effects of treatment were more common in patients with inferior than with anterior infarcts (16/42 (30%) v 3/24 (13%), p < 0.05). Conclusions - Low rates of prescription of thrombolytic treatment to elderly patients with suspected acute myocardial infarction were identified and corrected. Streptokinase treatment was associated with transient arrhythmias or hypotension in about a third of these patients with infarcts, particularly those with electrocardiographic changes in inferior leads.	DERRIFORD HOSP, DEPT CARDIOL, PLYMOUTH PL6 8DH, ENGLAND	Derriford Hospital								ALDRICH MS, 1985, JAMA-J AM MED ASSOC, V253, P1777, DOI 10.1001/jama.253.12.1777; [Anonymous], 1988, LANCET, V2, P349; [Anonymous], 1986, LANCET, V1, P397; BURRELL CJ, 1990, BMJ-BRIT MED J, V300, P237, DOI 10.1136/bmj.300.6719.237; GRINES CL, 1990, J AM COLL CARDIOL, V16, P223, DOI 10.1016/0735-1097(90)90482-5; KENNEDY JW, 1990, ANN INTERN MED, V113, P907, DOI 10.7326/0003-4819-113-12-907; LEW AS, 1987, AM J CARDIOL, V59, P1, DOI 10.1016/S0002-9149(87)80059-0; LEW AS, 1985, CIRCULATION, V72, P1321, DOI 10.1161/01.CIR.72.6.1321; MIDGETTE AS, 1990, ANN INTERN MED, V113, P961, DOI 10.7326/0003-4819-113-12-961; MULLER DWM, 1990, ANN INTERN MED, V113, P949, DOI 10.7326/0003-4819-113-12-949; MURRAY N, 1987, BRIT HEART J, V57, P144; PETCH MC, 1990, BMJ-BRIT MED J, V300, P483, DOI 10.1136/bmj.300.6723.483; SHAW C, 1990, MED AUDIT HOSPITAL H; SLEIGHT P, 1990, EUR HEART J, V11, P1; SMITH LDR, 1990, POSTGRAD MED J, V66, P263, DOI 10.1136/pgmj.66.774.263; TIMMIS AD, 1990, BMJ-BRIT MED J, V301, P941, DOI 10.1136/bmj.301.6758.941; WILCOX RG, 1988, LANCET, V2, P525; 1976, PUBLIC HLTH EUROPE, V5	18	22	22	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 15	1992	304	6824					423	425		10.1136/bmj.304.6824.423	http://dx.doi.org/10.1136/bmj.304.6824.423			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HE389	1547391	Green Published, Bronze			2023-01-03	WOS:A1992HE38900022
J	FITZPATRICK, A; SUTTON, R				FITZPATRICK, A; SUTTON, R			A GUIDE TO TEMPORARY PACING	BRITISH MEDICAL JOURNAL			English	Article							INFARCTION		WESTMINSTER MED SCH & HOSP,LONDON SW1P 2AP,ENGLAND; SOUTHAMPTON GEN HOSP,WESSEX REG CARDIOTHORAC CTR,SOUTHAMPTON SO9 4XY,HANTS,ENGLAND	Imperial College London; University of Southampton								ATKINS JM, 1973, NEW ENGL J MED, V288, P281, DOI 10.1056/NEJM197302082880603; GINKS W, 1977, BRIT HEART J, V196, P189; JULIAN DG, 1964, AM J MED, V37, P915, DOI 10.1016/0002-9343(64)90133-0; ROSEN M, 1988, BMJ, P88; SHAH PK, 1987, AM HEART J, V113, P194, DOI 10.1016/0002-8703(87)90029-9; WINNER S, 1989, J ROY COLL PHYS LOND, V23, P161; 1988, IONISING RAD REGULAT	7	21	23	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 8	1992	304	6823					365	369		10.1136/bmj.304.6823.365	http://dx.doi.org/10.1136/bmj.304.6823.365			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HD387	1540737	Bronze, Green Published			2023-01-03	WOS:A1992HD38700029
J	PETERSON, HB; WALKER, CK; KAHN, JG; WASHINGTON, AE; ESCHENBACH, DA; FARO, S				PETERSON, HB; WALKER, CK; KAHN, JG; WASHINGTON, AE; ESCHENBACH, DA; FARO, S			PELVIC INFLAMMATORY DISEASE - KEY TREATMENT ISSUES AND OPTIONS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CHLAMYDIA-TRACHOMATIS; CLINDAMYCIN-GENTAMICIN; GYNECOLOGIC INFECTIONS; SULBACTAM AMPICILLIN; DOXYCYCLINE; THERAPY; WOMEN; CIPROFLOXACIN; METRONIDAZOLE; SALPINGITIS	Objective. - To examine available data regarding optimal antimicrobial therapy for pelvic inflammatory disease (PID) and to address selected treatment issues confronting clinicians caring for women with PID. Data Sources. - Studies evaluated to help establish the Centers for Disease Control's 1989 Sexually Transmitted Diseases Treatment Guidelines and other reports published since 1985. A MEDLINE search of English-language literature was conducted using the indexing terms ''pelvic inflammatory disease'' or ''pelvic infections'' or ''salpingitis'' and ''treatment.'' In addition, abstracts and bibliographies of articles and books were reviewed. Study Selection. - Studies were selected for detailed review if they evaluated the effectiveness of an antimicrobial regimen for treatment of PID. Data Extraction. - All studies were evaluated to determine the numbers of women treated and the percentage with clinical or microbiologic evidence of cure. Data Synthesis. - A variety of combination antimicrobial regimens are highly effective in providing clinical and microbiologic evidence of cure; few data are available to assess optimal therapy for prevention of late sequelae. Because PID is polymicrobial in cause, recommended antimicrobial regimens are broad-spectrum in coverage. Conclusions. - No single agent that provides sufficient coverage is currently available. Several combination regimens appear highly effective clinically even among women with tubo-ovarian abscess formation. Uncertainties regarding the effectiveness of antimicrobial therapy for prevention of late sequelae complicate decisions regarding the choice among regimens and the appropriateness of ambulatory treatment of women with PID. Pending better data, hospitalization should be strongly considered, where feasible, particularly for those women with PID desiring further childbearing. Sex partners of all women with PID should be treated.	BAYLOR COLL MED,DEPT OBSTET & GYNECOL,HOUSTON,TX 77030; UNIV CALIF SAN FRANCISCO,SCH MED,DEPT OBSTET GYNECOL & REPROD SCI,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,SCH MED,INST HLTH POLICY STUDIES,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,SCH MED,DEPT EPIDEMIOL & BIOSTAT,SAN FRANCISCO,CA 94143; UNIV WASHINGTON,SCH MED,DEPT OBSTET & GYNECOL,SEATTLE,WA 98195	Baylor College of Medicine; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of Washington; University of Washington Seattle	PETERSON, HB (corresponding author), CTR DIS CONTROL,DIV REPROD HLTH,WOMENS HLTH & FERTIL BRANCH,1600 CLIFTON RD NE,ATLANTA,GA 30333, USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI024768] Funding Source: NIH RePORTER; NIAID NIH HHS [AI24768] Funding Source: Medline; PHS HHS [282-88-0018] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		APUZZIO JJ, 1989, AM J MED, V87, pS148, DOI 10.1016/0002-9343(89)90046-6; BRIHMER C, 1988, SCAND J INFECT DIS S, V53, P65; BROOK I, 1987, ARCH GYNECOL OBSTET, V241, P133, DOI 10.1007/BF00931309; BRUHAT MA, 1989, INT J GYNAECOL OBS S, V2, P41; BRUMSTED JR, 1988, FERTIL STERIL, V50, P667; BRUNHAM RC, 1984, AM J OBSTET GYNECOL, V148, P235, DOI 10.1016/S0002-9378(84)80061-7; BRUNHAM RC, 1988, J INFECT DIS, V158, P510, DOI 10.1093/infdis/158.3.510; CAMPBELL WF, 1990, AM J OBSTET GYNECOL, V162, P343, DOI 10.1016/0002-9378(90)90382-H; COVINO JM, 1990, ANTIMICROB AGENTS CH, V34, P148, DOI 10.1128/AAC.34.1.148; CROMBLEHOLME W, 1986, DRUGS, V31, P11, DOI 10.2165/00003495-198600312-00003; CROMBLEHOLME WR, 1990, OBSTET GYNECOL, V75, P752; CROMBLEHOLME WR, 1989, AM J MED, V87, pS142, DOI 10.1016/0002-9343(89)90045-4; DODSON MG, 1986, OBSTET GYNECOL, V67, P657, DOI 10.1097/00006250-198605000-00010; FARO S, 1988, CURR THER RES CLIN E, V43, P349; GALL SA, 1990, OBSTET GYNECOL, V75, P282; GUNNING J, 1986, DRUGS, V31, P14, DOI 10.2165/00003495-198600312-00004; HEINONEN PK, 1986, GENITOURIN MED, V62, P235; HEINONEN PK, 1989, AM J MED, V87, pS152, DOI 10.1016/0002-9343(89)90047-8; HEINONEN PK, 1989, SCAND J INFECT DIS S, V60, P66; HEMSELL DL, 1987, SURG GYNECOL OBSTET, V165, P223; HEMSELL DL, 1988, DRUGS, V35, P39, DOI 10.2165/00003495-198800357-00010; HEMSELL DL, 1988, AM J OBSTET GYNECOL, V158, P722, DOI 10.1016/S0002-9378(16)44535-7; HEMSELL DL, 1988, J REPROD MED, V33, P799; HENRYSUCHET J, 1986, CHLAMYDIAL INFECTION, P201; JONES RN, 1985, AM J MED, V78, P22, DOI 10.1016/0002-9343(85)90098-1; LANDERS DV, 1991, AM J OBSTET GYNECOL, V164, P849, DOI 10.1016/0002-9378(91)90528-Y; LARSEN JW, 1987, CLIN THER, V9, P77; MCGREGGOR JA, 1988, J REPROD MED S6, V33, P595; OBWEGESER J, 1989, J ANTIMICROB CHEMOTH, V24, P165, DOI 10.1093/jac/24.suppl_B.165; ORIEL JD, 1989, REV INFECT DIS, V11, pS1273; PAAVONEN J, 1987, BRIT J OBSTET GYNAEC, V94, P454, DOI 10.1111/j.1471-0528.1987.tb03125.x; PASTOREK JG, 1985, AM J MED, V78, P47, DOI 10.1016/0002-9343(85)90204-9; PATTON DL, 1989, OBSTET GYNECOL, V73, P622; PEARLMAN MD, 1990, ANTIMICROB AGENTS CH, V34, P1399, DOI 10.1128/AAC.34.7.1399; POINDEXTER AN, 1988, AM J OBSTET GYNECOL, V158, P717, DOI 10.1016/S0002-9378(16)44534-5; POULY J L, 1985, Journal de Gynecologie Obstetrique et biologie de la Reproduction, V14, P989; SELLORS JW, 1988, FERTIL STERIL, V49, P451; SHEPARD MK, 1989, FERTIL STERIL, V52, P232; SOPER DE, 1988, OBSTET GYNECOL, V72, P7; SOPER DE, 1990, OCT ANN M INF DIS SO; SWEET RL, 1983, JAMA-J AM MED ASSOC, V250, P2641, DOI 10.1001/jama.250.19.2641; SWEET RL, 1988, AM J OBSTET GYNECOL, V158, P736, DOI 10.1016/S0002-9378(16)44537-0; SWEET RL, 1985, 1985 INT C ANT AG CH; SWEET RL, 1989, INT J GYNAECOL OBS S, V2, P13; SWENSON CE, 1985, SEX TRANSM DIS, V13, P40; TEISALA K, 1989, ANN MED, V21, P63, DOI 10.3109/07853898909149184; TOOMEY KE, 1990, REV INFECT DIS, V12, P5645; WALTERS MD, 1990, OBSTET GYNECOL, V75, P867; WASHINGTON AE, 1991, JAMA-J AM MED ASSOC, V266, P2565, DOI 10.1001/jama.266.18.2565; WASHINGTON AE, 1985, J ADOLESCENT HEALTH, V6, P298, DOI 10.1016/S0197-0070(85)80067-X; WASSERHEIT JN, 1986, ANN INTERN MED, V104, P187, DOI 10.7326/0003-4819-104-2-187; WENDEL GD, 1989, REV INFECT DIS, V11, pS1314; WESTROM L, 1987, CONTRACEPTION, V36, P111, DOI 10.1016/0010-7824(87)90064-3; WOLNERHANSSEN P, 1988, AM J OBSTET GYNECOL, V158, P577, DOI 10.1016/0002-9378(88)90030-0; WOLNERHANSSEN P, 1988, OBSTET GYNECOL, V71, P595; 1986, PRECIS 3 UPDATE OBST, P17; 1989, MMWR-MORBID MORTAL W, V38, P31; 1985, MMWR-MORBID MORTAL W, V34, P19	58	19	21	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 13	1991	266	18					2605	2611		10.1001/jama.266.18.2605	http://dx.doi.org/10.1001/jama.266.18.2605			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GN660	1658404				2023-01-03	WOS:A1991GN66000038
J	LITTLEWOOD, R				LITTLEWOOD, R			FROM DISEASE TO ILLNESS AND BACK AGAIN	LANCET			English	Article											LITTLEWOOD, R (corresponding author), UNIV LONDON UNIV COLL,CTR MED ANTHROPOL,GOWER ST,LONDON WC1E 6BT,ENGLAND.							CHRISMAN N, 1982, CLIN APPLIED ANTHR; DOUGLAS M, 1985, RISK ACCEPTABILITY S; Eisenberg L, 1977, Cult Med Psychiatry, V1, P9, DOI 10.1007/BF00114808; Good Byron J., 1981, SCI CULTURES SOCIOLO, V5; Helman C. G., 1990, CULTURE HLTH ILLNESS; Holden P., 1991, ANTHR NURSING; Kleinman A., 1988, ILLNESS NARRATIVES; Kleinman A., 1980, PATIENTS HEALERS CON; LITTLEWOOD, 1990, BRIT J PSYCHIAT, V156, P308; Littlewood R., 1989, ALIENS ALIENISTS ETH; Littlewood Roland., 1988, PSYCHIATRIC B, V12, P486; MCKEOWN T, 1976, ROLE MED; THOMAS KJ, 1991, BRIT MED J, V302, P207, DOI 10.1136/bmj.302.6770.207	13	11	11	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 27	1991	337	8748					1013	1016		10.1016/0140-6736(91)92668-R	http://dx.doi.org/10.1016/0140-6736(91)92668-R			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FJ135	1673174				2023-01-03	WOS:A1991FJ13500012
J	CALLAHAM, M; BARTON, CW; KAYSER, S				CALLAHAM, M; BARTON, CW; KAYSER, S			POTENTIAL COMPLICATIONS OF HIGH-DOSE EPINEPHRINE THERAPY IN PATIENTS RESUSCITATED FROM CARDIAC-ARREST	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DEPENDENT VASOPRESSOR RESPONSE; MYOCARDIAL OXYGEN DELIVERY; CARDIOPULMONARY RESUSCITATION; HUMAN-BEINGS; CPR	Adults resuscitated from nontraumatic cardiac arrest who received intravenous epinephrine in doses chosen by the treating physician and who survived at least 6 hours were studied to determine if high-dose epinephrine produced more complications than standard-dose. A total of 68 patients were enrolled and evaluated for postresuscitation complications attributable to epinephrine, using a two-tailed t test, and contingency analysis. The 33 patients receiving high-dose epinephrine and 35 patients receiving standard-dose epinephrine were similar in demographics and variables known to affect outcome. There was no difference in potential complications between groups except serum calcium, which was 1.97 mmol/L (SD, 0.20) in the high-dose epinephrine group and 2.10 (SD, 0.20) in the standard-dose group. Hospital discharge rates (18% in the high-dose vs 30% in the standard-dose group) and neurological status on discharge were not significantly different. High-dose epinephrine did not produce increased direct complications in this cardiac arrest population compared with standard-dose epinephrine.	UNIV CALIF SAN FRANCISCO,DIV CLIN PHARMACOL,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco	CALLAHAM, M (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT MED,DIV EMERGENCY MED,SAN FRANCISCO,CA 94143, USA.			Callaham, Michael/0000-0003-2284-256X				BARTON CW, 1990, ANN EMERG MED, V19, P490; BROWN CG, 1987, CIRCULATION, V75, P491, DOI 10.1161/01.CIR.75.2.491; BROWN CG, 1988, CRIT CARE MED, V16, P536, DOI 10.1097/00003246-198805000-00013; BROWN DD, 1988, SKELETAL RADIOL, V17, P302, DOI 10.1007/BF00401818; BROWN MJ, 1983, NEW ENGL J MED, V309, P1414, DOI 10.1056/NEJM198312083092303; ERSOZ N, 1971, BRIT J ANAESTH, V43, P709, DOI 10.1093/bja/43.7.709; FRIEDMAN B, 1955, LANCET, P575; GOETTING MG, 1989, CRIT CARE MED, V17, P1258, DOI 10.1097/00003246-198912000-00004; GONZALEZ ER, 1989, ANN EMERG MED, V18, P920, DOI 10.1016/S0196-0644(89)80453-6; HALL AH, 1987, AM J EMERG MED, V5, P64, DOI 10.1016/0735-6757(87)90293-2; KARCH SB, 1987, AM J FOREN MED PATH, V8, P3, DOI 10.1097/00000433-198703000-00002; KELLNER M, 1966, ACTA MED HUNG, V23, P37; KELLNER M, 1966, ACTA MED HUNG, V22, P335; KIRIMLI B, 1969, ANESTH ANAL CURR RES, V48, P649; KOSCOVE EM, 1988, JAMA-J AM MED ASSOC, V259, P3031, DOI 10.1001/jama.259.20.3031; KURACHEK SC, 1985, JAMA-J AM MED ASSOC, V253, P1441, DOI 10.1001/jama.253.10.1441; LONGSTRETH WT, 1987, WESTERN J MED, V147, P175; LONGSTRETH WT, 1984, ANN NEUROL, V15, P59, DOI 10.1002/ana.410150111; MARTIN D, 1990, ANN EMERG MED, V19, P322, DOI 10.1016/S0196-0644(05)82055-4; MARTIN GB, 1985, ANN EMERG MED, V14, P293, DOI 10.1016/S0196-0644(85)80089-5; MUSCH W, 1987, ANN EMERG MED, V16, P514; NOVEY HS, 1969, J AMER MED ASSOC, V207, P2435, DOI 10.1001/jama.207.13.2435; PARADIS N A, 1990, Critical Care Medicine, V18, pS221, DOI 10.1097/00003246-199012001-00087; PARADIS NA, 1990, ANN EMERG MED, V19, P491; RITTER G, 1985, AM HEART J, V110, P932, DOI 10.1016/0002-8703(85)90187-5; SALERNO DM, 1989, CRIT CARE MED, V17, P1181, DOI 10.1097/00003246-198911000-00016; STEINGRUB J, 1990, Critical Care Medicine, V18, pS223, DOI 10.1097/00003246-199012001-00090; URBAN P, 1988, ANN INTERN MED, V109, P110, DOI 10.7326/0003-4819-109-2-110; 1986, JAMA-J AM MED ASSOC, V255, P2905	29	35	35	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 6	1991	265	9					1117	1122		10.1001/jama.265.9.1117	http://dx.doi.org/10.1001/jama.265.9.1117			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EZ474	1995996				2023-01-03	WOS:A1991EZ47400027
J	ENNALS, S				ENNALS, S			UNDERSTANDING BENEFITS - BENEFITS FOR PEOPLE IN HOSPITAL, NURSING-HOMES, AND RESIDENTIAL CARE HOMES	BRITISH MEDICAL JOURNAL			English	Editorial Material											ENNALS, S (corresponding author), ESSENTIAL RIGHTS,94 CHAWORTH RD,NOTTINGHAM NG2 7AD,ENGLAND.								0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 23	1991	302	6774					463	465		10.1136/bmj.302.6774.463	http://dx.doi.org/10.1136/bmj.302.6774.463			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EZ033	2004176	Green Published, Bronze			2023-01-03	WOS:A1991EZ03300029
J	THOMAS, KJ; CARR, J; WESTLAKE, L; WILLIAMS, BT				THOMAS, KJ; CARR, J; WESTLAKE, L; WILLIAMS, BT			USE OF NON-ORTHODOX AND CONVENTIONAL HEALTH-CARE IN GREAT-BRITAIN	BRITISH MEDICAL JOURNAL			English	Article							MEDICINE	Objective-To describe the characteristics of patients using non-orthodox health care and their pattern of use of conventional health care with respect to a particular problem. Design-Postal survey of all 2152 practitioners of acupuncture, chiropractic, homoeopathy, naturopathy, and osteopathy identified from 11 national professional association registers. Patients attending a representative sample of 101 responding practitioners completed questionnaires covering demographic characteristics, presenting problems, and use of the health service. Setting-Practices of practitioners of non-orthodox health care in England, Scotland, and Wales. Subjects-Qualified, non-medical practitioners of non-orthodox health care working in Great Britian and 2473 patients who had attended one of the sampled practitioners in an allocated time period between August 1987 and July 1988. Results-An estimated 1909 practitioners were actively practising one of the study treatments in Great Britian in 1987. Of the estimated 70 600 patients seen by this group of practitioners in an average week, most (78%) were attending with a musculoskeletal problem. Two thirds of the patients were women. Only 2% were aged under 16, but 15% were aged 65 or over. One in three patients had not received previous conventional care for their main problem; 18% were receiving concurrent non-orthodox and conventional care. Twenty two per cent of the patients reported having seen their general practitioner for any reason in the two weeks before the surveyed consultation. Conclusions-Patients of non-orthodox health care, as provided by this group of practitioners, had not turned their backs on conventional health care. Non-orthodox treatment was sought for a limited range of problems and used most frequently as a supplement to orthodox medicine.			THOMAS, KJ (corresponding author), UNIV SHEFFIELD,SCH MED,DEPT PUBL HLTH MED,MED CARE RES UNIT,SHEFFIELD S10 2RX,S YORKSHIRE,ENGLAND.							DAVIES P, 1987, REPORT TRENDS COMPLE; FULDER SJ, 1986, LANCET, V2, P542; INGLIS B, 1985, LANCET, V1, P95; Lamberts H., 1987, ICPC INT CLASSIFICAT; MURRAY J, 1988, J ROY COLL GEN PRACT, V38, P511; 1984, GENERAL HOUSEHOLD SU; 1987, PROFESSIONAL CONDUCT; 1986, WHICH            OCT, P443; 1986, ALTERNATIVE THERAPIE	9	159	160	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 26	1991	302	6770					207	210		10.1136/bmj.302.6770.207	http://dx.doi.org/10.1136/bmj.302.6770.207			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	EV228	1998760	Bronze, Green Published			2023-01-03	WOS:A1991EV22800024
J	OSBAND, ME; LAVIN, PT; BABAYAN, RK; GRAHAM, S; LAMM, DL; PARKER, B; SAWCZUK, I; ROSS, S; KRANE, RJ				OSBAND, ME; LAVIN, PT; BABAYAN, RK; GRAHAM, S; LAMM, DL; PARKER, B; SAWCZUK, I; ROSS, S; KRANE, RJ			EFFECT OF AUTOLYMPHOCYTE THERAPY ON SURVIVAL AND QUALITY OF LIFE IN PATIENTS WITH METASTATIC RENAL-CELL CARCINOMA	LANCET			English	Article									NEW ENGLAND BAPTIST HOSP,BOSTON,MA; HARVARD UNIV,SCH MED,DEPT SURG,BOSTON,MA 02115; BOSTON UNIV,MED CTR,DEPT UROL,BOSTON,MA 02215; EMORY UNIV,SCH MED,DEPT UROL,ATLANTA,GA 30322; W VIRGINIA UNIV,HLTH SCI CTR,DEPT UROL,MORGANTOWN,WV 26506; COLUMBIA UNIV COLL PHYS & SURG,DEPT UROL,NEW YORK,NY 10032; UNIV CALIF SAN DIEGO,CTR CANC,DIV MED ONCOL,SAN DIEGO,CA 92103	New England Baptist Hospital; Harvard University; Harvard Medical School; Boston University; Emory University; West Virginia University; Columbia University; University of California System; University of California San Diego	OSBAND, ME (corresponding author), BOSTON UNIV,SCH MED,JOINT CLIN IMMUNOTHERAPY PROGRAM,125 PARKER HILL AVE,BOSTON,MA 02120, USA.			Babayan, Richard/0000-0002-9316-5941				ASHWELL JD, 1987, SCIENCE, V237, P61, DOI 10.1126/science.3037698; BONOMI PD, 1989, J CLIN ONCOL, V7, P1602, DOI 10.1200/JCO.1989.7.11.1602; CARPINITO GA, 1986, SURG FORUM, V27, P418; CAVAGNARO J, 1983, BIOTECHNIQUES, V1, P30; CHEEVER MA, 1986, J EXP MED, V163, P1100, DOI 10.1084/jem.163.5.1100; DEKERNION JB, 1978, J UROLOGY, V120, P148, DOI 10.1016/S0022-5347(17)57082-2; FISHER RI, 1988, ANN INTERN MED, V108, P518, DOI 10.7326/0003-4819-108-4-518; GURLAND J, 1965, JAMA-J AM MED ASSOC, V29, P973; HERSH EM, 1980, CANCER RES, V40, P3134; KAYE FJ, 1989, NEW ENGL J MED, V321, P1784, DOI 10.1056/NEJM198912283212603; KHAN MM, 1985, J CLIN INVEST, V75, P1578, DOI 10.1172/JCI111863; KRANE RJ, IN PRESS UROLOGY; KROWN SE, 1987, CANCER, V59, P647, DOI 10.1002/1097-0142(19870201)59:3+<647::AID-CNCR2820591313>3.0.CO;2-#; METZLER MS, 1971, J NATL CANCER I, V47, P703; MEUER SC, 1984, P NATL ACAD SCI-BIOL, V81, P1509, DOI 10.1073/pnas.81.5.1509; MOERTEL CG, 1986, JAMA-J AM MED ASSOC, V256, P3141, DOI 10.1001/jama.256.22.3141; NEVES RJ, 1988, J UROLOGY, V139, P1173, DOI 10.1016/S0022-5347(17)42851-5; OKEN MM, 1982, AM J CLIN ONCOL-CANC, V5, P649, DOI 10.1097/00000421-198212000-00014; OLDHAM RK, 1985, CANCER INVEST, V3, P53, DOI 10.3109/07357908509040608; OLIVER R T D, 1988, Molecular Biotherapy, V1, P14; OSBAND ME, 1989, PEDIATR RES, V25, pA155; OSBAND ME, 1988, PATHOL IMMUNOPATH R, V7, P483, DOI 10.1159/000157077; OSBAND ME, 1989, CLIN RES, V37, pA469; OSBAND ME, 1987, WORLD J UROL, V4, P217; OSBAND ME, IN PRESS IMMUNOL TOD; ROSENBERG SA, 1987, NEW ENGL J MED, V316, P889, DOI 10.1056/NEJM198704093161501; ROSENBERG SA, 1989, CANCER PRINCIPLES PR, P301; SAHASRABUDHE DM, 1987, J IMMUNOL, V138, P2760; SCHRIER RD, 1979, J IMMUNOL, V123, P2525; SIMON R, 1989, CANCER PRINCIPLES PR, P398; STEVENSON HC, 1987, PRINCIPLES CANCER BI, P385; WASSERMAN J, 1982, J CLIN LAB IMMUNOL, V7, P139; WAYMACK JP, 1989, PROSTAGLANDINS, V38, P345, DOI 10.1016/0090-6980(89)90138-X; WEST WH, 1987, NEW ENGL J MED, V316, P898, DOI 10.1056/NEJM198704093161502	34	116	120	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 28	1990	335	8696					994	998		10.1016/0140-6736(90)91064-H	http://dx.doi.org/10.1016/0140-6736(90)91064-H			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DB072	1970108	hybrid			2023-01-03	WOS:A1990DB07200004
J	YOONG, AFE; LIM, J; HUDSON, CN; CHARD, T				YOONG, AFE; LIM, J; HUDSON, CN; CHARD, T			AUDIT OF COMPLIANCE WITH ANTENATAL PROTOCOLS	BMJ-BRITISH MEDICAL JOURNAL			English	Article							GUIDELINES; PHYSICIANS; POLICIES; CARE	Objective-To assess the implementation of action protocols dictated by antenatal risk factors noted at the initial (booking) antenatal visit. Design-Retrospective study of 2000 women delivered between 1 March 1990 and 29 March 1991. Setting-Maternity department of a district general hospital supporting a multiethnic population in inner London. Main outcome measures-Comparison of clinical actions performed against those dictated by the department's protocols. Analysis according to clinical importance, gestation at booking, maternal age, parity, birth order, ethnic origin, and certainty of gestational age. Results-Interobserver agreement between the two auditors was good (chi statistic for risk factors detected, 0.78; for actions generated, 0.80). Of the 15 658 actions dictated by department protocols, 3673 (23.5%) were actually performed by the clinicians. The 63 combinations of risk factors and actions believed by consultants to be of particular clinical importance had an action rate of 28.3% compared with 18.6% for those considered less important (p < 0.001). Mothers who first visited the hospital antenatal clinic at or before 24 weeks' gestation had 25.2% of relevant protocols fulfilled (p < 0.001). Compliance was significantly improved in women aged 36 or over (32.4%), black women (24.9%), and cases of uncertain gestation (24.5%). Parity and birth order were not associated with an altered action rate. Ethnic origin deemed as "other" (than white, black, Asian, or oriental) or "unknown" was associated with poor compliance (19.3%). Conclusions-Compliance to a set of agreed protocols was poor even though a computer system was available and a protocol manual had been distributed. Protocols were more likely to be implemented in women who booked early and in some groups of women deemed at high risk including older mothers, black women, and those denoted as having uncertain gestational age.			YOONG, AFE (corresponding author), ST BARTHOLOMEWS HOSP & MED COLL, JOINT ACAD UNIT OBSTET GYNAECOL & REPROD PHYSIOL, LONDON EC1A 7BE, ENGLAND.							BARRETT JFR, 1990, LANCET, V336, P549, DOI 10.1016/0140-6736(90)92097-2; BODDY K, 1982, ROYAL COLLEGE OBSTET, P40; BRENNAN P, 1992, BMJ-BRIT MED J, V304, P1491, DOI 10.1136/bmj.304.6840.1491; CARROLL S, 1988, J OBSTET GYNAECOL, V8, P222, DOI 10.3109/01443618809012289; CHNG PK, 1980, BMJ-BRIT MED J, V281, P1184, DOI 10.1136/bmj.281.6249.1184; COHEN J, 1968, PSYCHOL BULL, V70, P213, DOI 10.1037/h0026256; COHEN J, 1960, EDUC PSYCHOL MEAS, V20, P37, DOI 10.1177/001316446002000104; EDDY DM, 1990, JAMA-J AM MED ASSOC, V263, P1265, DOI 10.1001/jama.263.9.1265; EDDY DM, 1990, JAMA-J AM MED ASSOC, V263, P2239, DOI 10.1001/jama.263.16.2239; EDDY DM, 1982, NEW ENGL J MED, V307, P343, DOI 10.1056/NEJM198208053070604; GRILLI R, 1991, MED CARE, V29, P50, DOI 10.1097/00005650-199101000-00005; GUTHRIE KA, 1989, BRIT J OBSTET GYNAEC, V96, P552, DOI 10.1111/j.1471-0528.1989.tb03254.x; KOSECOFF J, 1987, JAMA-J AM MED ASSOC, V258, P2708, DOI 10.1001/jama.258.19.2708; LOMAS J, 1989, NEW ENGL J MED, V321, P1306, DOI 10.1056/NEJM198911093211906; ODOWD TC, 1991, BRIT MED J, V303, P450, DOI 10.1136/bmj.303.6800.450; SHAW CD, 1990, BRIT MED J, V300, P649, DOI 10.1136/bmj.300.6725.649; WOO B, 1985, JAMA-J AM MED ASSOC, V254, P1480, DOI 10.1001/jama.254.11.1480	17	11	11	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 14	1992	305	6863					1184	1186		10.1136/bmj.305.6863.1184	http://dx.doi.org/10.1136/bmj.305.6863.1184			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JY777	1467720	Green Submitted, Bronze, Green Published			2023-01-03	WOS:A1992JY77700019
J	ROGSTAD, KE; WHITE, DJ; AHMEDJUSHUF, IH				ROGSTAD, KE; WHITE, DJ; AHMEDJUSHUF, IH			EFFICACY OF LIGNOCAINE ANALGESIA DURING TREATMENT TO THE CERVIX	LANCET			English	Note							TRIAL	There is no consensus amongst physicians about the need for analgesia when a woman undergoes ablative therapy of the cervix. Many doctors believe that the discomfort felt during such procedures is insubstantial. By means of a randomised double-blind placebo-controlled trial, we have shown that patients experience considerable pain during cold-coagulation treatment of the cervix. We found that intracervical lignocaine leads to a significant (p < 0.01) reduction in this pain.			ROGSTAD, KE (corresponding author), CITY HOSP,DEPT GENITOURINARY MED,HUCKNALL RD,NOTTINGHAM NG5 1PB,ENGLAND.							BOAG FC, 1991, GENITOURIN MED, V67, P481; DODSON ME, 1985, CURRENT TOPICS ANAES, P38; Duncan I D, 1983, Clin Obstet Gynecol, V26, P996, DOI 10.1097/00003081-198312000-00022; Huskisson E., 1983, PAIN MEASUREMENT ASS, P33; JOHNSON N, 1989, BRIT J OBSTET GYNAEC, V96, P1410, DOI 10.1111/j.1471-0528.1989.tb06304.x; LEE ETC, 1986, BRIT J OBSTET GYNAEC, V93, P967, DOI 10.1111/j.1471-0528.1986.tb08017.x; MARTEAU TM, 1990, BRIT J OBSTET GYNAEC, V97, P589; 1989, LANCET, V2, P83	8	10	10	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 17	1992	340	8825					942	942		10.1016/0140-6736(92)92820-6	http://dx.doi.org/10.1016/0140-6736(92)92820-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JT823	1357350				2023-01-03	WOS:A1992JT82300006
J	MENIKOFF, JA; SACHS, GA; SIEGLER, M				MENIKOFF, JA; SACHS, GA; SIEGLER, M			BEYOND ADVANCE DIRECTIVES - HEALTH-CARE SURROGATE LAWS	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							SELF-DETERMINATION ACT; LIVING WILLS; INTERVENTIONS; ATTITUDES; PROXY; LIFE				MENIKOFF, JA (corresponding author), UNIV CHICAGO, CHICAGO, IL 60637 USA.							ANNAS GJ, 1991, NEW ENGL J MED, V324, P1210, DOI 10.1056/NEJM199104253241711; Areen J, 1991, Law Med Health Care, V19, P91; BRETT AS, 1991, JAMA-J AM MED ASSOC, V266, P825, DOI 10.1001/jama.266.6.825; BRUNETTI LL, 1991, J GEN INTERN MED, V6, P323, DOI 10.1007/BF02597430; CAPLAN AL, 1991, GERONTOLOGIST, V31, P582; CAPRON AM, 1990, HASTINGS CENT REP, V20, P35, DOI 10.2307/3562537; CAPRON AM, 1991, HASTINGS CENT REP, V21, P26, DOI 10.2307/3562887; COHENMANSFIELD J, 1991, ARCH INTERN MED, V151, P289, DOI 10.1001/archinte.151.2.289; EMANUEL LL, 1991, NEW ENGL J MED, V324, P889, DOI 10.1056/NEJM199103283241305; GAMBLE ER, 1991, ARCH INTERN MED, V151, P277, DOI 10.1001/archinte.151.2.277; Goldman G M, 1989, Law Med Health Care, V17, P298; GRECO PJ, 1991, ANN INTERN MED, V115, P639, DOI 10.7326/0003-4819-115-8-639; HARE J, 1991, J GEN INTERN MED, V6, P41, DOI 10.1007/BF02599390; HIGH DM, 1991, GERONTOLOGIST, V31, P611, DOI 10.1093/geront/31.5.611; LAPUMA J, 1991, JAMA-J AM MED ASSOC, V266, P402, DOI 10.1001/jama.266.3.402; Portman R M, 1991, J Health Hosp Law, V24, P311; RHODEN NK, 1988, HARVARD LAW REV, V102, P375, DOI 10.2307/1341384; Rouse F, 1991, Law Med Health Care, V19, P83; ROWLAND M, 1990, NY TIMES        1111, V3, P17; Sachs G.A., 1991, J CRIT ILLNESS, V6, P348; SACHS GA, 1992, J AM GERIATR SOC, V40, P269, DOI 10.1111/j.1532-5415.1992.tb02081.x; SECKLER AB, 1991, ANN INTERN MED, V115, P92, DOI 10.7326/0003-4819-115-2-92; WOLF SM, 1991, NEW ENGL J MED, V325, P1666, DOI 10.1056/NEJM199112053252334	23	60	60	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 15	1992	327	16					1165	1169		10.1056/NEJM199210153271612	http://dx.doi.org/10.1056/NEJM199210153271612			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JT153	1528214				2023-01-03	WOS:A1992JT15300012
J	GILL, TM				GILL, TM			ARE YOU SURE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material														Gill, Thomas/0000-0002-6450-0368					0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 1	1992	267	13					1750	1750						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HK672	1545454				2023-01-03	WOS:A1992HK67200009
J	MOUKARZEL, AA; SONG, MK; BUCHMAN, AL; VARGAS, J; GUSS, W; MCDIARMID, S; REYEN, L; AMENT, ME				MOUKARZEL, AA; SONG, MK; BUCHMAN, AL; VARGAS, J; GUSS, W; MCDIARMID, S; REYEN, L; AMENT, ME			EXCESSIVE CHROMIUM INTAKE IN CHILDREN RECEIVING TOTAL PARENTERAL-NUTRITION	LANCET			English	Article							MILD PERIPHERAL NEUROPATHY; GLUCOSE-TOLERANCE; DEFICIENCY; SUPPLEMENTATION; SUFFICIENCY; VITAMINS; INFANTS; INSULIN; BLOOD; SERUM	Various expert bodies have recommended that the daily parental intake of chromium in children receiving total parenteral nutrition (TPN) should be 0.20-mu-g/kg. To test whether this-recommendation is appropriate, we assessed chromium intake, serum chromium concentrations, and renal function in 15 children receiving TPN. The median duration of TPN use was 9.5 (range 1.3-14) years. The children's glomerular filtration rate (GFR), measured by plasma clearance of indium-111-DTPA was lower than that of non-TPN controls (70 [SD 17) vs 110 [10] ml/min per 1.73 m2). The daily chromium intake averaged 0.15 (0.09) mu-g/kg daily but the serum chromium concentration was 20 (4 to 42) times higher than that of the controls (2.1 [1.2] vs 0.10 [0.03] mu-g/l; p < 0.0001). GFR was significantly inversely correlated with serum chromium concentration (r = -0.60, p < 0.02), daily chromium intake (r = -0.69, p <0.01), cumulative parenteral chromium intake (r = -0.72, p < 0.01), and TPN duration (r = -0.52, p < 0.05). We discontinued chromium supplementation of TPN solutions and reassessed the children a year later. Contaminating chromium concentrations were 1.0-1.8-mu-g/l in TPN solutions and 0.9-mu-g/l in fat emulsions. Drinking water contained 4.3-5.7-mu-g/l. Thus, the chromium intake without supplementation was only 0.05 (0.01) mu-g/kg daily. The mean serum chromium concentration fell to 0.50 (0.30) mu-g/l but was still significantly higher than that in the controls (p < 0.01). The GFR did not change significantly (65 [14] ml/min per 1.73 m2). No patient has shown signs of chromium deficiency. Although our patients were receiving less than the recommended chromium intake during supplementation, their high serum concentrations suggested excessive intake. The recommended parenteral chromium intake for children should be lowered.	UNIV CALIF LOS ANGELES,SCH MED,DEPT PEDIAT,DIV PEDIAT GASTROENTEROL & NUTR,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA								ANDERSON RA, 1989, SCI TOTAL ENVIRON, V86, P75, DOI 10.1016/0048-9697(89)90196-4; BROWN RO, 1986, DIGEST DIS SCI, V31, P661, DOI 10.1007/BF01318699; BYRNE WJ, 1979, SURG GYNECOL OBSTET, V149, P593; CASEY CE, 1984, BRIT J NUTR, V52, P73, DOI 10.1079/BJN19840072; CHASSON AL, 1961, AM J CLIN PATHOL, V35, P83, DOI 10.1093/ajcp/35.1_ts.83; ESPINAL J, 1987, NATURE, V328, P574, DOI 10.1038/328574a0; EVANS GW, 1973, BIOCHEM BIOPH RES CO, V50, P718, DOI 10.1016/0006-291X(73)91303-X; FREUND H, 1979, JAMA-J AM MED ASSOC, V241, P496, DOI 10.1001/jama.241.5.496; GHISOLFI J, 1984, JOURNEES PARISIENNES, P97; GREENE HL, 1988, AM J CLIN NUTR, V48, P1324; GURSON CT, 1971, AM J CLIN NUTR, V24, P1313; HAMBRIDGE KM, 1989, TXB GASTROENTEROLOGY, P398; HOPKINS LL, 1968, AM J CLIN NUTR, V21, P203, DOI 10.1093/ajcn/21.3.203; ITO Y, 1990, JPEN-PARENTER ENTER, V14, P610, DOI 10.1177/0148607190014006610; JEEJEEBHOY KN, 1977, AM J CLIN NUTR, V30, P531; KIEN CL, 1986, JPEN-PARENTER ENTER, V10, P662, DOI 10.1177/0148607186010006662; KUMPULAINEN J, 1980, AM J CLIN NUTR, V33, P2299, DOI 10.1093/ajcn/33.11.2299; MCDIARMID SV, 1990, TRANSPLANTATION, V49, P81, DOI 10.1097/00007890-199001000-00018; MERTZ W, 1969, PHYSIOL REV, V49, P163, DOI 10.1152/physrev.1969.49.2.163; MOORE MC, 1986, PEDIATRICS, V77, P530; RIALES R, 1981, AM J CLIN NUTR, V34, P2670, DOI 10.1093/ajcn/34.12.2670; SCHERMAIER AJ, 1985, CLIN CHIM ACTA, V152, P123, DOI 10.1016/0009-8981(85)90183-4; SCHROEDER HA, 1966, J NUTR, V88, P439, DOI 10.1093/jn/88.4.439; SCHWARZ K, 1959, ARCH BIOCHEM BIOPHYS, V85, P292, DOI 10.1016/0003-9861(59)90479-5; 1989, FOOD NUTRITION BOARD, P242; 1988, CHROMIUM ENV HLTH CR, P61; 1979, DIABETES, V28, P1039; 1979, JAMA-J AM MED ASSOC, V241, P2051	28	70	70	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 15	1992	339	8790					385	388		10.1016/0140-6736(92)90078-H	http://dx.doi.org/10.1016/0140-6736(92)90078-H			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HD659	1346659				2023-01-03	WOS:A1992HD65900003
J	GRIBBEN, JG; FREEDMAN, AS; NEUBERG, D; ROY, DC; BLAKE, KW; WOO, SD; GROSSBARD, ML; RABINOWE, SN; CORAL, F; FREEMAN, GJ; RITZ, J; NADLER, LM				GRIBBEN, JG; FREEDMAN, AS; NEUBERG, D; ROY, DC; BLAKE, KW; WOO, SD; GROSSBARD, ML; RABINOWE, SN; CORAL, F; FREEMAN, GJ; RITZ, J; NADLER, LM			IMMUNOLOGICAL PURGING OF MARROW ASSESSED BY PCR BEFORE AUTOLOGOUS BONE-MARROW TRANSPLANTATION FOR B-CELL LYMPHOMA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NON-HODGKINS-LYMPHOMA; ACUTE LYMPHOBLASTIC-LEUKEMIA; DOSE COMBINATION CHEMOTHERAPY; BREAKPOINT-CLUSTER REGION; MONOCLONAL-ANTIBODY; FOLLICULAR LYMPHOMAS; CHROMOSOMAL TRANSLOCATION; BREAST-CANCER; T(14-18); ANTIGEN	Background. The use of autologous bone marrow transplantation is increasing in the management of advanced cancers. Many investigators have attempted to "purge" autologous marrow of residual tumor cells because of concern that reinfused tumor cells might contribute to relapse. The efficacy of purging remains unproved. Methods. We performed clonogenic assays in a tumor cell line in culture to determine the efficiency of immunologic purging. Amplification by the polymerase chain reaction (PCR) was used to detect residual lymphoma cells before and after purging of bone marrow from 114 patients with B-cell non-Hodgkin's lymphoma in whom a translocation (t(l4;18)) that could be amplified by PCR was detected at the time of their initial evaluation. Results. Immunologic purging in vitro resulted in a 3-to-6-log destruction of cells in the tumor cell line. Residual lymphoma cells were detected by PCR in the bone marrow of all patients before purging. No lymphoma cells could be detected in the marrow of 57 patients after purging. Disease-free survival was increased in these 57 patients as compared with those whose marrow contained detectable residual lymphoma (P < 0.00001). The ability to purge residual lymphoma cells was not associated with the degree of bone marrow involvement (P = 0.4494) or the previous response to therapy (P = 0.1298). Conclusions. The inability to purge residual lymphoma cells was the most important prognostic indicator in predicting relapse. These results provide evidence of the clinical usefulness of ex vivo purging of autologous bone marrow in the treatment of patients with lymphoma and suggest that the reinfusion of malignant cells in autologous marrow contributes to relapse.	HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV BIOSTAT,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School	GRIBBEN, JG (corresponding author), HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV TUMOR IMMUNOL,44 BINNEY ST,BOSTON,MA 02115, USA.		Jones, Jeffrey A/E-9827-2013; Freeman, Gordon/AAC-5380-2019	Freeman, Gordon/0000-0002-7210-5616; Roy, Denis-Claude/0000-0002-5921-1692; Grossbard, Michael/0000-0002-3919-3028	NATIONAL CANCER INSTITUTE [P01CA034183, R01CA040216] Funding Source: NIH RePORTER; FIC NIH HHS [TWO4496] Funding Source: Medline; NCI NIH HHS [CA-34183, CA-40216] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AISENBERG AC, 1988, BLOOD, V71, P969; ARMITAGE JO, 1989, BLOOD, V73, P1749; BAKHSHI A, 1985, CELL, V41, P899, DOI 10.1016/S0092-8674(85)80070-2; BALL ED, 1990, BLOOD, V75, P1199; BENJAMIN D, 1983, BLOOD, V61, P1017; BERLINER N, 1986, BLOOD, V67, P80; CLEARY ML, 1986, J EXP MED, V164, P315, DOI 10.1084/jem.164.1.315; CLEARY ML, 1984, P NATL ACAD SCI-BIOL, V81, P593, DOI 10.1073/pnas.81.2.593; CLEARY ML, 1985, P NATL ACAD SCI USA, V82, P7439, DOI 10.1073/pnas.82.21.7439; COSSMAN J, 1984, AM J PATHOL, V115, P117; Cox D.R., 1989, CONCISE ENCY STAT; COX DR, 1972, J R STAT SOC B, V34, P187; CRESCENZI M, 1988, P NATL ACAD SCI USA, V85, P4869, DOI 10.1073/pnas.85.13.4869; FREEDMAN AS, 1987, LEUKEMIA, V1, P9; FREEDMAN AS, 1985, J IMMUNOL, V134, P2228; FREEDMAN AS, 1990, J CLIN ONCOL, V8, P784, DOI 10.1200/JCO.1990.8.5.784; FREI E, 1989, J CLIN ONCOL, V7, P515, DOI 10.1200/JCO.1989.7.4.515; GRANINGER WB, 1987, J CLIN INVEST, V80, P1512, DOI 10.1172/JCI113235; GRIBBEN JG, 1989, J CLIN ONCOL, V7, P1621, DOI 10.1200/JCO.1989.7.11.1621; GRIBBEN JG, 1989, BLOOD, V73, P340; GRIBBEN JG, IN PRESS BLOOD; HIGUCHI R, 1986, PCR TECHNOLOGY, P31; HURD DD, 1988, AM J MED, V85, P829; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KWOK S, 1989, NATURE, V339, P490; LEE MS, 1987, BLOOD, V70, P90; LEE MS, 1987, SCIENCE, V237, P175, DOI 10.1126/science.3110950; MEHTA CR, 1984, BIOMETRICS, V40, P819, DOI 10.2307/2530927; NADLER LM, 1984, LANCET, V2, P427; NADLER LM, 1981, J CLIN INVEST, V67, P134, DOI 10.1172/JCI110005; NADLER LM, 1980, J IMMUNOL, V125, P570; NEGRIN RS, 1991, BLOOD, V77, P654; NGAN BY, 1989, BLOOD, V73, P1759; PETERS WP, 1988, J CLIN ONCOL, V6, P1368, DOI 10.1200/JCO.1988.6.9.1368; PETO R, 1972, J R STAT SOC SER A-G, V135, P185, DOI 10.2307/2344317; PHILIP T, 1987, NEW ENGL J MED, V316, P1493, DOI 10.1056/NEJM198706113162401; RITZ J, 1981, BLOOD, V58, P648; RITZ J, 1980, NATURE, V283, P583, DOI 10.1038/283583a0; ROY DC, 1990, LEUKEMIA RES, V14, P407, DOI 10.1016/0145-2126(90)90026-6; STEIN RS, 1976, CANCER, V37, P629, DOI 10.1002/1097-0142(197602)37:2<629::AID-CNCR2820370204>3.0.CO;2-K; TAKVORIAN T, 1987, NEW ENGL J MED, V316, P1499, DOI 10.1056/NEJM198706113162402; TASWELL C, 1981, J IMMUNOL, V126, P1614; TSUJIMOTO Y, 1985, SCIENCE, V229, P1390, DOI 10.1126/science.3929382; UCKUN FM, 1987, BLOOD, V69, P361; WALLERSTEIN R, 1990, J CLIN ONCOL, V8, P1782, DOI 10.1200/JCO.1990.8.11.1782; WEISS LM, 1987, NEW ENGL J MED, V317, P1185, DOI 10.1056/NEJM198711053171904; YUNIS JJ, 1989, NEW ENGL J MED, V320, P1047, DOI 10.1056/NEJM198904203201605; YUNIS JJ, 1982, NEW ENGL J MED, V307, P1231, DOI 10.1056/NEJM198211113072002	49	692	715	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 28	1991	325	22					1525	1533		10.1056/NEJM199111283252201	http://dx.doi.org/10.1056/NEJM199111283252201			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GR380	1944436				2023-01-03	WOS:A1991GR38000001
J	GALE, RP; BUTTURINI, A				GALE, RP; BUTTURINI, A			MAINTENANCE CHEMOTHERAPY AND CURE OF CHILDHOOD ACUTE LYMPHOBLASTIC-LEUKEMIA	LANCET			English	Article							LYMPHOCYTIC-LEUKEMIA; PROGNOSTIC FACTOR; DRUG-RESISTANCE; THERAPY; CHILDREN; 6-MERCAPTOPURINE; METHOTREXATE; LYMPHOMA; CELLS	Maintenance chemotherapy with 6-mercapto-purine and methotrexate, widely believed an essential contribution to the high cure rates achieved in children with acute lymphoblastic leukaemia (ALL), is thought to work by killing the leukaemia cells that remain after intensive chemotherapy. We suggest instead that ALL commonly arises in precursor B cells normally programmed to die, and that maintenance chemotherapy does not kill these cells but controls growth of the leukaemia clone so that programmed death can occur. A similar approach may apply to other cancers in which programmed death is intrinsic to the normal counterparts of the neoplastic cells.	UNIV CALIF LOS ANGELES, SCH MED, DEPT MED, DIV HEMATOL & ONCOL, LOS ANGELES, CA 90024 USA; UNIV PARMA, DEPT PAEDIAT, DIV HEMATOL & ONCOL, I-43100 PARMA, ITALY	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of Parma					NCI NIH HHS [CA 23175] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA023175] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARLOGIE B, 1989, BLOOD, V73, P865; BEISHUIZEN A, 1991, NEW ENGL J MED, V324, P772; BORZY MS, 1989, BLOOD, V73, P1608; CHESSELLS JM, 1986, J CLIN ONCOL, V4, P1758, DOI 10.1200/JCO.1986.4.12.1758; CLAVELL LA, 1986, NEW ENGL J MED, V315, P657, DOI 10.1056/NEJM198609113151101; FREI E, 1961, BLOOD, V18, P431, DOI 10.1182/blood.V18.4.431.431; GALLAGHER RB, 1991, IMMUNOL TODAY, V12, P1, DOI 10.1016/0167-5699(91)90102-Y; GAYNON PS, 1988, LANCET, V2, P921; GOLDIE JH, 1984, CANCER RES, V44, P3643; GREAVES MF, 1988, LEUKEMIA, V2, P120; HANN IM, 1990, BRIT J HAEMATOL, V76, P359, DOI 10.1111/j.1365-2141.1990.tb06368.x; HOROWITZ MM, 1990, BLOOD, V75, P555; JERMY A, 1987, EUR J CANCER CLIN ON, V23, P1365, DOI 10.1016/0277-5379(87)90121-0; KOIZUMI S, 1988, CANCER, V61, P1292, DOI 10.1002/1097-0142(19880401)61:7<1292::AID-CNCR2820610703>3.0.CO;2-O; KOREN G, 1990, NEW ENGL J MED, V323, P17, DOI 10.1056/NEJM199007053230104; LAYWARD L, 1981, BRIT J HAEMATOL, V49, P251, DOI 10.1111/j.1365-2141.1981.tb07221.x; LENNARD L, 1990, LANCET, V336, P225, DOI 10.1016/0140-6736(90)91745-V; LONSDALE D, 1975, CANCER, V36, P341, DOI 10.1002/1097-0142(197508)36:2<341::AID-CNCR2820360208>3.0.CO;2-3; MAUER AM, 1980, BLOOD, V56, P1; MOKYR MB, 1987, CANCER INVEST, V5, P31, DOI 10.3109/07357908709020304; Osmond D G, 1990, Semin Immunol, V2, P173; PATTE C, 1986, J CLIN ONCOL, V4, P1219, DOI 10.1200/JCO.1986.4.8.1219; PETO J, 1986, LANCET, V1, P408; PIETERS R, 1991, LANCET, V338, P399, DOI 10.1016/0140-6736(91)91029-T; PINKEL D, 1987, CANCER, V59, P1683, DOI 10.1002/1097-0142(19870515)59:10<1683::AID-CNCR2820591002>3.0.CO;2-G; PINKEL D, 1971, CANCER-AM CANCER SOC, V27, P247, DOI 10.1002/1097-0142(197102)27:2<247::AID-CNCR2820270202>3.0.CO;2-C; POCHEDLY C, 1990, HEMATOL ONCOL CLIN N, V4, P871; RAPSON NT, 1980, BRIT J HAEMATOL, V45, P41, DOI 10.1111/j.1365-2141.1980.tb03809.x; Riehm H, 1987, Haematol Blood Transfus, V30, P139; RIVERA GK, 1991, LANCET, V337, P61, DOI 10.1016/0140-6736(91)90733-6; SCHIMKE RT, 1978, SCIENCE, V202, P1051, DOI 10.1126/science.715457; STRYCKMANS PA, 1983, BLOOD, V62, P606; TERRY WD, 1982, IMMUNOTHERAPY HUMAN; TONEGAWA S, 1983, NATURE, V302, P575, DOI 10.1038/302575a0; WHITEHEAD VM, 1990, BLOOD, V76, P44; YAMADA M, 1990, NEW ENGL J MED, V323, P448, DOI 10.1056/NEJM199008163230705	36	58	59	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 23	1991	338	8778					1315	1318		10.1016/0140-6736(91)92604-Z	http://dx.doi.org/10.1016/0140-6736(91)92604-Z			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GR023	1682696				2023-01-03	WOS:A1991GR02300015
J	ODONNELL, M				ODONNELL, M			BATTLE OF THE CLOTBUSTERS	BRITISH MEDICAL JOURNAL			English	Article																			0	19	19	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 25	1991	302	6787					1259	1261		10.1136/bmj.302.6787.1259	http://dx.doi.org/10.1136/bmj.302.6787.1259			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FP272	1904288	Bronze, Green Published			2023-01-03	WOS:A1991FP27200030
J	PHILP, I; MAWHINNEY, S; MUTCH, WJ				PHILP, I; MAWHINNEY, S; MUTCH, WJ			SETTING STANDARDS FOR LONG-TERM CARE OF THE ELDERLY IN HOSPITAL	BRITISH MEDICAL JOURNAL			English	Article									UNIV DUNDEE,NINEWELLS HOSP & MED SCH,GERIATR MED,DUNDEE DD1 9SY,SCOTLAND	University of Dundee				philp, ian/0000-0002-3972-6496				DENHAM M, 1989, CARE ELDERLY, V1, P855; DONALDSON C, 1988, AGE AGEING, V17, P379, DOI 10.1093/ageing/17.6.379; Kane RA, 1987, LONG TERM CARE PRINC; PHILP I, IN PRESS INT J GERIA; WILSON L A, 1973, Age and Ageing, V2, P92, DOI 10.1093/ageing/2.2.92	5	3	3	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 4	1991	302	6784					1056	1056		10.1136/bmj.302.6784.1056	http://dx.doi.org/10.1136/bmj.302.6784.1056			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FK563	1903665	Green Published, Bronze			2023-01-03	WOS:A1991FK56300023
J	HIBBS, J; PERPER, J; WINEK, CL				HIBBS, J; PERPER, J; WINEK, CL			AN OUTBREAK OF DESIGNER DRUG RELATED DEATHS IN PENNSYLVANIA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note								3-Methylfentanyl ("China White") is a "designer" opiate that has caused more than 100 overdose deaths in California since 1979, but that has not been associated previously with deaths east of the Rocky Mountains. During 1988, 3-methylfentanyl was identified in 16 fatal overdose cases in Allegheny County, Pennsylvania, contributing to a fourfold rise in overdose mortality during October of that year. Morphine was detected in the blood of five persons (31%) and cocaine in the blood of three persons (19%) dying of 3-methylfentanyl overdoses; these were demographically similar to 99 other fatal overdose cases investigated by the county coroner from 1986 through 1988. This documents the contribution of 3-methylfentanyl to overdose mortality in an eastern city and the use of 3-methylfentanyl with other illegal drugs. Drug abusers in the northeastern United States should be considered at risk for more "designer drug" overdose outbreaks in the future.	CTR DIS CONTROL, DIV FIELD SERV, EPIDEMIOL PROGRAM OFF, ATLANTA, GA 30333 USA; ALLEGHENY CTY CORONERS OFF, PITTSBURGH, PA USA; ALLEGHENY CTY DEPT LABS, PITTSBURGH, PA USA	Centers for Disease Control & Prevention - USA								AYRES WA, 1981, J PSYCHOACTIVE DRUGS, V13, P91, DOI 10.1080/02791072.1981.10471455; FROEDE RC, 1980, MICROSCOPIC DIAGNOSI, P149; GILLESPIE TJ, 1982, J ANAL TOXICOL, V6, P139, DOI 10.1093/jat/6.3.139; HENDERSON GL, 1988, J FORENSIC SCI, V33, P569; HESS R, 1972, EUR J CLIN PHARMACOL, V4, P137, DOI 10.1007/BF00561135; Janssen P.A., 1985, OPIOIDS ANESTHESIA, P37; LABARBERA M, 1983, J PSYCHOACTIVE DRUGS, V15, P293, DOI 10.1080/02791072.1983.10471966; MARTIN ML, 1989, ANN EMERG MED, V18, P446; MURPHY MR, 1979, ANESTHESIOLOGY, V50, P13, DOI 10.1097/00000542-197901000-00004; RUTTENBER AJ, 1984, SCIENCE, V226, P14, DOI 10.1126/science.6474188; VANBEVER WF, 1974, J MED CHEM, V17, P1047, DOI 10.1021/jm00256a003	11	51	51	1	7	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 27	1991	265	8					1011	1013		10.1001/jama.265.8.1011	http://dx.doi.org/10.1001/jama.265.8.1011			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	EY432	1867667				2023-01-03	WOS:A1991EY43200031
J	TRUJILLO, KA; AKIL, H				TRUJILLO, KA; AKIL, H			INHIBITION OF MORPHINE-TOLERANCE AND DEPENDENCE BY THE NMDA RECEPTOR ANTAGONIST MK-801	SCIENCE			English	Article							ANALGESIC TOLERANCE; LOCUS COERULEUS; MECHANISMS; NEURONS; RATS	The N-methyl-D-aspartate (NMDA) subtype of the glutamate receptor is an important mediator of several forms of neural and behavioral plasticity. The present studies examined whether NMDA receptors might be involved in the development of opiate tolerance and dependence, two examples of behavioral plasticity. The noncompetitive NMDA receptor antagonist MK-801 attenuated the development of tolerance to the analgesic effect of morphine without affecting acute morphine analgesia. In addition, MK-801 attenuated the development of morphine dependence as assessed by nalox-one-precipitated withdrawal. These results suggest that NMDA receptors may be important in the development of opiate tolerance and dependence.			TRUJILLO, KA (corresponding author), UNIV MICHIGAN, MENTAL HLTH RES INST, 205 WASHTENAW PL, ANN ARBOR, MI 48109 USA.		Trujillo, Keith/E-8427-2012	Trujillo, Keith/0000-0002-8059-6347	NATIONAL INSTITUTE ON DRUG ABUSE [R01DA002265, F32DA005336] Funding Source: NIH RePORTER; NIDA NIH HHS [DA05336, DA02265] Funding Source: Medline; NIMH NIH HHS [MH422251] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		AGHAJANIAN GK, 1978, NATURE, V276, P186, DOI 10.1038/276186a0; ANDRADE R, 1983, EUR J PHARMACOL, V91, P161, DOI 10.1016/0014-2999(83)90461-2; BAKER TB, 1985, PSYCHOL REV, V92, P78, DOI 10.1037/0033-295X.92.1.78; BLASIG J, 1973, PSYCHOPHARMACOLOGIA, V33, P19; BUCHAN A, 1990, J NEUROSCI, V10, P311; Christie M J, 1987, NIDA Res Monogr, V78, P158; CHRISTIE MJ, 1987, MOL PHARMACOL, V32, P633; CLOUET DH, 1975, ANNU REV PHARMACOL, V15, P49, DOI 10.1146/annurev.pa.15.040175.000405; COLLIER HOJ, 1980, NATURE, V283, P625, DOI 10.1038/283625a0; COLLINGRIDGE GL, 1989, PHARMACOL REV, V41, P143; COTMAN CW, 1987, TRENDS NEUROSCI, V10, P263, DOI 10.1016/0166-2236(87)90170-6; CRISWELL HE, 1990, BRAIN RES, V512, P284, DOI 10.1016/0006-8993(90)90638-R; D'amour FE, 1941, J PHARMACOL EXP THER, V72, P74; DAFTERS R, 1989, BEHAV NEUROSCI, V103, P1082, DOI 10.1037/0735-7044.103.5.1082; FRANCIS DL, 1971, BRIT J PHARMACOL, V41, pP424; Goudie A. J., 1986, BEHAVIORAL BASIS DRU, P225; HARRIS LS, 1964, J PHARMACOL EXP THER, V143, P141; JOHNSON SM, 1989, PHARMACOL REV, V41, P435; KARLER R, 1989, LIFE SCI, V45, P599, DOI 10.1016/0024-3205(89)90045-3; LEWIS JW, 1987, BRAIN RES, V424, P65, DOI 10.1016/0006-8993(87)91193-0; NEHLS DG, 1990, BRAIN RES, V511, P271, DOI 10.1016/0006-8993(90)90172-8; NORTH RA, 1987, P NATL ACAD SCI USA, V84, P5487, DOI 10.1073/pnas.84.15.5487; RASMUSSEN K, 1989, BRAIN RES, V505, P346, DOI 10.1016/0006-8993(89)91466-2; RAY BA, 1988, NIDA RES MONOGR, V84; SHARP CW, 1984, NIDA RES MONOGR, V54; SIEGEL S, 1976, SCIENCE, V193, P323, DOI 10.1126/science.935870; Siegel S., 1983, RES ADV ALCOHOL DRUG, V1st, P207; TIFFANY ST, 1988, BEHAV NEUROSCI, V102, P534, DOI 10.1037/0735-7044.102.4.534; TUNG CS, 1990, ACTA PHYSIOL SCAND, V138, P581, DOI 10.1111/j.1748-1716.1990.tb08888.x; WATKINS JC, 1989, NMDA RECEPTOR; WEI E, 1973, PSYCHOPHARMACOLOGIA, V28, P35, DOI 10.1007/BF00413955; WIKLER A, 1973, ARCH GEN PSYCHIAT, V28, P611; WIKLER A, 1948, AM J PSYCHIAT, V105, P329, DOI 10.1176/ajp.105.5.329; WIKLER A, 1976, PAVLOVIAN J BIOL SCI, V11, P191	34	1066	1114	1	50	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 4	1991	251	4989					85	87		10.1126/science.1824728	http://dx.doi.org/10.1126/science.1824728			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EQ603	1824728				2023-01-03	WOS:A1991EQ60300033
J	WHITE, HD				WHITE, HD			GISSI-2 AND THE HEPARIN CONTROVERSY	LANCET			English	Editorial Material											WHITE, HD (corresponding author), GREEN LANE HOSP, AUCKLAND 3, NEW ZEALAND.							[Anonymous], 1990, LANCET, V335, P759; [Anonymous], 1988, LANCET, V2, P349; [Anonymous], 1990, Lancet, V336, P65; BLEICH SD, 1989, CIRCULATION S2, V80, P13; CHESEBRO JH, 1990, AM J CARDIOL, V65, pC12, DOI 10.1016/0002-9149(90)90109-E; CHESEBRO JH, 1987, CIRCULATION, V76, P142, DOI 10.1161/01.CIR.76.1.142; EISENBERG PR, 1987, J AM COLL CARDIOL, V10, P527, DOI 10.1016/S0735-1097(87)80194-8; FITZGERALD DJ, 1988, CIRCULATION, V77, P142, DOI 10.1161/01.CIR.77.1.142; FOX KAA, 1985, ANNU REV MED, V36, P125; GARABEDIAN HD, 1988, J AM COLL CARDIOL, V11, P729, DOI 10.1016/0735-1097(88)90204-5; GREENBAUM RA, 1987, CARDIOVASC RES, V21, P878, DOI 10.1093/cvr/21.12.878; HACKETT D, 1987, NEW ENGL J MED, V317, P1055, DOI 10.1056/NEJM198710223171704; KWON K, 1990, Journal of the American College of Cardiology, V15, p217A; MACMAHON S, 1988, CIRCULATION S2, V78, P389; MEYER J, 1989, LANCET, V1, P863; OWEN J, 1988, BLOOD, V72, P616; RAO AK, 1988, J AM COLL CARDIOL, V11, P1; RAPOLD HJ, 1989, CIRCULATION, V79, P980, DOI 10.1161/01.CIR.79.5.980; RASKOB G, 1986, CLIN INVEST MED, V9, pB30; ROSS A M, 1990, Journal of the American College of Cardiology, V15, p64A; SEITZ R, 1988, THROMB HAEMOSTASIS, V59, P541; TAVAZZI L, 1989, LANCET, V2, P182; TOPOL EJ, 1989, CIRCULATION, V79, P281, DOI 10.1161/01.CIR.79.2.281; TOPOL EJ, 1990, TXB INTERVENTIONAL C, P79; TURPIE AGG, 1989, NEW ENGL J MED, V320, P352, DOI 10.1056/NEJM198902093200604; VANDEWERF F, 1990, LANCET, V336, P71; VERSTRAETE M, 1985, LANCET, V1, P842, DOI 10.1016/S0140-6736(85)92208-1; WHITE HD, 1989, NEW ENGL J MED, V320, P817, DOI 10.1056/NEJM198903303201301	28	42	42	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 4	1990	336	8710					297	298		10.1016/0140-6736(90)91818-U	http://dx.doi.org/10.1016/0140-6736(90)91818-U			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DT007	1973983				2023-01-03	WOS:A1990DT00700016
J	GORDON, LI; HARRINGTON, D; ANDERSEN, J; COLGAN, J; GLICK, J; NEIMAN, R; MANN, R; RESNICK, GD; BARCOS, M; GOTTLIEB, A; OCONNELL, M				GORDON, LI; HARRINGTON, D; ANDERSEN, J; COLGAN, J; GLICK, J; NEIMAN, R; MANN, R; RESNICK, GD; BARCOS, M; GOTTLIEB, A; OCONNELL, M			COMPARISON OF A 2ND-GENERATION COMBINATION CHEMOTHERAPEUTIC REGIMEN (M-BACOD) WITH A STANDARD REGIMEN (CHOP) FOR ADVANCED DIFFUSE NON-HODGKINS-LYMPHOMA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LARGE-CELL LYMPHOMA; DOSE INTENSITY; HISTIOCYTIC LYMPHOMA; INTERMEDIATE-GRADE; RANDOMIZED TRIAL; ONCOLOGY-GROUP; METHOTREXATE; SUPERIORITY; LEUCOVORIN; SURVIVAL	Background. In 1984, the Eastern Cooperative Oncology Group began a randomized controlled clinical trial of patients with advanced (stage III or IV) diffuse mixed or diffuse large-cell lymphoma to determine whether complete-remission rates, survival, and toxicity differed when patients were treated with a chemotherapeutic regimen containing cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP), as compared with a regimen containing bleomycin, doxorubicin, cyclophosphamide, vincristine, dexamethasone, methotrexate, and leucovorin (m-BACOD). Methods. From July 1984 through January 1988, 392 patients were enrolled, 325 of whom (83 percent) were eligible for the analysis and capable of being evaluated. The extent of disease was defined according to standard staging techniques, including bilateral bone-core biopsies in 88 percent of patients. Randomization was stratified according to age (<60 or greater-than-or-equal-to 60 years), performance status (0, 1, or other), stage (III or IV), and histologic presentation (diffuse mixed or diffuse large-cell lymphoma). Results. After a median follow-up of four years, there were no significant differences in rates of complete remission, time to treatment failure, disease-free survival, or overall survival in the patients treated with CHOP as compared with those treated with m-BACOD. However, there was more severe and life-threatening pulmonary, infectious, and hematologic toxicity associated with the m-BACOD regimen. In an attempt to measure the importance of dose intensity in the 325 patients who could be analyzed, we retrospectively calculated dose intensity (measured in milligrams per square meter of body-surface area per week) and normalized dose intensity (defined as a percentage of the prescribed dose) for all drugs. The median normalized dose intensity for both cyclophosphamide and doxorubicin was found to be greater in the patients treated with CHOP than in those treated with m-BACOD. Conclusions. For patients with stage III or IV diffuse mixed or diffuse large-cell lymphoma, CHOP is superior to m-BACOD, but the role of dose intensity is not yet clear.	ROBERT F LURIE CANC CTR, CHICAGO, IL USA; HARVARD UNIV, SCH MED, DANA FARBER CANC INST, BOSTON, MA 02115 USA; MAYO CLIN & MAYO FDN, ROCHESTER, MN 55905 USA; INDIANA UNIV, MED CTR, INDIANAPOLIS, IN 46204 USA; NEW YORK STATE DEPT HLTH, ROSWELL PK MEM INST, BUFFALO, NY 14263 USA; UNIV PENN, CTR CANC, PHILADELPHIA, PA 19104 USA; JOHNS HOPKINS UNIV HOSP, CTR ONCOL, BALTIMORE, MD 21205 USA; CORNELL UNIV, MED CTR, NEW YORK HOSP, NEW YORK, NY 10021 USA; SUNY HOSP SYRACUSE, UPSTATE MED CTR, SYRACUSE, NY USA	Robert H. Lurie Comprehensive Cancer Center; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Mayo Clinic; Indiana University System; Indiana University-Purdue University Indianapolis; Roswell Park Cancer Institute; University of Pennsylvania; Johns Hopkins University; Johns Hopkins Medicine; Cornell University; NewYork-Presbyterian Hospital; State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center	GORDON, LI (corresponding author), NORTHWESTERN UNIV, SCH MED, DEPT MED, DIV HEMATOL ONCOL, 303 E CHICAGO AVE, CHICAGO, IL 60611 USA.			Gordon, Leo/0000-0003-1666-7064	NCI NIH HHS [CA 13650, CA 23318, CA 17145] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U10CA013650, U10CA023318, U10CA017145] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOYD DB, 1988, J CLIN ONCOL, V6, P425, DOI 10.1200/JCO.1988.6.3.425; CARDE P, 1991, ANN ONCOL, V2, P431, DOI 10.1093/oxfordjournals.annonc.a057979; Coltman CA, 1986, ADV CHEMOTHERAPY UPD, P71; Cox DR., 1989, ANAL BINARY DATA, V2nd; DANA BW, 1990, J CLIN ONCOL, V8, P1155, DOI 10.1200/JCO.1990.8.7.1155; DEVITA VT, 1975, LANCET, V1, P248; DEVITA VT, 1987, CANCER RES, V47, P5810; DEVITA VT, 1989, CANCER PRINCIPLES PR, V2, P1741; FISHER RI, 1983, ANN INTERN MED, V98, P304, DOI 10.7326/0003-4819-98-3-304; FREI E, 1980, AM J MED, V69, P585, DOI 10.1016/0002-9343(80)90472-6; GAYNOR ER, 1985, J CLIN ONCOL, V3, P1596, DOI 10.1200/JCO.1985.3.12.1596; GREEN JA, 1980, BRIT J CLIN PHARMACO, V9, P511, DOI 10.1111/j.1365-2125.1980.tb05847.x; HRYNIUK W, 1984, J CLIN ONCOL, V2, P1281, DOI 10.1200/JCO.1984.2.11.1281; HRYNIUK WM, 1990, J CLIN ONCOL, V8, P1935, DOI 10.1200/JCO.1990.8.12.1935; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KLIMO P, 1985, ANN INTERN MED, V102, P596, DOI 10.7326/0003-4819-102-5-596; KWAK LW, 1990, J CLIN ONCOL, V8, P963, DOI 10.1200/JCO.1990.8.6.963; LONGO, 1991, J CLIN ONCOL, V9, P710, DOI 10.1200/JCO.1991.9.4.710; LONGO DL, 1991, J CLIN ONCOL, V9, P25, DOI 10.1200/JCO.1991.9.1.25; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; MEHTA CR, 1984, BIOMETRICS, V40, P819, DOI 10.2307/2530927; MEYER RM, 1991, J CLIN ONCOL, V9, P339, DOI 10.1200/JCO.1991.9.2.339; OKEN MM, 1982, AM J CLIN ONCOL-CANC, V5, P649, DOI 10.1097/00000421-198212000-00014; ROSENBERG SA, 1982, CANCER, V49, P2112; SHIPP MA, 1986, ANN INTERN MED, V104, P757, DOI 10.7326/0003-4819-104-6-757; SHIPP MA, 1990, J CLIN ONCOL, V8, P84, DOI 10.1200/JCO.1990.8.1.84; SKARIN AT, 1983, J CLIN ONCOL, V1, P91, DOI 10.1200/JCO.1983.1.2.91; SKARIN AT, 1986, ADV CANCER CHEMOTHER, P23; Skipper H E, 1990, Important Adv Oncol, P43; SWEET DL, 1980, ANN INTERN MED, V92, P785, DOI 10.7326/0003-4819-92-6-785; 1966, TUMORS HEMATOPOIETIC, P91	31	292	304	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 5	1992	327	19					1342	1349		10.1056/NEJM199211053271903	http://dx.doi.org/10.1056/NEJM199211053271903			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JW077	1383819				2023-01-03	WOS:A1992JW07700003
J	CHAO, FF; BLANCHETTEMACKIE, EJ; TERTOV, VV; SKARLATOS, SI; CHEN, YJ; KRUTH, HS				CHAO, FF; BLANCHETTEMACKIE, EJ; TERTOV, VV; SKARLATOS, SI; CHEN, YJ; KRUTH, HS			HYDROLYSIS OF CHOLESTERYL ESTER IN LOW-DENSITY-LIPOPROTEIN CONVERTS THIS LIPOPROTEIN TO A LIPOSOME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ATHEROSCLEROTIC LESIONS; RICH LIPID PARTICLES; HUMAN AORTIC INTIMA; UNESTERIFIED CHOLESTEROL; DIFFERENT MECHANISMS; PLASMA-LIPOPROTEINS; CA++ ANTAGONISTS; PURIFICATION; HYDROLASE; LOCALIZATION	Previously, we isolated and characterized unique liposomal-like, cholesterol-rich lipid particles that accumulate in human atherosclerotic lesions. Human plasma low density lipoprotein (LDL) has a molar ratio of total cholesterol to phospholipid (3:1) similar to that of this lesion cholesterol-rich lipid particle. However, LDL is enriched in cholesteryl ester while the lesion lipid particle is enriched in unesterified cholesterol. To examine a possible precursor-product relationship between LDL and the lesion lipid particle, we hydrolyzed the cholesteryl ester core of LDL with cholesterol esterase. Cholesteryl ester hydrolysis occurred only after LDL was treated with trypsin. Trypsin pretreatment was not required for cholesteryl ester hydrolysis of LDL oxidized with copper, a treatment that also degrades apolipoprotein B, the major protein moiety in LDL. In contrast to greater than 90% hydrolysis of cholesteryl ester in trypsin-cholesterol esterase-treated or copper-oxidized LDL, there was only 18% hydrolysis of cholesteryl ester in similarly treated high density lipoprotein. With a limited 10-min hydrolysis of LDL cholesteryl ester, LDL-sized particles and newly formed larger flattened films or discs were present. With complete hydrolysis of LDL cholesteryl ester, LDL particles converted to complex multilamellar, liposomal-like, structures with sizes approximately five times larger than native LDL. These liposomal-like particles derived from LDL were chemically and structurally similar to unesterified cholesterol-rich lipid particles that accumulate in atherosclerotic lesions.	NHLBI,MOLEC DIS BRANCH,EXPTL ATHEROSCLEROSIS SECT,BLDG 10,RM 5N-113,BETHESDA,MD 20892; NIADDKD,CELLULAR & DEV BIOL LAB,BETHESDA,MD 20892; USSR CARDIOL RES CTR,INST EXPTL CARDIOL,MOSCOW,USSR	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Medical Research Center of Cardiology								ALAUPOVIC P, 1980, HDB ELECTROPHORESIS, V1, P27; BARTLETT GR, 1959, J BIOL CHEM, V234, P466; BOTCHER CJF, 1962, FED P S11, V21, P15; BUCK RC, 1951, AMA ARCH PATHOL, V51, P224; CARDIN AD, 1986, BIOCHEMISTRY-US, V25, P5258, DOI 10.1021/bi00366a041; CHAO FF, 1988, AM J PATHOL, V131, P73; CHAO FF, 1990, AM J PATHOL, V136, P169; CHAPMAN MJ, 1978, EUR J BIOCHEM, V87, P475, DOI 10.1111/j.1432-1033.1978.tb12398.x; Fiske CH, 1925, J BIOL CHEM, V66, P375; FOLCH J, 1957, J BIOL CHEM, V226, P497; FONG LG, 1987, J LIPID RES, V28, P1466; Fredrickson DS, 1972, METABOLIC BASIS INHE, P493; GAMBLE W, 1978, J LIPID RES, V19, P1068; GUYTON JR, 1989, AM J PATHOL, V134, P705; HATCH FT, 1968, PRACTICAL METHODS PL, P47; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; Helwig J.T., 1979, SAS USERS GUIDE; HOFF HF, 1974, BIOCHIM BIOPHYS ACTA, V351, P407, DOI 10.1016/0005-2795(74)90205-0; HOFF HF, 1982, ATHEROSCLEROSIS, V42, P273, DOI 10.1016/0021-9150(82)90157-5; INSULL W, 1966, J CLIN INVEST, V45, P513, DOI 10.1172/JCI105365; JURGENS G, 1987, CHEM PHYS LIPIDS, V45, P315, DOI 10.1016/0009-3084(87)90070-3; KATZ SS, 1980, J BIOL CHEM, V255, P9753; KHOO JC, 1979, J BIOL CHEM, V254, P1785; KOTHARI HV, 1975, LIPIDS, V10, P322, DOI 10.1007/BF02532453; KOTHARI HV, 1970, BIOCHIM BIOPHYS ACTA, V202, P325, DOI 10.1016/0005-2760(70)90194-3; KOTHARI HV, 1973, BIOCHIM BIOPHYS ACTA, V296, P446, DOI 10.1016/0005-2760(73)90102-1; KRUTH HS, 1984, AM J PATHOL, V114, P201; KRUTH HS, 1985, ATHEROSCLEROSIS, V57, P337, DOI 10.1016/0021-9150(85)90045-0; KRUTH HS, 1983, LAB INVEST, V50, P87; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; NOBLE RP, 1968, J LIPID RES, V9, P693; REDGRAVE TG, 1975, ANAL BIOCHEM, V65, P42, DOI 10.1016/0003-2697(75)90488-1; ROBENEK H, 1988, ARTERIOSCLEROSIS, V8, P57, DOI 10.1161/01.ATV.8.1.57; RUDEL LL, 1986, J LIPID RES, V27, P465; SAKURADA T, 1976, BIOCHIM BIOPHYS ACTA, V424, P204; SCHMITZ G, 1988, ARTERIOSCLEROSIS, V8, P46, DOI 10.1161/01.ATV.8.1.46; SIMIONESCU N, 1986, AM J PATHOL, V123, P109; SMITH EB, 1972, LANCET, V1, P463; SMITH EB, 1970, ATHEROSCLEROSIS, V11, P417, DOI 10.1016/0021-9150(70)90021-3; STEINBRECHER UP, 1984, P NATL ACAD SCI-BIOL, V81, P3883, DOI 10.1073/pnas.81.12.3883; WOLF AV, 1979, HDB CHEM PHYSICS, P227; 1984, JAMA-J AM MED ASSOC, V251, P365	43	55	56	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1992	267	7					4992	4998						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HF642	1537875				2023-01-03	WOS:A1992HF64200104
J	MARTELL, JV; SEITZ, RS; HARADA, JK; KOBAYASHI, J; SASAKI, VK; WONG, C				MARTELL, JV; SEITZ, RS; HARADA, JK; KOBAYASHI, J; SASAKI, VK; WONG, C			HOSPITALIZATION IN AN URBAN HOMELESS POPULATION - THE HONOLULU URBAN HOMELESS PROJECT	ANNALS OF INTERNAL MEDICINE			English	Article						HOMELESS PERSONS; HOSPITALIZATION; HOSPITALS, PSYCHIATRIC; COSTS AND COST ANALYSIS; SUBSTANCE ABUSE	MENTAL-HEALTH	Objective: To determine the rate and estimate the cost of hospitalization in a defined urban homeless population. Design: Retrospective chart review. Setting: Kalihi-Palama Health Clinic Health Care for the Homeless Project, Hawaii State Hospital, and seven acute care hospitals in Honolulu, Hawaii. Patients: A total of 1751 homeless clients contacted between 1 December 1988 and 30 November 1990. Measurements and Main Results: A total of 1751 individuals were studied for an aggregate of 871.3 person-years. Five hundred sixty-four hospitalizations were identified: ninety-two to the state psychiatric hospital and 472 to acute care hospitals. The age- and sex-adjusted hospitalization rate for acute care hospitals was 542/1000 person-years (compared with the state rate of 96/1000 person-years). Homeless persons were admitted to acute care hospitals for 4766 days compared with a predicted 640 days. The age- and sex-adjusted rate of admission to the state psychiatric hospital was 105/1000 person-years (compared with the state rate of 0.8/1000 person-years). Homeless persons were admitted to the state psychiatric hospital for 3837 days compared with a predicted 139 days. Conclusions: Homeless individuals in this study were hospitalized in acute care and psychiatric hospitals far more frequently than were members of the general population.	UNIV HAWAII, JOHN A BURNS SCH MED, OFF STUDENT AFFAIRS, HONOLULU, HI 96822 USA	University of Hawaii System								BAHR HM, 1971, PUBLIC OPIN QUART, V35, P374, DOI 10.1086/267922; BASSUK EL, 1984, SCI AM, V251, P40, DOI 10.1038/scientificamerican0784-40; BORLAND A, 1989, HOSP COMMUNITY PSYCH, V40, P369; Bowdler J E, 1989, Nurse Pract, V14, P50; BOWDLER JE, 1989, NURSE PRACTITIONER, V14, P47; BOWDLER JE, 1989, NURSE PRACT, V14, P50; BREAKEY WR, 1989, JAMA-J AM MED ASSOC, V262, P1352, DOI 10.1001/jama.262.10.1352; BRICKNER PW, 1972, ANN INTERN MED, V77, P565, DOI 10.7326/0003-4819-77-4-565; BRICKNER PW, 1986, ANN INTERN MED, V104, P405, DOI 10.7326/0003-4819-104-3-405; CHRIST WR, 1989, SOC WORK HEALTH CARE, V14, P33, DOI 10.1300/J010v14n01_03; COHEN CI, 1988, J GERONTOL, V43, pS121, DOI 10.1093/geronj/43.4.S121; FISCHER PJ, 1986, AM J PUBLIC HEALTH, V76, P519, DOI 10.2105/AJPH.76.5.519; GELBERG L, 1989, JAMA-J AM MED ASSOC, V262, P1973, DOI 10.1001/jama.262.14.1973; LAMB HR, 1986, JAMA-J AM MED ASSOC, V256, P498, DOI 10.1001/jama.256.4.498; MARWICK C, 1985, JAMA-J AM MED ASSOC, V253, P1232, DOI 10.1001/jama.253.9.1232; MARWICK C, 1985, JAMA-J AM MED ASSOC, V253, P3217, DOI 10.1001/jama.253.22.3217; MORRIS W, 1989, WESTERN J MED, V151, P472; ROBERTSON MJ, 1986, AM J PUBLIC HEALTH, V76, P561, DOI 10.2105/AJPH.76.5.561; ROPERS RH, 1987, SOC SCI MED, V24, P669, DOI 10.1016/0277-9536(87)90310-8; ROSSI PH, 1987, SCIENCE, V235, P1336, DOI 10.1126/science.2950592; TORREY EF, 1990, HOSP COMMUNITY PSYCH, V41, P526; WLODARCZYK D, 1988, WESTERN J MED, V148, P717; 1990, DHHS901232 US DEP HL, P184; 1990, HOSPITAL STATISTICS, P62; 1990, STATE HAWAII DATA BO, P37	25	65	65	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 15	1992	116	4					299	303		10.7326/0003-4819-116-4-299	http://dx.doi.org/10.7326/0003-4819-116-4-299			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HD546	1733384				2023-01-03	WOS:A1992HD54600005
J	MAKIN, AJ; CARTWRIGHT, KAV; BANKS, RA				MAKIN, AJ; CARTWRIGHT, KAV; BANKS, RA			KEEPING THE CAT OUT OF THE BAG - A HAZARD IN CONTINUOUS AMBULATORY PERITONEAL-DIALYSIS	BRITISH MEDICAL JOURNAL			English	Article									GLOUCESTER ROYAL HOSP,GLOUCESTER GL1 3NN,ENGLAND									DADONE C, 1985, PERITON DIALYSIS B, V5, P138; DAMANI NN, 1987, NEPHRON, V45, P160, DOI 10.1159/000184102; DENT VE, 1982, J APPL BACTERIOL, V52, P21, DOI 10.1111/j.1365-2672.1982.tb04368.x; FANNELLI C, 1990, PERITONEAL DIALYSIS, V10, P247; HEATON A, 1986, BRIT MED J, V293, P938, DOI 10.1136/bmj.293.6552.938	5	6	6	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 21	1991	303	6817					1610	1611		10.1136/bmj.303.6817.1610	http://dx.doi.org/10.1136/bmj.303.6817.1610			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GX956	1773192	Green Published, Bronze			2023-01-03	WOS:A1991GX95600025
J	PARKER, RK; HOLTMANN, B; WHITE, PF				PARKER, RK; HOLTMANN, B; WHITE, PF			PATIENT-CONTROLLED ANALGESIA - DOES A CONCURRENT OPIOID INFUSION IMPROVE PAIN MANAGEMENT AFTER SURGERY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							POST-OPERATIVE PAIN; POSTOPERATIVE PAIN; PLASMA-CONCENTRATIONS; BLOOD-CONCENTRATION; MORPHINE; RELIEF; PHARMACOKINETICS; METHADONE; FENTANYL; THERAPY	Objective. - To assess the influence of a continuous (basal) morphine infusion as part of a patient-controlled analgesia (PCA) system on the postoperative analgesic requirement and on recovery parameters following abdominal hysterectomy. Design. - Single-center, randomized, controlled protocol. Setting. - University medical center. Participants. - A total of 230 adult women were randomly assigned to receive no morphine infusion (control group) or a continuous 0.5-, 1.0-, or 2.0-mg/h morphine infusion. Each patient was able to self-administer supplemental intravenous bolus doses of morphine (1 to 2 mg) using a PCA infuser. Main Outcome Measures. - Use of the PCA device, opioid-related side effects, recovery times, and the patients' assessment of pain and sedation on linear visual analog scales were recorded during the 72-hour study period. Follow-up questionnaires were completed by the patients and their health care professionals to assess the overall adequacy of PCA therapy. Results. - Patients who received the 2-mg/h morphine infusions received significantly more opioid medication 9 to 72 hours after their operation than those who received no infusion (control group). The presence of a continuous morphine infusion of 0.5 to 2 mg/h did not significantly decrease the number of patient demands or supplemental bolus doses administered compared with the control group. Overall, 168 (84%) of the 199 patients who completed the 72-hour study were able to achieve adequate analgesia without requiring changes in the PCA regimen or experiencing major side effects. Recovery times and outcome variables were similar in all four groups. Conclusion. - The routine use of a continuous opioid infusion in combination with a standard PCA regimen does not improve pain management compared with PCA alone after abdominal hysterectomy.	WASHINGTON UNIV,SCH MED,DEPT ANESTHESIOL,BOX 8054,660 S EUCLID AVE,ST LOUIS,MO 63110	Washington University (WUSTL)								AUSTIN KL, 1980, PAIN, V8, P47, DOI 10.1016/0304-3959(80)90089-5; AUSTIN KL, 1980, ANESTHESIOLOGY, V53, P460, DOI 10.1097/00000542-198012000-00005; BOND A, 1974, BRIT J MED PSYCHOL, V47, P211, DOI 10.1111/j.2044-8341.1974.tb02285.x; CATLEY DM, 1985, ANESTHESIOLOGY, V63, P20, DOI 10.1097/00000542-198507000-00004; CHRUBASIK J, 1985, ANESTHESIOLOGY, V62, P263, DOI 10.1097/00000542-198503000-00009; CHRUBASIK J, 1988, ANESTHESIOLOGY, V68, P929, DOI 10.1097/00000542-198806000-00016; CHURCH JJ, 1979, BRIT MED J, V1, P977, DOI 10.1136/bmj.1.6169.977; DAHLSTROM B, 1982, CLIN PHARMACOKINET, V7, P266, DOI 10.2165/00003088-198207030-00006; DONOVAN M, 1987, PAIN, V30, P69, DOI 10.1016/0304-3959(87)90084-4; GOUDIE TA, 1985, ANAESTHESIA, V40, P1086, DOI 10.1111/j.1365-2044.1985.tb10607.x; GOURLAY GK, 1984, ANESTHESIOLOGY, V61, P19, DOI 10.1097/00000542-198461010-00005; GOURLAY GK, 1988, ANESTH ANALG, V67, P329; GOURLAY GK, 1986, ANESTHESIOLOGY, V64, P322; GOURLAY GK, 1982, ANESTHESIOLOGY, V57, P458, DOI 10.1097/00000542-198212000-00005; GRAVES DA, 1985, CLIN PHARMACY, V4, P41; HILL HF, 1990, PAIN, V40, P121, DOI 10.1016/0304-3959(90)90062-I; JONES RM, 1985, BRIT J ANAESTH, V57, P259, DOI 10.1093/bja/57.3.259; LEHMANN K A, 1988, Acta Anaesthesiologica Belgica, V39, P11; LEHMANN KA, 1985, SCHMERZ PAIN DOLEUR, V3, P88; LEVINE J, 1984, ANN INTERN MED, V100, P269, DOI 10.7326/0003-4819-100-2-269; LOPER KA, 1990, ANESTH ANALG, V70, P72; MARKS RM, 1973, ANN INTERN MED, V78, P173, DOI 10.7326/0003-4819-78-2-173; MARLOWE S, 1989, PAIN, V37, P97, DOI 10.1016/0304-3959(89)90158-9; MARSHALL H, 1985, BMJ-BRIT MED J, V291, P19, DOI 10.1136/bmj.291.6487.19; Mather L. G., 1983, CLIN ANAESTHESIOL, V1, P17; NIMMO WS, 1985, BRIT J ANAESTH, V57, P250, DOI 10.1093/bja/57.3.250; OWEN H, 1989, ANAESTHESIA, V44, P11, DOI 10.1111/j.1365-2044.1989.tb11088.x; RUTTER PC, 1980, BRIT MED J, V280, P12, DOI 10.1136/bmj.280.6206.12; SINATRA R, 1989, ANESTHESIOLOGY, V71, P502, DOI 10.1097/00000542-198910000-00005; STANSKI DR, 1987, ANAESTH INTENS CARE, V15, P23, DOI 10.1177/0310057X8701500105; STAPLETON JV, 1979, ANAESTH INTENS CARE, V7, P25, DOI 10.1177/0310057X7900700103; TAMSEN A, 1982, CLIN PHARMACOKINET, V7, P252, DOI 10.2165/00003088-198207030-00005; TAMSEN A, 1982, CLIN PHARMACOKINET, V7, P164, DOI 10.2165/00003088-198207020-00005; WHITE PF, 1988, JAMA-J AM MED ASSOC, V259, P243, DOI 10.1001/jama.259.2.243	34	109	112	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 9	1991	266	14					1947	1952		10.1001/jama.266.14.1947	http://dx.doi.org/10.1001/jama.266.14.1947			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GH406	1895471				2023-01-03	WOS:A1991GH40600019
J	VANDERVEN, AJAM; KOOPMANS, PP; VREE, TB; VANDERMEER, JWM				VANDERVEN, AJAM; KOOPMANS, PP; VREE, TB; VANDERMEER, JWM			ADVERSE REACTIONS TO COTRIMOXAZOLE IN HIV-INFECTION	LANCET			English	Note							ACQUIRED-IMMUNODEFICIENCY-SYNDROME; PNEUMOCYSTIS-CARINII PNEUMONIA; TRIMETHOPRIM-SULFAMETHOXAZOLE; CUTANEOUS REACTIONS; PLASMA; METABOLISM; DAPSONE; AIDS	The origin of the increased frequency of side-effects to co-trimoxazole in HIV-positive patients is unknown. Data on plasma concentrations of the parent compounds are inconclusive. Evidence points to the hydroxylamine derivatives of sulphamethoxazole as the reactive metabolites that cause adverse reactions to co-trimoxazole. HIV-positive individuals have a systemic glutathione deficiency, and therefore a reduced capacity to scavenge such metabolites. This process would lead to an increased exposure to toxic intermediates and would explain the high frequency of adverse reactions to co-trimoxazole in these patients.	CATHOLIC UNIV NIJMEGEN,HOSP ST RADMOUD,DEPT CLIN PHARM,6500 HB NIJMEGEN,NETHERLANDS	Radboud University Nijmegen	VANDERVEN, AJAM (corresponding author), CATHOLIC UNIV NIJMEGEN,HOSP ST RADMOUD,DEPT INTERNAL MED,DIV GEN INTERNAL MED,POB 9101,6500 HB NIJMEGEN,NETHERLANDS.		Koopmans, Peter/O-9276-2015; van der Meer, Jos W.M./C-8521-2013; van der Ven, A.J.A.M./H-8102-2014	van der Meer, Jos W.M./0000-0001-5120-3690; van der Ven, A.J.A.M./0000-0003-1833-3391				BOWDEN FJ, 1986, LANCET, V2, P853; BUHL R, 1989, LANCET, V2, P1294; BURGUNDER JM, 1989, EUR J CLIN PHARMACOL, V36, P127, DOI 10.1007/BF00609183; COLEBUNDERS R, 1987, ANN INTERN MED, V107, P599, DOI 10.7326/0003-4819-107-4-599_2; DEHOVITZ JA, 1985, ANN INTERN MED, V103, P479, DOI 10.7326/0003-4819-103-3-479_2; ECK HP, 1989, BIOL CHEM H-S, V370, P101, DOI 10.1515/bchm3.1989.370.1.101; GORDIN FM, 1984, ANN INTERN MED, V100, P495, DOI 10.7326/0003-4819-100-4-495; JAFFE HS, 1983, LANCET, V2, P1109; KOVACS JA, 1984, ANN INTERN MED, V100, P663, DOI 10.7326/0003-4819-100-5-663; LEE BL, 1989, ANN INTERN MED, V110, P606, DOI 10.7326/0003-4819-110-8-606; MEDINA I, 1990, NEW ENGL J MED, V323, P776, DOI 10.1056/NEJM199009203231202; OUTWATER E, 1985, 1ST INT C AIDS ATL; REFSUM H, 1990, TRENDS PHARMACOL SCI, V11, P411, DOI 10.1016/0165-6147(90)90148-2; RIEDER MJ, 1988, J PHARMACOL EXP THER, V244, P724; RIEDER MJ, 1989, ANN INTERN MED, V110, P286, DOI 10.7326/0003-4819-110-4-286; SATTLER FR, 1988, ANN INTERN MED, V109, P280, DOI 10.7326/0003-4819-109-4-280; SHEAR NH, 1985, CAN J PHYSIOL PHARM, V63, P1370, DOI 10.1139/y85-225; SHEAR NH, 1986, ANN INTERN MED, V105, P179, DOI 10.7326/0003-4819-105-2-179; SMALL CB, 1985, ARCH INTERN MED, V145, P837, DOI 10.1001/archinte.145.5.837; 1986, LANCET, V2, P958	20	128	133	1	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 17	1991	338	8764					431	433		10.1016/0140-6736(91)91046-W	http://dx.doi.org/10.1016/0140-6736(91)91046-W			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GB446	1678095	Green Submitted			2023-01-03	WOS:A1991GB44600016
J	ANDERSON, RM; GUPTA, S; MAY, RM				ANDERSON, RM; GUPTA, S; MAY, RM			POTENTIAL OF COMMUNITY-WIDE CHEMOTHERAPY OR IMMUNOTHERAPY TO CONTROL THE SPREAD OF HIV-1	NATURE			English	Article							PLACEBO-CONTROLLED TRIAL; AIDS-RELATED COMPLEX; AZIDOTHYMIDINE AZT; ZIDOVUDINE AZT; DOUBLE-BLIND; INFECTION	WHETHER zidovudine (3'-azido-3'-deoxythymidine, AZT) should be offered to symptomless individuals infected with human immunodeficiency virus type-1 (HIV-1), in the hope of delaying or even preventing progression to AIDS, has been much debated 1. The discussion has focused on the efficacy of the drug in delaying progression to disease 2, the severity of its side-effects 3, and the likelihood of its prolonged and widespread use resulting in zidovudine-resistant strains of the virus 4. Little attention has been given to the degree to which treatment reduces the infectiousness of symptomless patients, and to the concomitant implications for the overall transmission rate of HIV-1 in the community. Here we use simple mathematical models to show that community treatment with antiviral drugs or immunotherapies that lengthen the incubation period of AIDS without significantly reducing the infectiousness of treated individuals, can increase the rate at which HIV-1 infection spreads (which is fairly obvious) and can even, under certain circumstances, increase the AIDS-related death rate in the community (which is less obvious).			ANDERSON, RM (corresponding author), UNIV LONDON IMPERIAL COLL SCI & TECHNOL,DEPT BIOL,LONDON SW7 2BB,ENGLAND.			Anderson, Roy/0000-0002-9528-3175				ANDERSON R M, 1986, IMA Journal of Mathematics Applied in Medicine and Biology, V3, P229; ANDERSON RM, 1988, J ROY STAT SOC A STA, V151, P66, DOI 10.2307/2982185; ANDERSON RM, 1990, J ACQ IMMUN DEF SYND, V3, P417; ANDERSON RM, 1990, LANCET, V335, P641, DOI 10.1016/0140-6736(90)90420-A; CAPON DJ, 1989, NATURE, V337, P325; COOMBS RW, 1989, NEW ENGL J MED, V321, P1626, DOI 10.1056/NEJM198912143212402; FISCHL MA, 1987, NEW ENGL J MED, V317, P185, DOI 10.1056/NEJM198707233170401; HO DD, 1989, NEW ENGL J MED, V321, P1621, DOI 10.1056/NEJM198912143212401; JACKSON GG, 1988, ANN INTERN MED, V108, P175, DOI 10.7326/0003-4819-108-2-175; LARDER BA, 1989, SCIENCE, V243, P1731, DOI 10.1126/science.2467383; LAURIAN Y, 1989, NEW ENGL J MED, V320, P183; MAY RM, 1987, NATURE, V326, P137, DOI 10.1038/326137a0; MCLEAN AR, IN PRESS J MATH BIOL; MOSS AR, 1988, BRIT MED J, V296, P745, DOI 10.1136/bmj.296.6624.745; RATNER L, 1989, AIDS RES HUM RETROV, V5, P115, DOI 10.1089/aid.1989.5.115; RICHMAN DD, 1987, NEW ENGL J MED, V317, P192, DOI 10.1056/NEJM198707233170402; VOLBERDING PA, 1990, NEW ENGL J MED, V322, P941, DOI 10.1056/NEJM199004053221401; 1989, LANCET, V1, P415	18	95	95	0	7	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 28	1991	350	6316					356	359		10.1038/350356a0	http://dx.doi.org/10.1038/350356a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FD838	2008214				2023-01-03	WOS:A1991FD83800098
J	DANIS, M; SOUTHERLAND, LI; GARRETT, JM; SMITH, JL; HIELEMA, F; PICKARD, CG; EGNER, DM; PATRICK, DL				DANIS, M; SOUTHERLAND, LI; GARRETT, JM; SMITH, JL; HIELEMA, F; PICKARD, CG; EGNER, DM; PATRICK, DL			A PROSPECTIVE-STUDY OF ADVANCE DIRECTIVES FOR LIFE-SUSTAINING CARE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article								Background. The use of advance directives is recommended so that people can determine the medical care they will receive when they are no longer competent, but the effectiveness of such directives is not clear. Methods. In a prospective study conducted over a two-year period, 126 competent residents of a nursing home and 49 family members of incompetent patients were interviewed to determine their preferences with respect to hospitalization, intensive care, cardiopulmonary resuscitation, artificial ventilation, surgery, and tube feeding in the event of critical illness, terminal illness, or permanent unconsciousness. Advance directives, consisting of signed statements of treatment preferences, were placed in the medical record to assist in care in the nursing home and to be forwarded to the hospital if necessary. Results. In an analysis of 96 outcome events (hospitalization or death in the nursing home), care was consistent with previously expressed wishes 75 percent of the time; however, the presence of the written advance directive in the medical record did not facilitate consistency. Among the 24 events in which inconsistencies occurred, care was provided more aggressively than had been requested in 6 cases, largely because of unanticipated surgery or artificial ventilation, and less aggressively than requested in 18, largely because hospitalization or cardiopulmonary resuscitation was withheld. Inconsistencies were more likely in the nursing home than in the hospital. Conclusions. The effectiveness of written advance directives is limited by inattention to them and by decisions to place priority on considerations other than the patient's autonomy. Since our study was performed in only one nursing home and one hospital, other studies are necessary to determine the generalizability of our findings.	UNIV N CAROLINA,DEPT EPIDEMIOL,CHAPEL HILL,NC 27514; UNIV WASHINGTON,DEPT HLTH SERV,SEATTLE,WA 98195	University of North Carolina; University of North Carolina Chapel Hill; University of Washington; University of Washington Seattle	DANIS, M (corresponding author), UNIV N CAROLINA,DEPT MED,DIV GEN MED & CLIN EPIDEMIOL,CAMPUS BOX 7110,5025A OLD CLIN BLDG,CHAPEL HILL,NC 27599, USA.		Patrick, Donald/Y-2460-2019	Patrick, Donald/0000-0003-0756-0492				BOK S, 1976, NEW ENGL J MED, V295, P367, DOI 10.1056/NEJM197608122950706; EISENDRATH SJ, 1983, JAMA-J AM MED ASSOC, V249, P2054, DOI 10.1001/jama.249.15.2054; EMANUEL LL, 1989, JAMA-J AM MED ASSOC, V261, P3288, DOI 10.1001/jama.261.22.3288; HACKLER C, 1989, ADV DIRECTIVES MED S; JONSEN AR, 1982, CLIN ETHICS; KUTNER L, 1969, INDIANA LAW J, V44, P537; MURPHY DJ, 1989, ANN INTERN MED, V111, P199, DOI 10.7326/0003-4819-111-3-199; President's Commission for the Study of Ethical Problems in Medicine and Biomedical and Behavioral Research, 1983, DECIDING FOREGO LIFE; REDLEAF DL, 1979, STANFORD LAW REV, V31, P913, DOI 10.2307/1228530; 1982, SUDOC198203835158763; 1987, GUIDELINES TERMINATI; 1983, AM J PUBLIC HEALTH, V73, P918	12	387	389	0	8	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 28	1991	324	13					882	888		10.1056/NEJM199103283241304	http://dx.doi.org/10.1056/NEJM199103283241304			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FD111	2000110				2023-01-03	WOS:A1991FD11100004
J	BIGRIGG, MA; CODLING, BW; PEARSON, P; READ, MD; SWINGLER, GR				BIGRIGG, MA; CODLING, BW; PEARSON, P; READ, MD; SWINGLER, GR			COLPOSCOPIC DIAGNOSIS AND TREATMENT OF CERVICAL DYSPLASIA AT A SINGLE CLINIC VISIT - EXPERIENCE OF LOW-VOLTAGE DIATHERMY LOOP IN 1000 PATIENTS	LANCET			English	Article									GLOUCESTERSHIRE ROYAL HOSP,GLOUCESTER GL1 3NN,ENGLAND	Gloucestershire Royal Hospital								BAGGISH MS, 1989, AM J OBSTET GYNECOL, V162, P60; BELLINA JH, 1981, AM J OBSTET GYNECOL, V141, P828, DOI 10.1016/0002-9378(81)90712-2; BIGRIGG MA, 1990, J EXP CLIN CANCER S, V9, P73; BYRNE PF, 1989, LANCET, V2, P807; CAMPION MJ, 1987, BRIT MED J, V294, P1337, DOI 10.1136/bmj.294.6583.1337; CARTIER R, 1984, PRACTICAL COLPOSCOPY; CODLING BW, 1989, BRIT MED J, V299, P855, DOI 10.1136/bmj.299.6703.855; CODLING BW, 1990, J EXP CLIN CANCER S, V9, P1; FENTON D, 1989, LANCET, V2, P807; FOX H, 1987, BRIT MED J, V294, P1307, DOI 10.1136/bmj.294.6583.1307; HALLAM N, 1989, LANCET, V2, P1160; MCINDOE GAJ, 1989, LANCET, V2, P807; PHIPPS JH, 1989, LANCET, V2, P453; PRENDIVILLE W, 1989, BRIT J OBSTET GYNAEC, V96, P1054, DOI 10.1111/j.1471-0528.1989.tb03380.x; PRENDIVILLE WJ, 1986, BRIT J OBSTET GYNAEC, V93, P508; WEST JH, 1990, MAR ANN M BRIT SOC C; WOODMAN CBJ, 1989, BRIT MED J, V299, P899, DOI 10.1136/bmj.299.6704.899	17	130	135	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 28	1990	336	8709					229	231		10.1016/0140-6736(90)91746-W	http://dx.doi.org/10.1016/0140-6736(90)91746-W			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DQ701	1973781				2023-01-03	WOS:A1990DQ70100014
J	AGARWAL, MB; VISWANATHAN, C; RAMANATHAN, J; MASSIL, DE; SHAH, S; GUPTE, SS; VASANDANI, D; PUNIYANI, RR				AGARWAL, MB; VISWANATHAN, C; RAMANATHAN, J; MASSIL, DE; SHAH, S; GUPTE, SS; VASANDANI, D; PUNIYANI, RR			ORAL IRON CHELATION WITH L1	LANCET			English	Letter									LTMG HOSP,BOMBAY 400022,INDIA; LTM MED COLL,DEPT PATHOL,BOMBAY 400022,INDIA; JJ GRP HOSP,DEPT MED,BOMBAY,INDIA; INDIAN INST TECHNOL,DEPT AEROENGN,BOMBAY 400076,INDIA	Indian Institute of Technology System (IIT System); Indian Institute of Technology (IIT) - Bombay	AGARWAL, MB (corresponding author), LTM MED COLL,DEPT MED,BOMBAY 400022,INDIA.							AGARWAL MB, 1986, LIVING THALASSAEMIA; HOFFBRAND AV, 1989, LANCET, V2, P457; HOFFBRAND AV, 1989, 10TH P C INT SOC HAE, P23; Kontoghiorghes G J, 1989, Prog Clin Biol Res, V309, P107; 1989, LANCET, V2, P1016	5	27	27	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 10	1990	335	8689					601	601		10.1016/0140-6736(90)90380-N	http://dx.doi.org/10.1016/0140-6736(90)90380-N			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CT653	1968588				2023-01-03	WOS:A1990CT65300033
J	ANDREWS, PJD; PIPER, IR; DEARDEN, NM; MILLER, JD				ANDREWS, PJD; PIPER, IR; DEARDEN, NM; MILLER, JD			SECONDARY INSULTS DURING INTRAHOSPITAL TRANSPORT OF HEAD-INJURED PATIENTS	LANCET			English	Article											ANDREWS, PJD (corresponding author), UNIV EDINBURGH,WESTERN GEN HOSP,DEPT CLIN NEUROSCI,EDINBURGH EH4 2UX,SCOTLAND.							BION JF, 1985, BRIT MED J, V291, P432, DOI 10.1136/bmj.291.6493.432; BRAMAN SS, 1987, ANN INTERN MED, V107, P469, DOI 10.7326/0003-4819-107-4-469; EHRENWERTH J, 1986, CRIT CARE MED, V14, P543, DOI 10.1097/00003246-198606000-00005; FRANKEL LR, 1987, INT ANESTHESIOL CLIN, V25, P77, DOI 10.1097/00004311-198702520-00006; GENTLEMAN D, 1981, LANCET, V2, P853; GERVAIS HW, 1987, CRIT CARE MED, V15, P761, DOI 10.1097/00003246-198708000-00010; GRAHAM DI, 1989, J NEUROL NEUROSUR PS, V52, P346, DOI 10.1136/jnnp.52.3.346; INSEL J, 1986, CRIT CARE MED, V14, P539, DOI 10.1097/00003246-198606000-00004; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; KOHI YM, 1984, INJURY, V16, P25, DOI 10.1016/0020-1383(84)90110-4; MILLER JD, 1981, J NEUROSURG, V54, P289, DOI 10.3171/jns.1981.54.3.0289; MILLER JD, 1978, JAMA-J AM MED ASSOC, V240, P439, DOI 10.1001/jama.240.5.439; PEARL RG, 1987, INT ANESTHESIOL CLIN, V25, P43, DOI 10.1097/00004311-198702520-00005; WADDELL G, 1975, BRIT MED J, V2, P417, DOI 10.1136/bmj.2.5968.417; WADDELL G, 1975, BRIT MED J, V1, P386, DOI 10.1136/bmj.1.5954.386; WRIGHT I, 1988, ANN INTERN MED, V108, P638, DOI 10.7326/0003-4819-108-4-638_1	16	185	192	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 10	1990	335	8685					327	330		10.1016/0140-6736(90)90614-B	http://dx.doi.org/10.1016/0140-6736(90)90614-B			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CM846	1967776				2023-01-03	WOS:A1990CM84600011
J	REES, MR; BROWNE, T; SIVANANTHAN, UM; WHITTAKER, S; HICK, D; VERMA, SP; TAN, LB; DAVIES, GA				REES, MR; BROWNE, T; SIVANANTHAN, UM; WHITTAKER, S; HICK, D; VERMA, SP; TAN, LB; DAVIES, GA			CARDIAC RESUSCITATION WITH PERCUTANEOUS CARDIOPULMONARY SUPPORT	LANCET			English	Note							ACUTE MYOCARDIAL-INFARCTION; BYPASS; SHOCK	Percutaneous cardiopulmonary support (CPS) was initiated in 9 patients to provide haemodynamic stability after failure of conventional resuscitation. 4 patients were in cardiogenic shock and 4 remained in asystole, with 1 in resistant ventricular fibrillation, after cardiac arrest. During CPS for those in cardiogenic shock, the mean intra-arterial pressures ranged from 65 to 100 mm Hg (mean 84), at flow rates of between 3 to 5 l/min (mean 3.9). 2 patients underwent technically successful coronary angioplasty. No patient in this group survived. In the cardiac arrest group, acceptable mean intra-arterial blood pressures were achieved (mean 95, range 90-100 mm Hg) at flow rates of between 2 to 3 l/min (mean 2.6). All 5 subjects underwent technically successful coronary angioplasty whilst on CPS. 4 survived. 2 were alive and well at 12 months follow-up, 1 of whom had returned to work; the third is alive and well at 4 months.			REES, MR (corresponding author), KILLINGBECK HOSP,REG CARDIOTHORAC CTR,CARDIAC RES UNIT,YORK RD,LEEDS LS14 6UQ,ENGLAND.		Rees, Michael/Y-4640-2019					AFIFI AA, 1974, AM J CARDIOL, V33, P826, DOI 10.1016/0002-9149(74)90628-6; DEBARD ML, 1981, ANN EMERG MED, V10, P408, DOI 10.1016/S0196-0644(81)80307-1; LITZIE AK, 1987, P AM ACAD CV PERFUSI, V8, P60; PROCTOR E., 1967, CARDIOVASC RES, V1, P189, DOI 10.1093/cvr/1.2.189; ROZENBAUM EA, 1988, CRIT CARE MED, V16, P583, DOI 10.1097/00003246-198806000-00003; SAFAR P, 1990, AM J EMERG MED, V8, P55, DOI 10.1016/0735-6757(90)90298-E; SHAWL FA, 1989, AM J CARDIOL, V64, P967, DOI 10.1016/0002-9149(89)90791-1; TOPOL E, 1988, ACUTE CORONARY INTER, P195	8	33	33	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 29	1992	340	8818					513	514		10.1016/0140-6736(92)91711-G	http://dx.doi.org/10.1016/0140-6736(92)91711-G			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JL234	1354278				2023-01-03	WOS:A1992JL23400005
J	AUSTIN, SC; STOLLEY, PD; LASKY, T				AUSTIN, SC; STOLLEY, PD; LASKY, T			THE HISTORY OF MALARIOTHERAPY FOR NEUROSYPHILIS - MODERN PARALLELS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							AIDS TRIALS; THERAPY; DESIGN		UNIV MARYLAND, SCH MED, DEPT EPIDEMIOL & PREVENT MED, 600 REDWOOD ST, BALTIMORE, MD 21201 USA	University System of Maryland; University of Maryland Baltimore			Lasky, Tamar/AAR-3410-2021					Bennett AE, 1938, ARCH NEURO PSYCHIATR, V40, P1141, DOI 10.1001/archneurpsyc.1938.02270120091006; Bierman W, 1942, Bull N Y Acad Med, V18, P65; Bunker HA, 1926, ARCH NEURO PSYCHIATR, V16, P182, DOI 10.1001/archneurpsyc.1926.02200260054004; BUNKER HA, 1928, B N Y ACAD MED 2, V4, P307; BYAR DP, 1990, NEW ENGL J MED, V323, P1343, DOI 10.1056/NEJM199011083231912; CLANCY FJ, 1927, NW MED, V26, P427; Dattner B, 1944, MANAGEMENT NEUROSYPH; DELANEY M, 1989, J INFECT DIS, V159, P416, DOI 10.1093/infdis/159.3.416; EDGAR H, 1990, MILBANK Q, V68, P111, DOI 10.2307/3350178; FONG Theodore C. C., 1937, Southern Medical Journal, V30, P1084, DOI 10.1097/00007611-193711000-00012; GREEN SB, 1990, CONTROL CLIN TRIALS, V11, P80, DOI 10.1016/0197-2456(90)90002-J; KOLMER JA, 1926, PRINCIPLES PRACTICE; KRAUSS William, 1932, Southern Medical Journal, V25, P537, DOI 10.1097/00007611-193205000-00021; KUPPER WH, 1939, MALARIAL THERAPY GEN; Levi Jeffrey, 1991, BIOMEDICAL POLITICS, p[9, 14]; MERIGAN TC, 1990, NEW ENGL J MED, V323, P1341, DOI 10.1056/NEJM199011083231911; MOORE JE, 1946, PENICILLIN SYPHILIS; Moore JE, 1933, MODERN TREATMENT SYP, DOI [10.1001/jama.1943.02840480071034, DOI 10.1001/JAMA.1943.02840480071034]; O Leary PA, 1927, J AMER MED ASSOC, V89, P95, DOI 10.1001/jama.1927.02690020019007; PARRAN T, 1937, SHADOW LAND; PILCZ A, 1905, JB PSYCHIAT NEUROL, V25, P141; Rudolf G.d.M., 1927, THERAPEUTIC MALARIA; Schamberg J F, 1928, Bull N Y Acad Med, V4, P329; Schonbauer L, 1950, LEBENSERINNERUNGEN; Stone C W, 1928, Bull N Y Acad Med, V4, P322; Vedder Edward Bright, 1918, SYPHILIS PUBLIC HLTH; Wagner-Jauregg, 1922, J NERV MENT DIS, V55, P369, DOI 10.1097/00005053-192205000-00001; WAGNERJAUREGG J, 1965, NOBEL LECT PHYSL MED, P159; WHITROW M, 1990, MED HIST, V34, P294, DOI 10.1017/S0025727300052431	29	53	54	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 22	1992	268	4					516	519		10.1001/jama.268.4.516	http://dx.doi.org/10.1001/jama.268.4.516			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JD472	1619744				2023-01-03	WOS:A1992JD47200027
J	WHORWELL, PJ; HOUGHTON, LA; TAYLOR, EE; MAXTON, DG				WHORWELL, PJ; HOUGHTON, LA; TAYLOR, EE; MAXTON, DG			PHYSIOLOGICAL-EFFECTS OF EMOTION - ASSESSMENT VIA HYPNOSIS	LANCET			English	Article							IRRITABLE-BOWEL-SYNDROME; HYPNOTHERAPY; STRESS; PERTURBATION; MOTILITY; MOTOR	Assessment of the physiological effects of physical and emotional stress has been hampered by a lack of suitable laboratory techniques. Since hypnosis can be used safely to induce specific emotional states of considerable intensity, we studied the effect on distal colonic motility of three hypnotically induced emotions (excitement, anger, and happiness) in 18 patients aged 20-48 years with irritable bowel syndrome. Colonic motility index was reduced by hypnosis on its own (mean change 19.1; 95% Cl 0.8, 37.3; p<0.05) and this change was accompanied by decreases in both pulse (12; 8, 15) and respiration (6; 4, 8) rates (p<0.001 for both). Anger and excitement increased the colonic motility index (50.8; 29.4, 72.2; and 30.4; 8.9, 51.9, respectively; p<0.01 for both), pulse rate (26; 22, 30; and 28; 24, 32; p<0.001 for both), and respiration rate (14; 12, 16; and 12; 10, 14; p<0.001 for both). Happiness further reduced colonic motility although not significantly from that observed during hypnosis alone. Changes in motility were mainly due to alterations in rate than in amplitude of contractions. Our results indicate that hypnosis may help in the investigation of the effects of emotion on physiological functions; this approach could be useful outside the gastrointestinal system. Our observation that hypnosis strikingly reduces fasting colonic motility may partly explain the beneficial effects of this form of therapy in functional bowel disorders.			WHORWELL, PJ (corresponding author), UNIV HOSP S MANCHESTER,DEPT MED,MANCHESTER M20 8LR,LANCS,ENGLAND.			Houghton, Lesley/0000-0002-5351-0229; Whorwell, Peter/0000-0002-5220-8474				ALMY TP, 1949, GASTROENTEROLOGY, V12, P425, DOI 10.1016/S0016-5085(49)80125-9; CANN PA, 1983, GUT, V24, P236, DOI 10.1136/gut.24.3.236; FONE D, 1988, GASTROENTEROLOGY, V94, pA133; NARDUCCI F, 1985, DIGEST DIS SCI, V30, P40, DOI 10.1007/BF01318369; OBRIEN JD, 1985, GASTROENTEROLOGY, V88, P1520; PRIOR A, 1990, GUT, V31, P896, DOI 10.1136/gut.31.8.896; ROGERS J, 1989, GUT, V30, P642, DOI 10.1136/gut.30.5.642; STANGHELLINI V, 1983, GASTROENTEROLOGY, V85, P83; THOMPSON DG, 1983, GUT, V24, P277, DOI 10.1136/gut.24.4.277; THOMPSON DG, 1982, GASTROENTEROLOGY, V83, P1200; Waxman D., 1989, HARTLANDS MED DENTAL; WELGAN P, 1988, GASTROENTEROLOGY, V94, P1150, DOI 10.1016/0016-5085(88)90006-6; WHORWELL PJ, 1987, GUT, V28, P423, DOI 10.1136/gut.28.4.423; WHORWELL PJ, 1984, LANCET, V2, P1232, DOI 10.1016/S0140-6736(84)92793-4; WHORWELL PJ, 1991, BRIT J HOSP MED, V45, P27	15	103	104	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 11	1992	340	8811					69	72		10.1016/0140-6736(92)90394-I	http://dx.doi.org/10.1016/0140-6736(92)90394-I			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	JC582	1352012				2023-01-03	WOS:A1992JC58200002
J	WILSON, WC; SMEDIRA, NG; FINK, C; MCDOWELL, JA; LUCE, JM				WILSON, WC; SMEDIRA, NG; FINK, C; MCDOWELL, JA; LUCE, JM			ORDERING AND ADMINISTRATION OF SEDATIVES AND ANALGESICS DURING THE WITHHOLDING AND WITHDRAWAL OF LIFE-SUPPORT FROM CRITICALLY ILL PATIENTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DIAZEPAM; MIDAZOLAM; DECISION	Objective. - To determine why and how sedatives and analgesics are ordered and administered during the withholding and withdrawal of life support from critically ill patients. Design. - Prospective case series. Setting. - Medical-surgical intensive care units at a county hospital and a university hospital. Patients. - Consecutive 1-year sample of 22 patients from whom life support was withheld or withdrawn in one intensive care unit at a county hospital and a random sample of 22 similar patients in the intensive care unit in the university hospital over the same period. Main Outcome Measures. - Physicians and nurses were interviewed to determine their reasons for ordering and administering drugs, and medical records were reviewed to document amounts of drugs ordered and administered. Results. - Drugs were given to 75% of patients during withholding and withdrawal of life support. Patients who did not receive medication were comatose and considered incapable of benefiting from sedation and analgesia. The median time until death following the initiation of the withholding or withdrawal of life support was 3.5 hours in the patients who received drugs and 1.3 hours in those patients who did not (P, not significant). Physicians ordered drugs to decrease pain in 88% of patients, to decrease anxiety in 85%, to decrease air hunger in 76%, to comfort families in 82%, and to hasten death in 39%; in no instance was hastening death the only reason cited. The amounts of benzodiazepines and opiates averaged 2.2 mg/h of diazepam and 3.3 mg/h of morphine sulfate in the 24 hours before withholding and withdrawal of life support and 9.8 mg/h and 11.2 mg/h in the 24 hours thereafter (P < .025 and P < .001, respectively). Conclusions. - Large doses of sedatives and analgesics were ordered primarily to relieve pain and suffering during the withholding and withdrawal of life support, and death was not hastened by drug administration.	SAN FRANCISCO GEN HOSP,ROOM 5K1,1001 POTRERO AVE,SAN FRANCISCO,CA 94110; UNIV CALIF SAN FRANCISCO,DEPT ANESTHESIA,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT SURG,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT NURSING,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT SOCIAL WORK,SAN FRANCISCO,CA 94143	San Francisco General Hospital Medical Center; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco								ANGELL M, 1982, NEW ENGL J MED, V306, P98, DOI 10.1056/NEJM198201143060210; BERGGREN L, 1987, ACTA ANAESTH SCAND, V31, P667, DOI 10.1111/j.1399-6576.1987.tb02643.x; CLOUSER KD, 1977, ANN INTERN MED, V87, P622, DOI 10.7326/0003-4819-87-5-622; FLAKE JW, 1985, ANESTH ANALG, V64, P897; FORRESTER A, 1980, ANESTHESIOLOGY, V53, P494; GEORGE KA, 1977, BRIT J CLIN PHARMACO, V4, P45, DOI 10.1111/j.1365-2125.1977.tb00665.x; GREENBLATT DJ, 1981, BR J PHARM S, V11, pS2; HAMMOND J, 1989, CRIT CARE MED, V17, P136, DOI 10.1097/00003246-198902000-00006; JAFFE JH, 1981, PHARM BASIS THERAPEU; JONSEN AR, 1983, ANN INTERN MED, V99, P261, DOI 10.7326/0003-4819-99-2-261; JONSEN AR, 1986, CLIN ETHICS, P120; KEATS AS, 1985, ANNU REV PHARMACOL, V25, P41, DOI 10.1146/annurev.pa.25.040185.000353; LUCE JM, 1988, CHEST, V94, P621, DOI 10.1378/chest.94.3.621; PORRO GB, 1988, GASTROINTEST ENDOSC, V34, P252, DOI 10.1016/S0016-5107(88)71323-1; RUARK JE, 1988, NEW ENGL J MED, V318, P25, DOI 10.1056/NEJM198801073180106; SCHNEIDERMAN LJ, 1988, NEW ENGL J MED, V318, P984, DOI 10.1056/NEJM198804143181509; SMEDIRA NG, 1990, NEW ENGL J MED, V322, P309, DOI 10.1056/NEJM199002013220506; WANZER SH, 1989, NEW ENGL J MED, V320, P844, DOI 10.1056/NEJM198903303201306; WEIL MH, 1988, CRIT CARE MED, V16, P636, DOI 10.1097/00003246-198806000-00015; WHITE PF, 1988, PLAST RECONSTR SURG, V81, P703, DOI 10.1097/00006534-198805000-00009; ZAWACKI B, 1989, CRIT CARE MED, V17, P198; 1986, AM REV RESPIR DIS, V134, P1327	22	170	170	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 19	1992	267	7					949	953						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HD155	1370853				2023-01-03	WOS:A1992HD15500028
J	DWYER, JM				DWYER, JM			DRUG-THERAPY - MANIPULATING THE IMMUNE-SYSTEM WITH IMMUNE GLOBULIN	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							INTRAVENOUS GAMMA-GLOBULIN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; AUTOIMMUNE HEMOLYTIC-ANEMIA; PLACEBO-CONTROLLED TRIAL; CHRONIC FATIGUE SYNDROME; ANTI-IDIOTYPIC ANTIBODY; IMMUNOGLOBULIN-G IGG; RED-CELL APLASIA; RHEUMATOID-ARTHRITIS; LUPUS-ERYTHEMATOSUS				DWYER, JM (corresponding author), PRINCE WALES HOSP, DIV MED, HIGH ST, RANDWICK, NSW 2031, AUSTRALIA.							ABDOU NI, 1981, J CLIN INVEST, V67, P1297, DOI 10.1172/JCI110158; ANDERSON CL, 1989, CLIN IMMUNOL IMMUNOP, V53, pS63, DOI 10.1016/0090-1229(89)90071-8; ARSURA E, 1989, CLIN IMMUNOL IMMUNOP, V53, pS170, DOI 10.1016/0090-1229(89)90083-4; BALLOW M, 1990, J CLIN IMMUNOL, V10, pS3, DOI 10.1007/BF00918685; BARANDUN S, 1986, VOX SANG, V51, P157, DOI 10.1111/j.1423-0410.1986.tb00235.x; BARBUI T, 1984, BRIT J HAEMATOL, V58, P554, DOI 10.1111/j.1365-2141.1984.tb04004.x; BERCHTOLD P, 1991, P245; BERLIN G, 1985, LANCET, V1, P1153; BERNEY SI, 1985, BRIT J HAEMATOL, V61, P627, DOI 10.1111/j.1365-2141.1985.tb02876.x; BIJSTERBOSCH MK, 1985, J EXP MED, V162, P1825, DOI 10.1084/jem.162.6.1825; BREEDVELD FC, 1985, J RHEUMATOL, V12, P700; BUCKLEY RH, 1991, NEW ENGL J MED, V325, P110, DOI 10.1056/NEJM199107113250207; BUSSEL J, 1988, J PEDIATR-US, V112, P298, DOI 10.1016/S0022-3476(88)80074-X; BUSSEL J B, 1991, P253; BUSSEL JB, 1986, PROG HEMOST THROMB, V8, P103; BUSSEL JB, 1984, BRIT J HAEMATOL, V56, P1, DOI 10.1111/j.1365-2141.1984.tb01266.x; BUSSEL JB, 1989, CLIN IMMUNOL IMMUNOP, V53, pS147, DOI 10.1016/0090-1229(89)90080-9; CARRERAS LO, 1988, LANCET, V2, P393; CARROLL RR, 1984, AM J MED, V76, P181, DOI 10.1016/0002-9343(84)90339-5; CLARKSON SB, 1986, NEW ENGL J MED, V314, P1236, DOI 10.1056/NEJM198605083141907; COHN EJ, 1946, J AM CHEM SOC, V68, P459, DOI 10.1021/ja01207a034; COMBE B, 1985, AM J MED, V78, P920, DOI 10.1016/0002-9343(85)90213-X; COOK L, 1988, J CLIN IMMUNOL, V8, P23, DOI 10.1007/BF00915153; COTTIER H, 1986, VOX SANG, V51, P39, DOI 10.1111/j.1423-0410.1986.tb02006.x; COULAM C, 1991, P395; COUTINHO A, 1984, IMMUNOL REV, V79, P151, DOI 10.1111/j.1600-065X.1984.tb00492.x; DAFFOS F, 1988, LANCET, V2, P910; DELACAMARA C, 1988, NEW ENGL J MED, V318, P519; DIETRICH G, 1990, J CLIN INVEST, V85, P620, DOI 10.1172/JCI114483; DIETRICH G, 1989, PROGR IMMUNOLOGY, V7, P1221; DORF ME, 1989, PROGR IMMUNOLOGY, V7, P874; Dwyer J M, 1987, Adv Intern Med, V32, P111; DWYER J M, 1991, P427; DWYER J M, 1991, P387; DWYER JM, 1981, CLIN EXP IMMUNOL, V46, P237; Eibl M M, 1989, Immunodefic Rev, V1 Suppl, P1; EKERT H, 1985, LANCET, V2, P1310; ENGLE MA, 1989, AM J DIS CHILD, V143, P1300, DOI 10.1001/archpedi.1989.02150230058023; FASTH A, 1986, ARCH DIS CHILD, V61, P86, DOI 10.1136/adc.61.1.86; FATEHMOGHADAM A, 1984, LANCET, V1, P848; FEHR J, 1982, NEW ENGL J MED, V306, P1254, DOI 10.1056/NEJM198205273062102; FINN NG, 1987, ARCH INTERN MED, V147, P2165, DOI 10.1001/archinte.147.12.2165; FONG S, 1986, J IMMUNOL, V137, P122; FURUSHO K, 1984, LANCET, V2, P1055; GAEDICKE G, 1984, BLUT, V48, P387, DOI 10.1007/BF00319968; GAJDOS P, 1984, LANCET, V1, P406; GELFAND EW, 1989, J ALLERGY CLIN IMMUN, V84, P613, DOI 10.1016/0091-6749(89)90199-1; GELFAND EW, 1989, CLIN IMMUNOL IMMUNOP, V53, pS1, DOI 10.1016/0090-1229(89)90064-0; GIANELLABORRADORI A, 1984, BLUT, V48, P403, DOI 10.1007/BF00319972; GODARD W, 1985, ANN INTERN MED, V103, P965, DOI 10.7326/0003-4819-103-6-965_1; GOLDSTEIN R, 1986, ARTHRITIS RHEUM, V29, P426, DOI 10.1002/art.1780290319; GROOTHOFF JW, 1988, BRIT MED J, V296, P1362, DOI 10.1136/bmj.296.6633.1362; GUPTA A, 1986, AM J DIS CHILD, V140, P143, DOI 10.1001/archpedi.1986.02140160061033; HANADA T, 1987, EUR J HAEMATOL, V38, P400; HEINZE E, 1985, ACTA PAEDIATR SCAND, V74, P605, DOI 10.1111/j.1651-2227.1985.tb11039.x; HEYMAN MR, 1990, SOUTHERN MED J, V83, P1471, DOI 10.1097/00007611-199012000-00025; HIERNAUX J, 1981, J EXP MED, V153, P1004, DOI 10.1084/jem.153.4.1004; HUIZINGA TWJ, 1988, NATURE, V333, P667, DOI 10.1038/333667a0; IMBACH P, 1981, LANCET, V1, P1228; IMBACH P, 1981, HELV PAEDIATR ACTA, V36, P81; IMBACH P, 1991, P239; Imbach P., 1991, IMMUNOTHERAPY INTRAV; JERNE NK, 1976, IMMUNE SYSTEM WEB V; JORDAN SC, 1989, CLIN IMMUNOL IMMUNOP, V53, pS164, DOI 10.1016/0090-1229(89)90082-2; KEARNEY JF, 1989, FUNDAMENTAL IMMUNOLO, P663; KICKLER T, 1990, BLOOD, V75, P313; KINCADE PW, 1989, FUNDAMENTAL IMMUNOLO, P41; KLEYWEG RP, 1988, NEUROLOGY, V38, P1639, DOI 10.1212/WNL.38.10.1639; KURTZBERG J, 1987, AM J MED, V83, P4, DOI 10.1016/0002-9343(87)90544-4; KURTZBERG J, 1987, AM J MED, V83, P30, DOI 10.1016/0002-9343(87)90548-1; KURTZMAN G, 1989, NEW ENGL J MED, V321, P519, DOI 10.1056/NEJM198908243210807; LAKOS A, 1987, AM J DIS CHILD, V141, P12, DOI 10.1001/archpedi.1987.04460010012006; LANG B A, 1988, Arthritis and Rheumatism, V31, pS117; LARSEN G L, 1991, P319; LEKOVA ES, 1990, PEDIATR INFECT DIS J, V9, P620; LEONG G M, 1991, P269; LEUNG DYM, 1987, J CLIN INVEST, V79, P468, DOI 10.1172/JCI112835; LIN CY, 1989, NEPHRON, V53, P303, DOI 10.1159/000185772; LINDER N, 1990, DEV PHARMACOL THERAP, V14, P205, DOI 10.1159/000480899; LLOYD A, 1990, AM J MED, V89, P561, DOI 10.1016/0002-9343(90)90173-B; LUM LG, 1980, NEW ENGL J MED, V302, P892, DOI 10.1056/NEJM198004173021604; LUSHER JM, 1987, AM J MED, V83, P10, DOI 10.1016/0002-9343(87)90545-6; MACINTYRE EA, 1985, BRIT J HAEMATOL, V60, P387, DOI 10.1111/j.1365-2141.1985.tb07430.x; MCDEVITT HO, 1989, PROGR IMMUNOLOGY, V7, P68; MCGUIRE WA, 1987, NEW ENGL J MED, V317, P1004, DOI 10.1056/NEJM198710153171606; MELLMAN I, 1988, J CELL SCI, P45; MOFENSON LM, 1991, NEW ENGL J MED, V325, P73, DOI 10.1056/NEJM199107113250201; MORGENSTERN GR, 1983, BRIT MED J, V287, P584, DOI 10.1136/bmj.287.6392.584; MORI PG, 1983, ARCH DIS CHILD, V58, P851, DOI 10.1136/adc.58.11.851; MOSSMAN S, 1986, LANCET, V1, P116; MURAKAMI H, 1985, Keio Journal of Medicine, V34, P227; NEWBURGER JW, 1986, NEW ENGL J MED, V315, P341, DOI 10.1056/NEJM198608073150601; NILSSON IM, 1983, SCAND J HAEMATOL, V30, P458; NILSSON IM, 1988, NEW ENGL J MED, V318, P947, DOI 10.1056/NEJM198804143181503; OCHS H D, 1991, P359; ODA H, 1985, J PEDIATR-US, V107, P744, DOI 10.1016/S0022-3476(85)80405-4; OXELIUS VA, 1984, AM J MED, V76, P7, DOI 10.1016/0002-9343(84)90314-0; PETERSON PK, 1990, AM J MED, V89, P554, DOI 10.1016/0002-9343(90)90172-A; PHILLIPS RA, 1989, PROG IMMUNOL, V7, P305; POCECCO M, 1986, J PEDIATR-US, V109, P726, DOI 10.1016/S0022-3476(86)80252-9; POCECCO M, 1988, HELV PAEDIATR ACTA, V42, P289; POLLACK S, 1982, NEW ENGL J MED, V307, P253; RICEVUTI G, 1986, CLIN LAB HAEMATOL, V8, P325, DOI 10.1111/j.1365-2257.1986.tb00120.x; ROHR G, 1987, LANCET, V1, P170; ROSSI F, 1988, CLIN EXP IMMUNOL, V74, P311; ROSSI F, 1989, J IMMUNOL, V143, P4104; RUBINSTEIN A, 1984, Pediatric Research, V18, p264A, DOI 10.1203/00006450-198404001-01026; SALAMA A, 1983, LANCET, V2, P193; SALAMA A, 1984, BLUT, V48, P391, DOI 10.1007/BF00319969; SANY J, 1982, ARTHRITIS RHEUM, V25, P17, DOI 10.1002/art.1780250103; SCHAAD U B, 1991, P201; SCHMIDT RE, 1981, LANCET, V2, P475; SCHULLER E, 1983, EUR NEUROL, V22, P205, DOI 10.1159/000115560; SCHWARTZ SA, 1990, J CLIN IMMUNOL, V10, P81, DOI 10.1007/BF00918189; SEIFRIED E, 1984, BLUT, V48, P397, DOI 10.1007/BF00319971; SHETH KJ, 1990, AM J DIS CHILD, V144, P268, DOI 10.1001/archpedi.1990.02150270014009; SHULMAN ST, 1991, IMMUNOTHERAPY INTRAV, P261; SILVERMAN ED, 1990, ARTHRITIS RHEUM, V33, P1015, DOI 10.1002/art.1780330714; SOUKOP W, 1986, WIEN MED WOCHENSCHR, V136, P477; STASZEWSKI H, 1989, ACTA HAEMATOL-BASEL, V82, P201; Stokes J, 1944, J CLIN INVEST, V23, P531, DOI 10.1172/JCI101518; SULTAN Y, 1987, P NATL ACAD SCI USA, V84, P828, DOI 10.1073/pnas.84.3.828; SULTAN Y, 1984, LANCET, V2, P765; Sunakawa M, 1989, Metab Pediatr Syst Ophthalmol (1985), V12, P93; TANKERSLEY DL, 1988, MOL IMMUNOL, V25, P41, DOI 10.1016/0161-5890(88)90088-0; TUMIATI B, 1991, P458; UNKELESS JC, 1989, J CLIN INVEST, V83, P355, DOI 10.1172/JCI113891; VENTURA A, 1987, HELV PAEDIATR ACTA, V41, P495; VERMEULEN M, 1985, J NEUROL SCI, V70, P317, DOI 10.1016/0022-510X(85)90173-X; VERMEULEN M, 1991, P351; von Pirquet CE, 1911, ARCH INTERN MED, V7, P259; WENSKE C, 1983, BLUT, V46, P347, DOI 10.1007/BF00320695; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; WINSTON DJ, 1985, IMMUN INFEKT, V13, P296; ZUBLER R, 1981, IMMUNOCHEMOTHERAPY G, P65; 1990, 1990 NIH CONS DEV C, V8; 1989, LANCET, V1, P137	137	613	629	0	10	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 9	1992	326	2					107	116						10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GY045	1727218				2023-01-03	WOS:A1992GY04500006
J	SCHULMAN, KA; GLICK, HA; RUBIN, H; EISENBERG, JM				SCHULMAN, KA; GLICK, HA; RUBIN, H; EISENBERG, JM			COST-EFFECTIVENESS OF HA-1A MONOCLONAL-ANTIBODY FOR GRAM-NEGATIVE SEPSIS - ECONOMIC-ASSESSMENT OF A NEW THERAPEUTIC AGENT	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PROLONGED MECHANICAL VENTILATION; LINKED IMMUNOSORBENT ASSAYS; MEDICAL INTENSIVE-CARE; SURVIVAL; MORTALITY; DIAGNOSIS; OUTCOMES; CHARGES; BLOOD; VIRUS	Objective. - To assess the cost-effectiveness of the HA-1A monoclonal antibody for the treatment of gram-negative bacteremia. Design. - Cost-effectiveness analysis of a randomized, double-blind, placebo-controlled trial using clinical efficacy data reported in the medical literature. Setting. - Hospitalized patients with sepsis. Patients. - 543 patients with sepsis and suspected gram-negative infection. Patients enrolled in the study met strict criteria for sepsis, including fever or hypothermia (< 35.6-degrees-C or > 38.3-degrees-C), tachycardia (> 90 beats per minute), tachypnea (> 20 breaths per minute), and hypotension or two of six signs of systemic toxicity. Intervention. - HA-1A vs placebo in addition to usual care. Main Outcome Measures. - We determined the range of possible cost-effectiveness ratios for HA-1A therapy, using modeling techniques when clinical or economic variables were unknown. We subjected the model to rigorous sensitivity analysis. We calculated the incremental cost of care and years of life saved for patients with sepsis and modeled two different treatment strategies: treat all patients with sepsis or test and then treat only patients with positive test results. Results. - The cost-effectiveness of therapy based on our two models was $24 100 per year of life saved based on the treat strategy and $14 900 based on the test strategy. In sensitivity analysis the ratios ranged from $5200 to $110 200 per year of life gained. Annual costs of care for these two strategies are $1.3 billion for the test strategy and $2.3 billion for the treat strategy. Conclusion. - Economic assessment of new technologies early in their development can be used to guide their efficient clinical introduction.	UNIV PENN,LEONARD DAVIS INST HLTH ECON,PHILADELPHIA,PA 19104; UNIV PENN,DEPT MED,GEN INTERNAL MED SECT,PHILADELPHIA,PA 19104; UNIV PENN,DEPT MED,INFECT DIS SECT,PHILADELPHIA,PA 19104	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania	EISENBERG, JM (corresponding author), GEORGETOWN UNIV,MED CTR,DEPT MED,3800 RESERVOIR RD NW,WASHINGTON,DC 20007, USA.							BEIER JC, 1990, J MED ENTOMOL, V27, P377, DOI 10.1093/jmedent/27.3.377; BROOK FRH, 1971, NEW ENGL J MED, V285, P1509; CHASSIN MR, 1982, MED CARE, V20, P165, DOI 10.1097/00005650-198202000-00004; CHIODI F, 1986, J MED VIROL, V18, P149, DOI 10.1002/jmv.1890180207; CULLEN DJ, 1976, NEW ENGL J MED, V294, P982, DOI 10.1056/NEJM197604292941805; DALEY C, 1990, J CLIN MICROBIOL, V28, P1586, DOI 10.1128/JCM.28.7.1586-1590.1990; Donham C S, 1990, Health Care Financ Rev, V11, P169; EISENBERG JM, 1986, JAMA-J AM MED ASSOC, V255, P1584, DOI 10.1001/jama.255.12.1584; EISENBERG JM, 1983, MED DECIS MAKING, V3, P155, DOI 10.1177/0272989X8300300203; FANT WK, 1990, AM J HOSP PHARM S3, V47, P16; FIELD PR, 1988, J CLIN MICROBIOL, V26, P990, DOI 10.1128/JCM.26.5.990-994.1988; FOX JL, 1990, BIO-TECHNOL, V8, P1240; KINOSIAN BP, 1988, JAMA-J AM MED ASSOC, V259, P2249, DOI 10.1001/jama.259.15.2249; LINDE A, 1990, J INFECT DIS, V161, P903, DOI 10.1093/infdis/161.5.903; LUDWIGS UG, 1991, J INTERN MED, V229, P117, DOI 10.1111/j.1365-2796.1991.tb00318.x; NUNN JF, 1979, BRIT MED J, V1, P1525, DOI 10.1136/bmj.1.6177.1525; OBAYASHI T, 1990, ADV EXP MED BIOL, V256, P215; PANZRAM G, 1987, DIABETOLOGIA, V30, P123, DOI 10.1007/BF00274216; PARNO JR, 1982, CRIT CARE MED, V10, P569, DOI 10.1097/00003246-198209000-00002; PARNO JR, 1984, MED CARE, V22, P167, DOI 10.1097/00005650-198402000-00008; Pessi T T, 1973, Ann Chir Gynaecol Fenn Suppl, V185, P3; ROSOFF JD, 1989, J CLIN MICROBIOL, V27, P1997, DOI 10.1128/JCM.27.9.1997-2002.1989; ROTH RI, 1986, J LAB CLIN MED, V114, P306; SCHULMAN KA, 1991, ANN INTERN MED, V114, P798, DOI 10.7326/0003-4819-114-9-798; SCHWARTZ JS, 1990, JAMA-J AM MED ASSOC, V264, P1704, DOI 10.1001/jama.264.13.1704; SEARLE JF, 1985, ANN ROY COLL SURG, V67, P187; SPICHER JE, 1987, ARCH INTERN MED, V147, P421, DOI 10.1001/archinte.147.3.421; TANAKA R, 1987, LIVER, V7, P316; TEPLIZKI H, 1907, ISRAEL J MED SCI, V23, P1121; THIBAULT GE, 1980, NEW ENGL J MED, V302, P938, DOI 10.1056/NEJM198004243021703; THONER J, 1987, ACTA ANAESTH SCAND, V31, P693, DOI 10.1111/j.1399-6576.1987.tb02647.x; VANDEVENTER SJH, 1988, LANCET, V1, P605; WEINSTEIN MP, 1991, J CLIN MICROBIOL, V29, P879, DOI 10.1128/JCM.29.5.879-882.1991; YAMAGAMI S, 1990, INT J ARTIF ORGANS, V13, P205, DOI 10.1177/039139889001300403; YOUNG LS, 1985, PRINCIPLES PRACTICE; ZIEGLER EJ, 1991, NEW ENGL J MED, V324, P429, DOI 10.1056/NEJM199102143240701; 1989, LENGTH STAY; 1989, CANCER STATISTICS RE; 1990, MMWR, V39, P31; 1990, STATISTICAL ABSTRACT; 1989, FED REG         0130, V54, P4302	42	81	86	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 25	1991	266	24					3466	3471		10.1001/jama.266.24.3466	http://dx.doi.org/10.1001/jama.266.24.3466			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GV878	1744962				2023-01-03	WOS:A1991GV87800034
J	CALABRESE, G; VAGELLI, G; GUASCHINO, R; GONELLA, M				CALABRESE, G; VAGELLI, G; GUASCHINO, R; GONELLA, M			TRANSMISSION OF ANTI-HCV WITHIN THE HOUSEHOLD OF HEMODIALYSIS-PATIENTS	LANCET			English	Letter							HEPATITIS-C VIRUS		GEN HOSP CASALE MONFERRATO,IMMUNOHAEMOPATHOL SERV,I-15033 CASALE MONFERRATO,ITALY		CALABRESE, G (corresponding author), GEN HOSP CASALE MONFERRATO,NEPHROL & DIALYSIS SERV,I-15033 CASALE MONFERRATO,ITALY.							FASSBINDER W, 1991, NEPHROL DIAL TRAN S1, V6; HESS G, 1989, LANCET, V2, P987; KIYOSAWA K, 1991, J MED VIROL, V33, P114, DOI 10.1002/jmv.1890330209; MARCHESI D, 1988, NEPHROL DIAL TRANSPL, V3, P795; PEREZROMERO M, 1990, ANN INTERN MED, V113, P411, DOI 10.7326/0003-4819-113-5-411; SCHLIPKOETER U, 1990, 2ND INT C CURR TREND, P145; THALER MM, 1991, LANCET, V338, P17, DOI 10.1016/0140-6736(91)90006-B	7	61	61	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 7	1991	338	8780					1466	1466		10.1016/0140-6736(91)92774-V	http://dx.doi.org/10.1016/0140-6736(91)92774-V			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GT904	1683456				2023-01-03	WOS:A1991GT90400055
J	HIRSHFELD, EB				HIRSHFELD, EB			SHOULD PRACTICE PARAMETERS BE THE STANDARD OF CARE IN MALPRACTICE LITIGATION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							LIABILITY				HIRSHFELD, EB (corresponding author), AMER MED ASSOC,CHICAGO,IL 60610, USA.							BRENNAN TA, 1991, J HEALTH POLIT POLIC, V16, P67, DOI 10.1215/03616878-16-1-67; CHENEY FW, 1989, JAMA-J AM MED ASSOC, V261, P1599, DOI 10.1001/jama.261.11.1599; EDDY DM, 1990, JAMA-J AM MED ASSOC, V264, P389, DOI 10.1001/jama.264.3.389; FRYE R L, 1984, Journal of the American College of Cardiology, V4, P434; GARNICK DW, 1991, JAMA-J AM MED ASSOC, V266, P2856, DOI 10.1001/jama.266.20.2856; HIRSHFELD EB, 1990, JAMA-J AM MED ASSOC, V263, P1556; Holzer J F, 1990, QRB Qual Rev Bull, V16, P71; KELLIE SE, 1991, JAMA-J AM MED ASSOC, V265, P1265, DOI 10.1001/jama.265.10.1265; Kelly J T, 1990, QRB Qual Rev Bull, V16, P54; KELLY JT, 1990, ARCH PATHOL LAB MED, V114, P1119; KINNEY ED, 1989, UC DAVIS L REV, V22, P421; Leape L L, 1990, QRB Qual Rev Bull, V16, P42; Pierce E C Jr, 1990, QRB Qual Rev Bull, V16, P61; ROPER W, 1988, NEW ENGL J MED, V319, P1179; [No title captured]; 1990, LEGAL IMPLICATIONS P; 1991, US GAOPEMD9111 GEN A; 1988, 3RD SCOPE WORK CONTR	18	42	42	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 27	1991	266	20					2886	2891		10.1001/jama.266.20.2886	http://dx.doi.org/10.1001/jama.266.20.2886			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GQ722	1942459				2023-01-03	WOS:A1991GQ72200040
J	PANDEY, MR; DAULAIRE, NMP; STARBUCK, ES; HOUSTON, RM; MCPHERSON, K				PANDEY, MR; DAULAIRE, NMP; STARBUCK, ES; HOUSTON, RM; MCPHERSON, K			REDUCTION IN TOTAL UNDER-5 MORTALITY IN WESTERN NEPAL THROUGH COMMUNITY-BASED ANTIMICROBIAL TREATMENT OF PNEUMONIA	LANCET			English	Article							CHILDREN; INFECTION; IMPACT; GROWTH	Pneumonia is a leading cause of death among children world wide but those at highest risk in developing countries have limited access to clinical services; effective and low-cost alternatives are a global public health priority. We have done a controlled intervention trial among 13404 children under five in Jumla, Nepal, which relied exclusively on indigenous community health workers to detect and treat pneumonia according to the World Health Organisation decision strategy, with a five-day home-treatment course of oral co-trimoxazole. No other health services were provided, and referral of children to hospital was not practicable. During the three-year study, 2101 deaths were recorded. The programme led to a 28% reduction in the risk of death from all causes by the third year of services (relative risk 0.72, 95% confidence interval 0.63-0.82), with a significant trend (p < 0.02) of lower mortality with greater duration of the programme. The greatest benefit was among infants. In addition to reduction in deaths due to pneumonia, there was a significant reduction in deaths due to diarrhoea and measles, indicating that reduction in pneumonia morbidity had considerable carry-over effect. Our findings show that indigenous community workers can effectively detect and treat pneumonia, and reduce overall child mortality, even without other primary care activities.	INT CTR PREVENT & TREATMENT MAJOR CHILDHOOD DIS, POB 168, HANOVER, NH 03755 USA; MRIGENDRA MED TRUST, Kathmandu, NEPAL; UNIV LONDON LONDON SCH HYG & TROP MED, DEPT PUBL HLTH & POLICY, LONDON WC1E 7HT, ENGLAND; JOHN SNOW INC, BOSTON, MA USA	University of London; London School of Hygiene & Tropical Medicine								BANG AT, 1990, LANCET, V336, P201, DOI 10.1016/0140-6736(90)91733-Q; BRESLOW NE, 1987, IARC SCI PUBLICATION, V82; DAULAIRE NMP, 1990, ALRI CHILD SURVIVAL; FORGIE IM, 1991, PEDIATR INFECT DIS J, V10, P42, DOI 10.1097/00006454-199101000-00009; Gadomski A., 1990, Health Policy and Planning, V5, P235, DOI 10.1093/heapol/5.3.235; KHAN AJ, 1990, B WORLD HEALTH ORGAN, V68, P577; LAUNER LJ, 1990, AM J EPIDEMIOL, V131, P322, DOI 10.1093/oxfordjournals.aje.a115501; Leowski J, 1986, World Health Stat Q, V39, P138; MANTEL N, 1968, BIOMETRICS, V24, P997, DOI 10.2307/2528886; MARTORELL R, 1975, AM J DIS CHILD, V129, P1296, DOI 10.1001/archpedi.1975.02120480022007; Martorell R, 1984, POPUL DEV REV, V10, P49, DOI 10.2307/2807955; MCCORD C, 1978, TROP DOCT, V8, P220, DOI 10.1177/004947557800800420; MOSLEY WH, 1988, CHILD SURVIVAL PROGR; MTANGO FDE, 1986, T ROY SOC TROP MED H, V80, P851, DOI 10.1016/0035-9203(86)90241-5; PANDEY MR, 1989, ANN TROP PAEDIATR, V9, P212, DOI 10.1080/02724936.1989.11748635; ROWLAND MGM, 1988, AM J CLIN NUTR, V47, P134, DOI 10.1093/ajcn/47.1.134; SELWYN BJ, 1990, REV INFECT DIS, V12, pS870; SHANN F, 1984, B WORLD HEALTH ORGAN, V62, P749; SHANN F, 1986, PEDIATR INFECT DIS J, V5, P247, DOI 10.1097/00006454-198603000-00017; SHRESTHA MP, 1982, JUMLA COMMUNITY HLTH; ZUMRAWI FY, 1987, HUM NUTR-CLIN NUTR, V41C, P453; 1985, WHORSD85151985 DOC; 1990, WHOARI9051990 DOC; 1986, WHORSD8515REV21686 D; 1990, RATIONAL USE DRUGS M	25	90	90	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 19	1991	338	8773					993	997		10.1016/0140-6736(91)91847-N	http://dx.doi.org/10.1016/0140-6736(91)91847-N			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GK974	1681351				2023-01-03	WOS:A1991GK97400013
J	STEINBERG, KK; THACKER, SB; SMITH, SJ; STROUP, DF; ZACK, MM; FLANDERS, WD; BERKELMAN, RL				STEINBERG, KK; THACKER, SB; SMITH, SJ; STROUP, DF; ZACK, MM; FLANDERS, WD; BERKELMAN, RL			A METAANALYSIS OF THE EFFECT OF ESTROGEN REPLACEMENT THERAPY ON THE RISK OF BREAST-CANCER	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							EXOGENOUS ESTROGENS; MENOPAUSAL ESTROGENS; CARDIOVASCULAR-DISEASE; MYOCARDIAL-INFARCTION; CLINICAL-TRIALS; HORMONE USE; WOMEN; EPIDEMIOLOGY; OOPHORECTOMY; COHORT	To quantify the effect of estrogen replacement therapy on breast cancer risk, we combined dose-response slopes of the relative risk of breast cancer against the duration of estrogen use across 16 studies. Using this summary dose-response slope, we calculated the proportional increase in risk of breast cancer for each year of estrogen use. For women who experienced any type of menopause, risk did not appear to increase until after at least 5 years of estrogen use. After 15 years of estrogen use, we found a 30% increase in the risk of breast cancer (relative risk, 1.3; 95% confidence interval [Cl], 1.2 to 1.6). The increase in risk was largely due to results of studies that included premenopausal women or women using estradiol (with or without progestin), studies for which the estimated relative risk was 2.2 (Cl, 1.4 to 3.4) after 15 years. Among women with a family history of breast cancer, those who had ever used estrogen replacement had a significantly higher risk (3.4; Cl, 2.0 to 6.0) than those who had not (1.5; Cl, 1.2 to 1.7).	CTR DIS CONTROL,EPIDEMIOL PROGRAM OFF,ATLANTA,GA 30333; CTR DIS CONTROL,CTR CHRON DIS PREVENT & HLTH PROMOT,ATLANTA,GA 30333; CTR DIS CONTROL,CTR INFECT DIS,ATLANTA,GA 30333; EMORY UNIV,SCH PUBL HLTH,ATLANTA,GA 30322	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Emory University	STEINBERG, KK (corresponding author), CTR DIS CONTROL,CTR ENVIRONM HLTH & INJURY CONTROL,MS F-18,1600 CLIFTON RD,ATLANTA,GA 30333, USA.							ANGELL M, 1989, NEW ENGL J MED, V321, P464, DOI 10.1056/NEJM198908173210708; [Anonymous], 1974, N Engl J Med, V290, P15; ARMSTRONG BK, 1988, MED J AUSTRALIA, V148, P213, DOI 10.5694/j.1326-5377.1988.tb99424.x; BERGKVIST L, 1988, INT J EPIDEMIOL, V17, P732, DOI 10.1093/ije/17.4.732; BERGKVIST L, 1989, NEW ENGL J MED, V321, P293, DOI 10.1056/NEJM198908033210505; BLAND KI, 1980, CANCER, V45, P3027, DOI 10.1002/1097-0142(19800615)45:12<3027::AID-CNCR2820451225>3.0.CO;2-2; BRINTON LA, 1986, BRIT J CANCER, V54, P825, DOI 10.1038/bjc.1986.246; BRINTON LA, 1979, J NATL CANCER I, V62, P37; BRINTON LA, 1981, CANCER-AM CANCER SOC, V47, P2517, DOI 10.1002/1097-0142(19810515)47:10<2517::AID-CNCR2820471035>3.0.CO;2-L; BURING JE, 1987, AM J EPIDEMIOL, V125, P939, DOI 10.1093/oxfordjournals.aje.a114632; BUSH TL, 1985, EPIDEMIOL REV, V7, P80, DOI 10.1093/oxfordjournals.epirev.a036287; BUSH TL, 1983, JAMA-J AM MED ASSOC, V249, P903, DOI 10.1001/jama.249.7.903; BYRD BF, 1977, ANN SURG, V185, P574, DOI 10.1097/00000658-197705000-00010; CASAGRANDE J, 1976, J NATL CANCER I, V56, P839, DOI 10.1093/jnci/56.4.839; CHALMERS TC, 1987, STAT MED, V6, P315, DOI 10.1002/sim.4780060320; CRAIG TJ, 1974, J NATL CANCER I, V53, P1577; CUTTS JH, 1969, CANCER RES, V24, P1116; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; DIXON WJ, 1953, BIOMETRICS, V9, P74, DOI 10.2307/3001634; DUPONT WD, 1989, CANCER-AM CANCER SOC, V63, P948, DOI 10.1002/1097-0142(19890301)63:5<948::AID-CNCR2820630527>3.0.CO;2-U; ERNSTER VL, 1988, PREV MED, V17, P201, DOI 10.1016/0091-7435(88)90064-3; EWERTZ M, 1988, INT J CANCER, V42, P832, DOI 10.1002/ijc.2910420606; GAMBRELL RD, 1980, J AM GERIATR SOC, V28, P251, DOI 10.1111/j.1532-5415.1980.tb00530.x; GAMBRELL RD, 1983, OBSTET GYNECOL, V62, P435; GENANT HK, 1982, ANN INTERN MED, V97, P699, DOI 10.7326/0003-4819-97-5-699; HAMMOND CB, 1979, AM J OBSTET GYNECOL, V133, P537, DOI 10.1016/0002-9378(79)90289-8; HAMMOND CB, 1986, CLIN OBSTET GYNECOL, V29, P407, DOI 10.1097/00003081-198606000-00022; HARLAP S, 1984, INT J FERTIL, V29, P73; HEMMINKI E, 1988, American Journal of Public Health, V78, P1479, DOI 10.2105/AJPH.78.11.1479; HENDERSO.BE, 1974, J NATL CANCER I, V53, P609, DOI 10.1093/jnci/53.3.609; HENDERSON BE, 1988, AM J OBSTET GYNECOL, V159, P312, DOI 10.1016/S0002-9378(88)80074-7; HENDERSON BE, 1986, AM J OBSTET GYNECOL, V154, P1181, DOI 10.1016/0002-9378(86)90696-4; HENDERSON BE, 1982, CANCER RES, V42, P3232; HENDERSON BE, 1988, FERTIL STERIL, V49, pS9; HIATT RA, 1984, CANCER, V54, P139, DOI 10.1002/1097-0142(19840701)54:1<139::AID-CNCR2820540128>3.0.CO;2-X; HOOVER R, 1976, NEW ENGL J MED, V295, P401, DOI 10.1056/NEJM197608192950801; HOOVER R, 1981, J NATL CANCER I, V67, P815; HORWITZ RI, 1984, AM J MED, V76, P192, DOI 10.1016/0002-9343(84)90773-3; HULKA BS, 1982, AM J OBSTET GYNECOL, V143, P638, DOI 10.1016/0002-9378(82)90108-9; HULKA BS, 1990, CA-CANCER J CLIN, V40, P289, DOI 10.3322/canjclin.40.5.289; JICK H, 1980, AM J EPIDEMIOL, V112, P586, DOI 10.1093/oxfordjournals.aje.a113031; KAUFMAN DW, 1984, JAMA-J AM MED ASSOC, V252, P63, DOI 10.1001/jama.252.1.63; KELSEY JL, 1988, CANCER RES, V48, P5615; KELSEY JL, 1981, JNCI-J NATL CANCER I, V67, P327; LAVECCHIA C, 1986, INT J CANCER, V38, P853, DOI 10.1002/ijc.2910380612; LINDSAY R, 1980, LANCET, V2, P1151; LONGNECKER MP, 1988, JAMA-J AM MED ASSOC, V260, P652; LUFKIN EG, 1988, MAYO CLIN P, V27, P201; MACK TM, 1975, NEW ENGL J MED, V292, P1366, DOI 10.1056/NEJM197506262922603; MANN JI, 1975, BMJ-BRIT MED J, V2, P241, DOI 10.1136/bmj.2.5965.241; MCDONALD JA, 1986, BREAST CANCER RES TR, V7, P193, DOI 10.1007/BF01806250; NACHTIGALL LE, 1979, OBSTET GYNECOL, V54, P74, DOI 10.1097/00006250-197907000-00017; NOMURA AMY, 1986, INT J CANCER, V37, P49, DOI 10.1002/ijc.2910370109; RAVINHAR BA, 1979, EUR J CANCER, V15, P395; ROSS RK, 1980, JAMA-J AM MED ASSOC, V243, P1635, DOI 10.1001/jama.243.16.1635; ROTHMAN KJ, 1986, MODERN EPIDEMIOLOGY, P344; SARTWELL PE, 1977, JNCI-J NATL CANCER I, V59, P1589, DOI 10.1093/jnci/59.6.1589; SHERMAN B, 1983, CANCER, V51, P1527, DOI 10.1002/1097-0142(19830415)51:8<1527::AID-CNCR2820510828>3.0.CO;2-T; THACKER SB, 1988, JAMA-J AM MED ASSOC, V259, P1685, DOI 10.1001/jama.259.11.1685; THOMAS DB, 1982, JNCI-J NATL CANCER I, V69, P1017; THOMAS DB, 1984, CANCER-AM CANCER SOC, V53, P595, DOI 10.1002/1097-0142(19840201)53:3+<595::AID-CNCR2820531304>3.0.CO;2-Y; UTIAN WH, 1972, S AFR MED J, V46, P732; WALLACH S, 1959, JAMA-J AM MED ASSOC, V171, P1637, DOI 10.1001/jama.1959.03010300011002; WILSON RA, 1962, JAMA-J AM MED ASSOC, V182, P327, DOI 10.1001/jama.1962.03050430001001; WINGO PA, 1987, JAMA-J AM MED ASSOC, V257, P209, DOI 10.1001/jama.257.2.209; WREN BG, 1982, MED J AUSTRALIA, V2, P329, DOI 10.5694/j.1326-5377.1982.tb132453.x; WYNDER EL, 1978, CANCER-AM CANCER SOC, V41, P2341, DOI 10.1002/1097-0142(197806)41:6<2341::AID-CNCR2820410637>3.0.CO;2-N; 1987, CHEM ABSTR, V37, P12; 1979, IARC MONOGRAPHS S11, V21; 1983, JAMA-J AM MED ASSOC, V249, P1591; 1989, STATISTICAL ABSTRACT	71	567	576	0	14	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 17	1991	265	15					1985	1990		10.1001/jama.265.15.1985	http://dx.doi.org/10.1001/jama.265.15.1985			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FF768	1826136				2023-01-03	WOS:A1991FF76800026
J	BIGRIGG, MA; READ, MD				BIGRIGG, MA; READ, MD			MANAGEMENT OF WOMEN REFERRED TO EARLY-PREGNANCY ASSESSMENT UNIT - CARE AND COST-EFFECTIVENESS	BRITISH MEDICAL JOURNAL			English	Article								Objective - To assess the efficiency of an early pregnancy assessment unit in the care of women with bleeding or pain in early pregnancy. Design - Analysis of women attending in the first year of the unit's operation and in the six months immediately before its introduction. Setting - Early pregnancy assessment unit in a district general hospital serving a population of 310 000. Patients - 1141 women referred with bleeding or pain in early pregnancy. Main outcome measures - Length of stay in hospital required for diagnosis and treatment. Results - Before the unit was established the mean admission time was one and a half (range half to three) days for women who required no treatment and three (one and a half to five) days in women requiring evacuation of uterus. These times were reduced to two hours as an outpatient and one day respectively for most women after the unit was established . Between 318 and 505 women were estimated to have been saved from unnecessary admission and 233 had their stay reduced; the associated saving was between 95 000 pounds and 120 000 pounds in one year. Conclusions - The early pregnancy assessment unit improved the quality of care and also produced considerable savings in financial and staff resources.	GLOUCESTER ROYAL HOSP,OBSTET & GYNAECOL,GLOUCESTER GL1 3NN,ENGLAND									BUCK N, 1989, REPORT CONFIDENTIAL; 1982, MATERNITY CARE ACT 1; 1982, REPORT ROYAL COLLEGE; 1990, QUALITY MED CARE	4	86	87	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 9	1991	302	6776					577	579		10.1136/bmj.302.6776.577	http://dx.doi.org/10.1136/bmj.302.6776.577			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FB936	1902383	Green Published, Bronze			2023-01-03	WOS:A1991FB93600025
J	HIGGINSON, I; WADE, A; MCCARTHY, M				HIGGINSON, I; WADE, A; MCCARTHY, M			PALLIATIVE CARE - VIEWS OF PATIENTS AND THEIR FAMILIES	BRITISH MEDICAL JOURNAL			English	Article											HIGGINSON, I (corresponding author), UNIV COLL & MIDDLESEX SCH MED,DEPT COMMUNITY MED,LONDON WC1E 6EA,ENGLAND.		McCarthy, Mark/C-1117-2009; Higginson, Irene J/C-7309-2012	Higginson, Irene J/0000-0002-3687-1313				BARNETT M, 1987, INT C S SERIES, V123, P78; CARTWRIGHT A, 1973, LIFE DEATH; COPPERMAN H, 1988, J ROY COLL GEN PRACT, V38, P411; DOYLE D, 1989, INT C S SERIES, V149, P165; DUNLOP RJ, 1989, PALLIAT MED, V0003, P00197, DOI DOI 10.1177/026921638900300305; Fleiss J. L., 1981, STAT METHODS RATES P, V2, P22; GILLEY J, 1988, J ROY COLL GEN PRACT, V38, P121; HAINES A, 1986, BRIT MED J, V292, P1051, DOI 10.1136/bmj.292.6527.1051; HIGGINSON I, 1989, J ROY SOC MED, V82, P264, DOI 10.1177/014107688908200507; HIGGINSON I, 1988, SAFER DEATH, P205; HIGGINSON I, 1989, PALLIATIVE MED, V3, P267; HIGGINSON I, 1989, INT C S SERIES, V149, P217; HINTON J, 1979, LANCET, V1, P29; LUNT B, 1985, SOC SCI MED, V20, P753, DOI 10.1016/0277-9536(85)90066-8; MAGUIRE P, 1988, BRIT MED J, V297, P972, DOI 10.1136/bmj.297.6654.972; MOR V, 1988, HOSPICE EXPT; MOUNT BM, 1987, J CHRON DIS, V40, P545; Parkes C M, 1978, J R Coll Gen Pract, V28, P19; PARKES CM, 1984, POSTGRAD MED J, V60, P120, DOI 10.1136/pgmj.60.700.120; SEALE CF, 1989, SOC SCI MED, V28, P551, DOI 10.1016/0277-9536(89)90249-9; SPRENT P, 1989, APPLIED NONPARAMETRI; 1986, LANCET, V1, P1013; 1980, J R COLL GEN PRACT, V30, P466	23	194	196	0	9	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 4	1990	301	6746					277	281		10.1136/bmj.301.6746.277	http://dx.doi.org/10.1136/bmj.301.6746.277			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DT797	1697189	Green Published, Bronze			2023-01-03	WOS:A1990DT79700025
J	RESTRICK, LJ; DAVIES, SW; NOONE, L; WEDZICHA, JA				RESTRICK, LJ; DAVIES, SW; NOONE, L; WEDZICHA, JA			AMBULATORY OXYGEN IN CHRONIC HEART-FAILURE	LANCET			English	Note							OBSTRUCTIVE AIRWAYS DISEASE; PORTABLE OXYGEN; EXERCISE CAPACITY	Ambulatory oxygen therapy may be of benefit in bicycle exercise tests. We have assessed the effects of ambulatory oxygen during walk tests in 12 patients with chronic heart failure. In 6 min walks with the patient breathing air, mean (SD) arterial oxygen saturation (SaO2) fell from 94.4 (3.7)% at rest to 90.1 (6.1)% (p = 0.014) on exercise. 2 l/min oxygen increased resting SaO2 from 93.7 (4.0)% (air cylinder) to 96.5 (3.0)% (p < 0.001) with no effect on minimum SaO2, distance, or breathlessness. During endurance walks, 4 l/min oxygen increased minimum SaO2 from 90.4 (5.6)% to 93.5 (4.7)% (p = 0.011) but also had no effect on breathlessness or distance. Ambulatory oxygen in currently available cylinders cannot be recommended for patients with chronic heart failure.	LONDON CHEST HOSP,DEPT THORAC MED,BONNER RD,LONDON E2 9JX,ENGLAND; LONDON CHEST HOSP,DEPT CARDIOL,LONDON E2 9JX,ENGLAND	University of London; Queen Mary University London; University of London; Queen Mary University London								BUTLAND RJA, 1982, BRIT MED J, V284, P1607, DOI 10.1136/bmj.284.6329.1607; COCKROFT AL, 1989, Q J MED, V268, P669; DAVIDSON AC, 1988, THORAX, V43, P965, DOI 10.1136/thx.43.12.965; DAVIES S W, 1992, Pharmaceutical Medicine (London), V5, P239; DAVIES SW, 1991, BRIT HEART J, V65, P179; LEGGETT RJE, 1977, BRIT MED J, V2, P84, DOI 10.1136/bmj.2.6079.84; LIPKIN DP, 1986, BRIT MED J, V292, P653, DOI 10.1136/bmj.292.6521.653; LOCK SH, 1991, RESP MED, V85, P407, DOI 10.1016/S0954-6111(06)80186-1; MOORE DP, 1992, LANCET, V339, P850, DOI 10.1016/0140-6736(92)90288-E; WATERHOUSE JC, 1983, THORAX, V38, P302, DOI 10.1136/thx.38.4.302	10	30	31	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 14	1992	340	8829					1192	1193		10.1016/0140-6736(92)92893-K	http://dx.doi.org/10.1016/0140-6736(92)92893-K			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JY386	1359262				2023-01-03	WOS:A1992JY38600005
J	WEISSMAN, JS; GATSONIS, C; EPSTEIN, AM				WEISSMAN, JS; GATSONIS, C; EPSTEIN, AM			RATES OF AVOIDABLE HOSPITALIZATION BY INSURANCE STATUS IN MASSACHUSETTS AND MARYLAND	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MEDICAL-CARE; CASE-MIX; HEALTH; MORTALITY; QUALITY; AREA; INTERVENTION; SERVICES; DISTRICT; PAYMENT	Objective.-To determine whether uninsured and Medicaid patients have higher rates of avoidable hospitalizations than do insured patients. Design.-We used 1987 computerized hospital discharge data to select a cross-sectional sample of hospitalized patients. Population estimates from the Current Population Survey were used to estimate rates of admission, standardized for age and sex. Setting.-Nonfederal acute care hospitals in Massachusetts and Maryland. Patients.-All patients under 65 years of age who were uninsured, privately insured, or insured by Medicaid. Hospitalizations for obstetric and psychiatric conditions were excluded. Main Outcome Measures.-Relative risk of admission for 12 avoidable hospital conditions (AHCs) identified by a physician panel. Results.-Uninsured and Medicaid patients were more likely than insured patients to be hospitalized for AHCs. Rates for uninsured patients were significantly greater than for privately insured patients in Massachusetts for 10 of 12 individual AHCs, and in Maryland for five of 12 AHCs. After adjustment for baseline utilization, the results were statistically significant for 10 of 12 AHCs in Massachusetts and seven of 12 AHCs in Maryland. For Medicaid patients, rates were significantly greater than for privately insured patients for all AHCs in each state before adjustment, and for nine of 12 and seven of 12 AHCs in each state, respectively, after adjustment for baseline utilization. Conclusion.-Our findings suggest that patients who are uninsured or who have Medicaid coverage have higher rates of hospitalization for conditions that can often be treated out of hospital or avoided altogether. Our approach is potentially useful for routine monitoring of access and quality of care for selected groups of patients.	HARVARD UNIV,SCH MED,DEPT HLTH CARE POLICY,25 SHATTUCK ST,PARCEL B,1ST FLOOR,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DEPT MED,DIV GEN MED,HLTH SERV & POLICY RES SECT,BOSTON,MA 02115; HARVARD UNIV,SCH PUBL HLTH,DEPT BIOSTAT,BOSTON,MA 02115; HARVARD UNIV,SCH PUBL HLTH,DEPT HLTH POLICY & MANAGEMENT,BOSTON,MA 02115	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health					AHRQ HHS [R01 HS06235] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		ADAY LA, 1984, AM J PUBLIC HEALTH, V74, P1331, DOI 10.2105/AJPH.74.12.1331; BILLINGS J, 1990, HEALTH AFFAIR, V9, P158, DOI 10.1377/hlthaff.9.4.158; BRAVEMAN P, 1989, NEW ENGL J MED, V321, P508, DOI 10.1056/NEJM198908243210805; BROOK RH, 1983, NEW ENGL J MED, V309, P1426, DOI 10.1056/NEJM198312083092305; Brown E R, 1989, Med Care Rev, V46, P349, DOI 10.1177/107755878904600402; BUCK C, 1986, INT J HEALTH SERV, V16, P553, DOI 10.2190/QWWN-518N-5VFC-6272; CARR W, 1988, SERIES UNITED HOSPIT, V8, P5; CHARLTON JRH, 1983, LANCET, V1, P691; CHRISTOFFERSSON J, 1986, DRG MONITOR, V6, P1; Craddick J W, 1979, QRB Qual Rev Bull, V5, P2; DIEHR P, 1990, HEALTH SERV RES, V24, P741; GARFINKEL S, 1986, 20213 DEP HLTH HUM B; GONNELLA JS, 1984, JAMA-J AM MED ASSOC, V251, P637; HADLEY J, 1991, JAMA-J AM MED ASSOC, V265, P374, DOI 10.1001/jama.265.3.374; Howell E M, 1991, Health Care Financ Rev, V12, P1; HSIA DC, 1988, NEW ENGL J MED, V318, P352, DOI 10.1056/NEJM198802113180604; LURIE N, 1986, NEW ENGL J MED, V314, P1266, DOI 10.1056/NEJM198605083141934; MARTINI CJM, 1977, INT J HEALTH SERV, V7, P293, DOI 10.2190/XFYT-R576-0R6C-RJ4M; MOYER ME, 1989, HEALTH AFFAIR, V8, P102, DOI 10.1377/hlthaff.8.2.102; NEWHOUSE JP, 1991, HLTH SERVICES RES KE, P161; PERLOFF JD, 1987, J HEALTH POLIT POLIC, V12, P221, DOI 10.1215/03616878-12-2-221; Roos N P, 1988, Health Care Financ Rev, V9, P53; RUNDALL T, 1991, 119TH ANN M AM PUBL; RUTSTEIN DD, 1976, NEW ENGL J MED, V294, P582, DOI 10.1056/NEJM197603112941104; RUTSTEIN DD, 1977, NEW ENGL J MED, V297, P508; SCHWARTZ E, 1990, INT J EPIDEMIOL, V19, P591, DOI 10.1093/ije/19.3.591; SOLBERG LI, 1990, INQUIRY-J HEALTH CAR, V27, P359; WEISSMAN J, 1989, JAMA-J AM MED ASSOC, V261, P3572, DOI 10.1001/jama.261.24.3572; WEISSMAN JS, 1991, ANN INTERN MED, V114, P325, DOI 10.7326/0003-4819-114-4-325; WENNEKER MB, 1990, JAMA-J AM MED ASSOC, V264, P1255, DOI 10.1001/jama.264.10.1255; WISSOW LS, 1988, AM J PUBLIC HEALTH, V78, P777, DOI 10.2105/AJPH.78.7.777; WOOLHANDLER S, 1985, INT J HEALTH SERV, V15, P1, DOI 10.2190/90P3-LEFF-WNU0-GLY6; YERGAN J, 1988, MED CARE, V26, P1111, DOI 10.1097/00005650-198811000-00009; YOUNG GJ, 1991, INQUIRY-J HEALTH CAR, V28, P255; 1989, INT CLASSIFICATION D; 1987, SPECIAL REPORT ACCES, P2; 1989, CURRENT POPULATION S	37	516	520	0	30	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 4	1992	268	17					2388	2394		10.1001/jama.268.17.2388	http://dx.doi.org/10.1001/jama.268.17.2388			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	JV694	1404795				2023-01-03	WOS:A1992JV69400024
J	HAWKINS, MM; WILSON, LMK; STOVALL, MA; MARSDEN, HB; POTOK, MHN; KINGSTON, JE; CHESSELLS, JM				HAWKINS, MM; WILSON, LMK; STOVALL, MA; MARSDEN, HB; POTOK, MHN; KINGSTON, JE; CHESSELLS, JM			EPIPODOPHYLLOTOXINS, ALKYLATING-AGENTS, AND RADIATION AND RISK OF SECONDARY LEUKEMIA AFTER CHILDHOOD-CANCER	BRITISH MEDICAL JOURNAL			English	Article							ACUTE NONLYMPHOCYTIC LEUKEMIA; ACUTE MYELOID-LEUKEMIA; NON-HODGKINS LYMPHOMA; LOW-DOSE RADIATION; T-CELL LEUKEMIA; MYELODYSPLASTIC SYNDROME; 2ND MALIGNANCIES; OVARIAN-CANCER; NEURO-BLASTOMA; CHEMOTHERAPY	Objective-To investigate the incidence and aetiology of secondary leukaemia after childhood cancer in Britain. Design-Cohort study and a case-control study. Setting-Britain and population based National Register of Childhood Tumours. Subjects-Cohort of 16 422 one year survivors of childhood cancer diagnosed in Britain between 1962 and 1983, among whom 22 secondary leukaemias were observed. A case-control study of 26 secondary leukaemias observed among survivors of childhood cancer diagnosed in Britain between 1940 and 1983; % controls were selected matched for sex, type of first cancer, age at first cancer, and interval to diagnosis of secondary leukaemia. Main outcome measures-Dose of radiation averaged over patients' active bone marrow and total accumulated dose of epipodophyllotoxins, alkylating agents, vinca alkaloids, antimetabolites, and antibiotics (mg/m2) given for the original cancer. Results-Cumulative risk of secondary leukaemia within the cohort did not exceed 0.5% over the initial five years beyond one year survival, except that after non-Hodgkin's lymphomas 1.4% of patients developed secondary leukaemia. Corresponding figure for patients treated for non-Hodgkin's lymphomas in the early 1980s was 4%. The relative risk of secondary leukaemia increased significantly with exposure to epipodophyllotoxins and dose of radiation averaged over patients' active bone marrow. Ten patients developed leukaemia after having an epipodophyllotoxin-teniposide in nine cases, etoposide in one. Chromosomal translocations involving 11q23 were observed relating to two secondary leukaemias from a total of six for which there were successful cytogenetic studies after administration of an epipodophyllotoxin. Conclusions-Epipodophyllotoxins acting alone or together with alkylating agents or radiation seem to be involved in secondary leukaemia after childhood cancer.	ROYAL MANCHESTER CHILDRENS HOSP,PAEDIAT PATHOL,MANCHESTER M27 1HA,LANCS,ENGLAND; ST BARTHOLOMEWS HOSP,LONDON EC1,ENGLAND; HOSP SICK CHILDREN,HAEMATOL & ONCOL,LONDON WC1N 3JH,ENGLAND; UNIV TEXAS,MD ANDERSON CANC CTR,HOUSTON,TX 77025	Royal Manchester Children's Hospital; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust; University of Texas System; UTMD Anderson Cancer Center	HAWKINS, MM (corresponding author), UNIV OXFORD,CHILDHOOD CANC RES GRP,OXFORD OX2 6HJ,ENGLAND.							BOICE JD, 1983, NEW ENGL J MED, V309, P1079, DOI 10.1056/NEJM198311033091802; BOICE JD, 1987, J NATL CANCER I, V79, P1295; Boice Jr J., 1984, RAD CARCINOGENESIS E; BOIVIN JF, 1986, AM J EPIDEMIOL, V123, P993, DOI 10.1093/oxfordjournals.aje.a114351; Breslow N. E., 1980, IARC SCI PUBLICATION, V32; BRESLOW NE, 1987, IARC SCI PUBLICATION, V82; CURTIS RE, 1984, J NATL CANCER I, V72, P531; CUZICK J, 1987, BRIT J CANCER, V55, P523, DOI 10.1038/bjc.1987.107; DERBYSHIRE PJ, 1986, CLIN LAB HAEMATOL, V8, P71; DEVATHAIRE F, 1989, BRIT J CANCER, V59, P792, DOI 10.1038/bjc.1989.165; DEVEREUX S, 1990, BRIT MED J, V301, P1077, DOI 10.1136/bmj.301.6760.1077; DEVORE R, 1989, ANN INTERN MED, V110, P704, DOI 10.7326/0003-4819-110-9-740; GREENE MH, 1986, ANN INTERN MED, V105, P360, DOI 10.7326/0003-4819-105-3-360; HAAS JF, 1987, BRIT J CANCER, V55, P213, DOI 10.1038/bjc.1987.40; HAWKINS MM, 1987, BRIT J CANCER, V56, P339, DOI 10.1038/bjc.1987.200; INGRAM L, 1987, BRIT J CANCER, V55, P463, DOI 10.1038/bjc.1987.91; KALDOR JM, 1987, INT J CANCER, V39, P571, DOI 10.1002/ijc.2910390506; KALDOR JM, 1990, NEW ENGL J MED, V322, P1, DOI 10.1056/NEJM199001043220101; KALDOR JM, 1990, NEW ENGL J MED, V322, P7, DOI 10.1056/NEJM199001043220102; KANTARJIAN HM, 1986, J CLIN ONCOL, V4, P1748, DOI 10.1200/JCO.1986.4.12.1748; KREISSMAN SG, 1990, P AN M AM SOC CLIN, V9, P219; LEBEAU MM, 1986, J CLIN ONCOL, V4, P325, DOI 10.1200/JCO.1986.4.3.325; LONG BH, 1985, CANCER RES, V45, P3106; MOTT MG, 1984, BRIT J CANCER, V50, P463, DOI 10.1038/bjc.1984.202; MOTT MG, 1984, BRIT J CANCER, V50, P457, DOI 10.1038/bjc.1984.201; PEDERSENBJERGAARD J, 1991, LANCET, V338, P359, DOI 10.1016/0140-6736(91)90490-G; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; PRIETO F, 1990, CANCER GENET CYTOGEN, V45, P1, DOI 10.1016/0165-4608(90)90061-E; PUI CH, 1990, LANCET, V336, P1130, DOI 10.1016/0140-6736(90)92607-J; PUI CH, 1989, NEW ENGL J MED, V321, P136, DOI 10.1056/NEJM198907203210302; PUI CH, 1991, NEW ENGL J MED, V325, P1682, DOI 10.1056/NEJM199112123252402; PUI CH, 1990, LANCET, V336, P417, DOI 10.1016/0140-6736(90)91956-B; RATAIN MJ, 1987, BLOOD, V70, P1412; ROSS W, 1984, CANCER RES, V44, P5857; SECKERWALKER LM, 1985, MED PEDIATR ONCOL, V13, P48, DOI 10.1002/mpo.2950130112; STOVALL M, 1989, MED PHYS, V16, P726, DOI 10.1118/1.596331; THIRD MIC, 1988, CANCER GENET CYTOGEN, V32, P1; TRAVIS LB, 1991, CANCER-AM CANCER SOC, V67, P2002, DOI 10.1002/1097-0142(19910401)67:7<2002::AID-CNCR2820670729>3.0.CO;2-E; TUCKER MA, 1988, NEW ENGL J MED, V318, P76, DOI 10.1056/NEJM198801143180203; TUCKER MA, 1987, J NATL CANCER I, V78, P459, DOI 10.1093/jnci/78.3.459; TUCKER MA, 1984, RAD CARCINOGENESIS E, P211; WEH HJ, 1986, J CLIN ONCOL, V4, P1518, DOI 10.1200/JCO.1986.4.10.1518; WHANGPENG J, 1988, BLOOD, V71, P403; WHITLOCK JA, 1991, CANCER, V68, P600, DOI 10.1002/1097-0142(19910801)68:3<600::AID-CNCR2820680326>3.0.CO;2-F; 1980, ORNL NUREGCRE1159 RE; 1990, EGRET REFERENCE MANU	46	186	188	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 11	1992	304	6832					951	958		10.1136/bmj.304.6832.951	http://dx.doi.org/10.1136/bmj.304.6832.951			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HP064	1581717	Green Published, Bronze			2023-01-03	WOS:A1992HP06400021
J	ANNAS, GJ				ANNAS, GJ			CHANGING THE CONSENT RULES FOR DESERT-STORM	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material														Annas, George/0000-0001-5836-7831				ANNAS GJ, 1992, NAZI DOCTORS NUREMBE, P61; CURRIE DP, 1990, CONSTITUTION SUPREME, P280; HOWE EG, 1991, HASTINGS CENT REP, V21, P21, DOI 10.2307/3562332; JOHNSON WH, 1953, SCIENCE, V117, P212; KEELER JR, 1991, JAMA-J AM MED ASSOC, V266, P693, DOI 10.1001/jama.266.5.693; 1990, FED REGISTER, V55, P52814; 1991, AM J HOSP PHARM, V48, P1525	7	12	12	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 12	1992	326	11					770	773		10.1056/NEJM199203123261117	http://dx.doi.org/10.1056/NEJM199203123261117			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HH064	1738394	Green Published			2023-01-03	WOS:A1992HH06400032
J	KESSLER, DA				KESSLER, DA			COMMUNICATING WITH PATIENTS ABOUT THEIR MEDICATIONS	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material											KESSLER, DA (corresponding author), US FDA,ROCKVILLE,MD 20857, USA.							JOYCE G, 1988, J PHARM MARK MANAGE, V3, P11; KORSCH BM, 1972, SCI AM, V227, P66, DOI 10.1038/scientificamerican0872-66; LEY P, 1972, J HEALTH SOC BEHAV, V13, P311, DOI 10.2307/2136768; MORRIS LA, 1986, NATIONAL SURVEY PRES; 1990, MED REGIMENS CAUSES, P12; 1984, PRESCRIPTION DRUG AD; 1991, DHHS PHS9150212 PUBL; 1988, MARKET FACTS	8	63	67	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 5	1991	325	23					1650	1652		10.1056/NEJM199112053252312	http://dx.doi.org/10.1056/NEJM199112053252312			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GR770	1944456				2023-01-03	WOS:A1991GR77000012
J	KOES, BW; ASSENDELFT, WJJ; VANDERHEIJDEN, GJMG; BOUTER, LM; KNIPSCHILD, PG				KOES, BW; ASSENDELFT, WJJ; VANDERHEIJDEN, GJMG; BOUTER, LM; KNIPSCHILD, PG			SPINAL MANIPULATION AND MOBILIZATION FOR BACK AND NECK PAIN - A BLINDED REVIEW	BRITISH MEDICAL JOURNAL			English	Review							CLINICAL-TRIALS; THERAPY; MOBILIZATION; MANAGEMENT; SCIATICA	Objective - To assess the efficacy of spinal manipulation for patients with back or neck pain. Design - Computer aided search for published papers and blinded assessment of the methods of the studies. Subjects - 35 randomised clinical trials comparing spinal manipulation with other treatments. Main outcome measures - Score for quality of methods (based on four main categories: study population, interventions, measurement of effect, and data presentation and analysis) and main conclusion of author(s) with regard to spinal manipulation. Results - No trial scored 60 or more points (maximum score 100) suggesting that most were of poor quality. Eighteen studies (51%) showed favourable results for manipulation. In addition, five studies (140/o) reported positive results in one or more subgroups. Of the four studies with 50-60 points, one reported that manipulation was better, two reported that manipulation was better in only a subgroup, and one reported that manipulation was no better or worse than reference treatment. Eight trials attempted to compare manipulation with some placebo, with inconsistent results. Conclusions - Although some results are promising, the efficacy of manipulation has not been convincingly shown. Further trials are needed, but much more attention should be paid to the methods of study.			KOES, BW (corresponding author), UNIV LIMBURG,DEPT EPIDEMIOL & BIOSTAT,POB 616,6200 MD MAASTRICHT,NETHERLANDS.		Koes, Bart w/K-4614-2016; assendelft, willem/AAW-1854-2021; Assendelft, W.J.J./H-8008-2014	Koes, Bart w/0000-0002-0450-9969; assendelft, willem/0000-0002-2966-3778; Assendelft, W.J.J./0000-0002-2966-3778; Bouter, Lex/0000-0002-2659-5482				ARKUSZEWSKI Z, 1986, MANUAL MED, V2, P68; BERGQUISTULLMAN M, 1977, ACTA ORTHOP SCAND S, V170, P11; BRODIN H, 1984, INT J REHABIL RES, V7, P190, DOI 10.1097/00004356-198406000-00008; BRODIN H, 1983, MED PHYS, V6, P67; Bronfort G., 1989, AM J CHIROPRACTIC ME, V2, P145; BRUNARSKI DJ, 1984, J MANIP PHYSIOL THER, V7, P243; BUERGER AA, 1980, MANUAL MED, V2, P17; COXHEAD CE, 1981, LANCET, V1, P1065; DEYO RA, 1983, JAMA-J AM MED ASSOC, V250, P1057; DICKERSIN K, 1990, JAMA-J AM MED ASSOC, V263, P1385, DOI 10.1001/jama.263.10.1385; DIFABIO RP, 1986, PHYS THER, V66, P51, DOI 10.1093/ptj/66.1.51; DORAN DML, 1975, BRIT MED J, V2, P161, DOI 10.1136/bmj.2.5964.161; EVANS DP, 1978, RHEUMATOL REHABIL, V17, P46, DOI 10.1093/rheumatology/17.1.46; FARRELL JP, 1982, MED J AUSTRALIA, V1, P160, DOI 10.5694/j.1326-5377.1982.tb132242.x; Feinstein A.R., 1985, CLIN EPIDEMIOLOGY; FREIMAN JA, 1978, NEW ENGL J MED, V299, P690, DOI 10.1056/NEJM197809282991304; FRYMOYER JW, 1988, NEW ENGL J MED, V318, P291, DOI 10.1056/NEJM198802043180506; GATTERMAN MI, 1990, CHIROPRACTIC MANAGEM, P37; GIBSON T, 1985, LANCET, V1, P1258; GLOVER JR, 1974, BRIT J IND MED, V31, P59; GODFREY CM, 1984, SPINE, V9, P301, DOI 10.1097/00007632-198404000-00015; GREENLAND S, 1980, J OCCUP ENVIRON MED, V22, P670, DOI 10.1097/00043764-198010000-00014; HADLER NM, 1987, SPINE, V12, P703, DOI 10.1097/00007632-198709000-00012; Helliwell PS, 1987, PHYSICIAN        APR, P187; HOEHLER FK, 1981, JAMA-J AM MED ASSOC, V245, P1835, DOI 10.1001/jama.245.18.1835; HOWE DH, 1983, J ROY COLL GEN PRACT, V33, P574; JAYSON MIV, 1981, SPINE, V6, P409, DOI 10.1097/00007632-198107000-00012; KELSEY JL, 1980, SPINE, V5, P133, DOI 10.1097/00007632-198003000-00007; KINALSKI R, 1989, MANUAL MED, V4, P44; KOES BW, 1991, BRIT MED J, V302, P1572, DOI 10.1136/bmj.302.6792.1572; MACDONALD RS, 1990, SPINE, V15, P364, DOI 10.1097/00007632-199005000-00005; MATHEWS JA, 1987, BRIT J RHEUMATOL, V26, P416; MATHEWS W, 1988, Physiotherapy Practice, V4, P201; MEADE TW, 1990, BRIT MED J, V300, P1431, DOI 10.1136/bmj.300.6737.1431; MEALY K, 1986, BRIT MED J, V292, P656, DOI 10.1136/bmj.292.6521.656; Meinert CL., 1986, CLIN TRIALS DESIGN C; NORDEMAR R, 1980, PAIN, V10, P93; Nwuga VCB, 1982, AM J PHYS MED, V1, P160; ONGLEY MJ, 1987, LANCET, V2, P143; OTTENBACHER K, 1985, SPINE, V10, P833, DOI 10.1097/00007632-198511000-00010; POCOCK SJ, 1987, NEW ENGL J MED, V317, P426, DOI 10.1056/NEJM198708133170706; Postacchini F, 1988, NEURO-ORTHOPEDICS, V6, P28; Rasmussen G. G., 1979, MANUAL MED, V17, P8; RUPERT RL, 1985, ICA INT REV CHIR WIN, P58; Siehl D, 1971, J Am Osteopath Assoc, V70, P433; SIMSWILLIAMS H, 1978, BMJ-BRIT MED J, V2, P1338, DOI 10.1136/bmj.2.6148.1338; SIMSWILLIAMS H, 1979, BMJ-BRIT MED J, V2, P1318, DOI 10.1136/bmj.2.6201.1318; SLOOP PR, 1982, SPINE, V7, P532, DOI 10.1097/00007632-198211000-00003; Spitzer W. O., 1987, SPINE, V12, P1; TERRIET G, 1990, J CLIN EPIDEMIOL, V43, P1191, DOI 10.1016/0895-4356(90)90020-P; TOBIS JS, 1983, B NY ACAD MED, V7, P660; Waagen GN, 1986, MANUAL MED, V2, P63; WADDELL G, 1987, SPINE, V12, P632, DOI 10.1097/00007632-198709000-00002; WATERWORTH RF, 1985, NEW ZEAL MED J, V98, P372; ZYLBERGOLD RS, 1981, ARCH PHYS MED REHAB, V62, P176	55	196	194	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 23	1991	303	6813					1298	1303		10.1136/bmj.303.6813.1298	http://dx.doi.org/10.1136/bmj.303.6813.1298			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GT011	1836153	Green Submitted, Green Published, Bronze			2023-01-03	WOS:A1991GT01100020
J	MCLELLAN, DL				MCLELLAN, DL			REHABILITATION	BRITISH MEDICAL JOURNAL			English	Article											MCLELLAN, DL (corresponding author), UNIV SOUTHAMPTON,SOUTHAMPTON GEN HOSP,REHABIL RES UNIT,LEVEL C,W WING,SOUTHAMPTON S09 4XY,ENGLAND.							Alexander J. L., 1979, Evaluation of Efficacy of Medical Action, P287; BEARDSHAW V, 1988, LAST LIST COMMUNITY; CANTRELL E, 1985, PRISONERS HANDICAP; CARPENTER GI, 1990, BMJ-BRIT MED J, V300, P1253, DOI 10.1136/bmj.300.6734.1253; Cornes P, 1991, Int Disabil Stud, V13, P5; EDWARDS FC, 1990, HLTH SERVICES ADULTS; GODFREY HPD, 1988, ARCH PHYS MED REHAB, V69, P458; MCLELLAN DL, 1987, J SOC OCCUP MED, V37, P94; ROBINE JM, 1991, BMJ-BRIT MED J, V302, P457, DOI 10.1136/bmj.302.6774.457; THOMAS AP, 1989, CLIN DEV MED, V106; WILSON BA, 1988, NEUROPSYCHOL REHABIL, P69; 1989, SURVEY DISABILITY GR, V1; 1991, CM1523	13	9	9	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 10	1991	303	6798					355	357		10.1136/bmj.303.6798.355	http://dx.doi.org/10.1136/bmj.303.6798.355			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GA606	1833005	Green Published, Bronze			2023-01-03	WOS:A1991GA60600028
J	POPMA, JJ; TOPOL, EJ				POPMA, JJ; TOPOL, EJ			ADJUNCTS TO THROMBOLYSIS FOR MYOCARDIAL REPERFUSION	ANNALS OF INTERNAL MEDICINE			English	Review						MYOCARDIAL INFARCTION; THROMBOLYTIC THERAPY; ASPIRIN; HEPARIN; BETA BLOCKING AGENTS	TISSUE PLASMINOGEN-ACTIVATOR; LEFT-VENTRICULAR FUNCTION; RANDOMIZED CONTROLLED TRIAL; INTRAVENOUS STREPTOKINASE; CORONARY THROMBOLYSIS; PLATELET-AGGREGATION; MULTICENTER TRIAL; MONOCLONAL-ANTIBODY; THROMBIN INHIBITION; CANINE PREPARATION	Objective: To discuss adjunctive pharmacologic agents for acute myocardial infarction, to critique their initial effects in clinical trials, and to review their potential for improving the clinical conditions of patients with acute myocardial infarction. Data Sources: Relevant studies reported from January 1985 to December 1990 were identified through a MEDLINE search of the English-language literature and through a manual search of the bibliographies of all identified articles. Study Selection: Peer-reviewed experimental and clinical studies evaluating the role of pharmacologic adjuncts to thrombolytic therapy in experimental models of coronary occlusion and clinical trials of patients with acute myocardial infarction were selected for review. Data Extraction and Synthesis: The data presented were abstracted by the investigators. Differences with a univariate P value of less than 0.05 were considered to be statistically significant. Conclusions: Current clinical data suggest that adjunctive pharmacologic therapy to thrombolytic agents should include aspirin, at least 160 mg administered as soon as possible after the onset of symptoms; intravenous heparin; and, in selected patients without contraindications, intravenous beta-blockading agents.	CLEVELAND CLIN FDN, DEPT CARDIOL, 1 CLIN CTR, 9500 EUCLID AVE, CLEVELAND, OH 44195 USA; UNIV MICHIGAN, SCH MED, ANN ARBOR, MI 48109 USA	Cleveland Clinic Foundation; University of Michigan System; University of Michigan								[Anonymous], 1987, Lancet, V2, P871; [Anonymous], 1990, LANCET, V336, P65; [Anonymous], 1988, LANCET, V2, P349; [Anonymous], 1989, NEW ENGL J MED, V320, P618; [Anonymous], 1986, LANCET, V2, P57; BABBITT DG, 1989, CIRCULATION, V80, P1388, DOI 10.1161/01.CIR.80.5.1388; BADIMON L, 1988, CIRCULATION S2, V78, P119; BAJAJ AK, 1989, CIRCULATION, V79, P645, DOI 10.1161/01.CIR.79.3.645; BALSANO F, 1990, CIRCULATION, V82, P17, DOI 10.1161/01.CIR.82.1.17; BECKER RC, 1990, AM HEART J, V119, P1254, DOI 10.1016/S0002-8703(05)80172-3; BLEICH SD, 1989, CIRCULATION S2, V80, P113; BRANAGAN JP, 1986, EUR HEART J, V7, P859, DOI 10.1093/oxfordjournals.eurheartj.a061972; BUSH LR, 1989, CIRCULATION, V80, P23; CADROY X, 1989, CIRCULATION S2, V80, P24; CALIFF RM, 1990, CIRCULATION, V82, P1847, DOI 10.1161/01.CIR.82.5.1847; CHAMBERLAIN DA, 1988, LANCET, V1, P545; CHAO BH, 1989, P NATL ACAD SCI USA, V86, P8050, DOI 10.1073/pnas.86.20.8050; COLLER BS, 1989, CIRCULATION, V80, P1766, DOI 10.1161/01.CIR.80.6.1766; COLLER BS, 1990, NEW ENGL J MED, V322, P33, DOI 10.1056/NEJM199001043220107; COOK JJ, 1989, AM J PHYSIOL, V256, pH1038, DOI 10.1152/ajpheart.1989.256.4.H1038; DATA JL, 1981, CIRCULATION, V64, P4, DOI 10.1161/01.CIR.64.1.4; ELLIS SG, 1989, CIRCULATION, V80, P1159, DOI 10.1161/01.CIR.80.5.1159; ELLIS SG, 1990, CIRCULATION, V82, P755; ENGLER R, 1987, CIRC RES, V61, P20, DOI 10.1161/01.RES.61.1.20; ENGLER RL, 1986, AM J PHYSIOL, V251, pH314, DOI 10.1152/ajpheart.1986.251.2.H314; ERBEL R, 1988, AM HEART J, V115, P529, DOI 10.1016/0002-8703(88)90800-9; FITZGERALD DJ, 1988, CIRCULATION, V77, P142, DOI 10.1161/01.CIR.77.1.142; FITZGERALD DJ, 1989, P NATL ACAD SCI USA, V86, P7585, DOI 10.1073/pnas.86.19.7585; GIBSON RS, 1986, NEW ENGL J MED, V315, P423, DOI 10.1056/NEJM198608143150704; GOLD HK, 1988, CIRCULATION, V77, P670, DOI 10.1161/01.CIR.77.3.670; GOLD HK, 1989, CIRCULATION S2, V80, P267; GOLINO P, 1989, CIRCULATION, V79, P911, DOI 10.1161/01.CIR.79.4.911; GOLINO P, 1988, CIRCULATION, V77, P678, DOI 10.1161/01.CIR.77.3.678; GRINES CL, 1989, J AM COLL CARDIOL, V14, P573, DOI 10.1016/0735-1097(89)90095-8; HANSEN JF, 1984, EUR HEART J, V5, P516; HANSON SR, 1988, P NATL ACAD SCI USA, V85, P3184, DOI 10.1073/pnas.85.9.3184; HASKEL EJ, 1989, CIRCULATION, V80, P1775, DOI 10.1161/01.CIR.80.6.1775; HERAS M, 1989, CIRCULATION, V79, P657, DOI 10.1161/01.CIR.79.3.657; HJALMARSON A, 1983, CIRCULATION, V67, P26; HOGG KJ, 1988, BRIT HEART J, V60, P275; HSAI J, 1990, NEW ENGL J MED, V323, P1433; JANG IK, 1990, CIRCULATION, V81, P219, DOI 10.1161/01.CIR.81.1.219; JANG IK, 1989, CIRCULATION, V79, P920, DOI 10.1161/01.CIR.79.4.920; JEREMY RW, 1989, J AM COLL CARDIOL, V13, P304, DOI 10.1016/0735-1097(89)90503-2; KELLY AB, 1988, CIRCULATION S2, V78, P311; KERINS DM, 1989, CLIN RES, V37, pA4; KLONER RA, 1989, CIRCULATION, V80, P1115, DOI 10.1161/01.CIR.80.5.1115; MARAGANORE JM, 1989, J BIOL CHEM, V264, P8692; MARAS P, 1986, EUR HEART J, V7, P23; MAURI F, 1987, F ITAL CARDIOL, V1171, P37; MCKAY RG, 1986, CIRCULATION, V74, P693, DOI 10.1161/01.CIR.74.4.693; MELLOT MJ, 1989, CIRCULATION S2, V80, P216; MIRSHAHI M, 1989, BLOOD, V74, P1025; MOSS AJ, 1988, NEW ENGL J MED, V319, P385; MULLER JE, 1984, CIRCULATION, V69, P740, DOI 10.1161/01.CIR.69.4.740; NABEL EG, 1989, CIRCULATION S2, V80, P112; NICOLINI FA, 1990, CIRCULATION, V81, P1115, DOI 10.1161/01.CIR.81.3.1115; NORRIS RM, 1988, LANCET, V1, P104; OHMAN EM, 1990, CIRCULATION, V82, P781, DOI 10.1161/01.CIR.82.3.781; OPIE LH, 1989, CIRCULATION, V80, P1049, DOI 10.1161/01.CIR.80.4.1049; OWEN J, 1988, BLOOD, V72, P616; PASSAMANI E, 1985, NEW ENGL J MED, V312, P932; PEDERSEN TR, 1981, NEW ENGL J MED, V304, P801; PENG CF, 1989, AM HEART J, V117, P515, DOI 10.1016/0002-8703(89)90723-0; PFEFFER MA, 1988, NEW ENGL J MED, V319, P80, DOI 10.1056/NEJM198807143190204; PREWITT RM, 1991, IN PRESS CHEST; PULEO PR, 1987, CIRCULATION, V75, P1162, DOI 10.1161/01.CIR.75.6.1162; RAO AK, 1988, J AM COLL CARDIOL, V11, P1; RENTROP KP, 1989, J AM COLL CARDIOL, V14, P58, DOI 10.1016/0735-1097(89)90054-5; RICHARDSON SG, 1989, BRIT HEART J, V61, P390; ROMSON JL, 1982, CIRCULATION, V66, P1002, DOI 10.1161/01.CIR.66.5.1002; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; SCHAUB RG, 1989, CIRCULATION S2, V80, P217; SHARMA B, 1986, AM J CARDIOL, V58, P1161, DOI 10.1016/0002-9149(86)90375-9; SHARPE N, 1988, LANCET, V1, P255; SHEBUSKI RJ, 1989, THROMB HAEMOSTASIS, V61, P183; SHEBUSKI RJ, 1990, CIRCULATION, V82, P169, DOI 10.1161/01.CIR.82.1.169; SIMPSON PJ, 1990, CIRCULATION, V81, P226, DOI 10.1161/01.CIR.81.1.226; SIRNES PA, 1984, CIRCULATION, V70, P638, DOI 10.1161/01.CIR.70.4.638; SMALLING RW, 1990, J AM COLL CARDIOL, V15, P915, DOI 10.1016/0735-1097(90)90216-C; STEIN B, 1989, J AM COLL CARDIOL, V14, P813, DOI 10.1016/0735-1097(89)90453-1; SWEDBERG K, 1987, EUR HEART J, V8, P362, DOI 10.1093/oxfordjournals.eurheartj.a062287; TAVAZZI L, 1989, LANCET, V2, P182; THOMPSON PL, 1988, LANCET, V1, P203; TOPOL EJ, 1989, CIRCULATION, V79, P281, DOI 10.1161/01.CIR.79.2.281; TOPOL EJ, 1987, NEW ENGL J MED, V317, P581, DOI 10.1056/NEJM198709033171001; TOPOL EJ, 1988, NEW ENGL J MED, V318, P1083, DOI 10.1056/NEJM198804283181702; TOPOL EJ, 1989, J AM COLL CARDIOL, V14, P877, DOI 10.1016/0735-1097(89)90458-0; TSCHOPP TB, 1977, THROMB RES, V11, P619, DOI 10.1016/0049-3848(77)90020-2; VANDEWERF F, 1990, LANCET, V336, P71; VANDEWERF F, 1989, LANCET, V1, P1367; WARREN SE, 1988, J AM COLL CARDIOL, V11, P12, DOI 10.1016/0735-1097(88)90159-3; WEISMAN HF, 1988, CIRCULATION, V78, P186, DOI 10.1161/01.CIR.78.1.186; WERNS S, 1989, CIRCULATION S2, V80, P113; WHITE CW, 1987, CIRCULATION, V76, P400; WHITE HD, 1987, NEW ENGL J MED, V317, P850, DOI 10.1056/NEJM198710013171402; WHITE HD, 1987, CIRCULATION, V76, P44, DOI 10.1161/01.CIR.76.1.44; WILCOX RG, 1988, LANCET, V2, P525; YAMAZAKI S, 1986, J AM COLL CARDIOL, V7, P564, DOI 10.1016/S0735-1097(86)80466-1; YASUDA T, 1988, J CLIN INVEST, V81, P1284, DOI 10.1172/JCI113446; YUSUF S, 1990, CIRCULATION, V82, P117; 1989, CIRCULATION S2, V80, P114	102	32	43	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 1	1991	115	1					34	44		10.7326/0003-4819-115-1-34	http://dx.doi.org/10.7326/0003-4819-115-1-34			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FT937	1675557				2023-01-03	WOS:A1991FT93700008
J	HANSEN, SW				HANSEN, SW			AUTONOMIC NEUROPATHY AFTER TREATMENT WITH CISPLATIN, VINBLASTINE, AND BLEOMYCIN FOR GERM-CELL CANCER	BRITISH MEDICAL JOURNAL			English	Article											HANSEN, SW (corresponding author), RIGSHOSP,FINSEN INST,DEPT ONCOL,DK-2100 COPENHAGEN O,DENMARK.							EWING DJ, 1986, CLIN ENDOCRINOL META, V15, P855, DOI 10.1016/S0300-595X(86)80078-0; HANSEN SW, 1989, J CLIN ONCOL, V7, P1457, DOI 10.1200/JCO.1989.7.10.1457; MCLEOD JG, 1987, ANN NEUROL, V21, P419, DOI 10.1002/ana.410210502; PAGE MM, 1978, LANCET, V1, P14; SAMUELS BL, 1987, CANCER CHEMOTH PHARM, V19, P253	5	44	44	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 24	1990	300	6723					511	512		10.1136/bmj.300.6723.511	http://dx.doi.org/10.1136/bmj.300.6723.511			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CQ878	1690581	Green Published, Bronze			2023-01-03	WOS:A1990CQ87800021
J	GENTLEMAN, D; JENNETT, B				GENTLEMAN, D; JENNETT, B			AUDIT OF TRANSFER OF UNCONSCIOUS HEAD-INJURED PATIENTS TO A NEUROSURGICAL UNIT	LANCET			English	Article									INST NEUROL SCI,DEPT NEUROSURG,GLASGOW,SCOTLAND	University of Glasgow								ANDERSON ID, 1988, BRIT MED J, V296, P1305, DOI 10.1136/bmj.296.6632.1305; [Anonymous], 1986, REPORT WORKING PARTY; BION JF, 1988, BRIT MED J, V296, P170, DOI 10.1136/bmj.296.6616.170; BRYDEN JS, 1983, BRIT MED J, V286, P1791, DOI 10.1136/bmj.286.6380.1791; DRAAISMA JMT, 1986, AMBULANCE, V7, P15; FREY CF, 1984, JAMA-J AM MED ASSOC, V251, P2698; GENTLEMAN D, 1981, LANCET, V2, P853; HEWER RL, 1989, BRIT MED J, V298, P1219, DOI 10.1136/bmj.298.6682.1219; JEFFREYS RV, 1981, LANCET, V2, P459; JENNETT B, 1979, BRIT MED J, V2, P955, DOI 10.1136/bmj.2.6196.955; JENNETT B, 1975, LANCET, V1, P480; JENNETT B, 1978, INJURY, V10, P31; Jennett B, 1989, MILD HEAD INJURY, P23; Marsh H, 1989, Br J Neurosurg, V3, P13, DOI 10.3109/02688698909001021; McLaren C A, 1983, J R Coll Surg Edinb, V28, P399; OTTOSSON A, 1984, JAMA-J AM MED ASSOC, V251, P2668, DOI 10.1001/jama.251.20.2668; ROSE J, 1977, BRIT MED J, V2, P615, DOI 10.1136/bmj.2.6087.615; SMITH RW, 1986, J NEUROSURG, V65, P569; TEASDALE G, 1982, BRIT MED J, V285, P1965; van Alphen H A, 1985, Ned Tijdschr Geneeskd, V129, P645; WRIGHT IH, 1988, BRIT MED J, V296, P543, DOI 10.1136/bmj.296.6621.543; YATES DW, 1988, BRIT MED J, V297, P1419, DOI 10.1136/bmj.297.6661.1419; 1984, BRIT MED J, V288, P983	23	82	83	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 10	1990	335	8685					330	334		10.1016/0140-6736(90)90615-C	http://dx.doi.org/10.1016/0140-6736(90)90615-C			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CM846	1967777				2023-01-03	WOS:A1990CM84600012
J	COKER, RJ; NIEMAN, R; MCBRIDE, M; MITCHELL, DM; HARRIS, JRW; WEBER, JN				COKER, RJ; NIEMAN, R; MCBRIDE, M; MITCHELL, DM; HARRIS, JRW; WEBER, JN			COTRIMOXAZOLE VERSUS DAPSONE-PYRIMETHAMINE FOR PREVENTION OF PNEUMOCYSTIS-CARINII PNEUMONIA	LANCET			English	Letter									NATL LUNG & HEART INST,DEPT RESP MED,LONDON SW3,ENGLAND; ST MARYS HOSP,DEPT RESP MED,LONDON W2 1NY,ENGLAND	Imperial College London; Imperial College London	COKER, RJ (corresponding author), ST MARYS HOSP,DEPT GENITOURINARY MED,JEFFERISS WING,LONDON W2 1NY,ENGLAND.							ANTINORI, 1992, LANCET, V340, P788	1	21	21	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 31	1992	340	8827					1099	1099		10.1016/0140-6736(92)93120-C	http://dx.doi.org/10.1016/0140-6736(92)93120-C			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JV775	1357487				2023-01-03	WOS:A1992JV77500038
J	ANAISSIE, E; KONTOYIANNIS, DP; KANTARJIAN, H; ELTING, L; ROBERTSON, LE; KEATING, M				ANAISSIE, E; KONTOYIANNIS, DP; KANTARJIAN, H; ELTING, L; ROBERTSON, LE; KEATING, M			LISTERIOSIS IN PATIENTS WITH CHRONIC LYMPHOCYTIC-LEUKEMIA WHO WERE TREATED WITH FLUDARABINE AND PREDNISONE	ANNALS OF INTERNAL MEDICINE			English	Article						LISTERIA INFECTIONS; LEUKEMIA, LYMPHOCYTIC, CHRONIC; FLUDARABINE; PREDNISONE; ANTIGENS, CD4; ACQUIRED IMMUNODEFICIENCY SYNDROME; HUMAN IMMUNODEFICIENCY VIRUS	INFECTIONS; THERAPY; AGENT	Objective. To determine whether therapy with fludarabine plus prednisone in patients with chronic lymphocytic leukemia increases the risk for developing listeriosis. Design: Retrospective cohort study based on hospital surveillance data. Setting: Referral cancer center. Participants: A total of 795 patients with chronic lymphocytic leukemia who received care at The University of Texas M. D. Anderson Cancer Center between 1980 and 1990. Interventions: Patients were treated with fludarabine alone or fludarabine and prednisone. Measurements: The listeriosis attack rate was analyzed according to the type of treatment received. Results: Seven of 408 patients in the fludarabine group developed listeriosis (1.7%; 95% Cl, 0.2% to 6%) compared with 0 of 387 patients who received conventional chemotherapy alone (0% to 0.9%; P = 0.015). The 7 patients were among 248 patients who were treated with both fludarabine and prednisone; none of 160 patients treated with fludarabine alone developed listeriosis (P = 0.045 by the Fisher exact test). A dramatic reduction in CD4 counts occurred in patients after fludarabine and prednisone treatment and coincided with the development of listeriosis. Conclusion: The administration of fludarabine plus prednisone is associated with an increased incidence of listeriosis in patients with chronic lymphocytic leukemia. The depletion of CD4 cells may underlie the pathogenesis.			ANAISSIE, E (corresponding author), UNIV TEXAS, MD ANDERSON CANC CTR, 1515 HOLCOMBE BLVD, BOX 47, HOUSTON, TX 77030 USA.							AMPEL MN, 1990, 30TH P INT C ANT AG; ARMSTRONG D, 1990, PRINCIPLES PRACTICE, P1587; AROESTY JM, 1962, NEW YORK STATE J MED, V62, P1946; Bille J, 1988, B BUNDESAMTES GESUND, V3, P28; BOLDT DH, 1984, CANCER RES, V44, P4661; COX DR, 1953, BIOMETRIKA, V40, P354, DOI 10.1093/biomet/40.3-4.354; FAUCI AS, 1976, ANN INTERN MED, V84, P304, DOI 10.7326/0003-4819-84-3-304; HANSEN MM, 1973, SCAND J HAEMATOL, P1; HANTEL A, 1989, CANCER, V64, P516, DOI 10.1002/1097-0142(19890715)64:2<516::AID-CNCR2820640226>3.0.CO;2-I; HEATH ME, 1985, AM J HEMATOL, V19, P63, DOI 10.1002/ajh.2830190109; KEATING MJ, 1988, LEUKEMIA, V2, P157; KEATING MJ, 1989, BLOOD, V74, P19; LINNAN MJ, 1988, NEW ENGL J MED, V319, P823, DOI 10.1056/NEJM198809293191303; LOURIA DB, 1970, ANN NY ACAD SCI, V174, P545, DOI 10.1111/j.1749-6632.1970.tb45580.x; LOURIA DB, 1967, ANN INTERN MED, V67, P261, DOI 10.7326/0003-4819-67-2-261; MONSERRATCOSTA E, 1977, SANGRE, V22, P968; MYERS TJ, 1980, CANCER, V46, P619, DOI 10.1002/1097-0142(19800801)46:3<619::AID-CNCR2820460332>3.0.CO;2-I; NIEMAN RE, 1980, REV INFECT DIS, V2, P207; PISCIOTTA AV, 1957, ARCH INTERN MED, V99, P334, DOI 10.1001/archinte.1957.00260030012002; REVOL L, 1974, ENCY MED CHIRURGICAL; ROBERTSON LE, 1990, BLOOD, V76, pA314; SAMRA Y, 1984, POSTGRAD MED J, V60, P267, DOI 10.1136/pgmj.60.702.267; SCHILLING PJ, 1990, NEW ENGL J MED, V323, P833, DOI 10.1056/NEJM199009203231216; SCHLECH WF, 1983, NEW ENGL J MED, V308, P203, DOI 10.1056/NEJM198301273080407; SCHWARTZ B, 1988, LANCET, V2, P779; SHAW RK, 1960, ARCH INTERN MED, V106, P467, DOI 10.1001/archinte.1960.03820040005002; SPITZER PG, 1986, REV INFECT DIS, V8, P427; TRAVADE P, 1986, PRESSE MED, V15, P1715; TWOMEY JJ, 1973, ARCH INTERN MED, V132, P562, DOI 10.1001/archinte.132.4.562; UTMANN JE, 1959, ANN INTERN MED, V51, P501; WINSLOW DL, 1982, ANTIMICROB AGENTS CH, V22, P51, DOI 10.1128/AAC.22.1.51; 1989, MMWR, V38, P267	32	110	111	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 15	1992	117	6					466	469		10.7326/0003-4819-117-6-466	http://dx.doi.org/10.7326/0003-4819-117-6-466			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JN257	1354425				2023-01-03	WOS:A1992JN25700004
J	CHRISTMAN, K; MUSS, HB; CASE, LD; STANLEY, V				CHRISTMAN, K; MUSS, HB; CASE, LD; STANLEY, V			CHEMOTHERAPY OF METASTATIC BREAST-CANCER IN THE ELDERLY - THE PIEDMONT-ONCOLOGY-ASSOCIATION EXPERIENCE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RANDOMIZED TRIAL; CLINICAL ONCOLOGY; CYCLOPHOSPHAMIDE; 5-FLUOROURACIL; METHOTREXATE; AGE; VINCRISTINE; DOXORUBICIN; TOXICITY; PROGRAM	Objective.-To determine the effect of age on treatment outcome in women with metastatic breast cancer treated with chemotherapy. Design.-Case-comparison study of patients with metastatic breast cancer treated in five clinical trials of the Piedmont Oncology Association. Setting.-University and private practice physicians participating in the Piedmont Oncology Association clinical tri,als in the southeastern United States. Patients.-Seventy patients 70 years of age or older were compared with 60 patients aged 50 through 69 years and 40 patients less than 50 years of age. All patients were ambulatory or capable of self-care, with adequate hematologic, renal, and hepatic function. Interventions.-Treatment with multidrug chemotherapy regimens. Main Outcome Measures.-Response to treatment, time to disease progression, survival, and toxic effects. Results.-Pretreatment characteristics including race, performance status; disease-free interval, prior therapy, sites of metastatic disease, and number and dominant sites of metastases were similar for the three age groups. The response rates for the younger-than-50, 50-through-69, and 70-or-older age groups were 40%, 31%, and 29%, respectively (P=.53). There were no significant differences in time to disease progression or survival for patients in the three age groups. Estimates for time to progression and survival were 9.1 and 17.9 months, 6.2 and 12.8 months, and 7.2 and 14.2 months, respectively. Toxic effects, dose delivery, and dose delays were also similar for all three age groups. Conclusions.-Women 70 years of age or older who were enrolled in these trials were similar to their younger counterparts in response rates, time to disease progression, survival, and toxic effects. Women in this age group should not be excluded, based on age alone, from clinical trials involving chemotherapy for advanced breast cancer.	WAKE FOREST UNIV,CTR COMPREHENS CANC,MED CTR BLVD,WINSTON SALEM,NC 27157; PIEDMONT ONCOL ASSOC,WINSTON SALEM,NC	Wake Forest University					NATIONAL CANCER INSTITUTE [U10CA045808, U10CA037378, P30CA012197] Funding Source: NIH RePORTER; NCI NIH HHS [CA-45808, CA-37378, CA-12197] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BALDUCCI L, 1989, SEMIN ONCOL, V16, P76; BALDWIN JG, 1988, ARCH INTERN MED, V148, P2544, DOI 10.1001/archinte.148.12.2544; BEGG CB, 1980, CANCER CLIN TRIALS, V3, P369; BEGG CB, 1989, CANCER ELDERLY APPRO; BONADONNA G, 1981, NEW ENGL J MED, V304, P10, DOI 10.1056/NEJM198101013040103; BORING CC, 1991, CA-CANCER J CLIN, V41, P19, DOI 10.3322/canjclin.41.1.19; COX DR, 1972, J R STAT SOC B, V34, P187; GARBER JE, 1989, HEMATOL ONCOL CLIN N, V3, P807, DOI 10.1016/S0889-8588(18)30532-X; GELMAN RS, 1984, J CLIN ONCOL, V2, P1404, DOI 10.1200/JCO.1984.2.12.1404; GREENFIELD S, 1987, JAMA-J AM MED ASSOC, V257, P2766, DOI 10.1001/jama.257.20.2766; HAYWARD JL, 1977, CANCER, V39, P1289, DOI 10.1002/1097-0142(197703)39:3<1289::AID-CNCR2820390340>3.0.CO;2-F; HENDERSON IC, 1991, BREAST DIS, P604; HOAGLAND HC, 1982, SEMIN ONCOL, V9, P95; HOST H, 1986, CANCER, V58, P996; Hryniuk W M, 1986, NCI Monogr, P87; HUNTER CP, 1987, CANCER TREAT REP, V71, P559; KERR IG, 1989, CANC AGING PROGR RES, P139; MILLER AB, 1981, CANCER, V47, P207, DOI 10.1002/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6; MOR V, 1985, J AM GERIATR SOC, V33, P585, DOI 10.1111/j.1532-5415.1985.tb06313.x; MUSS HB, 1991, NEW ENGL J MED, V325, P1342, DOI 10.1056/NEJM199111073251904; MUSS HB, 1982, CANCER, V50, P2269, DOI 10.1002/1097-0142(19821201)50:11<2269::AID-CNCR2820501107>3.0.CO;2-L; MUSS HB, 1981, CANCER, V47, P2295, DOI 10.1002/1097-0142(19810501)47:9<2295::AID-CNCR2820470932>3.0.CO;2-8; MUSS HB, 1978, CANCER, V42, P2141, DOI 10.1002/1097-0142(197811)42:5<2141::AID-CNCR2820420509>3.0.CO;2-3; NERENZ DR, 1986, HEALTH SERV RES, V20, P961; SHANK W, 1991, P AN M AM SOC CLIN, V10, P326; STEWART JA, 1989, SEMIN ONCOL, V16, P41; YANCIK R, 1989, CANCER, V63, P976, DOI 10.1002/1097-0142(19890301)63:5<976::AID-CNCR2820630532>3.0.CO;2-A; ZEKAN PJ, 1984, CANCER, V54, P2338, DOI 10.1002/1097-0142(19841201)54:11<2338::AID-CNCR2820541105>3.0.CO;2-4	28	172	173	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 1	1992	268	1					57	62		10.1001/jama.268.1.57	http://dx.doi.org/10.1001/jama.268.1.57			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JA165	1608114				2023-01-03	WOS:A1992JA16500023
J	TRUOG, RD; BRETT, AS; FRADER, J				TRUOG, RD; BRETT, AS; FRADER, J			THE PROBLEM WITH FUTILITY	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							MEDICAL INTENSIVE-CARE; FAMILY; RESUSCITATE; PATIENT; ORDERS; POLICY; ETHICS		UNIV PITTSBURGH,PITTSBURGH,PA 15213	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	TRUOG, RD (corresponding author), HARVARD UNIV,SCH MED,BOSTON,MA 02115, USA.		Frader, Joel/A-8610-2010					AARON H, 1990, SCIENCE, V247, P418, DOI 10.1126/science.2300804; ANNAS GJ, 1990, NEW ENGL J MED, V323, P670, DOI 10.1056/NEJM199009063231010; [Anonymous], 1990, CRIT CARE MED, V18, P1435; BEDELL SE, 1983, NEW ENGL J MED, V309, P569, DOI 10.1056/NEJM198309083091001; BLACKHALL LJ, 1987, NEW ENGL J MED, V317, P1281, DOI 10.1056/NEJM198711123172009; BRAITHWAITE S, 1986, ANN INTERN MED, V104, P711, DOI 10.7326/0003-4819-104-5-711; BRENNAN TA, 1988, JAMA-J AM MED ASSOC, V260, P803, DOI 10.1001/jama.260.6.803; CALLAHAN D, 1991, HASTINGS CENT REP, V21, P30, DOI 10.2307/3562999; CAPRON AM, 1991, HASTINGS CENT REP, V21, P26, DOI 10.2307/3562887; DANIS M, 1988, CRIT CARE MED, V16, P594, DOI 10.1097/00003246-198806000-00006; DANIS M, 1988, JAMA-J AM MED ASSOC, V260, P797, DOI 10.1001/jama.260.6.797; DANIS M, 1987, CRIT CARE MED, V15, P138, DOI 10.1097/00003246-198702000-00012; EDDY DM, 1991, JAMA-J AM MED ASSOC, V266, P417, DOI 10.1001/jama.266.3.417; ELSTEIN AS, 1976, SCIENCE, V194, P696, DOI 10.1126/science.982034; HACKLER JC, 1990, JAMA-J AM MED ASSOC, V264, P1281, DOI 10.1001/jama.264.10.1281; HIPPOCRATES, 1977, ETHICS MED HIST PERS, P6; LANTOS JD, 1989, AM J MED, V87, P81; LAPUMA J, 1987, WESTERN J MED, V146, P633; MEISEL A, 1989, RIGHT DIE, P104; MILES SH, 1991, NEW ENGL J MED, V325, P512, DOI 10.1056/NEJM199108153250713; MISBIN RI, 1991, NEW ENGL J MED, V325, P1307, DOI 10.1056/NEJM199110313251811; MURPHY DJ, 1988, JAMA-J AM MED ASSOC, V260, P2098, DOI 10.1001/jama.260.14.2098; PARIS JJ, 1990, NEW ENGL J MED, V322, P1012, DOI 10.1056/NEJM199004053221420; POSES RM, 1989, CRIT CARE MED, V17, P827, DOI 10.1097/00003246-198908000-00021; POSES RM, 1985, JAMA-J AM MED ASSOC, V254, P925, DOI 10.1001/jama.254.7.925; SCHNEIDERMAN LJ, 1990, ANN INTERN MED, V112, P949, DOI 10.7326/0003-4819-112-12-949; TVERSKY A, 1974, SCIENCE, V185, P1124, DOI 10.1126/science.185.4157.1124; YOUNGER SJ, 1988, JAMA-J AM MED ASSOC, V260, P2094, DOI 10.1001/jama.260.14.2094; 1983, PRESIDENTS COMMISSIO, P188; 1991, NY TIMES        0705, pA8; 1986, DO NOT RESISCIATE OR, P96; 1986, DO NOT RESUSCITATE O, P83; 1987, GUIDELINES TERMINATI, P112; 1974, JAMA-J AM MED ASSOC, V227, P864; 1987, GUIDELINES TERMINATI, P32; 1991, JAMA-J AM MED ASSOC, V265, P1868	36	302	305	0	7	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 4	1992	326	23					1560	1564		10.1056/NEJM199206043262310	http://dx.doi.org/10.1056/NEJM199206043262310			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HW972	1285741				2023-01-03	WOS:A1992HW97200010
J	TORCHILIN, VP; KLIBANOV, AL; HUANG, L; ODONNELL, S; NOSSIFF, ND; KHAW, BA				TORCHILIN, VP; KLIBANOV, AL; HUANG, L; ODONNELL, S; NOSSIFF, ND; KHAW, BA			TARGETED ACCUMULATION OF POLYETHYLENE GLYCOL-COATED IMMUNOLIPOSOMES IN INFARCTED RABBIT MYOCARDIUM	FASEB JOURNAL			English	Note						IMMUNOLIPOSOME; POLYETHYLENEGLYCOL; TARGETED DRUG DELIVERY; INFARCTED MYOCARDIUM	LIPOSOMES; ANTIBODY	The less than optimal accumulation of immunoliposome-associated reagents at target sites has often been attributed to the rapid in vivo clearance of immunoliposomes from the blood. In an attempt to overcome the drawback of rapid clearance and use the targeting potential of immunoliposomes, we have prepared long-circulating, In-111-labeled immunoliposomes. Targeting properties and enhanced circulation times were demonstrated in a rabbit model of acute experimental myocardial infarct. The specificity of liposomes for newly exposed intracellular cardiac myosin at the necrotic sites was achieved by incorporating monoclonal antimyosin antibody. Extended circulation times were achieved by cocoating the antimyosin-liposomes with polyethylene glycol (PEG). The half-life of the immunoliposomes was 40 min, which increased to 200 min with 4% mol PEG and to approximately 1000 min with 10% mol PEG. The degree of binding of modified immunoliposomes at the target sites was also dependent on the concentration of PEG incorporated at the liposome surface. This study demonstrates the accumulation of long-circulating targeted liposomes at the area of acute rabbit experimental myocardial infarction.	MASSACHUSETTS GEN HOSP,DEPT NUCL MED,BOSTON,MA 02129; UNIV TENNESSEE,DEPT BIOCHEM,KNOXVILLE,TN 37996	Harvard University; Massachusetts General Hospital; University of Tennessee System; University of Tennessee Knoxville	TORCHILIN, VP (corresponding author), MASSACHUSETTS GEN HOSP E,CTR IMAGING & PHARMACEUT RES,DEPT RADIOL,BLDG 149,13TH ST,BOSTON,MA 02129, USA.							CARIDE VJ, 1977, SCIENCE, V198, P735, DOI 10.1126/science.910155; KABALKA G, 1987, RADIOLOGY, V163, P255, DOI 10.1148/radiology.163.1.3454163; KHAW BA, 1984, HYBRIDOMA, V3, P11, DOI 10.1089/hyb.1984.3.11; KLIBANOV AL, 1991, BIOCHIM BIOPHYS ACTA, V1062, P142, DOI 10.1016/0005-2736(91)90385-L; KLIBANOV AL, 1990, FEBS LETT, V268, P235, DOI 10.1016/0014-5793(90)81016-H; KLIBANOV AL, 1991, AM J PHYSL S, V2611, P60; Leserman LD, 1984, LIPOSOME TECHNOLOGY, V3, P29; MORI A, 1991, FEBS LETT, V284, P263, DOI 10.1016/0014-5793(91)80699-4; TORCHILIN VP, 1979, BIOCHEM BIOPH RES CO, V89, P1114, DOI 10.1016/0006-291X(79)92123-5; WEISSIG V, 1986, FEBS LETT, V202, P86, DOI 10.1016/0014-5793(86)80654-8	10	173	189	0	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JUN	1992	6	9					2716	2719		10.1096/fasebj.6.9.1612296	http://dx.doi.org/10.1096/fasebj.6.9.1612296			4	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	HZ481	1612296				2023-01-03	WOS:A1992HZ48100013
J	WATSON, AJ; HANKINSON, O				WATSON, AJ; HANKINSON, O			DIOXIN-DEPENDENT AND AH RECEPTOR-DEPENDENT PROTEIN-BINDING TO XENOBIOTIC RESPONSIVE ELEMENTS AND G-RICH DNA STUDIED BY INVIVO FOOTPRINTING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME P-450C GENE; FACTORS INTERACT; CYP1A1 GENE; ENHANCER; PROMOTER; EXPRESSION; UPSTREAM; TRANSCRIPTION; REQUIREMENT; INDUCTION	DNA-protein interactions before and after transcriptional activation of the carcinogen- and dioxin-inducible enhancer of the murine CYP1A1 gene were detected in vivo by treatment with dimethyl sulfate followed by ligation-mediated, polymerase chain reaction-aided genomic sequencing. Following 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) treatment of mouse Hepa-1 hepatoma cells, evidence of protein binding was detected at the sequence 5' CACGCNA/T 3' within two previously defined xenobiotic response elements (XREs). The observed XRE footprint was similar to that previously identified by in vitro methylation protection footprints and attributed to the binding protein for 2,3,7,8-tetrachlorodibenzo-p-dioxin the Ah receptor. No XRE footprinting was observed in Hepa-1 mutant cells possessing a defective Ah receptor. Unexpectedly, evidence of protein binding was also detected at a G-rich DNA sequence immediately adjacent to one of the XREs. Footprinting of the G-rich sequence element, like that of XRE1 and XRE2, was dependent on the presence of a functional Ah receptor. The Ah receptor is therefore able to bind to its own DNA target sites in vivo and is also required for the binding of a second factor to the G-rich element.	UNIV CALIF LOS ANGELES,BIOMED & ENVIRONM SCI LAB,900 VET AVE,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,SCH PUBL HLTH,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,DEPT PATHOL & LAB MED,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles					NATIONAL CANCER INSTITUTE [R01CA028868] Funding Source: NIH RePORTER; NCI NIH HHS [CA 28868] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAVAYA K, 1991, MOL CELL BIOL, V11, P586, DOI 10.1128/MCB.11.1.586; ANDERSEN RD, 1987, MOL CELL BIOL, V7, P3574, DOI 10.1128/MCB.7.10.3574; BECKER PB, 1987, CELL, V51, P435, DOI 10.1016/0092-8674(87)90639-8; CHURCH GM, 1985, NATURE, V313, P798, DOI 10.1038/313798a0; DENISON MS, 1989, J BIOL CHEM, V264, P16478; DENISON MS, 1988, P NATL ACAD SCI USA, V85, P2528, DOI 10.1073/pnas.85.8.2528; ELFERINK CJ, 1990, J BIOL CHEM, V265, P20708; EPHRUSSI A, 1985, SCIENCE, V227, P134, DOI 10.1126/science.3917574; FISHER JM, 1990, J BIOL CHEM, V265, P9676; FUJISAWASEHARA A, 1986, NUCLEIC ACIDS RES, V14, P1465; FUJISAWASEHARA A, 1988, P NATL ACAD SCI USA, V85, P5859, DOI 10.1073/pnas.85.16.5859; FUJISAWASEHARA A, 1987, NUCLEIC ACIDS RES, V15, P4179, DOI 10.1093/nar/15.10.4179; GILBERT W, 1976, CONTROL RIBOSOME SYN, P139; GODING CR, 1987, NUCLEIC ACIDS RES, V15, P7761, DOI 10.1093/nar/15.19.7761; GONZALEZ FJ, 1985, NUCLEIC ACIDS RES, V13, P7269, DOI 10.1093/nar/13.20.7269; HANKINSON O, 1985, J BIOL CHEM, V260, P1790; HAPGOOD J, 1989, P NATL ACAD SCI USA, V86, P60, DOI 10.1073/pnas.86.1.60; HAPGOOD J, 1991, MOL CELL BIOL, V11, P4314, DOI 10.1128/MCB.11.9.4314; HERRERA RE, 1989, NATURE, V340, P68, DOI 10.1038/340068a0; JOHNSRUD L, 1978, P NATL ACAD SCI USA, V75, P5314, DOI 10.1073/pnas.75.11.5314; JONES KW, 1990, MOL CELL BIOL, V10, P5098, DOI 10.1128/MCB.10.10.5098; JONES PBC, 1986, J BIOL CHEM, V261, P6647; JONES PBC, 1985, SCIENCE, V227, P1499, DOI 10.1126/science.3856321; KARA CJ, 1991, SCIENCE, V252, P709, DOI 10.1126/science.1902592; LEGRAVEREND C, 1982, J BIOL CHEM, V257, P6402; Maxam A M, 1980, Methods Enzymol, V65, P499; MUELLER PR, 1988, GENE DEV, V2, P412, DOI 10.1101/gad.2.4.412; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; NEUHOLD LA, 1989, MOL CELL BIOL, V9, P2378, DOI 10.1128/MCB.9.6.2378; NEUHOLD LA, 1986, DNA-J MOLEC CELL BIO, V5, P403, DOI 10.1089/dna.1986.5.403; PELKONEN O, 1982, PHARMACOL REV, V34, P189; POLAND A, 1975, MOL PHARMACOL, V11, P389; SAATCIOGLU F, 1990, J BIOL CHEM, V265, P9251; SAATCIOGLU F, 1990, MOL CELL BIOL, V10, P6408, DOI 10.1128/MCB.10.12.6408; SHEN ES, 1989, J BIOL CHEM, V264, P17754; WEIH F, 1990, GENE DEV, V4, P1437, DOI 10.1101/gad.4.8.1437; WHITLOCK JP, 1990, ANNU REV PHARMACOL, V30, P251	37	62	64	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1992	267	10					6874	6878						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HM053	1313025				2023-01-03	WOS:A1992HM05300065
J	CLASSEN, DC; EVANS, RS; PESTOTNIK, SL; HORN, SD; MENLOVE, RL; BURKE, JP				CLASSEN, DC; EVANS, RS; PESTOTNIK, SL; HORN, SD; MENLOVE, RL; BURKE, JP			THE TIMING OF PROPHYLACTIC ADMINISTRATION OF ANTIBIOTICS AND THE RISK OF SURGICAL-WOUND INFECTION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ANTI-MICROBIAL PROPHYLAXIS; ANTIMICROBIAL PROPHYLAXIS; SURGERY; PRINCIPLES	Background. Randomized, controlled trials have shown that prophylactic antibiotics are effective in preventing surgical-wound infections. However, it is uncertain how the timing of antibiotic administration affects the risk of surgical-wound infection in actual clinical practice. Methods. We prospectively monitored the timing of antibiotic prophylaxis and studied the occurrence of surgical-wound infections in 2847 patients undergoing elective clean or "clean-contaminated" surgical procedures at a large community hospital. The administration of antibiotics 2 to 24 hours before the surgical incision was defined as early; that during the 2 hours before the incision, as preoperative; that during the 3 hours after the incision, as peri-operative; and that more than 3 but less than 24 hours after the incision, as postoperative. Results. Of the 1708 patients who received the prophylactic antibiotics preoperatively, 10 (0.6 percent) subsequently had surgical-wound infections. Of the 282 patients who received the antibiotics perioperatively, 4 (1.4 percent) had such infections (P = 0.12; relative risk as compared with the preoperatively treated group, 2.4; 95 percent confidence interval, 0.9 to 7.9). Of 488 patients who received the antibiotics postoperatively, 16 (3.3 percent) had wound infections (P < 0.0001; relative risk, 5.8; 95 percent confidence interval, 2.6 to 12.3). Finally, of 369 patients who had antibiotics administered early, 14 (3.8 percent) had wound infections (P < 0.0001; relative risk, 6.7; 95 percent confidence interval, 2.9 to 14.7). Stepwise logistic-regression analysis confirmed that the administration of antibiotics in the preoperative period was associated with the lowest risk of surgical-wound infection. Conclusions. In surgical practice there is considerable variation in the timing of the prophylactic administration of antibiotics, and administration in the two hours before surgery reduces the risk of wound infection.	LATTER DAY ST HOSP, DEPT CLIN EPIDEMIOL, 8TH AVE & C ST, SALT LAKE CITY, UT 84143 USA; UNIV UTAH, SCH MED, DIV INFECT DIS, SALT LAKE CITY, UT 84112 USA	Utah System of Higher Education; University of Utah								BERGQUIST EJ, 1987, MED CLIN N AM, V71, P357, DOI 10.1016/S0025-7125(16)30845-8; BERMAN GD, 1990, MAYO CLIN PROC, V65, P657, DOI 10.1016/S0025-6196(12)65128-3; BURDON DW, 1982, WORLD J SURG, V6, P262, DOI 10.1007/BF01653540; BURKE JF, 1961, SURGERY, V50, P161; CROSSLEY K, 1981, JAMA-J AM MED ASSOC, V245, P722, DOI 10.1001/jama.245.7.722; DONABEDIAN A, 1990, INFECT CONT HOSP EP, V11, P117; EHRENKRANZ NJ, 1981, AM J MED, V70, P909, DOI 10.1016/0002-9343(81)90554-4; ELLWOOD PM, 1988, NEW ENGL J MED, V318, P1549, DOI 10.1056/NEJM198806093182329; EVANS RS, 1986, JAMA-J AM MED ASSOC, V256, P1007, DOI 10.1001/jama.256.8.1007; FINLAND M, 1960, R I Med J, V43, P499; FINLAND M, 1960, R I MED J, V43, P513; GILEGEA MJ, 1987, INFECT CONT HOSP EP, V8, P277, DOI 10.1017/S0195941700066236; GREENFIELD S, 1989, NEW ENGL J MED, V320, P1142, DOI 10.1056/NEJM198904273201710; GUGLIELMO BJ, 1983, ARCH SURG-CHICAGO, V118, P943; Hosmer D., 2000, APPL LOGISTIC REGRES, V2; HUNT TK, 1981, AM J MED, V70, P712, DOI 10.1016/0002-9343(81)90602-1; KAISER AB, 1986, NEW ENGL J MED, V315, P1129; LARSEN RA, 1989, INFECT CONT HOSP EP, V10, P316, DOI 10.2307/30146474; MOLESKI RJ, 1986, REV INFECT DIS, V8, P488; OLSON M, 1984, ANN SURG, V199, P253, DOI 10.1097/00000658-198403000-00001; POLISSAR L, 1982, MED CARE, V20, P959, DOI 10.1097/00005650-198209000-00008; POLK HC, 1969, SURGERY, V66, P97; Pryor T A, 1983, J Med Syst, V7, P87, DOI 10.1007/BF00995116; RONALD AR, 1983, SURGERY, V93, P172; ROPER WL, 1988, NEW ENGL J MED, V319, P1197, DOI 10.1056/NEJM198811033191805; SHAPIRO M, 1979, NEW ENGL J MED, V301, P351, DOI 10.1056/NEJM197908163010703; SHAPIRO M, 1980, J INFECT DIS, V141, P532, DOI 10.1093/infdis/141.4.532; SIMMONS RL, 1982, INFECT CONT HOSP EP, V3, P44, DOI 10.1017/S0195941700057118; STONE HH, 1984, J ANTIMICROB CHEMOTH, V14, P33, DOI 10.1093/jac/14.suppl_B.33; STONE HH, 1976, ANN SURG, V184, P443, DOI 10.1097/00000658-197610000-00007; 1980, AM J EPIDEMIOL, V111, P635; 1985, MED LETT DRUGS THER, V27, P105	32	1176	1220	0	37	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 30	1992	326	5					281	286		10.1056/NEJM199201303260501	http://dx.doi.org/10.1056/NEJM199201303260501			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HA991	1728731				2023-01-03	WOS:A1992HA99100001
J	ABE, O; ABE, R; ASAISHI, K; ENOMOTO, K; HATTORI, T; INO, Y; KIKUCHI, K; KOYAMA, H; SAWA, K; UCHINO, J; YOSHIDA, M; HAYBITTLE, JL; VANDEVELDE, T; VERMORKEN, JB; HARVEY, VJ; HOLDAWAY, TM; KAY, RG; MASON, BH; FORBES, JF; BASTERT, G; SAUERBREI, W; SCHEURLEN, H; SCHUMACHER, M; FOCAN, C; LOBELLE, JP; PEEK, U; OATES, GD; POWELL, J; DURAND, M; MAURIAC, L; GELMAN, RS; HENDERSON, IC; SHAPIRO, CL; HANCOCK, AK; JACKSON, S; RAGAZ, J; HENDERSON, IC; KORZUN, A; WOOD, WC; YOSHIMOTO, M; BAUM, M; HOUGHTON, J; HORGAN, K; HUGHES, L; STEWART, HJ; GORDON, NH; DAVIS, HL; DELOZIER, T; MACELESECH, J; RAMBERT, P; ANDRYSEK, O; BARKMANOVA, J; OWEN, JR; HOWELL, A; RIBEIRO, GC; SWINDELL, R; DEOLIVEIRA, CF; CARSTENSEN, B; PALSHOF, T; JOHANSEN, H; KORZENIOWSKI, S; SKOLYSZEWSKI, J; ANDERSEN, KW; DOMBERNOWSKY, P; MOURIDSEN, HT; ROSE, C; CORCORAN, N; TRAMPISCH, HJ; ABELOFF, MD; CARBONE, PC; GLICK, J; GRAY, R; TORMEY, DC; BUYSE, M; MIGNOLET, F; PARIDAENS, R; VANDRIEL, OJR; SYLVESTER, RJ; VANDEVELDE, CJH; VANDONGEN, JA; WELVAART, K; SCANLON, EF; SCHURMAN, S; CATALANO, R; CREECH, RH; DESCHRYVER, A; MCGREGOR, K; YOSEF, HMA; MCARDLE, CS; SMITH, DC; LARA, PC; DENT, DM; GUDGEON, CA; HACKING, A; BOCCARDO, F; IZUO, M; BENTLEY, A; DORAN, Z; FENTIMAN, IS; HAYWARD, JL; RUBENS, RD; KAUFMANN, M; JONAT, W; SCHEURLEN, H; VONFOURNIER, D; KAUFMANN, M; KLEFSTROM, P; CUZICK, J; MARGREITER, R; ASSELAIN, B; POUILLARD, P; BAHI, J; MILLA, A; SANCHIZ, F; CASTIGLIONE, M; CAVALLI, F; COLLINS, J; GELBER, RD; GOLDHIRSCH, A; ISLEY, MR; LINDTNER, J; PRICE, KN; RUDENSTAM, CM; SENN, HJ; BLISS, JM; CHILVERS, CED; COOMBES, RC; MARTY, M; BOROVIK, R; BRUFMAN, G; ROBINSON, E; PANNUTI, F; TAKASHIMA, S; YASUTOMI, T; HOLM, LE; SONOO, H; YAMASHITA, J; BONTE, J; BUZDAR, AU; SMITH, T; MARTIN, P; ROMAIN, S; AHMANN, D; SCHAID, DJ; HAKES, T; NORTON, L; WITTES, R; FOROGLOU, P; LISSAIOS, B; BONADONNA, G; DELVECCHIO, M; VALAGUSSA, P; VERONESI, U; DUBOIS, JB; BRUFMAN, G; HAYAT, H; BIANCO, AR; LIPPMAN, ME; PIERCE, LJ; SIMON, R; STEINBERG, SM; NOMURA, Y; DELAHUERTA, R; SAINZ, MG; BROWN, A; FISHER, B; REDMOND, C; WOLMARK, N; BAUM, M; JACKSON, IM; PALMER, MK; INGLE, JN; SCHAID, DJ; BENGTSSON, NO; LARSSON, LG; LYTHGOE, JP; SWINDELL, R; KISSIN, M; BLAMEY, RW; MITCHELL, AK; ROBERTSON, JFR; CASTIGLIONE, M; FLUCKIGER, H; SENN, HJ; NAKAMURA, Y; MATHE, G; MISSET, JL; DESHPANDE, N; DIMARTINO, L; CLARKE, EA; MCLAUGHLIN, JR; CLARK, RM; LEVINE, M; MORIMOTO, K; GUNDERSEN, S; HAUERJENSEN, M; HOST, H; CROSSLEY, E; DURRANT, K; HARRIS, A; CLARKE, M; COLLINS, R; GODWIN, J; GRAY, R; GREAVES, E; HARWOOD, C; MEAD, G; PETO, R; WHEATLEY, K; HILL, C; LACOUR, J; LAPLANCHE, A; LE, M; SARRAZIN, D; SEMIGLAZOV, V; BROCKSCHMIDT, J; COOPER, MR; MEAKIN, JW; PANZARELLA, T; PRITCHARD, KI; TREURNIETDONKER, AD; VANPUTTEN, WLJ; EASTON, D; POWLES, TJ; GAZET, JC; DOUGLAS, P; HACKING, A; HOST, H; LINDTNER, A; NOTTER, G; BRYANT, AJS; EWING, GH; KRUSHEN, JL; NISSENMEYER, R; FORREST, APM; MCDONALD, C; STEWART, HJ; MOLLER, TR; RYDEN, S; CARSTENSEN, J; HATSCHEK, T; SODERBERG, M; CARPENTER, JT; CRAWLEY, J; GREEN, S; OSBORNE, CK; RUTQVIST, LE; WALLGREN, A; BRENNER, H; HERCBERGS, A; DEBOER, G; PATERSON, AHG; PRITCHARD, KI; NAJA, A; REID, M; SPITTLE, M; SENANAYAKE, F; MEIER, P; TENGRUP, I; TENNVALLNITTBY, L; CAFFIER, H; BEZWODA, WR; HOLMBERG, L; SEVELDA, P; ZIELINSKY, CC; JAKESZ, R; BUCHANAN, RB; CROSS, M; DUNN, JA; GILLESPIE; KELLY, K; MORRISON, JM; LITTON, A; CHLEBOWSKI, RT				ABE, O; ABE, R; ASAISHI, K; ENOMOTO, K; HATTORI, T; INO, Y; KIKUCHI, K; KOYAMA, H; SAWA, K; UCHINO, J; YOSHIDA, M; HAYBITTLE, JL; VANDEVELDE, T; VERMORKEN, JB; HARVEY, VJ; HOLDAWAY, TM; KAY, RG; MASON, BH; FORBES, JF; BASTERT, G; SAUERBREI, W; SCHEURLEN, H; SCHUMACHER, M; FOCAN, C; LOBELLE, JP; PEEK, U; OATES, GD; POWELL, J; DURAND, M; MAURIAC, L; GELMAN, RS; HENDERSON, IC; SHAPIRO, CL; HANCOCK, AK; JACKSON, S; RAGAZ, J; HENDERSON, IC; KORZUN, A; WOOD, WC; YOSHIMOTO, M; BAUM, M; HOUGHTON, J; HORGAN, K; HUGHES, L; STEWART, HJ; GORDON, NH; DAVIS, HL; DELOZIER, T; MACELESECH, J; RAMBERT, P; ANDRYSEK, O; BARKMANOVA, J; OWEN, JR; HOWELL, A; RIBEIRO, GC; SWINDELL, R; DEOLIVEIRA, CF; CARSTENSEN, B; PALSHOF, T; JOHANSEN, H; KORZENIOWSKI, S; SKOLYSZEWSKI, J; ANDERSEN, KW; DOMBERNOWSKY, P; MOURIDSEN, HT; ROSE, C; CORCORAN, N; TRAMPISCH, HJ; ABELOFF, MD; CARBONE, PC; GLICK, J; GRAY, R; TORMEY, DC; BUYSE, M; MIGNOLET, F; PARIDAENS, R; VANDRIEL, OJR; SYLVESTER, RJ; VANDEVELDE, CJH; VANDONGEN, JA; WELVAART, K; SCANLON, EF; SCHURMAN, S; CATALANO, R; CREECH, RH; DESCHRYVER, A; MCGREGOR, K; YOSEF, HMA; MCARDLE, CS; SMITH, DC; LARA, PC; DENT, DM; GUDGEON, CA; HACKING, A; BOCCARDO, F; IZUO, M; BENTLEY, A; DORAN, Z; FENTIMAN, IS; HAYWARD, JL; RUBENS, RD; KAUFMANN, M; JONAT, W; SCHEURLEN, H; VONFOURNIER, D; KAUFMANN, M; KLEFSTROM, P; CUZICK, J; MARGREITER, R; ASSELAIN, B; POUILLARD, P; BAHI, J; MILLA, A; SANCHIZ, F; CASTIGLIONE, M; CAVALLI, F; COLLINS, J; GELBER, RD; GOLDHIRSCH, A; ISLEY, MR; LINDTNER, J; PRICE, KN; RUDENSTAM, CM; SENN, HJ; BLISS, JM; CHILVERS, CED; COOMBES, RC; MARTY, M; BOROVIK, R; BRUFMAN, G; ROBINSON, E; PANNUTI, F; TAKASHIMA, S; YASUTOMI, T; HOLM, LE; SONOO, H; YAMASHITA, J; BONTE, J; BUZDAR, AU; SMITH, T; MARTIN, P; ROMAIN, S; AHMANN, D; SCHAID, DJ; HAKES, T; NORTON, L; WITTES, R; FOROGLOU, P; LISSAIOS, B; BONADONNA, G; DELVECCHIO, M; VALAGUSSA, P; VERONESI, U; DUBOIS, JB; BRUFMAN, G; HAYAT, H; BIANCO, AR; LIPPMAN, ME; PIERCE, LJ; SIMON, R; STEINBERG, SM; NOMURA, Y; DELAHUERTA, R; SAINZ, MG; BROWN, A; FISHER, B; REDMOND, C; WOLMARK, N; BAUM, M; JACKSON, IM; PALMER, MK; INGLE, JN; SCHAID, DJ; BENGTSSON, NO; LARSSON, LG; LYTHGOE, JP; SWINDELL, R; KISSIN, M; BLAMEY, RW; MITCHELL, AK; ROBERTSON, JFR; CASTIGLIONE, M; FLUCKIGER, H; SENN, HJ; NAKAMURA, Y; MATHE, G; MISSET, JL; DESHPANDE, N; DIMARTINO, L; CLARKE, EA; MCLAUGHLIN, JR; CLARK, RM; LEVINE, M; MORIMOTO, K; GUNDERSEN, S; HAUERJENSEN, M; HOST, H; CROSSLEY, E; DURRANT, K; HARRIS, A; CLARKE, M; COLLINS, R; GODWIN, J; GRAY, R; GREAVES, E; HARWOOD, C; MEAD, G; PETO, R; WHEATLEY, K; HILL, C; LACOUR, J; LAPLANCHE, A; LE, M; SARRAZIN, D; SEMIGLAZOV, V; BROCKSCHMIDT, J; COOPER, MR; MEAKIN, JW; PANZARELLA, T; PRITCHARD, KI; TREURNIETDONKER, AD; VANPUTTEN, WLJ; EASTON, D; POWLES, TJ; GAZET, JC; DOUGLAS, P; HACKING, A; HOST, H; LINDTNER, A; NOTTER, G; BRYANT, AJS; EWING, GH; KRUSHEN, JL; NISSENMEYER, R; FORREST, APM; MCDONALD, C; STEWART, HJ; MOLLER, TR; RYDEN, S; CARSTENSEN, J; HATSCHEK, T; SODERBERG, M; CARPENTER, JT; CRAWLEY, J; GREEN, S; OSBORNE, CK; RUTQVIST, LE; WALLGREN, A; BRENNER, H; HERCBERGS, A; DEBOER, G; PATERSON, AHG; PRITCHARD, KI; NAJA, A; REID, M; SPITTLE, M; SENANAYAKE, F; MEIER, P; TENGRUP, I; TENNVALLNITTBY, L; CAFFIER, H; BEZWODA, WR; HOLMBERG, L; SEVELDA, P; ZIELINSKY, CC; JAKESZ, R; BUCHANAN, RB; CROSS, M; DUNN, JA; GILLESPIE; KELLY, K; MORRISON, JM; LITTON, A; CHLEBOWSKI, RT			SYSTEMIC TREATMENT OF EARLY BREAST-CANCER BY HORMONAL, CYTOTOXIC, OR IMMUNE THERAPY-133 RANDOMIZED TRIALS INVOLVING 31000 RECURRENCES AND 24000 DEATHS AMONG 75000 WOMEN .2.	LANCET			English	Review							REQUIRING PROLONGED OBSERVATION; SURGICAL ADJUVANT BREAST; TAMOXIFEN THERAPY; CHEMOTHERAPY; IRRADIATION; PATIENT; DESIGN		INTEGRAAL KANKERCTR, AMSTERDAM, NETHERLANDS; AUCKLAND BREAST CANC STUDY GRP, AUCKLAND, NETHERLANDS; AKAD WISSENSCH DDR, O-1086 BERLIN, GERMANY; BIRMINGHAM GEN HOSP, BIRMINGHAM, ENGLAND; FDN BERGONIE, F-33076 BORDEAUX, FRANCE; HARVARD UNIV, SCH MED,DANA FARBER CANC INST, BOSTON, MA 02115 USA; BRADFORD ROYAL INFIRM, BRADFORD, ENGLAND; BRITISH COLUMBIA CANC FDN, VANCOUVER V5Z 3J3, BC, CANADA; CANC INST HOSP, TOKYO, JAPAN; CANC RES CAMPAIGN, LONDON, ENGLAND; CARDIFF SURG TRIALISTS, CARDIFF, WALES; CASE WESTERN RESERVE UNIV, CLEVELAND, OH 44106 USA; CTR REG FRANCOIS BACLESSE, CAEN, FRANCE; CTR RENE HUGUENIN, ST CLOUD, FRANCE; CHARLES UNIV, CS-11636 PRAGUE 1, CZECHOSLOVAKIA; CHELTENHAM GEN HOSP, CHELTENHAM, ENGLAND; CHRISTIE HOSP & HOLT RADIUM INST, MANCHESTER M20 9BX, LANCS, ENGLAND; COIMBRA INST ONCOL, COIMBRA, PORTUGAL; DANISH CANC REGISTRY, COPENHAGEN, DENMARK; COPENHAGEN RADIUM CTR, COPENHAGEN, DENMARK; CRACOW INST ONCOL, KRAKOW, POLAND; ST LUKES HOSP, DUBLIN, IRELAND; UNIV DUSSELDORF, W-4000 DUSSELDORF 1, GERMANY; EUROPEAN ORG RES TREATMENT CANC, BRUSSELS, BELGIUM; EASTERN COOPERAT ONCOL GRP, BOSTON, MA USA; DANISH BREAST CANC COOPERAT GRP, COPENHAGEN, DENMARK; CANC & LEUKEMIA GRP B, BROOKLINE, MA USA; EVANSTON HOSP CORP, EVANSTON, IL 60201 USA; FOX CHASE CANC INST, PHILADELPHIA, PA 19111 USA; STATE UNIV GHENT HOSP, B-9000 GHENT, BELGIUM; GLASCOW BEATSON ONCOL CTR, GLASGOW, SCOTLAND; VICTORIA INFIRM, GLASGOW G42 9TY, SCOTLAND; GRANADA UNIV HOSP, GRANADA, SPAIN; GROOTE SCHUUR HOSP, CAPE TOWN 7925, SOUTH AFRICA; GUNMA UNIV, MAEBASHI, GUNMA 371, JAPAN; GUYS HOSP, LONDON SE1 9RT, ENGLAND; UNIV HEIDELBERG, W-6900 HEIDELBERG, GERMANY; UNIV HEIDELBERG 2, HEIDELBERG, GERMANY; UNIV HEIDELBERG 1, HEIDELBERG, GERMANY; DEACONESS MED CTR, HELSINKI, FINLAND; IMPERIAL CANC RES FUND, LONDON WC2A 3PX, ENGLAND; UNIV INNSBRUCK, A-6020 INNSBRUCK, AUSTRIA; INST CURIE, F-75231 PARIS 05, FRANCE; INST SALAH AZAIZ, TUNIS, TUNISIA; INST POLICLIN, BARCELONA, SPAIN; INT LUDWIG BREAST CANC STUDY GRP, LONDON, ENGLAND; CHARING CROSS HOSP, INT COLLABORAT CANC GRP, LONDON W6 8RP, ENGLAND; TECHNION ISRAEL INST TECHNOL, RAMBAM MED CTR, HAIFA, ISRAEL; KAROLINSKA HOSP, S-10401 STOCKHOLM 60, SWEDEN; Kawasaki Med Sch, KURASHIKI, OKAYAMA 70101, JAPAN; KUMAMOTO UNIV GRP, KUMAMOTO, JAPAN; ACAD HOSP ST RAFAEL, B-3000 LOUVAIN, BELGIUM; MD ANDERSON CANC CTR, HOUSTON, TX USA; LAB CANEROL BIOL APM, MARSEILLE, FRANCE; MAYO CLIN & MAYO FDN, ROCHESTER, MN 55905 USA; MEM SLOAN KETTERING CANC CTR, NEW YORK, NY 10021 USA; METAXAS MEM CANC HOSP, ATHENS, GREECE; IST NAZL STUDIO & CURA TUMORI, I-20133 MILAN, ITALY; CTR PAUL LAMARQUE, F-34033 MONTPELLIER, FRANCE; NAPLES UNIV, I-80138 NAPLES, ITALY; NCI, BETHESDA, MD 20892 USA; NATL KYUSHU CANC CTR HOSP, KYUSHU, JAPAN; NATL MED CTR, MEXICO CITY, DF, MEXICO; NATL SURG ADJUVANT PROJECT BREAST & BOWEL CANC, PITTSBURGH, PA USA; N CENT CANC TREATMENT GRP, ROCHESTER, MN USA; NORTHWICK PK HOSP & CLIN RES CTR, HARROW HA1 3UJ, MIDDX, ENGLAND; NOTTINGHAM CITY HOSP, NOTTINGHAM NG5 1PB, ENGLAND; OITA PREFECTURAL HOSP, OITA, JAPAN; ONCOL HOSP A BUSINICO, SARDINIA, FRANCE; ONTARIO CANC TREATMENT & RES FDN, TORONTO, ONTARIO, CANADA; ONTARIO CLIN ONCOL GRP, TORONTO, ONTARIO, CANADA; OSAKA CITY MED SCH, OSAKA, JAPAN; OSLO RADIUM HOSP, OSLO, NORWAY; CHURCHILL HOSP, OXFORD OX3 7LJ, ENGLAND; IMPERIAL CANC RES FUND, MRC,CLIN TRIAL SERV UNIT, OXFORD, ENGLAND; INST GUSTAVE ROUSSY, F-94805 VILLEJUIF, FRANCE; NN PETROV ONCOL RES INST, LENINGRAD 188646, USSR; PIEDMONT ONCOL ASSOC, ATLANTA, GA USA; PRINCESS MARGARET HOSP, TORONTO M4X 1K9, ONTARIO, CANADA; ROTTERDAM RADIOTHERAPEUT INST, ROTTERDAM, NETHERLANDS; ROYAL MARSDEN HOSP, INST CANC RES, LONDON, ENGLAND; ST GEORGE HOSP, LONDON, ENGLAND; SASKATCHEWAN CANC FDN, SASKATOON, SASKATCHEWAN, CANADA; SW ONCOL GRP, KANSAS CITY, KS 66103 USA; STOCKHOLM BREAST CANC STUDY GRP, STOCKHOLM, SWEDEN; TEL AVIV UNIV, IL-69978 TEL AVIV, ISRAEL; TORONTO EDMONTON BREAST CANC STUDY GRP, TORONTO, ONTARIO, CANADA; TOULOUSE CTR CLAUDIUS REGAUD, TOULOUSE, FRANCE; UNIV CHICAGO, CHICAGO, IL 60637 USA; UNIV LUND, S-22101 LUND, SWEDEN; UNIV WURZBURG, W-8700 WURZBURG, GERMANY; UNIV WITWATERSRAND, JOHANNESBURG 2001, SOUTH AFRICA; UPPSALA OREBRO CANC STUDY GRP, UPPSALA, SWEDEN; VIENNA UNIV HOSP, DEPT GYNAECOL 1, VIENNA, AUSTRIA; VIENNA UNIV HOSP, DEPT SURG 1, VIENNA, AUSTRIA; WESSEX RADIOTHERAPY CTR, WESSEX, ENGLAND; ADDENBROOKES HOSP, CAMBRIDGE CB2 2QQ, ENGLAND	University of Birmingham; UNICANCER; Institut Bergonie; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Bradford Royal Infirmary; Japanese Foundation for Cancer Research; Case Western Reserve University; UNICANCER; Centre Francois Baclesse; Rene Huguenin Hospital; Charles University Prague; Gloucestershire Hospitals NHS Foundation Trust; Cheltenham General Hospital; Christie NHS Foundation Trust; Christie Hospital; Maria Sklodowska-Curie National Research Institute of Oncology; Trinity College Dublin; Heinrich Heine University Dusseldorf; European Organisation for Research & Treatment of Cancer; Danish Breast Cancer Cooperative Group (DBCG); NorthShore University Health System; Fox Chase Cancer Center; Ghent University; Ghent University Hospital; Beatson Oncology Centre; University of Cape Town; Gunma University; Guy's & St Thomas' NHS Foundation Trust; Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg; Cancer Research UK; University of Innsbruck; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Universite de Tunis-El-Manar; Institut Salah Azaiez; Imperial College London; Rambam Health Care Campus; Technion Israel Institute of Technology; Karolinska Institutet; Karolinska University Hospital; Kawasaki Medical School; Kumamoto University; KU Leuven; University of Texas System; UTMD Anderson Cancer Center; Mayo Clinic; Memorial Sloan Kettering Cancer Center; Fondazione IRCCS Istituto Nazionale Tumori Milan; Universite de Montpellier; University of Naples Federico II; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Kyushu Cancer Center; Imperial College London; Nottingham University Hospital NHS Trust; Nottingham City Hospital; University of Oxford; University of Oxford; UNICANCER; Gustave Roussy; N.N. Petrov Research Institute of Oncology; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; St Georges University London; University of Saskatchewan; Southwest Oncology Group; Tel Aviv University; UNICANCER; Institut Claudius Regaud; University of Chicago; Lund University; University of Wurzburg; University of Witwatersrand; University Hospital Vienna; University Hospital Vienna; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge	ABE, O (corresponding author), RADCLIFFE INFIRM, NUFFIELD DEPT CLIN MED, ICRF MRC CLIN TRIAL SERV UNIT, OXFORD OX2 6HE, ENGLAND.		Brenner, Hermann/B-4627-2017; Barkmanova, Jaroslava/A-1411-2017; Pritchard, Kathleen I/I-2184-2014; Schurman, Shepherd/ABF-8125-2021; Fentiman, Ian S/I-7644-2019; McLaughlin, John R/E-4577-2013; Jonat, Walter/E-3024-2010; Fentiman, Ian/AAB-9886-2020; Boccardo, Francesco Mario/AAF-2654-2019; Brenner, Hermann/ABE-6383-2020	Brenner, Hermann/0000-0002-6129-1572; Barkmanova, Jaroslava/0000-0003-1406-7292; Pritchard, Kathleen I/0000-0003-0758-9666; Boccardo, Francesco Mario/0000-0002-5392-4077; Brenner, Hermann/0000-0002-6129-1572; Bliss, Judith/0000-0001-7957-7424; Coombes, Raoul Charles/0000-0002-4811-1100; Schurman, Shepherd/0000-0002-9133-7906				[Anonymous], 1988, LANCET, V2, P349; [Anonymous], 1988, BRIT MED J, V296, P320; [Anonymous], 1988, NEW ENGL J MED, V319, P1681; [Anonymous], 1984, Lancet, V2, P1205; [Anonymous], 1985, JAMA, V254, P3461; BIANCO AR, 1991, BRIT J CANCER, V63, P799, DOI 10.1038/bjc.1991.177; BONADONNA G, 1985, BREAST CANCER RES TR, V5, P95, DOI 10.1007/BF01805984; BONADONNA G, 1976, NEW ENGL J MED, V294, P405, DOI 10.1056/NEJM197602192940801; CARBONE PP, 1990, CANCER, V66, P1378, DOI 10.1002/1097-0142(19900915)66:14+<1378::AID-CNCR2820661413>3.0.CO;2-J; Early Breast Cancer Trialists' Collaborative Group, 1990, TREATMENT EARLY BREA, V1; FISHER B, 1990, J CLIN ONCOL, V8, P1005, DOI 10.1200/JCO.1990.8.6.1005; FISHER B, 1986, J CLIN ONCOL, V4, P459, DOI 10.1200/JCO.1986.4.4.459; FISHER B, 1989, NEW ENGL J MED, V320, P479, DOI 10.1056/NEJM198902233200802; FORNANDER T, 1989, LANCET, V1, P117; GOLDHIRSCH A, 1985, J CLIN ONCOL, V3, P1059; HALL WH, 1991, JAMA-J AM MED ASSOC, V265, P391; HORTOBAGYI GN, 1978, IMMUNOTHERAPY CANCER, P155; JORDAN VC, 1990, J NATL CANCER I, V82, P1662, DOI 10.1093/jnci/82.21.1662; LEGHA SS, 1988, ANN INTERN MED, V109, P219, DOI 10.7326/0003-4819-109-3-219; LOVE RR, 1989, J CLIN ONCOL, V7, P803, DOI 10.1200/JCO.1989.7.6.803; LOVE RR, 1990, JNCI-J NATL CANCER I, V82, P1327, DOI 10.1093/jnci/82.16.1327; MATTHEWS KA, 1989, NEW ENGL J MED, V321, P641, DOI 10.1056/NEJM198909073211004; MEAKIN JW, 1979, CAN MED ASSOC J, V120, P1221; NEVINNY HB, 1969, AM J SURG, V117, P531, DOI 10.1016/0002-9610(69)90012-9; NISSENMEYER R, 1991, ANN ONCOL, V2, P343, DOI 10.1093/oxfordjournals.annonc.a057952; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; PETO R, 1976, BRIT J CANCER, V34, P585, DOI 10.1038/bjc.1976.220; POWLES TJ, 1991, MED MANAGEMENT BREAS; RAVDIN RG, 1970, SURG GYNECOL OBSTETR, V131, P1055; RICHARDS MA, 1990, J CLIN ONCOL, V8, P2032, DOI 10.1200/JCO.1990.8.12.2032; SMITH PG, 1976, BRIT J RADIOL, V49, P224, DOI 10.1259/0007-1285-49-579-224; STEWART HJ, 1987, LANCET, V2, P171; WARLOW C, 1991, LANCET, V337, P1235, DOI 10.1016/0140-6736(91)92916-P; ZAMBETTI M, 1989, P AN M AM SOC CLIN, V8, P21; 1991, WORLD HLTH STATISTIC; 1988, BRIT J CANC, V57, P608; 1986, CARCINOGENICITY ALKY; 1986, BRIT MED J, V293, P946; 1990, SERIES MBI, V18	39	1226	1229	3	57	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 11	1992	339	8785					71	85						15	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GZ156	1345869				2023-01-03	WOS:A1992GZ15600001
J	CROSS, SJ; LEE, HS; RAWLES, JM; JENNINGS, K				CROSS, SJ; LEE, HS; RAWLES, JM; JENNINGS, K			SAFETY OF THROMBOLYSIS IN ASSOCIATION WITH CARDIOPULMONARY-RESUSCITATION	BMJ-BRITISH MEDICAL JOURNAL			English	Article									UNIV ABERDEEN, DEPT MED & THERAPEUT, ABERDEEN AB9 1FX, SCOTLAND	University of Aberdeen	CROSS, SJ (corresponding author), ABERDEEN ROYAL INFIRM, DEPT CARDIAC, ABERDEEN AB9 2ZD, SCOTLAND.							[Anonymous], 1988, LANCET, V2, P349; DEBONO D, 1990, PRACTICAL CORONARY T, P28; DUBOIS C, 1986, EUR HEART J, V7, P945, DOI 10.1093/oxfordjournals.eurheartj.a061999; PASTERNAK RC, 1988, HEART DISEASE TXB CA, P1222; SCHRODER R, 1986, NEW ENGL J MED, V314, P1465	5	24	25	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 16	1991	303	6812					1242	1242		10.1136/bmj.303.6812.1242	http://dx.doi.org/10.1136/bmj.303.6812.1242			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GQ342	1747647	Bronze, Green Published			2023-01-03	WOS:A1991GQ34200026
J	GRAY, WA; CAPONE, RJ; MOST, AS				GRAY, WA; CAPONE, RJ; MOST, AS			UNSUCCESSFUL EMERGENCY MEDICAL RESUSCITATION - ARE CONTINUED EFFORTS IN THE EMERGENCY DEPARTMENT JUSTIFIED	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HOSPITAL CARDIAC-ARREST; CARDIOPULMONARY RESUSCITATION; SURVIVAL; DEATH; DEFIBRILLATION; EXPERIENCE; OUTCOMES; CPR	Background. The majority of attempts to resuscitate victims of prehospital cardiopulmonary arrest are unsuccessful, and patients are frequently transported to the emergency department for further resuscitation efforts. We evaluated the efficacy and costs of continued hospital resuscitation for patients in whom resuscitation efforts outside the hospital have failed. Methods. We reviewed the records of 185 patients presenting to our emergency department after an initially unsuccessful, but ongoing, resuscitation for a prehospital arrest (cardiac, respiratory, or both) by an emergency medical team. Prehospital and hospital characteristics of treatment for the arrest were identified, and the patients' outcomes in the emergency room were ascertained. The hospital course and the hospital costs for the patients who were revived were determined. Results. Over a 19-month period, only 16 of the 185 patients (9 percent) were successfully resuscitated in the emergency department and admitted to the hospital. A shorter duration of prehospital resuscitation was the only characteristic of the resuscitation associated with an improved outcome in the emergency department. No patient survived until hospital discharge, and all but one were comatose throughout hospitalization. The mean stay in the hospital was 12.6 days (range, 1 to 132), with an average of 2.3 days (range, 1 to 11) in an intensive care unit. The total hospital cost for the 16 patients admitted was $180,908 (range per patient, $1,984 to $95,144). Conclusions. In general, continued resuscitation efforts in the emergency department tor victims of cardiopulmonary arrest in whom prehospital resuscitation has tailed are not worthwhile, and they consume precious institutional and economic resources without gain.	BROWN UNIV,PROGRAM MED,PROVIDENCE,RI 02912; UNIV ROCHESTER,MED CTR,DIV CARDIOL,ROCHESTER,NY 14642	Brown University; University of Rochester	GRAY, WA (corresponding author), RHODE ISL HOSP,DIV CARDIOL,593 EDDY ST,PROVIDENCE,RI 02903, USA.							APRAHAMIAN C, 1986, ANN EMERG MED, V15, P445, DOI 10.1016/S0196-0644(86)80185-8; BACHMAN JW, 1986, JAMA-J AM MED ASSOC, V256, P477, DOI 10.1001/jama.256.4.477; BEDELL SE, 1983, NEW ENGL J MED, V309, P569, DOI 10.1056/NEJM198309083091001; BLACKHALL LJ, 1987, NEW ENGL J MED, V317, P1281, DOI 10.1056/NEJM198711123172009; BRETT AS, 1986, NEW ENGL J MED, V315, P1347, DOI 10.1056/NEJM198611203152109; COBB LA, 1980, MOD CONC CARDIOV DIS, V49, P31; CUMMINS RO, 1985, AM J EMERG MED, V3, P114, DOI 10.1016/0735-6757(85)90032-4; CUMMINS RO, 1985, JAMA-J AM MED ASSOC, V253, P2408, DOI 10.1001/jama.253.16.2408; EINARSSON O, 1989, J INTERN MED, V225, P129, DOI 10.1111/j.1365-2796.1989.tb00052.x; EISENBERG M, 1979, AM J PUBLIC HEALTH, V69, P30, DOI 10.2105/AJPH.69.1.30; Hallstorm AP, 1983, EMERG HLTH SERV Q, V1, P41; HALLSTROM AP, 1985, CRIT CARE MED, V13, P927, DOI 10.1097/00003246-198511000-00019; KELLERMANN AL, 1988, ANN EMERG MED, V17, P589, DOI 10.1016/S0196-0644(88)80398-6; KOUWENHOVEN WB, 1960, JAMA-J AM MED ASSOC, V173, P1064, DOI 10.1001/jama.1960.03020280004002; McIntyre KM, 1983, TXB ADV CARDIAC LIFE; MURPHY DJ, 1989, ANN INTERN MED, V111, P199, DOI 10.7326/0003-4819-111-3-199; MYERBURG RJ, 1982, JAMA-J AM MED ASSOC, V247, P1485, DOI 10.1001/jama.247.10.1485; MYERBURG RJ, 1980, AM J MED, V68, P568, DOI 10.1016/0002-9343(80)90307-1; OROURKE PP, 1986, CRIT CARE MED, V14, P466, DOI 10.1097/00003246-198605000-00006; ROTH R, 1984, ANN EMERG MED, V13, P237, DOI 10.1016/S0196-0644(84)80470-9; SAPHIR R, 1968, MEDICINE, V47, P73, DOI 10.1097/00005792-196801000-00004; SCHNEIDERMAN LJ, 1990, ANN INTERN MED, V112, P949, DOI 10.7326/0003-4819-112-12-949; SHIMAZU S, 1983, J TRAUMA, V23, P213, DOI 10.1097/00005373-198303000-00006; STULTS KR, 1984, NEW ENGL J MED, V310, P219, DOI 10.1056/NEJM198401263100403; TAFFET GE, 1988, JAMA-J AM MED ASSOC, V260, P2069, DOI 10.1001/jama.260.14.2069; Talbott J., 1965, FUNDAMENTALS CARDIOP, P1; THOMPSON RG, 1979, ANN INTERN MED, V90, P437; TOMLINSON T, 1988, NEW ENGL J MED, V318, P43, DOI 10.1056/NEJM198801073180109; TRESCH DD, 1981, ARCH INTERN MED, V141, P1154, DOI 10.1001/archinte.141.9.1154; TWEED WA, 1984, CAN MED ASSOC J, V131, P429; WEAVER WD, 1976, CIRCULATION, V54, P895, DOI 10.1161/01.CIR.54.6.895; WEAVER WD, 1984, CIRCULATION, V69, P943, DOI 10.1161/01.CIR.69.5.943; WEAVER WD, 1988, NEW ENGL J MED, V319, P661, DOI 10.1056/NEJM198809153191101; WEAVER WD, 1986, ANN EMERG MED, V15, P1181; 1983, EUTHANASIA AIDING SU; 1980, JAMA-J AM MED ASSOC, V24, P453	36	202	204	1	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 14	1991	325	20					1393	1398		10.1056/NEJM199111143252001	http://dx.doi.org/10.1056/NEJM199111143252001			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GP524	1922249				2023-01-03	WOS:A1991GP52400001
J	LEVINE, AM; WERNZ, JC; KAPLAN, L; RODMAN, N; COHEN, P; METROKA, C; BENNETT, JM; RARICK, MU; WALSH, C; KAHN, J; MILES, S; EHMANN, WC; FEINBERG, J; NATHWANI, B; GILL, PS; MITSUYASU, R				LEVINE, AM; WERNZ, JC; KAPLAN, L; RODMAN, N; COHEN, P; METROKA, C; BENNETT, JM; RARICK, MU; WALSH, C; KAHN, J; MILES, S; EHMANN, WC; FEINBERG, J; NATHWANI, B; GILL, PS; MITSUYASU, R			LOW-DOSE CHEMOTHERAPY WITH CENTRAL-NERVOUS-SYSTEM PROPHYLAXIS AND ZIDOVUDINE MAINTENANCE IN AIDS-RELATED LYMPHOMA - A PROSPECTIVE MULTIINSTITUTIONAL TRIAL	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACQUIRED IMMUNODEFICIENCY SYNDROME; NON-HODGKINS LYMPHOMA; AGENTS M-BACOD; HOMOSEXUAL MEN; MALIGNANT-LYMPHOMA; UNDIFFERENTIATED LYMPHOMA; IMPROVED PROGNOSIS; CELL LYMPHOMA; EXPERIENCE; NEOPLASIA	Objective. - To ascertain if low-dose multiagent chemotherapy, with central nervous system prophylaxis and antiretroviral therapy, might be associated with increased efficacy and decreased risk of intercurrent infection in patients with malignant lymphoma related to the acquired immunodeficiency syndrome (AIDS). Design. - A phase 11 prospective clinical trial, with median follow-up of 33 months. Setting. - Eight university hospitals, within the context of the AIDS Clinical Trials Units, sponsored by the National institute of Allergy and Infectious Diseases. Patients. - Forty-two patients with AIDS-related malignant lymphoma. All were evaluable for toxicity assessment, and 35 for response. Intervention. - A low-dose modification of the M-BACOD regimen (day 1): cyclophosphamide, 300 mg/m2 intravenously (IV); doxorubicin, 25 mg/m2 IV; vincristine sulfate, 1.4 mg/m2 IV; bleomycin, 4 mg/m2 IV; dexamethasone, 3 mg/m2 orally on days 1 through 5; methotrexate, 500 mg/m2 IV on day 15, with leucovorin rescue. Intrathecal cytosine arabinoside (50 mg) to all on days 1, 8, 21, and 28, with radiation therapy to a helmet field to those with central nervous system involvement. Zidovudine for 12 months after completion of four to six cycles of chemotherapy. Main Outcome Measures. - Response rate and number of opportunistic infections. Results. - Response rate was 51% with a complete response of 46%. Of 16 complete responses, relapse occurred in four, none isolated to the central nervous system. Opportunistic infections occurred in 21% of those receiving treatment. Median duration of survival among all 42 patients is 5.6 months, 6.5 months in 35 patients evaluable for response, and 15 months in patients with complete response. Lower concentration of CD4 cells, history of prior AIDS, bone marrow involvement, and stage IV disease were independently associated with decreased survival. Conclusions. - Low-dose chemotherapy with central nervous system prophylaxis and zidovudine maintenance may be associated with durable remissions in AIDS-related lymphoma with fewer opportunistic infections than noted in prior reports.	UNIV SO CALIF,LOS ANGELES CTY MED CTR,LOS ANGELES,CA 90033; UNIV CALIF SAN FRANCISCO,SAN FRANCISCO,CA 94143; GEORGE WASHINGTON UNIV,WASHINGTON,DC 20052; UNIV ROCHESTER,CTR CANC,ROCHESTER,NY 14627; UNIV CALIF LOS ANGELES,LOS ANGELES,CA 90024; NYU,NEW YORK,NY 10003; SAN FRANCISCO GEN HOSP,SAN FRANCISCO,CA 94110; ST LUKES ROOSEVELT HOSP,NEW YORK,NY 10025; PENN STATE UNIV,MILTON S HERSHEY MED CTR,COLL MED,HERSHEY,PA 17033; NIAID,DIV AIDS,AIDS CLIN TRIALS UNIT,BETHESDA,MD 20892; RES TRIANGLE INST,RES TRIANGLE PK,NC 27709	University of Southern California; University of California System; University of California San Francisco; George Washington University; University of Rochester; University of California System; University of California Los Angeles; New York University; San Francisco General Hospital Medical Center; Mount Sinai St. Luke's; Mount Sinai West; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Research Triangle Institute	LEVINE, AM (corresponding author), UNIV SO CALIF,SCH MED,1975 ZONAL AVE,KAM 110F,LOS ANGELES,CA 90033, USA.			feinberg, judith/0000-0003-4206-7214				[Anonymous], 1982, CANCER, V49, P2112; BERMUDEZ MA, 1989, AM J MED, V86, P71, DOI 10.1016/0002-9343(89)90232-5; BERNARD EM, 1988, 4TH INT C AIDS STOCK; CARBONE PP, 1971, CANCER RES, V31, P1860; FISCHL MA, 1987, NEW ENGL J MED, V317, P185, DOI 10.1056/NEJM198707233170401; FISHER RI, 1983, ANN INTERN MED, V98, P304, DOI 10.7326/0003-4819-98-3-304; GILL PS, 1987, J CLIN ONCOL, V5, P1322, DOI 10.1200/JCO.1987.5.9.1322; GILL PS, 1985, AM J MED, V78, P742, DOI 10.1016/0002-9343(85)90277-3; GOLDIE JH, 1982, CANCER TREAT REP, V66, P439; HARDY D, 1985, 1ST INT C AIDS ATL; KALBFLEISCH JD, 1980, STATISTICAL ANAL FAI; KALTER SP, 1985, BLOOD, V66, P655; KAPLAN EL, 1958, AM STAT ASS J, P457; KAPLAN LD, 1989, JAMA-J AM MED ASSOC, V261, P719; Kaplan M H, 1987, Am J Med, V82, P389, DOI 10.1016/0002-9343(87)90435-9; KLIMO P, 1985, ANN INTERN MED, V102, P596, DOI 10.7326/0003-4819-102-5-596; KNOWLES DM, 1988, ANN INTERN MED, V108, P744, DOI 10.7326/0003-4819-108-5-744; LAUBENSTEIN LJ, 1984, J CLIN ONCOL, V103, P335; LEVINE AM, 1984, ANN INTERN MED, V100, P7, DOI 10.7326/0003-4819-100-1-7; LEVINE AM, 1985, JAMA-J AM MED ASSOC, V254, P1921, DOI 10.1001/jama.254.14.1921; LOWENTHAL DA, 1988, CANCER, V61, P2325, DOI 10.1002/1097-0142(19880601)61:11<2325::AID-CNCR2820611130>3.0.CO;2-0; LUKES RJ, 1974, CANCER, V34, P1488, DOI 10.1002/1097-0142(197410)34:8+<1488::AID-CNCR2820340822>3.0.CO;2-C; MCKELVEY EM, 1976, CANCER, V38, P1484, DOI 10.1002/1097-0142(197610)38:4<1484::AID-CNCR2820380407>3.0.CO;2-I; SCHEIN PS, 1976, ANN INTERN MED, V85, P415; SKARIN AT, 1983, J CLIN ONCOL, V1, P91, DOI 10.1200/JCO.1983.1.2.91; SO YT, 1986, ANN NEUROL, V20, P566, DOI 10.1002/ana.410200503; VOLBERDING PA, 1985, ANN INTERN MED, V103, P335, DOI 10.7326/0003-4819-103-3-335; WALSH C, 1991, UNPUB PHASE I STUDY; ZIEGLER JL, 1984, NEW ENGL J MED, V311, P565, DOI 10.1056/NEJM198408303110904; SAS USERS GUIDE STAT, P529; 1985, ANN INTERN MED, V103, P402	31	156	158	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 3	1991	266	1					84	88		10.1001/jama.266.1.84	http://dx.doi.org/10.1001/jama.266.1.84			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FT934	1710673				2023-01-03	WOS:A1991FT93400032
J	MANTLE, J; VERSI, E				MANTLE, J; VERSI, E			PHYSIOTHERAPY FOR STRESS URINARY-INCONTINENCE - A NATIONAL SURVEY	BRITISH MEDICAL JOURNAL			English	Article								Objective-To study the physiotherapeutic treatment of urinary stress incontinence in England. Design-Postal questionnaire survey. Setting-All 192 English district health authorities. Subjects-One physiotherapist from each district who was primarily concerned with urinary incontinence. A consensus view was requested. Main outcome measures-Responses to questionnaire and analysis of a visual analogue scale to indicate effectiveness. Results-There was a 98% response rate. Treatment was often by senior physiotherapists (108 senior I grade or above) who, in 117 districts, claimed to have made a specialty of treating the condition. Gynaecologists and obstetricians were far more likely to refer patients than any other agency (147 respondents said that they were the commonest source of referral). One hundred and fifty four respondents stated that physiotherapy was usually used as the first line of treatment. Pelvic floor exercises and interferential treatment were most commonly used (by 178 and 144 respondents respectively) and thought to be the most effective, especially in combination, though various techniques were used in applying them. Positive motivation (108), recent onset of symptoms (55), and youth (40) were viewed optimistically, and obesity (60), previous surgery (59), prolapse (42), and a chronic cough (36) were considered to be bad prognostic features. The number of patients treated varied greatly (range 10-360) between districts and was poorly correlated with catchment size (correlation coefficient 0.3). Conclusions-As physiotherapists are treating considerable numbers of patients with stress incontinence research is urgently needed to produce efficacy data to enable rationalisation of resources to cater for the whole population.	ROYAL LONDON HOSP,DEPT OBSTET & GYNAECOL,LONDON E1 1BB,ENGLAND; POLYTECH E LONDON,DIV PHYSIOTHERAPY,LONDON E15 4LZ,ENGLAND	Barts Health NHS Trust; Royal London Hospital; University of East London								Bo K, 1989, NEUROLOGY URODYNAMIC, V8, P355; Harrison S M, 1973, Physiotherapy, V59, P363; KEGEL A H, 1948, Ann West Med Surg, V2, P213; KLARSKOV P, 1986, UROL INT, V41, P129, DOI 10.1159/000281181; PEATTIE AB, 1988, BRIT J OBSTET GYNAEC, V95, P1049, DOI 10.1111/j.1471-0528.1988.tb06512.x; STANTON SL, 1990, CLIN OBSTET GYNAECOL, P346; STODDART GD, 1983, PHYSIOTHERAPY, V69, P143; SWITZER D, 1988, IRISH MED J, V81, P30; Tapp AJ, 1989, NEUROUROL URODYNAM, V8, P356; TAPP AJS, 1988, NEUROLOGY URODYNAMIC, V7, P259; TEHON D, 1988, PHYS THER, V68, P652; VERSI E, 1989, BRIT J OBSTET GYNAEC, V96, P752, DOI 10.1111/j.1471-0528.1989.tb03306.x; WILSON PD, 1987, BRIT J OBSTET GYNAEC, V94, P575, DOI 10.1111/j.1471-0528.1987.tb03153.x; 1987, SERIES VS OFFICE POP, V14, P74	14	34	34	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 30	1991	302	6779					753	755		10.1136/bmj.302.6779.753	http://dx.doi.org/10.1136/bmj.302.6779.753			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FF229	1888358	Bronze, Green Published			2023-01-03	WOS:A1991FF22900021
J	BAGENAL, FS; EASTON, DF; HARRIS, E; CHILVERS, CED; MCELWAIN, TJ				BAGENAL, FS; EASTON, DF; HARRIS, E; CHILVERS, CED; MCELWAIN, TJ			SURVIVAL OF PATIENTS WITH BREAST-CANCER ATTENDING BRISTOL-CANCER-HELP-CENTER	LANCET			English	Article									BRISTOL CANC HELP CTR, BRISTOL, ENGLAND; INST CANC RES, MED SECT, SUTTON SM2 5PX, SURREY, ENGLAND; ROYAL MARSDEN HOSP, SUTTON, SURREY, ENGLAND	University of London; Institute of Cancer Research - UK; Royal Marsden NHS Foundation Trust	BAGENAL, FS (corresponding author), INST CANC RES, EPIDEMIOL SECT, SUTTON SM2 5NG, SURREY, ENGLAND.							CHILVERS CED, 1988, STAT MED, V7, P1165, DOI 10.1002/sim.4780071109; COX DR, 1972, J R STAT SOC B, V34, P187; CRAWFORD SM, 1984, LANCET, V2, P582; DORAN DML, 1975, BRIT MED J, V2, P161, DOI 10.1136/bmj.2.5964.161; GREER S, 1983, BRIT J PSYCHIAT, V143, P535, DOI 10.1192/bjp.143.6.535; GUNN CC, 1980, SPINE, V5, P279, DOI 10.1097/00007632-198005000-00011; Pocock S J, 1982, Stat Med, V1, P93, DOI 10.1002/sim.4780010202; WHORWELL PJ, 1984, LANCET, V2, P1232, DOI 10.1016/S0140-6736(84)92793-4; 1984, SERIES MBI OPCS, V16; 1989, BRIT MED J, V299, P1121; 1986, GENERAL HOUSEHOLD SU; 1968, TNM CLASSIFICATION M	12	76	77	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 8	1990	336	8715					606	610						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DX401	1975387				2023-01-03	WOS:A1990DX40100013
J	GIAFFER, MH; NORTH, G; HOLDSWORTH, CD				GIAFFER, MH; NORTH, G; HOLDSWORTH, CD			CONTROLLED TRIAL OF POLYMERIC VERSUS ELEMENTAL DIET IN TREATMENT OF ACTIVE CROHNS-DISEASE	LANCET			English	Article									ROYAL HALLAMSHIRE HOSP,GASTROENTEROL UNIT,SHEFFIELD S10 2JF,S YORKSHIRE,ENGLAND	University of Sheffield								BARTHOLOMEUSZ FDL, 1989, J GASTROEN HEPATOL, V4, P81, DOI 10.1111/j.1440-1746.1989.tb00810.x; BEST WR, 1976, GASTROENTEROLOGY, V70, P439; COYLE B L, 1989, Journal of Human Nutrition and Dietetics, V2, P25, DOI 10.1111/j.1365-277X.1989.tb00004.x; GRAMABOHBOUTH G, 1989, GUT, V30, P1236; GREENBERG GR, 1988, GUT, V29, P1309, DOI 10.1136/gut.29.10.1309; HARRIES AD, 1983, LANCET, V1, P887; IMES S, 1988, DIGESTION, V39, P7, DOI 10.1159/000199602; JONES VA, 1985, LANCET, V2, P177; LOCHS H, 1989, MAR INT C FRONT INFL; LOGAN RFA, 1981, GUT, V22, P383, DOI 10.1136/gut.22.5.383; OMORAIN C, 1980, BRIT MED J, V281, P1173, DOI 10.1136/bmj.281.6249.1173; OMORAIN C, 1984, BRIT MED J, V288, P1859, DOI 10.1136/bmj.288.6434.1859; OMORAIN C, 1983, ARCH DIS CHILD, V53, P44; PARK RHR, 1988, GUT, V29, P821, DOI 10.1136/gut.29.6.821; SANDERSON IR, 1987, ARCH DIS CHILD, V61, P123; SPIRO HM, 1983, CLIN GASTROENTEROLOG; TEAHON K, 1988, GASTROENTEROLOGY, V94, pA457; VOITK AJ, 1973, ARCH SURG-CHICAGO, V107, P329	18	143	146	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 7	1990	335	8693					816	819		10.1016/0140-6736(90)90936-Y	http://dx.doi.org/10.1016/0140-6736(90)90936-Y			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CY371	1969560				2023-01-03	WOS:A1990CY37100004
J	COX, NH; SHARPE, G				COX, NH; SHARPE, G			EMOLLIENTS, SALICYLIC-ACID, AND ULTRAVIOLET ERYTHEMA	LANCET			English	Letter											COX, NH (corresponding author), ROYAL VICTORIA INFIRM,DEPT DERMATOL,NEWCASTLE TYNE NE1 4LP,TYNE & WEAR,ENGLAND.							FARR PM, 1984, BRIT J DERMATOL, V111, P673, DOI 10.1111/j.1365-2133.1984.tb14150.x; KRISTENSEN, 1989, LANCET, V2, P1109; LOWE JG, 1988, BR J DERMATOL S33, V119, P52; WEIRICH EG, 1975, DERMATOLOGICA, V151, P268, DOI 10.1159/000251346; WEIRICH EG, 1976, DERMATOLOGICA, V152, P87, DOI 10.1159/000251167	5	9	9	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 6	1990	335	8680					53	54		10.1016/0140-6736(90)90183-6	http://dx.doi.org/10.1016/0140-6736(90)90183-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CG766	1967359				2023-01-03	WOS:A1990CG76600045
J	BRECKER, SJD; XIAO, HB; SPARROW, J; GIBSON, DG				BRECKER, SJD; XIAO, HB; SPARROW, J; GIBSON, DG			EFFECTS OF DUAL-CHAMBER PACING WITH SHORT ATRIOVENTRICULAR DELAY IN DILATED CARDIOMYOPATHY	LANCET			English	Article							PULSED DOPPLER ECHOCARDIOGRAPHY; LEFT-VENTRICULAR FUNCTION; CONGESTIVE HEART-FAILURE; COMPARATIVE SURVIVAL; HEMODYNAMIC BENEFIT; GAS-EXCHANGE; BLOCK; EXERCISE; REGURGITATION; PACEMAKERS	Mitral or tricuspid regurgitation of long duration may so shorten the ventricular filling time in dilated cardiomyopathy that stroke volume is limited. We assessed the effects of changing the atrioventricular interval during temporary or permanent dual-chamber DDD pacing in twelve dilated cardiomyopathy patients with short ventricular filling times due to regurgitation. We measured ventricular filling time and cardiac output with doppler echocardiography and exercise capacity on a treadmill, at baseline and with the best atrioventricular delay during pacing. The durations of both mitral and tricuspid regurgitation were significantly shorter at the shorter atrioventricular interval (mean reductions 85 [95% Cl 60-110] ms and 110 [75-150] ms, respectively; p<0.001 for both). There were consequent increases in left-ventricular and right-ventricular filling times (65 [35-95] ms and 90 [60-120] ms, p<0.001). For each 50 ms reduction in atrioventricular delay, left-ventricular filling time increased by 35 ms in six subjects with presystolic mitral regurgitation and right-ventricular filling time by 30 ms in nine subjects with presystolic tricuspid regurgitation. At the short atrioventricular interval, cardiac output was greater than baseline (by 1.1 [0.8-1.4] I/min, p<0.01) and there were rises in exercise duration (104 [45-165] s, p<0.05) and maximum oxygen consumption (2.1 [1.5-2.7]ml kg-1min-1, p<0.05). There was a decrease in the Likert visual analogue score of breathlessness at peak exercise (8.6 [SD 2.1] vs 4.9 [3.1], p<0.01 ). Although from a small sample, these findings suggest that DDD pacing with a short atrioventricular delay may have therapeutic potential in patients with dilated cardiomyopathy, even in the absence of conventional indications for pacemaker implantation.			BRECKER, SJD (corresponding author), ROYAL BROMPTON NATL HEART & LUNG HOSP,DEPT CARDIAC,SYDNEY ST,LONDON SW3 6NP,ENGLAND.							ALPERT MA, 1986, J AM COLL CARDIOL, V7, P925, DOI 10.1016/S0735-1097(86)80358-8; ALPERT MA, 1987, AM HEART J, V113, P958, DOI 10.1016/0002-8703(87)90057-3; BULLER NP, 1988, BRIT HEART J, V59, P212; DAVIES NJH, 1979, RESP PHYSIOL, V36, P261, DOI 10.1016/0034-5687(79)90029-X; DICARLO LA, 1987, AM HEART J, V114, P746, DOI 10.1016/0002-8703(87)90784-8; HOCHLEITNER M, 1990, AM J CARDIOL, V66, P198, DOI 10.1016/0002-9149(90)90588-R; IWASE M, 1986, AM J CARDIOL, V58, P104, DOI 10.1016/0002-9149(86)90251-1; JANOSIK DL, 1989, J AM COLL CARDIOL, V14, P499, DOI 10.1016/0735-1097(89)90208-8; JEANRENAUD X, 1992, LANCET, V339, P1318, DOI 10.1016/0140-6736(92)91961-7; LEE CH, 1991, BRIT HEART J, V65, P342; LIPKIN DP, 1985, BRIT HEART J, V54, P321; MBASSOUROUM M, IN PRESS BR HEART J; MEHTA D, 1989, BRIT HEART J, V61, P161; NG KSK, 1989, BRIT HEART J, V62, P246; OCCHETTA E, 1990, PACE, V13, P916, DOI 10.1111/j.1540-8159.1990.tb02129.x; OLDERSHAW PJ, 1983, BRIT HEART J, V49, P568; PANIDIS IP, 1986, J AM COLL CARDIOL, V7, P768, DOI 10.1016/S0735-1097(86)80335-7; REITER MJ, 1982, AM J CARDIOL, V49, P687, DOI 10.1016/0002-9149(82)91947-6; RITTER P, 1989, EUR HEART J, V10, P637, DOI 10.1093/oxfordjournals.eurheartj.a059541; ROKEY R, 1986, AM J CARDIOL, V57, P692, DOI 10.1016/0002-9149(86)90864-7; ROSENQVIST M, 1991, AM J CARDIOL, V67, P148, DOI 10.1016/0002-9149(91)90437-P; RUTISHAUSER W, 1966, CIRCULATION, V34, P807, DOI 10.1161/01.CIR.34.5.807; RYDEN L, 1988, PACE, V11, P1051, DOI 10.1111/j.1540-8159.1988.tb03951.x; SACHER HL, 1989, ANGIOLOGY, V40, P489, DOI 10.1177/000331978904000511; SCHNITTGER I, 1988, J AM COLL CARDIOL, V11, P83, DOI 10.1016/0735-1097(88)90170-2; WILSON JR, 1984, CIRCULATION, V69, P1079, DOI 10.1161/01.CIR.69.6.1079; WISH M, 1987, AM J CARDIOL, V60, P566, DOI 10.1016/0002-9149(87)90306-7; XIAO HB, 1991, BRIT HEART J, V66, P443; ZILE MR, 1987, J AM COLL CARDIOL, V10, P702, DOI 10.1016/S0735-1097(87)80215-2; 1983, J AM COLL CARDIOL, V2, P755	30	243	263	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 28	1992	340	8831					1308	1312		10.1016/0140-6736(92)92492-X	http://dx.doi.org/10.1016/0140-6736(92)92492-X			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KA262	1360034				2023-01-03	WOS:A1992KA26200003
J	BRANGER, PJ; VANDERWOUDEN, JC; SCHUDEL, BR; VERBOOG, E; DUISTERHOUT, JS; VANDERLEI, J; VANBEMMEL, JH				BRANGER, PJ; VANDERWOUDEN, JC; SCHUDEL, BR; VERBOOG, E; DUISTERHOUT, JS; VANDERLEI, J; VANBEMMEL, JH			ELECTRONIC COMMUNICATION BETWEEN PROVIDERS OF PRIMARY AND SECONDARY CARE	BRITISH MEDICAL JOURNAL			English	Article							GENERAL-PRACTITIONERS; SPECIALISTS	Objective-To study the effects of the introduction of electronic data interchange between primary and secondary care providers on speed of communication, efficiency of data handling, and satisfaction of general practitioners with communication. Design-Comparison of traditional paper based communication for laboratory reports and admission-discharge reports between hospital and general practitioners and electronic data interchange. Setting-Twenty-seven general practitioners whose offices were equipped with a practice information system and two general hospitals. Outcome measures-Paper based communication was evaluated by questionnaire responses from and interviews with care providers; electronic communication was evaluated by measuring time intervals between generation and delivery of messages and by assessing doctors' satisfaction with electronic data interchange by questionnaire. Results-Via paper mail admission-discharge reports took a median of 2-4 days, and laboratory reports 2 days, to reach general practitioners. With electronic data interchange almost all admission-discharge reports were available to general practitioners within one hour of generation. When samples were analysed on the day of collection (as was the case for 174/542 samples in one hospital and 443/854 in the other) the laboratory reports were also available to the general practitioner the same day via electronic data interchange. Fifteen general practitioners (of the 24 who returned the questionnaire) reported that the use of electronic admission-discharge reports provided more accurate and complete information about the care delivered to their patients. Ten general practitioners reported that electronic laboratory reports lessened the work of processing the data. Conclusion-Electronic communication between primary and secondary care providers is a feasible option for improving communication.	ERASMUS UNIV,DEPT GEN PRACTICE,3000 DR ROTTERDAM,NETHERLANDS	Erasmus University Rotterdam; Erasmus MC	BRANGER, PJ (corresponding author), ERASMUS UNIV,DEPT MED INFORMAT,POB 1738,3000 DR ROTTERDAM,NETHERLANDS.		van der Wouden, Johannes C/O-5109-2019; van der Wouden, Johannes C/C-2597-2009; Greiver, Michelle/N-8764-2015	van der Wouden, Johannes C/0000-0001-6639-6050; Greiver, Michelle/0000-0001-8957-0285				AMENT A, 1990, LECTURE NOTES MED IN, V40, P130; DOELEMAN F, 1987, FAM PRACT, V4, P176, DOI 10.1093/fampra/4.3.176; DUISTERHOUT JS, 1991, TELEMATICS IN MEDICINE, P151; HULL FM, 1986, BRIT MED J, V293, P311, DOI 10.1136/bmj.293.6542.311; JACOBS LGH, 1990, BRIT MED J, V301, P470, DOI 10.1136/bmj.301.6750.470; KINKHORST OM, 1991, TELEMATICS IN MEDICINE, P313; MAGEEAN RJ, 1986, BRIT MED J, V293, P1283, DOI 10.1136/bmj.293.6557.1283; SANDLER DA, 1987, BRIT MED J, V295, P1523, DOI 10.1136/bmj.295.6612.1523; TULLOCH AJ, 1975, BRIT MED J, V4, P443, DOI 10.1136/bmj.4.5994.443; WALKER RJ, 1989, 1ST STEPS EDI; WESTERHOF HP, 1987, LECTURE NOTES MED IN, P1; WESTERMAN RF, 1990, BRIT J GEN PRACT, V40, P445; WILLIAMS EI, 1990, BRIT MED J, V300, P159, DOI 10.1136/bmj.300.6718.159; 1988, ISO9735 UN EC COMM E	14	76	77	1	9	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 31	1992	305	6861					1068	1070		10.1136/bmj.305.6861.1068	http://dx.doi.org/10.1136/bmj.305.6861.1068			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JW701	1467688	Bronze, Green Published			2023-01-03	WOS:A1992JW70100021
J	NIEMANN, JT				NIEMANN, JT			CURRENT CONCEPTS - CARDIOPULMONARY-RESUSCITATION	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							HOSPITAL VENTRICULAR-FIBRILLATION; TWO-DIMENSIONAL ECHOCARDIOGRAPHY; ESOPHAGEAL OBTURATOR AIRWAY; CORONARY PERFUSION-PRESSURE; CARDIAC-ARREST; BLOOD-FLOW; SODIUM-BICARBONATE; VALVE MOTION; MYOCARDIAL PERFUSION; ELECTRICAL MODEL		UNIV CALIF LOS ANGELES,SCH MED,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	NIEMANN, JT (corresponding author), UNIV CALIF LOS ANGELES,LOS ANGELES CTY HARBOR MED CTR,DEPT EMERGENCY MED,1000 W CARSON ST,TORRANCE,CA 90509, USA.			Niemann, James/0000-0002-2626-7681				BABBS CF, 1984, AM J EMERG MED, V2, P299, DOI 10.1016/0735-6757(84)90124-4; BARTON CW, 1988, ANN EMERG MED, V17, P393; BEDELL SE, 1983, NEW ENGL J MED, V309, P569, DOI 10.1056/NEJM198309083091001; BIRCHER N, 1984, ANN EMERG MED, V13, P770, DOI 10.1016/S0196-0644(84)80432-1; BLACKHALL LJ, 1987, NEW ENGL J MED, V317, P1281, DOI 10.1056/NEJM198711123172009; BROWN CG, 1992, NEW ENGL J MED, V327, P1051, DOI 10.1056/NEJM199210083271503; BROWN CG, 1990, RESUSCITATION, V19, P1, DOI 10.1016/0300-9572(90)90094-U; CHEUNG JY, 1986, NEW ENGL J MED, V314, P1670; CRILEY JM, 1976, JAMA-J AM MED ASSOC, V236, P1246, DOI 10.1001/jama.236.11.1246; CUMMINS RO, 1988, ANN EMERG MED, V17, P813, DOI 10.1016/S0196-0644(88)80561-4; CUMMINS RO, 1989, CLIN CRITICAL CARE M, V16, P87; DELGUERCIO LR, 1965, CIRCULATION, V31, P171; DESHMUKH HG, 1989, CHEST, V95, P1092, DOI 10.1378/chest.95.5.1092; EISENBERG M, 1981, JAMA-J AM MED ASSOC, V246, P50, DOI 10.1001/jama.246.1.50; EWY GA, 1981, CRIT CARE MED, V9, P841, DOI 10.1097/00003246-198112000-00008; FALK JL, 1988, NEW ENGL J MED, V318, P607, DOI 10.1056/NEJM198803103181005; FENELEY MP, 1987, CIRCULATION, V76, P363, DOI 10.1161/01.CIR.76.2.363; FISER DH, 1990, NEW ENGL J MED, V322, P1579; FISHER J, 1982, CIRCULATION, V65, P188, DOI 10.1161/01.CIR.65.1.188; FOX M, 1983, NEW ENGL J MED, V309, P607, DOI 10.1056/NEJM198309083091010; FRASS M, 1987, CRIT CARE MED, V15, P609, DOI 10.1097/00003246-198706000-00015; GANDO S, 1990, ANN EMERG MED, V19, P850, DOI 10.1016/S0196-0644(05)81556-2; GARNETT AR, 1987, JAMA-J AM MED ASSOC, V257, P512, DOI 10.1001/jama.257.4.512; GEEHR EC, 1986, NEW ENGL J MED, V314, P1189; GRAY WA, 1991, NEW ENGL J MED, V325, P1393, DOI 10.1056/NEJM199111143252001; GUERCI AD, 1986, CIRCULATION, V74, P75; HARGARTEN KM, 1990, ANN EMERG MED, V19, P157, DOI 10.1016/S0196-0644(05)81801-3; HAYNES RE, 1981, AM J CARDIOL, V48, P353, DOI 10.1016/0002-9149(81)90619-6; HEDGES JR, 1987, CIRCULATION, V76, P1337, DOI 10.1161/01.CIR.76.6.1337; HEDGES JR, 1984, ANN EMERG MED, V13, P822, DOI 10.1016/S0196-0644(84)80450-3; HERSHEY CO, 1982, LANCET, V1, P31, DOI 10.1016/S0140-6736(82)92567-3; KELLERMANN AL, 1988, ANN EMERG MED, V17, P589, DOI 10.1016/S0196-0644(88)80398-6; KETTE F, 1991, JAMA-J AM MED ASSOC, V266, P2121, DOI 10.1001/jama.266.15.2121; KETTE F, 1990, CIRCULATION, V81, P1660, DOI 10.1161/01.CIR.81.5.1660; KOUWENHOVEN WB, 1960, JAMA-J AM MED ASSOC, V173, P1064, DOI 10.1001/jama.1960.03020280004002; Kremers M S, 1989, Dis Mon, V35, P381; KRISCHER JP, 1987, CHEST, V92, P287, DOI 10.1378/chest.92.2.287; MAIER GW, 1984, CIRCULATION, V70, P86, DOI 10.1161/01.CIR.70.1.86; MARTIN GB, 1990, ANN EMERG MED, V19, P396, DOI 10.1016/S0196-0644(05)82345-5; MEADOR SA, 1986, RESUSCITATION, V13, P145, DOI 10.1016/0300-9572(86)90096-1; MICHAEL JR, 1984, CIRCULATION, V69, P822, DOI 10.1161/01.CIR.69.4.822; MICHAEL TAD, 1985, CHEST, V87, P814, DOI 10.1378/chest.87.6.814; MINUCK M, 1977, ANESTH ANALG, V56, P38; NIEMANN JT, 1981, CIRCULATION, V64, P985, DOI 10.1161/01.CIR.64.5.985; NIEMANN JT, 1980, CRIT CARE MED, V8, P141, DOI 10.1097/00003246-198003000-00011; NIEMANN JT, 1985, ANN EMERG MED, V14, P521, DOI 10.1016/S0196-0644(85)80774-5; NIEMANN JT, 1984, ANN EMERG MED, V13, P849, DOI 10.1016/S0196-0644(84)80458-8; NIEMANN JT, 1984, ANN EMERG MED, V13, P781, DOI 10.1016/S0196-0644(84)80435-7; PARADIS NA, 1990, ANN EMERG MED, V19, P1288, DOI 10.1016/S0196-0644(05)82289-9; PARADIS NA, 1989, CIRCULATION, V80, P361, DOI 10.1161/01.CIR.80.2.361; PEATFIELD RC, 1977, LANCET, V1, P1223; REDDING JS, 1968, J AMER MED ASSOC, V203, P255; RICH S, 1981, AM HEART J, V102, P368, DOI 10.1016/0002-8703(81)90311-2; RUDIKOFF MT, 1980, CIRCULATION, V61, P345, DOI 10.1161/01.CIR.61.2.345; SANDERS AB, 1985, J AM COLL CARDIOL, V6, P113, DOI 10.1016/S0735-1097(85)80261-8; SANDERS AB, 1984, CRIT CARE MED, V12, P871, DOI 10.1097/00003246-198410000-00007; SANDERS AB, 1984, ANN EMERG MED, V13, P672, DOI 10.1016/S0196-0644(84)80723-4; SANDERS AB, 1984, ANN EMERG MED, V13, P676, DOI 10.1016/S0196-0644(84)80724-6; SHERMAN BW, 1991, ANN EMERG MED, V20, P949; SMITH JP, 1983, JAMA-J AM MED ASSOC, V250, P1081, DOI 10.1001/jama.250.8.1081; STERNER S, 1991, ANN EMERG MED, V20, P949; SUTTONTYRRELL K, 1988, ANN EMERG MED, V17, P572, DOI 10.1016/S0196-0644(88)80394-9; SWENSON RD, 1988, CIRCULATION, V78, P630, DOI 10.1161/01.CIR.78.3.630; THOMPSON BM, 1986, CIRCULATION, V74, P90; URBAN P, 1988, ANN INTERN MED, V109, P110, DOI 10.7326/0003-4819-109-2-110; VINCENT JL, 1981, CIRCULATION, V64, P18, DOI 10.1161/01.CIR.64.1.18; WARNER LL, 1985, CHEST, V87, P22, DOI 10.1378/chest.87.1.22; WEAVER WD, 1985, ANN INTERN MED, V102, P53, DOI 10.7326/0003-4819-102-1-53; WEAVER WD, 1986, J AM COLL CARDIOL, V7, P752, DOI 10.1016/S0735-1097(86)80332-1; WEIL MH, 1986, NEW ENGL J MED, V315, P153, DOI 10.1056/NEJM198607173150303; WERNER JA, 1981, CIRCULATION, V63, P1417, DOI 10.1161/01.CIR.63.6.1417; 1988, LANCET, V1, P743; 1986, JAMA-J AM MED ASSOC, V255, P2920; 1986, JAMA-J AM MED ASSOC, V256, P1727	74	57	63	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 8	1992	327	15					1075	1080						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JR321	1522844				2023-01-03	WOS:A1992JR32100007
J	BORGEAT, A; WILDERSMITH, OHG; WILDERSMITH, CH; FORNI, M; SUTER, PM				BORGEAT, A; WILDERSMITH, OHG; WILDERSMITH, CH; FORNI, M; SUTER, PM			ADJUVANT PROPOFOL FOR REFRACTORY CISPLATIN-ASSOCIATED NAUSEA AND VOMITING	LANCET			English	Letter							HIGH-DOSE METOCLOPRAMIDE; CHEMOTHERAPY; ONDANSETRON		UNIV GENEVA HOSP,DEPT GYNAECOL & OBSTET,CH-1211 GENEVEA,SWITZERLAND; UNIV BERN,INSELSPITAL,DEPT GASTROENTEROL,CH-3010 BERN,SWITZERLAND	University of Bern; University Hospital of Bern	BORGEAT, A (corresponding author), UNIV GENEVA HOSP,DEPT ANAESTHESIOL,CH-1211 GENEVA,SWITZERLAND.		Wilder-Smith, Clive/W-4365-2019; Wilder-Smith, Clive/V-4868-2019; Wilder-Smith, Oliver H.G./E-7541-2012	Wilder-Smith, Oliver H.G./0000-0003-4390-2381				BORGEAT A, 1992, ANESTH ANALG, V74, P539; GRALLA RJ, 1981, NEW ENGL J MED, V305, P905, DOI 10.1056/NEJM198110153051601; MARTY M, 1990, NEW ENGL J MED, V322, P816, DOI 10.1056/NEJM199003223221205; MCCOLLUM JSC, 1988, ANAESTHESIA, V43, P239; SMITH DB, 1991, LANCET, V338, P487, DOI 10.1016/0140-6736(91)90555-4	5	8	8	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 12	1992	340	8820					679	680		10.1016/0140-6736(92)92222-2	http://dx.doi.org/10.1016/0140-6736(92)92222-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JM851	1355248				2023-01-03	WOS:A1992JM85100050
J	PARRILLO, JE				PARRILLO, JE			CRITICAL CARE MEDICINE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							GRAM-NEGATIVE BACTEREMIA; SEPTIC SHOCK; ENDOTOXIN; IMPACT; UNIT				PARRILLO, JE (corresponding author), RUSH PRESBYTERIAN ST LUKES MED CTR,CHICAGO,IL 60612, USA.							COBB LA, 1980, MOD CONC CARDIOV DIS, V49, P31; DANNER RL, 1991, CHEST, V99, P169, DOI 10.1378/chest.99.1.169; GOLDBERG RJ, 1991, NEW ENGL J MED, V325, P1117, DOI 10.1056/NEJM199110173251601; GRAY WA, 1991, NEW ENGL J MED, V325, P1393, DOI 10.1056/NEJM199111143252001; GREENMAN RL, 1991, JAMA-J AM MED ASSOC, V266, P1097, DOI 10.1001/jama.266.8.1097; HOLLENBERG SM, 1991, CHEST, V100, P1133, DOI 10.1378/chest.100.4.1133; KREGER BE, 1980, AM J MED, V68, P344, DOI 10.1016/0002-9343(80)90102-3; LEE L, 1988, CIRCULATION, V78, P1345, DOI 10.1161/01.CIR.78.6.1345; LI TCM, 1984, JAMA-J AM MED ASSOC, V252, P2023, DOI 10.1001/jama.252.15.2023; MUNDTH ED, 1976, CIRCULATION, V53, P176; NATANSON C, 1989, J EXP MED, V169, P823, DOI 10.1084/jem.169.3.823; NATANSON C, 1990, AM J PHYSIOL, V259, pH1440, DOI 10.1152/ajpheart.1990.259.5.H1440; OHLSSON K, 1990, NATURE, V348, P550, DOI 10.1038/348550a0; PARRILLO JE, 1991, ANN INTERN MED, V115, P491, DOI 10.7326/0003-4819-115-6-491; PARRILLO JE, 1985, JAMA-J AM MED ASSOC, V254, P2288, DOI 10.1001/jama.1985.03360160120029; PARRILLO JE, 1990, ANN INTERN MED, V113, P27; REYNOLDS HN, 1988, JAMA-J AM MED ASSOC, V260, P3446, DOI 10.1001/jama.260.23.3446; VANDEVENTER SJH, 1988, LANCET, V1, P605; ZIEGLER EJ, 1982, NEW ENGL J MED, V307, P1225, DOI 10.1056/NEJM198211113072001; ZIEGLER EJ, 1991, NEW ENGL J MED, V324, P429, DOI 10.1056/NEJM199102143240701	20	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 15	1992	268	3					340	342						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JC352	1613913				2023-01-03	WOS:A1992JC35200023
J	CHAUHAN, AJ; MCLINDON, JP; DILLON, P; SAWYER, JPC; GRAY, L; LEAHY, BC				CHAUHAN, AJ; MCLINDON, JP; DILLON, P; SAWYER, JPC; GRAY, L; LEAHY, BC			REGULAR BALLOON INFLATION FOR PATIENTS WITH CHRONIC-BRONCHITIS - A RANDOMIZED CONTROLLED TRIAL	BRITISH MEDICAL JOURNAL			English	Article											CHAUHAN, AJ (corresponding author), TRAFFORD GEN HOSP,DEPT MED,MANCHESTER M31 3SL,ENGLAND.							BELMAN MJ, 1980, AM REV RESPIR DIS, V121, P273; BELMAN MJ, 1991, CHEST, V99, P566, DOI 10.1378/chest.99.3.566; GUYATT GH, 1991, RESP MED, V85, P17, DOI 10.1016/S0954-6111(06)80164-2; SINCLAIR DJM, 1980, BRIT MED J, V1, P519	5	7	7	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 27	1992	304	6843					1668	1669		10.1136/bmj.304.6843.1668-a	http://dx.doi.org/10.1136/bmj.304.6843.1668-a			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JB939	1633520	Green Published, Bronze			2023-01-03	WOS:A1992JB93900023
J	WILKES, MS; DOBLIN, BH; SHAPIRO, MF				WILKES, MS; DOBLIN, BH; SHAPIRO, MF			PHARMACEUTICAL ADVERTISEMENTS IN LEADING MEDICAL JOURNALS - EXPERTS ASSESSMENTS	ANNALS OF INTERNAL MEDICINE			English	Article						ADVERTISING; DRUG INFORMATION SERVICES; DRUG INDUSTRY; UNITED-STATES-FOOD-AND-DRUG-ADMINISTRATION	DRUG COMPANIES; PHYSICIANS; INFORMATION; DOCTORS; GIFTS	Objective: To assess both the accuracy of scientific data presented in print pharmaceutical advertisements and the compliance of these advertisements with current Food and Drug Administration (FDA) standards. Design: Cross-sectional survey. Measurements: Each full-page pharmaceutical advertisement (n = 109) appearing in 10 leading medical journals, along with all available references cited in the advertisement (82% of the references cited were available) were sent to three reviewers: two physicians in the relevant clinical area who were experienced in peer review and one academic clinical pharmacist. Reviewers, 95% of whom responded, were asked to evaluate the advertisements using criteria based on FDA guidelines, to judge the educational value and overall quality of the advertisements, and to make a recommendation regarding publication. Results: In 30% of cases, two or more reviewers disagreed with the advertisers' claim that the drug was the "drug of choice." Reviewers felt that information on efficacy was balanced with that on side effects and contraindications in 49% of advertisements but was not balanced in 40%. Reviewers agreed with advertisements' claims that the drug was safe in 86% of the cases but judged that headlines in 32% of the advertisements containing headlines misled the reader about efficacy. In 44% of cases, reviewers felt that the advertisement would lead to improper prescribing if a physician had no other information about the drug other than that contained in the advertisement. Fifty-seven percent of advertisements were judged by two or more reviewers to have little or no educational value. Overall, reviewers would not have recommended publication of 28% of the advertisements and would have required major revisions in 34% before publication. Conclusion: In the opinion of the reviewers, many advertisements contained deficiencies in areas in which the FDA has established explicit standards of quality. New strategies are needed to ensure that advertisements comply with standards intended to promote proper use of the products and to protect the consumer.			WILKES, MS (corresponding author), UNIV CALIF LOS ANGELES, SCH MED, DEPT MED, DIV GEN INTERNAL MED, LOS ANGELES, CA 90024 USA.				PHS HHS [R01-90-1088] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AHMAD SR, 1991, LANCET, V338, P1384; AVORN J, 1982, AM J MED, V73, P4, DOI 10.1016/0002-9343(82)90911-1; CHREN MM, 1989, JAMA-J AM MED ASSOC, V262, P3448, DOI 10.1001/jama.262.24.3448; CHRISTENSEN DB, 1979, SOC SCI MED-MED SOC, V13, P313, DOI 10.1016/0160-7979(79)90066-3; FASSOLD RW, 1968, CAN MED ASSOC J, V98, P701; GARFUNKEL JM, 1990, JAMA-J AM MED ASSOC, V263, P1369, DOI 10.1001/jama.263.10.1369; GORSKI TN, 1990, JAMA-J AM MED ASSOC, V263, P2177, DOI 10.1001/jama.1990.03440160039016; JACOBY J, 1975, J MARKETING, V39, P65, DOI 10.2307/1250601; LINN LS, 1972, SOC SCI MED, V6, P199, DOI 10.1016/0037-7856(72)90025-X; LIPTON HL, 1988, DRUGS ELDERLY CLIN S; LOCK S, 1986, DIFFICULT BALANCE, P24; MILLSTEIN LG, 1983, AM PHARM, V23, P54, DOI 10.1016/S0160-3450(16)32075-X; MOSER M, 1991, JAMA-J AM MED ASSOC, V265, P498, DOI 10.1001/jama.265.4.498; MOSER RH, 1977, ANN INTERN MED, V87, P114, DOI 10.7326/0003-4819-87-1-114; RELMAN AS, 1979, NEW ENGL J MED, V301, P999, DOI 10.1056/NEJM197911013011811; SCHIFF G, 1990, JAMA-J AM MED ASSOC, V263, P658, DOI 10.1001/jama.1990.03440050052019; ZELLMER WA, 1987, AM J HOSP PHARM, V44, P1651, DOI 10.1093/ajhp/44.7.1651; ZUCKERMAN H, 1971, MINERVA, V9, P66, DOI 10.1007/BF01553188; 1991, OEI01900000000482 DE; 1989, HLTH CARE COMMUNICAT	20	206	212	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 1	1992	116	11					912	919		10.7326/0003-4819-116-11-912	http://dx.doi.org/10.7326/0003-4819-116-11-912			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HW137	1580449				2023-01-03	WOS:A1992HW13700007
J	MELZER, D; HALE, AS; MALIK, SJ; HOGMAN, GA; WOOD, S				MELZER, D; HALE, AS; MALIK, SJ; HOGMAN, GA; WOOD, S			COMMUNITY CARE FOR PATIENTS WITH SCHIZOPHRENIA ONE YEAR AFTER HOSPITAL DISCHARGE	BRITISH MEDICAL JOURNAL			English	Article							FOLLOW-UP	Objectives - To document the circumstances and care of patients with schizophrenia who had recently been discharged from local psychiatric inpatient services, and to establish the extent to which misgivings about community care might be justified. Design - Cross sectional surveys with review of case notes. Follow up interviews with questionnaires administered one year after discharge. Setting - Two inner London districts (West Lambeth and Lewisham) with high levels of social deprivation and at different stages of developing community services. Patients - 90 and 50 patients in the two services respectively, aged 18 to 65, who satisfied the Research Diagnostic Criteria for schizophrenia and who were discharged from inpatient services. Main outcome measures - Diagnosis elicited by present state examination, global social disability rating, use of services during the three months before interview. Results - 89 of the 140 patients (64%) had been ill for five or more years, yet few were former long stay inpatients. 55% (50/91; 95% confidence interval 45% to 65%) of those interviewed had current psychotic mental states and 22% (27/124; 16% to 31%) were functioning socially at very poor or severely maladjusted levels. 86% (107/124) were unemployed. The majority of patients had seen a mental health or social service professional, yet only 16% (20/124) were in specialised accommodation (excluding hospitals) and only 23% (17/73) of those eligible had used day care. Small numbers of people had experienced homelessness (two) or imprisonment (four over six months). Conclusions - Many schizophrenic patients leaving local psychiatric inpatient care have active symptomatology and profound social disabilities. Community care was characterised by high rates of contact with service professionals but little supported accommodation or day activity. This group of clients may require dedicated provision, which would actively encourage them to use services protected from the demands of those with less severe illness.	ST THOMAS HOSP,W LAMBETH HLTH AUTHOR,DIRECTORATE PUBL HLTH,LONDON SE1 7EH,ENGLAND; UNITED MED & DENT SCH GUYS & ST THOMAS HOSP,ST THOMAS HOSP,LONDON SE1 7EH,ENGLAND; GUYS HOSP,PSYCHIAT,LONDON SE1 9RT,ENGLAND	Guy's & St Thomas' NHS Foundation Trust; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; Guy's & St Thomas' NHS Foundation Trust				Melzer, David/0000-0002-0170-3838				BACHRACH LL, 1984, HOMELESS MENTALLY IL; BEECHAM J, IN PRESS SCHIZOPH B; CHEADLE AJ, 1978, BRIT J PSYCHIAT, V132, P221, DOI 10.1192/S0007125000283268; COID JW, 1988, BRIT MED J, V296, P1779, DOI 10.1136/bmj.296.6639.1779; CRAMER P, 1989, BRIT J PSYCHIAT, V155, P225, DOI 10.1192/bjp.155.2.225; Davis A., 1974, SCHIZOPHRENICS NEW C; DEAN AG, 1990, EPIINFO VERSION 5; ELLIS RH, 1984, COMMUNITY MENT HLT J, V20, P72; FRY AH, 1989, HLTH TRENDS, V21, P70; GROVES T, 1990, BRIT MED J, V300, P923, DOI 10.1136/bmj.300.6729.923; HOGG LI, 1990, ACTA PSYCHIAT SCAND, V81, P271, DOI 10.1111/j.1600-0447.1990.tb06495.x; JOHNSTONE EC, 1984, BRIT J PSYCHIAT, V145, P586, DOI 10.1192/bjp.145.6.586; JONES K, 1986, BRIT J PSYCHIAT, V149, P537, DOI 10.1192/bjp.149.5.537; KHOOSAL D, 1991, HLTH TRENDS, V22, P137; KNAPP M, 1990, CARE COMMUNITY LESSO; KNAPP M, IN PRESS PSYCHOL MED; KUIPERS L, 1988, PSYCHOL MED, V18, P893, DOI 10.1017/S0033291700009831; MCCREADIE RG, 1982, BRIT J PSYCHIAT, V140, P582, DOI 10.1192/bjp.140.6.582; MILNER G, 1991, HLTH TRENDS, V4, P141; NORUSIS MJ, 1986, STATISTICAL PACKAGE; OLFSON M, 1990, HOSP COMMUNITY PSYCH, V41, P634; RICE P, 1984, INFORMATION DISTRICT; SAYCE L, 1991, SOC PSYCH PSYCH EPID, V26, P14, DOI 10.1007/BF00783575; Spitzer RL, 1975, RES DIAGNOSTIC CRITE; TANTAM D, 1985, BRIT J PSYCHIAT, V146, P1, DOI 10.1192/bjp.146.1.1; THORNICROFT G, 1989, BRIT J PSYCHIAT, V155, P739, DOI 10.1192/bjp.155.6.739; WATT DC, 1983, PSYCHOL MED, V13, P663, DOI 10.1017/S0033291700048091; WELLER M, 1989, LANCET, V2, P1509; Wing J. K. C., 1974, MEASUREMENT CLASSIFI; WOOD S, 1990, CLOSURE MENTAL HOSPI; 1989, SLIPPING NET; 1990, CARE PROGRAMME APPRO; 1989, INFORMED ACTION HLTH; 1989, 4TH ANN C TEAM ASS P; 1988, WHO PSYCHIATRIC DISA	35	58	59	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 26	1991	303	6809					1023	1026		10.1136/bmj.303.6809.1023	http://dx.doi.org/10.1136/bmj.303.6809.1023			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GM478	1954452	Green Published, Bronze			2023-01-03	WOS:A1991GM47800018
J	SHAW, J; HOLLOWAY, J				SHAW, J; HOLLOWAY, J			WHO IS YOUR GENERAL-PRACTITIONER	BRITISH MEDICAL JOURNAL			English	Article											SHAW, J (corresponding author), PRESTWICH HOSP,REG SECURE UNIT,SALFORD,ENGLAND.			shaw, jennifer/0000-0003-2569-7687				BLUEGLASS R, 1983, GUIDE MENTAL HLTH AC	1	4	4	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 14	1991	303	6803					628	628		10.1136/bmj.303.6803.628	http://dx.doi.org/10.1136/bmj.303.6803.628			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GF675	1932906	Bronze, Green Published			2023-01-03	WOS:A1991GF67500026
J	WILMORE, DW; MOSES, A				WILMORE, DW; MOSES, A			CATABOLIC ILLNESS - STRATEGIES FOR ENHANCING RECOVERY	NEW ENGLAND JOURNAL OF MEDICINE			English	Discussion							TUMOR NECROSIS FACTOR; HUMAN GROWTH-HORMONE; CHAIN AMINO-ACIDS; PARENTERAL-NUTRITION; SURGICAL PATIENTS; NITROGEN-BALANCE; FACTOR-I; SEPTIC SHOCK; PROTEIN LOSS; HUMAN-BEINGS		HARVARD UNIV, SCH MED, DEPT SURG, SURG METAB & NUTR LABS, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT SURG, NUTR SUPPORT SERV, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	WILMORE, DW (corresponding author), BRIGHAM & WOMENS HOSP, DEPT SURG, 75 FRANCIS ST, BOSTON, MA 02115 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P50GM036428] Funding Source: NIH RePORTER; NIGMS NIH HHS [5P50 GM36428] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AOKI TT, 1975, DIABETES, V24, P463, DOI 10.2337/diabetes.24.5.463; ARDAWI MSM, 1985, BIOCHEM J, V231, P713, DOI 10.1042/bj2310713; BARBUL A, 1986, JPEN-PARENTER ENTER, V10, P227, DOI 10.1177/0148607186010002227; BARBUL A, 1981, SURGERY, V90, P244; BAUMGARTNER JD, 1985, LANCET, V2, P59; BEISEL WR, 1975, ANNU REV MED, V26, P9, DOI 10.1146/annurev.me.26.020175.000301; BITTINER SB, 1988, LANCET, V1, P378; BONE RC, 1987, NEW ENGL J MED, V317, P653, DOI 10.1056/NEJM198709103171101; BROWN GL, 1989, NEW ENGL J MED, V321, P76, DOI 10.1056/NEJM198907133210203; CALDWELL MD, 1989, METABOLISM, V38, P34, DOI 10.1016/0026-0495(89)90137-6; CERRA FB, 1987, SURGERY, V101, P1; CHANDRA RK, 1983, LANCET, V1, P688; CHENEY CL, 1987, J AM COLL NUTR, V6, P223; CLEMMONS DR, 1987, J CLIN ENDOCR METAB, V64, P878, DOI 10.1210/jcem-64-5-878; Cuthbertson DP, 1932, Q J MED, V1, P233; DALY JM, 1988, ANN SURG, V208, P512, DOI 10.1097/00000658-198810000-00013; EBERLEIN TJ, 1989, ARCH SURG-CHICAGO, V124, P542; ENDRES S, 1989, NEW ENGL J MED, V320, P265, DOI 10.1056/NEJM198902023200501; GULER HP, 1987, NEW ENGL J MED, V317, P137, DOI 10.1056/NEJM198707163170303; GULER HP, 1988, P NATL ACAD SCI USA, V85, P4889, DOI 10.1073/pnas.85.13.4889; HAMMARQVIST F, 1989, ANN SURG, V209, P455, DOI 10.1097/00000658-198904000-00011; HERDON DN, 1990, ANN SURG, V212, P424; JIANG ZM, 1989, ANN SURG, V210, P513, DOI 10.1097/00000658-198910000-00012; KAWAKAMI M, 1984, P IUPHAR, V2, P377; Keys A., 1950, BIOL HUMAN STARVATIO, V2; KINNEY JM, 1985, ACTA CHIR SCAND, P45; KREMER JM, 1987, ANN INTERN MED, V106, P497, DOI 10.7326/0003-4819-106-4-497; LILJEDAHL STEN-OTTO, 1961, ACTA CHIR SCAND, V122, P1; LODER PB, 1990, ANN SURG, V211, P360, DOI 10.1097/00000658-199003000-00008; MANSON JM, 1986, SURGERY, V100, P188; MICHIE HR, 1988, SURGERY, V104, P280; MICHIE HR, 1988, NEW ENGL J MED, V318, P1481, DOI 10.1056/NEJM198806093182301; NAYLOR CD, 1989, GASTROENTEROLOGY, V97, P1033, DOI 10.1016/0016-5085(89)91517-5; NEWSHOLME EA, 1988, NUTRITION, V4, P261; PARRYBILLINGS M, 1990, LANCET, V336, P523, DOI 10.1016/0140-6736(90)92083-T; RUGGIERO V, 1986, J IMMUNOL, V136, P2445; SAX HC, 1986, ARCH SURG-CHICAGO, V121, P358; SHERNAN S K, 1989, Surgical Forum (Chicago), V40, P37; SHIZGAL HM, 1983, SURGICAL NUTRITION, P3; STREAT SJ, 1987, J TRAUMA, V27, P262, DOI 10.1097/00005373-198703000-00006; SUN XM, 1988, J CLIN INVEST, V81, P1328, DOI 10.1172/JCI113459; TRACEY KJ, 1989, LANCET, V1, P1122; TRACEY KJ, 1987, NATURE, V330, P662, DOI 10.1038/330662a0; UNDERWOOD LE, 1986, HORM RES, V24, P166, DOI 10.1159/000180556; WAAGE A, 1988, J EXP MED, V167, P1987, DOI 10.1084/jem.167.6.1987; WELBOURNE TC, 1987, AM J PHYSIOL, V253, pF1069, DOI 10.1152/ajprenal.1987.253.6.F1069; WILMORE DW, 1974, SURG GYNECOL OBSTET, V138, P875; WILMORE DW, 1976, SURG CLIN N AM, V56, P999; WILMORE DW, 1983, NUTRITIONAL SUPPORT, P33; WINDMUELLER HG, 1982, ADV ENZYMOL RAMB, V53, P201; WINDSOR JA, 1988, BRIT J SURG, V75, P880, DOI 10.1002/bjs.1800750917; WINDSOR JA, 1988, BRIT J SURG, V75, P135, DOI 10.1002/bjs.1800750215; ZIEGLER EJ, 1991, NEW ENGL J MED, V324, P429, DOI 10.1056/NEJM199102143240701; ZIEGLER TR, 1988, ANN SURG, V208, P6, DOI 10.1097/00000658-198807000-00002; ZIEGLER TR, 1990, JPEN-PARENTER ENTER, V14, P574, DOI 10.1177/0148607190014006574; [No title captured]	56	282	288	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 5	1991	325	10					695	702						8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GD497	1908058				2023-01-03	WOS:A1991GD49700005
J	DELISA, JA; JAIN, SS				DELISA, JA; JAIN, SS			PHYSICAL MEDICINE AND REHABILITATION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article									KESSLER INST REHABIL,W ORANGE,NJ	Kessler Institute for Rehabilitation	DELISA, JA (corresponding author), UNIV MED & DENT NEW JERSEY,NEW JERSEY MED SCH,NEWARK,NJ 07103, USA.							AYERS JWT, 1988, FERTIL STERIL, V49, P1089; BACH JR, 1990, CHEST, V98, P613, DOI 10.1378/chest.98.3.613; BACH JR, IN PRESS B NY ACAD M; BEJJANI FJ, 1989, J BIOMECH, V22, P439, DOI 10.1016/0021-9290(89)90204-2; CAREY RG, 1988, ARCH PHYS MED REHAB, V69, P337; CHANG MS, 1987, ERGONOMICS, V30, P331; COHEN LG, 1991, BRAIN, V114, P615, DOI 10.1093/brain/114.1.615; Figoni S F, 1990, J Am Paraplegia Soc, V13, P33; GRESHAM GE, 1990, STROKE, V21, P1; JOHNSTON MV, IN PRESS BRAIN INJ; LINSENMEYER TA, 1991, NEUROREHABILITATION, V1, P22; PATTERSON RP, 1990, ARCH PHYS MED REHAB, V71, P340; ROBINSON LR, 1990, AM J PHYS MED REHAB, V69, P307, DOI 10.1097/00002060-199012000-00006; TRAVERS PH, 1988, OCCUP MED, V3, P271; VERVILLE RE, 1990, ARCH PHYS MED REHAB, V71, P1010	15	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 19	1991	265	23					3158	3160						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FQ770	1828273				2023-01-03	WOS:A1991FQ77000035
J	OCONNOR, DW; POLLITT, PA; BROOK, CPB; REISS, BB; ROTH, M				OCONNOR, DW; POLLITT, PA; BROOK, CPB; REISS, BB; ROTH, M			DOES EARLY INTERVENTION REDUCE THE NUMBER OF ELDERLY PEOPLE WITH DEMENTIA ADMITTED TO INSTITUTIONS FOR LONG-TERM CARE	BRITISH MEDICAL JOURNAL			English	Article							MINI-MENTAL STATE; COMMUNITY; SERVICES; VALIDITY	Objective-To test whether early diagnosis and practical help reduce the number of elderly people with dementia admitted to institutions. Design-Controlled trial of effect of help from a multidisciplinary team on admission rates of people with dementia. Setting-Seven general practices in Cambridge. Subjects-2889 subjects aged 75 and over, of whom 159 were identified as having dementia with a two stage community survey. Eighty six subjects were referred for extra help if they or their supporters wished. The other 73 subjects had access to the usual services and served as controls. Intervention-Subjects and families in the action group were offered a wide range of help, including financial benefits, physical aids, home helps, respite admissions, practical advice, and psychiatric assessments. Main outcome measure-Permanent admission to long term care within two years after diagnosis. Results-Early intervention did not affect admission rates in subjects who lived with supporters. By contrast, nine of the 14 (64%) subjects with moderate or severe dementia living alone were admitted in the action group in the study's second year compared with only one of 13 (8%) controls (p = 0.004). Conclusions-Some people with moderate or severe dementia who lived alone and were at serious risk may have been identified earlier by the resource team. Without the team these people would not have become known to the responsible authorities until families, neighbours, and wardens became unable to cope. The study was conducted during the team's formative period, however, and greater experience might have allowed some subjects to remain at home for longer.	HUGHES HALL PROJECT LATER LIFE,CAMBRIDGE CB1 2EW,ENGLAND	University of Cambridge				O'Connor, Daniel/0000-0003-0188-1340				ASKHAM J, 1990, DEMENTIA HOME CARE; BLENKNER M, 1971, SOC CASEWORK-JCSW, V52, P483, DOI 10.1177/104438947105200801; BOAS JW, 1971, BRIT J RADIOL, V44, P122; BRANCH LG, 1982, AM J PUBLIC HEALTH, V72, P1373, DOI 10.2105/AJPH.72.12.1373; CARPENTER GI, 1990, BMJ-BRIT MED J, V300, P1253, DOI 10.1136/bmj.300.6734.1253; Challis D, 1986, CASE MANAGEMENT COMM; Challis D., 1990, CASE MANAGEMENT SOCI; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Gilleard C. J., 1984, LIVING DEMENTIA COMM; GODBER C, 1977, AGE AGEING, V6, P100; OCONNOR DW, 1989, INT J GERIATR PSYCH, V4, P203, DOI 10.1002/gps.930040405; OCONNOR DW, 1989, J PSYCHIAT RES, V23, P87, DOI 10.1016/0022-3956(89)90021-6; OCONNOR DW, 1989, ACTA PSYCHIAT SCAND, V79, P190, DOI 10.1111/j.1600-0447.1989.tb08587.x; OCONNOR DW, 1990, BRIT J PSYCHIAT, V156, P835, DOI 10.1192/bjp.156.6.835; OCONNOR DW, 1990, ACTA PSYCHIAT SCAND, V81, P78, DOI 10.1111/j.1600-0447.1990.tb06453.x; OCONNOR DW, 1989, INT J GERIATR PSYCH, V4, P339, DOI 10.1002/gps.930040607; OPIT LJ, 1977, BRIT MED J, V1, P30, DOI 10.1136/bmj.1.6052.30; Pollitt PA, 1989, AGEING SOC, V9, P261; ROTH M, 1986, BRIT J PSYCHIAT, V149, P698, DOI 10.1192/bjp.149.6.698; 1987, DIAGNOSTIC STATISTIC; 1989, CARING PEOPLE	21	66	66	0	8	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 13	1991	302	6781					871	875		10.1136/bmj.302.6781.871	http://dx.doi.org/10.1136/bmj.302.6781.871			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FG421	1902752	Bronze, Green Published			2023-01-03	WOS:A1991FG42100019
J	SALUSKY, IB; FOLEY, J; NELSON, P; GOODMAN, WG				SALUSKY, IB; FOLEY, J; NELSON, P; GOODMAN, WG			ALUMINUM ACCUMULATION DURING TREATMENT WITH ALUMINUM HYDROXIDE AND DIALYSIS IN CHILDREN AND YOUNG-ADULTS WITH CHRONIC RENAL-DISEASE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							AMBULATORY PERITONEAL-DIALYSIS; CALCIUM-CARBONATE; PHOSPHATE BINDER; FAILURE; PHOSPHORUS; BONE; OSTEODYSTROPHY; ABSORPTION; METABOLISM; ACETATE	Background. The control of hyperphosphatemia is a major clinical problem in patients with chronic renal failure receiving regular dialysis treatment. Despite continuing concern about aluminum toxicity, aluminum-containing antacids are still used in many of these patients as phosphate-binding agents. Although maximal acceptable doses of aluminum hydroxide have been recommended, the safety and efficacy of these guidelines have not been evaluated. Methods. Seventeen children and young adults (mean [+/- SD] age, 14.1 +/- 3.7 years) undergoing regular peritoneal dialysis were randomly assigned to treatment with either aluminum hydroxide (n = 7; maximal dose, 30 mg per kilogram of body weight per day) or calcium carbonate (n = 10; dose range, 2.5 to 12 g per day, according to serum phosphorus levels). Aluminum retention was assessed by serial measurements of plasma aluminum, deferoxamine-infusion tests, and measurements of bone aluminum content during a mean (+/- SD) follow-up of 13 +/- 2 months. The evolution of bone disease was also evaluated. Results. Plasma aluminum levels and the increment in plasma aluminum after infusion of deferoxamine increased from base-line values in the patients treated with aluminum hydroxide, and aluminum-related bone disease developed in one patient. Serum phosphorus levels remained higher and serum calcium levels lower in the patients receiving aluminum hydroxide than in those receiving calcium carbonate. The skeletal lesions of secondary hyperparathyroidism improved in 7 of 10 patients receiving calcium carbonate but persisted or progressed in 6 of 7 patients given aluminum hydroxide (P < 0.025). Conclusions. Aluminum hydroxide is less effective than calcium carbonate as a phosphate-binding agent for the control of hyperphosphatemia and is associated with aluminum retention in children and young adults with chronic renal failure who are receiving dialysis therapy.	SEPULVEDA VET AFFAIRS MED CTR, MED SERV, SEPULVEDA, CA USA; SEPULVEDA VET AFFAIRS MED CTR, RES SERV, SEPULVEDA, CA USA; UNIV CALIF LOS ANGELES, SCH MED, DEPT MED, LOS ANGELES, CA 90024 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	SALUSKY, IB (corresponding author), UNIV CALIF LOS ANGELES, CTR HLTH SCI, SCH MED, DEPT PEDIAT, A2-331 MDCC, LOS ANGELES, CA 90024 USA.				NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000865] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR035470] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK035423] Funding Source: NIH RePORTER; NCRR NIH HHS [RR-00865] Funding Source: Medline; NIAMS NIH HHS [AR-35470] Funding Source: Medline; NIDDK NIH HHS [DK-35423] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDREOLI SP, 1984, NEW ENGL J MED, V310, P1079, DOI 10.1056/NEJM198404263101704; COBURN JW, 1989, NEW ENGL J MED, V320, P1140, DOI 10.1056/NEJM198904273201709; FOURNIER A, 1986, KIDNEY INT       S18, V29, pS114; FROMENT DP, 1989, KIDNEY INT, V36, P978, DOI 10.1038/ki.1989.290; GOKAL R, 1983, KIDNEY INT, V23, P15, DOI 10.1038/ki.1983.4; HERCZ G, 1986, KIDNEY INT, V30, P944, DOI 10.1038/ki.1986.277; HRUSKA KA, 1975, J CLIN INVEST, V56, P39, DOI 10.1172/JCI108077; JENKINS DAS, 1989, NEPHROL DIAL TRANSPL, V4, P51; LEGENDRE GR, 1976, CLIN CHEM, V22, P53; MACTIER RA, 1987, CLIN NEPHROL, V28, P222; MAI ML, 1989, KIDNEY INT, V36, P690, DOI 10.1038/ki.1989.247; MALONEY NA, 1982, J LAB CLIN MED, V99, P206; MORINIERE P, 1982, P EUR DIAL TRANS, V19, P784; PREECE MA, 1989, PEDIATRIC ADOLESCENT, V20, P4; SALUSKY IB, 1983, AM J CLIN NUTR, V38, P599, DOI 10.1093/ajcn/38.4.599; SALUSKY IB, 1987, KIDNEY INT, V32, P89, DOI 10.1038/ki.1987.176; SALUSKY IB, 1986, J PEDIATR-US, V108, P767, DOI 10.1016/S0022-3476(86)81064-2; SALUSKY IB, 1988, KIDNEY INT, V33, P975, DOI 10.1038/ki.1988.96; SALUSKY IB, 1984, J PEDIATR-US, V105, P717, DOI 10.1016/S0022-3476(84)80289-9; SCHILLER LR, 1989, NEW ENGL J MED, V320, P1110, DOI 10.1056/NEJM198904273201703; SEDMAN AB, 1984, KIDNEY INT, V26, P201, DOI 10.1038/ki.1984.156; SLATOPOLSKY E, 1986, NEW ENGL J MED, V315, P157, DOI 10.1056/NEJM198607173150304; SLATOPOLSKY E, 1989, KIDNEY INT, V36, P897, DOI 10.1038/ki.1989.277; WINNEY RJ, 1986, KIDNEY INT, pS91; [No title captured]	25	125	127	0	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 21	1991	324	8					527	531		10.1056/NEJM199102213240804	http://dx.doi.org/10.1056/NEJM199102213240804			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EX918	1992306				2023-01-03	WOS:A1991EX91800004
J	RIVERA, GK; RAIMONDI, SC; HANCOCK, ML; BEHM, FG; PUI, CH; ABROMOWITCH, M; MIRRO, J; OCHS, JS; LOOK, AT; WILLIAMS, DL; MURPHY, SB; DAHL, GV; KALWINSKY, DK; EVANS, WE; KUN, LE; SIMONE, JV; CRIST, WM				RIVERA, GK; RAIMONDI, SC; HANCOCK, ML; BEHM, FG; PUI, CH; ABROMOWITCH, M; MIRRO, J; OCHS, JS; LOOK, AT; WILLIAMS, DL; MURPHY, SB; DAHL, GV; KALWINSKY, DK; EVANS, WE; KUN, LE; SIMONE, JV; CRIST, WM			IMPROVED OUTCOME IN CHILDHOOD ACUTE LYMPHOBLASTIC-LEUKEMIA WITH REINFORCED EARLY TREATMENT AND ROTATIONAL COMBINATION CHEMOTHERAPY	LANCET			English	Article							BIOLOGIC FEATURES; ACUTE-LEUKEMIA; CHILDREN; IMMUNOPHENOTYPE; METHOTREXATE; THERAPY; AGE	To improve outcome in childhood acute lymphoblastic leukaemia (ALL), a stratified, randomised study of extended intensified chemotherapy was done. 358 evaluable patients received remission reinforcement therapy (teniposide, cytarabine, high-dose methotrexate) added to a four-drug induction regimen. Those achieving complete remission were randomised on the basis of risk group assignment to conventional continuation treatment or to four pairs of drugs rotated weekly or every 6 weeks. All patients received intrathecal chemotherapy; higher risk patients also received 1800 cGy cranial irradiation after 1 year of remission. Complete remission was induced in 96% of the patients. At median follow-up of 40 (range 19-73) months, 4-year event-free survival (SE) was 73 (4)% overall, 81 (6)% in the lower-risk group (n = 110), and 69 (5)% in the higher-risk group (n = 248). Outcome within risk groups was not significantly affected by the speed of rotation of drug pairs during continuation treatment. Various high-risk subgroups had apparently improved responses to this treatment. This intensified chemotherapy may cure 69-77% of children with ALL.	ST JUDE CHILDRENS RES HOSP, DEPT PATHOL & LAB MED, MEMPHIS, TN 38101 USA; ST JUDE CHILDRENS RES HOSP, DEPT BIOSTAT & INFORMAT SYST, MEMPHIS, TN 38101 USA; ST JUDE CHILDRENS RES HOSP, DIV PHARMACEUT, MEMPHIS, TN 38101 USA; ST JUDE CHILDRENS RES HOSP, DEPT RADIAT ONCOL, MEMPHIS, TN 38101 USA; UNIV TENNESSEE, CTR HLTH SCI, COLL MED, DEPT PEDIAT, MEMPHIS, TN 38163 USA; UNIV TENNESSEE, CTR HLTH SCI, COLL MED, DEPT RADIAT ONCOL, MEMPHIS, TN 38163 USA	St Jude Children's Research Hospital; St Jude Children's Research Hospital; St Jude Children's Research Hospital; St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center	RIVERA, GK (corresponding author), ST JUDE CHILDRENS RES HOSP, DEPT HEMATOL ONCOL, POB 318, MEMPHIS, TN 38101 USA.		Evans, William E./C-2069-2012; Raimondi, Susana C/N-8166-2018; Pui, Ching-Hon/N-8076-2018	Evans, William E./0000-0002-9333-5322; Pui, Ching-Hon/0000-0003-0303-5658	NCI NIH HHS [CA 21765, CA 20180] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA020180, P30CA021765] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABROMOWITCH M, 1988, MED PEDIATR ONCOL, V16, P297, DOI 10.1002/mpo.2950160502; BLEYER WA, 1977, CANCER TREAT REP, V61, P1419; CLAVELL LA, 1986, NEW ENGL J MED, V315, P657, DOI 10.1056/NEJM198609113151101; CRIST W, 1986, MED PEDIATR ONCOL, V14, P135, DOI 10.1002/mpo.2950140306; CRIST W, 1989, BLOOD, V74, P1252; CRIST W, 1990, BLOOD, V76, P489; CRIST WM, 1990, BLOOD, V76, P117; DAHL GV, 1987, J CLIN ONCOL, V5, P1015, DOI 10.1200/JCO.1987.5.7.1015; EVANS WE, 1988, BLUT, V56, P241, DOI 10.1007/BF00320282; FREI E, 1965, BLOOD-J HEMATOL, V26, P642, DOI 10.1182/blood.V26.5.642.642; GAGNON GA, 1989, BLOOD, V74, P2088; GOLDIE JH, 1982, CANCER TREAT REP, V66, P439; GOLDIN A, 1971, CANCER CHEMOTH REP 1, V55, P309; GOORIN AM, 1990, J PEDIATR-US, V116, P144, DOI 10.1016/S0022-3476(05)81668-3; HARNDEN DG, 1985, BIRTH DEFECTS-ORIG, P1; JAKASCHAUB GE, 1988, LEUKEMIA, V2, pS73; KALWINSKY DK, 1985, LEUKEMIA RES, V9, P817, DOI 10.1016/0145-2126(85)90300-5; LANE D M, 1970, Cancer Chemotherapy Reports, V54, P113; LOOK AT, 1988, PEDIATR CLIN N AM, V35, P723; MOE PJ, 1984, EUR PAEDIATR HAEMATO, V1, P113; PASTAN I, 1987, NEW ENGL J MED, V316, P1383; PETO J, 1986, LANCET, V1, P408; PUI CH, 1988, J CLIN ONCOL, V6, P56, DOI 10.1200/JCO.1988.6.1.56; PUI CH, 1989, NEW ENGL J MED, V321, P136, DOI 10.1056/NEJM198907203210302; Riehm H, 1990, Haematol Blood Transfus, V33, P439; Rivera G K, 1987, Haematol Blood Transfus, V30, P156; RIVERA GK, 1988, NEW ENGL J MED, V318, P1541; RIVERA GK, 1988, MED PADIATR ONCOL, V14, P177; SATHER HN, 1986, MED PEDIATR ONCOL, V14, P166, DOI 10.1002/mpo.2950140311; SHUSTER JJ, 1990, BLOOD, V75, P166; WILLIAMS DL, 1984, CANCER GENET CYTOGEN, V13, P239, DOI 10.1016/0165-4608(84)90046-3	31	366	371	0	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JAN 12	1991	337	8733					61	66		10.1016/0140-6736(91)90733-6	http://dx.doi.org/10.1016/0140-6736(91)90733-6			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ER477	1670723				2023-01-03	WOS:A1991ER47700001
J	ALLEN, CMC				ALLEN, CMC			TRIALS AND TRIBULATIONS IN SPEECH-THERAPY	BRITISH MEDICAL JOURNAL			English	Editorial Material											ALLEN, CMC (corresponding author), ADDENBROOKES HOSP,CAMBRIDGE CB2 2QQ,ENGLAND.							Allen CM, 1988, MANAGEMENT ACUTE STR; CAMPBELL MJ, 1984, J NEUROL SCI, V64, P65, DOI 10.1016/0022-510X(84)90056-X; DAVID R, 1982, J NEUROL NEUROSUR PS, V45, P957, DOI 10.1136/jnnp.45.11.957; FITZGIBBON CT, 1986, BRIT J DISORD COMMUN, V21, P117; HARTMAN J, 1987, ARCH NEUROL-CHICAGO, V44, P646, DOI 10.1001/archneur.1987.00520180064018; HOWARD D, 1986, BRIT J DISORD COMMUN, V21, P89; LENDREM W, 1985, J NEUROL NEUROSUR PS, V48, P743, DOI 10.1136/jnnp.48.8.743; LINCOLN NB, 1984, LANCET, V2, P197; PRING TR, 1986, BRIT J DISORD COMMUN, V21, P103; RICHARDSON KT, 1989, ARCH NEUROL-CHICAGO, V46, P249, DOI 10.1001/archneur.1989.00520390015003; WADE DT, 1983, BRIT MED J, V286, P50, DOI 10.1136/bmj.286.6358.50; WERTZ RT, 1986, ARCH NEUROL-CHICAGO, V43, P653, DOI 10.1001/archneur.1986.00520070011008	12	3	3	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 11	1990	301	6747					302	303		10.1136/bmj.301.6747.302	http://dx.doi.org/10.1136/bmj.301.6747.302			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	DU040	1697487	Green Published, Bronze			2023-01-03	WOS:A1990DU04000002
J	LACHMANN, B; ARMBRUSTER, S; SCHAIRER, W; LANDSTRA, M; TROUWBORST, A; VANDAAL, GJ; KUSUMA, A; ERDMANN, W				LACHMANN, B; ARMBRUSTER, S; SCHAIRER, W; LANDSTRA, M; TROUWBORST, A; VANDAAL, GJ; KUSUMA, A; ERDMANN, W			SAFETY AND EFFICACY OF XENON IN ROUTINE USE AS AN INHALATIONAL ANESTHETIC	LANCET			English	Article											LACHMANN, B (corresponding author), ERASMUS UNIV, HOSP DIJKZIGT, DEPT ANAESTHESIOL, POSTBOX 1738, ROOM EE2393, 3000 DR ROTTERDAM, NETHERLANDS.							AMESS JAL, 1978, LANCET, V2, P339; BOOMSMA F, 1990, ANAESTHESIA, V45, P273, DOI 10.1111/j.1365-2044.1990.tb14731.x; CHUDLER EH, 1983, PAIN, V16, P221, DOI 10.1016/0304-3959(83)90111-2; COHEN EN, 1971, ANESTHESIOLOGY, V35, P343; CULLEN SC, 1951, SCIENCE, V113, P580, DOI 10.1126/science.113.2942.580; CULLEN SC, 1969, ANESTHESIOLOGY, V31, P305, DOI 10.1097/00000542-196910000-00003; DELIMA VMF, 1982, PAIN, V14, P207, DOI 10.1016/0304-3959(82)90130-0; DYCK PJ, 1980, ANESTHESIOLOGY, V53, P205, DOI 10.1097/00000542-198009000-00005; HEYMANN MA, 1977, PROG CARDIOVASC DIS, V20, P55, DOI 10.1016/S0033-0620(77)80005-4; JONSON B, 1975, B PHYSIO-PATHOL RESP, V11, P729; LACHMANN B, 1988, 9TH WORLD C AN WASH; LANE GA, 1980, SCIENCE, V210, P899, DOI 10.1126/science.7434002; LAWRENCE JH, 1947, J PHYSIOL-LONDON, V105, P197; LAYZER RB, 1978, LANCET, V2, P1227; MORRIS LE, 1955, ANESTHESIOLOGY, V16, P312, DOI 10.1097/00000542-195505000-00003; PITTINGER CB, 1953, ANESTHESIOLOGY, V14, P10, DOI 10.1097/00000542-195301000-00002; SAXENA PR, 1985, BRIT J PHARMACOL, V84, P533, DOI 10.1111/j.1476-5381.1985.tb12938.x; SPENCE AA, 1987, BRIT J ANAESTH, V59, P96, DOI 10.1093/bja/59.1.96	18	161	172	0	9	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 16	1990	335	8703					1413	1415						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DJ234	1972207				2023-01-03	WOS:A1990DJ23400001
J	WILCOX, RG; VONDERLIPPE, G; OLSSON, CG; JENSEN, G; SKENE, AM; HAMPTON, JR				WILCOX, RG; VONDERLIPPE, G; OLSSON, CG; JENSEN, G; SKENE, AM; HAMPTON, JR			EFFECTS OF ALTEPLASE IN ACUTE MYOCARDIAL-INFARCTION - 6-MONTH RESULTS FROM THE ASSET STUDY	LANCET			English	Article											WILCOX, RG (corresponding author), UNIV NOTTINGHAM HOSP, QUEENS MED CTR, DEPT MED, NOTTINGHAM NG7 2UH, ENGLAND.							[Anonymous], 1987, Lancet, V2, P871; [Anonymous], 1988, LANCET, V2, P349; [Anonymous], 1986, LANCET, V1, P397; CHAMBERLAIN DA, 1988, LANCET, V1, P545; CHAMBERLAIN DA, 1990, LANCET, V335, P427; KELLY TL, 1985, AM HEART J, V110, P535; SPARROW D, 1978, J CHRON DIS, V31, P425, DOI 10.1016/0021-9681(78)90006-1; WHITE HD, 1987, NEW ENGL J MED, V317, P850, DOI 10.1056/NEJM198710013171402; WILCOX RG, 1988, LANCET, V2, P525; 1987, G ITAL CARDIOL, V17, P37	10	123	126	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 19	1990	335	8699					1175	1178						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DE448	1971034				2023-01-03	WOS:A1990DE44800002
C	FAITHFULL, NS		Erdmann, W; Bruley, DF		FAITHFULL, NS			ARTIFICIAL OXYGEN CARRYING BLOOD SUBSTITUTES	OXYGEN TRANSPORT TO TISSUE XIV	ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY		English	Proceedings Paper	19TH ANNUAL MEETING OF THE INTERNATIONAL SOC OXYGEN TRANSPORT TO TISSUE	AUG 24-30, 1991	WILLEMSTAD, NETH ANTILLES	INT SOC OXYGEN TRANSPORT TISSUE, BOEHRINGER INGELHEIM, HEWLETT PACKARD, KLM, LILLY NEDERLAND, MED SYSTEM, ORTOMED, ABM, CURACAOSCHE ZUURSTOFFABRIK, REFINERIA ISLA CURACAO															0	147	149	0	5	PLENUM PRESS DIV PLENUM PUBLISHING CORP	NEW YORK	NEW YORK	0065-2598		0-306-44232-9	ADV EXP MED BIOL	Adv.Exp.Med.Biol.		1992	317						55	72						18	Medicine, General & Internal; Medicine, Research & Experimental; Physiology	Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine; Research & Experimental Medicine; Physiology	BX33D	1288172				2023-01-03	WOS:A1992BX33D00006
